



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 153406

TO: Emily M Le
Location: 3c35/3c18
Art Unit: 1648
Monday, May 16, 2005

Case Serial Number: 08/869386

From: Noble Jarrell
Location: Biotech-Chem Library
Rem 1B71
Phone: 272-2556

Noble.jarrell@uspto.gov

Search Notes

Protein Sequence Searches - February 2005

All of the sequence databases on ABSS have recently been updated.

- Please note that the curators of the UniProt database have purged some temporary accession numbers from the most recent version of UniProt. These sequences have been assigned new permanent accession numbers. The new UniProt record may not contain the previous temporary accession number.
- If you encounter an accession number from an older search run against UniProt (results file extension .rup) that can no longer be found in the database, the permanent record with the new accession number can be found by searching the old accession number in the UniProt Protein Archive database (UniPARC) at:

<http://www.pir.uniprot.org/database/archive.shtml>

If you have any questions regarding this information or your results, please contact any STIC searcher.

When submitting sequence search results for scanning into IFW, please include a copy of this attachment to assist any future Examiners or members of the public who may encounter UniProt temporary accession numbers.



This Page Blank (uspto)

153406 CRFE

Jarrell, Noble

From: Le, Emily
Sent: Monday, May 16, 2005 12:04 PM
To: Jarrell, Noble
Subject: FW: Sequence Search: 08869386

update:

Please provide a search for the following:

1. RAFVTIGK, which is SEQ ID NO: 5 in the above case.
2. SEQ ID NO: 1
3. SEQ ID NO: 3

Please also limit the size to no more than 25 amino acids.

Thanks, Noble.

Emily

-----Original Message-----

From: Le, Emily
Sent: Friday, May 13, 2005 4:13 PM
To: Jarrell, Noble
Subject: Sequence Search: 08869386

Noble,

Please provide a search for the following:

1. RAFVTIGK

Please also limit the size to no more than 25 amino acids.

Thanks!

Emily Le
Office, Rem 3C35
Mailbox, Rem 3C18
Tel., 2-0903

Noble

May 16 2005

3 NA, computer

10 prep

10 onl

commercial

This Page Blank (uspto)

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: May 16, 2005, 07:26:50 ; Search time 167 Seconds
(without alignments)
24.531 Million cell updates/sec

Title: SEQ1

Perfect score: 39

Sequence: 1 rafvtgk 8

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 16988

Minimum DB seq length: 0

Maximum DB seq length: 25

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Uniprot_03.*

1: uniprot_sprot.*

2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	24	61.5	22	Q6U2M7	Q6u2m7 sechium edu
2	23	59.0	11	Q7S0C5	Q7s0c5 neurospora
3	23	59.0	16	Q6XA08	Q6xa08 equus caball
4	22	56.4	10	Q76V19	Q76v19 lactococcus
5	22	56.4	10	Q9QVK8	Q9qvk8 mus sp. mep
6	22	56.4	17	Q9SMC7	Q9smc7 lycopersico
7	22	56.4	21	Q9R890	Q9r890 chlamydia t
8	22	56.4	23	Q9ZG66	Q9zg66 chlamydia t
9	22	56.4	25	Q9TRE1	Q9tre1 ovis aries
10	22	56.4	25	O10481	O10481 human immun
11	21	53.8	13	Q6TUI7	Q6tui7 ascaris suu
12	21	53.8	14	Q27373	Q27373 trypanosoma
13	21	53.8	15	Q26825	Q26825 trypanosoma
14	21	53.8	16	Q47605	Q47605 escherichia
15	21	53.8	17	Q6EML4	Q6eml4 meleagris g
16	21	53.8	17	Q6EML5	Q6eml5 gallus gall
17	21	53.8	23	Q6U2M9	Q6u2m9 momordica c
18	21	53.8	24	Q6U2N2	Q6u2n2 citrullus l
19	20	51.3	9	Q9TVP1	Q9tvp1 trypanosoma
20	20	51.3	11	Q87882	Q87882 mycobacteri
21	20	51.3	15	Q86128	Q86128 vesicular s
22	20	51.3	19	Q91SF3	Q91sf3 feline cali
23	20	51.3	19	Q91SF5	Q91sf5 feline cali
24	20	51.3	19	Q91SF7	Q91sf7 feline cali
25	20	51.3	20	Q9TWP7	Q9twp7 leishmania
26	20	51.3	21	Q09166	Q09166 staphylococ
27	20	51.3	21	Q8QXS4	Q8qxs4 polyomaviru
28	20	51.3	21	Q8QXS5	Q8qxs5 polyomaviru
29	20	51.3	21	Q8QXS6	Q8qxs6 polyomaviru
30	20	51.3	21	Q8QXS8	Q8qxs8 polyomaviru
31	20	51.3	22	Q7S0M0	Q7s0m0 neurospora

32	20	51.3	24	2	Q945F1	Q945f1 cicer ariet
33	20	51.3	24	2	Q9QW22	Q9qw22 rattus sp.
34	20	51.3	24	2	Q9QW23	Q9qw23 rattus sp.
35	19	48.7	10	2	Q7MLV8	Q7mlv8 nicotiana p
36	19	48.7	12	2	Q9BR06	Q9br06 homo sapien
37	19	48.7	14	2	Q7S9F5	Q7s9f5 neurospora
38	19	48.7	16	2	Q9UCJ7	Q9ucj7 homo sapien
39	19	48.7	18	2	Q7Y4G6	Q7y4g6 lactococcus
40	19	48.7	20	2	Q9PWQ4	Q9pwq4 gallus gall
41	19	48.7	21	2	Q8HS54	Q8hs54 arabidopsis
42	19	48.7	21	2	Q8QYS3	Q8qys3 polyomaviru
43	19	48.7	21	2	Q8QYS7	Q8qys7 polyomaviru
44	19	48.7	21	2	Q8QYS9	Q8qys9 polyomaviru
45	19	48.7	21	2	Q8QYTO	Q8qyto polyomaviru

ALIGNMENTS

RESULT 1

Q6U2M7	PRELIMINARY;	PRT;	22	AA.
AC	Q6U2M7;			
DT	05-JUL-2004 (TrEMBLrel. 27, Created)			
DT	05-JUL-2004 (TrEMBLrel. 27, Last sequence update)			
DT	05-JUL-2004 (TrEMBLrel. 27, Last annotation update)			
DE	Galactinol synthase (BC 2.4.1.123) (Fragment).			
GN	Name=GAS1;			
OS	Sechium edule.			
OC	Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;			
OC	Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;			
OC	eurosid1; Cucurbitales; Cucurbitaceae; Sechium.			
OX	NCBI_TaxID=184140;			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RX	MEDLINE=22975109; PubMed=14526110; DOI=10.1104/pp.103.027714;			
RA	Ayre B.G., Blair J.E., Turgeon R.;			
RT	"Functional and phylogenetic analyses of a conserved regulatory			
RL	program in the phloem of minor veins."			
DR	Plant Physiol. 133:1229-1239(2003).			
DR	EMBL; AV379782; AAQ74884.1; "			
DR	GO; GO:0047216; F:inositol 3-alpha-galactosyltransferase acti. . ; IEA.			
DR	GO; GO:0016757; F:transferase activity, transferring glycosyl. . ; IEA.			
KW	Glycosyltransferase; Transferase.			
FT	NON TER 22			
SQ	SEQUENCE 22 AA; 2295 MW; A6673B5BFD06430C CRC64;			

Query Match 61.5%; Score 24; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 6.8e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	RAFFT 5
Db	18	RAFFT 22

RESULT 2

Q7S0C5	PRELIMINARY;	PRT;	11	AA.
ID	Q7S0C5			
AC	Q7S0C5;			
DT	01-MAR-2004 (TrEMBLrel. 26, Created)			
DT	01-MAR-2004 (TrEMBLrel. 26, Last sequence update)			
DT	01-MAR-2004 (TrEMBLrel. 26, Last annotation update)			
DE	Predicted protein.			
GN	Name=NCU09984.1;			
OS	Neurospora crassa.			
OC	Eukaryota; Fungi; Ascomycota; Pezizomycotina; Sordariomycetes;			
OC	Sordariomycetidae; Sordariales; Sordariaceae; Neurospora.			
OX	NCBI_TaxID=5141;			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RC	STRAIN=OK74A;			
RA	Galan J.E., Calvo S.E., Borkovich K.A., Selker E.U., Read N.D.,			

RA Jaffe D., FitzHugh W., Ma L.-J., Smirnov S., Purcell S., Rehman B.,
RA Elkins T., Engels R., Wang S., Nielsen C.B., Butler J., Endrizzi M.,
RA Qui D., Iankiev P., Pedersen D., Nelson M., Washburne M.,
RA Selitrennikoff C.P., Kinsey J.A., Braun E.L., Zelter A., Schulte U.,
RA Kothe G.O., Jedd G., Mewes W., Staben C., Marcotte E., Greenberg D.,
RA Roy A., Foley K., Naylor J., Thoman N., Barrett R., Gnerre S.,
RA Kamal M., Kamvysselis M., Mauceli E., Bielke C., Rudd S., Frishman D.,
RA Krystofova S., Rasmussen C., Metzenberg R.L., Perkins D.D., Kroken S.,
RA Cogoni C., Macino G., Catchside D., Li W., Pratt R.J., Omani S.A.,
RA DeSouza C.C., Glass L., Orbach M.J., Berglund J., Voelker R.,
RA Varden O., Planann M., Siller S., Dunlap J., Radford A., Aramayo R.,
RA Natvig D.O., Alex L.A., Mannhaupt G., Ebbole D.J., Freitag M.,
RA Paulsen I., Sachs M.S., Landier E.S., Nisbaum C., Birren B.,
RA "The Genome Sequence of the Filamentous Fungus Neurospora crassa."
RL Nature 0:0(2003).
CC -|- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
DR EMBL; AABX01000510; EAA28761.1; -;
SQ SEQUENCE 11 AA; 1251 MW; 4B2534E31B2C9C3 CRC64;

Query Match 59.0%; Score 23; DB 2; Length 11;
Best Local Similarity 80.0%; Pred. NO. 6.1e+02;
Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 3 FVTIG 7
Db 5 FVTIG 9
|||:|
|||:|

RESULT 3
Q6XA08 PRELIMINARY; PRT; 16 AA.
AC Q6XA08;
AT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Cytochrome c oxidase IV subunit (Fragment).
GN Name=COXIV;
OS Equus caballus (Horse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Perissodactyla; Equidae; Equus.
OX NCBI_TaxID=9796;
RN [1]
RP SEQUENCE FROM N.A.
RA Takafuji V.A., Crisman M.V., Seat K.L., Sharova L.V., Ward D.L.,
RA Howard R.D.;
RL Submitted (FEB-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY246701; AAP78686.1; -;
FT NON TER 16 16
SQ SEQUENCE 16 AA; 1839 MW; 70E9C10DD96C2B74 CRC64;

Query Match 59.0%; Score 23; DB 2; Length 16;
Best Local Similarity 62.5%; Pred. NO. 8.6e+02;
Matches 5; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1 RAFVTIGK 8
Db 5 RVFSLIGK 12
|||:|
|||:|

RESULT 4
Q76V19 PRELIMINARY; PRT; 10 AA.
AC Q76V19;
AT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Lysin (Fragment).
GN Name=lysA;
OS Lactococcus delbrueckii bacteriophage LL-H.
OC Viruses.
OX NCBI_TaxID=12348;

RA Jaffe D., Dupont L., Alatosava T., Ritzenthaler P.;
RA Mikonen M., Vuoristo J., Alatosava T.;
RT "Defective site-specific integration elements are present in the
RT genome of virulent bacteriophage LL-H of Lactobacillus delbrueckii.";
RN Appl. Environ. Microbiol. 62:1847-1851(1996).
[2]
SQ SEQUENCE FROM N.A.
RP MEDLINE=94237431; PubMed=7514146; DOI=10.1016/0378-1097(94)90053-1;
RA Mikonen M., Vuoristo J., Alatosava T.;
RT "Ribosome binding site consensus sequence of Lactobacillus delbrueckii
RT subsp. lactis bacteriophage LL-H.";
RL FEMS Microbiol. Lett. 116:315-320(1994).
[3]
SQ SEQUENCE FROM N.A.
RP MEDLINE=96064414; PubMed=8526515;
RA Vasala A., Valkkila M., Caldecay J., Alatosava T.;
RT "Genetic and biochemical characterization of the Lactobacillus
RT delbrueckii subsp. lactis bacteriophage LL-H lysin.";
RN Appl. Environ. Microbiol. 61:4004-4011(1995).
[4]
SQ SEQUENCE FROM N.A.
RP Mikonen M., Dupont L., Alatosava T., Ritzenthaler P.;
RT "Complex DNA rearrangements in the att-integration genome regions in
RT related virulent and temperate phages of Lactobacillus delbrueckii.";
RL Submitted (JUN-1996) to the EMBL/GenBank/DBJ databases.
DR EMBL; L42315; AAB06218.1; -;
FT NON TER 1 1
SQ SEQUENCE 10 AA; 1162 MW; 926B8D41B2C9CB1A CRC64;

Query Match 56.4%; Score 22; DB 2; Length 10;
Best Local Similarity 83.3%; Pred. NO. 9.5e+02;
Matches 5; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3 FVTIGK 8
Db 5 FVTITK 10
|||:|
|||:|

RESULT 5
Q9QVK8 PRELIMINARY; PRT; 10 AA.
AC Q9QVK8;
AT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE MEPRIN-METALLOENDOPEPTIDASE (Fragment).
OS Mus sp.
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10095;
RN [1]
RP SEQUENCE.
RA MEDLINE=91363409; PubMed=1888759; DOI=10.1016/0167-4838(91)90032-U;
RA Flannery A.V., Macadam G.C., Beynon R.J.;
RT "Immunological characterisation of different meprin species in mice.";
RL Biochim. Biophys. Acta 1079:119-122(1991).
FT NON TER 1 1
FT NON TER 10 10
SQ SEQUENCE 10 AA; 1163 MW; DD6436144731B2C9 CRC64;

Query Match 56.4%; Score 22; DB 2; Length 10;
Best Local Similarity 57.1%; Pred. NO. 9.5e+02;
Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 2 AFVTIGK 8
Db 2 AFVTILNE 8
|||:|
|||:|

RESULT 6
Q9SMC7

```

ID Q9SMC7 PRELIMINARY; PRT; 17 AA.
AC Q9SMC7;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE Putative proline-rich protein (Fragment).
GN Name=ctd5;
OS Lycopersicon esculentum (Tomato).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; asterids;
OC lamiales; Solanales; Solanaceae; Solanum.
OX NCBI_TaxID=4081;
RN [1]
RP MEDLINE=21323136; PubMed=11430427; DOI=10.1023/A:1010625203485;
RA Hoebrechts F.A., Orzaez D., van der Plas L.H.W., Woltering E.J.;
RT "Changes in gene expression during programmed cell death in tomato
RT cell suspensions.";
RL Plant Mol. Biol. 45:641-654(2001).
DR EMBL; AJ250000; CAB61884.1; -.
FT NON TER 1
SQ SEQUENCE 17 AA; 1837 MW; E35DE1561000PFDC CRC64;

Query Match 56.4%; Score 22; DB 2; Length 17;
Best Local Similarity 57.1%; Pred. No. 1.5e+03;
Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2 AFVTIGK 8
DB 1 AFIPCGK 7

RESULT 7
Q9R890 PRELIMINARY; PRT; 21 AA.
AC Q9R890;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein (Fragment).
OS Chlamydia trachomatis.
OC Bacteria; Chlamydiae; Chlamydiales; Chlamydiaceae; Chlamydia.
OX NCBI_TaxID=813;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=L2 434B;
RA Wang L., Steenburg S.D., Zheng Y., Larsen S.H.;
RL Submitted (AUG-1998) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF087312; AAD04087.1; -.
KW Hypothetical protein.
FT NON TER 21
SQ SEQUENCE 21 AA; 2346 MW; 5A282DC334CEB5EF CRC64;

Query Match 56.4%; Score 22; DB 2; Length 21;
Best Local Similarity 57.1%; Pred. No. 1.9e+03;
Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1 RAFVTIG 7
DB 10 RLFLTFG 16

RESULT 8
Q9ZG66 PRELIMINARY; PRT; 23 AA.
AC Q9ZG66;
DT 01-MAY-1999 (TrEMBLrel. 10, Created)
DT 01-MAY-1999 (TrEMBLrel. 10, Last sequence update)
DT 01-MAY-1999 (TrEMBLrel. 10, Last annotation update)
DE Virulence protein RGP7-D (Fragment).
OS Chlamydia trachomatis.
OC Bacteria; Chlamydiae; Chlamydiales; Chlamydiaceae; Chlamydia.
OX NCBI_TaxID=813;

```

```

RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=L2 434B;
RA Wang L., Steenburg S.D., Zheng Y., Larsen S.H.;
RL Submitted (AUG-1998) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF087290; AAD04067.1; -.
FT NON TER 23
SQ SEQUENCE 23 AA; 2596 MW; 95DA4A282DC334CE CRC64;

Query Match 56.4%; Score 22; DB 2; Length 23;
Best Local Similarity 57.1%; Pred. No. 2e+03;
Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1 RAFVTIG 7
DB 10 RLFLTFG 16

RESULT 9
Q9TRE1 PRELIMINARY; PRT; 25 AA.
AC Q9TRE1;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE PLACENTATION-SPECIFIC BINUCLEATE cell GLYCOPROTEIN=62 kDa major
DE phytohemagglutinin-binding protein.
OS Ovis aries (Sheep).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Caprinae; Ovis.
OX NCBI_TaxID=9940;
RN [1]
RP SEQUENCE
RX MEDLINE=94075364; PubMed=8253801;
RA Atkinson Y.H., Gogolin-Swens K.J., Hounsell E.F., Davies M.J.,
RA Brandon M.R., Seamark R.F.;
RT "Characterization of placental-specific binucleate call
RT glycoproteins possessing a novel carbohydrate. Evidence for a new
RT family of pregnancy-associated molecules.";
RL J. Biol. Chem. 268:26679-26685(1993).
DR PIR; B44524; B44524.
SQ SEQUENCE 25 AA; 2778 MW; 1053D1A02B4BA442 CRC64;

Query Match 56.4%; Score 22; DB 2; Length 25;
Best Local Similarity 57.1%; Pred. No. 2.2e+03;
Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1 RAFVTIG 7
DB 17 RGXITIG 23

RESULT 10
O10481 PRELIMINARY; PRT; 25 AA.
AC O10481;
DT 01-JUL-1997 (TrEMBLrel. 04, Created)
DT 01-JUL-1997 (TrEMBLrel. 04, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Envelope glycoprotein (Fragment).
GN Name=env;
OS Human immunodeficiency virus 1.
OC Viruses; Retroid viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=97255649; PubMed=9100996;
RA Rencher S.D., Lockey T.D., Slobod K.S., Hurwitz J.L.;
RT "Drift from the GPGRAF HIV-1 envelope V3 crown sequence in a North
RT American inner city.";
RL AIDS Res. Hum. Retroviruses 13:527-528(1997).
DR EMBL; U81241; AAB53843.1; -.

```

DR GO: GO:0016021; C: integral to membrane; IEA.
DR GO: GO:0019028; C: viral capsid; IEA.
DR GO: GO:0019031; C: viral envelope; IEA.
DR GO: GO:0005198; F: structural molecule activity; IEA.
DR InterPro: IPR000777; GP120.
DR InterPro: IPR011056; Pept_S24_S26_C.
DR Pfam: PF00516; GP120; 1.
KW AIDS; Coat protein; Envelope protein; Glycoprotein; Transmembrane.
FT NON_TER 1 1
FT NON_TER 25 25
SQ SEQUENCE 25 AA; 2801 MW; 25E1B150CD7C14B6 CRC64;

Query Match 56.4%; Score 22; DB 2; Length 25;
Best Local Similarity 71.4%; Pred. No. 2.2e+03;
Matches 5; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 RAFVTIG 7
Db |||||
18 RAFYTKG 24

RESULT 11
Q6TUI7 PRELIMINARY; PRT; 13 AA.
AC Q6TUI7; 2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE AF17 D (Fragment).
OS Ascaris suum (Pig roundworm) (Ascaris lumbricoides).
OC Eukaryota; Metazoa; Nematoda; Chromadorea; Ascaridida; Ascaridoidea;
OC Ascarididae; Ascaris.
OX NCBI_TaxID=6253;
RN [1]
RP SEQUENCE FROM N.A.
RA Nanda J.C., Stretton A.;
RL Submitted (SEP-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY396839; AAQ90312.1; -.
FT NON_TER 1 1
SQ SEQUENCE 13 AA; 1531 MW; 18DA23119D6C79C4 CRC64;

Query Match 53.8%; Score 21; DB 2; Length 13;
Best Local Similarity 50.0%; Pred. No. 2e+03;
Matches 4; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
Db |||||
2 RNFMNFGK 9

RESULT 12
Q27373 PRELIMINARY; PRT; 14 AA.
AC Q27373; 1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE VSG (14 AA) (Fragment).
OS Trypanosoma brucei.
OC Eukaryota; Euglenozoa; Kinetoplastida; Trypanosomatidae; Trypanosoma.
OX NCBI_TaxID=5691;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=427;
RA Timmers H.Th.M., De Lange T., Kooter J.M., Borst P.;
RT "Coincident multiple activations of the same surface antigen gene in Trypanosoma brucei";
RL J. Mol. Biol. 194: 81-90 (1987).
DR EMBL; X05267; CAA28883.1; -.
DR EMBL; X05266; CAA28882.1; -.
FT NON_TER 1 1
SQ SEQUENCE 14 AA; 1530 MW; DA5AF6569E9A13DD CRC64;

Query Match 53.8%; Score 21; DB 2; Length 14;
Best Local Similarity 80.0%; Pred. No. 2.2e+03;
Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2 AFVTI 6
Db |||||
8 AFVTL 12

RESULT 13
Q26825 PRELIMINARY; PRT; 15 AA.
AC Q26825; 1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-NOV-1996 (TrEMBLrel. 01, Last annotation update)
DE Variant surface glycoprotein C-terminus (1 is 2nd base in codon) (Fragment).
OS Trypanosoma brucei.
OC Eukaryota; Euglenozoa; Kinetoplastida; Trypanosomatidae; Trypanosoma.
OX NCBI_TaxID=5691;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=427;
RA Bernards A., van der Ploeg L.H.T., Gibson W.C., Leegwater P.,
RA Bijgenraam F., De Lange T., Weijers P., Calafat J., Borst P.;
RT "Rapid change of the repertoire of variant surface glycoprotein genes in trypanosomas by gene duplication and deletion.";
RL J. Mol. Biol. 190: 11-10 (1986).
DR EMBL; X04041; CAA27674.1; -.
FT NON_TER 1 1
SQ SEQUENCE 15 AA; 1658 MW; DA5AF6569E9A5788 CRC64;

Query Match 53.8%; Score 21; DB 2; Length 15;
Best Local Similarity 80.0%; Pred. No. 2.3e+03;
Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2 AFVTI 6
Db |||||
9 AFVTL 13

RESULT 14
Q47605 PRELIMINARY; PRT; 16 AA.
AC Q47605; 1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-NOV-1996 (TrEMBLrel. 08, Last annotation update)
DE C protein (Fragment).
OS Escherichia coli.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; Escherichia.
OX NCBI_TaxID=562;
RN [1]
RP SEQUENCE FROM N.A.
RC MEDLINE=91139577; PubMed=1995588;
RA Tao T., Bourne J.C., Blumenthal R.M.;
RT "A family of regulatory genes associated with type II restriction-modification systems";
RL J. Bacteriol. 173: 1367-1375 (1991).
DR EMBL; M63622; AAA24561.1; -.
FT NON_TER 1 1
SQ SEQUENCE 16 AA; 1853 MW; E46774511496607C CRC64;

Query Match 53.8%; Score 21; DB 2; Length 16;
Best Local Similarity 80.0%; Pred. No. 2.5e+03;
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3 FVTIG 7
Db |||||

```

Db      6 FTTIG 10

RESULT 15
Q6EML4
ID      Q6EML4      PRELIMINARY;      PRT;      17 AA.
AC      Q6EML4;
DT      25-OCT-2004 (TrEMBLrel. 28, Created)
DT      25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT      25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE      Aldolase B (Fragment).
OS      Meleagris gallopavo (Common turkey).
OC      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC      Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Meleagris.
OX      NCBI_TaxID=9103;
RN      [1]
RP      SEQUENCE FROM N.A.
RX      PubMed=15140948; DOI=10.1093/molbev/msh157;
RA      Axelsson E., Smith N.G., Sundstrom H., Berlin S., Ellegren H.;
RT      "Male-biased mutation rate and divergence in autosomal, z-linked and
RT      w-linked introns of chicken and Turkey.";
RL      Mol. Biol. Evol. 21:1538-1547(2004).
DR      EMBL; AY139847; AAN75280.1; -.
FT      NON_TER      1
FT      NON_TER      17
FT      NON_TER      17
SQ      SEQUENCE      17 AA; 1813 MW; E6CF8FF0BAFA8858 CRC64;

Query Match      53.8%; Score 21; DB 2; Length 17;
Best Local Similarity      66.7%; Pred. No. 2.6e+03;
Matches      4; Conservative      1; Mismatches      1; Indels      0; Gaps      0;

Qy      3 FVTIGK 8
Db      10 YVTSGK 15

RESULT 16
Q6EML5
ID      Q6EML5      PRELIMINARY;      PRT;      17 AA.
AC      Q6EML5;
DT      25-OCT-2004 (TrEMBLrel. 28, Created)
DT      25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT      25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE      Aldolase B (Fragment).
OS      Gallus gallus (Chicken).
OC      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC      Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC      Gallus.
OX      NCBI_TaxID=9031;
RN      [1]
RP      SEQUENCE FROM N.A.
RX      PubMed=15140948; DOI=10.1093/molbev/msh157;
RA      Axelsson E., Smith N.G., Sundstrom H., Berlin S., Ellegren H.;
RT      "Male-biased mutation rate and divergence in autosomal, z-linked and
RT      w-linked introns of chicken and Turkey.";
RL      Mol. Biol. Evol. 21:1538-1547(2004).
DR      EMBL; AY139841; AAN75280.1; -.
FT      NON_TER      1
FT      NON_TER      17
FT      NON_TER      17
SQ      SEQUENCE      17 AA; 1813 MW; E6CF8FF0BAFA8858 CRC64;

Query Match      53.8%; Score 21; DB 2; Length 17;
Best Local Similarity      66.7%; Pred. No. 2.6e+03;
Matches      4; Conservative      1; Mismatches      1; Indels      0; Gaps      0;

Qy      3 FVTIGK 8
Db      10 YVTSGK 15

RESULT 17
Q6U2M9
ID      Q6U2M9      PRELIMINARY;      PRT;      23 AA.
AC      Q6U2M9;
DT      05-JUL-2004 (TrEMBLrel. 27, Created)
DT      05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT      05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE      Galactinol synthase (EC 2.4.1.123) (Fragment).
GN      Name=GAS1;
OS      Momordica charantia (Bitter melon) (Balsam pear).
OC      Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC      Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC      eurosids I; Cucurbitales; Cucurbitaceae; Momordica.
OX      NCBI_TaxID=3673;
RN      [1]
RP      SEQUENCE FROM N.A.
RX      MEDLINE=22975109; PubMed=14526110; DOI=10.1104/pp.103.027714;
RA      Ayre B.G., Blair J.E., Turgeon R.;
RT      "Functional and phylogenetic analyses of a conserved regulatory
RT      program in the phloem of minor veins.";
RL      Plant Physiol. 133:1229-1239(2003).
DR      EMBL; AY379780; AAQ74882.1; -.
DR      GO; GO:0047216; F:inositol 3-alpha-galactosyltransferase acti. . .; IEA.
DR      GO; GO:0016757; F:transferase activity, transferring glycosyl. . .; IEA.
KW      Glycosyltransferase; Transferase.
FT      NON_TER      23
FT      NON_TER      23
FT      NON_TER      23
SQ      SEQUENCE      23 AA; 2444 MW; 62411699CAB81657 CRC64;

Query Match      53.8%; Score 21; DB 2; Length 23;
Best Local Similarity      80.0%; Pred. No. 3.4e+03;
Matches      4; Conservative      1; Mismatches      0; Indels      0; Gaps      0;

Qy      1 RAYVT 5
Db      18 RAYVT 22

RESULT 18
Q6U2N2
ID      Q6U2N2      PRELIMINARY;      PRT;      24 AA.
AC      Q6U2N2;
DT      05-JUL-2004 (TrEMBLrel. 27, Created)
DT      05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT      05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE      Galactinol synthase (EC 2.4.1.123) (Fragment).
GN      Name=GAS1;
OS      Citrullus lanatus (Watermelon) (Citrullus vulgaris).
OC      Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC      Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC      eurosids I; Cucurbitales; Cucurbitaceae; Citrullus.
OX      NCBI_TaxID=3654;
RN      [1]
RP      SEQUENCE FROM N.A.
RX      MEDLINE=22975109; PubMed=14526110; DOI=10.1104/pp.103.027714;
RA      Ayre B.G., Blair J.E., Turgeon R.;
RT      "Functional and phylogenetic analyses of a conserved regulatory
RT      program in the phloem of minor veins.";
RL      Plant Physiol. 133:1229-1239(2003).
DR      EMBL; AY379777; AAQ74879.1; -.
DR      GO; GO:0047216; F:inositol 3-alpha-galactosyltransferase acti. . .; IEA.
DR      GO; GO:0016757; F:transferase activity, transferring glycosyl. . .; IEA.
KW      Glycosyltransferase; Transferase.
FT      NON_TER      24
FT      NON_TER      24
FT      NON_TER      24
SQ      SEQUENCE      24 AA; 2538 MW; E2BC0AE9D7930C06 CRC64;

Query Match      53.8%; Score 21; DB 2; Length 24;
Best Local Similarity      80.0%; Pred. No. 3.6e+03;
Matches      4; Conservative      1; Mismatches      0; Indels      0; Gaps      0;

Qy      1 RAYVT 5
Db      19 RAYVT 23

RESULT 19
Q9TVF1

```

```

ID Q9TVF1 PRELIMINARY; PRT; 9 AA.
AC Q9TVF1;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-MAY-2000 (TrEMBLrel. 13, Last annotation update)
DE Mucin-like protein (Fragment).
GN Name=EMUCe-19c8;
OS Trypanosoma cruzi.
OC Eukaryota; Euglenozoa; Kinetoplastida; Trypanosomatidae; Trypanosoma.
OX NCBI_TaxID=5693;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C1-Brenner;
RX MEDLINE=98225151; PubMed=9556557; DOI=10.1074/jbc.273.18.10843;
RA Di Noia J.M., D'Orso I., Aslund L., Sanchez D.O., Frasch A.C.;
RT "The Trypanosoma cruzi mucin family is transcribed from hundreds of
RT genes having hypervariable regions."
RL J. Biol. Chem. 273.10843-10850 (1998).
DR EMBL; AF036447; AAC14246.1; -.
FT NON TER 1
SQ SEQUENCE 9 AA; 896 MW; DBA831B1BB5DD72D CRC64;

Query Match 51.3%; Score 20; DB 2; Length 9;
Best Local Similarity 50.0%; Pred. No. 1.6e+06;
Matches 3; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2 AFTVIG 7
Db 4 AYTTLG 9

RESULT 20
O87882 PRELIMINARY; PRT; 11 AA.
AC O87882;
DT 01-NOV-1998 (TrEMBLrel. 08, Created)
DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)
DT 01-NOV-1998 (TrEMBLrel. 08, Last annotation update)
DE Alkalyl hydroperoxide reductase (Fragment).
GN Name=ahpC;
OS Bacteria; Actinobacteridia; Actinobacteridae; Actinomycetales;
OC Corynebacterineae; Mycobacteriaceae; Mycobacterium.
OX NCBI_TaxID=1789;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=ATCC19250;
RX MEDLINE=98406038; PubMed=9733688;
RA Pagan-Ramos E., Song J., McFalone M., Mudd M.H., Deretic V.;
RT "Oxidative stress response and characterization of the oxyR-ahpC and
RT furA-katG loci in Mycobacterium marinum."
RL J. Bacteriol. 180:4856-4864 (1998).
DR EMBL; U43810; AAC61663.1; -.
FT NON TER 11
SQ SEQUENCE 11 AA; 1147 MW; 45458CE1787041A7 CRC64;

Query Match 51.3%; Score 20; DB 2; Length 11;
Best Local Similarity 66.7%; Pred. No. 3e+03;
Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2 AFTVIG 7
Db 2 ALLTIG 7

RESULT 21
O86128 PRELIMINARY; PRT; 15 AA.
AC O86128;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE N protein (fragment).

```

```

OS Vesicular stomatitis virus.
OC Viruses; ssRNA negative-strand viruses; Mononegavirales;
OC Rhabdoviridae; Vesiculovirus.
OX NCBI_TaxID=11276;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=80001959; PubMed=89911; DOI=10.1016/0092-8674(79)90274-5;
RA McGeoch D.J.;
RT "Structure of the gene N: gene NS intercalon function in the
RT genome of vesicular stomatitis virus."
RL Cell 17:673-681 (1979).
DR EMBL; V01210; CAA24521.1; -.
FT NON TER 1
SQ SEQUENCE 15 AA; 1800 MW; 16CA68A659416B51 CRC64;

Query Match 51.3%; Score 20; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 3.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5 TIGK 8
Db 4 TIGK 7

RESULT 22
Q91SF3 PRELIMINARY; PRT; 19 AA.
AC Q91SF3;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE Orf3 (Fragment).
OS Feline calicivirus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Caliciviridae;
OC Vesivirus.
OX NCBI_TaxID=11978;
RN [1]
RP SEQUENCE FROM N.A.
RA Rice C.C., Kruger J.M., Vilnis A., Venta P.J., Maes R.K.;
RL Submitted (MAR-2001) to the EMBL/GenBank/DBSJ databases.
DR EMBL; AF357012; AAK43706.1; -.
FT NON TER 19
SQ SEQUENCE 19 AA; 1989 MW; D599B127336A6177 CRC64;

Query Match 51.3%; Score 20; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5 TIGK 8
Db 14 TIGK 17

RESULT 23
Q91SF5 PRELIMINARY; PRT; 19 AA.
AC Q91SF5;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE Orf3 (Fragment).
OS Feline calicivirus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Caliciviridae;
OC Vesivirus.
OX NCBI_TaxID=11978;
RN [1]
RP SEQUENCE FROM N.A.
RA Rice C.C., Kruger J.M., Vilnis A., Venta P.J., Maes R.K.;
RL Submitted (MAR-2001) to the EMBL/GenBank/DBSJ databases.
DR EMBL; AF357011; AAK43704.1; -.
FT NON TER 19
SQ SEQUENCE 19 AA; 1989 MW; D599B127336A6177 CRC64;

```



```

Query Match      51.3%; Score 20; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5 TIGK 8
Db 14 TIGK 17

RESULT 24
Q91SF7 PRELIMINARY; PRT; 19 AA.
AC Q91SF7;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE Oxf3 (Fragment).
OS Peline calicivirus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Caliciviridae;
OC Vesivirus.
OX NCBI_TaxID=11978;
RN [1]
RP SEQUENCE FROM N.A.
RA Rice C.C., Kruger J.M., Villnis A., Venta P.J., Maes R.K.;
RL Submitted (MAR-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF357010; AAK43702.1; -.
FT NON TER 19
SQ SEQUENCE 19 AA; 1989 MW; D599B127336A6177 CRC64;

Query Match      51.3%; Score 20; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5 TIGK 8
Db 14 TIGK 17

RESULT 25
Q9TWP7 PRELIMINARY; PRT; 20 AA.
AC Q9TWP7;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-JUN-2000 (TrEMBLrel. 14, Last annotation update)
DE Cathespin B-like cysteine protease (Fragment).
OS Leishmania mexicana.
OC Eukaryota; Euglenozoa; Kinetoplastida; Trypanosomatidae; Leishmania.
OX NCBI_TaxID=5665;
RN [1]
RP SEQUENCE.
RX MEDLINE=94187801; PubMed=8139620; DOI=10.1016/0166-6851(93)90116-F;
RA Robertson C.D., Coombs G.H.;
RT "Cathespin B-like cysteine proteases of Leishmania mexicana.";
RL Mol. Biochem. Parasitol. 62:271-279(1993).
SQ SEQUENCE 20 AA; 2203 MW; FE1A260FA1DBB41F CRC64;

Query Match      51.3%; Score 20; DB 2; Length 20;
Best Local Similarity 80.0%; Pred. No. 5.1e+03;
Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 4 VTIGK 8
Db 16 VTIGK 20

RESULT 26
Q09166 PRELIMINARY; PRT; 21 AA.
AC Q09166;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)

```

```

DE Neutral metalloprotease (EC 3.4.24.31) (Fragment).
GN Names=shp1;
OS Staphylococcus carnosus.
OC Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX NCBI_TaxID=1281;
RN [1]
RP SEQUENCE.
RC STRAIN=TW300;
RX MEDLINE=94166751; PubMed=8121397;
RA Ayora S., Goetz F.;
RT "Genetic and biochemical properties of an extracellular neutral
metallopeptidase from Staphylococcus hyicus subsp. hyicus.";
RL Mol. Genet. 242:421-430(1994).
CC -1- CATALYTIC ACTIVITY: PREFERENTIAL CLEAVAGE OF BONDS WITH
HYDROPHOBIC RESIDUES IN P1'.
CC -1- COFACTOR: BINDS A ZINC ATOM.
CC -1- SUBCELLULAR LOCATION: SECRETED.
DR GO; GO:0016787; F:hydrolase activity; IEA.
DR GO; GO:0008237; F:metallopeptidase activity; IEA.
KW Hydrolase; Metal-binding; Metalloprotease; Zinc; Zymogen.
FT NON TER 21
SQ SEQUENCE 21 AA; 2328 MW; A7C361A536FEC614 CRC64;

Query Match      51.3%; Score 20; DB 2; Length 21;
Best Local Similarity 50.0%; Pred. No. 5.3e+03;
Matches 3; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 RAFVTI 6
Db 14 RSFTTV 19

RESULT 27
Q8QYS4 PRELIMINARY; PRT; 21 AA.
AC Q8QYS4;
DT 01-JUN-2002 (TrEMBLrel. 21, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Agnoprotein (Fragment).
OS Polyomavirus BK (BKV).
OC Viruses; dsDNA viruses, no RNA stage; Polyomaviridae; Polyomavirus.
OX NCBI_TaxID=10629;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22379369; PubMed=12490781;
RA Li R.M., Mannon R.B., Kleiner D., Tsokos M., Bynum M., Kirk A.D.,
RA Kopp J.B.;
RT "BK virus and SV40 co-infection in polyomavirus nephropathy.";
RL Transplantation 74:1497-1504(2002).
DR EMBL; AF442900; AAL78924.1; -.
DR GO; GO:0003677; F:DNA binding; IEA.
DR InterPro; IPR002643; Polyoma_agn.
DR Pfam; PF01736; Polyoma_agn.1.
DR ProDom; PD004470; Polyoma_agn.1.
FT NON TER 21
SQ SEQUENCE 21 AA; 2347 MW; E7D57BD9AE20D4E3 CRC64;

Query Match      51.3%; Score 20; DB 2; Length 21;
Best Local Similarity 50.0%; Pred. No. 5.3e+03;
Matches 4; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
Db 9 QASVKVGK 16

RESULT 28
Q8QYS5 PRELIMINARY; PRT; 21 AA.
AC Q8QYS5;
DT 01-JUN-2002 (TrEMBLrel. 21, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)

```

OC Viruses: dsDNA viruses, no RNA stage; Polyomaviridae; Polyomavirus.
OX NCBI_TaxID=10629;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22379369; PubMed=12490781;
RA Li R.M., Mannon R.B., Kleiner D., Tsokos M., Bynum M., Kirk A.D.,
Kopp J.B.;
RT "BK virus and SV40 co-infection in polyomavirus nephropathy.";
RL Transplantation 74:1497-1504(2002).
RN [2]
RP SEQUENCE FROM N.A.
RA Li R.-M., Kopp J.B.;
RL Submitted (NOV-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL: AF442897; AAL78922.1; -
DR GO: GO:0003677; F:DNA binding; IEA.
DR InterPro: IPR002643; Polyoma_agn.
DR Pfam: PF01736; Polyoma_agn; 1.
DR ProDom: PD004470; Polyoma_agn; 1.
FT NON_TER 21 21
SQ SEQUENCE 21 AA; 2347 MW; E7D57BD9AE20D4E3 CRC64;

Query Match 51.3%; Score 20; DB 2; Length 21;
Best Local Similarity 50.0%; Pred. No. 5.3e+03;
Matches 4; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
Db :|||:
9 QASVKVGK 16

RESULT 31
Q7SOM0
ID Q7SOM0 PRELIMINARY; PRT; 22 AA.
AC Q7SOM0;
DT 01-MAR-2004 (TrEMBLrel. 26, Created)
DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Predicted protein.
GN Name=NCU09457.1;
OS Neurospora crassa.
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Sordariomycetes;
OC Sordariomycetidae; Sordariales; Sordariaceae; Neurospora.
OX NCBI_TaxID=5141;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=OR74A;
RA Galagan J.E., Calvo S.E., Borkovich K.A., Selker E.U., Read N.D.,
Jaffe D., Fitzhugh W., Ma L.-J., Smirnov S., Purcell S., Rehman B.,
Elkins T., Engels R., Wang S., Nielsen C.B., Butler J., Endrizzi M.,
Qui D., Ianakiev P., Pedersen D., Nelson M., Washburne M.,
Selitrennikoff C.P., Kinsey J.A., Braun E.L., Zelter A., Schulte U.,
Kothe G.O., Jedd G., Mewes W., Staben C., Marcotte E., Greenberg D.,
Roy A., Foley K., Naylor J., Thomann N., Barrett R., Gherre S.,
Kamal M., Kamvasellis M., Mauceli E., Bielek C., Rudd S., Frishman D.,
Krystofova S., Rasmussen C., Metznerberg R.L., Perkins D.D., Kroken S.,
Cognoni C., Macino G., Catcheside D., Li W., Pratt R.J., Osman S.A.,
DeSouza C.C., Glass L., Orbach M.J., Berglund J., Voelker R.,
Yarden O., Plamann M., Seiler S., Dunlap J., Radford A., Aramayo R.,
Nativig D.O., Alex L.A., Mannhaupt G., Ebbole D.J., Freitag M.,
Paulsen I., Sachs M.S., Lander E.S., Nussbaum C., Birren B.;
RT "The Genome Sequence of the Filamentous Fungus Neurospora crassa.";
RL Nature 0:0-0(2003).
CC -!- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
DR EMBL: AABX01000490; EAA28866.1; -
SQ SEQUENCE 22 AA; 2584 MW; 59824A08F3774EAC CRC64;

Query Match 51.3%; Score 20; DB 2; Length 22;
Best Local Similarity 57.1%; Pred. No. 5.6e+03;
Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2 AFVTIGK 8

DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Agnoprotein (Fragment).
OS Polyomavirus BK (BKV).
OC Viruses: dsDNA viruses, no RNA stage; Polyomaviridae; Polyomavirus.
OX NCBI_TaxID=10629;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22379369; PubMed=12490781;
RA Li R.M., Mannon R.B., Kleiner D., Tsokos M., Bynum M., Kirk A.D.,
Kopp J.B.;
RT "BK virus and SV40 co-infection in polyomavirus nephropathy.";
RL Transplantation 74:1497-1504(2002).
DR EMBL: AF442897; AAL78922.1; -
DR GO: GO:0003677; F:DNA binding; IEA.
DR InterPro: IPR002643; Polyoma_agn.
DR Pfam: PF01736; Polyoma_agn; 1.
DR ProDom: PD004470; Polyoma_agn; 1.
FT NON_TER 21 21
SQ SEQUENCE 21 AA; 2375 MW; E5B8EBD9AE20D4E3 CRC64;

Query Match 51.3%; Score 20; DB 2; Length 21;
Best Local Similarity 50.0%; Pred. No. 5.3e+03;
Matches 4; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
Db :|||:
9 QASVKVGK 16

RESULT 29
Q8QYS6
ID Q8QYS6 PRELIMINARY; PRT; 21 AA.
AC Q8QYS6;
DT 01-JUN-2002 (TrEMBLrel. 21, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Agnoprotein (Fragment).
OS Polyomavirus BK (BKV).
OC Viruses: dsDNA viruses, no RNA stage; Polyomaviridae; Polyomavirus.
OX NCBI_TaxID=10629;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22379369; PubMed=12490781;
RA Li R.M., Mannon R.B., Kleiner D., Tsokos M., Bynum M., Kirk A.D.,
Kopp J.B.;
RT "BK virus and SV40 co-infection in polyomavirus nephropathy.";
RL Transplantation 74:1497-1504(2002).
DR EMBL: AF442896; AAL78922.1; -
DR GO: GO:0003677; F:DNA binding; IEA.
DR InterPro: IPR002643; Polyoma_agn.
DR Pfam: PF01736; Polyoma_agn; 1.
DR ProDom: PD004470; Polyoma_agn; 1.
FT NON_TER 21 21
SQ SEQUENCE 21 AA; 2347 MW; E7D57BD9AE20D4E3 CRC64;

Query Match 51.3%; Score 20; DB 2; Length 21;
Best Local Similarity 50.0%; Pred. No. 5.3e+03;
Matches 4; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
Db :|||:
9 QASVKVGK 16

RESULT 30
Q8QYS8
ID Q8QYS8 PRELIMINARY; PRT; 21 AA.
AC Q8QYS8;
DT 01-JUN-2002 (TrEMBLrel. 21, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Agnoprotein (Fragment).
OS Polyomavirus BK (BKV).


```
RL Submitted (MAR-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AL031659; CAC34516.1; -.
FT NON TER 12
SQ SEQUENCE 12 AA; 1422 MW; DC7FBF1578B2C9D2 CRC64;

Query Match
Best Local Similarity 48.7%; Score 19; DB 2; Length 12;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 FVTIG 6
Db |||
6 FVTI 9

RESULT 37
Q7S9F5 PRELIMINARY; PRT; 14 AA.
ID Q7S9F5
AC Q7S9F5
DT 01-MAR-2004 (TREMBlrel. 26, Created)
DT 01-MAR-2004 (TREMBlrel. 26, Last sequence update)
DT 01-MAR-2004 (TREMBlrel. 26, Last annotation update)
DE Predicted protein.
GN Name=NCU06392.1;
OS Neurospora crassa.
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Sordariomycetes;
OC Sordariomycetidae; Sordariales; Sordariaceae; Neurospora.
OX NCBI_TaxID=5141;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=OR74A;
RA Galagan J.E., Calvo S.E., Borkovich K.A., Selker E.U., Read N.D.,
RA Jaffe D., FitzHugh W., Ma L.-J., Smirnov S., Purcell S., Rehman B.,
RA Elkins T., Engels R., Wang S., Nielsen C.B., Butler J., Endrizzi M.,
RA Qui D., Ianakiev P., Pedersen D., Nelson M., Washburne M.,
RA Selitrennikoff C.P., Kinsey J.A., Braun E.L., Zeiter A., Schulte U.,
RA Kothe G.O., Jedd G., Mewes J., Staben C., Marcotte E., Greenberg D.,
RA Roy A., Foley K., Naylor J., Thomann N., Barrett R., Gnerre S.,
RA Kanal M., Kamyselis M., Mauceli E., Bielke C., Rudd S., Frishman D.,
RA Krystofova S., Rasmussen C., Metzenberg R.L., Perkins D.D., Kroken S.,
RA Cogoni C., Macino G., Catcheside D., Li W., Pratt R.J., Osmani S.A.,
RA DeSouza C.C., Glass L., Orbach M.J., Berglund J., Voelker R.,
RA Varden O., Plamann M., Seiler S., Dunlap J., Radford A., Aramayo R.,
RA Natvig D.O., Alex L.A., Manhaupt G., Ebbole D.J., Freitag M.,
RA Paulsen I., Sachs M.S., Lander E.S., Nusbaum C., Birren B.;
RT "The Genome Sequence of the Filamentous Fungus Neurospora crassa.";
RL Nature 0:0-0(2003)...
CC -!- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
DR EMBL; AABX01000214; EAA32994.1; -.
SQ SEQUENCE 14 AA; 1673 MW; 6865AE1F564FBD4 CRC64;

Query Match
Best Local Similarity 48.7%; Score 19; DB 2; Length 14;
Matches 4; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
Db |||
5 RRVAVGK 12

RESULT 38
Q9UCJ7 PRELIMINARY; PRT; 16 AA.
ID Q9UCJ7
AC Q9UCJ7
DT 01-MAY-2000 (TREMBlrel. 13, Created)
DT 01-MAY-2000 (TREMBlrel. 13, Last sequence update)
DT 01-JUN-2000 (TREMBlrel. 14, Last annotation update)
DE Tartrate-resistant acid phosphatase PEAK 2 isoform 23 kDa subunit
DE (fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

RL Submitted (MAR-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AL031659; CAC34516.1; -.
FT NON TER 12
SQ SEQUENCE 12 AA; 1422 MW; DC7FBF1578B2C9D2 CRC64;

Query Match
Best Local Similarity 48.7%; Score 19; DB 2; Length 12;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 FVTIG 6
Db |||
6 FVTI 9

RESULT 37
Q7S9F5 PRELIMINARY; PRT; 14 AA.
ID Q7S9F5
AC Q7S9F5
DT 01-MAR-2004 (TREMBlrel. 26, Created)
DT 01-MAR-2004 (TREMBlrel. 26, Last sequence update)
DT 01-MAR-2004 (TREMBlrel. 26, Last annotation update)
DE Predicted protein.
GN Name=NCU06392.1;
OS Neurospora crassa.
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Sordariomycetes;
OC Sordariomycetidae; Sordariales; Sordariaceae; Neurospora.
OX NCBI_TaxID=5141;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=OR74A;
RA Galagan J.E., Calvo S.E., Borkovich K.A., Selker E.U., Read N.D.,
RA Jaffe D., FitzHugh W., Ma L.-J., Smirnov S., Purcell S., Rehman B.,
RA Elkins T., Engels R., Wang S., Nielsen C.B., Butler J., Endrizzi M.,
RA Qui D., Ianakiev P., Pedersen D., Nelson M., Washburne M.,
RA Selitrennikoff C.P., Kinsey J.A., Braun E.L., Zeiter A., Schulte U.,
RA Kothe G.O., Jedd G., Mewes J., Staben C., Marcotte E., Greenberg D.,
RA Roy A., Foley K., Naylor J., Thomann N., Barrett R., Gnerre S.,
RA Kanal M., Kamyselis M., Mauceli E., Bielke C., Rudd S., Frishman D.,
RA Krystofova S., Rasmussen C., Metzenberg R.L., Perkins D.D., Kroken S.,
RA Cogoni C., Macino G., Catcheside D., Li W., Pratt R.J., Osmani S.A.,
RA DeSouza C.C., Glass L., Orbach M.J., Berglund J., Voelker R.,
RA Varden O., Plamann M., Seiler S., Dunlap J., Radford A., Aramayo R.,
RA Natvig D.O., Alex L.A., Manhaupt G., Ebbole D.J., Freitag M.,
RA Paulsen I., Sachs M.S., Lander E.S., Nusbaum C., Birren B.;
RT "The Genome Sequence of the Filamentous Fungus Neurospora crassa.";
RL Nature 0:0-0(2003)...
CC -!- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
DR EMBL; AABX01000214; EAA32994.1; -.
SQ SEQUENCE 14 AA; 1673 MW; 6865AE1F564FBD4 CRC64;

Query Match
Best Local Similarity 48.7%; Score 19; DB 2; Length 18;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 FVTI 6
Db |||
7 FVTI 10

RESULT 40
Q9PMQ4 PRELIMINARY; PRT; 20 AA.
ID Q9PMQ4
AC Q9PMQ4
DT 01-MAY-2000 (TREMBlrel. 13, Created)
DT 01-MAY-2000 (TREMBlrel. 13, Last sequence update)
DT 01-MAY-2000 (TREMBlrel. 23, Last annotation update)
DE Prolactin (fragment).
GN Name=prl;
OS Gallus gallus (Chicken).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC Gallus.
OX NCBI_TaxID=9031;
RN [1]
RP SEQUENCE FROM N.A.
RC MEDLINE=20078374; PubMed=10612250;
RA Miao Y., Burt D.W., Paton I.R., Sharp P.J., Dunn I.C.;
RT "Mapping of the prolactin gene to chicken chromosome 2.";
RL Anim. Genet. 30:473-473(1999).
DR EMBL; AJ239131; CAB43530.1; -.
HSSP; P01236; 1N9D.
```

FT NON_TER 1 1
 FT NON_TER 20 20
 SQ. SEQUENCE 20 AA; 2223 MW; 258CCCAA95F12D6 CRC64;

Query Match 48.7%; Score 19; DB 2; Length 20;
 Best Local Similarity 60.0%; Pred. No. 8e+03;
 Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 5
 Db 8 RGFIT 12

RESULT 41

Q8HS54 ID Q8HS54 PRELIMINARY; PRT; 21 AA.

AC Q8HS54
 DT 01-MAR-2003 (TrEMBLrel. 23, Created)
 DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 DE PdbH (Fragment).
 GN Name=psbh;
 OS Arabidopsis thaliana (Mouse-ear cress).
 OG Chloroplast.
 OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
 OC eurosids II; Brassicales; Brassicaceae; Arabidopsi.
 OX NCBI_TaxID=3702;
 RN [1]
 RP SEQUENCE FROM N.A.

RA Graham S.W., Reeves P.A., Burns A., Olmstead R.G.;
 RL Submitted (FEB-2000) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AY007458; AAG12346.1; -
 DR GO; GO:0009507; C:chloroplast; IEA.
 KW Chloroplast. 21 21

FT NON_TER 21 21
 SQ SEQUENCE 21 AA; 2195 MW; 88A9E60C91FF9544 CRC64;

Query Match 48.7%; Score 19; DB 2; Length 21;
 Best Local Similarity 75.0%; Pred. No. 9e+03;
 Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 5 TIGK 8
 Db 18 TVGK 21

RESULT 42

Q8QYS3 ID Q8QYS3 PRELIMINARY; PRT; 21 AA.

AC Q8QYS3
 DT 01-JUN-2002 (TrEMBLrel. 21, Created)
 DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE Agnoprotein (Fragment).
 OS Polyomavirus BK (BKV).
 OC Viruses; dsDNA viruses, no RNA stage; Polyomaviridae; Polyomavirus.
 OX NCBI_TaxID=10629;
 RN [1]
 RP SEQUENCE FROM N.A.

RA Li R.M., Mannon R.B., Kleiner D., Tsokos M., Bynum M., Kirk A.D.,
 RA Kopp J.B.;
 RL Transplantation 74:1497-1504(2002).
 DR EMBL; AF442903; AAL78925.1; -
 DR GO; GO:0003677; F:DNA binding; IEA.

DR InterPro; IPR002643; Polyoma_agn.
 DR Pfam; PF01736; Polyoma_agn; 1.
 DR ProDom; PD004470; Polyoma_agn; 1.
 FT NON_TER 21 21

SQ SEQUENCE 21 AA; 2361 MW; 65D57BD9AE20D4F6 CRC64;

Query Match 48.7%; Score 19; DB 2; Length 21;
 Best Local Similarity 50.0%; Pred. No. 9e+03;
 Matches 4; Conservative 2; Mismatches 0; Gaps 0;

QY 1 RAFVTIGK 8
 Db 9 QASVKLGK 16

RESULT 43

Q8QYS7 ID Q8QYS7 PRELIMINARY; PRT; 21 AA.

AC Q8QYS7
 DT 01-JUN-2002 (TrEMBLrel. 21, Created)
 DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE Agnoprotein (Fragment).
 OS Polyomavirus BK (BKV).
 OC Viruses; dsDNA viruses, no RNA stage; Polyomaviridae; Polyomavirus.
 OX NCBI_TaxID=10629;
 RN [1]
 RP SEQUENCE FROM N.A.

RA Li R.M., Mannon R.B., Kleiner D., Tsokos M., Bynum M., Kirk A.D.,
 RA Kopp J.B.;
 RL "BK virus and SV40 co-infection in polyomavirus nephropathy."
 RL Transplantation 74:1497-1504(2002).
 RN [2]
 RP SEQUENCE FROM N.A.

RA Li R.-M., Kopp J.B.;
 RL Submitted (NOV-2001) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AF442895; AAL78921.1; -
 DR GO; GO:0003677; F:DNA binding; IEA.
 DR InterPro; IPR002643; Polyoma_agn.
 DR Pfam; PF01736; Polyoma_agn; 1.
 DR ProDom; PD004470; Polyoma_agn; 1.
 FT NON_TER 21 21

SQ SEQUENCE 21 AA; 2361 MW; 65D57BD9AE20D4F6 CRC64;

Query Match 48.7%; Score 19; DB 2; Length 21;
 Best Local Similarity 50.0%; Pred. No. 9e+03;
 Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
 Db 9 QASVKLGK 16

RESULT 44

Q8QYS9 ID Q8QYS9 PRELIMINARY; PRT; 21 AA.

AC Q8QYS9
 DT 01-JUN-2002 (TrEMBLrel. 21, Created)
 DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE Agnoprotein (Fragment).
 OS Polyomavirus BK (BKV).
 OC Viruses; dsDNA viruses, no RNA stage; Polyomaviridae; Polyomavirus.
 OX NCBI_TaxID=10629;
 RN [1]
 RP SEQUENCE FROM N.A.

RA Li R.M., Mannon R.B., Kleiner D., Tsokos M., Bynum M., Kirk A.D.,
 RA Kopp J.B.;
 RL "BK virus and SV40 co-infection in polyomavirus nephropathy."
 RL Transplantation 74:1497-1504(2002).
 RN [2]
 RP SEQUENCE FROM N.A.

RA Li R.-M., Kopp J.B.;
 RL Submitted (NOV-2001) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AF442893; AAL78919.1; -
 DR GO; GO:0003677; F:DNA binding; IEA.
 DR InterPro; IPR002643; Polyoma_agn.

```

DR Pfam; PF01736; Polyoma_agno; 1.
DR ProDom; PD004470; Polyoma_agno; 1.
DR NON TER 21
SQ SEQUENCE 21 AA; 2361 MW; 65D57BD9AE20D4F6 CRC64;

Query Match 48.7%; Score 19; DB 2; Length 21;
Best Local Similarity 50.0%; Pred. No. 9e+03;
Matches 4; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
:| | :||
Db 9 QASVKLKG 16

RESULT 45
Q8QYTO PRELIMINARY; PRT; 21 AA.
ID Q8QYTO
AC Q8QYTO;
DT 01-JUN-2002 (TrEMBLrel. 21, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Agnoprotein (Fragment).
OS Polyomavirus BK (BKV).
OC Viruses; dsDNA viruses, no RNA stage; Polyomaviridae; Polyomavirus.
OX NCBITaxID=10629;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22379369; PubMed=12490781;
RA Li R.M., Mannon R.B., Kleiner D., Tsokos M., Bynum M., Kirk A.D.,
RA Kopp J.B.;
RT "BK virus and SV40 co-infection in polyomavirus nephropathy.";
RL Transplantation 74:1497-1504(2002).
RN [2]
RP SEQUENCE FROM N.A.
RX Li R.-M., Kopp J.B.;
RL Submitted (NOV-2001) to the EMBL/GenBank/DBSJ databases.
DR EMBL; AF442892; AAL78918.1; -.
DR GO; GO:0003677; F:DNA binding; IEA.
DR InterPro; IPR002643; Polyoma_agno.
DR Pfam; PF01736; Polyoma_agno; 1.
DR ProDom; PD004470; Polyoma_agno; 1.
DR NON TER 21
SQ SEQUENCE 21 AA; 2361 MW; 65D57BD9AE20D4F6 CRC64;

Query Match 48.7%; Score 19; DB 2; Length 21;
Best Local Similarity 50.0%; Pred. No. 9e+03;
Matches 4; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
:| | :||
Db 9 QASVKLKG 16

Search completed: May 16, 2005, 08:10:01
Job time : 170 secs

```

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 16, 2005, 07:55:20 ; Search time 37 Seconds
(without alignments)
20.804 Million cell updates/sec

Title: SEQ1

Perfect score: 39

Sequence: 1 rafvtgk 8

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 4989

Minimum DB seq length: 0

Maximum DB seq length: 25

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : PIR 79.*

1: pir1.*

2: pir2.*

3: pir3.*

4: pir4.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	36	92.3	20	2 S65399	immunodeficiency v
2	22	56.4	25	2 B44524	pregnancy-specific
3	19	48.7	10	2 D28027	protein P7 - curle
4	19	48.7	12	2 P20907	ig kappa-2 chain J
5	19	48.7	14	2 S11074	alcohol dehydrogen
6	19	48.7	22	2 B90996	probable transcrip
7	19	48.7	22	2 PT0052	translation initia
8	18	46.2	12	2 S11286	exo-alpha-sialidas
9	18	46.2	15	2 S21238	hydrogensulfite re
10	18	46.2	15	2 PA0106	protein QP200076 -
11	18	46.2	20	2 FL0145	carbon-monoxide de
12	18	46.2	21	2 A20359	translation elonga
13	18	46.2	23	2 S43289	cytochrome-c oxida
14	18	46.2	24	2 S47563	nucleoside-diphosp
15	18	46.2	24	2 PX0038	methemoglobin redu
16	17	43.6	10	2 C58501	48k bile/gallbladd
17	17	43.6	12	2 S10626	lipovitellin - Afr
18	17	43.6	13	2 S63492	dissimulatory sulf
19	17	43.6	14	2 PH1347	ig heavy chain DJ
20	17	43.6	14	2 PA0109	porin por 1B - Ara
21	17	43.6	14	2 PA0045	porin por1 - Arabi
22	17	43.6	15	2 S13973	chlorophyll a/b-bi
23	17	43.6	17	2 A46592	lactase-phlorizin
24	17	43.6	18	2 C56046	urinary tract ston
25	17	43.6	20	2 PL0161	hemagglutinin - In
26	17	43.6	20	2 S03505	T-cell receptor al
27	17	43.6	20	2 S05411	carboxylesterase (
28	17	43.6	20	2 B47642	T-cell surface gly
29	17	43.6	21	2 I49414	gene CTLA-1 protei

30	17	43.6	21	2 S47202	T-cell receptor J-
31	17	43.6	23	2 A47415	mannose-1-phosphat
32	17	43.6	24	2 T46622	hypothetical prote
33	17	43.6	24	2 S07699	T-cell receptor al
34	17	43.6	25	2 S65729	hemoglobin, extrac
35	16.5	42.3	21	2 S61410	pyruvate, phosphat
36	16	41.0	12	2 S65629	protoporphyrinogen
37	16	41.0	12	2 A60757	enterotoxin C-1 -
38	16	41.0	14	2 PN0151	omega-gliadine 2'
39	16	41.0	14	2 PN0147	omega-gliadine 1'
40	16	41.0	14	2 B61597	cytochrome P450 AL
41	16	41.0	16	2 JN0264	translation initia
42	16	41.0	16	2 D83865	hypothetical prote
43	16	41.0	16	2 T14224	NADH2 dehydrogenas
44	16	41.0	17	2 I78870	gene RB1 protein -
45	16	41.0	17	2 A37823	dihydrolipoamide S

ALIGNMENTS

RESULT 1

S65399
immunodeficiency virus type 1, HIV-1 gp120 - human (fragments)

C;Species: Homo sapiens (man)
C;Date: 28-Oct-1996 #sequence_revision 13-Mar-1997 #text_change 17-Mar-1999

C;Accession: S65399

R;Niwa, Y.; Yano, M.; Futaki, S.; Okumura, Y.; Kido, H.

Eur. J. Biochem. 237, 64-70, 1996

A;Title: T-cell membrane-associated serine protease, tryptase TL(2), binds human immunod

man immunodeficiency virus type 1 inhibit cleavage of gp120.

A;Reference number: S65399; PMID:96203909; PMID:8620895

A;Accession: S65399

A;Status: preliminary

A;Molecule type: protein

A;Residues: 1-10,11-20 <NIW>

C;Superfamily: type E retrovirus env polyprotein

Query Match 92.3%; Score 36; DB 2; Length 20;

Best Local Similarity 87.5%; Pred. No. 0.11;

Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTGK 8

Db 5 RAFVTGK 12

RESULT 2

B44524

pregnancy-specific glycoprotein SBU-3-62 - sheep (fragment)

C;Species: Ovis orientalis aries, Ovis ammon aries (domestic sheep)

C;Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 16-Aug-2004

C;Accession: B44524

R;Atkinson, Y.H.

submitted to the Protein Sequence Database, June 1993

A;Reference number: A44524

A;Accession: B44524

A;Status: preliminary

A;Molecule type: protein

A;Residues: 1-25 <ATK>

A;Cross-references: UNIPROT:Q9TREI

C;Superfamily: Pepsin

C;Keywords: glycoprotein

Query Match 56.4%; Score 22; DB 2; Length 25;

Best Local Similarity 57.1%; Pred. No. 2.6e+02;

Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1 RAFVTIG 7

Db 17 RGXITIG 23

RESULT 3

D28027
protein P7 - curled-leaved tobacco (fragment)
C:Species: Nicotiana glauca (curled-leaved tobacco)
C:Date: 19-May-1989 #sequence_revision 19-May-1989 #text_change 09-Jul-2004
C:Accession: D28027
R;Bauw, G.; De Loose, M.; Inze, D.; Van Montagu, M.; Vandekerckhove, J.
Proc. Natl. Acad. Sci. U.S.A. 84, 4806-4810, 1987
A:Title: Alterations in the phenotype of plant cells studied by NH2-terminal amino acid-
A:Reference number: A94167
A:Accession: D28027
A:Molecule type: protein
A:Residues: 1-10 <BAU>
A:Cross-references: UNIPROT:Q7M1V8

Query Match 48.7%; Score 19; DB 2; Length 10;
Best Local Similarity 66.7%; Pred. No. 5.3e+02;
Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RAFTVI 6
|:|:|
Db 4 RSFVPI 9

RESULT 4

F20907
Ig kappa-2 chain J5 chain - rabbit
C:Species: Oryctolagus cuniculus (domestic rabbit)
C:Date: 10-Aug-1990 #sequence_revision 10-Aug-1990 #text_change 05-Nov-1999
C:Accession: F20907
R;Emorine, L.; Max, E.E.
Nucleic Acids Res. 11, 8877-8890, 1983
A:Title: Structural analysis of a rabbit immunoglobulin kappa2 J-C locus reveals multiple
A:Reference number: A20907; MUID:84169523; PMID:6324107
A:Accession: F20907
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-12 <EMO>
A:Cross-references: GB:X00232; NID:gl1582; PIDN:CAA5055.1; PID:e8281; PID:gl364239
C:Keywords: heterotetramer; immunoglobulin

Query Match 48.7%; Score 19; DB 2; Length 12;
Best Local Similarity 60.0%; Pred. No. 6.3e+02;
Matches 3; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 4 VTIGK 8
|:|:|
Db 1 ITFGK 5

RESULT 5

S11074
alcohol dehydrogenase (EC 1.1.1.1) - Baltic cod (fragments)
C:Species: Gadus morhua callarias (Baltic cod)
C:Date: 30-Jun-1991 #sequence_revision 30-Jun-1991 #text_change 31-Jan-1997
C:Accession: S11074
R;Egestad, B.; Estonius, M.; Danielsson, O.; Persson, B.; Cederlund, E.; Kaiser, R.; Hol
FEBS Lett. 269, 194-196, 1990
A:Title: Fast atom bombardment mass spectrometry and chemical analysis in determinations
A:Reference number: S11074; MUID:90353571; PMID:2387402
A:Accession: S11074
A:Molecule type: protein
A:Residues: 1-5; 6-14 <EGE>
C:Keywords: acetylated amino end; alcohol metabolism; NAD; oxidoreductase
F:1/Modified site: acetylated amino end (Ala) #status experimental

Query Match 48.7%; Score 19; DB 2; Length 14;
Best Local Similarity 75.0%; Pred. No. 7.4e+02;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 5 TIGK 8
|:|:|
Db 2 TVGK 5

RESULT 6

B90996
probable transcription regulator [imported] - Escherichia coli (strain O157:H7, substrain
C:Species: Escherichia coli
C:Date: 18-Jul-2001 #sequence_revision 18-Jul-2001 #text_change 09-Jul-2004
C:Accession: B90996
R;Hayashi, T.; Makino, K.; Ohnishi, M.; Kurokawa, K.; Ishii, K.; Yokoyama, K.; Han, C.G.;
Gasawara, N.; Yasunaga, T.; Kuhara, S.; Shiba, T.; Hattori, M.; Shinagawa, H.
DNA Res. 8, 11-22, 2001
A:Title: Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and genom
A:Reference number: A99629; MUID:21156231; PMID:11258796
A:Accession: B90996
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-22 <HAY>
A:Cross-references: UNIPROT:Q8X365; GB:BA000007; PIDN:BA836361.1; PID:gl33362407; GSPDB:GN
A:Experimental source: strain O157:H7, substrain RIMD 0509952
C:Genetics:
A:Gene: ECA2938

Query Match 48.7%; Score 19; DB 2; Length 22;
Best Local Similarity 57.1%; Pred. No. 1.2e+03;
Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 2 AFVTIGK 8
|:|:|
Db 2 ALYTIGE 8

RESULT 7

PT0052
translation initiation factor eIF-2 gamma chain - pig (fragment)
C:Species: Sus scrofa domestica (domestic pig)
C:Date: 17-Jul-1992 #sequence_revision 17-Jul-1992 #text_change 09-Jul-2004
C:Accession: PT0052
R;Suzuki, H.; Mukoyama, E.B.
Agric. Biol. Chem. 52, 1397-1408, 1988
A:Title: Pig liver translational initiation factor eIF-2: N-terminal amino acid sequences
A:Reference number: PT0051
A:Accession: PT0052
A:Molecule type: protein
A:Residues: 1-22 <SUZ>
A:Cross-references: UNIPROT:P20461
A:Experimental source: liver
C:Keywords: protein biosynthesis

Query Match 48.7%; Score 19; DB 2; Length 22;
Best Local Similarity 57.1%; Pred. No. 1.2e+03;
Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 2 AFVTIGK 8
|:|:|
Db 5 AGVTILGQ 11

RESULT 8

S11286
exo-alpha-sialidase (EC 3.2.1.18) - influenza A virus (strain A/FPV/Rostock/34 [H7N1])
N:Alternate names: neuraminidase
C:Species: Influenza A virus
C:Date: 31-Dec-1990 #sequence_revision 31-Dec-1990 #text_change 22-Jun-1999
C:Accession: S11286
R;Robertson, J.S.
Nucleic Acids Res. 6, 3745-3757, 1979
A:Title: 5' and 3' terminal nucleotide sequences of the RNA genome segments of influenza
A:Reference number: S11286; MUID:80034428; PMID:493121
A:Accession: S11286
A:Molecule type: genomic RNA
A:Residues: 1-12 <ROB>
A:Cross-references: EMBL:J02114; NID:g324483; PIDN:AAA43398.1; PID:g324486
C:Genetics:

A;Map position: segment 6
C;Superfamily: influenza virus exo-alpha-sialidase
C;Keywords: glycosidase; hydrolase

Query Match 46.2%; Score 18; DB 2; Length 12;
Best Local Similarity 75.0%; Pred. No. 1.1e+03;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 4 VTIG 7
Db 8 ITIG 11

RESULT 9

S21238
hydrogensulfite reductase (EC 1.8.99.3) beta chain - Desulfovibrio vulgaris (fragment)
N;Alternate names: bisulfite reductase; desulfofusicidin; desulforubidin; desulfovibrin;
C;Species: Desulfovibrio vulgaris
C;Date: 19-Mar-1997 #sequence_revision 11-Jun-1999 #text_change 11-Jun-1999
C;Accession: S21238
R;Pierik, A.J.; Duyvis, M.G.; van Helvoort, J.M.L.M.; Wolbert, R.B.G.; Hagen, W.R.
Eur. J. Biochem. 205, 111-115, 1992
A;Title: The third subunit of desulfovibrin-type dissimilatory sulfite reductases.
A;Reference number: S21197; MUID:92209491; PMID:1555572

A;Accession: S21238

A;Molecule type: protein

A;Residues: 1-15 <PIE>

A;Experimental source: strain Hildenborough

C;Genetics:

A;Gene: dsbB

C;Complex: heterohexamer; two alpha, two beta and two gamma chains

C;Function:

A;Description: catalyzes the six-electron reduction of sulfite to sulfide

A;Pathway: the terminal oxidase in the sulfate-reduction pathway

C;Keywords: heterohexamer; oxidoreductase

Query Match 46.2%; Score 18; DB 2; Length 15;
Best Local Similarity 50.0%; Pred. No. 1.4e+03;
Matches 3; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 2 AFVTIG 7
Db 1 AFISG 6

RESULT 10

PA0106

protein QP200076 - fungus (Fusarium sporotrichioides) (fragment)

C;Species: Fusarium sporotrichioides

C;Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 09-Jul-2004

C;Accession: PA0106

R;Chow, L.P.; Fukaya, N.; Sugiyura, Y.; Ueno, Y.; Tabuchi, K.; Taugita, A.

submitted to JIPID, October 1994

A;Description: Two dimensional polyacrylamide gel electrophoresis of Fusarium sporotrichi

A;Reference number: PA0051

A;Accession: PA0106

A;Molecule type: protein

A;Residues: 1-15 <CHO>

A;Cross-references: UNIPROT:Q7M4Y1

Query Match 46.2%; Score 18; DB 2; Length 15;
Best Local Similarity 50.0%; Pred. No. 1.4e+03;
Matches 3; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 2 AFVTIG 7
Db 4 AILTIG 9

RESULT 11

PL0145

carbon-monoxide dehydrogenase (EC 1.2.99.2) small chain - Pseudomonas carboxydoflava (fr

C;Species: Pseudomonas carboxydoflava

C;Date: 07-Sep-1990 #sequence_revision 07-Sep-1990 #text_change 28-Apr-1993
C;Accession: PL0145
R;Kraut, M.; Hugendieck, I.; Herwig, S.; Meyer, O.
Arch. Microbiol. 152, 335-341, 1989

A;Title: Homology and distribution of CO dehydrogenase structural genes in carboxydofl

A;Reference number: PL0138; MUID:90055678; PMID:2818128

A;Accession: PL0145

A;Molecule type: protein

A;Residues: 1-20 <KRA>

C;Comment: Carbon-monoxide dehydrogenase consists of three polypeptide chains: large, me

C;Keywords: oxidoreductase

Query Match 46.2%; Score 18; DB 2; Length 20;
Best Local Similarity 60.0%; Pred. No. 1.8e+03;
Matches 3; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 4 VTIGK 8
Db 8 VNVGK 12

RESULT 12

A20359

translation elongation factor EF-Tu, mitochondrial - rabbit (fragment)

C;Species: Oryctolagus cuniculus (domestic rabbit)

C;Date: 05-Jun-1987 #sequence_revision 05-Jun-1987 #text_change 09-Jul-2004

C;Accession: A20359

R;Slobin, L.I.; Clark, R.V.; Olson, M.O.J.

Biochemistry 22, 1911-1917, 1983

A;Title: Limited cleavage of eucaryotic elongation factor Tu by trypsin: alignment of th

A;Reference number: A20359; MUID:83204805; PMID:6682677

A;Accession: A20359

A;Molecule type: protein

A;Residues: 1-21 <SLQ>

A;Cross-references: UNIPROT:Q7M2K3

A;Note: residue 19 has also been sequenced as Lys

C;Keywords: mitochondrion; protein biosynthesis

Query Match 46.2%; Score 18; DB 2; Length 21;
Best Local Similarity 75.0%; Pred. No. 1.9e+03;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 4 VTIG 7
Db 16 ITIG 19

RESULT 13

S43289

cytochrome-c oxidase (EC 1.9.3.1) chain III - Blastocrithidia culicis mitochondrion (fra

C;Species: mitochondrion Blastocrithidia culicis

C;Date: 19-Mar-1997 #sequence_revision 01-May-1998 #text_change 09-Jul-2004

C;Accession: S43289

R;Maslov, D.A.; Avila, H.A.; Lake, J.A.; Simpson, L.

Nature 368, 345-348, 1994

A;Title: Evolution of RNA editing in kinetoplastid protozoa.

A;Reference number: S43286; MUID:94173338; PMID:8127370

A;Accession: S43289

A;Molecule type: mRNA

A;Residues: 1-23 <MAS>

A;Cross-references: UNIPROT:Q33549

A;Experimental source: ATCC30268

C;Genetics:

A;Gene: COIII

A;Genome: mitochondrion

A;Genetic code: SGC6

C;Superfamily: cytochrome-c oxidase chain III

C;Keywords: electron transfer; membrane-associated complex; mitochondrion inner membrane
in

Query Match 46.2%; Score 18; DB 2; Length 23;
Best Local Similarity 75.0%; Pred. No. 2.1e+03;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 4 VTIG 7
:|:|
Db 7 ITIG 10

RESULT 14
S47563
nucleoside-diphosphate kinase (EC 2.7.4.6) - oat (fragment)
C:Species: Avena sativa (oat)
C>Date: 07-May-1995 #sequence_revision 24-Oct-1997 #text_change 09-Jul-2004
C:Accession: S47563
R;Sommer, D.; Song, P.S.
Biochim. Biophys. Acta 1222, 464-470, 1994
A>Title: A plant nucleoside diphosphate kinase homologous to the human Nm23 gene product
A:Reference number: S47563; MUID:94312444; PMID:8038216
A:Accession: S47563
A>Status: preliminary
A:Molecule type: protein
A:Residues: 1-24 <SOW>
A:Cross-references: UNIPROT:Q988M2
C:Superfamily: nucleoside diphosphate kinase
C:Keywords: phosphotransferase; pyrimidine nucleotide biosynthesis

Query Match 46.2%; Score 18; DB 2; Length 24;
Best Local Similarity 50.0%; Pred. No. 2.2e+03;
Matches 3; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1 RAFVTI 6
|:|:|
Db 5 RTFIAI 10

RESULT 15
PX0038
methemoglobin reductase (NADPH) (EC 1.6.2.-) - bullfrog (fragment)
C:Species: Rana catesbeiana (bullfrog)
C>Date: 17-Jul-1992 #sequence_revision 17-Jul-1992 #text_change 09-Jul-2004
C:Accession: PX0038
R;Abe, Y.; Ito, T.; Okazaki, T.
J. Biochem. 108, 255-260, 1990
A>Title: Purification and characterization of NADPH-dependent methemoglobin reductase fr
A:Reference number: PX0038; MUID:91035356; PMID:2172227
A:Accession: PX0038
A:Molecule type: protein
A:Residues: 1-24 <AB>
A:Cross-references: UNIPROT:P55736
A:Experimental source: nucleated erythrocyte
C:Keywords: NADP; oxidoreductase

Query Match 46.2%; Score 18; DB 2; Length 24;
Best Local Similarity 60.0%; Pred. No. 2.2e+03;
Matches 3; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 4 VTIGK 8
|:|:|
Db 17 VTIGQ 21

RESULT 16
G58501
48K bile/gallbladder stone protein - unidentified bacterium (fragment)
C:Species: unidentified bacterium
C>Date: 07-Feb-1997 #sequence_revision 07-Feb-1997 #text_change 09-Jul-2004
C:Accession: G58501
R;Binette, J.P.; Binette, M.B.
submitted to the Protein Sequence Database, October 1996
A:Description: The proteins of kidney and gallbladder stones.
A:Reference number: A58501
A:Accession: G58501
A>Status: preliminary
A:Molecule type: protein
A:Residues: 1-10 <BIN>

A;Cross-references: UNIPROT:Q7M1C8
A;Experimental source: human bile and gallbladder stones
A;Note: 1-Ser and 4-Glu were also found

Query Match 43.6%; Score 17; DB 2; Length 10;
Best Local Similarity 66.7%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3 FVTIGK 8
|:|:|
Db 3 FVEDGK 8

RESULT 17
S10626
lipovitellin - African clawed frog
C:Species: Xenopus laevis (African clawed frog)
C>Date: 18-Feb-1994 #sequence_revision 10-Nov-1995 #text_change 10-Nov-1995
C:Accession: S10626
R;Wallace, R.A.; Hoch, K.L.; Carnevali, O.
J. Mol. Biol. 213, 407-409, 1990
A>Title: Placement of small lipovitellin subunits within the vitellogenin precursor in X
A:Reference number: S10624; MUID:90278951; PMID:2352275
A:Accession: S10626
A:Molecule type: protein
A:Residues: 1-12 <WAL>

Query Match 43.6%; Score 17; DB 2; Length 12;
Best Local Similarity 62.5%; Pred. No. 1.9e+03;
Matches 5; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
|:|:|
Db 4 RAARTGK 11

RESULT 18
S63492
disimilatory sulfite reductase beta chain, soluble - Desulfovibrio desulfuricans (fragm
C:Species: Desulfovibrio desulfuricans
C>Date: 28-Oct-1996 #sequence_revision 13-Mar-1997 #text_change 17-Mar-1999
C:Accession: S63492
R;Steuber, J.; Arendsen, A.F.; Hagen, W.R.; Kroneck, P.M.H.
Eur. J. Biochem. 233, 873-879, 1995
A>Title: Molecular properties of the dissimilatory sulfite reductase from Desulfovibrio
A:Reference number: S63489; MUID:96085152; PMID:8521853
A:Accession: S63492
A>Status: preliminary
A:Molecule type: protein
A:Residues: 1-13 <STE>

Query Match 43.6%; Score 17; DB 2; Length 13;
Best Local Similarity 50.0%; Pred. No. 2e+03;
Matches 3; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2 AFVTIG 7
|:|:|
Db 1 AFIPTG 6

RESULT 19
PHI347
IG heavy chain DJ region (clone C100-103A) - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 07-May-1999
C:Accession: PHI347
R;Wasserman, R.; Galili, N.; Ito, Y.; Reichard, B.A.; Shane, S.; Rovera, G.
J. Exp. Med. 176, 1577-1581, 1992
A>Title: Predominance of fetal type DJH joining in young children with B precursor lymph
A:Reference number: PHI302; MUID:93094761; PMID:1460419
A:Accession: PHI347
A:Molecule type: DNA
A:Residues: 1-14 <WAS>

C;Keywords: heterotetramer; immunoglobulin

Query Match 43.6%; Score 17; DB 2; Length 14;
Best Local Similarity 60.0%; Pred. No. 2.2e+03;
Matches 3; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 3 FVTIG 7
|:|
Db 6 FLTTG 10

RESULT 20

PA0109

porin por 1B - Arabidopsis thaliana (fragment)
C;Species: Arabidopsis thaliana (mouse-ear cress)
C;Date: 07-Apr-1995 #sequence_revision 26-May-1995 #text_change 09-Jul-2004
C;Accession: PA0109
R;Kamo, M.; Kawakami, T.; Taugita, A.
submitted to JIPID, March 1995
A;Reference number: PA0109
A;Accession: PA0109
A;Molecule type: protein
A;Residues: 1-14 <KAM>
A;Cross-references: UNIPROT:Q8LA84; UNIPROT:Q42292
A;Experimental source: root

Query Match 43.6%; Score 17; DB 2; Length 14;
Best Local Similarity 50.0%; Pred. No. 2.2e+03;
Matches 3; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 3 FVTIGK 8
|:|
Db 7 YTEIGK 12

RESULT 21

PA0045

porin por1 - Arabidopsis thaliana (fragment)
C;Species: Arabidopsis thaliana (mouse-ear cress)
C;Date: 30-Jun-1992 #sequence_revision 06-Jan-1995 #text_change 09-Jul-2004
C;Accession: PA0045
R;Kamo, M.; Kawakami, T.; Miyatake, N.; Taugita, A.
submitted to JIPID, July 1994
A;Description: Separation and characterization of Arabidopsis proteins by two-dimensional electrophoresis
A;Reference number: PA0001
A;Accession: PA0045
A;Molecule type: protein
A;Residues: 1-14 <KAM>
A;Cross-references: UNIPROT:Q7M1W9
A;Experimental source: root

Query Match 43.6%; Score 17; DB 2; Length 14;
Best Local Similarity 50.0%; Pred. No. 2.2e+03;
Matches 3; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 3 FVTIGK 8
|:|
Db 7 YTEIGK 12

RESULT 22

SL13973

chlorophyll a/b-binding protein type II - garden pea (fragment)
C;Species: Pisum sativum (garden pea)
C;Date: 19-Mar-1997 #sequence_revision 24-Mar-1999 #text_change 24-Mar-1999
C;Accession: SL13973
R;Jahn, P.; Junge, W.
Eur. J. Biochem. 193, 731-736, 1990
A;Title: Dicyclohexylcarbodiimide-binding proteins related to the short circuit of the photosynthetic electron transport chain
A;Reference number: SL13973
A;Accession: SL13973
A;Molecule type: protein
A;Residues: 1-15 <JAH>

C;Genetics:

A;Genome: nuclear
C;Keywords: chlorophyll; chloroplast; light-harvesting complex; thylakoid; transmembrane
Query Match 43.6%; Score 17; DB 2; Length 15;
Best Local Similarity 60.0%; Pred. No. 2.3e+03;
Matches 3; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 3 FVTIG 7
|:|
Db 6 FTSIG 10

RESULT 23

A46592

lactase-phlorizin hydrolase, 200K isoform - rat (fragment)
C;Species: Rattus norvegicus (Norway rat)
C;Date: 16-Feb-1994 #sequence_revision 18-Nov-1994 #text_change 01-Nov-1996
C;Accession: A46592
R;Dudley, M.A.; Hachey, D.L.; Quaroni, A.; Hutchens, T.W.; Nichols, B.L.; Rosenberger, J.
J. Biol. Chem. 268, 13609-13616, 1993
A;Title: In vivo sucrose-isomaltase and lactase-phlorizin hydrolase turnover in the fed rat
A;Reference number: A46592; MUID:93293888; PMID:8514793
A;Accession: A46592
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-17 <DUD>
A;Note: sequence extracted from NCBI backbone (NCBIP:134559)
C;Keywords: carbohydrate digestion; intestine

Query Match 43.6%; Score 17; DB 2; Length 17;
Best Local Similarity 42.9%; Pred. No. 2.6e+03;
Matches 3; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 RPFVTIG 7
|:|
Db 5 RNFIAG 11

RESULT 24

C56046

urinary tract stone matrix protein 5, 32K - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 12-Apr-1995 #sequence_revision 12-Apr-1995 #text_change 09-Jul-2004
C;Accession: C56046
R;Binette, J.P.; Binette, M.B.; Gawinowicz, M.A.; Kendrick, N.
submitted to the Protein Sequence Database, February 1995
A;Description: Isolation, characterization and sequence of stone proteins.
A;Reference number: A56046
A;Accession: C56046
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-18 <BIN>
A;Cross-references: UNIPROT:Q7M4Q7

Query Match 43.6%; Score 17; DB 2; Length 18;
Best Local Similarity 28.6%; Pred. No. 2.8e+03;
Matches 2; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1 RPFVTIG 7
|:|
Db 9 RTYAAVG 15

RESULT 25

PL0161

hemagglutinin - Influenza H2N2 (fragment)
C;Species: influenza H2N2
C;Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 09-Jul-2004
C;Accession: PL0161
R;Sweetser, M.T.; Braciare, V.L.; Braciare, T.J.
J. Exp. Med. 170, 1357-1368, 1989
A;Title: Class I major histocompatibility complex-restricted T lymphocyte recognition of

A;Reference number: PL0161; MUID:90010790; PMID:2477491

A;Accession: PL0161

A;Molecule type: mRNA

A;Residues: 1-20 <SWB>

A;Cross-references: UNIPROT:Q7LZU6

A;Experimental source: strain A/JAP/305/57

C;Comment: This protein plays a major role in initiation of infection and in the pathogenesis of influenza virus hemagglutinin

C;Superfamily: Influenza virus hemagglutinin

C;Keywords: hemagglutinin

F;1-20/Region: immunodominant site recognized by T-lymphocytes

Query Match 43.6%; Score 17; DB 2; Length 20;

Best Local Similarity 40.0%; Pred. No. 3.1e+03;

Matches 2; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 3 FVTIG 7

Db 10 YVSVG 14

RESULT 26

S03505

T-cell receptor alpha chain J region (80) - mouse (fragment)

C;Species: Mus musculus (house mouse)

C;Date: 28-Feb-1990 #sequence_revision 28-Feb-1990 #text_change 30-May-1997

C;Accession: S03505

R;Winoto, A.; Mjolsness, S.; Hood, L.

Nature 316, 832-836, 1985

A;Title: Genomic organization of the genes encoding mouse T-cell receptor alpha-chain.

A;Reference number: S03503; MUID:85296332; PMID:2993908

A;Accession: S03505

A;Molecule type: DNA

A;Residues: 1-20 <WTN>

A;Cross-references: EMBL:X02859

A;Note: this sequence was determined from the germline gene

C;Keywords: T-cell receptor

Query Match 43.6%; Score 17; DB 2; Length 20;

Best Local Similarity 60.0%; Pred. No. 3.1e+03;

Matches 3; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 4 VTIGK 8

Db 8 LTFGK 12

RESULT 27

S05411

carboxylesterase (EC 3.1.1.1) - Sulfolobus acidocaldarius (fragment)

N;Alternate names: serine esterase

C;Species: Sulfolobus acidocaldarius

C;Date: 07-Sep-1990 #sequence_revision 07-Sep-1990 #text_change 09-Jul-2004

C;Accession: S05411

R;Sobek, H.; Goerlich, H.

Biochem. J. 261, 993-998, 1989

A;Title: Further kinetic and molecular characterization of an extremely heat-stable carb

A;Reference number: S05411; MUID:90026296; PMID:2508625

A;Accession: S05411

A;Molecule type: protein

A;Residues: 1-20 <SOB>

A;Cross-references: UNIPROT:Q7M529

A;Note: 1-Ala and 1-Ser were also found

C;Keywords: carboxylic ester hydrolase; tetramer

Query Match 43.6%; Score 17; DB 2; Length 20;

Best Local Similarity 60.0%; Pred. No. 3.1e+03;

Matches 3; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 4 VTIGK 8

Db 16 IPIGK 20

RESULT 28

B47642

T-cell surface glycoprotein CD4 - sheep (fragment)

C;Species: Ovis orientalis aries, Ovis ammon aries (domestic sheep)

C;Date: 31-Dec-1993 #sequence_revision 31-Dec-1993 #text_change 09-Jul-2004

C;Accession: B47642

R;Classon, B.J.; Tsagaratos, J.; Kirszbaum, L.; Maddox, J.; Mackay, C.R.; Brandon, M.; M

Immunogenetics 23, 129-132, 1986

A;Title: The L3T4 antigen in mouse and the sheep equivalent are immunoglobulin-like.

A;Reference number: A47642; MUID:86166694; PMID:3082751

A;Accession: B47642

A;Status: preliminary

A;Molecule type: protein

A;Residues: 1-20 <CLA>

A;Cross-references: UNIPROT:P05542

C;Keywords: glycoprotein

Query Match 43.6%; Score 17; DB 2; Length 20;

Best Local Similarity 60.0%; Pred. No. 3.1e+03;

Matches 3; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 4 VTIGK 8

Db 3 VVIGK 7

RESULT 29

I49414

Gene CTLA-1 protein - western wild mouse (fragment)

C;Species: Mus spretus (western wild mouse)

C;Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 09-Jul-2004

C;Accession: I49414

R;Ko, M.S.; Wang, X.; Horton, J.H.; Hagen, M.D.; Takahashi, N.; Maezaki, Y.; Nadeau, J.H

Mamm. Genome 5, 349-355, 1994

A;Title: Genetic mapping of 40 cDNA clones on the mouse genome by PCR.

A;Reference number: I49414; MUID:94319082; PMID:8043949

A;Accession: I49414

A;Status: preliminary; translated from GB/EMBL/DDBJ

A;Molecule type: DNA

A;Residues: 1-21 <RES>

A;Cross-references: UNIPROT:Q62538; EMBL:U05708; MID:g497037; PIDN:AAB60471.1; PID:g49703

C;Genetics:

A;Gene: CTLA-1

C;Superfamily: trypsin; trypsin homology

Query Match 43.6%; Score 17; DB 2; Length 21;

Best Local Similarity 50.0%; Pred. No. 3.2e+03;

Matches 3; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1 RAFVTI 6

Db 2 RAFTKV 7

RESULT 30

S47202

T-cell receptor J-alpha wN1.1 - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 06-Feb-1995 #sequence_revision 06-Feb-1995 #text_change 23-Jul-1999

C;Accession: S47202

R;Piazza, A.; Kono, D.H.; Theofilopoulos, A.N.

submitted to the EMBL Data Library, February 1993

A;Reference number: S40133

A;Accession: S47202

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-21 <PLA>

A;Cross-references: EMBL:X71039; MID:g506908; PIDN:CAA50356.1; PID:g510654

C;Superfamily: immunoglobulin V region; immunoglobulin homology

C;Keywords: T-cell receptor

Query Match 43.6%; Score 17; DB 2; Length 21;

Best Local Similarity 60.0%; Pred. No. 3.2e+03;

Matches 3; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 4 VTIGK 8
: |||
Db 9 LTFGK 13

RESULT 31
A47415
mannose-1-phosphate guanylyltransferase (EC 2.7.7.13) 37K beta chain - pig (fragment)
N;Alternate names: GDP-mannose pyrophosphorylase 37K beta chain
C;Species: Sus scrofa domestica (domestic pig)
C;Date: 25-Feb-1994 #sequence_revision 12-Aug-1996 #text_change 09-Jul-2004
C;Accession: A47415
R;Sumiilo, T.; Drake, R.R.; York, J.L.; Elbein, A.D.
J. Biol. Chem. 268, 17943-17950, 1993
A;Title: GDP-mannose pyrophosphorylase. Purification to homogeneity, properties, and utilization
A;Reference number: A47415; MUID:93352609; PMID:7688733
A;Contents: liver
A;Accession: A47415
A;Molecule type: protein
A;Residues: 1-23 <SZU>
A;Cross-references: UNIPROT:Q9TRF4
A;Note: sequence extracted from NCBI backbone (NCBIP:136438)
C;Complex: The enzyme appears to be a heterodimer of alpha and beta chains.
C;Function:
A;Description: generates GDP-mannose and pyrophosphate from mannose-1-phosphate and GTP
A;Note: also catalyzes synthesis of GDP-glucose from glucose-1-phosphate (EC 2.7.7.34 and
C;Superfamily: mannose-1-phosphate guanylyltransferase
C;Keywords: nucleotidyltransferase

Query Match 43.6%; Score 17; DB 2; Length 23;
Best Local Similarity 28.6%; Pred. No. 3.5e+03;
Matches 2; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1 RAFVTIG 7
: |||
Db 2 KALILVG 8

RESULT 32
T46622
hypothetical protein c1 - loblolly pine
C;Species: Pinus taeda (loblolly pine)
C;Date: 18-Feb-2000 #sequence_revision 18-Feb-2000 #text_change 18-Feb-2000
C;Accession: T46622
R;Chang, S.; Puryea, J.; Funkhouser, E.A.; Newton, R.J.; Cairney, J.
submitted to the EMBL Data Library, July 1995
A;Description: Cloning of a chitinase homolog which lacks chitin binding sites and is do
A;Reference number: 223105
A;Accession: T46622
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: mRNA
A;Residues: 1-24 <CHA>
A;Cross-references: EMBL:U31309; NID:9974285; PID:9974287
A;Experimental source: strain s6p2xs6pT3; 8 month seedlings

Query Match 43.6%; Score 17; DB 2; Length 24;
Best Local Similarity 57.1%; Pred. No. 3.7e+03;
Matches 4; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1 RAFVTIG 7
: |||
Db 7 RAFTCQG 13

RESULT 33
S07699
T-cell receptor alpha chain J segment (DT) - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 29-Jan-1993 #sequence_revision 29-Jan-1993 #text_change 05-Nov-1999
C;Accession: S07699
R;Yague, J.; Blackman, M.; Born, W.; Marrack, P.; Kappler, J.; Palmer, E.

Nucleic Acids Res. 16, 11355-11364, 1988
A;Title: The structure of V-alpha and J-alpha segments in the mouse.
A;Reference number: S06466; MUID:89083566; PMID:2849763
A;Accession: S07699
A;Molecule type: mRNA
A;Residues: 1-24 <YAG>
A;Cross-references: EMBL:M38675; NID:g201207; PIDN:AAA40193.1; PID:g201208
A;Experimental source: strain Balb/c
C;Genetics:
A;Map position: 14
C;Keywords: glycoprotein; heterodimer; T-cell receptor
F;1-22/Domain: J segment <JSE>
F;23-24/Domain: C region (fragment) <CRE>

Query Match 43.6%; Score 17; DB 2; Length 24;
Best Local Similarity 60.0%; Pred. No. 3.7e+03;
Matches 3; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 4 VTIGK 8
: |||
Db 10 LTFGK 14

RESULT 34
S65729
hemoglobin, extracellular, chain d2 - earthworm (Lumbricus terrestris) (fragment)
C;Species: Lumbricus terrestris (common earthworm)
C;Date: 06-Dec-1996 #sequence_revision 13-Mar-1997 #text_change 09-Jul-2004
C;Accession: S65729
R;Fushitani, K.; Higashiyama, K.; Asao, M.; Hosokawa, K.
Biochim. Biophys. Acta 1292, 273-280, 1996
A;Title: Characterization of the constituent polypeptides of the extracellular hemoglobin
A;Reference number: S65721; MUID:96176855; PMID:8597573
A;Accession: S65729
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-25 <FUS>
A;Cross-references: UNIPROT:Q9TWE4
C;Keywords: oxygen carrier

Query Match 43.6%; Score 17; DB 2; Length 25;
Best Local Similarity 80.0%; Pred. No. 3.9e+03;
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RAFVT 5
: |||
Db 16 RAFTG 20

RESULT 35
S61410
pyruvate, phosphate dikinase (EC 2.7.9.1), cytosolic - Flaveria trinervia (fragment)
C;Species: Flaveria trinervia
C;Date: 27-Apr-1996 #sequence_revision 13-Mar-1997 #text_change 09-Jul-2004
C;Accession: S61410
R;Rosche, E.; Westhoff, P.
Plant Mol. Biol. 29, 663-678, 1995
A;Title: Genomic structure and expression of the pyruvate, orthophosphate dikinase gene
A;Reference number: S61409; MUID:96128009; PMID:8541493
A;Accession: S61410
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-21 <ROS>
A;Cross-references: UNIPROT:Q42739; EMBL:X79095
A;Note: it is uncertain whether Met-1 or Met-18 is the initiator
C;Superfamily: pyruvate, phosphate dikinase
C;Keywords: transferase

Query Match 42.3%; Score 16.5; DB 2; Length 21;
Best Local Similarity 62.5%; Pred. No. 4.2e+03;
Matches 5; Conservative 0; Mismatches 2; Indels 1; Gaps 1;

Qy 1 RAFVTIG 8

Db 3 RVF-TFGK 9

RESULT 36
S65629
protoporphyrinogen oxidase (EC 1.3.3.4) - bovine (fragment)
C:Species: Bos primigenius taurus (cattle)
C:Date: 14-Feb-1997 #sequence_revision 13-Mar-1997 #text_change 26-May-2000
C:Accession: S65629
R:Takekani, S.; Yoshinaga, T.; Furukawa, R.; Kohno, H.; Tokunaga, K.; Ino, J. Biochem. 230, 760-765, 1995
A:Title: Induction of terminal enzymes for heme biosynthesis during differentiation of erythrocytes
A:Reference number: S65629; MUID:95331315; PMID:7607249
A:Accession: S65629
A:Molecule type: protein
A:Residues: 1-12 <TAK>
C:Genetics:
A:Genome: nuclear
C:Function:
A:Pathway: heme biosynthesis; porphyrin biosynthesis
C:Superfamily: phytoene dehydrogenase
C:Keywords: heme biosynthesis; mitochondrion; oxidoreductase; porphyrin biosynthesis

Query Match 41.0%; Score 16; DB 2; Length 12;
Best Local Similarity 42.9%; Pred. No. 3.2e+03;
Matches 3; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 1 RAFVTIG 7
| | | | |
Db 2 RTVVVLG 8

RESULT 37
A60757
enterotoxin C-1 - Staphylococcus aureus (fragments)
C:Species: Staphylococcus aureus
C:Date: 14-May-1993 #sequence_revision 14-May-1993 #text_change 30-Sep-1993
C:Accession: A60757
R:Bonach, G.A.; Handley, J.P.; Schlievert, P.M. Infect. Immun. 57, 23-28, 1989
A:Title: Biological and immunological properties of the carboxyl terminus of staphylococcal enterotoxin C-1
A:Reference number: A60757; MUID:89079292; PMID:2909489
A:Accession: A60757
A>Status: preliminary
A:Molecule type: protein
A:Residues: 1-12 <BOH>

Query Match 41.0%; Score 16; DB 2; Length 12;
Best Local Similarity 80.0%; Pred. No. 3.2e+03;
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 4 VTIGK 8
| | | |
Db 7 VTGGK 11

RESULT 38
PN0151
omega-gliadine 2' - Aegilops longissima (fragment)
C:Species: Aegilops longissima
C:Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 07-May-1999
C:Accession: PN0151
R:Odintsova, T.I.; Egorov, T.A. Biochimica 55, 509-516, 1990
A:Title: N-terminal sequences of omega-gliadins of Aegilops longissima: On the origin of wheat gliadins
A:Reference number: PN0146; MUID:90283493; PMID:2354218
A:Accession: PN0151
A:Molecule type: protein
A:Residues: 1-14 <ODI>
A:Experimental source: strain K-907

Query Match 41.0%; Score 16; DB 2; Length 14;
Best Local Similarity 80.0%; Pred. No. 3.2e+03;
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Best Local Similarity 50.0%; Pred. No. 3.7e+03;
Matches 4; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1 RAFVTIGK 8
| | | | |
Db 2 RQISPIGK 9

RESULT 39
PN0147
omega-gliadine 1 and 2 - Aegilops longissima (fragment)
C:Species: Aegilops longissima
C:Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 09-Jul-2004
C:Accession: PN0147; PN0146
R:Odintsova, T.I.; Egorov, T.A. Biochimica 55, 509-516, 1990
A:Title: N-terminal sequences of omega-gliadins of Aegilops longissima: On the origin of wheat gliadins
A:Reference number: PN0146; MUID:90283493; PMID:2354218
A:Accession: PN0147
A:Molecule type: protein
A:Residues: 1-14 <ODI>
A:Cross-references: UNIPROT:O7M1V5
A:Experimental source: strain K-202
A:Note: omega-gliadine 2 (amino-terminal fragment)
A:Accession: PN0146
A:Molecule type: protein
A:Residues: 1-9 <OD2>
A:Experimental source: strain K-202
A:Note: omega-gliadine 1 (amino-terminal fragment)

Query Match 41.0%; Score 16; DB 2; Length 14;
Best Local Similarity 50.0%; Pred. No. 3.7e+03;
Matches 4; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1 RAFVTIGK 8
| | | | |
Db 2 RQLSPIGK 9

RESULT 40
B61597
cytochrome P450 AL-2 - rat (fragment)
C:Species: Rattus norvegicus (Norway rat)
C:Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 09-Jul-2004
C:Accession: B61597
R:Shimeno, H.; Toda, A.; Ogata, S.; Nagamatsu, A. Drug Metab. Dispos. 19, 291-297, 1991
A:Title: Purification and aminopyrine monooxygenase activity of liver microsomal cytochrome P450 AL-2
A:Reference number: A61597; MUID:91292910; PMID:1676625
A:Accession: B61597
A>Status: preliminary
A:Molecule type: protein
A:Residues: 1-14 <SHI>
A:Cross-references: UNIPROT:Q7M047

Query Match 41.0%; Score 16; DB 2; Length 14;
Best Local Similarity 33.3%; Pred. No. 3.7e+03;
Matches 2; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 2 AFVTIG 7
| | | |
Db 8 SFLVLG 13

RESULT 41
JN0264
translation initiation factor eIF-2 gamma chain - pig (fragment)
N:Alternate names: eIF2 gamma chain
C:Species: Sus scrofa domestica (domestic pig)
C:Date: 09-Oct-1992 #sequence_revision 09-Oct-1992 #text_change 09-Jul-2004
C:Accession: JN0264
R:Mukoyama, E.B.; Shiohara, H.; Suzuki, H. Biosci. Biotechnol. Biochem. 56, 680-681, 1992

A;Title: GTP-binding sequences in the gamma subunit of pig liver initiation factor 2.
A;Reference number: JN0264; MUID:92282179; PMID:1368212
A;Accession: JN0264
A;Molecule type: protein
A;Residues: 1-16 <MUK>
A;Cross-references: UNIPROT:Q9TRQ9
A;Experimental source: liver
C;Keywords: GTP binding
F;1-16/Region: GTP binding #status experimental

Query Match 41.0%; Score 16; DB 2; Length 16;
Best Local Similarity 42.9%; Pred. No. 4.2e+03;
Matches 3; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1 RAFVTIG 7
|:|:
Db 1 QATINIG 7

RESULT 42
D83865
hypothetical protein BH1724 [imported] - Bacillus halodurans (strain C-125)
C;Species: Bacillus halodurans
C;Date: 01-Dec-2000 #sequence_revision 01-Dec-2000 #text_change 09-Jul-2004
C;Accession: D83865
R;Takami, H.; Nakasone, K.; Takaki, Y.; Maeno, G.; Sasaki, R.; Masui, N.; Fujii, F.; Hirai
Nucleic Acids Res. 28, 4317-4331, 2000
A;Title: Complete genome sequence of the alkaliphilic bacterium Bacillus halodurans and
A;Reference number: A83650; MUID:20512582; PMID:11058132
A;Accession: D83865
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-16 <STO>
A;Cross-references: UNIPROT:Q9KC50; GB:AP001512; GB:BA000004; NID:G10174030; PIDN:BA0054
A;Experimental source: strain C-125
C;Genetics:
A;Gene: BH1724

Query Match 41.0%; Score 16; DB 2; Length 16;
Best Local Similarity 60.0%; Pred. No. 4.2e+03;
Matches 3; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 4 VTIGK 8
|:|:
Db 4 ITQCK 8

RESULT 43
T14224
NADH2 dehydrogenase (ubiquinone) (EC 1.6.5.3) chain 6 - Euhadra herklotsi mitochondrion
C;Species: mitochondrion Euhadra herklotsi
C;Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 09-Jul-2004
C;Accession: T14224
R;Yamazaki, N.; Ueshima, R.; Terrett, J.A.; Yokobori, S.; Kaifu, M.; Segawa, R.; Kobayashi
submitted to the EMBL Data Library, May 1996
A;Description: Evolution of pulmonate gastropod mitochondrial genomes: Comparisons of co
A;Reference number: Z17932
A;Accession: T14224
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-16 <YAM>
A;Cross-references: UNIPROT:P92070; EMBL:Z71694; NID:6912660; PID:e244560; PIDN:CAA96364
A;Experimental source: adult; hepatopancreas
C;Genetics:
A;Genome: mitochondrion
C;Keywords: mitochondrion; NAD; oxidoreductase

Query Match 41.0%; Score 16; DB 2; Length 16;
Best Local Similarity 33.3%; Pred. No. 4.2e+03;
Matches 2; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2 AFVTIG 7

Db 9 SFLLVG 14
|:|:
RESULT 44
I78870
Gene Rb1 protein - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 02-Aug-1996 #sequence_revision 02-Aug-1996 #text_change 09-Jul-2004
C;Accession: I78870
R;Hogg, A.; Onadim, Z.; Baird, P.N.; Cowell, J.K.
Oncogene 7, 1445-1451, 1992
A;Title: Detection of heterozygous mutations in the Rb1 gene in retinoblastoma patients
A;Reference number: I58362; MUID:92319557; PMID:1352398
A;Accession: I78870
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-17 <RES>
A;Cross-references: UNIPROT:Q92727; GB:L41911; NID:G794004; PIDN:AAB59483.1; PID:G794005
C;Genetics:
A;Gene: GDB:RB1
A;Cross-references: GDB:118734; OMIM:180200
A;Map position: 13q14.3-13q14.3

Query Match 41.0%; Score 16; DB 2; Length 17;
Best Local Similarity 60.0%; Pred. No. 4.5e+03;
Matches 3; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 4 VTIGK 8
|:|:
Db 3 VSIGE 7

RESULT 45
A37823
dihydrolipoamide S-acetyltransferase (EC 2.3.3.1.12) - bovine (fragment)
C;Species: Bos primigenius taurus (cattle)
C;Date: 30-Apr-1991 #sequence_revision 30-Apr-1991 #text_change 09-Jul-2004
C;Accession: A37823
R;Rahmatullah, M.; Radke, G.A.; Andrews, P.C.; Roche, T.E.
J. Biol. Chem. 265, 14512-14517, 1990
A;Title: Changes in the core of the mammalian-pyruvate dehydrogenase complex upon select
A;Reference number: A37823; MUID:90354445; PMID:2167319
A;Accession: A37823
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-17 <RAH>
A;Cross-references: UNIPROT:Q7M2M8
C;Keywords: acyltransferase; coenzyme A

Query Match 41.0%; Score 16; DB 2; Length 17;
Best Local Similarity 60.0%; Pred. No. 4.5e+03;
Matches 3; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 RAFVT 5
|:|:
Db 5 RVFVS 9

Search completed: May 16, 2005, 08:10:44
Job time : 39 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 16, 2005, 12:53:32 ; Search time 18.0769 Seconds
(without alignments)
79.839 Million cell updates/sec

Title: US-08-869-386-1

Perfect score: 77
Sequence: 1 RIQPGGRAFTVIGK 15

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 4989

Minimum DB seq length: 0
Maximum DB seq length: 25

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR 79.*
1: pir1.*
2: pir2.*
3: pir3.*
4: pir4.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	60	77.9	20	2 S65399	immunodeficiency v
2	27	35.1	20	2 S48654	Plasmeprin II - ma
3	26.5	34.4	14	2 PA0109	porin por 1B - Ara
4	26.5	34.4	14	2 PA0045	porin por1 - Arabi
5	25	32.5	10	2 D28027	protein P7 - curle
6	25	32.5	12	2 S11286	exo-alpha-sialidas
7	25	32.5	25	2 S21197	hydrogensulfite re
8	24.5	31.8	17	2 A37823	dihydrolipoamide S
9	24	31.2	7	2 PT0515	T-cell receptor be
10	24	31.2	13	2 C53275	Ig kappa-1 chain J
11	24	31.2	14	2 PH0915	T-cell receptor be
12	24	31.2	20	2 S63490	disinfectant sulfi
13	24	31.2	21	2 S31427	biliary glycoprote
14	24	31.2	22	2 C42856	hypothetical prote
15	24	31.2	24	2 B60422	MSEL-neurophysin -
16	24	31.2	25	2 D41575	hombinin-like pept
17	23.5	30.5	13	2 P80453	36K protein 3124 -
18	23	29.9	10	2 S65388	cytochrome-c oxida
19	23	29.9	17	2 AF2093	heterocyst-inhibit
20	23	29.9	20	2 S77991	cytochrome-c oxida
21	22	28.6	12	2 S65629	protoporphyrinogen
22	22	28.6	20	2 S31220	82K protein - bovi
23	22	28.6	20	2 DIRT	dental fluid tra
24	22	28.6	21	2 A60225	pyruvate dehydroge
25	22	28.6	23	2 P00070	T-cell receptor be
26	22	28.6	23	2 S47192	T-cell receptor J-
27	22	28.6	25	2 S22221	peroxidase (EC 1.1
28	22	28.6	25	2 B44524	pregnancy-specific
29	22	28.6	25	2 S10850	alpha-amylase inhi

30 21 27.3 10 2 S77990
31 21 27.3 13 2 S33800
32 21 27.3 14 2 PH1347
33 21 27.3 16 2 H41299
34 21 27.3 16 2 A42411
35 21 27.3 16 2 I51879
36 21 27.3 18 2 S09722
37 21 27.3 19 2 I49037
38 21 27.3 22 2 A39269
39 21 27.3 24 4 T01780
40 20.5 26.6 18 2 A25941
41 20 26.0 11 2 S13279
42 20 26.0 15 2 S43634
43 20 26.0 15 2 D28587
44 20 26.0 15 2 C34874
45 20 26.0 16 2 PH1790

cytochrome-c oxida
chaperone, TCP1-re
Ig heavy chain D μ
T-cell receptor al
myosin light chain
cystathionine beta
2S albumin small c
TCR delta chain V-
LX-1 tumor antigen
probable gag polym
Ig heavy chain J-H
Ile-Sar-bradykinin
cytochrome-c oxida
T-cell receptor be
transforming prote
T cell receptor al

ALIGNMENTS

RESULT 1

S65399
immunodeficiency virus type 1, HIV-1 gp120 - human (fragments)
C:Species: Homo sapiens (man)
C:Date: 28-Oct-1996 #sequence_revision 13-Mar-1997 #text_change 17-Mar-1999
C:Accession: S65399
R:Niwa, Y.; Yano, M.; Futaki, S.; Okumura, Y.; Kido, H.
Eur. J. Biochem. 237, 64-70, 1996
A:Title: T-cell membrane-associated serine protease, tryptase TL(2), binds human immunode
man immunodeficiency virus type 1 inhibit cleavage of gp120.
A:Reference number: S65399; MUID:96203909; PMID:8620895
A:Accession: S65399
A>Status: preliminary
A:Molecule type: protein
A:Residues: 1-10,11-20 <NIW>
C:Superfamily: type E retrovirus env polyprotein

Query Match 77.9%; Score 60; DB 2; Length 20;
Best Local Similarity 91.7%; Pred. No. 0.00082;
Matches 11; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RGPGRFVTIGK 15
Db 1 RGPGRFVTIGR 12
|||||
|||||

RESULT 2

S48654
Plasmeprin II - malaria parasite (Plasmodium falciparum)
C:Species: Plasmodium falciparum
C:Date: 15-Jul-1995 #sequence_revision 19-Apr-1996 #text_change 09-Jun-2000
C:Accession: S48654
R:Hill, J.; Tyas, L.; Phylip, L.H.; Kay, J.; Dunn, B.M.; Berry, C.
FEBS Lett. 352, 155-158, 1994
A:Title: High level expression and characterisation of Plasmeprin II, an aspartic protei
A:Reference number: S48654; MUID:95010698; PMID:7925966
A:Accession: S48654
A>Status: preliminary
A:Molecule type: DNA
A:Residues: 1-20 <HIL>

Query Match 35.1%; Score 27; DB 2; Length 20;
Best Local Similarity 50.0%; Pred. No. 4.2e+02;
Matches 6; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

Qy 3 QRGPGRFVTIG 14
Db 9 QMGRGSEHLTIG 20
|||
|||

RESULT 3

PA0109

porin por 1B - Arabidopsis thaliana (fragment)
C:Species: Arabidopsis thaliana (mouse-ear cress)
C:Date: 07-Apr-1995 #sequence_revision 26-May-1995 #text_change 09-Jul-2004
C:Accession: PA0109
R:Kano, M.; Kawakami, T.; Tsugita, A.
submitted to JIPID, March 1995
A:Reference number: PA0109
A:Accession: PA0109
A:Molecule type: protein
A:Residues: 1-14 <RAM>
A:Cross-references: UNIPROT:Q8LA84; UNIPROT:Q42292
A:Experimental source: root

Query Match 34.4%; Score 26.5; DB 2; Length 14;
Best Local Similarity 50.0%; Pred. No. 3.7e+02;
Matches 6; Conservative 2; Mismatches 3; Indels 1; Gaps 1;

QY 4 RQPGRAFVTIGK 15
DB 2 KGPG-LYTEIGK 12

RESULT 4
PA0045
porin por1 - Arabidopsis thaliana (fragment)
C:Species: Arabidopsis thaliana (mouse-ear cress)
C:Date: 30-Jun-1992 #sequence_revision 06-Jan-1995 #text_change 09-Jul-2004
C:Accession: PA0045
R:Kano, M.; Kawakami, T.; Miyatake, N.; Tsugita, A.
submitted to JIPID, July 1994
A:Description: Separation and characterization of Arabidopsis proteins by two-dimensional electrophoresis
A:Reference number: PA0001
A:Accession: PA0045
A:Molecule type: protein
A:Residues: 1-14 <RAM>
A:Cross-references: UNIPROT:Q7MIW9
A:Experimental source: root

Query Match 34.4%; Score 26.5; DB 2; Length 14;
Best Local Similarity 50.0%; Pred. No. 3.7e+02;
Matches 6; Conservative 2; Mismatches 3; Indels 1; Gaps 1;

QY 4 RQPGRAFVTIGK 15
DB 2 KGPG-LYTEIGK 12

RESULT 5
D28027
protein P7 - curled-leaved tobacco (fragment)
C:Species: Nicotiana glauca (curled-leaved tobacco)
C:Date: 19-May-1989 #sequence_revision 19-May-1989 #text_change 09-Jul-2004
C:Accession: D28027
R:Bauw, G.; De Loose, M.; Inze, D.; Van Montagu, M.; Vandekerckhove, J.
Proc. Natl. Acad. Sci. U.S.A. 84, 4806-4810, 1987
A:Title: Alterations in the phenotype of plant cells studied by NH2-terminal amino acid sequencing
A:Reference number: A94167
A:Accession: D28027
A:Molecule type: protein
A:Residues: 1-10 <BAU>
A:Cross-references: UNIPROT:Q7MIW8

Query Match 32.5%; Score 25; DB 2; Length 10;
Best Local Similarity 71.4%; Pred. No. 5e+02;
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 7 GRAFVTI 13
DB 3 GRSFVPI 9

RESULT 6
S11286
porin por1B - Arabidopsis thaliana (fragment)
C:Species: Arabidopsis thaliana (mouse-ear cress)
C:Date: 07-Apr-1995 #sequence_revision 26-May-1995 #text_change 09-Jul-2004
C:Accession: PA0109
R:Kano, M.; Kawakami, T.; Tsugita, A.
submitted to JIPID, March 1995
A:Reference number: PA0109
A:Accession: PA0109
A:Molecule type: protein
A:Residues: 1-14 <RAM>
A:Cross-references: UNIPROT:Q8LA84; UNIPROT:Q42292
A:Experimental source: root

Query Match 34.4%; Score 26.5; DB 2; Length 14;
Best Local Similarity 50.0%; Pred. No. 3.7e+02;
Matches 6; Conservative 2; Mismatches 3; Indels 1; Gaps 1;

QY 4 RQPGRAFVTIGK 15
DB 2 KGPG-LYTEIGK 12

RESULT 4
PA0045
porin por1 - Arabidopsis thaliana (fragment)
C:Species: Arabidopsis thaliana (mouse-ear cress)
C:Date: 30-Jun-1992 #sequence_revision 06-Jan-1995 #text_change 09-Jul-2004
C:Accession: PA0045
R:Kano, M.; Kawakami, T.; Miyatake, N.; Tsugita, A.
submitted to JIPID, July 1994
A:Description: Separation and characterization of Arabidopsis proteins by two-dimensional electrophoresis
A:Reference number: PA0001
A:Accession: PA0045
A:Molecule type: protein
A:Residues: 1-14 <RAM>
A:Cross-references: UNIPROT:Q7MIW9
A:Experimental source: root

Query Match 34.4%; Score 26.5; DB 2; Length 14;
Best Local Similarity 50.0%; Pred. No. 3.7e+02;
Matches 6; Conservative 2; Mismatches 3; Indels 1; Gaps 1;

QY 4 RQPGRAFVTIGK 15
DB 2 KGPG-LYTEIGK 12

RESULT 5
D28027
protein P7 - curled-leaved tobacco (fragment)
C:Species: Nicotiana glauca (curled-leaved tobacco)
C:Date: 19-May-1989 #sequence_revision 19-May-1989 #text_change 09-Jul-2004
C:Accession: D28027
R:Bauw, G.; De Loose, M.; Inze, D.; Van Montagu, M.; Vandekerckhove, J.
Proc. Natl. Acad. Sci. U.S.A. 84, 4806-4810, 1987
A:Title: Alterations in the phenotype of plant cells studied by NH2-terminal amino acid sequencing
A:Reference number: A94167
A:Accession: D28027
A:Molecule type: protein
A:Residues: 1-10 <BAU>
A:Cross-references: UNIPROT:Q7MIW8

Query Match 32.5%; Score 25; DB 2; Length 10;
Best Local Similarity 71.4%; Pred. No. 5e+02;
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 7 GRAFVTI 13
DB 3 GRSFVPI 9

RESULT 6
S11286

exo-alpha-sialidase (EC 3.2.1.18) - influenza A virus (strain A/FPV/Rostock/34 [H7N1]) (1)
N:Alternate names: neuraminidase
C:Species: influenza A virus
C:Date: 31-Dec-1990 #sequence_revision 31-Dec-1990 #text_change 22-Jun-1999
C:Accession: S11286
R:Robertson, J.S.
Nucleic Acids Res. 6, 3745-3757, 1979
A:Title: 5' and 3' terminal nucleotide sequences of the RNA genome segments of influenza A virus
A:Reference number: S11286; MUID:80034428; PMID:493121
A:Accession: S11286
A:Molecule type: genomic RNA
A:Residues: 1-12 <ROB>
A:Cross-references: EMBL:J02114; NID:g324483; PIDN:AAA43398.1; PID:g324486
C:Genetics:
A:Map position: segment 6
C:Superfamily: influenza virus exo-alpha-sialidase
C:Keywords: glycosidase; hydrolase

Query Match 32.5%; Score 25; DB 2; Length 12;
Best Local Similarity 44.4%; Pred. No. 5.9e+02;
Matches 4; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 6 PGRAFVTIG 14
DB 3 PNQKIITIG 11

RESULT 7
S21197
hydrogensulfite reductase (EC 1.8.99.3) alpha chain - Desulfovibrio vulgaris (fragment)
N:Alternate names: bisulfite reductase; desulfosulfide; desulfosulfide; desulfosulfide;
C:Species: Desulfovibrio vulgaris
C:Date: 19-Mar-1997 #sequence_revision 11-Jun-1999 #text_change 09-Jul-2004
C:Accession: S21197
R:Pierik, A.J.; Duyvis, M.G.; van Helvoort, J.M.L.M.; Wolbert, R.B.G.; Hagen, W.R.
Eur. J. Biochem. 205, 111-115, 1992
A:Title: The third subunit of desulfovibrio-type dissimilatory sulfite reductases.
A:Reference number: S21197; MUID:92209491; PMID:1555572
A:Accession: S21197
A:Molecule type: protein
A:Residues: 1-25 <PIE>
A:Cross-references: UNIPROT:P45574
A:Experimental source: strain Hildenborough
C:Genetics:
A:Gene: dsvc
C:Complex: heterohexamer; two alpha, two beta and two gamma chains
C:Function:
A:Description: catalyzes the six-electron reduction of sulfite to sulfide
A:Pathway: the terminal oxidase in the sulfate-reduction pathway
C:Keywords: heterohexamer; oxidoreductase

Query Match 32.5%; Score 25; DB 2; Length 25;
Best Local Similarity 36.4%; Pred. No. 1.2e+03;
Matches 4; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1 RIQPGRAFV 11
DB 10 QLESQPMXSFV 20

RESULT 8
A37823
dihydrolipoamide S-acetyltransferase (EC 2.3.1.12) - bovine (fragment)
C:Species: Bos primigenius taurus (cattle)
C:Date: 30-Apr-1991 #sequence_revision 30-Apr-1991 #text_change 09-Jul-2004
C:Accession: A37823
R:Rahmatullah, M.; Radke, G.A.; Andrews, P.C.; Roche, T.E.
J. Biol. Chem. 265, 14512-14517, 1990
A:Title: Changes in the core of the mammalian-pyruvate dehydrogenase complex upon selecti
A:Reference number: A37823; MUID:90354445; PMID:2167319
A:Accession: A37823
A>Status: preliminary
A:Molecule type: protein

A:Residues: 1-17 <RAH>
A:Cross-references: UNIPROT:Q7M2M8
C:Keywords: acyltransferase; coenzyme A

Query Match 31.8%; Score 24.5; DB 2; Length 17;
Best Local Similarity 66.7%; Pred. No. 9.9e+02;
Matches 6; Conservative 1; Mismatches 1; Indels 1; Gaps 1;

QY 5 GP-GRAPVT 12
Db 1 GPKGRVFS 9

RESULT 9

PT0515
J. Exp. Med. 174, 115-124, 1991
A:Title: Junctional sequences of fetal T cell receptor beta chains have few N regions.
A:Reference number: PT0509; MUID:91277601; PMID:1711558
A:Accession: PT0515
A>Status: translation not shown
A:Molecule type: mRNA
A:Residues: 1-7 <FEE>
A:Experimental source: adult thymus, strain BALB/c
C:Keywords: T-cell receptor

R:Feeney, A.J.

Query Match 31.2%; Score 24; DB 2; Length 7;
Best Local Similarity 80.0%; Pred. No. 2.8e+05;
Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 5 GPGRA 9
Db 3 GPGQA 7

Query Match 31.2%; Score 24; DB 2; Length 7;
Best Local Similarity 80.0%; Pred. No. 2.8e+05;
Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 5 GPGRA 9
Db 3 GPGQA 7

RESULT 10

CS3275
Ig kappa-1 chain J3 segment b95 allotype - rabbit (fragment)
C:Species: Oryctolagus cuniculus (domestic rabbit)
C:Date: 02-May-1994 #sequence_revision 18-Nov-1994 #text_change 16-Aug-1996
C:Accession: CS3275
R:Ayadi, H.; Marche, P.N.; Cazenave, P.A.
Immunogenetics 34, 201-207, 1991
A:Title: Evolution of the rabbit immunoglobulin kappa chain genes.
A:Reference number: A53275; MUID:91372868; PMID:1909995
A:Accession: CS3275
A>Status: preliminary
A:Molecule type: DNA
A:Residues: 1-13 <AYA>
A>Note: sequence extracted from NCBI backbone (NCBIN:56069, NCBIP:56164)
C:Comment: This J3 segment may not be functional because of substitutions in the 7 mer
C:Keywords: heterotetramer; immunoglobulin

Query Match 31.2%; Score 24; DB 2; Length 13;
Best Local Similarity 100.0%; Pred. No. 9.5e+02; Mismatches 0; Indels 0; Gaps 0;

QY 4 RGPV 7
Db 3 RGPV 6

RESULT 11

PH0915
T-cell receptor beta chain V-D-J region (isolate 1) - rat (fragment)
C:Species: Rattus norvegicus (Norway rat)
C:Date: 09-Oct-1992 #sequence_revision 09-Oct-1992 #text_change 30-May-1997
C:Accession: PH0915
R:Gold, D.P.; Offner, H.; Sun, D.; Wiley, S.; Vandenbark, A.A.; Wilson, D.B.

J. Exp. Med. 174, 1467-1476, 1991

A:Title: Analysis of T cell receptor beta chains in Lewis rats with experimental allergic
A:Reference number: PH0891; MUID:92078857; PMID:1836012

A:Accession: PH0915

A:Molecule type: mRNA

A:Residues: 1-14 <COL>

A:Experimental source: concanavalin A-activated lymphoblast

A>Note: the authors translated the codon GGG for residue 8 as Glu and GAG for residue 9
C:Keywords: T-cell receptor

Query Match 31.2%; Score 24; DB 2; Length 14;
Best Local Similarity 50.0%; Pred. No. 1e+03;
Matches 4; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 3 QRGPGRAF 10
Db 4 RRGTEAY 11

RESULT 12

SG3490

disulfidory sulfite reductase alpha chain, soluble - Desulfovibrio desulfuricans (frag
C:Species: Desulfovibrio desulfuricans

C:Date: 28-Oct-1996 #sequence_revision 13-Mar-1997 #text_change 09-Jul-2004

C:Accession: SG3490

R:Steuber, J.; Arendsen, A.F.; Hagen, W.R.; Kroneck, P.M.H.

Eur. J. Biochem. 233, 873-879, 1995

A:Title: Molecular properties of the dissimilatory sulfite reductase from Desulfovibrio

A:Reference number: SG3489; MUID:96085152; PMID:8521853

A:Accession: SG3490

A>Status: preliminary

A:Molecule type: protein

A:Residues: 1-20 <STE>

A:Cross-references: UNIPROT:Q9R4H4

Query Match 31.2%; Score 24; DB 2; Length 20;
Best Local Similarity 36.4%; Pred. No. 1.4e+03;
Matches 4; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1 RIQPGPGRAFV 11
Db 10 QLESGPWPSFV 20

RESULT 13

S31427

biliary glycoprotein - human

C:Species: Homo sapiens (man)

C:Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 07-Feb-1997

C:Accession: S31427

R:Nedellec, P.; Turbide, C.; Barnett, T.R.; Beauchemin, N.

submitted to the EMBL Data Library, July 1992

A:Description: Characterization of the human biliary glycoprotein regulatory region.

A:Reference number: S31427

A:Accession: S31427

A:Molecule type: DNA

A:Residues: 1-21 <NED>

A:Cross-references: EMBL:X67277

C:Keywords: glycoprotein

Query Match 31.2%; Score 24; DB 2; Length 21;
Best Local Similarity 80.0%; Pred. No. 1.5e+03;
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 6 PGRAF 10
Db 14 PGRGF 18

RESULT 14

C42856
hypothetical protein 3 EPF-region [imported] - human (fragment)

C:Species: Homo sapiens (man)
C:Date: 10-Jun-1993 #sequence_revision 18-Nov-1994 #text_change 20-Jun-2000
C:Accession: C42856
R:Liou, Z.; Diaz, L.A.; Haas, A.L.; Giudice, G.J.
J. Biol. Chem. 267, 15829-15835, 1992
A:Title: cDNA cloning of a novel human ubiquitin carrier protein. An antigenic domain of this human epidermal transcript.
A:Reference number: A42856; MUID:92348449; PMID:1379239
A:Accession: C42856
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-22 <LIU>
A:Experimental source: keratinocyte
A:Note: sequence extracted from NCBI backbone (NCBIN:109895, NCBI:P:109899)

Query Match 31.2%; Score 24; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 RQPG 7
| | | |
DB 10 RQPG 13

RESULT 15
B60422
MSEL-neurophysin - African clawed frog (fragment)
N:Alternate names: vasopressin-associated neurophysin
C:Species: Xenopus laevis (African clawed frog)
C:Date: 12-Feb-1993 #sequence_revision 12-Feb-1993 #text_change 17-Mar-1999
C:Accession: B60422
R:Chauvet, J.; Michel, G.; Rouille, Y.; Chauvet, M.T.; Acher, R.
Neuropeptides 15, 123-127, 1990
A:Title: Identification of two types of neurophysins in Xenopus laevis neurointermediate
A:Reference number: A60422; MUID:91067001; PMID:2250763
A:Accession: B60422
A:Molecule type: protein
A:Residues: 1-24 <CHA>
C:Superfamily: oxytocin-neurophysin
C:Keywords: pituitary

Query Match 31.2%; Score 24; DB 2; Length 24;
Best Local Similarity 66.7%; Pred. No. 1.7e+03;
Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2 IQRGPG 7
: | | | |
DB 11 MQXGPG 16

RESULT 16
D41575
bombinin-like peptide 4 - Bombina orientalis
C:Species: Bombina orientalis
C:Date: 30-Jun-1992 #sequence_revision 30-Jun-1992 #text_change 09-Jul-2004
C:Accession: D41575
R:Gibson, B.W.; Tang, D.; Mandrell, R.; Kelly, M.; Spindel, E.R.
J. Biol. Chem. 266, 23103-23111, 1991
A:Title: Bombinin-like peptides with antimicrobial activity from skin secretions of the
A:Reference number: A41575; MUID:92078177; PMID:1744108
A:Accession: D41575
A:Status: preliminary
A:Molecule type: protein
A:Residues: 1-25 <GIB>
A:Cross-references: UNIPROT:P29005
C:Superfamily: bombinin H precursor

Query Match 31.2%; Score 24; DB 2; Length 25;
Best Local Similarity 45.5%; Pred. No. 1.7e+03;
Matches 5; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 5 GPGRAFTVTK 15
| | | | : |

C:Species: Homo sapiens (man)
C:Date: 10-Jun-1993 #sequence_revision 18-Nov-1994 #text_change 20-Jun-2000
C:Accession: C42856
R:Liou, Z.; Diaz, L.A.; Haas, A.L.; Giudice, G.J.
J. Biol. Chem. 267, 15829-15835, 1992
A:Title: cDNA cloning of a novel human ubiquitin carrier protein. An antigenic domain of this human epidermal transcript.
A:Reference number: A42856; MUID:92348449; PMID:1379239
A:Accession: C42856
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-22 <LIU>
A:Experimental source: keratinocyte
A:Note: sequence extracted from NCBI backbone (NCBIN:109895, NCBI:P:109899)

Query Match 31.2%; Score 24; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 RQPG 7
| | | |
DB 10 RQPG 13

RESULT 15
B60422
MSEL-neurophysin - African clawed frog (fragment)
N:Alternate names: vasopressin-associated neurophysin
C:Species: Xenopus laevis (African clawed frog)
C:Date: 12-Feb-1993 #sequence_revision 12-Feb-1993 #text_change 17-Mar-1999
C:Accession: B60422
R:Chauvet, J.; Michel, G.; Rouille, Y.; Chauvet, M.T.; Acher, R.
Neuropeptides 15, 123-127, 1990
A:Title: Identification of two types of neurophysins in Xenopus laevis neurointermediate
A:Reference number: A60422; MUID:91067001; PMID:2250763
A:Accession: B60422
A:Molecule type: protein
A:Residues: 1-24 <CHA>
C:Superfamily: oxytocin-neurophysin
C:Keywords: pituitary

Query Match 31.2%; Score 24; DB 2; Length 24;
Best Local Similarity 66.7%; Pred. No. 1.7e+03;
Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2 IQRGPG 7
: | | | |
DB 11 MQXGPG 16

RESULT 16
D41575
bombinin-like peptide 4 - Bombina orientalis
C:Species: Bombina orientalis
C:Date: 30-Jun-1992 #sequence_revision 30-Jun-1992 #text_change 09-Jul-2004
C:Accession: D41575
R:Gibson, B.W.; Tang, D.; Mandrell, R.; Kelly, M.; Spindel, E.R.
J. Biol. Chem. 266, 23103-23111, 1991
A:Title: Bombinin-like peptides with antimicrobial activity from skin secretions of the
A:Reference number: A41575; MUID:92078177; PMID:1744108
A:Accession: D41575
A:Status: preliminary
A:Molecule type: protein
A:Residues: 1-25 <GIB>
A:Cross-references: UNIPROT:P29005
C:Superfamily: bombinin H precursor

Query Match 31.2%; Score 24; DB 2; Length 25;
Best Local Similarity 45.5%; Pred. No. 1.7e+03;
Matches 5; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 5 GPGRAFTVTK 15
| | | | : |

Db 1 GIGAAILSAGK 11

RESULT 17
PS0453
36K protein 3124 - rice (strain Nihonbare) (fragment)
C:Species: Oryza sativa (rice)
C:Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 23-Mar-1995
C:Accession: PS0453
R:Taugita, A.
submitted to JIPID, April 1993
A:Reference number: PS0206
A:Accession: PS0453
A:Molecule type: protein
A:Residues: 1-13 <TSU>
A:Experimental source: leaf, chlorophyll, stem
A:Note: molecular weight 36K, pI 6.1

Query Match 30.5%; Score 23.5; DB 2; Length 13;
Best Local Similarity 50.0%; Pred. No. 1.2e+03;
Matches 6; Conservative 1; Mismatches 4; Indels 1; Gaps 1;

QY 2 IQRGPGRAFTVI 13
| | | | | :
DB 3 IQXAPG-XFVAV 13

RESULT 18
S65388
cytochrome-c oxidase (EC 1.9.3.1) chain VII c, hepatic - rat (fragment)
C:Species: Rattus norvegicus (Norway rat)
C:Date: 28-Oct-1996 #sequence_revision 13-Mar-1997 #text_change 09-Jul-2004
C:Accession: S65388; S65389
R:Schaegeer, H.; Noack, H.; Halang, W.; Brandt, U.; von Jagow, G.
Eur. J. Biochem. 230, 235-241, 1995
A:Title: Cytochrome-c oxidase in developing rat heart. Enzymic properties and amino-termi
A:Reference number: S65372; MUID:95324529; PMID:7601105
A:Accession: S65388
A:Status: preliminary
A:Molecule type: protein
A:Residues: 1-10 <SCH>
A:Cross-references: UNIPROT:P80432
A:Accession: S65389
A:Status: preliminary
A:Molecule type: protein
A:Residues: 1-10 <SC2>
C:Superfamily: cytochrome-c oxidase chain VIIC
C:Keywords: oxidoreductase

Query Match 29.9%; Score 23; DB 2; Length 10;
Best Local Similarity 50.0%; Pred. No. 1.1e+03;
Matches 3; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 3 QRGPGR 8
: | | | :
DB 4 BEGPGK 9

RESULT 19
AF2093
heterocyst-inhibiting signaling peptide [imported] - Nostoc sp. (strain PCC 7120)
C:Species: Nostoc sp. PCC 7120
A:Note: Nostoc sp. strain PCC 7120 is a synonym of Anabaena sp. strain PCC 7120
C:Date: 14-Dec-2001 #sequence_revision 14-Dec-2001 #text_change 09-Jul-2004
C:Accession: AF2093
R:Kaneko, T.; Nakamura, Y.; Wolk, C.P.; Kuritz, T.; Sasamoto, S.; Watanabe, A.; Iriguchi, N.; Shimpo, S.; Sugimoto, M.; Takazawa, M.; Yamada, M.; Yasuda, M.; Tabata, S.
DNA Res. 8, 205-213, 2001
A:Title: Complete Genomic Sequence of the Filamentous Nitrogen-fixing Cyanobacterium Anabaena
A:Reference number: AB1807; MUID:21595285; PMID:11759840
A:Accession: AF2093
A:Status: preliminary
A:Molecule type: DNA

A;Residues: 1-17 <UR>
A;Cross-references: UNIPROT:O52748; GB:BA000019; PIDN:BAB74000.1; PID:g17131393; GSPDB:Q531220
A;Experimental source: strain PCC 7120
C;Genetics:
A;Gene: pats

Query Match 29.9%; Score 23; DB 2; Length 17;
Best Local Similarity 66.7%; Pred. No. 1.8e+03;
Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 3 QRGPGR 8
:|:|:
Db 12 ERGGR 17

RESULT 20
S77991
cytochrome-c oxidase (EC 1.9.3.1) chain VIII.1 - bigeye tuna (fragment)
C;Species: Thunnus obesus (bigeye tuna)
C;Date: 17-Sep-1997 #sequence_revision 17-Sep-1997 #text_change 09-Jul-2004
C;Accession: S77991
R;Arnold, S.; Lee, J.; Kim, M.; Song, E.; Linder, D.; Lottepeich, F.; Kadenbach, B.
submitted to the Protein Sequence Database, June 1997
A;Reference number: S77980
A;Accession: S77991
A;Molecule type: protein
A;Residues: 1-20 <ARN>
A;Cross-references: UNIPROT:P80983
A;Experimental source: heart; liver
C;Genetics:
A;Genome: nuclear
C;Function:
A;Pathway: oxidative phosphorylation; respiratory chain
C;Keywords: electron transfer; membrane-associated complex; mitochondrial inner membrane

Query Match 29.9%; Score 23; DB 2; Length 20;
Best Local Similarity 40.0%; Pred. No. 2.1e+03;
Matches 4; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 6 PGRAPVTIGK 15
:|:|:
Db 5 PAKXXVTAGE 14

RESULT 21
S65629
protoporphyrinogen oxidase (EC 1.3.3.4) - bovine (fragment)
C;Species: Bos primigenius taurus (cattle)
C;Date: 14-Feb-1997 #sequence_revision 13-Mar-1997 #text_change 26-May-2000
C;Accession: S65629
R;Taketani, S.; Yoshinaga, T.; Furukawa, T.; Kohno, H.; Tokunaga, R.; Nishimura, K.; Ino, E.; J. Biochem. 230, 760-765, 1995
A;Title: Induction of terminal enzymes for heme biosynthesis during differentiation of m
A;Reference number: S65629; MUID:953331315; PMID:7607249
A;Accession: S65629
A;Molecule type: protein
A;Residues: 1-12 <TAK>
C;Genetics:
A;Genome: nuclear
C;Function:
A;Pathway: heme biosynthesis; porphyrin biosynthesis
C;Superfamily: phytoene dehydrogenase
C;Keywords: heme biosynthesis; mitochondrion; oxidoreductase; porphyrin biosynthesis

Query Match 28.6%; Score 22; DB 2; Length 12;
Best Local Similarity 50.0%; Pred. No. 2e+03;
Matches 4; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 7 GRAFVTIG 14
:|:|:
Db 1 GRTVVVLG 8

RESULT 22
S31220
82K protein - bovine
C;Species: Bos primigenius taurus (cattle)
C;Date: 19-Mar-1997 #sequence_revision 19-Mar-1997 #text_change 09-Jul-2004
C;Accession: S31220
R;Castillo, G.M.; Templeton, D.M.
FEBS Lett. 318, 292-296, 1993
A;Title: Subunit structure of bovine ESF (extracellular-matrix stabilizing factor(s)). A
A;Reference number: S31219; MUID:93178646; PMID:7680011
A;Accession: S31220
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-20 <CAS>
A;Cross-references: UNIPROT:Q9TRI0

Query Match 28.6%; Score 22; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 PGRA 9
:|:|:
Db 3 PGRA 6

RESULT 23
DIRT
dental fluid transport-stimulating peptide - rat
N;Alternate names: DFT-stimulating peptide
C;Species: Rattus norvegicus (Norway rat)
C;Date: 20-Jun-2000 #sequence_revision 20-Jun-2000 #text_change 16-Aug-2004
C;Accession: J00001
R;Yamamoto, T.; Kobayashi, M.; Kobayashi, M.; Yamamoto, M.; Nomura, M.; Aonuma, S.
Chem. Pharm. Bull. 34, 3803-3811, 1986
A;Title: Isolation and amino acid sequence of dental fluid transport-stimulating peptic
A;Reference number: J00001; MUID:87131231; PMID:3815601
A;Accession: J00001
A;Molecule type: protein
A;Residues: 1-20 <YAM>
A;Cross-references: UNIPROT:P07448
A;Experimental source: parotid gland
C;Comment: This peptide stimulates the transport of dental fluid, which is important fo
C;Keywords: hormone; parotid gland

Query Match 28.6%; Score 22; DB 2; Length 20;
Best Local Similarity 55.6%; Pred. No. 3.1e+03;
Matches 5; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 6 PGRAPVTIG 14
:|:|:
Db 12 PGRKDSAG 20

RESULT 24
A60225
pyruvate dehydrogenase (lipoamide) (EC 1.2.4.1) alpha chain - bovine (fragment)
C;Species: Bos primigenius taurus (cattle)
C;Date: 21-Oct-1992 #sequence_revision 21-Oct-1992 #text_change 09-Jul-2004
C;Accession: A60225
R;Lawson, R.; Aitken, A.; Yeaman, S.J.
Biochem. Soc. Trans. 11, 298-299, 1983
A;Title: Primary sequence of the N-terminal region of the alpha-subunit of pyruvate dehy
A;Reference number: A60225
A;Accession: A60225
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-21 <LAW>
A;Cross-references: UNIPROT:Q9N1X8
C;Superfamily: pyruvate dehydrogenase (lipoamide) alpha chain; thiamin pyrophosphate-bin
C;Keywords: oxidoreductase

Query Match 28.6%; Score 22; DB 2; Length 21;
Best Local Similarity 50.0%; Pred. No. 3.2e+03;

Matches 3; Conservative 2; Mismatches 1; Indels 0; Gaps 0;		C;Superfamily: peroxidase C;Keywords: blocked amino end; glycoprotein; oxidoreductase	
Qy	1 RIQRGP 6 : 16 RLEBGP 21	Query Match 28.6%; Score 22; DB 2; Length 25; Best Local Similarity 44.4%; Pred. No. 3.8e+03; Matches 4; Conservative 0; Mismatches 5; Indels 0; Gaps 0;	
Db			
RESULT 25			
PQ0070			
T-cell receptor beta chain (BTB15) - bovine (fragment)			
C;Species: Bos primigenius taurus (cattle)			
C;Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 20-Feb-1995			
C;Accession: PQ0070			
R;Tanaka, A.; Ishiguro, N.; Shinagawa, M.			
submitted to JIPID, May 1990			
A;Description: Sequence analysis of bovine T-cell receptor beta chain genes.			
A;Reference number: JQ0472			
A;Accession: PQ0070			
A;Molecule type: mRNA			
A;Residues: 1-22 <TAN>			
A;Experimental source: T cell			
C;Genetics:			
A;Gene: BTB15			
C;Keywords: receptor			
Query Match 28.6%; Score 22; DB 2; Length 22; Best Local Similarity 33.3%; Pred. No. 3.4e+03; Matches 3; Conservative 2; Mismatches 4; Indels 0; Gaps 0;			
Qy	5 GPGRAFVTI 13 : 14 GPGTRLIVL 22		
Db			
RESULT 26			
S47192			
T-cell receptor J-alpha wVII.2 - human (fragment)			
C;Species: Homo sapiens (man)			
C;Date: 06-Feb-1995 #sequence_revision 06-Feb-1995 #text_change 23-Jul-1999			
C;Accession: S47192			
R;Plaza, A.; Kono, D.H.; Theofilopoulos, A.N.			
submitted to the EMBL Data Library, February 1993			
A;Reference number: S40133			
A;Accession: S47192			
A;Status: preliminary			
A;Molecule type: mRNA			
A;Residues: 1-23 <PLA>			
A;Cross-references: EMBL:X71051; NID:G506974; PIDN:CMAS0368.1; PID:G510653			
C;Superfamily: immunoglobulin V region; immunoglobulin homology			
C;Keywords: T-cell receptor			
Query Match 28.6%; Score 22; DB 2; Length 23; Best Local Similarity 45.5%; Pred. No. 3.5e+03; Matches 5; Conservative 1; Mismatches 5; Indels 0; Gaps 0;			
Qy	4 RGPGRFVTIG 14 : 4 RTGRRALTFG 14		
Db			
RESULT 27			
S22221			
peroxidase (EC 1.11.1.7) - imperfect fungus (Arthromyces ramosus) (fragment)			
C;Species: Arthromyces ramosus			
C;Date: 12-Feb-1998 #sequence_revision 17-Apr-1998 #text_change 12-Jul-2004			
C;Accession: S22221			
R;Kjalke, M.; Andersen, M.B.; Schneider, P.; Christensen, B.; Schuelein, M.; Welinder, K.			
Biochim. Biophys. Acta 1120, 248-256, 1992			
A;Title: Comparison of structure and activities of peroxidases from Coprinus cinereus,			
A;Reference number: S21746; MUID:92247803; PMID:1576150			
A;Accession: S22221			
A;Molecule type: protein			
A;Residues: 1-25 <KJA>			
Query Match 28.6%; Score 22; DB 2; Length 25; Best Local Similarity 71.4%; Pred. No. 3.8e+03; Matches 5; Conservative 0; Mismatches 2; Indels 0; Gaps 0;			
Qy	6 PGRAFVTI 12 : 6 PGVAFPT 12		
Db			
RESULT 30			
S77990			
cytochrome-c oxidase (EC 1.9.3.1) chain VIIc - bigeye tuna (fragment)			
C;Species: Thunnus obesus (bigeye tuna)			
C;Date: 17-Sep-1997 #sequence_revision 17-Sep-1997 #text_change 09-Jul-2004			
C;Accession: S77990			
R;Arnold, S.; Lee, J.; Kim, M.; Song, E.; Linder, D.; Lottspeich, F.; Kadenbach, B.			
submitted to the Protein Sequence Database, June 1997			

A;Reference number: S77980
A;Accession: S77990
A;Molecule type: protein
A;Residues: 1-10 <ARN>
A;Cross-references: UNIPROT:P80982
A;Experimental source: heart; liver
C;Genetics:
A;Genome: nuclear
C;Function:
A;Pathway: oxidative phosphorylation; respiratory chain
C;Keywords: electron transfer; membrane-associated complex; mitochondrial inner membrane

Query Match 27.3%; Score 21; DB 2; Length 10;
Best Local Similarity 75.0%; Pred. No. 2.5e+03;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 5 GPGK 8
| | | |
Db 6 GPGK 9

RESULT 31
S33800
Chaperone, TCPI-related - oat
C;Species: Avena sativa (oat)
C;Date: 02-Dec-1993 #sequence_revision 27-Feb-1997 #text_change 09-Jul-2004
C;Accession: S33800
R;Mummert, E.; Grimm, R.; Speth, V.; Eckerskorn, C.; Schiltz, E.; Gatenby, A.A.; Schaefer
Nature 363, 644-648, 1993
A;Title: A TCPI-related molecular chaperone from plants refolds phytochrome to its photo
A;Reference number: S33800; MUID:93288140; PMID:8099715
A;Accession: S33800
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-13 <MW>
A;Cross-references: UNIPROT:Q7M1G8

Query Match 27.3%; Score 21; DB 2; Length 13;
Best Local Similarity 50.0%; Pred. No. 3.1e+03;
Matches 4; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 5 GPGKAVFT 12
| | | | |
Db 6 GPGNPFT 13

RESULT 32
PH1347
Ig heavy chain DJ region (clone C100-103A) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 07-May-1999
C;Accession: PH1347
R;Wasserman, R.; Gallili, N.; Ito, Y.; Reichard, B.A.; Shane, S.; Rovera, G.
J. Exp. Med. 176, 1577-1581, 1992
A;Title: Predominance of fetal type DJH joining in young children with B precursor lymph
A;Reference number: PH1302; MUID:93094761; PMID:1460419
A;Accession: PH1347
A;Molecule type: DNA
A;Residues: 1-14 <WAS>
C;Keywords: heterotetramer; immunoglobulin

Query Match 27.3%; Score 21; DB 2; Length 14;
Best Local Similarity 50.0%; Pred. No. 3.3e+03;
Matches 4; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 7 GRAFTTIG 14
| | | | |
Db 3 GEDFLTIG 10

RESULT 33
H41299
T-cell receptor alpha chain precursor J region (40) - human (fragment)

C;Species: Homo sapiens (man)
C;Date: 28-May-1992 #sequence_revision 28-May-1992 #text_change 05-Nov-1999
C;Accession: H41299
R;Uematsu, Y.; Wege, H.; Straus, A.; Ott, M.; Bannwarth, W.; Lanchbury, J.; Panayi, G.; S
Proc. Natl. Acad. Sci. U.S.A. 88, 8534-8538, 1991
A;Title: The T-cell-receptor repertoire in the synovial fluid of a patient with rheumatoid
A;Reference number: H41299; MUID:92020887; PMID:1656449
A;Accession: H41299
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-16 <UEN>
A;Cross-references: GB:S57504; NID:9236332; PIDN:AAB19963.1; PID:9236333
C;Keywords: T-cell receptor

Query Match 27.3%; Score 21; DB 2; Length 16;
Best Local Similarity 44.4%; Pred. No. 3.8e+03;
Matches 4; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 5 GPGKAVFTI 13
| | | | |
Db 7 GPGTSLSVI 15

RESULT 34
A42411
myosin light chain kinase - chicken
C;Species: Gallus gallus (chicken)
C;Date: 04-Mar-1993 #sequence_revision 18-Nov-1994 #text_change 09-Jul-2004
C;Accession: A42411
R;Leachman, S.A.; Gallagher, P.J.; Herring, B.P.; McPhaul, M.J.; Stull, J.T.
J. Biol. Chem. 267, 4930-4938, 1992
A;Title: Biochemical properties of chimeric skeletal and smooth muscle myosin light chain
A;Reference number: A42411; MUID:92165861; PMID:1371510
A;Accession: A42411
A;Status: preliminary; not compared with conceptual translation
A;Molecule type: nucleic acid; protein
A;Residues: 1-16 <LEA>
A;Cross-references: UNIPROT:Q7LZ16
A;Experimental source: skeletal muscle
A;Note: sequence extracted from NCBI backbone (NCBIP:84332)

Query Match 27.3%; Score 21; DB 2; Length 16;
Best Local Similarity 62.5%; Pred. No. 3.8e+03;
Matches 5; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 4 RGPGRFV 11
| | | | |
Db 1 RGPAPGV 8

RESULT 35
I51879
cystathionine beta-synthase - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 09-Jul-2004
C;Accession: I51879
R;Sebastiao, G.; Sperandio, M.P.; Panico, M.; de Franchis, R.; Kraus, J.P.; Andria, G.
Am. J. Hum. Genet. 56, 1324-1333, 1995
A;Title: The molecular basis of homocystinuria due to cystathionine beta-synthase deficie
A;Reference number: I51879; MUID:95282779; PMID:7762555
A;Accession: I51879
A;Status: preliminary; translated from GB/EMBL/DBD
A;Molecule type: DNA
A;Residues: 1-16 <RES>
A;Cross-references: UNIPROT:Q16350; GB:S78267; NID:g999349; PIDN:AAB34404.1; PID:g999350

Query Match 27.3%; Score 21; DB 2; Length 16;
Best Local Similarity 80.0%; Pred. No. 3.8e+03;
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 6 PGRFV 10
| | | | |
Db 7 PGRFV 11

```
RESULT 36
S09722
2S albumin small chain 1 nIV - rape (fragments)
C:Species: Brassica napus (rape)
C>Date: 19-Mar-1997 #sequence_revision 13-Mar-1998 #text_change 13-Mar-1998
C:Accession: S09722
R:Monsalve, R.I.; Menendez-Arias, L.; Lopez-Otin, C.; Rodriguez, R.
FEBS Lett. 263, 209-212, 1990
A:Title: beta-Turns as structural motifs for the proteolytic processing of seed proteins
A:Reference number: S09720; MUID:90242974; PMID:2185951
A:Accession: S09722
A:Molecule type: protein
A:Residues: 1-9;10-18 <MON>
A:Experimental source: seed

Query Match      27.3%; Score 21; DB 2; Length 18;
Best Local Similarity 57.1%; Pred. No. 4.2e+03;
Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1 RIQPGPG 7
Db 6 RIQPG 12

RESULT 37
I49037
TCR delta chain V-D-J region - mouse (fragment)
C:Species: Mus musculus (house mouse)
C>Date: 21-Jan-1994 #sequence_revision 18-Nov-1994 #text_change 05-Nov-1999
C:Accession: I49037
R:Rezqueria, A.; Wilde, D.B.; McConnell, T.J.; Sturmhofel, K.; Valas, R.B.; Shevach, E.M.
Eur. J. Immunol. 22, 491-498, 1992
A:Title: Mouse autoreactive gamma/delta T cells. II. Molecular characterization of the T
A:Reference number: A49037; MUID:92164730; PMID:1311262
A:Accession: I49037
A>Status: Preliminary
A:Molecule type: DNA
A:Residues: 1-19 <ZQ>
A:Cross-references: GB:S90660; NID:g246304; PIDN:AA21555.1; PID:g246305
A:Experimental source: dendritic epidermal T-cell lines
A>Note: sequence extracted from NCBI backbone (NCBI:90660, NCBIP:90671)

Query Match      27.3%; Score 21; DB 2; Length 19;
Best Local Similarity 50.0%; Pred. No. 4.4e+03;
Matches 5; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 5 GPGRAFVTIG 14
Db 2 GGGRIWRLIG 11

RESULT 38
A39269
LX-1 tumor antigen - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 18-Oct-1991 #sequence_revision 18-Oct-1991 #text_change 05-Jan-1996
C:Accession: A39269
R:Rosenbaum, L.C.; Neuwelt, E.A.; Van Tol, H.H.M.; Loh, Y.P.; Verbalis, J.G.; Hellstrom
Proc. Natl. Acad. Sci. U.S.A. 87, 9928-9932, 1990
A:Title: Expression of neurophysin-related precursor in cell membranes of a small-cell l
A:Reference number: A39269; MUID:91088624; PMID:1702222
A:Accession: A39269
A:Molecule type: protein
A:Residues: 1-22 <ROS>
C:Superfamily: oxytocin-neurophysin

Query Match      27.3%; Score 21; DB 2; Length 22;
Best Local Similarity 66.7%; Pred. No. 5e+03;
Matches 4; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 5 GPGRAF 10
```

```
Db 17 GKGRFF 22

RESULT 39
T01780
probable gag polymerase pseudogene - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 13-Aug-1999 #sequence_revision 13-Aug-1999 #text_change 20-Oct-2000
C:Accession: T01780
R:Repaske, R.; O'Neill, R.R.; Steele, P.E.; Martin, M.A.
Proc. Natl. Acad. Sci. U.S.A. 80, 678-682, 1983
A:Title: Characterization and partial nucleotide sequence of endogenous type C retrovirus
A:Reference number: Z14423; MUID:83143994; PMID:6298769
A:Accession: T01780
A>Status: translated from GB/EMBL/DBJ; conceptual translation of pseudogene
A:Molecule type: DNA
A:Residues: 1-24 <RSP>
A:Cross-references: EMBL:J00274; NID:g182154
C:Keywords: pseudogene

Query Match      27.3%; Score 21; DB 4; Length 24;
Best Local Similarity 33.3%; Pred. No. 5.4e+03;
Matches 5; Conservative 3; Mismatches 7; Indels 0; Gaps 0;

QY 1 RIQPGGFAFVTIG 15
Db 6 RRPRQGGGALLNLAE 20

RESULT 40
A25941
Ig heavy chain J-H1 region - rat (fragment)
C:Species: Rattus norvegicus (Norway rat)
C>Date: 05-Jun-1998 #sequence_revision 05-Jun-1998 #text_change 23-Jul-1999
C:Accession: A25941; JH0666
R:Brueggemann, M.; Free, J.; Diamond, A.; Howard, J.; Cobbold, S.; Waldmann, H.
Proc. Natl. Acad. Sci. U.S.A. 83, 6075-6079, 1986
A:Title: Immunoglobulin heavy chain locus of the rat: striking homology to mouse antibody
A:Reference number: A25941; MUID:86287397; PMID:3016742
A:Accession: A25941
A:Molecule type: DNA
A:Residues: 1-18 <BR>
A:Cross-references: GB:M13798; NID:g204707; PIDN:AAA41371.1; PID:g554447
R:Lang, P.; Mocikat, R.
Gene 102, 261-264, 1991
A:Title: Immunoglobulin heavy-chain joining genes in the rat: comparison with mouse and
A:Reference number: JH0666; MUID:91340162; PMID:1908401
A:Accession: JH0666
A:Molecule type: DNA
A:Residues: 1-18 <LAN>
A:Cross-references: EMBL:X56791
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin

Query Match      26.6%; Score 20.5; DB 2; Length 18;
Best Local Similarity 55.6%; Pred. No. 5.1e+03;
Matches 5; Conservative 1; Mismatches 2; Indels 1; Gaps 1;

QY 5 GPGRAFVTI 13
Db 9 GPG-TWTV 16

RESULT 41
S13279
Ile-Ser-bradykinin - human (fragment)
N:Alternate names: T-kinin
C:Species: Homo sapiens (man)
C>Date: 02-Dec-1993 #sequence_revision 13-Mar-1997 #text_change 09-Jul-2004
C:Accession: S13279
R:Wunderer, G.; Walter, I.; Eschenbacher, B.; Lang, M.; Kellermann, J.; Kindermann, G.
Biol. Chem. Hoppe-Seyler 371, 977-981, 1990
```


A;Title: Ile-Ser-bradykinin is an aberrant permeability factor in various human malignan
A;Reference number: S13279; MUID:91166748; PMID:2076202
A;Accession: S13279
A;Molecule type: protein
A;Residues: 1-11 <WUN>
A;Cross-references: UNIPROT:Q7M4P1
C;Keywords: bradykinin

Query Match 26.0%; Score 20; DB 2; Length 11;
Best Local Similarity 66.7%; Pred. No. 4e+03;
Matches 4; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 IQRPG 7
| | |
Db 1 ISRPG 6

RESULT 42

S43634
cytochrome-c oxidase (EC 1.9.3.1) chain VIIc, cardiac - rainbow trout (fragment)
C;Species: Oncorhynchus mykiss (rainbow trout)
C;Date: 20-Oct-1994 #sequence_revision 01-Nov-1996 #text_change 16-Jul-1999
A;Accession: S43634
R;Freund, R.; Kadenbach, B.
Eur. J. Biochem. 221, 1111-1116, 1994
A;Title: Identification of tissue-specific isoforms for subunits Vb and VIIa of cytochrome c oxidase
A;Reference number: S43624; MUID:94237150; PMID:8181469
A;Accession: S43634
A;Molecule type: protein
A;Residues: 1-15 <FRE>
A;Note: the source is designated as Salmo gairdneri
C;Genetics:
A;Genome: nuclear
C;Keywords: cardiac muscle; heart; membrane-associated complex; mitochondrion; oxidoreductase

Query Match 26.0%; Score 20; DB 2; Length 15;
Best Local Similarity 75.0%; Pred. No. 5.3e+03;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 5 GPGR 8
| | |
Db 6 GPGQ 9

RESULT 43

D28587
T-cell receptor beta-2 chain J-B2.5 segment - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 16-Aug-1988 #sequence_revision 16-Aug-1988 #text_change 05-Nov-1999
A;Accession: D28587
R;Toyonaga, B.; Yoshikai, Y.; Vadasz, V.; Chin, B.; Mak, T.W.
Proc. Natl. Acad. Sci. U.S.A. 82, 8624-8628, 1985
A;Title: Organization and sequences of the diversity, joining, and constant region genes of the T-cell receptor
A;Reference number: A94081; MUID:86094276; PMID:3866244
A;Accession: D28587
A;Molecule type: DNA
A;Residues: 1-15 <TOV>
A;Cross-references: GB:M14159; NID:g338852; PIDN:AAA60679.1; PID:g553690
C;Keywords: T-cell receptor

Query Match 26.0%; Score 20; DB 2; Length 15;
Best Local Similarity 33.3%; Pred. No. 5.3e+03;
Matches 3; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 5 GPGRAFVTI 13
| | |
Db 7 GPGTRLLVL 15

RESULT 44

C34874
transforming protein (N-rasB) - rat (fragment)
C;Species: Rattus norvegicus (Norway rat)

C;Date: 20-Jul-1990 #sequence_revision 20-Jul-1990 #text_change 09-Jul-2004
A;Accession: C34874
R;McMahon, G.; Davis, E.F.; Huber, L.J.; Kim, Y.; Wogan, G.N.
Proc. Natl. Acad. Sci. U.S.A. 87, 1104-1108, 1990
A;Title: Characterization of c-Ki-ras and N-ras oncogenes in aflatoxin B-1-induced rat l
A;Reference number: A34874; MUID:90138946; PMID:2105496
A;Accession: C34874
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-15 <MCM>
A;Cross-references: UNIPROT:Q7M030

Query Match 26.0%; Score 20; DB 2; Length 15;
Best Local Similarity 44.4%; Pred. No. 5.3e+03;
Matches 4; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 5 GPGRAFVTI 13
| | |
Db 6 GIGKSAULTI 14

RESULT 45

PH1790
T cell receptor alpha chain V region (clone 2PBL V alpha 24-6) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 16-Jul-1999 #sequence_revision 16-Jul-1999 #text_change 16-Jul-1999
A;Accession: PH1790
R;Porcellini, S.; Yockey, C.E.; Brenner, M.B.; Balk, S.P.
J. Exp. Med. 178, 1-16, 1993
A;Title: Analysis of T cell antigen receptor (TCR) expression by human peripheral blood c

A;Reference number: PH1754; MUID:93301585; PMID:8391057

A;Accession: PH1790
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-16 <POR>

Query Match 26.0%; Score 20; DB 2; Length 16;
Best Local Similarity 75.0%; Pred. No. 5.6e+03;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 3 QRGP 6
| | |
Db 5 ERGP 8

Search completed: May 16, 2005, 13:07:12
Job time : 21.0769 secs

This Page Blank (uspto)

2

```
; PRIOR APPLICATION NUMBER: PR 95/07914
; PRIOR FILING DATE: 1995-06-30
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 24
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: peptide
US-09-827-345-24

Query Match      73.2%; Score 90; DB 10; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.5e-06;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 NNTRKSRIQRGPGRFVFT 19
    ||||| ||||| ||||| |||||
Db 2 NNTRKSRIQRGPGRFVFT 20

RESULT 6
US-10-311-111-1
; Sequence 1, Application US/10311111
; Publication No. US20030121065A1
; GENERAL INFORMATION:
; APPLICANT: SHIBA, KIYOTAKA
; TITLE OF INVENTION: MULTIFUNCTIONAL BASE SEQUENCE AND ARTIFICIAL GENE CONTAINING THE
; FILE REFERENCE: 4439-4004
; CURRENT APPLICATION NUMBER: US/10/311,111
; CURRENT FILING DATE: 2002-12-13
; PRIOR APPLICATION NUMBER: JP 2000-180997
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: PRT
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Designed peptide
US-10-311-111-1

Query Match      71.5%; Score 88; DB 14; Length 20;
Best Local Similarity 90.0%; Pred. No. 3e-06;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4 RKSERIORGPGRFVFTIGKI 23
    ||||| ||||| ||||| |||||
Db 1 RKSERIORGPGRFVFTIGKI 20

RESULT 7
US-10-398-932-1
; Sequence 1, Application US/10398932
; Publication No. US20040171803A1
; GENERAL INFORMATION:
; APPLICANT: SHIBA, KIYOTAKA
; APPLICANT: OHNO, TSUNESYA
; TITLE OF INVENTION: ARTIFICIAL PROTEINS WITH ENRICHED IMMUNOGEN
; TITLE OF INVENTION: OF EPITOPE
; FILE REFERENCE: 024918-0103
; CURRENT APPLICATION NUMBER: US/10/398,932
; CURRENT FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: PCT/JP01/08893
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: JP 2000/314288
; PRIOR FILING DATE: 2000-10-13
; NUMBER OF SEQ ID NOS: 55
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: HIV PEPTIDE

; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetically Designed
US-10-398-932-1

Query Match      71.5%; Score 88; DB 16; Length 20;
Best Local Similarity 90.0%; Pred. No. 3e-06;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4 RKSERIORGPGRFVFTIGKI 23
    ||||| ||||| ||||| |||||
Db 1 RKSERIORGPGRFVFTIGKI 20

RESULT 8
US-10-062-710-45
; Sequence 45, Application US/10062710
; Publication No. US20030049253A1
; GENERAL INFORMATION:
; APPLICANT: Li, Frank Q.
; APPLICANT: Chu, Yong-Liang
; APPLICANT: Qiu, Jian-Tai
; TITLE OF INVENTION: Polymeric Conjugates for Delivery of
; TITLE OF INVENTION: MHC-Recognized Epitopes
; TITLE OF INVENTION: Via Peptide Vaccines
; FILE REFERENCE: 3781-001-27
; CURRENT APPLICATION NUMBER: US/10/062,710
; CURRENT FILING DATE: 2002-02-05
; PRIOR APPLICATION NUMBER: US 60/310,498
; PRIOR FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 232
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 45
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: HIV Helper-T Cell Epitopes
US-10-062-710-45

Query Match      66.7%; Score 82; DB 14; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.1e-05;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 9 IORGPGRAFVTIGKIG 24
    ||||| ||||| ||||| |||||
Db 2 IORGPGRAFVTIGKIG 17

RESULT 9
US-09-810-310-15
; Sequence 15, Application US/09810310
; Patent No. US20020044948A1
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Khleif, Samir N.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR CO-STIMULATION OF
; TITLE OF INVENTION: IMMUNOLOGICAL RESPONSES TO PEPTIDE ANTIGENS
; FILE REFERENCE: 15280-415100US
; CURRENT APPLICATION NUMBER: US/09/810,310
; CURRENT FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: 60/189,396
; PRIOR FILING DATE: 2000-03-15
; NUMBER OF SEQ ID NOS: 61
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: HIV PEPTIDE
```

OTHER INFORMATION: ANTIGEN
US-09-810-310-15

Query Match 62.6%; Score 77; DB 9; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.0001;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 RIQGPGRFVTVIGK 22
| | | | | | | | | | | | | | | |
DB 1 RIQGPGRFVTVIGK 15

RESULT 10
US-09-810-310-24
; Sequence 24, Application US/09810310
; Patent No. US20020044948A1
; GENERAL INFORMATION:
; APPLICANT: Kneif, Samir N.
; APPLICANT: Berzofsky, Jay A.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR CO-STIMULATION OF
; FILE OF INVENTION: IMMUNOLOGICAL RESPONSES TO PEPTIDE ANTIGENS
; FILE REFERENCE: 15280-415100US
; CURRENT APPLICATION NUMBER: US/09/810,310
; CURRENT FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: 60/189,396
; PRIOR FILING DATE: 2000-03-15
; NUMBER OF SEQ ID NOS: 61
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 24
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: HIV PEPTIDE
; OTHER INFORMATION: ANTIGEN
US-09-810-310-24

Query Match 62.6%; Score 77; DB 9; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.0001;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 RIQGPGRFVTVIGK 22
| | | | | | | | | | | | | | | |
DB 1 RIQGPGRFVTVIGK 15

RESULT 11
US-09-989-621-8
; Sequence 8, Application US/09989621
; Patent No. US20020151683A1
; GENERAL INFORMATION:
; APPLICANT: Mogam Biotechnology Research Institute
; APPLICANT: Kim, Tae-Youn
; APPLICANT: Lee, Ki-Young
; APPLICANT: Chang, Jin-Soo
; APPLICANT: Cho, Sung-Yoo
; APPLICANT: Hwang, Yu-Kyeong
; APPLICANT: Choi, Myeong
; APPLICANT: Cheong, Hong-Seok
; TITLE OF INVENTION: Liposomes Comprising Peptide Antigens
; FILE REFERENCE: 0136/08154
; CURRENT APPLICATION NUMBER: US/09/989,621
; CURRENT FILING DATE: 2001-11-20
; PRIOR APPLICATION NUMBER: 09/051,006
; PRIOR FILING DATE: 2000-11-17
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 15
; TYPE: PRT
; ORGANISM: HIV
US-09-989-621-8

Query Match 62.6%; Score 77; DB 9; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.0001;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 RIQGPGRFVTVIGK 22
| | | | | | | | | | | | | | | |
DB 1 RIQGPGRFVTVIGK 15

RESULT 12
US-09-827-688-9
; Sequence 9, Application US/09827688
; Publication No. US20030165476A1
; GENERAL INFORMATION:
; APPLICANT: ORSON, FRANK
; APPLICANT: KINSEY, BERMA
; APPLICANT: BHOGAL, BALBIR
; TITLE OF INVENTION: MACROAGGREGATED PROTEIN CONJUGATES AS ORAL GENETIC IMMUNIZATION DI
; FILE OF INVENTION: AGENTS
; FILE REFERENCE: P01949US1/10004014
; CURRENT APPLICATION NUMBER: US/09/827,688
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: 60/195,680
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9
; LENGTH: 15
; TYPE: PRT
; ORGANISM: HIV p18
US-09-827-688-9

Query Match 62.6%; Score 77; DB 10; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.0001;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 RIQGPGRFVTVIGK 22
| | | | | | | | | | | | | | | |
DB 1 RIQGPGRFVTVIGK 15

RESULT 13
US-09-077-439A-3
; Sequence 3, Application US/09077439A
; Publication No. US20030202989A1
; GENERAL INFORMATION:
; APPLICANT: Collier, R. John
; APPLICANT: Blanke, Steven R.
; APPLICANT: Milne, Jill C.
; APPLICANT: Benson, Ericka L.
; APPLICANT: Ballard, Jimmy D.
; APPLICANT: Starnbach, Michael N.
; TITLE OF INVENTION: Use of Toxin Peptides and/or Affinity
; FILE REFERENCE: 00246/187002
; CURRENT APPLICATION NUMBER: US/09/077,439A
; CURRENT FILING DATE: 1999-04-08
; PRIOR APPLICATION NUMBER: PCT/US96/20463
; PRIOR FILING DATE: 1996-12-13
; PRIOR APPLICATION NUMBER: US 60/019,275
; PRIOR FILING DATE: 1996-06-07
; PRIOR APPLICATION NUMBER: US 60/008,518
; PRIOR FILING DATE: 1995-12-13
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Homo sapien
US-09-077-439A-3

Query Match 62.6%; Score 77; DB 10; Length 15;

Best Local Similarity 100.0%; Pred. No. 0.0001;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 RIQPGGRAFTVIGK 22
| | | | | | | | | |
DB 1 RIQPGGRAFTVIGK 15

RESULT 14

US-10-133-210-246
; Sequence 246, Application US/10133210
; Publication No. US20030103964A1
; GENERAL INFORMATION:
; APPLICANT: Delisi, Charles
; APPLICANT: Berzofsky, Jay
; APPLICANT: Gulukota, Kamalakar
; APPLICANT: Vaccaro, Dennis
; APPLICANT: Weng, Zhiping
; APPLICANT: Zhang, Chao
; TITLE OF INVENTION: METHODS FOR DESIGNING MOLECULAR CONJUGATES AND
; FILE REFERENCE: BU-035AX
; CURRENT APPLICATION NUMBER: US/10/133,210
; CURRENT FILING DATE: 2002-04-26
; NUMBER OF SEQ ID NOS: 281
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 246
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-133-210-246

Query Match 62.6%; Score 77; DB 14; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.0001;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 RIQPGGRAFTVIGK 22
| | | | | | | | | |
DB 1 RIQPGGRAFTVIGK 15

RESULT 15

US-10-133-210-262
; Sequence 262, Application US/10133210
; Publication No. US20030103964A1
; GENERAL INFORMATION:
; APPLICANT: Delisi, Charles
; APPLICANT: Berzofsky, Jay
; APPLICANT: Gulukota, Kamalakar
; APPLICANT: Vaccaro, Dennis
; APPLICANT: Weng, Zhiping
; APPLICANT: Zhang, Chao
; TITLE OF INVENTION: METHODS FOR DESIGNING MOLECULAR CONJUGATES AND
; FILE REFERENCE: BU-035AX
; CURRENT APPLICATION NUMBER: US/10/133,210
; CURRENT FILING DATE: 2002-04-26
; NUMBER OF SEQ ID NOS: 281
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 262
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-133-210-262

Query Match 62.6%; Score 77; DB 14; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.0001;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 RIQPGGRAFTVIGK 22
| | | | | | | | | |
DB 1 RIQPGGRAFTVIGK 15

RESULT 16

US-10-147-910-6
; Sequence 6, Application US/10147910
; Publication No. US20030124718A1
; GENERAL INFORMATION:
; APPLICANT: Fuller, Deborah
; APPLICANT: Fuller, James
; APPLICANT: Haynes, Joel
; APPLICANT: Shipley, Timothy
; TITLE OF INVENTION: Vaccine Composition
; FILE REFERENCE: 033267-006
; CURRENT APPLICATION NUMBER: US/10/147,910
; CURRENT FILING DATE: 2002-05-20
; PRIOR APPLICATION NUMBER: US 60/291,654
; PRIOR FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: US 60/291,655
; PRIOR FILING DATE: 2001-05-18
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 15
; TYPE: PRT
; ORGANISM: HIV
US-10-147-910-6

Query Match 62.6%; Score 77; DB 14; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.0001;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 RIQPGGRAFTVIGK 22
| | | | | | | | | |
DB 1 RIQPGGRAFTVIGK 15

RESULT 17

US-10-787-880-2
; Sequence 2, Application US/10787880
; Publication No. US20050025777A1
; GENERAL INFORMATION:
; APPLICANT: Pohlmann, Edward L.
; APPLICANT: Sheehy, Michael J.
; APPLICANT: Barton, Kenneth A.
; TITLE OF INVENTION: PARTICLE-MEDIATED DELIVERY OF ANTIGENS
; FILE REFERENCE: 033267-018
; CURRENT APPLICATION NUMBER: US/10/787,880
; CURRENT FILING DATE: 2004-02-27
; PRIOR APPLICATION NUMBER: US/09/191,772
; PRIOR FILING DATE: 1998-11-13
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 15
; TYPE: PRT
; ORGANISM: HIVgp120
US-10-787-880-2

Query Match 62.6%; Score 77; DB 17; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.0001;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 RIQPGGRAFTVIGK 22
| | | | | | | | | |
DB 1 RIQPGGRAFTVIGK 15

RESULT 18

US-10-062-710-44
; Sequence 44, Application US/10062710

; Publication No. US20030049253A1

; GENERAL INFORMATION:

; APPLICANT: Li, Frank Q.

; APPLICANT: Chu, Yong-Liang

; APPLICANT: Qiu, Jian-Tai

; TITLE OF INVENTION: Polymeric Conjugates for Delivery of

; TITLE OF INVENTION: MHC-Recognized Epitopes

; TITLE OF INVENTION: Via Peptide Vaccines

; FILE REFERENCE: 3781-001-27

; CURRENT APPLICATION NUMBER: US/10/062,710

; CURRENT FILING DATE: 2002-02-05

; PRIOR APPLICATION NUMBER: US 60/310,498

; PRIOR FILING DATE: 2001-08-08

; NUMBER OF SEQ ID NOS: 232

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 44

; LENGTH: 16

; TYPE: PRT

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: HIV Helper-T Cell Epitopes

US-10-062-710-44

Query Match 62.6%; Score 77; DB 14; Length 16;

Best Local Similarity 100.0%; Pred. No. 0.00011;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 RIQPGGRAFTVIGK 22

Db 2 RIQPGGRAFTVIGK 16

RESULT 19

US-10-239-313A-186

; Sequence 186, Application US/10239313A

; Publication No. US20030175285A1

; GENERAL INFORMATION:

; APPLICANT: KLINGUER - HAMOUR, Christine

; APPLICANT: CORVAIA, Nathalie

; APPLICANT: BECK, Alain

; APPLICANT: GOETSCH, Liliane

; TITLE OF INVENTION: MOLECULE OF PHARMACEUTICAL INTEREST COMPRISING AT ITS

; TITLE OF INVENTION: N-TERMINAL A GLUTAMIC ACID OR A GLUTAMINE IN THE FORM

; TITLE OF INVENTION: OF A PHYSIOLOGICALLY ACCEPTABLE STRONG ACID

; FILE REFERENCE: 343 727 - US

; CURRENT APPLICATION NUMBER: US/10/239,313A

; CURRENT FILING DATE: 2002-09-19

; PRIOR APPLICATION NUMBER: FR 00/03711

; PRIOR FILING DATE: 2000-03-23

; PRIOR APPLICATION NUMBER: PCT 01/70772

; PRIOR FILING DATE: 2001-03-22

; NUMBER OF SEQ ID NOS: 697

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 186

; LENGTH: 15

; TYPE: PRT

; ORGANISM: Human immunodeficiency virus

US-10-239-313A-186

Query Match

Best Local Similarity 58.5%; Score 72; DB 14; Length 15;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 ORPGGRAFTVIGKI 23

Db 2 ORPGGRAFTVIGKI 15

RESULT 20

US-10-373-592-113

; Sequence 113, Application US/10373592

; Publication No. US20040001851A1

; GENERAL INFORMATION:

; APPLICANT: HAYNES, BARTON F.

; APPLICANT: KORBER, BETTE T.

; APPLICANT: DE LORIMIER, ROBERT M.

; TITLE OF INVENTION: POLYVALENT IMMUNOGEN

; FILE REFERENCE: 1579-785

; CURRENT APPLICATION NUMBER: US/10/373,592

; CURRENT FILING DATE: 2003-02-26

; PRIOR APPLICATION NUMBER: 10/289,228

; PRIOR FILING DATE: 2002-11-07

; PRIOR APPLICATION NUMBER: 60/331,036

; PRIOR FILING DATE: 2001-11-07

; NUMBER OF SEQ ID NOS: 120

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 113

; LENGTH: 22

; TYPE: PRT

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Synthetic

; OTHER INFORMATION: peptide

US-10-373-592-113

Query Match 56.1%; Score 69; DB 15; Length 22;

Best Local Similarity 76.2%; Pred. No. 0.0024;

Matches 16; Conservative 0; Mismatches 3; Indels 2; Gaps 1;

Qy 1 NNTKSRIRQPGGRAFTVIG 21

Db 4 NNTKRS--IQIGPGRAFTVIG 22

RESULT 21

US-10-621-675-154

; Sequence 154, Application US/10621675

; Publication No. US20050049398A1

; GENERAL INFORMATION:

; APPLICANT: De Leys, Robert

; TITLE OF INVENTION: PROCESS FOR THE DETERMINATION OF PEPTIDES CORRESPONDING

; TITLE OF INVENTION: TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND THEIR USE IN

; TITLE OF INVENTION: A PROCESS FOR DETERMINATION OF ANTIBODIES OF

; TITLE OF INVENTION: BIOTINYLATED PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT

; TITLE OF INVENTION: EPITOPES, A PROCESS FOR PREPARING THEM AND COMPOSITIONS

; TITLE OF INVENTION: CONTAINING THEM

; FILE REFERENCE: 2752-11

; CURRENT APPLICATION NUMBER: US/10/621,675

; CURRENT FILING DATE: 2003-07-18

; PRIOR APPLICATION NUMBER: US/09/576,824A

; PRIOR FILING DATE: 1996-09-30

; PRIOR APPLICATION NUMBER: 08/723,425

; PRIOR FILING DATE: 1993-11-22

; PRIOR APPLICATION NUMBER: PCT/EP93/00517

; PRIOR FILING DATE: 1993-03-08

; PRIOR APPLICATION NUMBER: EP 92400598.6

; PRIOR FILING DATE: 1992-03-06

; NUMBER OF SEQ ID NOS: 600

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 154

; LENGTH: 23

; TYPE: PRT

; ORGANISM: Human immunodeficiency virus

US-10-621-675-154

Query Match

Best Local Similarity 56.1%; Score 69; DB 17; Length 23;

Matches 16; Conservative 1; Mismatches 4; Indels 2; Gaps 1;

Qy 1 NNTKSRIRQPGGRAFTVIGKI 23

Db 1 NNTKRS--IHIGPGRAFTVIGI 21

RESULT 22


```
US-10-239-313A-536
; Sequence 536, Application US/10239313A
; Publication No. US20030175285A1
; GENERAL INFORMATION:
; APPLICANT: KLINGER - HAMOUR, Christine
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: BECK, Alain
; APPLICANT: GOETSCH, Liliane
; TITLE OF INVENTION: MOLECULE OF PHARMACEUTICAL INTEREST COMPRISING AT ITS
; N-TERMINAL A GLUTAMIC ACID OR A GLUTAMINE IN THE FORM
; TITLE OF INVENTION: OF A PHYSIOLOGICALLY ACCEPTABLE STRONG ACID
; FILE REFERENCE: 343 727 US
; CURRENT APPLICATION NUMBER: US/10/239,313A
; CURRENT FILING DATE: 2002-09-19
; PRIOR APPLICATION NUMBER: FR 00/03711
; PRIOR FILING DATE: 2000-03-23
; PRIOR APPLICATION NUMBER: PCT 01/70772
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 697
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 536
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Human immunodeficiency virus
US-10-239-313A-536

Query Match      55.3%; Score 68; DB 14; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.002;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      10  QRGPGRAFTVGK 22
Db      1  QRGPGRAFTVGK 13

RESULT 23
US-10-622-003-6
; Sequence 6, Application US/10622003
; Publication No. US20050014230A1
; GENERAL INFORMATION:
; APPLICANT: Chin, Li-Te
; TITLE OF INVENTION: PREPARATION OF FULLY HUMAN ANTIBODIES
; FILE REFERENCE: 16863-002001
; CURRENT APPLICATION NUMBER: US/10/622,003
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetically generated peptide
US-10-622-003-6

Query Match      55.3%; Score 68; DB 17; Length 15;
Best Local Similarity 93.3%; Pred. No. 0.0023;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      4  RKSERIQRGPAFV 18
Db      1  RKSIIRQGPGRFV 15

RESULT 24
US-10-621-675-155
; Sequence 155, Application US/10621675
; Publication No. US20050049398A1
; GENERAL INFORMATION:
; APPLICANT: De Leys, Robert
; TITLE OF INVENTION: PROCESS FOR THE DETERMINATION OF PEPTIDES CORRESPONDING
; TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND THEIR USE IN
; FILE REFERENCE: 1579-785
; CURRENT APPLICATION NUMBER: US/10/373,592
```

```
; TITLE OF INVENTION: BIOTINYLATED PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT
; TITLE OF INVENTION: EPITOPES, A PROCESS FOR PREPARING THEM AND COMPOSITIONS
; FILE REFERENCE: 2752-11
; CURRENT APPLICATION NUMBER: US/10/621,675
; CURRENT FILING DATE: 2003-07-18
; PRIOR APPLICATION NUMBER: US/09/576,824A
; PRIOR FILING DATE: 1996-09-30
; PRIOR APPLICATION NUMBER: 09/146,028
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP93/00517
; PRIOR FILING DATE: 1993-03-08
; PRIOR APPLICATION NUMBER: EP 92400598.6
; PRIOR FILING DATE: 1992-03-06
; NUMBER OF SEQ ID NOS: 600
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 155
; LENGTH: 23
; TYPE: PRT
; ORGANISM: Human immunodeficiency virus
US-10-621-675-155

Query Match      54.5%; Score 67; DB 17; Length 23;
Best Local Similarity 69.6%; Pred. No. 0.0051;
Matches 16; Conservative 1; Mismatches 4; Indels 2; Gaps 1;

Qy      1  NNTKSERIQRGPGRAFTVGKI 23
Db      1  NNTKRS--IYIGPGRAFTVTGRI 21

RESULT 25
US-09-993-307-21
; Sequence 21, Application US/09993307
; Publication No. US20030162733A1
; GENERAL INFORMATION:
; APPLICANT: HAYNES, Joel R.
; APPLICANT: ARRINGTON, Joshua
; TITLE OF INVENTION: NUCLEIC ACID ADJUVANTS
; FILE REFERENCE: APP41.20
; CURRENT APPLICATION NUMBER: US/09/993,307
; CURRENT FILING DATE: 2001-11-26
; PRIOR APPLICATION NUMBER: 60/253,381
; PRIOR FILING DATE: 2000-11-27
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 21
; LENGTH: 15
; TYPE: PRT
; ORGANISM: synthetic construct
US-09-993-307-21

Query Match      53.7%; Score 66; DB 10; Length 15;
Best Local Similarity 86.7%; Pred. No. 0.0046;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      8  RIQRGPGRAFTVGK 22
Db      1  RIQRGPGRAFTVGK 15

RESULT 26
US-10-373-592-112
; Sequence 112, Application US/10373592
; Publication No. US20040001851A1
; GENERAL INFORMATION:
; APPLICANT: HAYNES, BARTON F.
; APPLICANT: KORBER, BETTE T.
; APPLICANT: DE LORIMIER, ROBERT M.
; TITLE OF INVENTION: POLYVALENT IMMUNOGEN
; FILE REFERENCE: 1579-785
; CURRENT APPLICATION NUMBER: US/10/373,592
```

; CURRENT FILING DATE: 2003-02-26
; PRIOR APPLICATION NUMBER: 10/289,228
; PRIOR FILING DATE: 2002-11-07
; PRIOR APPLICATION NUMBER: 60/331,036
; PRIOR FILING DATE: 2001-11-07
; NUMBER OF SEQ ID NOS: 120
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 112
; LENGTH: 22
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: peptide
US-10-373-592-112

Query Match 52.0%; Score 64; DB 15; Length 22;
Best Local Similarity 71.4%; Pred. No. 0.014; 4; Indels 2; Gaps 1;
Matches 15; Conservative 0; Mismatches 4; Indels 2; Gaps 1;

Qy 1 NNTKSERIQRGPGRAFTVIG 21
| | | | | | | | | | | | | | | | | | | | | |
Db 4 NNTKRS--INIGPGRAFTYTG 22

RESULT 27
US-10-373-592-114
; Sequence 114, Application US/10373592
; Publication No. US20040001851A1
; GENERAL INFORMATION:
; APPLICANT: HAYNES, BARTON F.
; APPLICANT: KORBET, BETTE T.
; APPLICANT: DE LORIMIER, ROBERT M.
; TITLE OF INVENTION: POLYVALENT IMMUNOGEN
; FILE REFERENCE: 1579-785
; CURRENT APPLICATION NUMBER: US/10/373,592
; CURRENT FILING DATE: 2003-02-26
; PRIOR APPLICATION NUMBER: 10/289,228
; PRIOR FILING DATE: 2002-11-07
; PRIOR APPLICATION NUMBER: 60/331,036
; PRIOR FILING DATE: 2001-11-07
; NUMBER OF SEQ ID NOS: 120
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 114
; LENGTH: 22
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: peptide
US-10-373-592-114

Query Match 52.0%; Score 64; DB 15; Length 22;
Best Local Similarity 71.4%; Pred. No. 0.014;
Matches 15; Conservative 0; Mismatches 4; Indels 2; Gaps 1;

Qy 1 NNTKSERIQRGPGRAFTVIG 21
| | | | | | | | | | | | | | | | | | | | | |
Db 4 NNTKRS--INIGPGRAFTYTG 22

RESULT 28
US-10-628-004-12
; Sequence 12, Application US/10628004
; Publication No. US20050058983A1
; GENERAL INFORMATION:
; APPLICANT: ABGENIX, INC.
; APPLICANT: PUBLIC HEALTH RESEARCH INSTITUTE
; APPLICANT: PINTER, ABRAHAM
; APPLICANT: HE, YUXIAN
; APPLICANT: CORVALAN, JOSE R.
; TITLE OF INVENTION: USE OF TRANSGENIC MICE FOR THE EFFICIENT ISOLATION OF
; TITLE OF INVENTION: NOVEL HUMAN MONOCLONAL ANTIBODIES WITH NEUTRALIZING

; TITLE OF INVENTION: ACTIVITY AGAINST PRIMARY HIV-1 STRAINS
; FILE REFERENCE: ABX-PHRI PCT
; CURRENT APPLICATION NUMBER: US/10/628,004
; CURRENT FILING DATE: 2003-07-25
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
; LENGTH: 24
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: peptide
US-10-628-004-12

Query Match 52.0%; Score 64; DB 17; Length 24;
Best Local Similarity 63.6%; Pred. No. 0.015; 8; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 2 NTRKSERIQRGPGRAFTVIGKI 23
| | | | | | | | | | | | | | | | | | | | | |
Db 2 NKRKRIHIQRGPGRAFTTKNI 23

RESULT 29
US-10-239-313A-535
; Sequence 535, Application US/10239313A
; Publication No. US20030175285A1
; GENERAL INFORMATION:
; APPLICANT: KLINGUER - HAMOUR, Christine
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: BECK, Alain
; APPLICANT: GOETSCH, Liliane
; TITLE OF INVENTION: MOLECULE OF PHARMACEUTICAL INTEREST COMPRISING AT ITS
; TITLE OF INVENTION: N-TERMINAL A GLUTAMIC ACID OR A GLUTAMINE IN THE FORM
; TITLE OF INVENTION: OF A PHYSIOLOGICALLY ACCEPTABLE STRONG ACID
; FILE REFERENCE: 343 727 - US
; CURRENT APPLICATION NUMBER: US/10/239,313A
; CURRENT FILING DATE: 2002-09-19
; PRIOR APPLICATION NUMBER: FR 00/03711
; PRIOR FILING DATE: 2000-03-23
; PRIOR APPLICATION NUMBER: PCT 01/70772
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 697
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 535
; LENGTH: 12
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-239-313A-535

Query Match 51.2%; Score 63; DB 14; Length 12;
Best Local Similarity 100.0%; Pred. No. 0.01; 0; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 QRGPGRAFTVIG 21
| | | | | | | | | | | | | | | | | | | | | |
Db 1 QRGPGRAFTVIG 12

RESULT 30
US-10-621-675-7
; Sequence 7, Application US/10621675
; Publication No. US20050049398A1
; GENERAL INFORMATION:
; APPLICANT: De Leye, Robert
; TITLE OF INVENTION: PROCESS FOR THE DETERMINATION OF PEPTIDES CORRESPONDING
; TITLE OF INVENTION: TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND THEIR USE IN
; TITLE OF INVENTION: A PROCESS FOR DETERMINATION OF ANTIBODIES OF
; TITLE OF INVENTION: BIOTINYLATED PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT
; TITLE OF INVENTION: EPITOPES, A PROCESS FOR PREPARING THEM AND COMPOSITIONS
; TITLE OF INVENTION: CONTAINING THEM
; FILE REFERENCE: 2752-11

```

; OTHER INFORMATION: modified site
US-10-621-675-9

Query Match          49.2%; Score 60.5; DB 17; Length 24;
Best Local Similarity 69.6%; Pred. No. 0.052;
Matches 16; Conservative 1; Mismatches 3; Indels 3; Gaps 2;

QY      1 NNTKSRERIQGPGRAFTVIGKI 23
      ||||| | ||||| | |
DB      2 NNTKRS--IYIGGRAFTT-GRI 21

RESULT 32
US-09-956-940-15
; Sequence 15, Application US/09956940
; Publication No. US20030022826A1
; GENERAL INFORMATION:
; APPLICANT: HAYNES, BARTON F.
; TITLE OF INVENTION: USE OF SYNTHETIC PEPTIDES TO INDUCE
; TOLERANCE TO PATHOGENIC T AND B CELL EPITOPES OF
; AUTOANTIGENS OR INFECTIOUS AGENTS
; NUMBER OF SEQUENCES: 53
; CORRESPONDENCE ADDRESS:
; ADDRESSER: NIXON & VANDERHVE P.C.
; STREET: 1100 NORTH GLEBE ROAD
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/956,940
; FILING DATE: 12-Oct-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/460,673
; FILING DATE: <Unknown>
; APPLICATION NUMBER: US 08/015,987
; FILING DATE: 10-FEB-1993
; APPLICATION NUMBER: US 07/833,429
; FILING DATE: 10-FEB-1992
; APPLICATION NUMBER: US 07/591,109
; FILING DATE: 01-OCT-1990
; APPLICATION NUMBER: US 07/093,854
; FILING DATE: 08-SEP-1987
; ATTORNEY/AGENT INFORMATION:
; NAME: WILSON, MARY J.
; REGISTRATION NUMBER: 32,955
; REFERENCE/DOCKET NUMBER: 1579-5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 816-4000
; TELEFAX: (703) 816-4100
; TELEX: 200797 NIXN UR
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 15:

US-09-956-940-15

Query Match          48.0%; Score 59; DB 10; Length 13;
Best Local Similarity 92.3%; Pred. No. 0.045;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      3 TRKSRERIQGPGR 15
      ||||| |||||

```

Db 1 TRKSIRIQGPGR 13

RESULT 33

US-09-956-940-50

Sequence 50, Application US/09956940

Publication No. US20030022826A1

GENERAL INFORMATION:

APPLICANT: HAYNES, BARTON F.

TITLE OF INVENTION: USE OF SYNTHETIC PEPTIDES TO INDUCE TOLERANCE TO PATHOGENIC T AND B CELL EPITOPES OF AUTOANTIGENS OR INFECTIOUS AGENTS

NUMBER OF SEQUENCES: 53

CORRESPONDENCE ADDRESS:

ADDRESSER: NIXON & VANDERHYE P.C.

STREET: 1100 NORTH GLEBE ROAD

CITY: ARLINGTON

STATE: VIRGINIA

COUNTRY: U.S.A.

ZIP: 22201-4714

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/956,940

FILING DATE: 12-Oct-2001

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/08/460,673

FILING DATE: <Unknown>

APPLICATION NUMBER: US 08/015,987

FILING DATE: 10-FEB-1993

APPLICATION NUMBER: US 07/833,429

FILING DATE: 10-FEB-1992

APPLICATION NUMBER: US 07/591,109

FILING DATE: 01-OCT-1990

APPLICATION NUMBER: US 07/093,854

FILING DATE: 08-SEP-1987

ATTORNEY/AGENT INFORMATION:

NAME: WILSON, MARY J.

REGISTRATION NUMBER: 32,955

REFERENCE/DOCKET NUMBER: 1579-5

TELECOMMUNICATION INFORMATION:

TELEPHONE: (703) 816-4000

TELEFAX: (703) 816-4100

TELEX: 200797 NIXN UR

INFORMATION FOR SEQ ID NO: 50:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: protein

SEQUENCE DESCRIPTION: SEQ ID NO: 50:

US-09-956-940-50

Query Match 48.0%; Score 59; DB 10; Length 15;

Best Local Similarity 92.3%; Pred. No. 0.053;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3 TRKSIRIQGPGR 15

Db 2 TRKSIRIQGPGR 14

RESULT 34

US-10-360-647A-1

Sequence 1, Application US/10360647A

Publication No. US20040039178A1

GENERAL INFORMATION:

APPLICANT: Siedel, Christoph

APPLICANT: Wienhues, Ursula-Henrike

TITLE OF INVENTION: METAL CHELATE-LABELLED PEPTIDES

FILE REFERENCE: 2923-529

CURRENT APPLICATION NUMBER: US/10/360,647A

CURRENT FILING DATE: 2003-02-10

PRIOR APPLICATION NUMBER: US 08/776189

PRIOR FILING DATE: 1997-01-24

PRIOR APPLICATION NUMBER: PCT/EP95/02916

PRIOR FILING DATE: 1995-07-24

PRIOR APPLICATION NUMBER: DE 44 30 998.8

PRIOR FILING DATE: 1994-08-31

PRIOR APPLICATION NUMBER: DE 44 26 276.0

PRIOR FILING DATE: 1994-07-25

NUMBER OF SEQ ID NOS: 29

SOFTWARE: Patentin version 3.2

SEQ ID NO 1

LENGTH: 17

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: polypeptide/antigen/epitope

US-10-360-647A-1

Query Match 48.0%; Score 59; DB 15; Length 17;

Best Local Similarity 73.7%; Pred. No. 0.06;

Matches 14; Conservative 0; Mismatches 3; Indels 2; Gaps 1;

Qy 1 NNTKRSRIQGPGRFVT 19

Db 1 NNTKRS--ISIGPGRFYT 17

RESULT 35

US-10-613-018-1

Sequence 1, Application US/10613018

Publication No. US20050074750A1

GENERAL INFORMATION:

APPLICANT: WEINHUES, URSULA-HENRIKE

APPLICANT: KRUSE-MULLER, CORNELIA

APPLICANT: HOSS, EVA

APPLICANT: FAATZ, ELKE

APPLICANT: OFENLOCH-HAHNLE, BEATUS

APPLICANT: SEIDEL, CHRISTOPH

APPLICANT: WIEDMANN, MICHAEL

TITLE OF INVENTION: DETERMINATION OF A SPECIFIC IMMUNOGLOBULIN USING

TITLE OF INVENTION: MULTIPLE ANTIGENS

FILE REFERENCE: 100564-07003

CURRENT APPLICATION NUMBER: US/10/613,018

CURRENT FILING DATE: 2003-07-07

PRIOR APPLICATION NUMBER: PCT/EP95/02919

PRIOR FILING DATE: 1995-07-24

PRIOR APPLICATION NUMBER: P 44 26 276.0

PRIOR FILING DATE: 1994-07-25

PRIOR APPLICATION NUMBER: P 44 30 972.4

PRIOR FILING DATE: 1994-08-31

NUMBER OF SEQ ID NOS: 77

SOFTWARE: Patentin Ver. 2.1

SEQ ID NO 1

LENGTH: 17

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: Epitope region of HIV type 1, HIV type 2 or HIV subtype O

US-10-613-018-1

Query Match 48.0%; Score 59; DB 17; Length 17;

Best Local Similarity 73.7%; Pred. No. 0.06;

Matches 14; Conservative 0; Mismatches 3; Indels 2; Gaps 1;

Qy 1 NNTKRSRIQGPGRFVT 19

? PUBLICATION NO. US20050074750A1
 ?
 ? GENERAL INFORMATION:
 ?
 ? APPLICANT: WEINHUES, URSULA-HENRIKE
 ? APPLICANT: KRUSE-MULLER, CORNELIA
 ? APPLICANT: HOSS, EVA
 ? APPLICANT: PARTZ, ELKE
 ? APPLICANT: OFENLOCH-HAHNLE, BEATUS
 ? APPLICANT: SEIDEL, CHRISTOPH
 ? APPLICANT: WIEDMANN, MICHAEL
 ?

8 RIORGRAFEVT 19

Qy 1 NNTRKSERIQRGPAFVT 19
||| | | | | |
Db 5 NNTRKS--TSIGPGRFYT 21

APPLICANT: SHIBA, KIYOTAKA

```

, TITLE OF INVENTION: MULTIFUNCTIONAL BASE
, FILE REFERENCE: 4439-4004
, CURRENT APPLICATION NUMBER: US/10/311,111
, CURRENT FILING DATE: 2002-12-13
, PRIOR APPLICATION NUMBER: JP 2000-180997
, PRIOR FILING DATE: 2000-06-16
, NUMBER OF SEQ ID NOS: 34
, SOFTWARE: SEQ ID version 3.1

```

OTHER INFORMATION: Designed peptide

US-10-311-111-3

Query Match 47.2%; Score 58; DB 14; Length 13;
Best Local Similarity 91.7%; Pred. No. 0.064;
Matches 11; Conservative 0; Mismatches 1; Indels

8 RIORGRAFEVT 19

Db 2 RIQPGGRTFTV 13
|||||
RESULT 39
US-10-398-932-3
; Sequence 3, Application US/10398932
; Publication No. US20040171803A1
; GENERAL INFORMATION:
; APPLICANT: SHIBA, KIYOTAKA
; APPLICANT: OHNO, TSUNEYA
; TITLE OF INVENTION: ARTIFICIAL PROTEINS WITH ENRICHED IMMUNOGEN
; FILE OF INVENTION: OF EPITOPE
; CURRENT APPLICATION NUMBER: US/10/398,932
; CURRENT FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: PCT/JP01/08893
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: JP 2000/314288
; PRIOR FILING DATE: 2000-10-13
; NUMBER OF SEQ ID NOS: 55
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetically Designed
US-10-398-932-3
Query Match 47.2%; Score 58; DB 16; Length 13;
Best Local Similarity 91.7%; Pred. No. 0.064;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 8 RIQPGGRTFTV 13
|||||
Db 2 RIQPGGRTFTV 13
|||||
RESULT 40
US-09-901-106-10
; Sequence 10, Application US/09901106
; Patent No. US20020151067A1
; GENERAL INFORMATION:
; APPLICANT: Garoff, Henrik
; Liljestrom, Peter
; TITLE OF INVENTION: DNA Expression Systems Based on
; Alphaviruses
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/901,106
; FILING DATE: 10-Jul-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/920,281C
; FILING DATE: 13-AUG-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Murphy Jr., Gerald M.
; REGISTRATION NUMBER: 28,977
; REFERENCE/DOCKET NUMBER: 828-103P

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-241-1300
; TELEFAX: 703-241-2848
; TELEX: 248345
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-901-106-10
Query Match 47.2%; Score 58; DB 9; Length 15;
Best Local Similarity 84.6%; Pred. No. 0.075;
Matches 11; Conservative 1; Mismatches 0; Gaps 0;
Qy 8 RIQPGGRTFTV 20
|||||
Db 3 RIQPGGRTFTV 15
|||||
RESULT 41
US-10-621-675-158
; Sequence 158, Application US/10621675
; Publication No. US20050049398A1
; GENERAL INFORMATION:
; APPLICANT: De Leys, Robert
; TITLE OF INVENTION: PROCESS FOR THE DETERMINATION OF PEPTIDES CORRESPONDING
; TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND THEIR USE IN
; TITLE OF INVENTION: A PROCESS FOR DETERMINATION OF ANTIBODIES OF
; TITLE OF INVENTION: BIOTINYLATED PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT
; TITLE OF INVENTION: EPITOPES, A PROCESS FOR PREPARING THEM AND COMPOSITIONS
; TITLE OF INVENTION: CONTAINING THEM
; FILE REFERENCE: 2752-11
; CURRENT APPLICATION NUMBER: US/10/621,675
; CURRENT FILING DATE: 2003-07-18
; PRIOR APPLICATION NUMBER: US/09/576,824A
; PRIOR FILING DATE: 1996-09-30
; PRIOR APPLICATION NUMBER: 03/146,028
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP93/00517
; PRIOR FILING DATE: 1993-03-08
; PRIOR APPLICATION NUMBER: EP 92400598.6
; PRIOR FILING DATE: 1992-03-06
; NUMBER OF SEQ ID NOS: 600
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 158
; LENGTH: 23
; TYPE: PRT
; ORGANISM: Human immunodeficiency virus
US-10-621-675-158
Query Match 47.2%; Score 58; DB 17; Length 23;
Best Local Similarity 56.5%; Pred. No. 0.12;
Matches 13; Conservative 2; Mismatches 6; Indels 2; Gaps 1;
Qy 1 NNTRKSERIQPGGRTFTVTKI 23
|||||
Db 1 NNTRKSERIQPGGRTFTVTKI 21
|||||
RESULT 42
US-10-621-675-12
; Sequence 12, Application US/10621675
; Publication No. US20050049398A1
; GENERAL INFORMATION:
; APPLICANT: De Leys, Robert
; TITLE OF INVENTION: PROCESS FOR THE DETERMINATION OF PEPTIDES CORRESPONDING
; TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND THEIR USE IN
; TITLE OF INVENTION: A PROCESS FOR DETERMINATION OF ANTIBODIES OF
; TITLE OF INVENTION: BIOTINYLATED PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT

```
; TITLE OF INVENTION: EPITOPES, A PROCESS FOR PREPARING THEM AND COMPOSITIONS
; TITLE OF INVENTION: CONTAINING THEM
; FILE REFERENCE: 2752-11
; CURRENT APPLICATION NUMBER: US/10/621,675
; PRIOR FILING DATE: 2003-07-18
; PRIOR APPLICATION NUMBER: US/09/576,824A
; PRIOR APPLICATION NUMBER: 08/723,425
; PRIOR FILING DATE: 1996-09-30
; PRIOR APPLICATION NUMBER: 09/146,028
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP93/00517
; PRIOR FILING DATE: 1993-03-08
; PRIOR APPLICATION NUMBER: EP 92400598.6
; PRIOR FILING DATE: 1992-03-06
; NUMBER OF SEQ ID NOS: 600
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Human immunodeficiency virus
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)
; OTHER INFORMATION: modified site
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (25)
; OTHER INFORMATION: modified site
US-10-621-675-12

Query Match      47.2%; Score 58; DB 17; Length 25;
Best Local Similarity 56.5%; Pred. No. 0.13;
Matches 13; Conservative 2; Mismatches 6; Indels 2; Gaps 1;

QY 1 NNTKRSRIQRCGRGFAVTVIGKI 23
DB 2 NNTKRS--ITKGRGRIYATGQI 22

RESULT 43
US-10-239-313A-533
; Sequence 533, Application US/10239313A
; Publication No. US20030175285A1
; GENERAL INFORMATION:
; APPLICANT: KLINGUER - HAMOUR, Christine
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: BECK, Alain
; APPLICANT: GOETSCH, Liliane
; TITLE OF INVENTION: MOLECULE OF PHARMACEUTICAL INTEREST COMPRISING AT ITS
; N-TERMINAL A GLUTAMIC ACID OR A GLUTAMINE IN THE FORM
; OF A PHYSIOLOGICALLY ACCEPTABLE STRONG ACID
; FILE REFERENCE: 343 727 - US
; CURRENT APPLICATION NUMBER: US/10/239,313A
; CURRENT FILING DATE: 2002-09-19
; PRIOR APPLICATION NUMBER: FR 00/03711
; PRIOR FILING DATE: 2000-03-23
; PRIOR APPLICATION NUMBER: PCT 01/70772
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 597
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 533
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-239-313A-533

Query Match      46.3%; Score 57; DB 14; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.076;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 10 QRCGRGFAVTI 20
DB 1 QRCGRGFAVTI 11
```

RESULT 44

```
US-09-901-106-12
; Sequence 12, Application US/09901106
; Patent No. US20020151067A1
; GENERAL INFORMATION:
; APPLICANT: Garoff, Henrik
; Liljestrom, Peter
; TITLE OF INVENTION: DNA Expression Systems Based on
; Alphaviruses
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/901,106
; FILING DATE: 10-Jul-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/920,281C
; FILING DATE: 13-AUG-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Murphy Jr., Gerald M.
; REGISTRATION NUMBER: 28,977
; REFERENCE/DOCKET NUMBER: 828-103P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-241-1300
; TELEFAX: 703-241-2848
; TELEX: 248345
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-901-106-12
```

```
Query Match      46.3%; Score 57; DB 9; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 8 RIQRCGRGFAV 18

DB 4 RIQRCGRGFAV 14

RESULT 45

```
US-10-178-488-24
; Sequence 24, Application US/10178488
; Publication No. US20030165535A1
; GENERAL INFORMATION:
; APPLICANT: Rovinski, Benjamin
; APPLICANT: Cao, Shi-Xian
; APPLICANT: Yao, Fei-Long
; APPLICANT: Persson, Roy
; APPLICANT: Klein, Michel H.
; TITLE OF INVENTION: RETROVIRUS-LIKE PARTICLES MADE NON-INFECTIOUS BY A
; FILE REFERENCE: 1038-1238 MIS
; FILE REFERENCE: 1038-1238 MIS
; CURRENT APPLICATION NUMBER: US/10/178,488
; CURRENT FILING DATE: 2002-10-25
; PRIOR APPLICATION NUMBER: 09/258,128
```

```
; PRIOR FILING DATE: 1999-02-26
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 24
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Artificial
US-10-178-488-24
```

```
Query Match      46.3%; Score 57; DB 14; Length 19;
Best Local Similarity 66.7%; Pred. No. 0.14;
Matches 14; Conservative 1; Mismatches 4; Indels 2; Gaps 1;
```

```
QY      2 NTRKSERIQGPGRAFVTIGK 22
      ||||| | ||||| | |
Db      1 NTRKS--IYIGPGRAFHTTGR 19
```

```
Search completed: May 16, 2005, 13:10:22
Job time : 113.231 secs
```


GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: May 16, 2005, 12:52:18 ; Search time 36.9231 Seconds
(without alignments)
48.522 Million cell updates/sec

Title: US-08-869-386-3

Perfect score: 123

Sequence: 1 NNTKSEIRIQGPGRAFTVIGKIG 24

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 218077

Minimum DB seq length: 0

Maximum DB seq length: 25

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents AA*
1: /cgn2_6/ptodata/1/1aa/5A-COMB.pep:*
2: /cgn2_6/ptodata/1/1aa/5B-COMB.pep:*
3: /cgn2_6/ptodata/1/1aa/6A-COMB.pep:*
4: /cgn2_6/ptodata/1/1aa/6B-COMB.pep:*
5: /cgn2_6/ptodata/1/1aa/PCTUS-COMB.pep:*
6: /cgn2_6/ptodata/1/1aa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	115	93.5	24	1 US-08-097-751-1	Sequence 1, Appli
2	115	93.5	24	1 US-08-090-148-6	Sequence 6, Appli
3	115	93.5	24	2 US-08-146-028-160	Sequence 160, App
4	115	93.5	24	3 US-08-723-425A-160	Sequence 160, App
5	115	93.5	24	3 US-08-480-332-2	Sequence 2, Appli
6	115	93.5	24	3 US-09-112-206-160	Sequence 160, App
7	115	93.5	24	4 US-09-790-497A-160	Sequence 14, Appl
8	115	93.5	24	4 US-09-790-497A-160	Sequence 160, App
9	115	93.5	24	4 US-09-576-824A-160	Sequence 160, App
10	115	93.5	24	4 US-09-680-497-160	Sequence 160, App
11	115	93.5	24	5 PCT-US92-06688-12	Sequence 12, Appl
12	115	93.5	24	5 PCT-US92-10378-3	Sequence 3, Appli
13	115	93.5	25	3 US-08-485-324-13	Sequence 13, Appl
14	115	93.5	25	3 US-08-485-324-13	Sequence 31, Appl
15	115	93.5	25	3 US-08-447-506-13	Sequence 13, Appl
16	115	93.5	25	3 US-08-447-506-13	Sequence 31, Appl
17	115	93.5	25	3 US-08-235-437-13	Sequence 13, Appl
18	115	93.5	25	3 US-08-235-437-13	Sequence 31, Appl
19	115	93.5	25	3 US-08-447-515-13	Sequence 13, Appl
20	115	93.5	25	3 US-08-447-515-13	Sequence 31, Appl
21	109	88.6	24	1 US-08-257-528B-99	Sequence 99, Appl
22	109	88.6	24	1 US-08-460-602A-99	Sequence 99, Appl
23	109	88.6	24	1 US-08-463-966A-99	Sequence 99, Appl
24	109	88.6	24	1 US-08-465-217A-99	Sequence 99, Appl
25	109	88.6	24	2 US-08-464-329A-99	Sequence 99, Appl
26	109	88.6	24	2 US-08-462-507A-99	Sequence 99, Appl
27	109	88.6	24	2 US-08-467-881A-99	Sequence 99, Appl

28	109	88.6	25	2 US-08-266-448-1	Sequence 1, Appli
29	105	85.4	25	2 US-07-950-571A-1	Sequence 1, Appli
30	103	83.7	22	2 US-08-345-321-2	Sequence 2, Appli
31	101	82.1	22	2 US-08-537-245-1	Sequence 1, Appli
32	99	80.5	22	3 US-08-805-889-5	Sequence 5, Appli
33	99	80.5	22	3 US-09-070-291-5	Sequence 5, Appli
34	94	76.4	21	2 US-08-452-503A-4	Sequence 4, Appli
35	94	76.4	21	2 US-08-453-745A-4	Sequence 4, Appli
36	94	76.4	21	2 US-08-470-419-25	Sequence 25, Appl
37	94	76.4	21	2 US-08-761-828-25	Sequence 25, Appl
38	94	76.4	21	2 US-08-452-520B-4	Sequence 4, Appli
39	94	76.4	21	2 US-08-290-105-25	Sequence 25, Appl
40	94	76.4	21	3 US-08-776-949-25	Sequence 25, Appl
41	94	76.4	21	3 US-08-482-810-25	Sequence 25, Appl
42	94	76.4	21	3 US-09-027-955-25	Sequence 25, Appl
43	94	76.4	21	3 US-09-636-805-25	Sequence 25, Appl
44	94	76.4	21	4 US-09-258-128-25	Sequence 25, Appl
45	94	76.4	21	4 US-09-635-754-25	Sequence 25, Appl

ALIGNMENTS

RESULT 1
US-08-097-751-1
; Sequence 1, Application US/08097751
; Patent No. 5527666
; GENERAL INFORMATION:
; APPLICANT: DeRossi, Anita
; APPLICANT: Pasti, Marcella
; APPLICANT: Mammano, Fabrizio
; APPLICANT: Panozzo, Marina
; APPLICANT: Dettin, Monica
; APPLICANT: DiBello, Carlo
; APPLICANT: Chieco-Bianchi, Luigi
; TITLE OF INVENTION: METHOD FOR THE DIAGNOSIS IN VITRO OF
; TITLE OF INVENTION: HIV-1 VIRUS INFECTIONS
; NUMBER OF SEQUENCES: 2
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hedman, Gibson, Costigan & Hoare
; STREET: 1185 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: DOS
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/097,751
; FILING DATE: 19930723
; CLASSIFICATION: 530
; PRIOR APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Costigan, James V.
; REGISTRATION NUMBER: 25,669
; REFERENCE/DOCKET NUMBER: 515-4026
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 302-8989
; TELEFAX: (212) 302-8998
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 amino acids
; TYPE: amino acid
; TOPOLOGY: circular
; US-08-097-751-1

Query Match 93.5%; Score 115; DB 1; Length 24;
Best Local Similarity 95.8%; Pred. No. 2.5e-10;

```
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 NNTKSRIRIQGPGRAFTVIGKIG 24
    ||||| ||||| ||||| ||||| |||||
Db 1 NNTKSRIRIQGPGRAFTVIGKIG 24

RESULT 2
US-08-090-148-6
; Sequence 6, Application US/08090148
; Patent No. 5534257
; GENERAL INFORMATION:
; APPLICANT: Mastico, Robert Allan
; APPLICANT: Stockley, Peter George
; APPLICANT: Talbot, Simon John
; TITLE OF INVENTION: Antigen-Presenting Capsid with
; TITLE OF INVENTION: Fusion MS2-Coat Protein
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Rosenman & Colin
; STREET: 575 Madison Avenue
; CITY: New York
; STATE: NY
; COUNTRY: U.S.A.
; ZIP: 10022-2585
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5", 1.44Mb
; COMPUTER: IBM PS2-486
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/090,148
; FILING DATE: 08/11/93
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9101550.3
; FILING DATE: 01/24/91
; APPLICATION NUMBER: PCT/GB92/00124
; FILING DATE: 01/22/92
; ATTORNEY/AGENT INFORMATION:
; NAME: Nissenbaum, Israel
; REGISTRATION NUMBER: 27,582
; REFERENCE/DOCKET NUMBER:
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 940-8636
; TELEFAX: (212) 940-6404
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 AMINO ACIDS
; TYPE: AMINO ACID
; TOPOLOGY: NOT RELEVANT
; MOLECULE TYPE: PEPTIDE
US-08-090-148-6

Query Match 93.5%; Score 115; DB 1; Length 24;
Best Local Similarity 95.8%; Pred. No. 2.5e-10;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 NNTKSRIRIQGPGRAFTVIGKIG 24
    ||||| ||||| ||||| ||||| |||||
Db 1 NNTKSRIRIQGPGRAFTVIGKIG 24

RESULT 3
US-08-146-028-160
; Sequence 160, Application US/08146028
; Patent No. 5891640
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: PROCESS FOR THE DETERMINATION OF PEPTIDES
; TITLE OF INVENTION: CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND THEIR
; TITLE OF INVENTION: IN A PROCESS FOR DETERMINATION OF ANTIBODIES OR BIOTINYLATED
; TITLE OF INVENTION: PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT EPITOPES,
;

Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 NNTKSRIRIQGPGRAFTVIGKIG 24
    ||||| ||||| ||||| ||||| |||||
Db 1 NNTKSRIRIQGPGRAFTVIGKIG 24

RESULT 4
US-08-723-425A-160
; Sequence 160, Application US/08723425A
; Patent No. 6165730
; GENERAL INFORMATION:
; APPLICANT: DELEYS, ROBERT
; TITLE OF INVENTION: PROCESS FOR THE DETERMINATION OF
; TITLE OF INVENTION: PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT
; TITLE OF INVENTION: EPITOPES AND THEIR USE IN A PROCESS FOR DETERMINATION OF
; TITLE OF INVENTION: ANTIBODIES OR BIOTINYLATED PEPTIDES CORRESPONDING ...
; NUMBER OF SEQUENCES: 453
; CORRESPONDENCE ADDRESS:
; ADDRESSER: NIXON & VANDERHUYE, P.C.
; STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
; CITY: Arlington
; STATE: VA
; COUNTRY: USA
; ZIP: 22201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/723,425A
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: SADOFF, B.J.
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 1487-13
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-816-4000
; TELEFAX: 703-816-4100
; INFORMATION FOR SEQ ID NO: 160:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-723-425A-160

Query Match 93.5%; Score 115; DB 3; Length 24;
Best Local Similarity 95.8%; Pred. No. 2.5e-10;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

RESULT 6

```
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 NNTKRSRIQPGGPGRAFTVIGKIG 24
    |||||
Db 1 NNTKRSIRIQGPGRAFTVIGKIG 24
    |||||

RESULT 8
US-09-790-497A-160
; Sequence 160, Application US/09790497A
; Patent No. 6649735
; GENERAL INFORMATION:
; APPLICANT: De Leys, Robert
; TITLE OF INVENTION: PROCESS FOR THE DETERMINATION OF PEPTIDES CORRESPONDING
; TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND THEIR USE IN
; TITLE OF INVENTION: A PROCESS FOR DETERMINATION OF ANTIBODIES OF
; TITLE OF INVENTION: BIOTINYLATED PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT
; TITLE OF INVENTION: EPITOPES, A PROCESS FOR PREPARING THEM AND COMPOSITIONS
; TITLE OF INVENTION: CONTAINING THEM
; FILE REFERENCE: 2752-16
; CURRENT APPLICATION NUMBER: US/09/790,497A
; CURRENT FILING DATE: 2001-02-23
; PRIOR APPLICATION NUMBER: 09/576,824
; PRIOR FILING DATE: 2000-03-23
; PRIOR APPLICATION NUMBER: 08/723,425
; PRIOR FILING DATE: 1996-09-30
; PRIOR APPLICATION NUMBER: 09/146,028
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP93/00517
; PRIOR FILING DATE: 1993-03-08
; PRIOR APPLICATION NUMBER: EP 92400598.6
; PRIOR FILING DATE: 1992-03-06
; NUMBER OF SEQ ID NOS: 600
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 160
; LENGTH: 24
; TYPE: PRT
; ORGANISM: Human immunodeficiency virus
US-09-790-497A-160

Query Match 93.5%; Score 115; DB 4; Length 24;
Best Local Similarity 95.8%; Pred. No. 2.5e-10;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 NNTKRSRIQPGGPGRAFTVIGKIG 24
    |||||
Db 1 NNTKRSIRIQGPGRAFTVIGKIG 24
    |||||

RESULT 9
US-09-576-824A-160
; Sequence 160, Application US/09576824A
; Patent No. 6667387
; GENERAL INFORMATION:
; APPLICANT: De Leys, Robert
; TITLE OF INVENTION: PROCESS FOR THE DETERMINATION OF PEPTIDES CORRESPONDING
; TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND THEIR USE IN
; TITLE OF INVENTION: A PROCESS FOR DETERMINATION OF ANTIBODIES OF
; TITLE OF INVENTION: BIOTINYLATED PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT
; TITLE OF INVENTION: EPITOPES, A PROCESS FOR PREPARING THEM AND COMPOSITIONS
; TITLE OF INVENTION: CONTAINING THEM
; FILE REFERENCE: 2752-11
; CURRENT APPLICATION NUMBER: US/09/576,824A
; CURRENT FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 08/723,425
; PRIOR FILING DATE: 1996-09-30
; PRIOR APPLICATION NUMBER: 09/146,028
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP93/00517
; PRIOR FILING DATE: 1993-03-08
; PRIOR APPLICATION NUMBER: EP 92400598.6
; PRIOR FILING DATE: 1992-03-06
; NUMBER OF SEQ ID NOS: 600
```

```
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 160
; LENGTH: 24
; TYPE: PRT
; ORGANISM: Human immunodeficiency virus
US-09-576-824A-160

Query Match 93.5%; Score 115; DB 4; Length 24;
Best Local Similarity 95.8%; Pred. No. 2.5e-10;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 NNTKRSRIQPGGPGRAFTVIGKIG 24
    |||||
Db 1 NNTKRSIRIQGPGRAFTVIGKIG 24
    |||||

RESULT 10
US-09-680-497-160
; Sequence 160, Application US/09680497
; Patent No. 6709828
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: PROCESS FOR THE DETERMINATION OF PEPTIDES
; TITLE OF INVENTION: CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND THEIR
; TITLE OF INVENTION: IN A PROCESS FOR DETERMINATION OF ANTIBODIES OR BIOTINYLATED
; TITLE OF INVENTION: PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT EPITOPES,
; TITLE OF INVENTION: PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM
; NUMBER OF SEQUENCES: 453
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/680,497
; FILING DATE: 06-OCT-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/146,028
; FILING DATE: 22-NOV-1993
; INFORMATION FOR SEQ ID NO: 160:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-09-680-497-160

Query Match 93.5%; Score 115; DB 4; Length 24;
Best Local Similarity 95.8%; Pred. No. 2.5e-10;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 NNTKRSRIQPGGPGRAFTVIGKIG 24
    |||||
Db 1 NNTKRSIRIQGPGRAFTVIGKIG 24
    |||||

RESULT 11
PCT-US92-06688-12
; Sequence 12, Application PC/TUS9206688
; GENERAL INFORMATION:
; APPLICANT: REPLIGEN CORPORATION
; APPLICANT: THE ROCKEFELLER UNIVERSITY
; TITLE OF INVENTION: MULTIPLE ANTIGEN PEPTIDES FOR USE AS HIV
; TITLE OF INVENTION: VACCINES
; NUMBER OF SEQUENCES: 21
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
```

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM PS/2 Model 50Z or 55SX
OPERATING SYSTEM: IBM P.C. DOS (Version 3.30)
SOFTWARE: WordPerfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/06688
FILING DATE: 19920811
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 744,281
FILING DATE: 13 August 1992
ATTORNEY/AGENT INFORMATION:
NAME: Paul T. Clark
REGISTRATION NUMBER: 30,162
REFERENCE/DOCKET NUMBER: 00231/052WO1
TELEPHONE: (617) 542-5070
TELEFAX: (617) 542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 24
TYPE: AMINO ACID
TOPOLOGY: linear
PCT-US92-06688-12

Query Match 93.5%; Score 115; DB 5; Length 24;
Best Local Similarity 95.8%; Pred. No. 2.5e-10;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 NNTKRSRIQRGPGRAFTVIGKIG 24
Db 1 NNTKRSRIQRGPGRAFTVIGKIG 24

RESULT 12
PCT-US92-10378-3
Sequence 3, Application PC/TUS9210378
GENERAL INFORMATION:
APPLICANT: BOARD OF REGENTS, THE UNIVERSITY OF
APPLICANT: TEXAS SYSTEM
APPLICANT: SASTRY, Jagannadha K.
APPLICANT: ARLINGHAUS, Ralph B.
APPLICANT: PLATSOUKAS, Chris D.
APPLICANT: NEHETE, Pramod N.
TITLE OF INVENTION: METHODS AND COMPOSITIONS
FOR ELICITING IMMUNE OR ANTI-INFECTION RESPONSES
TITLE OF INVENTION: 7
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:
ADDRESSEE: Arnold, White & Durkee
STREET: P.O. Box 4433
CITY: Houston
STATE: Texas
COUNTRY: US
ZIP: 77210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/10378
FILING DATE: 19921202
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/800,932
FILING DATE: December 2, 1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/945865
FILING DATE: September 16, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Parker, David L.

REGISTRATION NUMBER: 32,165
REFERENCE/DOCKET NUMBER: UTFC305PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 512-320-7200
TELEFAX: 512-474-7577
TELEX: Not Applicable
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 amino acids
TYPE: AMINO ACID
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
PCT-US92-10378-3

Query Match 93.5%; Score 115; DB 5; Length 24;
Best Local Similarity 95.8%; Pred. No. 2.5e-10;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 NNTKRSRIQRGPGRAFTVIGKIG 24
Db 1 NNTKRSRIQRGPGRAFTVIGKIG 24

RESULT 13
US-08-485-324-13
Sequence 13, Application US/08485324
Patent No. 6043093
GENERAL INFORMATION:
APPLICANT: Wohlstadter, Jacob
TITLE OF INVENTION: SELECTION METHODS
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: Curtis, Morris, & Safford
ADDRESSEE: c/o Barry Evans
STREET: 530 Fifth Avenue
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/485,324
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/235,437
FILING DATE: 29-APR-1994
APPLICATION NUMBER: US 07/852,412
FILING DATE: 16-MAR-1992
ATTORNEY/AGENT INFORMATION:
NAME: Evans, Barry
REGISTRATION NUMBER: 22,802
REFERENCE/DOCKET NUMBER: 370132-2000
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
TELEFAX: (212) 840-0712
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 25 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-485-324-13

Query Match 93.5%; Score 115; DB 3; Length 25;
Best Local Similarity 95.8%; Pred. No. 2.6e-10;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 NNTKRSIRIQGPGRAFTVIGKIG 24
Db 1 NNTKRSIRIQGPGRAFTVIGKIG 24

RESULT 14

US-08-485-324-31
; Sequence 31, Application US/08485324
; Patent No. 6043093
; GENERAL INFORMATION:
; APPLICANT: Wohlstadter, Jacob
; TITLE OF INVENTION: SELECTION METHODS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris, & Safford
; ADDRESSEE: c/o Barry Evans
; STREET: 530 Fifth Avenue
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/485,324
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/235,437
; FILING DATE: 29-APR-1994
; APPLICATION NUMBER: US 07/852,412
; FILING DATE: 16-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Evans, Barry
; REGISTRATION NUMBER: 22,802
; REFERENCE/DOCKET NUMBER: 370132-2000
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-485-324-31

Query Match 93.5%; Score 115; DB 3; Length 25;
Best Local Similarity 95.8%; Pred. No. 2.6e-10;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 NNTKRSIRIQGPGRAFTVIGKIG 24
Db 1 NNTKRSIRIQGPGRAFTVIGKIG 24

RESULT 15

US-08-447-506-13
; Sequence 13, Application US/08447506
; Patent No. 6066499
; GENERAL INFORMATION:
; APPLICANT: Wohlstadter, Jacob
; TITLE OF INVENTION: SELECTION METHODS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris, & Safford
; ADDRESSEE: c/o Barry Evans
; STREET: 530 Fifth Avenue
; CITY: New York
; STATE: New York

; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/447,506
; FILING DATE: 23-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/235,437
; FILING DATE: 29-APR-1994
; APPLICATION NUMBER: US 07/852,412
; FILING DATE: 16-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Evans, Barry
; REGISTRATION NUMBER: 22,802
; REFERENCE/DOCKET NUMBER: 370132-2000
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-447-506-13

Query Match 93.5%; Score 115; DB 3; Length 25;
Best Local Similarity 95.8%; Pred. No. 2.6e-10;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 NNTKRSIRIQGPGRAFTVIGKIG 24
Db 1 NNTKRSIRIQGPGRAFTVIGKIG 24

RESULT 16

US-08-447-506-31
; Sequence 31, Application US/08447506
; Patent No. 6066499
; GENERAL INFORMATION:
; APPLICANT: Wohlstadter, Jacob
; TITLE OF INVENTION: SELECTION METHODS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris, & Safford
; ADDRESSEE: c/o Barry Evans
; STREET: 530 Fifth Avenue
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/447,506
; FILING DATE: 23-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/235,437
; FILING DATE: 29-APR-1994
; APPLICATION NUMBER: US 07/852,412
; FILING DATE: 16-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Evans, Barry
; REGISTRATION NUMBER: 22,802

; REFERENCE/DOCKET NUMBER: 370132-2000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-447-506-31

Query Match 93.5%; Score 115; DB 3; Length 25;
Best Local Similarity 95.8%; Pred.No. 2.6e-10;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1 NNTKSRIRIQGPGRAFTVIGKIG 24
Db 1 NNTKSRIRIQGPGRAFTVIGKIG 24

RESULT 17
US-08-235-437-13
; Sequence 13, Application US/08235437
; Patent No. 6087177
; GENERAL INFORMATION:
; APPLICANT: Wohlstadter, Jacob
; TITLE OF INVENTION: SELECTION METHODS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris, & Safford
; ADDRESS: c/o Barry Evans
; STREET: 530 Fifth Avenue
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/235,437
; FILING DATE: 29-APR-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/852,412
; FILING DATE: 16-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Evans, Barry
; REGISTRATION NUMBER: 22,802
; REFERENCE/DOCKET NUMBER: 370132-2000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-235-437-13

Query Match 93.5%; Score 115; DB 3; Length 25;
Best Local Similarity 95.8%; Pred.No. 2.6e-10;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1 NNTKSRIRIQGPGRAFTVIGKIG 24
Db 1 NNTKSRIRIQGPGRAFTVIGKIG 24

RESULT 18
US-08-235-437-31
; Sequence 31, Application US/08235437
; Patent No. 6087177
; GENERAL INFORMATION:
; APPLICANT: Wohlstadter, Jacob
; TITLE OF INVENTION: SELECTION METHODS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris, & Safford
; ADDRESS: c/o Barry Evans
; STREET: 530 Fifth Avenue
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/235,437
; FILING DATE: 29-APR-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/852,412
; FILING DATE: 16-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Evans, Barry
; REGISTRATION NUMBER: 22,802
; REFERENCE/DOCKET NUMBER: 370132-2000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-235-437-31

Query Match 93.5%; Score 115; DB 3; Length 25;
Best Local Similarity 95.8%; Pred.No. 2.6e-10;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1 NNTKSRIRIQGPGRAFTVIGKIG 24
Db 1 NNTKSRIRIQGPGRAFTVIGKIG 24

RESULT 19
US-08-447-515-13
; Sequence 13, Application US/08447515
; Patent No. 6162640
; GENERAL INFORMATION:
; APPLICANT: Wohlstadter, Jacob
; TITLE OF INVENTION: SELECTION METHODS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris, & Safford
; ADDRESS: c/o Barry Evans
; STREET: 530 Fifth Avenue
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25

```

; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-447-515-31

Query Match      93.5%; Score 115; DB 3; Length 25;
Best Local Similarity 95.8%; Pred. No. 2.6e-10;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1  NNTKRSRIQRGPGRAFTVIGKIG 24
      ||||| ||||| ||||| ||||| |||||
Db      1  NNTKRSIRIQRGPGRAFTVIGKIG 24

RESULT 21
US-08-257-528B-99
; Sequence 99, Application US/08257528B
; Patent No. 5639854
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/257,528B
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-336 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 99:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-257-528B-99

Query Match      88.6%; Score 109; DB 1; Length 24;
Best Local Similarity 95.7%; Pred. No. 1.9e-09;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2  NTRKRSRIQRGPGRAFTVIGKIG 24
      ||||| ||||| ||||| ||||| |||||
Db      1  NNTKRSIRIQRGPGRAFTVIGKIG 23

RESULT 22
US-08-460-602A-99
; Sequence 99, Application US/08460602A
; Patent No. 5759769
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides

```


NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/460,602A
FILING DATE: 02-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/257,528
FILING DATE: 09-JUN-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/073,378
FILING DATE: 09-JUN-1993
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, MICHAEL I.
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-450 MIS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 99:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-460-602A-99

Query Match 88.6%; Score 109; DB 1; Length 24;
Best Local Similarity 95.7%; Pred. No. 1.9e-09;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 NTRKSERIQRGPGRAFTVIGKIG 24
Db 1 NTRKSIIRIQGPGRAFTVIGKIG 23

RESULT 23

US-08-463-966A-99
Sequence 99, Application US/08463966A
Patent No. 5795955
GENERAL INFORMATION:
APPLICANT: SIA, Charles D.Y.
APPLICANT: CHONG, Pele
APPLICANT: KLEIN, Michel H.
TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/463,966A

FILING DATE: 05-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/257,528
FILING DATE: 09-JUN-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/073,378
FILING DATE: 09-JUN-1993
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, MICHAEL I.
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-487 MIS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 99:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-463-966A-99

Query Match 88.6%; Score 109; DB 1; Length 24;
Best Local Similarity 95.7%; Pred. No. 1.9e-09;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 NTRKSERIQRGPGRAFTVIGKIG 24
Db 1 NTRKSIIRIQGPGRAFTVIGKIG 23

RESULT 24

US-08-465-217A-99
Sequence 99, Application US/08465217A
Patent No. 5800822
GENERAL INFORMATION:
APPLICANT: SIA, Charles D.Y.
APPLICANT: CHONG, Pele
APPLICANT: KLEIN, Michel H.
TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/465,217A
FILING DATE: 05-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/257,528
FILING DATE: 09-JUN-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/073,378
FILING DATE: 09-JUN-1993
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, MICHAEL I.
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-486 MIS:jb
TELECOMMUNICATION INFORMATION:

TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 99:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-465-217A-99

Query Match 88.6%; Score 109; DB 1; Length 24;
Best Local Similarity 95.7%; Pred. No. 1.9e-09;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 NTRKSIHQGPGRFVTVIGKIG 24
Db 1 NTRKSIHQGPGRFVTVIGKIG 23

RESULT 25

US-08-464-329A-99
Sequence 99, Application US/08464329A
Patent No. 5817754
GENERAL INFORMATION:

APPLICANT: SIA, Charles D.Y.
APPLICANT: CHONG, Pele
APPLICANT: KLEIN, Michel H.
TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:

ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/464,329A

FILING DATE: 05-JUN-1995

CLASSIFICATION: 424

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/257,528

FILING DATE: 09-JUN-1994

CLASSIFICATION: 424

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/073,378

FILING DATE: 09-JUN-1993

CLASSIFICATION: 424

ATTORNEY/AGENT INFORMATION:

NAME: STEWART, MICHAEL I.

REGISTRATION NUMBER: 24,973

REFERENCE/DOCKET NUMBER: 1038-449 MIS:jib

TELECOMMUNICATION INFORMATION:

TELEPHONE: (416) 595-1155

TELEFAX: (416) 595-1163

INFORMATION FOR SEQ ID NO: 99:

SEQUENCE CHARACTERISTICS:

LENGTH: 24 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-464-329A-99

Query Match 88.6%; Score 109; DB 2; Length 24;
Best Local Similarity 95.7%; Pred. No. 1.9e-09;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 NTRKSIHQGPGRFVTVIGKIG 24

Db 1 NTRKSIHQGPGRFVTVIGKIG 23

RESULT 26

US-08-462-507A-99
Sequence 99, Application US/08462507A
Patent No. 5876731
GENERAL INFORMATION:

APPLICANT: SIA, Charles D.Y.
APPLICANT: CHONG, Pele
APPLICANT: KLEIN, Michel H.
TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:

ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/462,507A

FILING DATE: 05-JUN-1995

CLASSIFICATION: 424

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/257,528

FILING DATE: 09-JUN-1994

CLASSIFICATION: 424

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/073,378

FILING DATE: 09-JUN-1993

CLASSIFICATION: 424

ATTORNEY/AGENT INFORMATION:

NAME: STEWART, MICHAEL I.

REGISTRATION NUMBER: 24,973

REFERENCE/DOCKET NUMBER: 1038-451 MIS:jib

TELECOMMUNICATION INFORMATION:

TELEPHONE: (416) 595-1155

TELEFAX: (416) 595-1163

INFORMATION FOR SEQ ID NO: 99:

SEQUENCE CHARACTERISTICS:

LENGTH: 24 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-462-507A-99

Query Match 88.6%; Score 109; DB 2; Length 24;
Best Local Similarity 95.7%; Pred. No. 1.9e-09;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 NTRKSIHQGPGRFVTVIGKIG 24

Db 1 NTRKSIHQGPGRFVTVIGKIG 23

RESULT 27

US-08-467-881A-99
Sequence 99, Application US/08467881A
Patent No. 5951986
GENERAL INFORMATION:

APPLICANT: SIA, Charles D.Y.
APPLICANT: CHONG, Pele
APPLICANT: KLEIN, Michel H.
TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:

ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/467,881A
FILING DATE: 06-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/257,528
FILING DATE: 09-JUN-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/073,378
FILING DATE: 09-JUN-1993
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, MICHAEL I.
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-488 MIS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 99:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-467-881A-99

Query Match 88.6%; Score 109; DB 2; Length 24;
Best Local Similarity 95.7%; Pred. No. 1.9e-09;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 NTRKSERIQRGPGRAFTVIGKIG 24
Db 1 NTRKSIIRIQRGPGRAFTVIGKIG 23
|||||
RESULT 28
US-08-266-448-1
; Sequence 1, Application US/08266448
; Patent No. 5876724
; GENERAL INFORMATION:
; APPLICANT: GIRARD, Marc
; TITLE OF INVENTION: INDUCTION OF PROTECTION AGAINST VIRAL
; TITLE OF INVENTION: INFECTION BY SYNERGY BETWEEN VIRUS ENVELOPE GLYCOPROTEIN
; TITLE OF INVENTION: AND PEPTIDES CORRESPONDING TO NEUTRALIZATION EPITOPES OF
; TITLE OF INVENTION: THE GLYCOPROTEIN
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FINNEGAN, HENDERSON, FARABOW, GARRETT &
; ADDRESSEE: DUNNER, L.L.P.
; STREET: 1300 I Street, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/266,448

FILING DATE: 28-JUN-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/145,664
FILING DATE: 04-NOV-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/782,241
FILING DATE: 28-OCT-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/672,647
FILING DATE: 18-MAR-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/494,749
FILING DATE: 19-MAR-1990
ATTORNEY/AGENT INFORMATION:
NAME: Meyers, Kenneth J.
REGISTRATION NUMBER: 25,146
REFERENCE/DOCKET NUMBER: 03495.0088-13
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 408-4132
TELEFAX: (202) 408-4400
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 25 amino acids
TYPE: amino acid
STRANDEDNESS:
TOPOLOGY: not relevant
; MOLECULE TYPE: peptide
US-08-266-448-1

Query Match 88.6%; Score 109; DB 2; Length 25;
Best Local Similarity 95.7%; Pred. No. 2e-09;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 NTRKSERIQRGPGRAFTVIGKIG 24
Db 2 NTRKSIIRIQRGPGRAFTVIGKIG 24
|||||
RESULT 29
US-07-950-571A-1
; Sequence 1, Application US/07950571A
; Patent No. 5854400
; GENERAL INFORMATION:
; APPLICANT: Chang, Tse Wen, Fung, Michael S.C., Sun, Bill N.C., Sun, Cecily R.Y.,
; APPLICANT: Chang, Nancy T.
; TITLE OF INVENTION: Monoclonal Antibodies which Neutralize HIV-1 Infection
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Tanox Biosystems, Inc.
; STREET: 10301 Stella Link Rd.
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Hi Density Diskette
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: DOS, Version 3.30
; SOFTWARE: Wordperfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/950,571A
; FILING DATE: 19920922
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: No. 5854400 07/767,533
; FILING DATE: 09/26/1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Mirabel, Eric P.
; REGISTRATION NUMBER: 31,211
; REFERENCE/DOCKET NUMBER: TNX87-11BBC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713-664-2288

OTHER INFORMATION: to 303 to 324 of gp120 from the IIB isolate, "

```
; STREET: 620 Newport Center Drive 16th Floor
; CITY: Newport Beach
; STATE: CA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/805,889
; FILING DATE: 03-MAR-1997
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/165,314
; FILING DATE: 10-DEC-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Fuller, Michael L.
; REGISTRATION NUMBER: 36,516
; REFERENCE/DOCKET NUMBER: NIH079.001A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-235-8550
; TELEFAX: 619-235-0176
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: internal
; US-08-805-889-5

Query Match 80.5%; Score 99; DB 3; Length 22;
Best Local Similarity 95.2%; Pred. No. 5.2e-08;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 NTRKSERIQRGPGRAFTVIGK 22
Db 2 NTRKSIRIQRGPGRAFTVIGK 22

RESULT 33
US-09-070-291-5
; Sequence 5, Application US/09070291
; Patent No. 6171596
; GENERAL INFORMATION:
; APPLICANT: Earl, Patricia L.
; APPLICANT: Broder, Christopher C.
; APPLICANT: Doms, Robert W.
; APPLICANT: Moss, Bernard
; TITLE OF INVENTION: Oligomeric HIV-1 Envelope Glycoproteins
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Knobbe, Martens, Olson and Bear
; STREET: 620 Newport Center Drive 16th Floor
; CITY: Newport Beach
; STATE: CA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/070,291
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Vensko, Nancy Ways
; REGISTRATION NUMBER: 36,298
```

```
; REFERENCE/DOCKET NUMBER: NIH079.1DVCP1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-235-8550
; TELEFAX: 619-235-0176
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: internal
; US-09-070-291-5

Query Match 80.5%; Score 99; DB 3; Length 22;
Best Local Similarity 95.2%; Pred. No. 5.2e-08;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 NTRKSERIQRGPGRAFTVIGK 22
Db 2 NTRKSIRIQRGPGRAFTVIGK 22

RESULT 34
US-08-452-503A-4
; Sequence 4, Application US/08452503A
; Patent No. 5849475
; GENERAL INFORMATION:
; APPLICANT: Rovinski, Benjamin
; APPLICANT: Haynes, Joel
; APPLICANT: Cao, Shi Xian
; APPLICANT: Klein, Michel H
; TITLE OF INVENTION: Retrovirus-Like Particles Containing
; TITLE OF INVENTION: Modified Envelope Glycoproteins
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: 330 University Avenue, 6th Floor
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/452,503A
; FILING DATE: 30-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/073,526
; FILING DATE: 09-JAN-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Stewart, Michael I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-447 MIS:as
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-452-503A-4

Query Match 76.4%; Score 94; DB 2; Length 21;
```

Best Local Similarity 90.5%; Pred. No. 2.7e-07;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2 NTRKSERIQRGPGRAFTVIGK 22
Db 1 NTRKRIRIQRGPGRAFTVIGK 21

RESULT 35
US-08-453-745A-4
; Sequence 4, Application US/08453745A
; Patent No. 5866137
; GENERAL INFORMATION:
; APPLICANT: Rovinski, Benjamin
; APPLICANT: Haynes, Joel
; APPLICANT: Cao, Shi Xian
; APPLICANT: Klein, Michel H
; TITLE OF INVENTION: Retrovirus-Like Particles Containing
; TITLE OF INVENTION: Modified Envelope Glycoproteins
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: 330 University Avenue, 6th Floor
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION NUMBER: US/08/453,745A
; FILING DATE: 30-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/073,526
; FILING DATE: 09-JAN-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Stewart, Michael I
; REGISTRATION NUMBER: 24,73
; REFERENCE/DOCKET NUMBER: 1038-445 MIS:as
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-453-745A-4

Query Match 76.4%; Score 94; DB 2; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.7e-07;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 NTRKSERIQRGPGRAFTVIGK 22
Db 1 NTRKRIRIQRGPGRAFTVIGK 21

RESULT 36
US-08-470-419-25
; Sequence 25, Application US/08470419
; Patent No. 5866320
; GENERAL INFORMATION:
; APPLICANT: ROVINSKI, Benjamin
; APPLICANT: CAO, Shi-Xian
; APPLICANT: YAO, Fei-Long
; APPLICANT: PERSSON, Roy

; APPLICANT: KLEIN, Michel H
; TITLE OF INVENTION: ANTIGENICALLY-MARKED NON-INFECTIONOUS
; RETROVIRUS-LIKE PARTICLES
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION NUMBER: US/08/470,419
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/290,105
; FILING DATE: August 15, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, Michael I
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-385 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-470-419-25

Query Match 76.4%; Score 94; DB 2; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.7e-07;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 NTRKSERIQRGPGRAFTVIGK 22
Db 1 NTRKRIRIQRGPGRAFTVIGK 21

RESULT 37
US-08-761-828-25
; Sequence 25, Application US/08761828
; Patent No. 5879925
; GENERAL INFORMATION:
; APPLICANT: ROVINSKI, Benjamin
; APPLICANT: CAO, Shi-Xian
; APPLICANT: YAO, Fei-Long
; APPLICANT: PERSSON, Roy
; APPLICANT: KLEIN, Michel H
; TITLE OF INVENTION: ANTIGENICALLY-MARKED NON-INFECTIONOUS RETROVIRUS-LIKE PARTICLES
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: 6TH Floor, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/761,828

```
;
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/290,105
; FILING DATE: 15-AUG-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, Michael I
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-655 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-761-828-25

Query Match 76.4%; Score 94; DB 2; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.7e-07;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 NTRKSERIQRGPGRAFTVIGK 22
Db 1 NTRKRIRIQRGPGRAFTVIGK 21

RESULT 38
US-08-452-520B-4
; Sequence 4, Application US/08452520B
; Patent No. 5912338
; Patent No. 5912338 5840872
; GENERAL INFORMATION:
; APPLICANT: Rovinski, Benjamin
; APPLICANT: Haynes, Joel
; APPLICANT: Cao, Shi Xian
; APPLICANT: Klein, Michel H
; TITLE OF INVENTION: Retrovirus-Like Particles Containing
; TITLE OF INVENTION: Modified Envelope Glycoproteins
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: 330 University Avenue, 6th Floor
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/452,520B
; FILING DATE: 30-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/073,526
; FILING DATE: 09-JAN-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Stewart, Michael I
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-446 MIS:as
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 amino acids
; TYPE: amino acid
```

```
;
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-452-520B-4

Query Match 76.4%; Score 94; DB 2; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.7e-07;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 NTRKSERIQRGPGRAFTVIGK 22
Db 1 NTRKRIRIQRGPGRAFTVIGK 21

RESULT 39
US-08-290-105-25
; Sequence 25, Application US/08290105
; Patent No. 5955342
; GENERAL INFORMATION:
; APPLICANT: ROVINSKI, Benjamin
; APPLICANT: CAO, Shi-Xian
; APPLICANT: YAO, Fei-Long
; APPLICANT: PERSSON, Roy
; APPLICANT: KLEIN, Michel H
; TITLE OF INVENTION: ANTIGENICALLY-MARKED NON-INFECTIOUS
; TITLE OF INVENTION: RETROVIRUS-LIKE PARTICLES
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/290,105
; FILING DATE: August 15, 1994
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, Michael I
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-385 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-290-105-25

Query Match 76.4%; Score 94; DB 2; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.7e-07;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 NTRKSERIQRGPGRAFTVIGK 22
Db 1 NTRKRIRIQRGPGRAFTVIGK 21

RESULT 40
US-08-776-949-25
; Sequence 25, Application US/08776949
; Patent No. 6025125
; GENERAL INFORMATION:
; APPLICANT: Rovinski, Benjamin
; APPLICANT: Cao, Shi-Xian
```

APPLICANT: Yao, Fei-Long
APPLICANT: Persson, Roy
APPLICANT: Klein, Michel H
TITLE OF INVENTION: ANTIGENICALLY-MARKED NON-INFECTIOUS
RETROVIRUS-LIKE PARTICLES
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: 6th Floor, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/776,949
FILING DATE: 02-JUN-1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Stewart, Michael I
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-673 MIS:jb
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-776-949-25

Query Match 76.4%; Score 94; DB 3; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.7e-07;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 2 NTRKSERIQRGPGRAFTVIGK 22
Db 1 NTRKRIQRGPGRAFTVIGK 21

RESULT 41
US-08-482-810-25
Sequence 25, Application US/08482810
Patent No. 6080408
GENERAL INFORMATION:
APPLICANT: ROVINSKI, Benjamin
APPLICANT: CAO, Shi-Xian
APPLICANT: YAO, Fei-Long
APPLICANT: PERSSON, Roy
APPLICANT: KLEIN, Michel H
TITLE OF INVENTION: RETROVIRUS-LIKE PARTICLES MADE NON-
INFECTIOUS BY A PLURALITY OF MUTATIONS
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/482,810

FILING DATE: 07-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/292,967
FILING DATE: 22-AUG-1994
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, Michael I
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-490 MIS:vg
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-482-810-25

Query Match 76.4%; Score 94; DB 3; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.7e-07;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 2 NTRKSERIQRGPGRAFTVIGK 22
Db 1 NTRKRIQRGPGRAFTVIGK 21

RESULT 42
US-09-027-955-25
Sequence 25, Application US/09027955
Patent No. 6291157
GENERAL INFORMATION:
APPLICANT: ROVINSKI, Benjamin
APPLICANT: CAO, Shi-Xian
APPLICANT: YAO, Fei-Long
APPLICANT: PERSSON, Roy
APPLICANT: KLEIN, Michel H
TITLE OF INVENTION: ANTIGENICALLY-MARKED NON-INFECTIOUS
RETROVIRUS-LIKE PARTICLES
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: 6th Floor, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/027,955
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/290,105
FILING DATE: 15-AUG-1994
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, Michael I
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-798 MIS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 amino acids
TYPE: amino acid


```
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-027-955-25

Query Match      76.4%; Score 94; DB 3; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.7e-07;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 NTRKSERIORGPGRAFTVIGK 22
Db 1 NTRKRIIRIORGPGRAFTVIGK 21

RESULT 43
US-09-636-805-25
; Sequence 25, Application US/09636805
; Patent No. 6342228
; GENERAL INFORMATION:
; APPLICANT: ROVINSKI, Benjamin
; CAO, Shi-Xian
; YAO, Fei-Long
; PERSSON, Roy
; KLEIN, Michel H
; TITLE OF INVENTION: ANTIGENICALLY-MARKED NON-INFECTIONOUS
; RETROVIRUS-LIKE PARTICLES
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: 6th Floor, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/636,805
; FILING DATE: 10-Aug-2000
; CLASSIFICATION: <unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 09/027,955
; FILING DATE: 23-FEB-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, Michael I
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-1068 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 25:
US-09-636-805-25

Query Match      76.4%; Score 94; DB 3; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.7e-07;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 NTRKSERIORGPGRAFTVIGK 22
Db 1 NTRKRIIRIORGPGRAFTVIGK 21

RESULT 44
US-09-258-128-25
; Sequence 25, Application US/09258128
; Patent No. 6451322
; GENERAL INFORMATION:
; APPLICANT: ROVINSKI, Benjamin
; CAO, Shi-Xian
; YAO, Fei-Long
; PERSSON, Roy
; KLEIN, Michel H
; TITLE OF INVENTION: ANTIGENICALLY-MARKED NON-INFECTIONOUS
; RETROVIRUS-LIKE PARTICLES MADE NON-
; INFECTIONOUS BY A PLURALITY OF MUTATIONS
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: 6th Floor, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/258,128
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/292,967
; FILING DATE: 22-AUG-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, Michael I
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-924 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-258-128-25

Query Match      76.4%; Score 94; DB 4; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.7e-07;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 NTRKSERIORGPGRAFTVIGK 22
Db 1 NTRKRIIRIORGPGRAFTVIGK 21

RESULT 45
US-09-635-754-25
; Sequence 25, Application US/09635754
; Patent No. 6518030
; GENERAL INFORMATION:
; APPLICANT: ROVINSKI, Benjamin
; CAO, Shi-Xian
; YAO, Fei-Long
; PERSSON, Roy
; KLEIN, Michel H
; TITLE OF INVENTION: ANTIGENICALLY-MARKED NON-INFECTIONOUS
; RETROVIRUS-LIKE PARTICLES
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: 6th Floor, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
```

```

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/635,754
; FILING DATE: 10-Aug-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 09/027,955
; FILING DATE: 23-FEB-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, Michael I
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-1065 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 25:
US-09-635-754-25

```

```

Query Match      76.4%; Score 94; DB 4; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.7e-07;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      2 NTRKSERIQGPGRAFTVIGK 22
Db      1 NTRKRIRIQGPGRAFTVIGK 21

```

Search completed: May 16, 2005, 13:06:19
Job time : 37.9231 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 16, 2005, 12:40:16 ; Search time 169.846 Seconds
(without alignments)
54.651 Million cell updates/sec

Title: US-08-869-386-3

Perfect score: 123

Sequence: 1 NNTKSERIQRGPGRAFTVIGKIG 24

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 768190

Minimum DB seq length: 0

Maximum DB seq length: 25

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_16Dec04:*

- 1: Geneseqp1980s:*
- 2: Geneseqp1990s:*
- 3: Geneseqp2000s:*
- 4: Geneseqp2001s:*
- 5: Geneseqp2002s:*
- 6: Geneseqp2003bs:*
- 7: Geneseqp2003bs:*
- 8: Geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	115	93.5	24	2 AAR06211	Aar06211 Immunosp
2	115	93.5	24	2 AAR07018	Aar07018 Residues
3	115	93.5	24	2 AAR26565	Aar26565 Sequence
4	115	93.5	24	2 AAR29233	Aar29233 Heterocon
5	115	93.5	24	2 AAR26870	Aar26870 HIV gp120
6	115	93.5	24	2 AAR32406	Aar32406 Sequence
7	115	93.5	24	2 AAR38165	Aar38165 V3 loop p
8	115	93.5	24	2 AAY22581	Aay22581 HIV LDL b
9	115	93.5	24	3 AAB15873	Aab15873 Human che
10	115	93.5	24	4 AAB68602	Aab68602 HIV gp120
11	115	93.5	25	1 AAR90281	Aap90281 Peptide 1
12	115	93.5	25	2 AAR08276	Aar08276 HIV pep1
13	115	93.5	25	2 AAR31276	Aar31276 HIV princ
14	115	93.5	25	2 AAR30031	Aar30031 HIV princ
15	115	93.5	25	2 AAR26712	Aar26712 HIV-PND-p
16	115	93.5	25	2 AAR33222	Aar33222 HIV gp120
17	115	93.5	25	2 AAR41336	Aar41336 HIV gp120
18	115	93.5	25	2 AAR41330	Aar41330 HIV gp120
19	113	91.9	25	2 AAR04427	Aar04427 Human imm
20	111	90.2	24	2 AAY22583	Aay22583 HIV LDL b
21	109	88.6	23	2 AAR04502	Aar04502 Cpd. elic
22	109	88.6	24	2 AAR33190	Aar33190 Sequence
23	109	88.6	24	2 AAW67414	Aaw67414 HIV-1 pep
24	109	88.6	24	2 AAW98904	Aaw98904 HIV-1 vac
25	109	88.6	24	2 AAY39769	Aay39769 HIV1 chlm

26	109	88.6	25	2 AAR15058	Aar15058 HIV-1 amp
27	109	88.6	25	2 AAR36587	Aar36587 Virus neu
28	106	86.2	25	2 AAR04475	Aar04475 Human imm
29	105	85.4	25	2 AAW87618	AAW87618 Epitope o
30	103	83.7	22	2 AAR42153	Aar42153 gp120 V3
31	103	83.7	22	2 AAW07392	Aaw07392 HIV-1 str
32	103	83.7	22	2 AAY07488	Aay07488 HIV-1 str
33	100	81.3	25	2 AAR13120	Aar13120 Binding s
34	100	81.3	25	2 AAW72819	Aaw72819 HIV-1 gp1
35	99	80.5	22	3 AAY85137	Aay85137 HIV-1 III
36	94	76.4	20	2 AAW76842	Aaw76842 Fusion im
37	94	76.4	21	2 AAR04060	Aar04060 Epitope c
38	94	76.4	21	2 AAR93073	Aar93073 Antigenic
39	94	76.4	21	2 AAW75478	Aaw75478 HIV-1 str
40	94	76.4	21	2 AAY16052	Aay16052 HIV-1 iso
41	94	76.4	21	2 AAW85568	AAW85568 Human imm
42	94	76.4	21	4 AAU08699	Aau08699 Retroviri
43	94	76.4	22	2 AAR57470	Aar57470 HIV BRU V
44	94	76.4	24	2 AAE20149	Aae20149 Human imm
45	94	76.4	25	2 AAR63820	Aar63820 HIV-1 gp1

ALIGNMENTS

RESULT 1
AAR06211
ID AAR06211 standard; peptide; 24 AA.
XX
AC AAR06211;
XX
DT 10-DEC-1990 (first entry)
XX
DE Immunosuppressant protease inhibitor.
XX
KW Organ transplant; autoimmune disease; allergy; aplastic anaemia;
KW systemic erythematodes.
XX
OS Synthetic.
XX
PN JP02157229-A.
XX
PD 18-JUN-1990.
XX
PF 07-DEC-1988; 88JP-00310635.
XX
PR 07-DEC-1988; 88JP-00310635.
XX
PA (NITL) NITTO DENKO CORP.
XX
DR WPI; 1990-233739/31.
XX
PT Protease inhibiting peptide immuno-suppressant - used to suppress
PT rejection reaction in organs transplantation.
XX
PS Claim 1; Page 181; 6pp; Japanese.
XX
CC Protease inhibitor may be used to suppress organ transplant rejection
CC without serious side effects. It may also be used in prevention and
CC therapy of allergy, aplastic anaemia and systemic erythematodes. See
CC also AAR06212
XX
SQ Sequence 24 AA;
Query Match 93.5%; Score 115; DB 2; Length 24;
Best Local Similarity 95.8%; Pred. No. 2.8e-09;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 NNTKSERIQRGPGRAFTVIGKIG 24
DB 1 NNTKSERIQRGPGRAFTVIGKIG 24

```

RESULT 2
AA07018
ID AAR07018 standard; peptide; 24 AA.
AC
XX AAR07018;
XX
DT 24-OCT-2003 (revised)
DT 18-JAN-1991 (first entry)
XX
DE Residues 301-324 of HIV gp 120 protein used in isolation of sulphated
DE polysaccharide by affinity chromatography.
XX
KW HIV; AIDS; ARC; gp120; RP135.
XX
OS Human immunodeficiency virus 1.
XX
PN CA2007258-A.
XX
PD 11-JUL-1990.
XX
PF 05-JAN-1990; 90CA-02007258.
XX
PR 11-JAN-1989; 89US-00295856.
PR 05-JUL-1989; 89US-00375795.
XX
PA (RICH ) MERRELL DOW PHARM INC.
PI Cardin AD, Jackson RL;
XX
DR WPI; 1990-290631/39.
XX
PT Prepn. of anti-HIV sulphated polysaccharide - by affinity chromatography
PT using a resin-bound peptide corresp. to a HIV gp. 120 fragment.
XX
PS Disclosure; Page ?; 34pp; English.
XX
CC Anti-HIV sulphated polysaccharide (SPS) can prevent syncytium formation
CC in HIV infected C4 cells. SPS may be isolated by affinity chromatography
CC with the given resin bound peptide fragment RP135. (Updated on 24-OCT-
CC 2003 to standardise OS field)
XX
SQ Sequence 24 AA;
Query Match 93.5%; Score 115; DB 2; Length 24;
Best Local Similarity 95.8%; Pred. No. 2.8e-09;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 NNTKRSIRIQGPGRAFTVIGKIG 24
DB 1 NNTKRSIRIQGPGRAFTVIGKIG 24

RESULT 3
AAR26565
ID AAR26565 standard; peptide; 24 AA.
XX
XX AAR26565;
XX
XX
DT 24-OCT-2003 (revised)
DT 25-MAR-2003 (revised)
DT 28-JAN-1993 (first entry)
XX
DE Sequence of peptide DB1 determined from the V3 principal neutralising
DE domain (PND) region of HIV-1 strain HTLV-III B.
XX
KW Diagnostic; assay; detection; AIDS; human immunodeficiency virus.
XX
OS Human immunodeficiency virus 1; strain HTLV-III B.
XX
PN WO9213882-A1.
XX
PD 20-AUG-1992.
XX

```

```

PF 29-JAN-1992; 92WO-EP000187.
XX
PR 30-JAN-1991; 91IT-MI000220.
XX
PA (SUPE-) INST SUPERIORE DI SANITA.
PA (CNDR ) CONSIGLIO NAZ DELLE RICERCHE.
XX
PI De Rossi A, Pasti M, Mammano F, Panozzo M, Dettin M, Di Bello C;
PI Chieco-Bianchi L;
XX
DR WPI; 1992-299983/36.
XX
XX Synthetic peptide(s) which enhance infectivity of HIV-1 in cellular
PT cultures - are used for determining HIV-1 virus in blood and other
PT biological materials.
XX
PS Claim 1; Page 17; 31pp; English.
XX
XX The principal neutralizing domain (PND) of HIV-1 corresp. to a 24- amino
CC acid sequence arranged in a loop determined by a disulfide bridge in the
CC third hypervariable region, V3, of the protein gp 120. The central
CC portion of the V3-PND contains a sequence which is highly conserved in
CC different HIV-1 isolated strains, whereas the amino acids flanking this
CC sequence are variable. The antigenic properties of V3 region are known to
CC be virus-specific; antibodies elicited by MN-derived peptide do not
CC neutralize HTLV-III B virus and vice-versa. (Updated on 25-MAR-2003 to
CC correct PN field.) (Updated on 25-MAR-2003 to correct PR field.) (Updated
CC on 25-MAR-2003 to correct PA field.) (Updated on 24-OCT-2003 to
CC standardise OS field)
XX
SQ Sequence 24 AA;
Query Match 93.5%; Score 115; DB 2; Length 24;
Best Local Similarity 95.8%; Pred. No. 2.8e-09;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 NNTKRSIRIQGPGRAFTVIGKIG 24
DB 1 NNTKRSIRIQGPGRAFTVIGKIG 24

RESULT 4
AAR29233
ID AAR29233 standard; peptide; 24 AA.
XX
XX AAR29233;
XX
XX
DT 25-MAR-2003 (revised)
DT 14-APR-1993 (first entry)
XX
DE Heteroconjugate antibody immunogen RP135 (IIIB).
XX
KW V3 loop; gp41; envelope protein; MN; prototype; virus; variant; HIV;
KW homology; heteroconjugate; enzyme; epitope mapping; replication;
KW conjugate; immunogenic carrier; keyhole limpet hemocyanin; KLH;
KW ovalbumin; succinyl maleimidomethyl cyclohexanylethyl carbonylate; SMCC.
XX
XX Synthetic.
XX
XX
XX Key Location/Qualifiers
FT Misc-difference 24 /note= "Not in the natural sequence of this isolate"
FT
XX
XX WO9220373-A1.
XX
PD 26-NOV-1992.
XX
XX 29-APR-1992; 92WO-US003616.
XX
XX 14-MAY-1991; 91US-00699773.
XX
XX (REPK ) REPLIGEN CORP.
XX

```

PI Higgins PJ, Potts BJ;
 DR WPI; 1992-415475/50.
 XX
 PT Hetero-conjugate antibodies for treating HIV infections - comprise an
 PT antibody specific for an effector cell surface antigen and an antibody to
 PT a V3 loop of GP-120 envelope protein of HIV.
 XX
 PS Disclosure; Page 19; 69pp; English.
 XX
 CC The sequences given in AAR29226-35 represent peptides which were used as
 CC immunogens for the production of antibodies against HIV. These peptides
 CC may be either unconjugated or conjugated to an immunogenic carrier, eg. a
 CC keyhole limpet hemocyanin (KLH) or ovalbumin, using succinyl
 CC maleimidomethyl cyclohexanycarboxylate (SMCC) as a conjugating agent.
 CC Viruses containing these or similar sequences may be recognised by the
 CC heteroconjugate enzymes of the invention. The antibodies raised against
 CC these sequences may be identified by standard epitope mapping techniques.
 CC These antibodies are capable, even at low concentrations, of nearly
 CC eliminating viral replication of different strains of HIV. (Updated on 25
 CC -MAR-2003 to correct PN field.)
 XX
 SQ Sequence 24 AA;
 Query Match 93.5%; Score 115; DB 2; Length 24;
 Best Local Similarity 95.8%; Pred. No. 2.8e-09;
 Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 NNTKRSRIQRGPGRAFTVIGKIG 24
 DB 1 NNTKRSRIQRGPGRAFTVIGKIG 24
 RESULT 5
 ID AAR26870 standard; peptide; 24 AA.
 XX
 AC AAR26870;
 XX
 DT 25-MAR-2003 (revised)
 DT 20-MAY-1998 (first entry)
 XX
 DE HIV gp120 V3 region binding assay peptide IIIB.
 XX
 KW Human immunodeficiency virus; AIDS; anti-gp120 antibodies.
 OS Synthetic.
 XX
 PN EP503916-A1.
 XX
 PD 16-SEP-1992.
 XX
 PF 11-MAR-1992; 92EP-00302064.
 XX
 PR 11-MAR-1991; 91US-00668266.
 PR 06-MAR-1992; 92US-00894766.
 XX
 PA (IDEC-) IDEC PHARM CORP.
 XX
 PI Chang-Yuil K;
 XX
 DR WPI; 1992-309988/38.
 XX
 PT Anti-idiotype antibodies and methods for their selection - useful as
 PT vaccines for the prevention and treatment of HIV infection.
 XX
 PS Example; Page 9; 30pp; Japanese.
 XX
 CC The sequence is that of peptide IIIB, derived from the V3 region of HIV
 CC gp120, it was used in binding assays for anti-gp120 antibodies. The anti-
 CC gp120 antibodies are useful in vaccine formulations for the treatment or
 CC prevention of HIV infection. See also AAR26867-R26873. (Updated on 25-MAR
 CC -2003 to correct PN field.) (Updated on 25-MAR-2003 to correct PR field.)

XX Sequence 24 AA;
 SQ
 Query Match 93.5%; Score 115; DB 2; Length 24;
 Best Local Similarity 95.8%; Pred. No. 2.8e-09;
 Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 NNTKRSRIQRGPGRAFTVIGKIG 24
 DB 1 NNTKRSRIQRGPGRAFTVIGKIG 24
 RESULT 6
 ID AAR32406 standard; peptide; 24 AA.
 XX
 AC AAR32406;
 XX
 DT 25-MAR-2003 (revised)
 DT 04-JUL-1993 (first entry)
 XX
 DE Sequence of peptide B1 which comprises AAs 308-331 from the V3 region of
 DE HIV-1 isolate IIIB.
 XX
 KW HIV-1; vaccine; dendritic core; ss.
 XX
 OS Synthetic.
 XX
 PN WO9303766-A1.
 XX
 PD 04-MAR-1993.
 XX
 PF 11-AUG-1992; 92WO-US006688.
 PR 13-AUG-1991; 91US-00744281.
 XX
 PA (REPK) REPLIGEN CORP.
 PA (UYRQ) UNIV ROCKEFELLER.
 XX
 PI Tam JP, Profy AT;
 XX
 DR WPI, 1993-093730/11.
 XX
 PT New multiple antigen peptide(s) as HIV vaccines - include a dendritic
 PT core covalently bonded to peptide including the sequence IGPGR.
 XX
 PS Example; Fig 1; 35pp; English.
 XX
 CC Nine peptides from the V3 regions of HIV-1 isolates IIIB, RF and MN were
 CC incorporated into tetraivalent multiple antigen peptide systems (MAPS)
 CC (see AAR32406-14). Parallel groups of three peptides with chain lengths
 CC spanning from 11-24 residues were synthesised in MAPS format for each
 CC isolate. ELIS assays demonstrated that antisera titers in mice were
 CC closely related to the length of the IIIB peptide used for the
 CC immunisation - the longer the stronger the response. There was no
 CC substantial antibody prodn. in mice against the other two series of
 CC peptides, RF (B4-B6), and MN (B7-B9), except for a low reactivity in the
 CC gp. immunised with B8 (MN isolate). Specificity tests of the B cell
 CC response demonstrated that the T cell epitope (AAR32415) also serves as a
 CC B cell epitope. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 24 AA;
 Query Match 93.5%; Score 115; DB 2; Length 24;
 Best Local Similarity 95.8%; Pred. No. 2.8e-09;
 Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 NNTKRSRIQRGPGRAFTVIGKIG 24
 DB 1 NNTKRSRIQRGPGRAFTVIGKIG 24
 RESULT 7


```

OS Synthetic.
XX WO200042071-A2.
XX
XX 20-JUL-2000.
XX
XX 12-JAN-2000; 2000WO-US000821.
XX
XX 12-JAN-1999; 99US-00229071.
XX
XX 17-MAR-1999; 99US-00271192.
XX
XX 01-DEC-1999; 99US-00452406.
XX
XX (NEOR-) NEORX CORP.
XX
XX Grainger DJ, Tatalick LM;
XX
XX WPI; 2000-499101/44.
XX
XX New peptide 3, amide and heterocyclic compounds and saccharide conjugates
XX used for inhibiting chemokine induced activity and for treating e.g.
XX stroke, vascular diseases, autoimmune diseases and tumor growth.
XX
XX Disclosure; Fig 18; 387pp; English.
XX
XX The present invention concerns the identification of a number of
XX chemokines which can be used to produce derivatives, agonists and
XX antagonists which are then useful in disease treatment. The chemokines
XX include sequences AAB15785-B15794, AAB15803-B15813 and AAB15831-B15848.
XX These chemokine derivatives can be used to treat diseases such as
XX autoimmune diseases, atherosclerosis, osteoporosis, HIV infection and
XX AIDS, psoriasis, inflammatory diseases, hypertension, basophil-mediated
XX diseases, endotoxaemia, myocardial infarction, acute ischaemia and
XX rheumatoid arthritis, and can be used to prevent strokes and as
XX contraceptives. The coding sequences for the chemokines can be used in
XX gene therapy for the same diseases, as well as in the production of
XX animal models
XX
XX Sequence 24 AA;
XX
XX Query Match 93.5%; Score 115; DB 3; Length 24;
XX Best Local Similarity 95.8%; Pred. No. 2.8e-09;
XX Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1 NNTKRSRIQRGPGRAFTVIGKIG 24
XX ||||| ||||| ||||| ||||| |||||
XX DB 1 NNTKRSRIQRGPGRAFTVIGKIG 24
XX
XX RESULT 10
XX AAB68602
XX ID AAB68602 standard; peptide; 24 AA.
XX
XX AC AAB68602;
XX
XX 11-SEP-2003 (revised)
XX 25-APR-2001 (first entry)
XX
XX HIV gp120 V3 loop peptide #2.
XX
XX HIV gp120 V3 loop; liposome composition; HIV infection.
XX
XX Human immunodeficiency virus 1.
XX
XX US6180134-B1.
XX
XX 30-JAN-2001.
XX
XX 07-JUN-1995; 95US-00480332.
XX
XX 23-MAR-1993; 93US-00035443.
XX
XX 29-SEP-1994; 94US-00316436.
XX
XX (SEQU-) SEQUUS PHARM INC.

```

```

XX Zalipsky S, Woodle MC, Martin FJ, Barenholz Y;
XX WPI; 2001-201897/20.
XX
XX Liposome composition for use in treating septic shock comprises liposomes
XX having an outer surface layer of polyethylene glycol chains, and a
XX polypeptide or polysaccharide effector molecule.
XX
XX Disclosure; Fig 13; 32pp; English.
XX
XX The present invention relates to a liposome composition comprising
XX liposomes having an outer surface layer of polyethylene glycol chains,
XX each having a free distal end. A polypeptide or polysaccharide effector
XX molecule is covalently attached to a portion of the distal ends. The
XX effector interferes with specific binding of pathogen or cell in a
XX bloodstream to a target cell or cell matrix, and is rapidly removed by
XX renal clearance from the bloodstream when administered in free form. The
XX liposome composition may be used in treating a condition mediated by
XX binding a pathogen or cell in the bloodstream, to a target cell or cell
XX matrix. It can be used in treating septic shock, toxic shock, colonic
XX inflammation, leukaemic cell proliferation, or HIV infection. The present
XX sequence is a peptide of the V3 loop of HIV envelope protein gp120. This
XX peptide may be used in the composition of the present invention. gp120
XX binds to the CD4 receptor during HIV infection of lymphocytes. By
XX introducing the present peptide, the CD4 receptors are blocked, thereby
XX inhibiting HIV infection. (Updated on 11-SEP-2003 to standardise OS
XX field)
XX
XX Sequence 24 AA;
XX
XX Query Match 93.5%; Score 115; DB 4; Length 24;
XX Best Local Similarity 95.8%; Pred. No. 2.8e-09;
XX Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1 NNTKRSRIQRGPGRAFTVIGKIG 24
XX ||||| ||||| ||||| ||||| |||||
XX DB 1 NNTKRSRIQRGPGRAFTVIGKIG 24
XX
XX RESULT 11
XX AAP90281
XX ID AAP90281 standard; protein; 25 AA.
XX
XX AC AAP90281;
XX
XX 09-SEP-2004 (revised)
XX 24-OCT-2003 (revised)
XX 25-MAR-2003 (revised)
XX 22-JUN-1990 (first entry)
XX
XX Peptide 135 of HIV env gene.
XX
XX HIV; AIDS; env gene; HIV vaccine; ds.
XX
XX Simian-Human immunodeficiency virus.
XX Unidentified.
XX
XX EP306219-A.
XX
XX 08-MAR-1989.
XX
XX 25-AUG-1988; 88EP-00307889.
XX
XX 27-AUG-1987; 87US-00090080.
XX
XX (REFK ) REPLIGEN CORP.
XX
XX Rusche JR, Putney SD, Jayaherian K, Parley J, Grimalia R, Lynn D;
XX Petro J, Okeeffe T;
XX WPI; 1989-070387/10.
XX
XX

```


XX
101

/note= "not in natural sequence of isolate"

XX PN WO9304693-A1.
 XX PD 18-MAR-1993.
 XX PF 02-SEP-1992; 92WO-US007511.
 XX PR 09-SEP-1991; 91US-00756677.
 XX PR 20-JUL-1992; 92US-00916542.
 XX PA (REPK) REPLIGEN CORP.
 XX PI Potts BJ, Whiteschaf ME, Field KG, Herlihy WC;
 XX DR WPI; 1993-100653/12.
 XX PT Synergistic compen. for treating HIV-1 infection - comprises antibody to
 PT V3 loop of GP120 and antibody to CD4 binding site of GP120 or soluble CD4
 PT polypeptide.
 XX PS Example; Page 12; 56pp; English.
 XX CC The sequence is that of peptide RP135 (IIIB) used as an immunogen for the
 CC generation of antibodies directed against the V3 loop of HIV gp120. These
 CC antibodies can be used as part of a compen. with antibodies directed
 CC against the CD4 binding site of gp120. The antibodies act synergistically
 CC to neutralise HIV-1 in the treatment of HIV infection caused by different
 CC strains. (Updated on 25-MAR-2003 to correct PN field.) (Updated on 25-MAR
 CC -2003 to correct PI field.)
 XX SQ Sequence 25 AA;
 Query Match 93.5%; Score 115; DB 2; Length 25;
 Best Local Similarity 95.8%; Pred. No. 3e-09;
 Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 NNTKRSRIQRGPGRAFTVIGKIG 24
 Db ||||| ||||| ||||| ||||| |||||
 1 NNTKRSRIQRGPGRAFTVIGKIG 24
 RESULT 17
 AAR41336
 ID AAR41336 standard; peptide; 25 AA.
 AC AAR41336;
 XX 24-OCT-2003 (revised)
 DT 25-MAR-2003 (revised)
 DT 22-APR-1994 (first entry)
 XX HIV gp120 V3 region peptide HIV-III B.
 DE V3 region; HIV; envelope gp120; vaccine; human; humoral response;
 KW cellular immunity; carrier protein; human serum albumin; HSA;
 KW keyhole limpet haemocyanin; KLH; multiple antigen peptide.
 XX Human immunodeficiency virus 1.
 OS
 XX WO9318791-A1.
 XX 30-SEP-1993.
 XX 19-MAR-1993; 93WO-JP000327.
 XX 26-MAR-1992; 92JP-00098602.
 PR 14-AUG-1992; 92JP-00237648.
 PR 15-MAR-1993; 93JP-00054239.
 XX (TSDT-) TSD KK.
 PA
 XX Okuda K;
 XX

DR WPI; 1993-320455/40.
 XX Virus for prevention of HIV infected diseases - comprising several
 PT peptide(s) consisting of V3 region peptide of envelope Gp., 120, etc. and
 PT complex including carrier protein.
 XX PS Disclosure; Page 3; 35pp; Japanese.
 XX The sequences given in AAR41336-39 and AAR42664 represent peptides
 CC derived from the V3 region of HIV envelope gp120. These peptides may be
 CC used in a vaccine which is effective in humans and animals and activates
 CC humoral and cellular immunity. The vaccine also contains a carrier
 CC protein containing a cysteine group, eg. human serum albumin (HSA),
 CC keyhole limpet haemocyanin (KLH) or multiple antigen peptide. (Updated on
 CC 25-MAR-2003 to correct PN field.) (Updated on 24-OCT-2003 to standardise
 CC OS field)
 XX SQ Sequence 25 AA;
 Query Match 93.5%; Score 115; DB 2; Length 25;
 Best Local Similarity 95.8%; Pred. No. 3e-09;
 Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 NNTKRSRIQRGPGRAFTVIGKIG 24
 Db ||||| ||||| ||||| ||||| |||||
 1 NNTKRSRIQRGPGRAFTVIGKIG 24
 RESULT 18
 AAR41330
 ID AAR41330 standard; peptide; 25 AA.
 XX AAR41330;
 XX 25-MAR-2003 (revised)
 DT 21-APR-1994 (first entry)
 XX HIV gp120 epitope.
 DE HIV; haemagglutinin; reactants; catalysts; cofactors; repressors;
 KW enhancers; hormones; binders; human immunodeficiency virus.
 XX Human immunodeficiency virus.
 OS
 XX WO9319170-A1.
 XX 30-SEP-1993.
 XX 09-MAR-1993; 93WO-US002349.
 XX 16-MAR-1992; 92US-00852412.
 XX (WOHL/) WOHLSTADTER J N.
 XX Wohlstadter JN;
 XX WPI; 1993-320737/40.
 XX Obtaining a novel mol. - capable of a desired interaction with a
 PT substrate of interest and a selection molecule expressed by the host.
 XX Claim 151; Page 147; 165pp; English.
 XX The HIV gp120 epitope is used to isolate, create or evolve novel mols.
 CC including (in)organic and biomolecules such as proteins, peptides,
 CC nucleic acids, oligonucleotides, lipids, and polysaccharides for use as
 CC reactants, catalysts, enzymatic cofactors, repressors, enhancers,
 CC hormones and binders for a wide variety of substrates in industrial and
 CC therapeutic products. This epitope was isolated from variable region 3 of
 CC HIV gp120 (amino acids 271-295). (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX SQ Sequence 25 AA;

Query Match 93.5%; Score 115; DB 2; Length 25;
 Best Local Similarity 95.8%; Pred. No. 3e-09;
 Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 NNTKSEIRIQGPGRAFTVIGKIG 24
 DB 1 NNTKSEIRIQGPGRAFTVIGKIG 24

RESULT 19
 AAR04427
 ID AAR04427 standard; peptide; 25 AA.
 XX AAR04427;
 AC
 XX 09-SEP-2004 (revised)
 DT 25-MAR-2003 (revised)
 DT 20-SEP-1990 (first entry)
 XX
 DE Human immunodeficiency virus peptide 135.
 XX HIV-IIIB; peptide 135; principal neutralising domain; antibodies;
 KW diagnosis; prophylaxis; therapy; AIDS.
 XX
 OS Synthetic.
 XX WO9003984-A.
 XX 19-APR-1990.
 PD
 XX 03-OCT-1988; 88US-00252949.
 XX 03-OCT-1988; 88US-00252949.
 PR 01-JUN-1989; 89US-00359543.
 PR 19-SEP-1988; 89US-00407663.
 XX
 FA (REPK) REPLIGEN CORP.
 XX
 XX Rusche JR, Putney SD, Javaherian K, Farley J, Grimailla R;
 PI Lynn DU, Petrobre J;
 XX WPI; 1990-147824/19.
 DR
 XX
 XX Principal neutralising domain of HIV variants - used for producing
 PT peptide(s) and antibodies for diagnosis, prophylaxis and/or therapy
 PT therapy therapy of HIV infection.
 XX
 PS Claim 8 (30); Page 75; 108pp; English.
 XX
 CC Peptide 135 comprises segments of the Principal Neutralising Domain
 CC (envelope protein) from isolate HIV-IIIB. The last Cys residue is added
 CC for the purpose of crosslinking to carrier proteins. Cysteine residues
 CC can be added so that that residues at or near both ends form a disulfide
 CC bond, thus giving the peptide a loop-like configuration, which is
 CC utilised to enhance the immunogenic properties of the peptide. The
 CC peptide is capable of eliciting, and/or binding with, neutralising
 CC antibodies. The neutralising domain is bounded by cysteine residues which
 CC occur at positions 296 and 331. Peptides can be used as immunogens or
 CC screening reagents to generate or identify poly- or Mabs. See also
 CC AAR04427-R04506 and AAR04273-Q04279. (Updated on 25-MAR-2003 to correct
 CC PR field.) (Updated on 25-MAR-2003 to correct PA field.) (Updated on 25-
 CC MAR-2003 to correct PI field.)
 CC
 CC Revised record issued on 09-SEP-2004 : Correction to Feature Table Key
 XX
 SQ Sequence 25 AA;

Query Match 91.9%; Score 113; DB 2; Length 25;
 Best Local Similarity 91.7%; Pred. No. 5.7e-09;
 Matches 22; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY 1 NNTKSEIRIQGPGRAFTVIGKIG 24

RESULT 20
 AAY22583
 ID AAY22583 standard; peptide; 24 AA.
 XX AAY22583;
 AC
 XX 17-OCT-2003 (revised)
 DT 19-OCT-1999 (first entry)
 XX
 DE HIV LDL binding peptide, sequence "A" variant.
 XX HIV; LDL; low density lipoprotein; human; immune response; infection;
 KW immunodeficiency; neoplastic tissue; myalgic encephalomyelitis; ME;
 KW viral infection fatigue syndrome; tuberculosis; hepatitis; AIDS; ARC;
 KW acquired immunodeficiency syndrome; AIDS related complex;
 KW HIV-infected CD4 cell; immunosuppressive peptide.
 XX
 OS Human immunodeficiency virus 1.
 XX WO9938524-A2.
 XX 05-AUG-1999.
 XX 28-JAN-1999; 99WO-IB000149.
 XX 29-JAN-1998; 98US-0072980P.
 PR (PREN/) PRENDERGAST P T.
 PA
 XX Prendergast PT;
 PI
 XX WPI; 1999-494040/41.
 XX
 PT Enhancing the immune response using a recombinant human low-density
 PT lipoprotein receptor, useful for treating viral infections, especially
 PT human immunodeficiency virus (HIV) infection.
 XX
 PS Disclosure; Page 12; 24pp; English.
 XX
 CC This sequence represents a variant of the HIV sequence that binds human
 CC low density lipoprotein (LDL), and is designated sequence "A" (see
 CC AAY22581). The sequence "A" peptide is isolated from HIV isolate
 CC IIIB(BH10), and this sequence was isolated from HIV isolate IIIB(BH8).
 CC The invention relates to a method for enhancing the immune response in a
 CC patient with a condition, selected from immunodeficiency (due to a viral,
 CC bacterial, mycoplasmic, fungal or parasitic infection, or from the growth
 CC of neoplastic tissue), myalgic encephalomyelitis (ME), post inoculation
 CC or viral infection fatigue syndrome, tuberculosis, or hepatitis. The
 CC method comprises using a pharmaceutical composition, comprising a
 CC recombinant human LDL receptor or a mimic molecule to the cysteine rich
 CC domain of LDL receptor. The human recombinant LDL receptor forms
 CC pharmaceutical compositions for: the treatment of acquired
 CC immunodeficiency syndrome (AIDS) or ARC (AIDS related complex); reducing
 CC syncytium formation in HIV-infected CD4 cells; treating blood or body
 CC fluid or organs to neutralise/remove immunosuppressive peptides and/or
 CC viruses; or treating hepatitis A, B or C. The pharmaceutical compositions
 CC also treat a viral infection in a human or animal host. The human
 CC recombinant LDL receptor is also useful for manufacturing medicaments for
 CC treating all the conditions given above. The human recombinant LDL
 CC receptor is a highly specific inhibitor of HIV-1 replication in vitro.
 CC (Updated on 17-OCT-2003 to standardise OS field)
 XX
 SQ Sequence 24 AA;

Query Match 90.2%; Score 111; DB 2; Length 24;
 Best Local Similarity 91.7%; Pred. No. 1.1e-08;
 Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1 NNTKSEIRIQGPGRAFTVIGKIG 24

||||| ||||||| ||||||| ||||||| |||||||
1 NNRKKIRIQGPGRAFTVIGKIG 24

Db
RESULT 21
AAR04502
ID AAR04502 standard; protein; 23 AA.
XX
AC AAR04502;
XX
XX 09-SEP-2004 (revised)
DT 25-MAR-2003 (revised)
DT 20-SEP-1990 (first entry)
XX
DE Cpd. eliciting, binding with neutralising antibodies to HIV variants.
XX
XX HIV; therapy; AIDS; principal neutralising domain; antibodies; diagnosis;
KW prophylaxis.
KW
XX Synthetic.
OS
XX WO9003984-A.
PN
XX 19-APR-1990.
PD
XX 03-OCT-1988; 88US-00252949.
XX
XX 03-OCT-1988; 88US-00252949.
PR
XX 01-JUN-1989; 89US-00359543.
PR
XX 19-SEP-1989; 89US-00407663.
XX
XX (REPK) REPLIGEN CORP.
PA
XX Rusche JR, Putney SD, Javaherian K, Parley J, Grimalia R;
PI Lynn DU, Petrobre J;
PI
XX WPI; 1990-147824/19.
DR
XX Principal neutralising domain of HIV variants - used for producing
PT peptide(s) and antibodies for diagnosis, prophylaxis and/or therapy
PT therapy of HIV infection.
XX
XX Claim 27 (d); Page 84; 108pp; English.
XX
XX Either the N-terminal (a) or C-terminal (b), but not both, may be omitted
CC : either (a) or (b) may comprise any of the following: cysteine, a
CC protein or other moiety capable of enhancing immunogenicity, a peptide
CC from an HIV principal neutralising domain, peptide capable of stimulating
CC T-cells, or general immune stimulant. See also AAR0427-R04506 and
CC AAQ04273-Q04279. (Updated on 25-MAR-2003 to correct PR field.) (Updated
CC on 25-MAR-2003 to correct PA field.) (Updated on 25-MAR-2003 to correct
CC PI field.)
CC
CC Revised record issued on 09-SEP-2004 : Correction to Feature Table Key
XX
SQ Sequence 23 AA;
Query Match 88.6%; Score 109; DB 2; Length 23;
Best Local Similarity 95.7%; Pred. No. 2e-08;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 NTRKSERIQGPGRAFTVIGKIG 24
Db 1 NTRKSERIQGPGRAFTVIGKIG 23
||||| ||||||| ||||||| ||||||| |||||||
RESULT 22
AAR33190
ID AAR33190 standard; peptide; 24 AA.
XX
XX AAR33190;
AC
XX 25-MAR-2003 (revised)
DT

11-JUL-1993 (first entry)
Sequence of HIV-1 derived V3 loop peptide.
AIDS; HIV; therapy; autoimmune disease; gp120; ss.
Synthetic.
OS
XX WO9303762-A1.
PN
XX 04-MAR-1993.
PD
XX 10-AUG-1992; 92WO-AU000423.
PF
XX 13-AUG-1991; 91AU-00007725.
PR
XX (BIOT-) BIOTECH AUSTRALIA PTY LTD.
PA (SVIN-) ST VINCENT'S HOSPITAL SYDNEY LTD.
PA
XX Geczy AF, Russell-Jones GJ, Bell SJD, Cooper DA;
PI WPI; 1993-093727/11.
XX
XX Compans. contg. E.coli outer membrane proteins TraT, OmpA or OmpF -
PT increase immune response and are used for treating autoimmune diseases,
PT AIDS, cancer etc.
XX
XX Example; Page 13; 36pp; English.
PS
XX Two peptides, gp41[8] and V3 loop derived from the gp120 region of HIV-1
CC were synthesised and purified. To improve the solubility of the gp41[8]
CC peptide the sequence RSS was added to the amino terminal to produce
CC peptide R-S-Gp41[8]. The immunodominant HIV-derived peptides were used to
CC ascertain whether E.coli outer membrane protein TraT augments the in
CC vitro T-cell proliferative responses. (Updated on 25-MAR-2003 to correct
CC PN field.)
XX
SQ Sequence 24 AA;
Query Match 88.6%; Score 109; DB 2; Length 24;
Best Local Similarity 95.7%; Pred. No. 2.1e-08;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 NTRKSERIQGPGRAFTVIGKIG 24
Db 1 NTRKSERIQGPGRAFTVIGKIG 23
||||| ||||||| ||||||| ||||||| |||||||
RESULT 23
AAR67414
ID AAR67414 standard; peptide; 24 AA.
XX
XX AAR67414;
AC
XX 25-JAN-1999 (first entry)
DT
XX HIV-1 peptide epitope BRU.
DE
XX Immunogen; vaccine; HIV-1; T-cell; B-cell; epitope; core protein; gp120;
KW V3 loop.
KW
XX Synthetic.
OS Human immunodeficiency virus 1.
OS
XX US5817754-A.
PN
XX 06-OCT-1998.
PD
XX 05-JUN-1995; 95US-00464329.
PF
XX 09-JUN-1993; 93US-00073378.
PR
XX 09-JUN-1994; 94US-00257528.
PR
XX

PA (CONN-) CONNAUGHT LAB LTD.
 XX Chong P, Klein MH, Sia CDY;
 XX WPI; 1998-556461/47.
 XX Synthetic human immunodeficiency virus-1 peptide(s) - containing T-cell
 PT epitope and B-cell epitope(s) are candidate vaccines against HIV-1.
 XX Disclosure; Fig 3; 40pp; English.
 XX The invention relates to a novel immunogenic composition for use in
 CC vaccines for the treatment of HIV-1 comprising an HIV-1-derived T-cell
 CC epitope linked to an HIV-1-derived B-cell epitope. The T-cell epitopes
 CC are generally designed based on the p24 core protein and the B-cell
 CC epitopes from the V3 loop of the gp120 protein from various HIV-1
 CC strains. This sequence corresponds to an HIV-1 B-cell peptide epitope
 CC used to immunise a guinea pig
 XX
 XX Sequence 24 AA;
 SQ Query Match 88.6%; Score 109; DB 2; Length 24;
 Best Local Similarity 95.7%; Pred. No. 2.1e-08;
 Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2 NTRKSIRIQGPGRAFTVIGKIG 24
 DB 1 NTRKSIRIQGPGRAFTVIGKIG 23
 RESULT 25
 AAY39769
 ID AAY39769 standard; peptide; 24 AA.
 XX
 XX AAY39769;
 XX
 XX 17-OCT-2003 (revised)
 DT 26-NOV-1999 (first entry)
 XX
 XX HIV1 chimeric peptide.
 DE
 XX HIV; vaccine; immunogenic composition; T cell epitope; B cell epitope;
 KW infection; antibody; antiviral.
 KW
 XX Human immunodeficiency virus 1.
 OS
 XX US5951986-A.
 PN
 XX 14-SEP-1999.
 PD
 XX 06-JUN-1995; 95US-00467881.
 PF
 XX 09-JUN-1993; 93US-00073378.
 PR
 XX 09-JUN-1994; 94US-00257528.
 XX
 XX (CONN-) CONNAUGHT LAB LTD.
 PA
 XX Klein MH, Chong P, Sia CDY;
 PI WPI; 1999-550482/46.
 DR
 XX Immunogenic composition containing synthetic fusion polypeptides
 PT containing both the T and B cell epitopes of the human immunodeficiency
 PT virus, useful antigens in producing vaccines.
 PT
 XX Disclosure; Col 73-74; 43pp; English.
 PS
 XX This sequence represents a fragment of a HIV1 protein, and can be used in
 CC the immunogenic composition of the invention. The composition comprises a
 CC synthetic fusion polypeptide which includes a sequence encoding 1 or more
 CC T cell epitopes and a sequence encoding 1 or more B cell epitopes and a
 CC carrier. Both the T cell and B cell epitopes are derived from HIV
 CC proteins. The compositions are useful as vaccines against HIV infection.
 CC The composition induces HIV-1-specific polyclonal antibodies that are
 CC opsonising and antiviral. The peptide components may be selected to
 CC induce a response against different viral isolates and in subjects who
 CC recognise different T cell epitopes. (Updated on 17-OCT-2003 to
 CC standardise OS field)
 XX
 XX Sequence 24 AA;
 SQ Query Match 88.6%; Score 109; DB 2; Length 24;
 Best Local Similarity 95.7%; Pred. No. 2.1e-08;
 Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2 NTRKSIRIQGPGRAFTVIGKIG 24
 DB 1 NTRKSIRIQGPGRAFTVIGKIG 23

PA (CONN-) CONNAUGHT LAB LTD.
 XX Chong P, Klein MH, Sia CDY;
 XX WPI; 1998-556461/47.
 XX Synthetic human immunodeficiency virus-1 peptide(s) - containing T-cell
 PT epitope and B-cell epitope(s) are candidate vaccines against HIV-1.
 XX Disclosure; Fig 3; 40pp; English.
 XX The invention relates to a novel immunogenic composition for use in
 CC vaccines for the treatment of HIV-1 comprising an HIV-1-derived T-cell
 CC epitope linked to an HIV-1-derived B-cell epitope. The T-cell epitopes
 CC are generally designed based on the p24 core protein and the B-cell
 CC epitopes from the V3 loop of the gp120 protein from various HIV-1
 CC strains. This sequence corresponds to an HIV-1 B-cell peptide epitope
 CC used to immunise a guinea pig
 XX
 XX Sequence 24 AA;
 SQ Query Match 88.6%; Score 109; DB 2; Length 24;
 Best Local Similarity 95.7%; Pred. No. 2.1e-08;
 Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2 NTRKSIRIQGPGRAFTVIGKIG 24
 DB 1 NTRKSIRIQGPGRAFTVIGKIG 23
 RESULT 24
 AAW98904
 ID AAW98904 standard; peptide; 24 AA.
 XX
 XX AAW98904;
 AC
 XX 05-MAY-1999 (first entry)
 DT
 XX HIV-1 vaccine synthetic peptide SEQ ID NO:99.
 DE
 XX HIV-1; human immunodeficiency virus; vaccine; T-cell epitope;
 KW gag protein; B-cell epitope; gp41 protein; chimeric; infection.
 KW
 XX Synthetic.
 OS
 XX Human immunodeficiency virus 1.
 OS
 XX US5876731-A.
 PN
 XX 02-MAR-1999.
 PD
 XX 05-JUN-1995; 95US-00462507.
 PF
 XX 09-JUN-1993; 93US-00073378.
 PR
 XX 09-JUN-1994; 94US-00257528.
 XX
 XX (CONN-) CONNAUGHT LAB LTD.
 PA
 XX Chong P, Klein MH, Sia CDY;
 PI WPI; 1999-189590/16.
 DR
 XX Synthetic chimeric HIV polypeptides - comprising gag protein T-cell
 PT epitope linked to gp41 B-cell epitope.
 PT
 XX Example 1; Col 71-72; 41pp; English.
 PS
 XX The present invention describes a synthetic peptide comprising an amino
 CC acid sequence containing a T-cell epitope of an HIV gag protein linked at
 CC its C terminus to an amino acid sequence containing a B-cell epitope of
 CC an HIV gp41 protein and containing the amino acid sequence: XILKDWX2;
 CC where X1 = E, A, G or Q, and X2 = A or T, or an amino acid sequence
 CC capable of eliciting an HIV-specific antiserum and recognizing the
 CC sequence XILKDWX2. The synthetic peptide is useful in vaccines against

PD 13-MAY-1993.
XX'
XX' 28-OCT-1992; 92WO-EP002459.
XX
XX 28-OCT-1991; 91US-00782154.
XX 28-OCT-1991; 91US-00782241.
PR 28-OCT-1991; 91US-00782252.
XX
XX (INSP) INST PASTEUR.
PA
XX
XX Girard M;
XX
XX
XX WPI; 1993-167398/20.
XX
XX
XX Enhancing immunogenicity of viral envelope glycoprotein - by co-
PT administration of viral envelope glycoprotein itself, and an oligopeptide
PT derive.
PT
XX
XX Disclosure; Page 82; 107pp; English.
XX
XX A novel method of enhancing the immunogenicity of an envelope
XX glycoprotein (EGP) of a virus (esp. HIV gp120 or gp160) in a host
CC comprises admin. to the host at least one EGP of the virus in an amt.
CC sufficient for priming vaccination and at least one peptide derived from
CC an amino acid sequence of the EGP (e.g. the sequence shown), where the
CC peptide comprises at least one virus-neutralisation epitope (VNE). The
CC complex is able to enhance the induction of neutralising antibodies to
CC the virus and to confer long lasting immunity, longer than 6 months. See
CC also AAR36567-86. (Updated on 25-MAR-2003 to correct PN field.)
CC
XX
XX Sequence 25 AA;
XX
XX Query Match 88.6%; Score 109; DB 2; Length 25;
XX Best Local Similarity 95.7%; Pred. No. 2.1e-08;
XX Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0
Qy 2 NTRKSERIQRGGRAFTVIGKIG 24
Db ||||| ||||| ||||| ||||| |||||
2 NTRKSIRIQRGGRAFTVIGKIG 24
RESULT 28
AAR04475
ID AAR04475 standard; protein; 25 AA.
XX
XX AAR04475;
XX AC
XX 09-SEP-2004 (revised)
DT 25-MAR-2003 (revised)
DT 20-SEP-1990 (first entry)
XX
XX Human immunodeficiency virus hybrid peptide RP137.
XX
XX HIV isolates HIV-IITB and HIV-RF; hybrid peptide RP137; therapy; AIDS;
KW principal neutralising domain; antibodies; diagnosis; prophylaxis.
XX
XX Synthetic.
XX OS
XX WO9003984-A.
XX PN
XX 19-APR-1990.
XX PD
XX 03-OCT-1988; 88US-00252949.
XX PF
XX 03-OCT-1988; 88US-00252949.
PR 01-JUN-1989; 89US-00359543.
PR 19-SEP-1989; 89US-00407663.
XX
XX (REPK) REPLIGEN CORP.
XX PA
XX Rusche JR, Putney SD, Javaherian K, Farley J, Grimaila R;
PI Lynn DU, Petrobre J;
PI
XX

DR WPI; 1990-147824/19.

PT Principal neutralising domain of HIV variants - used for producing

PT peptide(s) and antibodies for diagnosis, prophylaxis and/or therapy

PT therapy of HIV infection.

XX

PS Claim 8 (58); Page 76; 108pp; English.

XX

CC Peptide RP137 comprises segments of the Principal Neutralising Domain

CC (envelope protein) from isolates HIV-RF and HIV-IIIB. The last Cys

CC residue is added for the purpose of crosslinking to carrier proteins.

CC Cysteine residues may be added, so that the residues at or near both ends

CC form a disulfide bond, giving peptide a loop-like configuration, which

CC can be utilised to enhance immunogenic properties of the peptides.

CC Protein is capable of eliciting, and/or binding with, neutralising

CC antibodies. The neutralising domain is bounded by cysteine residues which

CC occur at positions 296 and 331. The peptides can be used as immunogens

CC or screening reagents to generate or identify poly- or monoclonal

CC antibodies. See also AAR04427-R04506 and AAQ04273-Q04279. (Updated on 25-

CC MAR-2003 to correct PR field.) (Updated on 25-MAR-2003 to correct PA

CC field.) (Updated on 25-MAR-2003 to correct PI field.)

CC

CC Revised record issued on 09-SEP-2004 : Correction to Feature Table Key

XX

XX Sequence 25 AA;

SQ

Query Match 86.2%; Score 106; DB 2; Length 25;

Best Local Similarity 87.5%; Pred. No. 5.7e-08;

Matches 21; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

OY 1 NNTKSERIQRGPGRAFTVIGKIG 24

||||| : |||||

DB 1 NNTKRSIRITKPGRAFTVIGKIG 24

||||| : |||||

RESULT 29

AAW87618

ID AAW87618 standard; peptide; 25 AA.

XX

AC AAW87618;

XX

DT 17-OCT-2003 (revised)

DT 20-MAR-2003 (revised)

DT 03-MAR-1999 (first entry)

XX

DE Epitope of HIV-1 gp120 protein.

XX

XX Epitope; gp120 protein; monoclonal antibody; HIV-1; antibody BAT123;

KW antibody BAT267; antibody BAT085; T cell infection inhibition;

KW syncytia formation; acquired immune deficiency syndrome; AIDS;

KW AIDS-related complex; passive immunisation; antiviral; cytotoxic;

KW viral load measurement; vaccine.

XX

OS Human immunodeficiency virus 1.

XX

PN US5854400-A.

XX

PD 29-DEC-1998.

XX

PF 22-SEP-1992; 92US-00950571.

XX

XX 29-MAY-1987; 87US-00057445.

PR 24-DEC-1987; 87US-00137861.

PR 26-SEP-1991; 91US-00767533.

XX

PA (TANO-) TANOX INC.

XX

PI Fung MSC, Sun BNC, Sun CRY, Chang NT, Chang TW;

XX

XX WPI; 1999-095002/08.

DR

XX Monoclonal antibodies directed against regions of gp120 of human immune

PT deficiency virus-1 - are neutralising and able to inhibit infection of T

PT cells and formation of syncytia, used for treatment, prevention or

PT diagnosis of acquired immune deficiency syndrome.

PS Claim 2; Col 8; 16pp; English.

XX

CC The present sequence represents an epitope of the gp120 protein of human

CC immune deficiency virus (HIV)-1. The sequence comprises amino acids 298

CC to 322 of gp120. The specification describes monoclonal antibodies which

CC bind to sequences derived from the present epitope. Specifically, these

CC antibodies are designated BAT123, 267 and 085. Monoclonal antibodies

CC neutralise HIV-1, inhibiting both infection of T cells and formation of

CC syncytia, so are used to treat acquired immune deficiency syndrome (AIDS)

CC and AIDS-related complex, by passive immunisation, as carriers of

CC cytotoxic or antiviral agents, and in extracorporeal systems. They can

CC also be used as immunoassay reagents (for diagnosis or measurement of

CC viral load) and to screen for neutralising epitopes, potentially useful

CC in vaccine development. (Updated on 20-MAR-2003 to correct PR field.)

CC (Updated on 17-OCT-2003 to standardise OS field)

XX

XX Sequence 25 AA;

SQ

Query Match 85.4%; Score 105; DB 2; Length 25;

Best Local Similarity 95.5%; Pred. No. 8e-08;

Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 NNTKSERIQRGPGRAFTVIGK 22

||||| : |||||

DB 4 NNTKRSIRIQRGPGRAFTVIGK 25

||||| : |||||

RESULT 30

AAW42153

ID AAR42153 standard; peptide; 22 AA.

XX

AC AAR42153;

XX

DT 24-OCT-2003 (revised)

DT 25-MAR-2003 (revised)

DT 27-APR-1994 (first entry)

XX

DE gp120 V3 loop sequence of HIV-1 IIIB isolate.

XX

XX Human Immunodeficiency Virus; antigen; ELISA; recombinant antibody;

KW HIV-neutralising monoclonal antibody; immunoglobulin; AIDS;

KW acquired immune deficiency syndrome; chimeric antibody;

KW surface glycoprotein gp120; V3 loop; epitope mapping.

XX

OS Human immunodeficiency virus 1; (IIIB isolate).

XX

XX WO9319785-A1.

PN

PD 14-OCT-1993.

XX

PF 23-MAR-1993; 93WO-US002629.

XX

PR 01-APR-1992; 92US-00861701.

XX

PA (MERI) MERCK & CO INC.

XX

PI Emimi EA, Conley AJ, Mark GE, Johnson LS, Pfarr DS;

XX

XX WPI; 1993-336600/42.

DR

XX New recombinant human antibody - with HIV neutralising activity against

PT at least two isolates, useful for preventing or treating infection in

PT diagnosis, etc.

XX

XX Example 16; Page 100; 154pp; English.

PS

XX Antibodies able to neutralise more than one HIV-1 isolate are claimed.

CC The gp120 V3 loop sequences from different isolates comprising the

CC Principal Neutralising Determinant motif GGR are given in AAR42153-

CC R42161. (Updated on 25-MAR-2003 to correct PN field.) (Updated on 24-OCT-

CC 2003 to standardise OS field)

XX Sequence 22 AA;

Query Match 83.7%; Score 103; DB 2; Length 22;
 Best Local Similarity 95.5%; Pred. No. 1.4e-07;
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3 TRKSIRIQRGPGRAFTVIGKIG 24
 |||||
 Db 1 TRKSIRIQRGPGRAFTVIGKIG 22

RESULT 31

AAW07392

ID AAW07392 standard; peptide; 22 AA.

XX

AC AAW07392;

XX 16-OCT-2003 (revised)

DT 24-FEB-1997 (first entry)

XX HIV-1 strain IIIB gp120 V3 loop sequence.

KW HIV-1; gp120; V3 loop; common consensus PND domain; envelop; CD4;
 KW binding site; stem-loop; lysine branched peptide; AIDS.

XX OS Human immunodeficiency virus 1.
 XX PN JP08231423-A.

PD 10-SEP-1996.

XX 27-FEB-1995; 95JP-00038835.
 XX 27-FEB-1995; 95JP-00038835.

PA (TERU) TERUMO CORP.

PA (OKUD/) OKUDA K.

XX WPI; 1996-461278/46.

XX Novel AIDS vaccine - comprises branched lysine peptide fragments derived

PT from HIV env protein.

XX Example 2; Page 5-6; 8pp; Japanese.

CC This is the sequence of the V3 loop of the gp120 envelop protein from HIV
 CC -1 strain IIIB. The sequence was used with a construct comprising part of
 CC the HIV-1 gp120 V3 loop common consensus PND sequence (AAW07390) fused to
 CC part of the HIV-1 CD4 binding site (AAW07391) and with the V3 loop
 CC sequences from HIV-1 strains Thai B (AAW07393) or HGP-30 (AAW07394) to
 CC generate a lysine branched peptide which is useful for the prevention and
 CC treatment of AIDS. (Updated on 16-OCT-2003 to standardise OS field)

XX Sequence 22 AA;

Query Match 83.7%; Score 103; DB 2; Length 22;
 Best Local Similarity 95.5%; Pred. No. 1.4e-07;
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 NTRKSIRIQRGPGRAFTVIGKI 23
 |||||
 Db 1 NTRKSIRIQRGPGRAFTVIGKI 22

RESULT 32

AAW07488

ID AAW07488 standard; peptide; 22 AA.

XX

AC AAW07488;

XX 17-OCT-2003 (revised)

DT 17-AUG-1999 (first entry)

XX HIV-1 strain IIIB gp120 V3 loop sequence.
 XX Light chain; variable region; human; HIV-1; gp120; monoclonal antibody;

KW epitope; V3 loop; heterohybridoma; human immunodeficiency virus-1;
 KW peripheral blood lymphocyte; Epstein-Barr virus; EBV; AIDS.

XX OS Human immunodeficiency virus 1.
 XX PN US9914109-A.

XX 22-JUN-1999.

XX 21-NOV-1994; 94US-00345321.

XX 15-JUN-1990; 90US-00538451.

XX 12-APR-1991; 91US-00684090.

XX 23-APR-1992; 92US-00872675.

XX (UYNV) UNIV NEW YORK STATE.

XX Gorny MK, Zolla-Pazner S;

XX WPI; 1999-370481/31.

XX Heterohybridoma producing human monoclonal antibodies to human

PT immunodeficiency virus-1.

XX Example 5; Col 24; 42pp; English.

XX This sequence represents the V3 loop from the gp120 protein of the human
 CC immunodeficiency virus-1 (HIV-1) strain IIIB. The invention relates to
 CC the generation of heterohybridomas producing human monoclonal antibodies
 CC (see AAX9204-X79207) to a neutralising epitope of HIV-1 prepared by
 CC transforming peripheral blood lymphocytes with Epstein-Barr virus. The
 CC antibodies can be used to treat someone infected with HIV-1 or suffering
 CC from AIDS. (Updated on 17-OCT-2003 to standardise OS field)

XX Sequence 22 AA;

Query Match 83.7%; Score 103; DB 2; Length 22;
 Best Local Similarity 95.5%; Pred. No. 1.4e-07;
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3 TRKSIRIQRGPGRAFTVIGKIG 24
 |||||
 Db 1 TRKSIRIQRGPGRAFTVIGKIG 22

RESULT 33

AAW07392

ID AAW07392 standard; peptide; 25 AA.

XX AAW07392;

XX 24-OCT-2003 (revised)

DT 01-OCT-1991 (first entry)

XX Binding site of BAT123 and BAT267 HIV antibodies.

XX Anti-idiotypic; antibody; gp120; HIV; human immunodeficiency virus;
 KW paratope; complementarity determining region; CDR; immunisation; vaccine;
 KW immunotoxin; T-cell; AIDS; ARC.

XX Simian-Human immunodeficiency virus.
 XX WO9109625-A.

XX 11-JUL-1991.

XX 21-DEC-1989; 89US-00454161.

PR 21-DEC-1989; 89US-00454161.
 PR 12-JUN-1990; 90US-00531789.
 XX
 PA (TANO-) TANOX BIOSYSTEMS INC.
 XX Chang TW, Fung MSC, Sun CRY, Sun BNC, Chang NT;
 PI
 XX WPI; 1991-222664/30.
 DR
 XX Monoclonal antibodies specific to the gp120 HIV envelope protein - for
 PT immunisation against HIV in treatment of AIDS or ARC.
 XX
 PT Claim 5; Page 97; 124pp; English.
 PS
 XX The peptide corresponds to residues 294-318 of the gp120 envelope protein
 CC of HIV-1 which is a principal neutralising determinant (PND). Abs
 CC recognise residues 294-308 (Mab BAT267) or 304-318 (Mab 123). These Mab
 CC are used to raise anti-idiotypic Abs (AABs). The Abs are useful for
 CC passive immunisation and as components for immunotoxins which destroy T-
 CC cells infected with HIV. They inhibit T-cell infection and syncytium
 CC formation, are group specific and neutralise specific strains of HIV-1.
 CC They can be used to treat AIDS or ARC. The AABs can be used for active
 CC immunisation or can be admin with another vaccine to increase
 CC antigenicity. See also AAR13121. (Updated on 24-OCT-2003 to standardise
 CC OS field)
 XX SQ Sequence 25 AA;
 SQ Query Match 81.3%; Score 100; DB 2; Length 25;
 Best Local Similarity 90.9%; Pred. No. 4.1e-07;
 Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1 NNTKRSRIQRGPGRAFTVIGK 22
 ||||| ||||| ||||| |||||
 Db 4 NNTKRIRIQRGPGRAFTVIGK 25
 ||||| ||||| ||||| |||||
 RESULT 34
 AAW72819
 ID AAW72819 standard; peptide; 25 AA.
 XX
 AC AAW72819;
 XX
 DT 17-OCT-2003 (revised)
 DT 13-JAN-1999 (first entry)
 XX
 DE HIV-1 gp120 epitope 294 to 318.
 XX
 KW HIV-1; gp120; epitope; monoclonal antibody; envelope; neutralise;
 KW inhibit; infection; T-cell; inhibit syncytium formation; AIDS.
 XX
 OS Human immunodeficiency virus 1.
 XX
 FH Key Location/Qualifiers
 FT Peptide 1..15
 FT /label= peptide_a
 FT Peptide 11..25
 FT /label= peptide_b
 XX
 XX US5834599-A.
 PN
 XX
 PD 10-NOV-1998.
 XX
 PF 04-MAR-1993; 93US-00026276.
 XX
 PR 29-MAY-1987; 87US-00057445.
 PR 24-DEC-1987; 87US-00137861.
 PR 25-APR-1989; 89US-00343540.
 PR 05-JUN-1992; 92US-00895197.
 XX
 PA (TANO-) TANOX BIOSYSTEMS INC.
 XX Sun BN, Fung SC, Kim YW, Sun CR, Chang NT, Chang T;
 PI

XX WPI; 1999-008810/01.
 XX Antibody conjugate comprising monoclonal antibody - which binds to
 PT epitope within amino acid residue of gp120 which neutralises HIV-1
 PT conjugated with, e.g. cytotoxic agent.
 XX
 PS Disclosure; Col 8; 22pp; English.
 XX
 CC The present invention describes an antibody conjugate comprising an
 CC antibody (Ab) which binds to an epitope within amino acid residue 308-322
 CC of gp120 and neutralises HIV-1, conjugated with a cytotoxic agent, an
 CC anti-viral agent or an agent which facilitates passage through the blood
 CC brain barrier. Also described is an antibody conjugate as above but where
 CC the Ab binds to an epitope within amino acid residue 298-312 of gp120
 CC which neutralises HIV-1. The present sequence represents an HIV-1 gp120
 CC epitope corresponding to positions 294 to 318. The Ab are monoclonal Ab
 CC which bind to the gp120 protein on the envelope of HIV-1. They inhibit
 CC the infection of T-cells and also inhibit syncytium formation. The
 CC antibodies are group specific and neutralise different strains and
 CC isolates of HIV-1. The antibodies have a variety of uses, including the
 CC treatment and prevention of AIDS and AIDS related complex. They are
 CC especially used to kill infected T-cells. (Updated on 17-OCT-2003 to
 CC standardise OS field)
 XX SQ Sequence 25 AA;
 SQ Query Match 81.3%; Score 100; DB 2; Length 25;
 Best Local Similarity 90.9%; Pred. No. 4.1e-07;
 Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1 NNTKRSRIQRGPGRAFTVIGK 22
 ||||| ||||| ||||| |||||
 Db 4 NNTKRIRIQRGPGRAFTVIGK 25
 ||||| ||||| ||||| |||||
 RESULT 35
 AAY85137
 ID AAY85137 standard; protein; 22 AA.
 XX
 AC AAY85137;
 XX
 DT 12-SEP-2003 (revised)
 DT 20-JUN-2000 (first entry)
 XX
 DE HIV-1 IIIB V3 loop peptide sequence.
 XX
 KW Human immunodeficiency virus type 1; HIV-1; infection; prevent; detect;
 KW glycoprotein 140; gp140; neutralising antibody; conformational epitope;
 KW V3 loop.
 XX
 OS Human immunodeficiency virus 1.
 XX
 FN US6039957-A.
 XX
 PD 21-MAR-2000.
 XX
 PF 03-MAR-1997; 97US-00805889.
 XX
 PR 10-DEC-1993; 93US-00165314.
 XX
 PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX
 PI Dome RW, Moss B, Earl PL, Broder CC;
 XX
 XX WPI; 2000-270121/23.
 DR
 XX Producing neutralizing antibodies useful for preventing, treating and
 PT diagnosing an HIV infection in a mammal comprises administering
 PT recombinant uncleaved gp140 proteins to a human.
 XX
 XX Example 10; Col 12; 15pp; English.
 XX

CC This sequence represents a human immunodeficiency virus type-1 IIIB V3-loop peptide sequence. The peptide sequence is used to test the reactivity of the antibodies of the invention. The invention relates to a method for the production of neutralising antibodies against conformational epitopes of HIV-1 envelope proteins in humans. The method comprises administering to a human, a recombinant uncleaved gp140 protein retaining its oligomeric structure. The human produces neutralising antibodies against conformational epitopes of the HIV-1 gp140 protein found on the oligomeric structure of the gp140. The anti-HIV-1 gp140 antibodies of the invention can be used for preventing and diagnosing an HIV infection in a mammal. Gp140 antibodies are useful for treating an HIV infection. A diagnostic method using the antibodies involves isolating a body fluid, preferably blood, and contacting it with a labelled monoclonal antibody for gp140, and detecting any bound antibody. (Updated on 12-SEP-2003 to standardise OS field)

XX
SQ Sequence 22 AA;

Query Match 80.5%; Score 99; DB 3; Length 22;
Best Local Similarity 95.2%; Pred. No. 5.1e-07;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 NTRKSERIQGPGRAFTVIGK 22
DB 2 NTRKSIRIQGPGRAFTVIGK 22

RESULT 36
AAW76842

ID AAW76842 standard; peptide; 20 AA.
AC
AAW76842;
25-JAN-1999 (first entry)

DE Fusion immunoglobulin heavy chain HIV gp120 B cell epitope #12.
KW B cell; T cell; epitope; immunoglobulin; heavy chain; gp120; IGH;
KW human immune deficiency virus; HIV; tolerance; treatment; therapy;
KW prophylaxis; vaccine; chemotherapy; immune response; modifier; tumour;
KW microbial infection; autoimmune disease; antibody; apoptosis;
KW antiviral T cell immunity.

XX Mus sp.
XX Homo sapiens.
XX WO9836087-A1.
XX 20-AUG-1998.
XX 13-FEB-1998; 98WO-US002766.
XX 13-FEB-1997; 97US-0040581P.
XX (AMNA-) AMERICAN NAT RED CROSS.
XX Scott D, Zambidis E;
XX WPI; 1998-506315/43.
XX New fusion immunoglobulin heavy chain including gp120 epitopes and related complete antibodies - DNA, vectors and transformed cells, used to induce tolerance to the epitopes for treatment of human immune deficiency virus infection.

XX Claim 10; Page 119; 154pp; English.

CC This sequence is an epitope used in the construction of a novel fusion immunoglobulin heavy chain (IGH) protein with a mammalian, especially human, IGH chain fused in frame at its N-terminus to one or more human immune deficiency virus (HIV) gp120 epitopes. Fusion Ig proteins and/or transfected cells are used to tolerate subjects to gp120 epitopes and to maintain this tolerance, particularly for treatment of HIV infection,

CC optionally together with other therapeutic/prophylactic agents such as vaccines, chemotherapeutic agents and immune response modifiers. Such proteins can be used against other diseases where an immune response is deleterious, e.g. microbial infection, tumours or autoimmune disease.
CC Induction of tolerance suppresses production of antibodies against gp120, so prevents or inhibits 'bystander' apoptosis of uninfected T cells that are bound to gp120 protein, maximising induction of protective antiviral T cell immunity

XX
SQ Sequence 20 AA;

Query Match 76.4%; Score 94; DB 2; Length 20;
Best Local Similarity 95.0%; Pred. No. 2.4e-06;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 NTRKSERIQGPGRAFTVIG 21
DB 1 NTRKSIRIQGPGRAFTVIG 20

RESULT 37
AAR04060

ID AAR04060 standard; peptide; 21 AA.
XX
AC AAR04060;
25-MAR-2003 (revised)
23-JUL-1992 (first entry)

DE Epitope comprising residues 308-327 of HIV env gp 120.
KW Human immunodeficiency virus; retrovirus; vaccine; antibodies; HbC; HBe;
KW antigen; hepatitis B virus; HBV; core.
XX Synthetic.
XX JP02069194-A.
XX 08-MAR-1990.
XX 02-SEP-1988; 88JP-00220770.
XX 02-SEP-1988; 88JP-00220770.
XX (KAGA) KAGAKU OYOBI KESSEI RYOHU.
XX WPI; 1990-119518/16.
XX N-PSDB; AAQ02417.
XX Antigen granule comprising HBC or HBE antigen - and HIV neutralised epitope obtd. by expression of recombinant prod., for e.g. vaccine.
XX Claim Disclosure; Fig 4; 11pp; Japanese.
XX The synthetic epitope is used in a complex with either the hepatitis B core antigen (HBC) or a sol. cleavage prod. of HBC (HBe), to prepare a vaccine. The peptide corresponds to residues 308-327 of the HIV env glycoprotein 120, with an N-terminal initiation Met. (Updated on 25-MAR-2003 to correct PA field.)

XX
SQ Sequence 21 AA;

Query Match 76.4%; Score 94; DB 2; Length 21;
Best Local Similarity 95.0%; Pred. No. 2.5e-06;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 NTRKSERIQGPGRAFTVI 20
DB 2 NTRKSIRIQGPGRAFTVI 21

RESULT 38
AAR93073

ID AAR93073 standard; peptide; 21 AA.
AC AAR93073;
DT 27-SEP-1996 (first entry)
XX
DE Antigenic peptide CLTB73.
XX
XX Antigen; non-infectious; retrovirus; antigenic marker; immune response;
KW long terminal repeat; gag; pol; env; AIDS; HIV; antibody; therapy.
XX
OS Synthetic.
XX
XX WO9605292-A1.
PN
XX
PD 22-FEB-1996.
XX
PF 15-AUG-1995; 95WO-CA000483.
XX
PR 15-AUG-1994; 94US-00290105.
XX
PA (CONN-) CONNAUGHT LAB LTD.
XX
XX
PI Rovinski B, Cao S, Yao F, Persson R, Klein MH;
XX
XX WPI; 1996-139690/14.
DR
XX
PT Antigenically marked non-infectious retrovirus-like particles - used to
PT vaccinate against, and in the treatment of, AIDS and AIDS related
PT conditions.
XX
PS Example 4; Page 38; 75pp; English.
XX
CC AAR93071-R93074 represent sequences used as antigenic marker epitopes in
CC a non-infectious retrovirus-like particle of the invention. This sequence
CC represents the antigenic peptide CLTB73. The retrovirus-like particle
CC contains 1-4 repeats of this sequence (or AAR93061). The coding sequence
CC for the retroviral particle of the invention comprises a modified
CC retroviral genome deficient in long terminal repeats, but containing the
CC gag, pol and env genes in their natural genomic arrangement, along with
CC the antigenic marker sequence. The retroviral particle can be used in an
CC immunogenic composition capable of eliciting a retroviral specific immune
CC response. The composition is for parenteral or mucosal administration,
CC preferably oral, anal, vaginal or intranasal administration. The
CC composition can be used for immunising a host to produce a retroviral
CC specific immune response, such as against AIDS and AIDS related
CC conditions. The particles may also be used in the prophylactic (or
CC curative) treatment of AIDS and related conditions, by acting to displace
CC the binding of the HIV virus to human or animal cells, or by disrupting
CC the 3-dimensional organisation of the virus. The particle can also be
CC used to identify antibodies specifically reacting with retrovirus
CC antigens
XX
SQ Sequence 21 AA;
Query Match 76.4%; Score 94; DB 2; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.5e-06;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2 NTRKSRIRIQRGGRAFTVIGK 22
DB 1 NTRKRIRIQRGGRAFTVIGK 21
RESULT 39
AAW75478
ID AAW75478 standard; peptide; 21 AA.
XX
AC AAW75478;
XX
DT 17-OCT-2003 (revised)
DT 20-MAR-2003 (revised)
DT 27-APR-1999 (first entry)

XX HIV-1 strain HXB2 gp120 V3 loop peptide amino acids 302-322.
XX V3 loop; gp120 protein; HIV-1; retrovirus-like particle; genome; HIV-2;
KW long terminal repeat; LTR; chimeric; envelope; glycoprotein; HTLV-I;
KW HTLV-II; vaccine; human T-lymphotropic virus.
XX
OS Human immunodeficiency virus 1.
XX
XX US5866137-A.
PN
XX
PD 02-FEB-1999.
XX
XX 30-MAY-1995; 95US-00453745.
XX
XX 15-JUN-1992; 92US-00839751.
PR
XX 09-JUN-1993; 93US-00073526.
XX
PA (CONN-) CONNAUGHT LAB LTD.
XX
XX Klein MH, Cao SX, Haynes J, Rovinski B;
XX WPI; 1999-141864/12.
DR
XX
XX Immunogenic retrovirus-like particle - with chimeric HIV-1 envelope
PT protein containing heterologous retroviral amino acid sequence.
PT
XX
PS Example 4; Col 7-8; 12pp; English.
XX
CC This sequence represents a peptide from the V3 loop of the gp120 protein
CC from the human immunodeficiency virus type 1 (HIV-1) strain HXB2. The
CC peptide is used to determine antibody responses after immunisation with a
CC self-assembled, non-infectious, non-replicating, immunogenic, retrovirus-
CC like particle. The retrovirus-like particle comprises a modified HIV
CC genome devoid of long terminal repeats (LTRs) and contains a nucleotide
CC sequence coding for a chimeric envelope glycoprotein. The chimeric
CC envelope glycoprotein has the HIV-1 gp120 conserved region 2 and a second
CC retroviral envelope amino acid sequence from a heterologous strain of HIV
CC -1, HIV-2, HTLV-I or HTLV-II inserted into the first retroviral envelope
CC amino acid sequence (see AAW75474-W75477). The novel retrovirus-like
CC particle is useful in vaccines against HIV. (Updated on 20-MAR-2003 to
CC correct PA field.) (Updated on 17-OCT-2003 to standardise OS field)
XX
SQ Sequence 21 AA;
Query Match 76.4%; Score 94; DB 2; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.5e-06;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2 NTRKSRIRIQRGGRAFTVIGK 22
DB 1 NTRKRIRIQRGGRAFTVIGK 21
RESULT 40
AAW16052
ID AAW16052 standard; peptide; 21 AA.
XX
AC AAW16052;
XX
XX 17-OCT-2003 (revised)
DT
XX 20-MAR-2003 (revised)
DT
XX 04-AUG-1999 (first entry)
XX
XX HIV-1 isolate HXB2 gp120 peptide.
XX
XX Retrovirus-like particle; modified HIV genome;
KW chimeric envelope glycoprotein; HIV-1 gp120; conserved region 2; HIV-1;
KW HIV-2; HTLV-I; HTLV-II; vaccine.
XX
XX Human immunodeficiency virus 1.
OS
XX
XX US5912338-A.

XX 15-JUN-1999.
 XX 30-MAY-1995; 95US-00452520.
 XX 15-JUN-1992; 92US-00839751.
 PR 09-JUN-1993; 93US-00073526.
 XX (ROVI/) ROVINSKI B.
 PA Cao SX, Klein MH, Haynes J, Rovinski B;
 PI WPI; 1999-357220/30.
 DR
 XX Immunogenic retrovirus like particles comprising modified HIV genomes,
 PT useful as vaccines against HIV.
 XX Example 4; Col 9-10; 12pp; English.
 PS The specification describes a nucleic acid molecule encoding a self
 XX assembled, non-infectious, non-replicating, immunogenic, retrovirus-like
 CC particle. The retroviral particle comprises a modified HIV genome devoid
 CC of long terminal repeats containing a nucleotide sequence coding for a
 CC chimeric envelope glycoprotein which has a first (a) and second (b)
 CC retroviral envelope amino acid sequence, where (a) contains the HIV-1
 CC gp120 conserved region 2, and (b) contains a retroviral envelope amino
 CC acid sequence of a heterologous strain of HIV-1, HIV-2, HTLV-I or HTLV-II
 CC inserted into (a) at an endogenous site (BgIII and StuI). (b) may
 CC comprise peptides AAV16049-51 and AAV16055. The nucleic acids are useful
 CC as vaccines against HIV. The present sequence is used in the course of
 CC the invention. (Updated on 20-MAR-2003 to correct PR field.) (Updated on
 CC 17-OCT-2003 to standardise OS field)
 XX
 XX SQ Sequence 21 AA;
 Query Match 76.4%; Score 94; DB 2; Length 21;
 Best Local Similarity 90.5%; Pred. No. 2.5e-06;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2 NTRKSERIQRGPGRAFTVIGK 22
 ||||| ||||| ||||| ||||| |||||
 Db 1 NTRKRIRIQRGPGRAFTVIGK 21
 ||||| ||||| ||||| ||||| |||||
 RESULT 41
 AA085568
 ID AA085568 standard; peptide; 21 AA.
 XX
 AC AA085568;
 XX
 XX 20-MAR-2003 (revised)
 DT 24-FEB-1999 (first entry)
 XX
 XX Human immunodeficiency virus type 1 derived peptide.
 DE
 XX Immunoassay diagnostic kit; antibody detection;
 KW chimeric envelope protein; HIV-1 gp120 conserved region 2; HIV-1; HIV-2;
 KW HTLV-I; HTLV-II.
 XX
 OS Synthetic.
 OS Human immunodeficiency virus 1.
 XX
 PN US5849475-A.
 XX
 PD 15-DEC-1998.
 XX
 PF 30-MAY-1995; 95US-00452503.
 XX
 PR 15-JUN-1992; 92US-00839751.
 PR 09-JUN-1993; 93US-00073526.
 XX
 XX (CONN-) CONNAUGHT LAB LTD.

PI Klein MH, Cao SX, Haynes J, Rovinski B;
 XX WPI; 1999-069713/06.
 XX Immunoassay diagnostic kit for detecting antibodies - comprising chimeric
 PT retrovirus-like particles.
 XX Example 4; Col 9-10; 12pp; English.
 PS The present sequence represents a Human immunodeficiency virus type 1
 XX derived peptide. The peptide is used in the immunoassay diagnostic kit of
 CC the invention. The specification describes an immunoassay diagnostic kit
 CC for detecting antibodies in a sample, which comprises an antigen
 CC consisting of a self-assembled, non-infectious, non-replicating,
 CC immunogenic, retrovirus-like particle encoded by a modified HIV genome
 CC that is devoid of long terminal repeats and contains a nucleotide
 CC sequence coding for a chimeric envelope protein having a first amino acid
 CC sequence containing HIV-1 gp120 conserved region 2 and a second amino
 CC acid sequence containing an envelope sequence of a heterologous strain of
 CC HIV-1, HIV-2, HTLV-I or HTLV-II. (Updated on 20-MAR-2003 to correct PR
 CC field.) (Updated on 20-MAR-2003 to correct PA field.)
 XX SQ Sequence 21 AA;
 Query Match 76.4%; Score 94; DB 2; Length 21;
 Best Local Similarity 90.5%; Pred. No. 2.5e-06;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2 NTRKSERIQRGPGRAFTVIGK 22
 ||||| ||||| ||||| ||||| |||||
 Db 1 NTRKRIRIQRGPGRAFTVIGK 21
 ||||| ||||| ||||| ||||| |||||
 RESULT 42
 AA086699
 ID AA086699 standard; peptide; 21 AA.
 XX
 AC AA086699;
 XX
 XX 18-DEC-2001 (first entry)
 DT
 XX Retrovirus-like particle CLTB73 containing a V3 (HXB2) antigenic marker.
 DE
 XX Human immunodeficiency virus; HIV; retroviral antigen; gag; pol; env;
 KW immune response; antigenic marker; antigenic epitope; retrovirus.
 XX
 OS Human immunodeficiency virus.
 OS Synthetic.
 XX
 PN US6291157-B1.
 XX
 PD 18-SEP-2001.
 XX
 XX 23-FEB-1998; 98US-00027955.
 PF
 XX 23-FEB-1998; 98US-00027955.
 PR
 XX (CONN-) CONNAUGHT LAB LTD.
 PA
 XX
 PI Rovinski B, Cao S, Yao F, Persson R, Klein MH;
 XX WPI; 2001-595518/67.
 DR
 XX Differentiating between infection by human immunodeficiency virus (HIV)
 PT and antiserum generated by immunization against HIV, comprises use of non
 PT -infectious, non-replicating HIV-like particle with heterologous,
 PT antigenic anchor sequence.
 XX
 PS Disclosure; Col 17; 28pp; English.
 XX
 XX The invention relates to a method for determining the presence of
 CC antibodies specifically reactive with HIV retroviral antigens in a
 CC sample. This involves contacting a sample suspected of containing HIV-

CC specific antibodies with a non-infectious, non-replicating, immunogenic
 CC HIV-like particle as an antigen. The antigen comprises an assembly of a
 CC gag gene product, a pol gene product and a modified env gene product
 CC containing a non-retroviral heterologous, antigenic, anchor sequence that
 CC replaces the endogenous anchoring functions of the env gene product. The
 CC method detects immune complex formation between HIV-specific antibodies
 CC and the antigens. The method is also useful for identifying antiserum
 CC generated by immunisation with an immunogenic composition capable of
 CC eliciting HIV-specific immune response. The antigenic marker may comprise
 CC at least one antigenic epitope from another virus. This sequence
 CC represents a retrovirus-like particle containing an antigenic marker
 XX
 XX Sequence 21 AA;
 SQ

Query Match 76.4%; Score 94; DB 4; Length 21;
 Best Local Similarity 90.5%; Pred. No. 2.5e-06;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2 NTRKSERIQRGGRAPVTIGK 22
 ||||| ||||| ||||| ||||| |||||
 Db 1 NTRKRIRIQRGGRAPVTIGK 21

RESULT 43
 AAR57470
 ID AAR57470 standard; protein; 22 AA.
 XX
 AC AAR57470;
 XX
 DT 25-MAR-2003 (revised)
 DT 21-MAR-1995 (first entry)
 XX
 XX
 DE HIV BRU V3 loop peptide.
 XX
 KW Immunisation; vaccine; therapy; prophylaxis; defective gene;
 KW non-functional gene; template; antisense; ribozyme; bupivacaine;
 KW human immunodeficiency virus; acquired immune deficiency syndrome; HIV;
 KW AIDS; ss.
 XX
 OS Synthetic.
 XX
 PN WO9416737-A1.
 XX
 PD 04-AUG-1994.
 XX
 PF 26-JAN-1994; 94WO-US000899.
 XX
 PR 26-JAN-1993; 93US-0008342.
 PR 11-MAR-1993; 93US-00029336.
 PR 15-JUL-1993; 93US-00093235.
 PR 21-SEP-1993; 93US-00124962.
 PR 21-SEP-1993; 93US-00125012.
 XX
 PA (WEIN/) WEINER D B.
 PA (WILL/) WILLIAMS W V.
 PA (WANG/) WANG B.
 PA (CONE/) CONEY L R.
 PA (MERV/) MERVIA M J.
 PA (ZURA/) ZURAWSKI V R.
 XX
 PI Weiner DB, Williams WV, Wang B, Coney LR, Mervia MJ, Zurawski VR;
 DR WPI; 1994-263787/32.
 XX
 XX Method for introducing genetic material into cells - utilises
 PT polynucleotide function enhancer and nucleic acid free of retroviral
 PT particles, e.g. HIV immunisation.
 XX
 XX Example 3; Page 44; 136pp; English.
 PS
 CC A genetic vaccine against HIV contains a DNA construct which comprises
 CC the sequence encoding gp160. The genetic material was then introduced
 CC into the cells of an individual by (a) contacting the individual's cells

CC with a polynucleotide function enhancer (bupivacaine) and (b)
 CC administering to the cells the nucleic acid molecule free of retroviral
 CC particles. Nucleic acid molecules which are delivered to cells may serve
 CC as genetic templates for proteins that function as prophylactic and/or
 CC therapeutic immunising agents; replacement copies of defective, missing
 CC or non-functional genes; genetic templates for therapeutic proteins;
 CC genetic templates for antisense molecules or as genetic templates for
 CC ribozymes. This peptide was derived from the V3 loop of an HIV strain (an
 CC epitope targeted by HIV neutralising antibodies) and was used to
 CC determine whether the anti-gp160 antibodies elicited in mice immunised
 CC with the genetic vaccine were reactive with this region. (Updated on 25-
 CC MAR-2003 to correct PN field.)
 XX
 XX Sequence 22 AA;
 SQ

Query Match 76.4%; Score 94; DB 2; Length 22;
 Best Local Similarity 90.5%; Pred. No. 2.6e-06;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2 NTRKSERIQRGGRAPVTIGK 22
 ||||| ||||| ||||| ||||| |||||
 Db 2 NTRKRIRIQRGGRAPVTIGK 22

RESULT 44
 AAE20149
 ID AAE20149 standard; peptide; 24 AA.
 XX
 AC AAE20149;
 XX
 DT 29-AUG-2003 (revised)
 DT 18-JUN-2002 (first entry)
 XX
 XX Human immunodeficiency virus type 1 (HIV-1) V3IIB peptide.
 DE
 KW Human immunodeficiency virus type 1; HIV-1; adjuvant; immunomodulator;
 KW alpha-2-macroglobulin; 3-O-deacylated monophosphoryl lipidA; MPL; GM-CSF;
 KW granulocyte macrophage colony stimulating factor; immune response;
 KW vaccine; V3IIB peptide.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN WO200215930-A1.
 XX
 PD 28-FEB-2002.
 XX
 PF 27-AUG-2001; 2001WO-US026589.
 XX
 PR 25-AUG-2000; 2000US-0227624P.
 XX
 PA (UYDU-) UNIV DUKE.
 XX
 PI Haynes BF, Liao H, Patel DD;
 XX
 DR WPI; 2002-269315/31.
 XX
 XX Use of 2-macroglobulin (2Masterisk), 3-O-deacylated monophosphoryl lipid
 PT A (MPL) and granulocyte macrophage colony stimulating factor (GM-CSF) for
 PT eliciting an immune response.
 PT
 XX Example 2; Page 21; 53pp; English.
 PS
 XX The invention relates to a composition comprising activated alpha-2-
 CC macroglobulin (alpha 2M asterisk), 3-O-deacylated monophosphoryl lipid A
 CC (MPL) and granulocyte macrophage colony stimulating factor (GM-CSF). The
 CC invention also relates to an adjuvant suitable for use in multivalent HIV
 CC immunogenic compositions. The compositions is useful for eliciting an
 CC immune response. The present sequence is human immunodeficiency virus
 CC type 1 (HIV-1) V3IIB peptide used in the exemplification of the
 CC invention. (Updated on 29-AUG-2003 to standardise OS field)
 XX
 XX Sequence 24 AA;
 SQ

Query Match 76.4%; Score 94; DB 5; Length 24;
Best Local Similarity 95.0%; Pred. No. 2.9e-06;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 NNTRKSERIQRGPGRAFTVI 20
Db 5 NNTRKSIRIQRGPGRAFTVI 24

RESULT 45

AAR63820
ID AAR63820 standard; peptide; 25 AA.
XX
AC AAR63820;
XX
DT 16-OCT-2003 (revised)
DT 25-MAR-2003 (revised)
DT 29-JUN-1995 (first entry)
XX
DE HIV-1 gp120-23 epitope amino acids 296-230.
XX
KW Human immunodeficiency virus type 1; HIV-1; gp120 epitopes; vaccines;
KW HIV neutralising antibodies.
XX
OS Human immunodeficiency virus 1.
XX
PN WO9423746-A1.
XX
PD 27-OCT-1994.
XX
PF 15-APR-1994; 94WO-SE000340.
XX
PR 16-APR-1993; 93US-00048976.
XX
PA (SYNT-) SYNTELLO VACCINE DEV AB.
XX
PI Vahlne A, Svennerholm B, Rymo L, Jeansson S, Horal P;
XX
DR WPI; 1994-341488/42.
XX
PT New peptide(s) comprising HIV gp120 epitope(s) - for prodn. of vaccines
PT against HIV infections.
XX
PS Claim 1; Page 18; 77pp; English.

CC AAR63809-R63849 are epitopes from the human immunodeficiency virus type 1
CC (HIV-1) gp120, by binding one or more of these epitopes to a carrier a
CC HIV vaccine is produced. These vaccines can elicit the production of HIV-
CC neutralising antibodies in monkeys, and therefore may be used to prevent
CC HIV infections, and to heighten the immune response in HIV infected
CC humans. (Updated on 25-MAR-2003 to correct PN field.) (Updated on 16-OCT-
CC 2003 to standardise OS field)
XX
SQ Sequence 25 AA;

Query Match 76.4%; Score 94; DB 2; Length 25;
Best Local Similarity 95.0%; Pred. No. 3e-06;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 NNTRKSERIQRGPGRAFTVI 20
Db 6 NNTRKSIRIQRGPGRAFTVI 25

Search completed: May 16, 2005, 13:05:13
Job time : 171.846 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 16, 2005, 12:39:11 ; Search time 137.231 Seconds
(without alignments)
89.556 Million cell updates/sec

Title: US-08-869-386-3
Perfect score: 123
Sequence: 1 NNTKSRIRGPGRAFVTIGKI 24

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 16988

Minimum DB seq length: 0
Maximum DB seq length: 25

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : UniProt_03.*
1: uniprot_sprot.*
2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	62	50.4	23	2 Q9E8S7	Q9E8S7 human immun
2	56	45.5	25	2 Q8AQX9	Q8AQX9 human immun
3	56	45.5	25	2 Q8AQY0	Q8AQY0 human immun
4	52	42.3	25	2 O10481	O10481 human immun
5	48	39.0	25	2 Q9QEX7	Q9QEX7 human immun
6	46	37.4	25	2 Q8AQY1	Q8AQY1 human immun
7	46	37.4	25	2 Q8AQY2	Q8AQY2 human immun
8	45	36.6	25	2 Q7ZJT3	Q7ZJT3 human immun
9	39	31.7	18	2 Q9PXF1	Q9PXF1 human immun
10	39	31.7	23	2 Q9ENM9	Q9ENM9 human immun
11	34	27.6	17	2 Q78324	Q78324 human immun
12	33	26.8	17	2 Q78326	Q78326 human immun
13	32	26.0	17	2 Q78345	Q78345 human immun
14	32	26.0	17	2 Q78378	Q78378 human immun
15	31	25.2	17	2 Q78381	Q78381 human immun
16	31	25.2	24	2 Q6TOT6	Q6TOT6 saccharomyc
17	30.5	24.8	17	2 Q78328	Q78328 human immun
18	29	23.6	17	2 Q78323	Q78323 human immun
19	29	23.6	17	2 Q78327	Q78327 human immun
20	29	23.6	17	2 Q78380	Q78380 human immun
21	29	23.6	22	2 Q6U2M7	Q6U2M7 sechium edu
22	28	22.8	18	2 Q9ZG65	Q9ZG65 chlamydia t
23	27	22.0	16	2 Q9UCK9	Q9UCK9 homo sapien
24	27	22.0	16	2 Q9UCL0	Q9UCL0 homo sapien
25	27	22.0	17	2 Q16228	Q16228 homo sapien
26	27	22.0	19	2 Q6EML0	Q6EML0 meileagris g
27	27	22.0	19	2 Q6EML1	Q6EML1 gallus galli
28	27	22.0	22	2 Q924C7	Q924C7 mus musculu
29	27	22.0	23	2 Q94781	Q94781 trypanosoma
30	27	22.0	25	2 Q11890	Q11890 gb virus c/
31	27	22.0	25	2 O11891	O11891 gb virus c/

32	27	22.0	25	2 O11893	O11893 gb virus c/
33	26.5	21.5	14	2 Q7M1W9	Q7M1W9 arabidopsis
34	26	21.1	14	2 Q7PE81	Q7PE81 anopheles g
35	26	21.1	15	1 NF41 NAEFO	NF41 NAEFO naegleria f
36	26	21.1	17	2 Q9UCT3	Q9UCT3 homo sapien
37	26	21.1	17	2 Q9RSN0	Q9RSN0 bacillus su
38	26	21.1	20	2 Q6JCN3	Q6JCN3 escherichia
39	26	21.1	20	2 Q9R4H4	Q9R4H4 desulfovibr
40	26	21.1	21	2 Q9SKS4	Q9SKS4 ovis aries
41	26	21.1	21	2 Q6RCK2	Q6RCK2 pseudomonas
42	26	21.1	22	2 Q7Z992	Q7Z992 schizosacch
43	26	21.1	22	2 Q9SY23	Q9SY23 arabidopsis
44	26	21.1	23	2 Q6U2M9	Q6U2M9 momordica c
45	26	21.1	24	2 Q6U2N2	Q6U2N2 citrullus l

ALIGNMENTS

RESULT 1
Q9E8S7 ID Q9E8S7 PRELIMINARY; PRT; 23 AA.
AC Q9E8S7; 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Envelope glycoprotein (Fragment).
GN Name=env;
OS Human immunodeficiency virus 1.
OC Viruses; Retroid viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP MEDLINE=20411423; PubMed=10954550;
RX DOI=10.1128/JVI.74.18.8494-8501.2000;
RA Nelson J.A.E., Barbaud F., Edwards T., Swannstrom R.;
RT "Patterns of changes in human immunodeficiency virus type 1 V3
sequence populations late in infection."
RL J. Virol. 74:8494-8501(2000).
DR EMBL; AF155888; AAG09930.1; -.
DR GO; GO:0019031; C:viral envelope; IEA.
DR InterPro; IPR011056; Pept_S24_S26_C.
KW Envelope protein.
FT NON TER 1
FT NON TER 23
SQ SEQUENCE 23 AA; 2596 MW; 6C038F27BC0CA1E0 CRC64;

Query Match 50.4%; Score 62; DB 2; Length 23;
Best Local Similarity 60.9%; Pred. No. 0.0061;
Matches 14; Conservative 2; Mismatches 5; Indels 2; Gaps 1;

OY 1 NNTKSRIRGPGRAFVTIGKI 23
||||:||||:||||:||||:||||:||||:
DB 2 NNTKSRIRGPGRAFVTIGKI 22

RESULT 2
Q8AQX9 ID Q8AQX9 PRELIMINARY; PRT; 25 AA.
AC Q8AQX9; 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Envelope glycoprotein (Fragment).
GN Name=env;
OS Human immunodeficiency virus 1.
OC Viruses; Retroid viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP MEDLINE=22860939; PubMed=14502005;
RX Freil S.A., Fiscus S.A., Filcher C.D., Menezes P., Giner J.,
RA Patrick E., Lennox J.L., Hicks C.B., Eron J.J. Jr., Shugars D.C.;

```

RT "Envelope diversity, coreceptor usage and syncytium-inducing phenotype
RT of HIV-1 variants in saliva and blood during primary infection.";
RL AIDS 17:2025-2033(2003).
DR EMBL; AF536914; AAN63929.1; -.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0019028; C:viral capsid; IEA.
DR GO; GO:0019031; C:viral envelope; IEA.
DR GO; GO:0005198; F:structural molecule activity; IEA.
DR InterPro; IPR000777; GP120.
KW Envelope protein.
FT NON_TER 1
FT NON_TER 25
SQ SEQUENCE 25 AA; 2749 MW; 9B6E9DACB8D56C0C CRC64;

Query Match 45.5%; Score 56; DB 2; Length 25;
Best Local Similarity 58.3%; Pred. No. 0.069;
Matches 14; Conservative 1; Mismatches 7; Indels 2; Gaps 1;

QY 1 NNTKRSRIQPGGRAFTVIGKIG 24
DB 2 NNTRRS--INIGGRAFYATDIIG 23

RESULT 3
QY Q8AQY0 PRELIMINARY; PRT; 25 AA.
AC Q8AQY0;
DT 01-MAR-2003 (TReMBLrel. 23, Created)
DT 01-MAR-2003 (TReMBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TReMBLrel. 25, Last annotation update)
DE Envelope glycoprotein (Fragment).
GN Name=env;
OS Human immunodeficiency virus 1.
OC Viruses; Retrovirdae; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP MEDLINE=22860939; PubMed=14502005;
RA Frel S.A., Fiscus S.A., Pilcher C.D., Meneses P., Giner J.,
RA Patrick E., Lemox J.L., Hicks C.B., Eron J.J. Jr., Shugars D.C.;
RT "Envelope diversity, coreceptor usage and syncytium-inducing phenotype
RT of HIV-1 variants in saliva and blood during primary infection.";
RL AIDS 17:2025-2033(2003).
DR EMBL; AF536913; AAN63928.1; -.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0019028; C:viral capsid; IEA.
DR GO; GO:0019031; C:viral envelope; IEA.
DR GO; GO:0005198; F:structural molecule activity; IEA.
DR InterPro; IPR000777; GP120.
KW Envelope protein.
FT NON_TER 1
FT NON_TER 25
SQ SEQUENCE 25 AA; 2749 MW; 9B6E9DACB8D56C0C CRC64;

Query Match 45.5%; Score 56; DB 2; Length 25;
Best Local Similarity 58.3%; Pred. No. 0.069;
Matches 14; Conservative 1; Mismatches 7; Indels 2; Gaps 1;

QY 1 NNTKRSRIQPGGRAFTVIGKIG 24
DB 2 NNTRRS--INIGGRAFYATDIIG 23

RESULT 4
QY Q10481 PRELIMINARY; PRT; 25 AA.
AC Q10481;
DT 01-JUL-1997 (TReMBLrel. 04, Created)
DT 01-JUL-1997 (TReMBLrel. 04, Last sequence update)
DT 01-JUN-2003 (TReMBLrel. 24, Last annotation update)
DE Envelope glycoprotein (Fragment).
GN Name=env;
OS Human immunodeficiency virus 1.

```

```

OC Viruses; Retrovirdae; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=97255649; PubMed=9100996;
RA Rencher S.D., Lockey T.D., Slobod K.S., Hurwitz J.L.;
RT "Drift from the GPGRF HIV-1 envelope V3 crown sequence in a North
RT American inner city.";
RL AIDS Res. Hum. Retroviruses 13:527-528(1997).
DR EMBL; U81241; AAB53843.1; -.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0019028; C:viral capsid; IEA.
DR GO; GO:0019031; C:viral envelope; IEA.
DR GO; GO:0005198; F:structural molecule activity; IEA.
DR InterPro; IPR000777; GP120.
DR InterPro; IPR011056; Pept_S24_S26_C.
DR Pfam; PF00516; GP120; 1.
KW AIDS; Coat protein; Envelope protein; Glycoprotein; Transmembrane.
FT NON_TER 1
FT NON_TER 25
SQ SEQUENCE 25 AA; 2801 MW; 25E1B150CD7C14B6 CRC64;

Query Match 42.3%; Score 52; DB 2; Length 25;
Best Local Similarity 61.9%; Pred. No. 0.33;
Matches 13; Conservative 0; Mismatches 6; Indels 2; Gaps 1;

QY 1 NNTKRSRIQPGGRAFTVIG 21
DB 6 NNTKRG--IHGPGRAFTYTG 24

RESULT 5
QY Q9QEX7 PRELIMINARY; PRT; 25 AA.
AC Q9QEX7;
DT 01-MAY-2000 (TReMBLrel. 13, Created)
DT 01-MAY-2000 (TReMBLrel. 13, Last sequence update)
DT 01-JUN-2003 (TReMBLrel. 24, Last annotation update)
DE Envelope glycoprotein (Fragment).
GN Name=env;
OS Human immunodeficiency virus 1.
OC Viruses; Retrovirdae; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=21103026; PubMed=11170057;
RX DOI=10.1002/1096-9071(200103)63:3<197::AID-JMV1000>3.3.CO;2-G;
RA Lin H.J., Siwak B.B., Laufer I.J., Hollinger F.B.;
RT "Long-term culture of human immunodeficiency virus type 1 resulting in
RT loss of glycosylation sites.";
RL J. Med. Virol. 63:197-202(2001).
DR EMBL; AF178663; AAF04369.1; -.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0019028; C:viral capsid; IEA.
DR GO; GO:0019031; C:viral envelope; IEA.
DR GO; GO:0005198; F:structural molecule activity; IEA.
DR InterPro; IPR000777; GP120.
DR InterPro; IPR011056; Pept_S24_S26_C.
DR Pfam; PF00516; GP120; 1.
KW AIDS; Coat protein; Envelope protein; Glycoprotein; Transmembrane.
FT NON_TER 1
FT NON_TER 25
SQ SEQUENCE 25 AA; 2818 MW; 9C6EBA908EB5ED47 CRC64;

Query Match 39.0%; Score 48; DB 2; Length 25;
Best Local Similarity 57.1%; Pred. No. 1.5;
Matches 12; Conservative 2; Mismatches 5; Indels 2; Gaps 1;

QY 1 NNTKRSRIQPGGRAFTVIG 21
DB 7 NNTRRS--IPLGQGRAFTTG 25

```



```

RESULT 6
Q8AQY1 ID Q8AQY1 PRELIMINARY; PRT; 25 AA.
AC Q8AQY1;
DT 01-MAR-2003 (TRENBLrel. 23, Created)
DT 01-MAR-2003 (TRENBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TRENBLrel. 25, Last annotation update)
DE Envelope glycoprotein (Fragment).
GN Name=env;
OS Human immunodeficiency virus 1.
OC Viruses; Retroid viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22860939; PubMed=14502005;
RA Freil S.A., Fiscus S.A., Pilcher C.D., Menezes P., Giner J.,
RA Patrick E., Lennox J.L., Hicks C.B., Eron J.J. Jr., Shugars D.C.;
RT "Envelope diversity, coreceptor usage and syncytium-inducing phenotype
RT of HIV-1 variants in saliva and blood during primary infection.";
RL AIDS 17:2025-2033(2003).
DR EMBL; AF536912; AANG3927.1; -.
DR GO; GO:0019031; C:viral envelope; IEA.
DR InterPro; IPR000777; GP120.
KW Envelope protein.
FT NON TER 1
FT NON TER 25
SQ SEQUENCE 25 AA; 2601 MW; 71B5A774CE256C09 CRC64;

Query Match 37.4%; Score 46; DB 2; Length 25;
Best Local Similarity 54.2%; Pred. No. 3.4;
Matches 13; Conservative 0; Mismatches 9; Indels 2; Gaps 1;

QY 1 NNTKSERIQRGPGRAFTVIGKIG 24
DB 2 NNTKSG--IHIGPGGAFYGTDIIG 23

RESULT 7
Q8AQY2 ID Q8AQY2 PRELIMINARY; PRT; 25 AA.
AC Q8AQY2;
DT 01-MAR-2003 (TRENBLrel. 23, Created)
DT 01-MAR-2003 (TRENBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TRENBLrel. 25, Last annotation update)
DE Envelope glycoprotein (Fragment).
GN Name=env;
OS Human immunodeficiency virus 1.
OC Viruses; Retroid viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22860939; PubMed=14502005;
RA Freil S.A., Fiscus S.A., Pilcher C.D., Menezes P., Giner J.,
RA Patrick E., Lennox J.L., Hicks C.B., Eron J.J. Jr., Shugars D.C.;
RT "Envelope diversity, coreceptor usage and syncytium-inducing phenotype
RT of HIV-1 variants in saliva and blood during primary infection.";
RL AIDS 17:2025-2033(2003).
DR EMBL; AF536911; AANG3926.1; -.
DR GO; GO:0019031; C:viral envelope; IEA.
DR InterPro; IPR000777; GP120.
KW Envelope protein.
FT NON TER 1
FT NON TER 25
SQ SEQUENCE 25 AA; 2601 MW; 71B5A774CE256C09 CRC64;

Query Match 37.4%; Score 46; DB 2; Length 25;
Best Local Similarity 54.2%; Pred. No. 3.4;
Matches 13; Conservative 0; Mismatches 9; Indels 2; Gaps 1;

QY 1 NNTKSERIQRGPGRAFTVIGKIG 24
DB 2 NNTKSG--IHIGPGGAFYGTDIIG 23

RESULT 8
Q7ZJT3 ID Q7ZJT3 PRELIMINARY; PRT; 25 AA.
AC Q7ZJT3;
DT 01-JUN-2003 (TRENBLrel. 24, Created)
DT 01-JUN-2003 (TRENBLrel. 24, Last sequence update)
DT 01-MAR-2004 (TRENBLrel. 26, Last annotation update)
DE Envelope glycoprotein (Fragment).
GN Name=env;
OS Human immunodeficiency virus 1.
OC Viruses; Retroid viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22439926; PubMed=12552446;
RA Iversen A.K.N., Christiansen C.B., Attermann J., Eugen-Olsen J.,
RA Schulman S., Berntorp E., Ingerslev J., Fugger L., Scheibel E.,
RA Tengborn L., Gerstoft J., Dickmeis E., Sveigaard A., Skinhoj P.;
RT "Limited protective effect of the CCR5delta32/CCR5Delta32 genotype on
RT human immunodeficiency virus infection incidence in a cohort of
RT patients with hemophilia and selection for genotypic X4 virus.";
RL J. Infect. Dis. 187:215-225(2003).
DR EMBL; AY150666; AA061698.1; -.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0019028; C:viral capsid; IEA.
DR GO; GO:0019031; C:viral envelope; IEA.
DR GO; GO:0005198; F:structural molecule activity; IEA.
DR InterPro; IPR000777; GP120.
DR Pfam; PF00516; GP120; 1.
KW AIDS; Coat protein; Envelope protein; Glycoprotein; Transmembrane.
FT NON TER 1
FT NON TER 25
SQ SEQUENCE 25 AA; 2790 MW; CB4779D487B698D2 CRC64;

Query Match 36.6%; Score 45; DB 2; Length 25;
Best Local Similarity 50.0%; Pred. No. 5;
Matches 8; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 8 RIQRGPGRAFTVIGKI 23
DB 1 RLSMGPGRVVYTTGPI 16

RESULT 9
Q9PXF1 ID Q9PXF1 PRELIMINARY; PRT; 18 AA.
AC Q9PXF1;
DT 01-MAY-2000 (TRENBLrel. 13, Created)
DT 01-MAY-2000 (TRENBLrel. 13, Last sequence update)
DT 01-MAR-2004 (TRENBLrel. 26, Last annotation update)
DE GP120 protein (Fragment).
OS Human immunodeficiency virus 1.
OC Viruses; Retroid viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=95386957; PubMed=7658059;
RA Lawoko A., Johansson B., Dash R., Falck L., Dietrich U., Pipkorn R.,
RA Nilehn B., Blomberg J.;
RT "Continuity and discontinuity in the anti-V3 IgG response of human
RT immunodeficiency virus type 1-infected persons in a cross-sectional
RT and longitudinal study using synthetic peptides.";
RL J. Infect. Dis. 172:682-690(1995).
SQ SEQUENCE 18 AA; 2047 MW; F5884C2C32F15E55 CRC64;

Query Match 31.7%; Score 39; DB 2; Length 18;
Best Local Similarity 64.3%; Pred. No. 36;
Matches 9; Conservative 1; Mismatches 2; Indels 2; Gaps 1;

QY 1 NNTKSERIQRGPG 14
DB 7 NNTKSG--RWTWGP 18

```

RESULT 10

Q9ENM9 PRELIMINARY; PRT; 23 AA.
AC Q9ENM9
DT 01-MAR-2001 (TREMBLrel. 16, Created)
DT 01-MAR-2001 (TREMBLrel. 16, Last sequence update)
DT 01-MAR-2004 (TREMBLrel. 26, Last annotation update)
DE Envelope glycoprotein (Fragment).
GN Name=env;
OS Human immunodeficiency virus 1.
OC Viruses; Retroid viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=20411423; PubMed=10954550;
RX DOI=10.1128/JVI.74.18.8494-8501.2000;
RA Nelson J.A.E., Baribaud F., Edwards T., Swanstrom R.;
RT "Patterns of changes in human immunodeficiency virus type 1 V3
RT sequence populations late in infection.";
RL J. Virol. 74:8494-8501(2000).
DR EMBL; AF092639; AAD04382.1; -.
DR GO; GO:0019031; C:Viral envelope; IEA.
KW Envelope protein.
FT NON TER 1
FT NON TER 23
SQ SEQUENCE 23 AA; 2460 MW; 6108EAC9C0CA947 CRC64;

Query Match 31.7%; Score 39; DB 2; Length 23;
Best Local Similarity 47.8%; Pred. No. 47;
Matches 11; Conservative 2; Mismatches 8; Indels 2; Gaps 1;

OY 1 NNTKSERIORGPFAVTIGKI 23

Db 2 NNT--TIIIXIGPRAFTATGDI 22

RESULT 11

Q78324 PRELIMINARY; PRT; 17 AA.
AC Q78324
DT 01-NOV-1996 (TREMBLrel. 01, Created)
DT 01-NOV-1996 (TREMBLrel. 01, Last sequence update)
DT 01-OCT-2002 (TREMBLrel. 22, Last annotation update)
DE Immunodeficiency virus type 1, viral sample FLPARSB (Florida patient
DE A), partial env cds, V5 region. (Fragment).
OS Human immunodeficiency virus 1.
OC Viruses; Retroid viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=92271245; PubMed=1589796;
RA Ou C.-Y., Ciesielski C.A., Myers G., Bandea C.I., Luo C.C.,
RA Korber B.T.M., Mullins J.I., Schochetman G., Berkman R.L.,
RA Economou A.N., Witte J.J., Furman L.J., Satten G.A., Curran J.W.,
RA Jaffe H.W.;
RT "Molecular epidemiology of HIV transmission in a dental practice.";
RL Science 256:1165-1171(1992).
RN [2]
RP SEQUENCE FROM N.A.
RX Zhang L.Q., Leigh-Brown A.J.;
RL Submitted (APR-1992) to the EMBL/GenBank/DBJ databases.
DR EMBL; M92110; AAA44466.1; -.
FT NON TER 1
FT NON TER 17
SQ SEQUENCE 17 AA; 1651 MW; 3473A0BB802CA370 CRC64;

Query Match 27.6%; Score 34; DB 2; Length 17;
Best Local Similarity 50.0%; Pred. No. 2, 4e+02;
Matches 7; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

OY 1 NNTKSERIORGPG 14

Db 3 NNTKSETFRGGG 16

RESULT 12

Q78326 PRELIMINARY; PRT; 17 AA.
AC Q78326
DT 01-NOV-1996 (TREMBLrel. 01, Created)
DT 01-NOV-1996 (TREMBLrel. 01, Last sequence update)
DT 01-OCT-2002 (TREMBLrel. 22, Last annotation update)
DE Immunodeficiency virus type 1, viral sample FLPARSC (Florida patient
DE A), partial env cds, V5 region. (Fragment).
OS Human immunodeficiency virus 1.
OC Viruses; Retroid viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=92271245; PubMed=1589796;
RA Ou C.-Y., Ciesielski C.A., Myers G., Bandea C.I., Luo C.C.,
RA Korber B.T.M., Mullins J.I., Schochetman G., Berkman R.L.,
RA Economou A.N., Witte J.J., Furman L.J., Satten G.A., Curran J.W.,
RA Jaffe H.W.;
RT "Molecular epidemiology of HIV transmission in a dental practice.";
RL Science 256:1165-1171(1992).
RN [2]
RP SEQUENCE FROM N.A.
RX Zhang L.Q., Leigh-Brown A.J.;
RL Submitted (APR-1992) to the EMBL/GenBank/DBJ databases.
DR EMBL; M92111; AAA44467.1; -.
FT NON TER 1
FT NON TER 17
SQ SEQUENCE 17 AA; 1625 MW; 3E83A0BFD3FCA370 CRC64;

Query Match 26.8%; Score 33; DB 2; Length 17;
Best Local Similarity 50.0%; Pred. No. 3, 5e+02;
Matches 7; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

OY 1 NNTKSERIORGPG 14

Db 3 NNTNGSETFRGGG 16

RESULT 13

Q78345 PRELIMINARY; PRT; 17 AA.
AC Q78345
DT 01-NOV-1996 (TREMBLrel. 01, Created)
DT 01-NOV-1996 (TREMBLrel. 01, Last sequence update)
DT 01-OCT-2002 (TREMBLrel. 22, Last annotation update)
DE Immunodeficiency virus type 1, viral sample FLPARSF (Florida patient
DE A), partial env cds, V5 region. (Fragment).
OS Human immunodeficiency virus 1.
OC Viruses; Retroid viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=92271245; PubMed=1589796;
RA Ou C.-Y., Ciesielski C.A., Myers G., Bandea C.I., Luo C.C.,
RA Korber B.T.M., Mullins J.I., Schochetman G., Berkman R.L.,
RA Economou A.N., Witte J.J., Furman L.J., Satten G.A., Curran J.W.,
RA Jaffe H.W.;
RT "Molecular epidemiology of HIV transmission in a dental practice.";
RL Science 256:1165-1171(1992).
RN [2]
RP SEQUENCE FROM N.A.
RX Zhang L.Q., Leigh-Brown A.J.;
RL Submitted (APR-1992) to the EMBL/GenBank/DBJ databases.
DR EMBL; M92114; AAA44470.1; -.
FT NON TER 1
FT NON TER 17
SQ SEQUENCE 17 AA; 1635 MW; 3E83A0BFD12CA370 CRC64;

DR	EMBL; M92126; AAA44496.1; --.
FT	NON TER 1
FT	NON TER 17
SEQ	SEQUENCE 17 AA; 1708 MW; 347570D2D12CA370 CRC64;
 Query Match 25.2%; Score 31; DB 2; Length 17; Best Local Similarity 42.9%; Pred. No. 7.6e+02; Matches 6; Conservative 2; Mismatches 6; Indels 0; Gaps 0;	
Oy	1 NNTRKSERIORGPG 14 : 3 NNTNNTTFRPGG 16
Dd	
 RESULT 16	
Q6TQT6	PRELIMINARY; PRT; 24 AA.
ID Q6TQT6	
AC Q6TQT6;	
DT 05-JUL-2004	(TrEMBLrel. 27, Created)
DT 05-JUL-2004	(TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004	(TrEMBLrel. 27, Last annotation update)
DE YHR065Cp	(Fragment).
GN Name=YHR065C;	
OS Saccharomyces cerevisiae	(Baker's yeast).
OC Eukaryota; Fungi; Ascomycota;	Saccharomycotina; Saccharomycetes;
OC Saccharomycetales;	Saccharomycetaceae; Saccharomycetes.
OX NCBI_TaxID=4932;	
RN [1]	
RP SEQUENCE FROM N.A.	
RC SPRAIN-AB972;	
RA Kennedy M.C.; Dietrich F.S.;	
RL Submitted (SEP-2003) to the	EMBL/GenBank/DBJ databases.
DR EMBL; AY389302; AAQ97234.1; --.	
FT NON TER 1	
FT NON TER 1	
SEQ	SEQUENCE 24 AA; 2866 MW; 83820AB41EF59E7C CRC64;
 Query Match 25.2%; Score 31; DB 2; Length 24; Best Local Similarity 66.7%; Pred. No. 1.1e+03; Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;	
Oy	7 ERIORGPR 15
Dd	1 EKTAGRGR 9
 RESULT 17	
Q78328	PRELIMINARY; PRT; 17 AA.
ID Q78328	
AC Q78328;	
DT 01-NOV-1996	(TrEMBLrel. 01, Created)
DT 01-NOV-1996	(TrEMBLrel. 01, Last sequence update)
DT 01-OCT-2002	(TrEMBLrel. 22, Last annotation update)
DE Immunodeficiency virus type 1,	viral sample FLPARSE (Florida patient
DE A), partial env cds, V5 region.	(Fragment).
OS Human immunodeficiency virus 1.	
OC Viruses; Retroid viruses; Retroviridae;	Lentivirus.
OX NCBI_TaxID=11676;	
RN [1]	
RP SEQUENCE FROM N.A.	
RX MEDLINE=92271245; PubMed=1589796;	
RA Ou C.-Y., Chetalski C.A., Myers G.,	Bandeau C.I., Luo C.C.,
RA Korber B.T.M., Mullins J.I., Schochetman G.,	Berkelman R.L.,
RA Eschenbacher A.N., Witte J.J., Furman L.J.,	Satten G.A., Curran J.W.,
RA Jaffe H.W.;	
RT "Molecular epidemiology of HIV transmission	in a dental practice.";
RL Science 256:1165-1171(1992).	
RN [2]	
RP SEQUENCE FROM N.A.	
RA Zhang L.O., Leigh-Brown A.J.;	
RL Submitted (APR-1992) to the	EMBL/GenBank/DBJ databases.
DR EMBL; M92113; AAA44469.1; --.	
FT NON TER 1	
FT NON TER 17	

```
SQ SEQUENCE 17 AA; 1750 MW; 346FDOB802CA370 CRC64;
Query Match 24.8%; Score 30.5; DB 2; Length 17;
Best Local Similarity 53.3%; Pred. No. 9.3e+02;
Matches 8; Conservative 2; Mismatches 4; Indels 1; Gaps 1;

QY 1 NNTKRSERIQRGPG 15
|||:|:|:|
Db 3 NNTKGSETPRPG-GR 16

RESULT 18
Q78327 ID Q78323 PRELIMINARY; PRT; 17 AA.
AC Q78323;
DT 01-NOV-1996 (TReMBLrel. 01, Created)
DT 01-NOV-1996 (TReMBLrel. 01, Last sequence update)
DT 01-OCT-2002 (TReMBLrel. 22, Last annotation update)
DE Immunodeficiency virus type 1, viral sample FLPARSA (Florida patient
DE A), partial env cds, V5 region. (Fragment).
OS Human immunodeficiency virus 1.
OC Viruses; Retrovirdae; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=92271245; PubMed=1589796;
RA Ou C.-Y., Cieielecki C.A., Myers G., Bandea C.I., Luo C.C.,
RA Korber B.T.M., Mullins J.I., Schochetman G., Berkman R.L.,
RA Economou A.N., Witte J.J., Furman L.J., Satten G.A., Curran J.W.,
RA Jaffe H.W.;
RT "Molecular epidemiology of HIV transmission in a dental practice.";
RL Science 256:1165-1171(1992).
RN [2]
RP SEQUENCE FROM N.A.
RA Zhang L.Q., Leigh-Brown A.J.;
RL Submitted (APR-1992) to the EMBL/GenBank/DBJ databases.
DR EMBL; M92109; AAA44465.1; -.
FT NON TER 1
FT NON TER 1
SQ SEQUENCE 17 AA; 1649 MW; 3B857BBFD12CA370 CRC64;

Query Match 23.6%; Score 29; DB 2; Length 17;
Best Local Similarity 42.9%; Pred. No. 1.7e+03;
Matches 6; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 1 NNTKRSERIQRGPG 14
|||:|:|:|
Db 3 NNTNGTETFRPGG 16

RESULT 19
Q78327 ID Q78327 PRELIMINARY; PRT; 17 AA.
AC Q78327;
DT 01-NOV-1996 (TReMBLrel. 01, Created)
DT 01-NOV-1996 (TReMBLrel. 01, Last sequence update)
DT 01-MAR-2004 (TReMBLrel. 26, Last annotation update)
DE Immunodeficiency virus type 1, viral sample FLPARSD (Florida patient
DE A), partial env cds, V5 region. (Fragment).
OS Human immunodeficiency virus 1.
OC Viruses; Retrovirdae; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=92271245; PubMed=1589796;
RA Ou C.-Y., Cieielecki C.A., Myers G., Bandea C.I., Luo C.C.,
RA Korber B.T.M., Mullins J.I., Schochetman G., Berkman R.L.,
RA Economou A.N., Witte J.J., Furman L.J., Satten G.A., Curran J.W.,
RA Jaffe H.W.;
RT "Molecular epidemiology of HIV transmission in a dental practice.";
RL Science 256:1165-1171(1992).
RN [2]
RP SEQUENCE FROM N.A.
RA Zhang L.Q., Leigh-Brown A.J.;
RL Submitted (APR-1992) to the EMBL/GenBank/DBJ databases.
DR EMBL; M92109; AAA44465.1; -.
FT NON TER 1
FT NON TER 1
SQ SEQUENCE 17 AA; 1649 MW; 3B857BBFD12CA370 CRC64;

Query Match 23.6%; Score 29; DB 2; Length 17;
Best Local Similarity 42.9%; Pred. No. 1.7e+03;
Matches 6; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 1 NNTKRSERIQRGPG 14
|||:|:|:|
Db 3 NNTNGTETFRPGG 16

RESULT 20
Q78380 ID Q78380 PRELIMINARY; PRT; 17 AA.
AC Q78380;
DT 01-NOV-1996 (TReMBLrel. 01, Created)
DT 01-NOV-1996 (TReMBLrel. 01, Last sequence update)
DT 01-MAR-2004 (TReMBLrel. 26, Last annotation update)
DE Immunodeficiency virus type 1, viral sample FLPRSE (Florida patient
DE B), partial env cds, V5 region. (Fragment).
OS Human immunodeficiency virus 1.
OC Viruses; Retrovirdae; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=92271245; PubMed=1589796;
RA Ou C.-Y., Cieielecki C.A., Myers G., Bandea C.I., Luo C.C.,
RA Korber B.T.M., Mullins J.I., Schochetman G., Berkman R.L.,
RA Economou A.N., Witte J.J., Furman L.J., Satten G.A., Curran J.W.,
RA Jaffe H.W.;
RT "Molecular epidemiology of HIV transmission in a dental practice.";
RL Science 256:1165-1171(1992).
RN [2]
RP SEQUENCE FROM N.A.
RA Zhang L.Q., Leigh-Brown A.J.;
RL Submitted (APR-1992) to the EMBL/GenBank/DBJ databases.
DR EMBL; M92125; AAA44495.1; -.
FT NON TER 1
FT NON TER 1
SQ SEQUENCE 17 AA; 1651 MW; 34757BBFD12CA370 CRC64;

Query Match 23.6%; Score 29; DB 2; Length 17;
Best Local Similarity 42.9%; Pred. No. 1.7e+03;
Matches 6; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 1 NNTKRSERIQRGPG 14
|||:|:|:|
Db 3 NNTNGTETFRPGG 16

RESULT 21
Q6U2M7 ID Q6U2M7 PRELIMINARY; PRT; 22 AA.
AC Q6U2M7;
DT 05-JUL-2004 (TReMBLrel. 27, Created)
DT 05-JUL-2004 (TReMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TReMBLrel. 27, Last annotation update)
DE Galactinol synthase (EC 2.4.1.123) (Fragment).
GN Name=GAS1;
OS Sechium edule.
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC eurosids I; Cucurbitales; Cucurbitaceae; Sechium.
OX NCBI_TaxID=184140;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22975109; PubMed=14526110; DOI=10.1104/pp.103.027714;
RA Ayre B.G., Blair J.E., Turgeon R.;
```

```
RT "Functional and phylogenetic analyses of a conserved regulatory
RL program in the phloem of minor veins.";
DR EMBL; AY379782; AAQ74884.1; -.
DR GO; GO:0047216; P:inositol 3-alpha-galactosyltransferase acti. .; IEA.
DR GO; GO:0016757; P:transferase activity, transferring glycosyl. .; IEA.
KW Glycosyltransferase; Transferase.
FT NON TER 22
SQ SEQUENCE 22 AA; 2295 MW; A6673B5BFD06430C CRC64;

Query Match 23.6%; Score 29; DB 2; Length 22;
Best Local Similarity 85.7%; Pred. No. 2.2e+03;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 13 PGRAFTV 19
Db 16 PGRAFTV 22

RESULT 22
Q9ZG65 PRELIMINARY; PRT; 18 AA.
AC Q9ZG65;
DT 01-MAY-1999 (TrEMBLrel. 10, Created)
DT 01-MAY-1999 (TrEMBLrel. 10, Last sequence update)
DT 01-MAY-1999 (TrEMBLrel. 10, Last annotation update)
DE Orotidine-5'-phosphate decarboxylase (Fragment).
GN Name=pyrF;
OS Chlamydia trachomatis.
OC Bacteria; Chlamydiae; Chlamydiales; Chlamydiaceae; Chlamydia.
OX NCBI_TaxID=813;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=L2 434B;
RA Wang L., Steenburg S.D., Zheng Y., Larsen S.H.;
RL Submitted (AUG-1998) to the EMBL/GenBank/DDJB databases.
DR EMBL; AF087291; AAD04069.1; -.
FT NON TER 1
FT NON TER 18
FT NON TER 18
SQ SEQUENCE 18 AA; 2026 MW; CB911767583AF4E3 CRC64;

Query Match 22.8%; Score 28; DB 2; Length 18;
Best Local Similarity 50.0%; Pred. No. 2.6e+03;
Matches 5; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 2 NTRKSERIQ 11
Db 8 NTRNSSVVR 17

RESULT 23
Q9UCK9 PRELIMINARY; PRT; 16 AA.
AC Q9UCK9;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-MAY-2000 (TrEMBLrel. 13, Last annotation update)
DE Serum amyloid A isotype 2 alpha protein (Serum amyloid A protein)
(Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE.
RX MEDLINE=93099171; PubMed=1463770; DOI=10.1016/0925-4439(92)90068-X;
RA Baba S., Takahashi T., Kasama T., Shirasawa H.;
RL "Identification of two novel amyloid A protein subsets coexisting in
an individual patient of AA-amyloidosis.";
RT Biochim. Biophys. Acta 1180:195-200(1992).
DR EMBL; AF087291; AAD04069.1; -.
FT NON TER 1
FT NON TER 18
FT NON TER 18
SQ SEQUENCE 18 AA; 2026 MW; CB911767583AF4E3 CRC64;

Query Match 22.0%; Score 27; DB 2; Length 16;
Best Local Similarity 71.4%; Pred. No. 3.4e+03;
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 11 RGPGRGF 17
Db 1 RGPGRGF 7

RESULT 24
Q9UCL0 PRELIMINARY; PRT; 16 AA.
AC Q9UCL0;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-MAY-2000 (TrEMBLrel. 13, Last annotation update)
DE Serum amyloid A isotype 1 protein (Serum amyloid A protein)
(Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE.
RX MEDLINE=93099171; PubMed=1463770; DOI=10.1016/0925-4439(92)90068-X;
RA Baba S., Takahashi T., Kasama T., Shirasawa H.;
RL "Identification of two novel amyloid A protein subsets coexisting in
an individual patient of AA-amyloidosis.";
RT Biochim. Biophys. Acta 1180:195-200(1992).
DR EMBL; AF087291; AAD04069.1; -.
FT NON TER 1
FT NON TER 18
FT NON TER 18
SQ SEQUENCE 16 AA; 1585 MW; 1CAB41E77C839CC1 CRC64;

Query Match 22.0%; Score 27; DB 2; Length 16;
Best Local Similarity 71.4%; Pred. No. 3.4e+03;
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 11 RGPGRGF 17
Db 1 RGPGRGF 7

RESULT 25
Q16228 PRELIMINARY; PRT; 17 AA.
AC Q16228;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-NOV-1998 (TrEMBLrel. 08, Last annotation update)
DE Peripherin (Fragment).
GN Name=rd5;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=94290510; PubMed=8019570;
RA Gruning G., Millan J.M., Meins M., Beneyto M., Caballero M.,
RA Apfelscedt-Sylla E., Bosch R., Zrenner E., Prieto F., Gal A.;
RT "Mutations in the human peripherin/RDS gene associated with autosomal
dominant retinitis pigmentosa.";
RL Hum. Mutat. 3:321-323(1994).
DR EMBL; S73627; AAB31191.1; -.
FT NON TER 17
FT NON TER 17
SQ SEQUENCE 17 AA; 2342 MW; 96828BA695A9D1EB CRC64;
```

FT	NON TER	1	
FT	NON TER	19	19
SEQ	SEQUENCE	19 AA; 1985 MW; 79B98E106D048680 CRC64;	
Query Match			
Best Local Similarity 22.0%; Score 27; DB 2; Length 19;			
Matches 8; Conservative 2; Mismatches 3; Indels 4; Gaps 2;			
Qy	9 IQRG---PGRAFV-TIG 21		
Db	1 IQGVDPNGHPFMTVG 17		
RESULT 28			
Q924C7	PRELIMINARY;	PRT;	22 AA.
ID	Q924C7		
AC	Q924C7;		
DT	01-DEC-2001 (TrEMBLrel. 19, Created)		
DT	01-DEC-2001 (TrEMBLrel. 19, Last sequence update)		
DT	01-JUN-2003 (TrEMBLrel. 24, Last annotation update)		
DE	Glucagon-like peptide-2 receptor (Fragment).		
DE	Name=Glp2r;		
OS	Mus musculus (Mouse).		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.		
OX	NCBI_TaxID=10090;		
RN	[1]		
RP	SEQUENCE FROM N.A.		
RC	STRAIN=129/SVJ;		
RX	MEDLINE=21292988; PubMed=11262390; DOI=10.1074/jbc.M009382200;		
RA	Lovshin J.A., Estall J., Yusta B., Brown T.J., Drucker D.J.;		
RT	"Glucagon-like peptide (GLP)-2 action in the murine central nervous		
RT	system is enhanced by elimination of GLP-1 receptor signaling.";		
RL	J. Biol. Chem. 276:21489-21499(2001).		
DR	EMBL; AF338224; AAK63043.1; -.		
DR	MGI; 2136733; Glp2r.		
DR	GO; GO:0016021; C:integral to membrane; TAS.		
DR	GO; GO:0004967; F:glucagon receptor activity; TAS.		
DR	GO; GO:0007186; P:G-protein coupled receptor protein signalin. . .; TAS.		
KW	Receptor.		
FT	NON TER	22	22
SEQ	SEQUENCE	22 AA; 2526 MW; 2C5BF53DCCD425C9 CRC64;	
Query Match			
Best Local Similarity 44.4%; Score 27; DB 2; Length 22;			
Matches 4; Conservative 3; Mismatches 2; Indels 0; Gaps 0;			
Qy	12 GGRAFVTI 20		
Db	6 GGGTPFLSL 14		
RESULT 29			
Q94781	PRELIMINARY;	PRT;	23 AA.
ID	Q94781		
AC	Q94781;		
DT	01-FEB-1997 (TrEMBLrel. 02, Created)		
DT	01-FEB-1997 (TrEMBLrel. 02, Last sequence update)		
DT	01-JAN-1999 (TrEMBLrel. 09, Last annotation update)		
DE	Histone H2A (Fragment).		
OS	Trypanosoma cruzi.		
OC	Eukaryota; Euzoenozoa; Kinetoplastida; Trypanosomatidae; Trypanosoma.		
OC	NCBI_TaxID=5693;		
RN	[1]		
RP	SEQUENCE FROM N.A.		
RC	STRAIN=Berkeley;		
RA	Tanaka T., Tanaka M.;		
RL	Submitted. (AUG-1996) to the EMBL/GenBank/DBSJ databases.		
DR	EMBL; D87227; BAAL3318.1; -.		
FT	NON TER	1	1
SEQ	SEQUENCE	23 AA; 2790 MW; 12E9ED7592E52045 CRC64;	
Query Match			
Best Local Similarity 22.0%; Score 27; DB 2; Length 23;			

```
Best Local Similarity 46.2%; Pred. No. 5e+03;
Matches 6; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 4 RKSERIORGPG 14
DB 10 RRVDKQWGP 20

RESULT 32
O11893 PRELIMINARY; PRT; 25 AA.
AC O11893;
DT 01-JUL-1997 (TrEMBLrel. 04, Created)
DT 01-JUL-1997 (TrEMBLrel. 04, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE Polyprotein (Fragment).
OS GB virus C/Hepatitis G virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC GBV-C/HGV group.
OX NCBI_TaxID=54290;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=97323271; PubMed=9179760;
RX DOI=10.1002/(SICI)1096-9071(199706)52:2<149::AID-JMV5>3.3.CO;2-N;
RA Gonzalez-Perez M.A., Norder H., Bergstrom A., Lopez E., Visona K.A.,
RA Magnus L.O.;
RT "High prevalence of GB virus C strains genetically related to strains
RT with Asian origin in Nicaraguan hemophiliacs.";
RL J. Med. Virol. 52:149-155(1997).
DR EMBL; U86117; AAB58561.1; -.
KW Polyprotein.
FT NON TER 25
SQ SEQUENCE 25 AA; 2872 MW; B67E75F5C0B77BF6 CRC64;

Query Match 22.0%; Score 27; DB 2; Length 25;
Best Local Similarity 45.5%; Pred. No. 5.4e+03;
Matches 5; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 4 RKSERIORGPG 14
DB 10 RRVDKQWGP 20

RESULT 33
Q7M1W9 PRELIMINARY; PRT; 14 AA.
AC Q7M1W9;
DT 01-MAR-2004 (TrEMBLrel. 26, Created)
DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Porin por1 (Fragment).
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC eurosids II; Brassicales; Brassicaceae; Arabidopsi.
OX NCBI_TaxID=3702;
RN [1]
RP SEQUENCE.
RA Kamo M., Kawakami T., Miyatake N., Taugita A.;
RL Submitted (JUL-1994) to the PIR data bank.
DR PIR; PA0045; PA0045.
FT NON TER 1 14
FT NON TER 14 14
SQ SEQUENCE 14 AA; 1546 MW; 0728ED7FB3BE8FBB CRC64;

Query Match 21.5%; Score 26.5; DB 2; Length 14;
Best Local Similarity 50.0%; Pred. No. 3.6e+03;
Matches 6; Conservative 2; Mismatches 3; Indels 1; Gaps 1;

QY '11 RGPGRFVTTGK 22
DB 2 KGPGLYTEIGK 12

RESULT 34
Q7PE81
```

```
Best Local Similarity 46.2%; Pred. No. 5e+03;
Matches 6; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 4 RKSERIORGPGRA 16
DB 9 RDKKRGKRGRA 21

RESULT 30
O11890 PRELIMINARY; PRT; 25 AA.
AC O11890;
DT 01-JUL-1997 (TrEMBLrel. 04, Created)
DT 01-JUL-1997 (TrEMBLrel. 04, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE Polyprotein (Fragment).
OS GB virus C/Hepatitis G virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC GBV-C/HGV group.
OX NCBI_TaxID=54290;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=97323271; PubMed=9179760;
RX DOI=10.1002/(SICI)1096-9071(199706)52:2<149::AID-JMV5>3.3.CO;2-N;
RA Gonzalez-Perez M.A., Norder H., Bergstrom A., Lopez E., Visona K.A.,
RA Magnus L.O.;
RT "High prevalence of GB virus C strains genetically related to strains
RT with Asian origin in Nicaraguan hemophiliacs.";
RL J. Med. Virol. 52:149-155(1997).
DR EMBL; U86114; AAB58558.1; -.
KW Polyprotein.
FT NON TER 25
SQ SEQUENCE 25 AA; 2800 MW; B67CADD5DBB77BF6 CRC64;

Query Match 22.0%; Score 27; DB 2; Length 25;
Best Local Similarity 45.5%; Pred. No. 5.4e+03;
Matches 5; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 4 RKSERIORGPG 14
DB 10 RRVDKQWGP 20

RESULT 31
O11891 PRELIMINARY; PRT; 25 AA.
AC O11891;
DT 01-JUL-1997 (TrEMBLrel. 04, Created)
DT 01-JUL-1997 (TrEMBLrel. 04, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE Polyprotein (Fragment).
OS GB virus C/Hepatitis G virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC GBV-C/HGV group.
OX NCBI_TaxID=54290;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=97323271; PubMed=9179760;
RX DOI=10.1002/(SICI)1096-9071(199706)52:2<149::AID-JMV5>3.3.CO;2-N;
RA Gonzalez-Perez M.A., Norder H., Bergstrom A., Lopez E., Visona K.A.,
RA Magnus L.O.;
RT "High prevalence of GB virus C strains genetically related to strains
RT with Asian origin in Nicaraguan hemophiliacs.";
RL J. Med. Virol. 52:149-155(1997).
DR EMBL; U86115; AAB58559.1; -.
KW Polyprotein.
FT NON TER 25
SQ SEQUENCE 25 AA; 2872 MW; B67E75F5C0B77BF6 CRC64;

Query Match 22.0%; Score 27; DB 2; Length 25;
Best Local Similarity 45.5%; Pred. No. 5.4e+03;
Matches 5; Conservative 3; Mismatches 3; Indels 0; Gaps 0;
```

```
ID Q7PE81 PRELIMINARY; PRT; 14 AA.
AC Q7PE81;
DT 01-MAR-2004 (TREMBlrel. 26, Created)
DT 01-MAR-2004 (TREMBlrel. 26, Last sequence update)
DT 01-MAR-2004 (TREMBlrel. 26, Last annotation update)
DE ENSANGP0000024647.
GN Name=ENSANGG0000020916;
OS Anopheles gambiae str. PEST.
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Nematocera; Culicoidea; Anopheles.
ON NCBI_TaxID=180454;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=PEST;
RA Anopheles Genome Sequencing Consortium;
RL Submitted (APR-2003) to the EMBL/GenBank/DBJ databases.
CC -!- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
DR EMBL; AAAB01004344; EAA45843.1; -.
SQ SEQUENCE 14 AA; 1652 MW; 4A8A0A1AEC3F7FD3 CRC64;

Query Match 21.1%; Score 26; DB 2; Length 14;
Best Local Similarity 45.5%; Pred. No. 4.4e+03;
Matches 5; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

Qy 13 PGRAFTVITGI 23
Db 2 PERCFKQIGSV 12

RESULT 35
ID NF41 NAEFO STANDARD; PRT; 15 AA.
AC P83729;
DT 29-MAR-2004 (Rel. 43, Created)
DT 29-MAR-2004 (Rel. 43, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Unknown protein NF041 from 2D-PAGE (Fragment).
OS Naegleria fowleri.
OC Eukaryota; Heterolobosea; Schizopyrenida; Vahlkampfiidae; Naegleria.
ON NCBI_TaxID=5763;
RN [1]
RP SEQUENCE.
RC STRAIN=NF 66;
RA Omura M., Furushima-Shinogawara R., Izumiyama S., Endo T.;
RT "Comparative study of protein profiles on pathogenic and nonpathogenic
RT Naegleria species by 2D-PAGE."
RL J. Eukaryot. Microbiol. 0:0-0(2004).
CC -!- MISCELLANEOUS: On the 2D-gel the determined pI of this unknown
CC protein is: 5.9, its MW is: 47.0 kDa.
KW Direct protein sequencing.
FT NON TER 15
SQ SEQUENCE 15 AA; 1704 MW; C70F7D308AEC51B9 CRC64;

Query Match 21.1%; Score 26; DB 1; Length 15;
Best Local Similarity 50.0%; Pred. No. 4.7e+03;
Matches 6; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

Qy 2 NTRKSERIQRP 13
Db 1 DTHKSEIAHQRP 12

RESULT 36
ID Q9UCT3 PRELIMINARY; PRT; 17 AA.
AC Q9UCT3;
DT 01-MAY-2000 (TREMBlrel. 13, Created)
DT 01-MAY-2000 (TREMBlrel. 13, Last sequence update)
DT 01-JUN-2003 (TREMBlrel. 24, Last annotation update)
DE ALZHEIMER'S beta-amyloid precursor protein, kunitz-type protease
DE inhibitor, neutrophil elastase inhibitor, PI-VAL-APP-KD
```

```
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
ON NCBI_TaxID=9606;
RN [1]
RP SEQUENCE.
RX MEDLINE=92041969; PubMed=1939150;
RA Sinha S., Knops J., Esch F., Moyer E.D., Oltersdorf T.;
RT "Conversion of the Alzheimer's beta-amyloid precursor protein (APP)
RT Kunitz domain into a potent human neutrophil elastase inhibitor.";
RL J. Biol. Chem. 266:21011-21013(1991).
DR GO; GO:0004867; P:serine-type endopeptidase inhibitor activity; NAS.
DR GO; GO:0030162; P:regulation of proteolysis and peptidolysis; NAS.
FT NON TER 1
FT NON TER 17
SQ SEQUENCE 17 AA; 1778 MW; F0CCDC28D6712BA CRC64;

Query Match 21.1%; Score 26; DB 2; Length 17;
Best Local Similarity 38.5%; Pred. No. 5.3e+03;
Matches 5; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

Qy 6 SERIQRGFGRAVF 18
Db 5 SEQAETGFXVAMI 17

RESULT 37
ID Q9RSN0 PRELIMINARY; PRT; 17 AA.
AC Q9RSN0;
DT 01-MAY-2000 (TREMBlrel. 13, Created)
DT 01-MAY-2000 (TREMBlrel. 13, Last sequence update)
DT 01-OCT-2003 (TREMBlrel. 25, Last annotation update)
DE Gamma-glutamyltranspeptidase heavy subunit (EC 2.3.2.2) (Fragment).
OS Bacillus subtilis.
OC Bacteria; Firmicutes; Bacillales; Bacillaceae; Bacillus.
ON NCBI_TaxID=1423;
RN [1]
RP SEQUENCE.
RX MEDLINE=92144110; PubMed=1371053;
RA Ogawa Y., Hosoyama H., Hamano M., Motai H.;
RL Agric. Biol. Chem. 55:2971-2977(1991).
DR GO; GO:0003840; F:gamma-glutamyltransferase activity; IEA.
SQ SEQUENCE 17 AA; 1810 MW; 2619B7D40C958BEB CRC64;

Query Match 21.1%; Score 26; DB 2; Length 17;
Best Local Similarity 57.1%; Pred. No. 5.3e+03;
Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 18 VTICKIG 24
Db 6 VDVGKVG 12

RESULT 38
ID Q6JCN3 PRELIMINARY; PRT; 20 AA.
AC Q6JCN3;
DT 05-JUL-2004 (TREMBlrel. 27, Created)
DT 05-JUL-2004 (TREMBlrel. 27, Last sequence update)
DT 25-OCT-2004 (TREMBlrel. 28, Last annotation update)
DE Afac (Fragment) (Fragment).
OS Escherichia coli.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; Escherichia.
ON NCBI_TaxID=562;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=DAC18, DAEC19, DAEC213, DAECT14, DAEC7, DAEC5, DAEC20,
RC DAEC162, DAECT2b, DAECT11a, DAEC11b, DAEC218, DAECT19, EC7372,
RC ECOR37, DAEC9, ECOR50, IH11128, C1845, and ECOR64;
RX PubMed=15014151; DOI=10.1093/molbev/msh118;
```


RA Escobar-Paramo P., Clermont O., Blanc-Potard A.B., Bui H.,
 RA Le Bouguenec C., Denamur E.;
 RT "A Specific Genetic Background Is Required for Acquisition and
 RT Expression of Virulence Factors in *Escherichia coli*.";
 RL Mol. Biol. Evol. 21:1085-1094(2004).
 DR EMBL; AY525515; AAT00550.1; -
 DR EMBL; AY525516; AAT00552.1; -
 DR EMBL; AY525517; AAT00554.1; -
 DR EMBL; AY525518; AAT00556.1; -
 DR EMBL; AY525519; AAT00558.1; -
 DR EMBL; AY525520; AAT00560.1; -
 DR EMBL; AY525521; AAT00562.1; -
 DR EMBL; AY525522; AAT00564.1; -
 DR EMBL; AY525523; AAT00566.1; -
 DR EMBL; AY525524; AAT00568.1; -
 DR EMBL; AY525525; AAT00570.1; -
 DR EMBL; AY525526; AAT00572.1; -
 DR EMBL; AY525527; AAT00574.1; -
 DR EMBL; AY525528; AAT00576.1; -
 DR EMBL; AY525529; AAT00578.1; -
 DR EMBL; AY525530; AAT00580.1; -
 DR EMBL; AY525531; AAT00582.1; -
 DR EMBL; AY525532; AAT00584.1; -
 DR EMBL; AY525533; AAT00586.1; -
 DR EMBL; AY525534; AAT00588.1; -
 DR EMBL; AY525514; AAT00548.1; -
 FT NON_TER 1
 SQ SEQUENCE 20 AA; 2282 MW; A3406B687822556D CRC64;

Query Match 21.1%; Score 26; DB 2; Length 20;
 Best Local Similarity 40.0%; Pred. No. 6.3e+03;
 Matches 4; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 10 ORGPGRAFTV 19
 : : : : :
 Db 6 EKGPAGIFLT 15

RESULT 39
 Q9R4H4
 ID Q9R4H4 PRELIMINARY; PRT; 20 AA.
 AC Q9R4H4
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE Sulfite reductase 50 kDa alpha subunit (EC 1.8.99.3) (Fragment).
 OS Desulfovibrio desulfuricans.
 OC Bacteria; Proteobacteria; Deltaproteobacteria; Desulfovibrionales;
 OC Desulfovibrionaceae; Desulfovibrio.
 OX NCBI_TaxID=876;
 RN [1]
 RP SEQUENCE.
 EX MEDLINE=96085152; PubMed=8521853;
 RA Steuber J., Arendsen A.F., Hagen W.R., Kroneck P.M.;
 RT "Molecular properties of the dissimilatory sulfite reductase from
 RT Desulfovibrio desulfuricans (Essex) and comparison with the enzyme
 RT from Desulfovibrio vulgaris (Hildenborough).";
 RL Eur. J. Biochem. 233:873-879(1995).
 DR PIR; S63490; S63490.
 DR GO; GO:0018551; F:hydrogensulfite reductase activity; IEA.
 SQ SEQUENCE 20 AA; 2193 MW; F939E03B6E355135 CRC64;

Query Match 21.1%; Score 26; DB 2; Length 20;
 Best Local Similarity 33.3%; Pred. No. 6.3e+03;
 Matches 4; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

Qy 7 ERIQPGRAFY 18
 : : : : :
 Db 9 DQLESQWPSFV 20

RESULT 40
 Q95KS4

ID Q95KS4 PRELIMINARY; PRT; 21 AA.
 AC Q95KS4;
 DT 01-DEC-2001 (TrEMBLrel. 19, Created)
 DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
 DE DAP12 protein (Fragment).
 GN Name=dap12; (Sheep).
 OS Ovis aries (Sheep).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
 OC Caprinae; Ovis.
 OX NCBI_TaxID=9940;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Peripheral blood;
 RA Ellis S.A., Staines K.A.;
 RL Submitted (NOV-2001) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AJ419229; CAD11671.1; -
 FT NON_TER 1
 FT NON_TER 21
 SQ SEQUENCE 21 AA; 2316 MW; BE2E264A4CD38D6D CRC64;

Query Match 21.1%; Score 26; DB 2; Length 21;
 Best Local Similarity 54.5%; Pred. No. 6.7e+03;
 Matches 6; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 9 IORGPGRAFTV 19
 : : : : :
 Db 5 VPRGRGAFTV 15

RESULT 41
 Q6RCK2
 ID Q6RCK2 PRELIMINARY; PRT; 21 AA.
 AC Q6RCK2;
 DT 05-JUL-2004 (TrEMBLrel. 27, Created)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
 DE Catechol 2,3-dioxygenase (Fragment).
 OS Pseudomonas putida.
 OC Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales;
 OC Pseudomonadaceae; Pseudomonas.
 OX NCBI_TaxID=303;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=MT15;
 RA Hendrickx B., Junca H., Vosahlova J., Faber F., Lindner A., Ruegg I.,
 RA Bucheli-Witschel M., Egli T., Mau M., Schloemann M., Brennerova M.,
 RA Brenner V., Pieper D., Top E., Dejonghe W., Bastiaens L.,
 RA Springael D.;
 RL Submitted (DEC-2003) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AY504985; AAS46984.1; -
 DR GO; GO:0016702; F:oxidoreductase activity, acting on single d. . .; IEA.
 KW Dioxygenase.
 FT NON_TER 1
 FT NON_TER 21
 SQ SEQUENCE 21 AA; 2191 MW; 4200125E64F0F0DE CRC64;

Query Match 21.1%; Score 26; DB 2; Length 21;
 Best Local Similarity 50.0%; Pred. No. 6.7e+03;
 Matches 7; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

Qy 9 IORGPGRAFTVIGK 22
 : : : : :
 Db 5 IDIGFTRHGLTHGK 18

RESULT 42
 Q72992
 ID Q72992 PRELIMINARY; PRT; 22 AA.
 AC Q72992;
 DT 01-OCT-2003 (TrEMBLrel. 25, Created)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)

```

DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE SPAC11H1.01 protein (Fragment).
CN Name=SPAC11H1.01;
OS Schizosaccharomyces pombe (Fission yeast).
OC Eukaryota; Fungi; Ascomycota; Schizosaccharomycetes;
OC Schizosaccharomycetales; Schizosaccharomycetaceae;
OC Schizosaccharomycetes.
OX NCBI_TaxID=4896;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=972H-;
RX MEDLINE=21848401; PubMed=11859360; DOI=10.1038/nature724;
RA Wood V., Williams R., Rajandream M.A., Lyne R., Stewart A.,
RA Sproules J., Peat N., Hayes J., Baker S., Basham D., Bowman S.,
RA Brooks K., Brown D., Brown S., Chillingworth T., Churcher C.,
RA Collins M., Connor R., Cronin A., Davis P., Feltwell T., Fraser A.,
RA Gentles S., Goble A., Hamlin N., Harris D., Hidalgo J., Hodgson G.,
RA Holroyd S., Hornsby T., Howarth S., Huckle E.J., Hunt S., Jagels K.,
RA James K., Jones L., Jones M., Leather S., McDonald S., McLean J.,
RA Mooney P., Moule S., Mungall K., Murphy L., Niblett D., Odell C.,
RA Oliver K., O'Neill S., Pearson D., Quail M.A., Rabinowitsch E.,
RA Rutherford K., Rutter S., Saunders D., Seeger K., Sharp S.,
RA Skelton J., Simmonds M., Squares R., Squares S., Stevens K.,
RA Taylor K., Taylor R.G., Tivey A., Walsh S., Warren T., Whitehead S.,
RA Woodward J., Volkart G., Aert R., Robben J., Grymonprez B.,
RA Welte J., Vanstreels E., Rieger M., Schafer M., Muller-Auer S.,
RA Gabel C., Fuchs M., Dusterhoft A., Fritze C., Holzer E., Moestl D.,
RA Hilbert H., Borzym K., Langer I., Beck A., Lehrach H., Reinhardt R.,
RA Pohl T.M., Eger P., Zimmermann W., Wedler H., Wambutt R., Purnelle B.,
RA Goffeau A., Cadieu E., Dreano S., Gloux S., Lelaou V., Mottier S.,
RA Galibert F., Aves S.J., Xiang Z., Hunt C., Moore K., Hurst S.M.,
RA Lucas M., Rochet M., Gaillardin C., Tallada V.A., Garzon A., Thode G.,
RA Daga R.R., Cruzado L., Jimenez J., Sanchez M., del Rey F., Benito J.,
RA Dominguez A., Revuelta J.L., Moreno S., Armstrong J., Foreburg S.L.,
RA Cerutti L., Lowe T., McCombie W.R., Faulsen I., Potashkin J.,
RA Shpakovski G.V., Ussery D., Barrell B.G., Nurse P.;
RT "The genome sequence of Schizosaccharomyces pombe."
RL Nature 415:871-880(2002).
DR EMBL; AL158056; CAD99129.1; -.
DR GenDB Spombe; SPAC11H1.01; -.
FT NON_TER 22 22
SQ SEQUENCE 22 AA; 2622 MW; E4F9B589F9E35D9D9 CRC64;

Query Match 21.1%; Score 26; DB 2; Length 22;
Best Local Similarity 46.7%; Pred. No. 7e+03;
Matches 7; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 9 IORGPGRAFTVTKI 23
DB 6 INEHPRLILTKI 20

RESULT 43
Q9SY23 PRELIMINARY; PRT; 22 AA.
ID Q9SY23;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE T1H7.9.
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC eurosid II; Brassicales; Brassicaceae; Arabidopsis.
OX NCBI_TaxID=3702;
RN [1]
RP SEQUENCE FROM N.A.
RA Buehler E., Shinn P., Dewar K., Feng J., Kim C., Li Y., Sun H.,
RA Conway A., Conway A., Kurtz D., Oji O., Shen Y.K., Toriumi M.,
RA Vysotskaia V., Yu G., Davis R.W., Federspiel N.A., Theologis A.,
RA Ecker J.R.;
RL Submitted (MAY-1998) to the EMBL/GenBank/DBJ databases.
RN [2]

SEQUENCE FROM N.A.
Shinn P., Brooks S., Buehler E., Chao Q., Dunn P., Khan S., Kim C.,
Walker M., Altafi H., Araujo R., Conn L., Conway A., Gonzalez A.,
Hansen N., Huizar L., Kremenetskaia I., Lenz C., Li J., Liu S.,
Luros S., Rowley D., Schwartz J., Toriumi M., Vysotskaia V., Yu, G.,
Davis R., Federspiel N., Theologis A., Ecker J.;
RL Submitted (MAY-1999) to the EMBL/GenBank/DBJ databases.
RN [3]

SEQUENCE FROM N.A.
Cheuk R., Shinn P., Brooks S., Buehler E., Chao Q., Johnson-Hopson C.,
Khan S., Kim C., Altafi H., Bei B., Chin C., Chiou J., Choi E.,
Conn L., Conway A., Gonzalez A., Hansen N., Howing B., Koo T., Lam B.,
Lee J., Lenz C., Li J., Liu A., Liu J., Liu S., Mukharsy N.,
Nguyen M., Palm C., Pham P., Sakano H., Schwartz J., Southwick A.,
Thaveri A., Toriumi M., Vaysberg M., Yu G., Davis R., Federspiel N.,
Theologis A., Ecker J.;
RL Submitted (JUN-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AC004135; AA032934.1; -.
DR PIR; H86433; H86433.
SQ SEQUENCE 22 AA; 2642 MW; 747DFB4CF6342ED6 CRC64;

Query Match 21.1%; Score 26; DB 2; Length 22;
Best Local Similarity 62.5%; Pred. No. 7e+03;
Matches 5; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1 NNTKRSR 8
DB 8 NKKKSR 15

RESULT 44
Q6U2M9 PRELIMINARY; PRT; 23 AA.
ID Q6U2M9;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Galactinol synthase (EC 2.4.1.123) (fragment).
GN Name=GAS1;
OS Momordica charantia (Bitter melon) (Balsam pear).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC eurosid I; Cucurbitales; Cucurbitaceae; Momordica.
OX NCBI_TaxID=3673;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22975109; PubMed=14526110; DOI=10.1104/pp.103.027714;
RA Ayre B.G., Blair J.E., Turgeon R.;
RT "Functional and phylogenetic analyses of a conserved regulatory
RT program in the phloem of minor veins."
DR EMBL; AY379780; AAQ74882.1; -.
DR GO; GO:0047216; F:inositol 3-alpha-galactosyltransferase acti. .; IEA.
DR GO; GO:0016757; F:transferase activity, transferring glycosyl. .; IEA.
KW Glycosyltransferase, Transferase.
FT NON_TER 23 23
SQ SEQUENCE 23 AA; 2444 MW; 62411699CAB81657 CRC64;

Query Match 21.1%; Score 26; DB 2; Length 23;
Best Local Similarity 71.4%; Pred. No. 7.3e+03;
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 13 PGRAFTV 19
DB 16 PKRAYVT 22

RESULT 45
Q6U2N2 PRELIMINARY; PRT; 24 AA.
ID Q6U2N2;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)

```

DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
 DE Galactinol synthase (EC 2.4.1.123) (Fragment).
 GN Name=GAS1;
 OS Citrullus lanatus (Watermelon) (Citrullus vulgaris).
 OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
 OC euroside I; Cucurbitales; Cucurbitaceae; Citrullus.
 OX NCBI_TaxID=3654;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=22975109; PubMed=14526110; DOI=10.1104/pp.103.027714;
 RA Ayre B.G., Blair J.E., Turgeon R.;
 RT "Functional and phylogenetic analyses of a conserved regulatory
 RL program in the phloem of minor veins.";
 DR EMBL; AY379777; AAQ74879.1; -.
 DR GO; GO:0047216; P:inositol 3-alpha-galactosyltransferase acti. . .; IEA.
 DR GO; GO:0016757; P:transferase activity, transferring glycosyl. . .; IEA.
 KW Glycosyltransferase; Transferase.
 FT NON_TER 24 24
 SQ SEQUENCE 24 AA; 2538 MW; E2BC0AE9D7930C06 CRC64;
 Query Match 21.1%; Score 26; DB 2; Length 24;
 Best Local Similarity 71.4%; Pred No. 7.7e+03;
 Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 13 PGRFVVT 19
 Db 17 PKRAVVT 23

Search completed: May 16, 2005, 13:00:27
 Job time : 138.231 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 16, 2005, 12:53:32 ; Search time 28.9231 Seconds
(without alignments)
79.839 Million cell updates/sec

Title: US-08-869-386-3
Perfect score: 123
Sequence: 1 NNTKSERIQGRGFAVTIGIKIG 24
Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 4989

Minimum DB seq length: 0
Maximum DB seq length: 25

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR 79.*
1: pir1.*
2: pir2.*
3: pir3.*
4: pir4.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	64	52.0	20	2 S65399	immunodeficiency v
2	33	26.8	25	2 S21197	hydrogensulfite re
3	28	22.8	24	2 B60422	MSEL-neurophysin -
4	27	22.0	20	2 S48654	Plasmeppsin II - ma
5	27	22.0	20	2 S03505	T-cell receptor al
6	26.5	21.5	14	2 PA0109	porin por 1B - Ara
7	26.5	21.5	14	2 PA0045	porin por1 - Arabi
8	26	21.1	20	2 S63490	dissimilatory sulf
9	26	21.1	22	2 H86433	protein T17H7.9 [i
10	25	20.3	10	2 D28027	protein P7 curle
11	25	20.3	12	2 S11286	exo-alpha-sialidas
12	25	20.3	16	2 JN0264	translation initia
13	25	20.3	25	2 A60807	heat shock protein
14	25	20.3	25	2 S51071	ribosomal protein
15	24.5	19.9	17	2 A37823	dihydroliipoamide S
16	24	19.5	7	2 P70515	T-cell receptor be
17	24	19.5	11	2 G61497	seed protein ws-23
18	24	19.5	13	2 C53275	Ig kappa-1 chain J
19	24	19.5	14	2 PH0915	T-cell receptor be
20	24	19.5	20	2 S28405	lamin B receptor -
21	24	19.5	21	2 S31427	biliary glycoprote
22	24	19.5	22	2 B48395	probable angiotens
23	24	19.5	22	2 F41476	probable antigen 6
24	24	19.5	22	2 C42856	hypothetical prote
25	24	19.5	25	2 D41575	bovinin-like pept
26	23.5	19.1	13	2 PS0453	36K protein 3124 -
27	23.5	19.1	22	2 A28524	diaminopropionate
28	23.5	19.1	24	2 T01780	probable gag polym
29	23	18.7	10	2 S65388	cytochrome-c oxida

30 23 18.7 15 2 PN0629 integration host f
31 23 18.7 16 2 H29501 fibrinopeptide A -
32 23 18.7 17 2 I51203 myosin heavy chain
33 23 18.7 17 2 AF2093 heterocyst-inhibit
34 23 18.7 18 2 S39153 translation elonga
35 23 18.7 19 2 I49037 Tcr delta chain V-
36 23 18.7 20 1 LFBSTT tet leader peptide
37 23 18.7 20 2 S77991 cytochrome-c oxida
38 23 18.7 23 2 S47653 ribosomal protein
39 23 18.7 24 2 S47563 nucleoside-diphosp
40 22 17.9 12 2 S65629 protoporphyrinogen
41 22 17.9 16 2 PH1771 T cell receptor al
42 22 17.9 16 2 H41299 T-cell receptor al
43 22 17.9 19 2 S66213 glucose 1-dehydrog
44 22 17.9 19 2 A33361 CAMP-regulated pho
45 22 17.9 19 2 B48138 d(TTAGGG)n-binding

ALIGNMENTS

RESULT 1

S65399
immunodeficiency virus type 1, HIV-1 gp120 - human (fragments)
C:Species: Homo sapiens (man)
C>Date: 28-Oct-1996 #sequence_revision 13-Mar-1997 #text_change 17-Mar-1999
C:Accession: S65399
R:Niwa, Y.; Yano, M.; Futaki, S.; Okumura, Y.; Kido, H.
Eur. J. Biochem. 237, 64-70, 1996
A:Title: T-cell membrane-associated serine protease, tryptase TL(2), binds human immunode
man immunodeficiency virus type 1 inhibit cleavage of gp120.
A:Reference number: S65399; MUID:96203909; PMID:8620895
A:Accession: S65399
A>Status: preliminary
A:Molecule type: protein
A:Residues: 1-10;11-20 <NIW>
C:Superfamily: type E retrovirus env polyprotein

Query Match 52.0%; Score 64; DB 2; Length 20;
Best Local Similarity 92.3%; Pred. No. 0.0017;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 11 RGPGRGFAVTIGIKI 23
||| ||||| ||||| |||
DB 1 RGPGRGFAVTIGRI 13

RESULT 2

S21197
hydrogensulfite reductase (SC 1.8.99.3) alpha chain - Desulfovibrio vulgaris (fragment)
N:Alternate names: bisulfite reductase; desulfotubidin; desulfotubidin; desulfotubidin;
C:Species: Desulfovibrio vulgaris
C>Date: 19-Mar-1997 #sequence_revision 11-Jun-1999 #text_change 09-Jul-2004
C:Accession: S21197
R:Pieper, A.J.; Duyvis, M.G.; van Helvoort, J.M.L.M.; Wolbert, R.B.G.; Hagen, W.R.
Eur. J. Biochem. 205, 111-115, 1992
A:Title: The third subunit of desulfovibridin-type dissimilatory sulfite reductases.
A:Reference number: S21197; MUID:92209491; PMID:1555572
A:Accession: S21197
A:Molecule type: protein
A:Residues: 1-25 <PIB>
A:Cross-references: UNIPROT:P45574
A:Experimental source: strain Hildenborough
C:Genetics:
A:Gene: dsuC
C:Complex: heterohexamer; two alpha, two beta and two gamma chains
C:Function:
A:Description: catalyzes the six-electron reduction of sulfite to sulfide
A:Pathway: the terminal oxidase in the sulfate-reduction pathway
C:Keywords: heterohexamer; oxidoreductase

Query Match 26.8%; Score 33; DB 2; Length 25;
Best Local Similarity 37.5%; Pred. No. 1.7e+02;

Matches 6; Conservative 5; Mismatches 5; Indels 0; Gaps 0;

QY 3 TRKSERIORGPGRFV 18
DB 5 TPQLDQLESQWXSFE 20

RESULT 3
B60422
MSEL-neurophysin - African clawed frog (fragment)
N:Alternate names: vasopressin-associated neurophysin
C:Species: Xenopus laevis (African clawed frog)
C>Date: 12-Feb-1993 #sequence_revision 12-Feb-1993 #text_change 17-Mar-1999
C:Accession: B60422
R:Chauvet, J.; Michel, G.; Rouille, Y.; Chauvet, M.T.; Acher, R.
Neuropeptides 15, 123-127, 1990
A:Title: Identification of two types of neurophysins in Xenopus laevis neurointermediate
A:Reference number: A60422; MUID:91067001; PMID:2250763
A:Accession: B60422
A:Molecule type: protein
A:Residues: 1-24 <CHA>
C:Superfamily: oxytocin-neurophysin
C:Keywords: pituitary

Query Match 22.8%; Score 28; DB 2; Length 24;
Best Local Similarity 38.5%; Pred. No. 1e+03;
Matches 5; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

QY 2 NTRKSERIORGPG 14
DB 4 DTELQXMQXGPG 16

RESULT 4
S48654
Plasmeprin II - malaria parasite (Plasmodium falciparum)
C:Species: Plasmodium falciparum
C>Date: 15-Jul-1995 #sequence_revision 19-Apr-1996 #text_change 09-Jun-2000
C:Accession: S48654
R:Hill, J.; Tyae, L.; Philip, L.H.; Kay, J.; Dunn, B.M.; Berry, C.
FEBS Lett. 352, 155-158, 1994
A:Title: High level expression and characterization of Plasmeprin II, an aspartic protease
A:Reference number: S48654; MUID:95010698; PMID:7925966
A:Accession: S48654
A>Status: preliminary
A:Molecule type: DNA
A:Residues: 1-20 <HIL>

Query Match 22.0%; Score 27; DB 2; Length 20;
Best Local Similarity 50.0%; Pred. No. 1.2e+03;
Matches 6; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

QY 10 QRGPGRAFVTIG 21
DB 9 QMGRGSEHLTIG 20

RESULT 5
S03505
T-cell receptor alpha chain J region (80) - mouse (fragment)
C:Species: Mus musculus (house mouse)
C>Date: 28-Feb-1990 #sequence_revision 28-Feb-1990 #text_change 30-May-1997
C:Accession: S03505
R:Winkler, A.; Mjolsness, S.; Hood, L.
Nature 316, 832-836, 1995
A:Title: Genomic organization of the genes encoding mouse T-cell receptor alpha-chain.
A:Reference number: S03503; MUID:85296332; PMID:2993908
A:Accession: S03505
A:Molecule type: DNA
A:Residues: 1-20 <WIN>
A:Cross-references: EMBL:X02859
A>Note: this sequence was determined from the germline gene
C:Keywords: T-cell receptor

Query Match 22.0%; Score 27; DB 2; Length 20;
Best Local Similarity 29.4%; Pred. No. 1.2e+03;
Matches 5; Conservative 4; Mismatches 8; Indels 0; Gaps 0;

QY 2 NTRKSERIORGPGRFV 18
DB 1 NTEGADRLTFKGTQLI 17

RESULT 6
PA0109
porin por 1B - Arabidopsis thaliana (fragment)
C:Species: Arabidopsis thaliana (mouse-ear cress)
C>Date: 07-Apr-1995 #sequence_revision 26-May-1995 #text_change 09-Jul-2004
C:Accession: PA0109
R:Kamo, M.; Kawakami, T.; Taugita, A.
submitted to JIPID, March 1995
A:Reference number: PA0109
A:Accession: PA0109
A:Molecule type: protein
A:Residues: 1-14 <KAM>
A:Cross-references: UNIPROT:Q8LA84; UNIPROT:Q42292
A:Experimental source: root

Query Match 21.5%; Score 26.5; DB 2; Length 14;
Best Local Similarity 50.0%; Pred. No. 1.1e+03;
Matches 6; Conservative 2; Mismatches 3; Indels 1; Gaps 1;

QY 11 RGPGRFVTIGK 22
DB 2 KGPG-LYTEIGK 12

RESULT 7
PA0045
porin por1 - Arabidopsis thaliana (fragment)
C:Species: Arabidopsis thaliana (mouse-ear cress)
C>Date: 30-Jun-1992 #sequence_revision 06-Jan-1995 #text_change 09-Jul-2004
C:Accession: PA0045
R:Kamo, M.; Kawakami, T.; Miyatake, N.; Taugita, A.
submitted to JIPID, July 1994
A:Description: Separation and characterization of Arabidopsis proteins by two-dimensional
A:Reference number: PA0001
A:Accession: PA0045
A:Molecule type: protein
A:Residues: 1-14 <KAM>
A:Cross-references: UNIPROT:Q7MLW9
A:Experimental source: root

Query Match 21.5%; Score 26.5; DB 2; Length 14;
Best Local Similarity 50.0%; Pred. No. 1.1e+03;
Matches 6; Conservative 2; Mismatches 3; Indels 1; Gaps 1;

QY 11 RGPGRFVTIGK 22
DB 2 KGPG-LYTEIGK 12

RESULT 8
S63490
disulfide sulfitase reductase alpha chain, soluble - Desulfovibrio desulfuricans (frag
C:Species: Desulfovibrio desulfuricans
C>Date: 28-Oct-1996 #sequence_revision 13-Mar-1997 #text_change 09-Jul-2004
C:Accession: S63490
R:Steuber, J.; Arendsen, A.F.; Hagen, W.R.; Kroneck, P.M.H.
Eur. J. Biochem. 233, 873-879, 1995
A:Title: Molecular properties of the dissimilatory sulfite reductase from Desulfovibrio
A:Reference number: S63489; MUID:96085152; PMID:8521853
A:Accession: S63490
A>Status: preliminary
A:Molecule type: protein
A:Residues: 1-20 <STE>

A;Cross-references: UNIPROT:Q9R4H4

Query Match 21.1%; Score 26; DB 2; Length 20;
Best Local Similarity 33.3%; Pred. No. 1.8e+03;
Matches 4; Conservative 5; Mismatches 3; Indels 0; Gaps 0;
QY 7 ERIQPGRAFV 18
: : : : :
DB 9 DQLESGPWPSFV 20

RESULT 9
H86433
protein T1H7.9 [imported] - Arabidopsis thaliana
C;Species: Arabidopsis thaliana (mouse-ear cress)
C;Date: 02-Mar-2001 #sequence_revision 02-Mar-2001 #text_change 09-Jul-2004
C;Accession: H86433
R;Theologias, A.; Ecker, J.R.; Palm, C.J.; Pederspiel, N.A.; Kaul, S.; White, O.; Alonso,
Chin, C.W.; Chung, M.K.; Conn, L.; Conway, A.B.; Conway, A.R.; Creasy, T.H.; Dewar, K.;
Nature 408, 816-820, 2000
A;Authors: Hunter, J.L.; Jenkins, J.; Johnson-Hopson, C.; Khan, S.; Khaykin, E.; Kim, C.
C.A.; Li, J.H.; Li, Y.; Lin, X.; Liu, S.X.; Liu, Z.A.; Lueros, J.S.; Maiti, R.; Marziali,
Rizzo, M.; Rooney, T.; Rowley, D.; Sakano, H.
A;Authors: Salzberg, S.L.; Schwartz, J.R.; Shinn, P.; Southwick, A.M.; Sun, H.; Tallon,
ker, M.; Wu, D.; Yu, G.; Fraser, C.M.; Venter, J.C.; Davis, R.W.
A;Title: Sequence and analysis of chromosome 1 of the plant Arabidopsis.
A;Reference number: A86141; MUID:21016719; PMID:11130712
A;Accession: H86433
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-22 <STO>
A;Cross-references: UNIPROT:Q9SY23; GB:AE005172; NID:g4926824; PIDN:AAD32934.1; GSPDB:GN
C;Genetics:
A;Gene: T1H7.9
A;Map position: 1

Query Match 21.1%; Score 26; DB 2; Length 22;
Best Local Similarity 62.5%; Pred. No. 2e+03;
Matches 5; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 1 NNTRKSR 8
: : : : :
DB 8 NKKKKSR 15

RESULT 10
D28027
protein P7 - curled-leaved tobacco (fragment)
C;Species: Nicotiana glauca (curled-leaved tobacco)
C;Date: 19-May-1989 #sequence_revision 19-May-1989 #text_change 09-Jul-2004
C;Accession: D28027
R;Bauw, G.; De Loose, M.; Inze, D.; Van Montagu, M.; Vandekerckhove, J.
Proc. Natl. Acad. Sci. U.S.A. 84, 4806-4810, 1987
A;Title: Alterations in the phenotype of plant cells studied by NH2-terminal amino acid-
A;Reference number: A94167
A;Accession: D28027
A;Molecule type: protein
A;Residues: 1-10 <BAU>
A;Cross-references: UNIPROT:Q7MLV8

Query Match 20.3%; Score 25; DB 2; Length 10;
Best Local Similarity 71.4%; Pred. No. 1.3e+03;
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 14 GRAFTI 20
: : : : :
DB 3 GRSFVPI 9

RESULT 11
S11286
exo-alpha-sialidase (EC 3.2.1.18) - influenza A virus (strain A/FPV/Rostock/34 [H7N1])

N;Alternate names: neuraminidase

C;Species: influenza A virus
C;Date: 31-Dec-1990 #sequence_revision 31-Dec-1990 #text_change 22-Jun-1999
C;Accession: S11286
R;Robertson, J.S.
Nucleic Acids Res. 6, 3745-3757, 1979
A;Title: 5' and 3' terminal nucleotide sequences of the RNA genome segments of influenza
A;Reference number: S11286; MUID:80034428; PMID:493121
A;Accession: S11286
A;Molecule type: genomic RNA
A;Residues: 1-12 <ROB>
A;Cross-references: EMBL:J02114; NID:g324483; PIDN:AAA43398.1; PID:g324486
C;Genetics:

A;Map position: segment 6
A;Superfamily: influenza virus exo-alpha-sialidase
C;Keywords: glycosidase; hydrolase

Query Match 20.3%; Score 25; DB 2; Length 12;
Best Local Similarity 44.4%; Pred. No. 1.6e+03;
Matches 4; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 13 PGRAFVTIG 21
: : : : :
DB 3 PNQKIITIG 11

RESULT 12
JN0264
translation initiation factor eIF-2 gamma chain - pig (fragment)
N;Alternate names: eIF2 gamma chain
C;Species: Sus scrofa domestica (domestic pig)
C;Date: 09-Oct-1992 #sequence_revision 09-Oct-1992 #text_change 09-Jul-2004
C;Accession: JN0264
R;Mukoyama, E.B.; Shiohara, H.; Suzuki, H.
Biosci. Biotechnol. Biochem. 56, 680-681, 1992
A;Title: GTP-binding sequences in the gamma subunit of pig liver initiation factor 2.
A;Reference number: JN0264; MUID:92282179; PMID:1368212
A;Accession: JN0264
A;Molecule type: protein
A;Residues: 1-16 <MUK>
A;Cross-references: UNIPROT:Q9TRQ9
A;Experimental source: liver
C;Keywords: GTP binding
P;1-16/Region: GTP binding #status experimental

Query Match 20.3%; Score 25; DB 2; Length 16;
Best Local Similarity 50.0%; Pred. No. 2.1e+03;
Matches 5; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 15 RAFVTIGKIG 24
: : : : :
DB 1 QATINIGTIG 10

RESULT 13
A60807
heat shock protein 90 - rat (fragment)
C;Species: Rattus norvegicus (Norway rat)
C;Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 17-Mar-1999
C;Accession: A60807
R;Denis, M.
Anal. Biochem. 173, 405-411, 1988
A;Title: Two-step purification and N-terminal amino acid sequence analysis of the rat M-1
A;Reference number: A60807; MUID:89048319; PMID:3189818
A;Accession: A60807
A;Molecule type: protein
A;Residues: 1-25 <DEN>
A;Comment: This protein associates with steroid hormone receptors and with the Rous sarco
C;Superfamily: heat shock protein 90
C;Keywords: phosphoprotein

Query Match 20.3%; Score 25; DB 2; Length 25;
Best Local Similarity 40.0%; Pred. No. 3.2e+03;

A:Accession: PH0915

A:Molecule type: mRNA

A:Residues: 1-14 <COL>

A:Experimental source: concanavalin A-activated lymphoblast

A>Note: the authors translated the codon GGG for residue 8 as Glu and GAG for residue 9

C:Keywords: T-cell receptor

Query Match 19.5%; Score 24; DB 2; Length 14;

Best Local Similarity 50.0%; Pred. No. 2.6e+03;

Matches 4; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 10 ORGPCRAF 17

Db 4 RRGTEAY 11

RESULT 20

S28405

lamin B receptor - turkey (fragment)

A:Alternate names: inner nuclear membrane protein p58

C:Species: Meleagris gallopavo (common turkey)

C>Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 09-Jul-2004

C:Accession: S28405

R:Simos, G.; Georgatos, S.D.

EMBO J. 11, 4027-4036, 1992

A>Title: The inner nuclear membrane protein p58 associates in vivo with a p58 kinase and

A:Reference number: S28405; MUID:93010998; PMID:1327755

A:Accession: S28405

A>Status: preliminary

A:Molecule type: protein

A:Residues: 1-20 <Sim>

A:Cross-references: UNIPROT:Q7L211

C:Keywords: DNA binding; nucleus; receptor; transmembrane protein

Query Match

Best Local Similarity 19.5%; Score 24; DB 2; Length 20;

Matches 5; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

Qy 4 RKSERIQRGPR 15

Db 3 RKSSSSSSPSR 14

RESULT 21

S31427

biliary glycoprotein - human

C:Species: Homo sapiens (man)

C>Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 07-Feb-1997

C:Accession: S31427

R:Nedellec, P.; Turbide, C.; Barnett, T.R.; Beauchemin, N.

submitted to the EMBL Data Library, July 1992

A:Description: Characterization of the human biliary glycoprotein regulatory region.

A:Reference number: S31427

A:Accession: S31427

A>Status: preliminary

A:Molecule type: DNA

A:Residues: 1-21 <NED>

A:Cross-references: EMBL:X67277

C:Keywords: glycoprotein

Query Match

Best Local Similarity 19.5%; Score 24; DB 2; Length 21;

Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 13 PGRAF 17

Db 14 PGRGF 18

RESULT 22

B48395

probable angiotensin-converting enzyme - bovine (fragments)

C:Species: Bos primigenius taurus (cattle)

C>Date: 21-Jan-1994 #sequence_revision 23-Mar-1995 #text_change 09-Jul-2004

C:Accession: B48395

R:Maruyama, E.; Iwamatsu, A.; Takashima, S.

Biochem. Mol. Biol. Int. 29, 579-586, 1993

A>Title: Purification and amino acid microsequencing of alkaline phosphodiesterase I from

A:Reference number: A48395; MUID:93250579; PMID:8387370

A:Accession: B48395

A>Status: preliminary

A:Molecule type: protein

A:Residues: 1-22 <MAR>

A:Cross-references: UNIPROT:Q9TRH0

A:Experimental source: kidney

A>Note: sequence extracted from NCBI backbone

C:Superfamily: mammalian peptidyl-di-peptidase A

Query Match

Best Local Similarity 19.5%; Score 24; DB 2; Length 22;

Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RKSERIQRGPR 13

Db 5 RKKEAGHQGP 14

RESULT 23

F41476

probable antigen 6 - Mycobacterium leprae (fragment)

C:Species: Mycobacterium leprae

C>Date: 10-Apr-1992 #sequence_revision 10-Apr-1992 #text_change 18-Jun-1993

C:Accession: F41476

R:Hartskeerl, R.A.; van Rens, R.M.; Stabel, L.F.E.M.; de Wit, M.Y.L.; Klatser, P.R.

Infect. Immun. 58, 2821-2827, 1990

A>Title: Selection and characterization of recombinant clones that produce Mycobacterium

A:Reference number: A41476; MUID:90354041; PMID:1696931

A:Accession: F41476

A>Status: preliminary; not compared with conceptual translation

A:Molecule type: DNA

A:Residues: 1-22 <HAR>

Query Match

Best Local Similarity 19.5%; Score 24; DB 2; Length 22;

Matches 6; Conservative 2; Mismatches 8; Indels 0; Gaps 0;

Qy 3 TRKSERIQRGPRAPV 18

Db 4 TRNSDGLLDGKRGTV 19

RESULT 24

C42856

hypothetical protein 3 EPF-region [imported] - human (fragment)

C:Species: Homo sapiens (man)

C>Date: 10-Jun-1993 #sequence_revision 18-Nov-1994 #text_change 20-Jun-2000

C:Accession: C42856

R:Liu, Z.; Diaz, L.A.; Haas, A.L.; Giudice, G.J.

J. Biol. Chem. 267, 15829-15835, 1992

A>Title: cDNA cloning of a novel human ubiquitin carrier protein. An antigenic domain spe

this human epidermal transcript.

A:Reference number: A42856; MUID:92348449; PMID:1379239

A:Accession: C42856

A>Status: preliminary

A:Molecule type: mRNA

A:Residues: 1-22 <LIU>

A:Experimental source: keratinocyte

A>Note: sequence extracted from NCBI backbone (NCBIN:109895, NCBI:109899)

Query Match

Best Local Similarity 19.5%; Score 24; DB 2; Length 22;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RGRG 14

Db 10 RGP 13

RESULT 25

D41575
bombinin-like peptide 4 - Bombina orientalis
C:Species: Bombina orientalis
C:Date: 30-Jun-1992 #sequence_revision 30-Jun-1992 #text_change 09-Jul-2004
C:Accession: D41575
R:Gibson, B.W.; Tang, D.; Mandrell, R.; Kelly, M.; Spindel, E.R.
J. Biol. Chem. 266, 23103-23111, 1991
A:Title: Bombinin-like peptides with antimicrobial activity from skin secretions of the
A:Reference number: A41575; MUID:92078177; PMID:1744108
A:Accession: D41575
A:Status: preliminary
A:Molecule type: protein
A:Residues: 1-25 <GI>
A:CROSS-references: UNIPROT:P29005
C:Superfamily: bombinin H precursor

Query Match 19.5%; Score 24; DB 2; Length 25;
Best Local Similarity 45.5%; Pred. No. 4.5e+03;
Matches 5; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 12 GPGRAFTVIGK 22

DB 1 GIGAAILSAGK 11

RESULT 26

PS0453
36K protein 3124 - rice (strain Nihonbare) (fragment)
C:Species: Oryza sativa (rice)
C:Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 23-Mar-1995
C:Accession: PS0453
R:Tsugita, A.
submitted to JIPID, April 1993
A:Reference number: PS0206
A:Accession: PS0453
A:Molecule type: protein
A:Residues: 1-13 <TSU>
A:Experimental source: leaf, chlorophyll, stem
A:Note: molecular weight 36K, pI 6.1

Query Match 19.1%; Score 23.5; DB 2; Length 13;
Best Local Similarity 50.0%; Pred. No. 2.9e+03;
Matches 6; Conservative 1; Mismatches 4; Indels 1; Gaps 1;

QY 9 IQRGPGRAFTVI 20

DB 3 IQXAPG-XFVAV 13

RESULT 27

A28524
diaminopropionate ammonia-lyase - Salmonella typhimurium (fragment)
N:Alternate names: diaminopropionatase
C:Species: Salmonella typhimurium
C:Date: 28-Aug-1989 #sequence_revision 28-Aug-1989 #text_change 18-Jun-1993
C:Accession: A28524
R:Nagabawa, T.; Tanizawa, K.; Satoda, T.; Yamada, H.
J. Biol. Chem. 263, 958-964, 1988
A:Title: Diaminopropionate ammonia-lyase from Salmonella typhimurium. Purification and
tide.
A:Reference number: A28524; MUID:88087224; PMID:3275662
A:Accession: A28524
A:Molecule type: protein
A:Residues: 1-22 <NAG>

Query Match 19.1%; Score 23.5; DB 2; Length 22;
Best Local Similarity 46.7%; Pred. No. 4.8e+03;
Matches 7; Conservative 2; Mismatches 3; Indels 3; Gaps 1;

QY 2 NTRKSERIQPGRA 16

DB 10 NTR---RKKKGTGAA 21

RESULT 28

T01780
probable gag polymerase pseudogene - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 13-Aug-1999 #sequence_revision 13-Aug-1999 #text_change 20-Oct-2000
C:Accession: T01780
R:Repaske, R.; O'Neill, R.R.; Steele, P.E.; Martin, M.A.
Proc. Natl. Acad. Sci. U.S.A. 80, 678-682, 1983
A:Title: Characterization and partial nucleotide sequence of endogenous type C retrovirus
A:Reference number: Z14423; MUID:83143994; PMID:6298769
A:Accession: T01780

A:Status: translated from GB/EMBL/DBJ; conceptual translation of pseudogene
A:Molecule type: DNA
A:Residues: 1-24 <REP>
A:CROSS-references: EMBL:J00274; NID:g182154
C:Keywords: pseudogene

Query Match 19.1%; Score 23.5; DB 4; Length 24;
Best Local Similarity 33.3%; Pred. No. 5.2e+03;
Matches 6; Conservative 6; Mismatches 5; Indels 1; Gaps 1;

QY 5 KSERIQRGPGRAFTVIGK 22

DB 4 QSRPRQ3-GRALLNLAE 20

RESULT 29

S65388
cytochrome-c oxidase (EC 1.9.3.1) chain VII c, hepatic - rat (fragment)
C:Species: Rattus norvegicus (Norway rat)
C:Date: 28-Oct-1996 #sequence_revision 13-Mar-1997 #text_change 09-Jul-2004
C:Accession: S65388; S65389
R:Schaeffer, H.; Noack, H.; Halanek, W.; Brandt, U.; von Jagow, G.
Eur. J. Biochem. 230, 235-241, 1995
A:Title: Cytochrome-c oxidase in developing rat heart. Enzymic properties and amino-termi
A:Reference number: S65372; MUID:95324529; PMID:7601105
A:Accession: S65388

A:Status: preliminary
A:Molecule type: protein
A:Residues: 1-10 <SCH>
A:CROSS-references: UNIPROT:P80432
A:Accession: S65389
A:Status: preliminary
A:Molecule type: protein
A:Residues: 1-10 <SC2>
C:Superfamily: cytochrome-c oxidase chain VIIc
C:Keywords: oxidoreductase

Query Match 18.7%; Score 23; DB 2; Length 10;
Best Local Similarity 50.0%; Pred. No. 2.8e+03;
Matches 3; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 10 QRGPGR 15

DB 4 BEGPGK 9

RESULT 30

PN0629
integration host factor-like protein beta chain - Pseudomonas aeruginosa (fragment)
C:Species: Pseudomonas aeruginosa
C:Date: 05-Aug-1994 #sequence_revision 05-Aug-1994 #text_change 09-Jul-2004
C:Accession: PN0629
R:Toussaint, B.; Delic-Attree, I.; Vignais, P.M.
Biochem. Biophys. Res. Commun. 196, 416-421, 1993
A:Title: Pseudomonas aeruginosa contains an IHF-like protein that binds to the algD prom
A:Reference number: PN0628; MUID:94030028; PMID:8216322
A:Accession: PN0629
A:Molecule type: protein

A:Residues: 1-15 <TOU>
A:Cross-references: UNIPROT:Q9R533
C:Comment: This protein forms a stable complex with the algD promoter in vitro, indicating

Query Match 18.7%; Score 23; DB 2; Length 15;
Best Local Similarity 71.4%; Pred. No. 4e+03;
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 5 KSERIOR 11
|||:
Db 3 KSELIER 9

RESULT 31
H29501
fibrinopeptide A - gray seal
C:Species: Halichoerus grypus (gray seal)
C:Date: 21-Nov-1987 #sequence_revision 21-Nov-1987 #text_change 09-Jul-2004
C:Accession: H29501
R:Blombaek, B.; Blombaek, M.; Hann, C.
unpublished results, cited by Blombaek, B., and Blombaek, M., in Chemotaxonomy and Ser
A:Reference number: A29501
A:Accession: H29501
A:Status: preliminary
A:Molecule type: protein
A:Residues: 1-16 <BLD>
A:Cross-references: UNIPROT:Q7M316
C:Superfamily: fibrinogen beta chain; fibrinogen beta/gamma homology; fibrinogen disulf

Query Match 18.7%; Score 23; DB 2; Length 16;
Best Local Similarity 30.8%; Pred. No. 4.3e+03;
Matches 4; Conservative 5; Mismatches 4; Indels 0; Gaps 0;

QY 2 NTRKSERIQRGPG 14
:|:|:|:
Db 2 DTKESDFLAEGG 14

RESULT 32
I51203
myosin heavy chain - chicken (fragment)
C:Species: Gallus gallus (chicken)
C:Date: 04-Sep-1997 #sequence_revision 07-Nov-1997 #text_change 09-Jul-2004
C:Accession: I51203
R:Kelley, C.A.; Takahashi, M.; Yu, J.H.; Adelman, R.S.
J. Biol. Chem. 268, 12848-12854, 1993
A:Title: An insert of seven amino acids confers functional differences between smooth mu
A:Reference number: I51203; MUID:93286132; PMID:8509418
A:Accession: I51203
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-17 <KEL>
A:Cross-references: UNIPROT:Q91352; GB:S62578; NID:G386220; PIDN:AAB27156.1; PID:G386221

Query Match 18.7%; Score 23; DB 2; Length 17;
Best Local Similarity 28.6%; Pred. No. 4.5e+03;
Matches 4; Conservative 4; Mismatches 6; Indels 0; Gaps 0;

QY 4 RKSERIORGPGRF 17
:|:|:|:
Db 1 KKDTSITQPSFSY 14

RESULT 33
AF2093
heterocyst-inhibiting signaling peptide [imported] - Nostoc sp. (strain PCC 7120)
C:Species: Nostoc sp. PCC 7120
A:Note: Nostoc sp. strain PCC 7120 is a synonym of Anabaena sp. strain PCC 7120
C:Date: 14-Dec-2001 #sequence_revision 14-Dec-2001 #text_change 09-Jul-2004
C:Accession: AF2093
R:Kaneko, T.; Nakamura, Y.; Wolk, C.P.; Kuritz, T.; Sasamoto, S.; Watanabe, A.; Iriguchi
Nakazaki, N.; Shimpo, S.; Sugimoto, M.; Takazawa, M.; Yamada, M.; Yasuda, M.; Tabata, S
DNA Res. 8, 205-213, 2001

A:Title: Complete Genomic Sequence of the Filamentous Nitrogen-fixing Cyanobacterium Anan
A:Reference number: AB1807; MUID:21595285; PMID:11759840
A:Accession: AF2093
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-17 <KUR>
A:Cross-references: UNIPROT:O52748; GB:BA000019; PIDN:BA074000.1; PID:G17131393; GSPDB:G
A:Experimental source: strain PCC 7120
C:Genetics:
A:Gene: pats

Query Match 18.7%; Score 23; DB 2; Length 17;
Best Local Similarity 66.7%; Pred. No. 4.5e+03;
Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 10 QRGPGR 15
:|:|:
Db 12 ERGSGR 17

RESULT 34
S39153
translation elongation factor EF-Tu, chloroplast - common tobacco (fragment)
C:Species: Nicotiana tabacum (common tobacco)
C:Date: 07-Apr-1994 #sequence_revision 07-Apr-1994 #text_change 05-Dec-1997
C:Accession: S39153
R:Murayama, Y.; Matsubayashi, T.; Sugita, M.; Sugiura, M.
Plant Mol. Biol. 22, 767-774, 1993
A:Title: Purification of chloroplast elongation factor Tu and cDNA analysis in tobacco: t
A:Reference number: S36183; MUID:93363910; PMID:8358028
A:Accession: S39153
A:Molecule type: protein
A:Residues: 1-18 <MUR>
A:Superfamily: translation elongation factor Tu; translation elongation factor Tu homolog
C:Keywords: chloroplast; GTP binding; protein biosynthesis

Query Match 18.7%; Score 23; DB 2; Length 18;
Best Local Similarity 71.4%; Pred. No. 4.8e+03;
Matches 5; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 18 VTIGKIG 24
:|:|:|:
Db 12 VNIGTIG 18

RESULT 35
I49037
TcR delta chain V-D-J region - mouse (fragment)
C:Species: Mus musculus (house mouse)
C:Date: 21-Jan-1994 #sequence_revision 18-Nov-1994 #text_change 05-Nov-1999
C:Accession: I49037
R:Ezquerria, A.; Wilde, D.B.; McConnell, T.J.; Sturmhofel, K.; Valas, R.B.; Shevach, E.M.;
Eur. J. Immunol. 22, 491-498, 1992
A:Title: Mouse autoreactive gamma/delta T cells. II. Molecular characterization of the T
A:Reference number: A49037; MUID:92164730; PMID:1311262
A:Accession: I49037
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-19 <EZO>
A:Cross-references: NID:G246304; PIDN:AAB21555.1; PID:G246305
A:Experimental source: dendritic epidermal T-cell lines
A:Note: sequence extracted from NCBI backbone (NCBI:90660, NCBI:90671)

Query Match 18.7%; Score 23; DB 2; Length 19;
Best Local Similarity 50.0%; Pred. No. 5e+03;
Matches 6; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

QY 12 GPGRAFTVIGKI 23
:|:|:|:
Db 2 GGGRIWRLLIGGI 13

RESULT 36


```
RESULT 40
S65629
protoporphyrinogen oxidase (EC 1.3.3.4) - bovine (fragment)
C:Species: Bos primigenius taurus (cattle)
C:Date: 14-Feb-1997 #sequence_revision 13-Mar-1997 #text_change 26-May-2000
C:Accession: S65629
R:Taketani, S.; Yoshinaga, T.; Furukawa, T.; Kohno, H.; Tokunaga, R.; Nishimura, K.; Ino
Eur. J. Biochem. 230, 760-765, 1995
A:Title: Induction of terminal enzymes for heme biosynthesis during differentiation of m
A:Reference number: S65629; MUID:95331315; PMID:7607249
A:Accession: S65629
A:Molecule type: protein
A:Residues: 1-12 <TAK>
C:Genetics:
A:Genome: nuclear
C:Function:
A:Pathway: heme biosynthesis; porphyrin biosynthesis
C:Superfamily: phytoene dehydrogenase
C:Keywords: heme biosynthesis; mitochondrion; oxidoreductase; porphyrin biosynthesis

Query Match 17.9%; Score 22; DB 2; Length 12;
Best Local Similarity 50.0%; Pred. No. 4.7e+03;
Matches 4; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 14 GRAFTVIG 21
||| :|
Db 1 GRTVVVLG 8

RESULT 41
PH1771
T cell receptor alpha chain V region (clone 2V alpha 23-2) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 16-Jul-1999 #sequence_revision 16-Jul-1999 #text_change 16-Jul-1999
C:Accession: PH1771
R:Porcellini, S.; Yockey, C.E.; Brenner, M.B.; Balk, S.P.
J. Exp. Med. 178, 1-16, 1993
A:Title: Analysis of T cell antigen receptor (TCR) expression by human peripheral blood
A:Reference number: PH1754; MUID:93301585; PMID:8391057
A:Accession: PH1771
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-16 <POR>

Query Match 17.9%; Score 22; DB 2; Length 16;
Best Local Similarity 36.4%; Pred. No. 6.1e+03;
Matches 4; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 2 NTRKSERIQRG 12
||| :|
Db 6 NTRTASKLTGF 16

RESULT 42
H41299
T-cell receptor alpha chain precursor J region (40) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 28-May-1992 #sequence_revision 28-May-1992 #text_change 05-Nov-1999
C:Accession: H41299
R:Uenatsu, Y.; Wege, H.; Straus, A.; Ott, M.; Bannwarth, W.; Lanchbury, J.; Panayi, G.;
Proc. Natl. Acad. Sci. U.S.A. 88, 8534-8538, 1991
A:Title: The T-cell receptor repertoire in the synovial fluid of a patient with rheumatoid
A:Reference number: H41299; MUID:92020887; PMID:1656449
A:Accession: H41299
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-16 <UEM>
A:Cross-references: GB:S57504; NID:g236332; PIDN:AAB19963.1; PID:g236333
C:Keywords: T-cell receptor

Query Match 17.9%; Score 22; DB 2; Length 16;
Best Local Similarity 28.6%; Pred. No. 6.1e+03;
```

```
Matches 4; Conservative 4; Mismatches 6; Indels 0; Gaps 0;

QY 7 ERIQRGPGRAFVTI 20
::| | | |
Db 2 DKVIFGPGTSLSVI 15

RESULT 43
S66213
glucose 1-dehydrogenase (EC 1.1.1.47) - Haloferax mediterranei (fragment)
C:Species: Haloferax mediterranei
C:Date: 14-Feb-1997 #sequence_revision 13-Mar-1997 #text_change 09-Jul-2004
C:Accession: S66213
R:Bonnete, M.J.; Pire, C.; Llorca, F.I.; Camacho, M.L.
FEBS Lett. 383, 227-229, 1996
A:Title: Glucose dehydrogenase from the halophilic Archaeon Haloferax mediterranei: enzym
A:Reference number: S66213; MUID:96198607; PMID:8925901
A:Accession: S66213
A:Status: preliminary
A:Molecule type: protein
A:Residues: 1-17 <BON>
A:Cross-references: UNIPROT:Q977U7
C:Keywords: oxidoreductase

Query Match 17.9%; Score 22; DB 2; Length 17;
Best Local Similarity 35.7%; Pred. No. 6.5e+03;
Matches 5; Conservative 3; Mismatches 6; Indels 0; Gaps 0;

QY 5 KSERIQRGPGRAFY 18
||| :| |
Db 2 KAIIVKRGEDRPV 15

RESULT 44
A33361
cAMP-regulated phosphoprotein, 21K - rat (fragment)
C:Species: Rattus norvegicus (Norway rat)
C:Date: 08-Dec-1989 #sequence_revision 08-Dec-1989 #text_change 09-Jul-2004
C:Accession: A33361
R:Hemmings Jr., H.C.; Girault, J.A.; Williams, K.R.; LoPresti, M.B.; Greengard, P.
J. Biol. Chem. 264, 7726-7733, 1989
A:Title: ARPP-21, a cyclic AMP-regulated phosphoprotein (M-r=21,000) enriched in dopamine
netic studies of its phosphorylation in vitro.
A:Reference number: A33361; MUID:89214228; PMID:2540203
A:Accession: A33361
A:Status: preliminary
A:Molecule type: protein
A:Residues: 1-19 <HEM>
A:Cross-references: UNIPROT:Q7M049
C:Keywords: phosphoprotein

Query Match 17.9%; Score 22; DB 2; Length 19;
Best Local Similarity 26.7%; Pred. No. 7.2e+03;
Matches 4; Conservative 3; Mismatches 8; Indels 0; Gaps 0;

QY 1 NNTKRSERIQRGPCR 15
||| :|
Db 4 NQERRKSKGAGK 18

RESULT 45
B48138
d(TTAGGG)n-binding protein B39 - human (fragment)
N:Alternate names: type E heterogeneous nuclear ribonucleoprotein homolog
C:Species: Homo sapiens (man)
C:Date: 16-Feb-1994 #sequence_revision 18-Nov-1994 #text_change 16-Aug-2004
C:Accession: B48138
R:Ishikawa, F.; Matunis, M.J.; Dreyfuss, G.; Cech, T.R.
Mol. Cell. Biol. 13, 4301-4310, 1993
A:Title: Nuclear proteins that bind the pre-mRNA 3' splice site sequence r(UUAG/G) and t
A:Reference number: B48138; MUID:93309464; PMID:8321232
A:Accession: B48138
A:Status: preliminary
```

A:Molecule type: protein
 A:Residues: 1-19 <ISH>
 A:Cross-references: UNIPROT:Q9UCE9
 A:Experimental source: HeLa cell nuclei
 A>Note: sequence extracted from NCBI backbone (NCBI:134644)
 C:Superfamily: ribonucleoprotein repeat homology

Query Match 17.9%; Score 22; DB 2; Length 19;
 Best Local Similarity 37.5%; Pred. No. 7.2e+03;
 Matches 3; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

OY 4 RKSERIOR 11
 Db 8 KESERVDK 15

Search completed: May 16, 2005, 13:07:13
 Job time : 29.9231 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 16, 2005, 12:39:11 ; Search time 85.7692 Seconds
(without alignments)
89.556 Million cell updates/sec

Title: US-08-869-386-1

Perfect score: 77

Sequence: 1 IQRGPGRAFTVIGK 15

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 16988

Minimum DB seq length: 0
Maximum DB seq length: 25

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : UniProt_03.*

1: uniprot_sprot.*
2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	42	54.5	25	O10481	O10481 human immun
2	42	54.5	25	Q7ZJT3	Q7ZJT3 human immun
3	35	45.5	23	Q9E8S7	Q9E8S7 human immun
4	35	45.5	23	Q9ENM9	Q9ENM9 human immun
5	35	45.5	25	Q8AQX9	Q8AQX9 human immun
6	35	45.5	25	Q8AQY0	Q8AQY0 human immun
7	31	40.3	25	Q9QEX7	Q9QEX7 human immun
8	29	37.7	22	Q9U2M7	Q9U2M7 sechium edu
9	28	36.4	25	Q8AQY1	Q8AQY1 human immun
10	28	36.4	25	Q8AQY2	Q8AQY2 human immun
11	27	35.1	16	Q9UCK9	Q9UCK9 homo sapien
12	27	35.1	16	Q9UCL0	Q9UCL0 homo sapien
13	27	35.1	17	Q16228	Q16228 homo sapien
14	27	35.1	19	Q6EMLO	Q6EMLO melesgris g
15	27	35.1	19	Q6EML1	Q6EML1 gallus gall
16	27	35.1	22	Q924C7	Q924C7 mus musculu
17	26.5	34.4	14	Q7M1W9	Q7M1W9 arabidopsis
18	26	33.8	20	Q6JCN3	Q6JCN3 escherichia
19	26	33.8	21	Q95K34	Q95K34 ovis aries
20	26	33.8	21	Q6RCK2	Q6RCK2 pseudomonas
21	26	33.8	23	Q6U2M9	Q6U2M9 momordica c
22	26	33.8	24	Q6TQ76	Q6TQ76 saccharomyc
23	26	33.8	24	Q6U2N2	Q6U2N2 citrullus l
24	25	32.5	10	Q7M1V8	Q7M1V8 nicotiana p
25	25	32.5	12	Q84038	Q84038 influenza a
26	25	32.5	14	Q9P2A2	Q9P2A2 homo sapien
27	25	32.5	19	Q90630	Q90630 cercopithec
28	25	32.5	19	Q90633	Q90633 cercopithec
29	25	32.5	20	Q7R974	Q7R974 plasmodium
30	25	32.5	20	Q9PWQ4	Q9PWQ4 gallus gall
31	25	32.5	22	Q6V0X7	Q6V0X7 serratia ma

32 24.5 31.8 17 2 Q7M2M8 Q7m2m8 bos taurus
33 24 31.2 15 2 Q69173 Q69173 versinia pe
34 24 31.2 19 2 Q8UHU2 Q8uuh2 gallus gall
35 24 31.2 19 2 Q8UVE0 Q8uve0 gallus gall
36 24 31.2 20 2 Q9R4H4 Q9r4h4 desulfovibr
37 24 31.2 22 2 Q9AH71 Q9ah71 neisseria m
38 24 31.2 25 1 BLP4_BOMOR P29005 bombina ori
39 23.5 30.5 16 2 Q8JH96 Q8jh96 anthus spin
40 23.5 30.5 16 2 Q8JH97 Q8jh97 anthus prat
41 23.5 30.5 21 2 Q9TRK1 Q9trk1 canis famil
42 23 29.9 10 1 COXO_RAT P80432 rattus norv
43 23 29.9 11 2 Q7S0C5 Q7s0c5 neosporea
44 23 29.9 14 2 Q7PE81 Q7pe81 anopheles g
45 23 29.9 15 1 UC19_MAIZE P80625 zea mays (m

ALIGNMENTS

RESULT 1
O10481 PRELIMINARY; PRT; 25 AA.
AC O10481;
DT 01-JUL-1997 (TREMBLrel. 04, Created)
DT 01-JUL-1997 (TREMBLrel. 04, Last sequence update)
DT 01-JUN-2003 (TREMBLrel. 24, Last annotation update)
DE Envelope glycoprotein (Fragment).
GN Name=env;
OS Human immunodeficiency virus 1.
OC Viruses; Retrovird viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=97255649; PubMed=9100996;
RA Rencher S.D., Lockey T.D., Slobod K.S., Hurwitz J.L.;
RT "Drift from the GPRAP HIV-1 envelope V3 crown sequence in a North
RT American inner city.";
RL AIDS Res. Hum. Retroviruses 13:527-528 (1997).
DR EMBL; U81241; AAB53843.1; -;
DR GO; GO:0016021; C: integral to membrane; IEA.
DR GO; GO:0019028; C: viral capsid; IEA.
DR GO; GO:0019031; C: viral envelope; IEA.
DR GO; GO:0005198; F: structural molecule activity; IEA.
DR InterPro; IPR000777; GPI20.
DR Pfam; PF00516; GP120; 1.
KW AIDS; Coat protein; Envelope protein; Glycoprotein; Transmembrane.
FT NON_TER 1 25
FT NON_TER 25
SQ SEQUENCE 25 AA; 2801 MW; 25E1B150CD7C14B6 CRC64;

Query Match 54.5%; Score 42; DB 2; Length 25;
Best Local Similarity 69.2%; Pred. No. 4.2;
Matches 9; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Oy 2 IQRGPGRAFTVIG 14
Db 12 IHIGGPGRAFTVTKG 24

RESULT 2
Q7ZJT3 PRELIMINARY; PRT; 25 AA.
AC Q7ZJT3;
DT 01-JUN-2003 (TREMBLrel. 24, Created)
DT 01-JUN-2003 (TREMBLrel. 24, Last sequence update)
DT 01-MAR-2004 (TREMBLrel. 26, Last annotation update)
DE Envelope glycoprotein (Fragment).
GN Name=env;
OS Human immunodeficiency virus 1.
OC Viruses; Retrovird viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]

RESULT 4	ID	Q9ENN9	PRELIMINARY;	PRT;	23 AA.
Q9ENN9	AC	Q9ENN9;			
	DT	01-MAR-2001	(T-EMBLrel. 16, Created)		
	DT	01-MAR-2001	(T-EMBLrel. 16, Last sequence up		

RESULT 6
Q8AQY0
ID Q8AQY0
PRELIMINARY;
PRT; 25 AA.


```

AC Q8AQY0;
DT 01-MAR-2003 (TRENBLrel. 23, Created)
DT 01-MAR-2003 (TRENBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TRENBLrel. 25, Last annotation update)
DE Envelope glycoprotein (Fragment).
GN Name=env;
OS Human immunodeficiency virus 1.
OC Viruses; Retroid viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22860939; PubMed=14502005;
RA Freil S.A., Fiscus S.A., Pilcher C.D., Menezes P., Giner J.,
RA Patrick E., Lennox J.L., Hicks C.B., Eron J.J. Jr., Shugars D.C.;
RT "Envelope diversity, coreceptor usage and syncytium-inducing phenotype
RT of HIV-1 variants in saliva and blood during primary infection.";
RL AIDS 17:2025-2033(2003).
DR EMBL; AF536913; AAN63928.1; -.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0019028; C:viral capsid; IEA.
DR GO; GO:0019031; C:viral envelope; IEA.
DR GO; GO:0005198; F:structural molecule activity; IEA.
DR InterPro; IPR000777; GP120.
KW Envelope protein.
FT NON TER 1
FT NON TER 25
SQ SEQUENCE 25 AA; 2749 MW; 9B6E9DACB8D56C0C CRC64;

Query Match 45.5%; Score 35; DB 2; Length 25;
Best Local Similarity 77.8%; Pred. No. 77;
Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 IQGPGRAF 10
Db 8 INIGGRAF 16

RESULT 7
Q9QEX7
ID Q9QEX7 PRELIMINARY; PRT; 25 AA.
AC Q9QEX7;
DT 01-MAY-2000 (TRENBLrel. 13, Created)
DT 01-MAY-2000 (TRENBLrel. 13, Last sequence update)
DT 01-JUN-2003 (TRENBLrel. 24, Last annotation update)
DE Envelope glycoprotein (Fragment).
GN Name=env;
OS Human immunodeficiency virus 1.
OC Viruses; Retroid viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=21103026; PubMed=11170057;
RX DOI=10.1002/1096-9071(200103)63:3<197::AID-JMV1000>3.3.CO;2-G;
RA Lin H.J., Siwak E.B., Lauder J.J., Hollinger F.B.;
RT "Long-term culture of human immunodeficiency virus type 1 resulting in
RT loss of glycosylation sites.";
RL J. Med. Virol. 63:197-202(2001).
DR EMBL; AF178663; AAF04369.1; -.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0019028; C:viral capsid; IEA.
DR GO; GO:0019031; C:viral envelope; IEA.
DR GO; GO:0005198; F:structural molecule activity; IEA.
DR InterPro; IPR000777; GP120.
DR InterPro; IPR011056; Pept_S24_S26_C.
DR Pfam; PF00516; GP120; 1.
KW AIDS; Coat protein; Envelope protein; Glycoprotein; Transmembrane.
FT NON TER 1
FT NON TER 25
SQ SEQUENCE 25 AA; 2818 MW; 9C6EBA908EB5ED47 CRC64;

Query Match 40.3%; Score 31; DB 2; Length 25;
Best Local Similarity 53.8%; Pred. No. 4e+02;
Matches 7; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

Q8AQY0;
DT 01-MAR-2003 (TRENBLrel. 23, Created)
DT 01-MAR-2003 (TRENBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TRENBLrel. 25, Last annotation update)
DE Envelope glycoprotein (Fragment).
GN Name=env;
OS Human immunodeficiency virus 1.
OC Viruses; Retroid viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22860939; PubMed=14502005;
RA Freil S.A., Fiscus S.A., Pilcher C.D., Menezes P., Giner J.,
RA Patrick E., Lennox J.L., Hicks C.B., Eron J.J. Jr., Shugars D.C.;
RT "Envelope diversity, coreceptor usage and syncytium-inducing phenotype
RT of HIV-1 variants in saliva and blood during primary infection.";
RL AIDS 17:2025-2033(2003).
DR EMBL; AF536913; AAN63928.1; -.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0019028; C:viral capsid; IEA.
DR GO; GO:0019031; C:viral envelope; IEA.
DR GO; GO:0005198; F:structural molecule activity; IEA.
DR InterPro; IPR000777; GP120.
DR InterPro; IPR011056; Pept_S24_S26_C.
DR Pfam; PF00516; GP120; 1.
KW AIDS; Coat protein; Envelope protein; Glycoprotein; Transmembrane.
FT NON TER 1
FT NON TER 25
SQ SEQUENCE 25 AA; 2818 MW; 9C6EBA908EB5ED47 CRC64;

Query Match 40.3%; Score 31; DB 2; Length 25;
Best Local Similarity 53.8%; Pred. No. 4e+02;
Matches 7; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

Q8AQY1
ID Q8AQY1 PRELIMINARY; PRT; 25 AA.
AC Q8AQY1;
DT 01-MAR-2003 (TRENBLrel. 23, Created)
DT 01-MAR-2003 (TRENBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TRENBLrel. 25, Last annotation update)
DE Envelope glycoprotein (Fragment).
GN Name=env;
OS Human immunodeficiency virus 1.
OC Viruses; Retroid viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22860939; PubMed=14502005;
RA Freil S.A., Fiscus S.A., Pilcher C.D., Menezes P., Giner J.,
RA Patrick E., Lennox J.L., Hicks C.B., Eron J.J. Jr., Shugars D.C.;
RT "Envelope diversity, coreceptor usage and syncytium-inducing phenotype
RT of HIV-1 variants in saliva and blood during primary infection.";
RL AIDS 17:2025-2033(2003).
DR EMBL; AF536913; AAN63928.1; -.
DR GO; GO:0019031; C:viral envelope; IEA.
DR InterPro; IPR000777; GP120.
FT NON TER 1
FT NON TER 25
SQ SEQUENCE 25 AA; 2601 MW; 71B5A774CE256C09 CRC64;

Query Match 36.4%; Score 28; DB 2; Length 25;
Best Local Similarity 66.7%; Pred. No. 1.4e+03;

Qy 6 PGRAFV 12
Db 16 PKRAFV 22

RESULT 9
Q8AQY1
ID Q8AQY1 PRELIMINARY; PRT; 25 AA.
AC Q8AQY1;
DT 01-MAR-2003 (TRENBLrel. 23, Created)
DT 01-MAR-2003 (TRENBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TRENBLrel. 25, Last annotation update)
DE Envelope glycoprotein (Fragment).
GN Name=env;
OS Human immunodeficiency virus 1.
OC Viruses; Retroid viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22860939; PubMed=14502005;
RA Freil S.A., Fiscus S.A., Pilcher C.D., Menezes P., Giner J.,
RA Patrick E., Lennox J.L., Hicks C.B., Eron J.J. Jr., Shugars D.C.;
RT "Envelope diversity, coreceptor usage and syncytium-inducing phenotype
RT of HIV-1 variants in saliva and blood during primary infection.";
RL AIDS 17:2025-2033(2003).
DR EMBL; AF536913; AAN63928.1; -.
DR GO; GO:0019031; C:viral envelope; IEA.
DR InterPro; IPR000777; GP120.
FT NON TER 1
FT NON TER 25
SQ SEQUENCE 25 AA; 2601 MW; 71B5A774CE256C09 CRC64;

Query Match 36.4%; Score 28; DB 2; Length 25;
Best Local Similarity 66.7%; Pred. No. 1.4e+03;

Qy 2 IQGPGRAFVTTIG 14
Db 13 IPLQGRAWFTTG 25

RESULT 8
Q6U2M7
ID Q6U2M7 PRELIMINARY; PRT; 22 AA.
AC Q6U2M7;
DT 05-JUL-2004 (TRENBLrel. 27, Created)
DT 05-JUL-2004 (TRENBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TRENBLrel. 27, Last annotation update)
DE Galactinol synthase (EC 2.4.1.123) (Fragment).
GN Name=GASI;
OS Scium eule.
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC eucosids 1; Cucurbitales; Cucurbitaceae; Scium.
OX NCBI_TaxID=184140;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22975109; PubMed=14526110; DOI=10.1104/pp.103.027714;
RA Ayre B.G., Blair J.E., Turgeon R.;
RT "Functional and phylogenetic analyses of a conserved regulatory
RT program in the phloem of minor veins.";
RL Plant Physiol. 133:1229-1239(2003).
DR EMBL; AY379782; AA074884.1; -.
DR GO; GO:0047216; F:inositol 3-alpha-galactosyltransferase acti. .; IEA.
DR GO; GO:0016757; F:transferase activity, transferring glycosyl. .; IEA.
KW Glycosyltransferase; Transferase.
FT NON TER 22
FT NON TER 22
SQ SEQUENCE 22 AA; 2295 MW; A6673B5BFD06430C CRC64;

Query Match 37.7%; Score 29; DB 2; Length 22;
Best Local Similarity 85.7%; Pred. No. 8.2e+02;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 6 PGRAFV 12
Db 16 PKRAFV 22

RESULT 9
Q8AQY1
ID Q8AQY1 PRELIMINARY; PRT; 25 AA.
AC Q8AQY1;
DT 01-MAR-2003 (TRENBLrel. 23, Created)
DT 01-MAR-2003 (TRENBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TRENBLrel. 25, Last annotation update)
DE Envelope glycoprotein (Fragment).
GN Name=env;
OS Human immunodeficiency virus 1.
OC Viruses; Retroid viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22860939; PubMed=14502005;
RA Freil S.A., Fiscus S.A., Pilcher C.D., Menezes P., Giner J.,
RA Patrick E., Lennox J.L., Hicks C.B., Eron J.J. Jr., Shugars D.C.;
RT "Envelope diversity, coreceptor usage and syncytium-inducing phenotype
RT of HIV-1 variants in saliva and blood during primary infection.";
RL AIDS 17:2025-2033(2003).
DR EMBL; AF536913; AAN63928.1; -.
DR GO; GO:0019031; C:viral envelope; IEA.
DR InterPro; IPR000777; GP120.
FT NON TER 1
FT NON TER 25
SQ SEQUENCE 25 AA; 2601 MW; 71B5A774CE256C09 CRC64;

Query Match 36.4%; Score 28; DB 2; Length 25;
Best Local Similarity 66.7%; Pred. No. 1.4e+03;

```

```
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2 IORGPGRAF 10
Db 8 IHIGPGGAF 16

RESULT 10
Q8AQY2 PRELIMINARY; PRT; 25 AA.
AC Q8AQY2;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Envelope glycoprotein (Fragment).
GN Name=env;
OS Human immunodeficiency virus 1.
OC Viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22860939; PubMed=14502005;
RA Freil S.A., Fiscus S.A., Pilcher C.D., Menezes P., Giner J.,
RA Patrick E., Lennox J.L., Hicks C.B., Eron J.J. Jr., Shugars D.C.;
RT "Envelope diversity, coreceptor usage and syncytium-inducing phenotype
RT of HIV-1 variants in saliva and blood during primary infection.";
RL AIDS 17:2025-2033(2003).
DR EMBL; AF536911; AAN63926.1; -.
DR GO; GO:0019031; C:virial envelope; IEA.
DR InterPro; IPR000777; GP120.
KW Envelope protein.
FT NON_TER 1
FT NON_TER 25
SQ SEQUENCE 25 AA; 2601 MW; 71B5A774CE256C09 CRC64;

Query Match 36.4%; Score 28; DB 2; Length 25;
Best Local Similarity 66.7%; Pred. No. 1.4e+03;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2 IORGPGRAF 10
Db 8 IHIGPGGAF 16

RESULT 11
Q9UCK9 PRELIMINARY; PRT; 16 AA.
AC Q9UCK9;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Serum amyloid A isotype 2 alpha protein (Serum amyloid A protein)
DE (fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE.
RX MEDLINE=93099171; PubMed=1463770; DOI=10.1016/0925-4439(92)90068-X;
RA Baba S., Takahashi T., Kasama T., Shirasawa H.;
RA Apfelstedt-Sylla E., Bosch R., Zrenner E., Prieto F., Gal A.;
RT "Identification of two novel amyloid A protein subunits coexisting in
RT an individual patient of AA-amyloidosis.";
RL Biochim. Biophys. Acta 1180:195-200(1992).
DR EMBL; AF2902; YLHUA.
DR GO; GO:0005576; C:extracellular; IEA.
DR GO; GO:0006953; P:acute-phase response; IEA.
DR InterPro; IPR000096; Serum_amyloid_A.
DR Pfam; PF00277; SAA; 1.
SQ SEQUENCE 16 AA; 1612 MW; 1CAB4F077C9C8CC1 CRC64;

Query Match 35.1%; Score 27; DB 2; Length 16;
Best Local Similarity 71.4%; Pred. No. 1.4e+03;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2 IORGPGRAF 10
Db 8 IHIGPGGAF 16

RESULT 12
Q9UCL0 PRELIMINARY; PRT; 16 AA.
AC Q9UCL0;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Serum amyloid A isotype 1 protein (Serum amyloid A protein)
DE (fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE.
RX MEDLINE=93099171; PubMed=1463770; DOI=10.1016/0925-4439(92)90068-X;
RA Baba S., Takahashi T., Kasama T., Shirasawa H.;
RA "Identification of two novel amyloid A protein subunits coexisting in
RT an individual patient of AA-amyloidosis.";
RL Biochim. Biophys. Acta 1180:195-200(1992).
DR GO; GO:0005576; C:extracellular; IEA.
DR GO; GO:0006953; P:acute-phase response; IEA.
DR InterPro; IPR000096; Serum_amyloid_A.
DR Pfam; PF00277; SAA; 1.
SQ SEQUENCE 16 AA; 1585 MW; 1CAB41E77C839CC1 CRC64;

Query Match 35.1%; Score 27; DB 2; Length 16;
Best Local Similarity 71.4%; Pred. No. 1.4e+03;
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 4 RGPGRAP 10
Db 1 RGPGGAW 7

RESULT 13
Q16228 PRELIMINARY; PRT; 17 AA.
AC Q16228;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-NOV-1998 (TrEMBLrel. 08, Last annotation update)
DE Peripherin (Fragment).
GN Name=rd5;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=94290510; PubMed=8019570;
RA Gruning G., Millan J.M., Meins M., Beneyto M., Caballero M.,
RA Apfelstedt-Sylla E., Bosch R., Zrenner E., Prieto F., Gal A.;
RT "Mutations in the human peripherin/RDS gene associated with autosomal
RT dominant retinitis pigmentosa.";
RL Hum. Mutat. 3:321-323(1994).
DR EMBL; S73627; AAB31191.1; -.
DR NON_TER 17
DR NON_TER 17
SQ SEQUENCE 17 AA; 2342 MW; 96828BA695A9D1EB CRC64;

Query Match 35.1%; Score 27; DB 2; Length 17;
Best Local Similarity 60.0%; Pred. No. 1.5e+03;
Matches 6; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1 RIQPGGAF 10
```

Db	5	RACRRPGRPF	14	Matches	8;	Conservative	2;	Mismatches	3;	Indels	4;	Gaps	2;
RESULT 14													
Q6EML0	PRELIMINARY; PRT; 19 AA.												
AC	Q6EML0;												
DT	25-OCT-2004 (TrEMBLrel. 28, Created)												
DT	25-OCT-2004 (TrEMBLrel. 28, Last sequence update)												
DT	25-OCT-2004 (TrEMBLrel. 28, Last annotation update)												
DE	B-creatine kinase (Fragment).												
OS	Meleagris gallopavo (Common turkey).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Meleagris.												
NCBI_TaxID=9103;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												
NCBI_TaxID=10090;													
GN	Name=Glpr2;												
OS	Mus musculus (Mouse).												
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;												
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.												

```
Db          :||| : |||
            2 KPGG-LYTEIGK 12

RESULT 18
Q6JCN3      PRELIMINARY;      PRT;      20 AA.
AC Q6JCN3
DT 05-JUL-2004 (TRENBLrel. 27, Created)
DT 05-JUL-2004 (TRENBLrel. 27, Last sequence update)
DT 25-OCT-2004 (TRENBLrel. 28, Last annotation update)
DE AfaC (Fragment) (Fragment).
OS Escherichia coli.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; Escherichia.
OX NCBI_TaxID=562;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=DAEC18, DAEC19, DAEC213, DAECT14, DAEC7, DAEC5, DAEC20,
RC DAEC162, DAECT2a, DAECT2b, DAEC11a, DAEC11b, DAEC218, DAECT19, EC7372,
RC ECOR37, DAEC9, ECOR50, IH11128, C1845, and ECOR64;
RX PubMed=15014151; DOI=10.1093/molbev/meh118;
RA Escobar-Paramo P., Clermont O., Blanc-Potard A.B., Bui H.,
RA Le Bouguenec C., Denamur E.;
RT "A Specific Genetic Background Is Required for Acquisition and
RT Expression of Virulence Factors in Escherichia coli.";
RL Mol. Biol. Evol. 21:1085-1094(2004).
DR EMBL; AY525515; AAT00550.1; -
DR EMBL; AY525516; AAT00552.1; -
DR EMBL; AY525517; AAT00554.1; -
DR EMBL; AY525518; AAT00556.1; -
DR EMBL; AY525519; AAT00558.1; -
DR EMBL; AY525520; AAT00560.1; -
DR EMBL; AY525521; AAT00562.1; -
DR EMBL; AY525522; AAT00564.1; -
DR EMBL; AY525523; AAT00566.1; -
DR EMBL; AY525524; AAT00568.1; -
DR EMBL; AY525525; AAT00570.1; -
DR EMBL; AY525526; AAT00572.1; -
DR EMBL; AY525527; AAT00574.1; -
DR EMBL; AY525528; AAT00576.1; -
DR EMBL; AY525529; AAT00578.1; -
DR EMBL; AY525530; AAT00580.1; -
DR EMBL; AY525531; AAT00582.1; -
DR EMBL; AY525532; AAT00584.1; -
DR EMBL; AY525533; AAT00586.1; -
DR EMBL; AY525534; AAT00588.1; -
DR EMBL; AY525514; AAT00548.1; -
FT NON_TER 1
SQ SEQUENCE 20 AA; 2282 MW; A3406B687822556D CRC64;

Query Match 33.8%; Score 26; DB 2; Length 20;
Best Local Similarity 40.0%; Pred. No. 2.6e+03;
Matches 4; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 3 QRGPGRAFTV 12
Db          :||| : |||
            6 EKGPAGIFLT 15

RESULT 19
Q95KS4      PRELIMINARY;      PRT;      21 AA.
AC Q95KS4
DT 01-DEC-2001 (TRENBLrel. 19, Created)
DT 01-DEC-2001 (TRENBLrel. 19, Last sequence update)
DT 01-DEC-2001 (TRENBLrel. 19, Last annotation update)
DE DAP12 protein (Fragment).
GN Name=dap12;
OS Ovis aries (Sheep).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Caprinae; Ovis.

us-08-869-386-1.rup

OX NCBI_TaxID=9940;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Peripheral blood;
RA Ellis S.A., Staines K.A.;
RL Submitted (NOV-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AJ419229; CAD11671.1; -
FT NON_TER 1
FT NON_TER 21
SQ SEQUENCE 21 AA; 2316 MW; BE2E264A4CD38D6D CRC64;

Query Match 33.8%; Score 26; DB 2; Length 21;
Best Local Similarity 54.5%; Pred. No. 2.7e+03;
Matches 6; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 2 IQRGPGRAFTV 12
Db          :||| : |||
            5 VPRGRGAFTV 15

RESULT 20
Q6RCK2      PRELIMINARY;      PRT;      21 AA.
ID Q6RCK2
AC Q6RCK2
DT 05-JUL-2004 (TRENBLrel. 27, Created)
DT 05-JUL-2004 (TRENBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TRENBLrel. 27, Last annotation update)
DE Catechol 2,3-dioxygenase (Fragment).
OS Pseudomonas putida
OC Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales;
OC Pseudomonadaceae; Pseudomonas.
OX NCBI_TaxID=303;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=MT15;
RA Hendrickx B., Junca H., Vosahlova J., Faber F., Lindner A., Ruegg I.,
RA Bucheli-Witschel M., Egli I., Mau M., Schlomm M., Brennerova M.,
RA Brenner V., Pieper D., Top E., Dejonghe W., Bastiaens L.,
RA Springael D.;
RL Submitted (DEC-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY504985; AAS46984.1; -
DR GO; GO:0016702; F:oxidoreductase activity, acting on single d. . .; IEA.
KW Dioxigenase.
FT NON_TER 1
FT NON_TER 21
SQ SEQUENCE 21 AA; 2191 MW; 4200125E64F0F0DE CRC64;

Query Match 33.8%; Score 26; DB 2; Length 21;
Best Local Similarity 50.0%; Pred. No. 2.7e+03;
Matches 7; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 2 IQRGPGRAFTV 15
Db          :||| : |||
            5 IDIGPTRHGLTHGK 18

RESULT 21
Q6U2M9      PRELIMINARY;      PRT;      23 AA.
AC Q6U2M9
DT 05-JUL-2004 (TRENBLrel. 27, Created)
DT 05-JUL-2004 (TRENBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TRENBLrel. 27, Last annotation update)
DE Galactinol synthase (EC 2.4.1.123) (Fragment).
GN Name=GAS1;
OS Momordica charantia (Bitter melon) (Bitter melon).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC eusoids I; Cucurbitales; Cucurbitaceae; Momordica.
OX NCBI_TaxID=3673;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22975109; PubMed=14526110; DOI=10.1104/pp.103.027714;
```

RA Ayre B.G., Blair J.E., Turgeon R.;
 RT "Functional and phylogenetic analyses of a conserved regulatory
 program in the phloem of minor veins."; IEA.
 RL Plant Physiol. 133:1229-1239(2003).
 DR EMBL; AY379780; AAQ74882.1; -.
 DR GO; GO:0047216; F:inositol 3-alpha-galactosyltransferase acti. .; IEA.
 DR GO; GO:0016757; F:transferase activity, transferring glycosyl. .; IEA.
 KW Glycosyltransferase; Transferase.
 FT, NON TER 23 23
 SQ SEQUENCE 23 AA; 2444 MW; 62411699CAB81657 CRC64;
 Query Match 33.8%; Score 26; DB 2; Length 23;
 Best Local Similarity 71.4%; Pred. No. 3e+03;
 Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 6 PGRAFVT 12
 Db 16 PKRAYVT 22
 ID Q6TQ76 PRELIMINARY; PRT; 24 AA.
 AC Q6TQ76
 DT 05-JUL-2004 (TrEMBLrel. 27, Created)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
 DE YHR065Cp (Fragment).
 GN Name=YHR065C;
 OS Saccharomyces cerevisiae (Baker's yeast).
 OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
 OC Saccharomycetales; Saccharomycetaceae; Saccharomycetes.
 ON NCBI_TaxID=4932;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=AB972;
 RA Kennedy M.C., Dietrich F.S.;
 RL Submitted (SEP-2003) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AY389302; AAQ97234.1; -.
 FT, NON TER 1 1
 SQ SEQUENCE 24 AA; 2866 MW; 83820AB41EF59E7C CRC64;
 Query Match 33.8%; Score 26; DB 2; Length 24;
 Best Local Similarity 62.5%; Pred. No. 3.1e+03;
 Matches 5; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 1 RIORGEPGR 8
 Db 2 KIARGKGR 9
 ID Q6U2N2 PRELIMINARY; PRT; 24 AA.
 AC Q6U2N2;
 DT 05-JUL-2004 (TrEMBLrel. 27, Created)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
 DE Galactinol synthase (EC 2.4.1.123) (Fragment).
 GN Name=GNS1;
 OS Citrullus lanatus (Watermelon) (Citrullus vulgaris).
 OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
 OC eurosids I; Cucurbitales; Cucurbitaceae; Citrullus.
 ON NCBI_TaxID=3654;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC MEDLINE=22975109; PubMed=14526110; DOI=10.1104/pp.103.027714;
 RA Ayre B.G., Blair J.E., Turgeon R.;
 RT "Functional and phylogenetic analyses of a conserved regulatory
 program in the phloem of minor veins."; IEA.
 RL Plant Physiol. 133:1229-1239(2003).
 DR EMBL; AY379777; AAQ74879.1; -.

DR GO; GO:0047216; F:inositol 3-alpha-galactosyltransferase acti. .; IEA.
 DR GO; GO:0016757; F:transferase activity, transferring glycosyl. .; IEA.
 KW Glycosyltransferase; Transferase.
 FT, NON TER 24 24
 SQ SEQUENCE 24 AA; 2538 MW; E2BC0AE9D7930C06 CRC64;
 Query Match 33.8%; Score 26; DB 2; Length 24;
 Best Local Similarity 71.4%; Pred. No. 3.1e+03;
 Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 6 PGRAFVT 12
 Db 17 PKRAYVT 23
 ID Q7M1V8 PRELIMINARY; PRT; 10 AA.
 AC Q7M1V8
 DT 01-MAR-2004 (TrEMBLrel. 26, Created)
 DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
 DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
 DE Protein P7 (Fragment).
 OS Nicotiana plumbaginifolia (Leadwort-leaved tobacco).
 OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; asterids;
 OC lamids; Solanales; Solanaceae; Nicotiana.
 ON NCBI_TaxID=4092;
 RN [1]
 RP SEQUENCE.
 RA Bauw G., De Loose M., Inze D., Van Montagu M., Vandekerckhove J.;
 RT "Alterations in the phenotype of plant cells studied by NH2-terminal
 amino acid-sequence analysis of proteins electrophoretically separated from two-
 dimensional gel-separated total extracts";
 RL Proc. Natl. Acad. Sci. U.S.A. 84:4806-4810(1987).
 DR PIR; D28027; D28027.
 FT, NON TER 1 1
 FT, NON TER 10 10
 SQ SEQUENCE 10 AA; 1016 MW; 2697C972C9D5A408 CRC64;
 Query Match 32.5%; Score 25; DB 2; Length 10;
 Best Local Similarity 71.4%; Pred. No. 2e+03;
 Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 7 GRAFVTI 13
 Db 3 GRSEFVI 9
 ID Q84038 PRELIMINARY; PRT; 12 AA.
 AC Q84038;
 DT 01-NOV-1996 (TrEMBLrel. 01, Created)
 DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 DE Influenza A/Epv/rostock/34 (H7N1), neuraminidase (seg 6), 3' end of
 DE vRNA (initiator region for protein coding) (Fragment).
 OS Influenza A virus.
 OC Viruses; ssRNA negative-strand viruses; Orthomyxoviridae;
 OC Influenzavirus A.
 ON NCBI_TaxID=11320;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC MEDLINE=80034428; PubMed=493121;
 RA Robertson J.S.;
 RT "5' and 3' terminal nucleotide sequences of the RNA genome segments of
 influenza virus."; IEA.
 RL Nucleic Acids Res. 6:3745-3757(1979).
 DR EMBL; J02114; AAA43398.1; -.
 DR GO; GO:0016020; C:membrane; IEA.
 DR GO; GO:0004308; P:exo-alpha-sialidase activity; IEA.
 DR GO; GO:0005975; P:carbohydrate metabolism; IEA.

```

DR InterPro; IPR001860; Glyco_hydro_34.
DR Pfam; PF00064; Neur; 1.
FT NON TER 12
SQ SEQUENCE 12 AA; 1316 MW; DC0B3CEB99505326 CRC64;

Query Match 32.5%; Score 25; DB 2; Length 12;
Best Local Similarity 44.4%; Pred. No. 2.4e+03;
Matches 4; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 6 PGRFVTIG 14
   : : : :
Db 3 PNQKIITIG 11

RESULT 26
Q9P2A2 PRELIMINARY; PRT; 14 AA.
AC Q9P2A2
DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-OCT-2000 (TrEMBLrel. 15, Last annotation update)
DE Truncated aldo-keto reductase (fragment).
GN Name=truncated AKR;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Liver;
RX MEDLINE=20138537; PubMed=10672042;
RA Nishizawa M., Nakajima T., Yasuda K., Kanzaki H., Sasaguri Y.,
RA Watanabe K., Ito S.;
RT "Close kinship of human 20alpha-hydroxysteroid dehydrogenase gene with
RT three aldo-keto reductase genes.";
RL Genes Cells 5:111-125(2000).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Liver;
RA Nishizawa M., Nakajima T., Ito S.;
RL Submitted (FEB-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB037903; BAA92888.1; -.
FT NON TER 1
SQ SEQUENCE 14 AA; 1632 MW; 47EB1EE28D59A8D7 CRC64;

Query Match 32.5%; Score 25; DB 2; Length 14;
Best Local Similarity 80.0%; Pred. No. 2.8e+03;
Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 6 PGRAF 10
   : : : :
Db 9 PGRSP 13

RESULT 27
Q90630 PRELIMINARY; PRT; 19 AA.
AC Q90630
DT 01-NOV-1998 (TrEMBLrel. 08, Created)
DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)
DT 01-NOV-1998 (TrEMBLrel. 08, Last annotation update)
DE Glycoprotein G (Fragment).
GN Name=US4;
OS Carcipothecine herpesvirus 16 (CeHV-16) (Herpesvirus papio 2).
OC Viruses; dsDNA viruses, no RNA stage; Herpesviridae;
OC Alphaherpesvirinae; Simplexvirus.
OX NCBI_TaxID=36347;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=001-76;
RX MEDLINE=98440589; PubMed=9765470;
RA Smith A.L., Black D.H., Eberle R.;
RT "Molecular evidence for distinct genotypes of monkey B virus
RT "Molecular evidence for distinct genotypes of monkey B virus
RT "Molecular evidence for distinct genotypes of monkey B virus

```

```

RT (herpesvirus simiae) which are related to the macaque host species.";
RL J. Virol. 72:9224-9232(1998).
DR EMBL; AF082809; AAC34102.1; -.
FT NON TER 1
SQ SEQUENCE 19 AA; 2148 MW; FF552125C14FE8B8 CRC64;

Query Match 32.5%; Score 25; DB 2; Length 19;
Best Local Similarity 62.5%; Pred. No. 3.7e+03;
Matches 5; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 4 RGPGRFV 11
   : : : :
Db 2 RGPGRSRV 9

RESULT 28
Q90633 PRELIMINARY; PRT; 19 AA.
AC Q90633
DT 01-NOV-1998 (TrEMBLrel. 08, Created)
DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)
DT 01-NOV-1998 (TrEMBLrel. 08, Last annotation update)
DE Glycoprotein G (Fragment).
GN Name=US4;
OS Cercopithecine herpesvirus 16 (CeHV-16) (Herpesvirus papio 2).
OC Viruses; dsDNA viruses, no RNA stage; Herpesviridae;
OC Alphaherpesvirinae; Simplexvirus.
OX NCBI_TaxID=36347;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=A951;
RX MEDLINE=98440589; PubMed=9765470;
RA Smith A.L., Black D.H., Eberle R.;
RT "Molecular evidence for distinct genotypes of monkey B virus
RT (herpesvirus simiae) which are related to the macaque host species.";
RL J. Virol. 72:9224-9232(1998).
DR EMBL; AF082810; AAC34105.1; -.
FT NON TER 1
SQ SEQUENCE 19 AA; 2148 MW; FF552125C14FE8B8 CRC64;

Query Match 32.5%; Score 25; DB 2; Length 19;
Best Local Similarity 62.5%; Pred. No. 3.7e+03;
Matches 5; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 4 RGPGRFV 11
   : : : :
Db 2 RGPGRSRV 9

RESULT 29
Q7R974 PRELIMINARY; PRT; 20 AA.
AC Q7R974
DT 01-MAR-2004 (TrEMBLrel. 26, Created)
DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Hypothetical protein (fragment).
GN Name=PY06991;
OS Plasmodium yoelii yoelii.
OC Eukaryota; Alveolata; Apicomplexa; Haemosporidia; Plasmodium.
OX NCBI_TaxID=73239;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=17XNL;
RX PubMed=12368865; DOI=10.1038/nature01099;
RA Carlton J.M., Anguolli S.V., Suh B.B., Kooij T.W., Perte M.,
RA Silva J.C., Ermolaeva M.D., Allen J.E., Selengut J.D., Koo H.L.,
RA Peterson J.D., Pop M., Kosack D.S., Shumway M.F., Bidwell S.L.,
RA Shallom S.J., van Aken S.E., Riedmuller S.B., Feldblyum T.V.,
RA Cho J.K., Quackenbush J., Sedegh M., Shoabi A., Cummings L.M.,
RA Florens L., Yates F.R. III, Raine J.D., Sinden R.E., Harris M.A.,
RA Cunningham D.A., Preiser P.R., Bergman L.W., Vaidya A.B.,
RA van Lin L.H., Janse C.J., Waters A.P., Smith H.O., White O.R.,

```

RA Salzberg S.L., Venter J.C., Fraser C.M., Hoffman S.L., Gardner M.J.,
 RA Carucci D.J.;
 RT "Genome sequence and comparative analysis of the model rodent malaria
 RT parasite Plasmodium yoelii yoelii";
 RL Nature 419:512-519(2002).
 CC -!- CAUTION: The sequence shown here is derived from an
 CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
 CC preliminary data.
 DR EMBL; AABL01002466; EAA19325.1; -.
 KW Hypothetical protein.
 FT NON TER 20 20
 SQ SEQUENCE 20 AA; 2461 MW; C583B1AD3B45C3FC CRC64;
 Query Match 32.5%; Score 25; DB 2; Length 20;
 Best Local Similarity 40.0%; Pred. No. 3.9e+03;
 Matches 4; Conservative 3; Mismatches 3; Indels 0; Gaps 0;
 QY 2 IORGGRAPV 11
 Db 11 MKRGTSRLFI 20
 RESULT 30
 Q9PWQ4 PRELIMINARY; PRT; 20 AA.
 AC Q9PWQ4;
 DT 01-MAY-2000 (TReMBLrel. 13, Created)
 DT 01-MAY-2000 (TReMBLrel. 13, Last sequence update)
 DT 01-MAR-2003 (TReMBLrel. 23, Last annotation update)
 DE Prolactin (Fragment).
 GN Name=prl;
 OS Gallus gallus (Chicken).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Archoeauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
 OC Gallus
 OX NCBI_TaxID=9031;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=20078374; PubMed=10612250;
 RA Miao Y., Burt D.W., Paton I.R., Sharp P.J., Dunn I.C.;
 RT "Mapping of the prolactin gene to chicken chromosome 2.";
 RL Anim. Genet. 30:473-473(1999).
 DR EMBL; AJ239131; CAB43530.1; -.
 DR HSSP; P01236; IN9D.
 FT NON TER 1 1
 FT NON TER 20 20
 SQ SEQUENCE 20 AA; 2223 MW; 258CC8CAA95F12D6 CRC64;
 Query Match 32.5%; Score 25; DB 2; Length 20;
 Best Local Similarity 66.7%; Pred. No. 3.9e+03;
 Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 7 GRAFVT 12
 Db 7 GRGFTT 12
 RESULT 31
 Q6V0X7 PRELIMINARY; PRT; 22 AA.
 ID Q6V0X7
 AC Q6V0X7;
 DT 05-JUL-2004 (TReMBLrel. 27, Created)
 DT 05-JUL-2004 (TReMBLrel. 27, Last sequence update)
 DT 05-JUL-2004 (TReMBLrel. 27, Last annotation update)
 DE Bacteriocin (Fragment).
 GN Name=bin;
 OS Serratia marcescens.
 OG Plasmid pSMT1.
 OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
 OC Enterobacteriaceae; Serratia.
 OX NCBI_TaxID=615;
 RN [1]
 RP SEQUENCE FROM N.A.

RA Manzoor S.E., Gill M.J., Thomas C.M.;
 RL Submitted (JUL-2003) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AY355287; AAR18691.1; -.
 KW Plasmid.
 FT NON TER 22 22
 SQ SEQUENCE 22 AA; 2039 MW; 8F6B89343C822704 CRC64;
 Query Match 32.5%; Score 25; DB 2; Length 22;
 Best Local Similarity 66.7%; Pred. No. 4.3e+03;
 Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 4 RGPGR 9
 Db 7 RGPGRNS 12
 RESULT 32
 Q7M2M8 PRELIMINARY; PRT; 17 AA.
 ID Q7M2M8
 AC Q7M2M8;
 DT 01-MAR-2004 (TReMBLrel. 26, Created)
 DT 01-MAR-2004 (TReMBLrel. 26, Last sequence update)
 DT 01-MAR-2004 (TReMBLrel. 26, Last annotation update)
 DE Dihydrolipoamide S-acyltransferase (EC 2.3.1.12) (Fragment).
 OS Bos taurus (Bovine).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
 OC Bovinae; Bos.
 OX NCBI_TaxID=9913;
 RN [1]
 RP SEQUENCE.
 RX MEDLINE=90354445; PubMed=21673119;
 RA Rahmatullah M., Radke G.A., Andrews P.C., Roche T.E.;
 RT "Changes in the core of the mammalian-pyruvate dehydrogenase complex
 RT upon selective removal of the lipoyl domain from the transacetylase
 RT component but not from the protein X component.";
 RL J. Biol. Chem. 265:14512-14517(1990).
 DR PIR; A37823; A37823.
 DR GO; GO:0004742; F:dihydrolipoyllysine-residue acetyltransferase. . .; IEA.
 FT NON TER 1 1
 FT NON TER 17 17
 SQ SEQUENCE 17 AA; 1743 MW; 5BFC5FB662D014D5 CRC64;
 Query Match 31.8%; Score 24.5; DB 2; Length 17;
 Best Local Similarity 66.7%; Pred. No. 4.1e+03;
 Matches 6; Conservative 1; Mismatches 1; Indels 1; Gaps 1;
 QY 5 GP-GRFVT 12
 Db 1 GPKGRVFVS 9
 RESULT 33
 O69173 PRELIMINARY; PRT; 15 AA.
 ID O69173
 AC O69173;
 DT 01-AUG-1998 (TReMBLrel. 07, Created)
 DT 01-AUG-1998 (TReMBLrel. 07, Last sequence update)
 DT 01-DEC-2001 (TReMBLrel. 19, Last annotation update)
 DE Putative ferroxidase HemH (Fragment).
 GN Name=hemH;
 OS Yersinia pestis.
 OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
 OC Enterobacteriaceae; Yersinia.
 OX NCBI_TaxID=632;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Munier-Lehmann H.;
 RL Submitted (MAY-1998) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AF065382; AAC17437.1; -.
 FT NON TER 15 15
 SQ SEQUENCE 15 AA; 1606 MW; C8763FC5C9CCF10B CRC64;

Query Match 31.2%; Score 24; DB 2; Length 15;
Best Local Similarity 38.5%; Pred. No. 4.5e+03;
Matches 5; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

QY 2 IQRGPGRAFTVIG 14

DB 2 MQSKPGVLWNIG 14

RESULT 34

Q8UHU2 PRELIMINARY; PRT; 19 AA.

AC Q8UHU2 (TREMBlrel. 20, Created)
DT 01-MAR-2002 (TREMBlrel. 20, Last sequence update)
DT 05-JUL-2004 (TREMBlrel. 27, Last annotation update)
DE TGF-beta4 (Fragment)
OS Gallus gallus (Chicken)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC Gallus.
OX NCBI_TaxID=9031;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Blood;
RA Li H., Deeb N., Zhou H., Ashwell C.M., Lamont S.J.;
RL Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF459837; AAL67517.1; -;
DR EMBL; AF459838; AAL67518.1; -;
FT NON_TER 1
FT NON_TER 1
FT NON_TER 19
SQ SEQUENCE 19 AA; 2046 MW; 1250C1CBPE03C2F7 CRC64;

Query Match 31.2%; Score 24; DB 2; Length 19;
Best Local Similarity 57.1%; Pred. No. 5.6e+03;
Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 3 ORGPGRA 9

DB 4 EMGPGHA 10

RESULT 35

Q8UVE0 PRELIMINARY; PRT; 19 AA.

AC Q8UVE0 (TREMBlrel. 20, Created)
DT 01-MAR-2002 (TREMBlrel. 20, Last sequence update)
DT 01-MAR-2002 (TREMBlrel. 20, Last annotation update)
DE TGF-beta4 (Fragment)
OS Gallus gallus (Chicken)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC Gallus.
OX NCBI_TaxID=9031;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Blood;
RA Li H., Deeb N., Zhou H., Ashwell C.M., Lamont S.J.;
RL Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF459839; AAL67519.1; -;
FT NON_TER 1
FT NON_TER 1
FT NON_TER 19
SQ SEQUENCE 19 AA; 2032 MW; 1315C1CBPE03C2F7 CRC64;

Query Match 31.2%; Score 24; DB 2; Length 19;
Best Local Similarity 57.1%; Pred. No. 5.6e+03;
Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 3 ORGPGRA 9

DB 4 EMGPGHA 10

RESULT 36

Q9R4H4 PRELIMINARY; PRT; 20 AA.

AC Q9R4H4 (TREMBlrel. 13, Created)
DT 01-MAY-2000 (TREMBlrel. 13, Last sequence update)
DT 01-OCT-2003 (TREMBlrel. 25, Last annotation update)
DE Sulfite reductase 50 kDa alpha subunit (EC 1.8.99.3) (Fragment).
OS Desulfovibrio desulfuricans
OC Bacteria; Proteobacteria; Deltaproteobacteria; Desulfovibrionales;
OC Desulfovibrionaceae; Desulfovibrio.
OX NCBI_TaxID=876;
RN [1]
RP SEQUENCE.
RX MEDLINE=96085152; PubMed=8521853;
RA Steuber J., Arendsen A.F., Hagen W.R., Kroneck P.M.;
RT "Molecular properties of the dissimilatory sulfite reductase from
Desulfovibrio desulfuricans (Essex) and comparison with the enzyme
from Desulfovibrio vulgaris (Hildenborough).";
RT Eur. J. Biochem. 233:873-879 (1995).
RL PIR: S63490; S63490.
DR GO: 0018551; F:hydrogensulfite reductase activity; IEA.
SQ SEQUENCE 20 AA; 2193 MW; F939E03B6E355135 CRC64;

Query Match 31.2%; Score 24; DB 2; Length 20;
Best Local Similarity 36.4%; Pred. No. 5.9e+03;
Matches 4; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1 RIQPGGRAFV 11

DB 10 QLESGPWPSFV 20

RESULT 37

Q9AH71 PRELIMINARY; PRT; 22 AA.

AC Q9AH71 (TREMBlrel. 17, Created)
DT 01-JUN-2001 (TREMBlrel. 17, Last sequence update)
DT 01-JUN-2001 (TREMBlrel. 17, Last annotation update)
DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE Hmbr (Fragment).
GN Name=hmbR;
OS Neisseria meningitidis.
OC Bacteria; Proteobacteria; Betaproteobacteria; Neisseriales;
OC Neisseriaceae; Neisseria.
OX NCBI_TaxID=487;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=44/76;
RX MEDLINE=21116988; PubMed=1179344;
RX DOI=10.1128/IAI.69.3.1687-1696.2001;
RA Kahler C.M., Blum E., Miller Y.K., Ryan D., Popovic T., Stephens D.S.;
RT "exl, an exchangeable genetic island in Neisseria meningitidis.";
RL Infect. Immun. 69:1687-1696 (2001).
DR EMBL; AF319527; AAK08019.1; -;
FT NON_TER 1
FT NON_TER 1
SQ SEQUENCE 22 AA; 2584 MW; F1BEC6F2F3C2C49 CRC64;

Query Match 31.2%; Score 24; DB 2; Length 22;
Best Local Similarity 57.1%; Pred. No. 6.5e+03;
Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 4 RGPGRF 10

DB 8 RAPGRNY 14

RESULT 38

BLP4 BOMOR

ID BLP4 BOMOR STANDARD; PRT; 25 AA.

AC P29005;

DT 01-DEC-1992 (Rel. 24, Created)

DT 01-DEC-1992 (Rel. 24, Last sequence update)
 DT 05-JUL-2004 (Rel. 44, Last annotation update)
 DE Bombinin-like peptide 4 (BLP-4).
 OS Bombina orientalis (Oriental fire-bellied toad).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Amphibia; Batrachia; Anura; Archeobatrachia; Bombinatoridae; Bombina.
 OX NCBI_TaxID=8346;
 RN [1]
 RP SEQUENCE.

RC TISSUE=Skin secretion;
 RX MEDLINE=92078177; PubMed=1744108;
 RA Gibson B.W., Tang D., Mandrell R., Kelly M., Spindel E.R.;
 RT "Bombinin-like peptides with antimicrobial activity from skin
 secretions of the Asian toad, Bombina orientalis.";
 RL J. Biol. Chem. 266:23103-23111(1991).
 CC - FUNCTION: Has antimicrobial activity, but no hemolytic activity.
 CC - Preference on killing Gram-negative non-enteric bacteria.
 CC - SUBCELLULAR LOCATION: Secreted.
 CC - TISSUE SPECIFICITY: Skin.
 CC - SIMILARITY: Belongs to the bombinin family.
 DR PIR; D41575; D41575.
 KW Amidation; Amphibian defense peptide; Antibiotic;
 KW Direct protein sequencing.
 FT MOD RES 25 25 Phenylalanine amide.
 FT SEQUENCE 25 AA; 2409 MW; E97916634BC3F768 CRC64;
 SQ SEQUENCE 25 AA; 2409 MW; E97916634BC3F768 CRC64;

Query Match 31.2%; Score 24; DB 1; Length 25;

Best Local Similarity 45.5%; Pred. No. 7.3e+03;
 Matches 5; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 5 GPGRAFTVIGK 15

Db 1 GIGAAILSAGK 11

RESULT 39

Q8JH96 PRELIMINARY; PRT; 16 AA.
 AC Q8JH96;
 DT 01-OCT-2002 (TrEMBLrel. 22, Created)
 DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 DE B-CK (Fragment).
 OS Anthus spinoletta (Water pipit).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Archosauria; Aves; Neognathae; Passeriformes; Motacillidae; Anthus.
 OX NCBI_TaxID=45802;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Bures S., Nadvornik P., Saetre G.-P.;
 RT "Hybridization and apparent hybridization between meadow pipit (Anthus
 pratensis) and water pipit (A. spinoletta).";
 RL Hereditas 136:0-0(2002).
 DR EMBL; AF527053; AAM93208.1; --
 DR HSRP; P05122; IQH4.
 DR GO; GO:0016301; F:kinase activity; IEA.
 DR GO; GO:0016772; F:transferase activity, transferring phosphor. .; IEA.
 DR InterPro; IPR000749; ATP-gua_Ptrans.
 DR Pfam; PF02807; ATP-gua_Ptrans; 1.
 FT NON_TER 1 16
 FT NON_TER 16 16
 SQ SEQUENCE 16 AA; 1726 MW; 106D0486800C21E7 CRC64;

Query Match 30.5%; Score 23.5; DB 2; Length 16;

Best Local Similarity 46.2%; Pred. No. 5.9e+03;
 Matches 6; Conservative 1; Mismatches 3; Indels 3; Gaps 1;

Qy 2 IQRG---PGRFV 11

Db 1 IQTGVNFGHPFI 13

RESULT 40

Q8JH97 PRELIMINARY; PRT; 16 AA.
 AC Q8JH97;
 DT 01-OCT-2002 (TrEMBLrel. 22, Created)
 DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 DE B-CK (Fragment).
 OS Anthus pratensis.
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Archosauria; Aves; Neognathae; Passeriformes; Motacillidae; Anthus.
 OX NCBI_TaxID=45803;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Bures S., Nadvornik P., Saetre G.-P.;
 RT "Hybridization and apparent hybridization between meadow pipit (Anthus
 pratensis) and water pipit (A. spinoletta).";
 RL Hereditas 136:0-0(2002).
 DR EMBL; AF527052; AAM93207.1; --
 DR HSRP; P05122; IQH4.
 DR GO; GO:0016301; F:kinase activity; IEA.
 DR GO; GO:0016772; F:transferase activity, transferring phosphor. .; IEA.
 DR InterPro; IPR000749; ATP-gua_Ptrans.
 DR Pfam; PF02807; ATP-gua_Ptrans; 1.
 FT NON_TER 1 16
 FT NON_TER 16 16
 SQ SEQUENCE 16 AA; 1726 MW; 106D0486800C21E7 CRC64;

Query Match 30.5%; Score 23.5; DB 2; Length 21;

Best Local Similarity 66.7%; Pred. No. 7.6e+03;
 Matches 6; Conservative 2; Mismatches 0; Indels 1; Gaps 1;

RESULT 42

COXO RAT STANDARD; PRT; 10 AA.
 ID COXO RAT
 AC P80432;
 DT 01-NOV-1995 (Rel. 32, Created)
 DT 01-NOV-1995 (Rel. 32, Last sequence update)

Q8JH97

ID Q8JH97 PRELIMINARY; PRT; 16 AA.
 AC Q8JH97;
 DT 01-OCT-2002 (TrEMBLrel. 22, Created)
 DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 DE B-CK (Fragment).
 OS Anthus pratensis.
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Archosauria; Aves; Neognathae; Passeriformes; Motacillidae; Anthus.
 OX NCBI_TaxID=45803;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Bures S., Nadvornik P., Saetre G.-P.;
 RT "Hybridization and apparent hybridization between meadow pipit (Anthus
 pratensis) and water pipit (A. spinoletta).";
 RL Hereditas 136:0-0(2002).
 DR EMBL; AF527052; AAM93207.1; --
 DR HSRP; P05122; IQH4.
 DR GO; GO:0016301; F:kinase activity; IEA.
 DR GO; GO:0016772; F:transferase activity, transferring phosphor. .; IEA.
 DR InterPro; IPR000749; ATP-gua_Ptrans.
 DR Pfam; PF02807; ATP-gua_Ptrans; 1.
 FT NON_TER 1 16
 FT NON_TER 16 16
 SQ SEQUENCE 16 AA; 1726 MW; 106D0486800C21E7 CRC64;

Query Match 30.5%; Score 23.5; DB 2; Length 16;

Best Local Similarity 46.2%; Pred. No. 5.9e+03;
 Matches 6; Conservative 1; Mismatches 3; Indels 3; Gaps 1;

Qy 2 IQRG---PGRFV 11

Db 1 IQTGVNFGHPFI 13

RESULT 41

Q9TRK1 PRELIMINARY; PRT; 21 AA.
 AC Q9TRK1;
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
 DE Collagen type IV 24 kDa component (Fragment).
 OS Canis familiaris (Dog).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
 OX NCBI_TaxID=9615;
 RN [1]
 RP SEQUENCE.
 RA Thorne P.S., Bauman R., Valli V.E., Mahuran D., Marrano P.M.,
 RA Jacobs R.;
 RT "Production of anti-NC1 antibody by affected male dogs with X-linked
 hereditary nephritis: a probe for assessing the NCI domain of collagen
 type IV in dogs and humans with hereditary nephritis.";
 RL Submitted (FEB-1993) to the EMBL/GenBank/DBJ databases.
 SQ SEQUENCE 21 AA; 2300 MW; 08C6D4D9D3D62BEA CRC64;

Query Match 30.5%; Score 23.5; DB 2; Length 21;

Best Local Similarity 66.7%; Pred. No. 7.6e+03;
 Matches 6; Conservative 2; Mismatches 0; Indels 1; Gaps 1;

Qy 6 PGRFVTVIG 14

Db 3 PGRS-VSIG 10

```

DR 05-JUL-2004 (Rel. 44, Last annotation update)
DE Cytochrome c oxidase polypeptide VIIC, mitochondrial (EC 1.9.3.1)
DE (VIIIA) (Fragment).
DE Name=Cox7c; Synonym=Cox7c1;
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP SEQUENCE.
RC STRAIN=Wistar; TISSUE=Heart, and Liver;
RX MEDLINE=95324529; PubMed=7601105;
RA Schaeffer H., Noack H., Halangk W., Brandt U., von Jagow G.;
RT "Cytochrome-c oxidase in developing rat heart. Enzymic properties and
RT amino-terminal sequences suggest identity of the fetal heart and the
RT adult liver isoform.";
RL Eur. J. Biochem. 230:235-241(1995).
CC -!- FUNCTION: This protein is one of the nuclear-coded polypeptide
CC chains of cytochrome c oxidase, the terminal oxidase in
CC mitochondrial electron transport.
CC -!- CATALYTIC ACTIVITY: 4 ferrocyclochrome c + O(2) = 4 ferricytochrome
CC c + 2 H(2)O.
CC -!- SIMILARITY: Belongs to the cytochrome c oxidase VIIC family.
DR PIR; S65388; S65388.
KW Direct protein sequencing; Inner membrane; Mitochondrion;
KW Oxidoreductase.
FT NON_TER 10 10
SQ SEQUENCE 10 AA; 1117 MW; 126DE767687B1B0B CRC64;

Query Match 29.9%; Score 23; DB 1; Length 10;
Best Local Similarity 50.0%; Pred. No. 4.6e+03;
Matches 3; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 3 QRGPR 8
: |||:
DB 4 EGGPK 9

RESULT 43
Q7S0C5 PRELIMINARY; PRT; 11 AA.
AC Q7S0C5
DT 01-MAR-2004 (TrEMBLrel. 26, Created)
DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Predicted protein.
GN Names=NCU09984.1;
OS Neurospora crassa.
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Sordariomycetes;
OC Sordariomycetidae; Sordariales; Sordariaceae; Neurospora.
OX NCBI_TaxID=5141;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=OR74A;
RA Galagan J.E., Calvo S.E., Borkovich K.A., Selker E.U., Read N.D.,
RA Jaffe D., Fitzhugh W., Ma L.-J., Smirnov S., Purcell S., Rehman B.,
RA Elkins T., Engels R., Wang S., Nielsen C.B., Butler J., Endrizzi M.,
RA Qui D., Ianakiev P., Pedersen D., Nelson M., Washburne M.,
RA Selitrenikoff C.P., Kinsey J.A., Braun E.L., Zelter A., Schulte U.,
RA Kothe G.O., Jedd G., Mewes W., Staben C., Marcotte E., Greenberg D.,
RA Roy A., Foley K., Naylor J., Thomann N., Barrett R., Gnerre S.,
RA Kamal M., Kamysisselis M., Mauceli E., Bielke C., Rudd S., Frishman D.,
RA Krystofova S., Rasmussen C., Metzenberg R.L., Perkins D.D., Kroken S.,
RA Cogoni C., Macino G., Catchside D., Li W., Pratt R.J., Omani S.A.,
RA DeSouza C.C., Glass L., Orbach M.J., Berglund J., Voelker R.,
RA Yarden O., Flamm M., Seiler S., Dunlap J., Radford A., Aramayo R.,
RA Natvig D.O., Alex L.A., Mannhaupt G., Ebbio D.J., Freitag M.,
RA Paulsen I., Sachs M.S., Lander E.S., Nusbaum C., Birren B.;
RT "The Genome Sequence of the Filamentous Fungus Neurospora crassa.";
RL Nature 0:0-0(2003).
CC -!- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.

DR EMBL; AABX01000510; EAA28761.1; -.
SQ SEQUENCE 11 AA; 1251 MW; 4BF2534E31B2C9C3 CRC64;

Query Match 29.9%; Score 23; DB 2; Length 11;
Best Local Similarity 80.0%; Pred. No. 5e+03;
Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 10 FVTIG 14
|||:|
DB 5 FVTIG 9

RESULT 44
Q7PE81 PRELIMINARY; PRT; 14 AA.
AC Q7PE81;
DT 01-MAR-2004 (TrEMBLrel. 26, Created)
DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE ENSANGP00000024647.
GN Name=ENSANG00000020916;
OS Anopheles gambiae str. PEST.
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Nematocera; Culicoidea; Anopheles.
OX NCBI_TaxID=180454;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=PEST;
RA Anopheles Genome Sequencing Consortium;
RL Submitted (APR-2003) to the EMBL/GenBank/DBJ databases.
CC -!- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
DR EMBL; AAB01004344; EAA45843.1; -.
SQ SEQUENCE 14 AA; 1652 MW; 4A8A0A1AEC3F7FD3 CRC64;

Query Match 29.9%; Score 23; DB 2; Length 14;
Best Local Similarity 55.6%; Pred. No. 6.3e+03;
Matches 5; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 6 PGRAFVTIG 14
|||:|
DB 2 PERCFKQIG 10

RESULT 45
UC19 MAIZE
ID UC19 MAIZE STANDARD; PRT; 15 AA.
AC P80625;
DT 01-OCT-1996 (Rel. 34, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Unknown protein from 2D-PAGE of etiolated coleoptile (Spot 406)
DE (Fragment).
OS Zea mays (Maize)
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
OC PACAD clade; Panicoideae; Andropogoneae; Zea.
OX NCBI_TaxID=4577;
RN [1]
RP SEQUENCE.
RC TISSUE=Coleoptile;
RA Touzet P., Riccardi F., Morin C., Damerval C., Huet J.-C.,
RA Pernollet J.-C., Zivy M., de Vienne D.;
RT "The maize two dimensional gel protein database: towards an integrated
RT genome analysis program.";
RL Theor. Appl. Genet. 93:997-1005(1996).
CC -!- MISCELLANEOUS: On the 2D-gel the determined pI of this unknown
CC protein is: 5.6, its MW is: 18.4 kDa.
DR Maize-2DPAGE; P80625; COLEOPTILE.
DR MaizedB; 123951; -.
KW Direct protein sequencing.
FT NON_TER 1
```

FT NON_TER 15 15
SQ SEQUENCE 15 AA; 1672 MW; 1CF69D4DA8737F9D CRC64;
Query Match 29.9%; Score 23; DB 1; Length 15;
Best Local Similarity 50.0%; Pred. No. 6.8e+03;
Matches 4; Conservative 1; Mismatches 3; Indels 0; Gaps 0;
QY 7 GRAFVTIG 14
Db ||: ||
2 GRRYTYG 9

Search completed: May 16, 2005, 13:00:26
Job time : 88.7692 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 16, 2005, 14:37:35 ; Search time 41 Seconds
(without alignments)
27.311 Million cell updates/sec

Title: US-08-869-386-1

Perfect score: 77
Sequence: 1 RIQPGRAFTICK 15

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 218077

Minimum DB seq length: 0
Maximum DB seq length: 25

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 250 summaries

Database : Issued Patents_AA*
1: /cgn2_6/ptodata/1/1aa/5A_COMB.pep:*
2: /cgn2_6/ptodata/1/1aa/5B_COMB.pep:*
3: /cgn2_6/ptodata/1/1aa/6A_COMB.pep:*
4: /cgn2_6/ptodata/1/1aa/6B_COMB.pep:*
5: /cgn2_6/ptodata/1/1aa/PTCUS_COMB.pep:*
6: /cgn2_6/ptodata/1/1aa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	77	100.0	15	1 US-08-336-087-2	Sequence 2, Appli
2	77	100.0	15	1 US-08-218-025A-17	Sequence 17, Appli
3	77	100.0	15	1 US-08-709-047-7	Sequence 7, Appli
4	77	100.0	15	1 US-08-479-400-2	Sequence 2, Appli
5	77	100.0	15	1 US-08-410-360-7	Sequence 7, Appli
6	77	100.0	15	1 US-08-095-332-1	Sequence 1, Appli
7	77	100.0	15	1 US-08-707-801A-7	Sequence 7, Appli
8	77	100.0	15	1 US-08-709-008-7	Sequence 7, Appli
9	77	100.0	15	1 US-08-711-175-7	Sequence 7, Appli
10	77	100.0	15	1 US-08-488-252-27	Sequence 27, Appli
11	77	100.0	15	2 US-08-021-879-2	Sequence 2, Appli
12	77	100.0	15	2 US-07-760-530-1	Sequence 1, Appli
13	77	100.0	15	2 US-07-950-571A-3	Sequence 3, Appli
14	77	100.0	15	2 US-08-978-699-6	Sequence 6, Appli
15	77	100.0	15	2 US-08-972-089-6	Sequence 6, Appli
16	77	100.0	15	2 US-08-455-625-7	Sequence 7, Appli
17	77	100.0	15	2 US-08-395-204-2	Sequence 2, Appli
18	77	100.0	15	2 US-08-628-687-1	Sequence 1, Appli
19	77	100.0	15	2 US-07-847-311A-1	Sequence 1, Appli
20	77	100.0	15	2 US-08-986-234-13	Sequence 13, Appli
21	77	100.0	15	2 US-08-986-234-28	Sequence 28, Appli
22	77	100.0	15	3 US-08-492-076-22	Sequence 22, Appli
23	77	100.0	15	3 US-08-493-071-25	Sequence 25, Appli
24	77	100.0	15	3 US-08-480-332-1	Sequence 1, Appli
25	77	100.0	15	3 US-08-455-685-7	Sequence 7, Appli
26	77	100.0	15	3 US-08-060-988A-7	Sequence 7, Appli
27	77	100.0	15	3 US-09-051-006-8	Sequence 8, Appli

28	77	100.0	15	4 US-09-389-390-1	Sequence 1, Appli
29	77	100.0	15	4 US-09-508-552-15	Sequence 15, Appli
30	77	100.0	15	4 US-09-827-688-9	Sequence 9, Appli
31	77	100.0	15	5 PCT-US92-10378-1	Sequence 1, Appli
32	77	100.0	15	5 PCT-US94-05142-7	Sequence 7, Appli
33	77	100.0	16	2 US-08-657-392-28	Sequence 28, Appli
34	77	100.0	16	2 US-08-251-472-2	Sequence 2, Appli
35	77	100.0	16	2 US-08-484-905-35	Sequence 35, Appli
36	77	100.0	16	3 US-08-481-985B-35	Sequence 35, Appli
37	77	100.0	16	3 US-09-248-082-2	Sequence 2, Appli
38	77	100.0	16	3 US-08-370-476-35	Sequence 35, Appli
39	77	100.0	16	3 US-08-992-877-15	Sequence 15, Appli
40	77	100.0	16	5 PCT-US94-02539-28	Sequence 28, Appli
41	77	100.0	18	1 US-08-015-770B-4	Sequence 4, Appli
42	77	100.0	20	1 US-08-121-054C-3	Sequence 3, Appli
43	77	100.0	20	1 US-08-488-252-28	Sequence 28, Appli
44	77	100.0	20	3 US-08-539-436-3	Sequence 3, Appli
45	77	100.0	20	4 US-09-813-659-3	Sequence 3, Appli
46	77	100.0	20	4 US-09-549-067A-3	Sequence 3, Appli
47	77	100.0	21	2 US-08-452-503A-4	Sequence 4, Appli
48	77	100.0	21	2 US-08-453-745A-4	Sequence 4, Appli
49	77	100.0	21	2 US-08-470-419-25	Sequence 25, Appli
50	77	100.0	21	2 US-08-648-298-18	Sequence 18, Appli
51	77	100.0	21	2 US-08-761-828-25	Sequence 25, Appli
52	77	100.0	21	2 US-08-452-520B-4	Sequence 4, Appli
53	77	100.0	21	2 US-08-290-105-25	Sequence 25, Appli
54	77	100.0	21	3 US-08-776-949-25	Sequence 25, Appli
55	77	100.0	21	3 US-08-482-810-25	Sequence 25, Appli
56	77	100.0	21	3 US-09-027-955-25	Sequence 25, Appli
57	77	100.0	21	3 US-09-636-805-25	Sequence 25, Appli
58	77	100.0	21	4 US-09-258-128-25	Sequence 25, Appli
59	77	100.0	21	4 US-09-635-754-25	Sequence 25, Appli
60	77	100.0	21	4 US-08-680-525-25	Sequence 25, Appli
61	77	100.0	21	4 US-09-636-223-25	Sequence 25, Appli
62	77	100.0	22	1 US-08-125-012-13	Sequence 13, Appli
63	77	100.0	22	2 US-08-783-818-13	Sequence 13, Appli
64	77	100.0	22	2 US-08-453-349-13	Sequence 13, Appli
65	77	100.0	22	2 US-08-345-321-2	Sequence 2, Appli
66	77	100.0	22	2 US-08-979-385B-11	Sequence 11, Appli
67	77	100.0	22	2 US-08-537-245-1	Sequence 1, Appli
68	77	100.0	22	3 US-08-805-889-5	Sequence 5, Appli
69	77	100.0	22	3 US-09-070-291-5	Sequence 5, Appli
70	77	100.0	22	4 US-09-217-306B-22	Sequence 22, Appli
71	77	100.0	22	4 US-08-880-576-13	Sequence 13, Appli
72	77	100.0	24	1 US-08-097-751-1	Sequence 1, Appli
73	77	100.0	24	1 US-08-090-148-6	Sequence 6, Appli
74	77	100.0	24	1 US-08-257-528B-99	Sequence 99, Appli
75	77	100.0	24	1 US-08-460-602A-99	Sequence 99, Appli
76	77	100.0	24	1 US-08-463-966A-99	Sequence 99, Appli
77	77	100.0	24	1 US-08-465-217A-99	Sequence 99, Appli
78	77	100.0	24	2 US-08-464-329A-99	Sequence 99, Appli
79	77	100.0	24	2 US-08-493-235-24	Sequence 24, Appli
80	77	100.0	24	2 US-08-462-507A-99	Sequence 99, Appli
81	77	100.0	24	2 US-08-146-028-160	Sequence 160, App
82	77	100.0	24	2 US-08-467-861A-99	Sequence 99, Appli
83	77	100.0	24	3 US-08-723-425A-160	Sequence 160, App
84	77	100.0	24	3 US-08-480-332-2	Sequence 2, Appli
85	77	100.0	24	3 US-09-112-206-160	Sequence 160, App
86	77	100.0	24	4 US-09-790-497A-14	Sequence 14, Appli
87	77	100.0	24	4 US-09-790-457A-160	Sequence 160, App
88	77	100.0	24	4 US-09-576-824A-160	Sequence 160, App
89	77	100.0	24	4 US-09-680-497-160	Sequence 160, App
90	77	100.0	24	5 PCT-US92-06688-12	Sequence 12, Appli
91	77	100.0	24	5 PCT-US92-10378-3	Sequence 3, Appli
92	77	100.0	25	2 US-07-950-571A-1	Sequence 1, Appli
93	77	100.0	25	2 US-08-266-448-1	Sequence 1, Appli
94	77	100.0	25	3 US-08-485-324-13	Sequence 13, Appli
95	77	100.0	25	3 US-08-485-324-31	Sequence 31, Appli
96	77	100.0	25	3 US-08-447-506-13	Sequence 13, Appli
97	77	100.0	25	3 US-08-447-506-31	Sequence 31, Appli
98	77	100.0	25	3 US-08-235-437-13	Sequence 13, Appli
99	77	100.0	25	3 US-08-235-437-31	Sequence 31, Appli
100	77	100.0	25	3 US-08-447-515-13	Sequence 13, Appli

101	77	100.0	25	3	US-08-447-515-31	Sequence 31, Appl	174	68	88.3	14	3	US-08-060-988A-10	Sequence 10, Appl
102	77	100.0	25	4	US-09-593-870A-31	Sequence 31, Appl	175	68	88.3	14	5	PCT-US94-05142-10	Sequence 10, Appl
103	74	96.1	15	2	US-08-455-625-12	Sequence 12, Appl	176	67	87.0	20	1	US-08-257-528B-51	Sequence 51, Appl
104	74	96.1	15	3	US-08-455-685-12	Sequence 12, Appl	177	67	87.0	20	1	US-08-460-602A-51	Sequence 51, Appl
105	74	96.1	15	3	US-08-060-988A-12	Sequence 12, Appl	178	67	87.0	20	1	US-08-463-966A-51	Sequence 51, Appl
106	74	96.1	15	5	PCT-US94-05142-12	Sequence 12, Appl	179	67	87.0	20	1	US-08-465-217A-51	Sequence 51, Appl
107	73	94.8	15	2	US-08-455-625-17	Sequence 17, Appl	180	67	87.0	20	2	US-08-464-329A-51	Sequence 51, Appl
108	73	94.8	15	2	US-08-455-625-23	Sequence 23, Appl	181	67	87.0	20	2	US-08-462-507A-51	Sequence 51, Appl
109	73	94.8	15	3	US-08-455-685-17	Sequence 17, Appl	182	66	85.7	25	3	US-08-467-881A-51	Sequence 14, Appl
110	73	94.8	15	3	US-08-455-685-23	Sequence 23, Appl	183	66	85.7	25	2	US-08-930-917A-14	Sequence 14, Appl
111	73	94.8	15	3	US-08-060-988A-17	Sequence 17, Appl	184	66	85.7	25	2	US-08-493-235-23	Sequence 23, Appl
112	73	94.8	15	3	US-08-060-988A-23	Sequence 23, Appl	185	64	83.1	19	1	US-08-279-906A-19	Sequence 19, Appl
113	73	94.8	15	5	PCT-US94-05142-17	Sequence 17, Appl	186	63	81.8	12	1	US-08-488-252-30	Sequence 30, Appl
114	73	94.8	15	5	PCT-US94-05142-23	Sequence 23, Appl	187	63	81.8	12	1	US-08-488-252-30	Sequence 30, Appl
115	72	93.5	14	2	US-08-455-625-9	Sequence 9, Appl	188	63	81.8	12	5	PCT-US94-02631-52	Sequence 52, Appl
116	72	93.5	14	3	US-08-455-685-9	Sequence 9, Appl	189	63	81.8	12	5	PCT-US95-03236-43	Sequence 43, Appl
117	72	93.5	14	3	US-08-060-988A-9	Sequence 9, Appl	190	62.5	81.2	21	1	US-08-105-483-384	Sequence 384, App
118	72	93.5	14	5	PCT-US94-05142-9	Sequence 9, Appl	191	62.5	81.2	21	1	US-08-709-209-384	Sequence 79, Appl
119	72	93.5	14	5	PCT-US95-03236-29	Sequence 29, Appl	192	62.5	81.2	21	1	US-08-303-275-79	Sequence 384, App
120	72	93.5	14	5	PCT-US95-03236-52	Sequence 52, Appl	193	62.5	81.2	21	1	US-08-458-101-384	Sequence 384, App
121	72	93.5	15	1	US-08-704-170-72	Sequence 72, Appl	194	62	80.5	13	2	US-08-657-392-19	Sequence 19, Appl
122	72	93.5	15	2	US-08-455-625-19	Sequence 19, Appl	195	62	80.5	13	2	US-08-657-392-20	Sequence 20, Appl
123	72	93.5	15	2	US-08-455-625-20	Sequence 20, Appl	196	62	80.5	13	2	US-08-657-392-21	Sequence 21, Appl
124	72	93.5	15	2	US-08-455-625-21	Sequence 21, Appl	197	62	80.5	13	2	US-08-657-392-22	Sequence 22, Appl
125	72	93.5	15	3	US-08-455-685-19	Sequence 19, Appl	198	62	80.5	13	5	PCT-US94-02539-19	Sequence 19, Appl
126	72	93.5	15	3	US-08-455-685-20	Sequence 20, Appl	199	62	80.5	13	5	PCT-US94-02539-20	Sequence 20, Appl
127	72	93.5	15	3	US-08-455-685-21	Sequence 21, Appl	200	62	80.5	13	5	PCT-US94-02539-21	Sequence 21, Appl
128	72	93.5	15	3	US-08-060-988A-19	Sequence 19, Appl	201	62	80.5	13	5	PCT-US94-02539-22	Sequence 22, Appl
129	72	93.5	15	3	US-08-060-988A-20	Sequence 20, Appl	202	62	80.5	13	5	PCT-US94-02539-23	Sequence 23, Appl
130	72	93.5	15	3	US-08-060-988A-21	Sequence 21, Appl	203	62	80.5	13	5	PCT-US94-02539-24	Sequence 24, Appl
131	72	93.5	15	5	PCT-US94-05142-12	Sequence 12, Appl	204	62	80.5	13	5	US-08-973-551-24	Sequence 27, Appl
132	72	93.5	15	5	PCT-US94-05142-20	Sequence 20, Appl	205	62	80.5	23	2	US-08-657-392-27	Sequence 27, Appl
133	72	93.5	15	5	PCT-US94-05142-21	Sequence 21, Appl	206	62	80.5	23	2	US-08-657-392-28	Sequence 28, Appl
134	72	93.5	15	5	PCT-US94-05142-22	Sequence 22, Appl	207	61	79.2	13	2	US-08-111-080-6	Sequence 6, Appl
135	72	93.5	17	1	US-08-257-528B-35	Sequence 35, Appl	208	60	77.9	14	1	US-08-211-980-6	Sequence 6, Appl
136	72	93.5	17	1	US-08-460-602A-35	Sequence 35, Appl	209	60	77.9	14	5	PCT-US92-07111-6	Sequence 6, Appl
137	72	93.5	17	1	US-08-463-966A-35	Sequence 35, Appl	210	60	77.9	14	5	PCT-US93-07967-6	Sequence 6, Appl
138	72	93.5	17	1	US-08-465-217A-35	Sequence 35, Appl	211	60	77.9	14	5	US-08-704-170-73	Sequence 73, Appl
139	72	93.5	17	2	US-08-464-329A-35	Sequence 35, Appl	212	58	75.3	11	1	US-08-704-170-74	Sequence 74, Appl
140	72	93.5	17	2	US-08-462-507A-35	Sequence 35, Appl	213	58	75.3	11	1	PCT-US94-02631-73	Sequence 73, Appl
141	72	93.5	17	2	US-08-467-881A-35	Sequence 35, Appl	214	58	75.3	11	5	PCT-US94-02631-74	Sequence 74, Appl
142	72	93.5	17	5	PCT-US92-06688-13	Sequence 13, Appl	215	58	75.3	13	1	US-08-030-148-5	Sequence 5, Appl
143	71	92.2	15	2	US-08-455-625-13	Sequence 13, Appl	216	58	75.3	13	1	US-08-030-148-5	Sequence 5, Appl
144	71	92.2	15	2	US-08-455-625-15	Sequence 15, Appl	217	58	75.3	13	1	US-07-920-281C-10	Sequence 10, Appl
145	71	92.2	15	2	US-08-455-625-16	Sequence 16, Appl	218	58	75.3	13	1	US-08-466-277-10	Sequence 10, Appl
146	71	92.2	15	2	US-08-455-625-18	Sequence 18, Appl	219	58	75.3	15	4	US-09-688-842-10	Sequence 10, Appl
147	71	92.2	15	2	US-08-455-625-22	Sequence 22, Appl	220	57	74.0	11	5	PCT-US92-06688-14	Sequence 14, Appl
148	71	92.2	15	2	US-08-455-625-22	Sequence 22, Appl	221	57	74.0	11	5	US-08-704-170-70	Sequence 70, Appl
149	71	92.2	15	3	US-08-455-685-11	Sequence 11, Appl	222	57	74.0	15	5	PCT-US94-02631-70	Sequence 70, Appl
150	71	92.2	15	3	US-08-455-685-13	Sequence 13, Appl	223	57	74.0	15	5	US-07-920-281C-12	Sequence 12, Appl
151	71	92.2	15	3	US-08-455-685-15	Sequence 15, Appl	224	57	74.0	17	3	US-08-466-277-12	Sequence 12, Appl
152	71	92.2	15	3	US-08-455-685-16	Sequence 16, Appl	225	57	74.0	17	4	US-08-257-528B-16	Sequence 16, Appl
153	71	92.2	15	3	US-08-455-685-18	Sequence 18, Appl	226	57	74.0	21	1	US-08-460-602A-16	Sequence 16, Appl
154	71	92.2	15	3	US-08-455-685-22	Sequence 22, Appl	227	57	74.0	21	1	US-08-463-966A-16	Sequence 16, Appl
155	71	92.2	15	3	US-08-060-988A-11	Sequence 11, Appl	228	57	74.0	21	1	US-08-465-217A-16	Sequence 16, Appl
156	71	92.2	15	3	US-08-060-988A-13	Sequence 13, Appl	229	57	74.0	21	2	US-08-464-329A-16	Sequence 16, Appl
157	71	92.2	15	3	US-08-060-988A-15	Sequence 15, Appl	230	57	74.0	21	2	US-08-462-507A-16	Sequence 16, Appl
158	71	92.2	15	3	US-08-060-988A-16	Sequence 16, Appl	231	57	74.0	21	2	US-08-467-881A-16	Sequence 16, Appl
159	71	92.2	15	3	US-08-060-988A-18	Sequence 18, Appl	232	57	74.0	21	2	US-08-704-170-71	Sequence 71, Appl
160	71	92.2	15	3	US-08-060-988A-22	Sequence 22, Appl	233	53	68.8	10	1	PCT-US94-02631-71	Sequence 71, Appl
161	71	92.2	15	5	PCT-US94-05142-11	Sequence 11, Appl	234	53	68.8	14	5	US-08-257-528B-36	Sequence 36, Appl
162	71	92.2	15	5	PCT-US94-05142-13	Sequence 13, Appl	235	53	68.8	14	1	US-08-460-602A-36	Sequence 36, Appl
163	71	92.2	15	5	PCT-US94-05142-15	Sequence 15, Appl	236	53	68.8	14	1	US-08-463-966A-36	Sequence 36, Appl
164	71	92.2	15	5	PCT-US94-05142-16	Sequence 16, Appl	237	53	68.8	14	1	US-08-465-217A-36	Sequence 36, Appl
165	71	92.2	15	5	PCT-US94-05142-18	Sequence 18, Appl	238	53	68.8	14	2	US-08-464-329A-36	Sequence 36, Appl
166	71	92.2	15	5	PCT-US94-05142-22	Sequence 22, Appl	239	53	68.8	14	2	US-08-462-507A-36	Sequence 36, Appl
167	69	89.6	15	2	US-08-455-625-14	Sequence 14, Appl	240	53	68.8	14	2	US-08-467-881A-36	Sequence 36, Appl
168	69	89.6	15	3	US-08-455-685-14	Sequence 14, Appl	241	53	68.8	15	2	US-08-218-025A-16	Sequence 16, Appl
169	69	89.6	15	3	US-08-060-988A-14	Sequence 14, Appl	242	53	68.8	15	2	PCT-US92-01303-12	Sequence 12, Appl
170	69	89.6	15	5	PCT-US94-05142-14	Sequence 14, Appl	243	52	67.5	10	4	US-09-820-484-8	Sequence 8, Appl
171	68	88.3	13	1	US-08-279-906A-17	Sequence 17, Appl	244	52	67.5	10	4	US-09-430-470-24	Sequence 24, Appl
172	68	88.3	14	2	US-08-455-625-10	Sequence 10, Appl	245	52	67.5	10	4	US-08-937-276A-5	Sequence 5, Appl
173	68	88.3	14	3	US-08-455-685-10	Sequence 10, Appl	246	52	67.5	10	4		

247 52 67.5 10 4 US-09-454-204A-51 Sequence 51, Appl
248 52 67.5 10 4 US-09-454-204A-68 Sequence 68, Appl
249 52 67.5 10 4 US-09-508-552-16 Sequence 16, Appl
250 52 67.5 10 5 PCT-US92-01303-1 Sequence 1, Appl

ALIGNMENTS

RESULT 1
US-08-336-087-2
; Sequence 2, Application US/08336087
; Patent No. 5503829
; GENERAL INFORMATION:
; APPLICANT: Ladant, Daniel
; APPLICANT: Leclerc, Claude
; APPLICANT: Sebo, Peter
; APPLICANT: Ullmann, Agnes
; TITLE OF INVENTION: Recombinant Mutants for Inducing
; TITLE OF INVENTION: Specific Immune Responses
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Parabow, Garrett &
; ADDRESSEE: Dunner
; STREET: 1300 I Street, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/336,087
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/011,644
; FILING DATE: 29-JAN-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Meyers, Kenneth J.
; REGISTRATION NUMBER: 25,146
; REFERENCE/DOCKET NUMBER: 03495-0109-01000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-408-4000
; TELEFAX: 202-408-4400
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-336-087-2

Query Match 100.0%; Score 77; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQPGGRAFTVIGK 15
DB 1 RIQPGGRAFTVIGK 15

RESULT 2
US-08-218-025A-17
; Sequence 17, Application US/08218025A
; Patent No. 5556744
; GENERAL INFORMATION:
; APPLICANT: Weiner, David B.
; APPLICANT: Ugen, Kenneth E.
; APPLICANT: Williams, William V.

; TITLE OF INVENTION: Methods and Compositions for Diagnosing
; TITLE OF INVENTION: and Treating Certain HIV Infected Patients
; NUMBER OF SEQUENCES: 197
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Howson and Howson
; STREET: P.O. Box 457, 321 No. 5556744ristown Road
; CITY: Spring House
; STATE: Pennsylvania
; COUNTRY: U.S.A.
; ZIP: 19477

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/218,025A
; FILING DATE: 24-MAR-1994
; CLASSIFICATION: 424

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/891,451
; FILING DATE: 29-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Bak, Mary E.
; REGISTRATION NUMBER: 31,215
; REFERENCE/DOCKET NUMBER: WST33A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 540-9206
; TELEFAX: (215) 540-5818
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
US-08-218-025A-17

Query Match 100.0%; Score 77; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQPGGRAFTVIGK 15
DB 1 RIQPGGRAFTVIGK 15

RESULT 3
US-08-709-047-7
; Sequence 7, Application US/08709047
; Patent No. 5652333
; GENERAL INFORMATION:
; APPLICANT: Fung, Michael S.C., Sun, Bill N.C, Sun, Cecily R.Y., Kim, Young W., Yu,
; APPLICANT: Liming
; TITLE OF INVENTION: THE GCLq RECEPTOR, HIV-1 gp120 REGION BINDING THERETO,
; TITLE OF INVENTION: AND RELATED PEPTIDES AND TARGETING ANTIBODIES
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Tanox Biosystems, Inc.
; STREET: 10301 Stella Link Rd.
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77025

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: DOS 3.30
; SOFTWARE: Wordperfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/709,047
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:

Mon May 16 14:51:03 2005

us-08-869-386-1.ra1

APPLICATION NUMBER: US/08/410,360

FILING DATE:

ATTORNEY/AGENT INFORMATION:

NAME: Mirabel, Eric P.

REGISTRATION NUMBER: 31,211

REFERENCE/DOCKET NUMBER: TNX95-1

TELECOMMUNICATION INFORMATION:

TELEPHONE: (713) 664-2288

TELEFAX: (713) 664-8914

INFORMATION FOR SEQ ID NO: 7:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 amino acids

TYPE: amino acid

TOPOLOGY: linear

US-08-709-047-7

Query Match

Best Local Similarity 100.0%; Score 77; DB 1; Length 15;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIORGPGRAFTVIGK 15

|||||

DB 1 RIORGPGRAFTVIGK 15

|||||

RESULT 4

US-08-479-400-2

; Sequence 2, Application US/08479400

; Patent No. 5679784

; GENERAL INFORMATION:

; APPLICANT: Ladant, Daniel

; APPLICANT: Leclerc, Claude

; APPLICANT: Sebo, Peter

; APPLICANT: Ullmann, Agnes

; TITLE OF INVENTION: Recombinant Mutants for Inducing

; TITLE OF INVENTION: Specific Immune Responses

; NUMBER OF SEQUENCES: 7

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &

; ADDRESSEE: Dunner

; STREET: 1300 I Street, N.W.

; CITY: Washington

; STATE: D.C.

; COUNTRY: USA

; ZIP: 20005-3315

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patent In Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/479,400

; FILING DATE: 07-JUN-1995

; CLASSIFICATION: 424

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/011,644

; FILING DATE: 29-JAN-1993

; ATTORNEY/AGENT INFORMATION:

; NAME: Meyers, Kenneth J.

; REGISTRATION NUMBER: 25,146

; REFERENCE/DOCKET NUMBER: 03495-0109-01000

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 202-408-4000

; TELEFAX: 202-408-4400

; INFORMATION FOR SEQ ID NO: 2:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 15 amino acids

; TYPE: amino acid

; TOPOLOGY: linear

; MOLECULE TYPE: peptide

US-08-479-400-2

Query Match

Best Local Similarity 100.0%; Score 77; DB 1; Length 15;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Best Local Similarity 100.0%; Pred. No. 8.5e-06;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIORGPGRAFTVIGK 15

|||||

DB 1 RIORGPGRAFTVIGK 15

|||||

RESULT 5

US-08-410-360-7

; Sequence 7, Application US/08410360

; Patent No. 5691447

; GENERAL INFORMATION:

; APPLICANT: Fung, Michael S.C., Sun, Bill N.C, Sun, Cecily R.Y., Kim, Young W., Yu,

; APPLICANT: Liming

; TITLE OF INVENTION: THE 9CIQ RECEPTOR, HIV-1 gp120 REGION BINDING THERETO,

; TITLE OF INVENTION: AND RELATED PEPTIDES AND TARGETING ANTIBODIES

; NUMBER OF SEQUENCES: 13

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Tanox Biosystems, Inc.

; STREET: 10301 Stella Link Rd.

; CITY: Houston

; STATE: Texas

; COUNTRY: USA

; ZIP: 77025

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette, 3.5 inch

; COMPUTER: IBM PS/2

; OPERATING SYSTEM: DOS 3.30

; SOFTWARE: Wordperfect 5.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/410,360

; FILING DATE:

; CLASSIFICATION: 530

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER:

; FILING DATE:

; ATTORNEY/AGENT INFORMATION:

; NAME: Mirabel, Eric P.

; REGISTRATION NUMBER: 31,211

; REFERENCE/DOCKET NUMBER: TNX95-1

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (713) 664-2288

; TELEFAX: (713) 664-8914

; INFORMATION FOR SEQ ID NO: 7:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 15 amino acids

; TYPE: amino acid

; TOPOLOGY: linear

US-08-410-360-7

Query Match

Best Local Similarity 100.0%; Score 77; DB 1; Length 15;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIORGPGRAFTVIGK 15

|||||

DB 1 RIORGPGRAFTVIGK 15

|||||

RESULT 6

US-08-095-332-1

; Sequence 1, Application US/08095332

; Patent No. 5711947

; GENERAL INFORMATION:

; APPLICANT: Berzofsky, Jay A.

; APPLICANT: Takahashi, Hidemi

; APPLICANT: Germain, Ronald N.

; TITLE OF INVENTION: METHOD TO INDUCE CYTOTOXIC T LYMPHOCYTES

; TITLE OF INVENTION: SPECIFIC FOR A BROAD ARRAY OF HIV-1 ISOLATES USING HYBRID

; NUMBER OF SEQUENCES: 26

; CORRESPONDENCE ADDRESS:

Query Match

Best Local Similarity 100.0%; Pred. No. 8.5e-06;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;


```
/ ADDRESSEE: Birch, Stewart, Kolash & Birch
/ STREET: 301 N. Washington
/ CITY: Falls Church
/ STATE: Virginia
/ COUNTRY: USA
/ ZIP: 22046-0747
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/095,332
/ FILING DATE: 23-JUL-1993
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 07/760,530
/ FILING DATE: 18-SEP-1991
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Svensson, Leonard R.
/ REGISTRATION NUMBER: 30,330
/ REFERENCE/DOCKET NUMBER: 1173-354p
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 703-241-1300
/ TELEFAX: 703-241-2848
/ TELEX: 248345
/ INFORMATION FOR SEQ ID NO: 1:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 amino acids
/ TYPE: amino acid
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
/ FRAGMENT TYPE: Internal
/ ORIGINAL SOURCE:
/ ORGANISM: HIV-1
/ INDIVIDUAL ISOLATE: IIIB
/ FEATURE:
/ NAME/KEY: Peptide
/ LOCATION: 1..15
/ OTHER INFORMATION: /label= peptide
/ OTHER INFORMATION: /note= "synthetic peptide, sequence = residues 315
/ OTHER INFORMATION: to 329 of HIV-1, isolate IIIB, gp160 envelope
/ OTHER INFORMATION: glycoprotein."
/
US-08-095-332-1

Query Match 100.0%; Score 77; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQGGGFAFVTIGK 15
Db 1 RIQGGGFAFVTIGK 15

RESULT 7
US-08-707-801A-7
; Sequence 7, Application US/08707801A
; Patent No. 5728814
; GENERAL INFORMATION:
; APPLICANT: Fung, Michael S.C., Sun, Bill N.C, Sun, Cecily R.Y., Yu,
; APPLICANT: Liming
; TITLE OF INVENTION: THE GC1q RECEPTOR, HIV-1 gp120 REGION BINDING
; TITLE OF INVENTION: AND RELATED PEPTIDES AND TARGETING ANTIBODIES
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Tanox Biosystems, Inc.
; STREET: 10301 Stella Link Rd.
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch
/
COMPUTER: IBM PS/2
/ OPERATING SYSTEM: DOS 3.30
/ SOFTWARE: Wordperfect 5.1
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/709,006
/ FILING DATE: 09-SEP-1996
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/410,360
/ FILING DATE: 24-MAR-1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Mirabel, Eric P.
/ REGISTRATION NUMBER: 31,211
/ REFERENCE/DOCKET NUMBER: TNX95-1
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (713) 664-2288
/ TELEFAX: (713) 664-8914
/ INFORMATION FOR SEQ ID NO: 7:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 amino acids
/ MEDIUM TYPE: Diskette, 3.5 inch

Qy 1 RIQGGGFAFVTIGK 15
Db 1 RIQGGGFAFVTIGK 15

RESULT 8
US-08-709-006-7
; Sequence 7, Application US/08709006
; Patent No. 5731428
; GENERAL INFORMATION:
; APPLICANT: Fung, Michael S.C., Sun, Bill N.C, Sun, Cecily R.Y.,
; APPLICANT: Kim, Young W., Yu, Liming
; TITLE OF INVENTION: THE GC1q RECEPTOR, HIV-1 gp120 REGION BINDING
; TITLE OF INVENTION: THERETO, AND RELATED PEPTIDES AND TARGETING
; TITLE OF INVENTION: ANTIBODIES
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Tanox Biosystems, Inc.
; STREET: 10301 Stella Link Rd.
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch
/
COMPUTER: IBM PS/2
/ OPERATING SYSTEM: DOS 3.30
/ SOFTWARE: Wordperfect 5.1
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/709,006
/ FILING DATE: 09-SEP-1996
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/410,360
/ FILING DATE: 24-MAR-1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Mirabel, Eric P.
/ REGISTRATION NUMBER: 31,211
/ REFERENCE/DOCKET NUMBER: TNX95-1
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (713) 664-2288
/ TELEFAX: (713) 664-8914
/ INFORMATION FOR SEQ ID NO: 7:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 amino acids
```

```
/ COMPUTER: IBM PS/2
/ OPERATING SYSTEM: DOS 3.30
/ SOFTWARE: Wordperfect 5.1
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/707,801A
/ FILING DATE: 09/04/1996
/ CLASSIFICATION: 530
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/410,360
/ FILING DATE: 03/24/1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Mirabel, Eric P.
/ REGISTRATION NUMBER: 31,211
/ REFERENCE/DOCKET NUMBER: TNX95-1AA
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (713) 664-2288
/ TELEFAX: (713) 664-8914
/ INFORMATION FOR SEQ ID NO: 7:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 amino acids
/ TYPE: amino acid
/ TOPOLOGY: linear
/
US-08-707-801A-7

Query Match 100.0%; Score 77; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQGGGFAFVTIGK 15
Db 1 RIQGGGFAFVTIGK 15

RESULT 8
US-08-709-006-7
; Sequence 7, Application US/08709006
; Patent No. 5731428
; GENERAL INFORMATION:
; APPLICANT: Fung, Michael S.C., Sun, Bill N.C, Sun, Cecily R.Y.,
; APPLICANT: Kim, Young W., Yu, Liming
; TITLE OF INVENTION: THE GC1q RECEPTOR, HIV-1 gp120 REGION BINDING
; TITLE OF INVENTION: THERETO, AND RELATED PEPTIDES AND TARGETING
; TITLE OF INVENTION: ANTIBODIES
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Tanox Biosystems, Inc.
; STREET: 10301 Stella Link Rd.
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch
/
COMPUTER: IBM PS/2
/ OPERATING SYSTEM: DOS 3.30
/ SOFTWARE: Wordperfect 5.1
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/709,006
/ FILING DATE: 09-SEP-1996
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/410,360
/ FILING DATE: 24-MAR-1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Mirabel, Eric P.
/ REGISTRATION NUMBER: 31,211
/ REFERENCE/DOCKET NUMBER: TNX95-1
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (713) 664-2288
/ TELEFAX: (713) 664-8914
/ INFORMATION FOR SEQ ID NO: 7:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 amino acids
```

;
; TYPE: amino acid
; TOPOLOGY: linear
US-08-709-006-7

Query Match 100.0%; Score 77; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRPGRFVTVIGK 15
| | | | | | | | | | | | | | |
Db 1 RIQRPGRFVTVIGK 15

RESULT 9
US-08-711-175-7
; Sequence 7, Application US/08711175
; Patent No. 5739306
; GENERAL INFORMATION:
; APPLICANT: Fung, Michael S.C., Sun, Bill N.C, Sun, Cecily R.Y.,
; APPLICANT: Kim, Young W., Yu, Liming
; TITLE OF INVENTION: THE SC1Q RECEPTOR, HIV-1 GP120 REGION BINDING
; TITLE OF INVENTION: THERETO, AND RELATED PEPTIDES AND TARGETING
; TITLE OF INVENTION: ANTIBODIES
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Tanox Biosystems, Inc.
; STREET: 10301 Stella Link Rd.
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: DOS 3.30
; SOFTWARE: Wordperfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/711,175
; FILING DATE: 09-SEP-1996
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/410,360
; FILING DATE: 24-MAR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Mirabel, Eric P.
; REGISTRATION NUMBER: 31,211
; REFERENCE/DOCKET NUMBER: TNX95-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (713) 664-2288
; TELEFAX: (713) 664-8914
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acid
; TYPE: amino acid
; TOPOLOGY: linear
US-08-711-175-7

Query Match 100.0%; Score 77; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRPGRFVTVIGK 15
| | | | | | | | | | | | | | |
Db 1 RIQRPGRFVTVIGK 15

RESULT 10
US-08-488-252-27
; Sequence 27, Application US/08488252
; Patent No. 5763160
; GENERAL INFORMATION:
; APPLICANT: Chang Yi Wang
; TITLE OF INVENTION: SYNTHETIC PEPTIDES AND PROCESS

;
; TITLE OF INVENTION: OF USING SAME FOR THE DETECTION OF ANTIBODIES TO
; TITLE OF INVENTION: HUMAN IMMUNODEFICIENCY VIRUS (HIV) GP120 ENVELOPE
; TITLE OF INVENTION: PROTEIN, DIAGNOSIS OF AIDS AND PRE-AIDS CONDITIONS
; TITLE OF INVENTION: AND AS VACCINES
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORGAN & FINNEGAN
; STREET: 345 PARK AVE.
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10154
; COMPUTER READABLE FORM:
; MEDIUM TYPE: FLOPPY DISK
; COMPUTER: IBM PC COMPATIBLE
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/488,252
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08\326,676
; FILING DATE: 07-Jun-1995
; APPLICATION NUMBER: 07\726,605
; FILING DATE: 09-July-1991
; APPLICATION NUMBER: 07\663,262
; FILING DATE: 01-Mar-1991
; APPLICATION NUMBER: 07\155,321
; FILING DATE: 12-Feb-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Maria C. H. Lin
; REGISTRATION NUMBER: 29,323
; REFERENCE/DOCKET NUMBER: 1151-4004 USA
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-758-4800
; TELEFAX: (212) 751-6849
; TELEX: 421792
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: Amino acids
; STRANDEDNESS:
; TOPOLOGY: Unknown
US-08-488-252-27

Query Match 100.0%; Score 77; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRPGRFVTVIGK 15
| | | | | | | | | | | | | | |
Db 1 RIQRPGRFVTVIGK 15

RESULT 11
US-08-021-879-2
; Sequence 2, Application US/08021879
; Patent No. 5817767
; GENERAL INFORMATION:
; APPLICANT: Graham P. Allaway
; APPLICANT: Paul J. Maddon
; TITLE OF INVENTION: SYNERGISTIC COMPOSITION OF CD4-BASED
; TITLE OF INVENTION: PROTEIN AND ANTI-HIV-1 ANTIBODY, AND
; TITLE OF INVENTION: METHODS OF USING SAME
; NUMBER OF SEQUENCES: 2
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cooper & Dunham
; STREET: 30 Rockefeller Plaza
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10112

```
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.24
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/021,879
; FILING DATE: 24-FEB-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: White, John P.
; REGISTRATION NUMBER: 28,678
; REFERENCE/DOCKET NUMBER: 41189/JPW/AJM
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 664-0525
; TELEFAX: (212) 664-0525
; TELEX: 422523 COOPUI
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
;
US-08-021-879-2

Query Match 100.0%; Score 77; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTVIGK 15
Db 1 RIQPGGRAFTVIGK 15

RESULT 12
US-07-760-530-1
; Sequence 1, Application US/07760530
; Patent No. 5820865
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Takahashi, Hidemi
; APPLICANT: Germain, Ronald N.
; TITLE OF INVENTION: METHOD TO INDUCE CYTOTOXIC T LYMPHOCYTES
; TITLE OF INVENTION: SPECIFIC FOR A BROAD ARRAY OF HIV-1 ISOLATES USING HYBRID
; TITLE OF INVENTION: SYNTHETIC PEPTIDES
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolash & Birch
; STREET: 301 N. Washington
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22046-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/760,530
; FILING DATE: 19910918
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Svensson, Leonard R.
; REGISTRATION NUMBER: 30,330
; REFERENCE/DOCKET NUMBER: 1173-354p
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-241-1300
; TELEFAX: 703-241-2848
; TELEX: 248345
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
```

```
;
; TYPE: AMINO ACID
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: HIV-1
; INDIVIDUAL ISOLATE: IIB
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..15
; OTHER INFORMATION: /label= peptide
; OTHER INFORMATION: /note= "synthetic peptide, sequence = residues 315
; OTHER INFORMATION: to 329 of HIV-1, isolate IIB, gp160 envelope
; OTHER INFORMATION: glycoprotein."
;
US-07-760-530-1

Query Match 100.0%; Score 77; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTVIGK 15
Db 1 RIQPGGRAFTVIGK 15

RESULT 13
US-07-950-571A-3
; Sequence 3, Application US/07950571A
; Patent No. 5854400
; GENERAL INFORMATION:
; APPLICANT: Chang, Tse Wen, Fung, Michael S.C., Sun, Bill N.C., Sun, Cecily R.Y.,
; APPLICANT: Chang, Nancy T.
; TITLE OF INVENTION: Monoclonal Antibodies which Neutralize HIV-1 Infection
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Tanox Biosystems, Inc.
; STREET: 10301 Stella Link Rd.
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Hi Density Diskette
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: DOS, Version 3.30
; SOFTWARE: Wordperfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/950,571A
; FILING DATE: 19920922
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: No. 5854400 07/767,533
; FILING DATE: 09/26/1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Mirabel, Eric P.
; REGISTRATION NUMBER: 31,211
; REFERENCE/DOCKET NUMBER: TNX87-11BBC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713-664-2288
; TELEFAX: 713-664-8914
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: AMINO ACID
; TOPOLOGY: Linear
;
US-07-950-571A-3

Query Match 100.0%; Score 77; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTVIGK 15
```

Db 1 RIORGPGRAFTVIGK 15

RESULT 14
US-08-975-699-6 Application US/08975699
; Sequence 6, Application US/08975699
; Patent No. 5858369
; GENERAL INFORMATION:
; APPLICANT: MATSUO, KAZUHIRO
; APPLICANT: CHUJO, YOSHITOMO
; APPLICANT: YAMAZAKI, AKIHIRO
; APPLICANT: HONDA, MITSUO
; APPLICANT: TASAKA, HIROMICHI
; APPLICANT: YAMAKAZI, SHUDO
; TITLE OF INVENTION: ANTI-AIDS SECRETORY RECOMBINANT BCG
; TITLE OF INVENTION: VACCINE
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
; STREET: 1755 S. JEFFERSON DAVIS HIGHWAY, SUITE 400
; CITY: ARLINGTON
; STATE: VA
; COUNTRY: USA
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/975.699
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/619,512
; FILING DATE: 29-MAR-1996
; APPLICATION NUMBER: PCT/JP95/01515
; FILING DATE: 31-JUL-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 178462/1994
; FILING DATE: 29-JUL-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: OBLON, NORMAN F.
; REGISTRATION NUMBER: 24,618
; REFERENCE/DOCKET NUMBER: 10-795-0X PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-413-3000
; TELEFAX: 703-413-2220
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; ORIGINAL SOURCE:
; ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
; STRAIN: HIV-1 (JAPAN)
US-08-975-699-6

Query Match 100.0%; Score 77; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIORGPGRAFTVIGK 15
Db 1 RIORGPGRAFTVIGK 15

RESULT 16
US-08-455-625-7 Application US/08455625
; Sequence 7, Application US/08455625
; Patent No. 5932218
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. D.
; APPLICANT: Nara, Peter

Db 1 RIORGPGRAFTVIGK 15

RESULT 15
US-08-972-089-6 Application US/08972089
; Sequence 6, Application US/08972089

APPLICANT: Shirai, Mutunori
TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,625
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1:15
OTHER INFORMATION: /label= peptide
OTHER INFORMATION: /note= "p1811B peptide, see Table V"
US-08-455-625-7
Query Match 100.0%; Score 77; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 RIQGGPGRFVTIGK 15
Db 1 RIQGGPGRFVTIGK 15
RESULT 17
US-08-395-204-2
Sequence 2, Application US/08395204
Patent No. 5915580
GENERAL INFORMATION:
APPLICANT: Ladtant, Daniel
APPLICANT: Leclerc, Claude
APPLICANT: Sebo, Peter
APPLICANT: Ullmann, Agnes
TITLE OF INVENTION: Recombinant Mutants for Inducing
TITLE OF INVENTION: Specific Immune Responses
NUMBER OF SEQUENCES: 5
CORRESPONDENCE ADDRESS:
ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
ADDRESSEE: Dunner
STREET: 1300 I Street, N.W.
CITY: Washington
STATE: D.C.
COUNTRY: USA

ZIP: 20005-3315
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/395,204
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION NUMBER: US 07/871,795
FILING DATE: 21-APR-1992
ATTORNEY/AGENT INFORMATION:
NAME: Meyers, Kenneth J.
REGISTRATION NUMBER: 25,146
REFERENCE/DOCKET NUMBER: 03495-0109-00000
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-408-4000
TELEFAX: 202-408-4400
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-395-204-2
Query Match 100.0%; Score 77; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 RIQGGPGRFVTIGK 15
Db 1 RIQGGPGRFVTIGK 15
RESULT 18
US-08-628-687-1
Sequence 1, Application US/08628687
Patent No. 5939277
GENERAL INFORMATION:
APPLICANT: Rakowicz-Szulczynska, Eva M.
TITLE OF INVENTION: DETECTION AND TREATMENT OF BREAST AND
TITLE OF INVENTION: GYNECOLOGICAL CANCER
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: FISH & NEAVE
STREET: 1251 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10020
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/628,687
FILING DATE: 14-JUN-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/138,141
FILING DATE: 15-OCT-1993
ATTORNEY/AGENT INFORMATION:
NAME: Haley Jr., James F.
REGISTRATION NUMBER: 27,794
REFERENCE/DOCKET NUMBER: APPOLLO/1CIP1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-596-9000
TELEFAX: 212-596-9090
INFORMATION FOR SEQ ID NO: 1:

```
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: internal
;
US-08-628-687-1
Query Match 100.0%; Score 77; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRPGRGFAVTIGK 15
Db 1 RIQRPGRGFAVTIGK 15

RESULT 19
US-07-847-311A-1
; Sequence 1, Application US/07847311A
; Patent No. 5976541
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Takehita, Toshiyuki
; APPLICANT: Shirai, Mutsunori
; APPLICANT: Pendleton, C.D.
; APPLICANT: Koslowski, Steven
; APPLICANT: Margulies, David H.
; TITLE OF INVENTION: Potent Peptide for Stimulation of
; TITLE OF INVENTION: Cytotoxic T Lymphocytes Specific for the HIV-I Envelope
; NUMBER OF SEQUENCES: 20
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolash & Birch
; STREET: 301 N. Washington
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22046-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/847,311A
; FILING DATE: 06-MAR-1992
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Svensson, Leonard R.
; REGISTRATION NUMBER: 30,330
; REFERENCE/DOCKET NUMBER: 1173-392P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-241-1300
; TELEFAX: 703-241-2848
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: Human Immunodeficiency Virus Type I
; STRAIN: IIIB
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..15
; OTHER INFORMATION: /label= peptide
; OTHER INFORMATION: /note= "Cytotoxic T lymphocyte immunodominant
```

```
; OTHER INFORMATION: peptide of HIV-I envelope glycoprotein from strain
; OTHER INFORMATION: IIIB; activatable by protease cleavage to core
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 4..13
; OTHER INFORMATION: /label= peptide
; OTHER INFORMATION: /note= "Highly immunogenic core peptide from
; OTHER INFORMATION: immunodominant region of envelope glycoprotein of
; OTHER INFORMATION: HIV-I strain IIIB; peptide p18-I-10"
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 5..13
; OTHER INFORMATION: /label= peptide
; OTHER INFORMATION: /note= "peptide p18-I-9"
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 4..12
; OTHER INFORMATION: /label= peptide
; OTHER INFORMATION: /note= "peptide p18-T-9"
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 3..11
; OTHER INFORMATION: /label= peptide
; OTHER INFORMATION: /note= "peptide p18-V-9"
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 2..11
; OTHER INFORMATION: /label= peptide
; OTHER INFORMATION: /note= "peptide p18-V-10"
;
US-07-847-311A-1
Query Match 100.0%; Score 77; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRPGRGFAVTIGK 15
Db 1 RIQRPGRGFAVTIGK 15

RESULT 20
US-08-986-234-13
; Sequence 13, Application US/08986234
; Patent No. 5981706
; GENERAL INFORMATION:
; APPLICANT: Wallen, et al.
; TITLE OF INVENTION: Methods for Synthesizing Heat Shock Protein Complexes
; FILE REFERENCE: UNME-0008-1
; CURRENT APPLICATION NUMBER: US/08/986,234
; CURRENT FILING DATE: 1997-12-05
; NUMBER OF SEQ ID NOS: 114
; SOFTWARE: Patent in Ver. 2.0
; SEQ ID NO 13
; LENGTH: 15
; TYPE: PPT
; ORGANISM: Human immunodeficiency virus
;
US-08-986-234-13
Query Match 100.0%; Score 77; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRPGRGFAVTIGK 15
Db 1 RIQRPGRGFAVTIGK 15

RESULT 21
US-08-986-234-28
; Sequence 28, Application US/08986234
; Patent No. 5981706
; GENERAL INFORMATION:
; APPLICANT: Wallen, et al.
```

; TITLE OF INVENTION: Methods for Synthesizing Heat Shock Protein Complexes
; FILE REFERENCE: UNNE-0008-1
; CURRENT APPLICATION NUMBER: US/08/986,234
; CURRENT FILING DATE: 1997-12-05
; NUMBER OF SEQ ID NOS: 114
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 28
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Human immunodeficiency virus
US-08-986-234-28

Query Match 100.0%; Score 77; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTVIGK 15
| | | | | | | | | | | | | | |
Db 1 RIQPGGRAFTVIGK 15

RESULT 22
US-08-492-076-22
; Sequence 22, Application US/08492076A
; Patent No. 6060064
; GENERAL INFORMATION:
; APPLICANT: Adams, Sally E.
; APPLICANT: Burus, Nigel R.
; APPLICANT: Richardson, Simon M.
; TITLE OF INVENTION: No. 6060064el Proteinaceous Particles
; FILE REFERENCE: 10180.60968
; CURRENT APPLICATION NUMBER: US/08/492,076A
; CURRENT FILING DATE: 1995-06-28
; EARLIER APPLICATION NUMBER: PCT/GB93/02656
; EARLIER FILING DATE: 1993-12-24
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 22
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Human immunodeficiency virus type 1
US-08-492-076-22

Query Match 100.0%; Score 77; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTVIGK 15
| | | | | | | | | | | | | | |
Db 1 RIQPGGRAFTVIGK 15

RESULT 23
US-08-493-071-25
; Sequence 25, Application US/08493071
; Patent No. 6127149
; GENERAL INFORMATION:
; APPLICANT: Hirai, Yohei
; APPLICANT: Koshida, Shogo
; APPLICANT: Oka, Yumiko
; TITLE OF INVENTION: MODIFIED EPIMORPHIN
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LOWE, PRICE, LEBLANC & BECKER
; STREET: 99 CANAL CENTER PLAZA, SUITE 300
; CITY: ALEXANDRIA
; STATE: VA
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/493,071
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Price, Robert L.
; REGISTRATION NUMBER: 22,685
; REFERENCE/DOCKET NUMBER: 715-107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-684-1111
; TELEFAX: 703-684-1124
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-493-071-25

Query Match 100.0%; Score 77; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTVIGK 15
| | | | | | | | | | | | | | |
Db 1 RIQPGGRAFTVIGK 15

RESULT 24
US-08-480-332-1
; Sequence 1, Application US/08480332
; Patent No. 6180134
; GENERAL INFORMATION:
; APPLICANT: Zalipsky, Samuel; Woodle, Martin; Francis;
; APPLICANT: Barenholz, Yecheskel
; TITLE OF INVENTION: Enhanced Circulation Effector Composition and
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dehlinger & Associates
; STREET: 350 Cambridge Avenue, Suite 250
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94306
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/480,332
; FILING DATE: 7-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/316,436
; FILING DATE: 29-SEP-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/035,443
; FILING DATE: 23-MAR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Mohr, Judy M.
; REGISTRATION NUMBER: 38,563
; REFERENCE/DOCKET NUMBER: 5325-0115.31
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 324-0880
; TELEFAX: (415) 324-0960
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid

```

; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; INDIVIDUAL ISOLATE: Peptide 1, Fig. 13
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..15
; US-08-480-332-1

Query Match      100.0%; Score 77; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGFAFVTIGK 15
Db 1 RIQPGGFAFVTIGK 15

RESULT 25
US-08-455-685-7
; Sequence 7, Application US/08455685
; Patent No. 6214347
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. David
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
; TITLE OF INVENTION: HELPER T-LYMPHOCYTE AND
; TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FASTSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/455,685
; FILING DATE: 31-MAY-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/060,988
; FILING DATE: 14-MAY-1993
; FILING DATE: 07/847,311
; FILING DATE: 06-MAR-1992
; APPLICATION NUMBER: 07/751,998
; FILING DATE: 29-AUG-1991
; APPLICATION NUMBER: 07/148,692
; FILING DATE: 26-JAN-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Beattie, Ingrid A.
; REGISTRATION NUMBER: P-42,306
; REFERENCE/DOCKET NUMBER: 08830/022003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-480-332-1

Query Match      100.0%; Score 77; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGFAFVTIGK 15
Db 1 RIQPGGFAFVTIGK 15

; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; INDIVIDUAL ISOLATE: Peptide 1, Fig. 13
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..15
; US-08-480-332-1

Query Match      100.0%; Score 77; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGFAFVTIGK 15
Db 1 RIQPGGFAFVTIGK 15

RESULT 26
US-08-060-988A-7
; Sequence 7, Application US/08060988A
; Patent No. 6294322
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. David
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
; TITLE OF INVENTION: THAT ELICIT
; TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
; TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FASTSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/060,988A
; FILING DATE: 14-MAY-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/847,311
; FILING DATE: 06-MAR-1992
; APPLICATION NUMBER: 07/751,998
; FILING DATE: 29-AUG-1991
; APPLICATION NUMBER: 07/148,692
; FILING DATE: 26-JAN-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Beattie, Ingrid A.
; REGISTRATION NUMBER: P-42,306
; REFERENCE/DOCKET NUMBER: 08830/022001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-060-988A-7

Query Match      100.0%; Score 77; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGFAFVTIGK 15
Db 1 RIQPGGFAFVTIGK 15
```

```

US-08-455-685-7

Query Match      100.0%; Score 77; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGFAFVTIGK 15
Db 1 RIQPGGFAFVTIGK 15

RESULT 26
US-08-060-988A-7
; Sequence 7, Application US/08060988A
; Patent No. 6294322
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. David
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
; TITLE OF INVENTION: THAT ELICIT
; TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
; TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FASTSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/060,988A
; FILING DATE: 14-MAY-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/847,311
; FILING DATE: 06-MAR-1992
; APPLICATION NUMBER: 07/751,998
; FILING DATE: 29-AUG-1991
; APPLICATION NUMBER: 07/148,692
; FILING DATE: 26-JAN-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Beattie, Ingrid A.
; REGISTRATION NUMBER: P-42,306
; REFERENCE/DOCKET NUMBER: 08830/022001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-060-988A-7

Query Match      100.0%; Score 77; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGFAFVTIGK 15
Db 1 RIQPGGFAFVTIGK 15
```


RESULT 27

US-09-051-006-8
; Sequence 8, Application US/09051006
; Patent No. 6380359
; GENERAL INFORMATION:
; APPLICANT: Mogam Biotechnology Research Institute
; APPLICANT: Kim, Tae-Young
; APPLICANT: Lee, Ki-Young
; APPLICANT: Chang, Jin-Soo
; APPLICANT: Cho, Sung-Yoo
; APPLICANT: Hwang, Yu-Kyeong
; APPLICANT: Choi, Myeong
; APPLICANT: Cheong, Hong-Seok
; TITLE OF INVENTION: Liposomes Comprising Peptide Antigens
; TITLE OF INVENTION: Derived from X Protein of Hepatitis B virus
; FILE REFERENCE: 0136/0E154
; CURRENT APPLICATION NUMBER: US/09/051,006
; CURRENT FILING DATE: 1998-03-30
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 15
; TYPE: PRT
; ORGANISM: HIV
US-09-051-006-8

Query Match 100.0%; Score 77; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06; Mismatches 0; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTVIGK 15

Db 1 RIQPGGRAFTVIGK 15

|||||

RESULT 28

US-09-389-390-1
; Sequence 1, Application US/09389390
; Patent No. 6558961
; GENERAL INFORMATION:
; APPLICANT: SARPHIE
; TITLE OF INVENTION: IMMUNODIAGNOSTICS USING PARTICLE DELIVERY METHODS
; FILE REFERENCE: OPF1620
; CURRENT APPLICATION NUMBER: US/09/389,390
; CURRENT FILING DATE: 1999-09-03
; PRIOR APPLICATION NUMBER: 60/099,261
; PRIOR FILING DATE: 1998-09-04
; PRIOR APPLICATION NUMBER: 60/139,045
; PRIOR FILING DATE: 1999-06-10
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:synthetic
; OTHER INFORMATION: construct
US-09-389-390-1

Query Match 100.0%; Score 77; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06; Mismatches 0; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTVIGK 15

Db 1 RIQPGGRAFTVIGK 15

|||||

RESULT 29

US-09-508-552-15
; Sequence 15, Application US/09508552
; Patent No. 6749856

; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Belyakov, Igor M.
; APPLICANT: Derby, Michael A.
; APPLICANT: Keleall, Brian L.
; APPLICANT: Strober, Warren
; APPLICANT: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as
; TITLE OF INVENTION: MUCOSAL CYTOTOXIC T LYMPHOCYTE RESPONSES
; FILE REFERENCE: 368200PCSEQ
; CURRENT APPLICATION NUMBER: US/09/508,552
; CURRENT FILING DATE: 2000-06-12
; PRIOR APPLICATION NUMBER: 60/058,523
; PRIOR FILING DATE: 1997-09-11
; PRIOR APPLICATION NUMBER: 60/074,894
; PRIOR FILING DATE: 1998-02-17
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 15
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Human immunodeficiency virus type 1
US-09-508-552-15

Query Match 100.0%; Score 77; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06; Mismatches 0; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTVIGK 15

Db 1 RIQPGGRAFTVIGK 15

|||||

RESULT 30

US-09-827-688-9
; Sequence 9, Application US/09827688
; Patent No. 6821955
; GENERAL INFORMATION:
; APPLICANT: ORSON, FRANK
; APPLICANT: KINSEY, BERMA
; APPLICANT: BHOGAL, BALBIR
; TITLE OF INVENTION: MACROAGGREGATED PROTEIN CONJUGATES AS ORAL GENETIC IMMUNIZATION DI
; FILE REFERENCE: P01949US1/10004014
; CURRENT APPLICATION NUMBER: US/09/827,688
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: 60/195,680
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9
; LENGTH: 15
; TYPE: PRT
; ORGANISM: HIV p18
US-09-827-688-9

Query Match 100.0%; Score 77; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.5e-06; Mismatches 0; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTVIGK 15

Db 1 RIQPGGRAFTVIGK 15

|||||

RESULT 31

PCT-US92-10378-1
; Sequence 1, Application PC/TUS9210378
; GENERAL INFORMATION:
; APPLICANT: BOARD OF REGENTS, THE UNIVERSITY OF
; APPLICANT: TEXAS SYSTEM
; APPLICANT: SASTRY, Jagannadha K.
; APPLICANT: ARLINGHAUS, Ralph B.
; APPLICANT: PLATSOUKAS, Chris D.


```
; ATTORNEY/AGENT INFORMATION:
; NAME: Wong, Wean Khing
; REGISTRATION NUMBER: 33,561
; REFERENCE/DOCKET NUMBER: 5324.US.P1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (708) 938-3517
; TELEFAX: (708) 938-2623
; TELEX:
; INFORMATION FOR SEQ ID NO: 28:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 amino acid residues
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
; ORIGINAL SOURCE:
; ORGANISM:
; US-08-657-392-28

Query Match 100.0%; Score 77; DB 2; Length 16;
Best Local Similarity 100.0%; Pred. No. 9.1e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQGPGRGFAVTIGK 15
Db 2 RIQGPGRGFAVTIGK 16

RESULT 34
US-08-251-472-2
; Sequence 2, Application US/08251472
; Patent No. 5871746
; GENERAL INFORMATION:
; APPLICANT: BOUTILLON, CHRISTOPHE; MARTINON,
; APPLICANT: FREDERIC; GRAS-MASSE, HELENE;
; APPLICANT: COMARD, ELISABETH; SERGHERAERT,
; APPLICANT: CHRISTIAN; MAGNE, REMY; TARTAR,
; APPLICANT: ANDRE; LEVY, JEAN-PAUL
; TITLE OF INVENTION: CYTOTOXIC T LYMPHOCYTE
; INDUCING LIPOPEPTIDES AND USE AS VACCINES
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BIERMAN & MUSERLIAN
; STREET: 600 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10016
; COMPUTER READABLE FORM:
; MEDIUM TYPE: FLOPPY DISK
; COMPUTER: IBM PC COMPATIBLE
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/251.472
; FILING DATE: 31-MAY-1994
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: MUSERLIAN, CHARLES A
; REGISTRATION NUMBER: 19,683
; REFERENCE/DOCKET NUMBER: 102.1511
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 661-8000
; TELEFAX: (212) 661-8002
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16
; TYPE: amino acid
; STRANDEDNESS: unknown
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:

; ATTORNEY/AGENT INFORMATION:
; NAME: Wong, Wean Khing
; REGISTRATION NUMBER: 33,561
; REFERENCE/DOCKET NUMBER: 5324.US.P1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (708) 938-3517
; TELEFAX: (708) 938-2623
; TELEX:
; INFORMATION FOR SEQ ID NO: 28:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 amino acid residues
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
; ORIGINAL SOURCE:
; ORGANISM:
; US-08-657-392-28

Query Match 100.0%; Score 77; DB 2; Length 16;
Best Local Similarity 100.0%; Pred. No. 9.1e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQGPGRGFAVTIGK 15
Db 2 RIQGPGRGFAVTIGK 16

RESULT 35
US-08-484-905-35
; Sequence 35, Application US/08484905
; Patent No. 5976551
; GENERAL INFORMATION:
; APPLICANT: Mottez, Estelle
; APPLICANT: Abastado, Jean-Pierre
; APPLICANT: Kourilsky, Philippe
; TITLE OF INVENTION: An Altered Major Histocompatibility
; COMPLEX (MHC) Determinant and Methods for Using the
; COMPLEX
; TITLE OF INVENTION: Determinant
; NUMBER OF SEQUENCES: 127
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; DUNN
; STREET: 1300 I Street, N.W., Suite 700
; CITY: Washington
; STATE: D.C.
; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy Disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS-/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/484,905
; FILING DATE: 07-JUNE-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION NUMBER: US 07/801,818
; FILING DATE: 05-DEC-1991
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/792,473
; FILING DATE: 15-NOV-1991
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Potter, Jane E. R.
; REGISTRATION NUMBER: 33,332
; REFERENCE/DOCKET NUMBER: 03495.0106-03000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-408-4000
; TELEFAX: 202-408-4400
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-484-905-35

Query Match 100.0%; Score 77; DB 2; Length 16;
Best Local Similarity 100.0%; Pred. No. 9.1e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQGPGRGFAVTIGK 15
Db 2 RIQGPGRGFAVTIGK 16
```

```

CORRESPONDENCE ADDRESS:
ADDRESSEE: BIERMAN & MUSERLIAN
STREET: 600 THIRD AVENUE
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10016
COMPUTER READABLE FORM:
MEDIUM TYPE: FLOPPY DISK
COMPUTER: IBM PC COMPATIBLE
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: ASCII
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/248,082
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/251,472
FILING DATE: 31-MAY-1994
ATTORNEY/AGENT INFORMATION:
NAME: MUSERLIAN CHARLES A
REGISTRATION NUMBER: 19,683
REFERENCE/DOCKET NUMBER: 102,1511
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 661-8000
TELEFAX: (212) 661-8002
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 16
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: HIV-1
FEATURE:
LOCATION: ENV 312-327
US-09-248-082-2
Query Match 100.0%; Score 77; DB 3; Length 16;
Best Local Similarity 100.0%; Prod. No. 9.1e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0
QY 1 RIQGPGRFAFTVIGK 15
Db 2 RIQGPGRFAFTVIGK 16
RESULT 38
US-08-370-476-35
Sequence 35, Application US/08370476
Patent No. 6153408
GENERAL INFORMATION:
APPLICANT: Mottez, Estelle
APPLICANT: Abastado, Jean-Pierre
APPLICANT: Kourilsky, Philippe
APPLICANT: Lone, Yu-Chun
APPLICANT: Ojcius, David
APPLICANT: Castrouge, Armanda
TITLE OF INVENTION: Altered Major Histocompatibility Complex
TITLE OF INVENTION:
NUMBER OF SEQUENCES: 127
CORRESPONDENCE ADDRESS:
ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
ADDRESS: Dunner
STREET: 1300 I Street, N.W., Suite 700
CITY: Washington
STATE: D.C.
ZIP: 20005-3315
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible

```

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/370,476
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/117,575
FILING DATE: 07-SEP-1993
APPLICATION NUMBER: US 08/072,787
FILING DATE: 06-JUN-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/801,818
FILING DATE: 05-DEC-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/792,473
FILING DATE: 15-NOV-1991
ATTORNEY/AGENT INFORMATION:
NAME: Meyers, Kenneth J.
REGISTRATION NUMBER: 25,146
REFERENCE/DOCKET NUMBER: 05243.0001-01000
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-408-4000
TELEFAX: 202-408-4400
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-370-476-35

Query Match 100.0%; Score 77; DB 3; Length 16;
Best Local Similarity 100.0%; Pred. No. 9.1e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQPGGRAFTVIGK 15
|||
DB 2 RIQPGGRAFTVIGK 16

RESULT 39
US-08-992-877-15
Sequence 15, Application US/08992877
Patent No. 6340461
GENERAL INFORMATION:
APPLICANT: Terman, David S
TITLE OF INVENTION: SUPERANTIGEN BASED METHODS AND COMPOSITIONS FOR
FILE REFERENCE: superantigen
CURRENT APPLICATION NUMBER: US/08/992,877
CURRENT FILING DATE: 1997-12-17
PRIOR APPLICATION NUMBER: 60/044,074
PRIOR FILING DATE: 1997-04-17
NUMBER OF SEQ ID NOS: 78
SOFTWARE: Patent In Ver. 2.1
SEQ ID NO 15
LENGTH: 16
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: antigen
US-08-992-877-15

Query Match 100.0%; Score 77; DB 3; Length 16;
Best Local Similarity 100.0%; Pred. No. 9.1e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQPGGRAFTVIGK 15
|||
DB 2 RIQPGGRAFTVIGK 16

RESULT 40
PCT-US94-02539-28
Sequence 28, Application PC/TUS9402539
GENERAL INFORMATION:
APPLICANT: Brate, E.M.
APPLICANT: Brennan, C.A.
APPLICANT: Bridon, D.P.
APPLICANT: Jaffe, K.D.
APPLICANT: Krafft, G.A.
APPLICANT: Mandelki, W.
APPLICANT: March, S.C.
APPLICANT: Russell, J.R.
APPLICANT: Yue, V.T.
TITLE OF INVENTION: Genetically Engineered Enzymes
TITLE OF INVENTION: And Their
TITLE OF INVENTION: Conjugates For Diagnostic Assays
NUMBER OF SEQUENCES: 34
CORRESPONDENCE ADDRESS:
ADDRESSEE: ABBOTT LABORATORIES
STREET: One Abbott Park Road
CITY: Abbott Park
STATE: Illinois
COUNTRY: USA
ZIP: 60064-3500
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: SoftPC
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/02539
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Wong, Wean Khing
REGISTRATION NUMBER: 33,561
REFERENCE/DOCKET NUMBER: 5324.PC.01
TELECOMMUNICATION INFORMATION:
TELEPHONE: (708) 938-3517
TELEFAX: (708) 938-2623
TELEX:
INFORMATION FOR SEQ ID NO: 28:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 amino acid residues
TYPE: amino acid
STRANDEDNESS:
TOPOLOGY: unknown
MOLECULE TYPE: peptide
ORIGINAL SOURCE:
ORGANISM:
PCT-US94-02539-28

Query Match 100.0%; Score 77; DB 5; Length 16;
Best Local Similarity 100.0%; Pred. No. 9.1e-06;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQPGGRAFTVIGK 15
|||
DB 2 RIQPGGRAFTVIGK 16

RESULT 41
US-08-015-770B-4
Sequence 4, Application US/08015770B
Patent No. 5683695
GENERAL INFORMATION:
APPLICANT: Shen, De Fen
APPLICANT: Wang, Chang Yi
TITLE OF INVENTION: Production of recombinant proteins
TITLE OF INVENTION: containing multiple antigenic determinants linked by
TITLE OF INVENTION: flexible domains
NUMBER OF SEQUENCES: 73

;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: United Biomedical, Inc.
;; STREET: 25 Davids Drive
;; CITY: Hauppauge
;; STATE: NY
;; COUNTRY: USA
;; ZIP: 11788
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patent In Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/015,770B
;; FILING DATE: 10-FEB-1993
;; CLASSIFICATION: 435
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Wilson, M. Lisa
;; REGISTRATION NUMBER: 34,045
;; REFERENCE/DOCKET NUMBER: 2002
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (516)273-2828
;; TELEFAX: (516)273-1717
;; INFORMATION FOR SEQ ID NO: 4:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 18 amino acids
;; TYPE: amino acid
;; TOPOLOGY: linear
;; MOLECULE TYPE: peptide
US-08-015-770B-4

Query Match 100.0%; Score 77; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1e-05; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIGK 15
| | | | | | | | | | | | | | | | | |
Db 4 RIQRGPGRAFTVIGK 18

RESULT 42
US-08-121-054C-3
; Sequence 3, Application US/08121054C
; Patent No. 5637481
; GENERAL INFORMATION:
; APPLICANT: Ledbetter, Jeffrey A.
; APPLICANT: Gilliland, Lisa K.
; APPLICANT: Hayden, Martha S.
; APPLICANT: Linsley, Peter S.
; APPLICANT: Bajorath, Jurgen
; APPLICANT: Fell, Perry
; TITLE OF INVENTION: Expression Vectors Encoding Bispecific
; TITLE OF INVENTION: Fusion Proteins and Methods of Producing Biologically
; TITLE OF INVENTION: Active Bispecific Fusion Proteins in a Mammalian Cell
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merchant & Gould
; STREET: 11150 Santa Monica Blvd., Suite 400
; CITY: Los Angeles
; STATE: CA
; COUNTRY: USA
; ZIP: 90025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/121,054C
; FILING DATE: 13-SEP-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/013,420

;; FILING DATE: 01-FEB-1993
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Adriano, Sarah B.
;; REGISTRATION NUMBER: 34,470
;; REFERENCE/DOCKET NUMBER: 30436.18US01
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 310-445-1140
;; TELEFAX: 310-445-9031
;; INFORMATION FOR SEQ ID NO: 3:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20 amino acids
;; TYPE: amino acid
;; STRANDEDNESS:
;; TOPOLOGY: linear
;; MOLECULE TYPE: peptide
US-08-121-054C-3

Query Match 100.0%; Score 77; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e-05; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIGK 15
| | | | | | | | | | | | | | | | | |
Db 5 RIQRGPGRAFTVIGK 19

RESULT 43
US-08-488-252-28
; Sequence 28, Application US/08488252
; Patent No. 5763160
; GENERAL INFORMATION:
; APPLICANT: Chang Yi Wang
; TITLE OF INVENTION: SYNTHETIC PEPTIDES AND PROCESS
; TITLE OF INVENTION: OF USING SAME FOR THE DETECTION OF ANTIBODIES TO
; TITLE OF INVENTION: HUMAN IMMUNODEFICIENCY VIRUS (HIV) GP120 ENVELOPE
; TITLE OF INVENTION: PROTEIN, DIAGNOSIS OF AIDS AND PRE-AIDS CONDITIONS
; TITLE OF INVENTION: AND AS VACCINES
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORGAN & FINNEGAN
; STREET: 345 PARK AVE.
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10154
; COMPUTER READABLE FORM:
; MEDIUM TYPE: FLOPPY DISK
; COMPUTER: IBM PC COMPATIBLE
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/488,252
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/326,676
; FILING DATE: 07-Jun-1995
; APPLICATION NUMBER: 07/726,605
; FILING DATE: 09-July-1991
; APPLICATION NUMBER: 07/663,262
; FILING DATE: 01-Mar-1991
; APPLICATION NUMBER: 07/155,321
; FILING DATE: 12-Feb-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Maria C. H. Lin
; REGISTRATION NUMBER: 29,323
; REFERENCE/DOCKET NUMBER: 1151-4004 USA
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-758-4800
; TELEFAX: (212) 751-6849
; TELEX: 421792
; INFORMATION FOR SEQ ID NO: 28:
; SEQUENCE CHARACTERISTICS:

```
/ LENGTH: 20 amino acids
/ TYPE: Amino acids
/ STRANDEDNESS:
/ TOPOLOGY: Unknown
US-08-488-252-28

Query Match 100.0%; Score 77; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGGGFAFVTIGK 15
Db 6 RIQGGGFAFVTIGK 20

RESULT 44
US-08-539-436-3
/ Sequence 3, Application US/08539436
/ Patent No. 6132992
/ GENERAL INFORMATION:
/ APPLICANT: Ledbetter, Jeffrey A.
/ APPLICANT: Gilliland, Lisa K.
/ APPLICANT: Hayden, Martha S.
/ APPLICANT: Linsley, Peter S.
/ APPLICANT: Bajorath, Jurgen
/ APPLICANT: Fell, H. Perry
/ TITLE OF INVENTION: Expression Vectors Encoding Bispecific
/ TITLE OF INVENTION: Fusion Proteins and Methods of Producing Biologically
/ TITLE OF INVENTION: Active Bispecific Fusion Proteins in a Mammalian Cell
/ NUMBER OF SEQUENCES: 30
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Merchant & Gould
/ STREET: 11150 Santa Monica Blvd., Suite 400
/ CITY: Los Angeles
/ STATE: CA
/ COUNTRY: USA
/ ZIP: 90025
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.30
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/539,436
/ FILING DATE: 05-OCT-1995
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/121,054
/ FILING DATE: 13-SEP-1993
/ APPLICATION NUMBER: US 08/013,420
/ FILING DATE: 01-FEB-1993
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Adriano, Sarah B.
/ REGISTRATION NUMBER: 34,470
/ REFERENCE/DOCKET INFORMATION:
/ TELEPHONE: 310-445-1140
/ TELEFAX: 310-445-9031
/ INFORMATION FOR SEQ ID NO: 3:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 20 amino acids
/ TYPE: amino acid
/ STRANDEDNESS:
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
US-08-539-436-3

Query Match 100.0%; Score 77; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGGGFAFVTIGK 15
Db 1 RIQGGGFAFVTIGK 15

us-09-813-659-3
/ Sequence 3, Application US/09813659
/ Patent No. 6482919
/ GENERAL INFORMATION:
/ APPLICANT: Ledbetter, Jeffrey A.
/ APPLICANT: Hayden, Martha S.
/ APPLICANT: Linsley, Peter S.
/ APPLICANT: Bajorath, Jurgen
/ APPLICANT: Fell, H. Perry
/ APPLICANT: Gilliland, Lisa K.
/ TITLE OF INVENTION: EXPRESSION VECTORS ENCODING BISPECIFIC FUSION PROTEINS
/ TITLE OF INVENTION: AND METHODS OF PRODUCING BIOLOGICALLY ACTIVE BISPECIFIC
/ FILE REFERENCE: 30436.18USD2
/ CURRENT APPLICATION NUMBER: US/09/813,659
/ CURRENT FILING DATE: 2001-03-21
/ PRIOR APPLICATION NUMBER: 09/549,067
/ PRIOR FILING DATE: 2000-04-13
/ PRIOR APPLICATION NUMBER: 08/539,436
/ PRIOR FILING DATE: 1995-10-05
/ PRIOR APPLICATION NUMBER: 08/121,054
/ PRIOR FILING DATE: 1993-09-13
/ PRIOR APPLICATION NUMBER: 08/013,420
/ PRIOR FILING DATE: 1993-02-01
/ NUMBER OF SEQ ID NOS: 32
/ SOFTWARE: PatentIn Ver. 2.0
/ SEQ ID NO 3
/ LENGTH: 20
/ TYPE: PRT
/ ORGANISM: Homo sapiens
US-09-813-659-3

Query Match 100.0%; Score 77; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGGGFAFVTIGK 15
Db 5 RIQGGGFAFVTIGK 19

RESULT 46
US-09-549-067A-3
/ Sequence 3, Application US/09549067A
/ Patent No. 6623940
/ GENERAL INFORMATION:
/ APPLICANT: Ledbetter, Jeffrey A.
/ APPLICANT: Hayden, Martha S.
/ APPLICANT: Linsley, Peter S.
/ APPLICANT: Bajorath, Jurgen
/ APPLICANT: Fell, H. Perry
/ APPLICANT: Gilliland, Lisa K.
/ TITLE OF INVENTION: EXPRESSION VECTORS ENCODING BISPECIFIC FUSION PROTEINS
/ TITLE OF INVENTION: AND METHODS OF PRODUCING BIOLOGICALLY ACTIVE BISPECIFIC
/ FILE REFERENCE: 30436.18USC1
/ CURRENT APPLICATION NUMBER: US/09/549,067A
/ CURRENT FILING DATE: 2000-04-13
/ PRIOR APPLICATION NUMBER: 08/539,436
/ PRIOR FILING DATE: 1995-10-05
/ PRIOR APPLICATION NUMBER: 08/121,054
/ PRIOR FILING DATE: 1993-09-13
/ PRIOR APPLICATION NUMBER: 08/013,420
/ PRIOR FILING DATE: 1993-02-01
/ PRIOR APPLICATION NUMBER: 08/228,208
/ PRIOR FILING DATE: 1994-04-15
/ PRIOR APPLICATION NUMBER: 08/008,898
/ PRIOR FILING DATE: 1993-01-22
/ PRIOR APPLICATION NUMBER: 07/723,617
```


/ CITY: Toronto
/ STATE: Ontario
/ COUNTRY: Canada
/ ZIP: M5G 1R7
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/470,419
/ FILING DATE:
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/290,105
/ FILING DATE: August 15, 1994
/ ATTORNEY/AGENT INFORMATION:
/ NAME: STEWART, Michael I
/ REGISTRATION NUMBER: 24,973
/ REFERENCE/DOCKET NUMBER: 1038-385 MIS:jb
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (416) 595-1155
/ TELEFAX: (416) 595-1163
/ INFORMATION FOR SEQ ID NO: 25:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 21 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-470-419-25

Query Match 100.0%; Score 77; DB 2; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQPGGFAFTVIGK 15
DB 7 RIQPGGFAFTVIGK 21

RESULT 50
US-08-648-298-18
/ Sequence 18, Application US/08648298
/ Patent No. 5871990
/ GENERAL INFORMATION:
/ APPLICANT: Henrik Clausen
/ APPLICANT: Eric Paul Bennett
/ TITLE OF INVENTION: UDP-N-acetyl-alpha-D-galactosamine:polypeptide
/ NUMBER OF SEQUENCES: 19
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Darby & Darby PC
/ STREET: 805 Third Avenue
/ CITY: New York
/ STATE: NY
/ ZIP: 10022
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Diskette
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.30 (BPO)
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/648,298
/ FILING DATE: 15-JUN-1996
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Green, Reza
/ REGISTRATION NUMBER: 38,475
/ REFERENCE/DOCKET NUMBER: 4035/0B865
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 212527700
/ TELEFAX: 2127536237
/ TELEX: 236687

/ INFORMATION FOR SEQ ID NO: 18:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 21 amino acids
/ TYPE: peptide
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
/ ORIGINAL SOURCE:
/ ORGANISM: Homo sapiens
/ IMMEDIATE SOURCE:
/ CLONE: HIV-V3 acceptor peptide
/ US-08-648-298-18

Query Match 100.0%; Score 77; DB 2; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQPGGFAFTVIGK 15
DB 3 RIQPGGFAFTVIGK 17

RESULT 51
US-08-761-828-25
/ Sequence 25, Application US/08761828
/ Patent No. 5879925
/ GENERAL INFORMATION:
/ APPLICANT: ROVINSKI, Benjamin
/ APPLICANT: CAO, Shi-Xian
/ APPLICANT: YAO, Fei-Long
/ APPLICANT: PERSSON, Roy
/ APPLICANT: KLEIN, Michel H
/ TITLE OF INVENTION: ANTIGENICALLY-MARKED NON-INFECTIONOUS RETROVIRUS-LIKE PARTICLES
/ NUMBER OF SEQUENCES: 26
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Sim & McBurney
/ STREET: 6TH Floor, 330 University Avenue
/ CITY: Toronto
/ STATE: Ontario
/ COUNTRY: Canada
/ ZIP: M5G 1R7
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/761,828
/ FILING DATE:
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/290,105
/ FILING DATE: 15-AUG-1994
/ ATTORNEY/AGENT INFORMATION:
/ NAME: STEWART, Michael I
/ REGISTRATION NUMBER: 24,973
/ REFERENCE/DOCKET NUMBER: 1038-655 MIS:jb
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (416) 595-1155
/ TELEFAX: (416) 595-1163
/ INFORMATION FOR SEQ ID NO: 25:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 21 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-761-828-25

Query Match 100.0%; Score 77; DB 2; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQPGGFAFTVIGK 15

```
Db      |||||||
       7 RIQGGPGRFVTIGK 21

RESULT 52
US-08-452-520B-4
; Sequence 4, Application US/08452520B
; Patent No. 5912338
; Patent No. 5912338 5840872
; GENERAL INFORMATION:
; APPLICANT: Rovinski, Benjamin
; APPLICANT: Haynes, Joel
; APPLICANT: Cao, Shi-Xian
; APPLICANT: Klein, Michel H
; TITLE OF INVENTION: Retrovirus-Like Particles Containing
; TITLE OF INVENTION: Modified Envelope Glycoproteins
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: 330 University Avenue, 6th Floor
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/452,520B
; FILING DATE: 30-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/073,526
; FILING DATE: 09-JAN-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Stewart, Michael I
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-446 MIS:as
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-452-520B-4
Query Match 100.0%; Score 77; DB 2; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RIQGGPGRFVTIGK 15
DB      7 RIQGGPGRFVTIGK 21

RESULT 54
US-08-776-949-25
; Sequence 25, Application US/08776949
; Patent No. 6025125
; GENERAL INFORMATION:
; APPLICANT: Rovinski, Benjamin
; APPLICANT: Cao, Shi-Xian
; APPLICANT: Yao, Fei-Long
; APPLICANT: Persson, Roy
; APPLICANT: Klein, Michel H
; TITLE OF INVENTION: ANTIGENICALLY-MARKED NON-INFECTIOUS
; TITLE OF INVENTION: RETROVIRUS-LIKE PARTICLES
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: 6th Floor, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/776,949
; FILING DATE: 02-JUN-1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Stewart, Michael I
; REGISTRATION NUMBER: 24,973
;

QY      1 RIQGGPGRFVTIGK 15
DB      7 RIQGGPGRFVTIGK 21

Query Match 100.0%; Score 77; DB 2; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RIQGGPGRFVTIGK 15
DB      7 RIQGGPGRFVTIGK 21

RESULT 53
US-08-290-105-25
; Sequence 25, Application US/08290105
; Patent No. 5955342
; GENERAL INFORMATION:
; APPLICANT: ROVINSKI, Benjamin
; APPLICANT: CAO, Shi-Xian
; APPLICANT: YAO, Fei-Long
; APPLICANT: PERSSON, Roy
; APPLICANT: KLEIN, Michel H
; TITLE OF INVENTION: ANTIGENICALLY-MARKED NON-INFECTIOUS
; TITLE OF INVENTION: RETROVIRUS-LIKE PARTICLES
```

REFERENCE/DOCKET NUMBER: 1038-673 MIS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-776-949-25

Query Match 100.0%; Score 77; DB 3; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQPGGRAFTVIGK 15
DB 7 RIQPGGRAFTVIGK 21

RESULT 55
US-08-482-810-25
Sequence 25, Application US/08482810
Patent No. 6080408
GENERAL INFORMATION:
APPLICANT: ROVINSKI, Benjamin
APPLICANT: CAO, Shi-Xian
APPLICANT: YAO, Fei-Long
APPLICANT: PERSSON, Roy
APPLICANT: KLEIN, Michel H.

TITLE OF INVENTION: RETROVIRUS-LIKE PARTICLES MADE NON-
INFECTIONOUS BY A PLURALITY OF MUTATIONS
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/482,810
FILING DATE: 07-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/292,967
FILING DATE: 22-AUG-1994
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, Michael I
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-490 MIS:vg

TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-482-810-25

Query Match 100.0%; Score 77; DB 3; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQPGGRAFTVIGK 15
DB 7 RIQPGGRAFTVIGK 21

RESULT 56
US-09-027-955-25
Sequence 25, Application US/09027955
Patent No. 6291157
GENERAL INFORMATION:
APPLICANT: ROVINSKI, Benjamin
APPLICANT: CAO, Shi-Xian
APPLICANT: YAO, Fei-Long
APPLICANT: PERSSON, Roy
APPLICANT: KLEIN, Michel H.

TITLE OF INVENTION: ANTIGENICALLY-MARKED NON-INFECTIONOUS
RETROVIRUS-LIKE PARTICLES
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: 6th Floor, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/027,955
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/290,105
FILING DATE: 15-AUG-1994
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, Michael I
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-798 MIS:jb

TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-027-955-25

Query Match 100.0%; Score 77; DB 3; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQPGGRAFTVIGK 15
DB 7 RIQPGGRAFTVIGK 21

RESULT 57
US-09-636-805-25
Sequence 25, Application US/09636805
Patent No. 6342228
GENERAL INFORMATION:
APPLICANT: ROVINSKI, Benjamin
APPLICANT: CAO, Shi-Xian
APPLICANT: YAO, Fei-Long
APPLICANT: PERSSON, Roy
APPLICANT: KLEIN, Michel H.

TITLE OF INVENTION: ANTIGENICALLY-MARKED NON-INFECTIONOUS
RETROVIRUS-LIKE PARTICLES


```
;
; SEQUENCE DESCRIPTION: SEQ ID NO: 25:
US-09-635-754-25
Query Match      100.0%; Score 77; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRFVTVIGK 15
Db 7 RIQGPGRFVTVIGK 21

RESULT 60
US-08-680-525-25
; Sequence 25, Application US/08680525
; Patent No. 6544527
; GENERAL INFORMATION:
; APPLICANT: ROVINSKI, Benjamin
; APPLICANT: CAO, Shi-Xian
; APPLICANT: YAO, Fei-Long
; APPLICANT: PERSSON, Roy
; APPLICANT: KLEIN, Michel H
; TITLE OF INVENTION: RETROVIRUS-LIKE PARTICLES MADE NON-
; TITLE OF INVENTION: INFECTIOUS BY A PLURALITY OF MUTATIONS
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESS: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION NUMBER: US/08/680,525
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/292,967
; FILING DATE: 22-AUG-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, Michael I
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-617 MIS:jb
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-680-525-25
Query Match      100.0%; Score 77; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRFVTVIGK 15
Db 7 RIQGPGRFVTVIGK 21

RESULT 61
US-09-636-223-25
; Sequence 25, Application US/09636223
; Patent No. 6544752
; GENERAL INFORMATION:
; APPLICANT: ROVINSKI, Benjamin
; APPLICANT: CAO, Shi-Xian
; APPLICANT: YAO, Fei-Long
; APPLICANT: PERSSON, Roy
; APPLICANT: KLEIN, Michel H
; TITLE OF INVENTION: RETROVIRUS-LIKE PARTICLES MADE NON-
; TITLE OF INVENTION: INFECTIOUS BY A PLURALITY OF MUTATIONS
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESS: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION NUMBER: US/09/636,223
; FILING DATE: 29-Dec-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 09/027,955
; FILING DATE: 23-FEB-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, Michael I
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-1064 MIS:jb
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-636-223-25
Query Match      100.0%; Score 77; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRFVTVIGK 15
Db 7 RIQGPGRFVTVIGK 21

RESULT 62
US-08-125-012-13
; Sequence 13, Application US/08125012
; Patent No. 5593972
; GENERAL INFORMATION:
; APPLICANT: Weiner, David B.
; APPLICANT: Williams, William V.
; APPLICANT: Wang, Bin
; APPLICANT: Coney, Leslie R.
; TITLE OF INVENTION: Genetic Immunization
; NUMBER OF SEQUENCES: 34
; CORRESPONDENCE ADDRESS:
; ADDRESS: Woodcock Washburn Kurtz Mackiewicz & No. 5593972ria
; STREET: One Liberty Place 46th Floor
; CITY: Philadelphia
; STATE: Pennsylvania
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
```

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25 mb-MD/JAF
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/125,012
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/029,336
FILING DATE: 11-MAR-1993
NAME:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/008,342
FILING DATE: 26-JAN-1993
NAME:
ATTORNEY/AGENT INFORMATION:
NAME: DeLuca, Mark
REGISTRATION NUMBER: 33,229
REFERENCE/DOCKET NUMBER: APOL-0013
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3429
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 22 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-125-012-13

Query Match 100.0%; Score 77; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRGPGRAFTVIGK 15
Db 8 RIQRGPGRAFTVIGK 22

RESULT 63
US-08-783-818-13
Sequence 13, Application US/08783818
Patent No. 5817637
GENERAL INFORMATION:
APPLICANT: Weiner, David B.
APPLICANT: Williams, William V.
APPLICANT: Wang, Bin
APPLICANT: Coney, Leslie R.
TITLE OF INVENTION: Genetic Immunization
NUMBER OF SEQUENCES: 34
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5817637ris
STREET: One Liberty Place 46th Floor
CITY: Philadelphia
STATE: Pennsylvania
COUNTRY: USA
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25 mb-MD/JAF
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/783,818
FILING DATE: 13-JAN-1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/125,012
FILING DATE: 21-SEP-1993
APPLICATION NUMBER: 08/029,336
FILING DATE: 11-MAR-1993
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/008,342

FILING DATE: 26-JAN-1993
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: DeLuca, Mark
REGISTRATION NUMBER: 33,229
REFERENCE/DOCKET NUMBER: APOL-0013
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3429
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 22 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-783-818-13

Query Match 100.0%; Score 77; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRGPGRAFTVIGK 15
Db 8 RIQRGPGRAFTVIGK 22

RESULT 64
US-08-453-349-13
Sequence 13, Application US/08453349
Patent No. 5830876
GENERAL INFORMATION:
APPLICANT: Weiner, David B.
APPLICANT: Williams, William V.
APPLICANT: Wang, Bin
TITLE OF INVENTION: Genetic Immunization
NUMBER OF SEQUENCES: 34
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5830876ris
STREET: One Liberty Place 46th Floor
CITY: Philadelphia
STATE: Pennsylvania
COUNTRY: USA
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25 mb-MD/JAF
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/453,349
FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/029,336
FILING DATE: March 11, 1993
APPLICATION NUMBER: 08/008,342
FILING DATE: January 26, 1993
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: DeLuca, Mark
REGISTRATION NUMBER: 33,229
REFERENCE/DOCKET NUMBER: APOL-0013
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3429
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 22 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-453-349-13

Query Match 100.0%; Score 77; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQGGPGRFVTVIGK 15
| | | | | | | | | | | | | | | | | |
Db 8 RIQGGPGRFVTVIGK 22

RESULT 65

US-08-345-321-2
; Sequence 2, Application US/08345321
; Patent No. 591409
; GENERAL INFORMATION:
; APPLICANT: ZOLLA-PAZNER, Susan
; APPLICANT: GORNY, Miroslav K.
; TITLE OF INVENTION: HETEROHYBRIDOMAS PRODUCING HUMAN
; TITLE OF INVENTION: MONOCLONAL ANTIBODIES TO HIV-1
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Browdy and Neimark
; STREET: 419 Seventh Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20004

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/345,321
FILING DATE:

CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/07/872,675
FILING DATE:

ATTORNEY/AGENT INFORMATION:
NAME: Browdy, Roger L.
REGISTRATION NUMBER: 25,618
REFERENCE/DOCKET NUMBER: ZOLLA-PAZNER1B
TELEPHONE: 202-628-5197
TELEFAX: 202-737-3528
TELEX: 248633

INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 22 amino acids
TYPE: amino acid

TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
INDIVIDUAL ISOLATE: IIB
FEATURE:
NAME/KEY: Peptide

LOCATION: 1..22

OTHER INFORMATION: /notes "This sequence corresponds
to 303 to 324 of gp120 from the IIB isolate."
US-08-345-321-2

Query Match 100.0%; Score 77; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQGGPGRFVTVIGK 15
| | | | | | | | | | | | | | | | | |
Db 6 RIQGGPGRFVTVIGK 20

RESULT 66

US-08-979-385B-11
; Sequence 11, Application US/08979385B
; Patent No. 5981505
; GENERAL INFORMATION:
; APPLICANT: Weiner, David B.
; APPLICANT: Williams, William V.
; APPLICANT: Wang, Bin
; TITLE OF INVENTION: Compositions and Methods for Delivery of
; NUMBER OF SEQUENCES: 52
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5981505ris
; STREET: One Liberty Place 46th Floor
; CITY: Philadelphia
; STATE: Pennsylvania
; COUNTRY: USA
; ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25 mb-MD/JAF
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/979,385B
FILING DATE: 26-NOV-1997
CLASSIFICATION: 514

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/495,684
FILING DATE: 28-SEP-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/00899
FILING DATE: 26-JAN-1994

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/125,012
FILING DATE: 21-SEP-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/124,962
FILING DATE: 21-SEP-1993

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/093,235
FILING DATE: 15-JUL-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/029,336
FILING DATE: 11-MAR-1993

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/008,342
FILING DATE: 26-JAN-1993
ATTORNEY/AGENT INFORMATION:
NAME: Deluca, Mark

REGISTRATION NUMBER: 33,229
REFERENCE/DOCKET NUMBER: UPAP-0253
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3429

INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 22 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-979-385B-11

Query Match 100.0%; Score 77; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQGGPGRFVTVIGK 15
| | | | | | | | | | | | | | | | | |
Db 8 RIQGGPGRFVTVIGK 22

RESULT 67

US-08-537-245-1
; Sequence 1, Application US/08537245

```
/ Patent No. 5985275
/ GENERAL INFORMATION:
/ APPLICANT: Neurath, A. Robert, Debnath, Asim K.,
/ APPLICANT: Jiang, Shibo
/ TITLE OF INVENTION: Proteins and Peptides Modified By
/ TITLE OF INVENTION: Aromatic Acid Anhydride Compounds
/ NUMBER OF SEQUENCES: 1
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Frischauf, Holtz, Goodman & Woodward
/ STREET: 600 Third Avenue
/ CITY: New York
/ STATE: New York
/ COUNTRY: USA
/ ZIP: 10016
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Diskette, 3+ inch, 0.72 mb storage
/ COMPUTER: IBM PC
/ OPERATING SYSTEM: MS DOS
/ SOFTWARE: ASCII
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/537,245
/ FILING DATE:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/420,573
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Barth, Richard
/ REGISTRATION NUMBER: 28,180
/ REFERENCE/DOCKET NUMBER: 950157/RSB
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (212) 972-1400
/ TELEFAX: (212) 370-1622
/ TELEX: 236268
/ INFORMATION FOR SEQ ID NO: 1:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 22 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: single stranded
/ TOPOLOGY: linear
/ MOLECULE TYPE: cDNA to genomic RNA
/ US-08-537-245-1

Query Match 100.0%; Score 77; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGGRGFAVTVIGK 15
DB 8 RIQRGGRGFAVTVIGK 22

RESULT 68
US-08-805-889-5
/ Sequence 5, Application US/08805889
/ Patent No. 6039957
/ GENERAL INFORMATION:
/ APPLICANT: Earl, Patricia L.
/ APPLICANT: Broder, Christopher C.
/ APPLICANT: Doms, Robert W.
/ TITLE OF INVENTION: Oligomeric HIV-1 Envelope Glycoproteins
/ NUMBER OF SEQUENCES: 6
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Knobbe, Martens, Olson and Bear
/ STREET: 620 Newport Center Drive 16th Floor
/ CITY: Newport Beach
/ STATE: CA
/ ZIP: 92660
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/070,291
/ FILING DATE:
/ CLASSIFICATION:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Venskno, Nancy Ways
/ REGISTRATION NUMBER: 36,298
/ REFERENCE/DOCKET NUMBER: NIH079.1DVCPI
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 619-235-8550
/ TELEFAX: 619-235-0176
/ INFORMATION FOR SEQ ID NO: 5:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 22 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ CURRENT APPLICATION DATA:
```

```
/ APPLICATION NUMBER: US/08/805,889
/ FILING DATE: 03-MAR-1997
/ CLASSIFICATION: 424
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/165,314
/ FILING DATE: 10-DEC-1993
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Fuller, Michael L.
/ REGISTRATION NUMBER: 36,516
/ REFERENCE/DOCKET NUMBER: NIH079.001A
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 619-235-8550
/ TELEFAX: 619-235-0176
/ INFORMATION FOR SEQ ID NO: 5:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 22 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
/ HYPOTHETICAL: NO
/ ANTI-SENSE: NO
/ FRAGMENT TYPE: internal
/ US-08-805-889-5

Query Match 100.0%; Score 77; DB 3; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGGRGFAVTVIGK 15
DB 8 RIQRGGRGFAVTVIGK 22

RESULT 69
US-09-070-291-5
/ Sequence 5, Application US/09070291
/ Patent No. 6171596
/ GENERAL INFORMATION:
/ APPLICANT: Earl, Patricia L.
/ APPLICANT: Broder, Christopher C.
/ APPLICANT: Doms, Robert W.
/ APPLICANT: Mose, Bernard
/ TITLE OF INVENTION: Oligomeric HIV-1 Envelope Glycoproteins
/ NUMBER OF SEQUENCES: 10
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Knobbe, Martens, Olson and Bear
/ STREET: 620 Newport Center Drive 16th Floor
/ CITY: Newport Beach
/ STATE: CA
/ ZIP: 92660
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/070,291
/ FILING DATE:
/ CLASSIFICATION:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Venskno, Nancy Ways
/ REGISTRATION NUMBER: 36,298
/ REFERENCE/DOCKET NUMBER: NIH079.1DVCPI
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 619-235-8550
/ TELEFAX: 619-235-0176
/ INFORMATION FOR SEQ ID NO: 5:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 22 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ CURRENT APPLICATION DATA:
```



```
; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: internal
US-09-070-291-5
Query Match 100.0%; Score 77; DB 3; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIGK 15
Db 8 RIQRGPGRAFTVIGK 22

RESULT 70
US-09-217-306B-22
; Sequence 22, Application US/09217306B
; Patent No. 6465220
; GENERAL INFORMATION:
; APPLICANT: Hassan, Helle
; APPLICANT: Clausen, Henrik
; APPLICANT: Bennett, Eric P.
; TITLE OF INVENTION: Glycosylation Using GalNAc-T4 Transferase
; FILE REFERENCE: 8850*1
; CURRENT APPLICATION NUMBER: US/09/217,306B
; CURRENT FILING DATE: 1998-12-21
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 22
; LENGTH: 22
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: MISC FEATURE
; OTHER INFORMATION: HIVIIB gp120
US-09-217-306B-22

Query Match 100.0%; Score 77; DB 4; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIGK 15
Db 3 RIQRGPGRAFTVIGK 17

RESULT 71
US-08-880-576-13
; Sequence 13, Application US/08880576
; Patent No. 6468982
; GENERAL INFORMATION:
; APPLICANT: Weiner, David B.
; APPLICANT: Williams, William V.
; APPLICANT: Wang, Bin
; APPLICANT: Coney, Leslie R.
; TITLE OF INVENTION: Genetic Immunization
; NUMBER OF SEQUENCES: 34
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 6468982ris
; STREET: One Liberty Place 46th Floor
; CITY: Philadelphia
; STATE: Pennsylvania
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 mb-MD/JAF
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/880,576
; FILING DATE: 23-JUN-1997

; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: internal
US-09-070-291-5
Query Match 100.0%; Score 77; DB 3; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIGK 15
Db 8 RIQRGPGRAFTVIGK 22

RESULT 70
US-09-217-306B-22
; Sequence 22, Application US/09217306B
; Patent No. 6465220
; GENERAL INFORMATION:
; APPLICANT: Hassan, Helle
; APPLICANT: Clausen, Henrik
; APPLICANT: Bennett, Eric P.
; TITLE OF INVENTION: Glycosylation Using GalNAc-T4 Transferase
; FILE REFERENCE: 8850*1
; CURRENT APPLICATION NUMBER: US/09/217,306B
; CURRENT FILING DATE: 1998-12-21
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 22
; LENGTH: 22
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: MISC FEATURE
; OTHER INFORMATION: HIVIIB gp120
US-09-217-306B-22

Query Match 100.0%; Score 77; DB 4; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIGK 15
Db 3 RIQRGPGRAFTVIGK 17

RESULT 71
US-08-880-576-13
; Sequence 13, Application US/08880576
; Patent No. 6468982
; GENERAL INFORMATION:
; APPLICANT: Weiner, David B.
; APPLICANT: Williams, William V.
; APPLICANT: Wang, Bin
; APPLICANT: Coney, Leslie R.
; TITLE OF INVENTION: Genetic Immunization
; NUMBER OF SEQUENCES: 34
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 6468982ris
; STREET: One Liberty Place 46th Floor
; CITY: Philadelphia
; STATE: Pennsylvania
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 mb-MD/JAF
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/880,576
; FILING DATE: 23-JUN-1997

; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/125,012
; FILING DATE: 21-SEP-1993
; APPLICATION NUMBER: 08/029,336
; FILING DATE: 11-MAR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/008,342
; FILING DATE: 26-JAN-1993
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLuca, Mark
; REGISTRATION NUMBER: 33,229
; REFERENCE/DOCKET NUMBER: APOL-0013
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3429
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-880-576-13

Query Match 100.0%; Score 77; DB 4; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIGK 15
Db 8 RIQRGPGRAFTVIGK 22

RESULT 72
US-08-097-751-1
; Sequence 1, Application US/08097751
; Patent No. 5527666
; GENERAL INFORMATION:
; APPLICANT: DeRoosi, Anita
; APPLICANT: Pasti, Marcella
; APPLICANT: Mammano, Fabrizio
; APPLICANT: Panozzo, Marina
; APPLICANT: Dettin, Monica
; APPLICANT: DiBello, Carlo
; APPLICANT: Chieco-Bianchi, Luigi
; TITLE OF INVENTION: METHOD FOR THE DIAGNOSIS IN VITRO OF
; TITLE OF INVENTION: HIV-1 VIRUS INFECTIONS
; NUMBER OF SEQUENCES: 2
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hedman, Gibson, Costigan & Hoare
; STREET: 1185 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: DOS
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/097,751
; FILING DATE: 19930723
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Costigan, James V.
; REGISTRATION NUMBER: 25,669
; REFERENCE/DOCKET NUMBER: 515-4026
; TELECOMMUNICATION INFORMATION:
```

TELEPHONE: (212) 302-8989
TELEFAX: (212) 302-8998
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 amino acids
TYPE: amino acid
TOPOLOGY: circular
US-08-097-751-1

Query Match 100.0%; Score 77; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.3e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIGK 15
|||||
DB 8 RIQRGPGRAFTVIGK 22

RESULT 73
US-08-090-148-6
Sequence 6, Application US/08090148
Patent No. 5534257
GENERAL INFORMATION:
APPLICANT: Mastico, Robert Allan
APPLICANT: Stockley, Peter George
APPLICANT: Talbot, Simon John
TITLE OF INVENTION: Antigen-Presenting Capsid with
TITLE OF INVENTION: Fusion MS2-Coat Protein
NUMBER OF SEQUENCES: 6
CORRESPONDENCE ADDRESS:
ADDRESSEE: Rosenman & Colin
STREET: 575 Madison Avenue
CITY: New York
STATE: NY
COUNTRY: U.S.A.
ZIP: 10022-2585
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5", 1.44Mb
COMPUTER: IBM PS2-486
OPERATING SYSTEM: MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/090,148
FILING DATE: 08/11/93
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9101550.3
FILING DATE: 01/24/91
APPLICATION NUMBER: PCT/GB92/00124
FILING DATE: 01/22/92
ATTORNEY/AGENT INFORMATION:
NAME: Nissenbaum, Israel
REGISTRATION NUMBER: 27,582
REFERENCE/DOCKET NUMBER:
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 940-8636
TELEFAX: (212) 940-6404
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 AMINO ACIDS
TYPE: AMINO ACID
TOPOLOGY: NOT RELEVANT
MOLECULE TYPE: PEPTIDE
US-08-090-148-6

Query Match 100.0%; Score 77; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.3e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIGK 15
|||||
DB 8 RIQRGPGRAFTVIGK 22

RESULT 74
US-08-257-528B-99
Sequence 99, Application US/08257528B
Patent No. 5639854
GENERAL INFORMATION:
APPLICANT: SIA, Charles D.Y.
APPLICANT: CHONG, Pele
APPLICANT: KLEIN, Michel H.
TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/257,528B
FILING DATE: 09-JUN-1994
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, MICHAEL I.
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-336 MIS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 99:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-257-528B-99

Query Match 100.0%; Score 77; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.3e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIGK 15
|||||
DB 7 RIQRGPGRAFTVIGK 21

RESULT 75
US-08-460-602A-99
Sequence 99, Application US/08460602A
Patent No. 5759769
GENERAL INFORMATION:
APPLICANT: SIA, Charles D.Y.
APPLICANT: CHONG, Pele
APPLICANT: KLEIN, Michel H.
TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25

```
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/460,602A
; FILING DATE: 02-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/257,528
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/073,378
; FILING DATE: 09-JUN-1993
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-450 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 99:
; LENGTH: 24 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-460-602A-99

Query Match      100.0%; Score 77; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.3e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RIQGPGRFVTVIGK 15
Db      |||||
        7 RIQGPGRFVTVIGK 21

RESULT 76
US-08-463-966A-99
; Sequence 99, Application US/08463966A
; Patent No. 5795955
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: MSG IR7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/463,966A
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/257,528
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-450 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 99:
; LENGTH: 24 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-463-966A-99

Query Match      100.0%; Score 77; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.3e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RIQGPGRFVTVIGK 15
Db      |||||
        7 RIQGPGRFVTVIGK 21

RESULT 77
US-08-465-217A-99
; Sequence 99, Application US/08465217A
; Patent No. 5808222
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: MSG IR7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/465,217A
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/257,528
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/073,378
; FILING DATE: 09-JUN-1993
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-486 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 99:
; LENGTH: 24 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-465-217A-99

Query Match      100.0%; Score 77; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.3e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
; REFERENCE/DOCKET NUMBER: 1038-487 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 99:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-463-966A-99

Query Match      100.0%; Score 77; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.3e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RIQGPGRFVTVIGK 15
Db      |||||
        7 RIQGPGRFVTVIGK 21

RESULT 77
US-08-465-217A-99
; Sequence 99, Application US/08465217A
; Patent No. 5808222
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: MSG IR7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/465,217A
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/257,528
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/073,378
; FILING DATE: 09-JUN-1993
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-486 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 99:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-465-217A-99

Query Match      100.0%; Score 77; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.3e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 1 RIQRGPGRAFTIGK 15
|||
Db 7 RIQRGPGRAFTIGK 21

```

RESULT 78
US-08-464-329A-99
; Sequence 99, Application US/08464329A
; Patent No. 581754
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/464,329A
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/073,378
; FILING DATE: 09-JUN-1993
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-449 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 99:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; JS-08-464-329A-99

```

APPLICANT: Horal, Peter
 TITLE OF INVENTION: PEPTIDES FOR USE IN VACCINATION AND
 INDUCTION OF NEUTRALIZING ANTIBODIES AGAINST HUMAN
 IMMUNODEFICIENCY VIRUS
 TITLE OF INVENTION: INDUCTION OF NEUTRALIZING ANTIBODIES AGAINST HUMAN
 IMMUNODEFICIENCY VIRUS
 NUMBER OF SEQUENCES: 41
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: KNOBE, MARTENS, OLSON AND BEAR
 STREET: 620 NEWPORT CENTER DRIVE 16TH FLOOR
 CITY: NEWPORT BEACH
 STATE: CA
 COUNTRY: USA
 ZIP: 92660
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/493,235
 FILING DATE: 20 June 1995
 CLASSIFICATION: 530
 ATTORNEY/AGENT INFORMATION:
 NAME: Kaiser, AnneMarie
 REGISTRATION NUMBER: 37,649
 REFERENCE/DOCKET NUMBER: METRICS.12CPC1
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 619-235-8550
 TELEFAX: 619-235-0176
 INFORMATION FOR SEQ ID NO: 24:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 24 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 HYPOTHETICAL: NO
 ANTI-SENSE: NO
 FRAGMENT TYPE: internal
 US-08-493-235-24

Query Match: 100.0%; Score 77; DB 2; Length 24;
 Best Local Similarity 100.0%; Pred. No. 1.3e-05;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps

QY 1 RIQPGGPAFTVIGK 15
 Db 2 RIQPGGPAFTVIGK 16

RESULT 80
 US-08-462-507A-99
 Sequence 99, Application US/08462507A
 Patent No. 5876731
 GENERAL INFORMATION:
 APPLICANT: SIA, Charles D.Y.
 APPLICANT: CHONG, Pele
 APPLICANT: KLEIN, Michel H.
 TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
 NUMBER OF SEQUENCES: 101
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Sim & McBurney
 STREET: Suite 701, 330 University Avenue
 CITY: Toronto
 STATE: Ontario
 COUNTRY: Canada
 ZIP: M5G 1R7
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/462,507A

; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/257,528
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/073,378
; FILING DATE: 09-JUN-1993
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-451 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 99:
; LENGTH: 24 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-462-507A-99

Query Match 100.0%; Score 77; DB 2; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.3e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQGPGRFVTIGK 15
Db 7 RIQGPGRFVTIGK 21

RESULT 81
US-08-146-028-160
; Sequence 160, Application US/08146028
; Patent No. 5891640
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; TITLE OF INVENTION: PROCESS FOR THE DETERMINATION OF PEPTIDES
; TITLE OF INVENTION: CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND THEIR
; TITLE OF INVENTION: IN A PROCESS FOR DETERMINATION OF ANTIBODIES OR BIOTINYLATED
; TITLE OF INVENTION: PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT EPITOPES,
; TITLE OF INVENTION: PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM
; NUMBER OF SEQUENCES: 453
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/146,028
; INFORMATION FOR SEQ ID NO: 160:
; LENGTH: 24 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-146-028-160

Query Match 100.0%; Score 77; DB 2; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.3e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQGPGRFVTIGK 15
Db 8 RIQGPGRFVTIGK 22

RESULT 82
US-08-467-881A-99

; Sequence 99, Application US/08467881A
; Patent No. 5951986
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/467,881A
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/073,378
; FILING DATE: 09-JUN-1993
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-488 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 99:
; LENGTH: 24 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-467-881A-99

Query Match 100.0%; Score 77; DB 2; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.3e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQGPGRFVTIGK 15
Db 7 RIQGPGRFVTIGK 21

RESULT 83

US-08-723-425A-160
; Sequence 160, Application US/08723425A
; Patent No. 6165730
; GENERAL INFORMATION:
; APPLICANT: DELEYS, ROBERT
; TITLE OF INVENTION: PROCESS FOR THE DETERMINATION OF
; TITLE OF INVENTION: PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT
; TITLE OF INVENTION: EPITOPES AND THEIR USE IN A PROCESS FOR DETERMINATION OF
; TITLE OF INVENTION: ANTIBODIES OR BIOTINYLATED PEPTIDES CORRESPONDING ...
; NUMBER OF SEQUENCES: 453
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHUYE, P.C.
; STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
; CITY: Arlington
; STATE: VA
; COUNTRY: USA

ZIP: 22201
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/723,425A
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: SADOFF, B.J.
REGISTRATION NUMBER: 36,663
REFERENCE/DOCKET NUMBER: 1487-13
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-816-4000
TELEFAX: 703-816-4100
INFORMATION FOR SEQ ID NO: 160:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-723-425A-160

Query Match 100.0%; Score 77; DB 3; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.3e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIGK 15
Db 8 RIQRGPGRAFTVIGK 22

RESULT 84
US-08-480-332-2
Sequence 2, Application US/08480332
Patent No. 6180134
GENERAL INFORMATION:
APPLICANT: Zalipsky, Samuel; Woodle, Martin; Martin, Francis;
APPLICANT: Barenholz, Yechezkel
TITLE OF INVENTION: Enhanced Circulation Effector Composition and
TITLE OF INVENTION: Method
NUMBER OF SEQUENCES: 10
CORRESPONDENCE ADDRESS:
ADDRESSEE: Dehlinger & Associates
STREET: 350 Cambridge Avenue, Suite 250
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94306
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/480,332
FILING DATE: 7-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/316,436
FILING DATE: 29-SEP-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/035,443
FILING DATE: 23-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Mohr, Judy M.
REGISTRATION NUMBER: 38,563
REFERENCE/DOCKET NUMBER: 5325-0115.31
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 324-0880

TELEFAX: (415) 324-0960
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 amino acids
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: peptide
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: Peptide 2, Fig. 13
FEATURE:
NAME/KEY: CDS
LOCATION: 1..15
US-08-480-332-2

Query Match 100.0%; Score 77; DB 3; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.3e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIGK 15
Db 8 RIQRGPGRAFTVIGK 22

RESULT 85
US-09-112-206-160
Sequence 160, Application US/09112206
Patent No. 6210903
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: PROCESS FOR THE DETERMINATION OF PEPTIDES
CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND THEIR (I
TITLE OF INVENTION: IN A PROCESS FOR DETERMINATION OF ANTIBODIES OR BIOTINYLATED
TITLE OF INVENTION: PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT EPITOPES, I
TITLE OF INVENTION: PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM
NUMBER OF SEQUENCES: 453
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/112,206
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/146,028
FILING DATE:
INFORMATION FOR SEQ ID NO: 160:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-09-112-206-160

Query Match 100.0%; Score 77; DB 3; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.3e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIGK 15
Db 8 RIQRGPGRAFTVIGK 22

RESULT 86
US-09-790-497A-14
Sequence 14, Application US/09790497A
Patent No. 6649735
GENERAL INFORMATION:
APPLICANT: De Leys, Robert

1 TITLE OF INVENTION: PROCESS FOR THE DETERMINATION OF PEPTIDES CORRESPONDING
2 TITLE OF INVENTION: TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND THEIR USE IN
3 TITLE OF INVENTION: A PROCESS FOR DETERMINATION OF ANTIBODIES OF
4 TITLE OF INVENTION: BIOTINYLATED PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT
5 TITLE OF INVENTION: EPITOPES, A PROCESS FOR PREPARING THEM AND COMPOSITIONS
6 TITLE OF INVENTION: CONTAINING THEM

7 FILE REFERENCE: 2752-16
8 CURRENT APPLICATION NUMBER: US/09/790,497A
9 CURRENT FILING DATE: 2001-02-23
10 PRIOR APPLICATION NUMBER: 09/576,824
11 PRIOR FILING DATE: 2000-05-23
12 PRIOR APPLICATION NUMBER: 08/723,425
13 PRIOR FILING DATE: 1996-09-30
14 PRIOR APPLICATION NUMBER: 09/146,028
15 PRIOR FILING DATE: 1993-11-22
16 PRIOR APPLICATION NUMBER: PCT/EP93/00517
17 PRIOR FILING DATE: 1993-03-08
18 PRIOR APPLICATION NUMBER: EP 92400598.6
19 NUMBER OF SEQ ID NOS: 600
20 SOFTWARE: PatentIn Ver. 2.1
21 SEQ ID NO 14
22 LENGTH: 24
23 TYPE: PRT

24 ORGANISM: Human immunodeficiency virus
25 US-09-790-497A-14

Query Match 100.0%; Score 77; DB 4; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.3e-05; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRFAVTIGK 15
DB 8 RIQGPGRFAVTIGK 22

RESULT 87

1 US-09-790-497A-160
2 Sequence 160, Application US/09790497A
3 Patent No. 6649735
4 GENERAL INFORMATION:
5 APPLICANT: De Leys, Robert
6 TITLE OF INVENTION: PROCESS FOR THE DETERMINATION OF PEPTIDES CORRESPONDING
7 TITLE OF INVENTION: TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND THEIR USE IN
8 TITLE OF INVENTION: A PROCESS FOR DETERMINATION OF ANTIBODIES OF
9 TITLE OF INVENTION: BIOTINYLATED PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT
10 TITLE OF INVENTION: EPITOPES, A PROCESS FOR PREPARING THEM AND COMPOSITIONS
11 TITLE OF INVENTION: CONTAINING THEM
12 FILE REFERENCE: 2752-16
13 CURRENT APPLICATION NUMBER: US/09/790,497A
14 CURRENT FILING DATE: 2001-02-23
15 PRIOR APPLICATION NUMBER: 09/576,824
16 PRIOR FILING DATE: 2000-05-23
17 PRIOR APPLICATION NUMBER: 08/723,425
18 PRIOR FILING DATE: 1996-09-30
19 PRIOR APPLICATION NUMBER: 09/146,028
20 PRIOR FILING DATE: 1993-11-22
21 PRIOR APPLICATION NUMBER: PCT/EP93/00517
22 PRIOR FILING DATE: 1993-03-08
23 PRIOR APPLICATION NUMBER: EP 92400598.6
24 NUMBER OF SEQ ID NOS: 600
25 SOFTWARE: PatentIn Ver. 2.1
26 SEQ ID NO 160
27 LENGTH: 24
28 TYPE: PRT

29 ORGANISM: Human immunodeficiency virus
30 US-09-790-497A-160
31 Query Match 100.0%; Score 77; DB 4; Length 24;
32 Best Local Similarity 100.0%; Pred. No. 1.3e-05;
33 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRFAVTIGK 15
DB 8 RIQGPGRFAVTIGK 22

QY 1 RIQGPGRFAVTIGK 15
DB 8 RIQGPGRFAVTIGK 22

RESULT 88

1 US-09-576-824A-160
2 Sequence 160, Application US/09576824A
3 Patent No. 6667387
4 GENERAL INFORMATION:
5 APPLICANT: De Leys, Robert
6 TITLE OF INVENTION: PROCESS FOR THE DETERMINATION OF PEPTIDES CORRESPONDING
7 TITLE OF INVENTION: TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND THEIR USE IN
8 TITLE OF INVENTION: A PROCESS FOR DETERMINATION OF ANTIBODIES OF
9 TITLE OF INVENTION: BIOTINYLATED PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT
10 TITLE OF INVENTION: EPITOPES, A PROCESS FOR PREPARING THEM AND COMPOSITIONS
11 TITLE OF INVENTION: CONTAINING THEM
12 FILE REFERENCE: 2752-11
13 CURRENT APPLICATION NUMBER: US/09/576,824A
14 CURRENT FILING DATE: 2000-05-23
15 PRIOR APPLICATION NUMBER: 08/723,425
16 PRIOR FILING DATE: 1996-09-30
17 PRIOR APPLICATION NUMBER: 09/146,028
18 PRIOR FILING DATE: 1993-11-22
19 PRIOR APPLICATION NUMBER: PCT/EP93/00517
20 PRIOR FILING DATE: 1993-03-08
21 PRIOR APPLICATION NUMBER: EP 92400598.6
22 PRIOR FILING DATE: 1992-03-06
23 NUMBER OF SEQ ID NOS: 600
24 SOFTWARE: PatentIn Ver. 2.1
25 SEQ ID NO 160
26 LENGTH: 24
27 TYPE: PRT
28 ORGANISM: Human immunodeficiency virus
29 US-09-576-824A-160

Query Match 100.0%; Score 77; DB 4; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.3e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRFAVTIGK 15
DB 8 RIQGPGRFAVTIGK 22

RESULT 89

1 US-09-680-497-160
2 Sequence 160, Application US/09680497
3 Patent No. 6709828
4 GENERAL INFORMATION:
5 APPLICANT:
6 TITLE OF INVENTION: PROCESS FOR THE DETERMINATION OF PEPTIDES
7 TITLE OF INVENTION: CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND THEIR
8 TITLE OF INVENTION: IN A PROCESS FOR DETERMINATION OF ANTIBODIES OR BIOTINYLATED
9 TITLE OF INVENTION: PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT EPITOPES,
10 TITLE OF INVENTION: PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM
11 NUMBER OF SEQUENCES: 453
12 COMPUTER READABLE FORM:
13 MEDIUM TYPE: Floppy disk
14 COMPUTER: IBM PC compatible
15 OPERATING SYSTEM: PC-DOS/MS-DOS
16 SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
17 CURRENT APPLICATION DATA:
18 APPLICATION NUMBER: US/09/680,497
19 FILING DATE: 06-OCT-2000
20 PRIOR APPLICATION DATA:
21 APPLICATION NUMBER: US/08/146,028
22 FILING DATE: 22-NOV-1993
23 INFORMATION FOR SEQ ID NO: 160:
24 SEQUENCE CHARACTERISTICS:
25 LENGTH: 24 amino acids
26 TYPE: amino acid
27 STRANDEDNESS: single

TOPOLOGY: linear
MOLECULE TYPE: peptide
US-09-680-497-160

Query Match 100.0%; Score 77; DB 4; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.3e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRFVTVIGK 15
Db 8 RIQGPGRFVTVIGK 22

RESULT 90
PCT-US92-06688-12
Sequence 12, Application PC/TUS9206688
GENERAL INFORMATION:
APPLICANT: REPLIGEN CORPORATION
APPLICANT: THE ROCKEFELLER UNIVERSITY
TITLE OF INVENTION: MULTIPLE ANTIGEN PEPTIDES FOR USE AS HIV
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson
STREET: 225 Franklin Street
CITY: Boston
STATE: Massachusetts
COUNTRY: U.S.A.
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM PS/2 Model 50Z or 55SX
OPERATING SYSTEM: IBM P.C. DOS (Version 3.30)
SOFTWARE: WordPerfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/06688
FILING DATE: 19920811
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 744,281
FILING DATE: 13 August 1992
ATTORNEY/AGENT INFORMATION:
NAME: Paul T. Clark
REGISTRATION NUMBER: 30,162
REFERENCE/DOCKET NUMBER: 00231/052W01
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 542-5070
TELEFAX: (617) 542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 24
TYPE: AMINO ACID
TOPOLOGY: linear
PCT-US92-06688-12

Query Match 100.0%; Score 77; DB 5; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.3e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRFVTVIGK 15
Db 8 RIQGPGRFVTVIGK 22

RESULT 91
PCT-US92-10378-3
Sequence 3, Application PC/TUS9210378
GENERAL INFORMATION:
APPLICANT: BOARD OF REGENTS, THE UNIVERSITY OF
APPLICANT: TEXAS SYSTEM
APPLICANT: SASTRY, Jagannatha K.
APPLICANT: ARLINGHAUS, Ralph B.

APPLICANT: PLATSOUCAS, Chris D.
APPLICANT: NEHETE, Pramod N.
TITLE OF INVENTION: METHODS AND COMPOSITIONS
FOR ELICITING IMMUNE OR ANTI-INFECTION RESPONSES
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:
ADDRESSEE: Arnold, White & Durkee
STREET: P.O. Box 4433
CITY: Houston
STATE: Texas
COUNTRY: US
ZIP: 77210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/10378
FILING DATE: 19921202
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/800,932
FILING DATE: December 2, 1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/945865
FILING DATE: September 16, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Parker, David L.
REGISTRATION NUMBER: 32,165
REFERENCE/DOCKET NUMBER: UTFC305PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 512-320-7200
TELEFAX: 512-474-7577
TELEX: Not Applicable
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 amino acids
TYPE: AMINO ACID
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
PCT-US92-10378-3
Query Match 100.0%; Score 77; DB 5; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.3e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRFVTVIGK 15
Db 8 RIQGPGRFVTVIGK 22

RESULT 92
US-07-950-571A-1
Sequence 1, Application US/07950571A
Patent No. 5854400
GENERAL INFORMATION:
APPLICANT: Chang, Tse Wen, Fung, Michael S.C., Sun, Bill N.C., Sun, Cecily R.Y.,
APPLICANT: Chang, Nancy T.
TITLE OF INVENTION: Monoclonal Antibodies which Neutralize HIV-1 Infection
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSEE: Tanox Biosystems, Inc.
STREET: 10301 Stella Link Rd.
CITY: Houston
STATE: Texas
COUNTRY: USA
ZIP: 77025
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Hi Density Diskette
COMPUTER: IBM PS/2
OPERATING SYSTEM: DOS, Version 3.30


```
; SOFTWARE: Wordperfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/950,571A
; FILING DATE: 19920922
; CLASSIFICATION: 435
; PRIOR APPLICATION NUMBER: No. 5854400 07/767,533
; FILING DATE: 09/26/1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Mirabel, Eric P.
; REGISTRATION NUMBER: 31,211
; REFERENCE/DOCKET NUMBER: TXN87-11BBC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713-664-2288
; TELEFAX: 713-664-8914
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 amino acids
; TYPE: AMINO ACID
; TOPOLOGY: Linear
; US-07-950-571A-1

Query Match 100.0%; Score 77; DB 2; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQPGGRAFTVIGK 15
   |||||
Db 11 RIQPGGRAFTVIGK 25

RESULT 93
US-08-266-448-1
; Sequence 1, Application US/08266448
; Patent No. 5876724
; GENERAL INFORMATION:
; APPLICANT: GIRARD, Marc
; TITLE OF INVENTION: INDUCTION OF PROTECTION AGAINST VIRAL
; TITLE OF INVENTION: INFECTION BY SYNERGY BETWEEN VIRUS ENVELOPE GLYCOPROTEIN
; TITLE OF INVENTION: AND PEPTIDES CORRESPONDING TO NEUTRALIZATION EPITOPES OF
; TITLE OF INVENTION: THE GLYCOPROTEIN
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FINNEGAN, HENDERSON, FARABOW, GARRETT &
; ADDRESSER: DUNNER, L.L.P
; STREET: 1300 I Street, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/266,448
; FILING DATE: 28-JUN-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/145,664
; FILING DATE: 04-NOV-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/782,241
; FILING DATE: 28-OCT-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/672,647
; FILING DATE: 18-MAR-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/494,749
; FILING DATE: 19-MAR-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Meyers, Kenneth J.
```

```
; REGISTRATION NUMBER: 25,146
; REFERENCE/DOCKET NUMBER: 03495.0088-13
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4132
; TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: not relevant
; MOLECULE TYPE: peptide
; US-08-266-448-1

Query Match 100.0%; Score 77; DB 2; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQPGGRAFTVIGK 15
   |||||
Db 8 RIQPGGRAFTVIGK 22

RESULT 94
US-08-485-324-13
; Sequence 13, Application US/08485324
; Patent No. 6043093
; GENERAL INFORMATION:
; APPLICANT: Wohlstadter, Jacob
; TITLE OF INVENTION: SELECTION METHODS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris, & Safford
; ADDRESSER: c/o Barry Evans
; STREET: 530 Fifth Avenue
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/485,324
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/235,437
; FILING DATE: 29-APR-1994
; APPLICATION NUMBER: US 07/852,412
; FILING DATE: 16-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Evans, Barry
; REGISTRATION NUMBER: 22,802
; REFERENCE/DOCKET NUMBER: 370132-2000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-485-324-13

Query Match 100.0%; Score 77; DB 3; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQPGGRAFTVIGK 15
```

```
Db      ||||| ||||| ||||| |||||
      8 RIQGPGRFVTVIGK 22

RESULT 95
US-08-485-324-31
; Sequence 31, Application US/08485324
; Patent No. 6043093
; GENERAL INFORMATION:
; APPLICANT: Wohlstadter, Jacob
; TITLE OF INVENTION: SELECTION METHODS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris, & Safford
; ADDRESSEE: c/o Barry Evans
; STREET: 530 Fifth Avenue
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/485,324
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/235,437
; FILING DATE: 29-APR-1994
; APPLICATION NUMBER: US 07/852,412
; FILING DATE: 16-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Evans, Barry
; REGISTRATION NUMBER: 22,802
; REFERENCE/DOCKET NUMBER: 370132-2000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-485-324-31

Query Match      100.0%; Score 77; DB 3; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 RIQGPGRFVTVIGK 15
Db      ||||| ||||| ||||| |||||
      8 RIQGPGRFVTVIGK 22

RESULT 97
US-08-447-506-31
; Sequence 31, Application US/08447506
; Patent No. 6066499
; GENERAL INFORMATION:
; APPLICANT: Wohlstadter, Jacob
; TITLE OF INVENTION: SELECTION METHODS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris, & Safford
; ADDRESSEE: c/o Barry Evans
; STREET: 530 Fifth Avenue
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/447,506
; FILING DATE: 23-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/235,437
; FILING DATE: 29-APR-1994
; APPLICATION NUMBER: US 07/852,412
; FILING DATE: 16-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Evans, Barry
; REGISTRATION NUMBER: 22,802
; REFERENCE/DOCKET NUMBER: 370132-2000
; US-08-447-506-13

Query Match      100.0%; Score 77; DB 3; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 RIQGPGRFVTVIGK 15
Db      ||||| ||||| ||||| |||||
      8 RIQGPGRFVTVIGK 22

RESULT 96
US-08-447-506-13
; Sequence 13, Application US/08447506
; Patent No. 6066499
; GENERAL INFORMATION:
; APPLICANT: Wohlstadter, Jacob
; TITLE OF INVENTION: SELECTION METHODS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris, & Safford
; ADDRESSEE: c/o Barry Evans
; STREET: 530 Fifth Avenue
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/447,506
; FILING DATE: 23-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/235,437
; FILING DATE: 29-APR-1994
; APPLICATION NUMBER: US 07/852,412
; FILING DATE: 16-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Evans, Barry
; REGISTRATION NUMBER: 22,802
; REFERENCE/DOCKET NUMBER: 370132-2000
; US-08-447-506-13
```

TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
TELEFAX: (212) 840-0712
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:
LENGTH: 25 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-447-506-31

Query Match 100.0%; Score 77; DB 3; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGGGFAFVTIGK 15
Db 8 RIQGGGFAFVTIGK 22

RESULT 98

US-08-235-437-13
Sequence 13, Application US/08235437
Patent No. 6087177

GENERAL INFORMATION:
APPLICANT: Wohlstadter, Jacob
TITLE OF INVENTION: SELECTION METHODS
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: Curtis, Morris, & Safford
ADDRESSEE: c/o Barry Evans
STREET: 530 Fifth Avenue
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10036

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/235,437
FILING DATE: 29-APR-1994
CLASSIFICATION: 435

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/852,412
FILING DATE: 16-MAR-1992
ATTORNEY/AGENT INFORMATION:
NAME: Evans, Barry
REGISTRATION NUMBER: 22,802
REFERENCE/DOCKET NUMBER: 370132-2000

TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
TELEFAX: (212) 840-0712
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 25 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-235-437-13

Query Match 100.0%; Score 77; DB 3; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGGGFAFVTIGK 15
Db 8 RIQGGGFAFVTIGK 22

RESULT 99

US-08-235-437-31
Sequence 31, Application US/08235437
Patent No. 6087177
GENERAL INFORMATION:
APPLICANT: Wohlstadter, Jacob
TITLE OF INVENTION: SELECTION METHODS
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: Curtis, Morris, & Safford
ADDRESSEE: c/o Barry Evans
STREET: 530 Fifth Avenue
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10036

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/235,437
FILING DATE: 29-APR-1994
CLASSIFICATION: 435

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/852,412
FILING DATE: 16-MAR-1992
ATTORNEY/AGENT INFORMATION:
NAME: Evans, Barry
REGISTRATION NUMBER: 22,802
REFERENCE/DOCKET NUMBER: 370132-2000

TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
TELEFAX: (212) 840-0712
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:
LENGTH: 25 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-235-437-31

Query Match 100.0%; Score 77; DB 3; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGGGFAFVTIGK 15
Db 8 RIQGGGFAFVTIGK 22

RESULT 100

US-08-447-515-13
Sequence 13, Application US/08447515
Patent No. 6162640

GENERAL INFORMATION:
APPLICANT: Wohlstadter, Jacob
TITLE OF INVENTION: SELECTION METHODS
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: Curtis, Morris, & Safford
ADDRESSEE: c/o Barry Evans
STREET: 530 Fifth Avenue
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10036

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:

```
; APPLICATION NUMBER: US/08/447,515
; FILING DATE: 23-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/235,437
; FILING DATE: 29-APR-1994
; APPLICATION NUMBER: US 07/852,412
; FILING DATE: 16-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Evans, Barry
; REGISTRATION NUMBER: 22,802
; REFERENCE/DOCKET NUMBER: 370132-2000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-447-515-13

Query Match      100.0%; Score 77; DB 3; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RIQRGPGRAFTVIGK 15
Db      8 RIQRGPGRAFTVIGK 22

RESULT 102
US-09-593-870A-31
; Sequence 31, Application US/09593870A
; Patent No. 6548643
; GENERAL INFORMATION:
; APPLICANT: Mckenzie, Ian F.C.
; APPLICANT: Apostolopoulos, Vasso
; APPLICANT: Pietersz, Geoff Allan
; TITLE OF INVENTION: Antigen Carbohydrate Compounds and Their
; TITLE OF INVENTION: Use in Immunotherapy
; FILE REFERENCE: 2368-Mckenzie
; CURRENT APPLICATION NUMBER: US/09/593,870A
; CURRENT FILING DATE: 2000-06-14
; PRIOR APPLICATION NUMBER: 09/223,043
; PRIOR FILING DATE: 1998-12-30
; NUMBER OF SEQ ID NOS: 69
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 31
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-593-870A-31

Query Match      100.0%; Score 77; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RIQRGPGRAFTVIGK 15
Db      5 RIQRGPGRAFTVIGK 19

RESULT 103
US-08-455-625-12
; Sequence 12, Application US/08455625
; Patent No. 5932218
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. D.
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
; TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/447,515
; FILING DATE: 23-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/235,437
; FILING DATE: 29-APR-1994
; APPLICATION NUMBER: US 07/852,412
; FILING DATE: 16-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Evans, Barry
; REGISTRATION NUMBER: 22,802
; REFERENCE/DOCKET NUMBER: 370132-2000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 amino acids
; TYPE: amino acid
```

```
/ FILING DATE:
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/060,988
/ FILING DATE: 14-MAY-1993
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Svensson, Leonard R.
/ REGISTRATION NUMBER: 30330
/ REFERENCE/DOCKET NUMBER: 1173-434P
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 703-205-8000
/ TELEFAX: 703-205-8050
/ INFORMATION FOR SEQ ID NO: 12:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 amino acids
/ TYPE: amino acid
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
/ FRAGMENT TYPE: Internal
/ FEATURE:
/ NAME/KEY: Peptide
/ LOCATION: 1..15
/ OTHER INFORMATION: /label= peptide
/ OTHER INFORMATION: /note= "p18-4, see Table v"
US-08-455-625-12

Query Match          96.1%; Score 74; DB 2; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e-05;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQKGPGRFVTVIGK 15
   |||:|||||
Db 1 RIQKGPGRFVTVIGK 15

RESULT 104
US-08-455-685-12
; Sequence 12, Application US/08455685
; Patent No. 6214347
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. David
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
; TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
; TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/455,685
; FILING DATE: 31-MAY-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/060,988
; FILING DATE: 14-MAY-1993
; APPLICATION NUMBER: 07/847,311
; FILING DATE: 06-MAR-1992
; APPLICATION NUMBER: 07/751,998
; FILING DATE: 29-AUG-1991
; APPLICATION NUMBER: 07/148,692
; FILING DATE: 26-JAN-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Beattie, Ingrid A.
; REGISTRATION NUMBER: P-42,306
; REFERENCE/DOCKET NUMBER: 08830/022001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: Internal
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..15
; OTHER INFORMATION: /label= peptide
; OTHER INFORMATION: /note= "p18-4, see Table v"
US-08-455-625-12

Query Match          96.1%; Score 74; DB 3; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e-05;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQKGPGRFVTVIGK 15
   |||:|||||
Db 1 RIQKGPGRFVTVIGK 15

RESULT 105
US-08-060-988A-12
; Sequence 12, Application US/08060988A
; Patent No. 6294322
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. David
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
; TITLE OF INVENTION: THAT ELICIT
; TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
; TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/060,988A
; FILING DATE: 14-MAY-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/847,311
; FILING DATE: 06-MAR-1992
; APPLICATION NUMBER: 07/751,998
; FILING DATE: 29-AUG-1991
; APPLICATION NUMBER: 07/148,692
; FILING DATE: 26-JAN-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Beattie, Ingrid A.
; REGISTRATION NUMBER: P-42,306
; REFERENCE/DOCKET NUMBER: 08830/022001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: Internal
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..15
; OTHER INFORMATION: /label= peptide
; OTHER INFORMATION: /note= "p18-4, see Table v"
US-08-455-625-12
```

; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-060-988A-12

Query Match 96.1%; Score 74; DB 3; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e-05;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1 RIQKPGRAFTVIGK 15
|||:|||||
Db 1 RIQKPGRAFTVIGK 15

RESULT 106

PCT-US94-05142-12

; Sequence 12, Application PC/TUS9405142
; GENERAL INFORMATION:

; APPLICANT: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
; TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
; TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV

; NUMBER OF SEQUENCES: 36

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Birch, Stewart, Kolasch & Birch

; STREET: P.O. Box 747

; CITY: Falls Church

; STATE: Virginia

; COUNTRY: USA

; ZIP: 22040-0747

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION NUMBER: PCT/US94/05142

; FILING DATE: 13-MAY-1994

; CLASSIFICATION:

; PRIOR APPLICATION DATA: US 08/060,988

; APPLICATION NUMBER: US 08/060,988

; FILING DATE: 14-MAY-1993

; ATTORNEY/AGENT INFORMATION:

; NAME: Svensson, Leonard R.

; REGISTRATION NUMBER: 30330

; REFERENCE/DOCKET NUMBER: 1173-434P

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 703-205-8000

; TELEFAX: 703-205-8050

; INFORMATION FOR SEQ ID NO: 12:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 15 amino acids

; TYPE: amino acid

; TOPOLOGY: linear

; MOLECULE TYPE: peptide

; FRAGMENT TYPE: internal

; FEATURE:

; NAME/KEY: Peptide

; LOCATION: 1..15

; OTHER INFORMATION: /label= peptide

; OTHER INFORMATION: /note= "p18-4, see Table v"

PCT-US94-05142-12

Query Match 96.1%; Score 74; DB 5; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e-05;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1 RIQKPGRAFTVIGK 15
|||:|||||
Db 1 RIQKPGRAFTVIGK 15

RESULT 107

US-08-455-625-17

; Sequence 17, Application US/08455625

; Patent No. 5932218

; GENERAL INFORMATION:

; APPLICANT: Berzofsky, Jay A.

; APPLICANT: Ahlers, Jeffrey D.

; APPLICANT: Pendleton, C. D.

; APPLICANT: Nara, Peter

; APPLICANT: Shirai, Mutsunori

; TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT

; TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T

; TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV

; NUMBER OF SEQUENCES: 36

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Birch, Stewart, Kolasch & Birch

; STREET: P.O. Box 747

; CITY: Falls Church

; STATE: Virginia

; COUNTRY: USA

; ZIP: 22040-0747

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION NUMBER: US/08/455,625

; FILING DATE:

; CLASSIFICATION: 435

; PRIOR APPLICATION DATA: US 08/060,988

; APPLICATION NUMBER: US 08/060,988

; FILING DATE: 14-MAY-1993

; ATTORNEY/AGENT INFORMATION:

; NAME: Svensson, Leonard R.

; REGISTRATION NUMBER: 30330

; REFERENCE/DOCKET NUMBER: 1173-434P

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 703-205-8000

; TELEFAX: 703-205-8050

; INFORMATION FOR SEQ ID NO: 17:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 15 amino acids

; TYPE: amino acid

; TOPOLOGY: linear

; MOLECULE TYPE: peptide

; FRAGMENT TYPE: internal

; FEATURE:

; NAME/KEY: Peptide

; LOCATION: 1..15

; OTHER INFORMATION: /label= peptide

; OTHER INFORMATION: /note= "p18-9, see Table v"

US-08-455-625-17

Query Match 94.8%; Score 73; DB 2; Length 15;
Best Local Similarity 93.3%; Pred. No. 3.6e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 RIQKPGRAFTVIGK 15
|||:|||||
Db 1 RIQKPGRAFTVIGK 15

RESULT 108

US-08-455-625-23

; Sequence 23, Application US/08455625

; Patent No. 5932218

; GENERAL INFORMATION:

; APPLICANT: Berzofsky, Jay A.

; APPLICANT: Ahlers, Jeffrey D.

; APPLICANT: Pendleton, C. D.

; APPLICANT: Nara, Peter

; APPLICANT: Shirai, Mutsunori

; TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT

```
;
; TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
; TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/455,625
; FILING DATE:
;
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/060,988
; FILING DATE: 14-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Svensson, Leonard R.
; REGISTRATION NUMBER: 30330
; REFERENCE/DOCKET NUMBER: 1173-434P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-205-8000
; TELEFAX: 703-205-8050
;
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..15
; OTHER INFORMATION: /label= peptide
;
; OTHER INFORMATION: /note= "P18-15, see Table V"
;
US-08-455-625-23

Query Match 94.8%; Score 73; DB 2; Length 15;
Best Local Similarity 93.3%; Pred. No. 3.6e-05;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGPAFTVIGK 15
Db 1 RIQPGGPAFTVIGQ 15

RESULT 109
US-08-455-695-17
; Sequence 17, Application US/08455685
; Patent No. 6214347
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. David
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
; TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
; TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/455,685
; FILING DATE: 31-MAY-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/060,988
; FILING DATE: 14-MAY-1993
; APPLICATION NUMBER: 07/847,311
; FILING DATE: 06-MAR-1992
; APPLICATION NUMBER: 07/751,998
; FILING DATE: 29-AUG-1991
; APPLICATION NUMBER: 07/148,692
; FILING DATE: 26-JAN-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Beattie, Ingrid A.
; REGISTRATION NUMBER: P-42,306
; REFERENCE/DOCKET NUMBER: 08830/022003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
;
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
;
US-08-455-685-17

Query Match 94.8%; Score 73; DB 3; Length 15;
Best Local Similarity 93.3%; Pred. No. 3.6e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RIQPGGPAFTVIGK 15
Db 1 RIQPGGPAFTVIGK 15

RESULT 110
US-08-455-685-23
; Sequence 23, Application US/08455685
; Patent No. 6214347
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. David
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
; TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
; TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/455,685
; FILING DATE: 31-MAY-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/060,988
```

;/ FILING DATE: 14-MAY-1993
;/ APPLICATION NUMBER: 07/847,311
;/ FILING DATE: 06-MAR-1992
;/ APPLICATION NUMBER: 07/751,998
;/ FILING DATE: 29-AUG-1991
;/ APPLICATION NUMBER: 07/148,692
;/ FILING DATE: 26-JAN-1988
;/ ATTORNEY/AGENT INFORMATION:
;/ NAME: Beattie, Ingrid A.
;/ REGISTRATION NUMBER: P-42,306
;/ REFERENCE/DOCKET NUMBER: 08830/022003
;/ TELECOMMUNICATION INFORMATION:
;/ TELEPHONE: 617/542-5070
;/ TELEFAX: 617/542-8906
;/ TELEX: 200154
;/ INFORMATION FOR SEQ ID NO: 23:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 15 amino acids
;/ TYPE: amino acid
;/ TOPOLOGY: linear
;/ MOLECULE TYPE: peptide
;/ US-08-455-685-23

Query Match 94.8%; Score 73; DB 3; Length 15;
Best Local Similarity 93.3%; Pred. No. 3.6e-05;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIGK 15
||| ||| ||| ||| |||
DB 1 RIQRGPGRAFTVIGQ 15

RESULT 111
US-08-060-988A-17
; Sequence 17, Application US/08060988A
; Patent No. 6294322
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. David
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
; TITLE OF INVENTION: THAT ELICIT
; TITLE OF INVENTION: HELPER T-LYMPHOCYTE AND
; TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/060,988A
; FILING DATE: 14-MAY-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/847,311
; FILING DATE: 06-MAR-1992
; APPLICATION NUMBER: 07/751,998
; FILING DATE: 29-AUG-1991
; APPLICATION NUMBER: 07/148,692
; FILING DATE: 26-JAN-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Beattie, Ingrid A.
; REGISTRATION NUMBER: P-42,306
; REFERENCE/DOCKET NUMBER: 08830/022001

;/ TELECOMMUNICATION INFORMATION:
;/ TELEPHONE: 617/542-5070
;/ TELEFAX: 617/542-8906
;/ TELEX: 200154
;/ INFORMATION FOR SEQ ID NO: 17:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 15 amino acids
;/ TYPE: amino acid
;/ TOPOLOGY: linear
;/ MOLECULE TYPE: peptide
;/ US-08-060-988A-17

Query Match 94.8%; Score 73; DB 3; Length 15;
Best Local Similarity 93.3%; Pred. No. 3.6e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIGK 15
||| ||| ||| ||| |||
DB 1 RIQRGPGRAFTVIGK 15

RESULT 112
US-08-060-988A-23
; Sequence 23, Application US/08060988A
; Patent No. 6294322
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. David
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
; TITLE OF INVENTION: THAT ELICIT
; TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
; TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/060,988A
; FILING DATE: 14-MAY-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/847,311
; FILING DATE: 06-MAR-1992
; APPLICATION NUMBER: 07/751,998
; FILING DATE: 29-AUG-1991
; APPLICATION NUMBER: 07/148,692
; FILING DATE: 26-JAN-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Beattie, Ingrid A.
; REGISTRATION NUMBER: P-42,306
; REFERENCE/DOCKET NUMBER: 08830/022001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
;/ INFORMATION FOR SEQ ID NO: 23:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 15 amino acids
;/ TYPE: amino acid
;/ TOPOLOGY: linear
;/ MOLECULE TYPE: peptide
;/ US-08-060-988A-23

Query Match 94.8%; Score 73; DB 3; Length 15;
Best Local Similarity 93.3%; Pred. No. 3.6e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTVIGK 15
Db 1 RIQPGGRAFTVIGQ 15

RESULT 113

PCT-US94-05142-17
; Sequence 17, Application PC/TUS9405142
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
; TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
; TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/05142
; FILING DATE: 13-MAY-1994
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/060,988
; FILING DATE: 14-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Svensson, Leonard R.
; REGISTRATION NUMBER: 30330
; REFERENCE/DOCKET NUMBER: 1173-434P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-205-8050
; TELEFAX: 703-205-8050
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..15
; OTHER INFORMATION: /label= peptide
; OTHER INFORMATION: /note= "p18-9, see Table V"

Query Match 94.8%; Score 73; DB 5; Length 15;
Best Local Similarity 93.3%; Pred. No. 3.6e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTVIGK 15
Db 1 RIQPGGRAFTVIGQ 15

RESULT 114

PCT-US94-05142-23
; Sequence 23, Application PC/TUS9405142
; GENERAL INFORMATION:
; APPLICANT:

; TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
; TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
; TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/05142
; FILING DATE: 13-MAY-1994
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/060,988
; FILING DATE: 14-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Svensson, Leonard R.
; REGISTRATION NUMBER: 30330
; REFERENCE/DOCKET NUMBER: 1173-434P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-205-8000
; TELEFAX: 703-205-8050
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..15
; OTHER INFORMATION: /label= peptide
; OTHER INFORMATION: /note= "p18-15, see Table V"

PCT-US94-05142-23

Query Match 94.8%; Score 73; DB 5; Length 15;
Best Local Similarity 93.3%; Pred. No. 3.6e-05;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTVIGK 15
Db 1 RIQPGGRAFTVIGQ 15

RESULT 115

US-08-455-625-9
; Sequence 9, Application US/08455625
; Patent No. 5932218
; GENERAL INFORMATION:

; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. D.
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori

; TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
; TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
; TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA

ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,625
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..14
OTHER INFORMATION: /label= peptide
OTHER INFORMATION: /note= "p18-1, see Table V"
US-08-455-625-9

Query Match 93.5%; Score 72; DB 2; Length 14;
Best Local Similarity 100.0%; Pred. No. 4.8e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 IORGPGRAFTVIGK 15
Db 1 IORGPGRAFTVIGK 14

RESULT 116

US-08-455-685-9
Sequence 9, Application US/08455685
Patent No. 6214347
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 40
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,685
FILING DATE: 31-MAY-1995
PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/060,988
FILING DATE: 14-MAY-1993
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022003
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-455-685-9

Query Match 93.5%; Score 72; DB 3; Length 14;
Best Local Similarity 100.0%; Pred. No. 4.8e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 IORGPGRAFTVIGK 15
Db 1 IORGPGRAFTVIGK 14

RESULT 117

US-08-060-988A-9
Sequence 9, Application US/08060988A
Patent No. 6294322
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
TITLE OF INVENTION: THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/060,988A
FILING DATE: 14-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306

```
; REFERENCE/DOCKET NUMBER: 08830/022001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; PCT-US94-05142-9

Query Match          93.5%; Score 72; DB 3; Length 14;
Best Local Similarity 100.0%; Pred. No. 4.8e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2 IORGPGRAFTVIGK 15
DB      1 IORGPGRAFTVIGK 14

RESULT 118
PCT-US94-05142-9
; Sequence 9, Application PC/TUS9405142
; GENERAL INFORMATION:
; APPLICANT: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
; TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
; TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/05142
; FILING DATE: 13-MAY-1994
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/060,988
; FILING DATE: 14-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Svensson, Leonard R.
; REGISTRATION NUMBER: 30330
; REFERENCE/DOCKET NUMBER: 1173-434P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-205-8000
; TELEFAX: 703-205-8050
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..14
; OTHER INFORMATION: /label= peptide
; OTHER INFORMATION: /note= "p18-1, see Table V"
; PCT-US94-05142-9

Query Match          93.5%; Score 72; DB 5; Length 14;
Best Local Similarity 100.0%; Pred. No. 4.8e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

PCT-US94-05142-9
```

```
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2 IORGPGRAFTVIGK 15
DB      1 IORGPGRAFTVIGK 14

RESULT 119
PCT-US95-03236-29
; Sequence 29, Application PC/TUS9503236
; GENERAL INFORMATION:
; APPLICANT: University of Southern California
; TITLE OF INVENTION: Methods to Diagnose and Treat HIV-1
; TITLE OF INVENTION: Infection
; NUMBER OF SEQUENCES: 66
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Campbell and Flores
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego
; STATE: California
; COUNTRY: USA
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/03236
; FILING DATE: 13-MAR-1995
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Imbra, Richard J.
; REGISTRATION NUMBER: 37,643
; REFERENCE/DOCKET NUMBER: PP-SI 1394
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 535-9001
; TELEFAX: (619) 535-8949
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; PCT-US95-03236-29

Query Match          93.5%; Score 72; DB 5; Length 14;
Best Local Similarity 100.0%; Pred. No. 4.8e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RIORGPGRAFTVIG 14
DB      1 RIORGPGRAFTVIG 14

RESULT 120
PCT-US95-03236-52
; Sequence 52, Application PC/TUS9503236
; GENERAL INFORMATION:
; APPLICANT: University of Southern California
; TITLE OF INVENTION: Methods to Diagnose and Treat HIV-1
; TITLE OF INVENTION: Infection
; NUMBER OF SEQUENCES: 66
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Campbell and Flores
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego
; STATE: California
; COUNTRY: USA
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
```

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/03236
FILING DATE: 13-MAR-1995
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Imbra, Richard J.
REGISTRATION NUMBER: 37,643
REFERENCE/DOCKET NUMBER: FP-SI 1394
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 535-9001
TELEFAX: (619) 535-8949
INFORMATION FOR SEQ ID NO: 52:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
PCT-US95-03236-52

Query Match 93.5%; Score 72; DB 5; Length 14;
Best Local Similarity 100.0%; Pred. No. 4.8e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 RIQPGGPAFTVIG 14
Db 1 RIQPGGPAFTVIG 14

RESULT 121
US-08-704-170-72
Sequence 72, Application US/08704170
Patent No. 5707626
GENERAL INFORMATION:
APPLICANT: Douvas, Angeline
APPLICANT: Takehana, Yoshi
APPLICANT: Ehresmann, Glenn
TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR
TITLE OF INVENTION: IMMUNOINFECTIVE CLUSTER VIRUS INFECTIONS
NUMBER OF SEQUENCES: 121
CORRESPONDENCE ADDRESS:
ADDRESSEE: Robbins, Berliner & Carson
STREET: 201 No. 5707626th Figueroa Street, Suite 500
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90012
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/704,170
FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/029,850
FILING DATE: 11-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Spitals, John P.
REGISTRATION NUMBER: 29,215
REFERENCE/DOCKET NUMBER: 1920-331
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 977-1001
TELEFAX: (213) 977-1003
INFORMATION FOR SEQ ID NO: 72:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide

US-08-704-170-72

Query Match 93.5%; Score 72; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 RIQPGGPAFTVIG 14
Db 2 RIQPGGPAFTVIG 15

RESULT 122
US-08-455-625-19
Sequence 19, Application US/08455625
Patent No. 5932218
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. D.
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,625
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..15
OTHER INFORMATION: /label= peptide
OTHER INFORMATION: /note= "p18-11, see Table v"
US-08-455-625-19

Query Match 93.5%; Score 72; DB 2; Length 15;
Best Local Similarity 93.3%; Pred. No. 5.2e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1 RIQPGGPAFTVIG 15
Db 1 RIQPGGPAFTVIG 15

RESULT 123
US-08-455-625-20
; Sequence 20, Application US/08455625
; Patent No. 5932218
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. D.
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
; TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/455,625
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/060,988
; FILING DATE: 14-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Svensson, Leonard R.
; REGISTRATION NUMBER: 30330
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-205-8000
; TELEFAX: 703-205-8050
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..15
; OTHER INFORMATION: /label= peptide
; OTHER INFORMATION: /note= "p18-12, see Table v"
US-08-455-625-20
Query Match 93.5%; Score 72; DB 2; Length 15;
Best Local Similarity 93.3%; Pred. No. 5.2e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 RIQRGPGRAFTVIGK 15
Db 1 RIQRGPGRAFVAIGK 15
RESULT 124
US-08-455-625-21
; Sequence 21, Application US/08455625
; Patent No. 5932218
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. D.
; APPLICANT: Nara, Peter
; TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
; TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/455,625
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/060,988
; FILING DATE: 14-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Svensson, Leonard R.
; REGISTRATION NUMBER: 30330
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-205-8000
; TELEFAX: 703-205-8050
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..15
; OTHER INFORMATION: /label= peptide
; OTHER INFORMATION: /note= "p18-12, see Table v"
US-08-455-625-20
Query Match 93.5%; Score 72; DB 2; Length 15;
Best Local Similarity 93.3%; Pred. No. 5.2e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 RIQRGPGRAFTVIGK 15
Db 1 RIQRGPGRAFVAIGK 15

APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,625
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..15
OTHER INFORMATION: /label= peptide
OTHER INFORMATION: /note= "p18-13, see Table v"
US-08-455-625-21
Query Match 93.5%; Score 72; DB 2; Length 15;
Best Local Similarity 93.3%; Pred. No. 5.2e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 RIQRGPGRAFTVIGK 15
Db 1 RIQRGPGRAFTVIGK 15
RESULT 125
US-08-455-685-19
; Sequence 19, Application US/08455685
; Patent No. 6214347
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. David
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
; TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA

COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,685
FILING DATE: 31-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/060,988
FILING DATE: 14-MAY-1993
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022003
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-455-685-19
Query Match 93.5%; Score 72; DB 3; Length 15;
Best Local Similarity 93.3%; Pred. No. 5.2e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 RIQRGGRGFVTVGK 15
Db 1 RIQRGGRGFVTVGK 15
RESULT 126
US-08-455-685-20
Sequence 20, Application US/08455685
Patent No. 6214347
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 40
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,685
FILING DATE: 31-MAY-1995

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/060,988
FILING DATE: 14-MAY-1993
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022003
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 20:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-455-685-20
Query Match 93.5%; Score 72; DB 3; Length 15;
Best Local Similarity 93.3%; Pred. No. 5.2e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 RIQRGGRGFVTVGK 15
Db 1 RIQRGGRGFVTVGK 15
RESULT 127
US-08-455-685-21
Sequence 21, Application US/08455685
Patent No. 6214347
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 40
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,685
FILING DATE: 31-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/060,988
FILING DATE: 14-MAY-1993
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:

```
; NAME: Beattie, Ingrid A.
; REGISTRATION NUMBER: P-42,306
; REFERENCE/DOCKET NUMBER: 08830/022003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-455-685-21

Query Match          93.5%; Score 72; DB 3; Length 15;
Best Local Similarity 93.3%; Pred. No. 5.2e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQGPGRFAVTIGK 15
   |||||
Db 1 RIQGPGRFAVTIGK 15

RESULT 128
US-08-060-988A-19
; Sequence 19, Application US/08060988A
; Patent No. 6294322
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. David
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
; TITLE OF INVENTION: THAT ELICIT
; TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
; TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/060,988A
; FILING DATE: 14-MAY-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/847,311
; FILING DATE: 06-MAR-1992
; APPLICATION NUMBER: 07/751,998
; FILING DATE: 29-AUG-1991
; APPLICATION NUMBER: 07/148,692
; FILING DATE: 26-JAN-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Beattie, Ingrid A.
; REGISTRATION NUMBER: P-42,306
; REFERENCE/DOCKET NUMBER: 08830/022001
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-455-685-21

Query Match          93.5%; Score 72; DB 3; Length 15;
Best Local Similarity 93.3%; Pred. No. 5.2e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQGPGRFAVTIGK 15
   |||||
Db 1 RIQGPGRFAVTIGK 15
```

```
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-060-988A-19

Query Match          93.5%; Score 72; DB 3; Length 15;
Best Local Similarity 93.3%; Pred. No. 5.2e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQGPGRFAVTIGK 15
   |||||
Db 1 RIQGPGRFAVTIGK 15

RESULT 129
US-08-060-988A-20
; Sequence 20, Application US/08060988A
; Patent No. 6294322
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. David
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
; TITLE OF INVENTION: THAT ELICIT
; TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
; TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/060,988A
; FILING DATE: 14-MAY-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/847,311
; FILING DATE: 06-MAR-1992
; APPLICATION NUMBER: 07/751,998
; FILING DATE: 29-AUG-1991
; APPLICATION NUMBER: 07/148,692
; FILING DATE: 26-JAN-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Beattie, Ingrid A.
; REGISTRATION NUMBER: P-42,306
; REFERENCE/DOCKET NUMBER: 08830/022001
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-060-988A-20

Query Match          93.5%; Score 72; DB 3; Length 15;
Best Local Similarity 93.3%; Pred. No. 5.2e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQGPGRFAVTIGK 15
   |||||
Db 1 RIQGPGRFAVTIGK 15
```

RESULT 130
US-08-060-988A-21
; Sequence 21, Application US/08060988A
; Patent No. 6294322
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. David
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: MULTITERMINANT PEPTIDES
; TITLE OF INVENTION: THAT ELICIT
; TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
; TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/060,988A
; FILING DATE: 14-MAY-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/847,311
; FILING DATE: 06-MAR-1992
; APPLICATION NUMBER: 07/751,998
; FILING DATE: 29-AUG-1991
; APPLICATION NUMBER: 07/148,692
; FILING DATE: 26-JAN-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Beattie, Ingrid A.
; REGISTRATION NUMBER: P-42,306
; REFERENCE/DOCKET NUMBER: 08830/022001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-060-988A-21
Query Match 93.5%; Score 72; DB 3; Length 15;
Best Local Similarity 93.3%; Pred. No. 5.2e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 RIQRGPGRAFVTGK 15
Db 1 RIQRGPGRAFVTGK 15
RESULT 131
PCT-US94-02631-72
; Sequence 72, Application PC/TUS9402631
; GENERAL INFORMATION:
; APPLICANT: Douvas, Angeline
; APPLICANT: Takehana, Yoshi
; APPLICANT: Ehresmann, Glenn
; TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR
; TITLE OF INVENTION: IMMUNOINFECTIVE CLUSTER VIRUS INFECTIONS
; NUMBER OF SEQUENCES: 121
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Robbins, Berliner & Carson
; STREET: 201 North Figueroa Street, Suite 500
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90012
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/02631
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/029,850
; FILING DATE: 11-MAR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Spitals, John P.
; REGISTRATION NUMBER: 29,215
; REFERENCE/DOCKET NUMBER: 1920-331
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 977-1001
; TELEFAX: (213) 977-1003
; INFORMATION FOR SEQ ID NO: 72:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
PCT-US94-02631-72
Query Match 93.5%; Score 72; DB 5; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RIQRGPGRAFVTIG 14
Db 2 RIQRGPGRAFVTIG 15
RESULT 132
PCT-US94-05142-19
; Sequence 19, Application PC/TUS9405142
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
; TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
; TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/05142
; FILING DATE: 13-MAY-1994
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/060,988
; FILING DATE: 14-MAY-1993
; ATTORNEY/AGENT INFORMATION:

; NAME: Svensson, Leonard R.
; REGISTRATION NUMBER: 30330
; REFERENCE/DOCKET NUMBER: 1173-434P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-205-8000
; TELEFAX: 703-205-8050
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..15
; OTHER INFORMATION: /label= peptide
; OTHER INFORMATION: /note= "p18-11, see Table V"
PCT-US94-05142-19

Query Match 93.5%; Score 72; DB 5; Length 15;
Best Local Similarity 93.3%; Pred. No. 5.2e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTVIGK 15
||| ||| ||| ||| |||
Db 1 RIQPGGRAFTVIGK 15

RESULT 133
PCT-US94-05142-20
; Sequence 20, Application PC/TUS9405142
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
; TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
; TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/05142
; FILING DATE: 13-MAY-1994
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/060,988
; FILING DATE: 14-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Svensson, Leonard R.
; REGISTRATION NUMBER: 30330
; REFERENCE/DOCKET NUMBER: 1173-434P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-205-8000
; TELEFAX: 703-205-8050
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
; FEATURE:
; NAME/KEY: Peptide

; LOCATION: 1..15
; OTHER INFORMATION: /label= peptide
; OTHER INFORMATION: /note= "p18-12, see Table V"
PCT-US94-05142-20

Query Match 93.5%; Score 72; DB 5; Length 15;
Best Local Similarity 93.3%; Pred. No. 5.2e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTVIGK 15
||| ||| ||| ||| |||
Db 1 RIQPGGRAFTVIGK 15

RESULT 134
PCT-US94-05142-21
; Sequence 21, Application PC/TUS9405142
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
; TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
; TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/05142
; FILING DATE: 13-MAY-1994
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/060,988
; FILING DATE: 14-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Svensson, Leonard R.
; REGISTRATION NUMBER: 30330
; REFERENCE/DOCKET NUMBER: 1173-434P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-205-8000
; TELEFAX: 703-205-8050
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..15
; OTHER INFORMATION: /label= peptide
; OTHER INFORMATION: /note= "p18-13, see Table V"
PCT-US94-05142-21

Query Match 93.5%; Score 72; DB 5; Length 15;
Best Local Similarity 93.3%; Pred. No. 5.2e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTVIGK 15
||| ||| ||| ||| |||
Db 1 RIQPGGRAFTVIGK 15

RESULT 135

US-08-257-528B-35
; Sequence 35, Application US/08257528B
; Patent No. 5639854
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/257,528B
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-336 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-257-528B-35
Query Match 93.5%; Score 72; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 5.8e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RIQGGPGRAFTVIG 14
Db 4 RIQGGPGRAFTVIG 17
RESULT 136
US-08-460-602A-35
; Sequence 35, Application US/08460602A
; Patent No. 5759769
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/460,602A

; FILING DATE: 02-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/257,528
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/073,378
; FILING DATE: 09-JUN-1993
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-450 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-460-602A-35
Query Match 93.5%; Score 72; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 5.8e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RIQGGPGRAFTVIG 14
Db 4 RIQGGPGRAFTVIG 17
RESULT 137
US-08-463-966A-35
; Sequence 35, Application US/08463966A
; Patent No. 5795955
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/463,966A
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/257,528
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/073,378
; FILING DATE: 09-JUN-1993
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-487 MIS:jb
; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-463-966A-35

Query Match 93.5%; Score 72; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 5.8e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0;

OY 1 RIQGPGRFVTIG 14
DB 4 RIQGPGRFVTIG 17

RESULT 138

US-08-465-217A-35
; Sequence 35, Application US/08465217A
; Patent No. 5800822
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: MSG 1R7

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/465,217A
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/257,528
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/073,378
; FILING DATE: 09-JUN-1993
; CLASSIFICATION: 424

ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-486 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-465-217A-35

Query Match 93.5%; Score 72; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 5.8e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0;

OY 1 RIQGPGRFVTIG 14

DB 4 RIQGPGRFVTIG 17

RESULT 139

US-08-464-329A-35
; Sequence 35, Application US/08464329A
; Patent No. 5817754
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: MSG 1R7

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/464,329A
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424

PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/257,528
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/073,378
; FILING DATE: 09-JUN-1993
; CLASSIFICATION: 424

ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-449 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-464-329A-35

Query Match 93.5%; Score 72; DB 2; Length 17;
Best Local Similarity 100.0%; Pred. No. 5.8e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0;

OY 1 RIQGPGRFVTIG 14
DB 4 RIQGPGRFVTIG 17

RESULT 140

US-08-462-507A-35
; Sequence 35, Application US/08462507A
; Patent No. 5876731
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESS:

ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/462,507A
FILING DATE: 05-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/073,378
FILING DATE: 09-JUN-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/073,378
FILING DATE: 09-JUN-1994
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, MICHAEL I.
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-451 MIS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-462-507A-35

Query Match 93.5%; Score 72; DB 2; Length 17;
Best Local Similarity 100.0%; Pred. No. 5.8e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGGPGRAFTVIG 14
|||||
DB 4 RIQGGPGRAFTVIG 17

RESULT 141
US-08-467-881A-35
Sequence 35, Application US/08467881A
Patent No. 5951986
GENERAL INFORMATION:
APPLICANT: SIA, Charles D.Y.
APPLICANT: CHONG, Pele
APPLICANT: KLEIN, Michel H.
TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/467,881A
FILING DATE: 06-JUN-1995
CLASSIFICATION: 424

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/257,528
FILING DATE: 09-JUN-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/073,378
FILING DATE: 09-JUN-1994
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, MICHAEL I.
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-488 MIS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-467-881A-35

Query Match 93.5%; Score 72; DB 2; Length 17;
Best Local Similarity 100.0%; Pred. No. 5.8e-05;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGGPGRAFTVIG 14
|||||
DB 4 RIQGGPGRAFTVIG 17

RESULT 142
PCT-US92-06688-13
Sequence 13, Application PC/TUS9206688
GENERAL INFORMATION:
APPLICANT: REPLIGEN CORPORATION
APPLICANT: THE ROCKFELLER UNIVERSITY
TITLE OF INVENTION: MULTIPLE ANTIGEN PEPTIDES FOR USE AS HIV
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson
STREET: 225 Franklin Street
CITY: Boston
STATE: Massachusetts
COUNTRY: U.S.A.
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM PS/2 Model 50Z or 55SX
OPERATING SYSTEM: IBM P.C. DOS (Version 3.30)
SOFTWARE: WordPerfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/06688
FILING DATE: 19920811
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 744,281
FILING DATE: 13 August 1992
ATTORNEY/AGENT INFORMATION:
NAME: Paul T. Clark
REGISTRATION NUMBER: 30,162
REFERENCE/DOCKET NUMBER: 00231/052W01
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 542-5070
TELEFAX: (617) 542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 17
TYPE: AMINO ACID
TOPOLOGY: linear

APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,625
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..15
OTHER INFORMATION: /label= peptide
OTHER INFORMATION: /note= "p18-7, see Table v"
US-08-455-625-15
Query Match 92.2%; Score 71; DB 2; Length 15;
Best Local Similarity 93.3%; Pred. No. 7.4e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 RIQGPGRFAFVTIGK 15
Db 1 RIQGPGRFAFVTIGK 15
RESULT 146
US-08-455-625-16
Sequence 16, Application US/08455625
Patent No. 5932218
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. D.
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia

COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,625
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..15
OTHER INFORMATION: /label= peptide
OTHER INFORMATION: /note= "p18-8, see Table v"
US-08-455-625-16
Query Match 92.2%; Score 71; DB 2; Length 15;
Best Local Similarity 93.3%; Pred. No. 7.4e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 RIQGPGRFAFVTIGK 15
Db 1 RIQGPGRFAFVTIGK 15
RESULT 147
US-08-455-625-18
Sequence 18, Application US/08455625
Patent No. 5932218
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. D.
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,625
FILING DATE:

Qy 1 RIQRGPGRAFTVGK 15
 |||||
Db 1 RIQRGPGRAITVGK 15

```

RESULT 148
US-08-455-625-22
; Sequence 22, Application US/08455625
; Patent No. 5932218
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. D.
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
; TITLE OF INVENTION: ELYCITING NEUTRALIZING ANTIBODIES AND
; TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESS: Bitch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/455,625
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/060,988
; FILING DATE: 14-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Svensson, Leonard R.
; REGISTRATION NUMBER: 30330
; REFERENCE/DOCKET NUMBER: 1173-434P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-205-8000

```

```

/ TELEFAX: 703-205-8050
/ INFORMATION FOR SEQ ID NO: 22:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 amino acids
/ TYPE: amino acid
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
/ FRAGMENT TYPE: internal
/ FEATURE:
/ NAME/KEY: Peptide
/ LOCATION: 1..15
/ OTHER INFORMATION: /label= peptide
/ OTHER INFORMATION: /note= "p18-14, see Table V"
US-08-455-625-22

```

Query Match 92.2%; Score 71; DB 2; Length 15;
Best Local Similarity 93.3%; Pred. NO. 7.4e-05;
Matches 14; Conservative 0; Mismatches 1; Indels

Qy 1 RIQRGPGRAFTIGK 15
|||
Db 1 RIQRGPGRAFTIAK 15

RESULT 149

US-08-455-685-11
; Sequence 11, Application US/08455685
; Patent No. 6214347

GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 40
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Window95
SOFTWARE: FastSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,685
FILING DATE: 31-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/060,988
FILING DATE: 14-MAY-1993
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022003
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids

; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-455-685-11

Query Match 92.2%; Score 71; DB 3; Length 15;
Best Local Similarity 93.3%; Pred. No. 7.4e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTVIGK 15
Db 1 RITRGGRAFTVIGK 15

RESULT 150

US-08-455-685-13
; Sequence 13, Application US/08455685
; Patent No. 6214347
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. David
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
; TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
; TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/455,685
; FILING DATE: 31-MAY-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/060,988
; FILING DATE: 14-MAY-1993
; APPLICATION NUMBER: 07/847,311
; FILING DATE: 06-MAR-1992
; APPLICATION NUMBER: 07/751,998
; FILING DATE: 29-AUG-1991
; APPLICATION NUMBER: 07/148,692
; FILING DATE: 26-JAN-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Beattie, Ingrid A.
; REGISTRATION NUMBER: P-42,306
; REFERENCE/DOCKET NUMBER: 08830/022003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-455-685-13

Query Match 92.2%; Score 71; DB 3; Length 15;
Best Local Similarity 93.3%; Pred. No. 7.4e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTVIGK 15

Db 1 RIQAPGRAFTVIGK 15

RESULT 151

US-08-455-685-15
; Sequence 15, Application US/08455685
; Patent No. 6214347
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. David
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
; TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
; TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/455,685
; FILING DATE: 31-MAY-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/060,988
; FILING DATE: 14-MAY-1993
; APPLICATION NUMBER: 07/847,311
; FILING DATE: 06-MAR-1992
; APPLICATION NUMBER: 07/751,998
; FILING DATE: 29-AUG-1991
; APPLICATION NUMBER: 07/148,692
; FILING DATE: 26-JAN-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Beattie, Ingrid A.
; REGISTRATION NUMBER: P-42,306
; REFERENCE/DOCKET NUMBER: 08830/022003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-455-685-15

Query Match 92.2%; Score 71; DB 3; Length 15;
Best Local Similarity 93.3%; Pred. No. 7.4e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTVIGK 15
Db 1 RIQPGGRAFTVIGK 15

RESULT 152

US-08-455-685-16
; Sequence 16, Application US/08455685
; Patent No. 6214347
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.


```
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. David
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
; TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
; TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/455,685
; FILING DATE: 31-MAY-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/060,988
; FILING DATE: 14-MAY-1993
; APPLICATION NUMBER: 07/847,311
; FILING DATE: 06-MAR-1992
; APPLICATION NUMBER: 07/751,998
; FILING DATE: 29-AUG-1991
; APPLICATION NUMBER: 07/148,692
; FILING DATE: 26-JAN-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Beattie, Ingrid A.
; REGISTRATION NUMBER: P-42,306
; REFERENCE/DOCKET NUMBER: 08830/022003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-455-685-16

Query Match 92.2%; Score 71; DB 3; Length 15;
Best Local Similarity 93.3%; Pred. No. 7.4e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQGPGRGAFVTIGK 15
DB 1 RIQGPGRGAFVTIGK 15

RESULT 153
US-08-455-685-18
; Sequence 18, Application US/08455685
; Patent No. 6214347
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. David
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
; TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
; TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
```

```
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/455,685
; FILING DATE: 31-MAY-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/060,988
; FILING DATE: 14-MAY-1993
; APPLICATION NUMBER: 07/847,311
; FILING DATE: 06-MAR-1992
; APPLICATION NUMBER: 07/751,998
; FILING DATE: 29-AUG-1991
; APPLICATION NUMBER: 07/148,692
; FILING DATE: 26-JAN-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Beattie, Ingrid A.
; REGISTRATION NUMBER: P-42,306
; REFERENCE/DOCKET NUMBER: 08830/022003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-455-685-18

Query Match 92.2%; Score 71; DB 3; Length 15;
Best Local Similarity 93.3%; Pred. No. 7.4e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQGPGRGAFVTIGK 15
DB 1 RIQGPGRGAFVTIGK 15

RESULT 154
US-08-455-685-22
; Sequence 22, Application US/08455685
; Patent No. 6214347
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. David
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
; TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
; TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
```

;/ CURRENT APPLICATION DATA:
;/ APPLICATION NUMBER: US/08/455,685
;/ FILING DATE: 31-MAY-1995
;/ PRIOR APPLICATION DATA:
;/ APPLICATION NUMBER: 08/060,988
;/ FILING DATE: 14-MAY-1993
;/ APPLICATION NUMBER: 07/847,311
;/ FILING DATE: 06-MAR-1992
;/ APPLICATION NUMBER: 07/751,998
;/ FILING DATE: 29-AUG-1991
;/ APPLICATION NUMBER: 07/148,692
;/ FILING DATE: 26-JAN-1988
;/ ATTORNEY/AGENT INFORMATION:
;/ NAME: Beattie, Ingrid A.
;/ REGISTRATION NUMBER: P-42,306
;/ REFERENCE/DOCKET NUMBER: 08830/022003
;/ TELEPHONE: 617/542-5070
;/ TELEFAX: 617/542-8906
;/ TELEX: 200154
;/ INFORMATION FOR SEQ ID NO: 22:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 15 amino acids
;/ TYPE: amino acid
;/ TOPOLOGY: linear
;/ MOLECULE TYPE: peptide
;/ US-08-455-685-22

Query Match 92.2%; Score 71; DB 3; Length 15;
Best Local Similarity 93.3%; Pred. No. 7.4e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RIORGPGRAFTVIGK 15
Db 1 RIORGPGRAFTVIK 15

RESULT 155
US-08-060-988A-11
; Sequence 11, Application US/08060988A
; Patent No. 6294322
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. David
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
; TITLE OF INVENTION: THAT ELICIT
; TITLE OF INVENTION: HELPER T-LYMPHOCYTE AND
; TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/060,988A
; FILING DATE: 14-MAY-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/847,311
; FILING DATE: 06-MAR-1992
; APPLICATION NUMBER: 07/751,998
; FILING DATE: 29-AUG-1991
; APPLICATION NUMBER: 07/148,692
; FILING DATE: 26-JAN-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Beattie, Ingrid A.
; REGISTRATION NUMBER: P-42,306
; REFERENCE/DOCKET NUMBER: 08830/022001
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:

;/ FILING DATE: 26-JAN-1988
;/ ATTORNEY/AGENT INFORMATION:
;/ NAME: Beattie, Ingrid A.
;/ REGISTRATION NUMBER: P-42,306
;/ REFERENCE/DOCKET NUMBER: 08830/022001
;/ TELECOMMUNICATION INFORMATION:
;/ TELEPHONE: 617/542-5070
;/ TELEFAX: 617/542-8906
;/ TELEX: 200154
;/ INFORMATION FOR SEQ ID NO: 11:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 15 amino acids
;/ TYPE: amino acid
;/ TOPOLOGY: linear
;/ MOLECULE TYPE: peptide
;/ US-08-060-988A-11

Query Match 92.2%; Score 71; DB 3; Length 15;
Best Local Similarity 93.3%; Pred. No. 7.4e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RIORGPGRAFTVIGK 15
Db 1 RIORGPGRAFTVIK 15

RESULT 156
US-08-060-988A-13
; Sequence 13, Application US/08060988A
; Patent No. 6294322
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. David
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
; TITLE OF INVENTION: THAT ELICIT
; TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
; TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/060,988A
; FILING DATE: 14-MAY-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/847,311
; FILING DATE: 06-MAR-1992
; APPLICATION NUMBER: 07/751,998
; FILING DATE: 29-AUG-1991
; APPLICATION NUMBER: 07/148,692
; FILING DATE: 26-JAN-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Beattie, Ingrid A.
; REGISTRATION NUMBER: P-42,306
; REFERENCE/DOCKET NUMBER: 08830/022001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:

; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-060-988A-13

Query Match 92.2%; Score 71; DB 3; Length 15;
Best Local Similarity 93.3%; Pred. No. 7.4e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQGPGRFAFTVIGK 15
Db 1 RIQAPGRFAFTVIGK 15

RESULT 157

US-08-060-988A-15
; Sequence 15, Application US/08060988A
; Patent No. 6294322
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. David
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
; TITLE OF INVENTION: THAT ELICIT
; TITLE OF INVENTION: HELPER T-LYMPHOCYTE AND
; TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FASTSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/060,988A
; FILING DATE: 14-MAY-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/847,311
; FILING DATE: 06-MAR-1992
; APPLICATION NUMBER: 07/751,998
; FILING DATE: 29-AUG-1991
; APPLICATION NUMBER: 07/148,692
; FILING DATE: 26-JAN-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Beattie, Ingrid A.
; REGISTRATION NUMBER: P-42,306
; REFERENCE/DOCKET NUMBER: 08830/022001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-060-988A-15

Query Match 92.2%; Score 71; DB 3; Length 15;
Best Local Similarity 93.3%; Pred. No. 7.4e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQGPGRFAFTVIGK 15

Db 1 RIQGPGRFAFTVIGK 15

RESULT 158

US-08-060-988A-16
; Sequence 16, Application US/08060988A
; Patent No. 6294322
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. David
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
; TITLE OF INVENTION: THAT ELICIT
; TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
; TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FASTSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/060,988A
; FILING DATE: 14-MAY-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/847,311
; FILING DATE: 06-MAR-1992
; APPLICATION NUMBER: 07/751,998
; FILING DATE: 29-AUG-1991
; APPLICATION NUMBER: 07/148,692
; FILING DATE: 26-JAN-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Beattie, Ingrid A.
; REGISTRATION NUMBER: P-42,306
; REFERENCE/DOCKET NUMBER: 08830/022001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-060-988A-16

Query Match 92.2%; Score 71; DB 3; Length 15;
Best Local Similarity 93.3%; Pred. No. 7.4e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQGPGRFAFTVIGK 15
Db 1 RIQGPGRFAFTVIGK 15

RESULT 159

US-08-060-988A-18
; Sequence 18, Application US/08060988A
; Patent No. 6294322
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.

APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
TITLE OF INVENTION: THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FASTSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/060,988A
FILING DATE: 14-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022001
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-060-988A-18

Query Match 92.2%; Score 71; DB 3; Length 15;
Best Local Similarity 93.3%; Pred. No. 7.4e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RIQGPGRFAVTIGK 15
| | | | | | | | | | | | | | |
Db 1 RIQGPGRFAVTIGK 15

RESULT 160
US-08-060-988A-22
Sequence 22, Application US/08060988A
Patent No. 6294322
GENERAL INFORMATION:
APPLICANT: Herzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
TITLE OF INVENTION: THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street

CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FASTSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/060,988A
FILING DATE: 14-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022001
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-060-988A-22

Query Match 92.2%; Score 71; DB 3; Length 15;
Best Local Similarity 93.3%; Pred. No. 7.4e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RIQGPGRFAVTIGK 15
| | | | | | | | | | | | | | |
Db 1 RIQGPGRFAVTIGK 15

RESULT 161
PCT-US94-05142-11
Sequence 11, Application PC/TUS9405142
GENERAL INFORMATION:
APPLICANT: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/05142
FILING DATE: 13-MAY-1994
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:

```

; NAME: Svensson, Leonard R.
; REGISTRATION NUMBER: 30330
; REFERENCE/DOCKET NUMBER: 1173-434P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-205-8000
; TELEFAX: 703-205-8050
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..15
; OTHER INFORMATION: /label= peptide
; OTHER INFORMATION: /note= "p18-3, see Table v"
PCT-US94-05142-11

Query Match          92.2%; Score 71; DB 5; Length 15;
Best Local Similarity 93.3%; Pred. No. 7.4e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIGK 15
Db 1 RITRGPGRFAFTVIGK 15

RESULT 162
PCT-US94-05142-13
; Sequence 13, Application PC/TUS9405142
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
; TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE: 13-MAY-1994
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/060,988
; FILING DATE: 14-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Svensson, Leonard R.
; REGISTRATION NUMBER: 30330
; REFERENCE/DOCKET NUMBER: 1173-434P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-205-8000
; TELEFAX: 703-205-8050
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..15
; OTHER INFORMATION: /label= peptide
; OTHER INFORMATION: /note= "p18-7, see Table v"
PCT-US94-05142-15

Query Match          92.2%; Score 71; DB 5; Length 15;
Best Local Similarity 93.3%; Pred. No. 7.4e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIGK 15
Db 1 RITRGPGRFAFTVIGK 15

RESULT 164
PCT-US94-05142-13
; Sequence 13, Application PC/TUS9405142
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
; TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE: 13-MAY-1994
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/060,988
; FILING DATE: 14-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Svensson, Leonard R.
; REGISTRATION NUMBER: 30330
; REFERENCE/DOCKET NUMBER: 1173-434P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-205-8000
; TELEFAX: 703-205-8050
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
; FEATURE:
; NAME/KEY: Peptide

```

PCT-US94-05142-16
; Sequence 16, Application PC/TUS9405142
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
; TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
; TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/05142
; FILING DATE: 13-MAY-1994
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/060,988
; FILING DATE: 14-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Svensson, Leonard R.
; REGISTRATION NUMBER: 30330
; REFERENCE/DOCKET NUMBER: 1173-434P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-205-8000
; TELEFAX: 703-205-8050
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..15
; OTHER INFORMATION: /label= peptide
; OTHER INFORMATION: /note= "p18-8, see Table V"
PCT-US94-05142-16

Query Match 92.2%; Score 71; DB 5; Length 15;
Best Local Similarity 93.3%; Pred. No. 7.4e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1 RIQGPGRGAFVTIGK 15
| | | | | | | | | | | | | | |
Db 1 RIQGPGRGAFVTIGK 15

RESULT 165
PCT-US94-05142-18
; Sequence 18, Application PC/TUS9405142
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
; TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
; TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/05142
; FILING DATE: 13-MAY-1994
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/060,988
; FILING DATE: 14-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Svensson, Leonard R.
; REGISTRATION NUMBER: 30330
; REFERENCE/DOCKET NUMBER: 1173-434P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-205-8000
; TELEFAX: 703-205-8050
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..15
; OTHER INFORMATION: /label= peptide
; OTHER INFORMATION: /note= "p18-10, see Table V"
PCT-US94-05142-18

Query Match 92.2%; Score 71; DB 5; Length 15;
Best Local Similarity 93.3%; Pred. No. 7.4e-05;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1 RIQGPGRGAFVTIGK 15
| | | | | | | | | | | | | | |
Db 1 RIQGPGRGAFVTIGK 15

RESULT 166
PCT-US94-05142-22
; Sequence 22, Application PC/TUS9405142
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
; TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
; TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/05142
; FILING DATE: 13-MAY-1994
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/060,988
; FILING DATE: 14-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Svensson, Leonard R.
; REGISTRATION NUMBER: 30330

[illegible]

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RIQRGAGFAVTIGK 15
|||||
Db 1 RIQRGAGFAVTIGK 15

RESULT 169

US-08-060-988A-14
; Sequence 14, Application US/08060988A
; Patent No. 6294322

GENERAL INFORMATION:

APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
TITLE OF INVENTION: THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE AND
TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/060,988A
FILING DATE: 14-MAY-1993

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022001

TELECOMMUNICATION INFORMATION:

TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154

INFORMATION FOR SEQ ID NO: 14:

SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-060-988A-14

Query Match 89.6%; Score 69; DB 3; Length 15;
Best Local Similarity 93.3%; Pred. No. 0.00015;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RIQRGAGFAVTIGK 15
|||||
Db 1 RIQRGAGFAVTIGK 15

RESULT 170

PCT-US94-05142-14
; Sequence 14, Application PC/TUS9405142
; GENERAL INFORMATION:

APPLICANT: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/05142
FILING DATE: 13-MAY-1994
CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 14:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..15
OTHER INFORMATION: /label= peptide
OTHER INFORMATION: /note= "p18-6, see Table V"
PCT-US94-05142-14

Query Match 89.6%; Score 69; DB 5; Length 15;
Best Local Similarity 93.3%; Pred. No. 0.00015;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RIQRGAGFAVTIGK 15
|||||
Db 1 RIQRGAGFAVTIGK 15

RESULT 171

US-08-279-906A-17
; Sequence 17, Application US/08279906A
; Patent No. 5618922

GENERAL INFORMATION:

APPLICANT: Ohno, Tsuneya
APPLICANT: Terada, Masaki
APPLICANT: Yoneda, Yukio
TITLE OF INVENTION: NM03 Antibody Materials and Methods
NUMBER OF SEQUENCES: 27
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
ADDRESSEE: Borun
STREET: 6300 Sears Tower, 233 S. Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606
COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/279,906A
; FILING DATE:
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5618922and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32028
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-279-906A-17

Query Match 88.3%; Score 68; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.00019;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 ORGPGRAFTVIGK 15
DB 1 ORGPGRAFTVIGK 13

RESULT 172
US-08-455-625-10
; Sequence 10, Application US/08455625
; Patent No. 5932218
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. D.
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
; TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
; TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/455,625
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/060,988
; FILING DATE: 14-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Svensson, Leonard R.
; REGISTRATION NUMBER: 30330
; REFERENCE/DOCKET NUMBER: 1173-434P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-205-8000
; TELEFAX: 703-205-8050

; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..14
; OTHER INFORMATION: /label= peptide
; OTHER INFORMATION: /note= "p18-2, see Table V"
; US-08-455-625-10

Query Match 88.3%; Score 68; DB 2; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.0002;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 ORGPGRAFTVIGK 15
DB 2 ORGPGRAFTVIGK 14

RESULT 173
US-08-455-685-10
; Sequence 10, Application US/08455685
; Patent No. 6214347
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. David
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
; TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
; TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/455,685
; FILING DATE: 31-MAY-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/060,988
; FILING DATE: 14-MAY-1993
; APPLICATION NUMBER: 07/847,311
; FILING DATE: 06-MAR-1992
; APPLICATION NUMBER: 07/751,998
; FILING DATE: 29-AUG-1991
; APPLICATION NUMBER: 07/148,692
; FILING DATE: 26-JAN-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Beattie, Ingrid A.
; REGISTRATION NUMBER: P-42,306
; REFERENCE/DOCKET NUMBER: 08830/022003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 amino acids
; TYPE: amino acid

TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-455-685-10

Query Match 88.3%; Score 68; DB 3; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.0002;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 QRGPGRAFTVIGK 15
Db 2 QRGPGRAFTVIGK 14

RESULT 174

US-08-060-988A-10
Sequence 10, Application US/08060988A
Patent No. 6294322

GENERAL INFORMATION:

APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
TITLE OF INVENTION: THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 48

CORRESPONDENCE ADDRESS:

ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: Fast-SEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/060,988A
FILING DATE: 14-MAY-1993

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022001

TELECOMMUNICATION INFORMATION:

TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154

INFORMATION FOR SEQ ID NO: 10:

SEQUENCE CHARACTERISTICS:
LENGTH: 14 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide

US-08-060-988A-10

Query Match 88.3%; Score 68; DB 3; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.0002;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 QRGPGRAFTVIGK 15
Db 2 QRGPGRAFTVIGK 14

RESULT 175

PCT-US94-05142-10

Sequence 10, Application PC/TUS9405142
GENERAL INFORMATION:

APPLICANT:

TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
NUMBER OF SEQUENCES: 36

CORRESPONDENCE ADDRESS:

ADDRESSEE: Birch, Stewart, Kolasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/05142
FILING DATE: 13-MAY-1994
CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050

INFORMATION FOR SEQ ID NO: 10:

SEQUENCE CHARACTERISTICS:
LENGTH: 14 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..14
OTHER INFORMATION: /label= peptide
OTHER INFORMATION: /note= "p18-2, see Table v"

PCT-US94-05142-10

Query Match 88.3%; Score 68; DB 5; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.0002;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 QRGPGRAFTVIGK 15
Db 2 QRGPGRAFTVIGK 14

RESULT 176

US-08-257-528B-51
Sequence 51, Application US/08257528B
Patent No. 5639854

GENERAL INFORMATION:

APPLICANT: SIA, Charles D.Y.
APPLICANT: CHONG, Pele
APPLICANT: KLEIN, Michel H.
TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue

/ CITY: Toronto
/ STATE: Ontario
/ COUNTRY: Canada
/ ZIP: M5G 1R7
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/257,528B
/ FILING DATE: 09-JUN-1994
/ CLASSIFICATION: 424
/ ATTORNEY/AGENT INFORMATION:
/ NAME: STEWART, MICHAEL I.
/ REGISTRATION NUMBER: 24,973
/ REFERENCE/DOCKET NUMBER: 1038-336 MIS.jb
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (416) 595-1155
/ TELEFAX: (416) 595-1163
/ INFORMATION FOR SEQ ID NO: 51:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 20 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-257-528B-51

Query Match 87.0%; Score 67; DB 1; Length 20;
Best Local Similarity 92.9%; Pred. No. 0.00041;
Matches 13; Conservative 0; Mismatches 1; Indels 0;

QY 1 RIQRGPGRAFTVIG 14
Db 7 RIQRGPGRAFTYITG 20

RESULT 177
US-08-460-602A-51
/ Sequence 51, Application US/08460602A
/ Patent No. 5759769
/ GENERAL INFORMATION:
/ APPLICANT: SIA, Charles D.Y.
/ APPLICANT: CHONG, Pele
/ APPLICANT: KLEIN, Michel H.
/ TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
/ NUMBER OF SEQUENCES: 101
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Sim & McBurney
/ STREET: Suite 701, 330 University Avenue
/ CITY: Toronto
/ STATE: Ontario
/ COUNTRY: Canada
/ ZIP: M5G 1R7
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/460,602A
/ FILING DATE: 02-JUN-1995
/ CLASSIFICATION: 424
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/257,528
/ FILING DATE: 09-JUN-1994
/ CLASSIFICATION: 424
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/073,378
/ FILING DATE: 09-JUN-1993
/ CLASSIFICATION: 424
/ ATTORNEY/AGENT INFORMATION:
/ NAME: STEWART, MICHAEL I.

/ REGISTRATION NUMBER: 24,973
/ REFERENCE/DOCKET NUMBER: 1038-450 MIS.jb
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (416) 595-1155
/ TELEFAX: (416) 595-1163
/ INFORMATION FOR SEQ ID NO: 51:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 20 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-460-602A-51

Query Match 87.0%; Score 67; DB 1; Length 20;
Best Local Similarity 92.9%; Pred. No. 0.00041;
Matches 13; Conservative 0; Mismatches 1; Indels 0;

QY 1 RIQRGPGRAFTVIG 14
Db 7 RIQRGPGRAFTYITG 20

RESULT 178
US-08-463-966A-51
/ Sequence 51, Application US/08463966A
/ Patent No. 5795955
/ GENERAL INFORMATION:
/ APPLICANT: SIA, Charles D.Y.
/ APPLICANT: CHONG, Pele
/ APPLICANT: KLEIN, Michel H.
/ TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
/ NUMBER OF SEQUENCES: 101
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Sim & McBurney
/ STREET: Suite 701, 330 University Avenue
/ CITY: Toronto
/ STATE: Ontario
/ COUNTRY: Canada
/ ZIP: M5G 1R7
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/463,966A
/ FILING DATE: 05-JUN-1995
/ CLASSIFICATION: 424
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/257,528
/ FILING DATE: 09-JUN-1994
/ CLASSIFICATION: 424
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/073,378
/ FILING DATE: 09-JUN-1993
/ CLASSIFICATION: 424
/ ATTORNEY/AGENT INFORMATION:
/ NAME: STEWART, MICHAEL I.
/ REGISTRATION NUMBER: 24,973
/ REFERENCE/DOCKET NUMBER: 1038-487 MIS.jb
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (416) 595-1155
/ TELEFAX: (416) 595-1163
/ INFORMATION FOR SEQ ID NO: 51:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 20 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-463-966A-51

Query Match 87.0%; Score 67; DB 1; Length 20;
Best Local Similarity 92.9%; Pred. No. 0.00041;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQGPGRFVFTIG 14
 |||||
 Db 7 RIQGPGRFVFTIG 20

RESULT 179

US-08-465-217A-51
 ; Sequence 51, Application US/08465217A
 ; Patent No. 580822
 ; GENERAL INFORMATION:
 ; APPLICANT: SIA, Charles D.Y.
 ; APPLICANT: CHONG, Pele
 ; APPLICANT: KLEIN, Michel H.
 ; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
 ; NUMBER OF SEQUENCES: 101
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Sim & McBurney
 ; STREET: Suite 701, 330 University Avenue
 ; CITY: Toronto
 ; STATE: Ontario
 ; COUNTRY: Canada
 ; ZIP: M5G 1R7
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patent In Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/465,217A
 ; FILING DATE: 05-JUN-1995
 ; CLASSIFICATION: 424
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 08/257,528
 ; FILING DATE: 09-JUN-1994
 ; CLASSIFICATION: 424
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 08/073,378
 ; FILING DATE: 09-JUN-1993
 ; CLASSIFICATION: 424
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: STEWART, MICHAEL I.
 ; REGISTRATION NUMBER: 24,973
 ; REFERENCE/DOCKET NUMBER: 1038-486 MIS:j.b
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (416) 595-1155
 ; TELEFAX: (416) 595-1163
 ; INFORMATION FOR SEQ ID NO: 51:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 20 amino acids
 ; TYPE: amino acid
 ; STRANDEDNESS: linear
 ; TOPOLOGY: linear
 ; US-08-465-217A-51

Query Match 87.0%; Score 67; DB 1; Length 20;
 Best Local Similarity 92.9%; Pred. No. 0.00041;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQGPGRFVFTIG 14
 |||||
 Db 7 RIQGPGRFVFTIG 20

RESULT 180

US-08-464-329A-51
 ; Sequence 51, Application US/08464329A
 ; Patent No. 581754
 ; GENERAL INFORMATION:
 ; APPLICANT: SIA, Charles D.Y.
 ; APPLICANT: CHONG, Pele
 ; APPLICANT: KLEIN, Michel H.

; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
 ; NUMBER OF SEQUENCES: 101
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Sim & McBurney
 ; STREET: Suite 701, 330 University Avenue
 ; CITY: Toronto
 ; STATE: Ontario
 ; COUNTRY: Canada
 ; ZIP: M5G 1R7
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patent In Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/464,329A
 ; FILING DATE: 05-JUN-1995
 ; CLASSIFICATION: 424
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 08/257,528
 ; FILING DATE: 09-JUN-1994
 ; CLASSIFICATION: 424
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 08/073,378
 ; FILING DATE: 09-JUN-1993
 ; CLASSIFICATION: 424
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: STEWART, MICHAEL I.
 ; REGISTRATION NUMBER: 24,973
 ; REFERENCE/DOCKET NUMBER: 1038-449 MIS:j.b
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (416) 595-1155
 ; TELEFAX: (416) 595-1163
 ; INFORMATION FOR SEQ ID NO: 51:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 20 amino acids
 ; TYPE: amino acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; US-08-464-329A-51

Query Match 87.0%; Score 67; DB 2; Length 20;
 Best Local Similarity 92.9%; Pred. No. 0.00041;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQGPGRFVFTIG 14
 |||||
 Db 7 RIQGPGRFVFTIG 20

RESULT 181

US-08-462-507A-51
 ; Sequence 51, Application US/08462507A
 ; Patent No. 5876731
 ; GENERAL INFORMATION:
 ; APPLICANT: SIA, Charles D.Y.
 ; APPLICANT: CHONG, Pele
 ; APPLICANT: KLEIN, Michel H.
 ; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
 ; NUMBER OF SEQUENCES: 101
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Sim & McBurney
 ; STREET: Suite 701, 330 University Avenue
 ; CITY: Toronto
 ; STATE: Ontario
 ; COUNTRY: Canada
 ; ZIP: M5G 1R7
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patent In Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/462,507A
FILING DATE: 05-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/257,528
FILING DATE: 09-JUN-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/073,378
FILING DATE: 09-JUN-1993
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, MICHAEL I.
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-451 MIS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 51:
LENGTH: 20 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-462-507A-51

Query Match 87.0%; Score 67; DB 2; Length 20;
Best Local Similarity 92.9%; Pred. No. 0.00041;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQPGGRAFTVIG 14
|||||
Db 7 RIQPGGRAFTVIG 20

RESULT 182

US-08-467-881A-51
Sequence 51, Application US/08467881A
Patent No. 5951986
GENERAL INFORMATION:
APPLICANT: SIA, Charles D.Y.
APPLICANT: CHONG, Pele
APPLICANT: KLEIN, Michel H.
TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/467,881A
FILING DATE: 06-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/257,528
FILING DATE: 09-JUN-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/073,378
FILING DATE: 09-JUN-1993
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, MICHAEL I.
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-488 MIS:jb

TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 51:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-467-881A-51

Query Match 87.0%; Score 67; DB 2; Length 20;
Best Local Similarity 92.9%; Pred. No. 0.00041;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQPGGRAFTVIG 14
|||||
Db 7 RIQPGGRAFTVIG 20

RESULT 183

US-08-930-917A-14
Sequence 14, Application US/08930917A
Patent No. 6146635
GENERAL INFORMATION:
APPLICANT: DUARTE CANO, C. A.
APPLICANT: GUILL N NIETO, G. E.
APPLICANT: MART N DUNN, A. M.
APPLICANT: ALVAREZ ACOSTA, A.
APPLICANT: CARPIO MUÑOZ, E. L.
APPLICANT: QUINTANA V. D.
APPLICANT: G MEZ RODR GUEZ, C. E.
APPLICANT: SILVA RODR GUEZ, R. C.
APPLICANT: NAZ BAL G LVEZ, C.
APPLICANT: LEAL ANGULO, M. J.
TITLE OF INVENTION: System for the expression of heterologous
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lackenbach Siegel Marzullo Aronson & Greenspan
STREET: One Chase Road
CITY: Scarsdale
STATE: New York
COUNTRY: U.S.
ZIP: 10583
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk 3.5'' (1.4 MB).
COMPUTER: Compatible PC IBM (80486, 8 M Ram).
OPERATING SYSTEM: Windows 95.
SOFTWARE: Word Perfect 5.0 for Windows 95.
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/930,917A
FILING DATE: 16-Sep-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/CU97/00001
FILING DATE: 17-Jan-1997
ATTORNEY/AGENT INFORMATION:
NAME: HENEY A. MARZULLO, JR.
REGISTRATION NUMBER: 20,910
REFERENCE/DOCKET NUMBER: P-13
TELECOMMUNICATION INFORMATION:
TELEPHONE: (914) 723-4300
TELEFAX: (914) 723-4301
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 Amino acid residues
TYPE: Amino acid
STRANDEDNESS: Unknown
TOPOLOGY: Unknown
MOLECULE TYPE: Peptide
HYPOTHETICAL: NO
ANTI-SENSE: NO

FRAGMENT TYPE: Internal fragment
ORIGINAL SOURCE:
ORGANISM: VIH-1
INDIVIDUAL ISOLATE: IIB
FEATURE:
OTHER INFORMATION: Central region of the loop V3 belonging to the
OTHER INFORMATION: protein gp120 from the VIH-1, isolation IIB.
US-08-930-917A-14
Query Match 85.7%; Score 66; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.00045;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RIQPGGFAFVTI 13
Db 3 RIQPGGFAFVTI 15
RESULT 184
US-08-493-235-23
Sequence 23, Application US/08493235
Patent No. 5840313
GENERAL INFORMATION:
APPLICANT: Vahlne, Anders
APPLICANT: Svennerholm, Bo
APPLICANT: Rymo, Lars
APPLICANT: Jeansson, Stig
APPLICANT: Horal, Peter
TITLE OF INVENTION: PEPTIDES FOR USE IN VACCINATION AND
TITLE OF INVENTION: INDUCTION OF NEUTRALIZING ANTIBODIES AGAINST HUMAN
TITLE OF INVENTION: IMMUNODEFICIENCY VIRUS
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: KNOBBE, MARTENS, OLSON AND BEAR
STREET: 620 NEWPORT CENTER DRIVE 16TH FLOOR
CITY: NEWPORT BEACH
STATE: CA
COUNTRY: USA
ZIP: 92660
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/493,235
FILING DATE: 20 June 1995
CLASSIFICATION: 530
ATTORNEY/AGENT INFORMATION:
NAME: Kaiser, AnneMarie
REGISTRATION NUMBER: 37,649
REFERENCE/DOCKET NUMBER: METRICS.12CPCI
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-235-8550
TELEFAX: 619-235-0176
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 25 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE: internal
US-08-493-235-23
Query Match 85.7%; Score 66; DB 2; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.00074;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RIQPGGFAFVTI 13
Db 1 RIQPGGFAFVTI 13

Db 13 RIQPGGFAFVTI 25
RESULT 185
US-08-279-906A-19
Sequence 19, Application US/08279906A
Patent No. 5618922
GENERAL INFORMATION:
APPLICANT: Ohno, Tsuneya
APPLICANT: Terada, Masaki
APPLICANT: Yoneda, Yukio
TITLE OF INVENTION: NM03 Antibody Materials and Methods
NUMBER OF SEQUENCES: 27
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
ADDRESSEE: Borun
STREET: 6300 Sears Tower, 233 S. Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/279,906A
FILING DATE:
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: No. 5618922and, Greta E.
REGISTRATION NUMBER: 35,302
REFERENCE/DOCKET NUMBER: 32028
TELECOMMUNICATION INFORMATION:
TELEPHONE: (312) 474-6300
TELEFAX: (312) 474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-279-906A-19
Query Match 83.1%; Score 64; DB 1; Length 19;
Best Local Similarity 92.3%; Pred. No. 0.0012;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 3 RIQPGGFAFVTIGK 15
Db 1 RIQPGGFAFVTIGK 13
RESULT 186
US-08-704-170-52
Sequence 52, Application US/08704170
Patent No. 5707626
GENERAL INFORMATION:
APPLICANT: Douvas, Angeline
APPLICANT: Takehana, Yoshi
APPLICANT: Ehresmann, Glenn
TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR
TITLE OF INVENTION: IMMUNOINFECTIVE CLUSTER VIRUS INFECTIONS
NUMBER OF SEQUENCES: 121
CORRESPONDENCE ADDRESS:
ADDRESSEE: Robbins, Berliner & Carson
STREET: 201 No. 570/626th Figueroa Street, Suite 500
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90012

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/704,170
FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/029,850
FILING DATE: 11-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Spitals, John P.
REGISTRATION NUMBER: 29,215
REFERENCE/DOCKET NUMBER: 1920-331
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 977-1001
TELEFAX: (213) 977-1003
INFORMATION FOR SEQ ID NO: 52:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 amino acids
TYPE: amino acid
STRANDEDNESS: linear
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-704-170-52

Query Match 81.8%; Score 63; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 0.0011;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RGPGRFVTVIGK 15
| | | | | | | | | | | | | | | |
Db 1 RGPGRFVTVIGK 12

RESULT 187
US-08-488-252-30
; Sequence 30, Application US/08488252
; Patent No. 5763160
; GENERAL INFORMATION:
; APPLICANT: Chang Yi Wang
; TITLE OF INVENTION: SYNTHETIC PEPTIDES AND PROCESS
; TITLE OF INVENTION: OF USING SAME FOR THE DETECTION OF ANTIBODIES TO
; TITLE OF INVENTION: HUMAN IMMUNODEFICIENCY VIRUS (HIV) GP120 ENVELOPE
; TITLE OF INVENTION: PROTEIN, DIAGNOSIS OF AIDS AND PRE-AIDS CONDITIONS
; TITLE OF INVENTION: AND AS VACCINES
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORGAN & FINNEGAN
; STREET: 345 PARK AVE.
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10154
COMPUTER READABLE FORM:
MEDIUM TYPE: FLOPPY DISK
COMPUTER: IBM PC COMPATIBLE
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WORDPERFECT 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,252
FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/326,676
FILING DATE: 07-Jun-1995
APPLICATION NUMBER: 07/726,605
FILING DATE: 09-July-1991
APPLICATION NUMBER: 07/663,262
FILING DATE: 01-Mar-1991
APPLICATION NUMBER: 07/155,321
FILING DATE: 12-Feb-1988

ATTORNEY/AGENT INFORMATION:
NAME: Maria C. H. Lin
REGISTRATION NUMBER: 29,323
REFERENCE/DOCKET NUMBER: 1151-4004 US4
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-758-4800
TELEFAX: (212) 751-6849
TELEX: 421792
INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 amino acids
TYPE: amino acids
STRANDEDNESS: Unknown
TOPOLOGY: Unknown
US-08-488-252-30
Query Match 81.8%; Score 63; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 0.0011;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 4 RGPGRFVTVIGK 15
| | | | | | | | | | | | | | | |
Db 1 RGPGRFVTVIGK 12

RESULT 188
PCT-US94-02631-52
; Sequence 52, Application PC/TUS9402631
; GENERAL INFORMATION:
; APPLICANT: Douvas, Angeline
; APPLICANT: Takehana, Yoshi
; APPLICANT: Ehreemann, Glenn
; TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR
; TITLE OF INVENTION: IMMUNOINFECTION CLUSTER VIRUS INFECTIONS
; NUMBER OF SEQUENCES: 121
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Robbins, Berliner & Carson
; STREET: 201 North Figueroa Street, Suite 500
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90012
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/02631
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/029,850
FILING DATE: 11-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Spitals, John P.
REGISTRATION NUMBER: 29,215
REFERENCE/DOCKET NUMBER: 1920-331
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 977-1001
TELEFAX: (213) 977-1003
INFORMATION FOR SEQ ID NO: 52:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
PCT-US94-02631-52

Query Match 81.8%; Score 63; DB 5; Length 12;
Best Local Similarity 100.0%; Pred. No. 0.0011;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;


```

; LENGTH: 21 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-709-209-384

```

Query Match 81.2%; Score 62.5; DB 1; Length 21;
Best Local Similarity 93.3%; Pred. No. 0.0022;
Matches 14; Conservative 0; Mismatches 0; Indels

Qy 1 RIQRPGRFVTIGK 15
|||
Db 8 RIQRPGRFVT-GK 21

RESULT 192

RESOL 192
US-08-303-275-79
: Sequence 79. Application US/08303275

Sequence 79; Application 08/06303273
Patent No. 5766598
GENERAL INFORMATION:
APPLICANT: Paoletti, Enzo
APPLICANT: Tartaglia, James
APPLICANT: Cox, William I.
TITLE OF INVENTION: IMMUNODEFICIENCY VIRUS RECOMBINANT
TITLE OF INVENTION: POXVIRUS VACCINE
NUMBER OF SEQUENCES: 205
CORRESPONDENCE ADDRESS:
ADDRESSEE: Curtis, Morris & Safford
ADDRESSEE: c/o William S. Frommer
STREET: 530 Fifth Avenue
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10036

Query Match 81.2%; Score 62.5; DB 1; Length 21;
Best Local Similarity 93.3%; Pred. No. 0.0022;
Matches 14; Conservative 0; Mismatches 0; Indels

Qy 1 RIQRPGRFVTIGK 15
|||
db 8 RIQRPGRFVT-GK 21

RESULT 193

US-08-458-101-384
; Sequence 384, Application US/08458101

```

; Patent No. 5766599
;
; GENERAL INFORMATION:
; APPLICANT: Paoletti, Enzo
; APPLICANT: Perkus, Marlon E.
; APPLICANT: Taylor, Jill
; APPLICANT: Tartaglia James
; APPLICANT: No. 5766599ton, Elizabeth K.
; APPLICANT: Riviere, Michel
; APPLICANT: de Taisne, Charles
; APPLICANT: Limbach, Keith J.
; APPLICANT: Johnson, Gerard P.
; APPLICANT: Pincus, Steven E.
; APPLICANT: Cox, William I.
; APPLICANT: Audonnet, Jean-Christophe Francis
; APPLICANT: Gettig, Russell Robert
;
; TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE
;
; TITLE OF INVENTION: STRAIN
;
; NUMBER OF SEQUENCES: 467
;
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris & Safford
; ADDRESSEE: c/o William S. Frommer
; STREET: 530 Fifth Avenue
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/458,101
; FILING DATE: 01-JUN-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Frommer, William S.
; REGISTRATION NUMBER: 25,506
; REFERENCE/DOCKET NUMBER: 454310-2740
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 384:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-458-101-384

```

Query Match 81.2%; Score 62.5; DB 1; Length 21;
Best Local Similarity 93.3%; Pred. No. 0.0022;
Matches 14: Conservative 0; Mismatches 0; Indels 1; Gaps 1;

QY 1 RIQRPGRFVTIGK 15
|||
Db 8 RIQRPGRFVT-GK 21

RESULT 194

RESOL 194
US-08-657-392-19
; Sequence 19, Application US/08657392

Patent No. 5843634

GENERAL INFORMATION:

APPLICANT: Brate, E. M.

APPLICANT: Brennan, C. A.

APPLICANT: Bridon, D. P.

APPLICANT: Jaiffe, K. D.

APPLICANT: Krafft, G. A.

APPLICANT: Mandecki, W.

APPLICANT: March, S. C.

APPLICANT: Russell, J. R.

APPLICANT: Yue, V. T.

;; TITLE OF INVENTION: Genetically Engineered Enzymes And Their
;; CONJUGATES FOR DIAGNOSTIC ASSAYS
;; NUMBER OF SEQUENCES: 34
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: ABBOTT LABORATORIES
;; STREET: One Abbott Park Road
;; CITY: Abbott Park
;; STATE: Illinois
;; COUNTRY: USA
;;
;; ZIP: 60064-3500
;;
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: SoftPC
;;
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/657,392
;; FILING DATE:
;; CLASSIFICATION: 435
;;
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/100,708
;; FILING DATE: July 29, 1993
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Wong, Wean Khing
;; REGISTRATION NUMBER: 33,561
;; REFERENCE/DOCKET NUMBER: 5324.US.PI
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (708) 938-3517
;; TELEFAX: (708) 938-2623
;; TELEX:
;;
;; INFORMATION FOR SEQ ID NO: 19:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 13 amino acid residues
;; TYPE: amino acid
;; STRANDEDNESS:
;; TOPOLOGY: unknown
;; MOLECULE TYPE: peptide
;; ORIGINAL SOURCE:
;; ORGANISM:
;;
US-08-657-392-19

Query Match 80.5%; Score 62; DB 2; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0017;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRGPGRAFTV 12
Db 2 RIQRGPGRAFTV 13

RESULT 195
US-08-657-392-20
; Sequence 20, Application US/08657392
; Patent No. 5843634
; GENERAL INFORMATION:
; APPLICANT: Brate, E.M.
; APPLICANT: Brennan, C.A.
; APPLICANT: Bridon, D.P.
; APPLICANT: Jaffe, K.D.
; APPLICANT: Krafft, G.A.
; APPLICANT: Mandeckl, W.
; APPLICANT: March, S.C.
; APPLICANT: Russell, J.R.
; APPLICANT: Yue, V.T.
; TITLE OF INVENTION: Genetically Engineered Enzymes And Their
; CONJUGATES FOR DIAGNOSTIC ASSAYS
; NUMBER OF SEQUENCES: 34
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ABBOTT LABORATORIES
; STREET: One Abbott Park Road
; CITY: Abbott Park
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: SoftPC
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/657,392
; FILING DATE:

;; ZIP: 60064-3500
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: SoftPC
;;
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/657,392
;; FILING DATE:
;; CLASSIFICATION: 435
;;
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/100,708
;; FILING DATE: July 29, 1993
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Wong, Wean Khing
;; REGISTRATION NUMBER: 33,561
;; REFERENCE/DOCKET NUMBER: 5324.US.PI
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (708) 938-3517
;; TELEFAX: (708) 938-2623
;; TELEX:
;;
;; INFORMATION FOR SEQ ID NO: 20:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 13 amino acid residues
;; TYPE: amino acid
;; STRANDEDNESS:
;; TOPOLOGY: unknown
;; MOLECULE TYPE: peptide
;; ORIGINAL SOURCE:
;; ORGANISM:
;;
US-08-657-392-20

Query Match 80.5%; Score 62; DB 2; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0017;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRGPGRAFTV 12
Db 2 RIQRGPGRAFTV 13

RESULT 196
US-08-657-392-21
; Sequence 21, Application US/08657392
; Patent No. 5843634
; GENERAL INFORMATION:
; APPLICANT: Brate, E.M.
; APPLICANT: Brennan, C.A.
; APPLICANT: Bridon, D.P.
; APPLICANT: Jaffe, K.D.
; APPLICANT: Krafft, G.A.
; APPLICANT: Mandeckl, W.
; APPLICANT: March, S.C.
; APPLICANT: Russell, J.R.
; APPLICANT: Yue, V.T.
; TITLE OF INVENTION: Genetically Engineered Enzymes And Their
; CONJUGATES FOR DIAGNOSTIC ASSAYS
; NUMBER OF SEQUENCES: 34
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ABBOTT LABORATORIES
; STREET: One Abbott Park Road
; CITY: Abbott Park
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: SoftPC
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/657,392
; FILING DATE:

CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/100,708
FILING DATE: July 29, 1993
ATTORNEY/AGENT INFORMATION:
NAME: Wong, Wean Khing
REGISTRATION NUMBER: 33,561
REFERENCE/DOCKET NUMBER: 5324.US.P1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (708) 938-3517
TELEFAX: (708) 938-2623
TELEX:
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 amino acid residues
TYPE: amino acid
STRANDEDNESS:
TOPOLOGY: unknown
MOLECULE TYPE: peptide
ORIGINAL SOURCE:
ORGANISM:
US-08-657-392-21

Query Match 80.5%; Score 62; DB 2; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0017;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRGAVT 12
Db 2 RIQGPGRGAVT 13

RESULT 197
US-08-657-392-23
Sequence 23, Application US/08657392
Patent No. 5843634
GENERAL INFORMATION:

APPLICANT: Brate, E.M.
APPLICANT: Brennan, C.A.
APPLICANT: Bridon, D.P.
APPLICANT: Jaffe, K.D.
APPLICANT: Krafft, G.A.
APPLICANT: Mandeckl, W.
APPLICANT: March, S.C.
APPLICANT: Russell, J.R.
APPLICANT: Yue, V.T.
TITLE OF INVENTION: Genetically Engineered Enzymes And Their
TITLE OF INVENTION: Conjugates For Diagnostic Assays
NUMBER OF SEQUENCES: 34
CORRESPONDENCE ADDRESS:
ADDRESSEE: ABBOTT LABORATORIES
STREET: One Abbott Park Road
CITY: Abbott Park
STATE: Illinois
COUNTRY: USA
ZIP: 60064-3500
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: SoftPC
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/657,392
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/100,708
FILING DATE: July 29, 1993
ATTORNEY/AGENT INFORMATION:
NAME: Wong, Wean Khing
REGISTRATION NUMBER: 33,561
REFERENCE/DOCKET NUMBER: 5324.US.P1
TELECOMMUNICATION INFORMATION:

TELEPHONE: (708) 938-3517
TELEFAX: (708) 938-2623
TELEX:
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 amino acid residues
TYPE: amino acid
STRANDEDNESS:
TOPOLOGY: unknown
MOLECULE TYPE: peptide
ORIGINAL SOURCE:
ORGANISM:
US-08-657-392-23

Query Match 80.5%; Score 62; DB 2; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0017;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRGAVT 12
Db 2 RIQGPGRGAVT 13

RESULT 198
PCT-US94-02539-19
Sequence 19, Application PC/TUS9402539
GENERAL INFORMATION:
APPLICANT: Brate, E.M.
APPLICANT: Brennan, C.A.
APPLICANT: Bridon, D.P.
APPLICANT: Jaffe, K.D.
APPLICANT: Krafft, G.A.
APPLICANT: Mandeckl, W.
APPLICANT: March, S.C.
APPLICANT: Russell, J.R.
APPLICANT: Yue, V.T.
TITLE OF INVENTION: Genetically Engineered Enzymes
TITLE OF INVENTION: And Their
TITLE OF INVENTION: Conjugates For Diagnostic Assays
NUMBER OF SEQUENCES: 34
CORRESPONDENCE ADDRESS:
ADDRESSEE: ABBOTT LABORATORIES
STREET: One Abbott Park Road
CITY: Abbott Park
STATE: Illinois
COUNTRY: USA
ZIP: 60064-3500
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: SoftPC
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/02539
FILING DATE:
CLASSIFICATION:

ATTORNEY/AGENT INFORMATION:
NAME: Wong, Wean Khing
REGISTRATION NUMBER: 33,561
REFERENCE/DOCKET NUMBER: 5324.PC.01
TELECOMMUNICATION INFORMATION:
TELEPHONE: (708) 938-3517
TELEFAX: (708) 938-2623
TELEX:
INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 amino acid residues
TYPE: amino acid
STRANDEDNESS:
TOPOLOGY: unknown
MOLECULE TYPE: peptide
ORIGINAL SOURCE:
ORGANISM:

PCT-US94-02539-19

Query Match 80.5%; Score 62; DB 5; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0017;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRPGRGAFVT 12
Db 2 RIQRPGRGAFVT 13

RESULT 199

PCT-US94-02539-20

; Sequence 20, Application PC/TUS9402539

; GENERAL INFORMATION:

; APPLICANT: Brate, E.M.

; APPLICANT: Brennan, C.A.

; APPLICANT: Bridon, D.P.

; APPLICANT: Jaffe, K.D.

; APPLICANT: Kraft, G.A.

; APPLICANT: Mandeck, W.

; APPLICANT: March, S.C.

; APPLICANT: Russell, J.R.

; APPLICANT: Yue, V.T.

; TITLE OF INVENTION: Genetically Engineered Enzymes

; TITLE OF INVENTION: And Their

; TITLE OF INVENTION: Conjugates For Diagnostic Assays

; NUMBER OF SEQUENCES: 34

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: ABBOTT LABORATORIES

; STREET: One Abbott Park Road

; CITY: Abbott Park

; STATE: Illinois

; COUNTRY: USA

; ZIP: 60064-3500

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: SoftPC

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: PCT/US94/02539

; FILING DATE:

; CLASSIFICATION:

; ATTORNEY/AGENT INFORMATION:

; NAME: Wong, Wean Khing

; REGISTRATION NUMBER: 33,561

; REFERENCE/DOCKET NUMBER: 5324.PC.01

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (708) 938-3517

; TELEFAX: (708) 938-2623

; TELEX:

; INFORMATION FOR SEQ ID NO: 20:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 13 amino acid residues

; TYPE: amino acid

; STRANDEDNESS:

; TOPOLOGY: unknown

; MOLECULE TYPE: peptide

; ORIGINAL SOURCE:

; ORGANISM:

PCT-US94-02539-20

Query Match 80.5%; Score 62; DB 5; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0017;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRPGRGAFVT 12
Db 2 RIQRPGRGAFVT 13

RESULT 200

PCT-US94-02539-21

; Sequence 21, Application PC/TUS9402539

; GENERAL INFORMATION:

; APPLICANT: Brate, E.M.

; APPLICANT: Brennan, C.A.

; APPLICANT: Bridon, D.P.

; APPLICANT: Jaffe, K.D.

; APPLICANT: Kraft, G.A.

; APPLICANT: Mandeck, W.

; APPLICANT: March, S.C.

; APPLICANT: Russell, J.R.

; APPLICANT: Yue, V.T.

; TITLE OF INVENTION: Genetically Engineered Enzymes

; TITLE OF INVENTION: And Their

; TITLE OF INVENTION: Conjugates For Diagnostic Assays

; NUMBER OF SEQUENCES: 34

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: ABBOTT LABORATORIES

; STREET: One Abbott Park Road

; CITY: Abbott Park

; STATE: Illinois

; COUNTRY: USA

; ZIP: 60064-3500

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: SoftPC

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: PCT/US94/02539

; FILING DATE:

; CLASSIFICATION:

; ATTORNEY/AGENT INFORMATION:

; NAME: Wong, Wean Khing

; REGISTRATION NUMBER: 33,561

; REFERENCE/DOCKET NUMBER: 5324.PC.01

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (708) 938-3517

; TELEFAX: (708) 938-2623

; TELEX:

; INFORMATION FOR SEQ ID NO: 21:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 13 amino acid residues

; TYPE: amino acid

; STRANDEDNESS:

; TOPOLOGY: unknown

; MOLECULE TYPE: peptide

; ORIGINAL SOURCE:

; ORGANISM:

PCT-US94-02539-21

Query Match 80.5%; Score 62; DB 5; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0017;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRPGRGAFVT 12
Db 2 RIQRPGRGAFVT 13

RESULT 201

PCT-US94-02539-23

; Sequence 23, Application PC/TUS9402539

; GENERAL INFORMATION:

; APPLICANT: Brate, E.M.

; APPLICANT: Brennan, C.A.

; APPLICANT: Bridon, D.P.

; APPLICANT: Jaffe, K.D.

; APPLICANT: Kraft, G.A.

; APPLICANT: Mandeck, W.

; APPLICANT: March, S.C.

; APPLICANT: Russell, J.R.

; APPLICANT: Yue, V.T.

```

Query Match      80.5%; Score 62; DB 5; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0017;
Matches 12; Conservative 0; Mismatches 0; Indels 0;

QY      1 RIQPGGRAFTV 12
        | | | | | | | |
Db      2 RIQPGGRAFTV 13

RESULT 202
US-08-657-392-24
; Sequence 24, Application US/08657392
; Patent No. 5843634
; GENERAL INFORMATION:
; APPLICANT: Brate, E.M.
; APPLICANT: Brennan, C.A.
; APPLICANT: Bridon, D.P.
; APPLICANT: Jaffe, K.D.
; APPLICANT: Krafft, G.A.
; APPLICANT: Mandecki, W.
; APPLICANT: March, S.C.
; APPLICANT: Russell, J.R.
; APPLICANT: Yue, V.T.
; TITLE OF INVENTION: Genetically Engineered Enzymes And Their
; CONJUGATES FOR DIAGNOSTIC ASSAYS
; NUMBER OF SEQUENCES: 34
; TITLE OF INVENTION: Conjugates For Diagnostic Assays
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ABBOTT LABORATORIES
; STREET: One Abbott Park Road
; CITY: Abbott Park
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:

```

```

1 MEDIUM TYPE: Floppy disk
2 COMPUTER: IBM PC compatible
3 OPERATING SYSTEM: PC-DOS/MS-DOS
4 SOFTWARE: SoftPC
5 CURRENT APPLICATION DATA:
6 APPLICATION NUMBER: US/08/657,392
7 FILING DATE:
8 CLASSIFICATION: 435
9 PRIOR APPLICATION DATA:
10 APPLICATION NUMBER: 08/100,708
11 FILING DATE: July 29, 1993
12 ATTORNEY/AGENT INFORMATION:
13 NAME: Wong, Wean Khing
14 REGISTRATION NUMBER: 33,561
15 REFERENCE/DOCKET NUMBER: 5324.US.P1
16 TELECOMMUNICATION INFORMATION:
17 TELEPHONE: (708) 938-3517
18 TELEFAX: (708) 938-2623
19 TELEX:
20 INFORMATION FOR SEQ ID NO: 24:
21 SEQUENCE CHARACTERISTICS:
22 LENGTH: 15 amino acid residues
23 TYPE: amino acid
24 STRANDEDNESS:
25 TOPOLOGY: unknown
26 MOLECULE TYPE: peptide
27 ORIGINAL SOURCE:
28 ORGANISM:
29 US-08-657-392-24
30
31 Query Match 80.5%; Score 62; DB 2; Length 15;
32 Best Local Similarity 100.0%; Pred.No.0.0019;
33 Matches 12; Conservative 0; Mismatches 0; Indels
34
35 QY 1 RIQRGPGRAFPVT 12
36 DB 3 RIQRGPGRAFPVT 14
37
38 RESULT 203
39 PCT-US94-02539-24
40 Sequence 24, Application PC/TUS9402539
41 GENERAL INFORMATION:
42 APPLICANT: Brate, E.M.
43 APPLICANT: Brennan, C.A.
44 APPLICANT: Bridon, D.P.
45 APPLICANT: Jaffe, K.D.
46 APPLICANT: Krafft, G.A.
47 APPLICANT: Mandeck, W.
48 APPLICANT: March, S.C.
49 APPLICANT: Russell, J.R.
50 APPLICANT: Yue, V.T.
51 TITLE OF INVENTION: Genetically Engineered Enzymes
52 TITLE OF INVENTION: And Their
53 TITLE OF INVENTION: Conjugates For Diagnostic Assays
54 NUMBER OF SEQUENCES: 34
55 CORRESPONDENCE ADDRESS:
56 ADDRESSEE: ABBOTT LABORATORIES
57 STREET: One Abbott Park Road
58 CITY: Abbott Park
59 STATE: Illinois
60 COUNTRY: USA
61 ZIP: 60064-3500
62 COMPUTER READABLE FORM:
63 MEDIUM TYPE: Floppy disk
64 COMPUTER: IBM PC compatible
65 OPERATING SYSTEM: PC-DOS/MS-DOS
66 SOFTWARE: SoftPC
67 CURRENT APPLICATION DATA:
68 APPLICATION NUMBER: PCT/US94/02539
69 FILING DATE:
70 CLASSIFICATION:
71 ATTORNEY/AGENT INFORMATION:

```

```
/ NAME: Wong, Wean Khing
/ REGISTRATION NUMBER: 33,561
/ REFERENCE/DOCKET NUMBER: 5324.PC.01
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (708) 938-3517
/ TELEFAX: (708) 938-2623
/ TELEX:
/ INFORMATION FOR SEQ ID NO: 24:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 amino acid residues
/ TYPE: amino acid
/ STRANDEDNESS:
/ TOPOLOGY: unknown
/ MOLECULE TYPE: peptide
/ ORIGINAL SOURCE:
/ ORGANISM:
/ PCT-US94-02539-24

Query Match      80.5%; Score 62; DB 5; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.0019;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RIORGPGRAFTV 12
Db      3 RIORGPGRAFTV 14

RESULT 204
US-08-973-551-24
; Sequence 24, Application US/08973551
; Patent No. 6113902
; GENERAL INFORMATION:
; APPLICANT: Chermann, Jean-Claude
; APPLICANT: Le Contel, Carole
; APPLICANT: Galea, Pascale
; TITLE OF INVENTION: VACCINE AGAINST INFECTIOUS AGENTS HAVING
; TITLE OF INVENTION: AN INTRACELLULAR PHASE, COMPOSITION FOR THE TREATMENT AND
; TITLE OF INVENTION: PREVENTION OF HIV INFECTIONS, ANTIBODIES AND METHOD OF
; TITLE OF INVENTION: DIAGNOSIS
; NUMBER OF SEQUENCES: 28
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/973,551
; FILING DATE: 30-DEC-1997
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/FR96/01006
; FILING DATE: 28-JUN-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: FR 9507914
; FILING DATE: 30-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Granados, Patricia D.
; REGISTRATION NUMBER: 33,683
; REFERENCE/DOCKET NUMBER: 65691/130
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)672-5300
; TELEFAX: (202)672-5399
; TELEX: 904136
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 amino acids
```

```
/ TYPE: amino acid
/ STRANDEDNESS:
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
/ US-08-973-551-24

Query Match      80.5%; Score 62; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0025;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RIORGPGRAFTV 12
Db      9 RIORGPGRAFTV 20

RESULT 205
US-08-657-392-27
; Sequence 27, Application US/08657392
; Patent No. 5843634
; GENERAL INFORMATION:
; APPLICANT: Brate, E.M.
; APPLICANT: Brennan, C.A.
; APPLICANT: Bridon, D.P.
; APPLICANT: Jaffe, K.D.
; APPLICANT: Krafft, G.A.
; APPLICANT: Mandeckl, W.
; APPLICANT: March, S.C.
; APPLICANT: Russell, J.R.
; APPLICANT: Yue, V.T.
; TITLE OF INVENTION: Genetically Engineered Enzymes And Their
; TITLE OF INVENTION: Conjugates For Diagnostic Assays
; NUMBER OF SEQUENCES: 34
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ABBOTT LABORATORIES
; STREET: One Abbott Park Road
; CITY: Abbott Park
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: SoftPC
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/657,392
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/100,708
; FILING DATE: July 29, 1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Wong, Wean Khing
; REGISTRATION NUMBER: 33,561
; REFERENCE/DOCKET NUMBER: 5324.US.P1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (708) 938-3517
; TELEFAX: (708) 938-2623
; TELEX:
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 23 amino acid residues
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
; ORIGINAL SOURCE:
; ORGANISM:
; US-08-657-392-27

Query Match      80.5%; Score 62; DB 2; Length 23;
Best Local Similarity 100.0%; Pred. No. 0.0029;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 1 RIQPGGRAFTV 12
Db 12 RIQPGGRAFTV 23

RESULT 206

PCT-US94-02539-27
; Sequence 27, Application PC/TUS9402539
; GENERAL INFORMATION:
; APPLICANT: Brate, E.M.
; APPLICANT: Brennan, C.A.
; APPLICANT: Bridon, D.P.
; APPLICANT: Jaffe, K.D.
; APPLICANT: Krafft, G.A.
; APPLICANT: Mandeckl, W.
; APPLICANT: March, S.C.
; APPLICANT: Russell, J.R.
; APPLICANT: Yue, V.T.
; TITLE OF INVENTION: Genetically Engineered Enzymes
; TITLE OF INVENTION: And Their
; TITLE OF INVENTION: Conjugates For Diagnostic Assays
; NUMBER OF SEQUENCES: 34
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ABBOTT LABORATORIES
; STREET: One Abbott Park Road
; CITY: Abbott Park
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: SoftPC
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/02539
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Wong, Mean Khing
; REGISTRATION NUMBER: 33,561
; REFERENCE/DOCKET NUMBER: S324.PC.01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (708) 938-3517
; TELEFAX: (708) 938-2623
; TELEX:
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 23 amino acid residues
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
; ORIGINAL SOURCE:
; ORGANISM:
; PCT-US94-02539-27

Query Match 80.5%; Score 62; DB 5; Length 23;
Best Local Similarity 100.0%; Pred. No. 0.0029;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTV 12
Db 12 RIQPGGRAFTV 23

RESULT 207

US-07-847-311A-20
; Sequence 20, Application US/07847311A
; Patent No. 5976541
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.

; APPLICANT: Takeshita, Toshiyuki
; APPLICANT: Shirai, Mutsunori
; APPLICANT: Pendleton, C.D.
; APPLICANT: Koslowski, Steven
; APPLICANT: Margulies, David H.
; TITLE OF INVENTION: Potent Peptide for Stimulation of
; TITLE OF INVENTION: Cytotoxic T Lymphocytes Specific for the HIV-I Envelope
; NUMBER OF SEQUENCES: 20
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolash & Birch
; STREET: 301 N. Washington
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22046-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/847,311A
; FILING DATE: 06-MAR-1992
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Svensson, Leonard R.
; REGISTRATION NUMBER: 30,330
; REFERENCE/DOCKET NUMBER: 1173-392P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-241-1300
; TELEFAX: 703-241-2848
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: Human Immunodeficiency Virus Type I
; STRAIN: IIIB
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..13
; OTHER INFORMATION: /label= peptide
; OTHER INFORMATION: /note= "Active peptide of HIV-I envelope
; OTHER INFORMATION: from strain IIIB"
; US-07-847-311A-20

Query Match 79.2%; Score 61; DB 2; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0024;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 IQRGPGRAFTV 13
Db 2 IQRGPGRAFTV 13

RESULT 208

US-08-111-080-6
; Sequence 6, Application 08/111080
; Patent No. 5558865
; GENERAL INFORMATION:
; APPLICANT: Ohno, Tsuneya
; TITLE OF INVENTION: HIV Immunotherapeutics
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois

glycoprot

```
/
/ COUNTRY: USA
/ ZIP: 60606
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: 08/111,080
/ FILING DATE:
/ CLASSIFICATION: 424
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 07/748,562
/ FILING DATE: 22-AUG-1991
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: PCT/US92/07111
/ FILING DATE: 24-AUG-1992
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/039,457
/ FILING DATE: 22-APR-1993
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Borun, Michael F.
/ REGISTRATION NUMBER: 25,447
/ REFERENCE/DOCKET NUMBER: 31629
/ TELEPHONE: (312) 474-6300
/ TELEFAX: (312) 474-0448
/ TELEX: 25-3856
/ INFORMATION FOR SEQ ID NO: 6:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 14 amino acids
/ TYPE: amino acid
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
/ US-08-111-080-6

Query Match 77.9%; Score 60; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 0.0037;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 2 IORGPGRAFTVIGK 15
Db 1 IRIGPGRAFTVIGK 14

RESULT 209
US-08-211-980-6
/ Sequence 6, Application US/08211980
/ Patent No. 565569
/ GENERAL INFORMATION:
/ APPLICANT: Ohno, Tsuneya
/ TITLE OF INVENTION: HIV Immunotherapeutics
/ NUMBER OF SEQUENCES: 38
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
/ STREET: 6300 Sears Tower, 233 S. Wacker Drive
/ CITY: Chicago
/ STATE: Illinois
/ COUNTRY: USA
/ ZIP: 60606
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/211,980
/ FILING DATE:
/ CLASSIFICATION: 424
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: PCT/US92/07111
/ FILING DATE: 24-AUG-1992
```

```
/
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/039,457
/ FILING DATE: 22-APR-1993
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Borun, Michael F.
/ REGISTRATION NUMBER: 25,447
/ REFERENCE/DOCKET NUMBER: 31629
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (312) 474-6300
/ TELEFAX: (312) 474-0448
/ TELEX: 25-3856
/ INFORMATION FOR SEQ ID NO: 6:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 14 amino acids
/ TYPE: amino acid
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
/ US-08-211-980-6

Query Match 77.9%; Score 60; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 0.0037;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 2 IORGPGRAFTVIGK 15
Db 1 IRIGPGRAFTVIGK 14

RESULT 210
PCT-US92-07111-6
/ Sequence 6, Application PC/TUS9207111
/ GENERAL INFORMATION:
/ APPLICANT: Ohno, Tsuneya
/ TITLE OF INVENTION: HIV Immunotherapeutics
/ NUMBER OF SEQUENCES: 17
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
/ ADDRESSEE: Bicknell
/ STREET: Two First National Plaza, 20 South Clark
/ STREET: Street
/ CITY: Chicago
/ STATE: Illinois
/ COUNTRY: USA
/ ZIP: 60603
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: PCT/US92/07111
/ FILING DATE: 19920824
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 07/748,562
/ FILING DATE: 22-AUG-1991
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Noland, Greta E.
/ REGISTRATION NUMBER: 35,302
/ REFERENCE/DOCKET NUMBER: 31016
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (312) 346-5750
/ TELEFAX: (312) 984-9740
/ TELEX: 25-3856
/ INFORMATION FOR SEQ ID NO: 6:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 14 amino acids
/ TYPE: AMINO ACID
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
/ PCT-US92-07111-6

Query Match 77.9%; Score 60; DB 5; Length 14;
```



```
Best Local Similarity 85.7%; Pred. No. 0.0037;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2 IORGPGRAFTVIGK 15
DB 1 IRIIGRAFTVIGK 14

RESULT 211
PCT-US93-07967-6
; Sequence 6, Application PC/TUS9307967
; GENERAL INFORMATION:
; APPLICANT: Onno, Teuneya
; TITLE OF INVENTION: HIV Immunotherapeutics
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marehall, O'Toole, Gerstein, Murray &
; ADDRESS: Borun
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/07967
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US92/07111
; FILING DATE: 24-AUG-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/039,457
; FILING DATE: 22-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Borun, Michael F.
; REGISTRATION NUMBER: 25,447
; REFERENCE/DOCKET NUMBER: 31629
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
PCT-US93-07967-6

Query Match 77.9%; Score 60; DB 5; Length 14;
Best Local Similarity 85.7%; Pred. No. 0.0037;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2 IORGPGRAFTVIGK 15
DB 1 IRIIGRAFTVIGK 14

RESULT 212
US-08-704-170-73
; Sequence 73, Application US/08704170
; Patent No. 5707626
; GENERAL INFORMATION:
; APPLICANT: Douvas, Angeline
; APPLICANT: Takehana, Yoshi
; APPLICANT: Ehresmann, Glenn
; TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR
; IMMUNOINFECTIVE CLUSTER VIRUS INFECTIONS
```

```
; NUMBER OF SEQUENCES: 121
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Robbins, Berliner & Carson
; STREET: 201 No. 5707626th Figueroa Street, Suite 500
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90012
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/704,170
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/029,850
; FILING DATE: 11-MAR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Spitals, John P.
; REGISTRATION NUMBER: 29,215
; REFERENCE/DOCKET NUMBER: 1920-331
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 977-1001
; TELEFAX: (213) 977-1003
; INFORMATION FOR SEQ ID NO: 73:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-704-170-73

Query Match 75.3%; Score 58; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.006;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 RGPGRFVTIG 14
DB 1 RGPGRFVTIG 11

RESULT 213
US-08-704-170-74
; Sequence 74, Application US/08704170
; Patent No. 5707626
; GENERAL INFORMATION:
; APPLICANT: Douvas, Angeline
; APPLICANT: Takehana, Yoshi
; APPLICANT: Ehresmann, Glenn
; TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR
; IMMUNOINFECTIVE CLUSTER VIRUS INFECTIONS
; NUMBER OF SEQUENCES: 121
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Robbins, Berliner & Carson
; STREET: 201 No. 5707626th Figueroa Street, Suite 500
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90012
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/704,170
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/029,850
```

/ FILING DATE: 11-MAR-1993
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Spitals, John P.
/ REGISTRATION NUMBER: 29,215
/ REFERENCE/DOCKET NUMBER: 1920-331
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 977-1001
/ TELEFAX: (213) 977-1003
/ INFORMATION FOR SEQ ID NO: 74:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 11 amino acids
/ TYPE: amino acid
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
US-08-704-170-74

Query Match 75.3%; Score 58; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.006;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 RGPGRFVTVIG 14
| | | | | | | | | |
Db 1 RGPGRFVTVIG 11

RESULT 214
PCT-US94-02631-73
; Sequence 73, Application PC/TUS9402631
; GENERAL INFORMATION:
; APPLICANT: Douvas, Angeline
; APPLICANT: Takehana, Yoshi
; TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR
; NUMBER OF SEQUENCES: 121
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Robbins, Berliner & Carson
; STREET: 201 North Figueroa Street, Suite 500
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90012
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/02631
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/029,850
; FILING DATE: 11-MAR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Spitals, John P.
; REGISTRATION NUMBER: 29,215
; REFERENCE/DOCKET NUMBER: 1920-331
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 977-1001
; TELEFAX: (213) 977-1003
; INFORMATION FOR SEQ ID NO: 73:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
PCT-US94-02631-73

Query Match 75.3%; Score 58; DB 5; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.006;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 RGPGRFVTVIG 14
| | | | | | | | | |
Db 1 RGPGRFVTVIG 11

RESULT 215
PCT-US94-02631-74
; Sequence 74, Application PC/TUS9402631
; GENERAL INFORMATION:
; APPLICANT: Douvas, Angeline
; APPLICANT: Takehana, Yoshi
; APPLICANT: Ehresmann, Glenn
; TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR
; NUMBER OF SEQUENCES: 121
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Robbins, Berliner & Carson
; STREET: 201 North Figueroa Street, Suite 500
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90012
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/02631
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/029,850
; FILING DATE: 11-MAR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Spitals, John P.
; REGISTRATION NUMBER: 29,215
; REFERENCE/DOCKET NUMBER: 1920-331
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 977-1001
; TELEFAX: (213) 977-1003
; INFORMATION FOR SEQ ID NO: 74:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
PCT-US94-02631-74

Query Match 75.3%; Score 58; DB 5; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.006;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 RGPGRFVTVIG 14
| | | | | | | | | |
Db 1 RGPGRFVTVIG 11

RESULT 216
US-08-090-148-5
; Sequence 5, Application US/08090148
; Patent No. 5534257
; GENERAL INFORMATION:
; APPLICANT: Mastico, Robert Allan
; APPLICANT: Stockley, Peter George
; APPLICANT: Talbot, Simon John
; TITLE OF INVENTION: Antigen-Presenting Capsid with
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Rosenman & Colin
; STREET: 575 Madison Avenue
; CITY: New York

```
; STATE: NY
; COUNTRY: U.S.A.
; ZIP: 10022-2585
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5", 1.44Mb
; COMPUTER: IBM PS2-485
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/090,148
; FILING DATE: 08/11/93
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9101550.3
; FILING DATE: 01/24/91
; APPLICATION NUMBER: PCT/GB92/00124
; FILING DATE: 01/22/92
; ATTORNEY/AGENT INFORMATION:
; NAME: Nissenbaum, Israel
; REGISTRATION NUMBER: 27,582
; REFERENCE/DOCKET NUMBER:
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 940-8636
; TELEFAX: (212) 940-6404
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 AMINO ACIDS
; TYPE: AMINO ACID
; TOPOLOGY: NOT RELEVANT
; MOLECULE TYPE: PEPTIDE
; US-08-090-148-5

Query Match 75.3%; Score 58; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.007;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5 GPGRFVTVIGK 15
Db 1 GPGRFVTVIGK 11

RESULT 217
US-07-920-281C-10
; Sequence 10, Application US/07920281C
; Patent No. 5739026
; GENERAL INFORMATION:
; APPLICANT: Garoff, Henrik
; APPLICANT: Liljestrom, Peter
; TITLE OF INVENTION: DNA Expression Systems Based on
; TITLE OF INVENTION: Alphaviruses
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/920,281C
; FILING DATE: 13-AUG-1992
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Murphy Jr., Gerald M.
; REGISTRATION NUMBER: 28,977
; REFERENCE/DOCKET NUMBER: 828-103P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-241-1300
```

```
; TELEFAX: 703-241-2848
; TELEX: 248345
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-07-920-281C-10

Query Match 75.3%; Score 58; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 0.0081;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQRPGRAFVTI 13
Db 3 RIQRPGRAFVEL 15

RESULT 218
US-08-466-277-10
; Sequence 10, Application US/08466277
; Patent No. 6190566
; GENERAL INFORMATION:
; APPLICANT: Garoff, Henrik
; APPLICANT: Liljestrom, Peter
; TITLE OF INVENTION: DNA Expression Systems Based on
; TITLE OF INVENTION: Alphaviruses
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/466,277
; FILING DATE: 06-Jun-1995
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/920,281
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Murphy Jr., Gerald M.
; REGISTRATION NUMBER: 28,977
; REFERENCE/DOCKET NUMBER: 828-103P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-241-1300
; TELEFAX: 703-241-2848
; TELEX: 248345
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-08-466-277-10

Query Match 75.3%; Score 58; DB 3; Length 15;
Best Local Similarity 84.6%; Pred. No. 0.0081;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQRPGRAFVTI 13
Db 3 RIQRPGRAFVEL 15
```

RESULT 219
US-09-688-842-10
; Sequence 10, Application US/09688842
; Patent No. 6770283
; GENERAL INFORMATION:
; APPLICANT: Garoff, Henrik
; ; Liljestrom, Peter
; TITLE OF INVENTION: DNA Expression Systems Based on
; ; Alphaviruses
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/688,842
; FILING DATE: 17-Oct-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/466,277
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Murphy Jr., Gerald M.
; REGISTRATION NUMBER: 28,977
; REFERENCE/DOCKET NUMBER: 828-103P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-241-1300
; TELEFAX: 703-241-2848
; TELEX: 248345
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-688-842-10

Query Match 75.3%; Score 58; DB 4; Length 15;
Best Local Similarity 84.6%; Pred. No. 0.0081;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RIQPGGPAFTI 13
Db 3 RIQPGPAFVEL 15

RESULT 220
PCT-US92-06688-14
; Sequence 14, Application PC/TUS9206688
; GENERAL INFORMATION:
; APPLICANT: REPLIGEN CORPORATION
; TITLE OF INVENTION: THE ROCKEFELLER UNIVERSITY
; TITLE OF INVENTION: MULTIPLE ANTIGEN PEPTIDES FOR USE AS HIV
; TITLE OF INVENTION: VACCINES
; NUMBER OF SEQUENCES: 21
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM PS/2 Model 50Z or 55SX
OPERATING SYSTEM: IBM P.C. DOS (Version 3.30)
SOFTWARE: WordPerfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/06688
FILING DATE: 19920811
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 744,281
FILING DATE: 13 August 1992
ATTORNEY/AGENT INFORMATION:
NAME: Paul T. Clark
REGISTRATION NUMBER: 30,162
REFERENCE/DOCKET NUMBER: 00231/052WO1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 542-5070
TELEFAX: (617) 542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 11
TYPE: AMINO ACID
TOPOLOGY: linear
PCT-US92-06688-14

Query Match 74.0%; Score 57; DB 5; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.0086;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGPAFV 11
Db 1 RIQPGGPAFV 11

RESULT 221
US-08-704-170-70
; Sequence 70, Application US/08704170
; Patent No. 5707626
; GENERAL INFORMATION:
; APPLICANT: Douvas, Angeline
; APPLICANT: Takehana, Yoshi
; APPLICANT: Ehresmann, Glenn
; TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR
; TITLE OF INVENTION: IMMUNOINFECTION CLUSTER VIRUS INFECTIONS
; NUMBER OF SEQUENCES: 121
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Robbins, Berliner & Carson
; STREET: 201 No. 5707626th Figueroa Street, Suite 500
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90012
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/704,170
FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/029,850
FILING DATE: 11-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Spitals, John P.
REGISTRATION NUMBER: 29,215
REFERENCE/DOCKET NUMBER: 1920-331
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 977-1001
TELEFAX: (213) 977-1003
INFORMATION FOR SEQ ID NO: 70:

; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-704-170-70

Query Match 74.0%; Score 57; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.012;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFY 11
Db 5 RIQPGGRAFY 15

RESULT 222
PCT-US94-02631-70
; Sequence 70, Application PC/TUS9402631
; GENERAL INFORMATION:
; APPLICANT: Douvas, Angeline
; APPLICANT: Takehana, Yoshi
; APPLICANT: Ehresmann, Glenn
; TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR
; IMMUNOINFECTIVE CLUSTER VIRUS INFECTIONS
; NUMBER OF SEQUENCES: 121
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Robbins, Berliner & Carson
; STREET: 201 North Figueroa Street, Suite 500
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90012
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/02631
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/029,850
; FILING DATE: 11-MAR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Spitals, John P.
; REGISTRATION NUMBER: 29,215
; REFERENCE/DOCKET NUMBER: 1920-331
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 977-1001
; TELEFAX: (213) 977-1003
; INFORMATION FOR SEQ ID NO: 70:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
PCT-US94-02631-70

Query Match 74.0%; Score 57; DB 5; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.012;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFY 11
Db 5 RIQPGGRAFY 15

RESULT 223
US-07-920-281C-12
; Sequence 12, Application US/07920281C
; Patent No. 5739026

; GENERAL INFORMATION:
; APPLICANT: Garoff, Henrik
; APPLICANT: Liljestrom, Peter
; TITLE OF INVENTION: DNA Expression Systems Based on
; MOLECULE TYPE: Alphaviruses
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/920,281C
; FILING DATE: 13-AUG-1992
; CLASSIFICATION: 435

; ATTORNEY/AGENT INFORMATION:
; NAME: Murphy Jr., Gerald M.
; REGISTRATION NUMBER: 28,977
; REFERENCE/DOCKET NUMBER: 828-103P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-241-1300
; TELEFAX: 703-241-2848
; TELEX: 248345

; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-07-920-281C-12

Query Match 74.0%; Score 57; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.013;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFY 11
Db 4 RIQPGGRAFY 14

RESULT 224
US-08-466-277-12
; Sequence 12, Application US/08466277
; Patent No. 6190666
; GENERAL INFORMATION:
; APPLICANT: Garoff, Henrik
; APPLICANT: Liljestrom, Peter
; TITLE OF INVENTION: DNA Expression Systems Based on
; MOLECULE TYPE: Alphaviruses
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/466,277
; FILING DATE: 06-Jun-1995
; CLASSIFICATION: <Unknown>

; ATTORNEY/AGENT INFORMATION:
; NAME: Murphy Jr., Gerald M.
; REGISTRATION NUMBER: 28,977
; REFERENCE/DOCKET NUMBER: 828-103P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-241-1300
; TELEFAX: 703-241-2848
; TELEX: 248345

; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-07-920-281C-12

Query Match 74.0%; Score 57; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.013;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFY 11
Db 4 RIQPGGRAFY 14

RESULT 225
US-08-466-277-12
; Sequence 12, Application US/08466277
; Patent No. 6190666
; GENERAL INFORMATION:
; APPLICANT: Garoff, Henrik
; APPLICANT: Liljestrom, Peter
; TITLE OF INVENTION: DNA Expression Systems Based on
; MOLECULE TYPE: Alphaviruses
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/466,277
; FILING DATE: 06-Jun-1995
; CLASSIFICATION: <Unknown>

; ATTORNEY/AGENT INFORMATION:
; NAME: Murphy Jr., Gerald M.
; REGISTRATION NUMBER: 28,977
; REFERENCE/DOCKET NUMBER: 828-103P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-241-1300
; TELEFAX: 703-241-2848
; TELEX: 248345

; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-07-920-281C-12

Query Match 74.0%; Score 57; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.013;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFY 11
Db 4 RIQPGGRAFY 14

RESULT 226
US-08-466-277-12
; Sequence 12, Application US/08466277
; Patent No. 6190666
; GENERAL INFORMATION:
; APPLICANT: Garoff, Henrik
; APPLICANT: Liljestrom, Peter
; TITLE OF INVENTION: DNA Expression Systems Based on
; MOLECULE TYPE: Alphaviruses
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/466,277
; FILING DATE: 06-Jun-1995
; CLASSIFICATION: <Unknown>

; ATTORNEY/AGENT INFORMATION:
; NAME: Murphy Jr., Gerald M.
; REGISTRATION NUMBER: 28,977
; REFERENCE/DOCKET NUMBER: 828-103P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-241-1300
; TELEFAX: 703-241-2848
; TELEX: 248345

; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-07-920-281C-12

Query Match 74.0%; Score 57; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.013;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFY 11
Db 4 RIQPGGRAFY 14

RESULT 227
US-08-466-277-12
; Sequence 12, Application US/08466277
; Patent No. 6190666
; GENERAL INFORMATION:
; APPLICANT: Garoff, Henrik
; APPLICANT: Liljestrom, Peter
; TITLE OF INVENTION: DNA Expression Systems Based on
; MOLECULE TYPE: Alphaviruses
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/466,277
; FILING DATE: 06-Jun-1995
; CLASSIFICATION: <Unknown>

; ATTORNEY/AGENT INFORMATION:
; NAME: Murphy Jr., Gerald M.
; REGISTRATION NUMBER: 28,977
; REFERENCE/DOCKET NUMBER: 828-103P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-241-1300
; TELEFAX: 703-241-2848
; TELEX: 248345

; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-07-920-281C-12

Query Match 74.0%; Score 57; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.013;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFY 11
Db 4 RIQPGGRAFY 14

RESULT 228
US-08-466-277-12
; Sequence 12, Application US/08466277
; Patent No. 6190666
; GENERAL INFORMATION:
; APPLICANT: Garoff, Henrik
; APPLICANT: Liljestrom, Peter
; TITLE OF INVENTION: DNA Expression Systems Based on
; MOLECULE TYPE: Alphaviruses
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/466,277
; FILING DATE: 06-Jun-1995
; CLASSIFICATION: <Unknown>

; ATTORNEY/AGENT INFORMATION:
; NAME: Murphy Jr., Gerald M.
; REGISTRATION NUMBER: 28,977
; REFERENCE/DOCKET NUMBER: 828-103P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-241-1300
; TELEFAX: 703-241-2848
; TELEX: 248345

; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-07-920-281C-12

Query Match 74.0%; Score 57; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.013;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFY 11
Db 4 RIQPGGRAFY 14

RESULT 229
US-08-466-277-12
; Sequence 12, Application US/08466277
; Patent No. 6190666
; GENERAL INFORMATION:
; APPLICANT: Garoff, Henrik
; APPLICANT: Liljestrom, Peter
; TITLE OF INVENTION: DNA Expression Systems Based on
; MOLECULE TYPE: Alphaviruses
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/466,277
; FILING DATE: 06-Jun-1995
; CLASSIFICATION: <Unknown>

; ATTORNEY/AGENT INFORMATION:
; NAME: Murphy Jr., Gerald M.
; REGISTRATION NUMBER: 28,977
; REFERENCE/DOCKET NUMBER: 828-103P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-241-1300
; TELEFAX: 703-241-2848
; TELEX: 248345

; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-07-920-281C-12

Query Match 74.0%; Score 57; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.013;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFY 11
Db 4 RIQPGGRAFY 14

RESULT 230
US-08-466-277-12
; Sequence 12, Application US/08466277
; Patent No. 6190666
; GENERAL INFORMATION:
; APPLICANT: Garoff, Henrik
; APPLICANT: Liljestrom, Peter
; TITLE OF INVENTION: DNA Expression Systems Based on
; MOLECULE TYPE: Alphaviruses
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747

```
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 07/920,281
/ FILING DATE: <Unknown>
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Murphy Jr., Gerald M.
/ REGISTRATION NUMBER: 28,977
/ REFERENCE/DOCKET NUMBER: 828-103P
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 703-241-1300
/ TELEFAX: 703-241-2848
/ TELEX: 248345
/ INFORMATION FOR SEQ ID NO: 12:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 amino acids
/ TYPE: amino acid
/ TOPOLOGY: linear
/ MOLECULE TYPE: protein
/ SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-08-466-277-12
Query Match 74.0%; Score 57; DB 3; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.013;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQPGGRAFV 11
Db 4 RIQPGGRAFV 14

RESULT 225
US-09-688-842-12
/ Sequence 12, Application US/09688842
/ Patent No. 6770283
/ GENERAL INFORMATION:
/ APPLICANT: Garoff, Henrik
/ TITLE OF INVENTION: DNA Expression Systems Based on
/ Alphaviruses
/ NUMBER OF SEQUENCES: 27
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Birch, Stewart, Kolaich & Birch
/ STREET: P.O. Box 747
/ CITY: Falls Church
/ STATE: Virginia
/ COUNTRY: USA
/ ZIP: 22040-0747
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/688,842
/ FILING DATE: 17-Oct-2000
/ CLASSIFICATION: <Unknown>
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/466,277
/ FILING DATE: <Unknown>
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Murphy Jr., Gerald M.
/ REGISTRATION NUMBER: 28,977
/ REFERENCE/DOCKET NUMBER: 828-103P
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 703-241-1300
/ TELEFAX: 703-241-2848
/ TELEX: 248345
/ INFORMATION FOR SEQ ID NO: 12:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 amino acids
/ TYPE: amino acid
/ TOPOLOGY: linear
/ MOLECULE TYPE: protein
/ SEQUENCE DESCRIPTION: SEQ ID NO: 12:

/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 07/920,281
/ FILING DATE: <Unknown>
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Murphy Jr., Gerald M.
/ REGISTRATION NUMBER: 28,977
/ REFERENCE/DOCKET NUMBER: 828-103P
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 703-241-1300
/ TELEFAX: 703-241-2848
/ TELEX: 248345
/ INFORMATION FOR SEQ ID NO: 12:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 amino acids
/ TYPE: amino acid
/ TOPOLOGY: linear
/ MOLECULE TYPE: protein
/ SEQUENCE DESCRIPTION: SEQ ID NO: 12:

US-09-688-842-12
Query Match 74.0%; Score 57; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.013;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQPGGRAFV 11
Db 4 RIQPGGRAFV 14

RESULT 226
US-08-257-528B-16
/ Sequence 16, Application US/08257528B
/ Patent No. 5639854
/ GENERAL INFORMATION:
/ APPLICANT: SIA, Charles D.Y.
/ APPLICANT: CHONG, Pele
/ APPLICANT: KLEIN, Michel H.
/ TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
/ NUMBER OF SEQUENCES: 101
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Sim & McBurney
/ STREET: Suite 701, 330 University Avenue
/ CITY: Toronto
/ STATE: Ontario
/ COUNTRY: Canada
/ ZIP: M5G 1R7
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/257,528B
/ FILING DATE: 09-JUN-1994
/ CLASSIFICATION: 424
/ ATTORNEY/AGENT INFORMATION:
/ NAME: STEWART, MICHAEL I.
/ REGISTRATION NUMBER: 24,973
/ REFERENCE/DOCKET NUMBER: 1038-336 MIS:jb
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (416) 595-1155
/ TELEFAX: (416) 595-1163
/ INFORMATION FOR SEQ ID NO: 16:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 21 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-257-528B-16
Query Match 74.0%; Score 57; DB 1; Length 21;
Best Local Similarity 91.7%; Pred. No. 0.016;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQPGGRAFVT 12
Db 7 RIQPGGRAFYT 18

RESULT 227
US-08-460-602A-16
/ Sequence 16, Application US/08460602A
/ Patent No. 5759769
/ GENERAL INFORMATION:
/ APPLICANT: SIA, Charles D.Y.
/ APPLICANT: CHONG, Pele
/ APPLICANT: KLEIN, Michel H.
/ TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
/ NUMBER OF SEQUENCES: 101
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Sim & McBurney
```

```

; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/460,602A
; FILING DATE: 02-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/257,528
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/073,378
; FILING DATE: 09-JUN-1993
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-450 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-460-602A-16

Query Match 74.0%; Score 57; DB 1; Length 21;
Best Local Similarity 91.7%; Pred. No. 0.016;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RIQGPGRFVY 12
Db 7 RIQGPGRFVY 18

RESULT 228
US-08-463-966A-16
; Sequence 16, Application US/08463966A
; Patent No. 5795955
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/463,966A
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:

```

```

; APPLICATION NUMBER: 08/257,528
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/073,378
; FILING DATE: 09-JUN-1993
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-487 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-463-966A-16

Query Match 74.0%; Score 57; DB 1; Length 21;
Best Local Similarity 91.7%; Pred. No. 0.016;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RIQGPGRFVY 12
Db 7 RIQGPGRFVY 18

RESULT 229
US-08-465-217A-16
; Sequence 16, Application US/08465217A
; Patent No. 5800822
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/465,217A
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/257,528
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/073,378
; FILING DATE: 09-JUN-1993
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-486 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 16:

```

SEQUENCE CHARACTERISTICS:
LENGTH: 21 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-465-217A-16

Query Match 74.0%; Score 57; DB 1; Length 21;
Best Local Similarity 91.7%; Pred. No. 0.016;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTV 12
Db 7 RIQPGGRAFTV 18

RESULT 230

US-08-464-329A-16
Sequence 16, Application US/08464329A
Patent No. 5817754

GENERAL INFORMATION:

APPLICANT: SIA, Charles D.Y.
APPLICANT: CHONG, Pele
APPLICANT: KLEIN, Michel H.
TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/464,329A
FILING DATE: 05-JUN-1995
CLASSIFICATION: 424

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/257,528
FILING DATE: 09-JUN-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/073,378
FILING DATE: 09-JUN-1993
CLASSIFICATION: 424

ATTORNEY/AGENT INFORMATION:
NAME: STEWART, MICHAEL I.
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-449 MIS:jb
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 16:

SEQUENCE CHARACTERISTICS:
LENGTH: 21 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-464-329A-16

Query Match 74.0%; Score 57; DB 2; Length 21;
Best Local Similarity 91.7%; Pred. No. 0.016;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTV 12
Db 7 RIQPGGRAFTV 18

RESULT 231

US-08-462-507A-16
Sequence 16, Application US/08462507A
Patent No. 5876731

GENERAL INFORMATION:

APPLICANT: SIA, Charles D.Y.
APPLICANT: CHONG, Pele
APPLICANT: KLEIN, Michel H.
TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/462,507A
FILING DATE: 05-JUN-1995
CLASSIFICATION: 424

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/257,528
FILING DATE: 09-JUN-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/073,378
FILING DATE: 09-JUN-1993
CLASSIFICATION: 424

ATTORNEY/AGENT INFORMATION:
NAME: STEWART, MICHAEL I.
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-451 MIS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 16:

SEQUENCE CHARACTERISTICS:
LENGTH: 21 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-462-507A-16

Query Match 74.0%; Score 57; DB 2; Length 21;
Best Local Similarity 91.7%; Pred. No. 0.016;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTV 12
Db 7 RIQPGGRAFTV 18

RESULT 232

US-08-467-881A-16
Sequence 16, Application US/08467881A
Patent No. 5951986

GENERAL INFORMATION:

APPLICANT: SIA, Charles D.Y.
APPLICANT: CHONG, Pele
APPLICANT: KLEIN, Michel H.
TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto


```
; STATE: Ontario
; COUNTRY: Canada
; ZIP: MSG 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/467,881A
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/257,528
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/073,378
; FILING DATE: 09-JUN-1993
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-488 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-467-881A-16

Query Match 74.0%; Score 57; DB 2; Length 21;
Best Local Similarity 91.7%; Pred. No. 0.016;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFT 12
Db 7 RIQPGGRAFT 18

RESULT 233
US-08-704-170-71
; Sequence 71, Application US/08704170
; Patent No. 5707626
; GENERAL INFORMATION:
; APPLICANT: Douvas, Angeline
; APPLICANT: Takehana, Yoshi
; APPLICANT: Ehresmann, Glenn
; TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR
; NUMBER OF SEQUENCES: 121
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Robbins, Berliner & Carson
; STREET: 201 No. 5707626th Figueroa Street, Suite 500
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90012
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/704,170
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/029,850
; FILING DATE: 11-MAR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Spitals, John P.
; REGISTRATION NUMBER: 29,215
; REFERENCE/DOCKET NUMBER: 1920-331
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 977-1001
; TELEFAX: (213) 977-1003
; INFORMATION FOR SEQ ID NO: 71:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; PCT-US94-02631-71

Query Match 68.8%; Score 53; DB 5; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.033;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
; FILING DATE: 11-MAR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Spitals, John P.
; REGISTRATION NUMBER: 29,215
; REFERENCE/DOCKET NUMBER: 1920-331
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 977-1001
; TELEFAX: (213) 977-1003
; INFORMATION FOR SEQ ID NO: 71:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-704-170-71

Query Match 68.8%; Score 53; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.033;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 GPGRAFTVIG 14
Db 1 GPGRAFTVIG 10

RESULT 234
PCT-US94-02631-71
; Sequence 71, Application PC/TUS9402631
; GENERAL INFORMATION:
; APPLICANT: Douvas, Angeline
; APPLICANT: Takehana, Yoshi
; APPLICANT: Ehresmann, Glenn
; TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR
; NUMBER OF SEQUENCES: 121
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Robbins, Berliner & Carson
; STREET: 201 North Figueroa Street, Suite 500
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90012
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/02631
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/029,850
; FILING DATE: 11-MAR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Spitals, John P.
; REGISTRATION NUMBER: 29,215
; REFERENCE/DOCKET NUMBER: 1920-331
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 977-1001
; TELEFAX: (213) 977-1003
; INFORMATION FOR SEQ ID NO: 71:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; PCT-US94-02631-71

Query Match 68.8%; Score 53; DB 5; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.033;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 5 GPGRAFTVIG 14
Db 1 GPGRAFTVIG 10

RESULT 235
US-08-257-528B-36
; Sequence 36, Application US/08257528B
; Patent No. 5639854
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/257,528B
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-336 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 36:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-257-528B-36

Query Match 68.8%; Score 53; DB 1; Length 14;
Best Local Similarity 100.0%; Pred.No. 0.046;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIORGPGRAF 10
Db 5 RIORGPGRAF 14

RESULT 236
US-08-460-602A-36
; Sequence 36, Application US/08460602A
; Patent No. 5759769
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/460,602A
; FILING DATE: 02-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/257,528
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/073,378
; FILING DATE: 09-JUN-1993
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-450 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 36:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-460-602A-36

Query Match 68.8%; Score 53; DB 1; Length 14;
Best Local Similarity 100.0%; Pred.No. 0.046;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIORGPGRAF 10
Db 5 RIORGPGRAF 14

RESULT 237
US-08-463-966A-36
; Sequence 36, Application US/08463966A
; Patent No. 5795955
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/463,966A
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/257,528
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/073,378
; FILING DATE: 09-JUN-1993

CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, MICHAEL I.
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-487 MIS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 36:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-463-966A-36

Query Match 68.8%; Score 53; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.046;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRGF 10
DB 5 RIQGPGRGF 14

RESULT 238
US-08-465-217A-36
Sequence 36, Application US/08465217A
Patent No. 5800822
GENERAL INFORMATION:
APPLICANT: SIA, Charles D.Y.
APPLICANT: CHONG, Pele
APPLICANT: KLEIN, Michel H.
TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/465,217A
FILING DATE: 05-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/257,528
FILING DATE: 09-JUN-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/073,378
FILING DATE: 09-JUN-1993

CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, MICHAEL I.
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-486 MIS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 36:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-465-217A-36

Query Match 68.8%; Score 53; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.046;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RIQGPGRGF 10
DB 5 RIQGPGRGF 14

RESULT 239
US-08-464-329A-36
Sequence 36, Application US/08464329A
Patent No. 5817754
GENERAL INFORMATION:
APPLICANT: SIA, Charles D.Y.
APPLICANT: CHONG, Pele
APPLICANT: KLEIN, Michel H.
TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/464,329A
FILING DATE: 05-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/257,528
FILING DATE: 09-JUN-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/073,378
FILING DATE: 09-JUN-1993
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, MICHAEL I.
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-449 MIS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 36:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-464-329A-36

Query Match 68.8%; Score 53; DB 2; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.046;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRGF 10
DB 5 RIQGPGRGF 14

RESULT 240
US-08-462-507A-36
Sequence 36, Application US/08462507A
Patent No. 5876731
GENERAL INFORMATION:

APPLICANT: SIA, Charles D.Y.
APPLICANT: CHONG, Pele
APPLICANT: KLEIN, Michael H.
TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/462,507A
FILING DATE: 05-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/073,378
FILING DATE: 09-JUN-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/257,528
FILING DATE: 09-JUN-1994
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, MICHAEL I.
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-451 MIS:jb
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
LENGTH: 14 amino acids
SEQUENCE CHARACTERISTICS:
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-462-507A-36

Query Match 68.8%; Score 53; DB 2; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.046;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RIQGPGRAP 10
DB 5 RIQGPGRAP 14

RESULT 241
US-08-467-881A-36
Sequence 36, Application US/08467881A
Patent No. 5951986
GENERAL INFORMATION:
APPLICANT: SIA, Charles D.Y.
APPLICANT: CHONG, Pele
APPLICANT: KLEIN, Michael H.
TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/467,881A
FILING DATE: 06-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/257,528
FILING DATE: 09-JUN-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/073,378
FILING DATE: 09-JUN-1993
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, MICHAEL I.
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-488 MIS:jb
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
LENGTH: 14 amino acids
SEQUENCE CHARACTERISTICS:
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-467-881A-36

Query Match 68.8%; Score 53; DB 2; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.046;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RIQGPGRAP 10
DB 5 RIQGPGRAP 14

RESULT 242
US-08-218-025A-16
Sequence 16, Application US/08218025A
Patent No. 5556744
GENERAL INFORMATION:
APPLICANT: Weiner, David B.
APPLICANT: Ugen, Kenneth E.
APPLICANT: Williams, William V.
TITLE OF INVENTION: Methods and Compositions for Diagnosing
TITLE OF INVENTION: and Treating Certain HIV Infected Patients
NUMBER OF SEQUENCES: 197
CORRESPONDENCE ADDRESS:
ADDRESSEE: Howson and Howson
STREET: P.O. Box 457, 321 No. 5556744ristown Road
CITY: Spring House
STATE: Pennsylvania
COUNTRY: U.S.A.
ZIP: 19477
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/218,025A
FILING DATE: 24-MAR-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/891,451
FILING DATE: 29-MAY-1992
ATTORNEY/AGENT INFORMATION:
NAME: Bak, Mary E.
REGISTRATION NUMBER: 31,215
REFERENCE/DOCKET NUMBER: WST33A
TELECOMMUNICATION INFORMATION:

```
;
; TELEPHONE: (215) 540-9206
; TELEFAX: (215) 540-5818
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
US-08-218-025A-16

Query Match 68.8%; Score 53; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.049; Mismatches 0; Indels 0; Gaps 0;
Matches 10; Conservative 0;

QY 1 RIQPGGRAFI 10
Db 6 RIQPGGRAFI 15

RESULT 243
PCT-US92-01303-12
; Sequence 12, Application PC/TUS9201303
; GENERAL INFORMATION:
; APPLICANT: Murray, Michael G. et al. VACCINES
; TITLE OF INVENTION: POLIOVIRUS-BASED VACCINES
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 50Z or 55SX
; OPERATING SYSTEM: IBM P.C. DOS (Version 3.30)
; SOFTWARE: WordPerfect (Version 5.0)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US92/01303
; FILING DATE: 19920214
; CLASSIFICATION: 564
; PRIOR APPLICATION NUMBER:
; APPLICATION NUMBER: 07/655,669
; FILING DATE: 14-FEB-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: PAUL T. CLARK
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 00231/050W01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: AMINO ACID
; TOPOLOGY: linear
PCT-US92-01303-12

Query Match 68.8%; Score 53; DB 5; Length 20;
Best Local Similarity 83.3%; Pred. No. 0.064; Mismatches 1; Indels 1; Gaps 0;
Matches 10; Conservative 1;

QY 2 IORPGGRAFTI 13
Db 9 IORPGGRAFTI 20

RESULT 244
US-09-820-484-8
; Sequence 8, Application US/09820484
; Patent No. 6534062
```

```
;
; GENERAL INFORMATION:
; APPLICANT: Raz, Eyal
; APPLICANT: Cho, Hearn Jay
; APPLICANT: Richman, Douglas
; APPLICANT: Horner, Anthony A.
; TITLE OF INVENTION: Method for Increasing a Cytotoxic T
; TITLE OF INVENTION: Lymphocyte Response in vivo.
; FILE REFERENCE: 06510-188US1
; CURRENT APPLICATION NUMBER: US/09/820,484
; CURRENT FILING DATE: 2001-03-28
; PRIOR APPLICATION NUMBER: US 60/192,537
; PRIOR FILING DATE: 2000-03-28
; PRIOR APPLICATION NUMBER: US 60/203,567
; PRIOR FILING DATE: 2000-05-11
; PRIOR APPLICATION NUMBER: US 60/215,895
; PRIOR FILING DATE: 2000-07-05
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: HIV-1 class I-restricted gp120 peptide
US-09-820-484-8

Query Match 67.5%; Score 52; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.047;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 RGPGRFVTI 13
Db 1 RGPGRFVTI 10

RESULT 245
US-09-430-470-24
; Sequence 24, Application US/09430470
; Patent No. 6562800
; GENERAL INFORMATION:
; APPLICANT: McMillan, Minnie
; TITLE OF INVENTION: THE USE OF IMMUNOPOTENTIATING SEQUENCES
; TITLE OF INVENTION: FOR INDUCING IMMUNE RESPONSE
; FILE REFERENCE: 13761-725
; CURRENT APPLICATION NUMBER: US/09/430,470
; CURRENT FILING DATE: 1999-10-29
; EARLIER APPLICATION NUMBER: US 60/106,506
; EARLIER FILING DATE: 1998-10-30
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 24
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Human immunodeficiency virus (HIV)
; FEATURE:
; OTHER INFORMATION: Residues 318-327 of gp120 (GenBank accession
; OTHER INFORMATION: number gi224364)
US-09-430-470-24

Query Match 67.5%; Score 52; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.047;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 RGPGRFVTI 13
Db 1 RGPGRFVTI 10

RESULT 246
US-08-937-276A-5
; Sequence 5, Application US/08937276A
; Patent No. 6592872
; GENERAL INFORMATION:
```

```

; APPLICANT: Klimpel, Kurt
; Goletz, Theresa J.
; Aroca, Naveen
; Leppla, Stephen H.
; Berzofsky, Jay A.
; TITLE OF INVENTION: Targeting Antigens to the MHC Class I
; Processing Pathway With an Anthrax Toxin Fusion Protein
;
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/937,276A
; FILING DATE: 15-Sep-1997
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/025,270
; FILING DATE: 17-SEP-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Weber, Kenneth A.
; REGISTRATION NUMBER: 31,677
; REFERENCE/DOCKET NUMBER: 015280-290100US
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-08-937-276A-5

Query Match 67.5%; Score 52; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.047;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RGPGRFVTI 13
Db 1 RGPGRFVTI 10

RESULT 247
US-09-454-204A-51
; Sequence 51, Application US/09454204A
; Patent No. 6663871
; GENERAL INFORMATION:
; APPLICANT: McMichael, Andrew
; APPLICANT: Hill, Adrian V.S.
; APPLICANT: Gilbert, Sarah C.
; APPLICANT: Schneider, Jorg
; APPLICANT: Plebanski, Magdalena
; APPLICANT: Hanke, Tomas
; APPLICANT: Smith, Geoffrey L.
; APPLICANT: Blanchard, Tom
; TITLE OF INVENTION: Methods and Reagents for Vaccination
; FILE REFERENCE: 2907.1000-000
; CURRENT APPLICATION NUMBER: US/09/454,204A
; PRIOR FILING DATE: 1999-12-09
; PRIOR APPLICATION NUMBER: PCT/GB98/01681
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: GB 97 11957.2
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: CTL Peptide Epitope of HIV gag
US-09-454-204A-68

Query Match 67.5%; Score 52; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.047;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RGPGRFVTI 13
Db 1 RGPGRFVTI 10

RESULT 249
US-09-508-552-16
; Sequence 16, Application US/09508552
; Patent No. 6749856
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Belyakov, Igor M.
; APPLICANT: Derby, Michael A.
; APPLICANT: Kelsall, Brian L.
; APPLICANT: Strober, Warren
; APPLICANT: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as
```

```

; PRIOR APPLICATION NUMBER: GB 97 11957.2
; PRIOR FILING DATE: 1997-06-09
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 51
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: CTL Epitope of HIV-1 gp120
US-09-454-204A-51

Query Match 67.5%; Score 52; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.047;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RGPGRFVTI 13
Db 1 RGPGRFVTI 10

RESULT 248
US-09-454-204A-68
; Sequence 68, Application US/09454204A
; Patent No. 6663871
; GENERAL INFORMATION:
; APPLICANT: McMichael, Andrew
; APPLICANT: Hill, Adrian V.S.
; APPLICANT: Gilbert, Sarah C.
; APPLICANT: Schneider, Jorg
; APPLICANT: Plebanski, Magdalena
; APPLICANT: Hanke, Tomas
; APPLICANT: Smith, Geoffrey L.
; APPLICANT: Blanchard, Tom
; TITLE OF INVENTION: Methods and Reagents for Vaccination
; FILE REFERENCE: 2907.1000-000
; CURRENT APPLICATION NUMBER: US/09/454,204A
; PRIOR FILING DATE: 1999-12-09
; PRIOR APPLICATION NUMBER: PCT/GB98/01681
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: GB 97 11957.2
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 68
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: CTL Peptide Epitope of HIV gag
US-09-454-204A-68

Query Match 67.5%; Score 52; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.047;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RGPGRFVTI 13
Db 1 RGPGRFVTI 10

RESULT 249
US-09-508-552-16
; Sequence 16, Application US/09508552
; Patent No. 6749856
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Belyakov, Igor M.
; APPLICANT: Derby, Michael A.
; APPLICANT: Kelsall, Brian L.
; APPLICANT: Strober, Warren
; APPLICANT: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as
```

Search completed: May 16, 2005, 14:41:20
Job time : 45 secs

;; TITLE OF INVENTION: MUCOSAL CYTOTOXIC T LYMPHOCYTE RESPONSES
;; FILE REFERENCE: 368200PCSEQ
;; CURRENT APPLICATION NUMBER: US/09/508,552
;; CURRENT FILING DATE: 2000-06-12
;; PRIOR APPLICATION NUMBER: 60/058,523
;; PRIOR FILING DATE: 1997-09-11
;; PRIOR APPLICATION NUMBER: 60/074,894
;; PRIOR FILING DATE: 1998-02-17
;; NUMBER OF SEQ ID NOS: 20
;; SOFTWARE: PatentIn Ver. 2.0
;; SEQ ID NO 16
;; LENGTH: 10
;; TYPE: PRT
;; ORGANISM: Human immunodeficiency virus type 1
US-09-508-552-16

Query Match 67.5%; Score 52; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.047; Mismatches 0; Indels 0; Gaps 0;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy' 4 RGPGRFVTTI 13
| | | | | | | | | |
Db 1 RGPGRFVTTI 10

RESULT 250
PCT-US92-01303-1
; Sequence 1, Application PC/TUS9201303
; GENERAL INFORMATION:
; APPLICANT: Murray, Michael G. et al.
; TITLE OF INVENTION: POLIOVIRUS-BASED VACCINES
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 50Z or 55SX
; OPERATING SYSTEM: IBM P.C. DOS (Version 3.30)
; SOFTWARE: WordPerfect (Version 5.0)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US92/01303
; FILING DATE: 19920214
; CLASSIFICATION: 564
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/655,669
; FILING DATE: 14-FEB-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: PAUL T. CLARK
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 00231/050W01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10
; TYPE: AMINO ACID
; TOPOLOGY: linear
PCT-US92-01303-1

Query Match 67.5%; Score 52; DB 5; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.047; Mismatches 0; Indels 0; Gaps 0;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2 IQRGGRFV 11
| | | | | | | | | |
Db 1 IQRGGRFV 10

This Page Blank (uspto)

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: May 16, 2005, 12:57:08 ; Search time 70.7692 Seconds
(without alignments)
70.804 Million cell updates/sec

Title: US-08-869-386-1
Perfect score: 77
Sequence: 1 RIQRGPGRAFTVIGK 15

Scoring table: BLOSUM62
Gap 10.0 , Gapext 0.5

Searched: 1432185 seqs, 334051727 residues

Total number of hits satisfying chosen parameters: 325800

Minimum DB seq length: 0
Maximum DB seq length: 25

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA:
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/PTCT_NEW_PUB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/PTCTUS_PUBCOMB.pep.*
7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
8: /cgn2_6/ptodata/1/pubpaa/US09A_PUBCOMB.pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09A_PUBCOMB.pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep.*
11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep.*
12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep.*
16: /cgn2_6/ptodata/1/pubpaa/US10D_PUBCOMB.pep.*
17: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
18: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
19: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*
20: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	ID	Description
1	77	100.0	15	9	US-09-810-310-15
2	77	100.0	15	9	US-09-810-310-24
3	77	100.0	15	9	US-09-810-310-24
4	77	100.0	15	9	US-09-810-310-24
5	77	100.0	15	10	US-09-827-688-9
6	77	100.0	15	10	US-09-827-688-9
7	77	100.0	15	10	US-09-827-688-9
8	77	100.0	15	14	US-10-133-210-246
9	77	100.0	15	14	US-10-133-210-262
10	77	100.0	15	14	US-10-147-910-6
11	77	100.0	15	17	US-10-787-880-2
12	77	100.0	15	14	US-10-062-710-44
13	77	100.0	20	9	US-09-813-659-3
	77	100.0	20	15	US-10-283-610A-3
	77	100.0	21	14	US-10-178-488-25

14	77	100.0	24	17	US-10-621-675-160	Sequence 160, Appl
15	73	94.8	20	14	US-10-311-111-1	Sequence 1, Appl1
16	73	94.8	20	16	US-10-398-932-1	Sequence 1, Appl1
17	72	93.5	18	14	US-10-062-710-45	Sequence 45, Appl
18	68	88.3	13	14	US-10-239-313A-536	Sequence 536, Appl
19	68	88.3	15	14	US-10-239-313A-186	Sequence 186, Appl
20	66	85.7	15	10	US-09-993-307-21	Sequence 21, Appl
21	63	81.8	12	14	US-10-239-313A-535	Sequence 535, Appl
22	62	80.5	20	10	US-09-827-345-24	Sequence 24, Appl
23	58	75.3	13	14	US-10-311-111-3	Sequence 3, Appl1
24	58	75.3	13	16	US-10-398-932-3	Sequence 3, Appl1
25	58	75.3	15	9	US-09-901-106-10	Sequence 10, Appl1
26	57	74.0	11	14	US-10-239-313A-533	Sequence 533, Appl
27	57	74.0	15	17	US-10-622-003-6	Sequence 6, Appl1
28	57	74.0	17	9	US-09-901-106-12	Sequence 12, Appl
29	52	67.5	10	9	US-09-858-349-3	Sequence 3, Appl1
30	52	67.5	10	9	US-09-810-310-16	Sequence 16, Appl
31	52	67.5	10	9	US-09-820-484-8	Sequence 8, Appl1
32	52	67.5	10	9	US-09-087-513-7	Sequence 7, Appl1
33	52	67.5	10	9	US-09-087-513-13	Sequence 13, Appl1
34	52	67.5	10	10	US-09-997-848A-16	Sequence 16, Appl
35	52	67.5	10	10	US-09-993-307-22	Sequence 22, Appl
36	52	67.5	10	14	US-10-113-085-7	Sequence 7, Appl1
37	52	67.5	10	14	US-10-168-843A-2	Sequence 2, Appl1
38	52	67.5	10	14	US-10-147-910-12	Sequence 12, Appl
39	52	67.5	10	14	US-10-079-167-51	Sequence 51, Appl
40	52	67.5	10	14	US-10-079-167-68	Sequence 68, Appl
41	52	67.5	10	14	US-10-340-275-8	Sequence 8, Appl1
42	52	67.5	10	14	US-10-339-885-8	Sequence 8, Appl1
43	52	67.5	10	14	US-10-206-155-5	Sequence 5, Appl1
44	52	67.5	10	14	US-10-210-148-113	Sequence 113, Appl
45	52	67.5	10	14	US-10-360-836-48	Sequence 48, Appl

ALIGNMENTS

RESULT 1
US-09-810-310-15
; Sequence 15, Application US/09810310
; Patent No. US2002004948A1
; GENERAL INFORMATION:
; APPLICANT: Khleif, Samir N.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR CO-STIMULATION OF
; IMMUNOLOGICAL RESPONSES TO PEPTIDE ANTIGENS
; FILE REFERENCE: 15280-415100US
; CURRENT APPLICATION NUMBER: US/09/810,310
; CURRENT FILING DATE: 2001-03-14
; PRIOR FILING DATE: 2000-03-15
; NUMBER OF SEQ ID NOS: 61
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: HIV PEPTIDE
; OTHER INFORMATION: ANTIGEN
; US-09-810-310-15

Query Match 100.0%; Score 77; DB 9; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Cq 1 RIQRGPGRAFTVIGK 15
| | | | | | | | | | | | | | |
Db 1 RIQRGPGRAFTVIGK 15

RESULT 2
US-09-810-310-24

```
; Sequence 24, Application US/09810310
; Patent No. US20020044948A1
; GENERAL INFORMATION:
; APPLICANT: ORSON, FRANK
; APPLICANT: KINSEY, BERMA
; APPLICANT: BHOGAL, BALBIR
; TITLE OF INVENTION: MACROAGGREGATED PROTEIN CONJUGATES AS ORAL GENETIC IMMUNIZATION DI
; TITLE OF INVENTION: AGENTS
; FILE REFERENCE: P01949US1/10004014
; CURRENT APPLICATION NUMBER: US/09/827,688
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: 60/195,680
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9
; LENGTH: 15
; TYPE: PRT
; ORGANISM: HIV p18
; US-09-827-688-9

Query Match      100.0%; Score 77; DB 10; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RIQGGGGRFVTVIGK 15
DB      1 RIQGGGGRFVTVIGK 15

RESULT 5
US-09-077-439A-3
; Sequence 3, Application US/09077439A
; Publication No. US20030202989A1
; GENERAL INFORMATION:
; APPLICANT: Collier, R. John
; APPLICANT: Blanke, Steven R.
; APPLICANT: Milne, Jill C.
; APPLICANT: Benson, Ericka L.
; APPLICANT: Ballard, Jimmy D.
; APPLICANT: Starnbach, Michael N.
; TITLE OF INVENTION: Use of Toxin Peptides and/or Affinity
; FILE REFERENCE: 00246/187002
; CURRENT APPLICATION NUMBER: US/09/077,439A
; CURRENT FILING DATE: 1999-04-08
; PRIOR APPLICATION NUMBER: PCT/US96/20463
; PRIOR FILING DATE: 1996-12-13
; PRIOR APPLICATION NUMBER: US 60/019,275
; PRIOR FILING DATE: 1996-06-07
; PRIOR APPLICATION NUMBER: US 60/008,518
; PRIOR FILING DATE: 1995-12-13
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Homo sapien
; US-09-077-439A-3

Query Match      100.0%; Score 77; DB 10; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RIQGGGGRFVTVIGK 15
DB      1 RIQGGGGRFVTVIGK 15

RESULT 6
US-10-133-210-246
; Sequence 246, Application US/10133210
; Publication No. US20030103964A1
; GENERAL INFORMATION:
; APPLICANT: DeLisi, Charles
```

```
; Sequence 24, Application US/09810310
; Patent No. US20020044948A1
; GENERAL INFORMATION:
; APPLICANT: Khleif, Samir N.
; APPLICANT: Bezofsky, Jay A.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR CO-STIMULATION OF
; TITLE OF INVENTION: IMMUNOLOGICAL RESPONSES TO PEPTIDE ANTIGENS
; FILE REFERENCE: 15280-415100US
; CURRENT APPLICATION NUMBER: US/09/810,310
; CURRENT FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: 60/189,396
; PRIOR FILING DATE: 2000-03-15
; NUMBER OF SEQ ID NOS: 61
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 24
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: HIV PEPTIDE
; OTHER INFORMATION: ANTIGEN
; US-09-810-310-24

Query Match      100.0%; Score 77; DB 9; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RIQGGGGRFVTVIGK 15
DB      1 RIQGGGGRFVTVIGK 15

RESULT 3
US-09-989-621-8
; Sequence 8, Application US/09989621
; Patent No. US20020151683A1
; GENERAL INFORMATION:
; APPLICANT: Mogam Biotechnology Research Institute
; APPLICANT: Kim, Tae-Young
; APPLICANT: Lee, Ki-Young
; APPLICANT: Chang, Jin-Soo
; APPLICANT: Cho, Sung-Yoo
; APPLICANT: Hwang, Yu-Kyeong
; APPLICANT: Choi, Myeong
; APPLICANT: Cheong, Hong-Seok
; TITLE OF INVENTION: Liposomes Comprising Peptide Antigens
; TITLE OF INVENTION: Derived from X Protein of Hepatitis B virus
; FILE REFERENCE: 0136/08154
; CURRENT APPLICATION NUMBER: US/09/989,621
; CURRENT FILING DATE: 2001-11-20
; PRIOR APPLICATION NUMBER: 09/051,006
; PRIOR FILING DATE: 2000-11-17
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 15
; TYPE: PRT
; ORGANISM: HIV
; US-09-989-621-8

Query Match      100.0%; Score 77; DB 9; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RIQGGGGRFVTVIGK 15
DB      1 RIQGGGGRFVTVIGK 15

RESULT 4
US-09-827-688-9
; Sequence 9, Application US/09827688
; Publication No. US20030165476A1
```

; APPLICANT: Berzofsky, Jay
; APPLICANT: Gulukota, Kamalakar
; APPLICANT: Vaccaro, Dennis
; APPLICANT: Weng, Ziping
; APPLICANT: Zhang, Chao
; TITLE OF INVENTION: METHODS FOR DESIGNING MOLECULAR CONJUGATES AND
; TITLE OF INVENTION: COMPOSITIONS THEREOF
; FILE REFERENCE: BU-035AX
; CURRENT APPLICATION NUMBER: US/10/133,210
; CURRENT FILING DATE: 2002-04-26
; NUMBER OF SEQ ID NOS: 281
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 246
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-133-210-246

Query Match 100.0%; Score 77; DB 14; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQGPGRFVTVIGK 15
Db 1 RIQGPGRFVTVIGK 15

RESULT 7
US-10-133-210-262
; Sequence 262, Application US/10133210
; Publication No. US20030103964A1
; GENERAL INFORMATION:
; APPLICANT: DeLisi, Charles
; APPLICANT: Berzofsky, Jay
; APPLICANT: Gulukota, Kamalakar
; APPLICANT: Vaccaro, Dennis
; APPLICANT: Weng, Ziping
; APPLICANT: Zhang, Chao
; TITLE OF INVENTION: METHODS FOR DESIGNING MOLECULAR CONJUGATES AND
; TITLE OF INVENTION: COMPOSITIONS THEREOF
; FILE REFERENCE: BU-035AX
; CURRENT APPLICATION NUMBER: US/10/133,210
; CURRENT FILING DATE: 2002-04-26
; NUMBER OF SEQ ID NOS: 281
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 262
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-133-210-262

Query Match 100.0%; Score 77; DB 14; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQGPGRFVTVIGK 15
Db 1 RIQGPGRFVTVIGK 15

RESULT 8
US-10-147-910-6
; Sequence 6, Application US/10147910
; Publication No. US20030124718A1
; GENERAL INFORMATION:
; APPLICANT: Fuller, Deborah
; APPLICANT: Fuller, James
; APPLICANT: Haynes, Joel
; APPLICANT: Shipley, Timothy

; TITLE OF INVENTION: Vaccine Composition
; FILE REFERENCE: 033267-006
; CURRENT APPLICATION NUMBER: US/10/147,910
; CURRENT FILING DATE: 2002-05-20
; PRIOR APPLICATION NUMBER: US 60/291,654
; PRIOR FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: US 60/291,655
; PRIOR FILING DATE: 2001-05-18
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 15
; TYPE: PRT
; ORGANISM: HIV
US-10-147-910-6

Query Match 100.0%; Score 77; DB 14; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQGPGRFVTVIGK 15
Db 1 RIQGPGRFVTVIGK 15

RESULT 9
US-10-787-880-2
; Sequence 2, Application US/10787880
; Publication No. US2005002577A1
; GENERAL INFORMATION:
; APPLICANT: Pohlmann, Edward L.
; APPLICANT: Sheehy, Michael J.
; APPLICANT: Barton, Kenneth A.
; TITLE OF INVENTION: PARTICLE-MEDIATED DELIVERY OF ANTIGENS
; FILE REFERENCE: 033267-018
; CURRENT APPLICATION NUMBER: US/10/787,880
; CURRENT FILING DATE: 2004-02-27
; PRIOR APPLICATION NUMBER: US/09/191,772
; PRIOR FILING DATE: 1998-11-13
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 15
; TYPE: PRT
; ORGANISM: HIVgp120
US-10-787-880-2

Query Match 100.0%; Score 77; DB 17; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQGPGRFVTVIGK 15
Db 1 RIQGPGRFVTVIGK 15

RESULT 10
US-10-062-710-44
; Sequence 44, Application US/10062710
; Publication No. US20030049253A1
; GENERAL INFORMATION:
; APPLICANT: Li, Frank Q.
; APPLICANT: Chu, Yong-Liang
; APPLICANT: Qiu, Jian-Tai
; TITLE OF INVENTION: Polymeric Conjugates for Delivery of
; TITLE OF INVENTION: MHC-Recognized Epitopes
; TITLE OF INVENTION: Via Peptide Vaccines
; FILE REFERENCE: 3781-001-27
; CURRENT APPLICATION NUMBER: US/10/062,710
; CURRENT FILING DATE: 2002-02-05
; PRIOR APPLICATION NUMBER: US 60/310,498
; PRIOR FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 232

```
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 44
; LENGTH: 16
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: HIV Helper-T Cell Epitopes
US-10-062-710-44

Query Match      100.0%; Score 77; DB 14; Length 16;
Best Local Similarity 100.0%; Pred. No. 2e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRFAFVTIGK 15
   |||||
DB 2 RIQGPGRFAFVTIGK 16

RESULT 11
US-09-813-659-3
; Sequence 3, Application US/09813659
; Patent No. US20020012989A1
; GENERAL INFORMATION:
; APPLICANT: Ledbetter, Jeffrey A.
; APPLICANT: Hayden, Martha S.
; APPLICANT: Linsley, Peter S.
; APPLICANT: Bajorath, Jurgen
; APPLICANT: Fell, H. Perry
; APPLICANT: Gilliland, Lisa K.
; TITLE OF INVENTION: EXPRESSION VECTORS ENCODING BISPECIFIC FUSION PROTEINS
; TITLE OF INVENTION: AND METHODS OF PRODUCING BIOLOGICALLY ACTIVE BISPECIFIC
; TITLE OF INVENTION: FUSION PROTEINS IN A MAMMALIAN CELL
; FILE REFERENCE: 30436.18USD2
; CURRENT APPLICATION NUMBER: US/09/813,659
; CURRENT FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 09/549,067
; PRIOR FILING DATE: 2000-04-13
; PRIOR APPLICATION NUMBER: 08/539,436
; PRIOR FILING DATE: 1995-10-05
; PRIOR APPLICATION NUMBER: 08/121,054
; PRIOR FILING DATE: 1993-09-13
; PRIOR APPLICATION NUMBER: 08/013,420
; PRIOR FILING DATE: 1993-02-01
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-813-659-3

Query Match      100.0%; Score 77; DB 9; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.5e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRFAFVTIGK 15
   |||||
DB 5 RIQGPGRFAFVTIGK 19

RESULT 12
US-10-283-610A-3
; Sequence 3, Application US/10283610A
; Publication No. US20030219876A1
; GENERAL INFORMATION:
; APPLICANT: Ledbetter, Jeffrey A.
; APPLICANT: Hayden, Martha S.
; APPLICANT: Linsley, Peter S.
; APPLICANT: Bajorath, Jurgen
; APPLICANT: Fell, H. Perry
; APPLICANT: Gilliland, Lisa K.
; TITLE OF INVENTION: EXPRESSION VECTORS ENCODING BISPECIFIC FUSION PROTEINS
; TITLE OF INVENTION: AND METHODS OF PRODUCING BIOLOGICALLY ACTIVE BISPECIFIC
```

```
; TITLE OF INVENTION: FUSION PROTEINS IN A MAMMALIAN CELL
; FILE REFERENCE: ON107E/30436.18USD3
; CURRENT APPLICATION NUMBER: US/10/283,610A
; CURRENT FILING DATE: 2002-10-29
; PRIOR APPLICATION NUMBER: 09/549,067
; PRIOR FILING DATE: 2000-04-13
; PRIOR APPLICATION NUMBER: 08/539,436
; PRIOR FILING DATE: 1995-10-05
; PRIOR APPLICATION NUMBER: 08/121,054
; PRIOR FILING DATE: 1993-09-13
; PRIOR APPLICATION NUMBER: 08/013,420
; PRIOR FILING DATE: 1993-02-01
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-283-610A-3

Query Match      100.0%; Score 77; DB 15; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.5e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRFAFVTIGK 15
   |||||
DB 5 RIQGPGRFAFVTIGK 19

RESULT 13
US-10-178-488-25
; Sequence 25, Application US/10178488
; Publication No. US20030165535A1
; GENERAL INFORMATION:
; APPLICANT: Rovinski, Benjamin
; APPLICANT: Cao, Shi-Xian
; APPLICANT: Yao, Fei-Long
; APPLICANT: Persson, Roy
; APPLICANT: Klein, Michel H.
; TITLE OF INVENTION: RETROVIRUS-LIKE PARTICLES MADE NON-INFECTIOUS BY A
; TITLE OF INVENTION: PLURALITY OF MUTATIONS
; FILE REFERENCE: 1038-1238 MIS
; CURRENT APPLICATION NUMBER: US/10/178,488
; CURRENT FILING DATE: 2002-10-25
; PRIOR APPLICATION NUMBER: 09/258,128
; PRIOR FILING DATE: 1999-02-26
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 25
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Artificial
US-10-178-488-25

Query Match      100.0%; Score 77; DB 14; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.6e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRFAFVTIGK 15
   |||||
DB 7 RIQGPGRFAFVTIGK 21

RESULT 14
US-10-621-675-160
; Sequence 160, Application US/10621675
; Publication No. US20050049398A1
; GENERAL INFORMATION:
; APPLICANT: De Leys, Robert
; TITLE OF INVENTION: PROCESS FOR THE DETERMINATION OF PEPTIDES CORRESPONDING
; TITLE OF INVENTION: TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND THEIR USE IN
```

FILE REFERENCE: 024918-0103
CURRENT APPLICATION NUMBER: US/10/398,932
CURRENT FILING DATE: 2003-04-11
PRIOR APPLICATION NUMBER: PCT/JP01/08893
PRIOR FILING DATE: 2001-10-10
PRIOR APPLICATION NUMBER: JP 2000/314288
PRIOR FILING DATE: 2000-10-13
NUMBER OF SEQ ID NOS: 55
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 1
LENGTH: 20
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURES:
OTHER INFORMATION: Description of Artificial Sequence: Synthetically Designed Peptide
US-10-398-932-1

Query Match 94.8%; Score 73; DB 16; Length 20;
Best Local Similarity 93.3%; Pred. No. 0.00011;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQGGGRTFTVIGK 15
DB 5 RIQGGGRTFTVIGK 19

RESULT 17
US-10-062-710-45
Sequence 45, Application US/10062710
Publication No. US20030049253A1
GENERAL INFORMATION:
APPLICANT: Li, Frank Q.
APPLICANT: Chu, Yong-Liang
APPLICANT: Qiu, Jian-Tai
TITLE OF INVENTION: Polymeric Conjugates for Delivery of
TITLE OF INVENTION: MHC-Recognized Epitopes
TITLE OF INVENTION: Via Peptide Vaccines
FILE REFERENCE: 3781-001-27
CURRENT APPLICATION NUMBER: US/10/062,710
CURRENT FILING DATE: 2002-02-05
PRIOR APPLICATION NUMBER: US 60/310,498
PRIOR FILING DATE: 2001-08-08
NUMBER OF SEQ ID NOS: 232
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 45
LENGTH: 18
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: HIV Helper-T Cell Epitopes
US-10-062-710-45

Query Match 93.5%; Score 72; DB 14; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.00014;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 RIQGGGRTFTVIGK 15
DB 2 RIQGGGRTFTVIGK 15

RESULT 18
US-10-239-313A-536
Sequence 536, Application US/10239313A
Publication No. US20030175285A1
GENERAL INFORMATION:
APPLICANT: KLINGUER - HAMOUR, Christine
APPLICANT: CORVAIA, Nathalie
APPLICANT: BECK, Alain
APPLICANT: GOETSCH, Liliane
TITLE OF INVENTION: MOLECULE OF PHARMACEUTICAL INTEREST COMPRISING AT ITS
TITLE OF INVENTION: N-TERMINAL A GLUTAMIC ACID OR A GLUTAMINE IN THE FORM

TITLE OF INVENTION: A PROCESS FOR DETERMINATION OF ANTIBODIES OF
TITLE OF INVENTION: BOTTYPATED PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT
TITLE OF INVENTION: EPITOPES, A PROCESS FOR PREPARING THEM AND COMPOSITIONS
TITLE OF INVENTION: CONTAINING THEM
FILE REFERENCE: 2752-11
CURRENT APPLICATION NUMBER: US/10/621,675
CURRENT FILING DATE: 2003-07-18
PRIOR APPLICATION NUMBER: US/09/576,824A
PRIOR APPLICATION NUMBER: 08/723,425
PRIOR FILING DATE: 1996-09-30
PRIOR APPLICATION NUMBER: 09/146,028
PRIOR FILING DATE: 1993-11-22
PRIOR APPLICATION NUMBER: PCT/EP93/00517
PRIOR FILING DATE: 1993-03-08
PRIOR APPLICATION NUMBER: EP 92400598.6
PRIOR FILING DATE: 1992-03-06
NUMBER OF SEQ ID NOS: 600
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 160
LENGTH: 24
TYPE: PRT
ORGANISM: Human immunodeficiency virus
US-10-621-675-160

Query Match 100.0%; Score 77; DB 17; Length 24;
Best Local Similarity 100.0%; Pred. No. 2.9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGGGRTFTVIGK 15
DB 8 RIQGGGRTFTVIGK 22

RESULT 15
US-10-311-111-1
Sequence 1, Application US/1031111
Publication No. US20030121065A1
GENERAL INFORMATION:
APPLICANT: SHIBA, KIYOTAKA
TITLE OF INVENTION: MULTIFUNCTIONAL BASE SEQUENCE AND ARTIFICIAL GENE CONTAINING THE
FILE REFERENCE: 4439-4004
CURRENT APPLICATION NUMBER: US/10/311,111
CURRENT FILING DATE: 2002-12-13
PRIOR APPLICATION NUMBER: JP 2000-180997
PRIOR FILING DATE: 2000-06-16
NUMBER OF SEQ ID NOS: 34
SOFTWARE: PatentIn version 3.1
SEQ ID NO 1
LENGTH: 20
TYPE: PRT
ORGANISM: artificial
FEATURE:
OTHER INFORMATION: Designed peptide
US-10-311-111-1

Query Match 94.8%; Score 73; DB 14; Length 20;
Best Local Similarity 93.3%; Pred. No. 0.00011;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQGGGRTFTVIGK 15
DB 5 RIQGGGRTFTVIGK 19

RESULT 16
US-10-398-932-1
Sequence 1, Application US/10398932
Publication No. US20040171803A1
GENERAL INFORMATION:
APPLICANT: SHIBA, KIYOTAKA
APPLICANT: OHNO, TSUNOYA
TITLE OF INVENTION: ARTIFICIAL PROTEINS WITH ENRICHED IMMUNOGEN
TITLE OF INVENTION: OF EPITOPE

; TITLE OF INVENTION: OF A PHYSIOLOGICALLY ACCEPTABLE STRONG ACID
; FILE REFERENCE: 343 727 - US
; CURRENT APPLICATION NUMBER: US/10/239,313A
; PRIOR FILING DATE: 2002-09-19
; PRIOR APPLICATION NUMBER: FR 00/03711
; PRIOR FILING DATE: 2000-03-23
; PRIOR APPLICATION NUMBER: PCT 01/70772
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 697
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 536
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Human immunodeficiency virus
US-10-239-313A-536

Query Match 88.3%; Score 68; DB 14; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.00044;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 QRGPGRAFTVIGK 15
Db 1 QRGPGRAFTVIGK 13

RESULT 19

US-10-239-313A-186
; Sequence 186, Application US/10239313A
; Publication No. US20030175285A1
; GENERAL INFORMATION:
; APPLICANT: KLINGUER - HAMOUR, Christine
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: BECK, Alain
; APPLICANT: GOETSCH, Liliane
; TITLE OF INVENTION: MOLECULE OF PHARMACEUTICAL INTEREST COMPRISING AT ITS
; TITLE OF INVENTION: N-TERMINAL A GLUTAMIC ACID OR A GLUTAMINE IN THE FORM
; TITLE OF INVENTION: OF A PHYSIOLOGICALLY ACCEPTABLE STRONG ACID
; FILE REFERENCE: 343 727 - US
; CURRENT APPLICATION NUMBER: US/10/239,313A
; CURRENT FILING DATE: 2002-09-19
; PRIOR APPLICATION NUMBER: FR 00/03711
; PRIOR FILING DATE: 2000-03-23
; PRIOR APPLICATION NUMBER: PCT 01/70772
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 697
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 186
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Human immunodeficiency virus
US-10-239-313A-186

Query Match 89.3%; Score 68; DB 14; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.0005;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 QRGPGRAFTVIGK 15
Db 2 QRGPGRAFTVIGK 14

RESULT 20

US-09-993-307-21
; Sequence 21, Application US/09993307
; Publication No. US20030162733A1
; GENERAL INFORMATION:
; APPLICANT: HAYNES, Joel R.
; APPLICANT: ARRINGTON, Joshua
; TITLE OF INVENTION: NUCLEIC ACID ADJUVANTS
; FILE REFERENCE: AFP41-20
; CURRENT APPLICATION NUMBER: US/09/993,307
; CURRENT FILING DATE: 2001-11-26
; PRIOR APPLICATION NUMBER: 60/253,381

; PRIOR FILING DATE: 2000-11-27
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 21
; LENGTH: 15
; TYPE: PRT
; ORGANISM: synthetic construct
US-09-993-307-21

Query Match 85.7%; Score 66; DB 10; Length 15;
Best Local Similarity 86.7%; Pred. No. 0.001;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTVIGK 15
Db 1 RIQPGGRAFTVIGK 15

RESULT 21

US-10-239-313A-535
; Sequence 535, Application US/10239313A
; Publication No. US20030175285A1
; GENERAL INFORMATION:
; APPLICANT: KLINGUER - HAMOUR, Christine
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: BECK, Alain
; APPLICANT: GOETSCH, Liliane
; TITLE OF INVENTION: MOLECULE OF PHARMACEUTICAL INTEREST COMPRISING AT ITS
; TITLE OF INVENTION: N-TERMINAL A GLUTAMIC ACID OR A GLUTAMINE IN THE FORM
; TITLE OF INVENTION: OF A PHYSIOLOGICALLY ACCEPTABLE STRONG ACID
; FILE REFERENCE: 343 727 - US
; CURRENT APPLICATION NUMBER: US/10/239,313A
; CURRENT FILING DATE: 2002-09-19
; PRIOR APPLICATION NUMBER: FR 00/03711
; PRIOR FILING DATE: 2000-03-23
; PRIOR APPLICATION NUMBER: PCT 01/70772
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 697
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 535
; LENGTH: 12
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-239-313A-535

Query Match 81.8%; Score 63; DB 14; Length 12;
Best Local Similarity 100.0%; Pred. No. 0.0025;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 QRGPGRAFTVIGK 14
Db 1 QRGPGRAFTVIGK 12

RESULT 22

US-09-827-345-24
; Sequence 24, Application US/09827345
; Publication No. US20030021800A1
; GENERAL INFORMATION:
; APPLICANT: CHERMANN, JEAN-CLAUDE
; APPLICANT: LE CONTEL, CAROLE
; APPLICANT: GALEA, PASCALE
; TITLE OF INVENTION: VACCINE AGAINST INFECTIOUS AGENTS HAVING AN
; TITLE OF INVENTION: INTRACELLULAR PHASE, COMPOSITION FOR THE TREATMENT AND
; TITLE OF INVENTION: PREVENTION OF HIV INFECTIONS, ANTIBODIES AND METHOD OF
; TITLE OF INVENTION: DIAGNOSIS
; FILE REFERENCE: 065691-0216
; CURRENT APPLICATION NUMBER: US/09/827,345
; CURRENT FILING DATE: 2001-04-09
; PRIOR APPLICATION NUMBER: 09/599,549
; PRIOR FILING DATE: 2000-06-23
; PRIOR APPLICATION NUMBER: PCT/FR96/01006
; PRIOR FILING DATE: 1996-06-28

```
; PRIOR APPLICATION NUMBER: 08/973,551
; PRIOR FILING DATE: 1998-02-19
; PRIOR APPLICATION NUMBER: FR 95/07914
; PRIOR FILING DATE: 1995-06-30
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 24
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: peptide
US-09-827-345-24

Query Match      80.5%; Score 62; DB 10; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.006;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQPGGGRFVVT 12
   |||||
Db 9 RIQPGGGRFVVT 20

RESULT 23
US-10-311-111-3
; Sequence 3, Application US/10311111
; Publication No. US20030121065A1
; GENERAL INFORMATION:
; APPLICANT: SHIBA, KIYOTAKA
; TITLE OF INVENTION: MULTIFUNCTIONAL BASE SEQUENCE AND ARTIFICIAL GENE CONTAINING THE
; FILE REFERENCE: 4439-4004
; CURRENT APPLICATION NUMBER: US/10/311,111
; CURRENT FILING DATE: 2002-12-13
; PRIOR APPLICATION NUMBER: JP 2000-180997
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 3
; LENGTH: 13
; TYPE: PRT
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Designed peptide
US-10-311-111-3

Query Match      75.3%; Score 58; DB 14; Length 13;
Best Local Similarity 91.7%; Pred. No. 0.017;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQPGGGRFVVT 12
   |||||
Db 2 RIQPGGGRFVVT 13

RESULT 24
US-10-398-932-3
; Sequence 3, Application US/10398932
; Publication No. US20040171803A1
; GENERAL INFORMATION:
; APPLICANT: SHIBA, KIYOTAKA
; APPLICANT: OHNO, TSUNEYA
; TITLE OF INVENTION: ARTIFICIAL PROTEINS WITH ENRICHED IMMUNOGEN
; FILE REFERENCE: 024918-0103
; CURRENT APPLICATION NUMBER: US/10/398,932
; CURRENT FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: PCT/JP01/08893
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: JP 2000/314288
; PRIOR FILING DATE: 2000-10-13
; NUMBER OF SEQ ID NOS: 55
; SOFTWARE: Patentin Ver. 2.1

; SEQ ID NO 3
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetically Designed
; OTHER INFORMATION: Peptide
US-10-398-932-3

Query Match      75.3%; Score 58; DB 16; Length 13;
Best Local Similarity 91.7%; Pred. No. 0.017;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQPGGGRFVVT 12
   |||||
Db 2 RIQPGGGRFVVT 13

RESULT 25
US-09-901-106-10
; Sequence 10, Application US/09901106
; Patent No. US20020151067A1
; GENERAL INFORMATION:
; APPLICANT: Garoff, Henrik
; TITLE OF INVENTION: DNA Expression Systems Based on
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolaesch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/901,106
; FILING DATE: 10-Jul-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/920,281C
; FILING DATE: 13-AUG-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Murphy Jr., Gerald M.
; REGISTRATION NUMBER: 28,977
; REFERENCE/DOCKET NUMBER: 828-103P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-241-1300
; TELEFAX: 703-241-2848
; TELEX: 248345
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-901-106-10

Query Match      75.3%; Score 58; DB 9; Length 15;
Best Local Similarity 84.6%; Pred. No. 0.02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQPGGGRFVVTI 13
   |||||
Db 3 RIQPGGGRFVVEL 15
```

RESULT 26

US-10-239-313A-533
; Sequence 533, Application US/10239313A
; Publication No. US20030175285A1
; GENERAL INFORMATION:
; APPLICANT: KLINGUER - HAMOUR, Christine
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: BECK, Alain
; APPLICANT: GOETSCH, Liliane
; TITLE OF INVENTION: MOLECULE OF PHARMACEUTICAL INTEREST COMPRISING AT ITS
; TITLE OF INVENTION: N-TERMINAL A GLUTAMIC ACID OR A GLUTAMINE IN THE FORM
; TITLE OF INVENTION: OF A PHYSIOLOGICALLY ACCEPTABLE STRONG ACID
; FILE REFERENCE: 343 727 - US
; CURRENT APPLICATION NUMBER: US/10/239,313A
; CURRENT FILING DATE: 2002-09-19
; PRIOR APPLICATION NUMBER: FR 00/03711
; PRIOR FILING DATE: 2000-03-23
; PRIOR APPLICATION NUMBER: PCT 01/70772
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 697
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 533
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-239-313A-533

Query Match 74.0%; Score 57; DB 14; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.021;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 RQPGGRAFTV 13
Db 1 RQPGGRAFTV 11

RESULT 27

US-10-622-003-6
; Sequence 6, Application US/10622003
; Publication No. US20050014230A1
; GENERAL INFORMATION:
; APPLICANT: Chin, Li-Te
; TITLE OF INVENTION: PREPARATION OF FULLY HUMAN ANTIBODIES
; FILE REFERENCE: 16863-002001
; CURRENT APPLICATION NUMBER: US/10/622,003
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetically generated peptide
US-10-622-003-6

Query Match 74.0%; Score 57; DB 17; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.029;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RQPGGRAFV 11
Db 5 RQPGGRAFV 15

RESULT 28

US-09-901-106-12
; Sequence 12, Application US/09901106
; Patent No. US20020151067A1
; GENERAL INFORMATION:
; APPLICANT: Garoff, Henrik
; TITLE OF INVENTION: DNA Expression Systems Based on

Alphaviruses

NUMBER OF SEQUENCES: 27
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/901,106
FILING DATE: 10-Jul-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/07/920,281C
FILING DATE: 13-AUG-1992
ATTORNEY/AGENT INFORMATION:
NAME: Murphy Jr., Gerald M.
REGISTRATION NUMBER: 28,977
REFERENCE/DOCKET NUMBER: 828-103P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-241-1300
TELEFAX: 703-241-2848
TELEX: 248345
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-901-106-12

Query Match 74.0%; Score 57; DB 9; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.032;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RQPGGRAFV 11
Db 4 RQPGGRAFV 14

RESULT 29

US-09-858-349-3
; Sequence 3, Application US/09858349
; Patent No. US20020012909A1
; GENERAL INFORMATION:
; APPLICANT: PLAKSIN, Daniel
; TITLE OF INVENTION: SMALL FUNCTIONAL UNITS OF ANTIBODY HEAVY CHAIN VARIABLE REGIONS
; FILE REFERENCE: 87534-2800
; CURRENT APPLICATION NUMBER: US/09/858,349
; CURRENT FILING DATE: 2000-06-02
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 10
; TYPE: PRT
; ORGANISM: mouse hybridoma specific for H-2D + RQPGGRAFTV peptide
US-09-858-349-3

Query Match 67.5%; Score 52; DB 9; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RQPGGRAFTV 13
Db 1 RQPGGRAFTV 10


```
RESULT 30
US-09-810-310-16
; Sequence 16, Application US/09810310
; Patent No. US20020044948A1
; GENERAL INFORMATION:
; APPLICANT: Khleif, Samir N.
; APPLICANT: Bezofsky, Jay A.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR CO-STIMULATION OF
; TITLE OF INVENTION: IMMUNOLOGICAL RESPONSES TO PEPTIDE ANTIGENS
; FILE REFERENCE: 15280-415100US
; CURRENT APPLICATION NUMBER: US/09/810,310
; CURRENT FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: 60/189,396
; PRIOR FILING DATE: 2000-03-15
; NUMBER OF SEQ ID NOS: 61
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: HIV PEPTIDE
; OTHER INFORMATION: ANTIGEN
US-09-810-310-16

Query Match          67.5%; Score 52; DB 9; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RGPGRFVTI 13
Db 1 RGPGRFVTI 10

RESULT 31
US-09-820-484-8
; Sequence 8, Application US/09820484
; Patent No. US20020142977A1
; GENERAL INFORMATION:
; APPLICANT: Raz, Eyal
; APPLICANT: Cho, Hearn Jay
; APPLICANT: Richman, Douglas
; APPLICANT: Horner, Anthony A.
; TITLE OF INVENTION: Method for Increasing a Cytotoxic T
; TITLE OF INVENTION: Lymphocyte Response in vivo.
; FILE REFERENCE: 06510-188U1
; CURRENT APPLICATION NUMBER: US/09/820,484
; CURRENT FILING DATE: 2001-03-28
; PRIOR APPLICATION NUMBER: US 60/192,537
; PRIOR FILING DATE: 2000-03-28
; PRIOR APPLICATION NUMBER: US 60/203,567
; PRIOR FILING DATE: 2000-05-11
; PRIOR APPLICATION NUMBER: US 60/215,895
; PRIOR FILING DATE: 2000-07-05
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: HIV-1 class I-restricted gp120 peptide
US-09-820-484-8

Query Match          67.5%; Score 52; DB 9; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RGPGRFVTI 13
Db 1 RGPGRFVTI 10

RESULT 32
US-09-087-513-7
; Sequence 7, Application US/09087513
; Publication No. US20020182180A1
; GENERAL INFORMATION:
; APPLICANT: KANEKO, Yutaro
; APPLICANT: KOZBOR, Danuta
; TITLE OF INVENTION: METHOD OF INDUCING IMMUNITY TO VIRUSES
; FILE REFERENCE: 0010-0929-0X
; CURRENT APPLICATION NUMBER: US/09/087,513
; CURRENT FILING DATE: 1998-05-29
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:peptide
US-09-087-513-7

Query Match          67.5%; Score 52; DB 9; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RGPGRFVTI 13
Db 1 RGPGRFVTI 10

RESULT 33
US-09-087-513-13
; Sequence 13, Application US/09087513
; Publication No. US20020182180A1
; GENERAL INFORMATION:
; APPLICANT: KANEKO, Yutaro
; APPLICANT: KOZBOR, Danuta
; TITLE OF INVENTION: METHOD OF INDUCING IMMUNITY TO VIRUSES
; FILE REFERENCE: 0010-0929-0X
; CURRENT APPLICATION NUMBER: US/09/087,513
; CURRENT FILING DATE: 1998-05-29
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 13
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Human immunodeficiency virus
US-09-087-513-13

Query Match          67.5%; Score 52; DB 9; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RGPGRFVTI 13
Db 1 RGPGRFVTI 10

RESULT 34
US-09-997-848A-16
; Sequence 16, Application US/09997848A
; Publication No. US20030027322A1
; GENERAL INFORMATION:
; APPLICANT: Federoff, Howard J.
; APPLICANT: Bowers, William J.
; APPLICANT: Freilinger, John G.
; APPLICANT: Willis, Richard A.
; APPLICANT: Evans, Thomas J.
; APPLICANT: Dewhurst, Stephen
; APPLICANT: Tolba, Khaled A.
; APPLICANT: Rosenblatt, Joseph D.
; TITLE OF INVENTION: HELPER VIRUS-FREE HERPESVIRUS AMPLICON
```

```
; TITLE OF INVENTION: PARTICLES AND USES THEREOF
; FILE REFERENCE: 12610-011001
; CURRENT APPLICATION NUMBER: US/09/997,848A
; CURRENT FILING DATE: 2002-09-10
; PRIOR APPLICATION NUMBER: US 60/253,858
; PRIOR FILING DATE: 2000-11-29
; PRIOR APPLICATION NUMBER: US 60/250,079
; PRIOR FILING DATE: 2000-11-30
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 16
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Human immunodeficiency virus
US-09-997-848A-16

Query Match      67.5%; Score 52; DB 10; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 RGPGRFVTI 13
   |||||
Db 1 RGPGRFVTI 10

RESULT 35
US-09-993-307-22
; Sequence 22, Application US/09993307
; Publication No. US2003016273A1
; GENERAL INFORMATION:
; APPLICANT: HAYNES, Joel R.
; TITLE OF INVENTION: NUCLEIC ACID ADJUVANTS
; FILE REFERENCE: APF41.20
; CURRENT APPLICATION NUMBER: US/09/993,307
; CURRENT FILING DATE: 2001-11-26
; PRIOR APPLICATION NUMBER: 60/253,381
; PRIOR FILING DATE: 2000-11-27
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 22
; LENGTH: 10
; TYPE: PRT
; ORGANISM: synthetic construct
US-09-993-307-22

Query Match      67.5%; Score 52; DB 10; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 RGPGRFVTI 13
   |||||
Db 1 RGPGRFVTI 10

RESULT 36
US-10-113-085-7
; Sequence 7, Application US/10113085
; Publication No. US20030003086A1
; GENERAL INFORMATION:
; APPLICANT: Rock, Kenneth L.
; APPLICANT: Goldberg, Alfred L.
; TITLE OF INVENTION: MODULATION OF MHC CLASS 1 ANTIGEN PRESENTATION
; FILE REFERENCE: 07917-140001
; CURRENT APPLICATION NUMBER: US/10/113,085
; CURRENT FILING DATE: 2002-09-04
; PRIOR APPLICATION NUMBER: US 60/280,669
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 10
; TYPE: PRT

; ORGANISM: Homo sapiens
US-10-113-085-7

Query Match      67.5%; Score 52; DB 14; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 RGPGRFVTI 13
   |||||
Db 1 RGPGRFVTI 10

RESULT 37
US-10-168-843A-2
; Sequence 2, Application US/10168843A
; Publication No. US20030108562A1
; GENERAL INFORMATION:
; APPLICANT: Medical Research Council
; APPLICANT: International Aids Vaccine Initiative
; APPLICANT: University of Nairobi
; TITLE OF INVENTION: Improvements in or Relating to Immune Responses to HIV
; FILE REFERENCE: MJL/C1248/1/M
; CURRENT APPLICATION NUMBER: US/10/168,843A
; CURRENT FILING DATE: 2002-09-24
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Human immunodeficiency virus
US-10-168-843A-2

Query Match      67.5%; Score 52; DB 14; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 RGPGRFVTI 13
   |||||
Db 1 RGPGRFVTI 10

RESULT 38
US-10-147-910-12
; Sequence 12, Application US/10147910
; Publication No. US20030124718A1
; GENERAL INFORMATION:
; APPLICANT: Fuller, Deborah
; APPLICANT: Fuller, James
; APPLICANT: Haynes, Joel
; APPLICANT: Shipley, Timothy
; TITLE OF INVENTION: Vaccine Composition
; FILE REFERENCE: 033267-006
; CURRENT APPLICATION NUMBER: US/10/147,910
; CURRENT FILING DATE: 2002-05-20
; PRIOR APPLICATION NUMBER: US 60/291,654
; PRIOR FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: US 60/291,655
; PRIOR FILING DATE: 2001-05-18
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 12
; LENGTH: 10
; TYPE: PRT
; ORGANISM: HIV
US-10-147-910-12

Query Match      67.5%; Score 52; DB 14; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 RGPGRFVTI 13
   |||||
Db 1 RGPGRFVTI 10
```

```
RESULT 39
US-10-079-167-51
; Sequence 51, Application US/10079167
; Publication No. US20030138454A1
; GENERAL INFORMATION:
; APPLICANT: Hill, Adrian V.S.
; APPLICANT: McShane, Helen
; APPLICANT: Gilbert, Sarah C.
; APPLICANT: Reece, William
; APPLICANT: Schneider, Joerg
; TITLE OF INVENTION: Vaccination Method
; FILE REFERENCE: 2907.1000-001
; CURRENT APPLICATION NUMBER: US/10/079,167
; PRIOR FILING DATE: 2002-02-19
; PRIOR APPLICATION NUMBER: US 09/454,204
; PRIOR FILING DATE: 1998-12-09
; PRIOR APPLICATION NUMBER: PCT/GB98/01681
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: GB 97 11957.2
; PRIOR FILING DATE: 1997-06-09
; PRIOR APPLICATION NUMBER: PCT/GB01/04116
; PRIOR FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: GB 00 23203.3
; PRIOR FILING DATE: 2001-09-21
; NUMBER OF SEQ ID NOS: 99
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 51
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: CTL Epitope of HIV-1 gp120
US-10-079-167-51
```

```
Query Match      67.5%; Score 52; DB 14; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      4 RGPGRAFVTI 13
Db      1 RGPGRAFVTI 10
```

```
RESULT 40
US-10-079-167-68
; Sequence 58, Application US/10079167
; Publication No. US20030138454A1
; GENERAL INFORMATION:
; APPLICANT: Hill, Adrian V.S.
; APPLICANT: McShane, Helen
; APPLICANT: Gilbert, Sarah C.
; APPLICANT: Reece, William
; APPLICANT: Schneider, Joerg
; TITLE OF INVENTION: Vaccination Method
; FILE REFERENCE: 2907.1000-001
; CURRENT APPLICATION NUMBER: US/10/079,167
; PRIOR FILING DATE: 2002-02-19
; PRIOR APPLICATION NUMBER: US 09/454,204
; PRIOR FILING DATE: 1998-12-09
; PRIOR APPLICATION NUMBER: PCT/GB98/01681
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: GB 97 11957.2
; PRIOR FILING DATE: 1997-06-09
; PRIOR APPLICATION NUMBER: PCT/GB01/04116
; PRIOR FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: GB 00 23203.3
; PRIOR FILING DATE: 2001-09-21
; NUMBER OF SEQ ID NOS: 99
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 68
; LENGTH: 10
```

```
; TYPE: PRT
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: CTL Peptide Epitope of HIV gag
US-10-079-167-68

Query Match      67.5%; Score 52; DB 14; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      4 RGPGRAFVTI 13
Db      1 RGPGRAFVTI 10

RESULT 41
US-10-340-275-8
; Sequence 8, Application US/10340275
; Publication No. US20030143213A1
; GENERAL INFORMATION:
; APPLICANT: Raz, Eyal
; APPLICANT: Cho, Hearn Jay
; APPLICANT: Richman, Douglas
; APPLICANT: Horner, Anthony A.
; TITLE OF INVENTION: Method for Increasing a Cytotoxic T
; FILE REFERENCE: UCAL-188DIV
; CURRENT APPLICATION NUMBER: US/10/340,275
; CURRENT FILING DATE: 2003-01-10
; PRIOR APPLICATION NUMBER: 09/820,484
; PRIOR FILING DATE: 2001-03-28
; PRIOR APPLICATION NUMBER: US 60/192,537
; PRIOR FILING DATE: 2000-03-28
; PRIOR APPLICATION NUMBER: US 60/203,567
; PRIOR FILING DATE: 2000-05-11
; PRIOR APPLICATION NUMBER: US 60/215,895
; PRIOR FILING DATE: 2000-07-05
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: HIV-1 class I-restricted gp120 peptide
US-10-340-275-8
```

```
Query Match      67.5%; Score 52; DB 14; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      4 RGPGRAFVTI 13
Db      1 RGPGRAFVTI 10

RESULT 42
US-10-339-985-8
; Sequence 8, Application US/10339885
; Publication No. US20030147870A1
; GENERAL INFORMATION:
; APPLICANT: Raz, Eyal
; APPLICANT: Cho, Hearn Jay
; APPLICANT: Richman, Douglas
; APPLICANT: Horner, Anthony A.
; TITLE OF INVENTION: Method for Increasing a Cytotoxic T
; FILE REFERENCE: UCAL-188CON
; CURRENT APPLICATION NUMBER: US/10/339,885
; CURRENT FILING DATE: 2003-01-10
; PRIOR APPLICATION NUMBER: 09/820,484
; PRIOR FILING DATE: 2001-03-28
; PRIOR APPLICATION NUMBER: US 60/192,537
```

```
; PRIOR FILING DATE: 2000-03-28
; PRIOR APPLICATION NUMBER: US 60/203,567
; PRIOR FILING DATE: 2000-05-11
; PRIOR APPLICATION NUMBER: US 60/215,895
; PRIOR FILING DATE: 2000-07-05
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: HIV-1 class I-restricted gp120 peptide
US-10-339-885-8
```

```
Query Match 67.5%; Score 52; DB 14; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.12; Indels 0; Gaps 0;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 4 RGPGRFVTTI 13
Db 1 RGPGRFVTTI 10
```

RESULT 43

```
US-10-206-155-5
; Sequence 5, Application US/10206155
; Publication No. US20030157135A1
; GENERAL INFORMATION:
; APPLICANT: Tsuji, Moriya
; APPLICANT: Gonzalez-Aceguinolaza, Gloria
; APPLICANT: Nussenzweig, Ruth S.
; APPLICANT: Kozuka, Yasuhiko
; TITLE OF INVENTION: USE OF GLYCOSYLKERAMIDES AS ADJUVANTS
; TITLE OF INVENTION: FOR VACCINES AGAINST INFECTIONS AND CANCER
; FILE REFERENCE: 5986/1H958US1
; CURRENT APPLICATION NUMBER: US/10/206,155
; CURRENT FILING DATE: 2002-07-25
; PRIOR APPLICATION NUMBER: 60/308,056
; PRIOR FILING DATE: 2001-07-25
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 5
; LENGTH: 10
; TYPE: PRT
; ORGANISM: HIV-1
US-10-206-155-5
```

```
Query Match 67.5%; Score 52; DB 14; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.12; Indels 0; Gaps 0;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 4 RGPGRFVTTI 13
Db 1 RGPGRFVTTI 10
```

RESULT 44

```
US-10-210-148-113
; Sequence 113, Application US/10210148
; Publication No. US20030171280A1
; GENERAL INFORMATION:
; APPLICANT: Soderstrom, Karl Petter
; TITLE OF INVENTION: Compositions And Methods For Modulation Of Immune Response
; FILE REFERENCE: TROM0002
; CURRENT APPLICATION NUMBER: US/10/210,148
; CURRENT FILING DATE: 2002-07-31
; PRIOR APPLICATION NUMBER: PCT/US02/24311
; PRIOR FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 117
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 113
; LENGTH: 10
```

```
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-210-148-113
```

```
Query Match 67.5%; Score 52; DB 14; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.12; Indels 0; Gaps 0;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 4 RGPGRFVTTI 13
Db 1 RGPGRFVTTI 10
```

RESULT 45

```
US-10-360-836-48
; Sequence 48, Application US/10360836
; Publication No. US20030185854A1
; GENERAL INFORMATION:
; APPLICANT: Birkett, Ashley
; APPLICANT: Zavala, Fidel
; TITLE OF INVENTION: USE OF RECOMBINANT HEPATITIS B CORE
; TITLE OF INVENTION: PARTICLES TO DEVELOP VACCINES AGAINST INFECTIOUS PATHOGENS
; TITLE OF INVENTION: AND MALIGNANCIES
; FILE REFERENCE: 5986/LJ876
; CURRENT APPLICATION NUMBER: US/10/360,836
; CURRENT FILING DATE: 2003-02-07
; PRIOR APPLICATION NUMBER: 60/354,963
; PRIOR FILING DATE: 2002-02-08
; NUMBER OF SEQ ID NOS: 86
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 48
; LENGTH: 10
; TYPE: PRT
; ORGANISM: human immunodeficiency virus (HIV-1)
US-10-360-836-48
```

```
Query Match 67.5%; Score 52; DB 14; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.12; Indels 0; Gaps 0;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 4 RGPGRFVTTI 13
Db 1 RGPGRFVTTI 10
```

```
Search completed: May 16, 2005, 13:10:22
Job time : 72.7692 secs
```

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 16, 2005, 14:37:35 ; Search time 165 Seconds
(without alignments)
35.160 Million cell updates/sec

Title: US-08-869-386-1

Perfect score: 77

Sequence: 1 RIQPGGAFVTIGK 15

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 768190

Minimum DB seq length: 0

Maximum DB seq length: 25

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 250 summaries

Database : A_Geneseq_16Dec04:*

1: geneseqp1980s:*

2: geneseqp1990s:*

3: geneseqp2000s:*

4: geneseqp2001s:*

5: geneseqp2002s:*

6: geneseqp2003as:*

7: geneseqp2003bs:*

8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	77	100.0	15	1 AAP82095	Aap82095 Env-Xl pe
2	77	100.0	15	1 AAP91228	Aap91228 Peptide c
3	77	100.0	15	2 AAP21343	Aar21343 HIV-1 gp1
4	77	100.0	15	2 AAR38187	Aar38187 V3 loop p
5	77	100.0	15	2 AAR32207	Aar32207 Sequence
6	77	100.0	15	2 AAR51619	Aar51619 V3 loop r
7	77	100.0	15	2 AAR74603	Aar74603 HIV-1 var
8	77	100.0	15	2 AAR66414	Aar66414 HIV-1 III
9	77	100.0	15	2 AAR68789	Aar68789 Cytotoxic
10	77	100.0	15	2 AAW05535	Aaw05535 HIV-1 gp1
11	77	100.0	15	2 AAR92033	Aar92033 Hydrophil
12	77	100.0	15	2 AAW07931	Aaw07931 gp120 pep
13	77	100.0	15	2 AAR92007	Aar92007 HIV-1 V3
14	77	100.0	15	2 AAW24219	Aaw24219 CD4+ T-ly
15	77	100.0	15	2 AAW10348	Aaw10348 HIV epitope
16	77	100.0	15	2 AAW22031	Aaw22031 Antigenic
17	77	100.0	15	2 AAW39275	Aaw39275 HIV-1 syn
18	77	100.0	15	2 AAW40316	Aaw40316 HIV-1 III
19	77	100.0	15	2 AAW76898	Aaw76898 Fusion im
20	77	100.0	15	2 AAW54929	Aaw54929 HIV gp120
21	77	100.0	15	2 AAY06896	Aay06896 Sequence
22	77	100.0	15	2 AAY24466	Aay24466 HIV pepti
23	77	100.0	15	2 AAY25189	Aay25189 HIV prote
24	77	100.0	15	2 AAY25204	Aay25204 HIV V3 pe
25	77	100.0	15	2 AAY05356	Aay05356 HIV-1 CLU

26	77	100.0	15	2 AAW72821	Aaw72821 HIV-1 gp1
27	77	100.0	15	2 AAW87620	Aaw87620 Epitope o
28	77	100.0	15	2 AAY04680	Aay04680 HIV-1 gp1
29	77	100.0	15	3 AAY83916	Aay83916 HIV-1 env
30	77	100.0	15	3 AAY66439	Aay66439 HLA-A2-bi
31	77	100.0	15	3 AAY66455	Aay66455 HLA-A3-bi
32	77	100.0	15	3 AAY85591	Aay85591 HIV relat
33	77	100.0	15	3 AAB15875	Aab15875 Human che
34	77	100.0	15	4 AAB92345	Aab92345 Virus rel
35	77	100.0	15	4 AAB92348	Aab92348 Virus rel
36	77	100.0	15	4 AAB68601	Aab68601 HIV gp120
37	77	100.0	15	5 AAE15743	Aae15743 Human imm
38	77	100.0	15	5 AAU95031	Aau95031 HIV epitope
39	77	100.0	15	5 AAU97690	Aau97690 HIV CTL e
40	77	100.0	15	5 AEG68654	Aeg68654 HIV-1 P18
41	77	100.0	15	5 AEG68663	Aeg68663 HIV-1 P18
42	77	100.0	15	6 AAE35161	Aae35161 HIV CTL e
43	77	100.0	15	7 ADN14074	Adn14074 HIV helpe
44	77	100.0	15	8 ADR04041	Adr04041 Immune re
45	77	100.0	16	2 AAR24939	Aar24939 HIV pepti
46	77	100.0	16	2 AAW68326	Aaw68326 MHC bindi
47	77	100.0	16	3 AAY68203	Aay68203 Altered M
48	77	100.0	16	3 AAY52857	Aay52857 Altered M
49	77	100.0	16	4 AAB58618	Aab58618 Altered M
50	77	100.0	17	2 AAR42057	Aar42057 Peptide C
51	77	100.0	17	2 AAY40414	Aay40414 Lipopepti
52	77	100.0	18	2 AAR31277	Aar31277 HIV princ
53	77	100.0	18	2 AAR30032	Aar30032 HIV princ
54	77	100.0	18	2 AAR26713	Aar26713 HIV-PND-p
55	77	100.0	18	2 AAR44190	Aar44190 gp120 V3
56	77	100.0	18	2 AAR58548	Aar58548 HIV-1 iso
57	77	100.0	18	4 ABB83113	Abb83113 Lipopepti
58	77	100.0	20	2 AAR60203	Aar60203 HIV gp110
59	77	100.0	20	2 AAW54930	Aaw54930 HIV gp120
60	77	100.0	20	8 ADR18886	Adr18886 HIV-1 V3-
61	77	100.0	21	2 AAR93073	Aar93073 Antigenic
62	77	100.0	21	2 AAW34475	Aaw34475 Acceptor
63	77	100.0	21	2 AAW75478	Aaw75478 HIV-1 bcr
64	77	100.0	21	2 AAY16052	Aay16052 HIV-1 iso
65	77	100.0	21	3 AAW85568	Aaw85568 Human imm
66	77	100.0	21	3 AAB15012	Aab15012 Peptide p
67	77	100.0	21	4 AAU08699	Aau08699 Retroviru
68	77	100.0	22	2 AAR42153	Aar42153 gp120 V3
69	77	100.0	22	2 AAR57470	Aar57470 HIV BRU V
70	77	100.0	22	2 AAW07392	Aaw07392 HIV-1 str
71	77	100.0	22	2 AAY07488	Aay07488 HIV-1 bcr
72	77	100.0	22	3 AAY85137	Aay85137 HIV-1 III
73	77	100.0	22	6 ABU07537	Abu07537 Human N-a
74	77	100.0	23	2 AAR04502	Aar04502 Cpd. elic
75	77	100.0	23	4 AAB66704	Aab66704 HIV-1 III
76	77	100.0	24	2 AAR06211	Aar06211 Immunosu
77	77	100.0	24	2 AAR07018	Aar07018 Residues
78	77	100.0	24	2 AAR26565	Aar26565 Sequence
79	77	100.0	24	2 AAR29233	Aar29233 Heterocon
80	77	100.0	24	2 AAR26870	Aar26870 HIV gp120
81	77	100.0	24	2 AAR32406	Aar32406 Sequence
82	77	100.0	24	2 AAR33190	Aar33190 Sequence
83	77	100.0	24	2 AAR38165	Aar38165 V3 loop p
84	77	100.0	24	2 AAR44191	Aar44191 gp120 V3
85	77	100.0	24	2 AAR63821	Aar63821 HIV-1 gp1
86	77	100.0	24	2 AAW67414	Aaw67414 HIV-1 pep
87	77	100.0	24	2 AAW98904	Aaw98904 HIV-1 vac
88	77	100.0	24	2 AAY22581	Aay22581 HIV LDL b
89	77	100.0	24	2 AAY22583	Aay22583 HIV LDL b
90	77	100.0	24	2 AAY39769	Aay39769 HIV1 chim
91	77	100.0	24	3 AAB15873	Aab15873 Human che
92	77	100.0	24	4 AAB68602	Aab68602 HIV gp120
93	77	100.0	25	1 AAP82464	Aap82464 Peptide c
94	77	100.0	25	1 AAP90281	Aap90281 Peptide i
95	77	100.0	25	2 AAR08276	Aar08276 HIV pepti
96	77	100.0	25	2 AAR13120	Aar13120 Binding s
97	77	100.0	25	2 AAR15058	Aar15058 HIV-1 amp
98	77	100.0	25	2 AAR31276	Aar31276 HIV princ

99	77	100.0	25	2	AAR30031	Aar30031 HIV princ	172	66	85.7	21	2	AAR04060	Aar04060 Eptope c
100	77	100.0	25	2	AAR26712	Aar26712 HIV-PND-p	173	66	85.7	24	5	AAR20149	Aar20149 Human imm
101	77	100.0	25	2	AAR32222	Aar32222 HIV gp120	174	66	85.7	25	2	AAR63820	Aar63820 HIV-1 gp1
102	77	100.0	25	2	AAR41336	Aar41336 HIV gp120	175	64	83.1	19	2	AAR22329	Aar22329 HIV-1 cli
103	77	100.0	25	2	AAR41330	Aar41330 HIV gp120	176	64	83.1	19	2	AAR62892	Aar62892 Peptide s
104	77	100.0	25	2	AAR36587	Aar36587 Virus neu	177	63	81.8	12	2	AAR62152	Aar62152 HIV-1 gp1
105	77	100.0	25	2	AAR72819	Aar72819 HIV-1 gp1	178	63	81.8	12	2	AAR54932	Aar54932 HIV gp120
106	77	100.0	25	2	AAR87618	Aar87618 Eptope o	179	63	81.8	12	4	AAM99432	Aam99432 Vaccine r
107	77	100.0	25	4	AAR09522	Aar09522 Human imm	180	63	81.8	14	2	AAR76864	Aar76864 Fusion im
108	75	97.4	25	2	AAR04427	Aar04427 Human imm	181	63	81.8	23	2	AAR04476	Aar04476 Human imm
109	74	96.1	15	2	AAR66419	Aar66419 HIV-1 III	182	62.5	81.2	16	2	AAR38249	Aar38249 Tip of HI
110	73	94.8	15	2	AAR66430	Aar66430 HIV-1 III	183	62.5	81.2	21	2	AAR27465	Aar27465 V3 peptid
111	73	94.8	15	2	AAR66424	Aar66424 HIV-1 III	184	62.5	81.2	21	2	AAR31219	Aar31219 V3 peptid
112	73	94.8	20	5	ABR05775	Abbr05775 HIV gp120	185	62	80.5	12	2	AAR31278	Aar31278 HIV princ
113	73	94.8	20	5	ABR015657	Abbr015657 Strng im	186	62	80.5	12	2	AAR26714	Aar26714 HIV-PND-p
114	72	93.5	14	2	AAR66416	Aar66416 HIV-1 III	187	62	80.5	13	2	AAR58601	Aar58601 Alkaline
115	72	93.5	15	1	AAR95357	Aar95357 Variable	188	62	80.5	13	2	AAR58602	Aar58602 Alkaline
116	72	93.5	15	1	AAR95348	Aar95348 Variable	189	62	80.5	13	2	AAR58605	Aar58605 Alkaline
117	72	93.5	15	2	AAR33460	Aar33460 Sequence	190	62	80.5	13	2	AAR31254	Aar31254 HIV princ
118	72	93.5	15	2	AAR66427	Aar66427 HIV-1 gp1	191	62	80.5	15	2	AAR31254	Aar31254 Cyclic HI
119	72	93.5	15	2	AAR66428	Aar66428 HIV-1 III	192	62	80.5	15	2	AAR20214	Aar20214 Cyclic HI
120	72	93.5	15	2	AAR66426	Aar66426 HIV-1 III	193	62	80.5	15	2	AAR26689	Aar26689 HIV-PND-p
121	72	93.5	16	2	AAR33236	Aar33236 HIV-IIIB	194	62	80.5	15	2	AAR58606	Aar58606 Alkaline
122	72	93.5	17	1	AAR95348	Aar95348 Variable	195	60	77.9	14	2	AAR33336	Aar33336 Sequence
123	72	93.5	17	1	AAR95349	Aar95349 Variable	196	60	77.9	14	2	AAR48604	Aar48604 Sequence
124	72	93.5	17	2	AAR29241	Aar29241 V3 loop r	197	60	77.9	14	2	AAR09264	Aar09264 HIV-1 str
125	72	93.5	17	2	AAR32407	Aar32407 Sequence	198	58	75.3	11	2	AAR62167	Aar62167 HIV-1 gp1
126	72	93.5	17	2	AAR68664	Aar68664 T cell ep	199	58	75.3	11	2	AAR76852	Aar76852 Fusion im
127	72	93.5	17	2	AAR25834	Aar25834 HIV B-cel	200	58	75.3	13	5	ABR05777	Abbr05777 HIV gp120
128	72	93.5	17	2	AAR76848	Aar76848 Fusion im	201	58	75.3	13	5	ABR015659	Abbr015659 Strong im
129	72	93.5	17	2	AAR67350	Aar67350 HIV-1 str	202	58	75.3	19	2	AAR24218	Aar24218 CD4+ T-ly
130	72	93.5	17	2	AAR99958	Aar99958 HIV-1 vac	203	57	74.0	11	2	AAR32408	Aar32408 Sequence
131	72	93.5	17	2	AAR39756	Aar39756 HIV1 chim	204	57	74.0	11	4	AAR99430	Aar99430 Cytotoxic
132	72	93.5	17	7	ADN14075	Adn14075 HIV helpe	205	57	74.0	11	4	AAR99430	Aar99430 Vaccine r
133	72	93.5	17	8	ADRI8895	Adri8895 HIV-1 V3	206	57	74.0	12	2	ABR17102	Abbr17102 HIV B27 s
134	72	93.5	18	2	AAR38526	Aar38526 Cyclic HI	207	57	74.0	12	2	ABR10592	Abbr10592 Protease
135	72	93.5	18	2	AAR30340	Aar30340 HIV princ	208	57	74.0	15	2	AAR62164	Aar62164 HIV-1 gp1
136	72	93.5	18	8	ADRI8878	Adri8878 HIV-1 V3-	209	57	74.0	15	2	AAR76846	Aar76846 Fusion im
137	72	93.5	20	2	AAR25471	Aar25471 V3 loop s	210	57	74.0	15	8	ADP76013	Adp76013 Peptide e
138	72	93.5	20	2	AAR76842	Aar76842 Fusion im	211	57	74.0	17	2	AAR25139	Aar25139 SFV-HIV e
139	72	93.5	20	6	ABR57070	Abbr57070 HIV gp120	212	57	74.0	21	2	AAR68645	Aar68645 Chimaeic
140	71	92.2	15	2	AAR66425	Aar66425 HIV-1 III	213	57	74.0	21	2	AAR25815	Aar25815 HIV-1 pep
141	71	92.2	15	2	AAR66420	Aar66420 HIV-1 III	214	57	74.0	21	2	AAR99939	Aar99939 HIV-1 vac
142	71	92.2	15	2	AAR66429	Aar66429 HIV-1 III	215	57	74.0	21	2	AAR99939	Aar99939 HIV-1 vac
143	71	92.2	15	2	AAR66423	Aar66423 HIV-1 III	216	57	74.0	21	2	AAR99939	Aar99939 HIV-1 vac
144	71	92.2	15	2	AAR66422	Aar66422 HIV-1 III	217	55.5	72.1	14	2	AAR66418	Aar66418 HIV-1 III
145	69	89.6	15	2	AAR66421	Aar66421 HIV-1 III	218	54	70.1	15	2	AAR90229	Aar90229 Cyclic HI
146	68	88.3	13	2	AAR66421	Aar66421 HIV-1 str	219	53	68.8	10	2	AAR62165	Aar62165 HIV-1 gp1
147	68	88.3	13	2	AAR62890	Aar62890 Peptide s	220	53	68.8	13	2	AAR76861	Aar76861 Fusion im
148	68	88.3	13	4	AAR99433	Aar99433 Vaccine r	221	53	68.8	14	2	AAR04441	Aar04441 Human imm
149	68	88.3	14	2	AAR66417	Aar66417 HIV-1 III	222	53	68.8	14	2	AAR68665	Aar68665 T cell ep
150	68	88.3	15	2	AAR76897	Aar76897 Fusion im	223	53	68.8	14	2	AAR25835	Aar25835 HIV B-cel
151	68	88.3	15	4	AAR99083	Aar99083 Vaccine r	224	53	68.8	14	2	AAR67351	Aar67351 HIV-1 str
152	68	88.3	18	2	AAR63062	Aar63062 Human imm	225	53	68.8	14	2	AAR99959	Aar99959 HIV-1 vac
153	68	88.3	21	2	AAR79180	Aar79180 Fusion im	226	53	68.8	14	2	AAR99959	Aar99959 HIV-1 vac
154	68	88.3	21	2	AAR76901	Aar76901 Fusion im	227	53	68.8	14	2	AAR33757	Aar33757 HIV chim
155	68	88.3	24	2	AAR74608	Aar74608 HIV-1 gp1	228	53	68.8	18	2	AAR22593	Aar22593 HIV putat
156	68	88.3	25	2	AAR04475	Aar04475 Human imm	229	53	68.8	20	2	AAR26879	Aar26879 HIV epito
157	67	87.0	15	2	AAR32887	Aar32887 HIV envel	230	52	67.5	10	2	AAR26892	Aar26892 HIV epito
158	67	87.0	17	1	AAR95356	Aar95356 Variable	231	52	67.5	10	2	AAR33452	Aar33452 Sequence
159	67	87.0	20	2	AAR68680	Aar68680 B cell ep	232	52	67.5	10	2	AAR95920	Aar95920 HIV gp 12
160	67	87.0	20	2	AAR25898	Aar25898 HIV-1 str	233	52	67.5	10	2	AAR76839	Aar76839 Fusion im
161	67	87.0	20	2	AAR25850	Aar25850 HIV-1 str	234	52	67.5	10	2	AAR10172	Aar10172 T cell ep
162	67	87.0	20	2	AAR67366	Aar67366 HIV-1 str	235	52	67.5	10	2	AAY10164	Aay10164 T cell ep
163	67	87.0	20	2	AAR99974	Aar99974 HIV-1 vac	236	52	67.5	10	2	AAY03691	Aay03691 Amino aci
164	67	87.0	20	2	AAR99974	Aar99974 HIV1 chim	237	52	67.5	10	2	AAY03655	Aay03655 HIV gag C
165	66.5	86.4	18	3	AAR96191	Aar96191 Glycoprot	238	52	67.5	10	2	AAY05357	Aay05357 HIV-1 CUU
166	66	85.7	14	2	AAR76863	Aar76863 Fusion im	239	52	67.5	10	2	AAR03655	Aar03655 HIV-1 env
167	66	85.7	15	2	AAR36156	Aar36156 HIV-1 str	240	52	67.5	10	3	AAY05357	Aay05357 HIV-1 env
168	66	85.7	15	5	AAM49356	Aam49356 HIV-1 lfo	241	52	67.5	10	3	AAY59593	Aay59593 HIV-1 pep
169	66	85.7	15	7	ADH60862	Adh60862 HIV gp120	242	52	67.5	10	3	AAY94398	Aay94398 HIV pep
170	66	85.7	15	7	ADH60862	Adh60862 HIV gp120	243	52	67.5	10	3	AAY94398	Aay94398 HIV pep
171	66	85.7	16	8	ADRI8865	Adri8865 V3-IIIB b	244	52	67.5	10	3	AAY94588	Aay94588 Mouse H2-

245 52 67.5 10 3 AAB15874 Human che
246 52 67.5 10 4 AAB92350 Virus rel
247 52 67.5 10 4 AAB49397 HIV pepti
248 52 67.5 10 4 AAE04801 Human imm
249 52 67.5 10 5 AAE20153 Human imm
250 52 67.5 10 5 ABG31255 GP120 cla

ALIGNMENTS

RESULT 1
AAP82095
ID AAP82095 standard; peptide; 15 AA.
XX
AC AAP82095;
XX
DT 25-MAR-2003 (revised)
DT 17-DEC-2001 (revised)
DT 29-OCT-1990 (first entry)
XX
XX Env-K1 peptide.
XX
XX Env-K1; gp160 Env protein; T-cell cytotoxicity; HIV.
XX
OS Synthetic.
XX
XX USN7148692-N.
XX
PD 02-AUG-1988.
XX
PF 26-JAN-1988; 88US-00148692.
XX
XX 26-JAN-1988; 88US-00148692.
XX
XX (USSH) US DEPT HEALTH & HUMAN SERVICE.
PA (USDC) US SEC OF COMMERCE.
XX
XX Berzofsky J, Takahashi H, Hosmalin A, Germain R, Moss B;
PI WPI; 1988-264280/37.
XX
DR Synthetic peptide corresp. to HIV GP 160 ENV sequence - which elicits
XX cytotoxicity by T cells against HIV and proliferation of HIV-specific
PT cytotoxic T cells.
XX
XX Disclosure; Page ?; 3lpp; English.
XX
XX This peptide elicits cytotoxicity by T-cells against HIV antigens and
CC stimulates prodn. of HIV-specific cytotoxic T-lymphocytes (CTLs). It is
CC specific for the HIV envelope protein gp160. (Note: Revised entry
CC submitted to correct the patent number format of US Government-owned NTIS
CC applications to prevent clashes with ongoing US granted patent numbers.
CC For further information please visit the Derwent web site at
CC www.derwent.com/dwpi/updates/ntis.us.html.) (Updated on 25-MAR-2003 to
CC correct PF field.) (Updated on 25-MAR-2003 to correct PA field.)
XX
SQ Sequence 15 AA;
Query Match 100.0%; Score 77; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RIQRPGRGFAVTVIGK 15
DB 1 RIQRPGRGFAVTVIGK 15
RESULT 2
AAP91228
ID AAP91228 standard; peptide; 15 AA.
XX
AC AAP91228;
XX
QY 1 RIQRPGRGFAVTVIGK 15
DB 1 RIQRPGRGFAVTVIGK 15
RESULT 2
AAP91228
ID AAP91228 standard; peptide; 15 AA.
XX
AC AAP91228;

XX 24-OCT-2003 (revised)
DT 27-AUG-2003 (revised)
DT 25-MAR-2003 (revised)
DT 13-AUG-1990 (first entry)
XX
DE Peptide comprising AAs 308-322 of HIV-I IIIB env protein.
XX
XX AIDS; HIV-I; vaccine.
XX
XX Human immunodeficiency virus 1.
XX
XX EP339504-A.
XX
PD 02-NOV-1989.
XX
XX 21-APR-1989; 89EP-00107197.
XX
XX 26-APR-1988; 88US-00186333.
PR 20-MAR-1989; 89US-00324027.
XX
XX (DUPO) DU PONT DE NEMOURS & CO E I.
PA (DUPO) DU PONT MERCK PHARMACEUTICAL CO.
XX
XX Kenealy WR, Petteway SR, Durda PJ;
PI WPI; 1989-317386/44.
XX
XX Synthetic human immuno-deficiency virus env-coded peptide(s) - induce
PT antibodies that block human immuno-deficiency virus proliferation and
PT fusion between infected and non-infected cells.
XX
XX Claim 3; Page 21; 24pp; English.
XX
XX Peptide will induce an immune response in subject, and will thus act as a
CC non-infective vaccine, prophylactic or have therapeutic value for AIDS
CC patients. (Updated on 25-MAR-2003 to correct PA field.) (Updated on 27-
CC AUG-2003 to correct OS field.) (Updated on 24-OCT-2003 to standardise OS
CC field)
XX
SQ Sequence 15 AA;
Query Match 100.0%; Score 77; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RIQRPGRGFAVTVIGK 15
DB 1 RIQRPGRGFAVTVIGK 15
RESULT 3
AAR21343
ID AAR21343 standard; protein; 15 AA.
XX
XX AAR21343;
XX
XX 25-MAR-2003 (revised)
DT 16-MAY-1992 (first entry)
XX
DE HIV-1 gp120 epitope found in mouse immunoglobulin BAT123 and mouse/human
DE chimeric antibody CAG1-51-4.
XX
XX Chimeric immunoglobulin; viral-neutralising; HIV-1;
KW BAT123 mouse immunoglobulin; viral antigen-binding region; immunotherapy;
KW AIDS; ARC; ss.
XX
XX Human immunodeficiency virus 1.
XX
XX WO9201719-A.
XX
XX 06-FEB-1992.
XX

PF 18-JUL-1990; 90WO-US004048.
PR 18-JUL-1990; 90WO-US004048.
XX (TANO-) TANOX BIOSYST INC.
XX Liou RS, Rosen EM, Sun BN, Fung MS, Chang TW, Chang NT;
PI WPI; 1992-064897/08.
XX
XX New chimeric HIV-1-neutralising immunoglobulin(s) - comprising non-human
PT antigen binding regions and constant human region, for immuno-therapy of
PT AIDS and ARC.
XX
XX Example; Page 26; 39pp; English.
XX
XX The inventors claim a chimeric, viral-neutralising immunoglobulin which
CC binds to the gp120 region of HIV-1 with a potency and immunologic
CC specificity equal to BAT123 mouse Ig. It comprises a viral-specific
CC antigen-binding region of non-human origin and a constant region of
CC human origin. Specifically claimed is the chimeric immunoglobulin CGP
CC 47439. Probes V-kappa-1 and V-kappa-2 (AAQ21497, AAQ21498) were used to
CC screen a genomic DNA library for BAT123 cells for the functionally
CC rearranged variable region gene of BAT123 light chain (VL). The
CC identified clone, V-kappa-123-23, was used in the subsequent construction
CC of the mouse/human chimeric L chain gene. Probe VH-1 was used to screen
CC partial genomic libraries for the functionally rearranged variable region
CC genes for BAT123 heavy chain (VH). Clone VH-123-E3 hybridised with the
CC probe. This clone was used in the construction of the mouse-human
CC chimeric H chain gene. The chimeric antibody CAG1-51-4 was found to bind
CC to the same oligopeptide (AAR21343) as BAT123 which indicates that the
CC antigen specificity of the murine antibody BAT123 was preserved upon
CC conversion into a mouse/human chimeric antibody. (Updated on 25-MAR-2003
CC to correct PR field.)
XX
XX
SQ Sequence 15 AA;
Query Match 100.0%; Score 77; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RIQRGPGRAFTVIGK 15
Db |||||||||||
1 RIQRGPGRAFTVIGK 15
RESULT 4
AAR38187
ID AAR38187 standard; peptide; 15 AA.
XX
XX AAR38187;
AC
XX 27-AUG-2003 (revised)
DT 25-MAR-2003 (revised)
DT 12-OCT-1993 (first entry)
XX
XX V3 loop peptide D44 (R15K).
XX
XX gp120; HIV-1; cytotoxic T-lymphocyte; CTL; T-helper; AIDS; infection.
XX
XX Human immunodeficiency virus 1.
XX
XX WO9310816-A1.
XX
XX 10-JUN-1993.
XX
XX 02-DEC-1992; 92WO-US010378.
XX
XX 02-DEC-1991; 91US-00800932.
PR 16-SEP-1992; 92US-00945865.
XX
XX (TEXA) UNIV TEXAS SYSTEM.
PA
XX

PI Sastry JK, Arlinghaus RB, Platsoucas CD, Nehete PN;
XX WPI; 1993-196739/24.
XX
XX Peptide composition for treating and preventing viral infections -
PT comprise CTL-inducing epitope and HIV infection-inhibiting sequence or T
PT helper cell-inducing sequence.
XX
XX Claim 13 + 19; Page 94-95; 130pp; English.
XX
XX HIV gp120 V3 loop-derived peptides (AAR38170-87) are successful in
CC generating CTL responses, esp. peptide R15K (AAR38187); the T-helper cell
CC -inducing peptide includes the sequence C19A (AAR38164); HIV infection-
CC inhibiting peptides are given in AAR38188-206, and are esp. peptides
CC R15K, N24G, E13V, R8K, T13Q and H13N (AAR38165-69). The peptides may also
CC be derived from an influenza virus protein or a sendai virus protein
CC (AAR41014-15). It was observed that peptide R15K (amino acids 315-329),
CC with sequences derived from the V3 loop of HIV-1 IIIB, inhibits HIV-1
CC infection of primary human T cells by 92% at 1 microg/ml (ca. 0.4-0.6
CC microm). (Updated on 25-MAR-2003 to correct PN field.) (Updated on 27-AUG
CC -2003 to correct OS field.)
XX
XX Sequence 15 AA;
SQ
Query Match 100.0%; Score 77; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RIQRGPGRAFTVIGK 15
Db |||||||||||
1 RIQRGPGRAFTVIGK 15
RESULT 5
AAR32207
ID AAR32207 standard; peptide; 15 AA.
XX
XX AAR32207;
AC
XX 24-OCT-2003 (revised)
DT 17-DEC-2001 (revised)
DT 07-JUN-1993 (first entry)
XX
XX Sequence of peptide which corresp. to AA residues 315-329 of the V3 loop
DE of the gp160 envelope glycoprotein in HIV-1 strain MN.
DE
XX V3 loop; envelope glycoprotein; gp160; HIV-1; prophylaxis; immunotherapy.
XX
XX Human immunodeficiency virus; (HIV-1) isolate IIIB.
OS
XX USN7760530-N.
XX
XX 15-DEC-1992.
XX
XX 18-SEP-1991; 91US-00760530.
PF
XX 18-SEP-1991; 91US-00760530.
PR
XX (USSH) US DEPT HEALTH & HUMAN SERVICE.
PA
XX Berzofsky JA, Takahashi H, Germain RN;
XX
XX WPI; 1993-058406/07.
XX
XX Peptide(s) corresponding to the V3 loop of gp160 of HIV-1 - elicit
PT cytotoxic T lymphocyte(s) active against broad range of HIV-1 isolate(s).
PT
XX Example; Page 19; 41pp; English.
XX
XX The peptide corresponds to amino acid residues numbered 315-329 in the V3
CC loop of the envelope glycoprotein gp160 of human immunodeficiency virus
CC (HIV-1), as numbered by Ratner in the strain MN. It is useful for the
CC prophylaxis or immunotherapy of HIV-1 infection. It elicits an immunised
XX

CC subject cytotoxic T lymphocyte (CTL) activity against the corresp.
 CC clinical isolate of HIV-1. (Note: Revised entry submitted to correct the
 CC patent number format of US Government-owned NTIS applications to prevent
 CC clashes with ongoing US granted patent numbers. For further information
 CC please visit the Derwent web site at
 CC www.derwent.com/dwpi/updates/ntis_us.html.) (Updated on 24-OCT-2003 to
 CC standardise OS field)
 XX
 SQ Sequence 15 AA;

Query Match 100.0%; Score 77; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 9e-05;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTVIGK 15
 |||||
 Db 1 RIQPGGRAFTVIGK 15

RESULT 6

AARS1619
 ID AARS1619 standard; protein; 15 AA.

XX
 AC AARS1619;

XX 27-AUG-2003 (revised)

DT 25-MAR-2003 (revised)

DT 21-OCT-1994 (first entry)

XX V3 loop region of gp120 of HIV.

DE gp 120; HIV epitope; Human Immunodeficiency Virus fusion polypeptide.

KW Human immunodeficiency virus.
 XX
 OS WO9406469-A1.

FN 31-MAR-1994.

PD 18-SEP-1992; 92WO-US007966.

PF 18-SEP-1992; 92WO-US007966.

PR (LJOL-) LA JOLLA INST ALLERGY & IMMUNOLOGY.
 XX Altman A, Baier GJ;
 PI WPI; 1994-118166/14.

DR New fusion polypeptide of antigen binding domain and HIV epitope - useful
 XX as vaccine for treatment or prevention of HIV infection, ensures
 PT efficient focusing of epitopes on surface of antigen presenting cells.

XX Example 1; Page 24; 39pp; English.

XX AARS1619 shows a region of the V3 loop (residues 315-329) of the envelope
 CC glycoprotein, gp120, of HIV-1. It represents an epitope which forms part
 CC of a hybrid-fusion polypeptide with a Fab fragment of an IgG Fab
 CC fragment. The polypeptide is capable of presenting the epitope to antigen
 CC presenting cells. (Updated on 25-MAR-2003 to correct PN field.) (Updated
 CC on 27-AUG-2003 to correct OS field.)
 XX
 SQ Sequence 15 AA;

Query Match 100.0%; Score 77; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 9e-05;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTVIGK 15
 |||||
 Db 1 RIQPGGRAFTVIGK 15

RESULT 7

AAR74603
 ID AAR74603 standard; peptide; 15 AA.

XX
 AC AAR74603;

XX 16-OCT-2003 (revised)

DT 25-MAR-2003 (revised)

DT 01-NOV-1995 (first entry)

XX HIV-1 variable loop residues 308-322.

XX MAB 5023; variable V3 loop; HIV-1; human immunodeficiency virus;
 KW cancer antigen; monoclonal antibody.

XX Human immunodeficiency virus; I.

XX WO9510777-A1.

XX 20-APR-1995.

XX 14-OCT-1994; 94WO-US011754.

XX 15-OCT-1993; 93US-00138141.

XX (RAKO/) RAKOWICZSZULCZYNSKA E M.

XX Rakowiczszulczynska EM;

XX WPI; 1995-178531/23.

XX Detection of HIV-1 cross-reactive breast carcinoma-associated antigens -
 PT for diagnosis and anti-sense therapy of breast and gynaecological
 PT cancers.

XX Disclosure; Page 48; 71pp; English.

XX MAB 5023 was developed against AA residue 308-322 of the variable loop of
 CC HIV-1 (AAR74603). MAB 5023 binds to the epitope GRAF. G preceding RAF is
 CC believed to critical for internalization. MAB 5023 recognised p160, p120,
 CC p42 and p24 in cancer cells. AAR74603 competitively blocked binding of
 CC the MAB to the cancer antigens, indicating that at least the epitope
 CC GRAF, which is recognised by the MAB, must also be present in cancer
 CC antigens. (Updated on 25-MAR-2003 to correct PN field.) (Updated on 25-
 CC MAR-2003 to correct PI field.) (Updated on 16-OCT-2003 to standardise OS
 CC field)
 XX
 SQ Sequence 15 AA;

Query Match 100.0%; Score 77; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 9e-05;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGRAFTVIGK 15
 |||||
 Db 1 RIQPGGRAFTVIGK 15

RESULT 8

AAR66414
 ID AAR66414 standard; peptide; 15 AA.

XX
 AC AAR66414;

XX 25-MAR-2003 (revised)

DT 03-AUG-1995 (first entry)

XX HIV-1 IIIB peptide 18.

XX T cell helper site; cytotoxic T cell response; neutralising antibody;
 KW human immunodeficiency virus type 1; envelope glycoprotein gp120;
 KW cluster peptide; principal neutralising determinant; IIIB isolate.

OS Synthetic.
 PN WO9426785-A1.
 XX
 XX 24-NOV-1994.
 PD
 PD 13-MAY-1994; 94WO-US005142.
 PF
 XX 14-MAY-1993; 93US-00060988.
 .PR
 XX (USSH) US SEC DEPT HEALTH.
 PA
 PI Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
 XX WPI; 1995-006707/01.
 DR
 XX Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
 PT responses - to target antigen in hosts of different MHC haplotypes, esp.
 PT for therapeutic or prophylactic vaccines against HIV.
 XX
 XX Example 1; Page 33; 120pp; English.
 PS
 CC Synthetic peptides spanning multideterminant regions from the HIV
 CC envelope protein gp160 have been designed and are designated cluster
 CC peptides (PCLUS). These peptides each consist of a cluster of overlapping
 CC determinants and are known to induce in vitro T cell proliferation and
 CC cytokine production in mice and humans of multiple MHC types. The cluster
 CC peptides were co-linearly synthesised at the N-terminus of an
 CC immunodominant CTL determinant, Peptide 18 (AAR66414), corresp. to part
 CC of the gp160 V3 loop and principal neutralising determinant region of HIV
 CC -1 IIIB isolate. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 XX Sequence 15 AA;
 SQ

Query Match 100.0%; Score 77; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 9e-05;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFVTIGK 15
 |||||
 DB 1 RIQRGPGRAFVTIGK 15
 |||||

RESULT 9
 AAR68789
 ID AAR68789 standard; peptide; 15 AA.
 XX
 AC AAR68789;
 XX
 XX 25-MAR-2003 (revised)
 DT 23-AUG-1995 (first entry)
 DT
 XX Cytotoxic T lymphocyte epitope 46 derived from env gp120 protein.
 DE
 XX cytotoxic T lymphocyte; epitope; antigen; pathogenic; nef; gag; pol; env;
 KW gp120; gp41; HIV; cell-mediated immunity; human immunodeficiency virus;
 KW class I restricted.
 XX
 XX Human immunodeficiency virus.
 OS
 XX WO9428871-A1.
 PN
 XX 22-DEC-1994.
 PD
 PD 07-JUN-1994; 94WO-US006394.
 PF
 XX 07-JUN-1993; 93US-00072718.
 PR
 XX (ENDO-) ENDOCON INC.
 PA
 XX Leonard RJ;
 PI
 XX WPI; 1995-036067/05.
 DR

XX Implant for sustained release of pathogen-associated antigen - forming
 PT chronic inflammatory site producing cytotoxic T-lymphocytes lysing
 PT infected cells, esp. for treating AIDS.
 XX
 XX Disclosure; Page 12; 35pp; English.
 PS
 XX AAR68744-805 are cytotoxic T lymphocyte (CTL) class I and II restricted
 CC epitopes derived from human immunodeficiency virus proteins. AAR68789
 CC corresponds to amino acid residues 308-322 of the env gp120 protein.
 CC These antigens are examples of peptides that can be used with an
 CC immunogenic implant. The implant is associated with an antigen associated
 CC with a pathogen and used to form a discrete, localised chronic
 CC inflammation site which acts as a local 'factory' for prodn. of CTL's
 CC which lyse cells infected with a specific pathogen. The expanded set of
 CC pathogen-specific CTL's can eradicate or prevent development of
 CC infection, and can also be used to treat or arrest the development of
 CC cancers associated with infection. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX
 XX Sequence 15 AA;
 SQ

Query Match 100.0%; Score 77; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 9e-05;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFVTIGK 15
 |||||
 DB 1 RIQRGPGRAFVTIGK 15
 |||||

RESULT 10
 AAW05535
 ID AAW05535 standard; peptide; 15 AA.
 XX
 AC AAW05535;
 XX
 XX 16-OCT-2003 (revised)
 DT 17-JAN-1997 (first entry)
 DT
 XX HIV-1 gp120 peptide (aa308-322).
 DE
 XX gC1q receptor; gC1q-R; HIV-1; gp120; immunogen; vaccine.
 KW
 XX Human immunodeficiency virus 1; strain HXB2R.
 OS
 XX WO9630400-A1.
 PN
 XX 03-OCT-1996.
 PD
 XX 22-MAR-1996; 96WO-US003905.
 PF
 XX 24-MAR-1995; 95US-00410360.
 PR
 XX (TANO-) TANOX BIOSYSTEMS INC.
 PA
 XX Pung MSC, Sun BNV, Sun CRY, Kim YW, Yu L;
 PI
 XX WPI; 1996-455274/45.
 DR
 XX New gC1q receptor-based, HIV-1 gp 120 binding peptide(s) - for preventing
 PT and treating HIV-1 infection.
 PT
 XX Claim 10; Page 49; 53pp; English.
 PS
 XX A peptide (AAW05535) corresponds to amino acids 308-322 of the V3 region
 CC of gp120 from HIV-1 strain HXB2R2. It was used to examine the binding of
 CC gC1q receptor (gC1q-R) (see also AAW05534) to HIV-1 gp120. Anti-HIV-1
 CC gp120 V3 domain murine monoclonal antibody BART23 was able to react with
 CC gp120 bound to gC1q-R, showing that the binding of gC1q-R to gp120 does
 CC not involve the V3 region of gp120; the binding site was localised to
 CC amino acids 444-459 (see also AAW05533) of gp120. (Updated on 16-OCT-2003
 CC to standardise OS field)

```

XX SQ Sequence 15 AA;
Query Match 100.0%; Score 77; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RIQPGGFAFTVIGK 15
DB 1 RIQPGGFAFTVIGK 15

RESULT 11
AAR92033
ID AAR92033 standard; peptide; 15 AA.
XX AC AAR92033;
XX DT 29-MAY-1996 (first entry)
XX DE Hydrophilic peptide for epimorphin modification (5).
XX KW Epimorphin; human; mouse; wound; burn; epithelial tissue; diagnosis;
XX KW treatment; morphogenetic abnormality; cosmetic; hair growth stimulator.
XX OS Synthetic.
XX PN EP698666-A2.
XX PD 28-FEB-1996.
XX PF 20-JUN-1995; 95EP-00304270.
XX PR 21-JUN-1994; 94JP-00162874.
XX PR 31-MAR-1995; 95JP-00099979.
XX PR 31-MAR-1995; 95JP-00099980.
XX PA (SUME ) SUMITOMO ELECTRIC IND CO.
XX PI Hirai Y, Koshida S, Oka Y;
XX DR WPI; 1996-118213/13.
XX PT Novel polypeptide containing an epimorphin functional domain - has
XX PT possible benefits in epithelial tissue treatments, e.g. burns and for
XX PT artificial organs.
XX PS Claim 8; Page 57; 62pp; English.
XX CC New polypeptides contain a first portion of 5-99 amino acids joined to a
XX CC second portion contg. at least a functional domain of epimorphin. The
XX CC first portion may be selected from the peptides given in AAR92029 to
XX CC AAR92036. The second portion may be full-length epimorphin (see AAR92037
XX CC to AAR92042 for human and mouse epimorphins). Fragments of epimorphins
XX CC given in AAT16083 to AAT16090 are used in the prodn. of modified
XX CC epimorphins. The modified epimorphins are useful for the development of
XX CC diagnosis and treatment of morphogenetic abnormalities of epithelial
XX CC tissue or novel remedies for wounds, eg burns, after surgery and for
XX CC artificial organs. They may also be used as components of cosmetics, hair
XX CC growth stimulators, etc
XX SQ Sequence 15 AA;
Query Match 100.0%; Score 77; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RIQPGGFAFTVIGK 15
DB 1 RIQPGGFAFTVIGK 15

RESULT 12

```

```

AAW07931
ID AAW07931 standard; peptide; 15 AA.
XX AC AAW07931;
XX DT 16-OCT-2003 (revised)
XX DT 31-JAN-1997 (first entry)
XX DE gp120 peptide p18p.
XX KW HIV; gp120; HIV-IIIB strain; HIV-1 transmission; foetal transmission;
XX KW neutralising antibody; passive immunisation; anti-idiotypic antibody;
XX KW gp41; vaccine; active immunotherapy.
XX OS Human immunodeficiency virus 1.
XX PN US5556744-A.
XX PD 17-SEP-1996.
XX PF 24-MAR-1994; 94US-00218025.
XX PR 29-MAY-1992; 92US-00891451.
XX PA (UYPE-) UNIV PENNSYLVANIA.
XX PA (WIST-) WISTAR INST ANATOMY & BIOLOGY.
XX PI Williams WV, Weiner DB, Ugen KE;
XX DR WPI; 1996-432980/43.
XX PT Determining the likelihood of maternal transmission of HIV-1 to foetus -
XX PT by measuring maternal reactivity with specific gp120 and gp41 derived
XX PT peptide(s), also used for diagnosing HIV in infants.
XX PS Example 2; Col 18; 63pp; English.
XX CC This sequence represents a HIV gp120 peptide that can be used in the
XX CC method of the invention. The method of the invention is for determining
XX CC whether or not a mother will transmit HIV-1 to a foetus. The method
XX CC comprises incubating a sample from the HIV-infected mother, with a
XX CC collection of HIV peptides. The HIV peptides includes at least one of the
XX CC gp120 sequences (such as AAW07909-W07917), and at least one HIV gp41
XX CC derived peptide (see AAW07918-W07928). The number of peptides that react
XX CC with the sample is determined, and this number is compared with a
XX CC standard that shows pattern reactivity for a patient of transmission
XX CC status. A non-transmissible HIV sample is indicated if the test sample
XX CC reacts with twice as many peptides as the standard. The method detects
XX CC the presence of neutralising antibodies that protect against mother to
XX CC infant transmission of HIV. These sequences can also be used in vaccines
XX CC to protect against transmission. Antibodies against these sequences can
XX CC be used for passive immunisation, and to generate anti-idiotypic
XX CC antibodies for use in vaccines or active immunotherapy. (Updated on 16-
XX CC OCT-2003 to standardise OS field)
XX SQ Sequence 15 AA;
Query Match 100.0%; Score 77; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RIQPGGFAFTVIGK 15
DB 1 RIQPGGFAFTVIGK 15

RESULT 13
AAR92007
ID AAR92007 standard; protein; 15 AA.
XX AC AAR92007;
XX DT 16-OCT-2003 (revised)

```

DT 27-SEP-1996 (first entry)
 XX HIV-1 V3 loop epitope, for insertion in Mycobacterium alpha antigen.
 DE
 XX Mycobacterium bovis BCG; AIDS vaccine; surface protein; alpha antigen;
 KW Human immunodeficiency virus type 1; fusion protein; gp120 epitope;
 KW V3 loop.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN WO9604009-A1.
 XX
 PD 15-FEB-1996.
 XX
 PF 31-JUL-1995; 95WO-JP001515.
 XX
 PR 29-JUL-1994; 94JP-00178462.
 XX
 PA (AJIN) AJINOMOTO CO INC.
 XX (NINA-) JAPAN AGENCY NAT INST HEALTH.
 XX
 PI Matsuo K, Chujo Y, Yamazaki A, Honda M, Yamazaki S, Tasaka H;
 DR WPI; 1996-129127/13.
 DR N-PSDB; AAT16048, AAT16049.
 XX
 CC BCG containing vaccine secretes chimeric protein containing foreign
 PT antigen - has enhanced immunogenicity and antigenicity esp. when used as
 PT an anti-AIDS vaccine.
 XX
 PS Example 2; Page 17; 56pp; Japanese.
 XX
 CC Antigenic peptides can be inserted into the alpha-antigen sequence of a
 CC Mycobacterium and secreted from an appropriately transformed M.bovis BCG
 CC cell. The resulting chimeric antigen has greatly enhanced antigenicity
 CC and immunogenicity and is recognised in vivo by B-cells which recognise
 CC the alpha-antigen. The present sequence is that of a HIV-1 gp120 V3 loop
 CC epitope which was incorporated into the alpha antigen. M.bovis BCG cells
 CC secreting a chimeric protein comprising the epitope sequence are useful
 CC as anti-AIDS vaccines. (Updated on 16-OCT-2003 to standardise OS field)
 XX
 SQ Sequence 15 AA;
 Query Match 100.0%; Score 77; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 9e-05;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQRGPGRAFTVIGK 15
 DB 1 RIQRGPGRAFTVIGK 15
 RESULT 14
 AAW24219
 ID AAW24219 standard; peptide; 15 AA.
 AC AAW24219;
 XX
 DT 17-MAR-1998 (first entry)
 DE
 DE CD4+ T-lymphocyte epitope to HIV-1 V3 loop derived peptide V3-LAI-P18.
 XX
 KW T-lymphocyte epitope; diagnosis; antigen; infectious disease;
 KW delayed-type hypersensitivity assay; vaccine development.
 XX
 OS Synthetic.
 OS Human immunodeficiency virus.
 PN WO9727462-A2.
 XX
 PD 31-JUL-1997.
 XX
 PF 27-JAN-1997; 97WO-US001084.
 XX

XX 26-JAN-1996; 96US-0010679P.
 XX (USSA) US DEPT ARMY GOVERNMENT US ARMY MEDICAL.
 PA Sitz KV, Brix DL;
 PI
 XX WPI; 1997-393814/36.
 DR
 XX Peptide fragments containing antigen epitope(s) used to trace diseases -
 PT used in a delayed-type hypersensitivity assay for in vivo mapping of
 PT human T-lymphocyte epitope(s) e.g. for diagnosis, vaccine development
 PT etc.
 XX
 PS Disclosure; Page 6; 14pp; English.
 XX
 CC Peptide fragments AAW24217-20 were used to demonstrate a new method of
 CC tracing sources of infectious diseases. The method comprises preparing a
 CC short (9-50 amino acid) peptide containing at least one non-conserved
 CC epitope of an organism, injecting a composition containing the peptide
 CC intradermally into a test subject in a delayed-type hypersensitivity
 CC (DTH) assay and observing the injection site at intervals for induration.
 CC In this example CD4+ T-lymphocyte epitopes to the HIV-1 V3 loop were
 CC mapped by existing in vitro technique for two existing HIV infected
 CC individuals and used to design peptides AAW24217-20. The method allows
 CC the T-lymphocyte epitopes of a large antigen to be determined in vivo in
 CC humans. The method is useful in medicine e.g. in diagnosis, monitoring
 CC and treatment design for infectious disease exposure, active autoimmune
 CC disease, allergic diseases and malignancy. It is especially useful for
 CC tracing infectious diseases e.g. HIV, particularly when a sequence is
 CC present only in certain strains of an organism, and developing suitable
 CC vaccines. Vaccinated individuals can also be tested to verify protection
 CC against a particular strain. The method allows in vivo mapping of T-
 CC lymphocyte epitopes, not previously possible. The method is simpler, more
 CC rapid and more sensitive. It can also be applied in a variety of
 CC environments e.g. undeveloped regions since specialist equipment is not
 CC required
 XX
 SQ Sequence 15 AA;
 Query Match 100.0%; Score 77; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 9e-05;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQRGPGRAFTVIGK 15
 DB 1 RIQRGPGRAFTVIGK 15
 RESULT 15
 AAW10348
 ID AAW10348 standard; peptide; 15 AA.
 XX
 AC AAW10348;
 XX
 DT 15-OCT-1997 (first entry)
 DE
 DE HIV epitope env P18-IIIB amino acid residues 315-329 of gp160.
 XX
 KW Human immunodeficiency virus type-1; HIV-1; T cell response; detection;
 KW peripheral blood mononuclear cell; PBMC.
 XX
 OS Synthetic.
 OS WO9641189-A1.
 PN
 XX 19-DEC-1996.
 PD
 XX 07-JUN-1996; 96WO-US010108.
 PF
 XX 07-JUN-1995; 95US-00488435.
 PR
 XX (USSH) US DEPT HEALTH & HUMAN SERVICES.
 PA

XX Shearer GM, Berzofsky JA, Clerici M;
 XX WPI; 1997-108658/10.
 XX Diagnosis of exposure to infectious agents, partic. HIV - by detecting
 PT activation of peripheral blood mononuclear cells from patient by epitope
 PT of infectious agent.
 XX
 XX Claim 15; Page 62; 82pp; English.
 XX
 CC The present sequence represents a synthetic HIV-1 gp160 peptide env P18-
 CC IIB for use in a method for diagnosing exposure of a patient to human
 CC immunodeficiency virus (HIV). The method involves: (a) obtaining
 CC peripheral blood mononuclear cells (PBMC) from a patient; (b) incubating
 CC the PBMC with at least 1 synthetic peptide representing an epitope(s) of
 CC the infectious agent (e.g. the present sequence); and (c) determining the
 CC activation of the PBMC as a result of the incubation in step (b). The
 CC method can provide for the early detection of exposure to infectious
 CC organisms, specifically HIV in this case. The method can be used to
 CC assess exposure to HIV without concomitant infection. It also provides an
 CC earlier identification of HIV exposure, than is provided by
 CC seroconversion
 XX
 SQ Sequence 15 AA;
 Query Match 100.0%; Score 77; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 9e-05;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 RIQPGGRAFTVIGK 15
 Db 1 RIQPGGRAFTVIGK 15
 RESULT 16
 AAW22031
 ID AAW22031 standard; peptide; 15 AA.
 AC AAW22031;
 XX
 DT 20-FEB-1998 (first entry)
 DE Antigenic human immunodeficiency virus peptide P18.
 KW Antigenic peptide; human papillomavirus; MAGE gene; BAGE-1 peptide; P18;
 KW human immunodeficiency virus; cancer antigen; tyrosinase; signal protein;
 KW anthrax lethal factor; LF; toxin; cationic fusion peptide; translocation;
 KW gene therapy; polycationic affinity handle; therapeutic protein; LFN.
 XX
 OS Human immunodeficiency virus.
 OS WO9723236-A1.
 PN
 XX
 PD 03-JUL-1997.
 XX
 PF 13-DEC-1996; 96WO-US020463.
 XX
 PR 13-DEC-1995; 95US-0008518P.
 PR 07-JUN-1996; 96US-0019275P.
 XX
 PA (HARD) HARVARD COLLEGE.
 XX
 XX Collier RJ, Blanke SR, Milne JC, Lyszak EL, Ballard JD;
 PI Starnbach MN;
 PI
 XX WPI; 1997-350782/32.
 DR
 XX Introducing therapeutic proteins, especially antigens, into cells - using
 PT toxin molecules and/or polycationic handles for delivery.
 PT
 XX Claim 15; Page 36; 67pp; English.
 PS
 XX

CC This is the antigenic human immunodeficiency virus peptide P18. This
 CC antigenic compound can be introduced into the cytoplasm of a cell by a
 CC new method where the cell is contacted with a fusion molecule comprising
 CC a delivery molecule. The delivery molecule can either be a polycationic
 CC affinity handle, LFN (the protective antigen binding domain of anthrax
 CC lethal factor) or a toxin delivery molecule related to LFN. The antigenic
 CC compound is linked to either of the delivery molecules by a covalent
 CC bond. The B moiety of a toxin enhances delivery of the antigenic compound
 CC into a cell. The anthrax toxin system of the invention eliminates the
 CC need to generate fusion proteins with a toxin B moiety, which alleviates
 CC problems associated with incorrect folding of lengthy fusion proteins.
 CC Small cationic fusion peptides substituted for LFN may reduce the
 CC possibility of steric interference with the biological activity of the
 CC translocated protein. The method is used for the introduction of
 CC antigens, e.g. MHC class I antigens or any other therapeutic protein,
 CC e.g. toxin molecules, apoptosis-inducing molecules or signalling proteins
 CC into the cells
 XX
 SQ Sequence 15 AA;
 Query Match 100.0%; Score 77; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 9e-05;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 RIQPGGRAFTVIGK 15
 Db 1 RIQPGGRAFTVIGK 15
 RESULT 17
 AAW39275
 ID AAW39275 standard; peptide; 15 AA.
 AC AAW39275;
 XX
 DT 19-MAY-1998 (first entry)
 DE HIV-1 synthetic peptide IIB.
 KW Human immunodeficiency virus type I; HIV-1; cytotoxic T-cell; CTC;
 KW vaccine; prophylactic; immunotherapy.
 XX
 OS Synthetic.
 OS Human immunodeficiency virus 1.
 XX
 PN US5711947-A.
 XX
 PD 27-JAN-1998.
 XX
 PF 23-JUL-1993; 93US-00095332.
 XX
 PR 26-JAN-1988; 88US-00148692.
 PR 18-SEP-1991; 91US-00760530.
 XX
 XX (USSH) US DEPT HEALTH & HUMAN SERVICES.
 PA
 XX Germain RN, Berzofsky JA, Takahashi H;
 PI WPI; 1998-119931/11.
 DR
 XX Inducing cytotoxic T-cell response to HIV - by administering gp160 vector
 PT and chimeric gp160 peptide(s).
 PT
 XX Example 1; Col 3; 25pp; English.
 PS
 XX Peptides AAW39275-W39300 are used in a novel method for inducing
 CC cytotoxic T-cell (CTC) activity specific for a broad array of HIV-1
 CC isolates using hybrid synthetic peptides. The method involves first
 CC administering a recombinant viral vector expressing the HIV-1 gp160
 CC envelope glycoprotein and then administering at least 1 chimeric
 CC synthetic polypeptide. When several synthetic polypeptides having
 CC sequences corresponding to amino acids 315-329 of the gp160 envelope
 CC glycoprotein of HIV-1 strain IIB, in which amino acid 325 is substituted

CC by the corresponding amino acid from other strains or isolates, are used,
CC a CTC response to a broad range of HIV-1 isolates can be elicited. These
CC synthetic peptides are useful as vaccines for the prophylaxis or
CC immunotherapy of HIV-1 virus infection

XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 77; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQPGGFAFTVIGK 15
| | | | | | | | | | | | | | |
Db 1 RIQPGGFAFTVIGK 15

RESULT 18

AAW40316
ID AAW40316 standard; peptide; 15 AA.

XX
AC AAW40316;

XX 17-OCT-2003 (revised)

DT 23-JUN-1998 (first entry)

XX HIV-1 IIIB gp120 peptide fragment.

DE Epitope; vaccine; V3; gp120; immune response; hypervariable region;
XX immunoglobulin; histocompatibility antibody.

XX Human immunodeficiency virus 1.

XX JP10072369-A.

PN 17-MAR-1998.

XX 02-SEP-1996; 96JP-00232378.

PR 02-SEP-1996; 96JP-00232378.

XX (KAGA-) KAGAKU GIUTSU SHINKO JIGYODAN.

PA WPI; 1998-234701/21.

DR Vaccine against human immunodeficiency virus - induces immune response
XX reaction to V3 epitope of virus.

PT Example 1; Page 5; 8pp; Japanese.

PS This sequence represents a fragment of the human immunodeficiency virus
(HIV) Type 1 strain IIIB gp120 protein. This sequence is used in a method
CC resulting in the production of a vaccine against HIV which induces an
CC immune response to the V3 epitope of HIV. This method which comprises the
CC translocation of an epitope of HIV at plural sites in the hypervariable
CC region of immunoglobulin, the preparation of the epitope molecule
CC histocompatibility antibody, and optionally chemically cross linking the
CC epitope. An epitope histocompatibility antibody is also described in the
CC specification which specifically responds to HIV, prepared by
CC translocation of an epitope comprising a peptide obtained from at least
CC one V3 sequence of HIV. (Updated on 17-OCT-2003 to standardise OS field)

XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 77; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQPGGFAFTVIGK 15
| | | | | | | | | | | | | | |
Db 1 RIQPGGFAFTVIGK 15

RESULT 19

AAW76898

ID AAW76898 standard; peptide; 15 AA.

XX
AC AAW76898;

DT 25-JAN-1999 (first entry)

XX Fusion immunoglobulin heavy chain HIV gp120 T cell epitope #17.

DE B cell; T cell; epitope; immunoglobulin; heavy chain; gp120; IgH;
XX human immune deficiency virus; HIV; tolerance; treatment; therapy;
KW prophylaxis; vaccine; chemotherapy; immune response; modifier; tumour;
KW microbial infection; autoimmune disease; antibody; apoptosis;
KW antiviral T cell immunity.

OS Mus sp.

OS Homo sapiens.

XX WO9836087-A1.

XX 20-AUG-1998.

XX 13-FEB-1998; 98WO-US002766.

XX 13-FEB-1997; 97US-0040581P.

XX (AMNA-) AMERICAN NAT RED CROSS.

XX Scott D, Zambidis E;

XX WPI; 1998-506315/43.

XX New fusion immunoglobulin heavy chain including gp120 epitopes and
PT related complete antibodies - DNA, vectors and transformed cells, used to
PT induce tolerance to the epitopes for treatment of human immune deficiency
PT virus infection.

XX Claim 11; Page 120; 154pp; English.

XX This sequence is an epitope used in the construction of a novel fusion
CC immunoglobulin heavy chain (IgH) protein with a mammalian, especially
CC human, IgH chain fused in frame at its N-terminus to one or more human
CC immune deficiency virus (HIV) gp120 epitopes. Fusion Ig proteins and/or
CC transfected cells are used to tolerate subjects to gp120 epitopes and to
CC maintain this tolerance, particularly for treatment of HIV infection.
CC optionally together with other therapeutic/prophylactic agents such as
CC vaccines, chemotherapeutic agents and immune response modifiers. Such
CC deleterious, e.g. microbial infection, tumours or autoimmune disease.
CC Induction of tolerance suppresses production of antibodies against gp120,
CC so prevents or inhibits 'bystander' apoptosis of uninfected T cells that
CC are bound to gp120 protein, maximising induction of protective antiviral
CC T cell immunity

XX Sequence 15 AA;

Query Match 100.0%; Score 77; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQPGGFAFTVIGK 15
| | | | | | | | | | | | | | |
Db 1 RIQPGGFAFTVIGK 15

RESULT 20

AAW54929
ID AAW54929 standard; peptide; 15 AA.

XX
AC AAW54929;

XX 25-SEP-1998 (first entry)

XX

DE HIV gp120 envelope protein, peptide 127, analogue 127g'.

KW Immunoadsorbent; immunoassay; HIV gp120; immunogen; antibody; Human.

OS Human immunodeficiency virus.

XX US5763160-A.

XX 09-JUN-1998.

XX 07-JUN-1995; 95US-00488252.

XX 12-FEB-1988; 88US-00155321.

XX 01-MAR-1991; 91US-00663262.

XX 09-JUL-1991; 91US-00726605.

XX 19-OCT-1994; 94US-00326676.

XX (UNBI-) UNITED BIOMEDICAL INC.

XX Wang CY;

XX WPI; 1998-347301/30.

XX HIV gp120 peptides - useful as immunoassay reagents or vaccine components.

XX Example 8; Column 21/22; 34pp; English.

XX Peptides AAW54903-W54941 can be used as an immunoadsorbent in an immunoassay for detecting antibodies to HIV gp120, or as an immunogen for eliciting antibodies to HIV in a mammal

XX SQ Sequence 15 AA;

Query Match 100.0%; Score 77; DB 2; Length 15;

Best Local Similarity 100.0%; Pred. No. 9e-05;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRPGRFAVTIGK 15
|||||

Db 1 RIQRPGRFAVTIGK 15
|||||

RESULT 21

AY06896

ID AAY06896 standard; peptide; 15 AA.

XX AAY06896;

XX 01-JUL-1999 (first entry)

XX Sequence of gp120IIB P18 peptide.

XX Fusion protein; vaccine; cytokine; immunoglobulin; autoimmune disease; infectious disease; inflammatory disease; neoplastic disease; cancer; immunologic disease; immune response; malaria; tuberculosis; hepatitis; AIDS; influenza; interleukin; IL-2; Ig.

XX Synthetic.

XX WO9916466-A2.

XX 08-APR-1999.

XX 29-SEP-1998; 98WO-US020321.

XX 29-SEP-1997; 97US-0060338P.

XX 12-DEC-1997; 97US-00990180.

XX (BETH-) BETH ISRAEL DEACONESS MEDICAL CENT.

XX Letvin NL, Barouch DH;

DR WPI; 1999-254931/21.

XX New vaccine compositions for treating AIDS, malaria, tuberculosis, cancer or influenza.

XX Example 3; Page 22; 66pp; English.

XX The invention relates to vaccine compositions comprising a vaccine and a timed-release formulation of a cytokine or cytokine/immunoglobulin fusion protein or plasmid. The formulation or device releases the cytokine protein or plasmid at one or more temporal points subsequent to vaccine administration. The vaccines can be used for treating an autoimmune disease, an infectious disease, an inflammatory disease, a neoplastic disease, or an immunologic disease in an individual. The vaccines can be used to elicit immune responses against diseases such as AIDS, malaria, tuberculosis, hepatitis C, hepatitis B, cancer or influenza. The methods can provide for enhancement of one or more immunologic parameters such as an antibody response, a cellular proliferative response as well as cytotoxic T-lymphocyte levels. In addition the Ig can increase the circulating half life of the cytokine

XX SQ Sequence 15 AA;

Query Match 100.0%; Score 77; DB 2; Length 15;

Best Local Similarity 100.0%; Pred. No. 9e-05;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRPGRFAVTIGK 15
|||||

Db 1 RIQRPGRFAVTIGK 15
|||||

RESULT 22

AY24466

ID AAY24466 standard; peptide; 15 AA.

XX AAY24466;

XX 23-SEP-1999 (first entry)

XX HIV peptide R15K-1.

XX Hepatitis B virus; HBV; X protein; cytotoxic T lymphocyte; liposome; CTL; antigen; immunity; liver cancer.

XX Human immunodeficiency virus 1.

XX Synthetic.

XX WO9936434-A1.

XX 22-JUL-1999.

XX 19-JAN-1998; 98WO-KR000010.

XX 19-JAN-1998; 98WO-KR000010.

XX (MOGA-) MOGAM BIOTECHNOLOGY RES INST.

XX Kim T, Lee K, Chang J, Cho S, Hwang Y, Choi M, Cheong H;

XX WPI; 1999-444387/37.

XX Hepatitis B virus protein X-derived peptide antigens used to stimulate cytotoxic T lymphocytes, useful for treatment of HBV-associated diseases, especially liver cancer.

XX Example 5; Page 14; 33pp; English.

XX The present invention describes peptide antigens AAY24459 to AAY24463 derived from the X protein of hepatitis B virus (HBV) which are recognized by cytotoxic T lymphocytes (CTL). The peptide antigens derived from HBV X protein are useful for inducing CTLs against the virus or inducing immunological tolerance to the virus. pH-sensitive liposomes

CC containing the peptide antigens are used to induce cellular immunity so
CC that CTLs specific to the virus can be produced. This is useful for
CC prevention and treatment of HBV-associated diseases, especially HBV-
CC associated liver cancer. pH-sensitive liposomes permit the selective
CC transportation of anti-cancer drugs. The present sequence represents a
CC peptide used in an example from the present invention
XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 77; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRGPGRAFTVIGK 15
Db 1 RIQRGPGRAFTVIGK 15

RESULT 23
AAY25189
ID AAY25189 standard; peptide; 15 AA.
XX
AC AAY25189;
XX
DT 03-SEP-1999 (first entry)
XX
DE HIV protein gp160 peptide fragment #1.
XX
KW Heat shock protein; HSP; complex; denatured protein matrix; antigen;
KW vaccine; allergic disease; treatment; susceptibility; Th2; skin rash;
KW allergic reaction; asthma; gp160.
XX
OS Human immunodeficiency virus.
XX
PN WO9929182-A1.
XX
PD 17-JUN-1999.
XX
PF 04-DEC-1998; 98WO-US025734.
XX
PR 05-DEC-1997; 97US-00985548.
PR 05-DEC-1997; 97US-00986234.
XX
PA (UYNE-) UNIV NEW MEXICO STATE.
XX
PI Wallen ES, Moseley PL;
XX
DR WPI; 1999-394912/33.
XX
PT Synthesizing heat shock protein complexes using a denatured protein
PT matrix.
XX
PS Example 1; Fig 1A; 33pp; English.
XX
CC This invention describes a novel method for synthesizing heat shock
CC protein (HSP) complexes comprising adding a heat shock protein to a
CC denatured protein matrix for binding, and adding a complexing solution
CC comprising a peptide to elute a heat shock protein-peptide complex. A HSP
CC -antigen complex is useful as a vaccine for treating an allergic disease
CC (in a mammal, preferably a human) to reduce susceptibility of the Th2
CC response, the complex comprising a HSP-antigenic peptide complex. The
CC reaction is administered to prevent a mammal from having an allergic
CC complex to an allergic disease, or administered to a mammal having an
CC allergic disease, to reduce the allergic reactions. Allergic diseases
CC include asthma and skin rashes. Prior art methods or preventing/treating
CC allergic diseases include antihistamines which treat only the symptoms,
CC corticosteroids which have severe side effects and desensitization
CC therapy which has limited uses. The new method also allows more
CC flexibility of use of peptide-based vaccines, as prior art HSP-based
CC vaccines require isolation from a portion of the tumour itself. This
CC sequence represents a peptide fragment from the HIV gp160 protein which
CC is used in the method of the invention
XX

SQ Sequence 15 AA;

Query Match 100.0%; Score 77; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRGPGRAFTVIGK 15
Db 1 RIQRGPGRAFTVIGK 15

RESULT 24
AAY25204
ID AAY25204 standard; peptide; 15 AA.
XX
AC AAY25204;
XX
DT 03-SEP-1999 (first entry)
XX
DE HIV V3 peptide fragment #10.
XX
KW Heat shock protein; HSP; complex; denatured protein matrix; antigen;
KW vaccine; allergic disease; treatment; susceptibility; Th2; skin rash;
KW allergic reaction; asthma; V3 protein.
XX
OS Human immunodeficiency virus.
XX
PN WO9929182-A1.
XX
PD 17-JUN-1999.
XX
PF 04-DEC-1998; 98WO-US025734.
XX
PR 05-DEC-1997; 97US-00985548.
PR 05-DEC-1997; 97US-00986234.
XX
PA (UYNE-) UNIV NEW MEXICO STATE.
XX
PI Wallen ES, Moseley PL;
XX
DR WPI; 1999-394912/33.
XX
PT Synthesizing heat shock protein complexes using a denatured protein
PT matrix.
XX
PS Example 1; Fig 1B; 33pp; English.
XX
CC This invention describes a novel method for synthesizing heat shock
CC protein (HSP) complexes comprising adding a heat shock protein to a
CC denatured protein matrix for binding, and adding a complexing solution
CC comprising a peptide to elute a heat shock protein-peptide complex. A HSP
CC -antigen complex is useful as a vaccine for treating an allergic disease
CC (in a mammal, preferably a human) to reduce susceptibility of the Th2
CC response, the complex comprising a HSP-antigenic peptide complex. The
CC complex is administered to prevent a mammal from having an allergic
CC reaction to an allergic disease, or administered to a mammal having an
CC allergic disease, to reduce the allergic reactions. Allergic diseases
CC include asthma and skin rashes. Prior art methods or preventing/treating
CC allergic diseases include antihistamines which treat only the symptoms,
CC corticosteroids which have severe side effects and desensitization
CC therapy which has limited uses. The new method also allows more
CC flexibility of use of peptide-based vaccines, as prior art HSP-based
CC vaccines require isolation from a portion of the tumour itself. This
CC sequence represents a peptide fragment from the HIV V3 protein which is
CC used in the method of the invention
XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 77; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRGPGRAFTVIGK 15


```

Db      1 RIQRGPGRAFTVIGK 15
|||||
RESULT 25
AAW05356
ID      AAW05356 standard; peptide; 15 AA.
XX
AC      AAW05356;
XX
DT      17-OCT-2003 (revised)
DT      29-JUN-1999 (first entry)
XX
DE      HIV-1 CLUVAC peptide, SEQ ID NO. 15.
XX
KW      HIV-1; CLUVAC; cluster peptide vaccine construct; cytotoxic T lymphocyte;
KW      protective mucosal CTL response; hepatitis A virus; papilloma virus;
KW      feline immunodeficiency virus; feline leukaemia virus; M. tuberculosis;
KW      Listeria monocytogenes; M. leprae; Giardia lamblia;
KW      immune response induction.
XX
OS      Human immunodeficiency virus 1.
XX
PN      WO9912563-A2.
XX
PD      18-MAR-1999.
XX
PF      11-SEP-1998; 98WO-US019028.
XX
PR      11-SEP-1997; 97US-0058523P.
PR      17-FEB-1998; 98US-0074894P.
XX
PA      (USSH ) US DEPT HEALTH & HUMAN SERVICE.
XX
PI      Berzofsky JA, Belyakov IM, Derby MA, Kelsall BL, Strober W;
XX
DR      WPI; 1999-243663/20.
XX
PT      Method for inducing a protective mucosal cytotoxic T lymphocyte immune
PT      response.
XX
PS      Example 3; Page 85; 86pp; English.
XX
CC      This sequence represents a HIV-1 cluster peptide vaccine conjugate
CC      (CLUVAC) sequence. The invention relates to a method for inducing a
CC      protective mucosal cytotoxic T lymphocyte (CTL) response in a mammalian
CC      subject, which comprises contacting a mucosal tissue of the subject with
CC      a composition comprising a purified soluble antigen. The method can
CC      induce a protective mucosal CTL response in a subject. The method can be
CC      used for protection against e.g. hepatitis A virus, papilloma virus,
CC      feline immunodeficiency virus, feline leukaemia virus, Listeria
CC      monocytogenes, M. tuberculosis, M. leprae, or Giardia lamblia. The method
CC      induces long-lasting protective mucosal immune responses. (Updated on 17-
CC      OCT-2003 to standardise OS field)
XX
SQ      Sequence 15 AA;
      Query Match      100.0%; Score 77; DB 2; Length 15;
      Best Local Similarity 100.0%; Pred. No. 9e-05;
      Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 RIQRGPGRAFTVIGK 15
      |||||||
Db      1 RIQRGPGRAFTVIGK 15

RESULT 26
AAW72821
ID      AAW72821 standard; peptide; 15 AA.
XX
AC      AAW72821;
XX
DT      17-OCT-2003 (revised)

```

```

DT      13-JAN-1999 (first entry)
XX
DE      HIV-1 gp120 monoclonal antibody BAT123 residue 308 to 322.
XX
KW      HIV-1; gp120; epitope; monoclonal antibody; envelope; neutralise;
KW      inhibit; infection; T-cell; inhibit syncytium formation; AIDS.
XX
OS      Human immunodeficiency virus 1.
XX
PN      US5834599-A.
PD      10-NOV-1998.
XX
PF      04-MAR-1993; 93US-00026276.
XX
PR      29-MAY-1987; 87US-00057445.
PR      24-DEC-1987; 87US-00137861.
PR      25-APR-1989; 89US-00343540.
PR      05-JUN-1992; 92US-00895197.
XX
PA      (TANO-) TANOX BIOSYSTEMS INC.
XX
PI      Sun BN, Fung SC, Kim YW, Sun CR, Chang NT, Chang T;
XX
DR      WPI; 1999-008810/01.
XX
PT      Antibody conjugate comprising monoclonal antibody - which binds to
PT      epitope within amino acid residue of gp120 which neutralises HIV-1
PT      conjugated with, e.g. cytotoxic agent.
XX
PS      Example 4; Col 25; 22pp; English.
XX
CC      The present invention describes an antibody conjugate comprising an
CC      antibody (Ab) which binds to an epitope within amino acid residue 308-322
CC      of gp120 and neutralises HIV-1, conjugated with a cytotoxic agent, an
CC      anti-viral agent or an agent which facilitates passage through the blood
CC      brain barrier. Also described is an antibody conjugate as above but where
CC      the Ab binds to an epitope within amino acid residue 298-312 of gp12
CC      which neutralises HIV-1. The present sequence represents an HIV-1 gp120
CC      monoclonal antibody BAT123 residue 308 to 322 from an example of the
CC      present invention. The Ab are monoclonal Ab which bind to the gp120
CC      protein on the envelope of HIV-1. They inhibit the infection of T-cells
CC      and also inhibit syncytium formation. The antibodies are group specific
CC      and neutralise different strains and isolates of HIV-1. The antibodies
CC      have a variety of uses, including the treatment and prevention of AIDS
CC      and AIDS related complex. They are especially used to kill infected T-
CC      cells. (Updated on 17-OCT-2003 to standardise OS field)
XX
SQ      Sequence 15 AA;
      Query Match      100.0%; Score 77; DB 2; Length 15;
      Best Local Similarity 100.0%; Pred. No. 9e-05;
      Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 RIQRGPGRAFTVIGK 15
      |||||||
Db      1 RIQRGPGRAFTVIGK 15

RESULT 27
AAW87620
ID      AAW87620 standard; peptide; 15 AA.
XX
AC      AAW87620;
XX
DT      17-OCT-2003 (revised)
DT      20-MAR-2003 (revised)
DT      03-MAR-1999 (first entry)
XX
DE      Epitope of HIV-1 gp120 protein which binds antibody BAT123.
XX
KW      Epitope; gp120 protein; monoclonal antibody; HIV-1; antibody BAT123;
KW      antibody BAT267; antibody BAT085; T cell infection inhibition;

```

KW syncytia formation; acquired immune deficiency syndrome; AIDS;
KW AIDS-related complex; passive immunisation; antiviral; cytotoxic;
KW viral load measurement; vaccine.
XX
OS Human immunodeficiency virus 1.
XX
PN US5854400-A.
XX
PD 29-DEC-1998.
XX
PF 22-SEP-1992; 92US-00950571.
XX
PR 29-MAY-1987; 87US-00057445.
PR 24-DEC-1987; 87US-00137861.
PR 26-SEP-1991; 91US-00767533.
XX
XX (TANO-) TANOX INC.
XX
XX Fung MSC, Sun BNC, Sun CRY, Chang NT, Chang TW;
XX
XX WPI; 1999-095002/08.
DR
XX Monoclonal antibodies directed against regions of gp120 of human immune
PT deficiency virus-1 - are neutralising and able to inhibit infection of T
PT cells and formation of syncytia, used for treatment, prevention or
PT diagnosis of acquired immune deficiency syndrome.
XX
XX Claim 4; Col 8; 16pp; English.

XX The present sequence represents an epitope of the gp120 protein of human
CC immune deficiency virus (HIV)-1. The sequence comprises amino acids 308
CC to 322 of gp120. The specification describes monoclonal antibodies which
CC bind to epitopes of the gp120 protein. Specifically, these antibodies are
CC designated BA123, 267 and 085. Monoclonal antibodies neutralise HIV-1,
CC inhibiting both infection of T cells and formation of syncytia, so are
CC used to treat acquired immune deficiency syndrome (AIDS) and AIDS-related
CC complex, by passive immunisation, as carriers of cytotoxic or antiviral
CC agents, and in extracorporeal systems. They can also be used as
CC immunoassay reagents (for diagnosis or measurement of viral load) and to
CC screen for neutralising epitopes, potentially useful in vaccine
CC development. (Updated on 20-MAR-2003 to correct PR field.) (Updated on 17
CC -OCT-2003 to standardise OS field)
XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 77; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. NO. 9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RIQRGPGRAFTVIGK 15
| | | | | | | | | | | | | | |
Db 1 RIQRGPGRAFTVIGK 15

RESULT 28
AA04680
ID RAY04680 standard; peptide; 15 AA.

AC RAY04680;
XX
DT 17-OCT-2003 (revised)
DT 22-JUN-1999 (first entry)

XX HIV-1 gp120 amino acids 308-322.
XX
XX gp120; HIV-1; monoclonal antibody; homology; antigen; breast; prostate;
KW Gynecological; cancer; detection; diagnosis; cell membrane; chromatin.
XX
XX Human immunodeficiency virus 1.
OS
XX WO9909047-A1.
PN
XX 25-FEB-1999.
PD

XX 29-JUL-1998; 98WO-US015580.
XX
XX 29-JUL-1997; 97US-00902087.
PR
XX (RAKO/) RAKOWICZ-SZULCZYNSKA E M.
PA
XX Rakowicz-Szulczynska EM;
PI
XX WPI; 1999-190148/16.
DR
XX Use of HIV-1 polypeptides - for developing products for the detection and
PT treatment of breast, gynecological and prostate cancers.
PT
XX Disclosure; Page 39; 80pp; English.
XX

XX This peptide corresponds to amino acids 308-322 from the gp120 protein of
CC the human immunodeficiency virus type 1 (HIV-1). The peptide is used to
CC generate the monoclonal antibody Mab 5023. The invention relates to the
CC use of homology between HIV-1 antigens and breast, gynecological and
CC prostate cancer antigens to develop agents for use in the detection and
CC treatment of such cancers. The method especially uses an antibody which
CC recognises the p160, p80, p45 and p24 cell membrane proteins and the p24
CC chromatin protein. (Updated on 17-OCT-2003 to standardise OS field)
XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 77; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. NO. 9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RIQRGPGRAFTVIGK 15
| | | | | | | | | | | | | | |
Db 1 RIQRGPGRAFTVIGK 15

RESULT 29
AA83916
ID AAY83916 standard; peptide; 15 AA.

AC AAY83916;

XX
DT 12-SEP-2003 (revised)
DT 05-JUL-2000 (first entry)

XX HIV-1 env T-cell epitope #1.

XX Immunogen; particulate composition; immune response; assessment;
KW target skin site; skin immune reaction; HIV-1; immunocompetence;
KW antibody; cell mediated immunity; antigen exposure; allergy.
XX

OS Human immunodeficiency virus 1.

XX WO200014547-A1.

XX 16-MAR-2000.

XX 03-SEP-1999; 99WO-GB002915.

XX 04-SEP-1998; 98US-0099261P.

XX 10-JUN-1999; 99US-0139045P.

XX (POWD-) POWDERJECT RES LTD.

XX Sarphie DF, Roberts LK, Fuller DL;

XX WPI; 2000-257072/22.

XX Assessing an immune response against a selected agent in an individual
PT comprises accelerating a particulate composition, containing an
PT immunogenic compound from a selected agent, into the target skin site of
PT the individual.

XX

PS Disclosure; Page 23; 41pp; English.

XX The invention relates to a method of using an immunogenic compound from a

CC selected agent in the manufacture of a particulate composition for

CC assessing an immune response against the selected agent in an individual.

CC The method comprises: (a) accelerating the particulate composition into a

CC target skin site in the individual; and (b) assessing the target site to

CC determine the presence or absence of a localized skin immune reaction,

CC where the presence of the immune reaction is indicative of an immune

CC response against the selected agent. Peptides AAY83916-Y83925 represent

CC examples of peptides that could be used if the method is used to detect

CC human immunodeficiency virus type 1 (HIV-1). The method is useful for

CC assessing immunocompetence, antibody and cell mediated immunity, antigen

CC exposure, or allergic conditions in an individual. (Updated on 12-SEP-

CC 2003 to standardise OS field)

XX Sequence 15 AA;

Query Match 100.0%; Score 77; DB 3; Length 15;

Best Local Similarity 100.0%; Pred. No. 9e-05;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRFVFTGK 15

DB 1 RIQGPGRFVFTGK 15

RESULT 30

AAY66439

ID AAY66439 standard; peptide; 15 AA.

AC AAY66439;

DT 12-SEP-2003 (revised)

DT 22-FEB-2000 (first entry)

XX HLA-A2-binding HIV-1 GP120 CTL epitope #241.

XX HIV-1; MHC; major histocompatibility complex; Class I; HLA-A2;

KW human leukocyte antigen; CTL; cytotoxic T-cell; epitope; allele; binding;

KW conserved; genome; peptide; targeting; toxic; drug; antibody; antigen;

KW antiviral; molecular conjugate therapeutic; diagnosis; treatment;

KW pathogen; localisation; quantification; detection; infection;

KW drug resistance; immune response.

XX Human immunodeficiency virus 1.

XX WO9949893-A1.

PN 07-OCT-1999.

XX 31-MAR-1999; 99WO-US007111.

XX 31-MAR-1998; 98US-00052530.

XX (UYBO-) UNIV BOSTON.

PA Delisi C, Berzofsky J, Gulukota K, Vaccaro D, Weng Z, Zhang C;

XX WPI; 2000-038361/03.

XX Novel methods for designing molecular conjugate therapeutics which are

PT used for diagnosis, imaging and treatment against pathogens.

PS Example 3; Page 50; 62pp; English.

XX AAY66421-Y66453 are cytotoxic T-cell epitopes derived from conserved

CC portions of the HIV-1 genome that are presented by HLA-A2 MHC (major

CC histocompatibility complex) Class I molecules. The peptides are used to

CC construct targeting antigens comprising one or more peptides bound to

CC the corresponding MHC Class I molecule, which can be used to raise

CC antibodies. The antibody may then be used as a targeting vehicle to

CC deliver a potentially toxic drug to its target site of action, rather

CC than administering it systemically, which may result in adverse side

CC effects. The invention relates to improved methods for the design of

CC molecular conjugate therapeutics for the diagnosis and treatment of

CC infections caused by pathogens with a high mutation rate (such as HIV-1).

CC This method involves identifying conserved peptide-encoding regions among

CC the genomes of multiple variants of a pathogen, identifying the Class I

CC MHC molecules which occur with greatest frequency in a population of the

CC interest (e.g., human sub-populations), and determining which of the

CC peptides bind to the Class I MHC molecules. The MHC-binding peptides and

CC the corresponding Class I MHC molecules are selected and used to

CC construct targeting antigens, which are in turn used to produce

CC targeting antibodies. The methods may be used in localisation.

CC quantification and in situ detection of specific peptide-MHC Class I

CC complexes and also to detect and treat viral infection. The methods of

CC the invention mitigate against the development of viral resistance to

CC drugs and to the immune response, as well as providing a solution for

CC targeting toxic compounds to destroy viruses sequestered in sites not

CC accessible to T cells. In addition, the methods eliminate the virus, 12-

CC whereas current therapies only arrest viral replication. (Updated on 12-

CC SEP-2003 to standardise OS field)

XX Sequence 15 AA;

Query Match 100.0%; Score 77; DB 3; Length 15;

Best Local Similarity 100.0%; Pred. No. 9e-05;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRFVFTGK 15

DB 1 RIQGPGRFVFTGK 15

RESULT 31

AAY66455

ID AAY66455 standard; peptide; 15 AA.

AC AAY66455;

XX 12-SEP-2003 (revised)

DT 22-FEB-2000 (first entry)

XX HLA-A3-binding HIV-1 GP120 CTL epitope #257.

DE HIV-1; MHC; major histocompatibility complex; Class I; Caucasoid; HLA;

KW human leukocyte antigen; CTL; cytotoxic T-cell; Caucasian; epitope;

KW allele; binding; conserved; genome; peptide; targeting; toxic; drug;

KW antibody; antigen; antiviral; molecular conjugate therapeutic; diagnosis;

KW treatment; pathogen; localisation; quantification; detection; infection;

KW drug resistance; immune response.

XX Human immunodeficiency virus 1.

XX WO9949893-A1.

PN 07-OCT-1999.

XX 31-MAR-1999; 99WO-US007111.

XX 31-MAR-1998; 98US-00052530.

XX (UYBO-) UNIV BOSTON.

PA Delisi C, Berzofsky J, Gulukota K, Vaccaro D, Weng Z, Zhang C;

XX WPI; 2000-038361/03.

XX Novel methods for designing molecular conjugate therapeutics which are

PT used for diagnosis, imaging and treatment against pathogens.

PS Example 3; Page 51; 62pp; English.

XX AAY66454-Y66458 are cytotoxic T-cell epitopes derived from conserved

CC portions of the HIV-1 genome that are presented by MHC (major

CC histocompatibility complex) Class I alleles found with high frequency
CC among Caucasoids in the USA. The peptides are used to construct
CC targeting antigens comprising one or more peptides bound to the
CC corresponding MHC Class I molecule, which can be used to raise
CC antibodies. The antibody may then be used as a targeting vehicle to
CC deliver a potentially toxic drug to its target site of action, rather
CC than administering it systemically, which may result in adverse side
CC effects. The invention relates to improved methods for the design of
CC molecular conjugate therapeutics for the diagnosis and treatment of
CC infections caused by pathogens with a high mutation rate (such as HIV-1).
CC This method involves identifying conserved peptide-encoding regions among
CC the genomes of multiple variants of a pathogen, identifying the Class I
CC MHC molecules which occur with greatest frequency in a population of
CC interest (e.g., human sub-populations), and determining which of the
CC peptides bind to the Class I MHC molecules. The MHC-binding peptides and
CC the corresponding Class I MHC molecules are selected and used to
CC construct targeting antigens, which are in turn used to produce
CC targeting antibodies. The methods may be used in localisation,
CC quantification and in situ detection of specific peptide-MHC Class I
CC complexes and also to detect and treat viral infection. The methods of
CC the invention mitigate against the development of viral resistance to
CC drugs and to the immune response, as well as providing a solution for
CC targeting toxic compounds to destroy viruses sequestered in sites not
CC accessible to T cells. In addition, the methods eliminate the virus,
CC whereas current therapies only arrest viral replication. (Updated on 12-
CC SEP-2003 to standardise OS field)

XX Sequence 15 AA;

Query Match 100.0%; Score 77; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIGK 15
| | | | | | | | | | | | | | |
Db 1 RIQRGPGRAFTVIGK 15

RESULT 32

AA185591
ID AAY85591 standard; peptide; 15 AA.

XX AAY85591;

XX 12-SEP-2003 (revised)

DT 01-FEB-2001 (first entry)

XX HIV related peptide 13.

XX Immunogenic particle; human immunodeficiency virus; HIV; cytostatic;
KW antiarthritic; antiinflammatory; cell-mediated immune response; cancer;
KW rheumatoid arthritis; inflammatory disorder; viral infection.

XX Human immunodeficiency virus 1.

OS WO200057919-A2.

PN 05-OCT-2000.

XX 23-MAR-2000; 2000WO-CA000319.

XX 25-MAR-1999; 99US-00276057.

XX (SAPI-) SAPIENTIA THERAPEUTICS LTD.
PA (AGEN-) AGENE RES INST CO LTD.

XX Sugimoto M, Arella M, Furuichi Y;

XX WPI; 2000-664891/64.

XX Lipid based artificial particles useful for inducing a cell mediated
PT immune response in a subject having cancer, comprises a lipid based
PT matrix, glycolipids and peptide-lipid conjugates embedded in the matrix.

XX Claim 10; Page 34; 39pp; English.
PS This invention relates to artificial immunogenic particles comprising
XX glycolipids having a lipidic and a saccharide portion and peptide-lipid
CC conjugates having a lipidic and a peptide portion embedded into a lipid
CC based matrix. The peptide portion of the particle may be of viral origin.
CC Peptides AAY85579-Y85591 are human immunodeficiency virus (HIV) related
CC peptides which can be used as the peptide portion in an immunogenic
CC particle of the invention. The particles have cytostatic, antiarthritic
CC and antiinflammatory activity. The immunogenic particles are used for
CC inducing a cell-mediated immune response in a host directed towards the
CC peptide portion of the peptide-lipid conjugate. This means that the
CC particles may be used to treat diseases such as cancer, rheumatoid
CC arthritis, inflammatory disorders or viral infections such as HIV.
CC (Updated on 12-SEP-2003 to standardise OS field)

XX Sequence 15 AA;

Query Match 100.0%; Score 77; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIGK 15
| | | | | | | | | | | | | | |
Db 1 RIQRGPGRAFTVIGK 15

RESULT 33

AAB15875
ID AAB15875 standard; peptide; 15 AA.

XX AAB15875;

XX 17-JAN-2001 (first entry)

XX Human chemokine derived peptide #27.

XX Macrophage recruitment; chemokine derivative; MCP-1; osteoporosis;
KW monocyte chemoattractant protein-1; inflammation; atherosclerosis; HIV;
KW AIDS; stroke; psoriasis; autoimmune disease; hypertension; endotoxaemia;
KW basophil-mediated disease; myocardial infarction; acute ischaemia;
KW rheumatoid arthritis; contraception.

XX Synthetic.

XX WO200042071-A2.

XX 20-JUL-2000.

XX 12-JAN-2000; 2000WO-US000821.

XX 12-JAN-1999; 99US-00229071.

PR 17-MAR-1999; 99US-00271192.

PR 01-DEC-1999; 99US-00452406.

XX (NEOR-) NEORX CORP.

XX Grainger DJ, Tatalick LM;

XX WPI; 2000-499101/44.

XX New peptide 3, amide and heterocyclic compounds and saccharide conjugates
PT used for inhibiting chemokine induced activity and for treating e.g.
PT stroke, vascular diseases, autoimmune diseases and tumor growth.

XX Disclosure; Fig 18; 387pp; English.

XX The present invention concerns the identification of a number of
CC chemokines which can be used to produce derivatives, agonists and
CC antagonists which are then useful in disease treatment. The chemokines
CC include sequences AAB15785-B15794, AAB15803-B15813 and AAB15831-B15848.
CC These chemokine derivatives can be used to treat diseases such as

CC autoimmune diseases, atherosclerosis, osteoporosis, HIV infection and
CC AIDS, psoriasis, inflammatory diseases, hypertension, bacophil-mediated
CC diseases, endotoxaemia, myocardial infarction, acute ischaemia and
CC rheumatoid arthritis, and can be used to prevent strokes and as
CC contraceptives. The coding sequences for the chemokines can be used in
CC gene therapy for the same diseases, as well as in the production of
CC animal models

```

SQ      Sequence 15 AA;

Query Match      100.0%; Score 77; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

1 RIORPGRAFTICK 15
1 RIORPGRAFTICK 15
1 RIORPGRAFTICK 15
1 RIORPGRAFTICK 15

RESULT 34
AAB92345
ID AAB92345 standard; peptide; 15 AA.
XX
XX
AC
AC
AAB92345;
XX
XX
22-JUN-2001 (first entry)
DT

Virus related peptide SEQ ID NO:1521.

XX	
OS	Homo sapiens.
OS	Synthetic.

XX WO200069900-A2.
 PN
 XX
 XX 23-NOV-2000.
 PD

XX	17-MAY-2000; 200WO-US013576.
PF	
PF	
XX	
XX	
PR	17-MAY-1999; 99US-0134406P.

PR 10-SEP-1999; 3008-01594086.
 PR 15-OCT-1999; 9905-0159783P.
 XX
 (CONJ-) CONJUCHEM INC.
 PA

xx Bridon DP, Ezrin AM, Milner PG, Holmes DL, Thibodeau K;
 PI
 xx WPI: 2001-112059/12.
 DR

XX Modifying and attaching therapeutic peptides to albumin prevents
PT peptide degradation, useful for increasing length of in vivo activity.
XX
PS Disclosure: Page 702: 733pb: English.

The present invention describes a modified therapeutic peptide (I) comprising a therapeutically active amino acid region (iii) and a reactive group (ii) (e.g. succinimidyl and maleimido groups) attached to a less therapeutically active amino acid region (iv), which covalently bonds with amino/hydroxyl/thiol groups on blood components to form a peptide stabilised therapeutic peptide composed of 3-50 amino acids. (I) are useful for modifying therapeutic peptides e.g. hormones, growth factors and neurotransmitters, to protect them from peptidase activity *in vivo* for the treatment of various disorders. Endogenous therapeutic peptides are not suitable as drug candidates as they require frequent administration due to rapid degradation by peptidases in the body. Modifying and attaching therapeutic peptides to albumin prevents or reduces the action of peptidases to increase length of activity (half life) and specificity as bonding to large molecules decreases intracellular uptake and interference with physiological processes. AAB92441 to AAB92441 represent peptides which can be used in the

CC exemplification of the present invention
XX
Sequence 15 AA;
SQ

Query Match	100.0%	Score 77	DB 4	Length 15
Best Local Similarity	100.0%	Pred. No. 98-05		
Matches 15	Conservative 0	Mismatches 0	Indels 0	Gaps 0

Qy 1 RIORGRAFTIGK 15
| | | | | | | | | |
Db 1 RIORGRAFTIGK 15

RESULT 35
AAB92348
ID AAB92348 standard; peptide; 15 AA.

AA	
AC	AAB92348;
XX	
DT	22-JUN-2001 (first entry)

XX Virus related peptide SEQ ID NO:1524.
DE
XX
XX
KW Protection: endogenous therapeutic peptide; peptidase; conjugation;

XX Homo sapiens
OS
KW hydroxyl; thiol; hormone; growth factor; neurotransmitter.
KW blood component; modulation; succinimide; macromolecular group; amine;
KW

OS	Synthetic.
XX	
PN	WO200069900-A2.
YY	

PD 23-NOV-2000.
XX
PF 17-MAY-2000; 2000WO-US013576.
XX

PR 17-MAY-1999; 99US-0134406P.
PR 10-SEP-1999; 99US-0153406P.
PR 15-OCT-1999; 99US-0159783P.

PA (CONJ-) CONJUCHEM INC.
XX
PI Bridon DP, Ezrin AM, Milner PG, Holmes DL, Thibadeau K;

DR WPI; 2001-112059/12.
XX
PT Modifying and attaching therapeutic peptides to albumin prevents

XX
PS Disclosure; Page 703; 733pp; English.
XX

comprising a therapeutically active amino acid region (III) and a reactive group (II) (e.g. succinimidyl and maleimido groups) attached to a less therapeutically active amino acid region (IV), which covalently bonds with amino/hydroxyl/thiol groups on blood components to form a peptidase stabilised therapeutic peptide composed of 3-50 amino acids. (I) are useful for modifying therapeutic peptides e.g. hormones, growth factors and neurotransmitters, to protect them from peptidase activity *in vivo* for the treatment of various disorders. Endogenous therapeutic peptides are not suitable as drug candidates as they require frequent administration due to rapid degradation by peptidases in the body. Modifying and attaching therapeutic peptides to albumin prevents or reduces the action of peptidases to increase length of activity (half life) and specificity as bonding to large molecules decreases intracellular uptake and interference with physiological processes. AAB90829 to AAB92441 represent peptides which can be used in the exemplification of the present invention

Sequence 15 AA;

Query Match	100.0%	Score 77;	DB 4;	Length 15;
Best Local Similarity	100.0%	Pred. No. 9e-05;		

```
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRGPGRAFTVIGK 15
   |||||
Db 1 RIQRGPGRAFTVIGK 15

RESULT 36
AAB68601
ID AAB68601 standard; peptide; 15 AA.
AC AAB68601;
KW HIV gp120 V3 loop peptide #1.
KW HIV gp120 V3 loop; liposome composition; HIV infection.
XX Human immunodeficiency virus 1.
OS US6180134-B1.
PN 30-JAN-2001.
PD 07-JUN-1995; 95US-00480332.
PF 23-MAR-1993; 93US-00035443.
PR 29-SEP-1994; 94US-00316436.
XX (SEQU-) SEQUUS PHARM INC.
PI Zalipsky S, Woodle MC, Martin FJ, Barenholz Y;
XX WPI; 2001-201897/20.
XX
PT Liposome composition for use in treating septic shock comprises liposomes
PT having an outer surface layer of polyethylene glycol chains, and a
PT polypeptide or polysaccharide effector molecule.
XX Disclosure; Fig 13; 32pp; English.
XX
CC The present invention relates to a liposome composition comprising
CC liposomes having an outer surface layer of polyethylene glycol chains,
CC each having a free distal end. A polypeptide or polysaccharide effector
CC molecule is covalently attached to a portion of the distal ends. The
CC effector interferes with specific binding of pathogen or cell in a
CC bloodstream to a target cell or cell matrix, and is rapidly removed by
CC renal clearance from the bloodstream when administered in free form. The
CC liposome composition may be used in treating a condition mediated by
CC binding a pathogen or cell in the bloodstream, to a target cell or cell
CC matrix. It can be used in treating septic shock, toxic shock, colonic
CC inflammation, leukaemic cell proliferation, or HIV infection. The present
CC sequence is a peptide of the V3 loop of HIV envelope protein gp120. This
CC peptide may be used in the composition of the present invention. gp120
CC binds to the CD4 receptor during HIV infection of lymphocytes. By
CC introducing the present peptide, the CD4 receptors are blocked, thereby
CC inhibiting HIV infection. (Updated on 11-SEP-2003 to standardise OS
CC field)
XX
SQ Sequence 15 AA;
Query Match 100.0%; Score 77; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. No. 9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRGPGRAFTVIGK 15
   |||||
Db 1 RIQRGPGRAFTVIGK 15

RESULT 37
AAB68601
ID AAB68601 standard; peptide; 15 AA.
AC AAB68601;
KW HIV gp120 V3 loop peptide #1.
KW HIV gp120 V3 loop; liposome composition; HIV infection.
XX Human immunodeficiency virus 1.
OS US6180134-B1.
PN 30-JAN-2001.
PD 07-JUN-1995; 95US-00480332.
PF 23-MAR-1993; 93US-00035443.
PR 29-SEP-1994; 94US-00316436.
XX (SEQU-) SEQUUS PHARM INC.
PI Zalipsky S, Woodle MC, Martin FJ, Barenholz Y;
XX WPI; 2001-201897/20.
XX
PT Liposome composition for use in treating septic shock comprises liposomes
PT having an outer surface layer of polyethylene glycol chains, and a
PT polypeptide or polysaccharide effector molecule.
XX Disclosure; Fig 13; 32pp; English.
XX
CC The present invention relates to a liposome composition comprising
CC liposomes having an outer surface layer of polyethylene glycol chains,
CC each having a free distal end. A polypeptide or polysaccharide effector
CC molecule is covalently attached to a portion of the distal ends. The
CC effector interferes with specific binding of pathogen or cell in a
CC bloodstream to a target cell or cell matrix, and is rapidly removed by
CC renal clearance from the bloodstream when administered in free form. The
CC liposome composition may be used in treating a condition mediated by
CC binding a pathogen or cell in the bloodstream, to a target cell or cell
CC matrix. It can be used in treating septic shock, toxic shock, colonic
CC inflammation, leukaemic cell proliferation, or HIV infection. The present
CC sequence is a peptide of the V3 loop of HIV envelope protein gp120. This
CC peptide may be used in the composition of the present invention. gp120
CC binds to the CD4 receptor during HIV infection of lymphocytes. By
CC introducing the present peptide, the CD4 receptors are blocked, thereby
CC inhibiting HIV infection. (Updated on 11-SEP-2003 to standardise OS
CC field)
XX
SQ Sequence 15 AA;
Query Match 100.0%; Score 77; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. No. 9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRGPGRAFTVIGK 15
   |||||
Db 1 RIQRGPGRAFTVIGK 15

RESULT 38
AAU96031
ID AAU96031 standard; protein; 15 AA.
XX
```

```
AAE15743
ID AAE15743 standard; peptide; 15 AA.
XX
AC AAE15743;
XX
DT 26-MAR-2002 (first entry)
XX
DE Human immunodeficiency virus (HIV) p18 peptide.
XX
KW HIV; human immunodeficiency virus; cytostatic; immunosuppressive; p18;
KW virucide; antibacterial; fungicide; protozoacide; antirheumatic; vaccine;
KW antiinflammatory; antiarthritic; neuroprotective; rheumatoid arthritis;
KW cancer; multiple sclerosis; immune response; vasotropic; gene therapy;
KW autoimmune disease; vasculitis.
XX
OS Human immunodeficiency virus.
XX
FN WO200176643-A1.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-US011372.
XX
PR 07-APR-2000; 2000US-0195680P.
XX
PA (BAYU) BAYLOR COLLEGE MEDICINE.
XX
PI Orson FM, Kinsey BM, Bhogal BS;
XX
XX WPI; 2002-066308/09.
XX
PT Composition for oral delivery of vaccines, comprises expression vector
PT containing antigenic genomic sequence, bound to aggregated protein-
PT polycationic polymer conjugate or suspension.
XX
XX Example 10; Page 30; 145pp; English.
XX
CC The invention relates to a composition comprising an expression vector
CC bound to an aggregated protein-polycationic polymer conjugate or
CC suspension. The expression vector contains a promoter polynucleotide
CC sequence operatively linked to a polynucleotide sequence encoding an
CC antigen which is a fragment of a gene or genome associated with an
CC infectious disease, cancer and autoimmune disease such as rheumatoid
CC arthritis, vasculitis, and multiple sclerosis, pathogenic genomes
CC consisting of bacterium, fungus, protozoa and virus such as human
CC immunodeficiency virus (HIV), herpes simplex virus (HSV), hepatitis C
CC virus (HCV), influenza and respiratory syncytial virus (RSV), and
CC optionally comprising a nucleotide sequence encoding a cytokine (or a
CC cytokine expression vector), is useful for inducing an immune response
CC (systemic and/or mucosal) in an organism. The cytokine expression vector
CC contains a sequence for granulocyte macrophage-colony stimulating factor
CC (GM-CSF) or interleukin-12 (IL-12). The polynucleotide sequences encoding
CC the antigen and the cytokine are under transcriptional control of same or
CC different promoter polynucleotide sequences. The expression vector, as a
CC DNA vaccine is useful for treating a condition in an organism. The
CC present sequence is human immunodeficiency virus (HIV) p18 peptide,
CC related to the invention
XX
SQ Sequence 15 AA;
Query Match 100.0%; Score 77; DB 5; Length 15;
Best Local Similarity 100.0%; Pred. No. 9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRGPGRAFTVIGK 15
   |||||
Db 1 RIQRGPGRAFTVIGK 15

RESULT 39
AAU96031
ID AAU96031 standard; protein; 15 AA.
XX
```


XX The invention relates to a recombinant nucleic acid comprising a nucleic
 CC acid sequence encoding an antigen containing two or more cytolytic T
 CC lymphocyte (CTL) epitopes or its analogues. Sequences of the invention
 CC are used in vaccines and are useful for the treatment and prophylaxis of
 CC human immunodeficiency virus (HIV) infection, particularly acquired
 CC immune deficiency syndrome (AIDS). The invention is also useful in gene
 CC therapy. The present sequence is HIV CTL epitope. This sequence is used
 CC in the exemplification of the invention
 XX
 SQ Sequence 15 AA;
 Query Match 100.0%; Score 77; DB 6; Length 15;
 Best Local Similarity 100.0%; Pred. No. 9e-05;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQRGPGRAFTVIGK 15
 Db 1 RIQRGPGRAFTVIGK 15
 RESULT 43
 ADN14074
 ID ADN14074 standard; peptide; 15 AA.
 AC ADN14074;
 XX
 XX 17-JUN-2004 (first entry)
 DT
 XX HIV helper T cell epitope #41.
 DE
 XX HIV; antigen; epitope; T cell; MHC; major histocompatibility complex;
 KW CTL; cytotoxic T lymphocyte; HIV infection; cancer; tuberculosis; tumour;
 KW hepatitis; melanoma; breast cancer; Hodgkin lymphoma;
 KW nasopharyngeal carcinoma; vaccine; immune response; hyaluronic acid; HA;
 KW CD8+ T cell; CD4+ T cell; viral infection; bacterial infection;
 KW fungal infection; parasitic infection.
 XX
 OS Human immunodeficiency virus 1.
 XX
 XX US2003049253-A1.
 PN
 XX 13-MAR-2003.
 PD
 XX 05-FEB-2002; 2002US-00062710.
 PF
 XX 08-AUG-2001; 2001US-0310498P.
 PR
 XX (LIFQ/) LI F Q.
 PA (CHUY/) CHU Y.
 PA (QIUJ/) QIU J.
 XX
 XX Li FQ, Chu Y, Qiu J;
 PI
 XX WPI; 2003-540464/51.
 DR
 XX Modulating an immune system response to an antigen in a mammal, comprises
 PT administering a particle-free therapeutic comprising a hyaluronic acid
 PT polymer analogue covalently linked to a peptide that comprises a T cell
 PT epitope.
 XX
 XX Disclosure; Page 12; 23pp; English.
 XX
 CC The invention relates to modulating an immune system response to an
 CC antigen in a mammal comprising administering to the mammal a particle-
 CC free therapeutic comprising a hyaluronic acid (HA) polymer analogue
 CC covalently linked to at least one peptide that comprises a T cell epitope
 CC recognised by a major histocompatibility complex molecule of the mammal.
 CC The T cell epitope comprises a sequence of at least about eight amino
 CC acids of the antigen. Also included are a method of improving major
 CC histocompatibility complex (MHC) presentation of a T cell epitope of an
 CC antigen in a mammal (comprising administering to the mammal the
 CC conjugate). The T cell epitope is recognised by a major

CC histocompatibility complex (MHC) Class I molecule and by a CD8+ T cell of
 CC the mammal, or an MHC Class II molecule and a CD4+ T cell of the mammal.
 CC The immune system response comprises a cytotoxic T lymphocyte, a CD4+T
 CC cell, or an antibody that recognises the antigen. The immune system
 CC response to the antigen is increased after administration of the
 CC conjugate, where the antigen is an antigen of a pathogenic agent or a
 CC tumour cell. The immune system response to the antigen is decreased after
 CC administration of the conjugate, where the antigen is an antigen of a
 CC tissue or organ transplanted to the mammal. The composition and methods
 CC are useful for modulating, i.e. enhancing or diminishing, an immune
 CC system response to an antigen in a mammal. The composition is also useful
 CC for improving major histocompatibility complex presentation of a T cell
 CC epitope of an antigen in a mammal. The polymeric hyaluronic acid
 CC conjugates are useful as peptide vaccines against an antigen, a
 CC pathogenic agent such as viral, bacterial, fungal or parasitic protein,
 CC or a tumour cell) in a mammal. The peptide vaccine compositions are
 CC useful for treating or preventing diseases associated with any of the
 CC antigens above e.g. HIV infection, cancer, tuberculosis, hepatitis,
 CC melanoma, breast cancer, Hodgkin's lymphoma and nasopharyngeal carcinoma.
 CC The peptide vaccine compositions of the present invention do not require
 CC additional adjuvants, but still induce a stronger cell-mediated response
 CC than peptide vaccines of the prior art. The present sequence is an HIV-1
 CC derived epitope suitable for the vaccine of the invention.
 XX
 SQ Sequence 15 AA;
 Query Match 100.0%; Score 77; DB 7; Length 15;
 Best Local Similarity 100.0%; Pred. No. 9e-05;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQRGPGRAFTVIGK 15
 Db 1 RIQRGPGRAFTVIGK 15
 RESULT 44
 ADR04041
 ID ADR04041 standard; peptide; 15 AA.
 AC ADR04041;
 XX
 XX 04-NOV-2004 (first entry)
 DT
 XX Immune response induction composition peptide adjuvant #2.
 DE
 XX vaccine; viricide; antibacterial; immunosuppressive; antiallergic;
 KW cytostatic; peptide adjuvant.
 KW
 XX Synthetic.
 OS
 XX WO2004067020-A1.
 PN
 XX 12-AUG-2004.
 PD
 XX 30-JAN-2004; 2004WO-KR000177.
 PF
 XX 30-JAN-2003; 2003KR-00006393.
 PR
 XX (UYPO-) UNIV POHANG SCI & TECHNOLOGY.
 PA (GENE-) GENEXINE CO LTD.
 XX
 XX Park K, Park S, Yang S, Lee C, Choi S, Ryu S, Kim Y, Sung Y;
 PI
 XX WPI; 2004-580853/56.
 DR
 XX New vaccine composition comprising a peptide adjuvant and a DNA vaccine
 PT encoding an immunogenic protein, useful for inducing immune responses
 PT against diseases e.g. HIV infection, autoimmune diseases, tuberculosis or
 PT allergies.
 XX
 XX Example 2; Page 21; 37pp; English.
 PS
 XX The present invention relates to a vaccine composition comprising a

CC peptide adjuvant and a DNA vaccine encoding an immunogenic protein. The
CC composition may also comprise a gene of the influenza virus, preferably
CC the neuraminidase gene. The vaccine composition is useful for inducing
CC immune responses against diseases comprising HIV infection, herpes
CC simplex virus (HSV) infection, influenza virus infection, hepatitis A or
CC B infection, papillomavirus infection, tuberculosis, tumour growth,
CC autoimmune diseases or allergies. The present sequence is a peptide
CC adjuvant useful in the composition of the invention.

XX Sequence 15 AA;

Query Match 100.0%; Score 77; DB 8; Length 15;
Best Local Similarity 100.0%; Pred. No. 9e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQPGGGRFAFTVIGK 15
|||
Db 1 RIQPGGGRFAFTVIGK 15
|||

RESULT 45

AAR24939
ID AAR24939 standard; protein; 16 AA.

XX AAR24939;

XX 25-MAR-2003 (revised)
DT 09-DEC-1992 (first entry)
XX
XX
XX HIV peptide ENV 312-327.

XX Lipopeptide; lipoprotein; vaccine; cytotoxic T-cell; lymphocyte; HIV;
KW human immunodeficiency virus; AIDS; cancer; tumour cells; CB1; CB2; CB3.

XX Synthetic.

XX EP491628-A2.

XX 24-JUN-1992.

XX 18-DEC-1991; 91EP-00403446.

XX 18-DEC-1990; 90FR-00015870.

XX (INSP) INST PASTEUR LILLE.

PA (INRM) INSERM INST NAT SANTE & RECH MED.

PA (INSP) INST PASTEUR.

XX Boutillon C, Martinon F, Sergheraert C, Magne R, Gras-Masse H;

PI Gonnard E, Tartar A, Levy JP;

XX WPI; 1992-209776/26.

XX Lipopeptide(s) which stimulate cytotoxic T-cells - for treating HIV,
PT parasitic infections and cancer.

XX Example; Page 18; 32pp; French.

XX The sequence is that of peptide ENV 312-327 derived from the HIV, it is
CC made by standard methods of solid phase peptide synthesis. It is used as
CC part of lipoproteins CB1, CB2 and CB3 which comprise the peptide, and one
CC or more chains derived from 10-20C fatty acids and/ or modified steroid
CC groups, these being coupled to alpha or epsilon amino groups of the
CC peptide. The lipoproteins are useful in vaccines and acts by inducing
CC cytotoxic T lymphocytes against the HIV virus antigen from which the
CC peptide is derived. See also AAR24938 and AAR24940. (Updated on 25-MAR-
CC 2003 to correct PN field.)

XX Sequence 16 AA;

Query Match 100.0%; Score 77; DB 2; Length 16;
Best Local Similarity 100.0%; Pred. No. 9.5e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQPGGGRFAFTVIGK 15
|||
Db 2 RIQPGGGRFAFTVIGK 16
|||

RESULT 46

AAW68326
ID AAW68326 standard; peptide; 16 AA.

XX AAW68326;

XX 25-MAR-2003 (revised)

DT 14-OCT-1998 (first entry)

XX MHC binding peptide ENV.312-327.

XX Antigen; major histocompatibility complex; MHC; lymphocyte; detection;
KW immobilisation; cytotoxic T-cell; tumour; leukaemia; lymphoma;
KW viral infection.

XX Synthetic.

OS Human immunodeficiency virus 1.

XX WO9744667-A2.

XX 27-NOV-1997.

XX 21-MAY-1997; 97WO-FR000892.

XX 21-MAY-1996; 96US-00651925.

XX (INSP) INST PASTEUR.

PA (INRM) INSERM INST NAT SANTE & RECH MEDICALE.

XX Langladedemoyen P, Lone Y, Kourilsky P, Abastado J;

XX WPI; 1998-018653/02.

XX Detection, purification and elimination of antigen-specific lymphocytes -
PT for producing cytotoxic T cells for immuno-therapy of cancers and viral
PT infection.

XX Disclosure; Page 27; 222pp; French.

XX Peptides AAW68301-W68384 are examples of antigens (Ag) which can be
CC loaded onto recombinantly produced major histocompatibility complex (MHC)
CC molecules in a method of detecting antigen-specific lymphocytes. The MHC-
CC antigen complex is then immobilised on a solid support and a sample
CC containing cells recognising the MHC-Ag complex may be isolated. This
CC peptide is derived from amino acids 312-327 of the human immunodeficiency
CC virus type 1 (HIV-1) env protein. A similar method is used to isolate,
CC purify or eliminate Ag-specific T-cells or to produce Ag-specific
CC cytotoxic T-cells (CTC). The method is also used to detect and quantify
CC tumour-specific T-cells and to generate CTC for specific killing of
CC tumour cells (solid tumours, leukaemia or lymphoma) by injection into a
CC human or animal, but also for treating viral infections. (Updated on 25-
CC MAR-2003 to correct PI field.)

XX Sequence 16 AA;

Query Match 100.0%; Score 77; DB 2; Length 16;
Best Local Similarity 100.0%; Pred. No. 9.5e-05;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQPGGGRFAFTVIGK 15
|||
Db 2 RIQPGGGRFAFTVIGK 16
|||

RESULT 47

AAV68203
ID AAV68203 standard; peptide; 16 AA.

```
XX AC AAY68203;
XX DT 12-SEP-2003 (revised)
XX DT 13-APR-2000 (first entry)
XX DE
XX DE Altered MHC determinant binding peptide SEQ ID NO:35.
XX KW MHC class I; major histocompatibility complex; microglobulin; antigen;
XX KW immune response; immunisation; AIDS; multiple sclerosis; toxic shock;
XX KW cancer; lupus erythematosus; snake bite; cytostatic; antiviral;
XX KW immunomodulatory; dermatological; immunosuppressive; antiinflammatory;
XX KW neuroprotective.
XX OS Human immunodeficiency virus 1.
XX OS US6011146-A.
XX PN
XX PD 04-JAN-2000.
XX PF 07-JUN-1995; 95US-00481985.
XX PR 15-NOV-1991; 91US-00792473.
XX PR 05-DEC-1991; 91US-00801818.
XX XX
XX PA (INSP ) INST PASTEUR.
XX PA (INRM ) INST NAT SANTE & RECH MEDICALE.
XX PI Kourilsky P, Mottez E, Abastado J;
XX PI WPI; 2000-125951/11.
XX DR
XX PT New recombinant DNA encoding covalently linked form of major
XX PT histocompatibility complex Class I determinant, used for immune system
XX PT stimulation, e.g. for treating cancer.
XX PS Disclosure; Col 11; 88pp; English.
XX CC
XX CC The present invention describes a recombinant DNA molecule (I) containing
XX CC a sequence (Ia) that encodes an altered MHC (major histocompatibility
XX CC complex ) Class I determinant (II) comprises a polypeptide with alpha1,
XX CC alpha2, alpha3 and beta2-microglobulin domains, in which alpha3 and beta2
XX CC are covalently linked, thorough C- and N-termini respectively, via a
XX CC nucleotide spacer sequence encoding a polypeptide. (II) includes an
XX CC antigen-binding site and when (II) and the antigen are associated they
XX CC are recognized by a mammalian T cell receptor (TCR). (I) are used to
XX CC produce (II) which are used to study functional interactions between the
XX CC various MHC domains. They can also be used to modulate (in vivo or in
XX CC vitro) the immune system by inducing an effector response (cytotoxicity,
XX CC antibody synthesis, phagocytosis) of immune system cells, typically for
XX CC treating, or immunising against; cancer, acquired immune deficiency
XX CC syndrome, lupus erythematosus, multiple sclerosis, toxic shock and snake
XX CC bite, but also for selective destruction of autoreactive cells,
XX CC diagnostically to assay T cell receptors and to raise specific antibodies
XX CC (useful for diagnosis, therapy, studying MHC-associated cellular
XX CC processes and for affinity purification). AAZ57558 and AAY68186 to
XX CC AAY68316 are sequences used in the exemplification of the present
XX CC invention. (Updated on 12-SEP-2003 to standardise OS field)
XX SQ Sequence 16 AA;
XX Query Match 100.0%; Score 77; DB 3; Length 16;
XX Best Local Similarity 100.0%; Pred. No. 9.5e-05;
XX Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX QY 1 RIQGPGRFAFTVIGK 15
XX DB |||||||||||
XX 2 RIQGPGRFAFTVIGK 16
XX RESULT 48
XX AAY52857
XX ID AAY52857 standard; peptide; 16 AA.
```

```
XX AC AAY52857;
XX DT 14-FEB-2000 (first entry)
XX DE
XX DE Altered MHC determinant binding peptide SEQ ID NO:35.
XX KW Major histocompatibility complex; MHC class I; MHC class II; antigen;
XX KW immune response; diagnosis; antibody; immunisation; autoimmune disease;
XX KW acquired immune deficiency syndrome; AIDS; cytostatic; antithyroid;
XX KW anti-inflammatory; neuroprotective; immunosuppressive; antithyroid;
XX KW vaccine; lupus erythematosus; multiple sclerosis; thyroiditis;
XX KW toxic shock; tumour; snakebite.
XX OS Synthetic.
XX OS Human immunodeficiency virus 1.
XX PN US5976551-A.
XX PD 02-NOV-1999.
XX PF 07-JUN-1995; 95US-00484905.
XX PR 15-NOV-1991; 91US-00792473.
XX PR 05-DEC-1991; 91US-00801818.
XX XX
XX PA (INSP ) INST PASTEUR.
XX PA (INRM ) INSERM INST NAT SANTE & RECH MEDICALE.
XX PI Kourilsky P, Mottez E, Abastado J;
XX PI WPI; 2000-037081/03.
XX DR
XX PT Composition containing an antigen and altered major histocompatibility
XX PT Class II determinant, used to immunize against autoimmune diseases, e.g.
XX PT acquired immune deficiency syndrome.
XX XX
XX PS Claim 8; Col 11; 96pp; English.
XX CC
XX CC The present invention describes a composition capable of eliciting anti-
XX CC major histocompatibility (MHC) antibodies. The composition comprises an
XX CC antigen associated with an altered MHC Class II determinant (I)
XX CC comprising alpha1, alpha2, beta1 and beta2 polypeptide domains encoded by
XX CC a mammalian MHC Class II locus covalently linked to form a polypeptide
XX CC (I) containing beta2, alpha2, alpha1 and beta1 domains in sequence. The
XX CC resulting Antigen-MHC complex is recognizable by the T cell receptor. The
XX CC compositions are used for immunisation against, or treatment of, a wide
XX CC range of autoimmune diseases, e.g. acquired immune deficiency syndrome
XX CC (AIDS), lupus erythematosus, multiple sclerosis, thyroiditis, toxic
XX CC shock, tumour and snakebite, depending on the nature of antigen. (I) is
XX CC also used to analyse functional interactions between the various domains
XX CC and for targeting lymphocyte receptors. Antibodies against (I) are
XX CC produced by usual methods of immunisation or cell fusion, and may be
XX CC humanised by standard methods. These antibodies are useful for diagnosis
XX CC (detection or purification of MHC gene products), therapy (neutralising
XX CC MHC on cell surfaces) and in the study of MHC and cellular processes. In
XX CC the exemplification of the present invention
XX SQ Sequence 16 AA;
XX Query Match 100.0%; Score 77; DB 3; Length 16;
XX Best Local Similarity 100.0%; Pred. No. 9.5e-05;
XX Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX QY 1 RIQGPGRFAFTVIGK 15
XX DB |||||||||||
XX 2 RIQGPGRFAFTVIGK 16
XX RESULT 49
XX AAY58618
XX ID AAY58618 standard; peptide; 16 AA.
```

XX AC AAB58618;
 XX DT 11-SEP-2003 (revised)
 XX DT 13-MAR-2001 (first entry)
 XX DE Altered MHC determinant binding peptide #17.
 XX KW Major histocompatibility complex; MHC class I; immune; snake bite;
 XX KW T cell mediated autoimmune disease; AIDS; lupus erythematosus;
 XX KW toxic shock.
 XX OS Human immunodeficiency virus; type 8.
 XX PN US6153408-A.
 XX PD 28-NOV-2000.
 XX PF 09-JAN-1995; 95US-00370476.
 XX PR 15-NOV-1991; 91US-00792473.
 XX PR 05-DEC-1991; 91US-00801818.
 XX PR 07-JUN-1993; 93US-00072787.
 XX PR 07-SEP-1993; 93US-00117575.
 XX PA (INSP) INST PASTEUR.
 XX PA (INRM) INST NAT SANTE & RECH MEDICAL.
 XX PI Abastado J, Kourilsky P, Casrouge A, Ojcius D, Lone Y, Mottez E;
 XX WPI; 2001-060089/07.
 XX New altered major histocompatibility complex (MHC) class I determinant
 PT useful for eliciting an immune response and/or for immunizing against or
 PT treating diseases, for example, multiple sclerosis, AIDS, toxic shock or
 PT snake bite.
 XX PS Disclosure; Col 11; 105pp; English.
 XX The present invention relates to a major histocompatibility complex (MHC)
 CC class I determinant, which has alpha 1 alpha 2 alpha 3 and beta2-
 CC microglobulin polypeptide domains encoded by a mammalian MHC class I
 CC locus. The MHC class I determinants are useful for activating the immune
 CC system and presenting antigens to the immune system to elicit an
 CC antigenic response. The MHC class I determinants are also useful for
 CC treating diseases, e.g. T cell mediated autoimmune disease, AIDS, lupus
 CC erythematosus, toxic shock or snake bite. The altered MHC class I
 CC determinants and compositions containing antigens bound to the
 CC determinants are useful in diagnostic applications, e.g. altered
 CC determinants may be used to target lymphocyte receptors and the resulting
 CC bound determinant can be assayed. (Updated on 11-SEP-2003 to standardise
 CC OS field)
 XX SQ Sequence 16 AA;
 XX Query Match 100.0%; Score 77; DB 4; Length 16;
 XX Best Local Similarity 100.0%; Pred. No. 9.5e-05;
 XX Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQRPGRFAFTICK 15
 DB |||||||||||
 2 RIQRPGRFAFTICK 16
 RESULT 50
 AAR42057
 ID AAR42057 standard; peptide; 17 AA.
 XX AC AAR42057;
 XX 25-MAR-2003 (revised)
 XX DT 29-APR-1994 (first entry)
 XX

DE Peptide CG-P18 from HIV-1 IIIB env protein V3 loop.
 XX Human Immunodeficiency Virus type 1; envelope protein; immunogen;
 KW vaccine; AIDS; peptide P18; epitope.
 XX OS Synthetic.
 XX Key Location/Qualifiers
 FH Peptide 3.17
 FT /label= P-18
 FT /note= "the Cys-Gly dipeptide is opt. absent"
 XX WO9319775-A1.
 XX 14-OCT-1993.
 XX 25-MAR-1993; 93WO-US002978.
 XX 31-MAR-1992; 92US-00860707.
 XX (MEDI-) MEDIMMUNE INC.
 XX (USSA) US DEPT ARMY.
 XX Alving CR, Cassatt D, Koenig S, Wassef N, White W;
 XX WPI; 1993-336590/42.
 XX Inducing cytotoxic T lymphocyte response to HIV - with liposome contg.
 PT peptide or protein having CTL epitope of HIV and protein, also improving
 PT humoral immunity, useful in vaccines.
 XX Claim 4; Page 16; 25pp; English.
 XX Peptide P-18, opt. with a Cys-Gly dipeptide attached at its N-terminus,
 CC is the pref. peptide for use in raising a cytotoxic T lymphocyte response
 CC against HIV. The peptide is encapsulated in a liposome for admin.
 CC (Updated on 25-MAR-2003 to correct PN field.)
 XX SQ Sequence 17 AA;
 XX Query Match 100.0%; Score 77; DB 2; Length 17;
 XX Best Local Similarity 100.0%; Pred. No. 0.0001;
 XX Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQRPGRFAFTICK 15
 DB |||||||||||
 3 RIQRPGRFAFTICK 17
 RESULT 51
 AAY40414
 ID AAY40414 standard; peptide; 17 AA.
 XX AC AAY40414;
 XX 25-NOV-1999 (first entry)
 XX Lipopeptide comprising a fragment of the HIV env protein.
 KW Lipopeptide; antigen; cytotoxic T lymphocyte; steroid; vaccine;
 KW HIV related condition; tumor cell; NP protein.
 XX Synthetic.
 XX Human immunodeficiency virus 1.
 XX Key Location/Qualifiers
 FH Modified-site 1
 FT /note= "amidated residue"
 FT Modified-site 17
 FT /note= "this residue is -NH-CHR-CO-NH2, where R is a C14
 FT side chain"
 XX EP945461-A1.

```

XX PD 29-SEP-1999.
XX PF 18-DEC-1991; 99EP-00105773.
XX PR 18-DEC-1990; 90FR-00015870.
XX PR 18-DEC-1991; 91EP-00403446.
XX PA (INSP ) INST PASTEUR LILLE.
XX PA (INRM ) INSERM INST NAT SANTE & RECH MEDICALE.
XX PI Boutillon C, Martinon F, Sergheraert C, Magne R, Gras-Masse H;
XX PI Gonnard E, Tartar A, Levy J;
XX DR WPI; 1999-553128/47.
XX PT New lipopeptide inducers of cytotoxic T lymphocytes, useful as vaccine
XX PT against cancers, viruses, parasites and HIV-related conditions.
XX PS Example 4; Page 19; 35pp; French.
XX CC The specification describes lipopeptide that comprise a partial peptide
XX CC containing 10-40 amino acids and at least one antigenic determinant
XX CC specific for cytotoxic T lymphocytes. The lipopeptide comprises at least
XX CC one 10-20 carbon fatty acid derivatives and/or at least one modified
XX CC steroid group. The lipopeptides are useful for: the preparation of a
XX CC vaccine against HIV related conditions; immunizing a human or animal
XX CC against an antigen by inducing cytotoxic T-lymphocytes; immunizing a
XX CC human or animal against tumor cells; and immunizing human or animal
XX CC against pathogens (especially a virus e.g. HIV-1 and HIV-2, or
XX CC parasites). The present sequence represents a lipopeptide of the
XX CC invention, and comprises part of the HIV env protein
XX SQ Sequence 17 AA;
Query Match 100.0%; Score 77; DB 2; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.0001;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 RIQGGPGRAFTVIGK 15
Db 2 RIQGGPGRAFTVIGK 16
RESULT 52
AAR31277
ID AAR31277 standard; peptide; 18 AA.
AC AAR31277;
DT 12-FEB-1993 (first entry)
DE HIV principal determinant peptide.
KW AIDS; ARC; human immunodeficiency virus; vaccine; Neisseria;
KW meningitidis b; outer membrane protein complex; OMPC; PND135-18.
XX Synthetic.
XX OS
XX Key Location/Qualifiers
XX FT Modified-site 1
XX FT /note= "bonds to the OMPC of the conjugate via this site"
XX PN EP467700-A.
XX PD 22-JAN-1992.
XX PF 19-JUL-1991; 91EP-00306598.
XX PR 19-JUL-1990; 90US-00555339.
XX PR 19-JUL-1990; 90US-00555966.
XX PR 19-JUN-1991; 91US-00715276.
XX PR 19-JUN-1991; 91US-00715278.

```

```

XX PA (MERI ) MERCK & CO INC.
XX PI Leanza WJ, Marburg S, Tolman RL, Emini EA;
XX DR WPI; 1992-026505/04.
XX PT Conjugate proteins comprising HIV peptide components - useful for
XX PT preparing vaccines for e.g. AIDS or for treating infections.
XX PS Claim 12; Page 56; 63pp; English.
XX CC The invention relates to a co-conjugate comprising an immunogenic protein
XX CC or protein complex having a first set of covalent linkages to low
XX CC molecular weight moieties which have an anionic or polyanionic character
XX CC at physiological pH, and a second set of covalent linkages to peptides
XX CC comprising HIV principal neutralizing determinants (PND's) or
XX CC immunologically equivalent peptides. Preferably at least one set of the
XX CC covalent linkages is comprised of maleimide derivatives; the
XX CC (poly)anionic moiety is composed of one to five residues of the anionic
XX CC form of a carboxylic, sulphonic or phosphonic acid; the immunogenic
XX CC protein is the outer membrane protein complex (OMPC) of Neisseria
XX CC meningitidis b; and the PND peptide has a linear structure, a disulphide-
XX CC bonded cyclic structure, an amide-bonded cyclic structure or a thioether-
XX CC of a PND peptide component used in the co-conjugate. The co-conjugate is
XX CC useful for inducing anti-peptide immune response in mammals, for inducing
XX CC HIV-neutralizing antibodies in mammals, for formulating vaccines to
XX CC prevent HIV infection or disease, including AIDS, or for treating humans
XX CC afflicted with HIV infection or disease
XX SQ Sequence 18 AA;
Query Match 100.0%; Score 77; DB 2; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.00011;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 RIQGGPGRAFTVIGK 15
Db 1 RIQGGPGRAFTVIGK 15
RESULT 53
AAR30032
ID AAR30032 standard; peptide; 18 AA.
XX AC AAR30032;
XX DT 25-MAR-2003 (revised)
XX DT 28-APR-1993 (first entry)
XX DE HIV principle neutralising determinant 135-18.
XX KW Human immunodeficiency virus; AIDS; PND; MIEP; conjugate;
XX KW major immune enhancing protein; vaccine; anti-HIV antibodies; immunogen;
XX KW passive immunisation.
XX OS
XX OS Human immunodeficiency virus.
XX PN EP519554-A1.
XX XX 23-DEC-1992.
XX PF 11-JUN-1992; 92EP-00201693.
XX PF 19-JUN-1991; 91US-00715273.
XX PR 19-JUN-1991; 91US-00715273.
XX PA (MERI ) MERCK & CO INC.
XX PI Emini A, Liu MA, Marburg S, Tolman RL;
XX PR WPI; 1992-425771/52.
XX

```

PT Conjugates of HIV-1 PND peptide(s) with the MIEP of *Neisseria*
PT meningitidis - useful as a vaccine for treating and preventing HIV-1
PT infection, e.g. AIDS in humans.
XX
PS Claim 9; Page 59; 66pp; English.
XX
CC The peptide is HIV principle neutralising determinant (PND) 135-18 and is
CC used as part of a conjugate comprising the major immune enhancing protein
CC (MIEP) of *Neisseria meningitidis* covalently linked to the HIV PND. The
CC conjugate may be used to prepare vaccines against HIV infections, e.g.
CC AIDS, as research tools for studying PND structure-function
CC relationships, or as immunogens for use in the passive immunisation of
CC humans. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 18 AA;
Query Match 100.0%; Score 77; DB 2; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.00011;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RIQRGPGRAFTVIGK 15
Db 1 RIQRGPGRAFTVIGK 15
RESULT 54
AAR26713
ID AAR26713 standard; peptide; 18 AA.
AC AAR26713;
XX
DT 09-FEB-1993 (first entry)
XX
DE HIV-PND-polysaccharide-protein conjugate vaccine.
XX
KW Human immunodeficiency virus; principal neutralizing determinant;
KW outer membrane protein complex; OMPC; *Neisseria*; AIDS; PND-135-18.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 1
FT /note= "Joins onto polysaccharide-protein complex via
FT this site"
XX
PN EP468714-A.
XX
PD 29-JAN-1992.
XX
PF 19-JUL-1990; 90US-00555558.
XX
PR 19-JUL-1990; 90US-00555558.
PR 19-JUL-1990; 90US-00555974.
PR 19-JUN-1991; 91US-00715275.
PR 19-JUN-1991; 91US-00715277.
XX
PA (MERI) MERCK & CO INC.
XX
PI Marburg S, Tolman RL, Emini EA;
XX
DR WPI; 1992-034437/05.
XX
FT HIV peptide-polysaccharide-protein conjugates - used in vaccines or to
FT produce antibodies to prevent or treat HIV infection.
XX
PS Claim 9; Page 57; 63pp; English.
XX
CC The invention relates to a conjugate of an HIV principal neutralizing
CC determinant (PND), or an immunologically equivalent peptide (PEP),
CC covalently coupled to an immunogenic protein or protein complex through
CC an anionic polysaccharide linker. Pref. the immunogenic protein is the
CC outer membrane protein complex (OMPC) of *Neisseria meningitidis* b and the
CC PND peptide has a linear structure, a disulphide-bonded cyclic structure,

CC an amide-bonded cyclic structure or a thioether-bonded cyclic structure.
CC The present sequence (PND135-18) is an example of a PND peptide
CC component. The conjugates are used for inducing HIV-neutralising
CC antibodies or for making vaccines to prevent contraction of HIV infection
CC or disease. The antibodies can be used for passively protecting against
CC infection by HIV, or for protecting against proliferation of HIV post-
XX infection, or for treating AIDS, or in diagnostic assays
XX
SQ Sequence 18 AA;
Query Match 100.0%; Score 77; DB 2; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.00011;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RIQRGPGRAFTVIGK 15
Db 1 RIQRGPGRAFTVIGK 15
RESULT 55
AAR44190
ID AAR44190 standard; peptide; 18 AA.
XX
AC AAR44190;
XX
DT 24-OCT-2003 (revised)
DT 25-MAR-2003 (revised)
DT 20-MAY-1994 (first entry)
XX
DE gp120 V3 loop antigen B2.
XX
KW Antigen; B2; third variable domain; V3 loop; gp120; HIV-1; vaccine;
KW strain IIB; multiple antigenic peptide system; dendritic core;
KW lipophilic membrane anchoring group; mammal; humoral; immunisation;
KW cytotoxic T cell; CT; immune response; infection; Freund's adjuvant;
KW pathogen; HIV; influenza; malaria.
XX
OS Human immunodeficiency virus 1.
XX
PN WO9322343-A1.
XX
PD 11-NOV-1993.
XX
PF 03-MAY-1993; 93WO-US004179.
XX
PR 01-MAY-1992; 92US-00877613.
XX
PA (UYRQ) UNIV ROCKEFELLER.
XX
PI Tam JP;
XX
DR WPI; 1993-368723/46.
XX
FT New multiple antigen system esp. for use in HIV vaccines - contains
FT lipophilic membrane anchor imparting adjuvant activity, and peptide
FT antigens coupled to dendritic core.
XX
PS Example 3; Page 27; 55pp; English.
XX
CC The sequence given in AAR44190 is a peptide antigen, B2, which represents
CC residues 312-329 of the third variable domain (V3 loop) of gp120, of HIV-
CC 1 strain IIB. This sequence was attached to an amino acid linker (see
CC also AAR44191) in the production of a multiple antigenic peptide system.
CC This system comprises a dendritic core to which are covalently attached
CC at least one peptide, eg. an antigenic peptide, and a lipophilic membrane
CC anchoring group. This system may be injected into a mammal and elicits
CC both humoral and cytotoxic T cell (CTL) immune responses. This system may
CC be used to immunise against HIV infection. The lipophilic membrane
CC anchoring group provides efficient adjuvant activity without the toxicity
CC problems of Freund's adjuvant, while the dendritic structure allows
CC multiple antigens to be attached. Optionally the antigens may be derived
CC from different pathogens, providing vaccines which protect against more
CC than one disease, eg. HIV, influenza and malaria. (Updated on 25-MAR-2003

```
CC to correct PN field.) (Updated on 24-OCT-2003 to standardise OS field)
XX
SQ Sequence 18 AA;

  Query Match      100.0%; Score 77; DB 2; Length 18;
  Best Local Similarity 100.0%; Pred. No. 0.00011;
  Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGPGRAFTVIGK 15
Db 4 RIQPGGPGRAFTVIGK 18

RESULT 56
AAR58548
ID AAR58548 standard; peptide; 18 AA.
XX
AC AAR58548;
XX
DT 16-OCT-2003 (revised)
DT 25-MAR-2003 (revised)
DT 29-MAR-1995 (first entry)
XX
DE HIV-1 isolate IIIB V3 loop domain.
XX
KW HIV-1; V3 loop; multiple epitope; AIDS; vaccine; MEAV; Escherichia coli;
KW PKK-MEAV.
XX
OS Human immunodeficiency virus 1.
XX
PN WO9418234-A1.
XX
PD 18-AUG-1994.
XX
PF 10-FEB-1994; 94WO-US001523.
XX
PR 10-FEB-1993; 93US-00015770.
XX
PA (UNBI-) UNITED BIOMEDICAL INC.
XX
PI Shen DF, Wang CY;
XX
WPI; 1994-279687/34.
XX
New recombinant proteins contg multiple antigenic determinants - linked
PT by flexible hinge domains.
XX
FS Disclosure; Page 36; 56pp; English.
XX
MEAV gene (AAQ70535) encodes a portion of the CD4 binding domain
(AAR58550) of HIV env protein, the domain being capable of inducing a
helper T- cell response, and 5 peptide domains from the V3 loop of HIV-1
isolates MN, SC, RF, IIB and WMJ2 (AAR58545-49), each peptide being
separated by a spacer domain (AAR58551). The gene was expressed in E.
coli BL21/pKK-MEAV for preparation of a multiple epitope AIDS vaccine
(AAR58552). (Updated on 25-MAR-2003 to correct PN field.) (Updated on 16-
OCT-2003 to standardise OS field)
XX
SQ Sequence 18 AA;

  Query Match      100.0%; Score 77; DB 2; Length 18;
  Best Local Similarity 100.0%; Pred. No. 0.00011;
  Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGPGRAFTVIGK 15
Db 4 RIQPGGPGRAFTVIGK 18

RESULT 57
ABB83113
ID ABB83113 standard; peptide; 18 AA.
XX
```

```
AC ABB83113;
XX
DT 05-AUG-2002 (first entry)
XX
DE Lipopeptide #2 used in a vaccine.
XX
KW Lipopeptide; cytostatic; virucide; anti-HIV; antiparasitic; vaccine;
KW immunisation; tumour; pathogen; virus; antiviral.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 1 /label= Xaa
FT /note= "Xaa is optionally 2-acetyl-amino-hexadecanoyl, 2,4
FT -bis(hexadecanoylamino)butyryl, or not present"
FT Modified-site 18 /label= Xaa
FT /note= "Xaa is optionally 2-amino-hexadecanoamide or N-
FT epsilon-hexadecanoyl-Lys"
XX
PN EP1065212-A2.
XX
PD 03-JAN-2001.
XX
PF 18-DEC-1991; 2000EP-00117513.
XX
PR 18-DEC-1990; 90FR-00015870.
PR 18-DEC-1991; 91EP-00403446.
PR 18-DEC-1991; 99EP-00105773.
XX
PA (INSP ) INST PASTEUR LILLE.
PA (INRM ) INSERM INST NAT SANTE & RECH MEDICALE.
XX
PI Boutillon C, Martinon F, Sergheraert C, Magne R, Gras-Masse H;
PI Gomard B, Tartar A, Levy J;
XX
WPI; 2001-114040/13.
XX
DR Vaccine for immunization against tumor cells or pathogens, especially
PT HIV, comprising peptide part, antigenic determinant specifically inducing
PT cytotoxic T-lymphocytes and N-palmitoyl-lysine-derived chain(s).
XX
PS Example 4; Page 17; 31pp; French.
XX
CC The present sequence is a lipopeptide, which can be used for the
CC immunisation of humans or animals against tumour cells or pathogens,
CC specifically viruses, especially HIV-1 or HIV-2. The pathogens may also
CC include parasites. Examples illustrate immunisation of mice against
CC influenza, as well as HIV. The lipopeptide, with the appropriate
CC antigenic determinants, can induce a strong cytotoxic T-lymphocyte
CC response in a host organism against a wide range of pathogens. Addition
CC of an adjuvant is unnecessary
XX
SQ Sequence 18 AA;

  Query Match      100.0%; Score 77; DB 4; Length 18;
  Best Local Similarity 100.0%; Pred. No. 0.00011;
  Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGPGRAFTVIGK 15
Db 3 RIQPGGPGRAFTVIGK 17

RESULT 58
AAR60203
ID AAR60203 standard; protein; 20 AA.
XX
AC AAR60203;
XX
DT 27-AUG-2003 (revised)
DT 25-MAR-2003 (revised)
```

DT 13-MAR-1995 (first entry)
 XX HIV gp110 V3 loop molecular tag.
 DE
 KW fusion protein; recombinant bispecific single chain antibody;
 KW human immunodeficiency virus; glycoprotein gp110; V3 loop.
 OS Human immunodeficiency virus.
 XX
 PN EP610046-A2.
 XX
 PD 10-AUG-1994.
 XX
 PF 31-JAN-1994; 94EP-00300692.
 XX
 PR 01-FEB-1993; 93US-00013420.
 PR 13-SEP-1993; 93US-00121054.
 XX
 PA (BRIM) BRISTOL-MYERS SQUIBB CO.
 XX
 PI Ledbetter JA, Gilliland LK, Hayden MS, Linsley PS, Bajorath J;
 PI Fell PH;
 XX
 DR WPI; 1994-250885/31.
 XX
 XX Expression vector encoding bispecific fusion protein - having binding
 PT domains for separate targets joined by helical peptide, useful e.g. for
 PT diagnosis and treatment.
 XX
 PS Example 1; Page 12; 50pp; English.
 XX
 CC A molecular tag was created by annealing two complementary 76mer
 CC oligonucleotides with cohesive end overhangs. AAQ70167 is the sense
 CC strand and includes a BclI overhang, the HIV gp110 V3 loop coding
 CC sequence and a stop codon. The peptide encoded by the molecular tag
 CC (AAE60203), when part of a single chain fusion protein with binding
 CC regions from different antibodies, affected the avidity and binding
 CC specificity of the antibodies. For example, the tag failed to function
 CC properly when fused to I6 but performed successfully when fused to CD3.
 CC (Updated on 25-MAR-2003 to correct PN field.) (Updated on 27-AUG-2003 to
 CC correct OS field.)
 XX
 SQ Sequence 20 AA;
 Query Match 100.0%; Score 77; DB 2; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.00012;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQRGPGRAFTVIGK 15
 |||||
 DB 5 RIQRGPGRAFTVIGK 19
 |||||
 RESULT 59
 AAW54930
 ID AAW54930 standard; peptide; 20 AA.
 XX
 AC AAW54930;
 XX
 XX 25-SEP-1998 (first entry)
 DT
 DE HIV gp120 envelope protein, peptide 127, analogue 127h'.
 XX
 KW Immunoadsorbent; immunoassay; HIV gp120; immunogen; antibody; Human.
 XX
 OS Human immunodeficiency virus.
 XX
 PN US5763160-A.
 XX
 PD 09-JUN-1998.
 XX
 PF 07-JUN-1995; 95US-00488252.
 XX

PR 12-FEB-1988; 88US-00155321.
 PR 01-MAR-1991; 91US-00663262.
 PR 09-JUL-1991; 91US-00726605.
 PR 19-OCT-1994; 94US-00326676.
 XX
 PA (UNBI-) UNITED BIOMEDICAL INC.
 XX
 XX Wang CY;
 XX
 DR WPI; 1998-347301/30.
 XX
 PT HIV gp120 peptides - useful as immunoassay reagents or vaccine
 PT components.
 XX
 PS Example 8; Column 21/22; 34pp; English.
 XX
 CC Peptides AAW54903-W54941 can be used as an immunoassay in an
 CC immunoassay for detecting antibodies to HIV gp120, or as an immunogen for
 CC eliciting antibodies to HIV in a mammal
 XX
 SQ Sequence 20 AA;
 Query Match 100.0%; Score 77; DB 2; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.00012;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQRGPGRAFTVIGK 15
 |||||
 DB 6 RIQRGPGRAFTVIGK 20
 |||||
 RESULT 60
 ADR18886
 ID ADR18886 standard; peptide; 20 AA.
 XX
 AC ADR18886;
 XX
 DT 04-NOV-2004 (first entry)
 XX
 DE HIV-1 V3-IIIB related peptide SEQ ID NO:37.
 XX
 KW three-dimensional atomic structural conformation;
 KW protein co-ordinate data; V3 loop peptide; HIV-1; envelope glycoprotein;
 KW gp120; human monoclonal antibody 447-52D;
 KW murine monoclonal antibody 0.5 beta; immunogen; immunogenic;
 KW V3 loop epitope; HIV-1 infectivity inhibitor; anti-HIV; vaccine;
 KW HIV-1 infection.
 XX
 OS Human immunodeficiency virus 1.
 OS Synthetic.
 XX
 PN WO2004069863-A2.
 XX
 PD 19-AUG-2004.
 XX
 PF 04-FEB-2004; 2004WO-US003304.
 XX
 PR 04-FEB-2003; 2003US-0444682P.
 XX
 XX (UUNY) UNIV NEW YORK STATE.
 PA (YEDA) YEDA RES & DEV CO LTD.
 XX
 XX Anglister J, Sharon M, Schapira M, Zolla-Paznar S, Rosen O;
 XX WPI; 2004-625447/60.
 DR
 XX
 PT Composition for inhibiting HIV-1 infection, comprises isolated peptide
 PT molecule that mimics atomic structural conformation of V3 loop peptide of
 PT HIV-1 envelope glycoprotein that is bound to, and constrained by human
 PT monoclonal antibody.
 XX
 PS Example 1; SEQ ID NO 37; 127pp; English.
 XX

CC The present invention describes a composition (C1) which comprises an
 CC isolated peptide molecule or isostere that mimics the three-dimensional
 CC (3D) atomic structural conformation of the V3 loop peptide of the HIV-1
 CC envelope glycoprotein gp120 that is bound to, and constrained by, human
 CC monoclonal antibody (MAb) 447-52D, murine MAb 0.5 beta or an antigen
 CC binding fragment of the MAb, where the constrained V3 loop peptide
 CC differs in conformation from the same V3 loop peptide when it is in free
 CC form. Also described: (1) identifying (M1) from several existing
 CC compounds a molecule that is useful as an HIV-1 V3 loop immunogen or as
 CC an inhibitor of binding of HIV-1 to a chemokine receptor/HIV-1 co-
 CC receptor on the surface of a receptor-bearing target cell; (2) designing
 CC a molecule that is useful as an HIV-1 V3 loop immunogen or as an
 CC inhibitor of binding of HIV-1 to a chemokine receptor/HIV-1 co-receptor
 CC on the surface of a receptor-bearing target cell; (3) a composition (C2)
 CC that is useful as an HIV-1 V3 loop immunogen or as an inhibitor of
 CC binding of HIV-1 to a chemokine receptor/HIV-1 co-receptor on the surface
 CC of a receptor-bearing target cell; (4) an immunogenic composition (C3)
 CC for induction of an anti-HIV-1 antibody response specific for a V3 loop
 CC epitope, comprising (C1) and an excipient; (5) a pharmaceutical
 CC composition (C4) useful for blocking the interaction of HIV-1 with an R5
 CC or X4 co-receptor and thereby inhibiting HIV-1 infectivity, comprising
 CC (C1) and a carrier or excipient; (6) a computing platform for generating
 CC a 3D model of a constrained HIV V3 view peptide; (7) a computer generated
 CC model representing the conformationally constrained structure of a V3
 CC loop peptide that is bound to 447-52D or 0.5beta MAb or its antigen
 CC binding fragments, comprising a 3D atomic structure defined by NC; and
 CC (8) a computer readable medium (CM) comprising, in a retrievable format,
 CC data that includes a set of structure coordinates defining a 3D structure
 CC of a V3 loop peptide that is conformationally constrained by being bound
 CC to 447-52D or 0.5beta MAb or its antigen binding fragment. (C1) has anti-
 CC HIV activities, and can be used in vaccines, and as an inhibitor of
 CC binding of HIV-1 to chemokine receptor/HIV-1 co-receptor. (C1) is useful
 CC for in vivo inhibition of HIV-1 infection. (C1) or (C2) is useful for
 CC producing a medicament utilised for treating or preventing HIV-1
 CC infection. (C3) or (C4) is useful for inducing in a subject an anti-HIV-1
 CC neutralising antibody response specific for a V3 loop epitope. (C4) is
 CC useful for preventing an HIV-1 infection in an uninfected subject at risk
 CC for such infection or for inhibiting viral spread and disease progression
 CC in an infected subject. The present sequence represents a peptide used in
 CC the exemplification of the present invention.

XX SQ Sequence 20 AA;

Query Match 100.0%; Score 77; DB 8; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.00012;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQGPGRGFAFTIGK 15
 |||||
 Db 6 RIQGPGRGFAFTIGK 20

RESULT 61
 AAR93073
 ID AAR93073 standard; peptide; 21 AA.

XX AAR93073;

XX 27-SEP-1996 (first entry)

XX Antigenic peptide CLTB73.

XX Antigen; non-infectious; retrovirus; antigenic marker; immune response;
 XX long terminal repeat; gag; pol; env; AIDS; HIV; antibody; therapy.

XX Synthetic.

XX WO9605292-A1.

XX 22-FEB-1996.

XX 15-AUG-1995; 95WO-CA000483.

XX

PR 15-AUG-1994; 94US-00290105.

PA (CONN-) CONNAUGHT LAB LTD.

PI Rovinski B, Cao S, Yao F, Persson R, Klein MH;

XX WPI; 1996-139690/14.

XX Antigenically marked non-infectious retrovirus-like particles - used to
 PT vaccinate against, and in the treatment of, AIDS and AIDS related
 PT conditions.

PS Example 4; Page 38; 75pp; English.

XX AAR93071-R93074 represent sequences used as antigenic marker epitopes in
 CC a non-infectious retrovirus-like particle of the invention. This sequence
 CC represents the antigenic peptide CLTB73. The retrovirus-like particle
 CC contains 1-4 repeats of this sequence (or AAR93061). The coding sequence
 CC for the retroviral particle of the invention comprises a modified
 CC retroviral genome deficient in long terminal repeats, but containing the
 CC gag, pol and env genes in their natural genomic arrangement, along with
 CC the antigenic marker sequence. The retroviral particle can be used in an
 CC immunogenic composition capable of eliciting a retroviral specific immune
 CC response. The composition is for parenteral or mucosal administration,
 CC preferably oral, anal, vaginal or intranasal administration. The
 CC composition can be used for immunising a host to produce a retroviral
 CC specific immune response, such as against AIDS and AIDS related
 CC conditions. The particles may also be used in the prophylactic (or
 CC curative) treatment of AIDS and related conditions, by acting to displace
 CC the binding of the HIV virus to human or animal cells, or by disrupting
 CC the 3-dimensional organisation of the virus. The particle can also be
 CC used to identify antibodies specifically reacting with retrovirus
 CC antigens

XX SQ Sequence 21 AA;

Query Match 100.0%; Score 77; DB 2; Length 21;

Best Local Similarity 100.0%; Pred. No. 0.00012;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQGPGRGFAFTIGK 15
 |||||
 Db 7 RIQGPGRGFAFTIGK 21

RESULT 62

AAR934475

ID AAR934475 standard; peptide; 21 AA.

XX AAR934475;

XX 11-MAY-1998 (first entry)

XX Acceptor peptide HIV-V3.

XX UDP-N-acetyl-alpha-D-galactosamine;
 KW polypeptide N-acetylgalactosaminyltransferase; GalNAc-t3; human;
 KW glycosylation; HIV-V3.

XX Synthetic.

XX Human immunodeficiency virus.

XX WO9743405-A1.

XX 20-NOV-1997.

XX 15-MAY-1997; 97WO-DK000226.

XX 15-MAY-1996; 96US-00648298.

XX (CLAU/) CLAUSEN H.

XX (BENN/) BENNETT E P.

XX

PI Clausen H, Bennett EP;
 XX WPI; 1998-008874/01.
 XX New isolated N-acetyl-galactosaminyl-transferase enzyme - used for the
 PT production of glycosylated polypeptide(s) having particular enzymatic,
 PT immunogenic or other biological or physical properties.
 XX
 PS Example 2; Page 30; 70pp; English.
 XX
 CC Acceptor peptides Muc2, Muc5c (see AAW34474) and HIV-V3 (see AAW34475)
 CC were used to study the acceptor substrate specificity of the novel human
 CC N-acetylgalactosaminyltransferase GalNac-T3 (see AAW34470). Expression of
 CC a soluble GalNac-T3 construct in Sf9 cells resulted in significant
 CC increases in GalNac-transferase activity in the culture medium of
 CC infected cells compared to uninfected controls or cells infected with the
 CC host-blood group O2 gene. GalNac-transferase activity with the Muc2
 CC acceptor peptide was increased 20-fold, and activity with the HIV-V3
 CC peptide was increased nearly 100-fold. In contrast, expression of GalNac-
 CC T1 and -T2 constructs only increased the GalNac-transferase activity
 CC toward Muc2 and Muc5C peptide substrates. This illustrates the unique
 CC acceptor substrate specificity of GalNac-T3. The enzyme is used in
 CC claimed methods for the glycosylation of peptides and proteins and for
 CC producing vaccines by modifying the O-glycosylation pattern of eukaryotic
 CC cells
 XX
 XX Sequence 21 AA;

Query Match 100.0%; Score 77; DB 2; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.00012;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRGFAFTVIGK 15
 |||||
 DB 3 RIQGPGRGFAFTVIGK 17

RESULT 63
 AAW75478
 ID AAW75478 standard; peptide; 21 AA.

XX AAW75478;
 XX 17-OCT-2003 (revised)
 DT 20-MAR-2003 (revised)
 DT 27-APR-1999 (first entry)
 XX
 DE HIV-1 strain HXB2 gp120 V3 loop peptide amino acids 302-322.
 XX
 KW V3 loop; gp120 protein; HIV-1; retrovirus-like particle; genome; HIV-2;
 KW long terminal repeat; LTR; chimeric; envelope; glycoprotein; HTLV-I;
 KW HTLV-II; vaccine; human T-lymphotropic virus.
 XX
 OS Human immunodeficiency virus 1.

XX US5866137-A.
 XX 02-FEB-1999.
 XX
 XX 30-MAY-1995; 95US-00453745.
 XX
 XX 15-JUN-1992; 92US-00839751.
 PR 09-JUN-1993; 93US-00073526.
 XX
 PA (CONN-) CONNAUGHT LAB LTD.

XX Klein MH, Cao SX, Haynes J, Rovinski B;
 XX WPI; 1999-141864/12.
 XX Immunogenic retrovirus-like particle - with chimeric HIV-1 envelope
 PT protein containing heterologous retroviral amino acid sequence.
 XX

PS Example 4; Col 7-8; 12pp; English.

XX This sequence represents a peptide from the V3 loop of the gp120 protein
 CC from the human immunodeficiency virus type 1 (HIV-1) strain HXB2. The
 CC peptide is used to determine antibody responses after immunisation with a
 CC self-assembled, non-infectious, non-replicating, immunogenic, retrovirus-
 CC like particle. The retrovirus-like particle comprises a modified HIV
 CC genome devoid of long terminal repeats (LTRs) and contains a nucleotide
 CC sequence coding for a chimeric envelope glycoprotein. The chimeric
 CC envelope glycoprotein has the HIV-1 gp120 conserved region 2 and a second
 CC retroviral envelope amino acid sequence from a heterologous strain of HIV
 CC -1, HIV-2, HTLV-I or HTLV-II inserted into the first retroviral envelope
 CC amino acid sequence (see AAW75474-W75477). The novel retrovirus-like
 CC particle is useful in vaccines against HIV. (Updated on 20-MAR-2003 to
 CC correct PA field.) (Updated on 17-OCT-2003 to standardise OS field)

XX Sequence 21 AA;

Query Match 100.0%; Score 77; DB 2; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.00012;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRGFAFTVIGK 15
 |||||
 DB 7 RIQGPGRGFAFTVIGK 21

RESULT 64

AAV16052
 ID AAV16052 standard; peptide; 21 AA.

XX AAV16052;
 XX 17-OCT-2003 (revised)
 DT 20-MAR-2003 (revised)
 DT 04-AUG-1999 (first entry)
 XX

DE HIV-1 isolate HXB2 gp120 peptide.

XX Retrovirus-like particle; modified HIV genome;
 KW chimeric envelope glycoprotein; HIV-1 gp120; conserved region 2; HIV-1;
 KW HIV-2; HTLV-I; HTLV-II; vaccine.

XX Human immunodeficiency virus 1.

XX US5912338-A.

XX 15-JUN-1999.

XX 30-MAY-1995; 95US-00452520.

XX 15-JUN-1992; 92US-00839751.

PR 09-JUN-1993; 93US-00073526.

XX (ROVI/) ROVINSKI B.

XX Cao SX, Klein MH, Haynes J, Rovinski B;

XX WPI; 1999-357220/30.

XX Immunogenic retrovirus like particles comprising modified HIV genomes,
 useful as vaccines against HIV.

XX Example 4; Col 9-10; 12pp; English.

XX The specification describes a nucleic acid molecule encoding a self
 CC assembled, non-infectious, non-replicating, immunogenic, retrovirus-like
 CC particle. The retroviral particle comprises a modified HIV genome devoid
 CC of long terminal repeats containing a nucleotide sequence coding for a
 CC chimeric envelope glycoprotein which has a first (a) and second (b)
 CC retroviral envelope amino acid sequence, where (a) contains the HIV-1
 CC gp120 conserved region 2, and (b) contains a retroviral envelope amino
 CC acid sequence of a heterologous strain of HIV-1, HIV-2, HTLV-I or HTLV-II

CC inserted into (a) at an endogenous site (BgIII and StuI). (b) may
 CC comprise peptides AAY16049-51 and AAY16055. The nucleic acids are useful
 CC as vaccines against HIV. The present sequence is used in the course of
 CC the invention. (Updated on 20-MAR-2003 to correct PR field.) (Updated on
 CC 17-OCT-2003 to standardise OS field)

XX SQ Sequence 21 AA;

Query Match 100.0%; Score 77; DB 2; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.00012;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGPGRAFTVIGK 15
 |||||
 Db 7 RIQPGPGRAFTVIGK 21

RESULT 65
 AAW85568
 ID AAW85568 standard; peptide; 21 AA.
 AC AAW85568;
 XX

XX 20-MAR-2003 (revised)
 DT 24-FEB-1999 (first entry)
 XX

XX Human immunodeficiency virus type 1 derived peptide.

XX Immunassay diagnostic kit; antibody detection;
 KW chimeric envelope protein; HIV-1 gp120 conserved region 2; HIV-1; HIV-2;
 KW HTLV-I; HTLV-II.

XX Synthetic.
 OS Human immunodeficiency virus 1.

XX US5849475-A.

PN 15-DEC-1998.

XX 30-MAY-1995; 95US-00452503.

XX 15-JUN-1992; 92US-00839751.

PR 09-JUN-1993; 93US-00073526.

XX (CONN-) CONNAUGHT LAB LTD.

XX Klein MH, Cao SX, Haynes J, Rovinski B;

XX WPI; 1999-069713/06.

XX Immunassay diagnostic kit for detecting antibodies - comprising chimeric
 PT retrovirus-like particles.

XX Example 4; Col 9-10; 12pp; English.

XX The present sequence represents a Human immunodeficiency virus type 1
 CC derived peptide. The peptide is used in the immunoassay diagnostic kit of
 CC the invention. The specification describes an immunoassay diagnostic kit
 CC for detecting antibodies in a sample, which comprises an antigen
 CC consisting of a self-assembled, non-infectious, non-replicating,
 CC immunogenic, retrovirus-like particle encoded by a modified HIV genome
 CC that is devoid of long terminal repeats and contains a nucleotide
 CC sequence coding for a chimeric envelope protein having a first amino acid
 CC sequence containing HIV-1 gp120 conserved region 2 and a second amino
 CC acid sequence containing an envelope sequence of a heterologous strain of
 CC HIV-1, HIV-2, HTLV-I or HTLV-II. (Updated on 20-MAR-2003 to correct PR
 CC field.) (Updated on 20-MAR-2003 to correct PA field.)

XX Sequence 21 AA;

Query Match 100.0%; Score 77; DB 2; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.00012;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGPGRAFTVIGK 15
 |||||
 Db 7 RIQPGPGRAFTVIGK 21

RESULT 66

AA15012
 ID AAB15012 standard; peptide; 21 AA.

XX AAB15012;
 AC AAB15012;

XX 07-DEC-2000 (first entry)

XX Peptide P18 derived from V3 loop of HIV IIIB group 120 protein.

XX HIV; immune; diphosphonate.

XX Human immunodeficiency virus.

XX WO200044758-A1.

PN 03-AUG-2000.

XX 01-FEB-2000; 2000WO-US002755.

XX 01-FEB-1999; 99US-0118131P.

XX (EISA) EISAI CO LTD.

XX Hawkins LD, Ishizaka ST, Lewis M, McGuinness P, Nault A, Rose J;

PI Rosignol DP;

XX WPI; 2000-514809/46.

XX New diphosphonate compounds, useful as immunological adjuvants for
 PT stimulating an immune response to an antigen.

XX Example 8; Page 86; 130pp; English.

XX The present invention relates to diphosphonate compounds useful as
 CC immunological adjuvants. The compounds can be used for stimulating an
 CC immune response to an antigen. The present sequence is an immunogenic
 CC peptide used to test the ability of the compounds to cause an increase in
 CC the immune response. The peptide consists of an amino terminal cysteine
 CC residue, a glycine/alanine/glycine spacer and amino acids 308-322 of the
 CC V3 loop of HIV IIIB gp120 protein

XX Sequence 21 AA;

Query Match 100.0%; Score 77; DB 3; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.00012;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGPGRAFTVIGK 15
 |||||
 Db 6 RIQPGPGRAFTVIGK 20

RESULT 67

AAU08699

ID AAU08699 standard; peptide; 21 AA.

XX AAU08699;
 AC AAU08699;

XX 18-DEC-2001 (first entry)

XX Retrovirus-like particle CLTB73 containing a V3 (HXB2) antigenic marker.

XX Human immunodeficiency virus; HIV; retroviral antigen; gag; pol; env;
 KW immune response; antigenic marker; antigenic epitope; retrovirus.

XX Human immunodeficiency virus.

OS Synthetic.
 PN US6291157-B1.
 XX
 PD 18-SEP-2001.
 XX
 PF 23-FEB-1998; 98US-00027955.
 XX
 PR 23-FEB-1998; 98US-00027955.
 XX
 PA (CONN-) CONNAUGHT LAB LTD.
 XX
 PI Rovinski B, Cao S, Yao F, Persson R, Klein MH;
 XX WPI; 2001-595518/67.
 DR
 XX Differentiating between infection by human immunodeficiency virus (HIV)
 PT and antiserum generated by immunization against HIV, comprises use of non
 PT infectious, non-replicating HIV-like particle with heterologous,
 PT antigenic anchor sequence.
 XX
 PS Disclosure; Col 17; 28pp; English.
 XX
 CC The invention relates to a method for determining the presence of
 CC antibodies specifically reactive with HIV retroviral antigens in a
 CC sample. This involves contacting a sample suspected of containing HIV-
 CC specific antibodies with a non-infectious, non-replicating, immunogenic
 CC HIV-like particle as an antigen. The antigen comprises an assembly of a
 CC gag gene product, a pol gene product and a modified env gene product
 CC containing a non-retroviral heterologous, antigenic, anchor sequence that
 CC replaces the endogenous anchoring functions of the env gene product. The
 CC method detects immune complex formation between HIV-specific antibodies
 CC and the antigens. The method is also useful for identifying antisera
 CC generated by immunisation with an immunogenic composition capable of
 CC eliciting HIV-specific immune response. The antigenic marker may comprise
 CC at least one antigenic epitope from another virus. This sequence
 CC represents a retrovirus-like particle containing an antigenic marker
 XX
 SQ Sequence 21 AA;
 Query Match 100.0%; Score 77; DB 4; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.00012;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQRGPGRAFTVIGK 15
 DB |||||
 7 RIQRGPGRAFTVIGK 21
 RESULT 68
 AAR42153
 ID AAR42153 standard; peptide; 22 AA.
 XX
 AC AAR42153;
 XX
 DT 24-OCT-2003 (revised)
 DT 25-MAR-2003 (revised)
 DT 27-APR-1994 (first entry)
 XX
 DE gp120 V3 loop sequence of HIV-1 IIIB isolate.
 XX
 KW Human Immunodeficiency Virus; antigen; ELISA; recombinant antibody;
 KW HIV-neutralising monoclonal antibody; immunoglobulin; AIDS;
 KW acquired immune deficiency syndrome; chimeric antibody;
 KW surface glycoprotein gp120; V3 loop; epitope mapping.
 XX
 OS Human immunodeficiency virus 1; (IIIB isolate).
 XX
 XX WO9319785-A1.
 PN
 XX 14-OCT-1993.
 PD
 XX 23-MAR-1993; 93WO-US002629.
 PF

XX 01-APR-1992; 92US-00861701.
 PR (MERI) MERCK & CO INC.
 PA
 XX Emini EA, Conley AJ, Mark GE, Johnson LS, Pfarr DS;
 PI
 XX WPI; 1993-336600/42.
 DR
 XX New recombinant human antibody - with HIV neutralising activity against
 PT at least two isolates, useful for preventing or treating infection in
 PT diagnosis, etc.
 PT
 XX Example 16; Page 100; 154pp; English.
 PS
 XX Antibodies able to neutralise more than one HIV-1 isolate are claimed.
 CC The gp120 V3 loop sequences from different isolates comprising the
 CC Principal Neutralising Determinant motif GPR are given in AAR42153-
 CC R42161. (Updated on 25-MAR-2003 to correct PN field.) (Updated on 24-OCT-
 CC 2003 to standardise OS field)
 XX
 SQ Sequence 22 AA;
 Query Match 100.0%; Score 77; DB 2; Length 22;
 Best Local Similarity 100.0%; Pred. No. 0.00013;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQRGPGRAFTVIGK 15
 DB |||||
 6 RIQRGPGRAFTVIGK 20
 RESULT 69
 AAR57470
 ID AAR57470 standard; protein; 22 AA.
 XX
 AC AAR57470;
 XX
 DT 25-MAR-2003 (revised)
 DT 21-MAR-1995 (first entry)
 XX
 DE HIV BRU V3 loop peptide.
 XX
 KW Immunisation; vaccine; therapy; prophylaxis; defective gene;
 KW non-functional gene; template; antisense; ribozyme; bupivacaine;
 KW human immunodeficiency virus; acquired immune deficiency syndrome; HIV;
 KW AIDS; ss.
 XX
 OS Synthetic.
 XX
 XX WO9416737-A1.
 PN
 XX 04-AUG-1994.
 PD
 XX 26-JAN-1994; 94WO-US000899.
 PF
 XX 26-JAN-1993; 93US-00008342.
 PR 11-MAR-1993; 93US-00029336.
 PR 15-JUL-1993; 93US-00093235.
 PR 21-SEP-1993; 93US-00124962.
 PR 21-SEP-1993; 93US-00125012.
 XX
 XX (WEIN/) WEINER D B.
 PA (WILL/) WILLIAMS W V.
 PA (WANG/) WANG B.
 PA (CONE/) CONEY L R.
 PA (MERV/) MERVIA M J.
 PA (ZURA/) ZURAWSKI V R.
 XX
 XX Weiner DB, Williams WV, Wang B, Coney LR, Merva MJ, Zurawski VR;
 PI WPI; 1994-263787/32.
 XX
 DR
 XX

PT Method for introducing genetic material into cells - utilises
PT polynucleotide function enhancer and nucleic acid free of retroviral
PT particles, e.g. HIV immunisation.
XX
XX Example 3; Page 44; 136pp; English.
XX
XX A genetic vaccine against HIV contains a DNA construct which comprises
CC the sequence encoding gp160. The genetic material was then introduced
CC into the cells of an individual by (a) contacting the individual's cells
CC with a polynucleotide function enhancer (bupivacaine) and (b)
CC administering to the cells the nucleic acid molecule free of retroviral
CC particles. Nucleic acid molecules which are delivered to cells may serve
CC as genetic templates for proteins that function as prophylactic and/or
CC therapeutic immunising agents; replacement copies of defective, missing
CC or non-functional genes; genetic templates for therapeutic proteins;
CC genetic templates for antisense molecules or as genetic templates for
CC ribozymes. This peptide was derived from the V3 loop of an HIV strain (an
CC epitope targetted by HIV neutralising antibodies) and was used to
CC determine whether the anti-gp160 antibodies elicited in mice immunised
CC with the genetic vaccine were reactive with this region. (Updated on 25-
CC MAR-2003 to correct PN field.)
XX
XX SQ Sequence 22 AA;

Query Match 100.0%; Score 77; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 0.00013;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRGPGRAFTVIGK 15
| | | | | | | | | | | | | | |
Db 8 RIQRGPGRAFTVIGK 22

RESULT 70
AAW07392
ID AAW07392 standard; peptide; 22 AA.
XX
AC AAW07392;
XX
DT 16-OCT-2003 (revised)
DT 24-FEB-1997 (first entry)
XX
XX HIV-1 strain IIIB gp120 V3 loop sequence.
XX
XX HIV-1; gp120; V3 loop; common consensus PND domain; envelop; CD4;
KW binding site; stem-loop; lysine branched peptide; AIDS.
XX
XX Human immunodeficiency virus 1.
XX
XX JP08231423-A.
XX
XX 10-SEP-1996.
XX
XX 27-FEB-1995; 95JJP-00038835.
XX
XX 27-FEB-1995; 95JJP-00038835.
XX
XX (TERU) TERUMO CORP.
XX (OKUD/) OKUDA K.
XX
XX WPI; 1996-461278/46.
XX
XX Novel AIDS vaccine - comprises branched lysine peptide fragments derived
PT from HIV env protein.
XX
XX Example 2; Page 5-6; 8pp; Japanese.
XX
XX This is the sequence of the V3 loop of the gp120 envelop protein from HIV
CC -1 strain IIIB. The sequence was used with a construct comprising part of
CC the HIV-1 gp120 V3 loop common consensus PND sequence (AAW07390) fused to
CC part of the HIV-1 CD4 binding site (AAW07391) and with the V3 loop
CC sequences from HIV-1 strains Thai B (AAW07393) or HGP-30 (AAW07394) to
CC generate a lysine branched peptide which is useful for the prevention and

CC treatment of AIDS. (Updated on 16-OCT-2003 to standardise OS field)
XX
XX SQ Sequence 22 AA;

Query Match 100.0%; Score 77; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 0.00013;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRGPGRAFTVIGK 15
| | | | | | | | | | | | | | |
Db 7 RIQRGPGRAFTVIGK 21

RESULT 71
AAW07488
ID AAY07488 standard; peptide; 22 AA.
XX
AC AAY07488;
XX
DT 17-OCT-2003 (revised)
DT 17-AUG-1999 (first entry)
XX
XX HIV-1 strain IIIB gp120 V3 loop sequence.
XX
XX Light chain; variable region; human; HIV-1; gp120; monoclonal antibody;
KW epitope; V3 loop; heterohybridoma; human immunodeficiency virus-1;
KW peripheral blood lymphocyte; Epstein-Barr virus; EBV; AIDS.
XX
XX Human immunodeficiency virus 1.
XX
XX US5914109-A.
XX
XX 22-JUN-1999.
XX
XX 21-NOV-1994; 94US-00345321.
XX
XX 15-JUN-1990; 90US-00538451.
XX 12-APR-1991; 91US-00684090.
XX 23-APR-1992; 92US-00872675.
XX
XX (UWNY) UNIV NEW YORK STATE.
XX
XX Gorny MK, Zolla-Pazner S;
XX
XX WPI; 1999-370481/31.
XX
XX Heterohybridoma producing human monoclonal antibodies to human
PT immunodeficiency virus-1.
XX
XX Example 5; Col 24; 42pp; English.
XX
XX This sequence represents the V3 loop from the gp120 protein of the human
CC immunodeficiency virus-1 (HIV-1) strain IIIB. The invention relates to
CC the generation of heterohybridomas producing human monoclonal antibodies
CC (see AAX79204-X79207) to a neutralising epitope of HIV-1 prepared by
CC transforming peripheral blood lymphocytes with Epstein-Barr virus. The
CC antibodies can be used to treat someone infected with HIV-1 or suffering
CC from AIDS. (Updated on 17-OCT-2003 to standardise OS field)
XX
XX SQ Sequence 22 AA;

Query Match 100.0%; Score 77; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 0.00013;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRGPGRAFTVIGK 15
| | | | | | | | | | | | | | |
Db 6 RIQRGPGRAFTVIGK 20

RESULT 72
AAW85137
ID AAY85137 standard; protein; 22 AA.

XX AAY85137;
 XX
 DT 12-SEP-2003 (revised)
 DT 20-JUN-2000 (first entry)
 XX
 DE HIV-1 IIIB V3 loop peptide sequence.
 XX
 KW Human immunodeficiency virus type 1; HIV-1; infection; prevent; detect;
 KW glycoprotein 140; gp140; neutralising antibody; conformational epitope;
 KW V3 loop.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN US6039957-A.
 XX
 PD 21-MAR-2000.
 XX
 PF 03-MAR-1997; 97US-00805889.
 XX
 PR 10-DEC-1993; 93US-00165314.
 XX
 PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX
 PI Doms RW, Moss B, Earl PL, Broder CC;
 XX
 DR WPI; 2000-270121/23.
 XX
 PT Producing neutralizing antibodies useful for preventing, treating and
 PT diagnosing an HIV infection in a mammal comprises administering
 PT recombinant uncleaved gp140 proteins to a human.
 XX
 PS Example 10; Col 12; 15pp; English.
 XX
 CC This sequence represents a human immunodeficiency virus type-1 IIIB V3-
 CC loop peptide sequence. The peptide sequence is used to test the
 CC reactivity of the antibodies of the invention. The invention relates to a
 CC method for the production of neutralising antibodies against
 CC conformational epitopes of HIV-1 envelope proteins in humans. The method
 CC comprises administering to a human, a recombinant uncleaved gp140 protein
 CC retaining its oligomeric structure. The human produces neutralising
 CC antibodies against conformational epitopes of the HIV-1 gp140 protein
 CC found on the oligomeric structure of the gp140. The anti-HIV-1 gp140
 CC antibodies of the invention can be used for preventing and diagnosing an
 CC HIV infection in a mammal. Gp140 antibodies are useful for treating an
 CC HIV infection. A diagnostic method using the antibodies involves
 CC isolating a body fluid, preferably blood, and contacting it with a
 CC labelled monoclonal antibody for gp140, and detecting any bound antibody.
 CC (Updated on 12-SEP-2003 to standardise OS field)
 XX
 SQ Sequence 22 AA;
 Query Match 100.0%; Score 77; DB 3; Length 22;
 Best Local Similarity 100.0%; Pred. No. 0.00013;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQGGPGRAFTVIGK 15
 Db |||||
 8 RIQGGPGRAFTVIGK 22
 RESULT 73
 ABU07537
 ID ABU07537 standard; peptide; 22 AA.
 XX
 AC ABU07537;
 XX
 DT 23-OCT-2003 (revised)
 DT 13-MAR-2003 (first entry)
 XX
 DE Human N-acetylgalactosaminyl transferase T4, Galnac T4, substrate #9.
 XX
 KW Galnac T4; N-acetylgalactosaminyl transferase T4; acceptor substrate;

glycosylation; mucin 1; MUC1; vaccine; antiinflammatory; Galnac-T1;
 Galnac-T2; Galnac-T3; HIV.
 XX
 OS Human immunodeficiency virus 1.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 1
 FT /label= OTHER
 FT /note= "Gln is acetylated"
 XX
 FN US6465220-B1.
 XX
 PD 15-OCT-2002.
 XX
 PF 21-DEC-1998; 98US-00217306.
 XX
 PR 21-DEC-1998; 98US-00217306.
 XX
 PA (GLYC-) GLYCOZYM APS.
 XX
 PI Hassan FH, Clausen H, Bennett EP, Eisenkraetzer D, Gaetgens J;
 XX
 DR WPI; 2003-147066/14.
 XX
 CC Glycosylating MUC1 acceptor substrate, by glycosylating substrate with N-
 CC acetylgalactosaminyltransferase T1, Galnac-T2 or Galnac-T3, then with
 CC human Galnac-T4 to glycosylate specific Ser, Thr residues in substrate.
 XX
 PS Example 6; Col 9; 10pp; English.
 XX
 CC The invention relates to glycosylating a MUC1 (mucin 1) acceptor
 CC substrate, comprising glycosylating the substrate with enzymatically
 CC active N-acetylgalactosaminyltransferase (Galnac)-T1, Galnac-T2 or Galnac
 CC -T3, or with Galnac capable of glycosylating MUC1 glycosylation sites
 CC that can be glycosylated by Galnac-T1, Galnac-T2 or Galnac-T3, and
 CC glycosylating the substrate with enzymatically active human Galnac-T4 to
 CC glycosylate specific Ser, Thr positions in the MUC1 substrate. The method
 CC is used for glycosylating an MUC1 acceptor substrate. The glycosylated
 CC substrates are useful in preparation of vaccines and antiinflammatory
 CC agents. Galnac-T4 exhibits a different substrate specificity than
 CC previously characterised Galnac transferases. The activity of Galnac-T4
 CC is unique and specific to glycosylate specific serine and threonine
 CC residues in MUC1 tandem repeat. The present sequence is an acceptor
 CC substrate peptide used to test the substrate specificity the human Galnac
 CC T4 protein, HIVIBgp120. (Updated on 23-OCT-2003 to standardise OS field)
 XX
 SQ Sequence 22 AA;
 Query Match 100.0%; Score 77; DB 6; Length 22;
 Best Local Similarity 100.0%; Pred. No. 0.00013;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQGGPGRAFTVIGK 15
 Db |||||
 3 RIQGGPGRAFTVIGK 17
 RESULT 74
 AAR04502
 ID AAR04502 standard; protein; 23 AA.
 XX
 AC AAR04502;
 XX
 DT 09-SEP-2004 (revised)
 DT 25-MAR-2003 (revised)
 DT 20-SEP-1990 (first entry)
 XX
 DE Cpd. eliciting, binding with neutralising antibodies to HIV variants.
 XX
 KW HIV; therapy; AIDS; principal neutralising domain; antibodies; diagnosis;
 KW prophylaxis.
 XX
 OS Synthetic.

Best Local Similarity 100.0%; Pred. No. 0.00014; Mismatches 0; Indels 0; Gaps 0;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGGPGRAFTVIGK 15
 DB 8 RIQGGPGRAFTVIGK 22

RESULT 77
 AAR07018
 ID AAR07018 standard; peptide; 24 AA.
 AC AAR07018;
 XX
 XX 24-OCT-2003 (revised)
 DT 18-JAN-1991 (first entry)
 XX
 XX Residues 301-324 of HIV gp 120 protein used in isolation of sulphated
 DE polysaccharide by affinity chromatography.
 XX
 XX HIV; AIDS; ARC; gp120; RP135.
 KW
 XX
 XX Human immunodeficiency virus 1.
 OS
 XX
 XX CA2007258-A.
 FN
 XX
 XX 11-JUL-1990.
 PD
 XX
 XX 05-JAN-1990; 90CA-02007258.
 PF
 XX
 XX 11-JAN-1989; 89US-00295856.
 PR
 XX 05-JUL-1989; 89US-00375795.
 PR
 XX (RICH) MERRELL DOW PHARM INC.
 PA
 XX Cardin AD, Jackson RL;
 PI
 XX
 XX WPI; 1990-290631/39.
 DR
 XX
 XX Prepn. of anti-HIV sulphated polysaccharide - by affinity chromatography
 PT using a resin-bound peptide corresp. to a HIV gp. 120 fragment.
 PT
 XX
 XX Disclosure; Page ?; 34pp; English.
 PS
 XX
 XX Anti-HIV sulphated polysaccharide (SPS) can prevent syncytium formation
 CC in HIV infected C4 cells. SPS may be isolated by affinity chromatography
 CC with the given resin bound peptide fragment RP135. (Updated on 24-OCT-
 CC 2003 to standardise OS field)
 CC
 XX
 XX Sequence 24 AA;

Query Match 100.0%; Score 77; DB 2; Length 24;
 Best Local Similarity 100.0%; Pred. No. 0.00014;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGGPGRAFTVIGK 15
 DB 8 RIQGGPGRAFTVIGK 22

RESULT 78
 AAR26565
 ID AAR26565 standard; peptide; 24 AA.
 AC AAR26565;
 XX
 XX 24-OCT-2003 (revised)
 DT 25-MAR-2003 (revised)
 DT 28-JAN-1993 (first entry)
 XX
 XX Sequence of peptide DB1 determined from the V3 principal neutralising
 DE domain (PND) region of HIV-1 strain HTLV-III B.
 XX

Diagnostic; assay; detection; AIDS; human immunodeficiency virus.
 Human immunodeficiency virus 1; strain HTLV-III B.
 WO9213882-A1.
 20-AUG-1992.
 29-JAN-1992; 92WO-EP000187.
 30-JAN-1991; 91IT-MI000220.
 (SUPE-) INST SUPERIORE DI SANITA.
 (CNDR) CONSIGLIO NAZ DELLE RICERCHE.
 De Rossi A, Pasti M, Mammano F, Panozzo M, Dettin M, Di Bello C;
 Chieco-Bianchi L;
 WPI; 1992-299983/36.
 Synthetic peptide(s) which enhance infectivity of HIV-1 in cellular
 cultures - are used for determining HIV-1 virus in blood and other
 biological materials.
 Claim 1; Page 17; 31pp; English.
 The principal neutralizing domain (PND) of HIV-1 corresp. to a 24- amino
 acid sequence arranged in a loop determined by a disulfide bridge in the
 third hypervariable region, V3, of the protein gp 120. The central
 portion of the V3-PND contains a sequence which is highly conserved in
 different HIV-1 isolated strains, whereas the amino acids flanking this
 sequence are variable. The antigenic properties of V3 region are known to
 be virus-specific; antibodies elicited by MN-derived peptide do not
 neutralize HTLV-III B virus and vice-versa. (Updated on 25-MAR-2003 to
 correct PN field.) (Updated on 25-MAR-2003 to correct PR field.) (Updated
 on 25-MAR-2003 to correct PA field.) (Updated on 24-OCT-2003 to
 standardise OS field)
 XX
 XX Sequence 24 AA;

Query Match 100.0%; Score 77; DB 2; Length 24;
 Best Local Similarity 100.0%; Pred. No. 0.00014;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGGPGRAFTVIGK 15
 DB 8 RIQGGPGRAFTVIGK 22

RESULT 79
 AAR29233
 ID AAR29233 standard; peptide; 24 AA.
 AC AAR29233;
 XX
 XX 25-MAR-2003 (revised)
 DT 14-APR-1993 (first entry)
 XX
 XX Heteroconjugate antibody immunogen RP135 (IIIB).
 XX
 XX V3 loop; gp41; envelope protein; MN; prototype; virus; variant; HIV;
 KW homology; heteroconjugate; enzyme; epitope mapping; replication;
 KW conjugate; immunogenic carrier; keyhole limpet hemocyanin; KLH;
 KW ovalbumin; succinyl maleimidomethyl cyclohexanecarboxylate; SMCC.
 XX
 XX Synthetic.
 OS
 XX
 XX Key Location/Qualifiers
 FH Misc-difference 24
 FT /note= "Not in the natural sequence of this isolate"
 XX
 XX WO9220373-A1.
 XX

PD 26-NOV-1992.
 XX
 PF 29-APR-1992; 92WO-US003616.
 XX
 PR 14-MAY-1991; 91US-00699773.
 XX
 PA (REPK) REPLIGEN CORP.
 XX
 PI Higgins PJ, Potts BJ;
 XX
 XX WPI; 1992-415475/50.
 DR
 XX Hetero-conjugate antibodies for treating HIV infections - comprise an
 XX antibody specific for an effector cell surface antigen and an antibody to
 PT a V3 loop of GP-120 envelope protein of HIV.
 XX
 PS Disclosure; Page 19; 69pp; English.
 XX
 CC The sequences given in AAR29226-35 represent peptides which were used as
 CC immunogens for the production of antibodies against HIV. These peptides
 CC may be either unconjugated or conjugated to an immunogenic carrier, eg. a
 CC keyhole limpet hemocyanin (KLH) or ovalbumin, using succinyl
 CC maleimidomethyl cyclohexanecarboxylate (SMCC) as a conjugating agent.
 CC Viruses containing these or similar sequences may be recognised by the
 CC heteroconjugate enzymes of the invention. The antibodies raised against
 CC these sequences may be identified by standard epitope mapping techniques.
 CC These antibodies are capable, even at low concentrations, of nearly
 CC eliminating viral replication of different strains of HIV. (Updated on 25
 CC -MAR-2003 to correct PN field.)
 XX
 SQ Sequence 24 AA;
 Query Match 100.0%; Score 77; DB 2; Length 24;
 Best Local Similarity 100.0%; Pred. No. 0.00014;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQRGPGRAFTVIGK 15
 |||||
 DB 8 RIQRGPGRAFTVIGK 22
 RESULT 80
 AAR26870
 ID AAR26870 standard; peptide; 24 AA.
 AC AAR26870;
 XX
 XX 25-MAR-2003 (revised)
 DT 20-MAY-1998 (first entry)
 XX
 XX HIV gp120 V3 region binding assay peptide IIIB.
 DE Human immunodeficiency virus; AIDS; anti-gp120 antibodies.
 KW
 OS Synthetic.
 XX
 XX EP503916-A1.
 XX
 PD 16-SEP-1992.
 XX
 PF 11-MAR-1992; 92EP-00302064.
 XX
 PR 11-MAR-1991; 91US-00668266.
 PR 06-MAR-1992; 92US-00894766.
 XX
 XX (IDEC-) IDEC PHARM CORP.
 XX
 XX Chang-Yuil K;
 PI
 XX WPI; 1992-309988/38.
 DR
 XX Anti-idiotypic antibodies and methods for their selection - useful as
 PT vaccines for the prevention and treatment of HIV infection.

XX Example; Page 9; 30pp; Japanese.
 XX
 CC The sequence is that of peptide IIIB, derived from the V3 region of HIV
 CC gp120, it was used in binding assays for anti-gp120 antibodies. The anti-
 CC gp120 antibodies are useful in vaccine formulations for the treatment or
 CC prevention of HIV infection. See also AAR26867-R26873. (Updated on 25-MAR
 CC -2003 to correct PN field.) (Updated on 25-MAR-2003 to correct PR field.)
 XX
 SQ Sequence 24 AA;
 Query Match 100.0%; Score 77; DB 2; Length 24;
 Best Local Similarity 100.0%; Pred. No. 0.00014;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQRGPGRAFTVIGK 15
 |||||
 DB 8 RIQRGPGRAFTVIGK 22
 RESULT 81
 AAR32406
 ID AAR32406 standard; peptide; 24 AA.
 XX
 AC AAR32406;
 XX
 XX 25-MAR-2003 (revised)
 DT 04-JUL-1993 (first entry)
 XX
 XX Sequence of peptide B1 which comprises AAs 308-331 from the V3 region of
 DE HIV-1 isolate IIIB.
 DE
 XX HIV-1; vaccine; dendritic core; ss.
 KW
 XX Synthetic.
 OS
 XX WO9303766-A1.
 XX
 XX 04-MAR-1993.
 XX
 PF 11-AUG-1992; 92WO-US006688.
 XX
 PR 13-AUG-1991; 91US-00744281.
 XX
 PA (REPK) REPLIGEN CORP.
 PA (UYRK) UNIV ROCKEFELLER.
 XX
 PI Tam JP, Profy AT;
 XX
 XX WPI; 1993-093730/11.
 DR
 XX New multiple antigen peptide(s) as HIV vaccines - include a dendritic
 PT core covalently bonded to peptide including the sequence IGPGR.
 XX
 PS Example; Fig 1; 35pp; English.
 XX
 CC Nine peptides from the V3 regions of HIV-1 isolates IIIB, RF and MN were
 CC incorporated into tetraivalent multiple antigen peptide systems (MAPS)
 CC (see AAR32406-14). Parallel groups of three peptides with chain lengths
 CC spanning from 11-24 residues were synthesised in MAPS format for each
 CC isolate. ELIS assays demonstrated that antisera titers in mice were
 CC closely related to the length of the IIIB peptide used for the
 CC immunisation - the longer the stronger the response. There was no
 CC substantial antibody prodn. in mice against the other two series of
 CC peptides, RF (B4-B6), and MN (B7-B9), except for a low reactivity in the
 CC gp. immunised with B8 (MN isolate). Specificity tests of the B cell
 CC response demonstrated that the T cell epitope (AAR32415) also serves as a
 CC B cell epitope. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 24 AA;
 Query Match 100.0%; Score 77; DB 2; Length 24;
 Best Local Similarity 100.0%; Pred. No. 0.00014;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIGK 15
 |||||
 Db 8 RIQRGPGRAFTVIGK 22

RESULT 82
 AAR33190
 ID AAR33190 standard; peptide; 24 AA.
 AC AAR33190;
 XX
 XX 25-MAR-2003 (revised)
 DT 11-JUL-1993 (first entry)
 XX
 XX Sequence of HIV-1 derived V3 loop peptide.
 DE
 XX AIDS; HIV; therapy; autoimmune disease; gp120; ss.
 KW
 XX Synthetic.
 OS
 XX W09303762-A1.
 PN
 XX W09303762-A1.
 PD
 XX 04-MAR-1993.
 XX
 PF 10-AUG-1992; 92WO-AU000423.
 XX
 PR 13-AUG-1991; 91AU-00007725.
 XX
 XX (BIOT-) BIOTECH AUSTRALIA PTY LTD.
 PA
 XX (SVIN-) ST VINCENT'S HOSPITAL SYDNEY LTD.
 XX
 PI Geczy AF, Russell-Jones GJ, Bell SJD, Cooper DA;
 XX
 DR WPI; 1993-093727/11.
 XX
 XX Compens. contg. E.coli outer membrane proteins TraT, OmpA or OmpF -
 PT increase immune response and are used for treating autoimmune diseases,
 PT AIDS, cancer etc.
 XX
 PS Example; Page 13; 36pp; English.
 XX
 CC Two peptides, gp41[8] and V3 loop derived from the gp120 region of HIV-1
 CC were synthesised and purified. To improve the solubility of the gp41[8]
 CC peptide the sequence RSS was added to the amino terminal to produce
 CC peptide R-S-Sgp41[8]. The immunodominant HIV-derived peptides were used to
 CC ascertain whether E.coli outer membrane protein TraT augments the in
 CC vitro T-cell proliferative responses. (Updated on 25-MAR-2003 to correct
 CC PN field.)
 XX
 SQ Sequence 24 AA;

Query Match 100.0%; Score 77; DB 2; Length 24;
 Best Local Similarity 100.0%; Pred. No. 0.00014; Indels 0; Gaps 0;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIGK 15
 |||||
 Db 8 RIQRGPGRAFTVIGK 22

RESULT 84
 AAR44191
 ID AAR44191 standard; peptide; 24 AA.
 AC AAR44191;
 XX
 XX 25-MAR-2003 (revised)
 DT 20-MAY-1994 (first entry)
 XX
 XX gp120 V3 loop antigen B2 and lipophilic membrane anchoring group.
 DE
 XX Antigen; B2; third variable domain; V3 loop; gp120; HIV-1; vaccine;
 KW strain IIIB; multiple antigenic peptide system; dendritic core;
 KW lipophilic membrane anchoring group; mammal; humoral; immunisation;
 KW cytotoxic T cell; CT; immune response; infection; Freund's adjuvant;
 KW pathogen; HIV; influenza; malaria.
 XX
 XX Human immunodeficiency virus 1.
 OS Synthetic.
 OS
 XX Key Location/Qualifiers
 XX Peptide 1. .18
 FT Peptide /label= B2 antigenic peptide
 FT Peptide 19. .24

XX gp120; HIV-1; cytotoxic T-lymphocyte; CTL; T-helper; AIDS; infection.
 KW Human immunodeficiency virus 1.
 OS
 XX W09310816-A1.
 PN
 XX 10-JUN-1993.
 XX
 PD 02-DEC-1992; 92WO-US010378.
 PF
 XX 02-DEC-1991; 91US-00800932.
 PR
 PR 16-SEP-1992; 92US-00945865.
 XX
 XX (TEXA) UNIV TEXAS SYSTEM.
 PA
 XX Sastry JK, Arlinghaus RB, Platsoucas CD, Nehete PN;
 PI WPI; 1993-196739/24.
 XX
 DR Peptide composition for treating and preventing viral infections -
 PT comprise CTL-inducing epitope and HIV infection-inhibiting sequence or T
 PT helper cell-inducing sequence.
 XX
 PS Claim 19; Page 95; 130pp; English.
 XX
 CC HIV gp120 V3 loop-derived peptides (AAR38170-87) are successful in
 CC generating CTL responses, esp. peptide R15K (AAR38187); the T-helper cell
 CC -inducing peptide includes the sequence C15A (AAR38164); HIV infection-
 CC inhibiting peptides are given in AAR38188-206, and are esp. peptides
 CC R15K, N24G, E13V, R8K, T13Q and H13N (AAR38165-69). The peptides may also
 CC be derived from an influenza virus protein or a sendai virus protein
 CC (AAR41014-15). It was observed that peptide N24G (amino acids 308-311),
 CC with sequences derived from the V3 loop of HIV-1 IIIB, inhibits HIV-1,
 CC infection of primary human T cells by 92% at 1 microg/ml (ca. 0.4-0.6
 CC microm). (Updated on 25-MAR-2003 to correct PN field.) (Updated on 27-AUG
 CC -2003 to correct OS field.)
 XX
 SQ Sequence 24 AA;

Query Match 100.0%; Score 77; DB 2; Length 24;
 Best Local Similarity 100.0%; Pred. No. 0.00014; Indels 0; Gaps 0;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIGK 15
 |||||
 Db 8 RIQRGPGRAFTVIGK 22

RESULT 84
 AAR44191
 ID AAR44191 standard; peptide; 24 AA.
 AC AAR44191;
 XX
 XX 25-MAR-2003 (revised)
 DT 20-MAY-1994 (first entry)
 XX
 XX gp120 V3 loop antigen B2 and lipophilic membrane anchoring group.
 DE
 XX Antigen; B2; third variable domain; V3 loop; gp120; HIV-1; vaccine;
 KW strain IIIB; multiple antigenic peptide system; dendritic core;
 KW lipophilic membrane anchoring group; mammal; humoral; immunisation;
 KW cytotoxic T cell; CT; immune response; infection; Freund's adjuvant;
 KW pathogen; HIV; influenza; malaria.
 XX
 XX Human immunodeficiency virus 1.
 OS Synthetic.
 OS
 XX Key Location/Qualifiers
 XX Peptide 1. .18
 FT Peptide /label= B2 antigenic peptide
 FT Peptide 19. .24

FT /note= "Lipophilic membrane anchoring group"

XX PN W09322343-A1.
XX PD 11-NOV-1993.
XX PF 03-MAY-1993; 93WO-US004179.
XX PR 01-MAY-1992; 92US-00877613.
XX PA (UYRQ) UNIV ROCKEFELLER.
XX PI Tam JP;
XX DR WPI; 1993-368723/46.
XX PT New multiple antigen system esp. for use in HIV vaccines - contains
PT lipophilic membrane anchor imparting adjuvant activity, and peptide
PT antigens coupled to dendritic core.
XX PS Disclosure; Fig 8; 55pp; English.
XX CC The sequence given in AAR44190 is a peptide antigen, B2, which represents
CC residues 312-329 of the third variable domain (V3 loop) of gp120, of HIV-
CC 1 strain IIB. This sequence was attached to an amino acid linker (see
CC also AAR44191) in the production of a multiple antigenic peptide system.
CC This system comprises a dendritic core to which are covalently attached
CC at least one peptide, eg, an antigenic peptide, and a lipophilic membrane
CC anchoring group. This system may be injected into a mammal and elicits
CC both humoral and cytotoxic T cell (CTL) immune responses. This system may
CC be used to immunise against HIV infection. The lipophilic membrane
CC anchoring group provides efficient adjuvant activity without the toxicity
CC problems of Freund's adjuvant, while the dendritic structure allows
CC multiple antigens to be attached. Optionally the antigens may be derived
CC from different pathogens, providing vaccines which protect against more
CC than one disease, eg, HIV, influenza and malaria. (Updated on 25-MAR-2003
CC to correct PN field.)
XX SQ Sequence 24 AA;

Query Match 100.0%; Score 77; DB 2; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.00014;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRGFAVTIGK 15
| | | | | | | | | | | | | | |
Db 4 RIQGPGRGFAVTIGK 18

RESULT 85
AAR63821
ID AAR63821 standard; peptide; 24 AA.
XX AC AAR63821;
XX DT 16-OCT-2003 (revised)
XX DT 25-MAR-2003 (revised)
XX DT 29-JUN-1995 (first entry)
XX DE HIV-1 gp120-24 epitope amino acids 307-330.
XX KW Human immunodeficiency virus type 1; HIV-1; gp120 epitopes; vaccines;
KW HIV neutralising antibodies.
XX OS Human immunodeficiency virus 1.
XX PN W09423746-A1.
XX PD 27-OCT-1994.
XX PF 15-APR-1994; 94WO-SE000340.
XX PR 16-APR-1993; 93US-00048976.

XX PA (SYNT-) SYNTELLO VACCINE DEV AB.
XX PI Vahlne A, Svennerholm B, Rymo L, Jeansson S, Horal P;
XX DR WPI; 1994-341488/42.
XX PT New peptide(s) comprising HIV gp120 epitope(s) - for prodn. of vaccines
PT against HIV infections.
XX PS Claim 1; Page 18; 77pp; English.
XX CC AAR63809-R63849 are epitopes from the human immunodeficiency virus type 1
CC (HIV-1) gp120, by binding one or more of these epitopes to a carrier a
CC HIV vaccine is produced. These vaccines can elicit the production of HIV-
CC neutralising antibodies in monkeys, and therefore may be used to prevent
CC HIV infections, and to heighten the immune response in HIV infected
CC humans. (Updated on 25-MAR-2003 to correct PN field.) (Updated on 16-OCT-
CC 2003 to standardise OS field)
XX SQ Sequence 24 AA;

Query Match 100.0%; Score 77; DB 2; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.00014;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRGFAVTIGK 15
| | | | | | | | | | | | | | |
Db 2 RIQGPGRGFAVTIGK 16

RESULT 86
AAR67414
ID AAR67414 standard; peptide; 24 AA.
XX AC AAR67414;

XX DT 25-JAN-1999 (first entry)
XX DE HIV-1 peptide epitope BRU.
XX KW Immunogen; vaccine; HIV-1; T-cell; B-cell; epitope; core protein; gp120;
KW V3 loop.
XX OS Synthetic.
OS Human immunodeficiency virus 1.
XX PN US5817754-A.
XX PD 06-OCT-1998.
XX PF 05-JUN-1995; 95US-00464329.
XX PR 09-JUN-1993; 93US-00073378.
XX PR 09-JUN-1994; 94US-00257528.
XX PA (CONN-) CONNAUGHT LAB LTD.
XX PI Chong P, Klein MH, Sia CDY;
XX DR WPI; 1998-556461/47.

XX PT Synthetic human immunodeficiency virus-1 peptide(s) - containing T-cell
PT epitope and B-cell epitope(s) are candidate vaccines against HIV-1.
XX PS Disclosure; Fig 3; 40pp; English.

XX CC The invention relates to a novel immunogenic composition for use in
CC vaccines for the treatment of HIV-1 comprising an HIV-1-derived T-cell
CC epitope linked to an HIV-1-derived B-cell epitope. The T-cell epitopes
CC are generally designed based on the p24 core protein and the B-cell
CC epitopes from the V3 loop of the gp120 protein from various HIV-1
CC strains. This sequence corresponds to an HIV-1 B-cell peptide epitope

CC used to immunise a guinea pig

XX Sequence 24 AA;

Query Match 100.0%; Score 77; DB 2; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.00014;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIGK 15

Db 7 RIQRGPGRAFTVIGK 21

RESULT 87

AAW98904

ID AAW98904 standard; peptide; 24 AA.

AC AAW98904;

DT 05-MAY-1999 (first entry)

DE HIV-1 vaccine synthetic peptide SEQ ID NO:99.

KW HIV-1; human immunodeficiency virus; vaccine; T-cell epitope;
KW gag protein; B-cell epitope; gp41 protein; chimeric; infection.

XX Synthetic.

OS Human immunodeficiency virus 1.

PN US5876731-A.

PD 02-MAR-1999.

PF 05-JUN-1995; 95US-00462507.

PR 09-JUN-1993; 93US-00073378.

PR 09-JUN-1994; 94US-00257528.

PA (CONN-) CONNAUGHT LAB LTD.

PI Chong P, Klein MH, Sia CDY;

XX WPI; 1999-189590/16.

DR Synthetic chimeric HIV polypeptides - comprising gag protein T-cell
PT epitope linked to gp41 B-cell epitope.

XX Example 1; Col 71-72; 41pp; English.

CC The present invention describes a synthetic peptide comprising an amino
CC acid sequence containing a T-cell epitope of an HIV gag protein linked at
CC its C terminus to an amino acid sequence containing a B-cell epitope of
CC an HIV gp41 protein and containing the amino acid sequence: X1LKDWX2;
CC where X1 = E, A, G or Q, and X2 = A or T, or an amino acid sequence
CC capable of eliciting an HIV-specific antiserum and recognizing the
CC sequence X1LKDWX2. The synthetic peptide is useful in vaccines against
CC HIV infection and in diagnostic applications. AAW98892 to AAW98906, and
CC AAW98899 to AAW98989 represent synthetic peptides from the present
CC invention

XX Sequence 24 AA;

Query Match 100.0%; Score 77; DB 2; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.00014;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIGK 15

Db 7 RIQRGPGRAFTVIGK 21

RESULT 88

AAW22581

ID AAY22581 standard; peptide; 24 AA.

XX AAY22581;

DT 17-OCT-2003 (revised)

DT 19-OCT-1999 (first entry)

DE HIV LDL binding peptide, sequence A.

KW HIV; LDL; low density lipoprotein; human; immune response; infection;
KW immunodeficiency; neoplastic tissue; myalgic encephalomyelitis; ME;
KW viral infection fatigue syndrome; tuberculosis; hepatitis; AIDS; ARC;
KW acquired immunodeficiency syndrome; AIDS related complex;
KW HIV-infected CD4 cell; immunosuppressive peptide.

XX Human immunodeficiency virus 1.

XX WO9938524-A2.

PN 05-AUG-1999.

PD 28-JAN-1999; 99WO-IB000149.

PF 29-JAN-1998; 98US-0072980P.

PR (PREN/) PRENDERGAST P T.

XX Prendergast PT;

XX WPI; 1999-494040/41.

XX Enhancing the immune response using a recombinant human low density
PT lipoprotein receptor, useful for treating viral infections, especially
PT human immunodeficiency virus (HIV) infection.

XX Claim 7; Page 19; 24pp; English.

CC This sequence represents a HIV sequence that binds human low density
CC lipoprotein (LDL), and is designated sequence "A". The invention relates
CC to a method for enhancing the immune response in a patient with a
CC condition, selected from immunodeficiency (due to a viral, bacterial,
CC mycoplasmic, fungal or parasitic infection, or from the growth of
CC neoplastic tissue), myalgic encephalomyelitis (ME), post inoculation or
CC viral infection fatigue syndrome, tuberculosis, or hepatitis. The method
CC comprises using a pharmaceutical composition, comprising a recombinant
CC human LDL receptor or a mimic molecule to the cysteine rich domain of LDL
CC receptor. The human recombinant LDL receptor forms pharmaceutical
CC compositions for: the treatment of acquired immunodeficiency syndrome
CC (AIDS) or ARC (AIDS related complex); reducing syncytium formation in HIV
CC -infected CD4 cells; treating blood or body fluid or organs to
CC neutralise/remove immunosuppressive peptides and/or viruses; or treating
CC hepatitis A, B or C. The pharmaceutical compositions also treat a viral
CC infection in a human or animal host. The human recombinant LDL receptor
CC is also useful for manufacturing medicaments for treating all the
CC conditions given above. The human recombinant LDL receptor is a highly
CC specific inhibitor of HIV-1 replication in vitro. (Updated on 17-OCT-2003
CC to standardise OS field)

XX Sequence 24 AA;

Query Match 100.0%; Score 77; DB 2; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.00014;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIGK 15

Db 8 RIQRGPGRAFTVIGK 22

RESULT 89

AAW22583

ID AAY22583 standard; peptide; 24 AA.

XX

AC AAY22583;
 XX 17-OCT-2003 (revised)
 DT 19-OCT-1999 (first entry)
 XX HIV LDL binding peptide, sequence "A" variant.
 DE HIV; LDL; low density lipoprotein; human; immune response; infection;
 XX immunodeficiency; neoplastic tissue; myalgic encephalomyelitis; ME;
 KW viral infection fatigue syndrome; tuberculosis; hepatitis; AIDS; ARC;
 KW acquired immunodeficiency syndrome; AIDS related complex;
 KW HIV-infected CD4 cell; immunosuppressive peptide.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN WO9938524-A2.
 XX
 PD 05-AUG-1999.
 XX
 PF 28-JAN-1999; 99WO-IB000149.
 XX
 PR 29-JAN-1998; 98US-0072980P.
 XX
 PA (PREN/) PRENDERGAST P T.
 XX
 PI Prendergast PT;
 XX
 XX WPI; 1999-494040/41.
 DR
 XX Enhancing the immune response using a recombinant human low-density
 PT lipoprotein receptor, useful for treating viral infections, especially
 PT human immunodeficiency virus (HIV) infection.
 XX
 PS Disclosure; Page 12; 24pp; English.
 XX
 CC This sequence represents a variant of the HIV sequence that binds human
 CC low density lipoprotein (LDL), and is designated sequence "A" (see
 CC AAY22581). The sequence "A" peptide is isolated from HIV isolate
 CC IIB(BH10), and this sequence was isolated from HIV isolate IIB(BH8).
 CC The invention relates to a method for enhancing the immune response in a
 CC patient with a condition, selected from immunodeficiency (due to a viral,
 CC bacterial, mycoplasma, fungal or parasitic infection, or from the growth
 CC of neoplastic tissue), myalgic encephalomyelitis (ME), post inoculation
 CC or viral infection fatigue syndrome, tuberculosis, or hepatitis. The
 CC method comprises using a pharmaceutical composition, comprising a
 CC recombinant human LDL receptor or a mimic molecule to the cysteine rich
 CC domain of LDL receptor. The human recombinant LDL receptor forms
 CC pharmaceutical compositions for: the treatment of acquired
 CC immunodeficiency syndrome (AIDS) or ARC (AIDS related complex); reducing
 CC syncytium formation in HIV-infected CD4 cells; treating blood or body
 CC fluid or organs to neutralise/remove immunosuppressive peptides and/or
 CC viruses; or treating hepatitis A, B or C. The pharmaceutical compositions
 CC also treat a viral infection in a human or animal host. The human
 CC recombinant LDL receptor is also useful for manufacturing medicaments for
 CC treating all the conditions given above. The human recombinant LDL
 CC receptor is a highly specific inhibitor of HIV-1 replication in vitro.
 CC (Updated on 17-OCT-2003 to standardise OS field)
 XX.
 SQ Sequence 24 AA;
 Query Match 100.0%; Score 77; DB 2; Length 24;
 Best Local Similarity 100.0%; Pred. No. 0.00014;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQRGPGRAFTVIGK 15
 |||||
 DB 8 RIQRGPGRAFTVIGK 22
 RESULT 90
 AAY39769
 ID AAY39769 standard; peptide; 24 AA.
 XX

AC AAY39769;
 XX 17-OCT-2003 (revised)
 DT 26-NOV-1999 (first entry)
 XX HIV1 chimeric peptide.
 DE HIV; vaccine; immunogenic composition; T cell epitope; B cell epitope;
 KW infection; antibody; antiviral.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN US9591986-A.
 XX
 PD 14-SEP-1999.
 XX
 PF 06-JUN-1995; 95US-00467881.
 XX
 PR 09-JUN-1993; 93US-00073378.
 PR 09-JUN-1994; 94US-00257528.
 XX
 PA (CONN-) CONNAUGHT LAB LTD.
 XX
 PI Klein MH, Chong P, Sia CDY;
 XX
 XX WPI; 1999-550482/46.
 DR
 XX Immunogenic composition containing synthetic fusion polypeptides
 PT containing both the T and B cell epitopes of the human immunodeficiency
 PT virus, useful antigens in producing vaccines.
 XX
 PS Disclosure; Col 73-74; 43pp; English.
 XX
 CC This sequence represents a fragment of a HIV1 protein, and can be used in
 CC the immunogenic composition of the invention. The composition comprises a
 CC synthetic fusion polypeptide which includes a sequence encoding 1 or more
 CC T cell epitopes and a sequence encoding 1 or more B cell epitopes and a
 CC carrier. Both the T cell and B cell epitopes are derived from HIV
 CC proteins. The compositions are useful as vaccines against HIV infection.
 CC The composition induces HIV-1-specific polyclonal antibodies that are
 CC opsonising and antiviral. The peptide components may be selected to
 CC induce a response against different viral isolates and in subjects who
 CC recognise different T cell epitopes. (Updated on 17-OCT-2003 to
 CC standardise OS field)
 XX
 SQ Sequence 24 AA;
 Query Match 100.0%; Score 77; DB 2; Length 24;
 Best Local Similarity 100.0%; Pred. No. 0.00014;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQRGPGRAFTVIGK 15
 |||||
 DB 7 RIQRGPGRAFTVIGK 21
 RESULT 91
 AAB15873
 ID AAB15873 standard; peptide; 24 AA.
 XX
 AC AAB15873;
 XX
 DT 17-JAN-2001 (first entry)
 XX
 DE Human chemokine derived peptide #25.
 XX
 KW Macrophage recruitment; chemokine derivative; MCP-1; osteoporosis;
 KW monocyte chemoattractant protein-1; inflammation; atherosclerosis; HIV;
 KW AIDS; stroke; psoriasis; autoimmune disease; hypertension; endotoxaemia;
 KW basophil-mediated disease; myocardial infarction; acute ischaemia;
 KW rheumatoid arthritis; contraception.
 XX
 OS Synthetic.

XX PN WO200042071-A2.
XX PD 20-JUL-2000.
XX PF 12-JAN-2000; 2000WO-US000821.
XX PR 12-JAN-1999; 99US-00229071.
XX PR 17-MAR-1999; 99US-00271192.
XX PR 01-DEC-1999; 99US-00452406.
XX PA (NEOR-) NEORX CORP.
XX PF Grainger DJ, Tatalick LM;
XX PI WPI; 2000-499101/44.
XX DR
XX PT New peptide 3, amide and heterocyclic compounds and saccharide conjugates
XX PT used for inhibiting chemokine induced activity and for treating e.g.
XX PT stroke, vascular diseases, autoimmune diseases and tumor growth.
XX PS Disclosure; Fig 18; 387pp; English.
XX CC The present invention concerns the identification of a number of
XX CC chemokines which can be used to produce derivatives, agonists and
XX CC antagonists which are then useful in disease treatment. The chemokines
XX CC include sequences AAB15785-B15794, AAB15803-B15813 and AAB15831-B15848.
XX CC These chemokine derivatives can be used to treat diseases such as
XX CC autoimmune diseases, atherosclerosis, osteoporosis, HIV infection and
XX CC AIDS, psoriasis, inflammatory diseases, hypertension, basophil-mediated
XX CC diseases, endotoxaemia, myocardial infarction, acute ischaemia and
XX CC rheumatoid arthritis, and can be used to prevent strokes and as
XX CC contraceptives. The coding sequences for the chemokines can be used in
XX CC gene therapy for the same diseases, as well as in the production of
XX CC animal models
XX CC
XX SQ Sequence 24 AA;
Query Match 100.0%; Score 77; DB 3; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.00014;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 RIQGGGFAFTVIGK 15
Dy 8 RIQGGGFAFTVIGK 22
RESULT 92
AAB68602
ID AAB68602 standard; peptide; 24 AA.
AC AAB68602;
XX
XX 11-SEP-2003 (revised)
DT 25-APR-2001 (first entry)
XX
XX HIV gp120 V3 loop peptide #2.
DE
XX
XX HIV gp120 V3 loop; liposome composition; HIV infection.
KW
XX
XX Human immunodeficiency virus 1.
OS
XX
XX US6180134-B1.
PN
XX
XX 30-JAN-2001.
PD
XX
XX 07-JUN-1995; 95US-00480332.
PF
XX
XX 23-MAR-1993; 93US-00035443.
PR
XX 29-SEP-1994; 94US-00316436.
PR
XX
XX (SEQU-) SEQUUS PHARM INC.
PA
XX

PI Zalipsky S, Woodle MC, Martin FJ, Barenholz Y;
XX WPI; 2001-201897/20.
XX
XX PT Liposome composition for use in treating septic shock comprises liposomes
XX PT having an outer surface layer of polyethylene glycol chains, and a
XX PT polypeptide or polysaccharide effector molecule.
XX
XX PS Disclosure; Fig 13; 32pp; English.
XX CC The present invention relates to a liposome composition comprising
XX CC liposomes having an outer surface layer of polyethylene glycol chains,
XX CC each having a free distal end. A polypeptide or polysaccharide effector
XX CC molecule is covalently attached to a portion of the distal ends. The
XX CC effector interferes with specific binding of pathogen or cell in a
XX CC bloodstream to a target cell or cell matrix, and is rapidly removed by
XX CC renal clearance from the bloodstream when administered in free form. The
XX CC liposome composition may be used in treating a condition mediated by
XX CC binding a pathogen or cell in the bloodstream, to a target cell or cell
XX CC matrix. It can be used in treating septic shock, toxic shock, colonic
XX CC inflammation, leukaemic cell proliferation, or HIV infection. The present
XX CC sequence is a peptide of the V3 loop of HIV envelope protein gp120. This
XX CC peptide may be used in the composition of the present invention. gp120
XX CC binds to the CD4 receptor during HIV infection of lymphocytes. By
XX CC introducing the present peptide, the CD4 receptors are blocked, thereby
XX CC inhibiting HIV infection. (Updated on 11-SEP-2003 to standardise OS
XX CC field)
XX SQ Sequence 24 AA;
Query Match 100.0%; Score 77; DB 4; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.00014;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 RIQGGGFAFTVIGK 15
Dy 8 RIQGGGFAFTVIGK 22
RESULT 93
AAP82464
ID AAP82464 standard; protein; 25 AA.
XX
XX AAP82464;
AC
XX
XX 25-MAR-2003 (revised)
DT 12-NOV-1990 (first entry)
XX
XX Peptide component of AIDS vaccine.
DE
XX
XX AIDS vaccine; T-cells.
KW
XX
XX Synthetic.
OS
XX
XX EP273716-A.
PN
XX
XX 06-JUL-1988.
PD
XX
XX 23-DEC-1987; 87EP-00311391.
PF
XX
XX 30-DEC-1986; 86US-00947935.
PR
XX 12-FEB-1987; 87US-00014430.
PR
XX
XX (USDC) US SEC OF COMMERCE.
PA (USSH) US DEPT HEALTH & HUMAN SERVICE.
XX
XX Delisi C, Margalit H, Cornette JL, Ouyang CS;
PI
XX WPI; 1988-184640/27.
XX
XX Synthetic peptide(s) as vaccines for AIDS - selected from peptide regions
XX PT which can fold as a maximally amphipathic helix recognised by T cells.
XX

PS. Claim 9; Page 10; 16pp; English.

XX This peptide is a component of an AIDS vaccine. It can fold as a
 CC maximally amphipathic helix and is recognised by T-cells immune to the
 CC AIDS virus envelope protein. See also AAP82462-63 and AAP82465-79.
 CC (Updated on 25-MAR-2003 to correct PA field.)

XX Sequence 25 AA;

Query Match 100.0%; Score 77; DB 1; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.00014;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRGPGRAFTVIGK 15
 |||||
 Db 2 RIQRGPGRAFTVIGK 16

RESULT 94

AAP90281
 ID AAP90281 standard; protein; 25 AA.

XX

AC AAP90281;

DT 09-SEP-2004 (revised)

DT 24-OCT-2003 (revised)

DT 25-MAR-2003 (revised)

DT 22-JUN-1990 (first entry)

XX Peptide 135 of HIV env gene.

XX HIV; AIDS; env gene; HIV vaccine; ds.

XX Simian-Human immunodeficiency virus.

OS Unidentified.

XX EP306219-A.

XX 08-MAR-1989.

XX 25-AUG-1988; 88EP-00307889.

XX 27-AUG-1987; 87US-00090080.

XX (REPK) REPLIGEN CORP.

PI Rusche JR, Putney SD, Jayaherian K, Farley J, Grimailla R, Lynn D;

PI Petro J, Okeeffe T;

XX WPI; 1989-070387/10.

PT New HIV proteins and peptide(s) - used in diagnosis, prophylaxis or

PT therapy of AIDS, esp. for prepn. of vaccines against HIV infection.

XX Claim 1; Page 27; 29pp; English.

XX Protein derivative stimulates a lymphocyte proliferative response in HIV-

CC infected humans, providing a means of diagnosis, protection and

CC therapeutic value. (Updated on 25-MAR-2003 to correct PR field.) (Updated

CC on 25-MAR-2003 to correct PA field.) (Updated on 24-OCT-2003 to

CC standardise OS field)

CC Revised record issued on 09-SEP-2004 : Correction to location

XX Sequence 25 AA;

Query Match 100.0%; Score 77; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 0.00014;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRGPGRAFTVIGK 15

|||||

Db 8 RIQRGPGRAFTVIGK 22

RESULT 95

AAR08276

ID AAR08276 standard; protein; 25 AA.

XX

AC AAR08276;

DT 07-MAR-1991 (first entry)

XX HIV peptide fragment (IIIB isolate).

XX AIDS; ARC; conjugate immunogen; Neisseria outer membrane protein;

XX HIV major neutralisation determinant.

OS Human immunodeficiency virus.

XX EP402088-A.

XX 12-DEC-1990.

XX 05-JUN-1990; 90EP-00306082.

XX 06-JUN-1989; 89US-00362176.

XX 06-JUN-1989; 89US-00362177.

XX 06-JUN-1989; 89US-00362178.

XX 06-JUN-1989; 89US-00362179.

XX (MERI) MERCK & CO INC.

XX Emini EA, Marburg S, Scolnick EM, Larson VM;

XX WPI; 1990-370100/50.

XX Conjugate immunogen for AIDS and ARC treatment - composed of neutralising

PT determinant of HIV and Neisseria outer membrane.

XX Claim 2; Page 22; 24pp; English.

XX This peptide is derived from the HIV IIIB isolate and is cross- reactive

CC with the HIV major neutralisation determinant (MNTD). This MNTD is used

CC in a conjugate, covalently linked to the outer membrane protein (Omp)

CC from Neisseria, as an immunogen for vaccination against AIDS. A cocktail

CC of different MNTD poly- peptides can be used. See also AAR08274-75 and

CC AAR08277

XX Sequence 25 AA;

Query Match 100.0%; Score 77; DB 2; Length 25;

Best Local Similarity 100.0%; Pred. No. 0.00014;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRGPGRAFTVIGK 15

|||||

Db 8 RIQRGPGRAFTVIGK 22

RESULT 96

AAR13120

ID AAR13120 standard; peptide; 25 AA.

XX

AC AAR13120;

XX 24-OCT-2003 (revised)

DT 01-OCT-1991 (first entry)

XX Binding site of BART23 and BART267 HIV antibodies.

XX Anti-idiotypic; antibody; gp120; HIV; human immunodeficiency virus;

XX paratope; complementarity determining region; CDR; immunisation; vaccine;

XX immunotoxin; T-cell; AIDS; ARC.

XX Simian-Human immunodeficiency virus.

OS

XX PN WO9109625-A.
 XX PD 11-JUL-1991.
 XX PF 21-DEC-1989; 89US-00454161.
 XX PR 21-DEC-1989; 89US-00454161.
 XX PR 12-JUN-1990; 90US-00531789.
 XX PA (TANO-) TANOX BIOSYSTEMS IN.
 XX PI Chang TW, Fung MSC, Sun CRY, Sun BNC, Chang NT;
 XX DR WPI; 1991-222664/30.
 XX PT Monoclonal antibodies specific to the gp120 HIV envelope protein - for
 XX PT immunisation against HIV in treatment of AIDS or ARC.
 XX PS Claim 5; Page 97; 124pp; English.
 XX CC The peptide corresponds to residues 294-318 of the gp120 envelope protein
 CC of HIV-1 which is a principal neutralising determinant (PND). Abs
 CC recognise residues 294-308 (Mab BAT267) or 304-318 (Mab 123). These Mab
 CC are used to raise anti-idiotypic Abs (AAbs). The Abs are useful for
 CC passive immunisation and as components for immunotoxins which destroy T-
 CC cells infected with HIV. They inhibit T-cell infection and syncytium
 CC formation, are group specific and neutralise specific strains of HIV-1.
 CC They can be used to treat AIDS or ARC. The AAbs can be used for active
 CC immunisation or can be admin with another vaccine to increase
 CC antigenicity. See also AAR13121. (Updated on 24-OCT-2003 to standardise
 CC OS field)
 XX SQ Sequence 25 AA;
 Query Match 100.0%; Score 77; DB 2; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.00014;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQRGPGRAFTVIGK 15
 DB 11 RIQRGPGRAFTVIGK 25
 RESULT 97
 AAR15058
 ID AAR15058 standard; protein; 25 AA.
 AC AAR15058;
 XX DT 03-JAN-1992 (first entry)
 XX DE HIV-1 amplifier peptide #21.
 XX KW human immunodeficiency virus; vaccine; human retrovirus; AIDS;
 KW acquired immunodeficiency syndrome; envelope glycoprotein.
 XX OS Synthetic.
 XX PN WO9114449-A.
 XX PD 03-OCT-1991.
 XX PF 19-MAR-1990; 90US-00494749.
 XX PR 19-MAR-1990; 90US-00494749.
 XX PA (INSP) INST PASTEUR.
 XX PI Girard M;
 XX DR WPI; 1991-310366/42.
 XX

PT Enhancing immunogenicity of envelope glycoprotein - for use as vaccine
 PT or immuno:therapeutic drug especially against HIV, HTLV-I and HTLV-II.
 XX Claim 13; Page 50; 71pp; English.
 XX CC This peptide is one example of an HIV-1 amplifier peptide for use in a
 CC composition for enhancing the immunogenicity of an envelope glycoprotein
 CC of a virus. The sequence corresponds to the major neutralisation epitope
 CC (loop V3) of HIV-1 bruii isolate and enhances the induction of
 CC persistent neutralising antibodies in the host. The amplifier peptide is
 CC used in addition to an envelope glycoprotein for priming the induction of
 CC neutralising antibodies. The compositions are particularly useful for
 CC vaccinating against HIV, SIV, HTLV-I and HTLV-II
 XX SQ Sequence 25 AA;
 Query Match 100.0%; Score 77; DB 2; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.00014;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQRGPGRAFTVIGK 15
 DB 8 RIQRGPGRAFTVIGK 22
 RESULT 98
 AAR31276
 ID AAR31276 standard; peptide; 25 AA.
 XX AC AAR31276;
 XX DT 12-FEB-1993 (first entry)
 XX DE HIV principal determinant peptide.
 XX KW AIDS; ARC; human immunodeficiency virus; vaccine; Neisseria;
 KW meningitidis b; outer membrane protein complex; OMPC; PND135.
 XX OS Synthetic.
 XX FH Key Location/Qualifiers
 FT Modified-site 1 /note= "bonds to the OMPC of the conjugate via this site"
 FT EP467700-A.
 XX PN 22-JAN-1992.
 XX PF 19-JUL-1991; 91EP-00306598.
 XX PR 19-JUL-1990; 90US-00553339.
 XX PR 19-JUL-1990; 90US-00555966.
 XX PR 19-JUN-1991; 91US-00715276.
 XX PR 19-JUN-1991; 91US-00715278.
 XX PA (MERI) MERCK & CO INC.
 XX PI Leanza WJ, Marburg S, Tolman RL, Emini EA;
 XX DR WPI; 1992-026505/04.
 XX PT Conjugate proteins comprising HIV peptide components - useful for
 XX PT preparing vaccines for e.g. AIDS or for treating infections.
 XX PS Claim 12; Page 56; 63pp; English.
 XX CC The invention relates to a co-conjugate comprising an immunogenic protein
 CC or protein complex having a first set of covalent linkages to low
 CC molecular weight moieties which have an anionic or polyanionic character
 CC at physiological pH, and a second set of covalent linkages to peptides
 CC comprising HIV principal neutralizing determinants (PND's) or
 CC immunologically equivalent peptides. Preferably at least one set of the
 CC covalent linkages is comprised of maleimide derivatives; the

CC (poly)anionic moiety is composed of one to five residues of the anionic
 CC form of a carboxylic, sulphonic or phosphonic acid; the immunogenic
 CC protein is the outer membrane protein complex (OMPC) of *Neisseria*
 CC meningitidis b; and the PND peptide has a linear structure, a disulphide-
 CC bonded cyclic structure, an amide-bonded cyclic structure or a thioether-
 CC bonded cyclic structure. The present sequence (PND135) is an example of a
 CC PND peptide component used in the co-conjugate. The co-conjugate is
 CC useful for inducing anti-peptide immune response in mammals, for inducing
 CC HIV-neutralising antibodies in mammals, for formulating vaccines to
 CC prevent HIV infection or disease, including AIDS, or for treating humans
 CC afflicted with HIV infection or disease
 CC
 SQ Sequence 25 AA;

Query Match 100.0%; Score 77; DB 2; Length 25;

Best Local Similarity 100.0%; Pred. No. 0.00014; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRPGRFAFTVIGK 15
 |||||
 Db 8 RIQRPGRFAFTVIGK 22

RESULT 99

AAR30031
 ID AAR30031 standard; peptide; 25 AA.

AC AAR30031;

DT 25-MAR-2003 (revised)

DT 28-APR-1993 (first entry)

XX HIV principle neutralising determinant 135.

XX Human immunodeficiency virus; AIDS; PND; MIEP; conjugate;

KW major immune enhancing protein; vaccine; anti-HIV antibodies; immunogen;

KW passive immunisation.

XX Human immunodeficiency virus.

XX EP519554-A1.

XX 23-DEC-1992.

PF 11-JUN-1992; 92EP-00201693.

PR 19-JUN-1991; 91US-00715273.

XX (MERI) MERCK & CO INC.

PI Emini A, Liu MA, Marburg S, Tolman RL;

XX WPI; 1992-425771/52.

XX Conjugates of HIV-1 PND peptide(s) with the MIEP of *Neisseria*
 PT meningitidis - useful as a vaccine for treating and preventing HIV-1
 PT infection, e.g. AIDS in humans.

PS Claim 9; Page 59; 66pp; English.

XX The peptide is HIV principle neutralising determinant (PND) 135 and is
 CC used as part of a conjugate comprising the major immune enhancing protein
 CC (MIEP) of *Neisseria meningitidis* covalently linked to the HIV PND. The
 CC conjugate may be used to prepare vaccines against HIV infections, e.g.
 CC AIDS, as research tools for studying PND structure- function
 CC relationships, or as immunogens for use in the passive immunisation of
 CC humans. (Updated on 25-MAR-2003 to correct PN field.)

SQ Sequence 25 AA;

Query Match

Best Local Similarity 100.0%; Score 77; DB 2; Length 25;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRPGRFAFTVIGK 15
 |||||
 Db 8 RIQRPGRFAFTVIGK 22

RESULT 100

AAR26712
 ID AAR26712 standard; peptide; 25 AA.

AC AAR26712;

DT 09-FEB-1993 (first entry)

XX HIV-PND-polysaccharide-protein conjugate vaccine.

XX Human immunodeficiency virus; principal neutralizing determinant;

KW outer membrane protein complex; OMPC; *Neisseria*; AIDS; PND135.

XX Synthetic.

PH Key Location/Qualifiers

FT Modified-site 1..1
 FT /note= "Joins onto polysaccharide-protein complex via
 this site"

XX EP468714-A.

XX 29-JAN-1992.

XX 19-JUL-1990; 90US-00555558.

PR 19-JUL-1990; 90US-00555558.

PR 19-JUN-1991; 91US-00715275.

PR 19-JUN-1991; 91US-00715277.

XX (MERI) MERCK & CO INC.

PI Marburg S, Tolman RL, Emini EA;

XX WPI; 1992-034437/05.

XX HIV peptide-polysaccharide-protein conjugates - used in vaccines or to
 PT produce antibodies to prevent or treat HIV infection.

PS Claim 9; Page 57; 63pp; English.

XX The invention relates to a conjugate of an HIV principal neutralizing
 CC determinant (PND), or an immunologically equivalent peptide (PEP),
 CC covalently coupled to an immunogenic protein or protein complex through
 CC an anionic polysaccharide linker. Pref. the immunogenic protein is the
 CC outer membrane protein complex (OMPC) of *Neisseria meningitidis* b and the
 CC PND peptide has a linear structure, a disulphide-bonded cyclic structure,
 CC an amide-bonded cyclic structure or a thioether-bonded cyclic structure.
 CC The present sequence (PND135) is an example of a PND peptide component.
 CC The conjugates are used for inducing HIV-neutralising antibodies or for
 CC making vaccines to prevent contraction of HIV infection or disease. The
 CC antibodies can be used for passively protecting against infection by HIV,
 CC or for protecting against proliferation of HIV post-infection, or for
 CC treating AIDS, or in diagnostic assays

XX Sequence 25 AA;

Query Match

Best Local Similarity 100.0%; Score 77; DB 2; Length 25;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRPGRFAFTVIGK 15
 |||||
 Db 8 RIQRPGRFAFTVIGK 22

KW	cellular immunity; carrier protein; human serum albumin; HSA;
KW	keyhole limpet haemocyanin; KLH; multiple antigen peptide.
XX	
XX	Human immunodeficiency virus 1.
OS	WC9318791-A1.
XX	
XX	30-SEP-1993.
XX	
XX	19-MAR-1993; 93WO-JP000327.
XX	
XX	26-MAR-1992; 92JP-00098602.
PR	14-AUG-1992; 92JP-00237648.
PR	15-MAR-1993; 93JP-00054239.
XX	
PA	(TSDT-) TSD KK.
XX	
XX	Okuda K;
PI	
XX	WPI; 1993-320455/40.
XX	
XX	Virus for prevention of HIV infected diseases - comprising several
PT	peptide(s) consisting of V3 region peptide of envelope Gp., 120, etc. and
PT	complex including carrier protein.
XX	
XX	Disclosure; Page 3; 35pp; Japanese.
PS	
XX	The sequences given in AAR41336-39 and AAR42664 represent peptides
CC	derived from the V3 region of HIV envelope gp120. These peptides may be
CC	used in a vaccine which is effective in humans and animals and activates
CC	humoral and cellular immunity. The vaccine also contains a carrier
CC	protein containing a cysteine group, eg. human serum albumin (HSA),
CC	keyhole limpet haemocyanin (KLH) or multiple antigen peptide. (Updated on
CC	25-MAR-2003 to correct PN field.) (Updated on 24-OCT-2003 to standardise
CC	OS field)
XX	
XX	Sequence 25 AA;
SQ	
	Query Match 100.0%; Score 77; DB 2; Length 25;
	Best Local Similarity 100.0%; Pred. No. 0.00014;
	Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0
QY	1 RIORGPGRAFTVGK 15
DB	8 RIORGPGRAFTVGK 22
RESULT 103	
AAR41330	
ID	AAR41330 standard; peptide; 25 AA.
XX	
AC	AAR41330;
XX	
XX	25-MAR-2003 (revised)
DT	21-APR-1994 (first entry)
XX	
DE	HIV gp120 epitope.
XX	
KW	HIV; haemagglutinin; reactants; catalysts; cofactors; repressors;
KW	enhancers; hormones; binders; human immunodeficiency virus.
XX	
OS	Human immunodeficiency virus.
XX	
PN	WO9319170-A1.
XX	
XX	30-SEP-1993.
PD	
XX	09-MAR-1993; 93WO-US002349.
PF	
XX	16-MAR-1992; 92US-00852412.
PR	
XX	(WOHL/) WOHLSTADTER J N.
XX	
XX	

PI Wohlstadter JN;
 XX' WPI; 1993-320737/40.
 XX
 XX Obtaining a novel mol. - capable of a desired interaction with a
 PT substrate of interest and a selection molecule expressed by the host.
 XX
 XX Claim 151; Page 147; 165pp; English.
 XX
 CC The HIV gp120 epitope is used to isolate, create or evolve novel mols.
 CC including (in)organic and biomolecules such as proteins, peptides,
 CC nucleic acids, oligonucleotides, lipids, and polysaccharides for use as
 CC reactants, catalysts, enzymatic cofactors, repressors, enhancers,
 CC hormones and binders for a wide variety of substrates in industrial and
 CC therapeutic products. This epitope was isolated from variable region 3 of
 CC HIV gp120 (amino acids 271-295). (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX
 XX Sequence 25 AA;
 SQ

Query Match 100.0%; Score 77; DB 2; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.00014;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRPGRFAFTIGK 15
 |||||
 Db 8 RIQRPGRFAFTIGK 22

RESULT 104
 AAR36587
 ID AAR36587 standard; peptide; 25 AA.
 XX
 AC AAR36587;
 XX
 XX 25-MAR-2003 (revised)
 DT 06-SEP-1993 (first entry)
 DT
 XX Virus neutralising epitope of envelope glycoprotein of HIV.
 DE
 XX Human immunodeficiency virus; gp120; gp160; EGP; VNE; immunity.
 KW
 XX Synthetic.
 OS
 PN WO9308836-A1.
 XX
 XX 13-MAY-1993.
 PD
 XX 28-OCT-1992; 92WO-EP002459.
 PF
 XX 28-OCT-1991; 91US-00782154.
 PR 28-OCT-1991; 91US-00782241.
 PR 28-OCT-1991; 91US-00782252.
 XX
 XX (INSP) INST PASTEUR.
 PA
 XX Girard M;
 PI
 XX WPI; 1993-167398/20.
 DR
 XX Enhancing immunogenicity of viral envelope glycoprotein - by co-
 PT administration of viral envelope glycoprotein itself, and an oligopeptide
 PT derivative.
 PT
 XX Disclosure; Page 82; 107pp; English.
 PS
 XX A novel method of enhancing the immunogenicity of an envelope
 CC glycoprotein (EGP) of a virus (esp. HIV gp120 or gp160) in a host
 CC comprises admin. to the host at least one EGP of the virus in an amt.
 CC sufficient for priming vaccination and at least one peptide derived from
 CC an amino acid sequence of the EGP (e.g. the sequence shown), where the
 CC peptide comprises at least one virus-neutralisation epitope (VNE). The
 CC complex is able to enhance the induction of neutralising antibodies to

CC the virus and to confer long lasting immunity, longer than 6 months. See
 CC also AAR36567-86. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 25 AA;
 Query Match 100.0%; Score 77; DB 2; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.00014;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRPGRFAFTIGK 15
 |||||
 Db 8 RIQRPGRFAFTIGK 22

RESULT 105
 AAW72819
 ID AAW72819 standard; peptide; 25 AA.
 XX
 AC AAW72819;
 XX
 XX 17-OCT-2003 (revised)
 DT 13-JAN-1999 (first entry)
 DT
 XX HIV-1 gp120 epitope 294 to 318.
 DE
 XX HIV-1; gp120; epitope; monoclonal antibody; envelope; neutralise;
 KW inhibit; infection; T-cell; inhibit syncytium formation; AIDS.
 KW
 XX Human immunodeficiency virus 1.
 OS
 XX Key Location/Qualifiers
 FH Peptide 1. .15
 FT /label= peptide_a
 FT Peptide 11. .25
 FT /label= peptide_b
 XX
 XX US5834599-A.
 FN
 XX 10-NOV-1998.
 PD
 XX 04-MAR-1993; 93US-00026276.
 PF
 XX 29-MAY-1987; 87US-00057445.
 PR 24-DEC-1987; 87US-00137861.
 PR 25-APR-1989; 89US-00343540.
 PR 05-JUN-1992; 92US-00895197.
 XX
 XX (TANO-) TANOX BIOSYSTEMS INC.
 PA
 XX Sun BN, Fung SC, Kim YW, Sun CR, Chang NT, Chang T;
 PI WPI; 1999-008810/01.
 XX
 XX Antibody conjugate comprising monoclonal antibody - which binds to
 PT epitope within amino acid residue of gp120 which neutralises HIV-1
 PT conjugated with, e.g. cytotoxic agent.
 PT
 XX Disclosure; Col 8; 22pp; English.
 PS
 XX The present invention describes an antibody conjugate comprising an
 CC antibody (Ab) which binds to an epitope within amino acid residue 308-322
 CC of gp120 and neutralises HIV-1, conjugated with a cytotoxic agent, an
 CC anti-viral agent or an agent which facilitates passage through the blood
 CC brain barrier. Also described is an antibody conjugate as above but where
 CC the Ab binds to an epitope within amino acid residue 298-312 of gp120
 CC which neutralises HIV-1. The present sequence represents an HIV-1 gp120
 CC epitope corresponding to positions 294 to 318. The Ab are monoclonal Ab
 CC which bind to the gp120 protein on the envelope of HIV-1. They inhibit
 CC the infection of T-cells and also inhibit syncytium formation. The
 CC antibodies are group specific and neutralise different strains and
 CC isolates of HIV-1. The antibodies have a variety of uses, including the
 CC treatment and prevention of AIDS and AIDS related complex. They are
 CC especially used to kill infected T-cells. (Updated on 17-OCT-2003 to

```
CC standardise OS field)
XX
SQ Sequence 25 AA;

Query Match      100.0%; Score 77; DB 2; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.00014;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGGGGRFVTVIGK 15
   |||||
Db 11 RIQGGGGRFVTVIGK 25

RESULT 106
AAW87618
ID AAW87618 standard; peptide; 25 AA.
AC AAW87618;
XX
XX 17-OCT-2003 (revised)
DT 20-MAR-2003 (revised)
DT 03-MAR-1999 (first entry)
DE Epitope of HIV-1 gp120 protein.
XX
XX Epitope; gp120 protein; monoclonal antibody; HIV-1; antibody BAT123;
KW antibody BAT267; antibody BAT085; T cell infection inhibition;
KW syncytia formation; acquired immune deficiency syndrome; AIDS;
KW AIDS-related complex; passive immunisation; antiviral; cytotoxic;
KW viral load measurement; vaccine.
XX
XX Human immunodeficiency virus 1.
OS
XX
XX US5854400-A.
PN
XX
XX 29-DEC-1998.
PD
XX
XX 22-SEP-1992; 92US-00950571.
PF
XX
XX 29-MAY-1987; 87US-00057445.
PR 24-DEC-1987; 87US-00137861.
PR 26-SEP-1991; 91US-00767533.
XX
XX (TANO-) TANOX INC.
PA
XX
XX Fung MSC, Sun BNC, Sun CRY, Chang NT, Chang TW;
PI
XX
XX WPI; 1999-095002/08.
DR
XX
XX Monoclonal antibodies directed against regions of gp120 of human immune
PT deficiency virus-1 - are neutralising and able to inhibit infection of T
PT cells and formation of syncytia, used for treatment, prevention or
PT diagnosis of acquired immune deficiency syndrome.
XX
XX Claim 2; Col 8; 16pp; English.
PS
XX
XX The present sequence represents an epitope of the gp120 protein of human
CC immune deficiency virus (HIV)-1. The sequence comprises amino acids 298
CC to 322 of gp120. The specification describes monoclonal antibodies which
CC bind to sequences derived from the present epitope. Specifically, these
CC antibodies are designated BAT123, 267 and 085. Monoclonal antibodies
CC neutralise HIV-1, inhibiting both infection of T cells and formation of
CC syncytia, so are used to treat acquired immune deficiency syndrome (AIDS)
CC and AIDS-related complex, by passive immunisation, as carriers of
CC cytotoxic or antiviral agents, and in extracorporeal systems. They can
CC also be used as immunoassay reagents (for diagnosis or measurement of
CC viral load) and to screen for neutralising epitopes, potentially useful
CC in vaccine development. (Updated on 20-MAR-2003 to correct PR field.)
CC (Updated on 17-OCT-2003 to standardise OS field)
XX
SQ Sequence 25 AA;

Query Match      100.0%; Score 77; DB 2; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.00014;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGGGGRFVTVIGK 15
   |||||
Db 11 RIQGGGGRFVTVIGK 25

RESULT 107
AAE09522
ID AAE09522 standard; peptide; 25 AA.
AC AAE09522;
XX
XX 19-NOV-2001 (first entry)
DT
XX
XX Human immunodeficiency virus Dd haplotype peptide.
DE
XX
XX Mucin; cytostatic; immunostimulant; cell mediated immune response;
KW carcinoma; adenocarcinoma; breast cancer; dendritic cell; vaccine;
KW gene therapy; CTL; cytotoxin T-lymphocyte.
XX
XX Human immunodeficiency virus.
OS
XX
XX WO200157068-A1.
PN
XX
XX 09-AUG-2001.
PD
XX
XX 01-FEB-2001; 2001WO-AU000090.
PF
XX
XX 01-FEB-2000; 2000AU-00005369.
PR 14-JUN-2000; 2000US-00593870.
PR
XX
XX (AUST-) AUSTIN RES INST.
PA
XX
XX McKenzie IFC, Pietersz GA, Apostolopoulos V;
PI
XX
XX WPI; 2001-541537/60.
DR
XX
XX Immunostimulant peptide, used as an anti-carcinoma vaccine, comprises a
PT an epitope of the non-VNTR, non-leader region of a mucin.
PT
XX
XX Disclosure; Page 19; 84pp; English.
PS
XX
XX The patent discloses peptide or polypeptides capable of eliciting an
CC immune response, comprising an amino acid sequence corresponding to an
CC epitope of the non-central portion of varying numbers of an amino acid
CC motif (VNTR), non-leader region of a mucin. The peptides of the
CC invention, fusion proteins comprising the peptide and conjugate compounds
CC with carbohydrate polymers are used to induce a cell mediated immune
CC response against mucin in the prevention or treatment of carcinoma,
CC preferably adenocarcinoma, most preferably breast cancer. They are also
CC used to pulse dendritic cell for in vivo transfer and use as a vaccine.
CC They are also used in gene therapy. The present sequence is a human
CC immunodeficiency virus (HIV) haplotype kd peptide used as a negative
CC control for the prediction of CTL (cytotoxic T-lymphocyte) epitopes
XX
XX Sequence 25 AA;

Query Match      100.0%; Score 77; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.00014;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGGGGRFVTVIGK 15
   |||||
Db 5 RIQGGGGRFVTVIGK 19

RESULT 108
AAR04427
ID AAR04427 standard; peptide; 25 AA.
XX
XX AAR04427;
AC
```

XX 09-SEP-2004 (revised)
 DT 25-MAR-2003 (revised)
 DT 20-SEP-1990 (first entry)
 XX
 DE Human immunodeficiency virus peptide 135.
 XX HIV-IIIB; peptide 135; principal neutralising domain; antibodies;
 KW diagnosis; prophylaxis; therapy; AIDS.
 XX
 OS Synthetic.
 XX WO9003984-A.
 PN 19-APR-1990.
 PD
 XX 03-OCT-1988; 88US-00252949.
 PF
 XX 03-OCT-1988; 88US-00252949.
 PR 01-JUN-1989; 89US-00359543.
 PR. 19-SEP-1989; 89US-00407663.
 XX
 PA (REPK) REPLIGEN CORP.
 XX
 PI Rusche JR, Putney SD, Javaherian K, Farley J, Grimalia R;
 PI Lynn DU, Petrobre J;
 XX WPI; 1990-147824/19.
 DR
 XX Principal neutralising domain of HIV variants - used for producing
 PT peptide(s) and antibodies for diagnosis, prophylaxis and/or therapy
 PT therapy of HIV infection.
 XX
 PS Claim 8 (30); Page 75; 108pp; English.
 XX
 CC Peptide 135 comprises segments of the Principal Neutralising Domain
 CC (envelope protein) from isolate HIV-IIIB. The last Cys residue is added
 CC for the purpose of crosslinking to carrier proteins. Cysteine residues
 CC can be added so that that residues at or near both ends form a disulfide
 CC bond, thus giving the peptide a loop-like configuration, which is
 CC utilised to enhance the immunogenic properties of the peptide. The
 CC peptide is capable of eliciting, and/or binding with, neutralising
 CC antibodies. The neutralising domain is bounded by cysteine residues which
 CC occur at positions 296 and 331. Peptides can be used as immunogens or
 CC screening reagents to generate or identify poly- or WAbs. See also
 CC AAR04427-R04506 and AAR04273-004279. (Updated on 25-MAR-2003 to correct
 CC PR field.) (Updated on 25-MAR-2003 to correct PA field.) (Updated on 25-
 CC MAR-2003 to correct PI field.)
 CC
 CC Revised record issued on 09-SEP-2004 : Correction to Feature Table Key
 XX
 SQ Sequence 25 AA;
 Query Match 97.4%; Score 75; DB 2; Length 25;
 Best Local Similarity 93.3%; Pred. No. 0.00028;
 Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQGPGRFAFTVIGK 15
 |||||
 DB 8 RIQGPGRFAFTVIGK 22
 |||||
 RESULT 109
 AAR66419
 ID AAR66419 standard; peptide; 15 AA.
 XX
 AC AAR66419;
 XX
 XX 25-MAR-2003 (revised)
 DT 03-AUG-1995 (first entry)
 XX
 DE HIV-1 IIIB peptide 18-4.
 XX

KW T cell helper site; cytotoxic T cell response; neutralising antibody;
 KW human immunodeficiency virus type 1; envelope glycoprotein gp120;
 KW cluster peptide; principal neutralising determinant.
 OS Synthetic.
 XX WO9426785-A1.
 PN 24-NOV-1994.
 PD
 XX 13-MAY-1994; 94WO-US005142.
 PF
 XX 14-MAY-1993; 93US-00060988.
 PR (USSH) US SEC DEPT HEALTH.
 XX
 XX Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
 PI WPI; 1995-006707/01.
 DR
 XX Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
 XX responses - to target antigen in hosts of different MHC haplotypes, esp.
 PT for therapeutic or prophylactic vaccines against HIV.
 PT
 XX Example 1; Page 33; 120pp; English.
 PS
 XX Single residues from the HIV-1 RF sequence (AAR66415) replaced residues
 CC in the HIV-1 IIIB sequence (AAR66414) to test the effect of each residue
 CC on the binding of neutralising and non-neutralising sera from animals
 CC immunised with the cluster peptides PCLUS 3-18 and PCLUS 6-18 (see
 CC AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
 CC R66430) showed that binding was enhanced over peptide 18 control when a
 CC tyrosine was substd. for a Val at position 11 and subetns. at positions
 CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
 CC sera was reduced when subetns. were made in the principal neutralising
 CC determinant sequence (PGRF). In peptide 18-4, the Arg residue at
 CC position 4 in peptide 18 has been replaced by a Lys residue. (Updated on
 CC 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 15 AA;
 Query Match 96.1%; Score 74; DB 2; Length 15;
 Best Local Similarity 93.3%; Pred. No. 0.00025;
 Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQGPGRFAFTVIGK 15
 |||||
 DB 1 RIQGPGRFAFTVIGK 15
 |||||
 RESULT 110
 AAR66430
 ID AAR66430 standard; peptide; 15 AA.
 XX
 AC AAR66430;
 XX
 XX 25-MAR-2003 (revised)
 DT 03-AUG-1995 (first entry)
 XX
 DE HIV-1 IIIB peptide 18-15.
 XX
 KW T cell helper site; cytotoxic T cell response; neutralising antibody;
 KW human immunodeficiency virus type 1; envelope glycoprotein gp120;
 KW cluster peptide; principal neutralising determinant.
 OS Synthetic.
 XX WO9426785-A1.
 PN 24-NOV-1994.
 PD
 XX 13-MAY-1994; 94WO-US005142.
 PF
 XX

PR 14-MAY-1993; 93US-00060988.
 XX (USSH) US SEC DEPT HEALTH.
 XX Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
 XX WPI; 1995-006707/01.
 DR Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
 PT responses - to target antigen in hosts of different MHC haplotypes, esp.
 PT for therapeutic or prophylactic vaccines against HIV.
 XX
 PS Example 1; Page 33; 120pp; English.
 XX
 CC Single residues from the HIV-1 RF sequence (AAR66415) replaced residues
 CC in the HIV-1 IIIB sequence (AAR66414) to test the effect of each residue
 CC on the binding of neutralising and non-neutralising sera from animals
 CC immunised with the cluster peptides PCLUS 3-18 and PCLUS 6-18 (see
 CC AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
 CC R66430) showed that binding was enhanced over peptide 18 control when a
 CC tyrosine was substd. for a Val at position 11 and substns. at positions
 CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
 CC sera was reduced when substns. were made in the principal neutralising
 CC determinant sequence (PGRAP). In peptide 18-15, the Lys residue at
 CC position 15 in peptide 18 has been replaced by a Gln residue. (Updated on
 CC 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 15 AA;
 Query Match 94.8%; Score 73; DB 2; Length 15;
 Best Local Similarity 93.3%; Pred. No. 0.00036;
 Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 OY 1 RIQRGGRGFAVTIGK 15
 Db |||||||
 1 RIQRGGRGFAVTIGQ 15
 RESULT 111
 AAR66424
 ID AAR66424 standard; peptide; 15 AA.
 AC AAR66424;
 XX
 XX 25-MAR-2003 (revised)
 DT 03-AUG-1995 (first entry)
 XX
 XX HIV-1 IIIB peptide 18-9.
 DE
 XX T cell helper site; cytotoxic T cell response; neutralising antibody;
 KW human immunodeficiency virus type 1; envelope glycoprotein gp120;
 KW cluster peptide; principal neutralising determinant.
 XX
 OS Synthetic.
 XX
 PN WO9426785-A1.
 XX
 XX 24-NOV-1994.
 PD
 XX 13-MAY-1994; 94WO-US005142.
 PF
 XX 14-MAY-1993; 93US-00060988.
 PR
 XX (USSH) US SEC DEPT HEALTH.
 XX Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
 XX WPI; 1995-006707/01.
 DR Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
 PT responses - to target antigen in hosts of different MHC haplotypes, esp.
 PT for therapeutic or prophylactic vaccines against HIV.
 XX

PS Example 1; Page 33; 120pp; English.
 XX
 CC Single residues from the HIV-1 RF sequence (AAR66415) replaced residues
 CC in the HIV-1 IIIB sequence (AAR66414) to test the effect of each residue
 CC on the binding of neutralising and non-neutralising sera from animals
 CC immunised with the cluster peptides PCLUS 3-18 and PCLUS 6-18 (see
 CC AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
 CC R66430) showed that binding was enhanced over peptide 18 control when a
 CC tyrosine was substd. for a Val at position 11 and substns. at positions
 CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
 CC sera was reduced when substns. were made in the principal neutralising
 CC determinant sequence (PGRAP). In peptide 18-9, the Ala residue at
 CC position 9 in peptide 18 has been replaced by a Val residue. (Updated on
 CC 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 15 AA;
 Query Match 94.8%; Score 73; DB 2; Length 15;
 Best Local Similarity 93.3%; Pred. No. 0.00036;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 1 RIQRGGRGFAVTIGK 15
 Db |||||||
 1 RIQRGGRGFAVTIGK 15
 RESULT 112
 ABB05775
 ID ABB05775 standard; peptide; 20 AA.
 XX
 AC ABB05775;
 XX
 XX 29-AUG-2003 (revised)
 DT 07-MAY-2002 (first entry)
 XX
 XX HIV gp120 related peptide SEQ ID NO:1.
 DE
 XX Polyfunctional base sequence; microgene; industrial; cell culture;
 KW artificial matrix protein; transgenic animal; HIV.
 KW
 XX Human immunodeficiency virus 1.
 OS
 XX WO200196558-A1.
 PN
 XX 20-DEC-2001.
 PD
 XX 15-JUN-2001; 2001WO-JP005116.
 PF
 XX 16-JUN-2000; 2000JP-00180997.
 PR
 XX (NISC-) JAPAN SCI & TECHNOLOGY CORP.
 PA
 XX Shiba K;
 PI
 XX WPI; 2002-098069/13.
 DR
 XX Polyfunctional base sequence having two or more functions in different
 PT reading frames, useful for producing artificial matrix proteins for cell
 PT culture.
 XX
 PS Example 1; Page 46; 61pp; Japanese.
 XX
 CC The present invention describes a polyfunctional base sequence (N1)
 CC having two or more functions in different reading frames. Also described
 CC are: (1) a method for producing N1 and artificial gene expression vectors
 CC comprising N1; (2) transgenic non-human animals comprising N1; and (3)
 CC treatments and diagnostic reagents containing an artificial protein,
 CC artificial tissues or high molecular weight artificial proteins. N1 is
 CC useful for creating industrially useful artificial matrix proteins for
 CC cell culture. The present sequence represents a peptide which is used in
 CC an example from the present invention. (Updated on 29-AUG-2003 to
 CC standardise OS field)
 CC

SQ Sequence 20 AA;

Query Match 94.8%; Score 73; DB 5; Length 20;
 Best Local Similarity 93.3%; Pred. No. 0.00047;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQPGGRTFTVIGK 15
 |||||
 Db 5 RIQPGGRTFTVIGK 19

RESULT 113
 AAO15657
 ID AAO15657 standard; peptide; 20 AA.
 XX
 AC AAO15657;
 XX
 DT 08-NOV-2002 (first entry)
 XX
 DE Strong immune response induction-related peptide 1.
 XX
 KW Strong immune response induction; high-order protein structure formation;
 KW antigen presentation; HIV.
 XX
 OS Unidentified.
 XX
 PN WO200233074-A1.
 XX
 PD 25-APR-2002.
 XX
 PF 10-OCT-2001; 2001WO-JP008893.
 XX
 PR 13-OCT-2000; 2000JP-00314288.
 XX
 PA (NISC-) JAPAN SCI & TECHNOLOGY CORP.
 XX
 PI Shiba K, Ohno T;
 XX
 DR WPI; 2002-519151/55.
 XX
 PT. Artificial protein capable of inducing a strong immune response to a
 PT peptide group for assisting antibody production in vivo to viruses and
 PT other antigens.
 XX
 PS Claim 6; Page 5; 77pp; Japanese.
 CC The invention comprises an artificial protein which induces a strong
 CC immune response to a peptide group (the protein contains all or part of
 CC the peptide group). The artificial protein assists the formation of high-
 CC order protein structure and/or assists the antigen presentation of
 CC immunocompetent cells. The artificial protein of the invention is useful
 CC for inducing a strong immune response and the preparation of effective
 CC antibodies to specific antigens, especially HIV. The present amino acid
 CC sequence represents a peptide that was used in the invention
 XX

SQ Sequence 20 AA;

Query Match 94.8%; Score 73; DB 5; Length 20;
 Best Local Similarity 93.3%; Pred. No. 0.00047;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQPGGRTFTVIGK 15
 |||||
 Db 5 RIQPGGRTFTVIGK 19

RESULT 114
 AAR66416
 ID AAR66416 standard; peptide; 14 AA.
 XX
 AC AAR66416;
 XX
 DT 25-MAR-2003 (revised)

DT 03-AUG-1995 (first entry)
 XX
 DE HIV-1 IIIB peptide 18-1 (316-330).
 XX
 KW T cell helper site; cytotoxic T cell response; neutralising antibody;
 KW human immunodeficiency virus type 1; envelope glycoprotein gp120;
 KW cluster peptide; principal neutralising determinant.
 XX
 OS Synthetic.
 XX
 PN WO9426785-A1.
 XX
 PD 24-NOV-1994.
 XX
 PF 13-MAY-1994; 94WO-US005142.
 XX
 PR 14-MAY-1993; 93US-00060988.
 XX
 PA (USSH) US SEC DEPT HEALTH.
 XX
 PI Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
 XX
 DR WPI; 1995-006707/01.
 XX
 PT Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
 PT responses - to target antigen in hosts of different MHC haplotypes, esp.
 PT for therapeutic or prophylactic vaccines against HIV.
 XX
 PS Example 1; Page 33; 120pp; English.
 XX
 CC Single residues from the HIV-1 RF sequence (AAR66415) replaced residues
 CC in the HIV-1 IIIB sequence (AAR66414) to test the effect of each residue
 CC on the binding of neutralising and non-neutralising sera from animals
 CC immunised with the cluster peptides PCLUS 3-18 and PCLUS 6-18 (see
 CC AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
 CC R66430) showed that binding was enhanced over peptide 18 control when a
 CC tyrosine was substd. for a Val at position 11 and substns. at positions
 CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
 CC sera was reduced when substns. were made in the principal neutralising
 CC determinant sequence (PGRAF). In peptide 18-1, the N-terminal residue
 CC (Arg) in peptide 18 has been deleted. (Updated on 25-MAR-2003 to correct
 CC PN field.)
 XX
 SQ Sequence 14 AA;

Query Match 93.5%; Score 72; DB 2; Length 14;
 Best Local Similarity 100.0%; Pred. No. 0.00048;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 IQRGPGRAFVTIGK 15
 |||||
 Db 1 IQRGPGRAFVTIGK 14

RESULT 115
 AAP95357
 ID AAP95357 standard; peptide; 15 AA.
 XX
 AC AAP95357;
 XX
 DT 27-AUG-2003 (revised)
 DT 30-MAR-1992 (first entry)
 XX
 DE Variable region V3, found in the envelope protein gp120 of an AIDS or ARC
 DE causing or related virus.
 XX
 KW Vaccine; AIDS; ARC; HIV; diagnosis.
 XX
 OS HTLV-IIIB.
 XX
 FH Key Location/Qualifiers
 FT Misc-difference 3..15 /note= "an example of a peptide of the invention"

FT Misc-difference 3. .13 /note= "see above"
 FT Misc-difference 3. .12 /note= "see above"
 FT
 FT
 XX
 PN

EP311219-A.

PD 12-APR-1989.

PF 07-OCT-1988; 88EP-00202248.

PR 09-OCT-1987; 87NL-00002403.

XX (DIER-) STICHTING CENT DIER.

PA (UNAM) UNIV VAN AMSTERDAM.

PA (UYAM-) UNIV AMSTERDAM ZIEKENHUI.

PI Goudmit J, Meloen RH;

XX WPI; 1989-108193/15.

XX Oligopeptide(s) corresp. to beta-turn variable region of gp.120 - used
 PT for diagnosis of and prodn of vaccines against AIDS and ARC.

PS Disclosure; Page 3; 7pp; English.

CC The peptides of the invention comprise the beta-turn AA SQ GPG or GPGR at
 CC positions 312-314 or 312-315 in the AA numbering of HTLV-IIIB (BH10) and
 CC flanking AA SQs having a length equal to or greater than 1 and pref.
 CC equal to or greater than 2 AAs; variants in which the GPG or GPGR SQ has
 CC been replaced by a different beta-turn SQ; and variants in which the free
 CC NH2-terminal gp AA and/or the free carboxyl terminal gp. AA has been
 CC blocked or modified otherwise. (Updated on 27-AUG-2003 to correct OS
 CC field.)

XX SQ Sequence 15 AA;

Query Match 93.5%; Score 72; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.00051;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIG 14

DB 2 RIQRGPGRAFTVIG 15

RESULT 116

AAR33460
 ID AAR33460 standard; peptide; 15 AA.

XX AAR33460;

XX 27-AUG-2003 (revised)

DT 25-MAR-2003 (revised)

DT 17-DEC-2001 (revised)

DT 03-JUL-1993 (first entry)

XX Sequence of synthetic peptide which represents residues 315-329 of the
 DE pg160 envelope protein of HIV-1 isolate IIB.

XX Cytotoxic T lymphocyte; immunogenic peptide; V3 loop; treatment;
 KW glycoprotein 160.

XX Human immunodeficiency virus 1.

XX USN7847311-N.

PD 01-JAN-1993.

XX 06-MAR-1992; 92US-00847311.

XX 26-JAN-1988; 88US-00148692.

PR 18-SEP-1991; 91US-00760530.

XX (USSH) US DEPT HEALTH & HUMAN SERVICE.

XX Berzofsky JA, Taskeshita T, Shirai M, Pendleton CD, Kozlowski S;

XX WPI; 1993-093577/11.

XX Peptide(s) for stimulation of cytotoxic T cells specific for HIV-1 -
 PT which correspond to residues 318-327 of HIV-1 gp 160 envelope
 PT glycoprotein.

XX Disclosure; Page 9; 61pp; English.

XX The peptide corresp. to residues 319-329 of HIV-1 strain IIB gp. 160
 CC envelope glycoprotein. It is activated by cleavage with a protease to
 CC produce a peptide which is more active in eliciting a cytotoxic T
 CC lymphocyte (CTL) response. It can be used for the treatment and/or
 CC prophylaxis of HIV infection. (Note: Revised entry submitted to correct
 CC the patent number format of US Government-owned NTIS applications to
 CC prevent clashes with ongoing US granted patent numbers. For further
 CC information please visit the Derwent web site at
 CC www.derwent.com/dwpi/updates/ntis_us.html.) (Updated on 25-MAR-2003 to
 CC correct PF field.) (Updated on 27-AUG-2003 to correct OS field.)

XX SQ Sequence 15 AA;

Query Match 93.5%; Score 72; DB 2; Length 15;
 Best Local Similarity 93.3%; Pred. No. 0.00051;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIG 15

DB 1 RIQRGPGRAFTVIG 15

RESULT 117

AAR62166

ID AAR62166 standard; peptide; 15 AA.

XX AAR62166;

XX 27-AUG-2003 (revised)

DT 25-MAR-2003 (revised)

DT 03-MAY-1995 (first entry)

XX HIV-1 gp120 V3 loop dominant neutralising domain in chimpanzees.

XX epitope; autoantibody; immunoinfective cluster virus;
 KW nuclear protein antigen; systemic rheumatic disorder;
 KW human immunodeficiency virus; HIV-1; systemic lupus erythematosus;
 KW mixed connective tissue disease; scleroderma; glycoprotein 120.

XX Human immunodeficiency virus 1.

XX W09420141-A1.

XX 15-SEP-1994.

XX 10-MAR-1994; 94WO-US002631.

XX 11-MAR-1993; 93US-00029850.

XX (UYSC-) UNIV SOUTHERN CALIFORNIA.

XX Douvas A, Takehana Y, Ehresmann G;

XX WPI; 1994-302689/37.

XX Methods for treating immunoinfective cluster virus infections - utilise
 PT antibodies or fragments characteristic of auto antibodies produced by
 PT patients with rheumatic disorders.

XX Disclosure; Page 62; 106pp; English.

XX Previous immunological analyses of the V3 loop of HIV-1 (AAR62159) have
 CC localised the main neutralising domains. The target of more than 80% of
 CC neutralising antibodies in HIV-1 infected sera from AIDS patients has now
 CC been found to overlap the consensus binding sequence and domain A epitopes
 CC of the U1 snRNP 70K protein. In AIDS, antibody titres are too low to
 CC arrest the disease; however, the homologous sequences in 70K are
 CC immunodominant targets of autoantibodies in the systemic rheumatoid
 CC disorder of mixed connective tissue disease. The titers of such
 CC autoantibodies exceed 10 power 7. The anti-snRNP autoantibodies will
 CC cross-react with HIV-1 epitopes and are useful for treating HIV
 CC infection. (Updated on 25-MAR-2003 to correct OS field.) (Updated on 27-
 CC AUG-2003 to correct OS field.)

XX Sequence 15 AA;
 SQ
 Query Match 93.5%; Score 72; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.00051; Mismatches 0; Indels 0; Gaps 0;
 Matches 14; Conservative 0;

QY 1 RIQRGPGRAFTVIG 14
 |||||
 Db 2 RIQRGPGRAFTVIG 15

RESULT 118
 AAR66427
 ID AAR66427 standard; peptide; 15 AA.

XX AAR66427;
 AC
 XX 25-MAR-2003 (revised)
 DT 03-AUG-1995 (first entry)
 DT
 XX HIV-1 IIIB peptide 18-12.

XX T cell helper site; cytotoxic T cell response; neutralising antibody;
 KW human immunodeficiency virus type 1; envelope glycoprotein gp120;
 KW cluster peptide; principal neutralising determinant.
 XX Synthetic.

XX WO9426785-A1.
 PN
 XX 24-NOV-1994.

XX 13-MAY-1994; 94WO-US005142.
 PF
 XX 14-MAY-1993; 93US-00060988.
 PR
 XX (USSH) US SEC DEPT HEALTH.

XX Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
 PI
 XX WPI; 1995-006707/01.

XX Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
 PT responses - to target antigen in hosts of different MHC haplotypes, esp.
 PT for therapeutic or prophylactic vaccines against HIV.

XX Example 1; Page 33; 120pp; English.

XX Single residues from the HIV-1 RF sequence (AAR66415) replaced residues
 CC in the HIV-1 IIIB sequence (AAR66414) to test the effect of each residue
 CC on the binding of neutralising and non-neutralising sera from animals
 CC immunised with the cluster peptides PCLUS 3-18 and PCLUS 6-18 (see
 CC AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
 CC R66430) showed that binding was enhanced over peptide 18 control when a
 CC tyrosine was substd. for a Val at position 11 and substns. at positions
 CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
 CC sera was reduced when substns. were made in the principal neutralising
 CC determinant sequence (PGRAP). In peptide 18-12, the Thr residue at
 CC position 12 in peptide 18 has been replaced by an Ala residue. (Updated

CC on 25-MAR-2003 to correct PN field.)
 XX Sequence 15 AA;
 SQ

Query Match 93.5%; Score 72; DB 2; Length 15;
 Best Local Similarity 93.3%; Pred. No. 0.00051;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIG 15
 |||||
 Db 1 RIQRGPGRAFVAIGK 15

RESULT 119
 AAR66428
 ID AAR66428 standard; peptide; 15 AA.

XX AAR66428;
 AC
 XX 25-MAR-2003 (revised)
 DT 03-AUG-1995 (first entry)
 DT
 XX HIV-1 IIIB peptide 18-13.

XX T cell helper site; cytotoxic T cell response; neutralising antibody;
 KW human immunodeficiency virus type 1; envelope glycoprotein gp120;
 KW cluster peptide; principal neutralising determinant.
 XX Synthetic.

XX WO9426785-A1.
 PN
 XX 24-NOV-1994.

XX 13-MAY-1994; 94WO-US005142.
 PF
 XX 14-MAY-1993; 93US-00060988.
 PR
 XX (USSH) US SEC DEPT HEALTH.

XX Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
 PI
 XX WPI; 1995-006707/01.

XX Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
 PT responses - to target antigen in hosts of different MHC haplotypes, esp.
 PT for therapeutic or prophylactic vaccines against HIV.

XX Example 1; Page 33; 120pp; English.

XX Single residues from the HIV-1 RF sequence (AAR66415) replaced residues
 CC in the HIV-1 IIIB sequence (AAR66414) to test the effect of each residue
 CC on the binding of neutralising and non-neutralising sera from animals
 CC immunised with the cluster peptides PCLUS 3-18 and PCLUS 6-18 (see
 CC AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
 CC R66430) showed that binding was enhanced over peptide 18 control when a
 CC tyrosine was substd. for a Val at position 11 and substns. at positions
 CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
 CC sera was reduced when substns. were made in the principal neutralising
 CC determinant sequence (PGRAP). In peptide 18-13, the Ile residue at
 CC position 13 in peptide 18 has been replaced by a Thr residue. (Updated on
 CC 25-MAR-2003 to correct PN field.)

XX Sequence 15 AA;
 SQ

Query Match 93.5%; Score 72; DB 2; Length 15;
 Best Local Similarity 93.3%; Pred. No. 0.00051;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIG 15
 |||||
 Db 1 RIQRGPGRAFTVIGK 15

RESULT 120
 AAR66426
 ID AAR66426 standard; peptide; 15 AA.
 XX
 AC AAR66426;
 XX
 DT 25-MAR-2003 (revised)
 DT 03-AUG-1995 (first entry)
 XX
 DE HIV-1 IIIB peptide 18-11.
 XX
 KW T cell helper site; cytotoxic T cell response; neutralising antibody;
 KW human immunodeficiency virus type 1; envelope glycoprotein gp120;
 KW cluster peptide; principal neutralising determinant.
 XX
 OS Synthetic.
 XX
 PN WO9426785-A1.
 XX
 PD 24-NOV-1994.
 XX
 PF 13-MAY-1994; 94WO-US005142.
 XX
 PR 14-MAY-1993; 93US-00060988.
 XX
 PA (USSH) US SEC DEPT HEALTH.
 XX
 PI Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
 XX
 DR WPI; 1995-006707/01.
 XX
 PT Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
 PT responses - to target antigen in hosts of different MHC haplotypes, esp.
 PT for therapeutic or prophylactic vaccines against HIV.
 XX
 PS Example 1; Page 33; 120pp; English.
 XX
 CC Single residues from the HIV-1 RF sequence (AAR66415) replaced residues
 CC on the HIV-1 IIIB sequence (AAR66414) to test the effect of each residue
 CC on the binding of neutralising and non-neutralising sera from animals
 CC immunised with the cluster peptides PCLUS 3-18 and PCLUS 6-18 (see
 CC AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
 CC R66430) showed that binding was enhanced over peptide 18 control when a
 CC tyrosine was substd. for a Val at position 11 and substns. at positions
 CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
 CC sera was reduced when substns. were made in the principal neutralising
 CC determinant sequence (PGRF). In peptide 18-11, the Val residue at
 CC position 11 in peptide 18 has been replaced by a Tyr residue. (Updated on
 CC 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 15 AA;
 Query Match 93.5%; Score 72; DB 2; Length 15;
 Best Local Similarity 93.3%; Pred. No. 0.00051;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 1 RIQPGGGRFVTTGK 15
 |||||
 Db 1 RIQPGGGRFVTTGK 15
 |||||
 RESULT 121
 AAR33236
 ID AAR33236 standard; peptide; 16 AA.
 XX
 AC AAR33236;
 XX
 DT 25-MAR-2003 (revised)
 DT 13-JUL-1993 (first entry)
 XX
 DE HIV-IIIB gp120 V3 loop epitope peptide RP135.
 XX

KW HIV-1; human immunodeficiency virus; competition assay; AIDS; infection;
 KW CD4 binding site; soluble CD4.
 XX
 OS Synthetic.
 XX
 PN WO9304693-A1.
 XX
 PD 18-MAR-1993.
 XX
 PF 02-SEP-1992; 92WO-US007511.
 XX
 PR 09-SEP-1991; 91US-00756677.
 PR 20-JUL-1992; 92US-00916542.
 XX
 PA (REPK) REPLIGEN CORP.
 XX
 PI Potts BJ, Whiteschaf ME, Field KG, Herlihy WC;
 XX
 DR WPI; 1993-100653/12.
 XX
 PT Synergistic compen. for treating HIV-1 infection - comprises antibody to
 PT V3 loop of GP120 and antibody to CD4 binding site of GP120 or soluble CD4
 PT polypeptide.
 XX
 PS Example; Page 20; 56pp; English.
 XX
 CC The sequence is that of the HIV-IIIB V3 loop epitope peptide RP135 which
 CC was used in a competition assay to determine whether a given anti-V3 loop
 CC antibody will have strong neutralisation activity by itself, and if it
 CC has potential to act synergistically with a second agent. The assay can
 CC be used to test for potential neutralisation activity of any anti-V3 loop
 CC antibody towards any isolate by using a peptide derived from the V3 loop
 CC from the HIV isolate of interest as the competitor (Updated on 25-MAR-
 CC 2003 to correct PN field.) (Updated on 25-MAR-2003 to correct PI field.)
 XX
 SQ Sequence 16 AA;
 Query Match 93.5%; Score 72; DB 2; Length 16;
 Best Local Similarity 100.0%; Pred. No. 0.00054;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 RIQPGGGRFVTTG 14
 |||||
 Db 3 RIQPGGGRFVTTG 16
 |||||
 RESULT 122
 AAP95348
 ID AAP95348 standard; peptide; 17 AA.
 XX
 AC AAP95348;
 XX
 DT 27-AUG-2003 (revised)
 DT 30-MAR-1992 (first entry)
 XX
 DE Variable region V3 sequence found in the envelope protein gp120 of an
 DE AIDS or ARC causing or related virus.
 XX
 KW Vaccine; AIDS; ARC; HIV; diagnosis.
 XX
 OS HTLV-IIIB.
 XX
 PN EP311219-A.
 XX
 PD 12-APR-1989.
 XX
 PF 07-OCT-1988; 88EP-00202248.
 XX
 PR 09-OCT-1987; 87NL-00002403.
 XX
 PA (DIER-) STICHTING CENT DIER.
 PA (UNAM) UNIV VAN AMSTERDAM.
 PA (UYAM-) UNIV AMSTERDAM ZIEKENHUI.

XX Goudsmit J, Melloen RH;
 XX WPI; 1989-108193/15.
 XX Oligopeptide(s) corresp. to beta-turn variable region of gp.120 - used
 PT for diagnosis of and prodn of vaccines against AIDS and ARC.
 XX Disclosure; Page 3; 7pp; English.
 XX The peptides of the invention comprise the beta-turn AA SQ GPG or GPGR at
 CC positions 312-314 or 312-315 in the AA numbering of HTLV-IIIB (BH10) and
 CC flanking AA SQs having a length equal to or greater than 1 and pref.
 CC equal to or greater than 2 AAs; variants in which the GPG or GPGR SQ has
 CC been replaced by a different beta-turn SQ; and variants in which the free
 CC NH2-terminal gp AA and/or the free carboxyl terminal gp. AA has been
 CC blocked or modified otherwise. (Updated on 27-AUG-2003 to correct OS
 CC field.)
 XX Sequence 17 AA;
 SQ
 Query Match 93.5%; Score 72; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.00057; Mismatches 0; Indels 0; Gaps 0;
 Matches 14; Conservative 0;
 QY 1 RIQGPGRGFAFTIG 14
 DB 4 RIQGPGRGFAFTIG 17
 RESULT 123
 AAP95349
 ID AAP95349 standard; peptide; 17 AA.
 XX
 AC AAP95349;
 XX
 DT 27-AUG-2003 (revised)
 DT 30-MAR-1992 (first entry)
 XX
 DE Variable region V3 found in the envelope protein gp120 of an AIDS or ARC
 DE causing or related virus.
 XX
 KW Vaccine; AIDS; ARC; HIV; diagnosis.
 XX
 OS HTLV-IIIB.
 XX
 PN EP3111219-A.
 XX
 PD 12-APR-1989.
 XX
 PF 07-OCT-1988; 88EP-00202248.
 XX
 PR 09-OCT-1987; 87NL-00002403.
 XX
 PA (DIER-) STICHTING CENT DIER.
 PA (UNAM) UNIV VAN AMSTERDAM.
 PA (UYAM-) UNIV AMSTERDAM ZIEKENHUI.
 XX
 PI Goudsmit J, Melloen RH;
 XX
 DR WPI; 1989-108193/15.
 XX
 PT Oligopeptide(s) corresp. to beta-turn variable region of gp.120 - used
 PT for diagnosis of and prodn of vaccines against AIDS and ARC.
 XX Disclosure; Page 3; 7pp; English.
 XX The peptides of the invention comprise the beta-turn AA SQ GPG or GPGR at
 CC positions 312-314 or 312-315 in the AA numbering of HTLV-IIIB (BH10) and
 CC flanking AA SQs having a length equal to or greater than 1 and pref.
 CC equal to or greater than 2 AAs; variants in which the GPG or GPGR SQ has
 CC been replaced by a different beta-turn SQ; and variants in which the free
 CC NH2-terminal gp AA and/or the free carboxyl terminal gp. AA has been

CC blocked or modified otherwise. (Updated on 27-AUG-2003 to correct OS
 CC field.)
 XX Sequence 17 AA;
 SQ
 Query Match 93.5%; Score 72; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.00057; Mismatches 0; Indels 0; Gaps 0;
 Matches 14; Conservative 0;
 QY 1 RIQGPGRGFAFTIG 14
 DB 4 RIQGPGRGFAFTIG 17
 RESULT 124
 AAR29241
 ID AAR29241 standard; peptide; 17 AA.
 XX
 AC AAR29241;
 XX
 DT 24-OCT-2003 (revised)
 DT 25-MAR-2003 (revised)
 DT 14-APR-1993 (first entry)
 XX
 DE V3 loop region epitope from IIIB isolate.
 XX
 KW V3 loop; gp120; envelope protein; MN; prototype; virus; variant;
 KW homology; heteroconjugate; enzyme; HIV.
 XX
 OS Human immunodeficiency virus; IIIB variant.
 XX
 PN WO9220373-A1.
 XX
 PD 26-NOV-1992.
 XX
 PF 29-APR-1992; 92WO-US003616.
 XX
 PR 14-MAY-1991; 91US-00699773.
 XX
 PA (REPK) REPLIGEN CORP.
 XX
 PI Higgins RJ, Potts BJ;
 XX
 DR WPI; 1992-415475/50.
 XX
 PT Hetero-conjugate antibodies for treating HIV infections - comprise an
 PT antibody specific for an effector cell surface antigen and an antibody to
 PT a V3 loop of GP-120 envelope protein of HIV.
 XX
 PS Disclosure; Page 32; 69pp; English.
 XX
 CC The sequences given in AAR29237-43 represent a portion of the V3 loop
 CC region of the gp120 envelope protein of various HIV isolates. These
 CC sequences can be used to define the specific isolate. All these viral
 CC variants exhibit complete homology at residues 7-11 of the given sequence
 CC and at least 36% homology with the remaining 12 amino acids of the
 CC sequence. Viruses containing these sequences are recognised by the
 CC heteroconjugate enzyme of the invention. (Updated on 25-MAR-2003 to
 CC correct PN field.) (Updated on 24-OCT-2003 to standardise OS field)
 XX
 SQ Sequence 17 AA;
 Query Match 93.5%; Score 72; DB 2; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.00057;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQGPGRGFAFTIG 14
 DB 4 RIQGPGRGFAFTIG 17
 RESULT 125
 AAR32407

ID AAR32407 standard; peptide; 17 AA.
 AC AAR32407;
 XX
 XX
 DT 25-MAR-2003 (revised)
 DT 04-JUL-1993 (first entry)
 XX
 XX Sequence of peptide B2 which comprises AAs 312-281 from the V3 region of
 DE HIV-1 isolate IIB.
 DE HIV-1 isolate IIB.
 XX
 XX HIV-1; vaccine; dendritic core; ss.
 KW
 XX Synthetic.
 OS
 XX WO9303766-A1.
 PN
 XX
 PD 04-MAR-1993.
 XX
 PF 11-AUG-1992; 92WO-US006688.
 XX
 XX 13-AUG-1991; 91US-00744281.
 PR
 XX (REP) REPLIGEN CORP.
 PA
 PA (UVRQ) UNIV ROCKEFELLER.
 XX
 XX Tam JP, Profy AT;
 PI
 XX WPI; 1993-093730/11.
 DR
 XX New multiple antigen peptide(s) as HIV vaccines - include a dendritic
 PT core covalently bonded to peptide including the sequence IGPR.
 XX
 XX Example; Fig 1; 35pp; English.
 PS
 XX Nine peptides from the V3 regions of HIV-1 isolates IIB, RF and MN were
 CC incorporated into tetraivalent multiple antigen peptide systems (MAPS)
 CC (see AAR32406-14). Parallel groups of three peptides with chain lengths
 CC spanning from 11-24 residues were synthesised in MAPS format for each
 CC isolate. ELIS assays demonstrated that antisera titers in mice were
 CC closely related to the length of the IIB peptide used for the
 CC immunisation - the longer the stronger the response. There was no
 CC subantantial antibody prodn. in mice against the other two series of
 CC peptides, RF (B4-B6), and MN (B7-B9), except for a low reactivity in the
 CC 9p. immunised with B8 (MN isolate). Specificity tests of the B cell
 CC response demonstrated that the T cell epitope (AAR32415) also serves as a
 CC B cell epitope. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 17 AA;
 Query Match 93.5%; Score 72; DB 2; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.00057;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 RIQGGPGRAFTVIG 14
 Db 4 RIQGGPGRAFTVIG 17
 RESULT 126
 AAR68664
 ID AAR68664 standard; peptide; 17 AA.
 XX
 AC AAR68664;
 XX
 DT 16-OCT-2003 (revised)
 DT 25-MAR-2003 (revised)
 DT 06-SEP-1995 (first entry)
 XX
 XX T cell epitope derived from V3 isolate LAI.
 DE
 XX
 KW T-cell; epitope; HIV-1; core protein; p24E; B-cell; antigen; gp160; gag;
 KW pol; vaccine; multimeric peptide; AIDS; 3D organisation.
 XX

OS Human immunodeficiency virus 1.
 PN WO9429339-A1.
 XX
 XX 22-DEC-1994.
 PD
 XX 08-JUN-1994; 94WO-CA000317.
 PF
 XX 09-JUN-1993; 93US-00073378.
 PR
 XX (CONN-) CONNAUGHT LAB LTD.
 PA
 XX Sia CDY, Chong P, Klein MH;
 PI
 XX WPI; 1995-036400/05.
 DR
 XX Novel tandem synthetic HIV-1 peptide(s) - comprising T-cell epitope of
 PT gag protein linked to B-cell epitope of V3 loop protein of an HIV-1
 PT isolate.
 PT
 XX Disclosure; Page 39; 69pp; English.
 PS
 XX This sequence represents a T-cell epitope derived from the V3 sequence of
 CC the HIV-1 isolate LAI, which may be linked to a B-cell epitope from the
 CC V3 (MN) loop from HIV-1. These chimeric peptides may then be used in the
 CC production of HIV-1 vaccines. These peptide sequences may also be used in
 CC the production of multimeric peptides in which the peptides are C-
 CC terminally modified by the addition of a Lys residue which is modified on
 CC its epsilon amino acid to carry an additional copy of the peptide
 CC molecule. The linear and multimeric peptides may be used for the
 CC treatment of AIDS by acting to displace the binding of HIV virus to human
 CC or animal cells or by disturbing the 3D organisation of the virus.
 CC (Updated on 25-MAR-2003 to correct PN field.) (Updated on 16-OCT-2003 to
 CC standardise OS field)
 CC
 SQ Sequence 17 AA;
 Query Match 93.5%; Score 72; DB 2; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.00057;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 RIQGGPGRAFTVIG 14
 Db 4 RIQGGPGRAFTVIG 17
 RESULT 127
 AAW25834
 ID AAW25834 standard; peptide; 17 AA.
 XX
 AC AAW25834;
 XX
 DT 25-MAR-2003 (revised)
 DT 20-OCT-1997 (first entry)
 XX
 DE HIV B-cell strain LAI env protein V3 loop peptide.
 XX
 XX HIV; human immunodeficiency virus; gag; T-cell; B-cell; epitope; env;
 KW V3 loop; vaccine; determinant; chimaeric.
 KW
 XX Synthetic.
 OS
 XX US5639854-A.
 PN
 XX 17-JUN-1997.
 PD
 XX 09-JUN-1994; 94US-00257528.
 PF
 XX 09-JUN-1993; 93US-00073378.
 PR
 XX (CONN-) CONNAUGHT LAB LTD.
 PA
 XX Klein MH, Sia CDY, Chong P;
 PI

XX DR WPI; 1997-332082/30.
 XX PT Tandem synthetic HIV peptide(s) useful as immunogens - comprising gag
 XX PT protein T-cell epitope linked to env protein B-cell epitope.
 XX PS Disclosure; Col 21; 41pp; English.
 XX CC The invention relates to new synthetic peptides comprising at least one
 CC amino acid sequence comprising an HIV gag protein T-cell epitope linked
 CC at its C- or N-terminus to an amino acid sequence comprising a B-cell
 CC epitope of the V3 loop of an HIV env protein, which can be used to
 CC generate vaccines against HIV-1. The T-cell epitope sequence is pref.
 CC selected from the T-helper determinant core peptides P24E, P24N, P24L,
 CC P24M and P24H while the B-cell epitopes are derived from HIV strains
 CC including CTLB-56, V3MN, CTLB-29, CTLB-55, SF2, LAI, IIB, RF, Z6, 2054,
 CC 1714 and BX08. The peptides are chimeric and can be linked to a branched
 CC Lys backbone. This sequence represents the B-cell env protein V3 loop
 CC peptide from HIV-1 strain LAI. (Updated on 25-MAR-2003 to correct PF
 CC field.)
 XX SQ Sequence 17 AA;
 Query Match 93.5%; Score 72; DB 2; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.00057;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQGPGRGFAVTIG 14
 Db |||||
 4 RIQGPGRGFAVTIG 17
 RESULT 128
 AAW76848
 ID AAW76848 standard; peptide; 17 AA.
 AC AAW76848;
 XX 25-JAN-1999 (first entry)
 DT Fusion immunoglobulin heavy chain HIV gp120 B cell epitope #18.
 XX B cell; T cell; epitope; immunoglobulin; heavy chain; gp120; IGH;
 KW human immune deficiency virus; HIV; tolerance; treatment; therapy;
 KW prophylaxis; vaccine; chemotherapy; immune response; modifier; tumour;
 KW microbial infection; autoimmune disease; antibody; apoptosis;
 KW antiviral T cell immunity.
 XX Mus sp.
 OS Homo sapiens.
 XX WO9836087-A1.
 PN 20-AUG-1998.
 PD 13-FEB-1998; 98WO-US002766.
 XX 13-FEB-1997; 97US-0040581P.
 PR (AMNA-) AMERICAN NAT RED CROSS.
 XX Scott D, Zambidis E;
 PI WPI; 1998-506315/43.
 DR New fusion immunoglobulin heavy chain including gp120 epitopes and
 XX related complete antibodies - DNA, vectors and transformed cells, used to
 PT induce tolerance to the epitopes for treatment of human immune deficiency
 PT virus infection.
 XX Claim 10; Page 119; 154pp; English.
 PS This sequence is an epitope used in the construction of a novel fusion
 CC

CC immunoglobulin heavy chain (IGH) protein with a mammalian, especially
 CC human, IGH chain fused in frame at its N-terminus to one or more human
 CC immune deficiency virus (HIV) gp120 epitopes. Fusion Ig proteins and/or
 CC transfected cells are used to tolerate subjects to gp120 epitopes and to
 CC maintain this tolerance, particularly for treatment of HIV infection,
 CC optionally together with other therapeutic/prophylactic agents such as
 CC vaccines, chemotherapeutic agents and immune response modifiers. Such
 CC proteins can be used against other diseases where an immune response is
 CC deleterious, e.g. microbial infection, tumours or autoimmune disease.
 CC Induction of tolerance suppresses production of antibodies against gp120,
 CC so prevents or inhibits 'bystander' apoptosis of uninfected T cells that
 CC are bound to gp120 protein, maximising induction of protective antiviral
 CC T cell immunity
 XX SQ Sequence 17 AA;
 Query Match 93.5%; Score 72; DB 2; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.00057;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQGPGRGFAVTIG 14
 Db |||||
 4 RIQGPGRGFAVTIG 17
 RESULT 129
 AAW67350
 ID AAW67350 standard; peptide; 17 AA.
 AC AAW67350;
 XX 17-OCT-2003 (revised)
 DT 25-JAN-1999 (first entry)
 XX HIV-1 strain LAI gp120 V3 loop epitope peptide.
 DE Immunogen; vaccine; HIV-1; T-cell; B-cell; epitope; core protein; gp120;
 KW V3 loop.
 KW Human immunodeficiency virus 1.
 XX US5817754-A.
 PN 06-OCT-1998.
 PD 05-JUN-1995; 95US-00464329.
 XX 09-JUN-1993; 93US-00073378.
 PR 09-JUN-1994; 94US-00257528.
 XX (CONN-) CONNAUGHT LAB LTD.
 PA Chong P, Klein MH, Sia CDY;
 PI WPI; 1998-556461/47.
 XX Synthetic human immunodeficiency virus-1 peptide(s) - containing T-cell
 PT epitope and B-cell epitope(s) are candidate vaccines against HIV-1.
 XX Disclosure; Col 21; 40pp; English.
 XX The invention relates to a novel immunogenic composition for use in
 CC vaccines for the treatment of HIV-1 comprising an HIV-1-derived T-cell
 CC epitope linked to an HIV-1-derived B-cell epitope. The T-cell epitopes
 CC are generally designed based on the p24 core protein and the B-cell
 CC epitopes from the V3 loop of the gp120 protein from various HIV-1
 CC strains. This peptide represents the V3 loop epitope from the HIV-1
 CC strain LAI. (Updated on 17-OCT-2003 to standardise OS field)
 XX SQ Sequence 17 AA;
 Query Match 93.5%; Score 72; DB 2; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.00057;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIG 14
 Db 4 RIQRGPGRAFTVIG 17

RESULT 130
 AAW99958
 ID AAW99958 standard; peptide; 17 AA.
 XX
 AC AAW99958;
 XX
 DT 05-MAY-1999 (first entry)
 DE HIV-1 vaccine synthetic peptide SEQ ID NO:35.
 XX
 KW HIV-1; human immunodeficiency virus; vaccine; T-cell epitope;
 KW gag protein; B-cell epitope; gp41 protein; chimeric; infection.
 XX
 OS Synthetic.
 OS Human immunodeficiency virus 1.
 XX
 PN US5876731-A.
 XX
 PD 02-MAR-1999.
 XX
 PF 05-JUN-1995; 95US-00462507.
 XX
 PR 09-JUN-1993; 93US-00073378.
 PR 09-JUN-1994; 94US-00257528.
 XX
 PA (CONN-) CONNAUGHT LAB LTD.
 XX
 PI Chong P, Klein MH, Sia CDY;
 DR WPI; 1999-189590/16.
 XX
 PT Synthetic chimeric HIV polypeptides - comprising gag protein T-cell
 PT epitope linked to gp41 B-cell epitope.
 XX
 PS Example 1; Col 41-42; 41pp; English.
 XX
 CC The present invention describes a synthetic peptide comprising an amino
 CC acid sequence containing a T-cell epitope of an HIV gag protein linked at
 CC its C terminus to an amino acid sequence containing a B-cell epitope of
 CC an HIV gp41 protein and containing the amino acid sequence: XILKDWX2;
 CC where X1 = E, A, G or Q, and X2 = A or T, or an amino acid sequence
 CC capable of eliciting an HIV-specific antiserum and recognizing the
 CC sequence XILKDWX2. The synthetic peptide is useful in vaccines against
 CC HIV infection and in diagnostic applications. AAW98892 to AAW98906, and
 CC AAW98989 to AAW99989 represent synthetic peptides from the present
 CC invention
 XX
 SQ Sequence 17 AA;

Query Match 93.5%; Score 72; DB 2; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.00057;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIG 14
 Db 4 RIQRGPGRAFTVIG 17

RESULT 131
 AAY39756
 ID AAY39756 standard; peptide; 17 AA.
 XX
 AC AAY39756;
 XX
 DT 17-OCT-2003 (revised)
 DT 26-NOV-1999 (first entry)

XX HIV1 chimeric peptide V3-LAI.
 DE
 XX HIV; vaccine; immunogenic composition; T cell epitope; B cell epitope;
 KW infection; antibody; antiviral.
 KW
 XX Human immunodeficiency virus 1.
 OS
 XX US5951986-A.
 PN
 XX 14-SEP-1999.
 PD
 XX 06-JUN-1995; 95US-00467881.
 PF
 XX 09-JUN-1993; 93US-00073378.
 PR
 PR 09-JUN-1994; 94US-00257528.
 XX
 PA (CONN-) CONNAUGHT LAB LTD.
 XX
 PI Klein MH, Chong P, Sia CDY;
 DR WPI; 1999-550482/46.
 XX
 CC Immunogenic composition containing synthetic fusion polypeptides
 CC containing both the T and B cell epitopes of the human immunodeficiency
 CC virus, useful antigens in producing vaccines.
 XX
 PS Example 1; Col 22; 43pp; English.
 XX
 CC This sequence represents a fragment of a HIV1 protein, and can be used in
 CC the immunogenic composition of the invention. The composition comprises a
 CC synthetic fusion polypeptide which includes a sequence encoding 1 or more
 CC T cell epitopes and a sequence encoding 1 or more B cell epitopes and a
 CC carrier. Both the T cell and B cell epitopes are derived from HIV
 CC proteins. The compositions are useful as vaccines against HIV infection.
 CC The composition induces HIV-1-specific polyclonal antibodies that are
 CC opsonising and antiviral. The peptide components may be selected to
 CC induce a response against different viral isolates and in subjects who
 CC recognise different T cell epitopes. (Updated on 17-OCT-2003 to
 CC standardise OS field)
 XX
 SQ Sequence 17 AA;

Query Match 93.5%; Score 72; DB 2; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.00057;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTVIG 14
 Db 4 RIQRGPGRAFTVIG 17

RESULT 132
 ADN14075
 ID ADN14075 standard; peptide; 17 AA.
 XX
 AC ADN14075;
 XX
 DT 17-JUN-2004 (first entry)
 XX
 DE HIV helper T cell epitope #42.
 XX
 KW HIV; antigen; epitope; T cell; MHC; major histocompatibility complex;
 KW CTL; cytotoxic T lymphocyte; HIV infection; cancer; tuberculosis; tumour;
 KW hepatitis; melanoma; breast cancer; Hodgkin lymphoma;
 KW nasopharyngeal carcinoma; vaccine; immune response; hyaluronic acid; HA;
 KW CD8+ T cell; CD4+ T cell; viral infection; bacterial infection;
 KW fungal infection; parasitic infection.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN US2003049253-A1.
 XX

CC in an infected subject. The present sequence represents a peptide used in
 CC the exemplification of the present invention.

SQ Sequence 17 AA;

Query Match 93.5%; Score 72; DB 8; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.00057;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGFAFVTIG 14
 |||||
 Db 4 RIQPGGFAFVTIG 17
 |||||

RESULT 134
 AAR38526
 ID AAR38526 standard; peptide; 18 AA.

XX AC AAR38526;

XX XX 25-MAR-2003 (revised)

DT DT 21-DEC-1993 (first entry)

XX DE Cyclic HIV PND peptide cPND535.

XX Cyclic; HIV; principle neutralising determinant; PND; conjugate;
 KW immunological carrier; antipeptide; anti-HIV; HIV-neutralising; antibody;
 KW vaccine; immune response.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT Modified-site 1 /note= "Alpha amino group forms a cyclic peptide by
 FT condensing to the C-terminal of Gly18"

FT Misc-difference 2 /label= OTHER

FT /note= "Abu = gamma aminobutyric acid"

FT Modified-site 18 /note= "C-terminal condensed to the N-terminal of Lys1 to
 FT form cyclic peptide"

XX PN EP551689-A2.

XX XX 21-JUL-1993.

XX PF 10-JAN-1992; 92EP-00300243.

XX PR 19-DEC-1991; 91US-00807943.

XX PA (MERI) MERCK & CO INC.

XX PI Bednarek MA, Tolman RL;

XX XX WPI; 1993-228557/29.

XX Cyclic HIV principal neutralising determinant (PND) peptide(s) - useful
 PT as vaccines for treating and preventing HIV-mediated diseases e.g. AIDS
 PT and ARC.

XX PS Claim 3; Page 26; 27pp; English.

XX The sequences given in AAR38520-26 are cyclic HIV principle neutralising
 CC determinant (PND) peptides. They are stable compounds which, when
 CC conjugated with an immunological carrier, may be used to raise
 CC antipeptide, anti-HIV and HIV-neutralising antibodies. These may be used
 CC in vaccines for prevention or treatment of HIV-related diseases. They may
 CC also be used as reagents in the study of structure/function relationships
 CC in induction of HIV-neutralising immune response. (Updated on 25-MAR-2003
 CC to correct PN field.)

XX SQ Sequence 18 AA;

Query Match 93.5%; Score 72; DB 2; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0006;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Query Match 93.5%; Score 72; DB 2; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0006;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQPGGFAFVTIG 14
 |||||
 Db 5 RIQPGGFAFVTIG 18
 |||||

RESULT 135

AAW03404
 ID AAW03404 standard; peptide; 18 AA.

XX AC AAW03404;

XX XX 10-OCT-1996 (first entry)

XX DE HIV principal neutralising determinant cPND535.

XX conjugate; PND; HIV; principal neutralizing determinant; OMPC;
 KW outer membrane protein complex; anionic spacer; vaccine;
 KW human immunodeficiency virus; water-soluble.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT Modified-site 1 /label= cycle

FT /note= "one amino group of this lysine residue is linked
 FT to Neisseria meningitidis OMPC via a specified anionic
 FT spacer group; and the other forms a peptide bond with the
 FT terminal carboxy group of Gly(18), giving a cyclic
 FT peptide"

FT Modified-site 2 /label= Abu

FT Modified-site 18 /note= "the carboxy group is condensed onto an amino of
 FT Lys(1). See above"

XX PN GB2271995-A.

XX PD 04-MAY-1994.

XX PF 12-OCT-1993; 93GB-00020943.

XX PR 15-OCT-1992; 92US-00963327.

XX XX (MERI) MERCK & CO INC.

XX PA Tolman RL, Marburg S, Leanza WL, Lombardo VK;
 XX WPI; 1994-128412/16.

XX DR New conjugates of outer membrane protein and HIV epitope - for generating
 XX HIV-neutralising response, have components joined by anionic spacer to
 XX ensure solubility of prod.

XX PS Claim 10; Page 70; 73pp; English.

XX A new conjugate immunogen comprises (a) the OMPC of Neisseria
 CC meningitidis b as a protein carrier, (b) a principal neutralizing
 CC determinant (PND) of HIV as a peptidyl epitope against which immune
 CC responses are desired, and (c) a low mol. wt. anionic spacer linking (a)
 CC and (b). The conjugate is water-soluble, yet can carry a high peptide
 CC epitope loading. It is useful as a vaccine against HIV. The present
 CC sequence is an example of a PND used in the conjugate

XX SQ Sequence 18 AA;

Qy	1 RIQRPGRGAFVTIG 14	
Db	5 RIQRPGRGAFVTIG 18	
RESULT 136		
ADR18878		
ID	ADR18878 standard; peptide; 18 AA.	
XX	AC	
XX	ADR18878;	
XX		
DT	04-NOV-2004 (first entry)	
XX		
DE	HIV-1 V3-IIIB peptide SEQ ID NO:4.	
XX		
KW	three-dimensional atomic structural conformation;	
KW	protein co-ordinate data; V3 loop peptide; HIV-1; envelope glycoprotein;	
KW	gp120; human monoclonal antibody 447-52D;	
KW	murine monoclonal antibody 0.5 beta; immunogen; immunogenic;	
KW	V3 loop epitope; HIV-1 infectivity inhibitor; anti-HIV; vaccine;	
XX	HIV-1 infection.	
XX		
OS	Human immunodeficiency virus 1.	
OS	Synthetic.	
XX		
FN	WO2004069863-A2.	
XX		
PD	19-AUG-2004.	
XX		
PF	04-FEB-2004; 2004WO-US003304.	
XX		
PR	04-FEB-2003; 2003US-0444682P.	
XX		
PA	(UNYNY) UNIV NEW YORK STATE.	
PA	(YEDA) YEDA RES & DEV CO LTD.	
XX		
PI	Angliaster J, Sharon M, Schapira M, Zolla-Pazner S, Rosen O;	
XX	WPI; 2004-625447/60.	
DR		
XX		
PT	Composition for inhibiting HIV-1 infection, comprises isolated peptide	
PT	molecule that mimics atomic structural conformation of V3 loop peptide of	
PT	HIV-1 envelope glycoprotein that is bound to, and constrained by human	
PT	monoclonal antibody.	
XX		
PS	Disclosure; SEQ ID NO 4; 127pp; English.	
XX		
CC	The present invention describes a composition (C1) which comprises an	
CC	isolated peptide molecule or isostere that mimics the three-dimensional	
CC	(3D) atomic structural conformation of the V3 loop peptide of the HIV-1	
CC	envelope glycoprotein gp120 that is bound to, and constrained by, human	
CC	monoclonal antibody (Mab) 447-52D, murine Mab 0.5 beta or an antigen	
CC	binding fragment of the Mab, where the constrained V3 loop peptide	
CC	differs in conformation from the same V3 loop peptide when it is in free	
CC	form. Also described: (1) identifying (M1) from several existing	
CC	compounds a molecule that is useful as an HIV-1 V3 loop immunogen or as	
CC	an inhibitor of binding of HIV-1 to a chemokine receptor/HIV-1 co-	
CC	receptor on the surface of a receptor-bearing target cell; (2) designing	
CC	a molecule that is useful as an HIV-1 V3 loop immunogen or as an	
CC	inhibitor of binding of HIV-1 to a chemokine receptor/HIV-1 co-receptor	
CC	on the surface of a receptor-bearing target cell; (3) a composition (C2)	
CC	that is useful as an HIV-1 V3 loop immunogen or as an inhibitor of	
CC	binding of HIV-1 to a chemokine receptor/HIV-1 co-receptor on the surface	
CC	of a receptor-bearing target cell; (4) an immunogenic composition (C3)	
CC	for induction of an anti-HIV-1 antibody response specific for a V3 loop	
CC	epitope, comprising (C1) and an excipient; (5) a pharmaceutical	
CC	composition (C4) useful for blocking the interaction of HIV-1 with an R5	
CC	or X4 co-receptor and thereby inhibiting HIV-1 infectivity, comprising	
CC	(C1) and a carrier or excipient; (6) a computing platform for generating	
CC	a 3D model of a constrained HIV V3 view peptide; (7) a computer generated	
CC	model representing the conformationally constrained structure of a V3	
CC	loop peptide that is bound to 447-52D or 0.5beta Mab or its antigen	
CC	binding fragments, comprising a 3D atomic structure defined by NC; and	

XX SQ Sequence 20 AA;

Query Match 93.5%; Score 72; DB 2; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.00066;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRFVITG 14
 |||||
 Db 7 RIQGPGRFVITG 20
 |||||

RESULT 138
 AAW76842
 ID AAW76842 standard; peptide; 20 AA.
 XX AC AAW76842;
 XX DT 25-JAN-1999 (first entry)
 XX DE Fusion immunoglobulin heavy chain HIV gp120 B cell epitope #12.
 XX KW B cell; T cell; epitope; immunoglobulin; heavy chain; gp120; IGH;
 KW human immune deficiency virus; HIV; tolerance; treatment; therapy;
 KW prophylaxis; vaccine; chemotherapy; immune response; modifier; tumour;
 KW microbial infection; autoimmune disease; antibody; apoptosis;
 KW antiviral T cell immunity.
 XX OS Mus sp.
 XX OS Homo sapiens.
 XX PN WO9836087-A1.
 XX PD 20-AUG-1998.
 XX PF 13-FEB-1998; 98WO-US002766.
 XX PR 13-FEB-1997; 97US-0040581P.
 XX PA (AMNA-) AMERICAN NAT RED CROSS.
 XX PI Scott D, Zambidis E;
 XX WPI; 1998-506315/43.
 XX New fusion immunoglobulin heavy chain including gp120 epitopes and
 related complete antibodies - DNA, vectors and transformed cells, used to
 induce tolerance to the epitopes for treatment of human immune deficiency
 virus infection.
 XX Claim 10; Page 119; 154pp; English.

This sequence is an epitope used in the construction of a novel fusion
 immunoglobulin heavy chain (IGH) protein with a mammalian, especially
 human, IGH chain fused in frame at its N-terminus to one or more human
 immune deficiency virus (HIV) gp120 epitopes. Fusion Ig proteins and/or
 transfectected cells are used to tolerate subjects to gp120 epitopes and to
 maintain this tolerance, particularly for treatment of HIV infection,
 optionally together with other therapeutic/prophylactic agents such as
 vaccines, chemotherapeutic agents and immune response modifiers. Such
 proteins can be used against other diseases where an immune response is
 deleterious, e.g. microbial infection, tumours or autoimmune disease.
 Induction of tolerance suppresses production of antibodies against gp120,
 so prevents or inhibits 'bystander' apoptosis of uninfected T cells that
 are bound to gp120 protein, maximising induction of protective antiviral
 T cell immunity

Sequence 20 AA;

Query Match 93.5%; Score 72; DB 2; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.00066;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRFVITG 14
 |||||
 Db 7 RIQGPGRFVITG 20
 |||||

RESULT 139
 ABP57070
 ID ABP57070 standard; peptide; 20 AA.
 XX AC ABP57070;
 XX DT 23-OCT-2003 (revised)
 XX DT 14-APR-2003 (first entry)
 XX DE HIV gp120 V3 loop derived peptide ARP740/28.
 XX KW Anti-human leukocyte antigen antibody; anti-HLA antibody; anti-HIV;
 KW proliferative immune response; antiinflammatory; neuroprotective;
 KW cytostatic; gene therapy; vaccine; inflammatory disease; nerve damage;
 KW autoimmune disease; axonal damage; cancer; inflammatory; HIV.
 XX OS Human immunodeficiency virus 1.
 XX PN WO2003004049-A2.
 XX PD 16-JAN-2003.
 XX PF 02-JUL-2002; 2002WO-GB003037.
 XX PR 02-JUL-2001; 2001GB-00016151.
 XX PR 29-NOV-2001; 2001GB-00028638.
 XX PR 28-JAN-2002; 2002GB-00001896.
 XX PR 28-MAR-2002; 2002GB-00007509.
 XX PA (ICEB-) ICE BIOLOGICS LTD.
 XX PI Dalgleish AG, Cadogan M, Heeney J, White SDT;
 XX WPI; 2003-210314/20.
 XX Use of anti-HLA antibody for the preparation of a medicament for treating
 a disease involving a proliferative immune response e.g. HIV,
 inflammatory diseases, autoimmune diseases, axonal/nerve damage or
 related impairment, cancers.
 XX Example; Page 41; 69pp; English.

The present invention describes an anti-human leukocyte antigen (HLA)
 antibody (I) useful for the preparation of a medicament for treating a
 disease involving a proliferative immune response. (I) has anti-HIV,
 antiinflammatory, neuroprotective and cytostatic activities, and can be
 used in vaccines and in gene therapy. The antibody (I) is useful for the
 preparation of a medicament for treating diseases involving a
 proliferative immune response, e.g. HIV, inflammatory diseases,
 autoimmune diseases, axonal or nerve damage or related impairment or
 cancers, and other diseases or conditions with an inflammatory component.
 The present sequence represents an HIV gp120 V3 loop derived peptide,
 which is used in the exemplification of the present invention. (Updated
 on 23-OCT-2003 to standardise OS field)

Sequence 20 AA;

Query Match 93.5%; Score 72; DB 6; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.00066;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRFVITG 14
 |||||
 Db 7 RIQGPGRFVITG 20
 |||||

RESULT 140
 AAR66425

ID AAR66425 standard; peptide; 15 AA.
 AC AAR66425;
 XX
 DT 25-MAR-2003 (revised)
 DT 03-AUG-1995 (first entry)
 XX
 DE HIV-1 IIIB peptide 18-10.
 XX
 KW T cell helper site; cytotoxic T cell response; neutralising antibody;
 KW human immunodeficiency virus type 1; envelope glycoprotein gp120;
 KW cluster peptide; principal neutralising determinant.
 XX
 OS Synthetic.
 XX
 XX WO9426785-A1.
 XX
 PD 24-NOV-1994.
 XX
 XX
 PF 13-MAY-1994; 94WO-US005142.
 XX
 PR 14-MAY-1993; 93US-00060988.
 XX
 XX (USSH) US SEC DEPT HEALTH.
 XX
 PA Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
 XX WPI; 1995-006707/01.
 XX
 XX Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
 PT responses - to target antigen in hosts of different MHC haplotypes, esp.
 PT for therapeutic or prophylactic vaccines against HIV.
 XX
 PS Example 1; Page 33; 120pp; English.
 XX
 CC Single residues from the HIV-1 RF sequence (AAR66415) replaced residues
 CC in the HIV-1 IIIB sequence (AAR66414) to test the effect of each residue
 CC on the binding of neutralising and non-neutralising sera from animals
 CC immunised with the cluster peptides PCLUS 3-18 and PCLUS 6-18 (see
 CC AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
 CC R66430) showed that binding was enhanced over peptide 18 control when a
 CC tyrosine was substd. for a Val at position 11 and substns. at positions
 CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
 CC sera was reduced when substns. were made in the principal neutralising
 CC determinant sequence (PGRAP). In peptide 18-10, the Phe residue at
 CC position 10 in peptide 18 has been replaced by a Ile residue. (Updated on
 CC 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 15 AA;
 Query Match 92.2%; Score 71; DB 2; Length 15;
 Best Local Similarity 93.3%; Pred. No. 0.00072;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 RIQRGPGRAFTVIGK 15
 Db |||||
 1 RIQRGPGRAFTVIGK 15
 RESULT 141
 AAR66420
 ID AAR66420 standard; peptide; 15 AA.
 XX
 AC AAR66420;
 XX
 DT 25-MAR-2003 (revised)
 DT 03-AUG-1995 (first entry)
 XX
 DE HIV-1 IIIB peptide 18-5.
 XX
 KW T cell helper site; cytotoxic T cell response; neutralising antibody;
 KW human immunodeficiency virus type 1; envelope glycoprotein gp120;
 KW cluster peptide; principal neutralising determinant.

XX Synthetic.
 OS WO9426785-A1.
 XX
 PD 24-NOV-1994.
 XX
 PF 13-MAY-1994; 94WO-US005142.
 XX
 PR 14-MAY-1993; 93US-00060988.
 XX
 PA (USSH) US SEC DEPT HEALTH.
 XX
 PI Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
 XX WPI; 1995-006707/01.
 XX
 XX Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
 PT responses - to target antigen in hosts of different MHC haplotypes, esp.
 PT for therapeutic or prophylactic vaccines against HIV.
 XX
 PS Example 1; Page 33; 120pp; English.
 XX
 CC Single residues from the HIV-1 RF sequence (AAR66415) replaced residues
 CC in the HIV-1 IIIB sequence (AAR66414) to test the effect of each residue
 CC on the binding of neutralising and non-neutralising sera from animals
 CC immunised with the cluster peptides PCLUS 3-18 and PCLUS 6-18 (see
 CC AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
 CC R66430) showed that binding was enhanced over peptide 18 control when a
 CC tyrosine was substd. for a Val at position 11 and substns. at positions
 CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
 CC sera was reduced when substns. were made in the principal neutralising
 CC determinant sequence (PGRAP). In peptide 18-5, the Gly residue at
 CC position 5 in peptide 18 has been replaced by an Ala residue. (Updated on
 CC 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 15 AA;
 Query Match 92.2%; Score 71; DB 2; Length 15;
 Best Local Similarity 93.3%; Pred. No. 0.00072;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 RIQRGPGRAFTVIGK 15
 Db |||||
 1 RIQRGPGRAFTVIGK 15
 RESULT 142
 AAR66429
 ID AAR66429 standard; peptide; 15 AA.
 XX
 AC AAR66429;
 XX
 DT 25-MAR-2003 (revised)
 DT 03-AUG-1995 (first entry)
 XX
 DE HIV-1 IIIB peptide 18-14.
 XX
 KW T cell helper site; cytotoxic T cell response; neutralising antibody;
 KW human immunodeficiency virus type 1; envelope glycoprotein gp120;
 KW cluster peptide; principal neutralising determinant.
 XX
 OS Synthetic.
 XX
 XX WO9426785-A1.
 XX
 PD 24-NOV-1994.
 XX
 PF 13-MAY-1994; 94WO-US005142.
 XX
 PR 14-MAY-1993; 93US-00060988.
 XX
 PA (USSH) US SEC DEPT HEALTH.

XX Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
 XX WPI; 1995-006707/01.
 XX Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
 PT responses - to target antigen in hosts of different MHC haplotypes, esp.
 PT for therapeutic or prophylactic vaccines against HIV.
 XX Example 1; Page 33; 120pp; English.
 XX Single residues from the HIV-1 RF sequence (AAR66415) replaced residues
 CC in the HIV-1 IIIB sequence (AAR66414) to test the effect of each residue
 CC on the binding of neutralising and non-neutralising sera from animals
 CC immunised with the cluster peptides PCLUS 3-18 and PCLUS 6-18 (see
 CC AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
 CC R66430) showed that binding was enhanced over peptide 18 control when a
 CC tyrosine was substd. for a Val at position 11 and substns. at positions
 CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
 CC sera was reduced when substns. were made in the principal neutralising
 CC determinant sequence (PGRAP). In peptide 18-14, the Gly residue at
 CC position 14 in peptide 18 has been replaced by an Ala residue. (Updated
 CC on 25-MAR-2003 to correct PN field.)
 XX Sequence 15 AA;
 XX Query Match 92.2%; Score 71; DB 2; Length 15;
 XX Best Local Similarity 93.3%; Pred. No. 0.00072;
 XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 RIQRGPGRAFTVIGK 15
 DB |||||
 1 RIQRGPGRAFTVIGK 15

RESULT 143
 AAR66423
 ID AAR66423 standard; peptide; 15 AA.
 XX AC AAR66423;
 XX 25-MAR-2003 (revised)
 DT 03-AUG-1995 (first entry)
 XX HIV-1 IIIB peptide 18-8.
 XX T cell helper site; cytotoxic T cell response; neutralising antibody;
 KW human immunodeficiency virus type 1; envelope glycoprotein gp120;
 KW cluster peptide; principal neutralising determinant.
 XX Synthetic.
 OS WO9426785-A1.
 PN 24-NOV-1994.
 XX 13-MAY-1994; 94WO-US005142.
 PF 14-MAY-1993; 93US-00060988.
 XX (USSH) US SEC DEPT HEALTH.
 XX Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
 XX WPI; 1995-006707/01.
 XX Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
 PT responses - to target antigen in hosts of different MHC haplotypes, esp.
 PT for therapeutic or prophylactic vaccines against HIV.
 XX Example 1; Page 33; 120pp; English.
 XX Single residues from the HIV-1 RF sequence (AAR66415) replaced residues

CC in the HIV-1 IIIB sequence (AAR66414) to test the effect of each residue
 CC on the binding of neutralising and non-neutralising sera from animals
 CC immunised with the cluster peptides PCLUS 3-18 and PCLUS 6-18 (see
 CC AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
 CC R66430) showed that binding was enhanced over peptide 18 control when a
 CC tyrosine was substd. for a Val at position 11 and substns. at positions
 CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
 CC sera was reduced when substns. were made in the principal neutralising
 CC determinant sequence (PGRAP). In peptide 18-8, the Arg residue at
 CC position 8 in peptide 18 has been replaced by an Ala residue. (Updated on
 CC 25-MAR-2003 to correct PN field.)
 XX Sequence 15 AA;
 XX Query Match 92.2%; Score 71; DB 2; Length 15;
 XX Best Local Similarity 93.3%; Pred. No. 0.00072;
 XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 RIQRGPGRAFTVIGK 15
 DB |||||
 1 RIQRGPGRAFTVIGK 15

RESULT 144
 AAR66422
 ID AAR66422 standard; peptide; 15 AA.
 XX AC AAR66422;
 XX 25-MAR-2003 (revised)
 DT 03-AUG-1995 (first entry)
 XX HIV-1 IIIB peptide 18-7.
 XX T cell helper site; cytotoxic T cell response; neutralising antibody;
 KW human immunodeficiency virus type 1; envelope glycoprotein gp120;
 KW cluster peptide; principal neutralising determinant.
 XX Synthetic.
 OS WO9426785-A1.
 PN 24-NOV-1994.
 XX 13-MAY-1994; 94WO-US005142.
 PF 14-MAY-1993; 93US-00060988.
 XX (USSH) US SEC DEPT HEALTH.
 XX Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
 XX WPI; 1995-006707/01.
 XX Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
 PT responses - to target antigen in hosts of different MHC haplotypes, esp.
 PT for therapeutic or prophylactic vaccines against HIV.
 XX Example 1; Page 33; 120pp; English.
 XX Single residues from the HIV-1 RF sequence (AAR66415) replaced residues
 CC in the HIV-1 IIIB sequence (AAR66414) to test the effect of each residue
 CC on the binding of neutralising and non-neutralising sera from animals
 CC immunised with the cluster peptides PCLUS 3-18 and PCLUS 6-18 (see
 CC AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
 CC R66430) showed that binding was enhanced over peptide 18 control when a
 CC tyrosine was substd. for a Val at position 11 and substns. at positions
 CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
 CC sera was reduced when substns. were made in the principal neutralising
 CC determinant sequence (PGRAP). In peptide 18-7, the Gly residue at
 CC position 7 in peptide 18 has been replaced by an Ala residue. (Updated on
 CC 25-MAR-2003 to correct PN field.)
 XX

```

SQ      Sequence 15 AA;
Query Match      92.2%; Score 71; DB 2; Length 15;
Best Local Similarity 93.3%; Pred. No. 0.00072;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1 RIQRGPGRAFTVIGK 15
        ||||| |||||
Db      1 RIQRGPARAFTVIGK 15

RESULT 145
AAR66421
ID      AAR66421 standard; peptide; 15 AA.
XX
AC      AAR66421;
XX
XX      25-MAR-2003 (revised)
DT      03-AUG-1995 (first entry)
XX
XX      HIV-1 IIIB peptide 18-6.
XX
XX      T cell helper site; cytotoxic T cell response; neutralising antibody;
KW      human immunodeficiency virus type 1; envelope glycoprotein gp120;
KW      cluster peptide; principal neutralising determinant.
XX
XX      Synthetic.
XX
XX      WO9426785-A1.
XX
XX      24-NOV-1994.
XX
XX      13-MAY-1994; 94WO-US005142.
XX
XX      14-MAY-1993; 93US-00060988.
XX
XX      (USSH ) US SEC DEPT HEALTH.
XX
XX      Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
XX      WPI; 1995-006707/01.
XX
XX      Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
PT      responses - to target antigen in hosts of different MHC haplotypes, esp.
PT      for therapeutic or prophylactic vaccines against HIV.
XX
XX      Example 1; Page 33; 120pp; English.
XX
XX      Single residues from the HIV-1 RP sequence (AAR66415) replaced residues
CC      in the HIV-1 IIIB sequence (AAR66414) to test the effect of each residue
CC      on the binding of neutralising and non-neutralising sera from animals
CC      immunised with the cluster peptides PCLUS 3-18 and PCLUS 6-18 (see
CC      AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
CC      R6430) showed that binding was enhanced over peptide 18 control when a
CC      tyrosine was substd. for a Val at position 11 and substns. at positions
CC      12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
CC      sera was reduced when substns. were made in the principal neutralising
CC      determinant sequence (PGRAF). In peptide 18-6, the Pro residue at
CC      position 6 in peptide 18 has been replaced by an Ala residue. (Updated on
CC      25-MAR-2003 to correct PN field.)
XX
SQ      Sequence 15 AA;
Query Match      89.6%; Score 69; DB 2; Length 15;
Best Local Similarity 93.3%; Pred. No. 0.0015;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1 RIQRGPGRAFTVIGK 15
        ||||| |||||
Db      1 RIQRGAGRAFTVIGK 15

RESULT 146
AAR66421
ID      AAR66421 standard; peptide; 15 AA.
XX
AC      AAR66421;
XX
XX      25-MAR-2003 (revised)
DT      03-AUG-1995 (first entry)
XX
XX      HIV-1 IIIB peptide 18-6.
XX
XX      T cell helper site; cytotoxic T cell response; neutralising antibody;
KW      human immunodeficiency virus type 1; envelope glycoprotein gp120;
KW      cluster peptide; principal neutralising determinant.
XX
XX      Synthetic.
XX
XX      WO9426785-A1.
XX
XX      24-NOV-1994.
XX
XX      13-MAY-1994; 94WO-US005142.
XX
XX      14-MAY-1993; 93US-00060988.
XX
XX      (USSH ) US SEC DEPT HEALTH.
XX
XX      Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
XX      WPI; 1995-006707/01.
XX
XX      Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
PT      responses - to target antigen in hosts of different MHC haplotypes, esp.
PT      for therapeutic or prophylactic vaccines against HIV.
XX
XX      Example 1; Page 33; 120pp; English.
XX
XX      Single residues from the HIV-1 RP sequence (AAR66415) replaced residues
CC      in the HIV-1 IIIB sequence (AAR66414) to test the effect of each residue
CC      on the binding of neutralising and non-neutralising sera from animals
CC      immunised with the cluster peptides PCLUS 3-18 and PCLUS 6-18 (see
CC      AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
CC      R6430) showed that binding was enhanced over peptide 18 control when a
CC      tyrosine was substd. for a Val at position 11 and substns. at positions
CC      12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
CC      sera was reduced when substns. were made in the principal neutralising
CC      determinant sequence (PGRAF). In peptide 18-6, the Pro residue at
CC      position 6 in peptide 18 has been replaced by an Ala residue. (Updated on
CC      25-MAR-2003 to correct PN field.)
XX
SQ      Sequence 15 AA;
Query Match      89.3%; Score 68; DB 2; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0018;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      3 QRGGPGRAFTVIGK 15
        ||||| |||||
Db      1 QRGGPGRAFTVIGK 13

RESULT 147
AAR62890
ID      AAR62890 standard; peptide; 13 AA.
XX
AC      AAR62890;
XX
XX      30-SEP-1998 (first entry)
DT
DE      Peptide sequence of the specification.
XX
KW      Monoclonal antibody; HIV-1gp120; gp160; infection; H9 cell;

```

```

AAW22327
ID      AAW22327 standard; peptide; 13 AA.
XX
AC      AAW22327;
XX
XX      17-OCT-2003 (revised)
DT      18-SEP-1997 (first entry)
XX
XX      HIV-1 strain IIIB gp120 V3 loop peptide.
XX
XX      Epitope; human immunodeficiency virus type 1; HIV-1; gp120; gp160;
KW      monoclonal antibody; V3 loop; immunisation; mouse; splenocyte; hybridoma;
KW      membrane fraction; passive immunisation; human.
XX
XX      Human immunodeficiency virus 1.
XX
XX      US5618922-A.
XX
XX      08-APR-1997.
XX
XX      25-JUL-1994; 94US-00279906.
XX
XX      25-JUL-1994; 94US-00279906.
XX      (NISP ) NISSIN SHOKUHIN KAISHA LTD.
XX
XX      Yoneda Y, Ohno T, Terada M;
XX      WPI; 1997-225475/20.
XX
XX      Monoclonal antibody specific for human immunodeficiency virus type 1 MN
PT      strain - for passive immunisation against infection.
XX
XX      Example 3; Col 10; 14pp; English.
XX
XX      The invention relates to a novel monoclonal antibody (Mab) NM03 which
CC      binds to epitopes from the human immunodeficiency virus type 1 (HIV-1).
CC      The antibody was raised conventionally by immunising Balb/c mice with
CC      purified live HIV-1 MN, then isolating splenocytes and fusing them to P3-
CC      X63-Ag8-U1 cells. Hybridomas were then screened with membrane fractions
CC      from infected and non-infected H9 cells. The Mab was observed to bind to
CC      a protein band of 120 kD on a Western blot of separated, denatured HIV-1
CC      proteins. This binding was shown to be between residues 320-327 by
CC      epitope mapping by ELISA and competitive binding. The ability of the Mab
CC      to inhibit infection of cells by HIV-1 shown by infecting H9 cells with
CC      live strains of HIV-1 and testing infection by a p24 assay. This peptide
CC      sequence represents the V3 loop region from HIV-1 strain IIIB, where the
CC      Mab NM03 binds. The Mab can be used for the passive immunisation of
CC      humans susceptible to, or infected with HIV-1. (Updated on 17-OCT-2003 to
CC      standardise OS field)
XX
SQ      Sequence 13 AA;
Query Match      89.3%; Score 68; DB 2; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0018;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      3 QRGGPGRAFTVIGK 15
        ||||| |||||
Db      1 QRGGPGRAFTVIGK 13

RESULT 147
AAR62890
ID      AAR62890 standard; peptide; 13 AA.
XX
AC      AAR62890;
XX
XX      30-SEP-1998 (first entry)
DT
DE      Peptide sequence of the specification.
XX
KW      Monoclonal antibody; HIV-1gp120; gp160; infection; H9 cell;

```

KW HIV strain MN; treatment; human HIV infection.

XX Synthetic.

PN JP10182489-A.

PD 07-JUL-1998.

XX 25-DEC-1996; 96JP-00344904.

PR 25-DEC-1996; 96JP-00344904.

PA (NISP) NISSIN SHOKUHN KAISHA LTD.

XX WPI; 1998-433774/37.

XX Monoclonal antibody which binds to HIV-1gp120 or gp160 - used to prevent and treat human HIV infection.

PS Example 3; Page 8; 12pp; Japanese.

CC AAMG2889-900 represent peptides used to identify a peptide sequence (AAMG2874) present in HIV-1gp120 or gp160 which is bound by the monoclonal antibody of the invention. The antibody neutralises in vitro the infection of H9 cell by an active HIV strain MN according to the p24 analytical method. The antibody is used for treatment of human HIV infection

XX Sequence 13 AA;

Query Match 88.3%; Score 68; DB 2; Length 13;

Best Local Similarity 100.0%; Pred. No. 0.0018;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 QRGPGRAFTVIGK 15

Db 1 QRGPGRAFTVIGK 13

RESULT 148

AAM99433

ID AAM99433 standard; peptide; 13 AA.

XX AAM99433;

DT 11-SEP-2003 (revised)

DT 07-DEC-2001 (first entry)

XX Vaccine related MHC ligand peptide SEQ ID NO:536.

XX Glutamic acid; glutamine; vaccine; major histocompatibility complex; MHC; immunomodulator; antiallergic; endocrine; neuroprotectant; virucidal; bactericidal; antiparasitic; fungicidal; cytostatic; medicine; pharmaceutical; immune disorder; immune deficiency; autoimmune; hypersensitivity; allergy; graft rejection; infection; hormonal disorder; central nervous system disease; cancer; melanoma; anti-melanoma vaccine; human immunodeficiency virus.

XX Human immunodeficiency virus 1.

PN WO200170772-A2.

XX 27-SEP-2001.

XX 22-MAR-2001; 2001WO-FR000872.

XX 23-MAR-2000; 2000FR-00003711.

XX (FABR) FABRE MEDICAMENT SA PIERRE.

XX Klinguer-Hamour C, Corvala N, Beck A, Goetsch L;

XX WPI; 2001-611470/70.

XX

PT Stabilized pharmaceutical containing N-terminal glutamic acid or glutamine, useful e.g. in anti-melanoma vaccines, is an addition salt with strong acid.

PS Claim 9; Page 122; 149pp; French.

XX The present invention describes a pharmaceutical compound (I) that contains an N-terminal glutamic acid (Glu) or glutamine (Gln) residue in the form of an addition salt with a strong, physiologically acceptable acid (II). Also described are: (a) a pharmaceutical composition containing at least one (I); (b) a vaccine containing at least one (I) where this is a major histocompatibility complex (MHC) ligand (Ia); (c) a method for in vitro diagnosis of diseases associated with the presence of (Ia); (d) a kit for method (c) that includes a (Ia); and (e) a process for preparing (I). (I) has immunomodulator, endocrine, antiallergic, cytoprotectant, virucidal, bactericidal, antiparasitic, fungicidal and cytostatic activities. (I) are useful, in human or veterinary medicine, in pharmaceutical compositions (for treating immune disorders, e.g. immune deficiency, autoimmune states, hypersensitivity, allergy, graft rejection, infection, hormonal disorders and central nervous system diseases), also, where (I) is a MHC ligand (Ia), in vaccines for treatment or prevention of: (i) viral, bacterial, parasitic or fungal infections; or (ii) of cancers. A particular application is in anti-melanoma vaccines. (I) are also useful for in vitro diagnosis of diseases associated with interactions between MHC and (I), e.g. melanoma and human immunodeficiency virus infection. AAM98898 to AAM99592 represent peptides which can be used in pharmaceutical compounds from the present invention. (Updated on 11-SEP-2003 to standardise OS field)

XX Sequence 13 AA;

Query Match 88.3%; Score 68; DB 4; Length 13;

Best Local Similarity 100.0%; Pred. No. 0.0018;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 QRGPGRAFTVIGK 15

Db 1 QRGPGRAFTVIGK 13

RESULT 149

AAR66417

ID AAR66417 standard; peptide; 14 AA.

XX AAR66417;

DT 25-MAR-2003 (revised)

DT 03-AUG-1995 (first entry)

XX HIV-1 IIIB peptide 18-2.

XX T cell helper site; cytotoxic T cell response; neutralising antibody; human immunodeficiency virus type 1; envelope glycoprotein gp120; cluster peptide; principal neutralising determinant.

XX Synthetic.

XX WO9426785-A1.

XX 24-NOV-1994.

XX 13-MAY-1994; 94WO-US005142.

XX 14-MAY-1993; 93US-00060988.

XX (USSH) US SEC DEPT HEALTH.

XX Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;

XX WPI; 1995-006707/01.

XX Polypeptide inducing helper T cell, cytotoxic T cell and antibodies

PT responses - to target antigen in hosts of different MHC haplotypes, esp.
 PT for therapeutic or prophylactic vaccines against HIV.
 XX Example 1; Page 33; 120pp; English.
 XX Single residues from the HIV-1 RP sequence (AAR66415) replaced residues
 CC on the HIV-1 IIB sequence (AAR66414) to test the effect of each residue
 CC on the binding of neutralising and non-neutralising sera from animals
 CC immunised with the cluster peptides PCUS 3-18 and PCUS 6-18 (see
 CC AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
 CC R65430) showed that binding was enhanced over peptide 18 control when a
 CC tyrosine was substd. for a Val at position 11 and subetns. at positions of
 CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
 CC sera was reduced when subetns. were made in the principal neutralising
 CC determinant sequence (PCRAP). In peptide 18-2, the Ile residue at
 CC position 2 in peptide 18 has been deleted. (Updated on 25-MAR-2003 to
 CC correct PN field.)
 XX Sequence 14 AA;
 SQ Query Match 88.3%; Score 68; DB 2; Length 14;
 Best Local Similarity 100.0%; Pred. No. 0.0019;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 3 QRGPGRAFVTIGK 15
 DB |||||
 2 QRGPGRAFVTIGK 14
 RESULT 150
 AAU76897
 ID AAU76897 standard; peptide; 15 AA.
 AC AAU76897;
 XX 25-JAN-1999 (first entry)
 DT Fusion immunoglobulin heavy chain HIV gp120 T cell epitope #16.
 DE B cell; T cell; epitope; immunoglobulin; heavy chain; gp120; IGH;
 KW human immune deficiency virus; HIV; tolerance; treatment; therapy;
 KW prophylaxis; vaccine; chemotherapy; immune response; modifier; tumour;
 KW microbial infection; autoimmune disease; antibody; apoptosis;
 KW antiviral T cell immunity.
 XX Mus sp.
 OS Homo sapiens.
 XX WO9836087-A1.
 PN 20-AUG-1998.
 PD 13-FEB-1998; 98WO-US002766.
 PF 13-FEB-1997; 97US-0040581P.
 PR (AMNA-) AMERICAN NAT RED CROSS.
 XX Scott D, Zambidis E;
 PI WPI; 1998-506315/43.
 DR New fusion immunoglobulin heavy chain including gp120 epitopes and
 PT related complete antibodies - DNA, vectors and transformed cells, used to
 PT induce tolerance to the epitopes for treatment of human immune deficiency
 PT virus infection.
 XX Claim 11; Page 120; 154pp; English.
 PS This sequence is an epitope used in the construction of a novel fusion
 CC immunoglobulin heavy chain (IGH) protein with a mammalian, especially
 CC human, IGH chain fused in frame at its N-terminus to one or more human
 CC immune deficiency virus (HIV) gp120 epitopes. Fusion Ig proteins and/or

CC transfected cells are used to tolerate subjects to gp120 epitopes and to
 CC maintain this tolerance, particularly for treatment of HIV infection,
 CC optionally together with other therapeutic/prophylactic agents such as
 CC vaccines, chemotherapeutic agents and immune response modifiers. Such
 CC proteins can be used against other diseases where an immune response is
 CC deleterious, e.g. microbial infection, tumours or autoimmune disease.
 CC Induction of tolerance suppresses production of antibodies against gp120,
 CC so prevents or inhibits 'bystander' apoptosis of uninfected T cells that
 CC are bound to gp120 protein, maximising induction of protective antiviral
 CC T cell immunity
 XX Sequence 15 AA;
 SQ Query Match 88.3%; Score 68; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.0021;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 3 QRGPGRAFVTIGK 15
 DB |||||
 2 QRGPGRAFVTIGK 14
 RESULT 151
 AAU99083
 ID AAU99083 standard; peptide; 15 AA.
 AC AAU99083;
 XX 11-SEP-2003 (revised)
 DT 07-DEC-2001 (first entry)
 DE Vaccine related MHC ligand peptide SEQ ID NO:186.
 XX Glutamic acid; glutamine; vaccine; major histocompatibility complex; MHC;
 KW immunomodulator; antiallergic; endocrine; neuroprotectant; virucidal;
 KW bactericidal; antiparasitic; fungicidal; cytostatic; medicine;
 KW pharmaceutical; immune disorder; immune deficiency; autoimmune;
 KW hypersensitivity; allergy; graft rejection; infection; hormonal disorder;
 KW central nervous system disease; cancer; melanoma; anti-melanoma vaccine;
 KW human immunodeficiency virus.
 XX Human immunodeficiency virus 1.
 OS WO200170772-A2.
 PN 27-SEP-2001.
 PD 22-MAR-2001; 2001WO-FR000872.
 PF 23-MAR-2000; 2000FR-00003711.
 PR (FABR) FABRE MEDICAMENT SA PIERRE.
 PA Klinguer-Hamour C, Corvaia N, Beck A, Goetsch L;
 XX WPI; 2001-611470/70.
 DR Stabilized pharmaceutical containing N-terminal glutamic acid or
 PT glutamine, useful e.g. in anti-melanoma vaccines, is an addition salt
 PT with strong acid.
 XX Claim 9; Page 63; 149pp; French.
 PS The present invention describes a pharmaceutical compound (I) that
 CC contains an N-terminal glutamic acid (Glu) or glutamine (Gln) residue in
 CC the form of an addition salt with a strong, physiologically acceptable
 CC acid (iii). Also described are: (a) a pharmaceutical composition
 CC containing at least one (I); (b) a vaccine containing at least one (I)
 CC where this is a major histocompatibility complex (MHC) ligand (Ia); (c) a
 CC method for in vitro diagnosis of diseases associated with the presence of
 CC (Ia); (d) a kit for method (c) that includes a (Ia); and (e) a process
 CC for preparing (I). (I) has immunomodulator, endocrine, antiallergic, and
 CC neuroprotectant, virucidal, bactericidal, antiparasitic, fungicidal, and

CC cytostatic activities. (I) are useful, in human or veterinary medicine,
 CC in pharmaceutical compositions for treating immune disorders, e.g.
 CC immune deficiency, autoimmune states, hypersensitivity, allergy, graft
 CC rejection, infection, hormonal disorders and central nervous system
 CC diseases), also, where (I) is a MHC ligand (Ia), in vaccines for
 CC treatment or prevention of: (i) viral, bacterial, parasitic or fungal
 CC infections; or (ii) of cancers. A particular application is in anti-
 CC melanoma vaccines. (I) are also useful for in vitro diagnosis of diseases
 CC associated with interactions between MHC and (I), e.g. melanoma and human
 CC immunodeficiency virus infection. AM98898 to AM99592 represent peptides
 CC which can be used in pharmaceutical compounds from the present invention.
 CC (Updated on 11-SEP-2003 to standardise OS field)

XX
 SQ Sequence 15 AA;
 Query Match 88.3%; Score 68; DB 4; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.0021;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 QRGPGRAFTVIGK 15
 |||||
 Db 2 QRGPGRAFTVIGK 14

RESULT 152

AAW63062
 ID AAW63062 standard; peptide; 18 AA.

AC AAW63062;

DT 07-OCT-1998 (first entry)

DE Human immunodeficiency virus type 1 (HIV 1) Env peptide 312-327.

KW Superantigen; treatment; cancer; tumour-specific antigen;
 KW autoimmune disease related antigen; infection; bacterial; viral;
 KW eukaryotic; autoimmune disease; inhibit; pathological response;
 KW immune response.

XX Synthetic.

OS Human immunodeficiency virus 1.

XX WO9826747-A2.

XX 25-JUN-1998.

XX 17-DEC-1997; 97WO-US023637.

XX 17-DEC-1996; 96US-0033172P.

XX 17-APR-1997; 97US-0044074P.

XX (TERM/). TERMAN D S.

XX Terman DS;

XX WPI; 1998-362497/31.

XX Conjugates and polymers containing superantigen and therapeutic antigen -
 PT for treatment of cancer, infection, autoimmune disease and graft
 PT rejection, also treatment by administering lymphocytes treated in vitro
 PT by these antigens.

XX Example 2; Page 40; 139pp; English.

XX Synthetic peptides AAW63049-85 are used, with superantigens, to exemplify
 CC the invention. The specification describes a method for treatment of
 CC cancer which comprises incubating lymphocytes with a tumour-specific
 CC antigen or autoimmune disease related antigen and a superantigen. The
 CC treated cells are then introduced into the patient. The superantigen and
 CC the tumour-specific antigen or autoimmune disease related antigen can be
 CC conjugated together. The products are used to treat cancer (carcinoma,
 CC melanoma, lymphoma etc.), infections (bacterial, viral or eukaryotic) and
 CC autoimmune disease (e.g. idiopathic thrombocytopenic purpura, rheumatoid

CC arthritis, systemic lupus erythematosus, multiple sclerosis etc.). The
 CC antigens either induce an immune response or inhibit a pathological
 CC response

XX SQ Sequence 18 AA;

Query Match 88.3%; Score 68; DB 2; Length 18;

Best Local Similarity 100.0%; Pred. No. 0.0024;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 QRGPGRAFTVIGK 15

|||||

Db 6 QRGPGRAFTVIGK 18

RESULT 153

AAW79180
 ID AAW79180 standard; peptide; 21 AA.

XX AAW79180;

XX 25-JAN-1999 (first entry)

XX Fusion immunoglobulin heavy chain HIV gp120 T cell epitope #58.

KW B cell; T cell; epitope; immunoglobulin; heavy chain; gp120; IGH;
 KW human immune deficiency virus; HIV; tolerance; treatment; therapy;
 KW prophylaxis; vaccine; chemotherapy; immune response; modifier; tumour;
 KW microbial infection; autoimmune disease; antibody; apoptosis;
 KW antiviral T cell immunity.

XX Mus sp.

OS Homo sapiens.

XX WO9836087-A1.

XX 20-AUG-1998.

XX 13-FEB-1998; 98WO-US002766.

XX 13-FEB-1997; 97US-0040581P.

XX (AMNA-) AMERICAN NAT RED CROSS.

XX Scott D, Zambidis E;

XX WPI; 1998-506315/43.

XX New fusion immunoglobulin heavy chain including gp120 epitopes and
 PT related complete antibodies - DNA, vectors and transformed cells, used to
 PT induce tolerance to the epitopes for treatment of human immune deficiency
 PT virus infection.

XX Disclosure; Page 50; 154pp; English.

XX This sequence is an epitope used in the construction of a novel fusion
 CC immunoglobulin heavy chain (IgH) protein with a mammalian, especially
 CC human, IGH chain fused in frame at its N-terminus to one or more human
 CC immune deficiency virus (HIV) gp120 epitopes. Fusion Ig proteins and/or
 CC transfected cells are used to tolerate subjects to gp120 epitopes and to
 CC maintain this tolerance, particularly for treatment of HIV infection,
 CC optionally together with other therapeutic/prophylactic agents such as
 CC vaccines, chemotherapeutic agents and immune response modifiers. Such
 CC proteins can be used against other diseases where an immune response is
 CC deleterious, e.g. microbial infection, tumours or autoimmune disease.
 CC Induction of tolerance suppresses production of antibodies against gp120,
 CC so prevents or inhibits 'bystander' apoptosis of uninfected T cells that
 CC are bound to gp120 protein, maximising induction of protective antiviral
 CC T cell immunity

XX SQ Sequence 21 AA;

Query Match 88.3%; Score 68; DB 2; Length 21;


```
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 QRGPGRAFTVIGK 15
Db 1 QRGPGRAFTVIGK 13

RESULT 154
AAW76901
ID AAW76901 standard; peptide; 21 AA.
XX
AC AAW76901;
XX
DT 25-JAN-1999 (first entry)
XX
DE Fusion immunoglobulin heavy chain HIV gp120 T cell epitope #20.
XX
KW B cell; T cell; epitope; immunoglobulin; heavy chain; gp120; IGH;
KW human immune deficiency virus; HIV; tolerance; treatment; therapy;
KW prophylaxis; vaccine; chemotherapy; immune response; modifier; tumour;
KW microbial infection; autoimmune disease; antibody; apoptosis;
KW antiviral T cell immunity.
XX
OS Mus sp.
OS Homo sapiens.
XX
PN WO9836087-A1.
XX
PD 20-AUG-1998.
XX
PF 13-FEB-1998; 98WO-US002766.
XX
PR 13-FEB-1997; 97US-0040581P.
XX
FA (ANNA-) AMERICAN NAT RED CROSS.
XX
PI Scott D, Zambidis E;
XX
DR WPI; 1998-506315/43.
XX
PT New fusion immunoglobulin heavy chain including gp120 epitopes and
PT related complete antibodies - DNA, vectors and transformed cells, used to
PT induce tolerance to the epitopes for treatment of human immune deficiency
PT virus infection.
XX
PS Claim 11; Page 120; 154pp; English.
XX
CC This sequence is an epitope used in the construction of a novel fusion
CC immunoglobulin heavy chain (IGH) protein with a mammalian, especially
CC human, IGH chain fused in frame at its N-terminus to one or more human
CC immune deficiency virus (HIV) gp120 epitopes. Fusion Ig proteins and/or
CC transfected cells are used to tolerate subjects to gp120 epitopes and to
CC maintain this tolerance, particularly for treatment of HIV infection,
CC optionally together with other therapeutic/prophylactic agents such as
CC vaccines, chemotherapeutic agents and immune response modifiers. Such
CC proteins can be used against other diseases where an immune response is
CC deleterious, e.g. microbial infection, tumours or autoimmune disease.
CC Induction of tolerance suppresses production of antibodies against gp120,
CC so prevents or inhibits bystander apoptosis of uninfected T cells that
CC are bound to gp120 protein, maximising induction of protective antiviral
CC T cell immunity
XX
SQ Sequence 21 AA;

Query Match 88.3%; Score 68; DB 2; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 QRGPGRAFTVIGK 15
Db 1 QRGPGRAFTVIGK 13

RESULT 155
AAW74608
ID AAR74608 standard; peptide; 24 AA.
XX
AC AAR74608;
XX
DT 16-OCT-2003 (revised)
DT 04-JAN-1996 (first entry)
XX
DE HIV-1 gp120 peptide #5.
XX
KW HIV-1; HIV; AIDS; gp120; mucosal cell; epithelium; vagina; rectum;
KW antibody; mucosal administration; vaccine; infection.
XX
OS Human immunodeficiency virus 1.
XX
PN WO9511701-A1.
XX
PD 04-MAY-1995.
XX
PF 25-OCT-1994; 94WO-US012152.
XX
PR 26-OCT-1993; 93US-00143577.
XX
FA (SYNT-) SYNTELLO INC.
XX
PI Czerkinsky C, Holmgren J, Horal P, Svennerholm B, Vahlne A;
XX
DR WPI; 1995-178653/23.
XX
PT HIV-1 gp120 peptide to inhibit mucosal epithelium cell infection - useful
PT in peptide vaccine to inhibit HIV-1 infection of vaginal or rectal
PT mucosa.
XX
PS Claim 2; Page 23; 34pp; English.
XX
CC The peptide represented in this sequence, and those represented by
CC sequences AAR74604-7 are epitopes of HIV-1 gp120 that are effective to
CC generate antibodies that inhibit infection of mucosal cells by HIV-1.
CC These peptides are administered to the epithelium in a vaccine, or are
CC used to generate mucosal antibodies and thereby inhibit infection by HIV-
CC 1. These peptides are used for inhibiting the entry of HIV into vaginal
CC and rectal mucosal epithelium. The antibodies that can be generated from
CC them are able to block subsequent infection by HIV. (Updated on 16-OCT-
CC 2003 to standardise OS field)
XX
SQ Sequence 24 AA;

Query Match 88.3%; Score 68; DB 2; Length 24;
Best Local Similarity 93.3%; Pred. No. 0.0031;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RIQRGPGRAFTVIGK 15
Db 2 RIQRGPGRAFTVIGK 16

RESULT 156
AAR04475
ID AAR04475 standard; protein; 25 AA.
XX
AC AAR04475;
XX
DT 09-SEP-2004 (revised)
DT 25-MAR-2003 (revised)
DT 20-SEP-1990 (first entry)
XX
DE Human immunodeficiency virus hybrid peptide RPI37.
XX
KW HIV isolates HIV-IIIB and HIV-RF; hybrid peptide RPI37; therapy; AIDS;
KW principal neutralising domain; antibodies; diagnosis; prophylaxis.
XX
```

OS Synthetic.
 XX WO9003984-A.
 XX
 XX
 XX PD 19-APR-1990.
 XX
 XX PF 03-OCT-1988; 88US-00252949.
 XX
 XX PR 03-OCT-1988; 88US-00252949.
 XX PR 01-JUN-1989; 89US-00359543.
 XX PR 19-SEP-1989; 89US-00407663.
 XX
 XX PA (REPK) REPLIGEN CORP.
 XX
 XX PI Rusche JR, Putney SD, Javaherian K, Farley J, Grimailla R;
 XX PI Lynn DU, Petrobre J;
 XX
 XX DR WPI; 1990-147824/19.
 XX
 XX PT Principal neutralising domain of HIV variants - used for producing
 XX PT peptide(s) and antibodies for diagnosis, prophylaxis and/or therapy
 XX PT therapy of HIV infection.
 XX
 XX PS Claim 8 (58); Page 76; 108pp; English.
 XX
 XX CC Peptide RPI37 comprises segments of the Principal Neutralising Domain
 XX CC (envelope protein) from isolates HIV-RF and HIV-IIIB. The last Cys
 XX CC residue is added for the purpose of crosslinking to carrier proteins.
 XX CC Cysteine residues may be added, so that the residues at or near both ends
 XX CC form a disulfide bond, giving peptide a loop-like configuration, which
 XX CC can be utilised to enhance immunogenic properties of the peptides.
 XX CC Protein is capable of eliciting, and/or binding with, neutralising
 XX CC antibodies. The neutralising domain is bounded by cysteine residues which
 XX CC occur at positions 296 and 331. The peptides can be used as immunogens
 XX CC or screening reagents to generate or identify poly- or monoclonal
 XX CC antibodies. See also AAR04427-R04506 and AAR04273-Q04279. (Updated on 25-
 XX CC MAR-2003 to correct PR field.) (Updated on 25-MAR-2003 to correct PA
 XX CC field.) (Updated on 25-MAR-2003 to correct PI field.)
 XX CC
 XX CC Revised record issued on 09-SEP-2004 : Correction to Feature Table Key
 XX
 XX SQ Sequence 25 AA;
 Query Match 88.3%; Score 68; DB 2; Length 25;
 Best Local Similarity 86.7%; Pred. NO. 0.0032;
 Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 1 RIQGGGFAFTVIGK 15
 |||||
 Db 8 RITKGFGFAFTVIGK 22
 |||||
 RESULT 157
 AAW32887
 ID AAW32887 standard; peptide; 15 AA.
 AC
 XX AAW32887;
 XX
 XX DT 16-JAN-1998 (first entry)
 XX
 XX DE HIV envelope glycoprotein 120 T cell epitope P10.
 XX
 XX KW Hydrophilic; antigenic determinant; HIV; envelope; glycoprotein; env; gp;
 XX KW recognition; B lymphocyte; type specific; antibody; vaccine; protection;
 XX KW immune response; infection; neutralisation; epitope.
 XX
 XX OS Human immunodeficiency virus.
 XX
 XX PN WO9714436-A1.
 XX
 XX PD 24-APR-1997.
 XX
 XX PF 18-OCT-1996; 96WO-US016911.

XX 20-OCT-1995; 95US-00546515.
 PR 09-FEB-1996; 96US-00599266.
 XX
 XX PA (UYDU-) UNIV DUKE.
 XX
 XX PI Haynes BF, Falker TJ;
 XX
 XX DR WPI; 1997-244862/22.
 XX
 XX PT Synthetic human immunodeficiency virus vaccine - comprising hydrophilic
 XX PT peptide corresponding to at least 1 antigenic determinant of envelope
 XX PT glycoprotein recognised by B lymphocytes.
 XX
 XX PS Disclosure; Page 27; 104pp; English.
 XX
 XX CC An essentially pure hydrophilic peptide, comprising at least 1 antigenic
 XX CC determinant of human immunodeficiency virus (HIV) envelope (env)
 XX CC glycoprotein (gp) recognised by B lymphocytes, when covalently linked to
 XX CC a carrier molecule, i.e. the present sequence, induces the production of
 XX CC high titres of protective, type specific anti-HIV antibodies (Ab) in a
 XX CC mammal. The peptide can be used in vaccines for producing a protective
 XX CC immune response to HIV infection, while a HIV neutralising Ab can be
 XX CC induced in a primate by administering a composition comprising HIV env
 XX CC peptides that disrupt gp120/gp41 interactions
 XX
 XX SQ Sequence 15 AA;
 Query Match 87.08; Score 67; DB 2; Length 15;
 Best Local Similarity 93.3%; Pred. NO. 0.0029;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 RIQGGGFAFTVIGK 15
 |||||
 Db 1 RIQGGGFAFTVIGK 15
 |||||
 RESULT 158
 AAP95356
 ID AAP95356 standard; peptide; 17 AA.
 XX
 XX AC AAP95356;
 XX
 XX DT 27-AUG-2003 (revised)
 XX DT 30-MAR-1992 (first entry)
 XX
 XX DE Variable region V3, found in the envelope protein gp120 of an AIDS or ARC
 XX DE causing or related virus.
 XX
 XX KW Vaccine; AIDS; ARC; HIV; diagnosis.
 XX
 XX OS HTLV-IIIB.
 XX
 XX PN EP3111219-A.
 XX
 XX PD 12-APR-1989.
 XX
 XX PF 07-OCT-1988; 88EP-00202248.
 XX
 XX PR 09-OCT-1987; 87NL-00002403.
 XX
 XX PA (DIER-) STICHTING CENT DIER.
 XX PA (UNAM) UNIV VAN AMSTERDAM.
 XX PA (UYAM-) UNIV AMSTERDAM ZIEKENHUI.
 XX
 XX PI Goudsmit J, Melen RH;
 XX
 XX DR WPI; 1989-108193/15.
 XX
 XX PT Oligopeptide(s) corresp. to beta-turn variable region of gp.120 - used
 XX PT for diagnosis of and prodn of vaccines against AIDS and ARC.
 XX
 XX PS Disclosure; Page 3; 7pp; English.

DT 25-MAR-2003 (revised)
 DT 20-OCT-1997 (first entry)
 XX HIV-1 strain LAI env protein V3 loop B-cell epitope.
 DE HIV; human immunodeficiency virus; gag; T-cell; B-cell; epitope; env;
 KW V3 loop; vaccine; determinant; chimaeric.
 XX Synthetic.
 OS US5639854-A.
 PN 17-JUN-1997.
 XX 09-JUN-1994; 94US-00257528.
 PR 09-JUN-1993; 93US-00073378.
 XX (CONN-) CONNAUGHT LAB LTD.
 PA Klein MH, Sia CDY, Chong P;
 PI WPI; 1997-332082/30.
 DR Tandem synthetic HIV peptide(s) useful as immunogens - comprising gag
 PT protein T-cell epitope linked to env protein B-cell epitope.
 XX Claim 8; Col 74; 41pp; English.
 PS The invention relates to new synthetic peptides comprising at least one
 CC amino acid sequence comprising an HIV gag protein T-cell epitope linked
 CC at its C- or N-terminus to an amino acid sequence comprising a B-cell
 CC epitope of the V3 loop of an HIV env protein, which can be used to
 CC generate vaccines against HIV-1. The T-cell epitope sequence is pref.
 CC selected from the T-helper determinant core peptides P24E, P24N, P24L,
 CC P24M and P24H while the B-cell epitopes are derived from HIV strains
 CC including CTLB-56, V3MN, CTLB-29, CTLB-55, SF2, LAI, IIB, RF, Z6, 2054,
 CC 1714 and BX08. The peptides are chimaeric and can be linked to a branched
 CC lys backbone. This sequence represents the HIV-1 strain LAI env protein
 CC V3 loop B-cell epitope. (Updated on 25-MAR-2003 to correct PF field.)
 XX Sequence 20 AA;
 SQ
 Query Match 87.0%; Score 67; DB 2; Length 20;
 Best Local Similarity 92.9%; Pred. No. 0.0038;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 RIQGPGRFVTTIG 14
 DB 7 RIQGPGRFVTTIG 20
 RESULT 162
 AAW67366
 ID AAW67366 standard; peptide; 20 AA.
 XX AAW67366;
 AC AAW67366;
 XX 17-OCT-2003 (revised)
 DT 25-JAN-1999 (first entry)
 DE HIV-1 strain LAI V3 loop peptide epitope.
 XX Immunogen; vaccine; HIV-1; T-cell; B-cell; epitope; core protein; gp120;
 KW V3 loop.
 XX Human immunodeficiency virus 1.
 OS US5817754-A.
 PN 06-OCT-1998.
 XX 05-JUN-1995; 95US-00464329.

XX 09-JUN-1993; 93US-00073378.
 PR 09-JUN-1994; 94US-00257528.
 XX (CONN-) CONNAUGHT LAB LTD.
 PA Chong P, Klein MH, Sia CDY;
 PI WPI; 1998-556461/47.
 DR Synthetic human immunodeficiency virus-1 peptide(s) - containing T-cell
 XX epitope and B-cell epitope(s) are candidate vaccines against HIV-1.
 PT Disclosure; Col 9; 40pp; English.
 PS The invention relates to a novel immunogenic composition for use in
 CC vaccines for the treatment of HIV-1 comprising an HIV-1-derived T-cell
 CC epitope linked to an HIV-1-derived B-cell epitope. The T-cell epitopes
 CC are generally designed based on the p24 core protein and the B-cell
 CC epitopes from the V3 loop of the gp120 protein from various HIV-1
 CC strains. This peptide corresponds to the V3 loop peptide epitope from the
 CC HIV-1 strain LAI. The peptide is used to generate a hybrid T- and B-cell
 CC epitope (AAW67353). (Updated on 17-OCT-2003 to standardise OS field)
 XX Sequence 20 AA;
 SQ
 Query Match 87.0%; Score 67; DB 2; Length 20;
 Best Local Similarity 92.9%; Pred. No. 0.0038;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 RIQGPGRFVTTIG 14
 DB 7 RIQGPGRFVTTIG 20
 RESULT 163
 AAW99974
 ID AAW99974 standard; peptide; 20 AA.
 XX AAW99974;
 AC AAW99974;
 XX 05-MAY-1999 (first entry)
 DT HIV-1 vaccine synthetic peptide SEQ ID NO:51.
 DE HIV-1; human immunodeficiency virus; vaccine; T-cell epitope;
 KW gag protein; B-cell epitope; gp41 protein; chimeric; infection.
 XX Synthetic.
 OS Human immunodeficiency virus 1.
 XX US5876731-A.
 PN 02-MAR-1999.
 XX 05-JUN-1995; 95US-00462507.
 PF 09-JUN-1993; 93US-00073378.
 PR 09-JUN-1994; 94US-00257528.
 XX (CONN-) CONNAUGHT LAB LTD.
 PA Chong P, Klein MH, Sia CDY;
 PI WPI; 1999-189590/16.
 DR Synthetic chimeric HIV polypeptides - comprising gag protein T-cell
 XX epitope linked to gp41 B-cell epitope.
 PT Example 1; Col 49-50; 41pp; English.
 PS The present invention describes a synthetic peptide comprising an amino
 CC acid sequence containing a T-cell epitope of an HIV gag protein linked at

CC its C terminus to an amino acid sequence containing a B-cell epitope of
CC an HIV gp11 protein and containing the amino acid sequence: X1LKDWX2;
CC where X1 = E, A, G or Q, and X2 = A or T, or an amino acid sequence
CC capable of eliciting an HIV-specific antiserum and recognizing the
CC sequence X1LKDWX2. The synthetic peptide is useful in vaccines against
CC HIV infection and in diagnostic applications. AA98892 to AA98906, and
CC AA98989 to AA98999 represent synthetic peptides from the present
CC invention
XX
SQ Sequence 20 AA;

Query Match 87.0%; Score 67; DB 2; Length 20;
Best Local Similarity 92.9%; Pred. No. 0.0038;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1 RIQPGPGRAFTVIG 14
Db 7 RIQPGPGRAFTVIG 20

RESULT 164
AA939699
ID AA939699 standard; peptide; 20 AA.

AC AA939699;

XX,
DT 17-OCT-2003 (revised)
DT 26-NOV-1999 (first entry)
XX
DE HIV1 chimeric peptide LAI.

XX HIV; vaccine; immunogenic composition; T cell epitope; B cell epitope;
KW infection; antibody; antiviral.
XX Human immunodeficiency virus 1.

OS
XX US951986-A.

FN
XX 14-SEP-1999.

PD
XX 06-JUN-1995; 95US-00467881.

PP
XX 09-JUN-1993; 93US-00073378.

PR
XX 09-JUN-1994; 94US-00257528.

XX
PA (CONN-) CONNAUGHT LAB LTD.

XX
PI Klein MH, Chong P, Sia CDY;

XX
DR WPI; 1999-550482/46.

XX Immunogenic composition containing synthetic fusion polypeptides
PT containing both the T and B cell epitopes of the human immunodeficiency
PT virus, useful antigens in producing vaccines.

XX
PS Disclosure; Col 9; 43pp; English.

XX This sequence represents a fragment of a HIV1 protein, and can be used in
CC the immunogenic composition of the invention. The composition comprises a
CC synthetic fusion polypeptide which includes a sequence encoding 1 or more
CC T cell epitopes and a sequence encoding 1 or more B cell epitopes and a
CC carrier. Both the T cell and B cell epitopes are derived from HIV
CC proteins. The compositions are useful as vaccines against HIV infection.
CC The composition induces HIV-1-specific polyclonal antibodies that are
CC opsonising and antiviral. The peptide components may be selected to
CC induce a response against different viral isolates and in subjects who
CC recognise different T cell epitopes. (Updated on 17-OCT-2003 to
CC standardise OS field)

XX
SQ Sequence 20 AA;

Query Match 87.0%; Score 67; DB 2; Length 20;
Best Local Similarity 92.9%; Pred. No. 0.0038;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 1 RIQPGPGRAFTVIG 14
Db 7 RIQPGPGRAFTVIG 20

RESULT 165

AA96191
ID AA96191 standard; peptide; 18 AA.

XX
AC AA96191;

XX
DT 19-DEC-2000 (first entry)

XX
DE Glycoprotein gp120 glycosylated peptide.

XX
KW gp120; MUC1; immunomodulator; glycopeptide; T-lymphocyte; T-cell;
KW proliferation; cancer; sarcoma; carcinoma; leukaemia; diagnosis; therapy;
KW vaccine; adjuvant; glycosylation.

XX
OS Unidentified.

XX
FH Key Location/Qualifiers

FT Modified-site 15 /note= "O-glycosylated by GalNAc-beta-1-3Gal"

XX
FN WO200052046-A1.

XX
PD 08-SEP-2000.

XX
PP 01-MAR-2000; 2000MO-GB000724.

XX
PR 01-MAR-1999; 99GB-00004695.

XX
PA (IMCR) IMPERIAL CANCER RES TECHNOLOGY LTD.

XX
PI Burchell J, Taylor-Papadimitriou J;

XX
DR WPI; 2000-601868/57.

XX
PT New immunomodulating glycopeptide that causes super-proliferation of T
PT cells, useful for treating cells in vitro, for diagnosing or treating
PT cancer (e.g. carcinoma or sarcoma) or as an adjuvant.

XX
PS Disclosure; Page 24; 35pp; English.

XX The present sequence comprises a glycosylated fragment of gp120.
CC Glycopeptides comprising a fragment of the MUC1 repeat sequence,
CC especially having a Gal-GalNAc or GalNAc moiety on Thr-10 or Thr-17 (see
CC AA96172-74), are useful as immunomodulators, causing super-proliferation
CC of T cells. Such glycopeptides can be used in the treatment or diagnosis
CC of a disease, in particular cancer, or as vaccine adjuvants. The
CC glycopeptides are particularly useful in manufacturing a medicament for
CC preventing or treating cancer by stimulating T cells whose receptors
CC recognize the glycopeptide. They are also useful for diagnosing or
CC treating cancer, e.g. carcinoma (e.g. mammary, lung, bladder or colon
CC carcinomas, or ovary and endometrial tumours), or sarcoma (e.g. soft
CC tissue and bone sarcomas, or leukaemia). Human peripheral blood
CC lymphocytes were used in a proliferation assay. The proliferation index
CC of the gp120 glycopeptide (taking the index as 1 when no glycopeptide was
CC present) was 1-1.7

XX
SQ Sequence 18 AA;

Query Match 85.4%; Score 66.5; DB 3; Length 18;

Best Local Similarity 93.8%; Pred. No. 0.0041;
Matches 15; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

Oy 1 RIQ-RGPGRAFTVIGK 15

Db 3 RIQ-RGPGRAFTVIGK 18

RESULT 166
AAW76863
ID AAW76863 standard; peptide; 14 AA.
XX
XX
AC AAW76863;
XX
XX
DT 25-JAN-1999 (first entry)
XX
DE Fusion immunoglobulin heavy chain HIV gp120 B cell epitope #33.
XX
XX B cell; T cell; epitope; immunoglobulin; heavy chain; gp120; IGH;
KW human immune deficiency virus; HIV; tolerance; treatment; therapy;
KW prophylaxis; vaccine; chemotherapy; immune response; modifier; tumour;
KW microbial infection; autoimmune disease; antibody; apoptosis;
KW antiviral T cell immunity.
XX
XX Mus sp.
OS Homo sapiens.
XX
XX WO9836087-A1.
XX
XX 20-AUG-1998.
XX
XX 13-FEB-1998; 98WO-US002766.
XX
XX 13-FEB-1997; 97US-0040581P.
XX
XX (AMNA-) AMERICAN NAT RED CROSS.
XX
XX Scott D, Zambidis E;
XX
XX WPI; 1998-506315/43.
XX
XX New fusion immunoglobulin heavy chain including gp120 epitopes and
PT related complete antibodies - DNA, vectors and transformed cells, used to
PT induce tolerance to the epitopes for treatment of human immune deficiency
XX virus infection.
XX
XX Claim 10; Page 119; 154pp; English.
XX
XX This sequence is an epitope used in the construction of a novel fusion
CC immunoglobulin heavy chain (IGH) protein with a mammalian, especially
CC human, IGH chain fused in frame at its N-terminus to one or more human
CC immune deficiency virus (HIV) gp120 epitopes. Fusion Ig proteins and/or
CC transduced cells are used to tolerate subjects to gp120 epitopes and to
CC maintain this tolerance, particularly for treatment of HIV infection,
CC optionally together with other therapeutic/prophylactic agents such as
CC vaccines, chemotherapeutic agents and immune response modifiers. Such
CC proteins can be used against other diseases where an immune response is
CC deleterious, e.g. microbial infection, tumours or autoimmune disease.
CC Induction of tolerance suppresses production of antibodies against gp120,
CC so prevents or inhibits 'bystander' apoptosis of uninfected T cells that
CC are bound to gp120 protein, maximising induction of protective antiviral
XX T cell immunity
XX
XX Sequence 14 AA;
Query Match 85.7%; Score 66; DB 2; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.0039;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RIQRGPGRAFTVI 13
Dd 2 RIQRGPGRAFTVI 14
RESULT 167
AAW36156
ID AAW36156 standard; peptide; 15 AA.
XX
XX
AC AAW36156;
XX

DT 17-OCT-2003 (revised)
DT 25-MAR-2003 (revised)
DT 30-MAR-1998 (first entry)
XX
XX
DE HIV-1 strain IIIB gp120 variable region 3 epitope.
XX
XX Mutant; P64k; fusion protein; stabilisation peptide; purification;
KW immunoaffinity chromatography; epitope; vaccine; human; animal; HIV-1.
XX
XX Human immunodeficiency virus 1.
XX
XX WO9726359-A1.
XX
XX 24-JUL-1997.
XX
XX 17-JAN-1997; 97WO-CU000001.
XX
XX 17-JAN-1996; 96CU-00000010.
XX
XX (INGG-) CENT ING GENETICA & BIOTECNOLOGIA.
XX
XX Duarte Cano CA, Guillen Nieto GE, Alvarez Acosta A;
PI Carpio Munoz EU, Quintana Vazquez D, Gomez Rodriguez CE;
PI Silva Rodriguez RDLC, Nazabal Galvez C, Leal Angulo MDJ;
PI Martin Dunn AM;
XX
XX WPI; 1997-402193/37.
XX
XX Fusion protein for use as immunogen in vaccines - contains stabilising
PT peptide derived from N-terminal 47 amino acids of *Neisseria meningitidis*
PT P64k antigen.
XX
XX Example 4; Page 12; 49pp; Spanish.
XX
XX This sequence represents an epitope corresponding to the central region
CC of the variable region from the gp120 protein of the human
CC immunodeficiency virus type 1 (HIV-1) strain IIIB. The peptides AAW36151-
CC W36156 were used to generate the multiple epitope-containing polypeptides
CC TAB4, TAB9 and TAB13 (AAW36159-T36161). The peptides are especially fused
CC to a mutant version of the first 47 amino acids of the P64k protein of
CC *Neisseria meningitidis* B:4:PI.15 (AAW36149). The *Neisseria* peptide is
CC used as a stabilisation peptide for purification of the heterologous
CC protein, especially by immunoaffinity chromatography, when the fusion
CC protein is produced in *E. coli*. (Updated on 25-MAR-2003 to correct PI
XX field.) (Updated on 17-OCT-2003 to standardise OS field)
XX
XX Sequence 15 AA;
Query Match 85.7%; Score 66; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.0041;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RIQRGPGRAFTVI 13
Dd 3 RIQRGPGRAFTVI 15
RESULT 168
AAW49356
ID AAW49356 standard; peptide; 15 AA.
XX
XX
AC AAW49356;
XX
XX 02-SEP-2002 (first entry)
XX
XX HIV-1 isolate IIIB gp120 V3 loop epitope peptide.
XX
XX Antigen; immunogen; dendrimer; carrier protein; conjugate; vaccine;
KW antigenic structure; cross-reactivity; infection; autoimmune disease;
KW cancer; immunomodulator; cytostatic; HIV-1; gp120; V3 loop; isolate IIIB.
XX
XX Synthetic.
XX

```

PN WO200236160-A2.
XX
PD 10-MAY-2002.
XX
PF 01-NOV-2001; 2001WO-CU000007.
XX
XX 03-NOV-2000; 2000CU-00000242.
XX
XX (INGG-) CENT ING GENETICA & BIOTECNOLOGIA.
XX
PI Cruz Ricondo LJ, Aguilar Rubio JC, Iglesias Perez B;
PI Reyes Acosta O, Garay Perez HE, Muzio Gonzalez VL, Guillen Nieto GE;
PI Duarte Cano C, Panton Arias E;
XX
DR WPI; 2002-444347/47.
XX
XX Preparation of antigenic structures having enhanced cross-reactivity and
PT immunogenicity, useful for diagnosis or in vaccines, e.g. against cancer,
PT comprising dendrimeric antigenic epitope conjugated with carrier
PT molecule.
XX
PS Example 10; Fig 1c; 41pp; Spanish.
XX
CC The invention relates to the preparation of antigenic structures with a
CC high cross-reactivity which synergistically enhance immune responses to
CC systemically and/or mucosally administered peptide antigens. Dendrimeric
CC structures containing a desired epitope are synthesised and coupled to a
CC carrier molecule, and are then mixed with a CD4 fusion domain peptide (or
CC a conjugate containing it) and an adjuvant such as alumina. The antigenic
CC structures are used in prophylactic or therapeutic vaccine formulations
CC for the prevention or treatment of infections, autoimmune diseases or
CC cancer in humans and other animals, and may also be used as part of
CC diagnostic systems. The antigenic structures of the invention have
CC synergistically enhanced cross-reactivity and immunogenicity compared
CC with the parent dendrimeric epitope structures from which they are
CC obtained. Sequences AAM49354-AAM49359 represent gp120 V3 loop epitopes
CC from different HIV-1 isolates. These were used in an exemplification to
CC demonstrate that the potentiation of immunogenicity and cross-reactivity
CC associated with the structures of the invention is independent of the
CC sequence of the V3 loop peptide used in the antigenic structure. The
CC present sequence represents the gp120 V3 loop epitope from HIV-1 isolate
CC I11B
XX
SQ Sequence 15 AA;
Query Match 85.7%; Score 66; DB 5; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.0041;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGGPGRAFTVI 13
|||
DB 3 RIQGGPGRAFTVI 15
|||

RESULT 169
ABR39121
ID ABR39121 standard; peptide; 15 AA.
XX
AC ABR39121;
XX
XX 23-OCT-2003 (revised)
DT 10-MAY-2003 (first entry)
XX
XX HIV-1 gp120 peptide SEQ ID NO 21.
DE
XX ADP-ribosylating exotoxin; immune response; immunisation; vaccine;
KW adjuvant; HIV; gp120.
XX
XX Human immunodeficiency virus 1.
OS
XX WO2003004055-A2.
PN
XX 16-JAN-2003.
PD

XX 26-NOV-2001; 2001WO-US043151.
XX
XX 27-NOV-2000; 2000US-00724315.
XX
XX (POWD-) POWDERJECT VACCINES INC.
XX
XX Haynes JR, Arrington JE;
XX
XX WPI; 2003-221541/21.
XX
XX New compositions comprising nucleic acid adjuvants, useful in
PT immunization techniques, particularly for eliciting or enhancing an
PT immune response against an antigen in a human.
XX
PS Example 5; Page 70; 143pp; English.
XX
CC The invention relates to a composition comprising: (a) a first nucleic
CC acid sequence that is a truncated A subunit coding region obtained or
CC derived from a bacterial ADP-ribosylating exotoxin; and (b) a second
CC nucleic acid sequence that is a truncated B subunit coding region
CC obtained or derived from a bacterial ADP-ribosylating exotoxin. Each of
CC the truncated subunit coding regions has a 5' deletion and encodes a
CC subunit peptide not having an amino terminal bacterial signal peptide.
CC The composition is useful for eliciting an immune response against an
CC antigen or for manufacturing a medicament for enhancing an immune
CC response in a vertebrate subject (specifically a human) against an
CC antigen. The composition is particularly useful as nucleic acid adjuvants
CC for use in immunisation techniques. The present sequence is that of a HIV
CC gp120 peptide, used in examples of the invention to test for the adjuvant
CC effects of plasmids pPUV2002 and pPUV2003 in enhancing the humoral and
CC cellular immune responses to HIV-1 gp120. (Updated on 23-OCT-2003 to
XX standardise OS field)
XX
SQ Sequence 15 AA;
Query Match 85.7%; Score 66; DB 6; Length 15;
Best Local Similarity 86.7%; Pred. No. 0.0041;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 RIQGGPGRAFTVIGK 15
|||
DB 1 RIQGGPGRAFTVIGK 15
|||

RESULT 170
ADH60862
ID ADH60862 standard; peptide; 15 AA.
XX
AC ADH60862;
XX
XX 25-MAR-2004 (first entry)
DT
DE HIV gp120 peptide.
XX
XX Bacterial exotoxin; immune response; bacterial infection; vaccine;
KW Human immunodeficiency virus; HIV.
XX
XX Human immunodeficiency virus.
OS
XX US2003162733-A1.
PN
XX 28-AUG-2003.
PD
XX 26-NOV-2001; 2001US-00993307.
PF
XX 27-NOV-2000; 2000US-0253381P.
XX
XX (HAYN/) HAYNES J R.
PA (ARRI/) ARRINGTON J.
XX
XX Haynes JR, Arrington J;
PI
XX

```

DR WPI; 2003-897945/82.
 XX
 PT New composition comprising first or second nucleic acid sequence, which
 PT is a truncated A or B subunit coding region obtained or derived from a
 PT bacterial ADP-ribosylating exotoxin, useful as a vaccine against
 PT bacterial infection.
 XX
 PS Example 5; SEQ ID NO 21; 72pp; English.
 XX
 CC The present invention relates to a new composition comprising first and
 CC second nucleic acid sequences. The first or second nucleic acid sequence
 CC is a truncated A or B subunit coding region, respectively, derived from a
 CC bacterial ADP-ribosylating exotoxin, with the provision that each of the
 CC truncated subunit coding regions has a 5' deletion and encodes a subunit
 CC peptide not having an amino terminal bacterial signal peptide. The
 CC invention is useful for enhancing an immune response against bacterial
 CC infection. The present sequence is Human immunodeficiency virus gp120
 CC peptide.
 XX
 SQ Sequence 15 AA;
 Query Match 85.7%; Score 66; DB 7; Length 15;
 Best Local Similarity 86.7%; Pred. No. 0.0041;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1 RIORGPGRAFTVIGK 15
 DB |||||
 1 RIORGPGRAFTVIGK 15
 RESULT 171
 ADRI8865
 ID ADRI8865 standard; peptide; 16 AA.
 AC
 AC ADRI8865;
 DT 04-NOV-2004 (first entry)
 DE V3-IIIB beta-hairpin related peptide SEQ ID NO:24.
 XX
 KW three-dimensional atomic structural conformation;
 KW protein co-ordinate data; V3 loop peptide; HIV-1; envelope glycoprotein;
 KW gp120; human monoclonal antibody 447-52D;
 KW murine monoclonal antibody 0.5 beta; immunogen; immunogenic;
 KW V3 loop epitope; HIV-1 infectivity inhibitor; anti-HIV; vaccine;
 KW HIV-1 infection.
 XX
 OS Human immunodeficiency virus 1.
 OS Synthetic.
 XX WO2004069863-A2.
 PN
 PD 19-AUG-2004.
 PF 04-FEB-2004; 2004WO-US003304.
 XX
 PR 04-FEB-2003; 2003US-0444682P.
 XX
 XX (UNNY) UNIV NEW YORK STATE.
 PA (YEDA) YEDA RES & DEV CO LTD.
 XX
 PI Anglistar J, Sharon M, Schapira M, Zolla-Pazner S, Rosen O;
 XX WPI; 2004-625447/60.
 DR
 XX Composition for inhibiting HIV-1 infection, comprises isolated peptide
 PT molecule that mimics atomic structural conformation of V3 loop peptide of
 PT HIV-1 envelope glycoprotein that is bound to, and constrained by human
 PT monoclonal antibody.
 XX
 XX Example 7; SEQ ID NO 24; 127pp; English.
 PS
 XX The present invention describes a composition (C1) which comprises an

isolated peptide molecule or isostere that mimics the three-dimensional
 (3D) atomic structural conformation of the V3 loop peptide of the HIV-1
 envelope glycoprotein gp120 that is bound to, and constrained by, human
 monoclonal antibody (MAB) 447-52D, murine MAB 0.5 beta or an antigen
 binding fragment of the MAB, where the constrained V3 loop peptide
 differs in conformation from the same V3 loop peptide when it is in free
 form. Also described: (1) identifying (M1) from several existing
 compounds a molecule that is useful as an HIV-1 V3 loop immunogen or as
 an inhibitor of binding of HIV-1 to a chemokine receptor/HIV-1 co-
 receptor on the surface of a receptor-bearing target cell; (2) designing
 a molecule that is useful as an HIV-1 V3 loop immunogen or as an
 inhibitor of binding of HIV-1 to a chemokine receptor/HIV-1 co-receptor
 on the surface of a receptor-bearing target cell; (3) a composition (C2)
 that is useful as an HIV-1 V3 loop immunogen or as an inhibitor of
 binding of HIV-1 to a chemokine receptor/HIV-1 co-receptor on the surface
 of a receptor-bearing target cell; (4) an immunogenic composition (C3)
 for induction of an anti-HIV-1 antibody response specific for a V3 loop
 epitope, comprising (C1) and an adjuvant; (5) a pharmaceutical
 composition (C4) useful for blocking the interaction of HIV-1 with an R5
 or X4 co-receptor and thereby inhibiting HIV-1 infectivity, comprising
 (C1) and a carrier or excipient; (6) a computing platform for generating
 a 3D model of a constrained HIV V3 view peptide; (7) a computer generated
 model representing the conformationally constrained structure of a V3
 loop peptide that is bound to 447-52D or 0.5beta MAB or its antigen
 binding fragments, comprising a 3D atomic structure defined by NC; and
 (8) a computer readable medium (CM) comprising, in a retrievable format,
 data that includes a set of structure coordinates defining a 3D structure
 of a V3 loop peptide that is conformationally constrained by being bound
 to 447-52D or 0.5beta MAB or its antigen binding fragment. (C1) has anti-
 HIV activities, and can be used in vaccines, and as an inhibitor of
 binding of HIV-1 to chemokine receptor/HIV-1 co-receptor. (C1) is useful
 for in vivo inhibition of HIV-1 infection. (C1) or (C2) is useful for
 producing a medicament utilised for treating or preventing HIV-1
 infection. (C3) or (C4) is useful for inducing in a subject an anti-HIV-1
 neutralising antibody response specific for a V3 loop epitope. (C4) is
 useful for preventing an HIV-1 infection in an uninfected subject at risk
 for such infection or for inhibiting viral spread and disease progression
 in an infected subject. The present sequence represents a peptide used in
 the exemplification of the present invention.

Sequence 16 AA;
 Query Match 85.7%; Score 66; DB 8; Length 16;
 Best Local Similarity 100.0%; Pred. No. 0.0044;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIORGPGRAFTVIT 13
 DB |||||
 4 RIORGPGRAFTVIT 16
 RESULT 172
 AAR04060
 ID AAR04060 standard; peptide; 21 AA.
 AC
 AC AAR04060;
 XX
 XX 25-MAR-2003 (revised)
 DT 23-JUL-1992 (first entry)
 XX
 DE Epitope comprising residues 308-327 of HIV env gp 120.
 XX
 KW Human immunodeficiency virus; retrovirus; vaccine; antibodies; HBC; HBe;
 KW antigen; hepatitis B virus; HBV; core.
 XX
 OS Synthetic.
 OS
 XX JP02069194-A.
 PN
 XX 09-MAR-1990.
 PD
 XX 02-SEP-1988; 88JP-00220770.
 PF
 XX

PR	02-SEP-1988;	88JP-00220770.
XX		
XX	(KAGA) KAGAKU OYOBI KESSEI RYOH.	
XX		
DR	WPI; 1990-119518/16.	
DR	N-PSDB; AAQ02417.	
XX		
PT	Antigen granule comprising HBC or HBE antigen - and HIV neutralised epitope obt'd. by expression of recombinant prod., for e.g. vaccine.	
XX		
PS	Claim Disclosure; Fig 4; 11pp; Japanese.	
CC	The synthetic epitope is used in a complex with either the hepatitis B core antigen (Hbc) or a sol. cleavage prod. of Hbc (HBe), to prepare a vaccine. The peptide corresponds to residues 308-327 of the HIV env glycoprotein 120, with an N-terminal initiation Met. (Updated on 25-MAR-2003 to correct PA field.)	
XX		
SQ	Sequence 21 AA;	
	Query Match 85.7%; Score 66; DB 2; Length 21;	
	Best Local Similarity 100.0%; Pred.No. 0.0056;	
	Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0	
OY	1 RIQRGPGRAFTVI 13 	
Dd	9 RIQRGPGRAFTVI 21	
RESULT 173		
AAE20149		
ID	AAE20149 standard; peptide; 24 AA.	
AC	XX	
AC	AAE20149;	
XX		
DT	29-AUG-2003 (revised)	
DT	18-JUN-2002 (first entry)	
XX		
DE	Human immunodeficiency virus type 1 (HIV-1) V3IIIB peptide.	
XX		
KW	Human immunodeficiency virus type 1; HIV-1; adjuvant; immunomodulator; alpha-2-macroglobulin; 3-O-deacylated monophosphoryl lipidA; MPL; GM-CSF; granulocyte macrophage colony stimulating factor; immune response; vaccine; V3IIIB peptide.	
KW		
OS	Human immunodeficiency virus 1.	
XX		
PN	WO200215930-A1.	
XX		
PD	28-FEB-2002.	
XX		
PF	27-AUG-2001; 2001WO-US026589.	
XX		
PR	25-AUG-2000; 2000US-0227624P.	
XX		
PA	(UYDU-) UNIV DUKE.	
XX		
PI	Haynes BF, Liao H, Patel DD;	
XX		
XX	WPI; 2002-269315/31.	
DR		
PT	Use of 2-macroglobulin (2Masterisk), 3-O-deacylated monophosphoryl lipid A (MPL) and granulocyte macrophage colony stimulating factor (GM-CSF) for eliciting an immune response.	
PT		
XX		
XX	Example 2; Page 21; 53pp; English.	
XX		
CC	The invention relates to a composition comprising activated alpha-2--macroglobulin (alpha_2M asterisk), 3-O-deacylated monophosphoryl lipid A (MPL) and granulocyte macrophage colony stimulating factor (GM-CSF). The invention also relates to an adjuvant suitable for use in multivalent HIV immunogenic compositions. The compositions is useful for eliciting an immune response. The present sequence is human immunodeficiency virus	

AC AAW22329;
 XX
 DT 17-OCT-2003 (revised)
 DT 18-SEP-1997 (first entry)
 XX
 DE HIV-1 clinical strain 9622 gp120 V3 loop peptide.
 XX
 KW Epitope; human immunodeficiency virus type 1; HIV-1; gp120; gp160;
 KW monoclonal antibody; V3 loop; immunisation; mouse; splenocyte; hybridoma;
 KW membrane fraction; passive immunisation; human.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN US5618922-A.
 XX
 PD 08-APR-1997.
 XX
 XX 25-JUL-1994; 94US-00279906.
 PF
 XX 25-JUL-1994; 94US-00279906.
 PR
 XX (NISP) NISSIN SHOKUHIN KAISHA LTD.
 PA
 XX Yoneda Y, Ohno T, Terada M;
 PI
 XX WPI; 1997-225475/20.
 DR
 XX Monoclonal antibody specific for human immunodeficiency virus type 1 MN
 PT strain - for passive immunisation against infection.
 PT
 XX Example 3; Col 10; 14pp; English.
 PS
 XX The invention relates to a novel monoclonal antibody (MAB) NM03 which
 CC binds to epitopes from the human immunodeficiency virus type 1 (HIV-1).
 CC The antibody was raised conventionally by immunising Balb/c mice with
 CC purified live HIV-1 MN, then isolating splenocytes and fusing them to P3-
 CC X63-Ag8-UL cells. Hybridomas were then screened with membrane fractions
 CC from infected and non-infected H9 cells. The MAB was observed to bind to
 CC a protein band of 120 kD on a Western blot of separated, denatured HIV-1
 CC proteins. This binding was shown to be between residues 320-327 by
 CC epitope mapping by ELISA and competitive binding. The ability of the MAB
 CC to inhibit infection of cells by HIV-1 shown by infecting H9 cells with
 CC live strains of HIV-1 and testing infection by a p24 assay. This peptide
 CC sequence represents the V3 loop region from HIV-1 clinical strain 9622,
 CC where the MAB NM03 binds. The MAB can be used for the passive
 CC immunisation of humans susceptible to, or infected with HIV-1. (Updated
 CC on 17-OCT-2003 to standardise OS field)
 XX
 SQ Sequence 19 AA;
 Query Match 83.1%; Score 64; DB 2; Length 19;
 Best Local Similarity 92.3%; Pred. No. 0.01;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 3 QRGPGRAFTVIGK 15
 DB 1 QRGPGRTFTVIGK 13
 RESULT 176
 AAW62892
 ID AAW62892 standard; peptide, 19 AA.
 XX
 AC AAW62892;
 XX
 DT 30-SEP-1998 (first entry)
 DT
 DE Peptide sequence of the specification.
 DE
 XX Monoclonal antibody; HIV-1gp120; gp160; infection; H9 cell;
 KW HIV strain MN; treatment; human HIV infection.
 KW
 OS Synthetic.

XX JP10182489-A.
 PN
 XX 07-JUL-1998.
 PD
 XX 25-DEC-1996; 96JP-00344904.
 PF
 XX 25-DEC-1996; 96JP-00344904.
 PR
 XX (NISP) NISSIN SHOKUHIN KAISHA LTD.
 PA
 XX WPI; 1998-433774/37.
 DR
 XX Monoclonal antibody which binds to HIV-1gp120 or gp160 - used to prevent
 PT and treat human HIV infection.
 PT
 XX Example 3; Page 8; 12pp; Japanese.
 PS
 XX AAW62889-900 represent peptides used to identify a peptide sequence
 CC (AAW62874) present in HIV-1gp120 or gp160 which is bound by the
 CC monoclonal antibody of the invention. The antibody neutralises in vitro
 CC the infection of H9 cell by an active HIV strain MN according to the p24
 CC analytical method. The antibody is used for treatment of human HIV
 CC infection
 CC
 XX Sequence 19 AA;
 SQ
 Query Match 83.1%; Score 64; DB 2; Length 19;
 Best Local Similarity 92.3%; Pred. No. 0.01;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 3 QRGPGRAFTVIGK 15
 DB 1 QRGPGRTFTVIGK 13
 RESULT 177
 AAR62152
 ID AAR62152 standard; peptide, 12 AA.
 XX
 AC AAR62152;
 XX
 DT 27-AUG-2003 (revised)
 DT 25-MAR-2003 (revised)
 DT 02-MAY-1995 (first entry)
 DT
 XX HIV-1 gp120/41 protein consensus binding sequence.
 DE
 XX Small ribonucleoprotein complex; UL snRNP; 70K protein; epitope;
 KW autoantibody; immunoinfective cluster virus; nuclear protein antigen;
 KW systemic rheumatic disorder; human immunodeficiency virus; HIV-1;
 KW systemic lupus erythematosus; mixed connective tissue disease;
 KW scleroderma; glycoprotein 120; glycoprotein 41.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN WO9420141-A1.
 XX
 PD 15-SEP-1994.
 PD
 XX 10-MAR-1994; 94WO-US002631.
 PF
 XX 11-MAR-1993; 93US-00029850.
 PR
 XX (UYSC-) UNIV SOUTHERN CALIFORNIA.
 PA
 XX Douvas A, Takehana Y, Ehresmann G;
 PI
 XX WPI; 1994-302689/37.
 DR
 XX Methods for treating immunoinfective cluster virus infections - utilise
 PT antibodies or fragments characteristic of auto antibodies produced by
 PT patients with rheumatic disorders.

XX PS Disclosure; Page 56; 106pp; English.

XX CC The U1 snRNP is the target of high-titre, high avidity autoantibodies

CC occurring in the systemic rheumatoid disorders of mixed connective tissue

CC disease, scleroderma and systemic lupus erythematosus. It has been found

CC that some sites in the U1 snRNP 70K protein (see AAR62120-R62135) are

CC homologous to sites in HIV-1 gp120/41 (AAR62136-R62152) and that anti-RNP

CC autoantibodies can be used to neutralise HIV-1. In particular, the

CC sequence AAR62152 from HIV-1 gp120 matches a consensus binding sequence

CC which is necessary and sufficient for high affinity binding to U1 RNA.

CC (Updated on 25-MAR-2003 to correct for high affinity binding to U1 RNA.

CC correct OS field.)

XX SQ Sequence 12 AA;

Query Match 81.8%; Score 63; DB 2; Length 12;

Best Local Similarity 100.0%; Pred. No. 0.0096;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 RGPGRFVTIGK 15
|||||

DB 1 RGPGRFVTIGK 12
|||||

RESULT 178

AAM54932

ID AAM54932 standard; peptide; 12 AA.

XX AC AAM54932;

XX DT 25-SEP-1998 (first entry)

XX DE HIV gp120 envelope protein, peptide 127, analogue 267d.

XX KW Immunoadsorbent; immunoassay; HIV gp120; immunogen; antibody; Human.

XX OS Human immunodeficiency virus.

XX PN US5763160-A.

XX PD 09-JUN-1998.

XX PF 07-JUN-1995; 95US-00488252.

XX PR 12-FEB-1988; 88US-00155321.

XX PR 01-MAR-1991; 91US-00653262.

XX PR 09-JUL-1991; 91US-00726605.

XX PR 19-OCT-1994; 94US-00326676.

XX PA (UNBI-) UNITED BIOMEDICAL INC.

XX PI Wang CY;

XX DR WPI; 1998-347301/30.

XX PT HIV gp120 peptides - useful as immunoassay reagents or vaccine

PT components.

XX PS Example 8; Column 21/22; 34pp; English.

XX CC Peptides AAM54903-W54941 can be used as an immunoabsorbent in an

CC immunoassay for detecting antibodies to HIV gp120, or as an immunogen for

CC eliciting antibodies to HIV in a mammal

XX SQ Sequence 12 AA;

Query Match 81.8%; Score 63; DB 2; Length 12;

Best Local Similarity 100.0%; Pred. No. 0.0096;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 RGPGRFVTIGK 15
|||||

DB 1 RGPGRFVTIGK 12
|||||

RESULT 179

AAM99432

ID AAM99432 standard; peptide; 12 AA.

XX AC AAM99432;

XX DT 07-DEC-2001 (first entry)

XX DE Vaccine related MHC ligand peptide SEQ ID NO:535.

XX KW Glutamic acid; glutamine; vaccine; major histocompatibility complex; MHC;

KW immunomodulator; antiallergic; endocrine; neuroprotectant; virucidal;

KW bactericidal; antiparasitic; fungicidal; cytostatic; medicine;

KW pharmaceutical; immune disorder; immune deficiency; autoimmune;

KW hypersensitivity; allergy; graft rejection; infection; hormonal disorder;

KW central nervous system disease; cancer; melanoma; anti-melanoma vaccine;

KW human immunodeficiency virus.

XX OS Homo sapiens.

XX PN WO200170772-A2.

XX PD 27-SEP-2001.

XX PF 22-MAR-2001; 2001WO-FR000872.

XX PR 23-MAR-2000; 2000FR-00003711.

XX PA (FABR) FABRE MEDICAMENT SA PIERRE.

XX PI Klinguer-Hamour C, Corvaia N, Beck A, Goetsch L;

XX DR WPI; 2001-611470/70.

XX PT Stabilized pharmaceutical containing N-terminal glutamic acid or

PT glutamine, useful e.g. in anti-melanoma vaccines, is an addition salt

PT with strong acid.

XX PS Claim 9; Page 122; 149pp; French.

XX CC The present invention describes a pharmaceutical compound (I) that

CC contains an N-terminal glutamic acid (Glu) or glutamine (Gln) residue in

CC the form of an addition salt with a strong, physiologically acceptable

CC acid (II). Also described are: (a) a pharmaceutical composition

CC containing at least one (I); (b) a vaccine containing at least one (I)

CC where this is a major histocompatibility complex (MHC) ligand (Ia); (c) a

CC method for in vitro diagnosis of diseases associated with the presence of

CC (Ia); (d) a kit for method (c) that includes a (Ia); and (e) a process

CC for preparing (I). (I) has immunomodulator, endocrine, antiallergic,

CC neuroprotectant, virucidal, bactericidal, antiparasitic, fungicidal and

CC cytostatic activities. (I) are useful, in human or veterinary medicine,

CC in pharmaceutical compositions (for treating immune disorders, e.g.

CC immune deficiency, autoimmune states, hypersensitivity, allergy, graft

CC rejection, infection, hormonal disorders and central nervous system

CC diseases), also, where (I) is a MHC ligand (Ia), in vaccines for

CC treatment or prevention of: (i) viral, bacterial, parasitic or fungal

CC infections; or (ii) of cancers. A particular application is in anti-

CC melanoma vaccines. (I) are also useful for in vitro diagnosis of diseases

CC associated with interactions between MHC and (I), e.g. melanoma and human

CC immunodeficiency virus infection. AAM98898 to AAM99592 represent peptides

CC which can be used in pharmaceutical compounds from the present invention

XX SQ Sequence 12 AA;

Query Match 81.8%; Score 63; DB 4; Length 12;

Best Local Similarity 100.0%; Pred. No. 0.0096;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 RGPGRFVTIGK 14
|||||

Db 1 QRGPGRAFTVIG 12

RESULT 180
AAW76864
ID AAW76864 standard; peptide; 14 AA.
XX AAW76864;
AC AAW76864;
XX 25-JAN-1999 (first entry)
DT Fusion immunoglobulin heavy chain HIV gp120 B cell epitope #34.
DE
XX B cell; T cell; epitope; immunoglobulin; heavy chain; gp120; IgH;
KW human immune deficiency virus; HIV; tolerance; treatment; therapy;
KW prophylaxis; vaccine; chemotherapy; immune response; modifier; tumour;
KW microbial infection; autoimmune disease; antibody; apoptosis;
KW antiviral T cell immunity.
XX
OS Mus sp.
OS Homo sapiens.
XX WO9836087-A1.
PN 20-AUG-1998.
PD 13-FEB-1998; 98WO-US002766.
XX 13-FEB-1997; 97US-0040581P.
PR (AMNA-) AMERICAN NAT RED CROSS.
PA Scott D, Zambidis E;
XX WPI; 1998-506315/43.
DR New fusion immunoglobulin heavy chain including gp120 epitopes and
PT related complete antibodies - DNA, vectors and transformed cells, used to
PT induce tolerance to the epitopes for treatment of human immune deficiency
PT virus infection.
XX
PS Claim 10; Page 119; 154pp; English.
XX
CC This sequence is an epitope used in the construction of a novel fusion
CC immunoglobulin heavy chain (IgH) protein with a mammalian, especially
CC human, IgH chain fused in frame at its N-terminus to one or more human
CC immune deficiency virus (HIV) gp120 epitopes. Fusion Ig proteins and/or
CC infected cells are used to tolerate subjects to gp120 epitopes and to
CC maintain this tolerance, particularly for treatment of HIV infection,
CC optionally together with other therapeutic/prophylactic agents such as
CC vaccines, chemotherapeutic agents and immune response modifiers. Such
CC proteins can be used against other diseases where an immune response is
CC deleterious, e.g. microbial infection, tumours or autoimmune disease.
CC Induction of tolerance suppresses production of antibodies against gp120,
CC so prevents or inhibits 'bystander' apoptosis of uninfected T cells that
CC are bound to gp120 protein, maximising induction of protective antiviral
CC T cell immunity
XX
SQ Sequence 14 AA;
Query Match 81.8%; Score 63; DB 2; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.011; Mismatches 0; Indels 0; Gaps 0;
Matches 12; Conservative 0;
Qy 4 RGPGRGFTVIGK 15
Db 1 RGPGRGFTVIGK 12
RESULT 181
AAR04476
ID AAR04476 standard; protein; 23 AA.
XX

AC AAR04476;
XX 09-SEP-2004 (revised)
DT 25-MAR-2003 (revised)
DT 20-SEP-1990 (first entry)
XX Human immunodeficiency virus hybrid peptide RPI40.
DE HIV isolates HIV-IIIB and HIV-RF; hybrid peptide PPI40; therapy; AIDS;
KW Principal neutralising domain; antibodies; diagnosis; prophylaxis.
XX Synthetic.
OS WO9003984-A.
PN 19-APR-1990.
PD 03-OCT-1988; 88US-00252949.
XX 03-OCT-1988; 88US-00252949.
PR 01-JUN-1989; 89US-00359543.
PR 19-SEP-1989; 89US-00407663.
XX (REPK) REPLIGEN CORP.
PA Rusche JR, Putney SD, Javaherian K, Farley J, Grimaila R;
XX Lynn DU, Petrobre J;
PI WPI; 1990-147824/19.
DR Principal neutralising domain of HIV variants - used for producing
XX peptide(s) and antibodies for diagnosis, prophylaxis and/or therapy
PT therapy of HIV infection.
PT
XX Claim 8 (59); Page 76; 108pp; English.
PS Peptide RPI40 comprises segments of the Principal Neutralising Domain
CC (envelope protein) from isolates HIV-RF and HIV-IIIB. The last Cys
CC residue is added for the purpose of crosslinking to carrier proteins.
CC Cysteine residues may be added, so that the residues at or near both ends
CC form a disulfide bond, giving peptide a loop-like configuration, which
CC can be utilised to enhance immunogenic properties of the peptides.
CC Protein is capable of eliciting, and/or binding with, neutralising
CC antibodies. The neutralising domain is bounded by cysteine residues which
CC occur at positions 296 and 331. The peptides can be used as immunogens
CC or screening reagents to generate or identify poly- or monoclonal
CC antibodies. See also AAR04427-R04506 and AAR04273-Q04279. (Updated on 25-
CC MAR-2003 to correct PR field.) (Updated on 25-MAR-2003 to correct PA
CC field.) (Updated on 25-MAR-2003 to correct PI field.)
CC Revised record issued on 09-SEP-2004 : Correction to Feature Table Key
XX Sequence 23 AA;
SQ
Query Match 81.8%; Score 63; DB 2; Length 23;
Best Local Similarity 85.7%; Pred. No. 0.017; Mismatches 1; Indels 0; Gaps 0;
Matches 12; Conservative 1;
Qy 2 IQRGPGRAFTVIGK 15
Db 7 ITRGPGRAFTVIGK 20
RESULT 182
AAW38249
ID AAW38249 standard; peptide; 16 AA.
XX AAW38249;
AC
XX 19-MAR-1998 (first entry)
DT Tip of HIV-IIIB V3 loop peptide of gp120.
DE
XX

KW Multivalent chimeric peptide; tandem repeat unit; human; mucin 1; MUC1;
 KW Omega loop sequence; prophylaxis; therapy; V3 loop peptide;
 KW pathogenic virus neutralisation; gp120; HIV-IIIB.
 XX Human immunodeficiency virus.
 OS
 XX
 FN WO9728187-A2.
 XX
 XX
 PD 07-AUG-1997.
 XX
 PF 29-JAN-1997; 97WO-US001726.
 XX
 PR 31-JAN-1996; 96US-00594403.
 PR 15-OCT-1996; 96US-00730244.
 XX
 XX (POPU-) POPULATION COUNCIL INC.
 PA
 XX Fontenot JD, Phillips DM;
 PI
 XX WPI; 1997-402551/37.
 DR
 XX New multivalent chimeric peptide(s) for neutralising pathogenic microbes
 PT - comprising a loop structure of human mucin 1 and an omega loop of an
 PT immunoglobulin superfamily protein.
 XX
 PS Example 2; Page 39; 63pp; English.
 XX
 CC The present sequence was used in the development of a novel multivalent
 CC chimeric peptide, comprising at least 2 tandemly repeated units, where
 CC the 1st portion of the repeated unit comprises a human mucin 1 (MUC1)
 CC sequence which forms an extended connector and a base of a loop structure
 CC of human MUC1, and a 2nd portion comprising an immunoglobulin super
 CC family protein Omega loop sequence. In the peptide, the natural structure
 CC of MUC1 tandem repeats can be used to present an Omega loop sequence in a
 CC functional conformation that is both multivalent and biologically active.
 CC It can provide prophylactic and therapeutic agents which have the binding
 CC specificity of an immunoglobulin super family member protein but do not
 CC have the entire protein's backbone. It can be used to neutralise
 CC pathogenic viruses, e.g. human immunodeficiency virus (HIV)
 XX
 XX Sequence 16 AA;
 SQ
 Query Match 81.2%; Score 62.5; DB 2; Length 16;
 Best Local Similarity 93.3%; Pred. No. 0.015;
 Matches 14; Conservative 0; Mismatches 0; Indels 1; Gaps 1;
 Qy 1 RIQGPGRFAVTVIGK 15
 |||||
 Db 3 RIQGPGRFAVTVIGK 16
 |||||
 RESULT 183
 AAR27465
 ID AAR27465 standard; protein; 21 AA.
 XX
 AC AAR27465;
 XX
 XX 25-MAR-2003 (revised)
 DT 24-FEB-1993 (first entry)
 XX
 DE V3 peptide from HIV-1 (IIIB).
 XX
 XX Cytotoxic T lymphocyte; CTL; NVAC; ALVAC; HIV-1 IIIB; env;
 KW memory precursor; CTL antigen receptor; V3 loop; gp120; canarypox virus;
 KW Copenhagen strain; vaccinia virus; virulence factor; deletion loci;
 KW recipient loci.
 XX
 OS Synthetic.
 XX
 XX WO9215672-A1.
 FN
 XX 17-SEP-1992.
 PD
 XX

PF 09-MAR-1992; 92WO-US001906.
 XX
 PR 07-MAR-1991; 91US-00666056.
 PR 11-JUN-1991; 91US-00713967.
 PR 06-MAR-1992; 92US-00847951.
 XX
 PA (VIRO-) VIROGENETICS CORP.
 XX
 XX Paoletti E, Perkus ME, Taylor J, Tartaglia J, Norton EK;
 PI Riviere M, De Taisene C, Limbach KJ, Johnson GP, Pincus SE, Cox WI;
 PI Francis J, Gettig RR;
 XX
 DR WPI; 1992-331718/40.
 XX
 XX Vaccine comprises recombinant, attenuated pox-virus - use for vaccinating
 PT against viral infections such as rabies, hepatitis B, HIV, HSV, EBV, CMV,
 PT mumps etc.
 XX
 XX Disclosure; Page 295; 456pp; English.
 PS
 XX The sequences given in AAR27465-67 were used to perform assays for
 CC cytotoxic T lymphocytes (CTL). Mice were inoculated with cells
 CC transformed with NVAC or ALVAC recombinants expressing the HIV-1 IIIB
 CC env gene. These mice generated CTL's and memory precursors of CTL's. The
 CC target cells were pulsed overnight with the peptide sequences given to
 CC test specificity of CTL antigen receptor recognition of the V3 loop
 CC region of HIV IIIB gp120. ALVAC is derived from a canarypox virus and
 CC NVAC is derived from Copenhagen strain vaccinia virus which have been
 CC modified by deletion of non-essential regions of the genome encoding
 CC known or potential virulence factors. The deletion loci were engineered
 CC as recipient loci for the insertion of foreign genes. See also AAQ35501-
 CC 864. (Updated on 25-MAR-2003 to correct FN field.)
 XX
 SQ Sequence 21 AA;
 Query Match 81.2%; Score 62.5; DB 2; Length 21;
 Best Local Similarity 93.3%; Pred. No. 0.019;
 Matches 14; Conservative 0; Mismatches 0; Indels 1; Gaps 1;
 Qy 1 RIQGPGRFAVTVIGK 15
 |||||
 Db 8 RIQGPGRFAVTVIGK 21
 |||||
 RESULT 184
 AAR31219
 ID AAR31219 standard; peptide; 21 AA.
 XX
 AC AAR31219;
 XX
 XX 24-OCT-2003 (revised)
 DT 25-MAR-2003 (revised)
 DT 09-JAN-2003 (revised)
 DT 18-MAY-1993 (first entry)
 XX
 DE V3 peptide from HIV-1 IIIB.
 XX
 XX Human immunodeficiency virus; V3 loop.
 KW
 XX Human immunodeficiency virus 1.
 OS
 XX WO9222641-A1.
 FN
 XX 23-DEC-1992.
 PD
 XX 12-JUN-1992; 92WO-US005107.
 PF
 XX 14-JUN-1991; 91US-00715921.
 PR 11-JUN-1992; 92US-00897382.
 PR
 XX (VIRO-) VIROGENETICS CORP.
 PA
 XX Paoletti E, Tartaglia J, Cox WI;
 PI

XX WPI; 1993-018128/02.
 XX Modified recombinant virus with inactivated non-essential genetic
 PT functions - comprises e.g. vaccinia or avipox virus, used as HIV vaccine.
 XX
 XX Example 5; Page 65; 159pp; English.
 XX
 CC The peptide represents the V3 loop epitope of HIV-1 IIIB. The peptide was
 CC used to test the specificity of cytotoxic T lymphocyte antigen receptor
 CC recognition of the V3 loop region of HIV IIIB gp120. See also AAR31218-
 CC 26. (Updated on 09-JAN-2003 to add missing OS field.) (Updated on 25-MAR-
 CC 2003 to correct PN field.) (Updated on 24-OCT-2003 to standardise OS
 CC field)
 XX
 SQ Sequence 21 AA;
 Query Match 81.2%; Score 62.5; DB 2; Length 21;
 Best Local Similarity 93.3%; Pred. No. 0.019;
 Matches 14; Conservative 0; Mismatches 0; Indels 1; Gaps 1;
 QY 1 RIQRGPGRAFTVIGK 15
 |||||
 Db 8 RIQRGPGRAFTVIGK 21
 |||||
 RESULT 185
 AAR31278
 ID AAR31278 standard; peptide; 12 AA.
 XX
 AC AAR31278;
 XX
 DT 12-FEB-1993 (first entry)
 XX
 DE HIV principal determinant peptide.
 XX
 KW AIDS; ARC; human immunodeficiency virus; vaccine; Neisseria;
 KW meningitidis b; outer membrane protein complex; OMPC; PND135-12.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 1 /note= "bonds to the OMPC of the conjugate via this site"
 FT
 XX
 PN EP467700-A.
 XX
 PD 22-JAN-1992.
 XX
 PF 19-JUL-1991; 91EP-00306598.
 XX
 PR 19-JUL-1990; 90US-00555339.
 PR 19-JUL-1990; 90US-00555966.
 PR 19-JUN-1991; 91US-00715276.
 PR 19-JUN-1991; 91US-00715278.
 XX
 PA (MERI) MERCK & CO INC.
 XX
 PI Leanza WJ, Marburg S, Tolman RL, Emini EA;
 XX
 DR WPI; 1992-026505/04.
 XX
 XX Conjugate proteins comprising HIV peptide components - useful for
 PT preparing vaccines for e.g. AIDS or for treating infections.
 XX
 XX Claim 12; Page 56; 63pp; English.
 XX
 CC The invention relates to a co-conjugate comprising an immunogenic protein
 CC or protein complex having a first set of covalent linkages to low
 CC molecular weight moieties which have an anionic or polyanionic character
 CC at physiological pH, and a second set of covalent linkages to peptides
 CC comprising HIV principal neutralizing determinants (PND's) or
 CC immunologically equivalent peptides. Preferably at least one set of the

CC covalent linkages is comprised of maleimide derivatives; the
 CC (poly)anionic moiety is composed of one to five residues of the anionic
 CC form of a carboxylic, sulphonic or phosphonic acid; the immunogenic
 CC protein is the outer membrane protein complex (OMPC) of Neisseria
 CC meningitidis b; and the PND peptide has a linear structure, a disulphide-
 CC bonded cyclic structure, an amide-bonded cyclic structure or a thioether-
 CC bonded cyclic structure. The present sequence (PND135-12) is an example
 CC of a PND peptide component used in the co-conjugate. The co-conjugate is
 CC useful for inducing anti-peptide immune response in mammals, for inducing
 CC HIV-neutralizing antibodies in mammals, for formulating vaccines to
 CC prevent HIV infection or disease, including AIDS, or for treating humans
 CC afflicted with HIV infection or disease
 XX
 SQ Sequence 12 AA;
 Query Match 80.5%; Score 62; DB 2; Length 12;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQRGPGRAFTV 12
 |||||
 Db 1 RIQRGPGRAFTV 12
 |||||
 RESULT 186
 AAR26714
 ID AAR26714 standard; peptide; 12 AA.
 XX
 AC AAR26714;
 XX
 DT 09-FEB-1993 (first entry)
 XX
 DE HIV-PND-polysaccharide-protein conjugate vaccine.
 XX
 KW Human immunodeficiency virus; principal neutralizing determinant;
 KW outer membrane protein complex; OMPC; Neisseria; AIDS; PND-135-12.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 1 /note= "Joins onto polysaccharide-protein complex via
 FT this site"
 FT
 XX
 PN EP468714-A.
 XX
 PD 29-JAN-1992.
 XX
 PF 19-JUL-1990; 90US-00555558.
 XX
 PR 19-JUL-1990; 90US-00555558.
 PR 19-JUL-1990; 90US-00555974.
 PR 19-JUN-1991; 91US-00715275.
 PR 19-JUN-1991; 91US-00715277.
 XX
 PA (MERI) MERCK & CO INC.
 XX
 PI Marburg S, Tolman RL, Emini EA;
 XX
 DR WPI; 1992-034437/05.
 XX
 XX HIV peptide-polysaccharide-protein conjugates - used in vaccines or to
 PT produce antibodies to prevent or treat HIV infection.
 XX
 XX Claim 9; Page 57; 63pp; English.
 XX
 CC The invention relates to a conjugate of an HIV principal neutralizing
 CC determinant (PND), or an immunologically equivalent peptide (PEP),
 CC covalently coupled to an immunogenic protein or protein complex through
 CC an anionic polysaccharide linker. Pref. the immunogenic protein is the
 CC outer membrane protein complex (OMPC) of Neisseria meningitidis b and the
 CC PND peptide has a linear structure, a disulphide-bonded cyclic structure,
 CC an amide-bonded cyclic structure or a thioether-bonded cyclic structure.

CC The present sequence (PND135-12) is an example of a PND peptide component. The conjugates are used for inducing HIV-neutralising antibodies or for making vaccines to prevent contraction of HIV infection or disease. The antibodies can be used for passively protecting against infection by HIV, or for protecting against proliferation of HIV post-infection, or for treating AIDS, or in diagnostic assays

XX
SQ Sequence 12 AA;

Query Match 80.5%; Score 62; DB 2; Length 12;
Best Local Similarity 100.0%; Pred. No. 0.014;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRGPGRAFTV 12
| | | | | | | | | |
Db 1 RIQRGPGRAFTV 12

RESULT 187

AAR58603
ID AAR58603 standard; peptide; 13 AA.
XX
AC AAR58603;
XX
DT 25-MAR-2003 (revised)
DT 01-MAY-1995 (first entry)
XX
DE Alkaline phosphatase 168-169 insertion.
XX
KW Alkaline phosphatase; AP; amino acid moiety; AAM.
XX
OS Synthetic.
XX
PN WO9420636-A1.
XX
PD 15-SEP-1994.
XX
PF 09-MAR-1994; 94WO-US002539.
XX
PR 09-MAR-1993; 93US-00031165.
PR 29-JUL-1993; 93US-00100708.
XX
XX (ABBO) ABBOTT LAB.
XX
PI Brate EM, Brennan CA, Bridon DP, Jaffe KD, Krafft GA, Mandecki W;
PI March SC, Russell JC, Yue VT;
XX
XX WPI; 1994-303041/37.
DR N-PSDB; AAQ70593; AAQ70594.
XX
PT Genetically engineered hybrid enzymes and ligand conjugates - useful for diagnostic assay, to detect antigens and antibodies by changes in enzyme activity.
XX
PS Claim 8; Page 87; 133pp; English.
XX
CC AAR58603 is an amino acid moiety (AAM), when inserted between amino acid residues 168-169 of alkaline phosphatase (AP) (AAR58608) it enables the enzymatic activity of AP to be modulated upon the binding of a molecule to the inserted sequence. The modified AP can now be used as a diagnostic assay, where the presence of specific antigens and antibodies can be inferred by changes in the enzymes activity. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 13 AA;

Query Match 80.5%; Score 62; DB 2; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.015;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRGPGRAFTV 12
| | | | | | | | | |
Db 2 RIQRGPGRAFTV 13

RESULT 189

AAR58602
ID AAR58602 standard; peptide; 13 AA.
XX
AC AAR58602;
XX
DT 25-MAR-2003 (revised)
DT 01-MAY-1995 (first entry)
XX
DE Alkaline phosphatase 167-168 insertion.
XX
KW Alkaline phosphatase; AP; amino acid moiety; AAM.
XX
OS Synthetic.
XX

RESULT 188

AAR58601
ID AAR58601 standard; peptide; 13 AA.
XX
AC AAR58601;
XX
DT 25-MAR-2003 (revised)
DT 01-MAY-1995 (first entry)
XX
DE Alkaline phosphatase 407-408 insertion.
XX
KW Alkaline phosphatase; AP; amino acid moiety; AAM.
XX
OS Synthetic.
XX
PN WO9420636-A1.
XX
PD 15-SEP-1994.
XX
PF 09-MAR-1994; 94WO-US002539.
XX
PR 09-MAR-1993; 93US-00031165.
PR 29-JUL-1993; 93US-00100708.
XX
XX (ABBO) ABBOTT LAB.
XX
PI Brate EM, Brennan CA, Bridon DP, Jaffe KD, Krafft GA, Mandecki W;
PI March SC, Russell JC, Yue VT;
XX
XX WPI; 1994-303041/37.
DR N-PSDB; AAQ70593; AAQ70594.
XX
PT Genetically engineered hybrid enzymes and ligand conjugates - useful for diagnostic assay, to detect antigens and antibodies by changes in enzyme activity.
XX
PS Claim 8; Page 87; 133pp; English.
XX
CC AAR58601 is an amino acid moiety (AAM), when inserted between amino acid residues 407-408 of alkaline phosphatase (AP) (AAR58608) it enables the enzymatic activity of AP to be modulated upon the binding of a molecule to the inserted sequence. The modified AP can now be used as a diagnostic assay, where the presence of specific antigens and antibodies can be inferred by changes in the enzyme's activity. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 13 AA;

Query Match 80.5%; Score 62; DB 2; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.015;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RIQRGPGRAFTV 12
| | | | | | | | | |
Db 2 RIQRGPGRAFTV 13

RESULT 189

AAR58602
ID AAR58602 standard; peptide; 13 AA.
XX
AC AAR58602;
XX
DT 25-MAR-2003 (revised)
DT 01-MAY-1995 (first entry)
XX
DE Alkaline phosphatase 167-168 insertion.
XX
KW Alkaline phosphatase; AP; amino acid moiety; AAM.
XX
OS Synthetic.
XX

PN WO9420636-A1.
 XX
 PD 15-SEP-1994.
 XX
 PF 09-MAR-1994; 94WO-US002539.
 XX
 PR 09-MAR-1993; 93US-00031165.
 PR 29-JUL-1993; 93US-00100708.
 XX
 PA (ABBO) ABBOTT LAB.
 XX
 PI Brate EM, Brennan CA, Bridon DP, Jaffe KD, Krafft GA, Mandecki W;
 PI March SC, Russell JC, Yue VT;
 XX WPI; 1994-303041/37.
 DR
 XX Genetically engineered hybrid enzymes and ligand conjugates - useful for
 PT diagnostic assay, to detect antigens and antibodies by changes in enzyme
 PT activity.
 XX
 PS Claim 8; Page 87; 133pp; English.
 XX
 CC AAR58602 is an amino acid moiety (AAM), when inserted between amino acid
 CC residues 167-168 of alkaline phosphatase (AP) (AAR58608) it enables the
 CC enzymatic activity of AP to be modulated upon the binding of a molecule
 CC to the inserted sequence. The modified AP can now be used as a diagnostic
 CC assay, where the presence of specific antigens and antibodies can be
 CC inferred by changes in the enzymes activity. (Updated on 25-MAR-2003 to
 CC correct PN field.)
 XX
 SQ Sequence 13 AA;
 Query Match 80.5%; Score 62; DB 2; Length 13;
 Best Local Similarity 100.0%; Pred. No. 0.015;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 1 RIQGPGRGAVT 12
 DB |||||
 2 RIQGPGRGAVT 13
 |||||
 RESULT 191
 AAR31254
 ID AAR31254 standard; peptide; 15 AA.
 XX
 AC AAR31254;
 XX
 DT 12-FEB-1993 (first entry)
 XX
 DE HIV principal determinant peptide.
 XX
 KW AIDS; ARC; human immunodeficiency virus; vaccine; cyclic; Neisseria;
 KW meningitidis b; outer membrane protein complex; OMPC; cPN03.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 1 /label= Nle
 FT /note= "this position is linked to the OMPC of the
 FT conjugate"
 FT Modified-site 2
 FT /note= "omega-thiol is linked to the omega-thiol of
 FT Cys(15) via an o-xylylene bridge, forming cyclic peptide"
 FT Modified-site 15
 FT /note= "omega-thiol is linked to the omega-thiol of
 FT Cys(2) via an o-xylylene bridge, forming cyclic peptide"
 XX
 PN EP467700-A.
 XX
 XX 22-JAN-1992.
 XX
 PF 19-JUL-1991; 91EP-00306598.
 XX
 PR 19-JUL-1990; 90US-00555339.
 PR 19-JUL-1990; 90US-00555966.
 PR 19-JUN-1991; 91US-00715276.
 PR 19-JUN-1991; 91US-00715278.
 XX
 XX (MERI) MERCK & CO INC.
 XX
 PI Leanza WJ, Marburg S, Tolman RL, Emini EA;
 XX WPI; 1992-026505/04.
 DR
 XX Conjugate proteins comprising HIV peptide components - useful for
 PT preparing vaccines for e.g. AIDS or for treating infections.
 XX
 PS Claim 12; Page 53; 63pp; English.
 XX

PN WO9420636-A1.
 XX
 PD 15-SEP-1994.
 XX
 PF 09-MAR-1994; 94WO-US002539.
 XX
 PR 09-MAR-1993; 93US-00031165.
 PR 29-JUL-1993; 93US-00100708.
 XX
 PA (ABBO) ABBOTT LAB.
 XX
 PI Brate EM, Brennan CA, Bridon DP, Jaffe KD, Krafft GA, Mandecki W;
 PI March SC, Russell JC, Yue VT;
 XX WPI; 1994-303041/37.
 DR
 XX Genetically engineered hybrid enzymes and ligand conjugates - useful for
 PT diagnostic assay, to detect antigens and antibodies by changes in enzyme
 PT activity.
 XX
 PS Claim 8; Page 87; 133pp; English.
 XX
 CC AAR58602 is an amino acid moiety (AAM), when inserted between amino acid
 CC residues 167-168 of alkaline phosphatase (AP) (AAR58608) it enables the
 CC enzymatic activity of AP to be modulated upon the binding of a molecule
 CC to the inserted sequence. The modified AP can now be used as a diagnostic
 CC assay, where the presence of specific antigens and antibodies can be
 CC inferred by changes in the enzymes activity. (Updated on 25-MAR-2003 to
 CC correct PN field.)
 XX
 SQ Sequence 13 AA;
 Query Match 80.5%; Score 62; DB 2; Length 13;
 Best Local Similarity 100.0%; Pred. No. 0.015;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 1 RIQGPGRGAVT 12
 DB |||||
 2 RIQGPGRGAVT 13
 |||||
 RESULT 190
 AAR58605
 ID AAR58605 standard; peptide; 13 AA.
 XX
 AC AAR58605;
 XX
 DT 25-MAR-2003 (revised)
 DT 01-MAY-1995 (first entry)
 XX
 DE Alkaline phosphatase 91-93 replacement.
 XX
 KW Alkaline phosphatase; AP; amino acid moiety; AAM.
 XX
 OS Synthetic.
 XX
 PN WO9420636-A1.
 XX
 PD 15-SEP-1994.
 XX
 PF 09-MAR-1994; 94WO-US002539.
 XX
 PR 09-MAR-1993; 93US-00031165.
 PR 29-JUL-1993; 93US-00100708.
 XX
 XX (ABBO) ABBOTT LAB.
 XX
 PI Brate EM, Brennan CA, Bridon DP, Jaffe KD, Krafft GA, Mandecki W;
 PI March SC, Russell JC, Yue VT;
 XX WPI; 1994-303041/37.
 DR
 XX Genetically engineered hybrid enzymes and ligand conjugates - useful for

CC The invention relates to a co-conjugate comprising an immunogenic protein
 CC or protein complex having a first set of covalent linkages to low
 CC molecular weight moieties which have an anionic or polyanionic character
 CC at physiological pH, and a second set of covalent linkages to peptides
 CC comprising HIV principal neutralizing determinants (PND's) or
 CC immunologically equivalent peptides. Preferably at least one set of the
 CC covalent linkages is comprised of maleimide derivatives; the
 CC (poly)anionic moiety is composed of one to five residues of the anionic
 CC form of a carboxylic, sulphonic or phosphonic acid; the immunogenic
 CC protein is the outer membrane protein complex (OMPC) of *Neisseria*
 CC meningitidis b; and the PND peptide has a linear structure, a disulphide-
 CC bonded cyclic structure, an amide-bonded cyclic structure or a thioether-
 CC bonded cyclic structure. The present sequence (cPND3) is an example of a
 CC PND peptide component used in the co-conjugate. The co-conjugate is
 CC useful for inducing anti-peptide immune response in mammals, for inducing
 CC HIV-neutralizing antibodies in mammals, for formulating vaccines to
 CC prevent HIV infection or disease, including AIDS, or for treating humans
 CC afflicted with HIV infection or disease
 XX
 SQ Sequence 15 AA;

Query Match 80.5%; Score 62; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.017;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRGAFVT 12
 |||||
 DB 3 RIQGPGRGAFVT 14

RESULT 192
 AAR20214
 ID AAR20214 standard; peptide; 15 AA.

XX AAR20214;

DT 10-NOV-1992 (first entry)

XX Cyclic HIV principal neutralising determinant peptide.

DE PND; thio-ether cyclic linkage; HIV; AIDS; assay; vaccine.

XX Synthetic.

Key	Location/Qualifiers
FT Modified-site 1	/label= Nle
FT Modified-site 2	/note= "forms cyclic thio ether linkage with Cys(15)"
FT Modified-site 15	/note= "forms cyclic thio ether linkage with Cys(2)"

XX EP467699-A.

PN 22-JAN-1992.

XX 19-JUL-1991; 91EP-00306597.

XX 19-JUL-1990; 90US-00555227.

XX (MERI) MERCK & CO INC.

XX Hannah J, Tolman RL;

XX WPI; 1992-026504/04.

XX New cyclic HIV principal neutralising determinant peptide(s) - with ring
 PT of stable thio-ether bonds used as reagents in enzyme-linked immuno-
 PT sorbent assays or conjugates in vaccines for HIV and AIDS.

XX Claim 4; Page 13; 16pp; English.

XX The omega-mercapto groups of the Cys residues at the 2 and 15 positions

CC are bridged by o-xylylene, giving a ring system having a stable thio-
 CC ether bond. The peptide is a preferred example of a more generic molecule
 CC given in Claim 1, comprising the -GPER- core sequence as part of a
 CC peptide ring system completed by a thio-ether bond formed by linking the
 CC omega-mercapto groups of two Cys or homologous residues via xylylene. The
 CC ring is more stable than that formed using a disulphide bond. The
 CC peptides are useful as analytical tools, as reagents in ELISA assays, or
 CC as reagents for making covalent conjugate immunogens. The conjugates are
 CC useful for raising mammalian anti-peptide, anti-HIV or HIV-neutralising
 CC immune responses and can be used as vaccines and therapeutics for AIDS
 CC and ARC

SQ Sequence 15 AA;

Query Match 80.5%; Score 62; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.017;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRGAFVT 12
 |||||
 DB 3 RIQGPGRGAFVT 14

RESULT 193
 AAR26689
 ID AAR26689 standard; peptide; 15 AA.

XX AAR26689;

DT 09-FEB-1993 (first entry)

XX HIV-PND-polysaccharide-protein conjugate vaccine.

DE Human immunodeficiency virus; principal neutralizing determinant;

KW outer membrane protein complex; OMPC; *Neisseria*; AIDS; cyclic; cPND3.

XX Synthetic.

Key	Location/Qualifiers
FT Modified-site 1	/label= Nle
FT Modified-site 2	/note= "bonded via N-terminal to polysaccharide- protein complex"
FT Modified-site 15	/note= "forms cyclic thioether linkage with Cys(15) via o-xylylene"
FT Modified-site 15	/note= "forms cyclic thioether linkage with Cys(2) via o-xylylene"

XX EP468714-A.

XX 29-JAN-1992.

XX 19-JUL-1990; 90US-00555558.

XX 19-JUL-1990; 90US-00555558.

XX 19-JUN-1991; 91US-00715275.

XX (MERI) MERCK & CO INC.

XX Marburg S, Tolman RL, Emini EA;

XX WPI; 1992-034437/05.

XX HIV peptide-polysaccharide-protein conjugates - used in vaccines or to
 PT produce antibodies to prevent or treat HIV infection.

XX Claim 9; Page 53; 63pp; English.

XX The invention relates to a conjugate of an HIV principal neutralizing

CC determinant (PND), or an immunologically equivalent peptide (PEP),
 CC covalently coupled to an immunogenic protein or protein complex through
 CC an anionic polysaccharide linker. Pref. the immunogenic protein is the
 CC outer membrane protein complex (OMPC) of *Neisseria meningitidis* b and the
 CC PND peptide has a linear structure, a disulphide-bonded cyclic structure,
 CC an amide-bonded cyclic structure or a thioether-bonded cyclic structure.
 CC The present sequence (cPND3) is an example of a PND peptide component.
 CC The mercapto groups of Cys(2) and Cys(15) are bridged by o-xylylene. The
 CC conjugates are used for inducing HIV-neutralising antibodies or for
 CC making vaccines to prevent contraction of HIV infection or disease. The
 CC antibodies can be used for passively protecting against infection by HIV,
 CC or for protecting against proliferation of HIV post-infection, or for
 CC treating AIDS, or in diagnostic assays
 XX
 SQ Sequence 15 AA;

Query Match 80.5%; Score 62; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.017; 0; Mismatches 0; Indels 0; Gaps 0;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTV 12
 DB 3 RIQRGPGRAFTV 14

RESULT 194
 AAR58606
 ID AAR58606 standard; peptide; 15 AA.

AC AAR58606;
 DT 25-MAR-2003 (revised)
 DT 01-MAY-1995 (first entry)
 DE Alkaline phosphatase 91-93 replacement.
 XX Alkaline phosphatase; AP; amino acid moiety; AAM.
 KW Synthetic.

OS
 XX
 PN WO9420636-A1.
 XX
 PD 15-SEP-1994.

PF 09-MAR-1994; 94WO-US002539.
 XX
 PR 09-MAR-1993; 93US-00031165.
 PR 29-JUL-1993; 93US-00100708.
 XX
 PA (ABBO) ABBOTT LAB.

XX Brate EM, Brennan CA, Bridon DP, Jaffe KD, Krafft GA, Mandecki W;
 PI March SC, Russell JC, Yue VT;
 XX WPI; 1994-303041/37.

XX Genetically engineered hybrid enzymes and ligand conjugates - useful for
 PT diagnostic assay, to detect antigens and antibodies by changes in enzyme
 PT activity.

PS Claim 8; Page 88; 133pp; English.

XX AAR58606 is an amino acid moiety (AAM), when it replaces the amino acid
 CC residues 91-93 of alkaline phosphatase (AP) (AAR58608) it enables the
 CC enzymatic activity of AP to be modulated upon the binding of a molecule
 CC to the inserted sequence. The modified AP can now be used as a diagnostic
 CC assay, where the presence of specific antigens and antibodies can be
 CC inferred by changes in the enzymes activity. (Updated on 25-MAR-2003 to
 CC correct PN field.)

XX Sequence 15 AA;

Query Match 80.5%; Score 62; DB 2; Length 15;

Best Local Similarity 100.0%; Pred. No. 0.017;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFTV 12
 DB 3 RIQRGPGRAFTV 14

RESULT 195
 AAR33336
 ID AAR33336 standard; peptide; 14 AA.

AC AAR33336;
 XX
 DT 25-MAR-2003 (revised)
 DT 06-JUL-1993 (first entry)

XX Sequence of peptide which corresp. to the V3 loop region of gp120 of HIV-
 DE 1 isolate IIIB.

XX Monoclonal antibody; NM-01; HIV-1; gp120; gp160.

XX Synthetic.

XX WO9304090-A1.

XX 04-MAR-1993.

XX 24-AUG-1992; 92WO-US007111.

XX 22-AUG-1991; 91US-00748562.

XX (NISP) MISSIN SHOKUHN KAISHA LTD.

XX Ohno T;

XX WPI; 1993-093943/11.

XX Monoclonal antibodies against HIV-1 gp120 and gp160 proteins - for
 PT treating and preventing HIV-1 infection.

XX Example; Page 20; 57pp; English.

XX MN-01 is a monoclonal antibody. In order to characterize the viral
 CC epitope recognized by NM-01, the antibody was screened by ELISA for
 CC reactivity with overlapping peptides corresp. to the amino acid sequence
 CC of the V3 loop region of HIV-1 gp120 (AAR33332, AAR33333, AAR33334).
 CC While there was no detectable reactivity over background of MAb-01 with
 CC the peptides corresp. to AAs 302-316 or 322-336 of the V3 loop, binding
 CC of the antibody to the peptide representing AAs 3122-326 was apparent.
 CC The extent of this reactivity with other HIV-1 isolates was screened with
 CC peptides corresp. to the V3 loop region of HIV-1 isolates IIB, RF, CDC4,
 CC NV/5, Z6, Z2 and ELI (AAR33335-R33342). These results indicate that
 CC monoclonal antibody NM-01 recognizes an epitope of the V3 loop of gp120
 CC of multiple HIV-1 isolates having the amino acid sequence AAR33343. NM-01
 CC is also putatively reactive with the RF-like peptide set out in AAR33344.
 CC The variable region of the heavy and light chain of monoclonal antibody
 CC NM-01 were cloned by PCR and sequenced. Nucleotides 1-21 and 334-363 of
 CC AAQ37472 corresp. to the PCR primers used to amplify NM-01 light chain
 CC sequences and nucleotides 1-27 and 385-402 of AAQ57471 corresp. to the
 CC PCR primers used to amplify NM-01 heavy chain sequences. (Updated on 25-
 CC MAR-2003 to correct PN field.)

XX Sequence 14 AA;

Query Match 77.9%; Score 60; DB 2; Length 14;
 Best Local Similarity 85.7%; Pred. No. 0.031;
 Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2 IQRGPGRAFTVIGK 15
 DB 1 IIRGPGRAFTVIGK 14

RESULT 196
 AAR48604
 ID AAR48604 standard; peptide; 14 AA.
 AC AAR48604;
 XX
 DT 25-MAR-2003 (revised)
 DT 03-SEP-1994 (first entry)
 XX
 DE Sequence of portion of gp120 V3 loop peptide from HIV-1 isolate IIIB.
 XX
 KW Human immunodeficiency virus; HIV-1; AIDS; glycoprotein; V3 loop; gp120;
 KW epitope; isolate IIIB.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN WO9404574-A1.
 XX
 PD 03-MAR-1994.
 XX
 PF 24-AUG-1993; 93WO-US007967.
 XX
 PR 24-AUG-1992; 92WO-US007111.
 PR 22-APR-1993; 93US-00039457.
 XX
 PA (NISP) NISSIN SHOKUHIN KAISHA LTD.
 XX
 PI Ohno T;
 XX
 DR WPI; 1994-083117/10.
 XX
 PT New humanised antibody specific for epitope on HIV-1 gp 120 - able to
 PT neutralise infection of HG cells, also nucleic acid encoding it, useful
 PT for passive immunisation to treat or prevent HIV-1 infection.
 XX
 PS Example; Table 4, Page 18; 91pp; English.
 XX
 CC GPGR is a portion of HIV-1 gp120 or gp160 protein. Monoclonal antibodies
 CC (MABs) that react with this and which have the capacity to neutralise the
 CC infection of H9 cells in culture by live HIV-1 strains MN and IIIB are
 CC claimed. Specifically illustrating the invention are the murine MAB
 CC (designated NM-01) produced by hybridoma cell line HB 10726 which is
 CC deposited under ATCC No. HB 10726, and the humanised versions of Ab NM-
 CC 01. To identify the specific epitope of gp120 recognised by NM-01, the Ab
 CC was screened for reactivity with three overlapping peptides corresp. to
 CC the V3 loop region of gp120 (AAR48600-02). While there was no detectable
 CC reactivity over background of MAB NM-01 with the peptides corresp. to AAs
 CC 302-316 or 322-336 of the V3 loop, binding of the Ab to the peptide
 CC representing AAs312-326 was apparent. The demonstration that MAB NM-01
 CC binds to the V3 loop region of HIV-1MN gp120 prompted further studies on
 CC the extent of this reactivity with other HIV-1 isolates. The Ab was
 CC screened by ELISA for reactivity with peptides corresp. to the V3 loop
 CC region of HIV-1 isolates IIIB, RF, CDC4, NY/5, Z6, Z2 and ELI. The AA
 CC sequences of the peptides are given in AAR48603-10. NM-01 reacted with
 CC the loop peptides from the MN, IIIB, RF, and CDC4 isolates. It showed a
 CC lesser affinity for the NY/5 peptide. (Updated on 25-MAR-2003 to correct
 CC PN field.)
 XX
 SQ Sequence 14 AA;
 Query Match 77.9%; Score 60; DB 2; Length 14;
 Best Local Similarity 85.7%; Pred. No. 0.031;
 Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 2 IORGGRAFTVIGK 15
 Db : |||||
 1 IRIIGGRAFTVIGK 14
 RESULT 197
 AAW09264
 ID AAW09264 standard; peptide; 14 AA.
 AC AAW09264;
 XX
 DT 25-MAR-2003 (revised)
 DT 03-SEP-1994 (first entry)
 XX
 DE Sequence of portion of gp120 V3 loop peptide from HIV-1 isolate IIIB.
 XX
 KW Human immunodeficiency virus; HIV-1; AIDS; glycoprotein; V3 loop; gp120;
 KW epitope; isolate IIIB.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN WO9404574-A1.
 XX
 PD 03-MAR-1994.
 XX
 PF 24-AUG-1993; 93WO-US007967.
 XX
 PR 24-AUG-1992; 92WO-US007111.
 PR 22-APR-1993; 93US-00039457.
 XX
 PA (NISP) NISSIN SHOKUHIN KAISHA LTD.
 XX
 PI Ohno T;
 XX
 DR WPI; 1994-083117/10.
 XX
 PT New humanised antibody specific for epitope on HIV-1 gp 120 - able to
 PT neutralise infection of HG cells, also nucleic acid encoding it, useful
 PT for passive immunisation to treat or prevent HIV-1 infection.
 XX
 PS Example; Table 4, Page 18; 91pp; English.
 XX
 CC GPGR is a portion of HIV-1 gp120 or gp160 protein. Monoclonal antibodies
 CC (MABs) that react with this and which have the capacity to neutralise the
 CC infection of H9 cells in culture by live HIV-1 strains MN and IIIB are
 CC claimed. Specifically illustrating the invention are the murine MAB
 CC (designated NM-01) produced by hybridoma cell line HB 10726 which is
 CC deposited under ATCC No. HB 10726, and the humanised versions of Ab NM-
 CC 01. To identify the specific epitope of gp120 recognised by NM-01, the Ab
 CC was screened for reactivity with three overlapping peptides corresp. to
 CC the V3 loop region of gp120 (AAR48600-02). While there was no detectable
 CC reactivity over background of MAB NM-01 with the peptides corresp. to AAs
 CC 302-316 or 322-336 of the V3 loop, binding of the Ab to the peptide
 CC representing AAs312-326 was apparent. The demonstration that MAB NM-01
 CC binds to the V3 loop region of HIV-1MN gp120 prompted further studies on
 CC the extent of this reactivity with other HIV-1 isolates. The Ab was
 CC screened by ELISA for reactivity with peptides corresp. to the V3 loop
 CC region of HIV-1 isolates IIIB, RF, CDC4, NY/5, Z6, Z2 and ELI. The AA
 CC sequences of the peptides are given in AAR48603-10. NM-01 reacted with
 CC the loop peptides from the MN, IIIB, RF, and CDC4 isolates. It showed a
 CC lesser affinity for the NY/5 peptide. (Updated on 25-MAR-2003 to correct
 CC PN field.)
 XX
 SQ Sequence 14 AA;
 Query Match 77.9%; Score 60; DB 2; Length 14;
 Best Local Similarity 85.7%; Pred. No. 0.031;
 Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 2 IORGGRAFTVIGK 15
 Db : |||||
 1 IRIIGGRAFTVIGK 14

XX AAW09264;
 AC 25-MAR-2003 (revised)
 DT 03-MAR-1997 (first entry)
 XX
 DE HIV-1 strain IIIB gp120 V3 loop peptide.
 XX
 KW Human immunodeficiency virus type-1; HIV-1; gp120; gp160; epitope;
 KW monoclonal antibody; infection; heavy chain; light chain; hybridoma;
 KW complementarity determining region; CDR; V3 loop.
 XX
 OS Synthetic.
 XX
 PN US5558865-A.
 XX
 PD 24-SEP-1996.
 XX
 PF 24-AUG-1993; 93US-00111080.
 XX
 PR 22-AUG-1991; 91US-00748562.
 PR 24-AUG-1992; 92WO-US007111.
 PR 22-APR-1993; 93US-00039457.
 XX
 PA (NISP) NISSIN SHOKUHIN KAISHA LTD.
 XX
 PI Ohno T;
 XX
 DR WPI; 1996-442363/44.
 XX
 PT New monoclonal antibodies to HIV-1 - used for the prevention, treatment
 PT or diagnosis of HIV-1 infection.
 XX
 PS Example 2; Col 11; 56pp; English.
 XX
 CC The invention relates to a novel monoclonal antibody designated NM-01.
 CC The antibody was raised by immunising 2-month old Balb/c mice with live
 CC HIV-1 strain MN. Splenocytes from the mice were fused to P3-X63-Ag8-U1
 CC cells (ATCC CRL1597). Hybridomas were screened using membranes from non-
 CC infected and MN-infected H9 cells, by reacting with hybridoma culture
 CC supernatants. This screening was followed by immunofluorescence and
 CC radioimmunoassays. The screening isolated the hybridoma HB 10726 which
 CC secretes the antibody NM-01. The peptides AAW09263-72 are derived from
 CC other HIV strains and were used to determine which other HIV-1 isolates
 CC antibody NM-01 reacted with. This peptide is from HIV-1 strain IIIB. The
 CC antibody is used for the diagnosis of HIV-1 in a fluid e.g. blood, and
 CC can be used to treat or prevent an HIV-1 infection. (Updated on 25-MAR-
 CC 2003 to correct PF field.)
 XX
 SQ Sequence 14 AA;
 Query Match 77.9%; Score 60; DB 2; Length 14;
 Best Local Similarity 85.7%; Pred. No. 0.031;
 Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 2 IORGGRAFTVIGK 15
 Db : |||||
 1 IRIIGGRAFTVIGK 14
 RESULT 198
 AAR62167
 ID AAR62167 standard; peptide; 11 AA.
 AC AAR62167;
 XX
 DT 27-AUG-2003 (revised)
 DT 25-MAR-2003 (revised)
 DT 03-MAY-1995 (first entry)
 XX
 DE HIV-1 gp120 V3 loop domain containing U1 snRNP 70K consensus epitope.
 XX
 KW epitope; autoantibody; immunoinfective cluster virus;

KW nuclear protein antigen; systemic rheumatic disorder;
 KW human immunodeficiency virus; HIV-1; systemic lupus erythematosus;
 KW mixed connective tissue disease; scleroderma; glycoprotein 120;
 KW U1 small nuclear ribonucleoprotein; U1 snRNP 70K protein.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN WO9420141-A1.
 XX
 PD 15-SEP-1994.
 XX
 PF 10-MAR-1994; 94WO-US002631.
 XX
 PR 11-MAR-1993; 93US-00029850.
 XX
 PA (UYSC-) UNIV SOUTHERN CALIFORNIA.
 XX
 XX Douvas A, Takehana Y, Ehresmann G;
 XX WPI; 1994-302689/37.
 DR
 PT Methods for treating immunoinfective cluster virus infections - utilise
 PT antibodies or fragments characteristic of auto antibodies produced by
 PT patients with rheumatic disorders.
 XX
 PS Disclosure; Page 62; 106pp; English.
 XX
 CC Previous immunological analyses of the V3 loop of HIV-1 (AAR62159) have
 CC localised the main neutralising domains. The target of more than 80% of
 CC neutralising antibodies in HIV-1 infected sera from AIDS patients has now
 CC been found to overly the consensus binding sequence and domain A epitopes
 CC of the U1 snRNP 70K protein. In AIDS, antibody titres are too low to
 CC arrest the disease; however, the homologous sequences in 70K are
 CC immunodominant targets of autoantibodies in the systemic rheumatoid
 CC disorder of mixed connective tissue disease. The titers of such
 CC autoantibodies exceed 10 power 7. The anti-snRNP autoantibodies will
 CC cross-react with HIV-1 epitopes and are useful for treating HIV
 CC infection. (Updated on 25-MAR-2003 to correct FN field.) (Updated on 27-
 CC AUG-2003 to correct OS field.)
 XX
 SQ Sequence 11 AA;
 Query Match 75.3%; Score 58; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 0.051;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 4 RGPGRFVTVIG 14
 DB 1 RGPGRFVTVIG 11
 RESULT 199
 AAW76852
 ID AAW76852 standard; peptide; 11 AA.
 AC AAW76852;
 XX 25-JAN-1999 (first entry)
 DT
 DE Fusion immunoglobulin heavy chain HIV gp120 B cell epitope #22.
 KW B cell; T cell; epitope; immunoglobulin; heavy chain; gp120; IgH;
 KW human immune deficiency virus; HIV; tolerance; treatment; therapy;
 KW prophylaxis; vaccine; chemotherapy; immune response; modifier; tumour;
 KW microbial infection; autoimmune disease; antibody; apoptosis;
 KW antiviral T cell immunity.
 XX
 OS Mus sp.
 OS Homo sapiens.
 XX
 PN WO9836087-A1.
 XX
 PD 20-AUG-1998.

XX
 PF 13-FEB-1998; 98WO-US002766.
 XX
 PR 13-FEB-1997; 97US-0040581P.
 XX
 PA (AMNA-) AMERICAN NAT RED CROSS.
 XX
 PI Scott D, Zambidis E;
 XX WPI; 1998-506315/43.
 DR
 PT New fusion immunoglobulin heavy chain including gp120 epitopes and
 PT related complete antibodies - DNA, vectors and transformed cells, used to
 PT induce tolerance to the epitopes for treatment of human immune deficiency
 PT virus infection.
 XX
 PS Claim 10; Page 119; 154pp; English.
 XX
 CC This sequence is an epitope used in the construction of a novel fusion
 CC immunoglobulin heavy chain (IgH) protein with a mammalian, especially
 CC human, IgH chain fused in frame at its N-terminus to one or more human
 CC immune deficiency virus (HIV) gp120 epitopes. Fusion Ig proteins and/or
 CC transfect cells are used to tolerate subjects to gp120 epitopes and to
 CC maintain this tolerance, particularly for treatment of HIV infection,
 CC optionally together with other therapeutic/prophylactic agents such as
 CC vaccines, chemotherapeutic agents and immune response modifiers. Such
 CC proteins can be used against other diseases where an immune response is
 CC deleterious, e.g. microbial infection, tumours or autoimmune disease.
 CC Induction of tolerance suppresses production of antibodies against gp120,
 CC so prevents or inhibits 'bystander' apoptosis of uninfected T cells that
 CC are bound to gp120 protein, maximising induction of protective antiviral
 CC T cell immunity
 XX
 SQ Sequence 11 AA;
 Query Match 75.3%; Score 58; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 0.051;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 4 RGPGRFVTVIG 14
 DB 1 RGPGRFVTVIG 11
 RESULT 200
 ABB05777
 ID ABB05777 standard; peptide; 13 AA.
 XX
 AC ABB05777;
 XX 29-AUG-2003 (revised)
 DT 07-MAY-2002 (first entry)
 DE HIV gp120 related peptide SEQ ID NO:3.
 KW Polyfunctional base sequence; microgene; industrial; cell culture;
 KW artificial matrix protein; transgenic animal; HIV.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN WO200196558-A1.
 XX
 PD 20-DEC-2001.
 XX
 PF 15-JUN-2001; 2001WO-JP005116.
 XX
 PR 16-JUN-2000; 2000JP-00180997.
 XX
 PA (NISC-) JAPAN SCI & TECHNOLOGY CORP.
 XX Shiba K;
 XX WPI; 2002-098069/13.

XX Polyfunctional base sequence having two or more functions in different
PT reading frames, useful for producing artificial matrix proteins for cell
PT culture.
XX
PS Example 1; Page 47; 61pp; Japanese.
XX
CC The present invention describes a polyfunctional base sequence (N1)
CC having two or more functions in different reading frames. Also described
CC are: (1) a method for producing N1 and artificial gene expression vectors
CC comprising N1; (2) transgenic non-human animals comprising N1; and (3)
CC treatments and diagnostic reagents containing an artificial protein,
CC artificial tissues or high molecular weight artificial proteins. N1 is
CC useful for creating industrially useful artificial matrix proteins for
CC cell culture. The present sequence represents a peptide which is used in
CC an example from the present invention. (Updated on 29-AUG-2003 to
CC standardise OS field)
XX
SQ Sequence 13 AA;
Query Match 75.3%; Score 58; DB 5; Length 13;
Best Local Similarity 91.7%; Pred. No. 0.059;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 RIQPGGPAFVT 12
Db ||||| |||
2 RIQPGGRTFVT 13
RESULT 201
AAO15659
ID AAO15659 standard; peptide; 13 AA.
XX
AC AAO15659;
XX
DT 08-NOV-2002 (first entry)
XX
DE Strong immune response induction-related peptide 3.
XX
KW Strong immune response induction; high-order protein structure formation;
KW antigen presentation; HIV.
XX
OS Unidentified.
XX
PN WO200233074-A1.
XX
PD 25-APR-2002.
XX
PF 10-OCT-2001; 2001WO-JP008893.
XX
PR 13-OCT-2000; 2000JP-00314288.
XX
PA (NTSC-) JAPAN SCI & TECHNOLOGY CORP.
XX
PI Shiba K, Ohno T;
XX
DR WPI; 2002-519151/55.
XX
PT Artificial protein capable of inducing a strong immune response to a
PT peptide group for assisting antibody production in vivo to viruses and
PT other antigens.
XX
PS Example 1; Page 46; 77pp; Japanese.
XX
CC The invention comprises an artificial protein which induces a strong
CC immune response to a peptide group (the protein contains all or part of
CC the peptide group). The artificial protein assists the formation of high-
CC order protein structure and/or assists the antigen presentation of
CC immunocompetent cells. The artificial protein of the invention is useful
CC for inducing a strong immune response and the preparation of effective
CC antibodies to specific antigens, especially HIV. The present amino acid
CC sequence represents a peptide that was used in the invention
XX

SQ Sequence 13 AA;
Query Match 75.3%; Score 58; DB 5; Length 13;
Best Local Similarity 91.7%; Pred. No. 0.059;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 RIQPGGPAFVT 12
Db ||||| |||
2 RIQPGGRTFVT 13
RESULT 202
AAW24218
ID AAW24218 standard; peptide; 19 AA.
XX
AC AAW24218;
XX
DT 17-MAR-1998 (first entry)
XX
DE CD4+ T-lymphocyte epitope to HIV-1 V3 loop derived peptide V3-LAI-B.
XX
KW T-lymphocyte epitope; diagnosis; antigen; infectious disease;
KW delayed-type hypersensitivity assay; vaccine development.
XX
OS Synthetic.
OS Human immunodeficiency virus.
XX
FH Key Location/Qualifiers
FT Region 5..13
FT /note= "Mapped CD4+T-lymphocyte epitope of patient 2"
XX
PN WO3727462-A2.
XX
PD 31-JUL-1997.
XX
PF 27-JAN-1997; 97WO-US001084.
XX
PR 26-JAN-1996; 96US-0010679P.
XX
PA (USSA) US DEPT ARMY GOVERNMENT US ARMY MEDICAL.
XX
PI Sitz KV, Brix DL;
XX
DR WPI; 1997-393814/36.
XX
PT Peptide fragments containing antigen epitope(s) used to trace diseases -
PT used in a delayed-type hypersensitivity assay, for in vivo mapping of
PT human T-lymphocyte epitope(s) e.g. for diagnosis, vaccine development
PT etc.
XX
PS Disclosure; Page 6; 14pp; English.
XX
CC Peptide fragments AAW24217-20 were used to demonstrate a new method of
CC tracing sources of infectious diseases. The method comprises preparing a
CC short (9-50 amino acid) peptide containing at least one non-conserved
CC epitope of an organism, injecting a composition containing the peptide
CC intradermally into a test subject in a delayed-type hypersensitivity
CC (DTH) assay and observing the injection site at intervals for induration.
CC In this example CD4+ T-lymphocyte epitopes to the HIV-1 V3 loop were
CC mapped by existing in vitro technique for two existing HIV infected
CC individuals and used to design peptides AAW24217-20. The method allows
CC the T-lymphocyte epitopes of a large antigen to be determined in vivo in
CC humans. The method is useful in medicine e.g. in diagnosis, monitoring
CC and treatment design for infectious disease exposure, active autoimmune
CC disease, allergic diseases and malignancy. It is especially useful for
CC tracing infectious diseases e.g. HIV, particularly when a sequence is
CC present only in certain strains of an organism, and developing suitable
CC vaccines. Vaccinated individuals can also be tested to verify protection
CC against a particular strain. The method allows in vivo mapping of T-
CC lymphocyte epitopes, not previously possible. The method is simpler, more
CC rapid and more sensitive. It can also be applied in a variety of
CC environments e.g. undeveloped regions since specialist equipment is not
CC required

```

XX SQ Sequence 19 AA;
Query Match 75.3%; Score 58; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.083; 0; Indels 0; Gaps 0;
Matches 11; Conservative 0; Mismatches 0;

QY 5 GPGRAFTVIGK 15
DB 1 GPGRAFTVIGK 11

RESULT 203
AAR32408
ID AAR32408 standard; peptide; 11 AA.
XX AC AAR32408;
XX DT 25-MAR-2003 (revised)
XX DT 04-JUL-1993 (first entry)
XX DE Sequence of peptide B3 which comprises AAs 315-325 from the V3 region of
XX DE HIV-1 isolate IIIB.
XX KW HIV-1; vaccine; dendritic core; ss.
XX OS Synthetic.
XX PN WO9303766-A1.
XX PD 04-MAR-1993.
XX PF 11-AUG-1992; 92WO-US006688.
XX PR 13-AUG-1991; 91US-00744281.
XX PA (REPK ) REPLIGEN CORP.
XX PA (UYRQ ) UNIV ROCKEFELLER.
XX PI Tam JP, Profy AT;
XX DR WPI; 1993-093730/11.
XX PT New multiple antigen peptide(s) as HIV vaccines - include a dendritic
XX PT core covalently bonded to peptide including the sequence IGPGR.
XX PS Example; Fig 1; 35pp; English.
XX CC Nine peptides from the V3 regions of HIV-1 isolates IIIB, RF and MN were
XX CC incorporated into tetravalent multiple antigen peptide systems (MAPS)
XX CC (see AAR32406-14). Parallel groups of three peptides with chain lengths
XX CC spanning from 11-24 residues were synthesised in MAPS format for each
XX CC isolate. ELIS assays demonstrated that antisera titers in mice were
XX CC closely related to the length of the IIIB peptide used for the
XX CC immunisation - the longer the stronger the response. There was no
XX CC substantial antibody prodn. in mice against the other two series of
XX CC peptides, RF (B4-B6), and MN (B7-B9), except for a low reactivity in the
XX CC gp. immunised with B8 (MN isolate). Specificity tests of the B cell
XX CC response demonstrated that the T cell epitope (AAR32415) also serves as a
XX CC B cell epitope. (Updated on 25-MAR-2003 to correct PN field.)
XX SQ Sequence 11 AA;
Query Match 74.0%; Score 57; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAFY 11
DB 1 RIQRGPGRAFY 11

RESULT 204
AAR68799
ID AAR68799 standard; peptide; 11 AA.
XX AC AAR68799;
XX DT 25-MAR-2003 (revised)
XX DT 23-AUG-1995 (first entry)
XX DE Cytotoxic T lymphocyte epitope 56 derived from env gp120 protein.
XX DE cytotoxic T lymphocyte; epitope; antigen; pathogenic; nef; gag; pol; env;
XX DE gp120; gp41; HIV; cell-mediated immunity; human immunodeficiency virus;
XX DE class II restricted.
XX OS Human immunodeficiency virus.
XX PN WO9428871-A1.
XX PD 22-DEC-1994.
XX PF 07-JUN-1994; 94WO-US006394.
XX PR 07-JUN-1993; 93US-00072718.
XX PA (ENDO-) ENDOCON INC.
XX PI Leonard RJ;
XX DR WPI; 1995-036067/05.
XX PT Implant for sustained release of pathogen-associated antigen - forming
XX PT chronic inflammatory site producing cytotoxic T-lymphocytes lysing
XX PT infected cells, esp. for treating AIDS.
XX PS Disclosure; Page 12; 35pp; English.
XX CC AAR68744-805 are cytotoxic T lymphocyte (CTL) class I and II restricted
XX CC epitopes derived from human immunodeficiency virus proteins. AAR68799
XX CC corresponds to amino acid residues 310-316 of the env gp120 protein.
XX CC These antigens are examples of peptides that can be used with an
XX CC immunogenic implant. The implant is associated with an antigen associated
XX CC with a pathogen and used to form a discrete, localised chronic
XX CC inflammation site which acts as a local 'factory' for prodn. of CTL's
XX CC which lyse cells infected with a specific pathogen. The expanded set of
XX CC pathogen-specific CTL's can eradicate or prevent development of
XX CC infection, and can also be used to treat or arrest the development of
XX CC cancers associated with infection. (Updated on 25-MAR-2003 to correct PN
XX CC field.)
XX SQ Sequence 11 AA;
Query Match 74.0%; Score 57; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 QRQPGRAFTVI 13
DB 1 QRQPGRAFTVI 11

RESULT 205
AAM99430
ID AAM99430 standard; peptide; 11 AA.
XX AC AAM99430;
XX DT 07-DEC-2001 (first entry)
XX DE Vaccine related MHC ligand peptide SEQ ID NO:533.
XX DE Glutamic acid; glutamine; vaccine; major histocompatibility complex; MHC;
XX KW immunomodulator; antiallergic; endocrine; neuroprotectant; virucidal;
XX KW bactericidal; antiparasitic; fungicidal; cytostatic; medicine;

```

pharmaceutical; immune disorder; immune deficiency; autoimmune; hypersensitivity; allergy; graft rejection; infection; hormonal disorder; central nervous system disease; cancer; melanoma; anti-melanoma vaccine; human immunodeficiency virus.

Mus musculus.

WO200170772-A2.

27-SEP-2001.

22-MAR-2001; 2001WO-PR000872.

23-MAR-2000; 2000FR-00003711.

(FABR) FABRE MEDICAMENT SA PIERRE.

Klinguer-Hamour C, Corvaia N, Beck A, Goetsch L;

WPI; 2001-611470/70.

Stabilized pharmaceutical containing N-terminal glutamic acid or glutamine, useful e.g. in anti-melanoma vaccines, is an addition salt with strong acid.

Claim 9; Page 122; 149pp; French.

The present invention describes a pharmaceutical compound (I) that contains an N-terminal glutamic acid (Glu) or glutamine (Gln) residue in the form of an addition salt with a strong, physiologically acceptable acid (II). Also described are: (a) a pharmaceutical composition containing at least one (I); (b) a vaccine containing at least one (I) where this is a major histocompatibility complex (MHC) ligand (Ia); (c) a method for in vitro diagnosis of diseases associated with the presence of (Ia); (d) a kit for method (c) that includes a (Ia); and (e) a process for preparing (I). (I) has immunomodulator, endocrine, antiallergic, neuroprotectant, virucidal, bactericidal, antiparasitic, fungicidal and cytostatic activities. (I) are useful, in human or veterinary medicine, in pharmaceutical compositions (for treating immune disorders, e.g. immune deficiency, autoimmune states, hypersensitivity, allergy, graft rejection, infection, hormonal disorders and central nervous system diseases), also, where (I) is a MHC ligand (Ia), in vaccines for treatment or prevention of: (i) viral, bacterial, parasitic or fungal infections; or (ii) of cancers. A particular application is in anti-melanoma vaccines. (I) are also useful for in vitro diagnosis of diseases associated with interactions between MHC and (I), e.g. melanoma and human immunodeficiency virus infection. AM98898 to AM99592 represent peptides which can be used in pharmaceutical compounds from the present invention

Sequence 11 AA;

Query Match 74.0%; Score 57; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 QRGPGRAFTVI 13
| | | | | | | | | | | |
Db 1 QRGPGRAFTVI 11

RESULT 206
ABP17102
ID ABP17102 standard; peptide; 11 AA.
XX
AC ABP17102;
XX
XX
11-SEP-2003 (revised)
DT 15-JUL-2002 (first entry)
XX
XX
HIV B27 super motif env peptide #127.
XX
HIV; HIV-1; human immunodeficiency virus; env; pol; gag; nef; vpr; vpu; vif; tat; cytotoxic T lymphocyte; CTL; immune response; epitope; antigen;

vaccine; HIV infection; immunisation; virucide.

Human immunodeficiency virus 1.

WO200124810-A1.

12-APR-2001.

05-OCT-2000; 2000WO-US027766.

05-OCT-1999; 99US-00412863.

(EPIM-) EPIMUNE INC.

Sette A, Sidney J, Southwood S, Livingston BD, Chesnut R;
Baker DM, Celis E, Kubo RT, Grey HM;

WPI; 2001-354887/37.

Vaccine compositions comprising human immunodeficiency virus-1 (HIV-1) peptide groups, useful for vaccinating against HIV-1.

Claim 32; Page 219; 448pp; English.

The present invention describes a composition (I) comprising a prepared human immunodeficiency virus-1 (HIV-1) group comprising an amino acid sequence selected from 51 defined amino acid sequences (ABL25347 to ABP25397). (I) has virucide activity and can be used in vaccines. (I) may be used for immunising subjects against HIV-1 infections. The use of group-based vaccines has several advantages over traditional vaccines, particularly when compared to the use of whole antigens in vaccine compositions. There is evidence that the immune response to whole antigens is directed largely toward variables. The groups for inclusion in allowing for immune escape due to mutations. The groups for inclusion in an group-based vaccine may be selected from conserved regions of viral or tumour-associated antigens, which therefore reduces the likelihood of escape mutants. Furthermore, immunosuppressive groups that may be present in whole antigens can be avoided with the use of group-based vaccines. An additional advantage of an group-based vaccine approach is the ability to combine selected groups (CTL and HTL), and further, to modify the composition of the groups, achieving, for example, enhanced immunogenicity. Accordingly, the immune response can be modulated, as appropriate, for the target disease. Similar engineering of the response is not possible with traditional approaches. ABP1501 to ABP25412 represent peptide sequences used in the exemplification of the present invention. (Updated on 11-SEP-2003 to standardise OS field)

Sequence 11 AA;

Query Match 74.0%; Score 57; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 QRGPGRAFTVI 13
| | | | | | | | | | | |
Db 1 QRGPGRAFTVI 11

RESULT 207
AAR10592
ID AAR10592 standard; peptide; 12 AA.
XX
AC AAR10592;
XX
XX
18-APR-1991 (first entry)
DT
XX
Protease inhibitory peptide #1.
DE
XX
protease inhibitor; immunoglobulins; anti-inflammatory agent;
KW
XX
anti-tumour agent.
XX
Synthetic.
OS
XX

PN JP03002195-A.
 XX 08-JAN-1991.
 XX 29-MAY-1989; 89JP-00135678.
 XX 29-MAY-1989; 89JP-00135678.
 XX (NITL) NITTO DENKO CORP.
 XX WPI; 1991-048837/07.
 XX New peptide protease inhibitor - used as hapten for prodn. of
 PT immunoglobulin(s) and as antiinflammatory antitumour agent etc.
 XX Claim 1; Page 1; 9pp; Japanese.
 XX A protease inhibitor which exhibits an improved inhibitory effect
 CC comprises this peptide or its salt. The peptide must include at least the
 CC tetrapeptide GPCR and does not contain the sequence NNTKSIIRIQRGFRA.
 XX See also AAR10593-4
 XX Sequence 12 AA;
 SQ

Query Match 74.0%; Score 57; DB 2; Length 12;
 Best Local Similarity 100.0%; Pred. NO. 0.078;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQRGFGRAVF 11
 DB 2 RIQRGFGRAVF 12
 |||||

RESULT 208
 AAR62164
 ID AAR62164 standard; peptide; 15 AA.
 XX AAR62164;
 AC
 XX 27-AUG-2003 (revised)
 DT 25-MAR-2003 (revised)
 DT 03-MAY-1995 (first entry)
 XX HIV-1 gp120 V3 loop neutralising domain.
 DE epitope; autoantibody; immunoinfective cluster virus;
 XX nuclear protein antigen; systemic rheumatic disorder;
 KW human immunodeficiency virus; HIV-1; systemic lupus erythematosus;
 KW mixed connective tissue disease; scleroderma; glycoprotein 120.
 XX Human immunodeficiency virus 1.
 OS
 XX WO9420141-A1.
 PN
 XX 15-SEP-1994.
 PD
 XX 10-MAR-1994; 94WO-US002631.
 PF
 XX 11-MAR-1993; 93US-00029850.
 PR
 XX (UYSC-) UNIV SOUTHERN CALIFORNIA.
 PA
 XX Douvas A, Takehana Y, Ehresmann G;
 PI WPI; 1994-302689/37.
 DR
 XX Methods for treating immunoinfective cluster virus infections - utilise
 PT antibodies or fragments characteristic of auto antibodies produced by
 PT patients with rheumatic disorders.
 XX
 PS Disclosure; Page 61; 106pp; English.
 XX Previous immunological analyses of the V3 loop of HIV-1 (AAR62159) have

CC localised the main neutralising domains. The target of more than 80% of
 CC neutralising antibodies in HIV-1 infected sera from AIDS patients
 CC (AAR62164) has now been found to overly the consensus binding sequence
 CC and domain A epitopes of the UI snRNP 70K protein. In AIDS, antibody
 CC titres are too low to arrest the disease; however, the homologous
 CC sequences in 70K are immunodominant targets of autoantibodies in the
 CC systemic rheumatoid disorder of mixed connective tissue disease. The
 CC titers of such autoantibodies exceed 10 power 7. The anti-sRNP
 CC autoantibodies will cross-react with HIV-1 epitopes and are useful for
 CC treating HIV infection. (Updated on 25-MAR-2003 to correct PN field.)
 CC (Updated on 27-AUG-2003 to correct OS field.)
 XX
 XX Sequence 15 AA;
 SQ

Query Match 74.0%; Score 57; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. NO. 0.095;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQRGFGRAVF 11
 DB 5 RIQRGFGRAVF 15
 |||||

RESULT 209
 AAW76846
 ID AAW76846 standard; peptide; 15 AA.
 XX AAW76846;
 AC
 XX 25-JAN-1999 (first entry)
 DT
 XX Fusion immunoglobulin heavy chain HIV gp120 B cell epitope #16.
 DE B cell; T cell; epitope; immunoglobulin; heavy chain; gp120; IgH;
 KW human immune deficiency virus; HIV; tolerance; treatment; therapy;
 KW prophylaxis; vaccine; chemotherapy; immune response; modifier; tumour;
 KW microbial infection; autoimmune disease; antibody; apoptosis;
 KW antiviral T cell immunity.
 XX Mus sp.
 OS Homo sapiens.
 OS
 XX WO9836087-A1.
 PN
 XX 20-AUG-1998.
 PD
 XX 13-FEB-1998; 98WO-US002766.
 PF
 XX 13-FEB-1997; 97US-0040581P.
 PR
 XX (AMNA-) AMERICAN NAT RED CROSS.
 PA
 XX Scott D, Zambidis E;
 PI WPI; 1998-506315/43.
 DR
 XX New fusion immunoglobulin heavy chain including gp120 epitopes and
 PT related complete antibodies - DNA, vectors and transformed cells, used to
 PT induce tolerance to the epitopes for treatment of human immune deficiency
 PT virus infection.
 XX
 XX Claim 10; Page 119; 154pp; English.
 PS
 XX This sequence is an epitope used in the construction of a novel fusion
 CC immunoglobulin heavy chain (IgH) protein with a mammalian, especially
 CC human, IgH chain fused in frame at its N-terminus to one or more human
 CC immune deficiency virus (HIV) gp120 epitopes. Fusion Ig proteins and/or
 CC transfectant cells are used to tolerate subjects to gp120 epitopes and to
 CC maintain this tolerance, particularly for treatment of HIV infection,
 CC optionally together with other therapeutic/prophylactic agents such as
 CC vaccines, chemotherapeutic agents and immune response modifiers. Such
 CC proteins can be used against other diseases where an immune response is
 CC deleterious, e.g. microbial infection, tumours or autoimmune disease.

CC Induction of tolerance suppresses production of antibodies against gp120,
 CC so prevents or inhibits 'bystander' apoptosis of uninfected T cells that
 CC are bound to gp120 protein, maximising induction of protective antiviral
 CC T cell immunity

XX Sequence 15 AA;

Query Match 74.0%; Score 57; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.095;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRFV 11
 |||||
 Db 5 RIQGPGRFV 15

RESULT 210

ADP76013
 ID ADP76013 standard; peptide; 15 AA.

XX AC ADP76013;

DT 09-SEP-2004 (first entry)

XX Peptide epitope from HIV-1 gp120 protein corresponding to aa 304-318.

XX antigen specific activation; antibody producing cell;
 KW non-adherent mononuclear immune cell; T helper cell;
 KW lysosome-containing cell; differentiation.

XX. Human immunodeficiency virus 1.

XX WO2004053139-A1.

XX PD 24-JUN-2004.

XX PF 10-DEC-2003; 2003WO-AU001655.

XX PR 10-DEC-2002; 2002US-0432395P.

XX PA (APOL-) APOLLO LIFE SCI PTY LTD.

XX PI Chen J;

XX WPI; 2004-487905/46.

XX In vitro antigen specific activation of antibody producing cells

PT comprises culturing a population of isolated, non-adherent mononuclear
 PT immune cells for a time and under conditions sufficient to induce
 PT differentiation of the cell.

PS Claim 29; SEQ ID NO 4; 88pp; English.

CC The invention relates to a method of in vitro antigen specific activation
 CC of antibody producing cells by culturing a population of isolated, non-
 CC adherent mononuclear immune cells, which population comprises T helper
 CC cells or its functional equivalent, where the antibody producing cells
 CC and a functionally insignificant number of lysosome-containing cells, for
 CC a time and under conditions sufficient to induce differentiation of the
 CC antibody producing cell. The method is useful for in vitro antigen
 CC specific activation of antibody producing cells. This sequence
 CC corresponds to an epitope corresponding to amino acid 304-318 of the HIV-
 CC 1 gp120 protein and used in the method of the invention.

XX Sequence 15 AA;

Query Match 74.0%; Score 57; DB 8; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.095;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRFV 11
 |||||
 Db 5 RIQGPGRFV 15

RESULT 211

AAR25139
 ID AAR25139 standard; protein; 17 AA.

XX AC AAR25139;

XX 25-MAR-2003 (revised)

DT 05-JAN-1993 (first entry)

XX SFV-HIV epitope.

XX Semliki forest virus; SFV; E2 protien; vaccine.

XX Synthetic.

XX WO9210578-A1.

XX PD 25-JUN-1992.

XX PF 12-DEC-1991; 91WO-SE000855.

XX PR 13-DEC-1990; 90SE-00003978.

XX PA (BIOP-) BIOPTION AB.

XX Garoff H, Liljestrom P;

XX WPI; 1992-234633/28.

XX DR N-PSDB; AAQ26034.

XX RNA mol. derived from alphavirus RNA genome - chimeric alphavirus antigen
 XX and vaccine for immunisation against viral infections.

XX Disclosure; Fig 12; 94pp; English.

XX The sequence given shows a chimeric region between Semliki forest virus
 CC (SFV) cDNA and HIV gp120. The HIV sequence was inserted into an antigenic
 CC region of the E2 protein of SFV. This new antigen could then be used in
 CC the production of a safe and effective vaccine. The possibility of viral
 CC spread was eliminated by te use of a conditionally lethal mutant.
 CC (Updated on 25-MAR-2003 to correct PN field.) (Updated on 25-MAR-2003 to
 CC correct PI field.)

XX Sequence 17 AA;

Query Match 74.0%; Score 57; DB 2; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.11;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRFV 11
 |||||

Db 4 RIQGPGRFV 14

RESULT 212

AAR68645
 ID AAR68645 standard; peptide; 21 AA.

XX AC AAR68645;

XX 16-OCT-2003 (revised)

DT 25-MAR-2003 (revised)

DT 30-AUG-1995 (first entry)

XX VP hybrid V3 loop sequence, VP.

XX T-cell; epitope; HIV-1; core protein; p24E; B-cell; antigen; gp160; gag;

XX pol; vaccine; multimeric peptide; AIDS; 3D organisation.

XX Human immunodeficiency virus 1.

XX

FH Key Location/Qualifiers
 FT Peptide 1..10
 FT /note= "Residues 307-316 of the V3 (BRU) loop"
 FT Peptide 11..21
 FT /note= "Residues 315-325 of the V3 (MN) loop"
 XX WO9429339-A1.
 XX 22-DEC-1994.
 XX 08-JUN-1994; 94WO-CA000317.
 XX 09-JUN-1993; 93US-00073378.
 XX (CONN-) CONNAUGHT LAB LTD.
 XX PI Sia CDY, Chong P, Klein MH;
 XX WPI; 1995-036400/05.
 XX Novel tandem synthetic HIV-1 peptide(s) - comprising T-cell epitope of
 PT gag protein linked to B-cell epitope of V3 loop protein of an HIV-1
 PT isolate.
 XX Disclosure; Page 12; 69pp; English.
 XX This sequence represents the a hybrid B-cell epitope derived from the HIV
 CC -1 V3 (BRU) and (MN) loops. This peptide can be ligated to a T cell
 CC epitope, eg. p24E (see also AAR68631) to form a chimeric peptide.
 CC Chimeric peptides such as this, may then be used in the production of HIV
 CC -1 vaccines. These peptide sequences may also be used in the production
 CC of multimeric peptides in which the peptides are C-terminally modified by
 CC the addition of a lys residue which is modified on its epsilon amino acid
 CC to carry an additional copy of the peptide molecule. The linear and
 CC multimeric peptides may be used for the treatment of AIDS by acting to
 CC displace the binding of HIV virus to human or animal cells or by
 CC disturbing the 3D organisation of the virus. (Updated on 25-MAR-2003 to
 CC correct PN field.) (Updated on 16-OCT-2003 to standardise OS field)
 XX Sequence 21 AA;
 SQ Query Match 74.0%; Score 57; DB 2; Length 21;
 Best Local Similarity 91.7%; Pred. No. 0.13;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 RIQGGPGRAFT 12
 DB |||||
 7 RIQGGPGRAFT 18
 RESULT 213
 AAW25815
 ID AAW25815 standard; peptide; 21 AA.
 AC AAW25815;
 DT 25-MAR-2003 (revised)
 DT 20-OCT-1997 (first entry)
 DE Chimaeric B cell epitope peptide VP.
 XX HIV; human immunodeficiency virus; gag; T-cell; B-cell; epitope; env;
 KW V3 loop; vaccine; determinant; chimaeric.
 XX Synthetic.
 OS US5639854-A.
 PN 17-JUN-1997.
 PD 09-JUN-1994; 94US-00257528.
 PF 09-JUN-1993; 93US-00073378.
 XX 09-JUN-1993; 93US-00073378.
 PR

XX (CONN-) CONNAUGHT LAB LTD.
 XX Klein MH, Sia CDY, Chong P;
 XX WPI; 1997-332082/30.
 DR Tandem synthetic HIV peptide(s) useful as immunogens - comprising gag
 PT protein T-cell epitope linked to env protein B-cell epitope.
 XX Disclosure; Col 7; 41pp; English.
 XX The invention relates to new synthetic peptides comprising at least one
 CC amino acid sequence comprising an HIV gag protein T-cell epitope linked
 CC at its C- or N-terminus to an amino acid sequence comprising a B-cell
 CC epitope of the V3 loop of an HIV env protein, which can be used to
 CC generate vaccines against HIV-1. The T-cell epitope sequence is pref.
 CC selected from the 1-helper determinant core peptides P24E, P24N, P24L,
 CC including CTLB-56, V3MN, CTLB-29, CTLB-55, SF2, LAI, IIB, RF, Z6, 2054,
 CC 1714 and BX08. The peptides are chimaeric and can be linked to a branched
 CC Lys backbone. This sequence represents a hybrid HIV-1 env protein V3 loop
 CC B-cell epitope comprising amino acids 307-316 of the V3 loop from the BRU
 CC strain (AAW25816) linked at its C-terminus to amino acids 315-325 of the
 CC MN strain V3 loop (AAW25817). The VP peptide is linked to the C-terminus
 CC of the p24E peptide to generate the chimaeric peptide VP-T-B (AAW25814).
 CC (Updated on 25-MAR-2003 to correct PF field.)
 XX Sequence 21 AA;
 SQ Query Match 74.0%; Score 57; DB 2; Length 21;
 Best Local Similarity 91.7%; Pred. No. 0.13;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 RIQGGPGRAFT 12
 DB |||||
 7 RIQGGPGRAFT 18
 RESULT 214
 AAW67331
 ID AAW67331 standard; peptide; 21 AA.
 AC AAW67331;
 DT 25-JAN-1999 (first entry)
 DT HIV-1 peptide epitope VP.
 DE Immunogen; vaccine; HIV-1; T-cell; B-cell; epitope; core protein; gp120;
 KW V3 loop.
 XX Synthetic.
 OS Human immunodeficiency virus 1.
 XX US5817754-A.
 PN 06-OCT-1998.
 PD 05-JUN-1995; 95US-00464329.
 PF 09-JUN-1993; 93US-00073378.
 PR 09-JUN-1994; 94US-00257528.
 XX (CONN-) CONNAUGHT LAB LTD.
 XX Chong P, Klein MH, Sia CDY;
 XX WPI; 1998-556461/47.
 DR Synthetic human immunodeficiency virus-1 peptide(s) - containing T-cell
 PT epitope and B-cell epitope(s) are candidate vaccines against HIV-1.
 XX

PS Disclosure; Col 7; 40pp; English.

XX The invention relates to a novel immunogenic composition for use in
CC vaccines for the treatment of HIV-1 comprising an HIV-1-derived T-cell
CC epitope linked to an HIV-1-derived B-cell epitope. The T-cell epitopes
CC are generally designed based on the p24 core protein and the B-cell
CC epitopes from the V3 loop of the gp120 protein from various HIV-1
CC strains. This peptide corresponds to a hybrid B-cell epitope which is a
CC chimera of the B-cell epitopes V3(BRU) and V3(MN) (AAW67332-W67333),
CC respectively. The peptide is used to generate the chimeric T- and B-cell
CC epitope VP-T-B (AAW67330)

XX Sequence 21 AA;

Query Match 74.0%; Score 57; DB 2; Length 21;

Best Local Similarity 91.7%; Pred. No. 0.13;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQGPGRGAFVT 12
Db |||||

7 RIQGPGRGAFVT 18

RESULT 215

AAW99939

ID AAW99939 standard; peptide; 21 AA.

AC AAW99939;

DT 05-MAY-1999 (first entry)

DE HIV-1 vaccine synthetic peptide SEQ ID NO:16.

KW HIV-1; human immunodeficiency virus; vaccine; T-cell epitope;
KW gag protein; B-cell epitope; gp41 protein; chimeric; infection.

XX Synthetic.

OS Human immunodeficiency virus 1.

XX US5876731-A.

PD 02-MAR-1999.

PF 05-JUN-1995; 95US-00462507.

PR 09-JUN-1993; 93US-00073378.

PR 09-JUN-1994; 94US-00257528.

XX (CONN-) CONNAUGHT LAB LTD.

PI Chong P, Klein MH, Sia CDY;

XX WPI; 1999-189590/16.

XX Synthetic chimeric HIV polypeptides - comprising gag protein T-cell
PT epitope linked to gp41 B-cell epitope.

XX Example 1; Col 33-34; 41pp; English.

XX The present invention describes a synthetic peptide comprising an amino
CC acid sequence containing a T-cell epitope of an HIV gag protein linked at
CC its C terminus to an amino acid sequence containing a B-cell epitope of
CC an HIV gp41 protein and containing the amino acid sequence: X1LKDWX2;
CC where X1 = E, A, G or Q, and X2 = A or T, or an amino acid sequence
CC capable of eliciting an HIV-specific antiserum and recognizing the
CC sequence X1LKDWX2. The synthetic peptide is useful in vaccines against
CC HIV infection and in diagnostic applications. AAW98892 to AAW98906, and
CC AAW98909 to AAW99989 represent synthetic peptides from the present
CC invention

XX Sequence 21 AA;

Query Match 74.0%; Score 57; DB 2; Length 21;

Best Local Similarity 91.7%; Pred. No. 0.13;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQGPGRGAFVT 12
Db |||||

7 RIQGPGRGAFVT 18

RESULT 216

AAV39690

ID AAV39690 standard; peptide; 21 AA.

AC AAV39690;

DT 17-OCT-2003 (revised)

DT 26-NOV-1999 (first entry)

DE HIV1 gag protein epitope VP-p24.

XX HIV; vaccine; immunogenic composition; T cell epitope; B cell epitope;
KW infection; antibody; antiviral.

OS Human immunodeficiency virus 1.

XX US5951986-A.

XX 14-SEP-1999.

PF 06-JUN-1995; 95US-00467881.

XX 09-JUN-1993; 93US-00073378.

PR 09-JUN-1994; 94US-00257528.

XX (CONN-) CONNAUGHT LAB LTD.

XX Klein MH, Chong P, Sia CDY;

XX WPI; 1999-550482/46.

XX Immunogenic composition containing synthetic fusion polypeptides
PT containing both the T and B cell epitopes of the human immunodeficiency
PT virus, useful antigens in producing vaccines.

XX Disclosure; Col 7; 43pp; English.

XX This sequence represents a fragment of a HIV1 protein, and can be used in
CC the immunogenic composition of the invention. The composition comprises a
CC synthetic fusion polypeptide which includes a sequence encoding 1 or more
CC T cell epitopes and a sequence encoding 1 or more B cell epitopes and a
CC carrier. Both the T cell and B cell epitopes are derived from HIV
CC proteins. The compositions are useful as vaccines against HIV infection.
CC The composition induces HIV-1-specific polyclonal antibodies that are
CC opsonising and antiviral. The peptide components may be selected to
CC induce a response against different viral isolates and in subjects who
CC recognise different T cell epitopes. (Updated on 17-OCT-2003 to
CC standardise OS field)

XX Sequence 21 AA;

Query Match 74.0%; Score 57; DB 2; Length 21;

Best Local Similarity 91.7%; Pred. No. 0.13;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RIQGPGRGAFVT 12
Db |||||

7 RIQGPGRGAFVT 18

RESULT 217

AAR66418

ID AAR66418 standard; peptide; 14 AA.

XX AAR66418;

XX 25-MAR-2003 (revised)
 DT 03-AUG-1995 (first entry)
 XX HIV-1 IIIB peptide 18-3.
 XX T cell helper site; cytotoxic T cell response; neutralising antibody;
 KW human immunodeficiency virus type 1; envelope glycoprotein gp120;
 KW cluster peptide; principal neutralising determinant.
 XX Synthetic.
 XX WO9426785-A1.
 PN 24-NOV-1994.
 XX 13-MAY-1994; 94WO-US005142.
 PF 14-MAY-1993; 93US-00060988.
 PR (USSH) US SEC DEPT HEALTH.
 XX Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
 XX WPI; 1995-006707/01.
 XX Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
 PT responses - to target antigen in hosts of different MHC haplotypes, esp.
 PT for therapeutic or prophylactic vaccines against HIV.
 PS Example 1; Page 33; 120pp; English.
 XX Single residues from the HIV-1 RF sequence (AAR66415) replaced residues
 CC in the HIV-1 IIIB sequence (AAR66414) to test the effect of each residue
 CC on the binding of neutralising and non-neutralising sera from animals
 CC immunised with the cluster peptides PCLUS 3-18 and PCLUS 6-18 (see
 CC AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
 CC R66430) showed that binding was enhanced over peptide 18 control when a
 CC tyrosine was substd. for a Val at position 11 and substns. at positions
 CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
 CC sera was reduced when substns. were made in the principal neutralising
 CC determinant sequence (PGRAP). In peptide 18-3, the Gln residue at
 CC position 3 in peptide 18 has been replaced by a Thr residue. (Updated on
 CC 25-WAR-2003 to correct FN field.)
 XX Sequence 14 AA;
 SQ Query Match 72.1%; Score 55.5; DB 2; Length 14;
 Best Local Similarity 86.7%; Pred. No. 0.15; Mismatches 1; Indels 1; Gaps 1;
 Matches 13; Conservative 0; Mismatches 1; Indels 1; Gaps 1;
 QY 1 RIQPGGPAFVTIGK 15
 DB 1 RITRGPGPAFV-IGK 14
 RESULT 218
 AAR90229
 ID AAR90229 standard; peptide; 15 AA.
 XX AAR90229;
 AC AAR90229;
 XX 06-APR-1996 (first entry)
 DT Cyclic HIV PND peptide attached to annular antigen scaffold.
 XX annular antigen scaffold core; AASC; HIV V3 loop; lysine;
 KW principal neutralising determinant; PND; cyclic; vaccine.
 XX Synthetic.
 OS Key Location/Qualifiers
 FH Modified-site 1
 FT

/note= "This residue is bonded to the thiol sulphur of
 Cys(13) via a -CO-CH2- linkage, formed by introducing a
 bromoacetyl group onto the N-terminal and allowing the Br
 to condense with the Cys side chain"
 13
 Modified-site /note= "see above"
 15
 Modified-site /note= "this is an epsilon-Lys residue, the alpha-amino
 and carboxy terminals of which are incorporated into an
 annular antigen scaffold core of formula KKKKCC as
 described in AAR90224"
 XX GB2282813-A.
 PN 19-APR-1995.
 XX 07-OCT-1994; 94GB-00020263.
 PF 15-OCT-1993; 93US-00138514.
 PR (MERI) MERCK & CO INC.
 XX Cunningham B, Hannah J, Tolman RL;
 PI WPI; 1995-141219/19.
 XX New poly:lysine annular core for carrying epitope(s) - esp HIV V3 loop
 PT peptide; gonadotropin releasing hormone, malarial or bacterial peptide,
 PT useful in vaccines.
 XX Claim 5; Page 49; 52pp; English.
 PS New annular antigen scaffold cores are provided for antigens or epitopes
 CC such as HIV V3 loop peptides (e.g. the present sequence; but see also
 CC GB2282813; AAR90219 - AAR90223), GnRH peptides, malaria antigenic
 CC peptides or bacterial capsular polysaccharides. The scaffolds comprise a
 CC ring of 3-10 Lys residues cyclised via a thioether linkage. The epitopes
 CC or antigens are bonded to each of the Lys side-chain amino groups. The C-
 CC terminus of the scaffold may be linked to a moiety such as beta-alanine
 CC or a peptide providing a T cell epitope, a lipopeptide which may provide
 CC an adjuvant effect, or another moiety providing a carrier function. The
 CC scaffolds constitute effective synthetic vaccines. The present sequence
 CC represents one of four identical thioether-cyclised HIV V3 loop peptides
 CC which are attached to each of the four Lys residues in the the annular
 CC scaffold core described in AAR90224
 XX Sequence 15 AA;
 SQ Query Match 70.1%; Score 54; DB 2; Length 15;
 Best Local Similarity 73.3%; Pred. No. 0.27;
 Matches 11; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 1 RIQPGGPAFVTIGK 15
 DB 1 RIHIGPGPAFYTCK 15
 RESULT 219
 AAR62165
 ID AAR62165 standard; peptide; 10 AA.
 XX AAR62165;
 AC AAR62165;
 XX 27-AUG-2003 (revised)
 DT 25-MAR-2003 (revised)
 DT 03-MAY-1995 (first entry)
 XX HIV-1 gp120 V3 loop neutralising domain.
 DE epitope; autoantibody; immunoinfective cluster virus;
 KW nuclear protein antigen; systemic rheumatic disorder;
 KW human immunodeficiency virus; HIV-1; systemic lupus erythematosus;
 KW mixed connective tissue disease; scleroderma; glycoprotein 120.
 KW

```

XX OS Human immunodeficiency virus 1.
XX PN WO9420141-A1.
XX PD 15-SEP-1994.
XX PF 10-MAR-1994; 94WO-US002631.
XX PR 11-MAR-1993; 93US-00029850.
XX PA (UYSC-) UNIV SOUTHERN CALIFORNIA.
XX PI Douvas A, Takehana Y, Ehresmann G;
XX DR WPI; 1994-302689/37.
XX PT Methods for treating immunoinfective cluster virus infections - utilise
XX PT antibodies or fragments characteristic of auto antibodies produced by
XX PT patients with rheumatic disorders.
XX PS Disclosure; Page 62; 106pp; English.
XX CC Previous immunological analyses of the V3 loop of HIV-1 (AAR62159) have
XX CC localised the main neutralising domains. The target of more than 80% of
XX CC neutralising antibodies in HIV-1 infected sera from AIDS patients has now
XX CC been found to overlap the consensus binding sequence and domain A epitopes
XX CC of the U1 snRNP 70K protein. In AIDS, antibody titres are too low to
XX CC arrest the disease; however, the homologous sequences in 70K are
XX CC immunodominant targets of autoantibodies in the systemic rheumatoid
XX CC disorder of mixed connective tissue disease. The titres of such
XX CC autoantibodies exceed 10 power 7. The anti-snRNP autoantibodies will
XX CC cross-react with HIV-1 epitopes and are useful for treating HIV
XX CC infection. (Updated on 25-MAR-2003 to correct PN field.) (Updated on 27-
XX CC AUG-2003 to correct OS field.)
XX SQ Sequence 10 AA;

Query Match 68.8%; Score 53; DB 2; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.27;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5 GPGRFVTVIG 14
DB 1 GPGRFVTVIG 10

RESULT 220
AAW76861
XX ID AAW76861 standard; peptide; 10 AA.
XX AC AAW76861;
XX DT 25-JAN-1999 (first entry)
XX DE Fusion immunoglobulin heavy chain HIV gp120 B cell epitope #31.
XX KW B cell; T cell; epitope; immunoglobulin; heavy chain; gp120; IGH;
XX KW human immune deficiency virus; HIV; tolerance; treatment; therapy;
XX KW prophylaxis; vaccine; chemotherapy; immune response; modifier; tumour;
XX KW microbial infection; autoimmune disease; antibody; apoptosis;
XX KW antiviral T cell immunity.
XX OS Mus sp.
XX OS Homo sapiens.
XX PN WO9836087-A1.
XX PD 20-AUG-1998.
XX PF 13-FEB-1998; 98WO-US002766.
XX PR 13-FEB-1997; 97US-0040581P.

XX PA (AMNA-) AMERICAN NAT RED CROSS.
XX PI Scott D, Zambidis B;
XX DR WPI; 1998-506315/43.
XX PT New fusion immunoglobulin heavy chain including gp120 epitopes and
XX PT related complete antibodies - DNA, vectors and transformed cells, used to
XX PT induce tolerance to the epitopes for treatment of human immune deficiency
XX PS virus infection.
XX PS Claim 10; Page 119; 154pp; English.
XX CC This sequence is an epitope used in the construction of a novel fusion
XX CC immunoglobulin heavy chain (IGH) protein with a mammalian, especially
XX CC human, IGH chain fused in frame at its N-terminus to one or more human
XX CC immune deficiency virus (HIV) gp120 epitopes. Fusion Ig proteins and/or
XX CC transfected cells are used to tolerate subjects to gp120 epitopes and to
XX CC maintain this tolerance, particularly for treatment of HIV infection,
XX CC optionally together with other therapeutic/prophylactic agents such as
XX CC vaccines, chemotherapeutic agents and immune response modifiers. Such
XX CC proteins can be used against other diseases where an immune response is
XX CC deleterious, e.g. microbial infection, tumours or autoimmune disease.
XX CC Induction of tolerance suppresses production of antibodies against gp120,
XX CC so prevents or inhibits 'bystander' apoptosis of uninfected T cells that
XX CC are bound to gp120 protein, maximising induction of protective antiviral
XX CC T cell immunity
XX SQ Sequence 10 AA;

Query Match 68.8%; Score 53; DB 2; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.27;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQRGPGRAF 10
DB 1 RIQRGPGRAF 10

RESULT 221
AAW03409
XX ID AAW03409 standard; peptide; 13 AA.
XX AC AAW03409;
XX DT 10-OCT-1996 (first entry)
XX DE HIV principal neutralizing determinant cPND495.
XX KW conjugate; PND; HIV; principal neutralizing determinant; OMPC;
XX KW outer membrane protein complex; anionic spacer; vaccine;
XX KW human immunodeficiency virus; water-soluble.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 1 /label= Nle
XX FT /note= "the N-terminal of this norleucine residue can be
XX FT linked to Neisseria meningitidis OMPC via a specified
XX FT anionic spacer group"
XX FT Disulfide-bond 2..13
XX FT /note= "the peptide is cyclised"
XX PN GB2271995-A.
XX PD 04-MAY-1994.
XX PF 12-OCT-1993; 93GB-00020943.
XX PR 15-OCT-1992; 92US-00963327.

```

PA (MERI) MERCK & CO INC.
 XX Tolman RL, Marburg S, Leanza WL, Lombardo VK;
 XX WPI; 1994-128412/16.
 XX New conjugates of outer membrane protein and HIV epitope - for generating
 PT HIV-neutralising response, have components joined by anionic spacer to
 PT ensure solubility of prod.
 XX Disclosure; Page 21; 73pp; English.
 XX A new conjugate immunogen comprises (a) the OMP of *Neisseria*
 CC meningitidis b as a protein carrier, (b) a principal neutralizing
 CC determinant (PND) of HIV as a peptidyl epitope against which immune
 CC responses are desired, and (c) a low mol. wt. anionic spacer linking (a)
 CC and (b). The conjugate is water-soluble, yet can carry a high peptide
 CC epitope loading. It is useful as a vaccine against HIV. The present
 CC sequence is an example of a PND used in the conjugate
 XX
 SQ Sequence 13 AA;
 Query Match 68.8%; Score 53; DB 2; Length 13;
 Best Local Similarity 100.0%; Pred. No. 0.34;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 3 QRGPGRAFTV 12
 Db 3 QRGPGRAFTV 12
 AAR04441
 ID AAR04441 standard; protein; 14 AA.
 AC AAR04441;
 XX 09-SEP-2004 (revised)
 DT 25-MAR-2003 (revised)
 DT 20-SEP-1990 (first entry)
 XX Human immunodeficiency virus peptide RP337.
 DE HIV-IIIB; peptide RP337; principal neutralising domain; antibodies;
 KW diagnosis; prophylaxis; therapy; AIDS.
 XX Synthetic.
 OS WO9003984-A.
 PN 19-APR-1990.
 PD 03-OCT-1988; 88US-00252949.
 PF 03-OCT-1988; 88US-00252949.
 PR 01-JUN-1989; 89US-00359543.
 PR 19-SEP-1989; 89US-00407663.
 XX (REPK) REPLIGEN CORP.
 PA Rusche JR, Putney SD, Javaherian K, Farley J, Grimaila R;
 PI Lynn DU, Petrobre J;
 PI WPI; 1990-147824/19.
 XX Principal neutralising domain of HIV variants - used for producing
 PT peptide(s) and antibodies for diagnosis, prophylaxis and/or therapy
 PT therapy of HIV infection.
 XX Claim 8 (44); Page 76; 108pp; English.
 PS Peptide RP335 comprises segments of the Principal Neutralising Domain
 CC (envelope protein) from isolate HIV-IIIB. The last Cys residue is added

CC for the purpose of crosslinking to carrier proteins. Cysteine residues
 CC can be added so that that residues at or near both ends form a disulfide
 CC bond, thus giving the peptide a loop-like configuration, which is
 CC utilised to enhance the immunogenic properties of the peptide. The
 CC peptide is capable of eliciting, and/or binding with, neutralising
 CC antibodies. The neutralising domain is bounded by cysteine residues which
 CC occur at positions 296 and 331. Peptides can be used as immunogens or
 CC screening reagents to generate or identify poly- or monoclonal Abs. See
 CC also AAR04427-R04506 and AAQ04273-Q04279. (Updated on 25-MAR-2003 to
 CC correct PR field.) (Updated on 25-MAR-2003 to correct PA field.) (Updated
 CC on 25-MAR-2003 to correct PI field.)
 CC Revised record issued on 09-SEP-2004 : Correction to Feature Table Key
 XX Sequence 14 AA;
 SQ Query Match 68.8%; Score 53; DB 2; Length 14;
 Best Local Similarity 100.0%; Pred. No. 0.36;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RIQRGPGRAF 10
 Db 4 RIQRGPGRAF 13
 AAR68665
 ID AAR68665 standard; peptide; 14 AA.
 AC AAR68665;
 XX 16-OCT-2003 (revised)
 DT 25-MAR-2003 (revised)
 DT 06-SEP-1995 (first entry)
 XX T cell epitope derived from V3 isolate HXB2.
 DE T-cell; epitope; HIV-1; core protein; p24E; B-cell; antigen; gp160; gag;
 KW pol; vaccine; multimeric peptide; AIDS; 3D organisation.
 XX Human immunodeficiency virus 1.
 OS WO9429339-A1.
 PN 22-DEC-1994.
 PD 08-JUN-1994; 94WO-CA000317.
 PF 09-JUN-1993; 93US-00073378.
 PR (CONN-) CONNAUGHT LAB LTD.
 PA Sia CDY, Chong P, Klein MH;
 PI WPI; 1995-036400/05.
 XX Novel tandem synthetic HIV-1 peptide(s) - comprising T-cell epitope of
 PT gag protein linked to B-cell epitope of V3 loop protein of an HIV-1
 PT isolate.
 XX Disclosure; Page 39; 69pp; English.
 PS This sequence represents a T-cell epitope derived from the V3 sequence of
 CC the HIV-1 isolate HXB2, which may be linked to a B-cell epitope from the
 CC V3 (MN) loop from HIV-1. These chimeric peptides may then be used in the
 CC production of HIV-1 vaccines. These peptide sequences may also be used in
 CC the production of multimeric peptides in which the peptides are C-
 CC terminally modified by the addition of a Lys residue which is modified on
 CC its epsilon amino acid to carry an additional copy of the peptide
 CC molecule. The linear and multimeric peptides may be used for the
 CC treatment of AIDS by acting to displace the binding of HIV virus to human
 CC or animal cells or by disturbing the 3D organisation of the virus.
 CC (Updated on 25-MAR-2003 to correct PN field.) (Updated on 16-OCT-2003 to

```
CC standardise OS field)
XX SQ Sequence 14 AA;

Query Match      68.8%; Score 53; DB 2; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.36;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRAP 10
DB 5 RIQGPGRAP 14

RESULT 224
AAW25835
ID AAW25835 standard; peptide; 14 AA.
XX AC AAW25835;
XX XX
XX DT 25-MAR-2003 (revised)
XX DT 20-OCT-1997 (first entry)
XX DE HIV B-cell strain HXB2 env protein V3 loop peptide.
XX KW HIV; human immunodeficiency virus; gag; T-cell; B-cell; epitope; env;
XX KW V3 loop; vaccine; determinant; chimeric.
XX OS Synthetic.
XX PN US5639854-A.
XX PD 17-JUN-1997.
XX PF 09-JUN-1994; 94US-00257528.
XX XX
XX PR 09-JUN-1993; 93US-00073378.
XX PA (CONN-) CONNAUGHT LAB LTD.
XX PI Klein MH, Sia CDY, Chong P;
XX XX
XX DR WPI; 1997-332082/30.
XX XX
XX PT Tandem synthetic HIV peptide(s) useful as immunogens - comprising gag
XX PT protein T-cell epitope linked to env protein B-cell epitope.
XX PS Disclosure; Col 21; 41pp; English.
XX CC The invention relates to new synthetic peptides comprising at least one
XX CC amino acid sequence comprising an HIV gag protein T-cell epitope linked
XX CC at its C- or N-terminus to an amino acid sequence comprising a B-cell
XX CC epitope of the V3 loop of an HIV env protein, which can be used to
XX CC generate vaccines against HIV-1. The T-cell epitope sequence is pref.
XX CC selected from the T-helper determinant core peptides P24E, P24N, P24L,
XX CC P24M and P24H while the B-cell epitopes are derived from HIV strains
XX CC including CTLB-56, V3MN, CTLB-29, CTLB-55, SF2, LA1, IIB, RP, Z6, 2054,
XX CC 1714 and BX08. The peptides are chimeric and can be linked to a branched
XX CC Lys backbone. This sequence represents the B-cell env protein V3 loop
XX CC peptide from HIV-1 strain HXB2. (Updated on 25-MAR-2003 to correct PF
XX CC field.)
XX SQ Sequence 14 AA;

Query Match      68.8%; Score 53; DB 2; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.36;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRAP 10
DB 5 RIQGPGRAP 14

RESULT 225
AAW25835
ID AAW25835 standard; peptide; 14 AA.
XX AC AAW25835;
XX XX
XX DT 25-MAR-2003 (revised)
XX DT 20-OCT-1997 (first entry)
XX DE HIV B-cell strain HXB2 env protein V3 loop peptide.
XX KW HIV; human immunodeficiency virus; gag; T-cell; B-cell; epitope; env;
XX KW V3 loop; vaccine; determinant; chimeric.
XX OS Synthetic.
XX PN US5639854-A.
XX PD 17-JUN-1997.
XX PF 09-JUN-1994; 94US-00257528.
XX XX
XX PR 09-JUN-1993; 93US-00073378.
XX PA (CONN-) CONNAUGHT LAB LTD.
XX PI Klein MH, Sia CDY, Chong P;
XX XX
XX DR WPI; 1997-332082/30.
XX XX
XX PT Tandem synthetic HIV peptide(s) useful as immunogens - comprising gag
XX PT protein T-cell epitope linked to env protein B-cell epitope.
XX PS Disclosure; Col 21; 41pp; English.
XX CC The invention relates to new synthetic peptides comprising at least one
XX CC amino acid sequence comprising an HIV gag protein T-cell epitope linked
XX CC at its C- or N-terminus to an amino acid sequence comprising a B-cell
XX CC epitope of the V3 loop of an HIV env protein, which can be used to
XX CC generate vaccines against HIV-1. The T-cell epitope sequence is pref.
XX CC selected from the T-helper determinant core peptides P24E, P24N, P24L,
XX CC P24M and P24H while the B-cell epitopes are derived from HIV strains
XX CC including CTLB-56, V3MN, CTLB-29, CTLB-55, SF2, LA1, IIB, RP, Z6, 2054,
XX CC 1714 and BX08. The peptides are chimeric and can be linked to a branched
XX CC Lys backbone. This sequence represents the B-cell env protein V3 loop
XX CC peptide from HIV-1 strain HXB2. (Updated on 25-MAR-2003 to correct PF
XX CC field.)
XX SQ Sequence 14 AA;

Query Match      68.8%; Score 53; DB 2; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.36;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRAP 10
DB 5 RIQGPGRAP 14

RESULT 226
AAW99959
ID AAW99959 standard; peptide; 14 AA.
XX AC AAW99959;
XX XX
XX DT 05-MAY-1999 (first entry)
XX DE HIV-1 vaccine synthetic peptide SEQ ID NO:36.
XX KW HIV-1; human immunodeficiency virus; vaccine; T-cell epitope;
XX KW gag protein; B-cell epitope; gp41 protein; chimeric; infection.
XX OS Synthetic.
XX OS Human immunodeficiency virus 1.
XX PN US5876731-A.
XX XX
XX PD 02-MAR-1999.
```

```
AAW67351
ID AAW67351 standard; peptide; 14 AA.
XX AC AAW67351;
XX XX
XX DT 17-OCT-2003 (revised)
XX DT 25-JAN-1999 (first entry)
XX DE HIV-1 strain HXB2 gp120 V3 loop epitope peptide.
XX KW Immunogen; vaccine; HIV-1; T-cell; B-cell; epitope; core protein; gp120;
XX KW V3 loop.
XX OS Human immunodeficiency virus 1.
XX PN US5817754-A.
XX PD 06-OCT-1998.
XX XX
XX PF 05-JUN-1995; 95US-00464329.
XX PR 09-JUN-1993; 93US-00073378.
XX PR 09-JUN-1994; 94US-00257528.
XX XX
XX PA (CONN-) CONNAUGHT LAB LTD.
XX PI Chong P, Klein MH, Sia CDY;
XX XX
XX DR WPI; 1998-556461/47.
XX XX
XX PT Synthetic human immunodeficiency virus-1 peptide(s) - containing T-cell
XX PT epitope and B-cell epitope(s) are candidate vaccines against HIV-1.
XX PS Disclosure; Col 21; 40pp; English.
XX XX
XX CC The invention relates to a novel immunogenic composition for use in
XX CC vaccines for the treatment of HIV-1 comprising an HIV-1-derived T-cell
XX CC epitope linked to an HIV-1-derived B-cell epitope. The T-cell epitopes
XX CC are generally designed based on the p24 core protein and the B-cell
XX CC epitopes from the V3 loop of the gp120 protein from various HIV-1
XX CC strains. This peptide represents the V3 loop epitope from the HIV-1
XX CC strain HXB2. (Updated on 17-OCT-2003 to standardise OS field)
XX SQ Sequence 14 AA;

Query Match      68.8%; Score 53; DB 2; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.36;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RIQGPGRAP 10
DB 5 RIQGPGRAP 14

RESULT 226
AAW99959
ID AAW99959 standard; peptide; 14 AA.
XX AC AAW99959;
XX XX
XX DT 05-MAY-1999 (first entry)
XX DE HIV-1 vaccine synthetic peptide SEQ ID NO:36.
XX KW HIV-1; human immunodeficiency virus; vaccine; T-cell epitope;
XX KW gag protein; B-cell epitope; gp41 protein; chimeric; infection.
XX OS Synthetic.
XX OS Human immunodeficiency virus 1.
XX PN US5876731-A.
XX XX
XX PD 02-MAR-1999.
```

XX 05-JUN-1995; 95US-00462507.
 XX PF 09-JUN-1993; 93US-00073378.
 PR 09-JUN-1994; 94US-00257528.
 XX (CONN-) CONNAUGHT LAB LTD.
 PA Chong P, Klein MH, Sia CDY;
 PI WPI; 1999-189590/16.
 XX Synthetic chimeric HIV polypeptides - comprising gag protein T-cell
 PT epitope linked to gp41 B-cell epitope.
 XX Example 1; Col 41-42; 41pp; English.
 PS The present invention describes a synthetic peptide comprising an amino
 CC acid sequence containing a T-cell epitope of an HIV gag protein linked at
 CC its C terminus to an amino acid sequence containing a B-cell epitope of
 CC an HIV gp41 protein and containing the amino acid sequence: X1LKDWX2;
 CC where X1 = E, A, G or Q, and X2 = A or T, or an amino acid sequence
 CC capable of eliciting an HIV-specific antiserum and recognizing the
 CC sequence X1LKDWX2. The synthetic peptide is useful in vaccines against
 CC HIV infection and in diagnostic applications. AAW98892 to AAW98906, and
 CC AAW99899 to AAW99989 represent synthetic peptides from the present
 CC invention
 XX Sequence 14 AA;
 SQ Query Match 68.8%; Score 53; DB 2; Length 14;
 Best Local Similarity 100.0%; Pred. No. 0.36;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 RIQRGPGRAF 10
 DB |||||
 5 RIQRGPGRAF 14
 RESULT 227
 AAY39757
 ID AAY39757 standard; peptide; 14 AA.
 AC AAY39757;
 XX 17-OCT-2003 (revised)
 DT 26-NOV-1999 (first entry)
 XX HIV1 chimeric peptide V3-HXB2.
 DE HIV; vaccine; immunogenic composition; T cell epitope; B cell epitope;
 KW infection; antibody; antiviral.
 XX Human immunodeficiency virus 1.
 OS US5951986-A.
 XX 14-SEP-1999.
 PD 06-JUN-1995; 95US-00467881.
 PF 09-JUN-1993; 93US-00073378.
 PR 09-JUN-1994; 94US-00257528.
 XX (CONN-) CONNAUGHT LAB LTD.
 PA Klein MH, Chong P, Sia CDY;
 PI WPI; 1999-550482/46.
 DR Immunogenic composition containing synthetic fusion polypeptides
 PT containing both the T and B cell epitopes of the human immunodeficiency
 PT virus, useful antigens in producing vaccines.

XX Example 1; Col 22; 43pp; English.
 PS This sequence represents a fragment of a HIV1 protein, and can be used in
 CC the immunogenic composition of the invention. The composition comprises a
 CC synthetic fusion polypeptide which includes a sequence encoding 1 or more
 CC T cell epitopes and a sequence encoding 1 or more B cell epitopes and a
 CC carrier. Both the T cell and B cell epitopes are derived from HIV
 CC proteins. The compositions are useful as vaccines against HIV infection.
 CC The composition induces HIV-1-specific polyclonal antibodies that are
 CC opsonising and antiviral. The peptide components may be selected to
 CC induce a response against different viral isolates and in subjects who
 CC recognise different T cell epitopes. (Updated on 17-OCT-2003 to
 CC standardise OS field)
 XX Sequence 14 AA;
 SQ Query Match 68.8%; Score 53; DB 2; Length 14;
 Best Local Similarity 100.0%; Pred. No. 0.36;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 RIQRGPGRAF 10
 DB |||||
 5 RIQRGPGRAF 14
 RESULT 228
 AAY22593
 ID AAY22593 standard; peptide; 18 AA.
 AC AAY22593;
 XX 17-OCT-2003 (revised)
 DT 19-OCT-1999 (first entry)
 XX HIV putative gp120 LDL-R binding region.
 DE HIV; LDL; low density lipoprotein; human; immune response; infection;
 KW immunodeficiency; neoplastic tissue; myalgic encephalomyelitis; MS;
 KW viral infection fatigue syndrome; tuberculosis; hepatitis; AIDS; ARC;
 KW acquired immunodeficiency syndrome; AIDS related complex; gp120; LDL-R;
 KW HIV-infected CD4 cell; immunosuppressive peptide.
 XX Human immunodeficiency virus 1.
 OS WO9938524-A2.
 XX 05-AUG-1999.
 PD 28-JAN-1999; 99WO-IB000149.
 PF 29-JAN-1998; 98US-0072980P.
 XX (PREN/) PRENDERGAST P T.
 PA Prendergast PT;
 PI WPI; 1999-494040/41.
 DR Enhancing the immune response using a recombinant human low-density
 XX lipoprotein receptor, useful for treating viral infections, especially
 XX human immunodeficiency virus (HIV) infection.
 PS Disclosure; Page 17; 24pp; English.
 CC This sequence represents a putative gp120 low density lipoprotein
 CC receptor (LDL-R) binding region of HIV. The invention relates to a method
 CC for enhancing the immune response in a patient with a condition, selected
 CC from immunodeficiency (due to a viral, bacterial, mycoplasmaic, fungal or
 CC parasitic infection, or from the growth of neoplastic tissue), myalgic
 CC encephalomyelitis (ME), post inoculation or viral infection fatigue
 CC syndrome, tuberculosis, or hepatitis. The method comprises using a
 CC pharmaceutical composition, comprising a recombinant human LDL receptor

or a mimic molecule to the cysteine rich domain of LDL receptor. The human recombinant LDL receptor forms pharmaceutical compositions for: the treatment of acquired immunodeficiency syndrome (AIDS) or ARC (AIDS related complex); reducing syncytium formation in HIV-infected CD4 cells; treating blood or body fluid or organs to neutralise/remove immunosuppressive peptides and/or viruses; or treating hepatitis A, B or C. The pharmaceutical compositions also treat a viral infection in a human or animal host. The human recombinant LDL receptor is also useful for manufacturing medicaments for treating all the conditions given above. The human recombinant LDL receptor is a highly specific inhibitor of HIV-1 replication in vitro. (Updated on 17-OCT-2003 to standardise OS field)

XX SQ Sequence 18 AA;

Query Match 68.8%; Score 53; DB 2; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.45;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RIQPGGRAFP 10
| | | | | | | | | |
Db 9 RIQPGGRAFP 18

RESULT 229

AAR26890
ID AAR26890 standard; peptide; 20 AA.

XX AC AAR26890;
XX 25-MAR-2003 (revised)
DT 20-MAY-1998 (first entry)
XX HIV epitope #12.

XX Principle neutralising domain; PND; HIV-1; gp120; envelope; vaccine;
KW prophylaxis.

XX Synthetic.

XX WO9214489-A1.

XX PD 03-SEP-1992.

XX PF 14-FEB-1992; 92WO-US001303.

XX PR 14-FEB-1991; 91US-00655669.

XX PA (REPK) REPLIGEN CORP.

XX PI Murray MG, Putney SD;

XX DR WPI; 1992-315940/38.

XX Hybrid polio virus useful as vaccine against HIV-1 infections - contains epitope of heterologous protein inserted into the BC loop of polio virus.

XX Disclosure; Page 21; 35pp; English.

XX The sequences given in AAR26879-93 are portions of the HIV-1 principle neutralising domain (PND) protein which were used as neutralising epitopes. HIV-1 PND is an approx. 40 amino acid region of the external envelope protein gp120 which forms a looped structure in native gp120. The epitopes were inserted into the BC loop of a hybrid poliovirus. This construct could be used as a vaccine. The vaccine may be used for prophylaxis or treatment of human patients infected with HIV-1. (Updated on 25-MAR-2003 to correct PN field.)

XX Sequence 20 AA;

Query Match 68.8%; Score 53; DB 2; Length 20;
Best Local Similarity 83.3%; Pred. No. 0.49;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY 2 IQRGPGRAFTV 13
| | | | | | | | | |
Db 9 IQRGPGRAFTV 20

RESULT 230

AAR26879
ID AAR26879 standard; peptide; 10 AA.

XX AC AAR26879;

XX 25-MAR-2003 (revised)

DT 20-MAY-1998 (first entry)

XX HIV epitope #1.

XX Principle neutralising domain; PND; HIV-1; gp120; envelope; vaccine;
KW prophylaxis.

XX Synthetic.

XX WO9214489-A1.

XX PD 03-SEP-1992.

XX PF 14-FEB-1992; 92WO-US001303.

XX PR 14-FEB-1991; 91US-00655669.

XX PA (REPK) REPLIGEN CORP.

XX PI Murray MG, Putney SD;

XX DR WPI; 1992-315940/38.

XX Hybrid polio virus useful as vaccine against HIV-1 infections - contains epitope of heterologous protein inserted into the BC loop of polio virus.

XX Disclosure; Page 18; 35pp; English.

XX The sequences given in AAR26879-93 are portions of the HIV-1 principle neutralising domain (PND) protein which were used as neutralising epitopes. HIV-1 PND is an approx. 40 amino acid region of the external envelope protein gp120 which forms a looped structure in native gp120. The epitopes were inserted into the BC loop of a hybrid poliovirus. This construct could be used as a vaccine. The vaccine may be used for prophylaxis or treatment of human patients infected with HIV-1. (Updated on 25-MAR-2003 to correct PN field.)

XX Sequence 10 AA;

Query Match 67.5%; Score 52; DB 2; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.38;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2 IQRGPGRAFTV 11
| | | | | | | | | |
Db 1 IQRGPGRAFTV 10

RESULT 231

AAR26892
ID AAR26892 standard; peptide; 10 AA.

XX AC AAR26892;

XX 25-MAR-2003 (revised)

DT 20-MAY-1998 (first entry)

XX HIV epitope #14.

XX Principle neutralising domain; PND; HIV-1; gp120; envelope; vaccine;
KW

KW prophylaxis.
 XX
 OS Synthetic.
 XX
 PN WO9214489-A1.
 XX
 XX PD 03-SEP-1992.
 XX
 PF 14-FEB-1992; 92WO-US001303.
 XX
 PR 14-FEB-1991; 91US-00655669.
 XX
 PA (REPK) REPLIGEN CORP.
 XX
 XX PI Murray MG, Putney SD;
 XX WPI; 1992-315940/38.
 XX
 XX Hybrid polio virus useful as vaccine against HIV-1 infections - contains
 PT epitope of heterologous protein inserted into the BC loop of polio virus.
 XX
 PS Disclosure; Page 23; 35pp; English.
 XX
 CC The sequences given in AAR26879-93 are portions of the HIV-1 principle
 CC neutralising domain (PND) protein which were used as neutralising
 CC epitopes. HIV-1 PND is an approx. 40 amino acid region of the external
 CC envelope protein gp120 which forms a looped structure in native gp120.
 CC The epitopes were inserted into the BC loop of a hybrid poliovirus. This
 CC construct could be used as a vaccine. The vaccine may be used for
 CC prophylaxis or treatment of human patients infected with HIV-1. (Updated
 CC on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 10 AA;
 Query Match 67.5%; Score 52; DB 2; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.38;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 2 IQRGPGRAV 11
 DB 1 IQRGPGRAV 10
 RESULT 232
 AAR33452
 ID AAR33452 standard; peptide; 10 AA.
 XX
 AC AAR33452;
 XX
 XX 27-AUG-2003 (revised)
 DT 25-MAR-2003 (revised)
 DT 17-DEC-2001 (revised)
 DT 03-JUL-1993 (first entry)
 XX
 XX Sequence of synthetic peptide which represents immunogenic region of the
 DE V loop of HIV isolate IIB.
 DE
 DE Cytotoxic T lymphocyte; immunogenic peptide; V3 loop; treatment;
 KW glycoprotein 160.
 KW
 XX Human immunodeficiency virus 1.
 OS
 XX USN7847311-N.
 PN
 XX
 PD 01-JAN-1993.
 XX
 XX 06-MAR-1992; 92US-00847311.
 PF
 XX 26-JAN-1988; 88US-00148692.
 PR 18-SEP-1991; 91US-00760530.
 PR
 XX (USSH) US DEPT HEALTH & HUMAN SERVICE.
 PA
 XX

PI Berzofsky JA, Taskeshita T, Shirai M, Pendleton CD, Kozlowski S;
 XX WPI; 1993-093577/11.
 DR
 XX
 PT Peptide(s) for stimulation of cytotoxic T cells specific for HIV-1 -
 PT which correspond to residues 318-327 of HIV-1 gp 160 envelope
 PT glyco:protein.
 XX
 XX Disclosure; Page 8; 61pp; English.
 PS
 CC The peptide elicits cytotoxic T lymphocyte (CTL) response at concns. of
 CC 10(-12) to 10(-6) M. It corresp. to residues 318-327 of HIV-1 strain IIB
 CC gp. 160 envelope glycoprotein. It can be used for the treatment and/or
 CC prophylaxis of HIV infection. (Note: Revised entry submitted to correct
 CC the patent number format of US Government-owned NIS applications to
 CC prevent clashes with ongoing US granted patent numbers. For further
 CC information please visit the Derwent web site at
 CC www.derwent.com/dwpi/updates/ntis us.html.) (Updated on 25-MAR-2003 to
 CC correct PF field.) (Updated on 27-AUG-2003 to correct OS field.)
 XX
 SQ Sequence 10 AA;
 Query Match 67.5%; Score 52; DB 2; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.38;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 4 RGPGRAFV 13
 DB 1 RGPGRAFV 10
 RESULT 233
 AAR95920
 ID AAR95920 standard; peptide; 10 AA.
 XX
 AC AAR95920;
 XX
 DT 16-OCT-2003 (revised)
 DT 14-JAN-1997 (first entry)
 XX
 DE HIV gp 120 antigen, component of mucosal binding compsn.
 XX
 KW Mucosal binding composition; mucosal binding polypeptide; antigen;
 KW viral pathogen; sexually transmitted disease; administration; vaginal;
 KW rectal; oral; immune response; secretory immunity; mucous; HIV-1;
 KW glycoprotein 120; gp120.
 XX
 OS Human immunodeficiency virus 1.
 XX
 XX WO9616178-A1.
 PN
 XX 30-MAY-1996.
 XX
 PF 17-NOV-1995; 95WO-GB002708.
 XX
 PR 17-NOV-1994; 94US-00342241.
 XX
 XX (LEBE/) LEBENS M R.
 PA (HOLM/) HOLMGREN J R.
 XX
 XX Lebens MR, Holmgren JR;
 PI
 XX WPI; 1996-268614/27.
 DR
 XX
 XX Mucosal binding compositions for generating mucosal immune response -
 PT comprises mucosal binding peptide, pref. derived from cholera toxin, and
 PT an antigen, e.g. derived from E. coli, HIV, etc.
 XX
 XX Claim 29; Page 43; 65pp; English.
 PS
 CC A novel mucosal binding compsn. (MBC) comprises a mucosal binding
 CC polypeptide linked to at least 1 antigen from a viral pathogen, which
 CC causes a sexually transmitted disease (STD), e.g. the present HIV gp120
 CC

CC antigen. The MBC, which is administered vaginally, rectally or orally,
 CC generates a mucosal immune response against the viral STD by allowing for
 CC the prodn. of high levels of secretory immunity, which forms the 1st line
 CC of defence against the majority of STD. (Updated on 16-OCT-2003 to
 CC standardise OS field)

XX Sequence 10 AA;

Query Match 67.5%; Score 52; DB 2; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.38;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 IORGPGRAV 11
 Db 1 IORGPGRAV 10
 |||||

RESULT 234

AAW76839
 ID AAW76839 standard; peptide; 10 AA.

AC AAW76839;
 XX
 DT 25-JAN-1999 (first entry)
 DE Fusion immunoglobulin heavy chain HIV gp120 B cell epitope #9.
 KW B cell; T cell; epitope; immunoglobulin; heavy chain; gp120; IGH;
 KW human immune deficiency virus; HIV; tolerance; treatment; therapy;
 KW prophylaxis; vaccine; chemotherapy; immune response; modifier; tumour;
 KW microbial infection; autoimmune disease; antibody; apoptosis;
 KW antiviral T cell immunity.

XX Mus sp.

OS Homo sapiens.

XX WO9836087-A1.

XX 20-AUG-1998.

XX 13-FEB-1998; 98WO-US002766.

XX 13-FEB-1997; 97US-0040581P.

XX (AMNA-) AMERICAN NAT RED CROSS.

XX Scott D, Zambidis E;

XX WPI; 1998-506315/43.

XX New fusion immunoglobulin heavy chain including gp120 epitopes and
 PT related complete antibodies - DNA, vectors and transformed cells, used to
 PT induce tolerance to the epitopes for treatment of human immune deficiency
 PT virus infection.

XX Claim 10; Page 119; 154pp; English.

XX This sequence is an epitope used in the construction of a novel fusion
 CC immunoglobulin heavy chain (IGH) protein with a mammalian, especially
 CC human, IGH chain fused in frame at its N-terminus to one or more human
 CC immune deficiency virus (HIV) gp120 epitopes. Fusion Ig proteins and/or
 CC transfected cells are used to tolerate subjects to gp120 epitopes and to
 CC maintain this tolerance, particularly for treatment of HIV infection,
 CC optionally together with other therapeutic/prophylactic agents such as
 CC vaccines, chemotherapeutic agents and immune response modifiers. Such
 CC proteins can be used against other diseases where an immune response is
 CC deleterious, e.g. microbial infection, tumours or autoimmune disease.
 CC Induction of tolerance suppresses production of antibodies against gp120,
 CC so prevents or inhibits 'bystander' apoptosis of uninfected T cells that
 CC are bound to gp120 protein, maximising induction of protective antiviral
 CC T cell immunity

XX Sequence 10 AA;

Query Match 67.5%; Score 52; DB 2; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.38;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 IORGPGRAV 11
 Db 1 IORGPGRAV 10
 |||||

RESULT 235

RAY10172
 ID AAY10172 standard; peptide; 10 AA.

XX AC AAY10172;

XX 12-MAY-1999 (first entry)

XX T cell epitope/MHC ligand SEQ ID NO:102.

XX Cytotoxic T-lymphocyte response; CTL; antigen; lymphatic system;
 KW immunisation; tumour; infectious disease; immunotherapy; cancer;
 KW malignant melanoma; viral disease; hepatitis; AIDS.

XX Synthetic.

XX Human immunodeficiency virus 1.

XX WO9902183-A2.

XX 21-JAN-1999.

XX 10-JUL-1998; 98WO-US014289.

XX 10-JUL-1997; 97CA-02209815.

XX 10-DEC-1997; 97US-00988320.

XX (CTLI-) CTL IMMUNOTHERAPIES CORP.

XX Kuendig TW, Simard JVL;

XX WPI; 1999-120514/10.

XX Inducing a cytotoxic T lymphocyte response - by maintaining a level of
 PT antigen in the lymphatic system of a mammal so as to provide a sustained
 PT CTL response, used to treat, e.g. AIDS.

XX Disclosure; Page 27; 199pp; English.

XX The present invention describes a method of inducing and/or sustaining an
 CC immunological cytotoxic T lymphocyte (CTL) response in a mammal. The
 CC method comprises: (a) delivering an antigen to the mammal at a level to
 CC induce an immunological CTL response in the mammal; and (b) maintaining
 CC the level of the antigen in the mammal's lymphatic system to maintain the
 CC immunologic CTL response. The method can be used for the delivery of e.g.
 CC a differentiation antigen, a tumour-specific multilineage antigen, an
 CC embryonic antigen, an oncogene antigen, a mutated tumour-suppressor gene
 CC antigen, or a viral antigen. They can be used for the treatment of
 CC disease such as cancer, e.g. malignant melanoma or infectious disease,
 CC e.g. viral disease such as hepatitis or AIDS. Sustained antigen delivery
 CC to the lymphatic system provides for potent CTL stimulation that takes
 CC place in the milieu of the lymphoid organ, and it sustains stimulation
 CC that is necessary to keep CTL active, cytotoxic and recirculating through
 CC the body. AAY10071 to AAY10639 represent examples of peptide antigens
 CC given in the present invention

XX Sequence 10 AA;

XX Query Match 67.5%; Score 52; DB 2; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.38;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RGPGRFVTI 13
 |||||

```

Db      1 RGPGRFVTI 10

RESULT 236
AAY10547
ID AAY10547 standard; peptide; 10 AA.
XX
XX
AC AAY10547;
XX
XX 12-MAY-1999 (first entry)
XX
XX HLA Class I motif peptide SEQ ID NO:477.
XX
XX Cytotoxic T-lymphocyte response; CTL; antigen; lymphatic system;
KW immunisation; tumour; infectious disease; immunotherapy; cancer;
KW malignant melanoma; viral disease; hepatitis; AIDS.
XX
XX Synthetic.
OS Human immunodeficiency virus 1.
OS
XX WO9902183-A2.
PN
XX
XX 21-JAN-1999.
PD
XX
XX 10-JUL-1998; 98WO-US014289.
PF
XX
XX 10-JUL-1997; 97CA-02209815.
PR
XX 10-DEC-1997; 97US-00988320.
PR
XX
XX (CTLI-) CTL IMMUNOTHERAPIES CORP.
PA
XX
XX Kuendig TM, Simard JUL;
PI
XX WPI; 1999-120514/10.
DR
XX
XX Inducing a cytotoxic T lymphocyte response - by maintaining a level of
PT antigen in the lymphatic system of a mammal so as to provide a sustained
PT CTL response, used to treat, e.g. AIDS.
XX
XX Disclosure; Page 46; 199pp; English.
XX
XX The present invention describes a method of inducing and/or sustaining an
CC immunological cytotoxic T lymphocyte (CTL) response in a mammal. The
CC method comprises: (a) delivering an antigen to the mammal at a level to
CC induce an immunological CTL response in the mammal; and (b) maintaining
CC the level of the antigen in the mammal's lymphatic system to maintain the
CC immunologic CTL response. The method can be used for the delivery of e.g.
CC a differentiation antigen, a tumour-specific multilineage antigen, an
CC embryonic antigen, an oncogene antigen, a mutated tumour-suppressor gene
CC disease such as cancer, e.g. malignant melanoma or infectious disease,
CC e.g. viral disease such as hepatitis or AIDS. Sustained antigen delivery
CC to the lymphatic system provides for potent CTL stimulation that takes
CC place in the milieu of the lymphoid organ, and it sustains stimulation
CC that is necessary to keep CTL active, cytotoxic and recirculating through
CC the body. AAY10071 to AAY10639 represent examples of peptide antigens
CC given in the present invention
XX Sequence 10 AA;
SQ
Query Match 67.5%; Score 52; DB 2; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.38;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 RGPGRFVTI 13
Db 1 RGPGRFVTI 10

RESULT 237
AAY10164
ID AAY10164 standard; peptide; 10 AA.
XX
XX
AC AAY03691;
XX
XX 17-OCT-2003 (revised)
DT 07-JUN-1999 (first entry)
XX
XX Amino acid fragment of CTL epitope of HIV/SIV (H) string.
XX

```

KW CD8+ T-cell; immune response; antigen; priming composition; CTL; epitope;
 KW cytotoxic T lymphocyte; boosting; poxvirus vector; PVV; pathogen; tumour;
 KW malaria; parasite; P. falciparum; viral; bacterial; parasitic; cancer;
 KW melanoma; HIV; breast; colon; vaccination.
 XX
 OS Human immunodeficiency virus 1.
 XX
 FN WO9856919-A2.
 XX
 PD 17-DEC-1998.
 XX
 PF 09-JUN-1998; 98WO-GB001681.
 XX
 PR 09-JUN-1997; 97GB-00011957.
 XX
 PA (ISIS-) ISIS INNOVATION LTD.
 XX
 PI McMichael AJ, Hill AVS, Gilbert SC, Schneider J, Plebanski M;
 PI Hanke T, Smith GL, Blanchard T;
 XX
 DR WPI; 1999-070325/06.
 XX
 XX Generating CD8-positive T cell response to target antigen using
 PT recombinant poxvirus - for treating or preventing malaria and HIV
 PT infection, also epitope strings from Plasmodium and HIV.
 XX
 PS Claim 43; Page 20; 85pp; English.
 XX
 CC The invention relates to methods and reagents for generating a protective
 CC CD8+ T-cell immune response against at least one target antigen. The kits
 CC of the invention comprises (i) as priming composition, a source of one or
 CC more CD8+ T-cell [cytotoxic T lymphocytes-(CTL)] epitopes of the target
 CC antigen, plus a carrier and (ii) as boosting composition a source of CTL
 CC epitopes, with at least one CTL epitope the same as used in (i), with
 CC this source being a non-replicating or replication-impaired recombinant
 CC poxvirus vector (pVv) plus a carrier. If the source of CTL epitopes in
 CC (i) is a viral vector, then the vector in (ii) is from a different virus.
 CC The kits are used to generate an immune response (prophylactic or
 CC therapeutic) against pathogens or tumours, specifically against malaria
 CC parasites such as P. falciparum, or HIV, and also many other bacterial,
 CC viral or parasitic pathogens. The kits are also used for protective
 CC response against melanoma and cancer of breast or colon, and generally
 CC wherever a strong CD8+ response is protective. The boosting composition
 CC may be used alone to boost a naturally primed response against malaria.
 CC The specified pVv provide an excellent booster effect, better than that
 CC from wild-type poxvirus, resulting in complete rather than partial
 CC protection against sporozoite challenge. Also pVv are safer to use than
 CC protection against sporozoite challenge. Also pVv are safer to use than
 CC wild-type virus. Sequences AAY03681-704 represent CTL peptide epitopes of
 CC the HIV/SIV (H) epitope string. (Updated on 17-OCT-2003 to standardise OS
 CC field)
 XX
 SQ Sequence 10 AA;
 Query Match 67.5%; Score 52; DB 2; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.38;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 4 RGPGRFVTI 13
 |||||
 Db 1 RGPGRFVTI 10
 RESULT 239
 AAY03655
 ID AAY03655 standard; peptide; 10 AA.
 XX
 AC AAY03655;
 XX
 DT 07-JUN-1999 (first entry)
 XX
 DE HIV gag CTL peptide epitope.
 XX
 KW CD8+ T-cell; immune response; antigen; priming composition; CTL; epitope;

KW cytotoxic T lymphocyte; boosting; poxvirus vector; PVV; pathogen; tumour;
 KW malaria; parasite; P. falciparum; viral; bacterial; parasitic; cancer;
 KW melanoma; HIV; breast; colon; vaccination; PLA tumour antigen.
 OS Synthetic.
 OS Human immunodeficiency virus 1.
 XX
 FN WO9856919-A2.
 XX
 PD 17-DEC-1998.
 XX
 PF 09-JUN-1998; 98WO-GB001681.
 XX
 PR 09-JUN-1997; 97GB-00011957.
 XX
 PA (ISIS-) ISIS INNOVATION LTD.
 XX
 PI McMichael AJ, Hill AVS, Gilbert SC, Schneider J, Plebanski M;
 PI Hanke T, Smith GL, Blanchard T;
 XX
 DR WPI; 1999-070325/06.
 XX
 XX Generating CD8-positive T cell response to target antigen using
 PT recombinant poxvirus - for treating or preventing malaria and HIV
 PT infection, also epitope strings from Plasmodium and HIV.
 XX
 PS Example 1; Page 22; 85pp; English.
 XX
 CC The invention relates to methods and reagents for generating a protective
 CC CD8+ T-cell immune response against at least one target antigen. The kits
 CC of the invention comprises (i) as priming composition, a source of one or
 CC more CD8+ T-cell [cytotoxic T lymphocytes-(CTL)] epitopes of the target
 CC antigen, plus a carrier and (ii) as boosting composition a source of CTL
 CC epitopes, with at least one CTL epitope the same as used in (i), with
 CC this source being a non-replicating or replication-impaired recombinant
 CC poxvirus vector (pVv) plus a carrier. If the source of CTL epitopes in
 CC (i) is a viral vector, then the vector in (ii) is from a different virus.
 CC The kits are used to generate an immune response (prophylactic or
 CC therapeutic) against pathogens or tumours, specifically against malaria
 CC parasites such as P. falciparum, or HIV, and also many other bacterial,
 CC viral or parasitic pathogens. The kits are also used for protective
 CC response against melanoma and cancer of breast or colon, and generally
 CC wherever a strong CD8+ response is protective. The boosting composition
 CC may be used alone to boost a naturally primed response against malaria.
 CC The specified pVv provide an excellent booster effect, better than that
 CC from wild-type poxvirus, resulting in complete rather than partial
 CC protection against sporozoite challenge. Also pVv are safer to use than
 CC protection against sporozoite challenge. Also pVv are safer to use than
 CC wild-type virus. Sequences AAY03653-60 represent CTL peptide epitopes
 CC used during the course of the invention
 XX
 SQ Sequence 10 AA;
 Query Match 67.5%; Score 52; DB 2; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.38;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 4 RGPGRFVTI 13
 |||||
 Db 1 RGPGRFVTI 10
 RESULT 240
 AAY05357
 ID AAY05357 standard; peptide; 10 AA.
 XX
 AC AAY05357;
 XX
 DT 17-OCT-2003 (revised)
 DT 29-JUN-1999 (first entry)
 XX
 DE HIV-1 CLUVAC peptide, SEQ ID NO. 16.
 XX
 KW HIV-1; CLUVAC; cluster peptide vaccine construct; cytotoxic T lymphocyte;

KW protective mucosal CTL response; hepatitis A virus; papilloma virus;
 KW feline immunodeficiency virus; feline leukaemia virus; M. tuberculosis;
 KW Listeria monocytogenes; M. leprae; Giardia lamblia;
 XX immune response induction.
 OS Human immunodeficiency virus 1.
 XX
 PN WO9912563-A2.
 XX
 PD 18-MAR-1999.
 XX
 PF 11-SEP-1998; 98WO-US019028.
 XX
 PR 11-SEP-1997; 97US-0058523P.
 PR 17-FEB-1998; 98US-0074894P.
 XX
 PA (USSH) US DEPT HEALTH & HUMAN SERVICE.
 XX
 PI Berzofsky JA, Belyakov IM, Derby MA, Kelsall BL, Strober W;
 XX WPI; 1999-243663/20.
 DR
 XX Method for inducing a protective mucosal cytotoxic T lymphocyte immune
 PT response.
 PT
 PS Example 3; Page 85; 86pp; English.
 XX
 CC This sequence represents a HIV-1 cluster peptide vaccine conjugate
 CC (CLUVAC) sequence. The invention relates to a method for inducing a
 CC protective mucosal cytotoxic T lymphocyte (CTL) response in a mammalian
 CC subject, which comprises contacting a mucosal tissue of the subject with
 CC a composition comprising a purified soluble antigen. The method can
 CC induce a protective mucosal CTL response in a subject. The method can be
 CC used for protection against e.g. hepatitis A virus, papilloma virus,
 CC feline immunodeficiency virus, feline leukaemia virus, Listeria
 CC monocytogenes, M. tuberculosis, M. leprae, or Giardia lamblia. The method
 CC induces long-lasting protective mucosal immune responses. (Updated on 17-
 CC OCT-2003 to standardise OS field)
 XX
 SQ Sequence 10 AA;

Query Match 67.5%; Score 52; DB 2; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.38;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 RGPGRFVTI 13
 |||||
 DB 1 RGPGRFVTI 10

RESULT 241
 AAY59593
 ID AAY59593 standard; peptide; 10 AA.
 XX
 AC AAY59593;

DT 12-SEP-2003 (revised)
 DT 05-APR-2000 (first entry)
 XX
 DE HIV-1 env peptide 1-10.
 XX
 KW HIV-1; env gene; cellular immunity; virus; therapy;
 KW envelope glycoprotein; infection; immunisation; immune response.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN EP972523-A2.
 XX
 PD 19-JAN-2000.
 XX
 PF 27-MAY-1999; 99EP-00401265.
 XX
 PR 29-MAY-1998; 98US-00087513.

XX
 PA (NIHE-) JAPAN HEALTH SCI FOUND.
 PA (AJIN) AJINOMOTO CO INC.
 PA (UJJE-) UNIV JEFFERSON THOMAS.
 XX
 PI Kaneko Y, Kozbor D;
 XX WPI; 2000-099746/09.
 DR
 XX New composition for inducing viral immunity, useful for production of HIV
 PT vaccines.
 PT
 PS Example 3; Page 11; 28pp; English.
 XX
 CC This sequence represents a fragment of the HIV-1 env protein. The
 CC invention relates to a therapeutic composition for inducing cellular
 CC immunity against a virus, which comprises a nucleic acid encoding an
 CC envelope glycoprotein of the virus which: (a) contains a modified
 CC immunodominant epitope; and (b) induces cellular immunity to a conserved
 CC epitope of the envelope glycoprotein. The nucleic acid may be introduced
 CC into a vector DNA or a liposome and mixed with an adjuvant to prepare a
 CC vaccine effective against and induce cellular immunity against the HIV
 CC virus. The therapeutic composition can be used to prevent or treat
 CC infection. Prior art methods of immunising patients against viruses which
 CC frequently mutate have resulted in chronic immune activation and high T
 CC cell turnover because of secondary responses induced by the V3 loop
 CC mutated epitopes. The full length envelope glycoprotein expressed on the
 CC cell surface or released from HIV infected cells can also trigger
 CC detrimental effects which are essential in AIDS pathogenesis. The
 CC composition provides antigen presenting cells (APCs) which contain the
 CC modified envelope glycoprotein and are resistant to antibody-dependent
 CC cell mediated cytotoxicity (ADCC), do not form syncytia, do not undergo
 CC apoptosis and induce cellular immunity to the virus without inducing
 CC responses of CD4+ T cells. The composition therefore redirects immune
 CC responses towards the conserved epitope of the envelope glycoprotein,
 CC inducing cellular immunity to multiple strains of the virus. (Updated on
 CC 12-SEP-2003 to standardise OS field)
 XX
 SQ Sequence 10 AA;

Query Match 67.5%; Score 52; DB 3; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.38;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 RGPGRFVTI 13
 |||||
 DB 1 RGPGRFVTI 10

RESULT 242
 AAY67361
 ID AAY67361 standard; peptide; 10 AA.
 XX
 AC AAY67361;

DT 25-APR-2000 (first entry)
 XX
 DE Human immunodeficiency virus-10 (HIV-10) peptide.
 XX
 KW Therapeutic antigen; cytotoxic T lymphocyte; CTL; CTL immune response;
 KW cellular immune response induction method; vaccine; human; tumour;
 KW melanoma glycoprotein 75.
 XX
 OS Human immunodeficiency virus.
 XX
 PN WO9963945-A2.
 XX
 PD 16-DEC-1999.
 XX
 PF 11-JUN-1999; 99WO-US013146.
 XX
 PR 12-JUN-1998; 98US-0089055P.
 PR 30-OCT-1998; 98US-0106339P.

```

XX PA (SLOK ) SLOAN KETTERING INST CANCER RES.
XX PI Nikolic-Zugic J, Dyall R, Houghton AN;
XX XX WPI; 2000-126432/11.
XX DR
XX PT Induction of a cellular immune response to a weakly immunogenic protein,
XX PT used to target and kill tumor cells.
XX XX
XX PS Example 2; Page 15; 44pp; English.
XX XX
XX CC This sequence represents a human immunodeficiency virus (HIV-10) peptide
XX CC used in the method of the invention. The invention relates to a method
XX CC for inducing a cytotoxic T lymphocyte (CTL) immune response to non/weakly
XX CC immunogenic proteins which are expressed on tumour cells. The method for
XX CC inducing a cellular immune response to a non-immunogenic or weakly
XX CC immunogenic target peptide expressed on tumour cells of a mammalian
XX CC subject comprises administering antigen to induce a cellular immune
XX CC response to the target peptide. The antigen comprises an immunogenic
XX CC portion having a major histocompatibility complex (MHC) binding domain
XX CC which binds to the MHC and an immune recognition domain which is
XX CC recognized by T-cells. The antigen is derived from the target peptide
XX CC such that the MHC-binding portion binds to MHC with a greater affinity
XX CC than the target peptide without material alteration of the immune
XX CC recognition portion. The methods are used for inducing a cellular immune
XX CC response to a non-immunogenic or weakly immunogenic target peptide
XX CC expressed on tumour cells of a mammalian subject. The antigens and
XX CC immunogens of the invention, as well as polynucleotides encoding them,
XX CC are used in vaccine compositions against tumour cells
XX SQ Sequence 10 AA;

Query Match 67.5%; Score 52; DB 3; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.38;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 RGPGRFVTI 13
DB 1 RGPGRFVTI 10

RESULT 243
AA94398
ID AA94398 standard; peptide; 10 AA.
AC AA94398;
XX
XX DT 12-SEP-2003 (revised)
XX DT 10-JAN-2001 (first entry)
XX
XX DE Mouse H2-d-class I restricted minimal cytolytic T lymphocyte epitope.
XX KW Hepatitis B virus nucleocapsid antigen; HBCAG; T cell epitope;
XX KW cytolytic T lymphocyte; immunogenic; ICE; CTL; HIV;
XX KW immunodominant core epitope; immunisation; mouse.
XX OS
XX OS Human immunodeficiency virus 1.
XX PN WO200026385-A1.
XX
XX PD 11-MAY-2000.
XX PF 05-NOV-1999; 99WO-US026291.
XX PR 05-NOV-1998; 98US-0107169P.
XX
XX PA (POWD-) POWDERJECT VACCINES INC.
XX PI Fuller DL, Fuller JT;
XX DR WPI; 2000-451623/39.
XX
XX PT Use of expression vector for nucleic acid immunization that comprises
XX PT promoter and recombinant nucleic acid sequences encoding Hepatitis B core
XX PT antigen and T cell epitope from antigen.
XX PS Example 7; Page 41; 55pp; English.
XX XX
XX CC The present invention relates to an immunogenic recombinant nucleic acid
XX CC molecule. The molecule consists of a modified hepatitis B virus

```

```

XX PT Small functional units of antibody heavy chain variable regions useful
XX PT for diagnosis and treatment of disease.
XX XX
XX PS Example 1; Page 18; 48pp; English.
XX XX
XX CC The present sequence is an HIV peptide. A gene encoding a single-domain
XX CC VH protein belonging to mouse VH group 1(A) was cloned from a mouse
XX CC hybridoma generated against the present sequence in complex with H-2Dd.
XX CC The gene was amplified by PCR. The 3' primer contained a sequence which
XX CC randomised 9 amino acids in the third hypervariable loop (CDR3) of the VH
XX CC and therefore generated the single-domain VH library repertoire. CDR3
XX CC typically makes most antigen contacts in antibody combining sites. The
XX CC PCR product was reamplified to avoid non-symmetric pairing of strands due
XX CC to primer exhaustion. The final product was ligated into the phagemid
XX CC vector pCANTAB 5 E and electroporated into E. coli strain TGI. Phage
XX CC clones capable of binding a specific antigen, e.g. Tumour necrosis factor
XX CC alpha (TNFalpha), can be selected by library panning. Single-domain VH
XX CC proteins can be used to treat or diagnose associated disorders. For
XX CC example, disorders in which TNF plays a role include inflammatory bowel
XX CC disease, rheumatoid arthritis, septic shock, multiple sclerosis, chronic
XX CC inflammation and allograft rejection
XX SQ Sequence 10 AA;

Query Match 67.5%; Score 52; DB 3; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.38;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 RGPGRFVTI 13
DB 1 RGPGRFVTI 10

RESULT 244
AA94588
ID AA94588 standard; peptide; 10 AA.
AC AA94588;
XX
XX DT 12-SEP-2003 (revised)
XX DT 10-JAN-2001 (first entry)
XX
XX DE Mouse H2-d-class I restricted minimal cytolytic T lymphocyte epitope.
XX KW Hepatitis B virus nucleocapsid antigen; HBCAG; T cell epitope;
XX KW cytolytic T lymphocyte; immunogenic; ICE; CTL; HIV;
XX KW immunodominant core epitope; immunisation; mouse.
XX OS
XX OS Human immunodeficiency virus 1.
XX PN WO200026385-A1.
XX
XX PD 11-MAY-2000.
XX PF 05-NOV-1999; 99WO-US026291.
XX PR 05-NOV-1998; 98US-0107169P.
XX
XX PA (POWD-) POWDERJECT VACCINES INC.
XX PI Fuller DL, Fuller JT;
XX DR WPI; 2000-451623/39.
XX
XX PT Use of expression vector for nucleic acid immunization that comprises
XX PT promoter and recombinant nucleic acid sequences encoding Hepatitis B core
XX PT antigen and T cell epitope from antigen.
XX PS Example 7; Page 41; 55pp; English.
XX XX
XX CC The present invention relates to an immunogenic recombinant nucleic acid
XX CC molecule. The molecule consists of a modified hepatitis B virus

```

CC nucleocapsid antigen (HBcAg) with a T cell epitope sequence inserted
CC within the HBcAg. The creation of a unique restriction site in HBcAg
CC facilitated the insertion of the T cell epitope into the DNA encoding the
CC immunodominant core epitope of the HBcAg. An example of a suitable
CC insertion epitope is the present sequence, the mouse H2-d-restricted
CC minimal cytolytic T lymphocyte epitope of HIV LAI gp 120. Alternatively
CC other T cell epitopes may be inserted (AA94583, AA94584, AA94585,
CC AA94586, AA94587). The recombinant nucleic acid molecule may then be
CC used as a reagent in various nucleic acid immunisation strategies. The
CC advantage of this method of immunisation is that the nucleic acid
CC reagents that encode hybrid HBcAg generate an extremely high frequency
CC cellular immune response against the CTL epitope. (Updated on 12-SEP-2003
CC to standardise OS field)
SQ Sequence 10 AA;
Query Match 67.5%; Score 52; DB 3; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.38;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 4 RGPGRFVVTI 13
Db 1 RGPGRFVVTI 10
RESULT 245
AAB15874
ID AAB15874 standard; peptide; 10 AA.
AC AAB15874;
XX
XX
DT 17-JAN-2001 (first entry)
DE Human chemokine derived peptide #26.
KW Macrophage recruitment; chemokine derivative; MCP-1; osteoporosis;
KW monocyte chemoattractant protein-1; inflammation; atherosclerosis; HIV;
KW AIDS; stroke; psoriasis; autoimmune disease; hypertension; endotoxaemia;
KW basophil-mediated disease; myocardial infarction; acute ischaemia;
KW rheumatoid arthritis; contraception.
OS Synthetic.
XX
XX
PN WO200042071-A2.
XX
XX
PD 20-JUL-2000.
XX
XX
PF 12-JAN-2000; 2000WO-US000821.
XX
XX
PR 12-JAN-1999; 99US-00229071.
PR 17-MAR-1999; 99US-00271132.
PR 01-DEC-1999; 99US-00452406.
XX
XX
PA (NEOR-) NEORX CORP.
XX
XX
PI Grainger DJ, Tatalick LM;
XX
XX
DR WPI; 2000-499101/44.
XX
XX
PT New peptide 3, amide and heterocyclic compounds and saccharide conjugates
PT used for inhibiting chemokine induced activity and for treating e.g.
PT stroke, vascular diseases, autoimmune diseases and tumor growth.
XX
XX
PS Disclosure; Fig 18; 387pp; English.
XX
XX
CC The present invention concerns the identification of a number of
CC chemokines which can be used to produce derivatives, agonists and
CC antagonists which are then useful in disease treatment. The chemokines
CC include sequences AAB15785-B15794, AAB15803-B15813 and AAB15831-B15848.
CC These chemokine derivatives can be used to treat diseases such as
CC autoimmune diseases, atherosclerosis, osteoporosis, HIV infection and
CC AIDS, psoriasis, inflammatory diseases, hypertension, basophil-mediated
CC diseases, endotoxaemia, myocardial infarction, acute ischaemia and

CC rheumatoid arthritis, and can be used to prevent strokes and as
CC contraceptives. The coding sequences for the chemokines can be used in
CC gene therapy for the same diseases, as well as in the production of
CC animal models
XX
SQ Sequence 10 AA;
Query Match 67.5%; Score 52; DB 3; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.38;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 4 RGPGRFVVTI 13
Db 1 RGPGRFVVTI 10
RESULT 246
AAB92350
ID AAB92350 standard; peptide; 10 AA.
XX
XX
AC AAB92350;
XX
XX
DT 22-JUN-2001 (first entry)
DE Virus related peptide SEQ ID NO:1526.
KW Protection; endogenous therapeutic peptide; peptidase; conjugation;
KW blood component; modification; succinimide; maleimido group; amino;
KW hydroxyl; thiol; hormone; growth factor; neurotransmitter.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX
PN WO2000069900-A2.
XX
XX
PD 23-NOV-2000.
XX
XX
PF 17-MAY-2000; 2000WO-US013576.
XX
XX
PR 17-MAY-1999; 99US-0134406P.
PR 10-SEP-1999; 99US-0153406P.
PR 15-OCT-1999; 99US-0159783P.
XX
XX
PA (CONJ-) CONJUCHEM INC.
XX
XX
PI Bridon DP, Ezrin AM, Milner PG, Holmes DL, Thibadeau K;
XX
XX
DR WPI; 2001-112059/12.
XX
XX
PT Modifying and attaching therapeutic peptides to albumin prevents
PT peptidase degradation, useful for increasing length of in vivo activity.
XX
XX
PS Disclosure; Page 704; 733pp; English.
XX
XX
CC The present invention describes a modified therapeutic peptide (I)
CC comprising a therapeutically active amino acid region (III) and a
CC reactive group (II) (e.g. succinimide and maleimide groups) attached to
CC a less therapeutically active amino acid region (IV), which covalently
CC bonds with amino/hydroxyl/thiol groups on blood components to form a
CC peptidase stabilised therapeutic peptide composed of 3-50 amino acids.
CC (I) are useful for modifying therapeutic peptides e.g. hormones, growth
CC factors and neurotransmitters, to protect them from peptidase activity in
CC vivo for the treatment of various disorders. Endogenous therapeutic
CC peptides are not suitable as drug candidates as they require frequent
CC administration due to rapid degradation by peptidases in the body.
CC Modifying and attaching therapeutic peptides to albumin prevents or
CC reduces the action of peptidases to increase length of activity (half
CC life) and specificity as bonding to large molecules decreases
CC intracellular uptake and interference with physiological processes.
CC AAB90829 to AAB92441 represent peptides which can be used in the
CC exemplification of the present invention
XX
SQ Sequence 10 AA;

Query Match 67.5%; Score 52; DB 4; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.38;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 4 RGPGRFVTI 13
 |||||
 DB 1 RGPGRFVTI 10

RESULT 247
 AAB49397
 ID AAB49397 standard; peptide; 10 AA.
 XX AC AAB49397;
 XX DT 06-MAR-2001 (first entry)
 XX DE HIV peptide SEQ ID NO: 12.
 XX HIV; immunogenic peptide; immune response; monophosphoryl lipid A;
 KW antigen; infection; cancer; amyloid deposition.
 XX OS Human immunodeficiency virus.
 XX FN WO200069456-A2.
 XX PD 23-NOV-2000.
 XX PF 12-MAY-2000; 2000WO-US013156.
 XX PR 13-MAY-1999; 99US-0133963P.
 XX PA (AMCY) AMERICAN CYANAMID CO.
 XX PI Hagen M;
 XX WPI; 2001-024946/03.
 XX Antigenic composition having an antigen (e.g. viral protein) and an
 PT adjuvant, useful for enhancing humoral and cellular immune response in a
 PT host or as a prophylaxis against virus, bacterium, parasite, cancer cell
 PT or allergen.
 XX Example 1; Page 41; 129pp; English.
 CC The present invention provides an antigenic composition comprising an
 CC antigen with a 3-O-deacylated monophosphoryl lipid A or monophosphoryl
 CC lipid A adjuvant. The presence of the adjuvant causes an increased immune
 CC response. The antigen may be from a pathogenic bacterium, fungus, virus
 CC or parasite, a cancer cell, an allergen or from amyloid peptide protein.
 CC The composition can be used in the prevention and treatment of infection,
 CC cancer and diseases caused by amyloid deposition. It is particularly
 CC useful against HIV, Neisseria gonorrhoeae and respiratory syncytial virus
 XX Sequence 10 AA;
 SQ

Query Match 67.5%; Score 52; DB 4; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.38;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 4 RGPGRFVTI 13
 |||||
 DB 1 RGPGRFVTI 10

RESULT 248
 AAE04801
 ID AAE04801 standard; peptide; 10 AA.
 XX AC AAE04801;
 XX DT 10-SEP-2001 (first entry)

XX Human immunodeficiency virus env protein derived restricted CTL epitope.
 DE
 XX Human immunodeficiency virus; HIV; immunogen; anti-HIV; vaccine;
 KW gene therapy; fusion protein; modified vaccinia virus Ankara vector; MVA;
 KW cytotoxic T-lymphocyte; CTL; epitope.
 XX Human immunodeficiency virus.
 OS
 XX WO200147955-A2.
 PN
 XX 05-JUL-2001.
 PD
 XX 22-DEC-2000; 2000WO-GB004984.
 PF
 XX 23-DEC-1999; 99GB-00030294.
 PR
 XX 14-OCT-2000; 2000GB-00025234.
 PR
 XX (MEDI-) MEDICAL RES COUNCIL.
 PA (ITAL-) INT AIDS VACCINE INITIATIVE.
 PA (UTNA-) UNIV NAIROBI.
 XX
 PI Hanke T, McMichael AJ;
 XX WPI; 2001-418221/44.
 DR
 XX Novel immunogen for stimulating anti-HIV immune response, has a portion
 XX of gag protein of HIV from HIV clade, parts of p17, p24 and synthetic
 PT polypeptide comprising human cytotoxic T-lymphocyte epitopes of HIV
 PT protein.
 XX Example 1; Page 8; 65pp; English.
 PS
 XX The invention relates to human immunodeficiency virus immunogens and
 CC their corresponding DNA molecules. An immunogen comprises a portion of
 CC gag protein of HIV from an HIV clade, parts of p17 and p24, modified to
 CC prevent N-terminal myristoylation; and a synthetic polypeptide comprising
 CC human cytotoxic T-lymphocyte (CTL) epitopes of HIV protein. This
 CC immunogen is designed to elicit an HIV-specific immune response in
 CC humans. The immunogen is useful in the preparation of a medicament such
 CC as vaccine to prevent or treat HIV infection in a human subject. The
 CC invention also relates to method of stimulating anti-HIV immune response
 CC in a human subject which comprises administering one or more times an
 CC amount of nucleic acid molecule sufficient to prime an immune response to
 CC the immunogen, or else may be packaged within a delivery means, such as a
 CC modified vaccinia virus Ankara (MVA) to boost the immune response to
 CC common portion of the immunogens. The present sequence is human
 CC immunodeficiency virus env protein derived restricted CTL epitope related
 CC to the invention. This restricted CTL epitope is presented by a murine
 CC MHC class I used for the mouse potency assay
 XX Sequence 10 AA;
 SQ

Query Match 67.5%; Score 52; DB 4; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.38;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 4 RGPGRFVTI 13
 |||||
 DB 1 RGPGRFVTI 10

RESULT 249
 AAE20153
 ID AAE20153 standard; peptide; 10 AA.
 XX AC AAE20153;
 XX 29-AUG-2003 (revised)
 DT 18-JUN-2002 (first entry)
 XX Human immunodeficiency virus type 1 (HIV-1) R101 peptide.
 DE
 XX

KW Human immunodeficiency virus type 1; HIV-1; adjuvant; immunomodulator;
 KW alpha-2-macroglobulin; 3-O-deacylated monophosphoryl lipid; MPL; GM-CSF;
 KW granulocyte macrophage colony stimulating factor; immune response;
 KW vaccine; R101 peptide.
 XX
 OS Human immunodeficiency virus 1.
 PN WO200215930-A1.
 XX
 XX 28-FEB-2002.
 XX
 XX 27-AUG-2001; 2001WO-US026589.
 XX
 XX 25-AUG-2000; 2000US-0227624P.
 XX
 XX (UYDU-) UNIV DUKE.
 XX
 XX Haynes BF, Liao H, Patel DD;
 XX
 XX WPI; 2002-269315/31.
 XX
 XX Use of 2-macroglobulin (2Masterisk), 3-O-deacylated monophosphoryl lipid
 PT A (MPL) and granulocyte macrophage colony stimulating factor (GM-CSF) for
 PT eliciting an immune response.
 XX
 XX Example 2; Page 21; 53pp; English.
 XX
 XX The invention relates to a composition comprising activated alpha-2-
 CC macroglobulin (alpha 2M asterisk), 3-O-deacylated monophosphoryl lipid A
 CC (MPL) and granulocyte macrophage colony stimulating factor (GM-CSF). The
 CC invention also relates to an adjuvant suitable for use in multivalent HIV
 CC immunogenic compositions. The compositions is useful for eliciting an
 CC immune response. The present sequence is human immunodeficiency virus
 CC type 1 (HIV-1) R101 peptide used in the exemplification of the invention.
 CC (Updated on 29-AUG-2003 to standardise OS field)
 XX
 XX Sequence 10 AA;
 SQ
 Query Match 67.5%; Score 52; DB 5; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.38;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 4 RGPGRFVVTI 13
 Db 1 RGPGRFVVTI 10
 RESULT 250
 ID ABG31255
 XX ABG31255 standard; peptide; 10 AA.
 AC ABG31255;
 XX
 XX 29-AUG-2003 (revised)
 DT 21-OCT-2002 (first entry)
 XX
 XX GP120 classI restricted peptide.
 DE
 XX HSV; herpes; anti-HIV; cytostatic; immunomodulator; antibacterial;
 KW antiparasitic; cancer; lymphocytic leukaemia; lymphoma; glioblastoma;
 KW lung cancer; infectious disease; HIV; human immunodeficiency virus;
 KW human papilloma; influenza; bacteria; parasite; vaccine; tumour cells;
 KW gp120.
 XX
 OS Human immunodeficiency virus 1.
 XX
 XX WO200256828-A2.
 PN
 XX 25-JUL-2002.
 PD
 XX 29-NOV-2001; 2001WO-US047808.
 PF
 XX 29-NOV-2000; 2000US-0253858P.
 PR

PR 30-NOV-2000; 2000US-0250079P.
 XX
 XX (UYRP) UNIV ROCHESTER.
 XX
 PI Federoff HJ, Bowers WJ, Frelinger JG, Willis RA, Evans TG;
 PI Dewhurst S, Hocknell PK;
 XX
 XX WPI; 2002-590693/63.
 XX
 XX Generating a herpesvirus amplicon particle for treating patients with
 PT cancer or infectious disease, comprises transfecting a cell with an
 PT amplicon vector, amplicon plasmid or nucleic acid sequence encoding an
 PT accessory protein.
 XX
 XX Example 8; Page 21; 68pp; English.
 XX
 XX This invention relates to a method for generating a herpesvirus amplicon
 CC particle comprising transfecting a cell with a Herpes simplex virus (HSV)
 CC amplicon vector, an amplicon plasmid or a nucleic acid sequence that
 CC encodes an accessory protein. The method of the invention may have anti-
 CC HIV; cytostatic; immunomodulator; antibacterial; and antiparasitic
 CC activity. The method of the invention is useful in generating herpesvirus
 CC amplicon particles for treating patients with cancer (e.g. chronic
 CC lymphocytic leukaemia, lymphoma, glioblastoma or lung cancer) or an
 CC infectious disease such as HIV or those caused by human papilloma virus,
 CC influenza virus, bacteria or parasite. The HSV amplicon particles or the
 CC herpes simplex virus exhibit a broad cellular tropism, they have the
 CC capacity to package large amounts of genetic material (which makes them
 CC useful in expressing multiple genes or gene sequences), they have a high
 CC transduction efficiency, and they are maintained episomally, which makes
 CC them less prone to insertional mutagenesis. In addition to infecting many
 CC different types of cells, HSV vectors can also transduce non-replicating
 CC or slowly-replicating cells. The method can also be carried out fairly
 CC quickly. As a result, cells (such as tumour cells) can be removed from a
 CC patient, treated, and readministered to the patient in the course of a
 CC single operative procedure. The present sequence represents a herpes
 CC simplex virus (HSV) gp120 peptide used to induce an immune response in
 CC the method of the invention. (Updated on 29-AUG-2003 to standardise OS
 CC field)
 XX
 XX Sequence 10 AA;
 SQ
 Query Match 67.5%; Score 52; DB 5; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.38;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 4 RGPGRFVVTI 13
 Db 1 RGPGRFVVTI 10
 Search completed: May 16, 2005, 14:40:35
 Job time : 171 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 16, 2005, 07:58:01 ; Search time 131 Seconds
(without alignments)
20.400 Million cell updates/sec

Title: SEQ1

Perfect score: 39

Sequence: 1 rafvtgk 8

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1432185 seqs, 334051727 residues

Total number of hits satisfying chosen parameters: 325800

Minimum DB seq length: 0

Maximum DB seq length: 25

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications_AA*

1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep.*
7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09A_PUBCOMB.pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep.*
11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep.*
12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep.*
16: /cgn2_6/ptodata/1/pubpaa/US10D_PUBCOMB.pep.*
17: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
18: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
19: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*
20: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	39	100.0	9	14	US-10-079-167-52
2	39	100.0	9	14	US-10-360-836-49
3	39	100.0	9	15	US-10-367-580-115
4	39	100.0	9	15	US-10-367-593-115
5	39	100.0	9	15	US-10-367-594-115
6	39	100.0	9	15	US-10-367-654-115
7	39	100.0	9	15	US-10-367-658-115
8	39	100.0	9	15	US-10-367-668-115
9	39	100.0	9	16	US-10-367-674-115
10	39	100.0	9	16	US-10-653-624-52
11	39	100.0	9	16	US-10-833-439-52
12	39	100.0	9	16	US-10-833-745-52
13	39	100.0	9	16	US-10-833-744-52

14	39	100.0	13	14	US-10-239-313A-536	Sequence 536, App
15	39	100.0	15	9	US-09-810-310-15	Sequence 15, Appl
16	39	100.0	15	9	US-09-810-310-24	Sequence 24, Appl
17	39	100.0	15	9	US-09-989-621-8	Sequence 8, Appl
18	39	100.0	15	10	US-09-827-688-9	Sequence 9, Appl
19	39	100.0	15	10	US-09-077-439A-3	Sequence 3, Appl
20	39	100.0	15	14	US-10-133-210-246	Sequence 246, App
21	39	100.0	15	14	US-10-133-210-262	Sequence 262, App
22	39	100.0	15	14	US-10-147-910-6	Sequence 6, Appl
23	39	100.0	15	14	US-10-239-313A-186	Sequence 186, App
24	39	100.0	15	17	US-10-787-880-2	Sequence 2, Appl
25	39	100.0	16	14	US-10-062-710-44	Sequence 44, Appl
26	39	100.0	18	14	US-10-062-710-45	Sequence 45, Appl
27	39	100.0	20	9	US-09-813-659-3	Sequence 3, Appl
28	39	100.0	20	15	US-10-283-610A-3	Sequence 3, Appl
29	39	100.0	21	14	US-10-178-488-25	Sequence 25, Appl
30	39	100.0	24	17	US-10-621-675-160	Sequence 160, App
31	37	94.9	9	16	US-10-777-053-131	Sequence 131, App
32	35	89.7	20	14	US-10-311-111-1	Sequence 1, Appl
33	35	89.7	20	16	US-10-398-932-1	Sequence 1, Appl
34	34	87.2	12	14	US-10-239-313A-535	Sequence 535, App
35	30	76.9	7	14	US-10-311-111-4	Sequence 4, Appl
36	30	76.9	7	16	US-10-398-932-4	Sequence 4, Appl
37	28	71.8	9	9	US-09-825-886-30	Sequence 30, Appl
38	28	71.8	9	10	US-09-997-848A-17	Sequence 17, Appl
39	28	71.8	9	10	US-09-997-848A-18	Sequence 18, Appl
40	28	71.8	9	16	US-10-777-053-139	Sequence 139, App
41	28	71.8	9	17	US-10-494-161-17	Sequence 17, Appl
42	28	71.8	10	9	US-09-858-349-3	Sequence 3, Appl
43	28	71.8	10	9	US-09-810-310-16	Sequence 16, Appl
44	28	71.8	10	9	US-09-820-484-8	Sequence 8, Appl
45	28	71.8	10	9	US-09-087-513-7	Sequence 7, Appl

ALIGNMENTS

RESULT 1

US-10-079-167-52
; Sequence 52, Application US/10079167
; Publication No. US20030138454A1
; GENERAL INFORMATION:
; APPLICANT: Hill, Adrian V.S.
; APPLICANT: McShane, Helen
; APPLICANT: Gilbert, Sarah C.
; APPLICANT: Reece, William
; APPLICANT: Schneider, Joerg
; TITLE OF INVENTION: Vaccination Method
; FILE REFERENCE: 2907.1000-001
; CURRENT APPLICATION NUMBER: US/10/079,167
; CURRENT FILING DATE: 2002-02-19
; PRIOR APPLICATION NUMBER: US 09/454,204
; PRIOR FILING DATE: 1999-12-09
; PRIOR APPLICATION NUMBER: PCT/GB98/01681
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: GB 97 11957.2
; PRIOR FILING DATE: 1997-06-09
; PRIOR APPLICATION NUMBER: PCT/GB01/04116
; PRIOR FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: GB 00 23203.3
; PRIOR FILING DATE: 2001-09-21
; NUMBER OF SEQ ID NOS: 99
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 52
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: CTL Epitope of HIV-1 gp120
US-10-079-167-52

Query Match 100.0%; Score 39; DB 14; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;

```
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
   |||||
Db 2 RAFVTIGK 9

RESULT 2
US-10-360-836-49
; Sequence 49, Application US/10360836
; Publication No. US20030185854A1
; GENERAL INFORMATION:
; APPLICANT: Zavala, Fidel
; TITLE OF INVENTION: USE OF RECOMBINANT HEPATITIS B CORE
; TITLE OF INVENTION: PARTICLES TO DEVELOP VACCINES AGAINST INFECTIOUS PATHOGENS
; TITLE OF INVENTION: AND MALIGANCIES
; FILE REFERENCE: 5986/1J876
; CURRENT APPLICATION NUMBER: US/10/360,836
; CURRENT FILING DATE: 2003-02-07
; PRIOR APPLICATION NUMBER: 60/354,963
; PRIOR FILING DATE: 2002-02-08
; NUMBER OF SEQ ID NOS: 86
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 49
; LENGTH: 9
; TYPE: PRT
; ORGANISM: human immunodeficiency virus (HIV-1)
US-10-360-836-49

Query Match 100.0%; Score 39; DB 14; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
   |||||
Db 2 RAFVTIGK 9

RESULT 3
US-10-367-580-115
; Sequence 115, Application US/10367580
; Publication No. US20040071720A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461061
; CURRENT APPLICATION NUMBER: US/10/367,580
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,832
; PRIOR FILING DATE: 2001-02-27
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 115
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-580-115

Query Match 100.0%; Score 39; DB 14; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
   |||||
Db 2 RAFVTIGK 9

RESULT 4
US-10-367-593-115
; Sequence 115, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 115
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-115

Query Match 100.0%; Score 39; DB 15; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
   |||||
Db 2 RAFVTIGK 9

RESULT 5
US-10-367-594-115
; Sequence 115, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
```

```
Query Match 100.0%; Score 39; DB 15; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
   |||||
Db 2 RAFVTIGK 9

RESULT 4
US-10-367-593-115
; Sequence 115, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 115
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-115

Query Match 100.0%; Score 39; DB 15; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
   |||||
Db 2 RAFVTIGK 9

RESULT 5
US-10-367-594-115
; Sequence 115, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
```

; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 115
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-654-115

Query Match 100.0%; Score 39; DB 15; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTICK 8
| | | | |
Db 2 RAFVTICK 9

RESULT 6
US-10-367-654-115
; Sequence 115, Application US/10367654
; Publication No. US20040071723A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/171,734
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/636,295
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 115
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide

Query Match 100.0%; Score 39; DB 15; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTICK 8
| | | | |
Db 2 RAFVTICK 9

RESULT 7
US-10-367-658-115
; Sequence 115, Application US/10367658
; Publication No. US20040071724A1

; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 115
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-115

Query Match 100.0%; Score 39; DB 15; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTICK 8
| | | | |
Db 2 RAFVTICK 9

RESULT 8
US-10-367-668-115
; Sequence 115, Application US/10367668
; Publication No. US20040071725A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461072
; CURRENT APPLICATION NUMBER: US/10/367,668
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,517
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 115
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide

US-10-367-668-115

Query Match 100.0%; Score 39; DB 15; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.3e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTIGK 8
 |||||
 Db 2 RAFVTIGK 9

RESULT 9

US-10-367-674-115
 ; Sequence 115, Application US/10367674
 ; Publication No. US20040127684A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Rothman, James E.
 ; APPLICANT: Hartl, F. Ulrich
 ; APPLICANT: Hoe, Mee H.
 ; APPLICANT: Houghton, Alan
 ; APPLICANT: Takechi, Yoshizumi
 ; APPLICANT: Mayhew, Mark
 ; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
 ; FILE REFERENCE: 11746/4610211
 ; CURRENT APPLICATION NUMBER: US/10/367,674
 ; CURRENT FILING DATE: 2003-02-14
 ; PRIOR FILING DATE: 2002-06-13
 ; PRIOR APPLICATION NUMBER: US 10/170,738
 ; PRIOR FILING DATE: 2002-06-13
 ; PRIOR APPLICATION NUMBER: US 09/552,868
 ; PRIOR FILING DATE: 2000-04-20
 ; PRIOR APPLICATION NUMBER: US 09/011,645
 ; PRIOR FILING DATE: 1998-02-13
 ; PRIOR APPLICATION NUMBER: PCT/US96/13363
 ; PRIOR FILING DATE: 1996-08-16
 ; PRIOR APPLICATION NUMBER: US 60/002,490
 ; PRIOR FILING DATE: 1995-08-18
 ; PRIOR APPLICATION NUMBER: US 60/002,479
 ; PRIOR FILING DATE: 1995-08-18
 ; NUMBER OF SEQ ID NOS: 349
 ; SOFTWARE: WordPerfect 8.0 for Windows
 ; SEQ ID NO 115
 ; LENGTH: 9
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: synthetic peptide

Query Match 100.0%; Score 39; DB 16; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.3e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTIGK 8
 |||||
 Db 2 RAFVTIGK 9

RESULT 10

US-10-653-624-52
 ; Sequence 52, Application US/10653624
 ; Publication No. US20040131594A1
 ; GENERAL INFORMATION:
 ; APPLICANT: McMichael, Andrew
 ; APPLICANT: Hill, Adrian V.S.
 ; APPLICANT: Gilbert, Sarah C.
 ; APPLICANT: Schneider, Jorg
 ; APPLICANT: Plebanski, Magdalena
 ; APPLICANT: Hanke, Tomas
 ; APPLICANT: Smith, Geoffrey L.
 ; TITLE OF INVENTION: Methods and Reagents for Vaccination
 ; FILE REFERENCE: 2907.1000-000

; CURRENT APPLICATION NUMBER: US/10/653,624
 ; CURRENT FILING DATE: 2003-09-02
 ; PRIOR FILING DATE: US/09/454,204A
 ; PRIOR FILING DATE: 1999-12-09
 ; PRIOR APPLICATION NUMBER: PCT/GB98/01681
 ; PRIOR FILING DATE: 1998-06-09
 ; PRIOR APPLICATION NUMBER: GB 97 11957.2
 ; PRIOR FILING DATE: 1997-06-09
 ; NUMBER OF SEQ ID NOS: 78
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 52
 ; LENGTH: 9
 ; TYPE: PRT
 ; ORGANISM: Unknown
 ; FEATURE:
 ; OTHER INFORMATION: CTL Epitope of HIV-1 gp120
 ; US-10-653-624-52

Query Match 100.0%; Score 39; DB 16; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.3e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTIGK 8
 |||||
 Db 2 RAFVTIGK 9

RESULT 11

US-10-833-439-52
 ; Sequence 52, Application US/10833439
 ; Publication No. US20040175365A1
 ; GENERAL INFORMATION:
 ; APPLICANT: McMichael, Andrew
 ; APPLICANT: Hill, Adrian V.S.
 ; APPLICANT: Gilbert, Sarah C.
 ; APPLICANT: Schneider, Jorg
 ; APPLICANT: Plebanski, Magdalena
 ; APPLICANT: Hanke, Tomas
 ; APPLICANT: Smith, Geoffrey L.
 ; APPLICANT: Blanchard, Tom
 ; TITLE OF INVENTION: Methods and Reagents for Vaccination
 ; FILE REFERENCE: 2907.1000-000
 ; CURRENT APPLICATION NUMBER: US/10/833,439
 ; CURRENT FILING DATE: 2004-04-28
 ; PRIOR FILING DATE: US/10/686,943
 ; PRIOR FILING DATE: 2003-10-16
 ; PRIOR APPLICATION NUMBER: US/09/454,204
 ; PRIOR FILING DATE: 1999-12-09
 ; PRIOR APPLICATION NUMBER: PCT/GB98/01681
 ; PRIOR FILING DATE: 1998-06-09
 ; PRIOR APPLICATION NUMBER: GB 97 11957.2
 ; PRIOR FILING DATE: 1997-06-09
 ; NUMBER OF SEQ ID NOS: 78
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 52
 ; LENGTH: 9
 ; TYPE: PRT
 ; ORGANISM: Unknown
 ; FEATURE:
 ; OTHER INFORMATION: CTL Epitope of HIV-1 gp120
 ; US-10-833-439-52

Query Match 100.0%; Score 39; DB 16; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.3e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTIGK 8
 |||||
 Db 2 RAFVTIGK 9

RESULT 12

```
US-10-833-745-52
; Sequence 52, Application US/10833745
; Publication No. US20040191272A1
; GENERAL INFORMATION:
; APPLICANT: McMichael, Andrew
; APPLICANT: Hill, Adrian V.S.
; APPLICANT: Gilbert, Sarah C.
; APPLICANT: Schneider, Jorg
; APPLICANT: Plebanski, Magdalena
; APPLICANT: Hanke, Tomas
; APPLICANT: Smith, Geoffrey L.
; APPLICANT: Blanchard, Tom
; TITLE OF INVENTION: Methods and Reagents for Vaccination
; FILE OF INVENTION: Which Generate A CD8 T Cell Immune Response
; FILE REFERENCE: 2907.1000-000
; CURRENT APPLICATION NUMBER: US/10/833,745
; CURRENT FILING DATE: 2004-04-28
; PRIOR APPLICATION NUMBER: US/10/686,943
; PRIOR FILING DATE: 2003-10-16
; PRIOR APPLICATION NUMBER: US/09/454,204
; PRIOR FILING DATE: 1999-12-09
; PRIOR APPLICATION NUMBER: PCT/GB98/01681
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: GB 97 11957.2
; PRIOR FILING DATE: 1997-06-09
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 52
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: CTL Epitope of HIV-1 gp120
US-10-833-745-52
Query Match 100.0%; Score 39; DB 16; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTICK 8
Db 2 RAFVTICK 9

RESULT 14
US-10-239-313A-536
; Sequence 536, Application US/10239313A
; Publication No. US20030175285A1
; GENERAL INFORMATION:
; APPLICANT: KLINGUER - HAMOUR, Christine
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: BECK, Alain
; APPLICANT: GOETSCH, Liliane
; TITLE OF INVENTION: MOLECULE OF PHARMACEUTICAL INTEREST COMPRISING AT ITS
; TITLE OF INVENTION: N-TERMINAL A GLUTAMIC ACID OR A GLUTAMINE IN THE FORM
; TITLE OF INVENTION: OF A PHYSIOLOGICALLY ACCEPTABLE STRONG ACID
; FILE REFERENCE: 343 727 - US
; CURRENT APPLICATION NUMBER: US/10/239,313A
; CURRENT FILING DATE: 2002-09-19
; PRIOR APPLICATION NUMBER: FR 00/03711
; PRIOR FILING DATE: 2000-03-23
; PRIOR APPLICATION NUMBER: PCT 01/70772
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 697
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 536
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Human immunodeficiency virus
US-10-239-313A-536
Query Match 100.0%; Score 39; DB 14; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.092;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTICK 8
Db 6 RAFVTICK 13

RESULT 15
US-09-810-310-15
; Sequence 15, Application US/09810310
; Patent No. US20020044948A1
; GENERAL INFORMATION:
; APPLICANT: Khleif, Samir N.
; APPLICANT: Berzofsky, Jay A.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR CO-STIMULATION OF
; TITLE OF INVENTION: IMMUNOLOGICAL RESPONSES TO PEPTIDE ANTIGENS
; FILE REFERENCE: 15280-415100US
; CURRENT APPLICATION NUMBER: US/09/810,310
; CURRENT FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: 60/189,396
; PRIOR FILING DATE: 2000-03-15
; NUMBER OF SEQ ID NOS: 61
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
```

OTHER INFORMATION: Description of Artificial Sequence: HIV PEPTIDE
OTHER INFORMATION: ANTIGEN
US-09-810-310-15

Query Match 100.0%; Score 39; DB 9; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTIGK 8
Db 8 RAFVTIGK 15

RESULT 16

US-09-810-310-24
Sequence 24, Application US/09810310
Publication No. US20020044948A1
GENERAL INFORMATION:
APPLICANT: Khleif, Samir N.
APPLICANT: Bezofsky, Jay A.
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR CO-STIMULATION OF
TITLE OF INVENTION: IMMUNOLOGICAL RESPONSES TO PEPTIDE ANTIGENS
FILE REFERENCE: 15280-415100US
CURRENT APPLICATION NUMBER: US/09/810,310
CURRENT FILING DATE: 2001-03-14
PRIOR APPLICATION NUMBER: 60/189,396
PRIOR FILING DATE: 2000-03-15
NUMBER OF SEQ ID NOS: 61
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 24
LENGTH: 15
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: HIV PEPTIDE
OTHER INFORMATION: ANTIGEN
US-09-810-310-24

Query Match 100.0%; Score 39; DB 9; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTIGK 8
Db 8 RAFVTIGK 15

RESULT 17

US-09-989-621-8
Sequence 8, Application US/09989621
Patent No. US20020151683A1
GENERAL INFORMATION:
APPLICANT: Mogam Biotechnology Research Institute
APPLICANT: Kim, Tae-Youn
APPLICANT: Lee, Ki-Young
APPLICANT: Chang, Jin-Soo
APPLICANT: Cho, Sung-Yoo
APPLICANT: Hwang, Yu-Kyeong
APPLICANT: Choi, Myeong
APPLICANT: Cheong, Hong-Seok
TITLE OF INVENTION: Liposomes Comprising Peptide Antigens
TITLE OF INVENTION: Derived from X Protein of Hepatitis B virus
FILE REFERENCE: 0136/0E154
CURRENT APPLICATION NUMBER: US/09/989,621
CURRENT FILING DATE: 2001-11-20
PRIOR APPLICATION NUMBER: 09/051,006
PRIOR FILING DATE: 2000-11-17
NUMBER OF SEQ ID NOS: 10
SOFTWARE: FastSEQ for Windows Version 3.0
SEQ ID NO 8
LENGTH: 15
TYPE: PRT
ORGANISM: HIV

US-09-989-621-8

Query Match 100.0%; Score 39; DB 9; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTIGK 8
Db 8 RAFVTIGK 15

RESULT 18

US-09-827-688-9
Sequence 9, Application US/09827688
Publication No. US20030165476A1
GENERAL INFORMATION:
APPLICANT: ORSON, FRANK
APPLICANT: KINSEY, BERNA
APPLICANT: BHOGAL, BALBIR
TITLE OF INVENTION: MACROAGGREGATED PROTEIN CONJUGATES AS ORAL GENETIC IMMUNIZATION DE
TITLE OF INVENTION: AGENTS
FILE REFERENCE: P01949US1/10004014
CURRENT APPLICATION NUMBER: US/09/827,688
CURRENT FILING DATE: 2001-04-06
PRIOR APPLICATION NUMBER: 60/195,680
PRIOR FILING DATE: 2000-04-07
NUMBER OF SEQ ID NOS: 13
SOFTWARE: PatentIn version 3.0
SEQ ID NO 9
LENGTH: 15
TYPE: PRT
ORGANISM: HIV p18
US-09-827-688-9

Query Match 100.0%; Score 39; DB 10; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTIGK 8
Db 8 RAFVTIGK 15

RESULT 19

US-09-077-439A-3
Sequence 3, Application US/09077439A
Publication No. US20030202989A1
GENERAL INFORMATION:
APPLICANT: Collier, R. John
APPLICANT: Blanke, Steven R.
APPLICANT: Milne, Jill C.
APPLICANT: Benson, Ericka L.
APPLICANT: Ballard, Jimmy D.
APPLICANT: Starnbach, Michael N.
TITLE OF INVENTION: Use of Toxin Peptides and/or Affinity
TITLE OF INVENTION: Handles for Delivering Compounds into Cells
FILE REFERENCE: 00246/187002
CURRENT APPLICATION NUMBER: US/09/077,439A
CURRENT FILING DATE: 1999-04-08
PRIOR APPLICATION NUMBER: PCT/US96/20463
PRIOR FILING DATE: 1996-12-13
PRIOR APPLICATION NUMBER: US 60/019,275
PRIOR FILING DATE: 1996-06-07
PRIOR APPLICATION NUMBER: US 60/008,518
PRIOR FILING DATE: 1995-12-13
NUMBER OF SEQ ID NOS: 26
SOFTWARE: FastSEQ for Windows Version 4.0
SEQ ID NO 3
LENGTH: 15
TYPE: PRT
ORGANISM: Homo sapien
US-09-077-439A-3

Query Match 100.0%; Score 39; DB 10; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
| | | | |
DB 8 RAFVTIGK 15

RESULT 20
US-10-133-210-246
; Sequence 246, Application US/10133210
; Publication No. US20030103964A1
; GENERAL INFORMATION:
; APPLICANT: Delisi, Charles
; APPLICANT: Berzofsky, Jay
; APPLICANT: Gulukota, Kamalakar
; APPLICANT: Vaccaro, Dennis
; APPLICANT: Weng, Zhiping
; APPLICANT: Zhang, Chao
; TITLE OF INVENTION: METHODS FOR DESIGNING MOLECULAR CONJUGATES AND
; OTHER INFORMATION: COMPOSITIONS THEREOF
; FILE REFERENCE: BU-035AX
; CURRENT APPLICATION NUMBER: US/10/133,210
; CURRENT FILING DATE: 2002-04-26
; NUMBER OF SEQ ID NOS: 281
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 246
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-133-210-246

Query Match 100.0%; Score 39; DB 14; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
| | | | |
DB 8 RAFVTIGK 15

RESULT 21
US-10-133-210-262
; Sequence 262, Application US/10133210
; Publication No. US20030103964A1
; GENERAL INFORMATION:
; APPLICANT: Delisi, Charles
; APPLICANT: Berzofsky, Jay
; APPLICANT: Gulukota, Kamalakar
; APPLICANT: Vaccaro, Dennis
; APPLICANT: Weng, Zhiping
; APPLICANT: Zhang, Chao
; TITLE OF INVENTION: METHODS FOR DESIGNING MOLECULAR CONJUGATES AND
; OTHER INFORMATION: COMPOSITIONS THEREOF
; FILE REFERENCE: BU-035AX
; CURRENT APPLICATION NUMBER: US/10/133,210
; CURRENT FILING DATE: 2002-04-26
; NUMBER OF SEQ ID NOS: 281
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 262
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-133-210-262

Query Match 100.0%; Score 39; DB 14; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
| | | | |
DB 8 RAFVTIGK 15

RESULT 22
US-10-147-910-6
; Sequence 6, Application US/10147910
; Publication No. US20030124718A1
; GENERAL INFORMATION:
; APPLICANT: Fuller, Deborah
; APPLICANT: Fuller, James
; APPLICANT: Haynes, Joel
; APPLICANT: Shipley, Timothy
; TITLE OF INVENTION: Vaccine Composition
; FILE REFERENCE: 033267-006
; CURRENT APPLICATION NUMBER: US/10/147,910
; CURRENT FILING DATE: 2002-05-20
; PRIOR APPLICATION NUMBER: US 60/291,654
; PRIOR FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: US 60/291,655
; PRIOR FILING DATE: 2001-05-18
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 15
; TYPE: PRT
; ORGANISM: HIV
US-10-147-910-6

Query Match 100.0%; Score 39; DB 14; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
| | | | |
DB 8 RAFVTIGK 15

RESULT 23
US-10-239-313A-186
; Sequence 186, Application US/10239313A
; Publication No. US20030175285A1
; GENERAL INFORMATION:
; APPLICANT: KLINGUER - HAMOUR, Christine
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: BECK, Alain
; APPLICANT: GOETSCH, Lilliane
; TITLE OF INVENTION: MOLECULE OF PHARMACEUTICAL INTEREST COMPRISING AT ITS
; TITLE OF INVENTION: N-TERMINAL A GLUTAMIC ACID OR A GLUTAMINE IN THE FORM
; TITLE OF INVENTION: OF A PHYSIOLOGICALLY ACCEPTABLE STRONG ACID
; FILE REFERENCE: 343 727 - US
; CURRENT APPLICATION NUMBER: US/10/239,313A
; CURRENT FILING DATE: 2002-09-19
; PRIOR APPLICATION NUMBER: FR 00/03711
; PRIOR FILING DATE: 2000-03-23
; PRIOR APPLICATION NUMBER: PCT 01/70772
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 697
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 186
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Human immunodeficiency virus
US-10-239-313A-186

Query Match 100.0%; Score 39; DB 14; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
| | | | |

```

Db          7 RAFVTIGK 14

RESULT 24
US-10-787-880-2
; Sequence 2, Application US/10787880
; Publication No. US2005002577A1
; GENERAL INFORMATION:
; APPLICANT: Pohlmann, Edward L.
; APPLICANT: Sheehy, Michael J.
; APPLICANT: Barton, Kenneth A.
; TITLE OF INVENTION: PARTICLE-MEDIATED DELIVERY OF ANTIGENS
; FILE REFERENCE: 033267-018
; CURRENT APPLICATION NUMBER: US/10/787,880
; CURRENT FILING DATE: 2004-02-27
; PRIOR APPLICATION NUMBER: US/09/191,772
; PRIOR FILING DATE: 1998-11-13
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 15
; TYPE: PRT
; ORGANISM: HIVgp120
US-10-787-880-2

Query Match          100.0%; Score 39; DB 17; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.11; Indels 0; Gaps 0;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY          1 RAFVTIGK 8
            |||||
Db          8 RAFVTIGK 15

RESULT 25
US-10-062-710-44
; Sequence 44, Application US/10062710
; Publication No. US20030049253A1
; GENERAL INFORMATION:
; APPLICANT: Li, Frank Q.
; APPLICANT: Chu, Yong-Liang
; APPLICANT: Qiu, Jian-Tai
; TITLE OF INVENTION: Polymeric Conjugates for Delivery of
; TITLE OF INVENTION: MHC-Recognized Epitopes
; TITLE OF INVENTION: Via Peptide Vaccines
; FILE REFERENCE: 3781-001-27
; CURRENT APPLICATION NUMBER: US/10/062,710
; CURRENT FILING DATE: 2002-02-05
; PRIOR APPLICATION NUMBER: US 60/310,498
; PRIOR FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 232
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 44
; LENGTH: 16
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: HIV Helper-T Cell Epitopes
US-10-062-710-44

Query Match          100.0%; Score 39; DB 14; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.11; Indels 0; Gaps 0;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY          1 RAFVTIGK 8
            |||||
Db          9 RAFVTIGK 16

RESULT 26
US-10-062-710-45
; Sequence 45, Application US/10062710
; Publication No. US20030049253A1
; GENERAL INFORMATION:
; APPLICANT: Li, Frank Q.
; APPLICANT: Chu, Yong-Liang
; APPLICANT: Qiu, Jian-Tai
; TITLE OF INVENTION: Polymeric Conjugates for Delivery of
; TITLE OF INVENTION: MHC-Recognized Epitopes
; TITLE OF INVENTION: Via Peptide Vaccines
; FILE REFERENCE: 3781-001-27
; CURRENT APPLICATION NUMBER: US/10/062,710
; CURRENT FILING DATE: 2002-02-05
; PRIOR APPLICATION NUMBER: US 60/310,498
; PRIOR FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 232
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 45
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: HIV Helper-T Cell Epitopes
US-10-062-710-45

Query Match          100.0%; Score 39; DB 14; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.13; Indels 0; Gaps 0;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY          1 RAFVTIGK 8
            |||||
Db          8 RAFVTIGK 15

RESULT 27
US-09-813-659-3
; Sequence 3, Application US/09813659
; Patent No. US20020012989A1
; GENERAL INFORMATION:
; APPLICANT: Ledbetter, Jeffrey A.
; APPLICANT: Hayden, Martha S.
; APPLICANT: Linsley, Peter S.
; APPLICANT: Bajorath, Jurgen
; APPLICANT: Fell, H. Perry
; APPLICANT: Gilliland, Lisa K.
; TITLE OF INVENTION: EXPRESSION VECTORS ENCODING BISPECIFIC FUSION PROTEINS
; TITLE OF INVENTION: AND METHODS OF PRODUCING BIOLOGICALLY ACTIVE BISPECIFIC
; TITLE OF INVENTION: FUSION PROTEINS IN A MAMMALIAN CELL
; FILE REFERENCE: 30436.18USD2
; CURRENT APPLICATION NUMBER: US/09/813,659
; CURRENT FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 09/549,067
; PRIOR FILING DATE: 2000-04-13
; PRIOR APPLICATION NUMBER: 08/539,436
; PRIOR FILING DATE: 1995-10-05
; PRIOR APPLICATION NUMBER: 08/121,054
; PRIOR FILING DATE: 1993-09-13
; PRIOR APPLICATION NUMBER: 08/013,420
; PRIOR FILING DATE: 1993-02-01
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-813-659-3

Query Match          100.0%; Score 39; DB 9; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.14; Indels 0; Gaps 0;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY          1 RAFVTIGK 8
            |||||
Db          12 RAFVTIGK 19

```

RESULT 28
US-10-283-610A-3
; Sequence 3, Application US/10283610A
; Publication No. US20030219876A1
; GENERAL INFORMATION:
; APPLICANT: Ledbetter, Jeffrey A.
; APPLICANT: Hayden, Martha S.
; APPLICANT: Linsley, Peter S.
; APPLICANT: Bajorath, Jurgun
; APPLICANT: Fell, H. Perry
; APPLICANT: Gilliland, Lisa K.
; TITLE OF INVENTION: EXPRESSION VECTORS ENCODING BISPECIFIC FUSION PROTEINS
; TITLE OF INVENTION: AND METHODS OF PRODUCING BIOLOGICALLY ACTIVE BISPECIFIC
; TITLE OF INVENTION: FUSION PROTEINS IN A MAMMALIAN CELL
; FILE REFERENCE: ON107E/30436.18USD3
; CURRENT APPLICATION NUMBER: US/10/283.610A
; CURRENT FILING DATE: 2002-10-29
; PRIOR APPLICATION NUMBER: 09/549,067
; PRIOR FILING DATE: 2000-04-13
; PRIOR APPLICATION NUMBER: 09/539,436
; PRIOR FILING DATE: 1995-10-05
; PRIOR APPLICATION NUMBER: 08/121,054
; PRIOR FILING DATE: 1993-09-13
; PRIOR APPLICATION NUMBER: 08/013,420
; PRIOR FILING DATE: 1993-02-01
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-283-610A-3

Query Match 100.0%; Score 39; DB 15; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.14; Indels 0; Gaps 0;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
Db 12 RAFVTIGK 19
|||||

RESULT 29
US-10-178-488-25
; Sequence 25, Application US/10178488
; Publication No. US20030165535A1
; GENERAL INFORMATION:
; APPLICANT: Rovinski, Benjamin
; APPLICANT: Cao, Shi-Xian
; APPLICANT: Yao, Fei-Long
; APPLICANT: Persson, Roy
; APPLICANT: Klein, Michel H.
; TITLE OF INVENTION: RETROVIRUS-LIKE PARTICLES MADE NON-INFECTIOUS BY A
; TITLE OF INVENTION: PLURILITY OF MUTATIONS
; FILE REFERENCE: 1038-1238 MIS
; CURRENT APPLICATION NUMBER: US/10/178,488
; CURRENT FILING DATE: 2002-10-25
; PRIOR APPLICATION NUMBER: 09/258,128
; PRIOR FILING DATE: 1999-02-26
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 25
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Artificial
US-10-178-488-25

Query Match 100.0%; Score 39; DB 14; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.15; Indels 0; Gaps 0;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
Db 14 RAFVTIGK 21
|||||

RESULT 30
US-10-621-675-160
; Sequence 160, Application US/10621675
; Publication No. US20050049398A1
; GENERAL INFORMATION:
; APPLICANT: De Leys, Robert
; TITLE OF INVENTION: PROCESS FOR THE DETERMINATION OF PEPTIDES CORRESPONDING
; TITLE OF INVENTION: TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND THEIR USE IN
; TITLE OF INVENTION: A PROCESS FOR DETERMINATION OF ANTIBODIES OF
; TITLE OF INVENTION: BIOTINYLATED PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT
; TITLE OF INVENTION: EPITOPES, A PROCESS FOR PREPARING THEM AND COMPOSITIONS
; TITLE OF INVENTION: CONTAINING THEM
; FILE REFERENCE: 2752-11
; CURRENT APPLICATION NUMBER: US/10/621,675
; CURRENT FILING DATE: 2003-07-18
; PRIOR APPLICATION NUMBER: US/09/576,824A
; PRIOR APPLICATION NUMBER: 08/723,425
; PRIOR FILING DATE: 1996-09-30
; PRIOR APPLICATION NUMBER: 09/146,028
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP93/00517
; PRIOR FILING DATE: 1993-03-08
; PRIOR APPLICATION NUMBER: EP 92400598.6
; PRIOR FILING DATE: 1992-03-06
; NUMBER OF SEQ ID NOS: 600
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 160
; LENGTH: 24
; TYPE: PRT
; ORGANISM: Human immunodeficiency virus
US-10-621-675-160

Query Match 100.0%; Score 39; DB 17; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.18; Indels 0; Gaps 0;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
Db 15 RAFVTIGK 22
|||||

RESULT 31
US-10-777-053-131
; Sequence 131, Application US/10777053
; Publication No. US20040132088A1
; GENERAL INFORMATION:
; APPLICANT: Simard, John J. L.
; APPLICANT: Diamond, David C.
; APPLICANT: Qiu, Zhiyong
; APPLICANT: Lei, Xiang-Dong
; TITLE OF INVENTION: EXPRESSION VECTORS ENCODING EPITOPES OF
; TITLE OF INVENTION: TARGET-ASSOCIATED ANTIGENS AND METHODS FOR THEIR DESIGN
; FILE REFERENCE: MANNK.022C1
; CURRENT APPLICATION NUMBER: US/10/777,053
; CURRENT FILING DATE: 2004-02-10
; PRIOR APPLICATION NUMBER: 10/292,413
; PRIOR FILING DATE: 2002-11-07
; PRIOR APPLICATION NUMBER: 60/336,968
; PRIOR FILING DATE: 2001-11-07
; NUMBER OF SEQ ID NOS: 979
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 131
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Human Immunodeficiency Virus
US-10-777-053-131

Query Match 94.9%; Score 37; DB 16; Length 9;

Best Local Similarity 87.5%; Pred. No. 1.3e+06;
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTIGK 8
Db 2 RAFVTIGK 9

RESULT 32
US-10-311-111-1
; Sequence 1, Application US/10311111
; Publication No. US20030121065A1
; GENERAL INFORMATION:
; APPLICANT: SHIBA, KIYOTAKA
; TITLE OF INVENTION: MULTIFUNCTIONAL BASE SEQUENCE AND ARTIFICIAL GENE CONTAINING THE
; FILE REFERENCE: 4439-4004
; CURRENT APPLICATION NUMBER: US/10/311,111
; CURRENT FILING DATE: 2002-12-13
; PRIOR APPLICATION NUMBER: JP 2000-180997
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: PRT
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Designed peptide
US-10-311-111-1

Query Match 89.7%; Score 35; DB 14; Length 20;
Best Local Similarity 87.5%; Pred. No. 1.1;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RAFVTIGK 8
Db 12 RTFVTIGK 19

RESULT 33
US-10-398-932-1
; Sequence 1, Application US/10398932
; Publication No. US20040171803A1
; GENERAL INFORMATION:
; APPLICANT: SHIBA, KIYOTAKA
; APPLICANT: OHNO, TSUNEYA
; TITLE OF INVENTION: ARTIFICIAL PROTEINS WITH ENRICHED IMMUNOGEN
; FILE REFERENCE: 024918-0103
; CURRENT APPLICATION NUMBER: US/10/398,932
; CURRENT FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: PCT/JP01/08893
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: JP 2000/314288
; PRIOR FILING DATE: 2000-10-13
; NUMBER OF SEQ ID NOS: 55
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetically Designed
US-10-398-932-1

Query Match 89.7%; Score 35; DB 16; Length 20;
Best Local Similarity 87.5%; Pred. No. 1.1;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RAFVTIGK 8
Db 12 RTFVTIGK 19

RESULT 34
US-10-239-313A-535
; Sequence 535, Application US/10239313A
; Publication No. US20030175285A1
; GENERAL INFORMATION:
; APPLICANT: KLINGUER - HAMOUR, Christine
; APPLICANT: CORVAIA, Nathalie
; APPLICANT: BECK, Alain
; APPLICANT: GOETSCH, Liliane
; TITLE OF INVENTION: MOLECULE OF PHARMACEUTICAL INTEREST COMPRISING AT ITS
; TITLE OF INVENTION: OF A PHYSIOLOGICALLY ACCEPTABLE STRONG ACID
; FILE REFERENCE: 343 727 - US
; CURRENT APPLICATION NUMBER: US/10/239,313A
; CURRENT FILING DATE: 2002-09-19
; PRIOR APPLICATION NUMBER: FR 00/03711
; PRIOR FILING DATE: 2000-03-23
; PRIOR APPLICATION NUMBER: PCT 01/70772
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 697
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 535
; LENGTH: 12
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-239-313A-535

Query Match 87.2%; Score 34; DB 14; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.1;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTIG 7
Db 6 RAFVTIG 12

RESULT 35
US-10-311-111-4
; Sequence 4, Application US/10311111
; Publication No. US20030121065A1
; GENERAL INFORMATION:
; APPLICANT: SHIBA, KIYOTAKA
; TITLE OF INVENTION: MULTIFUNCTIONAL BASE SEQUENCE AND ARTIFICIAL GENE CONTAINING THE
; FILE REFERENCE: 4439-4004
; CURRENT APPLICATION NUMBER: US/10/311,111
; CURRENT FILING DATE: 2002-12-13
; PRIOR APPLICATION NUMBER: JP 2000-180997
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 7
; TYPE: PRT
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Designed peptide
US-10-311-111-4

Query Match 76.9%; Score 30; DB 14; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 FVTICK 8
Db 1 FVTICK 6

RESULT 36
US-10-398-932-4
; Sequence 4, Application US/10398932
; Publication No. US20040171803A1


```
Db      4 RAFVTI 9
|||||
RESULT 40
US-10-777-053-139
; Sequence 139, Application US/10777053
; Publication No. US20040132088A1
; GENERAL INFORMATION:
; APPLICANT: Simard, John J. L.
; APPLICANT: Diamond, David C.
; APPLICANT: Qiu, Zhiyong
; APPLICANT: Lei, Xiang-Dong
; TITLE OF INVENTION: EXPRESSION VECTORS ENCODING EPITOPES OF
; TARGET-ASSOCIATED ANTIGENS AND METHODS FOR THEIR DESIGN
; FILE REFERENCE: MANK.022C1
; CURRENT APPLICATION NUMBER: US/10/777,053
; CURRENT FILING DATE: 2004-02-10
; PRIOR FILING DATE: 2002-11-07
; PRIOR APPLICATION NUMBER: 60/336,968
; PRIOR FILING DATE: 2001-11-07
; NUMBER OF SEQ ID NOS: 979
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 139
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Human Immunodeficiency Virus
US-10-777-053-139
Query Match      71.8%; Score 28; DB 16; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 RAFVTI 6
|||||
Db      4 RAFVTI 9
|||||
RESULT 41
US-10-494-161-17
; Sequence 17, Application US/10494161
; Publication No. US20050042747A1
; GENERAL INFORMATION:
; APPLICANT: Clayton, Frederic
; APPLICANT: Fantini, Jacques
; TITLE OF INVENTION: HIVP120-INDUCED BOB/GPR15 ACTIVATION
; FILE REFERENCE: 21101.0022P1
; CURRENT APPLICATION NUMBER: US/10/494,161
; CURRENT FILING DATE: 2004-04-29
; PRIOR APPLICATION NUMBER: PCT/US 02/34336
; PRIOR FILING DATE: 2002-10-25
; PRIOR APPLICATION NUMBER: 60/341,045
; PRIOR FILING DATE: 2001-10-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 17
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:note =
; OTHER INFORMATION: Synthetic Construct
US-10-494-161-17
Query Match      71.8%; Score 28; DB 17; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 RAFVTI 6
|||||
Db      4 RAFVTI 9
|||||
RESULT 42
US-09-858-349-3
; Sequence 3, Application US/09858349
; Patent No. US20020012909A1
; GENERAL INFORMATION:
; APPLICANT: PLAKSIN, Daniel
; TITLE OF INVENTION: SMALL FUNCTIONAL UNITS OF ANTIBODY HEAVY CHAIN VARIABLE REGIONS
; FILE REFERENCE: 87534-2800
; CURRENT APPLICATION NUMBER: US/09/858,349
; CURRENT FILING DATE: 2000-06-02
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 10
; TYPE: PRT
; ORGANISM: mouse hybridoma specific for H-2D + RGPGRAPFTI peptide
US-09-858-349-3
Query Match      71.8%; Score 28; DB 9; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 RAFVTI 6
|||||
Db      5 RAFVTI 10
|||||
RESULT 43
US-09-810-310-16
; Sequence 16, Application US/09810310
; Patent No. US20020044948A1
; GENERAL INFORMATION:
; APPLICANT: Kheif, Samir N.
; APPLICANT: Berzofsky, Jay A.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR CO-STIMULATION OF
; FILE REFERENCE: 15280-415100US
; CURRENT APPLICATION NUMBER: US/09/810,310
; CURRENT FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: 60/189,396
; PRIOR FILING DATE: 2000-03-15
; NUMBER OF SEQ ID NOS: 61
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: HIV PEPTIDE
; OTHER INFORMATION: ANTIGEN
US-09-810-310-16
Query Match      71.8%; Score 28; DB 9; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 RAFVTI 6
|||||
Db      5 RAFVTI 10
|||||
RESULT 44
US-09-820-484-8
; Sequence 8, Application US/09820484
; Patent No. US20020142977A1
; GENERAL INFORMATION:
; APPLICANT: Raz, Eyal
; APPLICANT: Cho, Hearn Jay
; APPLICANT: Richman, Douglas
; APPLICANT: Horner, Anthony A.
; TITLE OF INVENTION: Method for Increasing a Cytotoxic T
; LYMPHOCYTE RESPONSE IN VIVO
US-09-820-484-8
Query Match      71.8%; Score 28; DB 17; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.3e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 RAFVTI 6
|||||
Db      4 RAFVTI 9
|||||
```

```
; FILE REFERENCE: 06510-188US1
; CURRENT APPLICATION NUMBER: US/09/820,484
; CURRENT FILING DATE: 2001-03-28
; PRIOR APPLICATION NUMBER: US 60/192,537
; PRIOR FILING DATE: 2000-03-28
; PRIOR APPLICATION NUMBER: US 60/203,567
; PRIOR FILING DATE: 2000-05-11
; PRIOR APPLICATION NUMBER: US 60/215,895
; PRIOR FILING DATE: 2000-07-05
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: HIV-1 class I-restricted gp120 peptide
US-09-820-484-8

Query Match          71.8%; Score 28; DB 9; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RAFVTI 6
Db      5 RAFVTI 10

RESULT 45
US-09-087-513-7
; Sequence 7, Application US/09087513
; Publication NO. US20020182180A1
; GENERAL INFORMATION:
; APPLICANT: KANEKO, Yutaro
; APPLICANT: KOZBOR, Danuta
; TITLE OF INVENTION: METHOD OF INDUCING IMMUNITY TO VIRUSES
; FILE REFERENCE: 0010-0929-0X
; CURRENT APPLICATION NUMBER: US/09/087,513
; CURRENT FILING DATE: 1998-05-29
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:peptide
US-09-087-513-7

Query Match          71.8%; Score 28; DB 9; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RAFVTI 6
Db      5 RAFVTI 10
```

Search completed: May 16, 2005, 08:13:00
Job time : 132 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 16, 2005, 09:40:42 ; Search time 66 Seconds
(without alignments)
46.880 Million cell updates/sec

Title: SEQ1

Perfect score: 39

Sequence: 1 rafvtgk 8

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 768190

Minimum DB seq length: 0

Maximum DB seq length: 25

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 250 summaries

Database :

A_Geneseq_16Dec04:*

1: Geneseq1980s:*

2: Geneseq1990s:*

3: Geneseq2000s:*

4: Geneseq2001s:*

5: Geneseq2002s:*

6: Geneseq2003as:*

7: Geneseq2003bs:*

8: Geneseq2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	39	100.0	8	2	AAR38167 V3 loop p
2	39	100.0	8	2	AAR72313 Anti-HIV
3	39	100.0	8	4	AAB68603 HIV gp120
4	39	100.0	9	2	AAR46523 HIV gp120
5	39	100.0	9	2	AAR62144 HIV-1 gp1
6	39	100.0	9	2	AAY10157 T cell ep
7	39	100.0	9	2	AAY03692 Amino aci
8	39	100.0	9	5	AAU96033 HIV gp120
9	39	100.0	9	5	ABG79839 MHC class
10	39	100.0	9	7	ADG79993 HIV1 carr
11	39	100.0	9	7	ADK50933 Breast/bl
12	39	100.0	9	8	ADR69467 Novel hyb
13	39	100.0	10	2	AAW76840 Fusion im
14	39	100.0	11	2	AAW19056 Hypervari
15	39	100.0	11	2	AAW34472 HIV gp120
16	39	100.0	12	2	AAR62152 HIV-1 gp1
17	39	100.0	12	2	AAW54932 HIV gp120
18	39	100.0	13	2	AAW22327 HIV-1 str
19	39	100.0	13	2	AAW62890 Peptide s
20	39	100.0	13	4	AAW99433 Vaccine r
21	39	100.0	14	2	AAR33336 Sequence
22	39	100.0	14	2	AAR48604 Sequence
23	39	100.0	14	2	AAR66416 HIV-1 III
24	39	100.0	14	2	AAR66417 HIV-1 III
25	39	100.0	14	2	AAW09264 HIV-1 str

26	39	100.0	14	2	AAW76864	Aaw76864 Fusion im
27	39	100.0	15	1	AAAP82095	Asp82095 Env-K1 pe
28	39	100.0	15	1	AAAP91228	Asp91228 Peptide c
29	39	100.0	15	2	AAR06294	Aar06294 Peptide d
30	39	100.0	15	2	AAR21343	Aar21343 HIV-1 gp1
31	39	100.0	15	2	AAR38187	Aar38187 V3 loop p
32	39	100.0	15	2	AAR32207	Aar32207 Sequence
33	39	100.0	15	2	AAAR51619	Aar51619 V3 loop r
34	39	100.0	15	2	AAAR74603	Aar74603 HIV-1 var
35	39	100.0	15	2	AAAR66420	Aar66420 HIV-1 III
36	39	100.0	15	2	AAAR66421	Aar66421 HIV-1 III
37	39	100.0	15	2	AAAR66414	Aar66414 HIV-1 III
38	39	100.0	15	2	AAAR66419	Aar66419 HIV-1 III
39	39	100.0	15	2	AAAR66422	Aar66422 HIV-1 III
40	39	100.0	15	2	AAAR68789	Aar68789 Cytotoxic
41	39	100.0	15	2	AAW05535	Aaw05535 HIV-1 gp1
42	39	100.0	15	2	AAAR92033	Aar92033 Hydrophil
43	39	100.0	15	2	AAW07931	Aaw07931 gp120 pep
44	39	100.0	15	2	AAAR92007	Aar92007 HIV-1 V3
45	39	100.0	15	2	AAAR24219	Aar24219 CD4+ T-ly
46	39	100.0	15	2	AAW10348	Aaw10348 HIV gp120
47	39	100.0	15	2	AAW22031	Aaw22031 Antigenic
48	39	100.0	15	2	AAW39275	Aaw39275 HIV-1 syn
49	39	100.0	15	2	AAW40316	Aaw40316 HIV-1 III
50	39	100.0	15	2	AAW76897	Aaw76897 Fusion im
51	39	100.0	15	2	AAW76898	Aaw76898 Fusion im
52	39	100.0	15	2	AAW76900	Aaw76900 Fusion im
53	39	100.0	15	2	AAW54929	Aaw54929 HIV gp120
54	39	100.0	15	2	AAW06896	Aaw06896 Sequence
55	39	100.0	15	2	AAW24466	Aaw24466 HIV pep1
56	39	100.0	15	2	AAW25189	Aaw25189 HIV prote
57	39	100.0	15	2	AAW25204	Aaw25204 HIV V3 pe
58	39	100.0	15	2	AAW05356	Aaw05356 HIV-1 CLU
59	39	100.0	15	2	AAW72821	Aaw72821 HIV-1 gp1
60	39	100.0	15	2	AAW87620	Aaw87620 Epitope o
61	39	100.0	15	2	AAW04680	Aaw04680 HIV-1 gp1
62	39	100.0	15	3	AAW83916	Aaw83916 HIV-1 env
63	39	100.0	15	3	AAW66439	Aaw66439 HLA-A2-b1
64	39	100.0	15	3	AAW66455	Aaw66455 HLA-A3-b1
65	39	100.0	15	3	AAW85591	Aaw85591 HIV relat
66	39	100.0	15	3	AAW15875	Aaw15875 Human che
67	39	100.0	15	4	AAW99083	Aaw99083 Vaccine r
68	39	100.0	15	4	AAW92345	Aaw92345 Virus rel
69	39	100.0	15	4	AAW68601	Aaw68601 HIV gp120
70	39	100.0	15	4	AAW15743	Aaw15743 Human imm
71	39	100.0	15	5	AAU96031	Aau96031 HIV gp120
72	39	100.0	15	5	AAU97690	Aau97690 HIV CTL e
73	39	100.0	15	5	ABG68654	Abg68654 HIV-1 P18
74	39	100.0	15	5	ABG68663	Abg68663 HIV-1 P18
75	39	100.0	15	6	AAE35161	Aae35161 HIV CTL e
76	39	100.0	15	7	ADN14074	Adn14074 HIV helpe
77	39	100.0	15	8	ADR04041	Adr04041 Immune re
78	39	100.0	16	2	AAR24939	Aar24939 HIV pep1
79	39	100.0	16	2	AAW68326	Aaw68326 MHC bindi
80	39	100.0	16	2	AAW68203	Aaw68203 Altered M
81	39	100.0	16	3	AAW52857	Aaw52857 Altered M
82	39	100.0	16	4	AAW58618	Aaw58618 Altered M
83	39	100.0	16	4	AAW58618	Aaw58618 Altered M
84	39	100.0	17	2	AAW42057	Aaw42057 Peptide C
85	39	100.0	17	2	AAW40414	Aaw40414 Lipopepti
86	39	100.0	17	7	ADN14075	Adn14075 HIV helpe
87	39	100.0	18	2	AAAR31277	Aar31277 HIV princ
88	39	100.0	18	2	AAAR30032	Aar30032 HIV princ
89	39	100.0	18	2	AAR26713	Aar26713 HIV-PND-p
90	39	100.0	18	2	AAR44190	Aar44190 gp120 V3
91	39	100.0	18	2	AAW58548	Aaw58548 HIV-1 iso
92	39	100.0	18	2	AAW63062	Aaw63062 Human imm
93	39	100.0	18	3	AAW96191	Aaw96191 Glycoprot
94	39	100.0	18	4	ABB83113	Abb83113 Lipopepti
95	39	100.0	19	2	AAW24218	Aaw24218 CD4+ T-ly
96	39	100.0	20	2	AAW04434	Aaw04434 Human imm
97	39	100.0	20	2	AAW60203	Aaw60203 HIV gp120
98	39	100.0	20	2	AAW76943	Aaw76943 Fusion im

99	39	100.0	20	2	AAW54930	Aaw54930 HIV gp120	172	34	87.2	15	2	AAW66427	Aar66427 HIV-1 III
100	39	100.0	20	8	ADR18886	Adr18886 HIV-1 V3-	173	34	87.2	15	2	AAW66428	Aar66428 HIV-1 III
101	39	100.0	21	2	AAW3073	Aar3073 Antigenic	174	34	87.2	15	2	AAW66429	Aar66429 HIV-1 III
102	39	100.0	21	2	AAW34475	Aaw34475 Accepter	175	34	87.2	15	2	AAW66430	Aar66430 HIV-1 III
103	39	100.0	21	2	AAW79180	Aaw79180 Fusion im	176	34	87.2	16	2	AAW66431	Aar66431 HIV-1 III
104	39	100.0	21	2	AAW76901	Aaw76901 Fusion im	177	34	87.2	16	2	AAW66432	Aar66432 HIV-1 III
105	39	100.0	21	2	AAW75478	Aaw75478 HIV-1 I str	178	34	87.2	17	1	AAW66433	Aar66433 HIV-1 III
106	39	100.0	21	2	AAW16052	Aay16052 HIV-1 I str	179	34	87.2	17	1	AAW66434	Aar66434 HIV-1 III
107	39	100.0	21	2	AAW85568	Aaw85568 Human imm	180	34	87.2	17	1	AAW66435	Aar66435 HIV-1 III
108	39	100.0	21	3	AAW15012	Aab15012 Peptide P	181	34	87.2	17	2	AAW66436	Aar66436 HIV-1 III
109	39	100.0	21	4	AAW08699	Aau08699 Retroviri	182	34	87.2	17	2	AAW66437	Aar66437 HIV-1 III
110	39	100.0	22	2	AAW42153	Aar42153 gp120 V3	183	34	87.2	17	2	AAW66438	Aar66438 HIV-1 III
111	39	100.0	22	2	AAW57470	Aar57470 HIV BRU V	184	34	87.2	17	2	AAW66439	Aar66439 HIV-1 III
112	39	100.0	22	2	AAW07392	Aaw07392 HIV-1 I str	185	34	87.2	17	2	AAW66440	Aar66440 HIV-1 III
113	39	100.0	22	2	AAW07488	Aay07488 HIV-1 I str	186	34	87.2	17	2	AAW66441	Aar66441 HIV-1 III
114	39	100.0	22	3	AAW85137	Aay85137 HIV-1 III	187	34	87.2	17	2	AAW66442	Aar66442 HIV-1 III
115	39	100.0	22	6	ABU07537	Abu07537 Human N-a	188	34	87.2	17	2	AAW66443	Aar66443 HIV-1 III
116	39	100.0	23	2	AAW04502	Aar04502 Cpd. elic	189	34	87.2	17	8	AAW66444	Aar66444 HIV-1 III
117	39	100.0	23	4	AAW04476	Aar04476 Human imm	190	34	87.2	17	2	AAW66445	Aar66445 HIV-1 III
118	39	100.0	23	4	AAW06211	Aar06211 Immunopu	191	34	87.2	18	2	AAW66446	Aar66446 HIV-1 III
119	39	100.0	24	2	AAW07018	Aar07018 Residues	192	34	87.2	18	8	AAW66447	Aar66447 HIV-1 III
120	39	100.0	24	2	AAW26565	Aar26565 Sequence	193	34	87.2	18	2	AAW66448	Aar66448 HIV-1 III
121	39	100.0	24	2	AAW29233	Aar29233 Heterocon	194	34	87.2	20	1	AAW66449	Aar66449 HIV-1 III
122	39	100.0	24	2	AAW26870	Aar26870 HIV gp120	195	34	87.2	20	2	AAW66450	Aar66450 HIV-1 III
123	39	100.0	24	2	AAW32406	Aar32406 Sequence	196	34	87.2	20	6	AAW66451	Aar66451 HIV-1 III
124	39	100.0	24	2	AAW33190	Aar33190 Sequence	197	33	84.6	15	2	AAW66452	Aar66452 HIV-1 III
125	39	100.0	24	2	AAW38165	Aar38165 V3 loop p	198	33	84.6	15	2	AAW66453	Aar66453 HIV-1 III
126	39	100.0	24	2	AAW44191	Aar44191 gp120 V3	199	30	76.9	7	5	AAW66454	Aar66454 HIV-1 III
127	39	100.0	24	2	AAW63821	Aar63821 HIV-1 gp1	200	30	76.9	7	5	AAW66455	Aar66455 HIV-1 III
128	39	100.0	24	2	AAW74608	Aar74608 HIV-1 gp1	201	30	76.9	15	2	AAW66456	Aar66456 HIV-1 III
129	39	100.0	24	2	AAW67414	Aaw67414 HIV-1 pep	202	29	74.4	15	2	AAW66457	Aar66457 HIV-1 III
130	39	100.0	24	2	AAW98904	Aaw98904 HIV-1 vac	203	29	74.4	15	2	AAW66458	Aar66458 HIV-1 III
131	39	100.0	24	2	AAW22581	Aay22581 HIV LDL b	204	29	74.4	15	2	AAW66459	Aar66459 HIV-1 III
132	39	100.0	24	2	AAW22583	Aay22583 HIV LDL b	205	29	74.4	15	2	AAW66460	Aar66460 HIV-1 III
133	39	100.0	24	2	AAW39769	Aay39769 HIV1 chim	206	29	74.4	20	2	AAW66461	Aar66461 HIV-1 III
134	39	100.0	24	2	AAW15873	Aab15873 Human che	207	29	74.4	20	2	AAW66462	Aar66462 HIV-1 III
135	39	100.0	24	3	AAW68602	Aar68602 HIV gp120	208	29	74.4	20	2	AAW66463	Aar66463 HIV-1 III
136	39	100.0	24	1	AAW82464	Aap82464 Peptide c	209	29	74.4	20	2	AAW66464	Aar66464 HIV-1 III
137	39	100.0	25	1	AAW90281	Aap90281 Peptide 1	210	29	74.4	20	2	AAW66465	Aar66465 HIV-1 III
138	39	100.0	25	1	AAW04475	Aar04475 Human imm	211	28	71.8	9	2	AAW66466	Aar66466 HIV-1 III
139	39	100.0	25	2	AAW08276	Aar08276 HIV pepti	212	28	71.8	9	2	AAW66467	Aar66467 HIV-1 III
140	39	100.0	25	2	AAW13120	Aar13120 Binding s	213	28	71.8	9	5	AAW66468	Aar66468 HIV-1 III
141	39	100.0	25	2	AAW15058	Aar15058 HIV-1 amp	214	28	71.8	9	6	AAW66469	Aar66469 HIV-1 III
142	39	100.0	25	2	AAW31276	Aar31276 HIV princ	215	28	71.8	9	8	AAW66470	Aar66470 HIV-1 III
143	39	100.0	25	2	AAW30031	Aar30031 HIV princ	216	28	71.8	9	8	AAW66471	Aar66471 HIV-1 III
144	39	100.0	25	2	AAW26712	Aar26712 HIV-PND-p	217	28	71.8	10	2	AAW66472	Aar66472 HIV-1 III
145	39	100.0	25	2	AAW41336	Aar41336 HIV gp120	218	28	71.8	10	2	AAW66473	Aar66473 HIV-1 III
146	39	100.0	25	2	AAW41330	Aar41330 HIV gp120	219	28	71.8	10	2	AAW66474	Aar66474 HIV-1 III
147	39	100.0	25	2	AAW36587	Aar36587 Virus neu	220	28	71.8	10	2	AAW66475	Aar66475 HIV-1 III
148	39	100.0	25	2	AAW72819	Aaw72819 HIV-1 gp1	221	28	71.8	10	2	AAW66476	Aar66476 HIV-1 III
149	39	100.0	25	2	AAW87618	Aaw87618 Epitope o	222	28	71.8	10	2	AAW66477	Aar66477 HIV-1 III
150	39	100.0	25	4	AAW09522	Aae09522 Human imm	223	28	71.8	10	2	AAW66478	Aar66478 HIV-1 III
151	39	100.0	25	8	AAW04427	Aac04427 Human imm	224	28	71.8	10	3	AAW66479	Aar66479 HIV-1 III
152	37	94.9	25	8	AAW05666	Aac05666 Human imm	225	28	71.8	10	3	AAW66480	Aar66480 HIV-1 III
153	37	94.9	25	8	AAW05666	Aac05666 Human imm	226	28	71.8	10	3	AAW66481	Aar66481 HIV-1 III
154	37	94.9	25	8	AAW05666	Aac05666 Human imm	227	28	71.8	10	3	AAW66482	Aar66482 HIV-1 III
155	35	89.7	15	2	AAW66430	Aar66430 HIV-1 III	228	28	71.8	10	3	AAW66483	Aar66483 HIV-1 III
156	35	89.7	15	2	AAW66430	Aar66430 HIV-1 III	229	28	71.8	10	3	AAW66484	Aar66484 HIV-1 III
157	35	89.7	15	2	AAW66430	Aar66430 HIV-1 III	230	28	71.8	10	3	AAW66485	Aar66485 HIV-1 III
158	35	89.7	19	2	AAW22329	Aaw22329 HIV-1 cll	231	28	71.8	10	4	AAW66486	Aar66486 HIV-1 III
159	35	89.7	19	2	AAW62892	Aaw62892 Peptide s	232	28	71.8	10	4	AAW66487	Aar66487 HIV-1 III
160	35	89.7	20	5	AAW05775	Abw05775 HIV gp120	233	28	71.8	10	4	AAW66488	Aar66488 HIV-1 III
161	35	89.7	20	5	AAW05775	Abw05775 HIV gp120	234	28	71.8	10	4	AAW66489	Aar66489 HIV-1 III
162	34	87.2	8	2	AAW62151	Aar62151 Strong im	235	28	71.8	10	4	AAW66490	Aar66490 HIV-1 III
163	34	87.2	9	2	AAW62138	Aar62138 HIV-1 gp1	236	28	71.8	10	4	AAW66491	Aar66491 HIV-1 III
164	34	87.2	9	2	AAW62138	Aar62138 HIV-1 gp1	237	28	71.8	10	4	AAW66492	Aar66492 HIV-1 III
165	34	87.2	9	2	AAW62138	Aar62138 HIV-1 gp1	238	28	71.8	10	4	AAW66493	Aar66493 HIV-1 III
166	34	87.2	10	2	AAW62165	Aar62165 Epitope 1	239	28	71.8	10	4	AAW66494	Aar66494 HIV-1 III
167	34	87.2	10	2	AAW62165	Aar62165 Epitope 1	240	28	71.8	10	4	AAW66495	Aar66495 HIV-1 III
168	34	87.2	11	2	AAW62167	Aar62167 Peptide f	241	28	71.8	10	4	AAW66496	Aar66496 HIV-1 III
169	34	87.2	11	2	AAW62167	Aar62167 Peptide f	242	28	71.8	10	4	AAW66497	Aar66497 HIV-1 III
170	34	87.2	12	4	AAW76852	Aaw76852 Fusion im	243	28	71.8	10	4	AAW66498	Aar66498 HIV-1 III
171	34	87.2	12	4	AAW76852	Aaw76852 Fusion im	244	28	71.8	10	4	AAW66499	Aar66499 HIV-1 III
172	34	87.2	12	4	AAW76852	Aaw76852 Fusion im	245	28	71.8	10	4	AAW66500	Aar66500 HIV-1 III
173	34	87.2	12	4	AAW76852	Aaw76852 Fusion im	246	28	71.8	10	4	AAW66501	Aar66501 HIV-1 III
174	34	87.2	12	4	AAW76852	Aaw76852 Fusion im	247	28	71.8	10	4	AAW66502	Aar66502 HIV-1 III
175	34	87.2	12	4	AAW76852	Aaw76852 Fusion im	248	28	71.8	10	4	AAW66503	Aar66503 HIV-1 III
176	34	87.2	12	4	AAW76852	Aaw76852 Fusion im	249	28	71.8	10	4	AAW66504	Aar66504 HIV-1 III
177	34	87.2	12	4	AAW76852	Aaw76852 Fusion im	250	28	71.8	10	4	AAW66505	Aar66505 HIV-1 III
178	34	87.2	12	4	AAW76852	Aaw76852 Fusion im	251	28	71.8	10	4	AAW66506	Aar66506 HIV-1 III
179	34	87.2	12	4	AAW76852	Aaw76852 Fusion im	252	28	71.8	10	4	AAW66507	Aar66507 HIV-1 III
180	34	87.2	12	4	AAW76852	Aaw76852 Fusion im	253	28	71.8	10	4	AAW66508	Aar66508 HIV-1 III
181	34	87.2	12	4	AAW76852	Aaw76852 Fusion im	254	28	71.8	10	4	AAW66509	Aar66509 HIV-1 III
182	34	87.2	12	4	AAW76852	Aaw76852 Fusion im	255	28	71.8	10	4	AAW66510	Aar66510 HIV-1 III
183	34	87.2	12	4	AAW76852	Aaw76852 Fusion im	256	28	71.8	10	4	AAW66511	Aar66511 HIV-1 III
184	34	87.2	12	4	AAW76852	Aaw76852 Fusion im	257	28	71.8	10	4	AAW66512	Aar66512 HIV-1 III
185	34	87.2	12	4	AAW76852	Aaw76852 Fusion im	258	28	71.8	10	4	AAW66513	Aar66513 HIV-1 III
186	34	87.2	12	4	AAW76852	Aaw76852 Fusion im	259	28	71.8	10	4	AAW66514	Aar66514 HIV-1 III
187	34	87.2	12	4	AAW76852	Aaw76852 Fusion im	260	28	71.8	10	4	AAW66515	Aar66515 HIV-1 III
188	34	87.2	12	4	AAW76852	Aaw76852 Fusion im	261	28	71.8	10	4	AAW66516	Aar66516 HIV-1 III
189	34	87.2	12	4	AAW76852	Aaw76852 Fusion im	262	28	71.8	10	4	AAW66517	Aar66517 HIV-1 III
190	34	87.2	12	4	AAW76852	Aaw76852 Fusion im	263	28	71.8	10	4	AAW66518	Aar66518 HIV-1 III
191	34	87.2	12	4	AAW76852	Aaw76852 Fusion im	264	28	71.8	10	4	AAW66519	Aar66519 HIV-1 III

245 28 71.8 10 6 ABP60029 Abp60029 HIV antig
 246 28 71.8 10 6 ABR39122 ABR39122 HIV-1 gp1
 247 28 71.8 10 6 ABP72314 ABP72314 HIV-1 p18
 248 28 71.8 10 6 ADA50228 ADA50228 Human imm
 249 28 71.8 10 7 ADE79992 ADE79992 HIV1 carr
 250 28 71.8 10 7 ADE79994 ADE79994 HIV1 carr

ALIGNMENTS

RESULT 1

AAR38167
 ID AAR38167 standard; peptide; 8 AA.

XX AC AAR38167;
 XX
 DT 27-AUG-2003 (revised)
 DT 25-MAR-2003 (revised)
 DT 12-OCT-1993 (first entry)
 XX
 DE V3 loop peptide R8K.
 XX
 KW gp120; HIV-1; cytotoxic T-lymphocyte; CTL; T-helper; AIDS; infection.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN WO9310816-A1.
 XX
 PD 10-JUN-1993.
 XX
 PF 02-DEC-1992; 92WO-US010378.
 XX
 PR 02-DEC-1991; 91US-00800932.
 PR 16-SEP-1992; 92US-00945865.
 XX
 PA (TEXA) UNIV TEXAS SYSTEM.
 XX
 PI Sastry JK, Arlinghaus RB, Platsoucas CD, Nehete PN;
 XX WPI; 1993-196739/24.
 XX

PT Peptide composition for treating and preventing viral infections -
 PT comprise CTL-inducing epitope and HIV infection-inhibiting sequence or T
 PT helper cell-inducing sequence.
 XX
 PS Claim 19; Page 95; 130pp; English.
 XX
 CC HIV gp120 V3 loop-derived peptides (AAR38170-87) are successful in
 CC generating CTL responses, esp. peptide R15K (AAR38187); the T-helper cell
 CC -inducing peptide includes the sequence C19A (AAR38164); HIV infection-
 CC inhibiting peptides are given in AAR38188-206, and are esp. peptides
 CC R15K, N24G, E13V, R8K, T13Q and H13N (AAR38165-69). The peptides may also
 CC be derived from an influenza virus protein or a sendai virus protein
 CC (AAR41014-15). It was observed that peptide R8K (amino acids 322-329),
 CC with sequences derived from the V3 loop of HIV-1 IIIB, inhibits HIV-1
 CC infection of primary human T cells by 66% at 1 microg/ml (ca. 1.25
 CC microm). (Updated on 25-MAR-2003 to correct PN field.) (Updated on 27-AUG
 CC -2003 to correct OS field.)
 XX

SQ Sequence 8 AA;

Query Match 100.0%; Score 39; DB 2; Length 8;
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
 |||||
 Db 1 RAFVTIGK 8

RESULT 2

AAR72313

ID AAR72313 standard; peptide; 8 AA.
 XX
 AC AAR72313;
 XX
 DT 25-MAR-2003 (revised)
 DT 20-OCT-1995 (first entry)
 XX
 DE Anti-HIV MBPC peptide moiety.
 XX
 KW Multiple branch peptide construction; MBPC; HIV-1;
 KW human immunodeficiency virus type 1; virucide.
 XX
 OS Synthetic.
 XX
 PN WO9507929-A1.
 XX
 PD 23-MAR-1995.
 XX
 PF 13-SEP-1994; 94WO-GB001992.
 XX
 PR 13-SEP-1993; 93GB-00018901.
 PR 15-JUN-1994; 94US-00260086.
 XX
 PA (ARME-) ARMEL SA.
 PA (MCKE/) MCKELVEY I E.
 XX
 PI Sabatier JM, Benjouad A, Yahi N, Fenouillet E, Mabrouk K;
 PI Gluckman J, Van Rietschoten J, Rochat H;
 XX
 DR WPI; 1995-131312/17.
 XX
 PT Multiple branch peptide constructions formed from the V3 loop of HIV-1
 PT gp120 - used to treat HIV infection.
 XX
 PS Example 2; Page 11; 39pp; English.
 XX
 CC Multiple branch peptide constructions (MBPCs) are formed from the V3 loop
 CC of HIV-1 gp120. Each MBPC includes multiple peptide moieties
 CC incorporating the GPCR consensus sequence, each attached to the amino
 CC group of a lysine residue, forming a dendritic structure. A peptide
 CC moiety (AAR72313) not including the consensus was unable to inhibit HIV-1
 CC syncytia formation. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 8 AA;
 Query Match 100.0%; Score 39; DB 2; Length 8;
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RAFVTIGK 8
 |||||
 Db 1 RAFVTIGK 8
 RESULT 3
 AAB68603
 ID AAB68603 standard; peptide; 8 AA.
 XX
 AC AAB68603;
 XX
 DT 11-SEP-2003 (revised)
 DT 25-APR-2001 (first entry)
 XX
 DE HIV gp120 V3 loop peptide #3.
 XX
 KW HIV gp120 V3 loop; liposome composition; HIV infection.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN US6180134-B1.
 XX
 PD 30-JAN-2001.
 XX

```

PF 07-JUN-1995; 95US-00480332.
XX
XX 23-MAR-1993; 93US-00035443.
PR 29-SEP-1994; 94US-00316436.
XX
XX (SEQU-) SEQUUS PHARM INC.
PA
PI Zalipsky S, Woodle MC, Martin FJ, Barenholz Y;
XX
XX WPI; 2001-201897/20.
DR
XX Liposome composition for use in treating septic shock comprises liposomes
PT having an outer surface layer of polyethylene glycol chains, and a
PT polypeptide or polysaccharide effector molecule.
XX
XX Disclosure; Fig 13; 32pp; English.
XX
XX The present invention relates to a liposome composition comprising
CC liposomes having an outer surface layer of polyethylene glycol chains,
CC each having a free distal end. A polypeptide or polysaccharide effector
CC molecule is covalently attached to a portion of the distal ends. The
CC effector interferes with specific binding of pathogen or cell in a
CC bloodstream to a target cell or cell matrix, and is rapidly removed by
CC renal clearance from the bloodstream when administered in free form. The
CC liposome composition may be used in treating a condition mediated by
CC binding a pathogen or cell in the bloodstream to a target cell or cell
CC matrix. It can be used in treating septic shock, toxic shock, colonic
CC inflammation, leukemic cell proliferation, or HIV infection. The present
CC sequence is a peptide of the V3 loop of HIV envelope protein gp120. This
CC peptide may be used in the composition of the present invention. gp120
CC binds to the CD4 receptor during HIV infection of lymphocytes. By
CC introducing the present peptide, the CD4 receptors are blocked, thereby
CC inhibiting HIV infection. (Updated on 11-SEP-2003 to standardise OS
CC field)
XX
XX Sequence 8 AA;
SQ
Query Match 100.0%; Score 39; DB 4; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
Db |||||
1 RAFVTIGK 8

RESULT 4
AAR46523
ID AAR46523 standard; peptide; 9 AA.
XX
AC AAR46523;
XX
XX 25-MAR-2003 (revised)
DT 30-MAR-1994 (first entry)
XX
DE HIV gp120 residues 314-322.
XX
XX Vaccine; polar lipid; targeting; immune response; antigenic peptide;
XX antigen; human immunodeficiency virus.
XX
XX Synthetic.
XX
XX US2556641-A.
PN
XX
XX 26-OCT-1993.
XX
XX 09-JUL-1992; 92US-00911209.
XX
XX 01-NOV-1990; 90US-00607982.
XX
XX (OREG-) STATE OF OREGON.
XX
XX Yavtin MB, Stowell MHB, Malkovsky M;

PF 07-JUN-1995; 95US-00480332.
XX
XX 23-MAR-1993; 93US-00035443.
PR 29-SEP-1994; 94US-00316436.
XX
XX (SEQU-) SEQUUS PHARM INC.
PA
PI Zalipsky S, Woodle MC, Martin FJ, Barenholz Y;
XX
XX WPI; 2001-201897/20.
DR
XX Liposome composition for use in treating septic shock comprises liposomes
PT having an outer surface layer of polyethylene glycol chains, and a
PT polypeptide or polysaccharide effector molecule.
XX
XX Disclosure; Fig 13; 32pp; English.
XX
XX The present invention relates to a liposome composition comprising
CC liposomes having an outer surface layer of polyethylene glycol chains,
CC each having a free distal end. A polypeptide or polysaccharide effector
CC molecule is covalently attached to a portion of the distal ends. The
CC effector interferes with specific binding of pathogen or cell in a
CC bloodstream to a target cell or cell matrix, and is rapidly removed by
CC renal clearance from the bloodstream when administered in free form. The
CC liposome composition may be used in treating a condition mediated by
CC binding a pathogen or cell in the bloodstream to a target cell or cell
CC matrix. It can be used in treating septic shock, toxic shock, colonic
CC inflammation, leukemic cell proliferation, or HIV infection. The present
CC sequence is a peptide of the V3 loop of HIV envelope protein gp120. This
CC peptide may be used in the composition of the present invention. gp120
CC binds to the CD4 receptor during HIV infection of lymphocytes. By
CC introducing the present peptide, the CD4 receptors are blocked, thereby
CC inhibiting HIV infection. (Updated on 11-SEP-2003 to standardise OS
CC field)
XX
XX Sequence 8 AA;
SQ
Query Match 100.0%; Score 39; DB 4; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
Db |||||
1 RAFVTIGK 8

RESULT 5
AAR62144
ID AAR62144 standard; peptide; 9 AA.
XX
AC AAR62144;
XX
XX 27-AUG-2003 (revised)
DT 25-MAR-2003 (revised)
DT 02-MAY-1995 (first entry)
XX
DE HIV-1 gp120/41 protein motif similar to U1 snRNP 70K protein.
XX
XX Small ribonucleoprotein complex; U1 snRNP; 70K protein; epitope;
XX autoantibody; immunoinfective cluster virus; nuclear protein antigen;
XX systemic rheumatic disorder; human immunodeficiency virus; HIV-1;
XX systemic lupus erythematosus; mixed connective tissue disease;
XX scleroderma; glycoprotein 120; glycoprotein 41.
XX
XX Human immunodeficiency virus 1.
XX
XX WO9420141-A1.
PN
XX
XX 15-SEP-1994.
PD
XX
XX 10-MAR-1994; 94WO-US002631.
PF
XX
XX 11-MAR-1993; 93US-00029850.
PR
XX
XX (UYSC-) UNIV SOUTHERN CALIFORNIA.
PA
XX
XX Douvas A, Takehana Y, Ehresmann G;
PI
XX
XX WPI; 1994-302689/37.
DR
XX
XX Methods for treating immunoinfective cluster virus infections - utilise
PT antibodies or fragments characteristic of auto antibodies produced by
PT patients with rheumatic disorders.

```

XX PS. Disclosure; Page 54; 106pp; English.

XX CC The UI snRNP is the target of high-titre, high avidity autoantibodies occurring in the systemic rheumatoid disorders of mixed connective tissue disease, scleroderma and systemic lupus erythematosus. It has been found CC that some sites in the UI snRNP 70K protein (see AAR62120-R62135) are CC homologous to sites in HIV-1 gp120/41 (AAR62136-R62152) and that anti-RNP CC autoantibodies can be used to neutralise HIV-1. (Updated on 25-MAR-2003 CC to correct PN field.) (Updated on 27-AUG-2003 to correct OS field.)

XX CC Sequence 9 AA;

XX QY Query Match 100.0%; Score 39; DB 2; Length 9;

XX Db Best Local Similarity 100.0%; Pred. No. 1.8e+06;

XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX 1 RAFVTIGK 8

XX 2 RAFVTIGK 9

XX RESULT 6

XX AAY10157

XX ID AAY10157 standard; peptide; 9 AA.

XX AC AAY10157;

XX DT 12-MAY-1999 (first entry)

XX DE T cell epitope/MHC ligand SEQ ID NO:87.

XX CC Cytotoxic T-lymphocyte response; CTL; antigen; lymphatic system;

XX KW immunisation; tumour; infectious disease; immunotherapy; cancer;

XX KW malignant melanoma; viral disease; hepatitis; AIDS.

XX OS Synthetic.

XX OS Human immunodeficiency virus 1.

XX PN WO9902183-A2.

XX PD 21-JAN-1999.

XX PF 10-JUL-1998; 98WO-US014289.

XX PR 10-JUL-1997; 97CA-02209815.

XX PR 10-DEC-1997; 97US-00988320.

XX PA (CTL1-) CTL IMMUNOTHERAPIES CORP.

XX PI Kuendig TM, Simard JUL;

XX DR WPI; 1999-120514/10.

XX Inducing a cytotoxic T lymphocyte response - by maintaining a level of antigen in the lymphatic system of a mammal so as to provide a sustained CTL response, used to treat, e.g. AIDS.

XX Disclosure; Page 26; 199pp; English.

XX The present invention describes a method of inducing and/or sustaining an immunological cytotoxic T lymphocyte (CTL) response in a mammal. The method comprises: (a) delivering an antigen to the mammal at a level to induce an immunological CTL response in the mammal; and (b) maintaining the level of the antigen in the mammal's lymphatic system to maintain the immunologic CTL response. The method can be used for the delivery of e.g. embryonic antigen, an oncogene antigen, a mutated tumour-suppressor gene antigen, or a viral antigen. They can be used for the treatment of disease such as cancer, e.g. malignant melanoma or infectious disease, e.g. viral disease such as hepatitis or AIDS. Sustained antigen delivery to the lymphatic system provides for potent CTL stimulation that takes place in the milieu of the lymphoid organ, and it sustains stimulation

CC that is necessary to keep CTL active, cytotoxic and recirculating through the body. AAY10071 to AAY10639 represent examples of peptide antigens given in the present invention

XX Sequence 9 AA;

XX QY Query Match 100.0%; Score 39; DB 2; Length 9;

XX Db Best Local Similarity 100.0%; Pred. No. 1.8e+06;

XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX 1 RAFVTIGK 8

XX 2 RAFVTIGK 9

XX RESULT 7

XX AAY03692

XX ID AAY03692 standard; peptide; 9 AA.

XX AC AAY03692;

XX DT 17-OCT-2003 (revised)

XX DT 07-JUN-1999 (first entry)

XX DE Amino acid fragment of CTL epitope of HIV/SIV (H) string.

XX CC CD8+ T-cell; immune response; antigen; priming composition; CTL; epitope;

XX KW cytotoxic T lymphocyte; boosting; poxvirus vector; PVV; pathogen; tumour;

XX KW malaria; parasite; P. falciparum; viral; bacterial; parasitic; cancer;

XX KW melanoma; HIV; breast; colon; vaccination.

XX OS Human immunodeficiency virus 1.

XX PN WO9856919-A2.

XX PD 17-DEC-1998.

XX PF 09-JUN-1998; 98WO-GB001681.

XX PR 09-JUN-1997; 97GB-00011957.

XX PA (ISIS-) ISIS INNOVATION LTD.

XX PI McMichael AJ, Hill AVS, Gilbert SC, Schneider J, Plebanski M;

XX PI Hanke T, Smith GL, Blanchard T;

XX DR WPI; 1999-070325/06.

XX Generating CD8-positive T cell response to target antigen using recombinant poxvirus - for treating or preventing malaria and HIV infection, also epitope strings from Plasmodium and HIV.

XX Claim 43; Page 20; 85pp; English.

XX The invention relates to methods and reagents for generating a protective CD8+ T-cell immune response against at least one target antigen. The kits of the invention comprises (i) as priming composition, a source of one or more CD8+ T-cell cytotoxic T lymphocytes-(CTL) epitopes of the target antigen, plus a carrier and (ii) as boosting composition a source of CTL epitopes, with at least one CTL epitope the same as used in (i), with this source being a non-replicating or replication-impaired recombinant poxvirus vector (PVV) plus a carrier. If the source of CTL epitopes in (i) is a viral vector, then the vector in (ii) is from a different virus. The kits are used to generate an immune response (prophylactic or therapeutic) against pathogens or tumours, specifically against malaria parasites such as P. falciparum, or HIV, and also many other bacterial, viral or parasitic pathogens. The kits are also used for protective response against melanoma and cancer of breast or colon, and generally wherever a strong CD8+ response is protective. The boosting composition may be used alone to boost a naturally primed response against malaria. The specified PVV provide an excellent booster effect, better than that from wild-type poxvirus, resulting in complete rather than partial protection against sporozoite challenge. Also PVV are safer to use than

CC wild-type virus. Sequences AAU03681-704 represent CTL peptide epitopes of
 CC the HIV/SIV (H) epitope string. (Updated on 17-OCT-2003 to standardise OS
 CC field)

XX Sequence 9 AA;
 SQ Query Match 100.0%; Score 39; DB 2; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTIGK 8
 Db 2 RAFVTIGK 9
 |||||

RESULT 8
 AAU96033
 ID AAU96033 standard; protein; 9 AA.

XX AC AAU96033;
 XX 29-AUG-2003 (revised)
 DT 02-JUL-2002 (first entry)
 XX HIV epitope, HIV-1 gp120 B*2705, peptide sequence.
 DE Vaccine; non-replicating; viral tubule; immunogen; antibody; BTV;
 KW Bluetongue virus; foot and mouth disease virus; FMDV; influenza virus;
 KW human immunodeficiency virus; HIV; protective immunity; epitope; TUB;
 KW virus-derived tubule; anti-HIV; virucide.

XX OS Human immunodeficiency virus 1.
 XX WO200226254-A2.
 XX 04-APR-2002.

XX 27-SEP-2001; 2001WO-US030464.

XX 27-SEP-2000; 2000US-0235614P.

XX (UABR-) UAB RES FOUND.

XX Roy P;

XX WPI; 2002-339987/37.

XX A vaccine, for inducing an antiviral immune response, comprises a non-
 PT replicating vaccine delivery vehicle (which comprises a non-infectious
 PT recombinant viral tubule) carrying one or more immunogens.

XX Claim 8; Page 39; 65pp; English.

XX The present invention relates to a new vaccine comprising a non-
 CC replicating vaccine delivery vehicle (which comprises a non-infectious
 CC recombinant viral tubule) carrying one or more immunogens. The invention
 CC is useful for inducing an immune response, preferably anti-viral, in a
 CC subject. The administration of the vaccine is preferably followed by
 CC administering one or more virus like particles carrying an immunogen. It
 CC is also useful for administering to a patient for generating antibodies
 CC specific for one or more immunogens, such as Bluetongue virus (BTV), foot
 CC and mouth disease virus (FMDV), influenza virus and human
 CC immunodeficiency virus (HIV). The invention provides an effective means
 CC of delivering multiple peptide components representing viral/tumour
 CC antigenic groups to elicit protective immunity, which has not previously
 CC been possible. The present amino acid sequence represents one of a
 CC collection (AAU96022-AAU96045) of HIV epitopes that were used in the
 CC methods of the invention as immunogens. These epitopes were used to
 CC construct chimeric NSI-TUBS (virus-derived tubules) which show
 CC immunogenicity. (Updated on 29-AUG-2003 to standardise OS field)

XX Sequence 9 AA;

Query Match 100.0%; Score 39; DB 5; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTIGK 8
 Db 2 RAFVTIGK 9
 |||||

RESULT 9
 ABG79839
 ID ABG79839 standard; peptide; 9 AA.

XX AC ABG79839;
 XX 15-NOV-2002 (first entry)
 DT MHC class I molecule, viral epitope #87.
 XX Major histocompatibility complex; MHC; MHC class I molecule; virus;
 KW epitope; cytotoxic T lymphocyte response; CTL response; lymphatic system;
 KW antigen; immunogenic; malignant tumour; carcinoma; melanoma; leukaemia;
 KW lymphoma; infectious disease; hepatitis; malaria; measles; tuberculosis;
 KW acquired immune deficiency syndrome; AIDS.

XX OS Human immunodeficiency virus.

XX WO200262368-A2.

XX 15-AUG-2002.

XX 22-JAN-2002; 2002WO-US0020233.

XX 02-FEB-2001; 2001US-00776232.

XX (CTLI-) CTL IMMUNOTHERAPIES CORP.

XX Kundig TM, Simard JUl;

XX WPI; 2002-657506/70.

XX Inducing or sustaining immunological cytotoxic T lymphocyte response in a
 PT mammal, useful for treating a mammal with malignant tumor or infectious
 PT disease, by directly administering an antigen to the lymphatic system of
 PT the mammal.

XX Disclosure; Page 20; 73pp; English.

XX The invention relates to a method of inducing and/or sustaining an
 CC immunological cytotoxic T lymphocyte (CTL) response in a mammal
 CC comprising administering directly to the lymphatic system of the mammal:
 CC (a) an antigen in the form of a polypeptide; (b) a vector comprising a
 CC nucleic acid encoding the antigen; or (c) a non-peptide antigen. The
 CC method is useful for inducing and/or sustaining CTL response in a mammal.
 CC This is particularly useful for treating a mammal having a malignant
 CC tumour (e.g. carcinoma, melanoma, leukaemia or lymphoma) or infectious
 CC disease (e.g. hepatitis, acquired immune deficiency syndrome (AIDS),
 CC malaria, measles or tuberculosis), or in an animal having a
 CC predisposition to these diseases. The mammal may be dogs, cats, mice,
 CC cattle, sheep, pigs, goats, rabbits, or preferably humans. ABG79753-
 CC ABG80319 represent viral epitopes on major histocompatibility complex
 CC (MHC) class I molecules, used in the method of the invention

XX Sequence 9 AA;

Query Match 100.0%; Score 39; DB 5; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTIGK 8
 Db 2 RAFVTIGK 9
 |||||

```

RESULT 10
ADE79993
ID ADE79993 standard; peptide; 9 AA.
XX
XX
AC ADE79993;
XX
XX
DT 29-JAN-2004 (first entry)
XX
DE HIV1 carrier peptide to augment anti-malaria CD8+ T-cell immune response.
XX
XX antimalarial; cytostatic; vaccine; immune response;
KW non-hepadnaviral antigen; hepatitis B core particle; CD8+ T-cell;
KW epitope; poxvirus vector; cancer; malaria; epitope.
XX
OS Human immunodeficiency virus 1.
XX
XX WO2003066833-A2.
XX
PD 14-AUG-2003.
XX
XX 07-FEB-2003; 2003WO-US003897.
XX
XX 08-FEB-2002; 2002US-0354963P.
XX
PA (UUNY-) UNIV NEW YORK MEDICAL CENT.
XX
PI Zavala F, Birkett AJ;
XX
XX WPI; 2003-748124/70.
XX
XX Generating an immune response against a non-hepadnaviral antigen in a
PT mammal, useful for treating or preventing cancer or malaria, by
PT administering a priming component comprising a recombinant hepatitis B
PT core particle.
XX
PS Disclosure; SEQ ID NO 49; 85pp; English.
XX
XX The invention relates to a method of generating an immune response
CC against a non-hepadnaviral antigen in a mammal by administering (to the
CC mammal) at least 1 dose of a priming component comprising a recombinant
CC hepatitis B core particle (rHEP) (which is a carrier for 1 or more non-
CC hepadnaviral CD8+ T-cell epitopes of the antigen). The method may be
CC supplemented by the use of a boosting stage comprising a non-replicating
CC or replication-impaired recombinant poxvirus vector. The method is useful
CC for generating an immune response against a non-hepadnaviral antigen in a
CC mammal for treating or preventing cancer or malaria. This sequence
CC represents a peptide from human immunodeficiency virus type 1 (HIV-1)
CC used as a carrier peptide to augment the immune response against a
CC Plasmodium peptide.
XX
XX Sequence 9 AA;
SQ
Query Match 100.0%; Score 39; DB 7; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTIGK 8
Db 2 RAFVTIGK 9
|||||

RESULT 11
ADK50933
ID ADK50933 standard; peptide; 9 AA.
XX
XX ADK50933;
XX
DT 04-NOV-2004 (first entry)
XX
DE Breast/bladder carcinoma-related HLA-B*2705-binding peptide.
XX
XX C35 epitope; cytostatic; vaccine; tumour; breast; bladder carcinoma;
KW

```

```

KW HLA-B*2705.
XX
OS Unidentified.
XX
PN WO2003104428-A2.
XX
XX 18-DEC-2003.
XX
XX 10-JUN-2003; 2003WO-US018252.
XX
XX 10-JUN-2002; 2002US-0386738P.
XX
XX 11-DEC-2002; 2002US-0432241P.
XX
XX 23-APR-2003; 2003US-0464650P.
XX
XX (VACC-) VACCINEX INC.
XX
XX (UYRP ) UNIV ROCHESTER.
XX
XX Zauderer M, Evans EE, Borrello MA;
XX
XX WPI; 2004-062349/06.
XX
XX Novel C35 polypeptide useful for formulation of immunogenic composition
PT to induce antibodies and cell-mediated immunity against tumor cells.
XX
XX Example 12; Page 493; 626pp; English.
XX
XX The invention relates to a novel isolated polypeptide comprising or
CC consisting of two or more C35 peptide epitopes. The polypeptide of the
CC invention demonstrates cytostatic activity and may be useful for the
CC formulation of an immunogenic composition, such as a vaccine, to induce
CC antibodies and cell-mediated immunity against target cells such as tumour
CC cells. Furthermore, the polypeptide and its analogues may be useful as
CC prognostic markers for carcinoma, such as human breast or bladder
CC carcinoma. The current sequence is that of breast/bladder carcinoma-
CC related HLA-B*2705-binding peptide of the invention.
XX
XX Sequence 9 AA;
SQ
Query Match 100.0%; Score 39; DB 8; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTIGK 8
Db 2 RAFVTIGK 9
|||||

RESULT 12
ADR69467
ID ADR69467 standard; peptide; 9 AA.
XX
XX ADR69467;
XX
XX 18-NOV-2004 (first entry)
XX
XX Novel hybrid antigen-related peptide SeqID115.
XX
XX hybrid antigen; antigenic domain; infectious agent; tumour antigen;
KW binding domain; heat shock protein; antimicrobial; cytostatic; vaccine;
KW gene therapy; infectious disease; cancer; HLA-A2; binding peptide.
XX
XX Viruses.
XX
XX WO2004071457-A2.
XX
XX 26-AUG-2004.
XX
XX 13-FEB-2004; 2004WO-US004340.
XX
XX 13-FEB-2003; 2003US-0447142P.
XX
XX 11-APR-2003; 2003US-0462469P.
XX
XX 18-APR-2003; 2003US-0463746P.
XX
XX 16-SEP-2003; 2003US-0503417P.

```

```

PR 12-FEB-2004; 2004US-00776521.
XX (MOJA-) MOJAVE THERAPEUTICS INC.
XX
XX Fletchner J, Prince-Cohane K, Mehta S, Slusarewicz P, Andjelic S;
XX Barber B;
XX WPI; 2004-625768/60.
XX
XX New hybrid antigens comprising an antigenic domain and improved heat
XX shock protein-binding domains, useful for preventing or treating
XX infectious diseases or cancer.
XX
XX Disclosure; SEQ ID NO 115; 56pp; English.
XX
XX This invention relates to a novel hybrid antigen which comprises at least
XX one antigenic domain of an infectious agent or tumour antigen and a
XX binding domain that non-covalently binds to a heat shock protein. The
XX invention may be useful for the production of compounds with an
XX antimicrobial or cytostatic activity. In addition, the invention may
XX prove useful for the production of a vaccine or for gene therapy. The
XX composition and methods disclosed are useful for preventing or treating
XX infectious diseases or cancer. The present sequence is that of a HLA-A2
XX binding peptide which was used in the exemplification of the invention.
XX
XX SQ Sequence 9 AA;
    Query Match      100.0%; Score 39; DB 8; Length 9;
    Best Local Similarity 100.0%; Pred. No. 1.8e+06;
    Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTICK 8
Db 2 RAFVTICK 9
    |||||

RESULT 13
AAW76840
ID AAW76840 standard; peptide; 10 AA.
XX
XX AAW76840;
XX
XX 25-JAN-1999 (first entry)
XX
XX Fusion immunoglobulin heavy chain HIV gp120 B cell epitope #10.
XX
XX B cell; T cell; epitope; immunoglobulin; heavy chain; gp120; IgH;
XX human immune deficiency virus; HIV; tolerance; treatment; therapy;
XX prophylaxis; vaccine; chemotherapy; immune response; modifier; tumour;
XX microbial infection; autoimmune disease; antibody; apoptosis;
XX antiviral T cell immunity.
XX
XX Mus sp.
XX Homo sapiens.
XX
XX WO9836087-A1.
XX
XX 20-AUG-1998.
XX
XX 13-FEB-1998; 98WO-US002766.
XX
XX 13-FEB-1997; 97US-0040581P.
XX
XX (AMNA-) AMERICAN NAT RED CROSS.
XX
XX Scott D, Zambidis E;
XX
XX WPI; 1998-506315/43.
XX
XX New fusion immunoglobulin heavy chain including gp120 epitopes and
XX related complete antibodies - DNA, vectors and transformed cells, used to
XX induce tolerance to the epitopes for treatment of human immune deficiency
XX virus infection.
XX

```

```

XX Claim 10; Page 119; 154pp; English.
XX
XX This sequence is an epitope used in the construction of a novel fusion
XX immunoglobulin heavy chain (IgH) protein with a mammalian, especially
XX human, IgH chain fused in frame at its N-terminus to one or more human
XX immune deficiency virus (HIV) gp120 epitopes. Fusion Ig proteins and/or
XX transfected cells are used to tolerate subjects to gp120 epitopes and to
XX maintain this tolerance, particularly for treatment of HIV infection.
XX optionally together with other therapeutic/prophylactic agents such as
XX vaccines, chemotherapeutic agents and immune response modifiers. Such
XX proteins can be used against other diseases where an immune response is
XX deleterious, e.g. microbial infection, tumours or autoimmune disease.
XX Induction of tolerance suppresses production of antibodies against gp120,
XX so prevents or inhibits 'bystander' apoptosis of uninfected T cells that
XX are bound to gp120 protein, maximising induction of protective antiviral
XX T cell immunity
XX
XX SQ Sequence 10 AA;
    Query Match      100.0%; Score 39; DB 2; Length 10;
    Best Local Similarity 100.0%; Pred. No. 0.086;
    Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTICK 8
Db 2 RAFVTICK 9
    |||||

RESULT 14
AAW19056
ID AAW19056 standard; peptide; 11 AA.
XX
XX AAW19056;
XX
XX 12-JAN-1998 (first entry)
XX
XX Hypervariable region of HIV envelope glycoprotein.
XX
XX Hydrophilic; antigenic determinant; HIV; envelope; glycoprotein; env; gp;
XX recognition; B lymphocyte; type specific; antibody; vaccine; protection;
XX immune response; infection; neutralisation; hypervariable region.
XX
XX Human immunodeficiency virus.
XX
XX WO9714436-A1.
XX
XX 24-APR-1997.
XX
XX 18-OCT-1996; 96WO-US016911.
XX
XX 20-OCT-1995; 95US-00546515.
XX
XX 09-FEB-1996; 96US-00599266.
XX
XX (UYDU-) UNIV DUKE.
XX
XX Haynes BF, Palker TJ;
XX
XX WPI; 1997-244862/22.
XX
XX Synthetic human immunodeficiency virus vaccine - comprising hydrophilic
XX peptide corresponding to at least 1 antigenic determinant of envelope
XX glyco:protein recognised by B lymphocytes.
XX
XX Claim 14; Page 64; 104pp; English.
XX
XX An essentially pure hydrophilic peptide, comprising the SP-10 region of
XX the human immunodeficiency virus (HIV) envelope (env) glycoprotein (gp)
XX covalently linked to the present sequence and a carrier molecule, induces
XX the production of high titres of protective, type specific anti-HIV
XX antibodies (Ab) in a mammal. The peptide can be used in vaccines for
XX producing a protective immune response to HIV infection, while a HIV
XX neutralising Ab can be induced in a primate by administering a
XX

```


CC composition comprising HIV env peptides that disrupt gp120/gp41

CC interactions

SQ Sequence 11 AA;

Query Match 100.0%; Score 39; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.095;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTICK 8

Db 1 RAFVTICK 8

RESULT 15

AAW34472

ID AAW34472 standard; peptide; 11 AA.

XX

AC AAW34472;

XX

DT 11-MAY-1998 (first entry)

DE HIV gp120 V3 peptide.

XX

KW UDP-N-acetyl-alpha-D-galactosamine;

KW polypeptide N-acetylgalactosaminyltransferase; GalNAc-t3; human;

KW glycosylation; HIV gp120.

XX

OS Human immunodeficiency virus.

XX

PN WO9743405-A1.

XX

PD 20-NOV-1997.

XX

PF 15-MAY-1997; 97WO-DK000226.

XX

PR 15-MAY-1996; 96US-00648298.

XX

PA (CLAU/) CLAUSEN H.

XX

PA (BENN/) BENNETT E P.

XX

PI Clausen H, Bennett EP;

XX

DR WPI; 1998-008874/01.

XX

PT New isolated N-acetyl-galactosaminyl-transferase enzyme - used for the

PT production of glycosylated polypeptide(s) having particular enzymatic,

PT immunogenic or other biological or physical properties.

XX

PS Disclosure; Page 4; 70pp; English.

XX

CC This HIV-V3 peptide was used, together with a fibronectin peptide (see

CC AAW34471), to demonstrate the acceptor substrate specificity of a novel

CC human UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-

CC acetylgalactosaminyltransferase (GalNAc-T3) (see AAW34470). GalNAc-T3 has

CC a hitherto unknown acceptor substrate specificity exemplified by its

CC ability to glycosylate these peptides. The enzyme initiates O-

CC glycosylation of specific serine and threonine in proteins by adding N-

CC acetylgalactosamine to the hydroxy group of these amino acids. It is used

CC in claimed methods for the glycosylation of peptides and proteins and for

CC producing vaccines by modifying the O-glycosylation pattern of eukaryotic

XX cells

SQ Sequence 11 AA;

Query Match 100.0%; Score 39; DB 2; Length 11;

Best Local Similarity 100.0%; Pred. No. 0.095;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTICK 8

Db 2 RAFVTICK 9

RESULT 16

AAW62152

ID AAR62152 standard; peptide; 12 AA.

XX

AC AAR62152;

XX

DT 27-AUG-2003 (revised)

DT 25-MAR-2003 (revised)

DT 02-MAY-1995 (first entry)

XX

DE HIV-1 gp120/41 protein consensus binding sequence.

XX

KW Small ribonucleoprotein complex; UI snRNP; 70K protein; epitope;

KW autoantibody; immunoinfective cluster virus; nuclear protein antigen;

KW systemic rheumatic disorder; human immunodeficiency virus; HIV-1;

KW systemic lupus erythematosus; mixed connective tissue disease;

KW scleroderma; glycoprotein 120; glycoprotein 41.

XX

OS Human immunodeficiency virus 1.

XX

PN WO9420141-A1.

XX

PD 15-SEP-1994.

XX

PF 10-MAR-1994; 94WO-US002631.

XX

PR 11-MAR-1993; 93US-00029850.

XX

PA (UYSC-) UNIV SOUTHERN CALIFORNIA.

XX

PI Douvas A, Takehana Y, Ehresmann G;

XX

DR WPI; 1994-302689/37.

XX

PT Methods for treating immunoinfective cluster virus infections - utilise

PT antibodies or fragments characteristic of auto antibodies produced by

PT patients with rheumatic disorders.

XX

PS Disclosure; Page 56; 106pp; English.

XX

CC The UI snRNP is the target of high-titre, high avidity autoantibodies

CC occurring in the systemic rheumatoid disorders of mixed connective tissue

CC disease, scleroderma and systemic lupus erythematosus. It has been found

CC that some sites in the UI snRNP 70K protein (see AAR62120-R62135) are

CC homologous to sites in HIV-1 gp120/41 (AAR62136-R62152) and that anti-RNP

CC autoantibodies can be used to neutralise HIV-1. In particular, the

CC sequence AAR62152 from HIV-1 gp120 matches a consensus binding sequence

CC which is necessary and sufficient for high affinity binding to UI RNA.

CC (Updated on 25-MAR-2003 to correct PN field.) (Updated on 27-AUG-2003 to

CC correct OS field.)

XX

SQ Sequence 12 AA;

Query Match 100.0%; Score 39; DB 2; Length 12;

Best Local Similarity 100.0%; Pred. No. 0.1;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTICK 8

Db 5 RAFVTICK 12

RESULT 17

AAW54932

ID AAW54932 standard; peptide; 12 AA.

XX

AC AAW54932;

XX

DT 25-SEP-1998 (first entry)

XX

DE HIV gp120 envelope protein, peptide 127, analogue 267d.

XX

KW Immunoadsorbent; immunoassay; HIV gp120; immunogen; antibody; Human.
 XX Human immunodeficiency virus.
 XX US5763160-A.
 PN 09-JUN-1998.
 PD 07-JUN-1995; 95US-00488252.
 XX 12-FEB-1988; 88US-00155321.
 PR 01-MAR-1991; 91US-00663262.
 PR 09-JUL-1991; 91US-00726605.
 PR 19-OCT-1994; 94US-00326676.
 XX (UNBI-) UNITED BIOMEDICAL INC.
 PA Wang CY;
 XX WPI; 1998-347301/30.
 DR HIV gp120 peptides - useful as immunoassay reagents or vaccine
 XX components.
 PT Example 8; Column 21/22; 34pp; English.
 PS Peptides AAW54903-W54941 can be used as an immunoassay in an
 CC immunoassay for detecting antibodies to HIV gp120, or as an immunogen for
 CC eliciting antibodies to HIV in a mammal
 XX Sequence 12 AA;
 SQ
 Query Match 100.0%; Score 39; DB 2; Length 12;
 Best Local Similarity 100.0%; Pred. No. 0.1;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 RAFPVTIGK 8
 Db |||||
 5 RAFPVTIGK 12
 RESULT 18
 AAW22327
 ID AAW22327 standard; peptide; 13 AA.
 XX AAW22327;
 AC 17-OCT-2003 (revised)
 XX 18-SEP-1997 (first entry)
 DT HIV-1 strain IIIB gp120 V3 loop peptide.
 DE Epitope; human immunodeficiency virus type 1; HIV-1; gp120; gp160;
 XX monoclonal antibody; V3 loop; immunisation; mouse; splenocyte; hybridoma;
 KW membrane fraction; passive immunisation; human.
 XX Human immunodeficiency virus 1.
 OS US5618922-A.
 XX 08-APR-1997.
 PN 25-JUL-1994; 94US-00279906.
 XX 25-JUL-1994; 94US-00279906.
 PR (NISP) NISSIN SHOKUHIN KAISHA LTD.
 XX Yoneda Y, Ohno T, Terada M;
 PI WPI; 1997-225475/20.
 DR Monoclonal antibody specific for human immunodeficiency virus type 1 MN
 XX
 PT strain - for passive immunisation against infection.
 Example 3; Col 10; 14pp; English.
 The invention relates to a novel monoclonal antibody (MAB) NM03 which
 binds to epitopes from the human immunodeficiency virus type 1 (HIV-1).
 The antibody was raised conventionally by immunising Balb/c mice with
 purified live HIV-1 MN, then isolating splenocytes and fusing them to P3-
 X63-Ag8-UI cells. Hybridomas were then screened with membrane fractions
 from infected and non-infected H9 cells. The MAB was observed to bind to
 a protein band of 120 kD on a Western blot of separated, denatured HIV-1
 proteins. This binding was shown to be between residues 320-327 by
 epitope mapping by ELISA and competitive binding. The ability of the MAB
 to inhibit infection of cells by HIV-1 shown by infecting H9 cells with
 live strains of HIV-1 and testing infection by a p24 assay. This peptide
 sequence represents the V3 loop region from HIV-1 strain IIIB, where the
 MAB NM03 binds. The MAB can be used for the passive immunisation of
 CC humans susceptible to, or infected with HIV-1. (Updated on 17-OCT-2003 to
 CC standardise OS field)
 XX Sequence 13 AA;
 SQ
 Query Match 100.0%; Score 39; DB 2; Length 13;
 Best Local Similarity 100.0%; Pred. No. 0.11;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 RAFPVTIGK 8
 Db |||||
 6 RAFPVTIGK 13
 RESULT 19
 AAW62890
 ID AAW62890 standard; peptide; 13 AA.
 XX AAW62890;
 AC 30-SEP-1998 (first entry)
 DT Peptide sequence of the specification.
 DE Monoclonal antibody; HIV-1gp120; gp160; infection; H9 cell;
 KW HIV strain MN; treatment; human HIV infection.
 XX Synthetic.
 OS JP10182489-A.
 PN 07-JUL-1998.
 PD 25-DEC-1996; 96JP-00344904.
 PF 25-DEC-1996; 96JP-00344904.
 PR (NISP) NISSIN SHOKUHIN KAISHA LTD.
 XX WPI; 1998-433774/37.
 DR Monoclonal antibody which binds to HIV-1gp120 or gp160 - used to prevent
 XX and treat human HIV infection.
 PT Example 3; Page 8; 12pp; Japanese.
 PS AAW62889-900 represent peptides used to identify a peptide sequence
 CC (AAW62874) present in HIV-1gp120 or gp160 which is bound by the
 CC monoclonal antibody of the invention. The antibody neutralises in vitro
 CC the infection of H9 cell by an active HIV strain MN according to the p24
 CC analytical method. The antibody is used for treatment of human HIV
 XX infection
 XX Sequence 13 AA;
 SQ
 Query Match 100.0%; Score 39; DB 2; Length 13;

Best Local Similarity 100.0%; Pred. No. 0.11; Mismatches 0; Indels 0; Gaps 0;
Matches 8; Conservative 0

QY 1 RAFVTIGK 8
Db 6 RAFVTIGK 13

RESULT 20

AAW99433
ID AAW99433 standard; peptide; 13 AA.

XX AC AAW99433;

XX DT 11-SEP-2003 (revised)

XX DT 07-DEC-2001 (first entry)

XX DE Vaccine related MHC ligand peptide SEQ ID NO:536.

XX KW Glutamic acid; glutamine; vaccine; major histocompatibility complex; MHC;
XX KW immunomodulator; antiallergic; endocrine; neuroprotectant; virucidal;
XX KW bactericidal; antiparasitic; fungicidal; cytostatic; medicine;
XX KW pharmaceutical; immune disorder; immune deficiency; autoimmune;
XX KW hypersensitivity; allergy; graft rejection; infection; hormonal disorder;
XX KW central nervous system disease; cancer; melanoma; anti-melanoma vaccine;
XX KW human immunodeficiency virus.

XX OS Human immunodeficiency virus 1.

XX PN WO20017072-A2.

XX PD 27-SEP-2001.

XX PF 22-MAR-2001; 2001WO-PRO00872.

XX PR 23-MAR-2000; 2000FR-00003711.

XX PA (FABR) FABRE MEDICAMENT SA PIERRE.

XX PI Klinguer-Hamour C, Corvaia N, Beck A, Goetsch L;

XX DR WPI; 2001-611470/70.

XX PT Stabilized pharmaceutical containing N-terminal glutamic acid or
XX PT glutamine, useful e.g. in anti-melanoma vaccines, is an addition salt
XX PT with strong acid.

XX PS Claim 9; Page 122; 149pp; French.

XX CC The present invention describes a pharmaceutical compound (I) that
XX CC contains an N-terminal glutamic acid (Glu) or glutamine (Gln) residue in
XX CC the form of an addition salt with a strong, physiologically acceptable
XX CC acid (II). Also described are: (a) a pharmaceutical composition
XX CC containing at least one (I); (b) a vaccine containing at least one (I)
XX CC where this is a major histocompatibility complex (MHC) ligand (Ia); (c) a
XX CC method for in vitro diagnosis of diseases associated with the presence of
XX CC (Ia); (d) a kit for method (c) that includes a (Ia); and (e) a process
XX CC for preparing (I). (I) has immunomodulator, endocrine, antiallergic,
XX CC neuroprotectant, virucidal, bactericidal, antiparasitic, fungicidal and
XX CC cytostatic activities. (I) are useful, in human or veterinary medicine,
XX CC in pharmaceutical compositions (for treating immune disorders, e.g.
XX CC immune deficiency, autoimmune states, hypersensitivity, allergy, graft
XX CC rejection, infection, hormonal disorders and central nervous system
XX CC diseases), also, where (I) is a MHC ligand (Ia), in vaccines for
XX CC treatment or prevention of: (i) viral, bacterial, parasitic or fungal
XX CC infections; or (ii) of cancers. A particular application is in anti-
XX CC melanoma vaccines. (I) are also useful for in vitro diagnosis of diseases
XX CC associated with interactions between MHC and (I), e.g. melanoma and human
XX CC immunodeficiency virus infection. AAW99433 to AAW99592 represent peptides
XX CC which can be used in pharmaceutical compounds from the present invention.
XX CC (Updated on 11-SEP-2003 to standardise OS field)

XX SQ Sequence 13 AA;

Query Match 100.0%; Score 39; DB 4; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
Db 6 RAFVTIGK 13

RESULT 21

AAW99433
ID AAW99433 standard; peptide; 14 AA.

XX AC AAW99433;

XX DT 25-MAR-2003 (revised)

XX DT 06-JUL-1993 (first entry)

XX DE Sequence of peptide which corresp. to the V3 loop region of gp120 of HIV-1 isolate IIIB.

XX KW Monoclonal antibody; NM-01; HIV-1; gp120; gp160.

XX OS Synthetic.

XX PN WO9304090-A1.

XX PD 04-MAR-1993.

XX PF 24-AUG-1992; 92WO-US007111.

XX PR 22-AUG-1991; 91US-00748562.

XX PA (NISP) NISSIN SHOKUHIN KAISHA LTD.

XX PI Ohno T;

XX DR WPI; 1993-093943/11.

XX PT Monoclonal antibodies against HIV-1 gp120 and gp160 proteins - for
XX PT treating and preventing HIV-1 infection.

XX PS Example; Page 20; 57pp; English.

XX CC NM-01 is a monoclonal antibody. In order to characterize the viral
XX CC epitope recognized by NM-01, the antibody was screened by ELISA for
XX CC reactivity with overlapping peptides corresponding to the amino acid sequence
XX CC of the V3 loop region of HIV-1 gp120 (AAR33332, AAR33333, AAR33334).
XX CC While there was no detectable reactivity over background of Mab-01 with
XX CC the peptides corresponding to AAs 302-316 or 322-336 of the V3 loop, binding
XX CC of the antibody to the peptide representing AAs 312-326 was apparent.
XX CC The extent of this reactivity with other HIV-1 isolates was screened with
XX CC peptides corresponding to the V3 loop region of HIV-1 isolates IIIB, RF, CDC4,
XX CC NY/5, Z6, Z2 and ELI (AAR33335-R33342). These results indicate that
XX CC monoclonal antibody NM-01 recognizes an epitope of the V3 loop of gp120
XX CC of multiple HIV-1 isolates having the amino acid sequence AAR33343. NM-01
XX CC is also putatively reactive with the RF-like peptide set out in AAR33344.
XX CC The variable region of the heavy and light chain of monoclonal antibody
XX CC NM-01 were cloned by PCR and sequenced. Nucleotides 1-21 and 334-363 of
XX CC AAR33343 correspond to the PCR primers used to amplify NM-01 light chain
XX CC sequences and nucleotides 1-27 and 385-402 of AAR33343 correspond to the
XX CC PCR primers used to amplify NM-01 heavy chain sequences. (Updated on 25-
XX CC MAR-2003 to correct PN field.)

XX SQ Sequence 14 AA;

Query Match 100.0%; Score 39; DB 2; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
Db 6 RAFVTIGK 13

Db 7 RAFVTIGK 14

RESULT 22
AAR48604
ID AAR48604 standard; peptide; 14 AA.
XX AC AAR48604;
XX DT 25-MAR-2003 (revised)
XX DT 03-SEP-1994 (first entry)
XX DE Sequence of portion of gp120 V3 loop peptide from HIV-1 isolate IIIB.
XX KW Human immunodeficiency virus; HIV-1; AIDS; glycoprotein; V3 loop; gp120;
XX KW epitope; isolate IIIB.
XX OS Human immunodeficiency virus 1.
XX PN WO9404574-A1.
XX PD 03-MAR-1994.
XX PF 24-AUG-1993; 93WO-US007967.
XX PR 24-AUG-1992; 92WO-US007111.
XX PR 22-APR-1993; 93US-00039457.
XX PA (NISP) NISSIN SHOKUIN KAISHA LTD.
XX PI Ohno T;
XX WPI; 1994-083117/10.
XX New humanised antibody specific for epitope on HIV-1 gp 120 - able to
XX neutralise infection of HG cells, also nucleic acid encoding it, useful
XX for passive immunisation to treat or prevent HIV-1 infection.
XX Example; Table 4, Page 18; 91pp; English.
XX GPCR is a portion of HIV-1 gp120 or gp160 protein. Monoclonal antibodies
XX (MABs) that react with this and which have the capacity to neutralise the
XX infection of H9 cells in culture by live HIV-1 strains MN and IIIB are
XX claimed. Specifically illustrating the invention are the murine MAB
XX (designated NM-01) produced by hybridoma cell line HB 10726 which is
XX deposited under ATCC No. HB 10726, and the humanised versions of Ab NM-
XX 01. To identify the specific epitope of gp120 recognised by NM-01, the Ab
XX was screened for reactivity with three overlapping peptides corresp. to
XX the V3 loop region of gp120 (AAR48600-02). While there was no detectable
XX reactivity over background of MAb NM-01 with the peptides corresp. to AAs
XX 302-316 or 322-336 of the V3 loop, binding of the Ab to the peptide
XX representing AAs312-326 was apparent. The demonstration that MAB NM-01
XX binds to the V3 loop region of HIV-1MN gp120 prompted further studies on
XX the extent of this reactivity with other HIV-1 isolates. The Ab was
XX screened by ELISA for reactivity with peptides corresp. to the V3 loop
XX region of HIV-1 isolates IIIB, RF, CDC4, NY/5, Z6, Z2 and ELI. The AA
XX sequences of the peptides are given in AAR48603-10. NM-01 reacted with
XX the loop peptides from the MN, IIIB, RF, and CDC4 isolates. It showed a
XX lesser affinity for the NY/5 peptide. (Updated on 25-MAR-2003 to correct
XX PN field.)
XX SQ Sequence 14 AA;
Query Match 100.0%; Score 39; DB 2; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RAFVTIGK 8
DB 7 RAFVTIGK 14
RESULT 23
AAR48604
ID AAR48604 standard; peptide; 14 AA.
XX AC AAR48604;
XX DT 25-MAR-2003 (revised)
XX DT 03-SEP-1994 (first entry)
XX DE Sequence of portion of gp120 V3 loop peptide from HIV-1 isolate IIIB.
XX KW Human immunodeficiency virus; HIV-1; AIDS; glycoprotein; V3 loop; gp120;
XX KW epitope; isolate IIIB.
XX OS Human immunodeficiency virus 1.
XX PN WO9404574-A1.
XX PD 03-MAR-1994.
XX PF 24-AUG-1993; 93WO-US007967.
XX PR 24-AUG-1992; 92WO-US007111.
XX PR 22-APR-1993; 93US-00039457.
XX PA (NISP) NISSIN SHOKUIN KAISHA LTD.
XX PI Ohno T;
XX WPI; 1994-083117/10.
XX New humanised antibody specific for epitope on HIV-1 gp 120 - able to
XX neutralise infection of HG cells, also nucleic acid encoding it, useful
XX for passive immunisation to treat or prevent HIV-1 infection.
XX Example; Table 4, Page 18; 91pp; English.
XX GPCR is a portion of HIV-1 gp120 or gp160 protein. Monoclonal antibodies
XX (MABs) that react with this and which have the capacity to neutralise the
XX infection of H9 cells in culture by live HIV-1 strains MN and IIIB are
XX claimed. Specifically illustrating the invention are the murine MAB
XX (designated NM-01) produced by hybridoma cell line HB 10726 which is
XX deposited under ATCC No. HB 10726, and the humanised versions of Ab NM-
XX 01. To identify the specific epitope of gp120 recognised by NM-01, the Ab
XX was screened for reactivity with three overlapping peptides corresp. to
XX the V3 loop region of gp120 (AAR48600-02). While there was no detectable
XX reactivity over background of MAb NM-01 with the peptides corresp. to AAs
XX 302-316 or 322-336 of the V3 loop, binding of the Ab to the peptide
XX representing AAs312-326 was apparent. The demonstration that MAB NM-01
XX binds to the V3 loop region of HIV-1MN gp120 prompted further studies on
XX the extent of this reactivity with other HIV-1 isolates. The Ab was
XX screened by ELISA for reactivity with peptides corresp. to the V3 loop
XX region of HIV-1 isolates IIIB, RF, CDC4, NY/5, Z6, Z2 and ELI. The AA
XX sequences of the peptides are given in AAR48603-10. NM-01 reacted with
XX the loop peptides from the MN, IIIB, RF, and CDC4 isolates. It showed a
XX lesser affinity for the NY/5 peptide. (Updated on 25-MAR-2003 to correct
XX PN field.)
XX SQ Sequence 14 AA;
Query Match 100.0%; Score 39; DB 2; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RAFVTIGK 8
DB 7 RAFVTIGK 14
RESULT 24
AAR66417
ID AAR66417 standard; peptide; 14 AA.
XX AC AAR66417;
XX DT 25-MAR-2003 (revised)
XX DT 03-AUG-1995 (first entry)
XX DE HIV-1 IIIB peptide 18-2.
XX KW T cell helper site; cytotoxic T cell response; neutralising antibody;
XX human immunodeficiency virus type 1; envelope glycoprotein gp120;

AAR66416
ID AAR66416 standard; peptide; 14 AA.
XX AC AAR66416;
XX DT 25-MAR-2003 (revised)
XX DT 03-AUG-1995 (first entry)
XX DE HIV-1 IIIB peptide 18-1 (316-330).
XX KW T cell helper site; cytotoxic T cell response; neutralising antibody;
XX KW human immunodeficiency virus type 1; envelope glycoprotein gp120;
XX KW cluster peptide; principal neutralising determinant.
XX OS Synthetic.
XX PN WO9426785-A1.
XX PD 24-NOV-1994.
XX PF 13-MAY-1994; 94WO-US005142.
XX PR 14-MAY-1993; 93US-00060988.
XX PA (USSH) US SEC DEPT HEALTH.
XX PI Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
XX WPI; 1995-006707/01.
XX Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
XX responses - to target antigen in hosts of different MHC haplotypes, esp.
XX for therapeutic or prophylactic vaccines against HIV.
XX Example 1; Page 33; 120pp; English.
XX Single residues from the HIV-1 RF sequence (AAR66415) replaced residues
XX in the HIV-1 IIIB sequence (AAR66414) to test the effect of each residue
XX on the binding of neutralising and non-neutralising sera from animals
XX immunised with the cluster peptides PCLUS 3-18 and PCLUS 6-18 (see
XX AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
XX R66430) showed that binding was enhanced over peptide 18 control when a
XX tyrosine was substd. for a Val at position 11 and substns. at positions
XX 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
XX sera was reduced when substns. were made in the principal neutralising
XX determinant sequence (PGRAP). In peptide 18-1, the N-terminal residue
XX (Arg) in peptide 18 has been deleted. (Updated on 25-MAR-2003 to correct
XX PN field.)
XX SQ Sequence 14 AA;
Query Match 100.0%; Score 39; DB 2; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RAFVTIGK 8
DB 7 RAFVTIGK 14
RESULT 24
AAR66417
ID AAR66417 standard; peptide; 14 AA.
XX AC AAR66417;
XX DT 25-MAR-2003 (revised)
XX DT 03-AUG-1995 (first entry)
XX DE HIV-1 IIIB peptide 18-2.
XX KW T cell helper site; cytotoxic T cell response; neutralising antibody;
XX human immunodeficiency virus type 1; envelope glycoprotein gp120;

KW cluster peptide; principal neutralising determinant.
 XX Synthetic.
 OS
 XX
 PN WO9426785-A1.
 XX
 XX 24-NOV-1994.
 PD
 XX
 XX 13-MAY-1994; 94WO-US005142.
 PF
 XX 14-MAY-1993; 93US-00060988.
 PR
 XX (USSH) US SEC DEPT HEALTH.
 PA
 XX Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
 PI
 XX WPI; 1995-006707/01.
 DR
 XX Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
 PT responses - to target antigen in hosts of different MHC haplotypes, esp.
 PT for therapeutic or prophylactic vaccines against HIV.
 XX
 XX Example 1; Page 33; 120pp; English.
 PS
 XX Single residues from the HIV-1 RF sequence (AAR66415) replaced residues
 CC in the HIV-1 IIRB sequence (AAR66414) to test the effect of each residue
 CC on the binding of neutralising and non-neutralising sera from animals
 CC immunised with the cluster peptides PCLUS 3-18 and PCLUS 6-18 (see
 CC AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
 CC R66430) showed that binding was enhanced over peptide 18 control when a
 CC tyrosine was subst. for a Val at position 11 and substns. at positions
 CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
 CC sera was reduced when substns. were made in the principal neutralising
 CC determinant sequence (PGRAF). In peptide 18-2, the Ile residue at
 CC position 2 in peptide 18 has been deleted. (Updated on 25-MAR-2003 to
 CC correct PN field.)
 XX
 SQ Sequence 14 AA;
 Query Match 100.0%; Score 39; DB 2; Length 14;
 Best Local Similarity 100.0%; Pred. No. 0.12; Mismatches 0; Gaps 0;
 Matches 8; Conservative 0; Indels 0;
 QY 1 RAFVTIGK 8
 DB |||||
 7 RAFVTIGK 14
 DE
 XX
 RESULT 25
 AAW09264
 ID AAW09264 standard; peptide; 14 AA.
 XX
 AC AAW09264;
 XX
 XX 25-MAR-2003 (revised)
 DT 03-MAR-1997 (first entry)
 XX
 XX HIV-1 strain IIRB gp120 V3 loop peptide.
 DE
 XX Human immunodeficiency virus type-1; HIV-1; gp120; epitope;
 KW monoclonal antibody; infection; heavy chain; light chain; hybridoma;
 KW complementarity determining region; CDR; V3 loop.
 XX
 XX Synthetic.
 OS
 XX US5558865-A.
 PN
 XX 24-SEP-1996.
 PD
 XX 24-AUG-1993; 93US-00111080.
 PF
 XX 22-AUG-1991; 91US-00748562.
 PR 24-AUG-1992; 92WO-US0007111.
 PR

PR 22-APR-1993; 93US-00039457.
 XX
 PA (NISP) NISSIN SHOKUHIN KAISHA LTD.
 XX
 PI Ohno T;
 XX
 XX WPI; 1996-442363/44.
 DR
 XX New monoclonal antibodies to HIV-1 - used for the prevention, treatment
 PT or diagnosis of HIV-1 infection.
 XX
 XX Example 2; Col 11; 56pp; English.
 PS
 XX The invention relates to a novel monoclonal antibody designated NM-01.
 CC The antibody was raised by immunising 2-month old Balb/c mice with live
 CC HIV-1 strain MN. Splenocytes from the mice were fused to P3-X63-Ag8-U1
 CC cells (ATCC CRL1597). Hybridomas were screened using membranes from non-
 CC infected and MN-infected H9 cells, by reacting with hybridoma culture
 CC supernatants. This screening was followed by immunofluorescence and
 CC radioimmunoassays. The screening isolated the hybridoma HB 10726 which
 CC secretes the antibody NM-01. The peptides AAW09263-72 are derived from
 CC other HIV strains and were used to determine which other HIV-1 isolates
 CC antibody NM-01 reacted with. This peptide is from HIV-1 strain IIRB. The
 CC antibody is used for the diagnosis of HIV-1 in a fluid e.g. blood, and
 CC can be used to treat or prevent an HIV-1 infection. (Updated on 25-MAR-
 CC 2003 to correct PF field.)
 XX
 SQ Sequence 14 AA;
 Query Match 100.0%; Score 39; DB 2; Length 14;
 Best Local Similarity 100.0%; Pred. No. 0.12; Mismatches 0; Gaps 0;
 Matches 8; Conservative 0; Indels 0;
 QY 1 RAFVTIGK 8
 DB |||||
 7 RAFVTIGK 14
 DE
 XX
 XX 25-JAN-1999 (first entry)
 DT
 XX Fusion immunoglobulin heavy chain HIV gp120 B cell epitope #34.
 DE
 XX B cell; T cell; epitope; immunoglobulin; heavy chain; gp120; IgH;
 KW human immune deficiency virus; HIV; tolerance; treatment; therapy;
 KW prophylaxis; vaccine; chemotherapy; immune response; modifier; tumour;
 KW microbial infection; autoimmune disease; antibody; apoptosis;
 KW antiviral T cell immunity.
 XX
 XX Mus sp.
 OS Homo sapiens.
 OS
 XX WO9836087-A1.
 PN
 XX 20-AUG-1998.
 PD
 XX 13-FEB-1998; 98WO-US002766.
 PF
 XX 13-FEB-1997; 97US-0040581P.
 PR
 XX (AMNA-) AMERICAN NAT RED CROSS.
 PA
 XX Scott D, Zambidis E;
 PI
 XX WPI; 1998-506315/43.
 DR
 XX New fusion immunoglobulin heavy chain including gp120 epitopes and
 XX related complete antibodies - DNA, vectors and transformed cells, used to
 PT

PT induce tolerance to the epitopes for treatment of human immune deficiency
 PT virus infection.

PS Claim 10; Page 119; 154pp; English.

XX
 CC This sequence is an epitope used in the construction of a novel fusion
 CC immunoglobulin heavy chain (Igh) protein with a mammalian, especially
 CC human, IGH chain fused in frame at its N-terminus to one or more human
 CC immune deficiency virus (HIV) gp120 epitopes. Fusion Ig proteins and/or
 CC transfect cells are used to tolerate subjects to gp120 epitopes and to
 CC maintain this tolerance, particularly for treatment of HIV infection,
 CC optionally together with other therapeutic/prophylactic agents such as
 CC vaccines, chemotherapeutic agents and immune response modifiers. Such
 CC proteins can be used against other diseases where an immune response is
 CC deleterious, e.g. microbial infection, tumours or autoimmune disease.
 CC Induction of tolerance suppresses production of antibodies against gp120,
 CC so prevents or inhibits 'bystander' apoptosis of uninfected T cells that
 CC are bound to gp120 protein, maximising induction of protective antiviral
 CC T cell immunity

XX SQ Sequence 14 AA;

Query Match 100.0%; Score 39; DB 2; Length 14;
 Best Local Similarity 100.0%; Pred. No. 0.12; Indels 0; Gaps 0;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTIGK 8
 |||||
 Db 5 RAFVTIGK 12

RESULT 27

AAP82095
 ID AAP82095 standard; peptide; 15 AA.

XX AC AAP82095;

XX 25-MAR-2003 (revised)
 DT 17-DEC-2001 (revised)
 DT 29-OCT-1990 (first entry)

XX Env-K1 peptide.

XX Env-K1; gp160 Env protein; T-cell cytotoxicity; HIV.

XX Synthetic.

XX USN7148692-N.

XX 02-AUG-1988.

XX 26-JAN-1988; 88US-00148692.

XX 26-JAN-1988; 88US-00148692.

XX (USSH) US DEPT HEALTH & HUMAN SERVICE.

XX (USDC) US SEC OF COMMERCE.

XX Berzofsky J, Takahashi H, Hosmalin A, Germain R, Moss B;

XX WPI; 1988-264280/37.

XX Synthetic peptide corresp. to HIV GP 160 ENV sequence - which elicits
 PT cytotoxicity by T cells against HIV and proliferation of HIV-specific
 PT cytotoxic T cells.

PS Disclosure; Page 7; 31pp; English.

XX This peptide elicits cytotoxicity by T-cells against HIV antigens and
 CC stimulates prodn. of HIV-specific cytotoxic T-lymphocytes (CTLs). It is
 CC specific for the HIV envelope protein gp160. (Note: Revised entry
 CC submitted to correct the patent number format of US Government-owned NTIS
 CC applications to prevent clashes with ongoing US granted patent numbers.

CC For further information please visit the Derwent web site at
 CC www.derwent.com/dwpi/updates/ntis_us.html.) (Updated on 25-MAR-2003 to
 CC correct PF field.) (Updated on 25-MAR-2003 to correct PA field.)

XX SQ Sequence 15 AA;

Query Match 100.0%; Score 39; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.13; Indels 0; Gaps 0;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTIGK 8
 |||||
 Db 8 RAFVTIGK 15

RESULT 28

AAP91228
 ID AAP91228 standard; peptide; 15 AA.

XX AC AAP91228;

XX 24-OCT-2003 (revised)
 DT 27-AUG-2003 (revised)
 DT 25-MAR-2003 (revised)
 DT 13-AUG-1990 (first entry)

XX Peptide comprising AAs 308-322 of HIV-1 IIIB env protein.

XX AIDS; HIV-I; vaccine.

XX Human immunodeficiency virus 1.

XX EP339504-A.

XX 02-NOV-1989.

XX 21-APR-1989; 89EP-00107197.

XX 26-APR-1988; 88US-00186333.

XX 20-MAR-1989; 89US-00324027.

XX (DUPO) DU PONT DE NEMOURS & CO E I.

XX (DUPO) DU PONT MERCK PHARMACEUTICAL CO.

XX Kenealy WR, Petteway SR, Durda PJ;

XX WPI; 1989-317386/44.

XX Synthetic human immuno-deficiency virus env-coded peptide(s) - induce
 PT antibodies that block human immuno-deficiency virus proliferation and
 PT fusion between infected and non-infected cells.

XX Claim 3; Page 21; 24pp; English.

XX Peptide will induce an immune response in subject, and will thus act as a
 CC non-infective vaccine, prophylactic or have therapeutic value for AIDS
 CC patients. (Updated on 25-MAR-2003 to correct PA field.) (Updated on 27-
 CC AUG-2003 to correct OS field.) (Updated on 24-OCT-2003 to standardise OS
 CC field)

XX SQ Sequence 15 AA;

Query Match 100.0%; Score 39; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.13;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTIGK 8
 |||||
 Db 8 RAFVTIGK 15

RESULT 29

AAR06294

ID AAR06294 standard; protein; 15 AA.
 XX AC AAR06294;
 XX DT 24-OCT-2003 (revised)
 XX DT 17-DEC-1990 (first entry)
 XX DE Peptide derived from HIV-1 gp 120 envelope glycoprotein.
 XX KW AIDS; vaccine; T-cell proliferation; keyhole limpet haemocyanin.
 XX OS Human immunodeficiency virus 1.
 XX PN US9493628-A.
 XX PD 24-JUL-1990.
 XX PF 13-JUN-1988; 88US-00205983.
 XX PR 13-JUN-1988; 88US-00205983.
 XX PA (ORTH) ORTHO PHARM CORP.
 XX PI Rosen JI, Warner JF;
 XX DR WPI; 1990-246652/32.
 XX PT Peptide(s) derived from HIV-1 - stimulate T-cell proliferation, etc.
 XX PT useful in immunisation against HIV.
 XX PS Claim 1; Page 13; 13pp; English.
 XX CC Peptide is a fragment of HIV-1 gp 120 glyco-protein, useful in providing
 CC vaccines, preferably operatively linked to an immunogenic carrier eg.
 CC keyhole limpet haemocyanin, HSA, tetanus toxoid etc. (Updated on 24-OCT-
 CC 2003 to standardise OS field)
 XX SQ Sequence 15 AA;
 Query Match 100.0%; Score 39; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.13; Mismatches 0; Indels 0; Gaps 0;
 Matches 8; Conservative 0;
 QY 1 RAFVTIGK 8
 Db 2 RAFVTIGK 9
 AAR21343
 ID AAR21343 standard; protein; 15 AA.
 XX AC AAR21343;
 XX DT 25-MAR-2003 (revised)
 XX DT 16-MAY-1992 (first entry)
 XX DE HIV-1 gp120 epitope found in mouse immunoglobulin BAT123 and mouse/human
 DE chimeric antibody CAG1-51-4.
 XX KW Chimeric immunoglobulin; viral-neutralising; HIV-1;
 KW BAT123 mouse immunoglobulin; viral antigen-binding region; immunotherapy;
 KW AIDS; ARC; ss.
 XX OS Human immunodeficiency virus 1.
 XX PN WO9201719-A.
 XX PD 06-FEB-1992.
 XX PF 18-JUL-1990; 90WO-US004048.
 XX PR 18-JUL-1990; 90WO-US004048.

XX (TANO-) TANOX BIOSYST INC.
 XX PA Liov RS, Rosen EM, Sun BN, Pung MS, Chang TW, Chang NT;
 XX PI WPI; 1992-064897/08.
 XX DR
 XX PT New chimeric HIV-1-neutralising immunoglobulin(s) - comprising non-human
 PT antigen binding regions and constant human region, for immuno-therapy of
 PT AIDS and ARC.
 XX PS Example; Page 26; 39pp; English.
 XX CC The inventors claim a chimeric, viral-neutralising immunoglobulin which
 CC binds to the gp120 region of HIV-1 with a potency and immunologic
 CC specificity equal to BAT123 mouse Ig. It comprises a viral-specific
 CC antigen-binding region of non-human origin and a constant region of
 CC human origin. Specifically claimed is the chimeric immunoglobulin CGP
 CC 47439. Probes V-kappa-1 and V-kappa-2 (AAQ21497, AAQ21498) were used to
 CC screen a genomic DNA library for BAT123 cells for the functionally
 CC rearranged variable region gene of BAT123 light chain (VL). The
 CC identified clone, V-kappa-123-23, was used in the subsequent construction
 CC of the mouse/human chimeric L chain gene. Probe VH-1 was used to screen
 CC partial genomic libraries for the functionally rearranged variable region
 CC genes for BAT123 heavy chain (VH). Clone VH-123-E3 hybridised with the
 CC chimeric H chain gene. This clone was used in the construction of the mouse-human
 CC chimeric H chain gene. The chimeric antibody CAG1-51-4 was found to bind
 CC to the same oligopeptide (AAR21343) as BAT123 which indicates that the
 CC antigen specificity of the murine antibody BAT123 was preserved upon
 CC conversion into a mouse/human chimeric antibody. (Updated on 25-MAR-2003
 CC to correct PR field.)
 XX SQ Sequence 15 AA;
 Query Match 100.0%; Score 39; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.13; Mismatches 0; Indels 0; Gaps 0;
 Matches 8; Conservative 0;
 QY 1 RAFVTIGK 8
 Db 8 RAFVTIGK 15
 AAR38187
 ID AAR38187 standard; peptide; 15 AA.
 XX AC AAR38187;
 XX DT 27-AUG-2003 (revised)
 XX DT 25-MAR-2003 (revised)
 XX DT 12-OCT-1993 (first entry)
 XX DE V3 loop peptide D44 (R15K).
 XX KW gp120; HIV-1; cytotoxic T-lymphocyte; CTL; T-helper; AIDS; infection.
 XX OS Human immunodeficiency virus 1.
 XX PN WO9310816-A1.
 XX PD 10-JUN-1993.
 XX PF 02-DEC-1992; 92WO-US010378.
 XX PR 02-DEC-1991; 91US-00800932.
 XX PR 16-SEP-1992; 92US-00945865.
 XX PA (TEXA) UNIV TEXAS SYSTEM.
 XX PI Sastry JK, Arlinghaus RB, Plattsoucas CD, Nehete PN;
 XX WPI; 1993-196739/24.

XX Peptide composition for treating and preventing viral infections -
PT comprise CTL-inducing epitope and HIV infection-inhibiting sequence or T
PT helper cell-inducing sequence.
XX
XX Claim 13 + 19; Page 94-95; 130pp; English.
XX
CC HIV gp120 V3 loop-derived peptides (AAR38170-87) are successful in
CC generating CTL responses, esp. peptide R15K (AAR38187); the T-helper cell
CC -inducing peptide includes the sequence C19A (AAR38184); HIV infection-
CC inhibiting peptides are given in AAR38188-206, and are esp. peptides
CC R15K, N24G, E13V, R8K, T13Q and H13N (AAR38165-69). The peptides may also
CC be derived from an influenza virus protein or a sendai virus protein
CC (AAR41014-15). It was observed that peptide R15K (amino acids 315-329),
CC with sequences derived from the V3 loop of HIV-1 IIIB, inhibits HIV-1,
CC infection of primary human T cells by 92% at 1 microg/ml (ca. 0.4-0.6
CC microm). (Updated on 25-MAR-2003 to correct PN field.) (Updated on 27-AUG
CC -2003 to correct OS field.)
XX
XX Sequence 15 AA;
XX
XX Query Match 100.0%; Score 39; DB 2; Length 15;
XX Best Local Similarity 100.0%; Pred. No. 0.13;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 RAFVTIGK 8
XX |||||
XX Db 8 RAFVTIGK 15
XX
XX
XX RESULT 32
XX AAR32207
XX ID AAR32207 standard; peptide; 15 AA.
XX
XX AC AAR32207;
XX
XX DT 24-OCT-2003 (revised)
XX DT 17-DEC-2001 (revised)
XX DT 07-JUN-1993 (first entry)
XX
XX DE Sequence of peptide which corresp.to AA residues 315-329 of the V3 loop
XX of the gp160 envelope glycoprotein in HIV-1 strain MN.
XX
XX DE V3 loop; envelope glycoprotein; gp160; HIV-1; prophylaxis; immunotherapy.
XX
XX KW Human immunodeficiency virus; (HIV-1) isolate IIIB.
XX OS
XX USN7760530-N.
XX PN
XX PD 15-DEC-1992.
XX
XX PF 18-SEP-1991; 91US-00760530.
XX
XX PR 18-SEP-1991; 91US-00760530.
XX
XX PA (USSH) US DEPT HEALTH & HUMAN SERVICE.
XX
XX PI Berzofsky JA, Takahashi H, Germain RN;
XX WPI; 1993-058406/07.
XX
XX DR
XX
XX PT Peptide(s) corresponding to the V3 loop of gp=160 of HIV-1 - elicit
XX PT cytotoxic T lymphocyte(s) active against broad range of HIV-1 isolate(s).
XX
XX PS Example; Page 19; 41pp; English.
XX
XX CC The peptide corresponds to amino acid residues numbered 315-329 in the V3
XX CC loop of the envelope glycoprotein gp160 of human immunodeficiency virus
XX CC (HIV-1), as numbered by Ratner in the strain MN. It is useful for the
XX CC prophylaxis or immunotherapy of HIV-1 infection. It elicits an immunised
XX CC subject cytotoxic T lymphocyte (CTL) activity against the corresp.
XX CC clinical isolate of HIV-1. (Note: Revised entry submitted to correct
XX CC patent number format of US Government-owned NTIS applications to prevent

CC clashes with ongoing US granted patent numbers. For further information
CC please visit the Derwent web site at
CC www.derwent.com/dwpi/updates/ntis_us.html.) (Updated on 24-OCT-2003 to
CC standardise OS field)
XX
XX SQ Sequence 15 AA;

Query Match 100.0%; Score 39; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.13;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
|||
Db 8 RAFVTIGK 15

RESULT 33
AAR51619
ID AAR51619 standard; protein; 15 AA.
XX
XX AC AAR51619;
XX
XX DT 27-AUG-2003 (revised)
XX DT 25-MAR-2003 (revised)
XX DT 21-OCT-1994 (first entry)
XX
XX DE V3 loop region of gp120 of HIV.
XX
XX KW GP 120; HIV epitope; Human Immunodeficiency Virus fusion polypeptide.
XX OS
XX Human immunodeficiency virus.
XX PN WO9406469-A1.
XX
XX PD 31-MAR-1994.
XX
XX PF 18-SEP-1992; 92WO-US007966.
XX
XX PR 18-SEP-1992; 92WO-US007966.
XX
XX PA (LJOL-) LA JOLLA INST ALLERGY & IMMUNOLOGY.
XX
XX PI Altman A, Baier GJ;
XX WPI; 1994-118166/14.
XX
XX DR
XX
XX PT New fusion polypeptide of antigen binding domain and HIV epitope - useful
XX PT as vaccine for treatment or prevention of HIV infection, ensures
XX PT efficient focusing of epitopes on surface of antigen presenting cells.
XX
XX PS Example 1; Page 24; 39pp; English.
XX
XX CC AAR51619 shows a region of the V3 loop (residues 315-329) of the envelope
XX CC glycoprotein, gp120, of HIV-1. It represents an epitope which forms part
XX CC of a hybrid-fusion polypeptide with a Fab fragment of an IGG Fab
XX CC fragment. The polypeptide is capable of presenting the epitope to antigen
XX CC presenting cells. (Updated on 25-MAR-2003 to correct PN field.) (Updated
XX CC on 27-AUG-2003 to correct OS field.)
XX
XX SQ Sequence 15 AA;

Query Match 100.0%; Score 39; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.13;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
|||
Db 8 RAFVTIGK 15

RESULT 34
AAR74603
ID AAR74603 standard; peptide; 15 AA.


```

XX AC AAR74603;
XX DT 16-OCT-2003 (revised)
XX DT 25-MAR-2003 (revised)
XX DT 01-NOV-1995 (first entry)
XX DE HIV-I variable loop residues 308-322.
XX KW MAb 5023; variable V3 loop; HIV-I; human immunodeficiency virus;
XX KW cancer antigen; monoclonal antibody.
XX OS Human immunodeficiency virus; I.
XX PN WO9510777-A1.
XX PD 20-APR-1995.
XX PF 14-OCT-1994; 94WO-US011754.
XX PR 15-OCT-1993; 93US-00138141.
XX PA (RAKO/) RAKOWICZSZULCZYNSKA E M.
XX PI Rakowiczszulczynska EM;
XX DR WPI; 1995-178531/23.
XX PT Detection of HIV-1 cross-reactive breast carcinoma-associated antigens -
XX PT for diagnosis and anti:sense therapy of breast and gynaecological
XX PT cancers.
XX PS Disclosure; Page 48; 71pp; English.
XX CC MAb 5023 was developed against AA residue 308-322 of the variable loop of
XX CC HIV-1 (AAR74603). MAb 5023 binds to the epitope GRAF. G preceding RAF is
XX CC believed to critical for internalization. MAb 5023 recognised p160, p120,
XX CC p42 and p24 in cancer cells. AAR74603 competitively blocked binding of
XX CC the MAb to the cancer antigens, indicating that at least the epitope
XX CC GRAF, which is recognised by the MAb, must also be present in cancer
XX CC antigens. (Updated on 25-MAR-2003 to correct PN field.) (Updated on 25-
XX CC MAR-2003 to correct PI field.) (Updated on 16-OCT-2003 to standardise OS
XX CC field.)
XX SQ Sequence 15 AA;
XX Query Match 100.0%; Score 39; DB 2; Length 15;
XX Best Local Similarity 100.0%; Pred. No. 0.13; Mismatches 0; Gaps 0;
XX Matches 8; Conservative 0; Indels 0;
XX QY 1 RAFVTIGK 8
XX DB |||||
XX 8 RAFVTIGK 15
XX RESULT 35
XX AAR66420
XX ID AAR66420 standard; peptide; 15 AA.
XX AC AAR66420;
XX DT 25-MAR-2003 (revised)
XX DT 03-AUG-1995 (first entry)
XX DE HIV-1 IIIB peptide 18-5.
XX KW T cell helper site; cytotoxic T cell response; neutralising antibody;
XX KW human immunodeficiency virus type 1; envelope glycoprotein gp120;
XX KW cluster peptide; principal neutralising determinant.
XX OS Synthetic.
XX PN WO9426785-A1.
XX DT 25-MAR-2003 (revised)
XX DT 03-AUG-1995 (first entry)
XX DE HIV-1 IIIB peptide 18-5.
XX KW T cell helper site; cytotoxic T cell response; neutralising antibody;
XX KW human immunodeficiency virus type 1; envelope glycoprotein gp120;
XX KW cluster peptide; principal neutralising determinant.
XX OS Synthetic.
XX PN WO9426785-A1.

```

```

XX 24-NOV-1994.
XX 13-MAY-1994; 94WO-US005142.
XX 14-MAY-1993; 93US-00060988.
XX (USSH ) US SEC DEPT HEALTH.
XX Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
XX WPI; 1995-006707/01.
XX Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
XX PT responses - to target antigen in hosts of different MHC haplotypes, esp.
XX PT for therapeutic or prophylactic vaccines against HIV.
XX PS Example 1; Page 33; 120pp; English.
XX CC Single residues from the HIV-1 RF sequence (AAR66415) replaced residues
XX CC in the HIV-1 IIIB sequence (AAR66414) to test the effect of each residue
XX CC on the binding of neutralising and non-neutralising sera from animals
XX CC immunised with the cluster peptides PCLUS 3-18 and PCLUS 6-18 (see
XX CC AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
XX CC R66430) showed that binding was enhanced over peptide 18 control when a
XX CC tyrosine was substd. for a Val at position 11 and substns. at positions
XX CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
XX CC sera was reduced when substns. were made in the principal neutralising
XX CC determinant sequence (PGRAP). In peptide 18-5, the Gly residue at
XX CC position 5 in peptide 18 has been replaced by an Ala residue. (Updated on
XX CC 25-MAR-2003 to correct PN field.)
XX SQ Sequence 15 AA;
XX Query Match 100.0%; Score 39; DB 2; Length 15;
XX Best Local Similarity 100.0%; Pred. No. 0.13; Mismatches 0; Gaps 0;
XX Matches 8; Conservative 0; Indels 0;
XX QY 1 RAFVTIGK 8
XX DB |||||
XX 8 RAFVTIGK 15
XX RESULT 36
XX AAR66421
XX ID AAR66421 standard; peptide; 15 AA.
XX AC AAR66421;
XX DT 25-MAR-2003 (revised)
XX DT 03-AUG-1995 (first entry)
XX DE HIV-1 IIIB peptide 18-6.
XX KW T cell helper site; cytotoxic T cell response; neutralising antibody;
XX KW human immunodeficiency virus type 1; envelope glycoprotein gp120;
XX KW cluster peptide; principal neutralising determinant.
XX OS Synthetic.
XX PN WO9426785-A1.
XX DT 24-NOV-1994.
XX PF 13-MAY-1994; 94WO-US005142.
XX PR 14-MAY-1993; 93US-00060988.
XX PA (USSH ) US SEC DEPT HEALTH.
XX PI Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
XX WPI; 1995-006707/01.

```

XX Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
PT responses - to target antigen in hosts of different MHC haplotypes, esp.
PT for therapeutic or prophylactic vaccines against HIV.
XX
PS Example 1; Page 33; 120pp; English.
XX
CC Single residues from the HIV-1 RF sequence (AAR66415) replaced residues
CC in the HIV-1 IIIB sequence (AAR66414) to test the effect of each residue
CC on the binding of neutralising and non-neutralising sera from animals
CC immunised with the cluster peptides PC1US 3-18 and PC1US 6-18 (see
CC AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
CC R66430) showed that binding was enhanced over peptide 18 control when a
CC tyrosine was substd. for a Val at position 11 and substdns. at positions
CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
CC sera was reduced when substdns. were made in the principal neutralising
CC determinant sequence (PCRAP). In peptide 18-6, the Pro residue at
CC position 6 in peptide 18 has been replaced by an Ala residue. (Updated on
CC 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 39; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.13;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTIGK 8
Db 8 RAFVTIGK 15
|||||

RESULT 37
AAR66414
ID AAR66414 standard; peptide; 15 AA.
XX
AC AAR66414;
XX
XX
DT 25-MAR-2003 (revised)
DT 03-AUG-1995 (first entry)
XX
XX
DE HIV-1 IIIB peptide 18.
XX
XX T cell helper site; cytotoxic T cell response; neutralising antibody;
KW human immunodeficiency virus type 1; envelope glycoprotein gp120;
KW cluster peptide; principal neutralising determinant; IIIB isolate.
XX
OS Synthetic.
XX
XX WO9426785-A1.
XX
XX 24-NOV-1994.
XX
XX 13-MAY-1994; 94WO-US0005142.
XX
XX 14-MAY-1993; 93US-00060988.
XX
XX (USSH) US SEC DEPT HEALTH.
XX
XX Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
XX WPI; 1995-006707/01.
XX
XX Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
PT responses - to target antigen in hosts of different MHC haplotypes, esp.
PT for therapeutic or prophylactic vaccines against HIV.
XX
PS Example 1; Page 33; 120pp; English.
XX
CC Synthetic peptides spanning multideterminant regions from the HIV
CC envelope protein gp160 have been determined and are designated cluster
CC peptides (PC1US). These peptides each consist of a cluster of overlapping
CC determinants and are known to induce in vitro T cell proliferation and
CC cytokine production in mice and humans of multiple MHC types. The cluster

CC peptides were co-linearly synthesised at the N-terminus of an
CC immunodominant CTL determinant, peptide 18 (AAR66414), corresp. to part
CC of the gp160 V3 loop and principal neutralising determinant region of HIV
CC -1 IIIB isolate. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 39; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.13;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTIGK 8
Db 8 RAFVTIGK 15
|||||

RESULT 38
AAR66419
ID AAR66419 standard; peptide; 15 AA.
XX
AC AAR66419;
XX
XX
DT 25-MAR-2003 (revised)
DT 03-AUG-1995 (first entry)
XX
XX
DE HIV-1 IIIB peptide 18-4.
XX
XX T cell helper site; cytotoxic T cell response; neutralising antibody;
KW human immunodeficiency virus type 1; envelope glycoprotein gp120;
KW cluster peptide; principal neutralising determinant.
XX
OS Synthetic.
XX
XX WO9426785-A1.
XX
XX 24-NOV-1994.
XX
XX 13-MAY-1994; 94WO-US0005142.
XX
XX 14-MAY-1993; 93US-00060988.
XX
XX (USSH) US SEC DEPT HEALTH.
XX
XX Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
XX WPI; 1995-006707/01.
XX
XX Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
PT responses - to target antigen in hosts of different MHC haplotypes, esp.
PT for therapeutic or prophylactic vaccines against HIV.
XX
PS Example 1; Page 33; 120pp; English.
XX
CC Single residues from the HIV-1 RF sequence (AAR66415) replaced residues
CC in the HIV-1 IIIB sequence (AAR66414) to test the effect of each residue
CC on the binding of neutralising and non-neutralising sera from animals
CC immunised with the cluster peptides PC1US 3-18 and PC1US 6-18 (see
CC AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
CC R66430) showed that binding was enhanced over peptide 18 control when a
CC tyrosine was substd. for a Val at position 11 and substdns. at positions
CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
CC sera was reduced when substdns. were made in the principal neutralising
CC determinant sequence (PCRAP). In peptide 18-4, the Arg residue at
CC position 4 in peptide 18 has been replaced by a Lys residue. (Updated on
CC 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 39; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.13;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTIGK 8

```

Db      |||||
      8 RAFVTIGK 15

RESULT 39
AAR66422 ID AAR66422 standard; peptide; 15 AA.
XX AC AAR66422;
XX DT 25-MAR-2003 (revised)
XX DT 03-AUG-1995 (first entry)
XX XX
XX DE HIV-1 IIB peptide 18-7.
XX XX
XX T cell helper site; cytotoxic T cell response; neutralising antibody;
KW human immunodeficiency virus type 1; envelope glycoprotein gp120;
KW cluster peptide; principal neutralising determinant.
XX XX
XX Synthetic.
XX XX
XX WO9426785-A1.
XX XX
XX PD 24-NOV-1994.
XX XX
XX PF 13-MAY-1994; 94WO-US005142.
XX XX
XX PR 14-MAY-1993; 93US-00060988.
XX XX
XX PA (USSH ) US SEC DEPT HEALTH.
XX PI
XX PI Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
XX DR WPI; 1995-006707/01.
XX XX
XX Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
PT responses - to target antigen in hosts of different MHC haplotypes, esp.
PT for therapeutic or prophylactic vaccines against HIV.
XX XX
XX Example 1; Page 33; 120pp; English.
XX CC
XX Single residues from the HIV-1 RF sequence (AAR66415) replaced residues
CC in the HIV-1 IIB sequence (AAR66414) to test the effect of each residue
CC on the binding of neutralising and non-neutralising sera from animals
CC immunised with the cluster peptides PCUS 3-18 and PCUS 6-18 (see
CC AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
CC R66430) showed that binding was enhanced over peptide 18 control when a
CC tyrosine was subst. for a Val at position 11 and substns. at positions
CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
CC sera was reduced when substns. were made in the principal neutralising
CC determinant sequence (PGRAP). In peptide 18-7, the Gly residue at
CC position 7 in peptide 18 has been replaced by an Ala residue. (Updated on
CC 25-MAR-2003 to correct PN field.)
XX XX
XX SQ Sequence 15 AA;
      Query Match 100.0%; Score 39; DB 2; Length 15;
      Best Local Similarity 100.0%; Pred. No. 0.13;
      Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      1 RAFVTIGK 8
      |||||
Db      8 RAFVTIGK 15

RESULT 41
AAR05535 ID AAR05535 standard; peptide; 15 AA.
XX AC AAR05535;
XX XX
XX DT 16-OCT-2003 (revised)
XX DT 17-JAN-1997 (first entry)
XX XX
XX DE HIV-1 gp120 peptide (aa308-322).
XX XX
XX gC1q receptor; gC1q-R; HIV-1; gp120; immunogen; vaccine.
XX OS Human immunodeficiency virus 1; strain HXB2R.
XX XX
XX WO9630400-A1.
XX PN
XX PD 03-OCT-1996.
XX XX
XX PF 22-MAR-1996; 96WO-US003905.

Cytotoxic T lymphocyte epitope 46 derived from env gp120 protein.
XX
XX cytotoxic T lymphocyte; epitope; antigen; pathogenic; nef; gag; pol; env;
KW gp120; gp41; HIV; cell-mediated immunity; human immunodeficiency virus;
KW class I restricted.
XX
XX Human immunodeficiency virus.
XX
XX WO9428871-A1.
XX PN
XX XX
XX PD 22-DEC-1994.
XX XX
XX PF 07-JUN-1994; 94WO-US006394.
XX XX
XX PR 07-JUN-1993; 93US-00072718.
XX XX
XX PA (ENDO-) ENDOCON INC.
XX XX
XX PI Leonard RJ;
XX XX
XX WPI; 1995-036067/05.
XX DR
XX XX
XX PT Implant for sustained release of pathogen-associated antigen - forming
PT chronic inflammatory site producing cytotoxic T-lymphocytes lysing
PT infected cells, esp. for treating AIDS.
XX XX
XX PS Disclosure; Page 12; 35pp; English.
XX XX
XX AAR68744-805 are cytotoxic T lymphocyte (CTL) class I and II restricted
CC epitopes derived from human immunodeficiency virus proteins. AAR68789
CC corresponds to amino acid residues 308-322 of the env gp120 protein.
CC These antigens are examples of peptides that can be used with an
CC immunogenic implant. The implant is associated with an antigen associated
CC with a pathogen and used to form a discrete, localised chronic
CC inflammation site which acts as a local 'factory' for prodn. of CTL's
CC which lyse cells infected with a specific pathogen. The expanded set of
CC pathogen-specific CTL's can eradicate or prevent development of
CC infection, and can also be used to treat or arrest the development of
CC cancers associated with infection. (Updated on 25-MAR-2003 to correct PN
CC field.)
XX XX
XX SQ Sequence 15 AA;
      Query Match 100.0%; Score 39; DB 2; Length 15;
      Best Local Similarity 100.0%; Pred. No. 0.13;
      Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      1 RAFVTIGK 8
      |||||
Db      8 RAFVTIGK 15

RESULT 40
AAR68789 ID AAR68789 standard; peptide; 15 AA.
XX AC AAR68789;
XX XX
XX DT 25-MAR-2003 (revised)
XX DT 23-AUG-1995 (first entry)
XX XX

```

XX 24-MAR-1995; 95US-00410360.
 PR (TANO-) TANOX BIOSYSTEMS INC.
 PA Fung MSC, Sun BNV, Sun CRY, Kim YW, Yu L;
 PI WPI; 1996-455274/45.
 XX New gC1q-receptor-based, HIV-1 gp 120 binding peptide(s) - for preventing
 PT and treating HIV-1 infection.
 PS Claim 10; Page 49; 53pp; English.
 CC A peptide (AAW05535) corresponds to amino acids 308-322 of the V3 region
 CC of gp120 from HIV-1 strain HXB2R2. It was used to examine the binding of
 CC gC1q receptor (gC1q-R) (see also AAW05534) to HIV-1 gp120. Anti-HIV-1
 CC gp120 V3 domain murine monoclonal antibody BAT123 was able to react with
 CC gp120 bound to gC1q-R, showing that the binding of gC1q-R to gp120 does
 CC not involve the V3 region of gp120; the binding site was localised to
 CC amino acids 444-459 (see also AAW05533) of gp120. (Updated on 16-OCT-2003
 CC to standardise OS field)
 XX Sequence 15 AA;
 SQ

Query Match 100.0%; Score 39; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.13;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
 DB 8 RAFVTIGK 15
 |||||

RESULT 42
 AAR92033
 ID AAR92033 standard; peptide; 15 AA.
 AC AAR92033;
 XX 29-MAY-1996 (first entry)
 DT Hydrophilic peptide for epimorphin modification (5).
 DE Epimorphin; human; mouse; wound; burn; epithelial tissue; diagnosis;
 KW treatment; morphogenetic abnormality; cosmetic; hair growth stimulator.
 XX Synthetic.
 OS EP698666-A2.
 PN 28-FEB-1996.
 PD 20-JUN-1995; 95EP-00304270.
 XX 21-JUN-1994; 94JP-00162874.
 PR 31-MAR-1995; 95JP-00099979.
 XX 31-MAR-1995; 95JP-00099980.
 XX (SUME) SUMITOMO ELECTRIC IND CO.
 PA Hirai Y, Koshida S, Oka Y;
 PI WPI; 1996-118213/13.
 XX Novel polypeptide containing an epimorphin functional domain - has
 PT possible benefits in epithelial tissue treatments, e.g. burns and for
 PT artificial organs.
 PS Claim 8; Page 57; 62pp; English.
 XX New polypeptides contain a first portion of 5-99 amino acids joined to a
 CC second portion contg. at least a functional domain of epimorphin. The

CC first portion may be selected from the peptides given in AAR92029 to
 CC AAR92036. The second portion may be full-length epimorphin (see AAR92037
 CC to AAR92042 for human and mouse epimorphins). Fragments of epimorphins
 CC given in AAT16083 to AAT16090 are used in the prodn. of modified
 CC epimorphins. The modified epimorphins are useful for the development of
 CC diagnosis and treatment of morphogenetic abnormalities of epithelial
 CC tissue or novel remedies for wounds, eg burns, after surgery and for
 CC artificial organs. They may also be used as components of cosmetics, hair
 CC growth stimulators, etc
 XX Sequence 15 AA;
 SQ

Query Match 100.0%; Score 39; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.13;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
 DB 8 RAFVTIGK 15
 |||||

RESULT 43
 AAW07931
 ID AAW07931 standard; peptide; 15 AA.
 AC AAW07931;
 XX 16-OCT-2003 (revised)
 DT 31-JAN-1997 (first entry)
 XX gp120 peptide p18p.
 DE HIV; gp120; HIV-IIIB strain; HIV-1 transmission; foetal transmission;
 KW neutralising antibody; passive immunisation; anti-idiotypic antibody;
 KW gp41; vaccine; active immunotherapy.
 XX Human immunodeficiency virus 1.
 OS US5556744-A.
 PN 17-SEP-1996.
 PD 24-MAR-1994; 94US-00218025.
 XX 29-MAY-1992; 92US-00891451.
 PR (UYPE-) UNIV PENNSYLVANIA.
 PA (WIST-) WISTAR INST ANATOMY & BIOLOGY.
 XX Williams WV, Weiner DB, Ugen KE;
 PI WPI; 1996-432980/43.
 DR Determining the likelihood of maternal transmission of HIV-1 to foetus -
 PT by measuring maternal reactivity with specific gp120 and gp41 derived
 PT peptide(s), also used for diagnosing HIV in infants.
 XX Example 2; Col 18; 63pp; English.
 XX This sequence represents a HIV gp120 peptide that can be used in the
 CC method of the invention. The method of the invention is for determining
 CC whether or not a mother will transmit HIV-1 to a foetus. The method
 CC comprises incubating a sample from the HIV-infected mother, with a
 CC collection of HIV peptides. The HIV peptides includes at least one of the
 CC gp120 sequences (such as AAW07909-W07917), and at least one HIV gp41
 CC derived peptide (see AAW07918-W07928). The number of peptides that react
 CC with the sample is determined, and this number is compared with a
 CC standard that shows pattern reactivity for a patient of transmission
 CC status. A non-transmissible HIV sample is indicated if the test sample
 CC reacts with twice as many peptides as the standard. The method detects
 CC the presence of neutralising antibodies that protect against mother to
 CC infant transmission of HIV. These sequences can also be used in vaccines
 CC to protect against transmission. Antibodies against these sequences can

CC be used for passive immunisation, and to generate anti-idiotypic
 CC antibodies for use in vaccines or active immunotherapy. (Updated on 16-
 CC OCT-2003 to standardise OS field)
 XX
 SQ Sequence 15 AA;

Query Match 100.0%; Score 39; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.13;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
 Db 8 RAFVTIGK 15
 |||||

RESULT 44
 AAR92007
 ID AAR92007 standard; protein; 15 AA.
 XX
 AC AAR92007;
 XX
 DT 16-OCT-2003 (revised)
 DT 27-SEP-1996 (first entry)
 XX
 DE HIV-1 V3 loop epitope, for insertion in Mycobacterium alpha antigen.
 XX
 KW Mycobacterium bovis BCG; AIDS vaccine; surface protein; alpha antigen;
 KW Human immunodeficiency virus type 1; fusion protein; gp120 epitope;
 KW V3 loop.
 XX
 OS Human immunodeficiency virus i.
 XX
 PN WO9604009-A1.
 XX
 PD 15-FEB-1996.
 XX
 PF 31-JUL-1995; 95WO-JP001515.
 XX
 PR 29-JUL-1994; 94JP-00178462.
 XX
 PA (AJIN) AJINOMOTO CO INC.
 PA (NINA-) JAPAN AGENCY NAT INST HEALTH.
 XX
 PI Matsuo K, Chujo Y, Yamazaki A, Honda M, Yamazaki S, Tasaka H;
 XX
 DR WPI; 1996-129127/13.
 DR N-PSDB; AAT16048, AAT16049.
 XX
 PT BCG containing vaccine secretes chimeric protein containing foreign
 PT antigen - has enhanced immunogenicity and antigenicity esp. when used as
 PT an anti-AIDS vaccine.
 XX
 PS Example 2; Page 17; 56pp; Japanese.
 XX
 CC Antigenic peptides can be inserted into the alpha-antigen sequence of a
 CC Mycobacterium and secreted from an appropriately transformed M.bovis BCG
 CC cell. The resulting chimeric antigen has greatly enhanced antigenicity
 CC and immunogenicity and is recognised in vivo by B-cells which recognise
 CC the alpha-antigen. The present sequence is that of a HIV-1 gp120 V3 loop
 CC epitope which was incorporated into the alpha antigen. M.bovis BCG cells
 CC secreting a chimeric protein comprising the epitope sequence are useful
 CC as anti-AIDS vaccines. (Updated on 16-OCT-2003 to standardise OS field)
 XX
 SQ Sequence 15 AA;

Query Match 100.0%; Score 39; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.13;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
 Db 8 RAFVTIGK 15
 |||||

RESULT 45
 AAW24219
 ID AAW24219 standard; peptide; 15 AA.
 XX
 AC AAW24219;
 XX
 DT 17-MAR-1998 (first entry)
 DE CD4+ T-lymphocyte epitope to HIV-1 V3 loop derived peptide V3-LAI-P18.
 XX
 KW T-lymphocyte epitope; diagnosis; antigen; infectious disease;
 KW delayed-type hypersensitivity assay; vaccine development.
 XX
 OS Synthetic.
 OS Human immunodeficiency virus.
 XX
 PN WO9727462-A2.
 XX
 PD 31-JUL-1997.
 XX
 PF 27-JAN-1997; 97WO-US001084.
 XX
 PR 26-JAN-1996; 96US-0010679P.
 XX
 PA (USSA) US DEPT ARMY GOVERNMENT US ARMY MEDICAL.
 XX
 PI Sitz KV, Brix DL;
 XX
 DR WPI; 1997-393814/36.
 XX
 PT Peptide fragments containing antigen epitope(s) used to trace diseases -
 PT used in a delayed-type hypersensitivity assay, for in vivo mapping of
 PT human T-lymphocyte epitope(s) e.g. for diagnosis, vaccine development
 PT etc.
 XX
 PS Disclosure; Page 6; 14pp; English.
 XX
 CC Peptide fragments AAW24217-20 were used to demonstrate a new method of
 CC tracing sources of infectious diseases. The method comprises preparing a
 CC short (9-50 amino acid) peptide containing at least one non-conserved
 CC epitope of an organism, injecting a composition containing the peptide
 CC intradermally into a test subject in a delayed-type hypersensitivity
 CC (DTH) assay and observing the injection site at intervals for induration.
 CC In this example CD4+ T-lymphocyte epitopes to the HIV-1 V3 loop were
 CC mapped by existing in vitro technique for two existing HIV infected
 CC individuals and used to design peptides AAW24217-20. The method allows
 CC the T-lymphocyte epitopes of a large antigen to be determined in vivo in
 CC humans. The method is useful in medicine e.g. in diagnosis, monitoring.
 CC and treatment design for infectious disease exposure, active autoimmune
 CC disease, allergic diseases and malignancy. It is especially useful for
 CC tracing infectious diseases e.g HIV, particularly when a sequence is
 CC present only in certain strains of an organism, and developing suitable
 CC vaccines. Vaccinated individuals can also be tested to verify protection
 CC against a particular strain. The method allows in vivo mapping of T-
 CC lymphocyte epitopes, not previously possible. The method is simpler, more
 CC rapid and more sensitive. It can also be applied in a variety of
 CC environments e.g. undeveloped regions since specialist equipment is not
 CC required
 XX
 SQ Sequence 15 AA;

Query Match 100.0%; Score 39; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.13;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
 Db 8 RAFVTIGK 15
 |||||

RESULT 46
 AAW10348

```

ID AAW10348 standard; peptide; 15 AA.
XX
AC AAW10348;
XX
DT 15-OCT-1997 (first entry)
XX
DE HIV epitope env P18-IIIB amino acid residues 315-329 of gp160.
XX
DE Human immunodeficiency virus type-1; HIV-1; T cell response; detection;
KW peripheral blood mononuclear cell; PBMC.
XX
OS Synthetic.
XX
XX WO9641189-A1.
XX
XX 19-DEC-1996.
XX
XX 07-JUN-1996; 96WO-US010108.
XX
XX 07-JUN-1995; 95US-00488435.
XX
XX (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
XX Shearer GM, Berzofsky JA, Clerici M;
XX
XX WPI; 1997-108658/10.
XX
XX Diagnosis of exposure to infectious agents, partic. HIV - by detecting
PT activation of peripheral blood mononuclear cells from patient by epitope
PT of infectious agent.
XX
XX Claim 15; Page 62; 82pp; English.
XX
XX The present sequence represents a synthetic HIV-1 gp160 peptide env P18-
CC IIIB for use in a method for diagnosing exposure of a patient to human
CC immunodeficiency virus (HIV). The method involves: (a) obtaining
CC peripheral blood mononuclear cells (PBMC) from a patient; (b) incubating
CC the PBMC with at least 1 synthetic peptide representing an epitope(s) of
CC the infectious agent (e.g. the present sequence); and (c) determining the
CC activation of the PBMC as a result of the incubation in step (b). The
CC method can provide for the early detection of exposure to infectious
CC organisms, specifically HIV in this case. The method can be used to
CC assess exposure to HIV without concomitant infection. It also provides an
CC earlier identification of HIV exposure, than is provided by
CC seroconversion
XX
XX Sequence 15 AA;
XX
Query Match 100.0%; Score 39; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.13;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 RAFVTIGK 8
Db |||||
8 RAFVTIGK 15
XX
RESULT 47
AAW22031
ID AAW22031 standard; peptide; 15 AA.
XX
AC AAW22031;
XX
XX 20-FEB-1998 (first entry)
XX
XX Antigenic human immunodeficiency virus peptide P18.
XX
XX Antigenic peptide; human papillomavirus; MAGE gene; BAGE-1 peptide; P18;
KW human immunodeficiency virus; cancer antigen; tyrosinase; signal protein;
KW anthrax lethal factor; LF; toxin; cationic fusion peptide; translocation;
KW gene therapy; polycationic affinity handle; therapeutic protein; LFN.
XX
XX Human immunodeficiency virus.
OS

```

```

XX
PN WO9723236-A1.
XX
XX 03-JUL-1997.
XX
XX 13-DEC-1996; 96WO-US020463.
XX
XX 13-DEC-1995; 95US-0008518P.
PR 07-JUN-1996; 96US-0019275P.
XX
XX (HARD ) HARVARD COLLEGE.
XX
XX Collier RJ, Blanke SR, Milne JC, Lyszak EL, Ballard JD;
PI Starnbach MN;
XX
XX WPI; 1997-350782/32.
XX
XX Introducing therapeutic proteins, especially antigens, into cells - using
PT toxin molecules and/or polycationic handles for delivery.
XX
XX Claim 15; Page 36; 67pp; English.
XX
XX This is the antigenic human immunodeficiency virus peptide P18. This
CC antigenic compound can be introduced into the cytoplasm of a cell by a
CC new method where the cell is contacted with a fusion molecule comprising
CC a delivery molecule. The delivery molecule can either be a polycationic
CC affinity handle, LFN (the protective antigen binding domain of anthrax
CC lethal factor) or a toxin delivery molecule related to LFN. The antigenic
CC compound is linked to either of the delivery molecules by a covalent
CC bond. The B moiety of a toxin enhances delivery of the antigenic compound
CC into a cell. The anthrax toxin system of the invention eliminates the
CC need to generate fusion proteins with a toxin B moiety, which alleviates
CC problems associated with incorrect folding of lengthy fusion proteins.
CC Small cationic fusion peptides substituted for LFN may reduce the
CC possibility of steric interference with the biological activity of the
CC translocated protein. The method is used for the introduction of
CC antigens, e.g. MHC class I antigens or any other therapeutic protein,
CC e.g. toxin molecules, apoptosis-inducing molecules or signalling proteins
CC into the cells
XX
XX Sequence 15 AA;
XX
Query Match 100.0%; Score 39; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.13;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 RAFVTIGK 8
Db |||||
8 RAFVTIGK 15
XX
RESULT 48
AAW39275
ID AAW39275 standard; peptide; 15 AA.
XX
AC AAW39275;
XX
XX 19-MAY-1998 (first entry)
XX
XX HIV-1 synthetic peptide IIIB.
DE
XX
XX Human immunodeficiency virus type I; HIV-1; cytotoxic T-cell; CTC;
KW vaccine; prophylactic; immunotherapy.
XX
XX Synthetic.
OS
XX Human immunodeficiency virus 1.
XX
XX US5711947-A.
XX
XX 27-JAN-1998.
XX
XX 23-JUL-1993; 93US-00095332.
XX

```

PR 26-JAN-1988; 88US-00148692.
 PR 18-SEP-1991; 91US-00760530.
 XX (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX Germain RN, Berzofsky JA, Takahashi H;
 PI WPI; 1998-119931/11.
 XX Inducing cytotoxic T-cell response to HIV - by administering gp160 vector
 XX and chimeric gp160 peptide(s).
 PT Example 1; Col 3; 25pp; English.
 PS
 XX Peptides AAW39275-W39300 are used in a novel method for inducing
 CC cytotoxic T-cell (CTC) activity specific for a broad array of HIV-1
 CC isolates using hybrid synthetic peptides. The method involves first
 CC administering a recombinant viral vector expressing the HIV-1 gp160
 CC envelope glycoprotein and then administering at least 1 chimeric
 CC synthetic polypeptide. When several synthetic polypeptides having
 CC sequences corresponding to amino acids 315-329 of the gp160 envelope
 CC glycoprotein of HIV-1 strain IIB, in which amino acid 325 is substituted
 CC by the corresponding amino acid from other strains or isolates, are used,
 CC a CTC response to a broad range of HIV-1 isolates can be elicited. These
 CC synthetic peptides are useful as vaccines for the prophylaxis or
 CC immunotherapy of HIV-1 virus infection
 XX
 XX Sequence 15 AA;
 SQ
 Query Match 100.0%; Score 39; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.13;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RAPVTIGK 8
 DB |||||
 8 RAPVTIGK 15
 RESULT 49
 AAW40316
 ID AAW40316 standard; peptide; 15 AA.
 XX
 AC AAW40316;
 XX
 DT 17-OCT-2003 (revised)
 DT 23-JUN-1998 (first entry)
 XX
 XX HIV-1 IIB gp120 peptide fragment.
 DE
 XX Epitope; vaccine; V3; gp120; immune response; hypervariable region;
 KW immunoglobulin; histocompatibility antibody.
 XX
 OS Human immunodeficiency virus 1.
 XX
 XX JP10072369-A.
 XX
 PD 17-MAR-1998.
 XX
 PF 02-SEP-1996; 96JP-00232378.
 XX
 XX 02-SEP-1996; 96JP-00232378.
 PR
 XX (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
 PA
 XX WPI; 1998-234701/21.
 DR
 XX Vaccine against human immunodeficiency virus - induces immune response
 PT reaction to V3 epitope of virus.
 PT
 XX Example 1; Page 5; 8pp; Japanese.
 PS
 XX This sequence represents a fragment of the human immunodeficiency virus
 CC (HIV) Type 1 strain IIB gp120 protein. This sequence is used in a method

CC resulting in the production of a vaccine against HIV which induces an
 CC immune response to the V3 epitope of HIV. This method which comprises the
 CC transplantation of an epitope of HIV at plural sites in the hypervariable
 CC region of immunoglobulin, the preparation of the epitope molecule
 CC histocompatibility antibody, and optionally chemically cross linking the
 CC epitope. An epitope histocompatibility antibody is also described in the
 CC specification which specifically responds to HIV, prepared by
 CC transplantation of an epitope comprising a peptide obtained from at least
 CC one V3 sequence of HIV. (Updated on 17-OCT-2003 to standardise OS field)
 XX
 SQ Sequence 15 AA;
 Query Match 100.0%; Score 39; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.13;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RAPVTIGK 8
 DB |||||
 8 RAPVTIGK 15
 RESULT 50
 AAW76897
 ID AAW76897 standard; peptide; 15 AA.
 XX
 AC AAW76897;
 XX
 DT 25-JAN-1999 (first entry)
 XX
 DE Fusion immunoglobulin heavy chain HIV gp120 T cell epitope #15.
 XX
 KW B cell; T cell; epitope; immunoglobulin; heavy chain; gp120; IgH;
 KW human immune deficiency virus; HIV; tolerance; treatment; therapy;
 KW prophylaxis; vaccine; chemotherapy; immune response; modifier; tumour;
 KW microbial infection; autoimmune disease; antibody; apoptosis;
 KW antiviral T cell immunity.
 XX
 OS Mus sp.
 OS Homo sapiens.
 XX
 PN WO9836087-A1.
 XX
 PD 20-AUG-1998.
 XX
 PF 13-FEB-1998; 98WO-US002766.
 XX
 PR 13-FEB-1997; 97US-0040581P.
 XX
 XX (AMNA-) AMERICAN NAT RED CROSS.
 XX
 XX Scott D, Zambidis E;
 XX
 XX WPI; 1998-506315/43.
 DR
 XX New fusion immunoglobulin heavy chain including gp120 epitopes and
 PT related complete antibodies - DNA, vectors and transformed cells, used to
 PT induce tolerance to the epitopes for treatment of human immune deficiency
 PT virus infection.
 XX
 PS Claim 11; Page 120; 154pp; English.
 XX
 CC This sequence is an epitope used in the construction of a novel fusion
 CC immunoglobulin heavy chain (IgH) protein with a mammalian, especially
 CC human, IgH chain fused in frame at its N-terminus to one or more human
 CC immune deficiency virus (HIV) gp120 epitopes. Fusion Ig proteins and/or
 CC transfected cells are used to tolerate subjects to gp120 epitopes and to
 CC maintain this tolerance, particularly for treatment of HIV infection,
 CC optionally together with other therapeutic/prophylactic agents such as
 CC vaccines, chemotherapeutic agents and immune response modifiers. Such
 CC proteins can be used against other diseases where an immune response is
 CC deleterious, e.g. microbial infection, tumours or autoimmune disease.
 CC Induction of tolerance suppresses production of antibodies against gp120,
 CC so prevents or inhibits 'bystander' apoptosis of uninfected T cells that

CC are bound to gp120 protein, maximising induction of protective antiviral
 XX T cell immunity
 SQ Sequence 15 AA;

Query Match 100.0%; Score 39; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.13;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFVTIGK 8
 DB 7 RAFVTIGK 14
 |||||

RESULT 51
 AAW76898
 ID AAW76898 standard; peptide; 15 AA.

XX AC AAW76898;

DT 25-JAN-1999 (first entry)

DE Fusion immunoglobulin heavy chain HIV gp120 T cell epitope #17.

XX B cell; T cell; epitope; immunoglobulin; heavy chain; gp120; IgH;
 KW human immune deficiency virus; HIV; tolerance; treatment; therapy;
 KW prophylaxis; vaccine; chemotherapy; immune response; modifier; tumour;
 KW microbial infection; autoimmune disease; antibody; apoptosis;
 KW antiviral T cell immunity.

XX Mus sp.

OS Homo sapiens.

XX WO9836087-A1.

XX 20-AUG-1998.

PF 13-FEB-1998; 98WO-US002766.

PR 13-FEB-1997; 97US-0040581P.

XX (AMNA-) AMERICAN NAT RED CROSS.

XX Scott D, Zambidis E;

XX WPI; 1998-506315/43.

XX New fusion immunoglobulin heavy chain including gp120 epitopes and
 related complete antibodies - DNA, vectors and transformed cells, used to
 induce tolerance to the epitopes for treatment of human immune deficiency
 virus infection.

PS Claim 11; Page 120; 154pp; English.

XX This sequence is an epitope used in the construction of a novel fusion
 immunoglobulin heavy chain (IgH) protein with a mammalian, especially
 human, IgH chain fused in frame at its N-terminus to one or more human
 immune deficiency virus (HIV) gp120 epitopes. Fusion Ig proteins and/or
 transfected cells are used to tolerate subjects to gp120 epitopes and to
 maintain this tolerance, particularly for treatment of HIV infection,
 optionally together with other therapeutic/prophylactic agents such as
 vaccines, chemotherapeutic agents and immune response modifiers. Such
 proteins can be used against other diseases where an immune response is
 deleterious, e.g. microbial infection, tumours or autoimmune disease.

XX Induction of tolerance suppresses production of antibodies against gp120,
 so prevents or inhibits 'bystander' apoptosis of uninfected T cells that
 are bound to gp120 protein, maximising induction of protective antiviral
 T cell immunity

XX Sequence 15 AA;

Query Match 100.0%; Score 39; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.13;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 RAFVTIGK 8
 DB 8 RAFVTIGK 15
 |||||

RESULT 52
 AAW76900
 ID AAW76900 standard; peptide; 15 AA.

XX AC AAW76900;

DT 25-JAN-1999 (first entry)

DE Fusion immunoglobulin heavy chain HIV gp120 T cell epitope #19.

XX B cell; T cell; epitope; immunoglobulin; heavy chain; gp120; IgH;
 KW human immune deficiency virus; HIV; tolerance; treatment; therapy;
 KW prophylaxis; vaccine; chemotherapy; immune response; modifier; tumour;
 KW microbial infection; autoimmune disease; antibody; apoptosis;
 KW antiviral T cell immunity.

XX Mus sp.

OS Homo sapiens.

XX WO9836087-A1.

XX 20-AUG-1998.

PF 13-FEB-1998; 98WO-US002766.

PR 13-FEB-1997; 97US-0040581P.

XX (AMNA-) AMERICAN NAT RED CROSS.

XX Scott D, Zambidis E;

XX WPI; 1998-506315/43.

XX New fusion immunoglobulin heavy chain including gp120 epitopes and
 related complete antibodies - DNA, vectors and transformed cells, used to
 induce tolerance to the epitopes for treatment of human immune deficiency
 virus infection.

PS Claim 11; Page 120; 154pp; English.

XX This sequence is an epitope used in the construction of a novel fusion
 immunoglobulin heavy chain (IgH) protein with a mammalian, especially
 human, IgH chain fused in frame at its N-terminus to one or more human
 immune deficiency virus (HIV) gp120 epitopes. Fusion Ig proteins and/or
 transfected cells are used to tolerate subjects to gp120 epitopes and to
 maintain this tolerance, particularly for treatment of HIV infection,
 optionally together with other therapeutic/prophylactic agents such as
 vaccines, chemotherapeutic agents and immune response modifiers. Such
 proteins can be used against other diseases where an immune response is
 deleterious, e.g. microbial infection, tumours or autoimmune disease.

XX Induction of tolerance suppresses production of antibodies against gp120,
 so prevents or inhibits 'bystander' apoptosis of uninfected T cells that
 are bound to gp120 protein, maximising induction of protective antiviral
 T cell immunity

XX Sequence 15 AA;

Query Match 100.0%; Score 39; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.13;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFVTIGK 8
 DB 2 RAFVTIGK 9
 |||||


```

RESULT 53
AAW54929
ID AAW54929 standard; peptide; 15 AA.
XX AC AAW54929;
XX DT 25-SEP-1998 (first entry)
XX DE HIV gp120 envelope protein, peptide 127, analogue 127g'.
XX KW Immunoabsorbent; immunoassay; HIV gp120; immunogen; antibody; Human.
XX OS Human immunodeficiency virus.
XX PN US5763160-A.
XX PD 09-JUN-1998.
XX PF 07-JUN-1995; 95US-00488252.
XX PR 12-FEB-1988; 88US-00155321.
XX PR 01-MAR-1991; 91US-00663262.
XX PR 09-JUL-1991; 91US-00726605.
XX PR 19-OCT-1994; 94US-00326676.
XX (UNBI-) UNITED BIOMEDICAL INC.
XX Wang CY;
XX WPI; 1998-347301/30.
XX HIV gp120 peptides - useful as immunoassay reagents or vaccine
XX components.
XX Example 8; Column 21/22; 34pp; English.
XX Peptides AAW54903-W54941 can be used as an immunoabsorbent in an
XX immunoassay for detecting antibodies to HIV gp120, or as an immunogen for
XX eliciting antibodies to HIV in a mammal
XX
XX Sequence 15 AA;
Query Match 100.0%; Score 39; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.13;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RAFVTICK 8
Db |||||
8 RAFVTICK 15

RESULT 54
AAW06896
ID AAY06896 standard; peptide; 15 AA.
XX AC AAY06896;
XX DT 01-JUL-1999 (first entry)
XX DE Sequence of gp120IIB P18 peptide.
XX KW Fusion protein; vaccine; cytokine; immunoglobulin; autoimmune disease;
XX KW infectious disease; inflammatory disease; neoplastic disease; cancer;
XX KW immunologic disease; immune response; malaria; tuberculosis; hepatitis;
XX KW AIDS; influenza; interleukin; IL-2; Ig.
XX OS Synthetic.
XX PN WO9916466-A2.
XX PD 08-APR-1999.
XX PF 29-SEP-1998; 98WO-US020321.

RESULT 55
AAY24466
ID AAY24466 standard; peptide; 15 AA.
XX AC AAY24466;
XX DT 23-SEP-1999 (first entry)
XX DE HIV peptide R15K-1.
XX KW Hepatitis B virus; HBV; X protein; cytotoxic T lymphocyte; liposome; CTL;
XX KW antigen; immunity; liver cancer.
XX OS Human immunodeficiency virus 1.
XX OS Synthetic.
XX PN WO9936434-A1.
XX PD 22-JUL-1999.
XX PF 19-JAN-1998; 98WO-KR000010.
XX PR 19-JAN-1998; 98WO-KR000010.
XX (MOGA-) MOGAM BIOTECHNOLOGY RES INST.
XX Kim T, Lee K, Chang J, Cho S, Hwang Y, Choi M, Cheong H;
XX WPI; 1999-444387/37.
XX Hepatitis B virus protein X-derived peptide antigens used to stimulate
XX cytotoxic T lymphocytes, useful for treatment of HBV-associated diseases,
XX especially liver cancer.

```

```

XX 29-SEP-1997; 97US-0060338P.
XX 12-DEC-1997; 97US-00990180.
XX (BETH-) BETH ISRAEL DEACONESS MEDICAL CENT.
XX Letvin NL, Barouch DH;
XX WPI; 1999-254931/21.
XX New vaccine compositions for treating AIDS, malaria, tuberculosis, cancer
XX or influenza.
XX Example 3; Page 22; 66pp; English.
XX The invention relates to vaccine compositions comprising a vaccine and a
XX timed-release formulation of a cytokine or cytokine/immunoglobulin fusion
XX protein or plasmid. The formulation or device releases the cytokine
XX protein or plasmid at one or more temporal points subsequent to vaccine
XX administration. The vaccines can be used for treating an autoimmune
XX disease, an infectious disease, an inflammatory disease, a neoplastic
XX disease, or an immunologic disease in an individual. The vaccines can be
XX used to elicit immune responses against diseases such as AIDS, malaria,
XX tuberculosis, hepatitis C, hepatitis B, cancer or influenza. The methods
XX can provide for enhancement of one or more immunologic parameters such as
XX an antibody response, a cellular proliferative response as well as
XX cytotoxic T-lymphocyte levels. In addition the Ig can increase the
XX circulating half life of the cytokine
XX
XX Sequence 15 AA;
Query Match 100.0%; Score 39; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.13;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RAFVTICK 8
Db |||||
8 RAFVTICK 15

RESULT 55
AAY24466
ID AAY24466 standard; peptide; 15 AA.
XX AC AAY24466;
XX DT 23-SEP-1999 (first entry)
XX DE HIV peptide R15K-1.
XX KW Hepatitis B virus; HBV; X protein; cytotoxic T lymphocyte; liposome; CTL;
XX KW antigen; immunity; liver cancer.
XX OS Human immunodeficiency virus 1.
XX OS Synthetic.
XX PN WO9936434-A1.
XX PD 22-JUL-1999.
XX PF 19-JAN-1998; 98WO-KR000010.
XX PR 19-JAN-1998; 98WO-KR000010.
XX (MOGA-) MOGAM BIOTECHNOLOGY RES INST.
XX Kim T, Lee K, Chang J, Cho S, Hwang Y, Choi M, Cheong H;
XX WPI; 1999-444387/37.
XX Hepatitis B virus protein X-derived peptide antigens used to stimulate
XX cytotoxic T lymphocytes, useful for treatment of HBV-associated diseases,
XX especially liver cancer.

```

XX Example 5; Page 14; 33pp; English.

PS The present invention describes peptide antigens AAY24459 to AAY24463

CC derived from the X protein of hepatitis B virus (HBV) which are

CC recognized by cytotoxic T lymphocytes (CTL). The peptide antigens derived

CC from HBV X protein are useful for inducing CTLs against the virus or

CC inducing immunological tolerance to the virus. pH-sensitive liposomes

CC containing the peptide antigens are used to induce cellular immunity so

CC that CTLs specific to the virus can be produced. This is useful for

CC prevention and treatment of HBV-associated diseases, especially HBV-

CC associated liver cancer. pH-sensitive liposomes permit the selective

CC transportation of anti-cancer drugs. The present sequence represents a

CC peptide used in an example from the present invention

XX

SQ Sequence 15 AA;

Query Match 100.0%; Score 39; DB 2; Length 15;

Best Local Similarity 100.0%; Pred. No. 0.13;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFVTIGK 8

Db 8 RAFVTIGK 15

RESULT 56

AAV25189

ID AAY25189 standard; peptide; 15 AA.

AC AAY25189;

XX

XX 03-SEP-1999 (first entry)

DT HIV protein gp160 peptide fragment #1.

DE

XX

XX Heat shock protein; HSP; complex; denatured protein matrix; antigen;

KW vaccine; allergic disease; treatment; susceptibility; Th2; skin rash;

KW allergic reaction; asthma; gp160.

XX

OS Human immunodeficiency virus.

XX

XX WO9929182-A1.

PN

XX 17-JUN-1999.

PD

XX

XX 04-DEC-1998; 98WO-US025734.

PF

XX

XX 05-DEC-1997; 97US-00985548.

PR

XX

XX 05-DEC-1997; 97US-00986234.

PR

XX

XX (UYNE-) UNIV NEW MEXICO STATE.

PA

XX

XX Wallen ES, Moseley PL;

PI

XX

XX WPI; 1999-394912/33.

DR

XX

XX Synthesizing heat shock protein complexes using a denatured protein

PT matrix.

PT

XX

XX Example 1; Fig 1A; 33pp; English.

PS

XX

XX This invention describes a novel method for synthesizing heat shock

CC protein (HSP) complexes comprising adding a heat shock protein to a

CC denatured protein matrix for binding, and adding a complexing solution

CC comprising a peptide to elute a heat shock protein-peptide complex. A HSP

CC -antigen complex is useful as a vaccine for treating an allergic disease

CC (in a mammal, preferably a human) to reduce susceptibility of the Th2

CC response, the complex comprising a HSP-antigenic peptide complex. The

CC complex is administered to prevent a mammal from having an allergic

CC reaction to an allergic disease, or administered to a mammal having an

CC allergic disease, to reduce the allergic reactions. Allergic diseases

CC include asthma and skin rashes. Prior art methods or preventing/treating

CC allergic diseases include antihistamines which treat only the symptoms,

CC corticosteroids which have severe side effects and desensitization

CC therapy which has limited uses. The new method also allows more

CC flexibility of use of peptide-based vaccines, as prior art HSP-based

CC vaccines require isolation from a portion of the tumour itself. This

CC sequence represents a peptide fragment from the HIV gp160 protein which

CC is used in the method of the invention

XX

SQ Sequence 15 AA;

Query Match 100.0%; Score 39; DB 2; Length 15;

Best Local Similarity 100.0%; Pred. No. 0.13;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFVTIGK 8

Db 8 RAFVTIGK 15

RESULT 57

AAV25204

ID AAY25204 standard; peptide; 15 AA.

XX

AC AAY25204;

XX

XX 03-SEP-1999 (first entry)

DT HIV V3 peptide fragment #10.

DE

XX

XX Heat shock protein; HSP; complex; denatured protein matrix; antigen;

KW vaccine; allergic disease; treatment; susceptibility; Th2; skin rash;

KW allergic reaction; asthma; V3 protein.

XX

OS Human immunodeficiency virus.

XX

XX WO9929182-A1.

PN

XX 17-JUN-1999.

PD

XX

XX 04-DEC-1998; 98WO-US025734.

PF

XX

XX 05-DEC-1997; 97US-00985548.

PR

XX

XX 05-DEC-1997; 97US-00986234.

PR

XX

XX (UYNE-) UNIV NEW MEXICO STATE.

PA

XX

XX Wallen ES, Moseley PL;

PI

XX

XX WPI; 1999-394912/33.

DR

XX

XX Synthesizing heat shock protein complexes using a denatured protein

PT matrix.

PT

XX

XX Example 1; Fig 1B; 33pp; English.

PS

XX

XX This invention describes a novel method for synthesizing heat shock

CC protein (HSP) complexes comprising adding a heat shock protein to a

CC denatured protein matrix for binding, and adding a complexing solution

CC comprising a peptide to elute a heat shock protein-peptide complex. A HSP

CC -antigen complex is useful as a vaccine for treating an allergic disease

CC (in a mammal, preferably a human) to reduce susceptibility of the Th2

CC response, the complex comprising a HSP-antigenic peptide complex. The

CC complex is administered to prevent a mammal from having an allergic

CC reaction to an allergic disease, or administered to a mammal having an

CC allergic disease, to reduce the allergic reactions. Allergic diseases

CC include asthma and skin rashes. Prior art methods or preventing/treating

```

XX SQ Sequence 15 AA;
Query Match 100.0%; Score 39; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.13;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFVTIGK 8
DB 8 RAFVTIGK 15

RESULT 58
AAW05356
ID AAY05356 standard; peptide; 15 AA.
XX AC AAY05356;
XX DT 17-OCT-2003 (revised)
XX DT 29-JUN-1999 (first entry)
XX DE HIV-1 CLUVAC peptide, SEQ ID NO. 15.
XX KW HIV-1; CLUVAC; cluster peptide vaccine construct; cytotoxic T lymphocyte;
XX KW protective mucosal CTL response; hepatitis A virus; papilloma virus;
XX KW feline immunodeficiency virus; feline leukaemia virus; M. tuberculosis;
XX KW Listeria monocytogenes; M. leprae; Giardia lamblia;
XX KW immune response induction.
XX OS Human immunodeficiency virus 1.
XX PN WO9912563-A2.
XX PD 18-MAR-1999.
XX PF 11-SEP-1998; 98MO-US019028.
XX PR 11-SEP-1997; 97US-0058523P.
XX PR 17-FEB-1998; 98US-0074894P.
XX PA (USSH ) US DEPT HEALTH & HUMAN SERVICE.
XX PI Berzofsky JA, Belyakov IM, Derby MA, Kelsall BL, Strober W;
XX WI; 1999-243663/20.
XX PT Method for inducing a protective mucosal cytotoxic T lymphocyte immune
XX response.
XX PS Example 3; Page 85; 86pp; English.
XX CC This sequence represents a HIV-1 cluster peptide vaccine conjugate
XX CC (CLUVAC) sequence. The invention relates to a method for inducing a
XX CC protective mucosal cytotoxic T lymphocyte (CTL) response in a mammalian
XX CC subject, which comprises contacting a mucosal tissue of the subject with
XX CC a composition comprising a purified soluble antigen. The method can
XX CC induce a protective mucosal CTL response in a subject. The method can be
XX CC used for protection against e.g. hepatitis A virus, papilloma virus,
XX CC feline immunodeficiency virus, feline leukaemia virus, Listeria
XX CC monocytogenes, M. tuberculosis, M. leprae, or Giardia lamblia. The method
XX CC induces long-lasting protective mucosal immune responses. (Updated on 17-
XX CC OCT-2003 to standardise OS field)
XX SQ Sequence 15 AA;

Query Match 100.0%; Score 39; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.13;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFVTIGK 8
DB 8 RAFVTIGK 15

RESULT 59
AAW72821
ID AAW72821 standard; peptide; 15 AA.
XX AC AAW72821;
XX DT 17-OCT-2003 (revised)
XX DT 13-JAN-1999 (first entry)
XX DE HIV-1 gp120 monoclonal antibody BAT123 residue 308 to 322.
XX KW HIV-1; gp120; epitope; monoclonal antibody; envelope; neutralise;
XX KW inhibit; infection; T-cell; inhibit syncytium formation; AIDS.
XX OS Human immunodeficiency virus 1.
XX PN US5834599-A.
XX PD 10-NOV-1998.
XX PF 04-MAR-1993; 93US-00026276.
XX PR 29-MAY-1987; 87US-00057445.
XX PR 24-DEC-1987; 87US-00137861.
XX PR 25-APR-1989; 89US-00343540.
XX PR 05-JUN-1992; 92US-00895197.
XX PA (TANO-) TANOX BIOSYSTEMS INC.
XX PI Sun BN, Fung SC, Kim YW, Sun CR, Chang NT, Chang T;
XX WI; 1999-008810/01.
XX PT Antibody conjugate comprising monoclonal antibody - which binds to
XX PT epitope within amino acid residue of gp120 which neutralises HIV-1
XX PT conjugated with, e.g. cytotoxic agent.
XX PS Example 4; Col 25; 23pp; English.
XX CC The present invention describes an antibody conjugate comprising an
XX CC antibody (Ab) which binds to an epitope within amino acid residue 308-322
XX CC of gp120 and neutralises HIV-1, conjugated with a cytotoxic agent, an
XX CC anti-viral agent or an agent which facilitates passage through the blood
XX CC brain barrier. Also described is an antibody conjugate as above but where
XX CC the Ab binds to an epitope within amino acid residue 298-312 of gp120
XX CC which neutralises HIV-1. The present sequence represents an HIV-1 gp120
XX CC monoclonal antibody-BAT123 residue 308 to 322 from an example of the
XX CC present invention. The Ab are monoclonal Ab which bind to the gp120
XX CC protein on the envelope of HIV-1. They inhibit the infection of T-cells
XX CC and also inhibit syncytium formation. The antibodies are group specific
XX CC and neutralise different strains and isolates of HIV-1. The antibodies
XX CC have a variety of uses, including the treatment and prevention of AIDS
XX CC and AIDS related complex. They are especially used to kill infected T-
XX CC cells. (Updated on 17-OCT-2003 to standardise OS field)
XX SQ Sequence 15 AA;

Query Match 100.0%; Score 39; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.13;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFVTIGK 8
DB 8 RAFVTIGK 15

RESULT 60
AAW87620
ID AAW87620 standard; peptide; 15 AA.
XX AC AAW87620;
XX
```

DT 17-OCT-2003 (revised)
 DT 20-MAR-2003 (revised)
 DT 03-MAR-1999 (first entry)
 XX
 DE Epitope of HIV-1 gp120 protein which binds antibody BAT123.
 XX
 KW Epitope; gp120 protein; monoclonal antibody; HIV-1; antibody BAT123;
 KW antibody BAT267; antibody BAT085; T cell infection inhibition;
 KW syncytia formation; acquired immune deficiency syndrome; AIDS;
 KW AIDS-related complex; passive immunisation; antiviral; cytotoxic;
 KW viral load measurement; vaccine.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN US5854400-A.
 XX
 PD 29-DEC-1998.
 XX
 PF 22-SEP-1992; 92US-00950571.
 XX
 PR 29-MAY-1987; 87US-00057445.
 PR 24-DEC-1987; 87US-00137861.
 PR 26-SEP-1991; 91US-00767533.
 XX
 PA (TANO-) TANOX INC.
 XX
 FI Fung MSC, Sun BNC, Sun CRY, Chang NT, Chang TW;
 XX
 DR WPI; 1999-095002/08.
 XX
 PT Monoclonal antibodies directed against regions of gp120 of human immune
 PT deficiency virus-1 - are neutralising and able to inhibit infection of T
 PT cells and formation of syncytia, used for treatment, prevention or
 PT diagnosis of acquired immune deficiency syndrome.
 XX
 PS Claim 4; Col 8; 16pp; English.
 XX
 CC The present sequence represents an epitope of the gp120 protein of human
 CC immune deficiency virus (HIV)-1. The sequence comprises amino acids 308
 CC to 322 of gp120. The specification describes monoclonal antibodies which
 CC bind to epitopes of the gp120 protein. Specifically, these antibodies are
 CC designated BAT123, 267 and 085. Monoclonal antibodies neutralise HIV-1,
 CC inhibiting both infection of T cells and formation of syncytia, so are
 CC used to treat acquired immune deficiency syndrome (AIDS) and AIDS-related
 CC complex, by passive immunisation, as carriers of cytotoxic or antiviral
 CC agents, and in extracorporeal systems. They can also be used as
 CC immunoassay reagents (for diagnosis or measurement of viral load) and to
 CC screen for neutralising epitopes, potentially useful in vaccine
 CC development. (Updated on 20-MAR-2003 to correct PR field.) (Updated on 17
 CC -OCT-2003 to standardise OS field)
 XX
 SQ Sequence 15 AA;
 Query Match 100.0%; Score 39; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.13; Mismatches 0; Gaps 0;
 Matches 8; Conservative 0; Indels 0; Indels 0; Gaps 0;
 QY 1 RAFVTIGK 8
 Db |||||
 8 RAFVTIGK 15
 RESULT 61
 AAY04680
 ID AAY04680 standard; peptide; 15 AA.
 XX
 AC AAY04680;
 XX
 DT 17-OCT-2003 (revised)
 DT 22-JUN-1999 (first entry)
 XX
 DE HIV-1 gp120 amino acids 308-322.
 XX

KW gp120; HIV-1; monoclonal antibody; homology; antigen; breast; prostate;
 KW gynecological; cancer; detection; diagnosis; cell membrane; chromatin.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN WO9909047-A1.
 XX
 PD 25-FEB-1999.
 XX
 PF 29-JUL-1998; 98WO-US015580.
 XX
 PR 29-JUL-1997; 97US-00902087.
 XX
 PA (RAKO/) RAKOWICZ-SZULCZYNSKA E M.
 XX
 FI Rakowicz-Szulczynska EM;
 XX
 DR WPI; 1999-190148/16.
 XX
 PT Use of HIV-1 polypeptides - for developing products for the detection and
 PT treatment of breast, gynecological and prostate cancers.
 XX
 PS Disclosure; Page 39; 80pp; English.
 XX
 CC This peptide corresponds to amino acids 308-322 from the gp120 protein of
 CC the human immunodeficiency virus type 1 (HIV-1). The peptide is used to
 CC generate the monoclonal antibody Mab 5023. The invention relates to the
 CC use of homology between HIV-1 antigens and breast, gynecological and
 CC prostate cancer antigens to develop agents for use in the detection and
 CC treatment of such cancers. The method especially uses an antibody which
 CC recognises the p160, p80, p45 and p24 cell membrane proteins and the p24
 CC chromatin protein. (Updated on 17-OCT-2003 to standardise OS field)
 XX
 SQ Sequence 15 AA;
 Query Match 100.0%; Score 39; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.13; Mismatches 0; Gaps 0;
 Matches 8; Conservative 0; Indels 0; Indels 0; Gaps 0;
 QY 1 RAFVTIGK 8
 Db |||||
 8 RAFVTIGK 15
 RESULT 62
 AAY83916
 ID AAY83916 standard; peptide; 15 AA.
 XX
 AC AAY83916;
 XX
 DT 12-SEP-2003 (revised)
 DT 05-JUL-2000 (first entry)
 XX
 DE HIV-1 env T-cell epitope #1.
 XX
 KW Immunogen; particulate composition; immune response; assessment;
 KW target skin site; skin immune reaction; HIV-1; immunocompetence;
 KW antibody; cell mediated immunity; antigen exposure; allergy.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN WO200014547-A1.
 XX
 PD 16-MAR-2000.
 XX
 PF 03-SEP-1999; 99WO-GB002915.
 XX
 PR 04-SEP-1998; 98US-0099261P.
 PR 10-JUN-1999; 99US-0139045P.
 XX
 PA (POWD-) POWDERJECT RES LTD.
 XX
 FI Sarphie DF, Roberts LK, Fuller DL;

XX WPI; 2000-257072/22.

XX Assessing an immune response against a selected agent in an individual

PT comprises accelerating a particulate composition, containing an

PT immunogenic compound from a selected agent, into the target skin site of

PT the individual.

XX Disclosure; Page 23; 41pp; English.

XX The invention relates to a method of using an immunogenic compound from a

CC selected agent in the manufacture of a particulate composition for

CC assessing an immune response against the selected agent in an individual.

CC The method comprises: (a) accelerating the particulate composition into a

CC target skin site in the individual; and (b) assessing the target site to

CC determine the presence or absence of a localized skin immune reaction,

CC where the presence of the immune reaction is indicative of an immune

CC response against the selected agent. Peptides AAY83916-Y83925 represent

CC examples of peptides that could be used if the method is used to detect

CC human immunodeficiency virus type 1 (HIV-1). The method is useful for

CC assessing immunocompetence, antibody and cell mediated immunity, antigen

CC exposure, or allergic conditions in an individual. (Updated on 12-SEP-

CC 2003 to standardise OS field)

XX Sequence 15 AA;

QY 1 RAFVTIGK 8

DB 8 RAFVTIGK 15

RESULT 63

AAY66439

ID AAY66439 standard; peptide; 15 AA.

XX

AC AAY66439;

XX

DT 12-SEP-2003 (revised)

DT 22-FEB-2000 (first entry)

XX

XX HLA-A2-binding HIV-1 GP120 CTL epitope #241.

DE

XX HIV-1; MHC; major histocompatibility complex; Class I; HLA-A2;

KW human leukocyte antigen; CTL; cytotoxic T-cell; epitope; allele; binding;

KW conserved; genome; peptide; targeting; toxic; drug; antibody; antigen;

KW antiviral; molecular conjugate therapeutic; diagnosis; treatment;

KW pathogen; localisation; quantification; detection; infection;

KW drug resistance; immune response.

XX

OS Human immunodeficiency virus 1.

XX

XX WO9949893-A1.

XX

PD 07-OCT-1999.

XX

PF 31-MAR-1999; 99WO-US0007111.

XX

PR 31-MAR-1998; 98US-00052530.

XX

PA (UYBO-) UNIV BOSTON.

XX

PI Delisi C, Berzofsky J, Gulukota K, Vaccaro D, Weng Z, Zhang C;

XX WPI; 2000-038361/03.

XX

XX Novel methods for designing molecular conjugate therapeutics which are

PT used for diagnosis, imaging and treatment against pathogens.

XX

PS Example 3; Page 50; 62pp; English.

XX AAY66421-Y66453 are cytotoxic T-cell epitopes derived from conserved

CC portions of the HIV-1 genome that are presented by HLA-A2 MHC (major

CC histocompatibility complex) Class I molecules. The peptides are used to

CC construct targeting antigens comprising one or more peptides bound to

CC the corresponding MHC Class I molecule, which can be used to raise

CC antibodies. The antibody may then be used as a targeting vehicle to

CC deliver a potentially toxic drug to its target site of action, rather

CC than administering it systemically, which may result in adverse side

CC effects. The invention relates to improved methods for the design of

CC molecular conjugate therapeutics for the diagnosis and treatment of

CC infections caused by pathogens with a high mutation rate (such as HIV-1).

CC This method involves identifying conserved peptide-encoding regions among

CC the genomes of multiple variants of a pathogen, identifying the Class I

CC MHC molecules which occur with greatest frequency in a population of

CC interest (e.g., human sub-populations), and determining which of the

CC peptides bind to the Class I MHC molecules. The MHC-binding peptides and

CC the corresponding Class I MHC molecules are selected and used to

CC construct targeting antigens, which are in turn used to produce

CC targeting antibodies. The methods may be used in localisation,

CC quantification and in situ detection of specific peptide-MHC Class I

CC complexes and also to detect and treat viral infection. The methods of

CC the invention mitigate against the development of viral resistance to

CC drugs and to the immune response, as well as providing a solution for

CC targeting toxic compounds to destroy viruses sequestered in sites not

CC accessible to T cells. In addition, the methods eliminate the virus,

CC whereas current therapies only arrest viral replication. (Updated on 12-

CC SEP-2003 to standardise OS field)

XX Sequence 15 AA;

QY 1 RAFVTIGK 8

DB 8 RAFVTIGK 15

RESULT 64

AAY66455

ID AAY66455 standard; peptide; 15 AA.

XX

AC AAY66455;

XX

DT 12-SEP-2003 (revised)

DT 22-FEB-2000 (first entry)

XX

XX HLA-A3-binding HIV-1 GP120 CTL epitope #257.

DE

XX HIV-1; MHC; major histocompatibility complex; Class I; Caucasoid; HLA;

KW human leukocyte antigen; CTL; cytotoxic T-cell; Caucasian; epitope;

KW allele; binding; conserved; genome; peptide; targeting; toxic; drug;

KW antibody; antigen; antiviral; molecular conjugate therapeutic; diagnosis;

KW treatment; pathogen; localisation; quantification; detection; infection;

KW drug resistance; immune response.

XX

OS Human immunodeficiency virus 1.

XX

XX WO9949893-A1.

XX

PD 07-OCT-1999.

XX

PF 31-MAR-1999; 99WO-US0007111.

XX

PR 31-MAR-1998; 98US-00052530.

XX

PA (UYBO-) UNIV BOSTON.

XX

PI Delisi C, Berzofsky J, Gulukota K, Vaccaro D, Weng Z, Zhang C;

XX WPI; 2000-038361/03.

XX

XX Novel methods for designing molecular conjugate therapeutics which are
 PT used for diagnosis, imaging and treatment against pathogens.
 XX
 XX Example 3; Page 51; 62pp; English.
 XX
 CC AAY66454-Y66458 are cytotoxic T-cell epitopes derived from conserved
 CC portions of the HIV-1 genome that are presented by MHC (major
 CC histocompatibility complex) Class I alleles found with high frequency
 CC among Caucasoids in the USA. The peptides are used to construct
 CC targeting antigens comprising one or more peptides bound to the
 CC corresponding MHC Class I molecule, which can be used to raise
 CC antibodies. The antibody may then be used as a targeting vehicle to
 CC deliver a potentially toxic drug to its target site of action, rather
 CC than administering it systemically, which may result in adverse side
 CC effects. The invention relates to improved methods for the design of
 CC molecular conjugate therapeutics for the diagnosis and treatment of
 CC infections caused by pathogens with a high mutation rate (such as HIV-1).
 CC This method involves identifying conserved peptide-encoding regions among
 CC the genomes of multiple variants of a pathogen, identifying the Class I
 CC MHC molecules which occur with greatest frequency in a population of
 CC interest (e.g., human sub-populations), and determining which of the
 CC peptides bind to the Class I MHC molecules. The MHC-binding peptides and
 CC the corresponding Class I MHC molecules are selected and used to
 CC construct targeting antigens, which are in turn used to produce
 CC targeting antibodies. The methods may be used in localisation,
 CC quantification and in situ detection of specific peptide-MHC Class I
 CC complexes and also to detect and treat viral infection. The methods of
 CC drugs and to the immune response, as well as providing a solution for
 CC targeting toxic compounds to destroy viruses sequestered in sites not
 CC accessible to T cells. In addition, the methods eliminate the virus,
 CC whereas current therapies only arrest viral replication. (Updated on 12-
 CC SEP-2003 to standardise OS field)
 XX
 XX Sequence 15 AA;
 SQ
 Query Match 100.0%; Score 39; DB 3; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.13;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RAFVTIGK 8
 Db |||||
 8 RAFVTIGK 15
 RESULT 66
 AAY85591
 ID AAY85591 standard; peptide; 15 AA.
 XX
 AC AAY85591;
 XX
 DT 12-SEP-2003 (revised)
 DT 01-FEB-2001 (first entry)
 XX
 DE HIV related peptide 13.
 XX
 KW Immunogenic particle; human immunodeficiency virus; HIV; cytostatic;
 KW antiarthritic; antiinflammatory; cell-mediated immune response; cancer;
 KW rheumatoid arthritis; inflammatory disorder; viral infection.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN WO200057919-A2.
 XX
 PD 05-OCT-2000.
 XX
 PF 23-MAR-2000; 2000WO-CA000319.
 XX
 XX 25-MAR-1999; 99US-00276057.
 FR
 XX (SAPI-) SAPIENTIA THERAPEUTICS LTD.
 PA (AGEN-) AGENE RES INST CO LTD.
 PA

XX Sugimoto M, Arella M, Furuichi Y;
 PI WPI; 2000-664891/64.
 XX
 DR Lipid based artificial particles useful for inducing a cell mediated
 XX immune response in a subject having cancer, comprises a lipid based
 XX matrix, glycolipids and peptide-lipid conjugates embedded in the matrix.
 XX
 PT Claim 10; Page 34; 39pp; English.
 XX
 CC This invention relates to artificial immunogenic particles comprising
 CC glycolipids having a lipidic and a saccharide portion and peptide-lipid
 CC conjugates having a lipidic and a peptide portion embedded into a lipid
 CC based matrix. The peptide portion of the particle may be of viral origin.
 CC Peptides AAY85579-Y85591 are human immunodeficiency virus (HIV) related
 CC peptides which can be used as the peptide portion in an immunogenic
 CC particle of the invention. The particles have cytostatic, antiarthritic
 CC and antiinflammatory activity. The immunogenic particles are used for
 CC inducing a cell-mediated immune response in a host directed towards the
 CC peptide portion of the peptide-lipid conjugate. This means that the
 CC particles may be used to treat diseases such as cancer, rheumatoid
 CC arthritis, inflammatory disorders or viral infections such as HIV.
 CC (Updated on 12-SEP-2003 to standardise OS field)
 XX
 XX Sequence 15 AA;
 SQ
 Query Match 100.0%; Score 39; DB 3; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.13;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RAFVTIGK 8
 Db |||||
 8 RAFVTIGK 15
 RESULT 66
 AAB15875
 ID AAB15875 standard; peptide; 15 AA.
 XX
 AC AAB15875;
 XX
 DT 17-JAN-2001 (first entry)
 XX
 DE Human chemokine derived peptide #27.
 XX
 KW Macrophage recruitment; chemokine derivative; MCP-1; osteoporosis;
 KW monocyte chemoattractant protein-1; inflammation; atherosclerosis; HIV;
 KW AIDS; stroke; psoriasis; autoimmune disease; hypertension; endotoxaemia;
 KW basophil-mediated disease; myocardial infarction; acute ischaemia;
 KW rheumatoid arthritis; contraception.
 XX
 OS Synthetic.
 XX
 PN WO200042071-A2.
 XX
 PD 20-JUL-2000.
 XX
 PF 12-JAN-2000; 2000WO-US000821.
 XX
 PR 12-JAN-1999; 99US-00229071.
 PR 17-MAR-1999; 99US-00271192.
 PR 01-DEC-1999; 99US-00452406.
 XX
 PA (NEOR-) NEORX CORP.
 XX
 XX Grainger DJ, Tatalick LM;
 PI WPI; 2000-499101/44.
 DR
 XX New peptide 3, amide and heterocyclic compounds and saccharide conjugates
 PT used for inhibiting chemokine induced activity and for treating e.g.
 PT stroke, vascular diseases, autoimmune diseases and tumor growth.

XX Disclosure; Fig 18; 387pp; English.

XX The present invention concerns the identification of a number of

CC chemokines which can be used to produce derivatives, agonists and

CC antagonists which are then useful in disease treatment. The chemokines

CC include sequences AAB15785-B15794, AAB15803-B15813 and AAB15831-B15848.

CC These chemokine derivatives can be used to treat diseases such as

CC autoimmune diseases, atherosclerosis, osteoporosis, HIV infection and

CC AIDS, psoriasis, inflammatory diseases, hypertension, basophil-mediated

CC diseases, endotoxaemia, myocardial infarction, acute ischaemia and

CC rheumatoid arthritis, and can be used to prevent strokes and as

CC contraceptives. The coding sequences for the chemokines can be used in

CC gene therapy for the same diseases, as well as in the production of

CC animal models

XX Sequence 15 AA;

XX Query Match 100.0%; Score 39; DB 3; Length 15;

XX Best Local Similarity 100.0%; Pred. No. 0.13;

XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8

DB 8 RAFVTIGK 15

|||||

RESULT 67

AM99083

ID AAM99083 standard; peptide; 15 AA.

XX AC AAM99083;

XX 11-SEP-2003 (revised)

DT 07-DEC-2001 (first entry)

XX Vaccine related MHC ligand peptide SEQ ID NO:186.

DE

XX Glutamic acid; glutamine; vaccine; major histocompatibility complex; MHC;

XX immunomodulator; antiallergic; endocrine; neuroprotectant; virucidal;

KW bactericidal; antiparasitic; fungicidal; cytostatic; medicine;

KW pharmaceutical; immune disorder; immune deficiency; autoimmunity;

KW hypersensitivity; allergy; graft rejection; infection; hormonal disorder;

KW central nervous system disease; cancer; melanoma; anti-melanoma vaccine;

KW human immunodeficiency virus.

XX

OS Human immunodeficiency virus 1.

OS

PN WO200170772-A2.

XX

PD 27-SEP-2001.

XX

XX 22-MAR-2001; 2001WO-FR000872.

PF

XX 23-MAR-2000; 2000FR-00003711.

PR

XX (FABR) FABRE MEDICAMENT SA PIERRE.

PA

XX Klingner-Hamour C, Corvaia N, Beck A, Goetsch L;

PI

XX WPI; 2001-611470/70.

DR

XX Stabilized pharmaceutical containing N-terminal glutamic acid or

PT glutamine, useful e.g. in anti-melanoma vaccines, is an addition salt

PT with strong acid.

XX

XX Claim 9; Page 63; 149pp; French.

PS

XX The present invention describes a pharmaceutical compound (I) that

CC contains an N-terminal glutamic acid (Glu) or glutamine (Gln) residue in

CC the form of an addition salt with a strong, physiologically acceptable

CC acid (II). Also described are: (a) a pharmaceutical composition

CC containing at least one (I); (b) a vaccine containing at least one (I)

CC

CC where this is a major histocompatibility complex (MHC) ligand (Ia); (c) a

CC method for in vitro diagnosis of diseases associated with the presence of

CC (Ia); (d) a kit for method (c) that includes a (Ia); and (e) a process

CC for preparing (I). (I) has immunomodulator, endocrine, antiallergic,

CC neuroprotectant, virucidal, bactericidal, antiparasitic, fungicidal and

CC cytostatic activities. (I) are useful, in human or veterinary medicine,

CC in pharmaceutical compositions for treating immune disorders, e.g.

CC immune deficiency, autoimmune states, hypersensitivity, allergy, graft

CC rejection, infection, hormonal disorders and central nervous system

CC diseases), also, where (I) is a MHC ligand (Ia), in vaccines for

CC treatment or prevention of: (i) viral, bacterial, parasitic or fungal

CC infections; or (ii) of cancers. A particular application is in anti-

CC melanoma vaccines. (I) are also useful for in vitro diagnosis of diseases

CC associated with interactions between MHC and (I), e.g. melanoma and human

CC immunodeficiency virus infection. AAM98898 to AAM99592 represent peptides

CC which can be used in pharmaceutical compounds from the present invention.

CC (Updated on 11-SEP-2003 to standardise OS field)

XX

XX Sequence 15 AA;

XX Query Match 100.0%; Score 39; DB 4; Length 15;

XX Best Local Similarity 100.0%; Pred. No. 0.13;

XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8

DB 7 RAFVTIGK 14

|||||

RESULT 68

AAB92345

ID AAB92345 standard; peptide; 15 AA.

XX AC AAB92345;

XX 22-JUN-2001 (first entry)

DT

XX Virus related peptide SEQ ID NO:1521.

DE

XX Protection; endogenous therapeutic peptide; peptidase; conjugation;

KW blood component; modification; succinimide; maleimido group; amino;

KW hydroxyl; thiol; hormone; growth factor; neurotransmitter.

XX

OS Homo sapiens.

OS Synthetic.

OS

PN WO200069900-A2.

XX

PD 23-NOV-2000.

XX

XX 17-MAY-2000; 2000WO-US013576.

PF

XX 17-MAY-1999; 99US-0134406P.

PR

XX 10-SEP-1999; 99US-0153406P.

PR

XX 15-OCT-1999; 99US-0159783P.

PR

XX (CONJ-) CONJUCHEM INC.

PA

XX Bridon DP, Ezrin AM, Milner PG, Holmes DL, Thibaudau K;

PI

XX WPI; 2001-112059/12.

DR

XX Modifying and attaching therapeutic peptides to albumin prevents

PT peptidase degradation, useful for increasing length of in vivo activity.

PT

XX Disclosure; Page 702; 733pp; English.

PS

XX The present invention describes a modified therapeutic peptide (I)

CC comprising a therapeutically active amino acid region (II) and a

CC reactive group (II) (e.g. succinimide and maleimido groups) attached to

CC a less therapeutically active amino acid region (IV), which covalently

CC bonds with amino/hydroxyl/thiol groups on blood components to form a

CC peptidase stabilised therapeutic peptide composed of 3-50 amino acids.

CC (I) are useful for modifying therapeutic peptides e.g. hormones, growth
 CC factors and neurotransmitters, to protect them from peptidase activity in
 CC vivo for the treatment of various disorders. Endogenous therapeutic
 CC peptides are not suitable as drug candidates as they require frequent
 CC administration due to rapid degradation by peptidases in the body.
 CC Modifying and attaching therapeutic peptides to albumin prevents or
 CC reduces the action of peptidases to increase length of activity (half
 CC life) and specificity as bonding to large molecules decreases
 CC intracellular uptake and interference with physiological processes.
 CC AAB90829 to AAB92441 represent peptides which can be used in the
 CC exemplification of the present invention
 XX Sequence 15 AA;

Query Match 100.0%; Score 39; DB 4; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.13;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8,
 |||||
 Db 8 RAFVTIGK 15

RESULT 69
 AAB92348
 ID AAB92348 standard; peptide; 15 AA.

XX AC AAB92348;

XX DT 22-JUN-2001 (first entry)

XX DE Virus related peptide SEQ ID NO:1524.

XX KW Protection; endogenous therapeutic peptide; peptidase; conjugation;
 XX blood component; modification; succinimidyl; maleimido group; amino;
 XX hydroxyl; thiol; hormone; growth factor; neurotransmitter.

XX OS Homo sapiens.
 XX Synthetic.

XX PN WO200069900-A2.

XX PD 23-NOV-2000.

XX PF 17-MAY-2000; 2000WO-US013576.

XX PR 17-MAY-1999; 99US-0134406P.

XX PR 10-SEP-1999; 99US-0153406P.

XX PR 15-OCT-1999; 99US-0159783P.

XX PA (CONJ-) CONJUCHEM INC.

XX PI Bridon DP, Ezrin AM, Milner PG, Holmes DL, Thibaudeau K;

XX WPI; 2001-112059/12.

XX PT Modifying and attaching therapeutic peptides to albumin prevents
 XX peptidase degradation, useful for increasing length of in vivo activity.

XX PS Disclosure; Page 703; 733pp; English.

XX CC The present invention describes a modified therapeutic peptide (I)
 XX comprising a therapeutically active amino acid region (III) and a
 XX reactive group (II) (e.g. succinimidyl and maleimido groups) attached to
 XX a less therapeutically active amino acid region (IV), which covalently
 XX bonds with amino/hydroxyl/thiol groups on blood components to form a
 XX peptidase stabilised therapeutic peptide composed of 3-50 amino acids.
 XX (I) are useful for modifying therapeutic peptides e.g. hormones, growth
 XX factors and neurotransmitters, to protect them from peptidase activity in
 XX vivo for the treatment of various disorders. Endogenous therapeutic
 XX peptides are not suitable as drug candidates as they require frequent
 XX administration due to rapid degradation by peptidases in the body.
 XX Modifying and attaching therapeutic peptides to albumin prevents or

CC reduces the action of peptidases to increase length of activity (half
 CC life) and specificity as bonding to large molecules decreases
 CC intracellular uptake and interference with physiological processes.
 CC AAB90829 to AAB92441 represent peptides which can be used in the
 CC exemplification of the present invention
 XX Sequence 15 AA;

Query Match 100.0%; Score 39; DB 4; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.13;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8,
 |||||
 Db 8 RAFVTIGK 15

RESULT 70

AAB68601

ID AAB68601 standard; peptide; 15 AA.

XX AC AAB68601;

XX DT 11-SEP-2003 (revised)

XX DT 25-APR-2001 (first entry)

XX DE HIV gp120 V3 loop peptide #1.

XX KW HIV gp120 V3 loop; liposome composition; HIV infection.

XX OS Human immunodeficiency virus 1.

XX PN US6180134-B1.

XX PD 30-JAN-2001.

XX PF 07-JUN-1995; 95US-00480332.

XX PR 23-MAR-1993; 93US-00035443.

XX PR 29-SEP-1994; 94US-00316436.

XX PA (SEQU-) SEQUUS PHARM INC.

XX PI Zalipsky S, Woodle MC, Martin FJ, Barenholz Y;

XX WPI; 2001-201897/20.

XX PT Liposome composition for use in treating septic shock comprises liposomes
 XX having an outer surface layer of polyethylene glycol chains, and a
 XX polypeptide or polysaccharide effector molecule.

XX PS Disclosure; Fig 13; 32pp; English.

XX CC The present invention relates to a liposome composition comprising
 XX liposomes having an outer surface layer of polyethylene glycol chains,
 XX each having a free distal end. A polypeptide or polysaccharide effector
 XX molecule is covalently attached to a portion of the distal ends. The
 XX effector interferes with specific binding of pathogen or cell in a
 XX bloodstream to a target cell or cell matrix, and is rapidly removed by
 XX renal clearance from the bloodstream when administered in free form. The
 XX liposome composition may be used in treating a condition mediated by
 XX binding a pathogen or cell in the bloodstream, to a target cell or cell
 XX matrix. It can be used in treating septic shock, toxic shock, colonic
 XX inflammation, leukaemic cell proliferation, or HIV infection. The present
 XX sequence is a peptide of the V3 loop of HIV envelope protein gp120. This
 XX peptide may be used in the composition of the present invention. gp120
 XX binds to the CD4 receptor during HIV infection of lymphocytes. By
 XX introducing the present peptide, the CD4 receptors are blocked, thereby
 XX inhibiting HIV infection. (Updated on 11-SEP-2003 to standardise OS
 XX field)

XX Sequence 15 AA;

Query Match 100.0%; Score 39; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.13;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
| | | | |
DB 8 RAFVTIGK 15

RESULT 71

AAE15743
ID AAE15743 standard; peptide; 15 AA.

XX AC AAE15743;

DT 26-MAR-2002 (first entry)

DE Human immunodeficiency virus (HIV) p18 peptide.

XX HIV; human immunodeficiency virus; cytostatic; immunosuppressive; p18;
KW virucide; antibacterial; fungicide; protozoacide; antirheumatic; vaccine;
KW antiinflammatory; antiarthritic; neuroprotective; rheumatoid arthritis;
KW cancer; multiple sclerosis; immune response; vasotropic; gene therapy;
KW autoimmune disease; vasculitis.

XX Human immunodeficiency virus.

OS WO200176643-A1.

PN 18-OCT-2001.

XX 06-APR-2001; 2001WO-US011372.

PF 07-APR-2000; 2000US-0195680P.

PR (BAYU) BAYLOR COLLEGE MEDICINE.

XX Orson FM, Kinsey BM, Bhogal BS;

PI WPI; 2002-066308/09.

DR Composition for oral delivery of vaccines, comprises expression vector
containing antigenic genomic sequence, bound to aggregated protein-
polycationic polymer conjugate or suspension.

PS Example 10; Page 30; 145pp; English.

XX The invention relates to a composition comprising an expression vector
bound to an aggregated protein-polycationic polymer conjugate or
suspension. The expression vector contains a promoter polynucleotide
sequence operatively linked to a polynucleotide sequence encoding an
antigen which is a fragment of a gene or genome associated with an
infectious disease, cancer and autoimmune disease such as rheumatoid
arthritis, vasculitis, and multiple sclerosis, pathogenic genomes
consisting of bacterium, fungus, protozoa and virus such as human
immunodeficiency virus (HIV), herpes simplex virus (HSV), hepatitis C
virus (HCV), influenza and respiratory syncytial virus (RSV), and
optionally comprising a nucleotide sequence encoding a cytokine (or a
cytokine expression vector), is useful for inducing an immune response
(systemic and/or mucosal) in an organism. The cytokine expression vector
contains a sequence for granulocyte macrophage-colony stimulating factor
(GM-CSF) or interleukin-12 (IL-12). The polynucleotide sequences encoding
the antigen and the cytokine are under transcriptional control of same or
different promoter polynucleotide sequences. The expression vector, as a
DNA vaccine is useful for treating a condition in an organism. The
present sequence is human immunodeficiency virus (HIV) p18 peptide,
related to the invention

XX Sequence 15 AA;

Query Match 100.0%; Score 39; DB 5; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.13;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
| | | | |
DB 8 RAFVTIGK 15

RESULT 72

AAU96031
ID AAU96031 standard; protein; 15 AA.

XX AC AAU96031;

XX 29-AUG-2003 (revised)

DT 02-JUL-2002 (first entry)

XX HIV epitope, HIV-1 gp120 H-2Dd, help, peptide sequence.

XX Vaccine; non-replicating; viral tubule; immunogen; antibody; BTV;
KW Bluetongue virus; foot and mouth disease virus; FMDV; influenza virus;
KW human immunodeficiency virus; HIV; protective immunity; epitope; TUB;
KW virus-derived tubule; anti-HIV; virucide.

OS Human immunodeficiency virus 1.

XX WO200226254-A2.

PN 04-APR-2002.

XX 27-SEP-2001; 2001WO-US030464.

PF 27-SEP-2000; 2000US-0235614P.

PR (UABR-) UAB RES FOUND.

XX Roy P;

PI WPI; 2002-339987/37.

DR A vaccine, for inducing an antiviral immune response, comprises a non-
replicating vaccine delivery vehicle (which comprises a non-infectious
recombinant viral tubule) carrying one or more immunogens.

PS Claim 8; Page 39; 65pp; English.

XX The present invention relates to a new vaccine comprising a non-
replicating vaccine delivery vehicle (which comprises a non-infectious
recombinant viral tubule) carrying one or more immunogens. The invention
is useful for inducing an immune response, preferably anti-viral, in a
subject. The administration of the vaccine is preferably followed by
administering one or more virus like particles carrying an immunogen. It
is also useful for administering to a patient for generating antibodies
specific for one or more immunogens, such as Bluetongue virus (BTV), foot
and mouth disease virus (FMDV), influenza virus and human
immunodeficiency virus (HIV). The invention provides an effective means
of delivering multiple peptide components representing viral/tumour
antigenic groups to elicit protective immunity, which has not previously
been possible. The present amino acid sequence represents one of a
collection (AAU96022-AAU96045) of HIV epitopes that were used in the
methods of the invention as immunogens. These epitopes were used to
construct chimeric NS1-TUBs (virus-derived tubules) which show
immunogenicity. (Updated on 29-AUG-2003 to standardise OS field)

XX Sequence 15 AA;

Query Match 100.0%; Score 39; DB 5; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.13;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
| | | | |
DB 8 RAFVTIGK 15

RESULT 73
 AAU97690
 ID AAU97690 standard; peptide; 15 AA.
 XX
 AC AAU97690;
 XX
 DT 29-AUG-2003 (revised)
 DT 13-AUG-2002 (first entry)
 XX
 DE HIV CTL epitope peptide sequence.
 XX
 KW Adjuvant; acid-fast bacterium; acquired immunodeficiency syndrome;
 KW DNA vaccine; AIDS; hepatitis C virus; alpha-antigen gene; CTL;
 KW Mycobacterium kansasii; antigenic; immunogenic; epitope;
 KW human immunodeficiency virus; HIV.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN JP2002114708-A.
 XX
 PD 16-APR-2002.
 XX
 PF 06-OCT-2000; 2000JP-00307674.
 XX
 PR 06-OCT-2000; 2000JP-00307674.
 XX
 PA (PRIM-) PRIMUNE CORP YG.
 XX
 DR WPI; 2002-448884/48.
 XX
 PT An adjuvant of a DNA vaccine composed of alpha-antigen genes derived from
 PT acid-fast bacterium.
 XX
 PS Example 1; Page 7; 12pp; Japanese.
 XX
 CC The present invention relates to a new adjuvant of a gene derived from
 CC acid-fast bacterium for a DNA vaccine against AIDS (acquired
 CC immunodeficiency syndrome) and hepatitis C virus. The invention is
 CC composed of an effective component of alpha-antigen gene derived from
 CC acid-fast bacterium for DNA vaccine, particularly encoding for an alpha-
 CC antigen, particularly derived from Mycobacterium kansasii or its variant
 CC which has the same function, with an effective ingredient of an
 CC expression vector of the gene, used as an adjuvant, particularly a
 CC chimera DNA vaccine with a gene encoding for an antigenic peptide
 CC inserted, used for a DNA vaccine using a gene encoding for an immunogenic
 CC peptide derived from AIDS or hepatitis C virus. The adjuvant is useful
 CC for the treatment of AIDS or hepatitis C. The adjuvant enhances the
 CC immune inductive effect of the DNA vaccine. The present amino acid
 CC sequence represents the HIV (human immunodeficiency virus) CTL epitope
 CC peptide of the invention. (Updated on 29-AUG-2003 to standardise OS
 CC field)
 XX
 SQ Sequence 15 AA;
 Query Match 100.0%; Score 39; DB 5; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.13;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RAFVTIGK 8
 DB 8 RAFVTIGK 15
 RESULT 74
 ABG68654
 ID ABG68654 standard; peptide; 15 AA.
 XX
 AC ABG68654;
 XX
 DT 29-AUG-2003 (revised)
 DT 07-OCT-2002 (first entry)
 XX
 DE HIV-1 P18IIB peptide antigen.

XX
 KW Eliciting an immune response; peptide antigen; T-cell epitope;
 KW tumour antigen; viral antigen; non-viral vector; HIV-1;
 KW T-cell co-stimulatory molecule; human immunodeficiency virus;
 KW immunostimulant.
 XX
 OS Human immunodeficiency virus 1; (IIB isolate).
 XX
 PN US2002044948-A1.
 XX
 PD 18-APR-2002.
 XX
 PF 14-MAR-2001; 2001US-00810310.
 XX
 PR 15-MAR-2000; 2000US-0189396P.
 XX
 PA (KHLE/) KHLEIF S.
 PA (BERZ/) BERZOFKY J.
 XX
 PI Khleif S, Berzofsky J;
 XX
 DR WPI; 2002-507231/54.
 XX
 PT Administering a non-viral vector encoding a co-stimulatory molecule
 PT alongside a peptide or protein T cell epitope, elicits increased response
 PT to the antigen and is useful to enhance peptide and protein based
 PT vaccines and treatments.
 XX
 PS Disclosure; Page 7; 39pp; English.
 XX
 CC The present invention relates to a method for eliciting an immune
 CC response in a subject. The method comprises administering a peptide or
 CC protein antigen comprising T-cell epitope(s) (e.g. tumour antigen, viral
 CC or non-viral antigen) coordinately with a non-viral vector comprising a
 CC polynucleotide encoding a T-cell co-stimulatory molecule. Viral peptide
 CC antigens may include human immunodeficiency virus (HIV) antigen,
 CC hepatitis B virus (HBV), herpes simplex virus (HSV) or human papilloma
 CC virus (HPV). The method is useful to elicit an immune response in a
 CC subject, and to supplement and enhance peptide and protein based vaccines
 CC and treatment methods. ABG68640-ABG68700 represent HIV-1 peptide antigens
 CC useful in the method of the present invention. (Updated on 29-AUG-2003 to
 CC standardise OS field)
 XX
 SQ Sequence 15 AA;
 Query Match 100.0%; Score 39; DB 5; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.13;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RAFVTIGK 8
 DB 8 RAFVTIGK 15
 RESULT 75
 ABG68663
 ID ABG68663 standard; peptide; 15 AA.
 XX
 AC ABG68663;
 XX
 DT 29-AUG-2003 (revised)
 DT 07-OCT-2002 (first entry)
 XX
 DE HIV-1 P18 based peptide antigen #1.
 XX
 KW Eliciting an immune response; peptide antigen; T-cell epitope;
 KW tumour antigen; viral antigen; non-viral vector; HIV-1;
 KW T-cell co-stimulatory molecule; human immunodeficiency virus;
 KW immunostimulant.
 XX
 OS Human immunodeficiency virus 1; (IIB isolate).
 XX
 PN US2002044948-A1.

XX 18-APR-2002.
 XX 14-MAR-2001; 2001US-00810310.
 XX 15-MAR-2000; 2000US-0189396P.
 XX (KHLE/) KHLERIF S.
 XX (BERZ/) BERZOFISKY J.
 XX Khleif S, Berzofsky J;
 XX WPI; 2002-507231/54.
 XX Administering a non-viral vector encoding a co-stimulatory molecule
 PT alongside a peptide or protein T cell epitope, elicits increased response
 PT to the antigen and is useful to enhance peptide and protein based
 PT vaccines and treatments.
 XX Disclosure; Page 7; 39pp; English.
 XX The present invention relates to a method for eliciting an immune
 CC response in a subject. The method comprises administering a peptide or
 CC protein antigen comprising T-cell epitope(s) (e.g. tumour antigen, viral
 CC or non-viral antigen) coordinately with a non-viral vector comprising a
 CC polynucleotide encoding a T-cell co-stimulatory molecule. Viral peptide
 CC antigens may include human immunodeficiency virus (HIV) antigen,
 CC hepatitis B virus (HBV), herpes simplex virus (HSV) or human papilloma
 CC virus (HPV). The method is useful to elicit an immune response in a
 CC subject, and to supplement and enhance peptide and protein based vaccines
 CC and treatment methods. ABG68640-ABG68700 represent HIV-1 peptide antigens
 CC useful in the method of the present invention. (Updated on 29-AUG-2003 to
 CC standardise OS field)
 XX Sequence 15 AA;
 SQ
 Query Match 100.0%; Score 39; DB 5; Length 15;
 Best Local Similarity 100.0%; Pred. NO. 0.13;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RAFVTIGK 8
 Db |||||
 8 RAFVTIGK 15
 RESULT 76
 AAE35161 standard; peptide; 15 AA.
 ID AAE35161
 AC AAE35161;
 XX 28-MAY-2003 (first entry)
 DT HIV CTL epitope #6.
 DE Cytolytic T lymphocyte; epitope; vaccine; prophylaxis; HIV infection;
 XX human immunodeficiency virus; acquired immune deficiency syndrome; CTL;
 KW gene therapy; AIDS.
 KW Human immunodeficiency virus.
 XX WO200294313-A2.
 XX 28-NOV-2002.
 PD 20-MAY-2002; 2002WO-GB002336.
 PF 18-MAY-2001; 2001US-0291654P.
 PR 18-MAY-2001; 2001US-0291655P.
 XX (POWD-) POWDERJECT VACCINES INC.
 PA (POWD-) POWDERJECT RES LTD.
 XX

PI Fuller D, Fuller J, Haynes J, Shipley T;
 XX WPI; 2003-148439/14.
 XX Recombinant nucleic acid for the treatment and prophylaxis of acquired
 PT immunodeficiency syndrome, comprises a nucleic acid sequence encoding an
 PT antigen containing two or more cytolytic T lymphocyte (CTL) epitopes or
 XX its analogs.
 XX Claim 1; Col 78; 42pp; English.
 XX The invention relates to a recombinant nucleic acid comprising a nucleic
 CC acid sequence encoding an antigen containing two or more cytolytic T
 CC lymphocyte (CTL) epitopes or its analogues. Sequences of the invention
 CC are used in vaccines and are useful for the treatment and prophylaxis of
 CC human immunodeficiency virus (HIV) infection, particularly acquired
 CC immune deficiency syndrome (AIDS). The invention is also useful in gene
 CC therapy. The present sequence is HIV CTL epitope. This sequence is used
 CC in the exemplification of the invention
 XX Sequence 15 AA;
 SQ
 Query Match 100.0%; Score 39; DB 6; Length 15;
 Best Local Similarity 100.0%; Pred. NO. 0.13;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RAFVTIGK 8
 Db |||||
 8 RAFVTIGK 15
 RESULT 77
 ADN14074
 ID ADN14074 standard; peptide; 15 AA.
 XX ADN14074;
 AC ADN14074;
 XX 17-JUN-2004 (first entry)
 DT HIV helper T cell epitope #41.
 DE HIV; antigen; epitope; T cell; MHC; major histocompatibility complex;
 KW CTL; cytotoxic T lymphocyte; HIV infection; cancer; tuberculosis; tumour;
 KW hepatitis; melanoma; breast cancer; Hodgkin lymphoma;
 KW nasopharyngeal carcinoma; vaccine; immune response; hyaluronic acid; HA;
 KW CD8+ T cell; CD4+ T cell; viral infection; bacterial infection;
 KW fungal infection; parasitic infection.
 XX Human immunodeficiency virus 1.
 OS US2003049253-A1.
 XX 13-MAR-2003.
 PD 05-FEB-2002; 2002US-00062710.
 PF 08-AUG-2001; 2001US-0310498P.
 XX (LIQO/) LI P Q.
 PA (CHUX/) CHU Y.
 PA (QIUJ/) QIU J.
 XX Li Q, Chu Y, Qiu J;
 PI WPI; 2003-540464/51.
 XX Modulating an immune system response to an antigen in a mammal, comprises
 PT administering a particle-free therapeutic comprising a hyaluronic acid
 PT polymer analogue covalently linked to a peptide that comprises a T cell
 PT epitope.
 XX Disclosure; Page 12; 23pp; English.
 PS
 XX

CC The invention relates to modulating an immune system response to an
 CC antigen in a mammal comprising administering to the mammal a particulate
 CC free therapeutic comprising a hyaluronic acid (HA) polymer analogue
 CC covalently linked to at least one peptide that comprises a T cell epitope
 CC recognised by a major histocompatibility complex molecule of the mammal.
 CC The T cell epitope comprises a sequence of at least about eight amino
 CC acids of the antigen. Also included are a method of improving major
 CC histocompatibility complex (MHC) presentation of a T cell epitope of an
 CC antigen in a mammal (comprising administering to the mammal the
 CC conjugate). The T cell epitope is recognised by a major
 CC histocompatibility complex (MHC) Class I molecule and by a CD8+ T cell of
 CC the mammal, or an MHC Class II molecule and a CD4+ T cell of the mammal.
 CC The immune system comprises a cytotoxic T lymphocyte, a CD4+T
 CC cell, or an antibody that recognises the antigen. The immune system
 CC response to the antigen is increased after administration of the
 CC conjugate, where the antigen is an antigen of a pathogenic agent or a
 CC tumour cell. The immune system response to the antigen is decreased after
 CC administration of the conjugate, where the antigen is an antigen of a
 CC tissue or organ transplanted to the mammal. The composition and methods
 CC are useful for modulating, i.e. enhancing or diminishing, an immune
 CC system response to an antigen in a mammal. The composition is also useful
 CC for improving major histocompatibility complex presentation of a T cell
 CC epitope of an antigen in a mammal. The polymeric hyaluronic acid
 CC conjugates are useful as peptide vaccines against an antigen, a
 CC pathogenic agent such as viral, bacterial, fungal or parasitic protein,
 CC or a tumour cell) in a mammal. The peptide vaccine compositions are
 CC useful for treating or preventing diseases associated with any of the
 CC antigens above e.g. HIV infection, cancer, tuberculosis, hepatitis,
 CC melanoma, breast cancer, Hodgkin's lymphoma and nasopharyngeal carcinoma.
 CC The peptide vaccine compositions of the present invention do not require
 CC additional adjuvants, but still induce a stronger cell-mediated response
 CC than peptide vaccines of the prior art. The present sequence is an HIV-1
 CC derived epitope suitable for the vaccine of the invention.

XX Sequence 15 AA;

Query Match 100.0%; Score 39; DB 7; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.13;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
 |||||
 Db 8 RAFVTIGK 15

RESULT 78

ADRO4041
 ID ADRO4041 standard; peptide; 15 AA.

XX AC ADRO4041;

XX DT 04-NOV-2004 (first entry)

XX DE Immune response induction composition peptide adjuvant #2.

XX KW vaccine; virucide; antibacterial; immunosuppressive; anti-allergic;
 KW cytostatic; peptide adjuvant.

XX OS Synthetic.

XX PN WO2004067020-A1.

XX PD 12-AUG-2004.

XX PF 30-JAN-2004; 2004WO-KR000177.

XX PR 30-JAN-2003; 2003KR-00006393.

XX (UYPO-) UNIV POHANG SCI & TECHNOLOGY.
 PA (GENE-) GENEXINE CO LTD.

XX PI Park K, Park S, Yang S, Lee C, Choi S, Ryu S, Kim Y, Sung Y;

DR WPI; 2004-580853/56.

XX New vaccine composition comprising a peptide adjuvant and a DNA vaccine
 PT encoding an immunogenic protein, useful for inducing immune responses
 PT against diseases e.g. HIV infection, autoimmune diseases, tuberculosis or
 PT allergies.

XX Example 2; Page 21; 37pp; English.

XX The present invention relates to a vaccine composition comprising a
 CC peptide adjuvant and a DNA vaccine encoding an immunogenic protein. The
 CC composition may also comprise a gene of the influenza virus, preferably
 CC the neuraminidase gene. The vaccine composition is useful for inducing
 CC immune responses against diseases comprising HIV infection, herpes
 CC simplex virus (HSV) infection, influenza virus infection, hepatitis A or
 CC B infection, papillomavirus infection, tuberculosis, tumour growth, or
 CC autoimmune diseases or allergies. The present sequence is a peptide
 CC adjuvant useful in the composition of the invention.

XX Sequence 15 AA;

Query Match 100.0%; Score 39; DB 8; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.13;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
 |||||
 Db 8 RAFVTIGK 15

RESULT 79

AAR24939
 ID AAR24939 standard; protein; 16 AA.

XX AC AAR24939;

XX DT 25-MAR-2003 (revised)

XX DT 09-DEC-1992 (first entry)

XX DE HIV peptide ENV 312-327.

XX KW Lipopeptide; lipoprotein; vaccine; cytotoxic T-cell; lymphocyte; HIV;
 KW human immunodeficiency virus; AIDS; cancer; tumour cells; CB1; CB2; CB3.

XX OS Synthetic.

XX PN EP491628-A2.

XX PD 24-JUN-1992.

XX PF 18-DEC-1991; 91EP-00403446.

XX PR 18-DEC-1990; 90PR-00015870.

XX PA (INSP) INST PASTEUR LILLE.

XX PA (INRM) INSERM INST NAT SANTE & RECH MED.

XX PA (INSP) INST PASTEUR.

PI Boutillon C, Martinon F, Sergheraert C, Magne R, Gras-Masse H;

PI Gomard E, Tartar A, Levy JP;

XX WPI; 1992-209776/26.

XX Lipopeptide(s) which stimulate cytotoxic T-cells - for treating HIV,
 PT parasitic infections and cancer.

XX Example; Page 18; 32pp; French.

XX The sequence is that of peptide ENV 312-327 derived from the HIV, it is
 CC made by standard methods of solid phase peptide synthesis. It is used as
 CC part of lipopeptides CB1, CB2 and CB3 which comprise the peptide, and one
 CC or more chains derived from 10-20C fatty acids and/or modified steroid
 CC groups, these being coupled to alpha or epsilon amino groups of the

CC peptide. The lipoproteins are useful in vaccines and acts by inducing
 CC cytotoxic T lymphocytes against the HIV virus antigen from which the
 CC peptide is derived. See also AAR24938 and AAR24940. (Updated on 25-MAR-
 CC 2003 to correct PN field.)

XX SQ Sequence 16 AA;

Query Match 100.0%; Score 39; DB 2; Length 16;
 Best Local Similarity 100.0%; Pred. No. 0.14;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
 DB 9 RAFVTIGK 16

RESULT 80
 AAW68326
 ID AAW68326 standard; peptide; 16 AA.

XX AC AAW68326;
 XX DT 25-MAR-2003 (revised)
 XX DT 14-OCT-1998 (first entry)
 XX DE MHC binding peptide Env.312-327.
 XX KW Antigen; major histocompatibility complex; MHC; lymphocyte; detection;
 XX KW immobilisation; cytotoxic T-cell; tumour; leukaemia; lymphoma;
 XX KW viral infection.

XX OS Synthetic.
 XX OS Human immunodeficiency virus 1.
 XX PN WO9744667-A2.

XX PD 27-NOV-1997.

XX PF 21-MAY-1997; 97WO-FR000892.

XX PR 21-MAY-1996; 96US-00651925.

XX PA (INSP) INST PASTEUR.

XX PA (INRM) INSERM INST NAT SANTE & RECH MEDICALE.

XX PI Langladedemoyen P, Lone Y, Kourileky P, Abastado J;

XX PS WPI; 1998-018653/02.

XX PT Detection, purification and elimination of antigen-specific lymphocytes -
 XX PT for producing cytotoxic T cells for immuno-therapy of cancers and viral
 XX PT infection.

XX PS Disclosure; Page 27; 222pp; French.

XX CC Peptides AAW68301-W68384 are examples of antigens (Ag) which can be
 CC loaded onto recombinantly produced major histocompatibility complex (MHC)
 CC molecules in a method of detecting antigen-specific lymphocytes. The MHC-
 CC antigen complex is then immobilised on a solid support and a sample
 CC containing cells recognising the MHC-Ag complex may be isolated. This
 CC peptide is derived from amino acids 312-327 of the human immunodeficiency
 CC virus type 1 (HIV-1) env protein. A similar method is used to isolate,
 CC purify or eliminate Ag-specific T-cells or to produce Ag-specific
 CC cytotoxic T-cells (CTC). The method is also used to detect and quantify
 CC tumour-specific T-cells and to generate CTC for specific killing of
 CC tumour cells (solid tumours, leukaemia or lymphoma) by injection into a
 CC human or animal, but also for treating viral infections. (Updated on 25-
 CC MAR-2003 to correct PI field.)

XX SQ Sequence 16 AA;

Query Match 100.0%; Score 39; DB 2; Length 16;
 Best Local Similarity 100.0%; Pred. No. 0.14;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RAFVTIGK 8
 DB 9 RAFVTIGK 16

RESULT 81
 AAY68203
 ID AAY68203 standard; peptide; 16 AA.

XX AC AAY68203;

XX DT 12-SEP-2003 (revised)

XX DT 13-APR-2000 (first entry)

XX DE Altered MHC determinant binding peptide SEQ ID NO:35.

XX KW MHC class I; major histocompatibility complex; microglobulin; antigen;
 XX KW immune response; immunisation; AIDS; multiple sclerosis; toxic shock;
 XX KW cancer; lupus erythematosus; snake bite; cytostatic; antiviral;
 XX KW immunomodulatory; dermatological; immunosuppressive; antiinflammatory;
 XX KW neuroprotective.

XX OS Human immunodeficiency virus 1.

XX PN US6011146-A.

XX PD 04-JAN-2000.

XX PF 07-JUN-1995; 95US-00481985.

XX PR 15-NOV-1991; 91US-00792473.

XX PR 05-DEC-1991; 91US-00801818.

XX PA (INSP) INST PASTEUR.

XX PA (INRM) INST NAT SANTE & RECH MEDICALE.

XX PI Kourilsky P, Mottez E, Abastado J;

XX PS WPI; 2000-125951/11.

XX PT New recombinant DNA encoding covalently linked form of major
 XX PT histocompatibility complex Class I determinant, used for immune system
 XX PT stimulation, e.g. for treating cancer.

XX PS Disclosure; Col 11; 88pp; English.

XX CC The present invention describes a recombinant DNA molecule (I) containing
 CC a sequence (Ia) that encodes an altered MHC (major histocompatibility
 CC complex) Class I determinant (II) comprises a polypeptide with alpha1,
 CC alpha2, alpha3 and beta2-microglobulin domains, in which alpha3 and beta2
 CC are covalently linked, thorough C- and N-termini respectively, via a
 CC nucleotide spacer sequence encoding a polypeptide. (II) includes an
 CC antigen-binding site and when (II) and the antigen are associated they
 CC are recognized by a mammalian T cell receptor (TCR). (I) are used to
 CC produce (II) which are used to study functional interactions between the
 CC various MHC domains. They can also be used to modulate (in vivo or in
 CC vitro) the immune system by inducing an effector response (cytotoxicity,
 CC antibody synthesis, phagocytosis) of immune system cells, typically for
 CC treating, or immunising against; cancer, acquired immune deficiency
 CC syndrome, lupus erythematosus, multiple sclerosis, toxic shock and snake
 CC bite, but also for selective destruction of autoreactive cells,
 CC diagnostically to assay T cell receptors and to raise specific antibodies
 CC (useful for diagnosis, therapy, studying MHC-associated cellular
 CC processes and for affinity purification). AAY57558 and AAY68186 to
 CC AAY68316 are sequences used in the exemplification of the present
 CC invention. (Updated on 12-SEP-2003 to standardise OS field)

XX SQ Sequence 16 AA;

Query Match 100.0%; Score 39; DB 3; Length 16;
 Best Local Similarity 100.0%; Pred. No. 0.14;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
 |||||
 Db 9 RAFVTIGK 16

RESULT 82
 AAY52857
 ID AAY52857 standard; peptide; 16 AA.
 AC AAY52857;
 XX
 DT 14-FEB-2000 (first entry)
 XX
 DE Altered MHC determinant binding peptide SEQ ID NO:35.
 XX
 KW Major histocompatibility complex; MHC class I; MHC class II; antigen;
 KW immune response; diagnosis; antibody; immunisation; autoimmune disease;
 KW acquired immune deficiency syndrome; AIDS; cytostatic; dermatological;
 KW anti-inflammatory; neuroprotective; immunosuppressive; antithyroid;
 KW vaccine; lupus erythematosus; multiple sclerosis; thyroiditis;
 KW toxic shock; tumour; snakebite.
 XX
 OS Synthetic.
 OS Human immunodeficiency virus 1.
 XX
 PN US5976551-A.
 XX
 PD 02-NOV-1999.
 XX
 PF 07-JUN-1995; 95US-00484905.
 XX
 PR 15-NOV-1991; 91US-00792473.
 XX
 PR 05-DEC-1991; 91US-00801818.
 XX
 PA (INSP) INST PASTEUR.
 PA (INRM) INSRM INST NAT SANTE & RECH MEDICALE.
 XX
 PI Kourilsky P, Mottez E, Abastado J;
 XX WPI; 2000-037081/03.
 DR
 DR
 XX
 PT Composition containing an antigen and altered major histocompatibility
 PT Class II determinant, used to immunize against autoimmune diseases, e.g.
 PT acquired immune deficiency syndrome.
 XX
 PS Claim 8; Col 11; 96pp; English.
 XX
 CC The present invention describes a composition capable of eliciting anti-
 CC major histocompatibility (MHC) antibodies. The composition comprises an
 CC antigen associated with an altered MHC Class II determinant (I)
 CC comprising alpha1, alpha2, beta1 and beta2 polypeptide domains encoded by
 CC a mammalian MHC Class II locus covalently linked to form a polypeptide
 CC (I) containing beta2, alpha2, alpha1 and beta1 domains in sequence. The
 CC resulting Antigen-MHC complex is recognizable by the T cell receptor. The
 CC compositions are used for immunisation against, or treatment of, a wide
 CC range of autoimmune diseases, e.g. acquired immune deficiency syndrome
 CC (AIDS), lupus erythematosus, multiple sclerosis, thyroiditis, toxic
 CC shock, tumour and snakebite, depending on the nature of antigen. (I) is
 CC also used to analyse functional interactions between the various domains
 CC and for targeting lymphocyte receptors. Antibodies against (I) are
 CC produced by usual methods of immunisation or cell fusion, and may be
 CC humanised by standard methods. These antibodies are useful for diagnosis
 CC (detection or purification of MHC gene products), therapy (neutralising
 CC MHC on cell surfaces) and in the study of MHC and cellular processes.
 CC AAZ33240 to AAZ33242 and AAY52840 to AAY52970 represent sequences used in
 CC the exemplification of the present invention
 XX
 SQ Sequence 16 AA;

Query Match 100.0%; Score 39; DB 3; Length 16;
 Best Local Similarity 100.0%; Pred. No. 0.14;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
 |||||
 Db 9 RAFVTIGK 16

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
 |||||
 Db 9 RAFVTIGK 16

RESULT 83
 AAB58618
 ID AAB58618 standard; peptide; 16 AA.
 XX
 AC AAB58618;
 XX
 DT 11-SEP-2003 (revised)
 DT 13-MAR-2001 (first entry)
 XX
 DE Altered MHC determinant binding peptide #17.
 XX
 KW Major histocompatibility complex; MHC class I; immune; snake bite;
 KW T cell mediated autoimmune disease; AIDS; lupus erythematosus;
 KW toxic shock.
 XX
 OS Human immunodeficiency virus; type 8.
 XX
 PN US6153408-A.
 XX
 PD 28-NOV-2000.
 XX
 PF 09-JAN-1995; 95US-00370476.
 XX
 PR 15-NOV-1991; 91US-00792473.
 PR 05-DEC-1991; 91US-00801818.
 PR 07-JUN-1993; 93US-00072787.
 PR 07-SEP-1993; 93US-00117575.
 XX
 PA (INSP) INST PASTEUR.
 PA (INRM) INST NAT SANTE & RECH MEDICAL.
 XX
 PI Abastado J, Kourilsky P, Casrouge A, Ojcius D, Lone Y, Mottez E;
 XX WPI; 2001-060089/07.
 DR
 DR
 XX
 PT New altered major histocompatibility complex (MHC) class I determinant
 PT useful for eliciting an immune response and/or for immunizing against or
 PT treating diseases, for example, multiple sclerosis, AIDS, toxic shock or
 PT snake bite.
 XX
 PS Disclosure; Col 11; 105pp; English.
 XX
 CC The present invention relates to a major histocompatibility complex (MHC)
 CC class I determinant, which has alpha 1 alpha 2 alpha 3 and beta2-
 CC microglobulin polypeptide domains encoded by a mammalian MHC class I
 CC locus. The MHC class I determinants are useful for activating the immune
 CC system and presenting antigens to the immune system to elicit an
 CC antigenic response. The MHC class I determinants are also useful for
 CC treating diseases, e.g. T cell mediated autoimmune disease, AIDS, lupus
 CC erythematosus, toxic shock or snake bite. The altered MHC class I
 CC determinants and compositions containing antigens bound to the
 CC determinants are useful in diagnostic applications, e.g. altered
 CC determinants may be used to target lymphocyte receptors and the resulting
 CC bound determinant can be assayed. (Updated on 11-SEP-2003 to standardise
 CC OS field)
 XX
 SQ Sequence 16 AA;

Query Match 100.0%; Score 39; DB 4; Length 16;
 Best Local Similarity 100.0%; Pred. No. 0.14;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
 |||||
 Db 9 RAFVTIGK 16

```

RESULT 84
AA42057
ID AAR42057 standard; peptide; 17 AA.
XX
AC AAR42057;
XX
DT 25-MAR-2003 (revised)
DT 29-APR-1994 (first entry)
XX
DE Peptide CG-P18 from HIV-1 IIIB env protein V3 loop.
XX
KM Human Immunodeficiency Virus type 1; envelope protein; immunogen;
KM vaccine; AIDS; peptide P18; epitope.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Peptide 3..17
FT /label= P-18
FT /note= "the Cys-Gly dipeptide is opt. absent"
FT
XX
PN W09J19775-A1.
XX
PD 14-OCT-1993.
XX
PF 25-MAR-1993; 93MO-US002978.
XX
PR 31-MAR-1992; 92US-00860707.
XX
PS (MEDI-) MEDIMMUNE INC.
PA (USSA ) US DEPT ARMY.
XX
PI Alving CR, Cassatt D, Koenig S, Waseef N, White W;
XX
DR WPI; 1993-336590/42.
XX
PT Inducing cytotoxic T lymphocyte response to HIV - with liposome contg.
PT peptide or protein having CTL epitope of HIV and protein, also improving
PT humoral immunity, useful in vaccines.
XX
PS
XX
CC Claim 4; Page 16; 25pp; English.
XX
CC Peptide P-18, opt. with a Cys-Gly dipeptide attached at its N-terminus,
CC is the pref. peptide for use in raising a cytotoxic T lymphocyte response
CC against HIV. The peptide is encapsulated in a liposome for admin.
CC (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 17 AA;
XX
Query Match 100.0%; Score 39; DB 2; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.15;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 RAFVTIGK 8
DB 10 RAFVTIGK 17
XX
RESULT 85
AA40414
ID AAY40414 standard; peptide; 17 AA.
XX
AC AAY40414;
XX
DT 25-NOV-1999 (first entry)
XX
DE Lipopeptide comprising a fragment of the HIV env protein.
XX
KM Lipopeptide; antigen; cytotoxic T lymphocyte; steroid; vaccine;
KM HIV related condition; tumor cell; NP protein.
XX
OS Synthetic.

```

```

OS Human immunodeficiency virus 1.
XX
FH Key Location/Qualifiers
FT Modified-site 1
FT /note= "amidated residue"
FT Modified-site 17
FT /note= "this residue is -NH-CHR-CO-NH2, where R is a C14
FT side chain"
XX
PN EP945461-A1.
XX
PD 29-SEP-1999.
XX
PF 18-DEC-1991; 99EP-00105773.
XX
PR 18-DEC-1990; 90FR-00015870.
PR 18-DEC-1991; 91EP-00403446.
XX
PA (INSP ) INST PASTEUR LILLE.
PA (INRM ) INSERM INST NAT SANTE & RECH MEDICALE.
XX
PI Boutillon C, Martinon F, Sergheraert C, Magne R, Gras-Masse H;
PI Gomard E, Tartar A, Levy J;
XX
DR WPI; 1999-553128/47.
XX
PT New lipopeptide inducers of cytotoxic T lymphocytes, useful as vaccine
PT against cancers, viruses, parasites and HIV-related conditions.
XX
PS Example 4; Page 19; 35pp; French.
XX
CC The specification describes lipopeptide that comprise a partial peptide
CC containing 10-40 amino acids and at least one antigenic determinant
CC specific for cytotoxic T lymphocytes. The lipopeptide comprises at least
CC one 10-20 carbon fatty acid derivatives and/or at least one modified
CC steroid group. The lipopeptides are useful for: the preparation of a
CC vaccine against HIV related conditions; immunizing a human or animal
CC against an antigen by inducing cytotoxic T-lymphocytes; immunizing a
CC human or animal against tumor cells; and immunizing human or animal
CC against pathogens (especially a virus e.g. HIV-1 and HIV-2, or
CC parasites). The present sequence represents a lipopeptide of the
CC invention, and comprises part of the HIV env protein
XX
SQ Sequence 17 AA;
XX
Query Match 100.0%; Score 39; DB 2; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.15;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 RAFVTIGK 8
DB 9 RAFVTIGK 16
XX
RESULT 86
ADN14075
ID ADN14075 standard; peptide; 17 AA.
XX
AC ADN14075;
XX
DT 17-JUN-2004 (first entry)
XX
DE HIV helper T cell epitope #42.
XX
KM HIV; antigen; epitope; T cell; MHC; major histocompatibility complex;
KM CTL; cytotoxic T lymphocyte; HIV infection; cancer; tuberculosis; tumour;
KM hepatitis; melanoma; breast cancer; Hodgkin lymphoma;
KM nasopharyngeal carcinoma; vaccine; immune response; hyaluronic acid; HA;
KM CD8+ T cell; CD4+ T cell; viral infection; bacterial infection;
KM fungal infection; parasitic infection.
XX
OS Human immunodeficiency virus 1.

```

PN US2003049253-A1.
 XX 13-MAR-2003.
 XX 05-FEB-2002; 2002US-00062710.
 XX 08-AUG-2001; 2001US-0310498P.
 XX (LIRFO) LI F Q.
 XX (CHUY) CHU Y.
 XX (QIUJ) QIU J.
 XX Li FO, Chu Y, Qiu J;
 XX WPI, 2003-540664/51.
 DR
 XX
 PT Modulating an immune system response to an antigen in a mammal, comprises
 PT administering a particle-free therapeutic comprising a hyaluronic acid
 PT polymer analogue covalently linked to a peptide that comprises a T cell
 PT epitope.
 XX
 XX Disclosure: Page 12; 23pp; English.
 XX
 XX The invention relates to modulating an immune system response to an
 CC antigen in a mammal comprising administering to the mammal a particle-
 CC free therapeutic comprising a hyaluronic acid (HA) polymer analogue
 CC covalently linked to at least one peptide that comprises a T cell epitope
 CC recognised by a major histocompatibility complex molecule of the mammal.
 CC The T cell epitope comprises a sequence of at least about eight amino
 CC acids of the antigen. Also included are a method of improving major
 CC histocompatibility complex (MHC) presentation of a T cell epitope of an
 CC antigen in a mammal (comprising administering to the mammal the
 CC histocompatibility complex (MHC) Class I molecule and by a CD8+ T cell of
 CC the mammal, or an MHC Class II molecule and a CD4+ T cell of the mammal.
 CC The immune system response comprises a cytotoxic T lymphocyte, a CD4+T
 CC cell, or an antibody that recognises the antigen. The immune system
 CC response to the antigen is increased after administration of the
 CC conjugate, where the antigen is an antigen of a pathogenic agent or a
 CC tumour cell. The immune system response to the antigen is decreased after
 CC administration of the conjugate, where the antigen is an antigen of a
 CC tissue or organ transplanted to the mammal. The composition and methods
 CC are useful for modulating, i.e. enhancing or diminishing, an immune
 CC system response to an antigen in a mammal. The composition is also useful
 CC for improving major histocompatibility complex presentation of a T cell
 CC epitope of an antigen in a mammal. The polymeric hyaluronic acid
 CC conjugates are useful as peptide vaccines against an antigen, a
 CC pathogenic agent such as viral, bacterial, fungal or parasitic protein,
 CC or a tumour cell) in a mammal. The peptide vaccine compositions are
 CC useful for treating or preventing diseases associated with any of the
 CC antigens above e.g. HIV infection, cancer, tuberculosis, hepatitis,
 CC melanoma, breast cancer, Hodgkin's lymphoma and nasopharyngeal carcinoma.
 CC The peptide vaccine compositions of the present invention do not require
 CC additional adjuvants, but still induce a stronger cell-mediated response
 CC than peptide vaccines of the prior art. The present sequence is an HIV-1
 CC derived epitope suitable for the vaccine of the invention.
 XX
 SQ Sequence 17 AA;
 XX
 Query Match 100.0%; Score 39; DB 7; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.15; Indels 0; Gaps 0;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RAFVTIGK 8
 DB 7 RAFVTIGK 14
 RESULT 87
 AAR31277
 ID AAR31277 standard; peptide; 18 AA.
 XX
 AC AAR31277;

XX 12-FEB-1993 (first entry)
 DT HIV principal determinant peptide.
 XX
 DE
 XX AIDS; ARC; human immunodeficiency virus; vaccine; Neisseria;
 XX meningitidis b; outer membrane protein complex; OMPC; PND135-18.
 XX
 XX Synthetic.
 XX
 XX Key Location/Qualifiers
 FT Modified-site 1 /note="bonds to the OMPC of the conjugate via this site"
 FT
 XX
 XX EP467700-A.
 XX
 XX 22-JAN-1992.
 XX
 XX 19-JUL-1991; 91EP-00306598.
 XX
 XX 19-JUL-1990; 90US-00555339.
 XX 19-JUL-1990; 90US-00555966.
 XX 19-JUN-1991; 91US-00715276.
 XX 19-JUN-1991; 91US-00715278.
 XX
 XX (MERT) MERCK & CO INC.
 XX
 XX Leanza WJ, Marburg S, Tolman RL, Emini EA;
 XX WPI, 1992-026505/04.
 XX
 XX Claim 12; Page 56; 63pp; English.
 XX
 XX The invention relates to a co-conjugate comprising an immunogenic protein
 CC or protein complex having a first set of covalent linkages to low
 CC molecular weight moieties which have an anionic or polyanionic character
 CC at physiological pH, and a second set of covalent linkages to peptides
 CC comprising HIV principal neutralizing determinants (PND's) or
 CC immunologically equivalent peptides. Preferably at least one set of the
 CC covalent linkages is comprised of maleimide derivatives; the
 CC (poly)anionic moiety is composed of one to five residues of the anionic
 CC form of a carboxylic, sulphonic or phosphonic acid; the immunogenic
 CC protein is the outer membrane protein complex (OMPC) of Neisseria
 CC meningitidis b; and the PND peptide has a linear structure, a disulphide-
 CC bonded cyclic structure, an amide-bonded cyclic structure or a thioether-
 CC of a PND peptide component used in the co-conjugate. The co-conjugate is
 CC useful for inducing anti-peptide immune response in mammals, for inducing
 CC HIV-neutralizing antibodies in mammals, for formulating vaccines to
 CC prevent HIV infection or disease, including AIDS, or for treating humans
 CC afflicted with HIV infection or disease
 XX
 SQ Sequence 18 AA;
 XX
 Query Match 100.0%; Score 39; DB 2; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.16; Indels 0; Gaps 0;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RAFVTIGK 8
 DB 8 RAFVTIGK 15
 RESULT 88
 AAR30032
 ID AAR30032 standard; peptide; 18 AA.
 XX
 AC AAR30032;
 XX
 DT 25-MAR-2003 (revised)

DT 28-APR-1993 (first entry)
 XX
 DE HIV principle neutralising determinant 135-18.
 XX
 KW Human immunodeficiency virus; AIDS; PND; MIEP; conjugate;
 KW major immune enhancing protein; vaccine; anti-HIV antibodies; immunogen;
 KW passive immunisation.
 XX
 OS Human immunodeficiency virus.
 XX
 PN EP519554-A1.
 XX
 PD 23-DEC-1992.
 XX
 PF 11-JUN-1992; 92EP-00201693.
 XX
 PR 19-JUN-1991; 91US-00715273.
 XX
 PA (MERI) MERCK & CO INC.
 XX
 PI Emlint A, Liu MA, Marburg S, Tolman RL;
 XX
 DR WPI; 1992-425771/52.
 XX
 PT Conjugates of HIV-1 PND peptide(s) with the MIEP of Neisseria
 PT meningitidis - useful as a vaccine for treating and preventing HIV-1
 CC infection, e.g. AIDS in humans.
 XX
 PS Claim 9; Page 59; 66pp; English.
 XX
 CC The peptide is HIV principle neutralising determinant (PND) 135-18 and is
 CC used as part of a conjugate comprising the major immune enhancing protein
 CC (MIEP) of Neisseria meningitidis covalently linked to the HIV PND. The
 CC conjugate may be used to prepare vaccines against HIV infections, e.g.
 CC AIDS, as research tools for studying PND structure- function
 CC relationships, or as immunogens for use in the passive immunisation of
 CC humans. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SO Sequence 18 AA;
 XX
 QY Query Match 100.0%; Score 39; DB 2; Length 18;
 DB Best Local Similarity 100.0%; Pred. No. 0.16;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 1 RAFTTICK 8
 8 RAFTTICK 15
 DB
 RESULT 89
 AAR26713
 ID AAR26713 standard; peptide; 18 AA.
 XX
 AC AAR26713;
 XX
 DT 09-FEB-1993 (first entry)
 XX
 DE HIV-PND-polysaccharide-protein conjugate vaccine.
 XX
 KW Human immunodeficiency virus; principal neutralizing determinant;
 KW outer membrane protein complex; OMPc; Neisseria; AIDS; PND-135-18.
 XX
 OS Synthetic.
 XX
 PN Key
 XX Modified-site 1 Location/Qualifiers
 FT /note= "Joins onto polysaccharide-protein complex via
 FT this site"
 XX
 XX EP468714-A.
 XX
 XX 29-JAN-1992.
 XX

PF 19-JUL-1990; 90US-00555558.
 XX
 PR 19-JUL-1990; 90US-00555558.
 PR 19-JUL-1990; 90US-00555574.
 PR 19-JUN-1991; 91US-00715275.
 PR 19-JUN-1991; 91US-00715277.
 XX
 PA (MERI) MERCK & CO INC.
 XX
 PI Marburg S, Tolman RL, Emlint EA;
 XX
 DR WPI; 1992-034437/05.
 XX
 DR
 XX
 PT HIV peptide-polysaccharide-protein conjugates - used in vaccines or to
 PT produce antibodies to prevent or treat HIV infection.
 XX
 PS Claim 9; Page 57; 63pp; English.
 XX
 CC The invention relates to a conjugate of an HIV principal neutralising
 CC determinant (PND), or an immunologically equivalent peptide (PEP),
 CC covalently coupled to an immunogenic protein or protein complex through
 CC an anionic polysaccharide linker. Pref. the immunogenic protein is the
 CC outer membrane protein complex (OMPc) of Neisseria meningitidis b and the
 CC PND peptide has a linear structure, a disulphide-bonded cyclic structure,
 CC an amide-bonded cyclic structure or a thioether-bonded cyclic structure.
 CC The present sequence (PND135-18) is an example of a PND peptide
 CC component. The conjugates are used for inducing HIV-neutralising
 CC antibodies or for making vaccines to prevent contraction of HIV infection
 CC or disease. The antibodies can be used for passively protecting against
 CC infection by HIV, or for protecting against proliferation of HIV post-
 CC infection, or for treating AIDS, or in diagnostic assays
 XX
 SO Sequence 18 AA;
 XX
 QY Query Match 100.0%; Score 39; DB 2; Length 18;
 DB Best Local Similarity 100.0%; Pred. No. 0.16;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 1 RAFTTICK 8
 8 RAFTTICK 15
 DB
 RESULT 90
 AAR44190
 ID AAR44190 standard; peptide; 18 AA.
 XX
 AC AAR44190;
 XX
 DT 24-OCT-2003 (revised)
 DT 25-MAR-2003 (revised)
 DT 20-MAY-1994 (first entry)
 XX
 DE SPI20 V3 loop antigen B2.
 XX
 KW Antigen; B2; third variable domain; V3 loop; SPI20; HIV-1; vaccine;
 KW strain IIB; multiple antigenic peptide system; dendritic core;
 KW lipophilic membrane anchoring group; mammal; humoral; immunisation;
 KW cytotoxic T cell; CT; immune response; infection; Freund's adjuvant;
 KW pathogen; HIV; influenza; malaria.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN W09322343-A1.
 XX
 PD 11-NOV-1993.
 XX
 PF 03-MAY-1993; 93WO-US004179.
 XX
 PR 01-MAY-1992; 92US-00877613.
 XX
 XX (UYRQ) UNIV ROCKEFELLER.
 XX

```

PI Tam JP;
XX
XX WPI; 1993-368723/46.
XX
XX New multiple antigen system esp. for use in HIV vaccines - contains
PT lipophilic membrane anchor imparting adjuvant activity, and peptide
PT antigens coupled to dendritic core.
XX
XX Example 3; Page 27; 55pp; English.
XX
XX The sequence given in AAR44190 is a peptide antigen, B2, which represents
CC residues 312-329 of the third variable domain (V3 loop) of gp120, of HIV-
CC 1 strain IIB. This sequence was attached to an amino acid linker (see
CC also AAR44191) in the production of a multiple antigenic peptide system.
CC This system comprises a dendritic core to which are covalently attached
CC at least one peptide, eg. an antigenic peptide, and a lipophilic membrane
CC anchoring group. This system may be injected into a mammal and elicits
CC both humoral and cytotoxic T cell (CTL) immune responses. This system may
CC be used to immunise against HIV infection. The lipophilic membrane
CC anchoring group provides efficient adjuvant activity without the toxicity
CC problems of Freund's adjuvant, while the dendritic structure allows
CC multiple antigens to be attached. Optionally the antigens may be derived
CC from different pathogens, providing vaccines which protect against more
CC than one disease, eg. HIV, influenza and malaria. (Updated on 25-MAR-2003
CC to correct PN field.) (Updated on 24-OCT-2003 to standardise OS field)
XX
XX Sequence 18 AA;
SQ
Query Match 100.0%; Score 39; DB 2; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.16;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 RAFVTTGK 8
DB 11 RAFVTTGK 18
RESULT 91
AAR58548
ID AAR58548 standard; peptide; 18 AA.
XX
XX AAR58548;
XX
XX 16-OCT-2003 (revised)
XX 25-MAR-2003 (revised)
XX 29-MAR-1995 (first entry)
DE HIV-1 isolate IIB V3 loop domain.
XX
XX HIV-1 isolate IIB V3 loop domain.
XX
XX HIV-1; V3 loop; multiple epitopes; AIDS; vaccine; MEAV; Escherichia coli;
XX PKK-MEAV.
XX
XX Human immunodeficiency virus 1.
XX
XX WO9418234-A1.
XX
XX 18-AUG-1994.
XX
XX 10-FEB-1994; 94WO-US001523.
XX
XX 10-FEB-1993; 93US-00015770.
XX
XX (UNBI-) UNITED BIOMEDICAL INC.
XX
XX Shen DF, Wang CY;
XX
XX WPI; 1994-279687/34.
XX
XX New recombinant proteins contg multiple antigenic determinants - linked
PT by flexible hinge domains.
XX
XX Disclosure; Page 36; 56pp; English.

```

```

CC MEAV gene (AA070535) encodes a portion of the CD4 binding domain
CC (AAR38550) of HIV env protein, the domain being capable of inducing a
CC helper T- cell response, and 5 peptide domains from the V3 loop of HIV-1
CC isolates MN, SC, RF, IIB and WMJ2 (AAR58545-49), each peptide being
CC separated by a spacer domain (AAR58551). The gene was expressed in E.
CC coli BL21/pKK-MEAV for preparation of a multiple epitope AIDS vaccine
CC (AAR58552). (Updated on 25-MAR-2003 to correct PN field.) (Updated on 16-
CC OCT-2003 to standardise OS field)
XX
XX Sequence 18 AA;
SQ
Query Match 100.0%; Score 39; DB 2; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.16;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 RAFVTTGK 8
DB 11 RAFVTTGK 18
RESULT 92
AAM63062
ID AAM63062 standard; peptide; 18 AA.
XX
XX AAM63062;
XX
XX 07-OCT-1998 (first entry)
XX
XX Human immunodeficiency virus type 1 (HIV 1) Env peptide 312-327.
DE
XX Superantigen; treatment; cancer; tumour-specific antigen;
XX autoimmune disease related antigen; infection; bacterial; viral;
XX eukaryotic; autoimmune disease; inhibit; pathological response;
XX immune response.
XX
XX Synthetic.
XX
XX Human immunodeficiency virus 1.
XX
XX WO9826747-A2.
XX
XX 25-JUN-1998.
XX
XX 17-DEC-1997; 97WO-US023637.
XX
XX 17-DEC-1996; 96US-0033172P.
XX 17-APR-1997; 97US-0044074P.
XX
XX (TERM/) Terman D S.
XX
XX Terman DS;
XX
XX WPI; 1998-362497/31.
XX
XX Conjugates and polymers containing superantigen and therapeutic antigen -
PT for treatment of cancer, infection, autoimmune disease and graft
PT rejection, also treatment by administering lymphocytes treated in vitro
PT by these antigens.
XX
XX Example 2; Page 40; 139pp; English.
XX
XX Synthetic peptides AAM63049-85 are used, with superantigens, to exemplify
XX the invention. The specification describes a method for treatment of
XX cancer which comprises incubating lymphocytes with a tumour-specific
XX antigen or autoimmune disease related antigen and a superantigen. The
XX treated cells are then introduced into the patient. The superantigen and
XX the tumour-specific antigen or autoimmune disease related antigen can be
XX conjugated together. The products are used to treat cancer (carcinoma,
XX melanoma, lymphoma etc.), infections (bacterial, viral or eukaryotic) and
XX autoimmune disease (e.g. idiopathic thrombocytopenic purpura, rheumatoid
XX arthritis, systemic lupus erythematosus, multiple sclerosis etc.). The
XX antigens either induce an immune response or inhibit a pathological
XX response

```

SQ Sequence 18 AA;
 Query Match 100.0%; Score 39; DB 2; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.16;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTTGK 8
 |||||
 DB 11 RAFVTTGK 18

RESULT 93
 AAY96191
 ID AAY96191 standard; peptide; 18 AA.
 AC AAY96191;
 DT 19-DEC-2000 (first entry)
 XX
 DE Glycoprotein gp120 glycosylated peptide.
 XX
 KM gp120; MUC1; immunomodulator; glycopeptide; T-lymphocyte; T-cell;
 KM proliferation; cancer; sarcoma; carcinoma; leukaemia; diagnosis; therapy;
 KM vaccine; adjuvant; glycosylation.
 XX
 OS Unidentified.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 15
 FT /note="O-glycosylated by GalNAc-beta-1-3Gal"
 XX
 PN MO200052046-A1.
 XX
 PD 08-SEP-2000.
 XX
 PF 01-MAR-2000; 2000MO-GB000724.
 XX
 PR 01-MAR-1999; 99GB-00004695.
 XX
 PA (IMCR) IMPERIAL CANCER RES TECHNOLOGY LTD.
 PI Burchell J, Taylor-Papadimitriou J;
 XX
 DR WPI; 2000-601868/57.
 XX
 PT New immunomodulating glycopeptide that causes super-proliferation of T
 PT cells, useful for treating cells in vitro, for diagnosing or treating
 PT cancer (e.g. carcinoma or sarcoma) or as an adjuvant.
 XX
 PS Disclosure; Page 24; 35pp; English.
 XX
 CC The present sequence comprises a glycosylated fragment of gp120.
 CC glycopeptides comprising a fragment of the MUC1 repeat sequence,
 CC especially having a Gal-GalNAc or GalNAc moiety on Thr-10 or Thr-17 (see
 CC AAY96172-74), are useful as immunomodulators, causing super-proliferation
 CC of T cells. Such glycopeptides can be used in the treatment or diagnosis
 CC of a disease, in particular cancer, or as vaccine adjuvants. The
 CC glycopeptides are particularly useful in manufacturing a medicament for
 CC preventing or treating cancer by stimulating T cells whose receptors
 CC recognize the glycopeptide. They are also useful for diagnosing or
 CC treating cancer, e.g. carcinoma (e.g. mammary, lung, bladder or colon
 CC carcinomas, or ovary and endometrial tumours), or sarcoma (e.g. soft
 CC tissue and bone sarcomas, or leukaemia). Human peripheral blood
 CC lymphocytes were used in a proliferation assay. The proliferation index
 CC of the gp120 glycopeptide (taking the index as 1 when no glycopeptide was
 CC present) was 1-1.7
 XX
 SQ Sequence 18 AA;
 Query Match 100.0%; Score 39; DB 3; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.16;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTTGK 8
 |||||
 DB 11 RAFVTTGK 18

RESULT 94
 ABB83113
 ID ABB83113 standard; peptide; 18 AA.
 AC ABB83113;
 DT 05-AUG-2002 (first entry)
 XX
 DE Lipopeptide #2 used in a vaccine.
 XX
 KM Lipopeptide; cytostatic; virucide; anti-HIV; antiparasitic; vaccine;
 KM immunisation; tumour; pathogen; virus; antiviral.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 1
 FT /label="Xaa
 FT /note="Xaa is optionally 2-acetylamino-hexadecanoyl, 2,4
 FT -bis(hexadecanoylamino)butyryl, or not present"
 FT Modified-site 18
 FT /label="Xaa
 FT /note="Xaa is optionally 2-amino-hexadecanoamide or N-
 FT epsilon-hexadecanoyl-Lys"
 XX
 PN EP1065212-A2.
 XX
 PD 03-JAN-2001.
 XX
 PF 18-DEC-1991; 2000EP-00117513.
 XX
 PR 18-DEC-1990; 90FR-00015870.
 PR 18-DEC-1991; 91EP-00403446.
 PR 18-DEC-1991; 99EP-00105773.
 XX
 PA (INSP) INST PASTEUR LILLE.
 PA (INRM) INSERM INST NAT SANTE & RECH MEDICALE.
 PI Boutillon C, Martinon F, Sergheraert C, Magne R, Gras-Masse H;
 PI Gornard E, Tartar A, Levy J;
 XX
 DR WPI; 2001-114040/13.
 XX
 PT Vaccine for immunization against tumor cells or pathogens, especially
 PT HIV, comprising peptide part, antigenic determinant specifically inducing
 PT cytotoxic T-lymphocytes and N-palmitoyl-L-lysine-derived chain(s).
 XX
 PS Example 4; Page 17; 31pp; French.
 XX
 CC The present sequence is a lipopeptide, which can be used for the
 CC immunisation of humans or animals against tumour cells or pathogens,
 CC specifically viruses, especially HIV-1 or HIV-2. The pathogens may also
 CC include parasites. Examples illustrate immunisation of mice against
 CC influenza, as well as HIV. The lipopeptide, with the appropriate
 CC antigenic determinants, can induce a strong cytotoxic T-lymphocyte
 CC response in a host organism against a wide range of pathogens. Addition
 CC of an adjuvant is unnecessary
 XX
 SQ Sequence 18 AA;
 Query Match 100.0%; Score 39; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.16;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTTGK 8
 |||||
 DB 10 RAFVTTGK 17

```

RESULT 95
AAW24218
ID AAW24218 standard; peptide; 19 AA.
XX
XX AAW24218;
XX
XX 17-MAR-1998 (first entry)
XX
XX CD4+ T-lymphocyte epitope to HIV-1 V3 loop derived peptide V3-LAI-B.
XX
XX T-lymphocyte epitope; diagnosis; antigen; infectious disease;
XX delayed-type hypersensitivity assay; vaccine development.
XX
XX Synthetic.
XX Human immunodeficiency virus.
XX
XX Key Location/Qualifiers
XX FT 5. .13
XX FT Region
XX /note= "Mapped CD4+T-lymphocyte epitope of patient 2"
XX
XX MO9727462-A2.
XX
XX 31-JUL-1997.
XX
XX 27-JAN-1997; 97WO-US001084.
XX
XX 26-JAN-1996; 96US-0010679P.
XX
XX (USSA ) US DEPT ARMY GOVERNMENT US ARMY MEDICAL.
XX
XX Sltz KV, Brix DL;
XX
XX WPI; 1997-393814/36.
XX
XX Peptide fragments containing antigen epitope(s) used to trace diseases -
XX used in a delayed-type hypersensitivity assay, for in vivo mapping of
XX human T-lymphocyte epitope(s) e.g. for diagnosis, vaccine development
XX etc.
XX
XX Disclosure; Page 6; 14pp; English.
XX
XX Peptide fragments AAW24217-20 were used to demonstrate a new method of
XX tracing sources of infectious diseases. The method comprises preparing a
XX short (9-50 amino acid) peptide containing at least one non-conserved
XX epitope of an organism. Injecting a composition containing the peptide
XX intradermally into a test subject in a delayed-type hypersensitivity
XX (DTH) assay and observing the injection site at intervals for induration.
XX In this example CD4+ T-lymphocyte epitopes to the HIV-1 V3 loop were
XX mapped by existing in vitro technique for two existing HIV infected
XX individuals and used to design peptides AAW24217-20. The method allows
XX the T-lymphocyte epitopes of a large antigen to be determined in vivo in
XX humans. The method is useful in medicine e.g. in diagnosis, monitoring
XX and treatment design for infectious disease exposure, active autoimmune
XX disease, allergic diseases and malignancy. It is especially useful for
XX tracing infectious diseases e.g HIV, particularly when a sequence is
XX present only in certain strains of an organism, and developing suitable
XX vaccines. Vaccinated individuals can also be tested to verify protection
XX against a particular strain. The method allows in vivo mapping of T-
XX lymphocyte epitopes, not previously possible. The method is simpler, more
XX rapid and more sensitive. It can also be applied in a variety of
XX environments e.g. undeveloped regions since specialist equipment is not
XX required
XX
XX Sequence 19 AA;
XX
XX Query Match 100.0%; Score 39; DB 2; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 0.17;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 RAFVTIGK 8
XX 4 RAFVTIGK 11

```

```

RESULT 96
AAR04434
ID AAR04434 standard; protein; 20 AA.
XX
XX AAR04434;
XX
XX 09-SEP-2004 (revised)
XX 25-MAR-2003 (revised)
XX 20-SEP-1990 (first entry)
XX
XX Human immunodeficiency virus peptide 132.
XX
XX HIV-1IIB; peptide 132; principal neutralising domain; antibodies;
XX diagnosis; prophylaxis; therapy; AIDS.
XX
XX Synthetic.
XX
XX MO9003984-A.
XX
XX 19-APR-1990.
XX
XX 03-OCT-1988; 88US-00252949.
XX
XX 03-OCT-1988; 88US-00252949.
XX 01-JUN-1989; 89US-00355543.
XX 19-SEP-1989; 89US-00407663.
XX
XX (REPK ) REPLIGN CORP.
XX
XX Rusche JR, Putney SD, Javaherian K, Farley J, Grimalia R;
XX Lynn DU, Petrobre J;
XX
XX WPI; 1990-147824/19.
XX
XX Principal neutralising domain of HIV variants - used for producing
XX peptide(s) and antibodies for diagnosis, prophylaxis and/or therapy
XX therapy of HIV infection.
XX
XX Claim 8 (37); Page 76; 108pp; English.
XX
XX Peptide 132 comprises segments of the Principal Neutralising Domain
XX (envelope protein) from isolate HIV-1IIB. A Cysteine can be added, so
XX that the residues at or near both ends can form a disulfide bond, thus
XX giving the peptides a loop configuration. The loop configuration can be
XX utilised to enhance the immunogenic properties of the peptides. The
XX protein is capable of eliciting, and/or binding with, neutralising
XX antibodies. The neutralising domain is bounded by cysteine residues
XX occur at positions 296 and 331. The peptides can be used as immunogens
XX or screening reagents to generate or identify poly- or monoclonal
XX antibodies. The first Tyr residue is an immunologically silent spacer. See
XX also AAR04427-R04506 and AAR04273-004279. (Updated on 25-MAR-2003 to
XX correct PR field.) (Updated on 25-MAR-2003 to correct PA field.) (Updated
XX on 25-MAR-2003 to correct PI field.)
XX
XX Revised record issued on 09-SEP-2004 : Correction to Feature Table Key
XX
XX Sequence 20 AA;
XX
XX Query Match 100.0%; Score 39; DB 2; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 0.18;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 RAFVTIGK 8
XX 3 RAFVTIGK 10
XX
XX RESULT 97
XX AAR60203
XX ID AAR60203 standard; protein; 20 AA.
XX

```

```

AC AAR60203;
XX
XX 27-AUG-2003 (revised)
DT 25-MAR-2003 (revised)
XX
XX 13-MAR-1995 (first entry)
DT
DE HIV gp120 V3 loop molecular tag.
XX
XX fusion protein; recombinant bispecific single chain antibody;
KM human immunodeficiency virus; glycoprotein gp120; V3 loop.
XX
XX Human immunodeficiency virus.
OS
XX BP610046-A2.
XX
XX 10-AUG-1994.
PD
XX
XX 31-JAN-1994; 94BP-00300692.
PF
XX
XX 01-FEB-1993; 93US-00013420.
PR 13-SEP-1993; 93US-00121054.
XX
XX (BRIM ) BRISTOL-MYERS SQUIBB CO.
PA
XX Ledbetter JA, Gilliland IK, Hayden MS, Linsley PS, Bajorath J;
PI Fell PH;
XX WPI, 1994-250885/31.
DR
XX Expression vector encoding bispecific fusion protein - having binding
PT domains for separate targets joined by helical peptide, useful e.g. for
PT diagnosis and treatment.
XX
XX Example 1; Page 12; 50pp; English.
PS
XX A molecular tag was created by annealing two complementary 76mer
CC oligonucleotides with cohesive end overhangs. AAG70167 is the sense
CC strand and includes a BclI overhang, the HIV gp120 V3 loop coding
CC sequence and a stop codon. The peptide encoded by the molecular tag
CC (AAR60203), when part of a single chain fusion protein with binding
CC regions from different antibodies, affected the avidity and binding
CC specificity of the antibodies. For example, the tag failed to function
CC properly when fused to I6 but performed successfully when fused to CD3.
CC *Updated on 25-MAR-2003 to correct PN field.) (Updated on 27-AUG-2003 to
CC correct OS field.)
XX
XX Sequence 20 AA;
SQ
XX
XX Query Match 100.0%; Score 39; DB 2; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 0.18;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RAFVTIGK 8
DB 12 RAFVTIGK 19
XX
XX
XX RESULT 98
XX AAM76943
XX ID AAM76943 standard; peptide; 20 AA.
XX
XX AAM76943;
XX
XX 25-JAN-1999 (first entry)
XX
XX Fusion immunoglobulin heavy chain HIV gp120 B cell epitope #83.
XX
XX B cell; T cell; epitope; immunoglobulin; heavy chain; gp120; IGH;
KM human immune deficiency virus; HIV; tolerance; treatment; therapy;
KM prophylaxis; vaccine; chemotherapy; immune response; modifier; tumour;
KM microbial infection; autoimmune disease; antibody; apoptosis;
KM antiviral T cell immunity.
XX

```

```

OS Mus sp.
XX Homo sapiens.
XX
XX MO9836087-A1.
XX
XX 20-AUG-1998.
XX
XX 13-FEB-1998; 98MO-US002766.
PF
XX 13-FEB-1997; 97US-0040581P.
PR
XX (AMNA-) AMERICAN NAT RED CROSS.
XX
XX Scott D, Zambidis E;
XX
XX WPI, 1998-506315/43.
DR
XX
XX New fusion immunoglobulin heavy chain including gp120 epitopes and
PT related complete antibodies - DNA, vectors and transformed cells, used to
PT induce tolerance to the epitopes for treatment of human immune deficiency
PT virus infection.
XX
XX Disclosure; Page 39; 154pp; English.
PS
XX
XX This sequence is an epitope used in the construction of a novel fusion
CC immunoglobulin heavy chain (IGH) protein with a mammalian, especially
CC human, IGH chain fused in frame at its N-terminus to one or more human
CC immune deficiency virus (HIV) gp120 epitopes. Fusion Ig proteins and/or
CC transfected cells are used to tolerate subjects to gp120 epitopes and to
CC maintain this tolerance, particularly for treatment of HIV infection,
CC optionally together with other therapeutic/prophylactic agents such as
CC vaccines, chemotherapeutic agents and immune response modifiers. Such
CC proteins can be used against other diseases where an immune response is
CC deleterious, e.g. microbial infection, tumours or autoimmune disease.
CC Induction of tolerance suppresses production of antibodies against gp120,
CC so prevents or inhibits 'bystander' apoptosis of uninfected T cells that
CC are bound to gp120 protein, maximising induction of protective antiviral
CC T cell immunity.
XX
XX Sequence 20 AA;
SQ
XX
XX Query Match 100.0%; Score 39; DB 2; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 0.18;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RAFVTIGK 8
DB 2 RAFVTIGK 9
XX
XX
XX RESULT 99
XX AAM54930
XX ID AAM54930 standard; peptide; 20 AA.
XX
XX AAM54930;
XX
XX 25-SEP-1998 (first entry)
XX
XX HIV gp120 envelope protein, peptide 127, analogue 127h.
XX
XX Immunosorbent; immunoassay; HIV gp120; immunogen; antibody; Human.
KM
XX Human immunodeficiency virus.
OS
XX US5763160-A.
XX
XX 09-JUN-1998.
PD
XX
XX 07-JUN-1995; 95US-00488252.
PF
XX 12-FEB-1988; 88US-00155321.
PR 01-MAR-1991; 91US-00663262.
PR 09-JUL-1991; 91US-00726605.
XX

```

```

PR 19-OCT-1994; 94US-00326676.
XX
XX (UNBI-) UNITED BIOMEDICAL INC.
XX
XX Wang CY;
XX
XX WPI, 1998-347301/30.
XX
XX HIV gp120 peptides - useful as immunoassay reagents or vaccine
XX components.
XX
XX Example 8; Column 21/22; 34gp; English.
XX
XX Peptides AAW54903-W54941 can be used as an immunoadsorbent in an
XX immunoassay for detecting antibodies to HIV gp120, or as an immunogen for
XX eliciting antibodies to HIV in a mammal
XX
XX Sequence 20 AA;
XX
XX Query Match 100.0%; Score 39; DB 2; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 0.18;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 RAFVTIGK 8
XX 13 RAFVTIGK 20
XX
XX RESULT 100
XX ADR1886
XX ID ADR1886 standard; peptide; 20 AA.
XX
XX ADR1886;
XX
XX 04-NOV-2004 (first entry)
XX
XX HIV-1 V3-IIIB related peptide SEQ ID NO:37.
XX
XX three-dimensional atomic structural conformation;
XX protein co-ordinate data; V3 loop peptide; HIV-1; envelope glycoprotein;
XX gp120; human monoclonal antibody 447-52D;
XX murine monoclonal antibody 0.5 beta; immunogen; immunogenic;
XX V3 loop epitope; HIV-1 infectivity inhibitor; anti-HIV; vaccine;
XX HIV-1 infection.
XX
XX Human immunodeficiency virus 1.
XX Synthetic.
XX
XX WO2004069863-A2.
XX
XX 19-AUG-2004.
XX
XX 04-FEB-2004; 2004WO-US003304.
XX
XX 04-FEB-2003; 2003US-0444682P.
XX
XX (UYNX ) UNIV NEW YORK STATE.
XX (YEDA ) YEDA RES & DEV CO LTD.
XX
XX Anglister J, Sharon M, Schapira M, Zolla-Pazner S, Rosen O;
XX WPI, 2004-625447/60.
XX
XX Composition for inhibiting HIV-1 infection, comprises isolated peptide of
XX molecule that mimics atomic structural conformation of V3 loop peptide of
XX HIV-1 envelope glycoprotein that is bound to, and constrained by human
XX monoclonal antibody.
XX
XX Example 1; SEQ ID NO 37; 127pp; English.
XX
XX The present invention describes a composition (C1) which comprises an
XX isolated peptide molecule or isostere that mimics the three-dimensional
XX (3D) atomic structural conformation of the V3 loop peptide of the HIV-1

```

```

CC envelope glycoprotein gp120 that is bound to, and constrained by, human
CC monoclonal antibody (Mab) 447-52D, murine Mab 0.5 beta or an antigen
CC binding fragment of the Mab, where the constrained V3 loop peptide
CC differs in conformation from the same V3 loop peptide when it is in free
CC form. Also described: (1) identifying (M1) from several existing
CC compounds a molecule that is useful as an HIV-1 V3 loop immunogen or as
CC an inhibitor of binding of HIV-1 to a chemokine receptor/HIV-1 co-
CC receptor on the surface of a receptor-bearing target cell; (2) designing
CC a molecule that is useful as an HIV-1 V3 loop immunogen or as an
CC inhibitor of binding of HIV-1 to a chemokine receptor/HIV-1 co-receptor
CC on the surface of a receptor-bearing target cell; (3) a composition (C2)
CC that is useful as an HIV-1 V3 loop immunogen or as an inhibitor of
CC binding of HIV-1 to a chemokine receptor/HIV-1 co-receptor on the surface
CC of a receptor-bearing target cell; (4) an immunogenic composition (C3)
CC for induction of an anti-HIV-1 antibody response specific for a V3 loop
CC epitope, comprising (C1) and an excipient; (5) a pharmaceutical
CC composition (C4) useful for blocking the interaction of HIV-1 with an R5
CC or X4 co-receptor and thereby inhibiting HIV-1 infectivity, comprising
CC (C1) and a carrier or excipient; (6) a computing platform for generating
CC a 3D model of a constrained HIV V3 view peptide; (7) a computer generated
CC model representing the conformationally constrained structure of a V3
CC loop peptide that is bound to 447-52D or 0.5beta Mab or its antigen
CC binding fragments, comprising a 3D atomic structure defined by NC; and
CC (8) a computer readable medium (CM) comprising, in a retrievable format,
CC data that includes a set of structure coordinates defining a 3D structure
CC of a V3 loop peptide that is conformationally constrained by being bound
CC to 447-52D or 0.5beta Mab or its antigen binding fragment. (C1) has anti-
CC HIV activities, and can be used in vaccines, and as an inhibitor of
CC binding of HIV-1 to chemokine receptor/HIV-1 co-receptor. (C1) is useful
CC for in vivo inhibition of HIV-1 infection. (C1) or (C2) is useful for
CC producing a medicament utilised for treating or preventing HIV-1
CC infection. (C3) or (C4) is useful for inducing in a subject an anti-HIV-1
CC neutralising antibody response specific for a V3 loop epitope. (C4) is
CC useful for preventing an HIV-1 infection in an uninfected subject at risk
CC for such infection or for inhibiting viral spread and disease progression
CC in an infected subject. The present sequence represents a peptide used in
CC the exemplification of the present invention.
XX
XX Sequence 20 AA;
XX
XX Query Match 100.0%; Score 39; DB 8; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 0.18;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 RAFVTIGK 8
XX 13 RAFVTIGK 20
XX
XX RESULT 101
XX AAR93073
XX ID AAR93073 standard; peptide; 21 AA.
XX
XX AAR93073;
XX
XX 27-SEP-1996 (first entry)
XX
XX Antigenic peptide CTRB73.
XX
XX Antigen; non-infectious; retrovirus; antigenic marker; immune response;
XX long terminal repeat; gag; pol; env; AIDS; HIV; antibody; therapy.
XX
XX Synthetic.
XX
XX WO9605292-A1.
XX
XX 22-FEB-1996.
XX
XX 15-AUG-1995; 95WO-CA000483.
XX
XX 15-AUG-1994; 94US-00290105.
XX
XX (CONN-) CONNAUGHT LAB LTD.
XX

```

XX
PI Rovinski B, Cao S, Yao F, Persson R, Klein MH;
XX
XX WPI, 1996-139690/14.
XX
XX Antigenically marked non-infectious retrovirus-like particles - used to
PT vaccinate against, and in the treatment of, AIDS and AIDS related
PT conditions.
XX
XX Example 4, Page 38, 75pp; English.
XX
PS AAR93071-R93074 represent sequences used as antigenic marker epitopes in
CC a non-infectious retrovirus-like particle of the invention. This sequence
CC represents the antigenic peptide CTRB73. The retrovirus-like particle
CC contains 1-4 repeats of this sequence (or AAR93061). The coding sequence
CC for the retroviral particle of the invention comprises a modified
CC retroviral genome deficient in long terminal repeats, but containing the
CC gag, pol and env genes in their natural genomic arrangement, along with
CC the antigenic marker sequence. The retroviral particle can be used in an
CC immunogenic composition capable of eliciting a retroviral specific immune
CC response. The composition is for parenteral or mucosal administration.
CC Preferably oral, anal, vaginal or intranasal administration. The
CC composition can be used for immunising a host to produce a retroviral
CC specific immune response, such as against AIDS and AIDS related
CC conditions. The particles may also be used in the prophylactic (or
CC curative) treatment of AIDS and related conditions, by acting to displace
CC the binding of the HIV virus to human or animal cells, or by disrupting
CC the 3-dimensional organisation of the virus. The particle can also be
CC used to identify antibodies specifically reacting with retrovirus
CC antigens
XX
XX Sequence 21 AA;
SQ

Query Match 100.0%; Score 39; DB 2; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.19;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTTGK 8
DB 14 RAFVTTGK 21

RESULT 102
AAW34475
ID AAW34475 standard; peptide; 21 AA.
XX
AC AAW34475;
XX
DT 11-MAY-1998 (first entry)
XX
DE Acceptor peptide HIV-V3.
XX
XX UDP-N-acetyl-alpha-D-galactosamine;
KM polypeptide N-acetyl-galactosaminyltransferase; GalNac-T3; human;
KM glycosylation; HIV-V3.
XX
OS Synthetic.
OS Human immunodeficiency virus.
XX
PN WO9743405-A1.
XX
PD 20-NOV-1997.
XX
PF 15-MAY-1997; 97WO-DK000226.
XX
PR 15-MAY-1996; 96US-00648298.
XX
XX (CLAU/) CLAUSEN H.
PA (BENN/) BENNETT E P.
XX
PI Clausen H, Bennett EP;
XX
XX WPI, 1998-008874/01.

XX
PT New isolated N-acetyl-galactosaminyl-transferase enzyme - used for the
PT production of glycosylated polypeptide(s) having particular enzymatic,
PT immunogenic or other biological or physical properties.
XX
XX Example 2, Page 30, 70pp; English.
XX
PS Acceptor peptides Muc2, Muc5c (see AAW34474) and HIV-V3 (see AAW34475)
CC were used to study the acceptor substrate specificity of the novel human
CC N-acetyl-galactosaminyltransferase GalNac-T3 (see AAW34470). Expression of
CC a soluble GalNac-T3 construct in Sf9 cells resulted in significant
CC increases in GalNac-transferase activity in the culture medium of
CC infected cells compared to uninfected controls or cells infected with the
CC host blood group O2 gene. GalNac-transferase activity with the Muc2
CC acceptor peptide was increased 20-fold, and activity with the HIV-V3
CC peptide was increased nearly 100-fold. In contrast, expression of GalNac-
CC T1 and -T2 constructs only increased the GalNac-transferase activity
CC toward Muc2 and Muc5c peptide substrates. This illustrates the unique
CC acceptor substrate specificity of GalNac-T3. The enzyme is used in
CC claimed methods for the glycosylation of peptides and proteins and for
CC producing vaccines by modifying the O-glycosylation pattern of eukaryotic
CC cells
XX
XX Sequence 21 AA;
SQ

Query Match 100.0%; Score 39; DB 2; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.19;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTTGK 8
DB 10 RAFVTTGK 17

RESULT 103
AAW79180
ID AAW79180 standard; peptide; 21 AA.
XX
AC AAW79180;
XX
DT 25-JAN-1999 (first entry)
XX
DE Fusion immunoglobulin heavy chain HIV gp120 T cell epitope #58.
XX
XX B cell; T cell; epitope; immunoglobulin; heavy chain; gp120; IGH;
KM human immune deficiency virus; HIV; tolerance; treatment; therapy;
KM prophylaxis; vaccine; chemotherapy; immune response; modifier; tumour;
KM microbial infection; autoimmune disease; antibody; apoptosis;
KM antiviral T cell immunity.
XX
XX Mus sp.
OS Homo sapiens.
OS
PN WO9836087-A1.
XX
PD 20-AUG-1998.
XX
PF 13-FEB-1998; 98WO-US002766.
XX
PR 13-FEB-1997; 97US-0040581P.
XX
XX (AMNA-) AMERICAN NAT RED CROSS.
PA
PI Scott D, Zambidis E;
XX
XX WPI, 1998-506315/43.
XX
XX New fusion immunoglobulin heavy chain including gp120 epitopes and
PT related complete antibodies - DNA, vectors and transformed cells, used to
PT induce tolerance to the epitopes for treatment of human immune deficiency
PT virus infection.
XX
XX Disclosure; Page 50, 154pp; English.

XX This sequence is an epitope used in the construction of a novel fusion
 CC immunoglobulin heavy chain (IGH) protein with a mammalian, especially
 CC human, IGH chain fused in frame at its N-terminus to one or more human
 CC immune deficiency virus (HIV) gp120 epitopes. Fusion Ig proteins and/or
 CC transduced cells are used to tolerate subjects to gp120 epitopes and to
 CC maintain this tolerance, particularly for treatment of HIV infection,
 CC optionally together with other therapeutic/prophylactic agents such as
 CC vaccines, chemotherapeutic agents and immune response modifiers. Such
 CC proteins can be used against other diseases where an immune response is
 CC deleterious, e.g. microbial infection, tumours or autoimmune disease.
 CC Induction of tolerance suppresses production of antibodies against gp120,
 CC so prevents or inhibits 'bystander' apoptosis of uninfected T cells that
 CC are bound to gp120 protein, maximising induction of protective antiviral
 CC T cell immunity

SQ Sequence 21 AA;

Query Match 100.0%; Score 39; DB 2; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.19;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTICK 8
 Db 6 RAFTICK 13

RESULT 104
 AAW76901
 ID AAW76901 standard; peptide: 21 AA.
 XX AAW76901;
 AC
 XX 25-JAN-1999 (first entry)
 DT
 XX Fusion immunoglobulin heavy chain HIV gp120 T cell epitope #20.
 DE
 XX B cell; T cell; epitope; immunoglobulin; heavy chain; gp120; IGH;
 KM human immune deficiency virus; HIV; tolerance; treatment; therapy;
 KM prophylaxis; vaccine; chemotherapy; immune response; modifier; tumour;
 KM microbial infection; autoimmune disease; antibody; apoptosis;
 KM antiviral T cell immunity.

XX Mus sp.
 OS Homo sapiens.
 OS
 XX WO9836087-A1.
 PN
 XX 20-AUG-1998.
 PD
 XX 13-FEB-1998; 98WC-US002766.
 PF
 XX 13-FEB-1997; 97US-0040581P.
 PR
 XX (AMNA-) AMERICAN NAT RED CROSS.
 PA
 XX Scott D, Zambidis B;
 PI
 XX WPI; 1998-506315/43.
 DR
 XX New fusion immunoglobulin heavy chain including gp120 epitopes and
 PT related complete antibodies - DNA, vectors and transformed cells, used to
 PT induce tolerance to the epitopes for treatment of human immune deficiency
 PT virus infection.
 PT
 XX Claim 11, Page 120; 154pp; English.

XX This sequence is an epitope used in the construction of a novel fusion
 CC immunoglobulin heavy chain (IGH) protein with a mammalian, especially
 CC human, IGH chain fused in frame at its N-terminus to one or more human
 CC immune deficiency virus (HIV) gp120 epitopes. Fusion Ig proteins and/or
 CC transduced cells are used to tolerate subjects to gp120 epitopes and to
 CC maintain this tolerance, particularly for treatment of HIV infection.

CC optionally together with other therapeutic/prophylactic agents such as
 CC vaccines, chemotherapeutic agents and immune response modifiers. Such
 CC proteins can be used against other diseases where an immune response is
 CC deleterious, e.g. microbial infection, tumours or autoimmune disease.
 CC Induction of tolerance suppresses production of antibodies against gp120,
 CC so prevents or inhibits 'bystander' apoptosis of uninfected T cells that
 CC are bound to gp120 protein, maximising induction of protective antiviral
 CC T cell immunity

SQ Sequence 21 AA;

Query Match 100.0%; Score 39; DB 2; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.19;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTICK 8
 Db 6 RAFTICK 13

RESULT 105
 AAW75478
 ID AAW75478 standard; peptide: 21 AA.
 XX AAW75478;
 AC
 XX 17-OCT-2003 (revised)
 DT 20-MAR-2003 (revised)
 DT 27-APR-1999 (first entry)
 DT
 XX HIV-1 strain HXB2 gp120 V3 loop peptide amino acids 302-322.
 DE
 XX V3 loop; gp120 protein; HIV-1; retrovirus-like particle; genome; HIV-2;
 KM long terminal repeat; LTR; chimeric; envelope; glycoprotein; HTLV-I;
 KM HTLV-II; vaccine; human T-lymphotropic virus.
 KM
 XX Human immunodeficiency virus 1.
 OS
 XX US5866137-A.
 PN
 XX 02-FEB-1999.
 PD
 XX 30-MAY-1995; 95US-00453745.
 PF
 XX 15-JUN-1992; 92US-00839751.
 PR
 XX 09-JUN-1993; 93US-00073526.
 PR
 XX (CONN-) CONNAUGHT LAB LTD.
 PA
 XX Klein MH, Cao SX, Haynes J, Rovinski B;
 PI
 XX WPI; 1999-141864/12.
 DR
 XX Immunogenic retrovirus-like particle - with chimeric HIV-1 envelope
 PT protein containing heterologous retroviral amino acid sequence.
 PT
 XX Example 4; Col 7-8; 12pp; English.

XX This sequence represents a peptide from the V3 loop of the gp120 protein
 CC from the human immunodeficiency virus type 1 (HIV-1) strain HXB2. The
 CC peptide is used to determine antibody responses after immunisation with a
 CC self-assembled, non-infectious, non-replicating, immunogenic, retrovirus-
 CC like particle. The retrovirus-like particle comprises a modified HIV
 CC genome devoid of long terminal repeats (LTRs) and contains a nucleotide
 CC sequence coding for a chimeric envelope glycoprotein. The chimeric
 CC envelope glycoprotein has the HIV-1 gp120 conserved region 2 and a second
 CC retroviral envelope amino acid sequence from a heterologous strain of HIV
 CC -1, HIV-2, HTLV-I or HTLV-II inserted into the first retroviral envelope
 CC amino acid sequence (see AAW75474-W75477). The novel retrovirus-like
 CC particle is useful in vaccines against HIV. (Updated on 20-MAR-2003 to
 CC correct PA field.) (Updated on 17-OCT-2003 to standardise OS field)

SQ Sequence 21 AA;

Query Match 100.0%; Score 39; DB 2; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.19;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTTICK 8
 |||||
 DB 14 RAFTTICK 21

RESULT 106
 ID AAY16052 standard; peptide; 21 AA.
 AC AAY16052;
 DT 17-OCT-2003 (revised)
 DT 20-MAR-2003 (revised)
 DT 04-AUG-1999 (first entry)
 DE HIV-1 isolate HXB2 gp120 peptide.
 XX
 XX Retrovirus-like particle; modified HIV genome;
 KM chimeric envelope glycoprotein; HIV-1 gp120; conserved region 2; HIV-1;
 KM HIV-2; HTLV-I; HTLV-II; vaccine.
 OS Human immunodeficiency virus 1.
 XX
 XX US5912338-A.
 PN 15-JUN-1999.
 PD 30-MAY-1995; 95US-00452520.
 PF 15-JUN-1992; 92US-00839751.
 PR 09-JUN-1993; 93US-00073526.
 XX
 XX (ROVI/) ROVINSKI B.
 PI Cao SX, Klein MH, Haynes J, Rovinski B;
 DR WPI; 1999-357220/30.
 XX
 PT Immunogenic retrovirus like particles comprising modified HIV genomes,
 PT useful as vaccines against HIV.
 XX
 XX Example 4; Col 9-10; 12pp; English.
 PS The specification describes a nucleic acid molecule encoding a self
 CC assembled, non-infectious, non-replicating, immunogenic, retrovirus-like
 CC particle. The retroviral particle comprises a modified HIV genome devoid
 CC of long terminal repeats containing a nucleotide sequence coding for a
 CC chimeric envelope glycoprotein which has a first (a) and second (b)
 CC retroviral envelope amino acid sequence, where (a) contains the HIV-1
 CC gp120 conserved region 2, and (b) contains a retroviral envelope amino
 CC acid sequence of a heterologous strain of HIV-1, HIV-2, HTLV-I or HTLV-II
 CC inserted into (a) at an endogenous site (BgIII and StuI). (b) may
 CC comprise peptides AAY16049-51 and AAY16055. The nucleic acids are useful
 CC as vaccines against HIV. The present sequence is used in the course of
 CC the invention. (Updated on 20-MAR-2003 to correct PR field.) (Updated on
 CC 17-OCT-2003 to standardise OS field)
 XX
 XX Sequence 21 AA;
 SQ

Query Match 100.0%; Score 39; DB 2; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.19;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTTICK 8
 |||||
 DB 14 RAFTTICK 21

RESULT 107
 ID AAW85568 standard; peptide; 21 AA.
 AC AAW85568;
 DT 20-MAR-2003 (revised)
 DT 24-FEB-1999 (first entry)
 DE Human immunodeficiency virus type 1 derived peptide.
 XX
 XX Immunoassay diagnostic kit; antibody detection;
 KM chimeric envelope protein; HIV-1 gp120 conserved region 2; HIV-1; HIV-2;
 KM HTLV-I; HTLV-II.
 OS Synthetic.
 OS Human immunodeficiency virus 1.
 XX
 XX US5849475-A.
 PN 15-DEC-1998.
 PD 30-MAY-1995; 95US-00452503.
 PF 15-JUN-1992; 92US-00839751.
 PR 09-JUN-1993; 93US-00073526.
 XX
 XX (CONN-) CONNUGHT LAB LTD.
 PA Klein MH, Cao SX, Haynes J, Rovinski B;
 PI WPI; 1999-069713/06.
 DR
 XX
 XX Immunoassay diagnostic kit for detecting antibodies - comprising chimeric
 PT retrovirus-like particles.
 PS Example 4; Col 9-10; 12pp; English.
 XX
 XX The present sequence represents a Human immunodeficiency virus type 1
 CC derived peptide. The peptide is used in the immunoassay diagnostic kit of
 CC the invention. The specification describes an immunoassay diagnostic kit
 CC for detecting antibodies in a sample, which comprises an antigen
 CC consisting of a self-assembled, non-infectious, non-replicating,
 CC immunogenic, retrovirus-like particle encoded by a modified HIV genome
 CC that is devoid of long terminal repeats and contains a nucleotide
 CC sequence coding for a chimeric envelope protein having a first amino acid
 CC sequence containing HIV-1 gp120 conserved region 2 and a second amino
 CC acid sequence containing an envelope sequence of a heterologous strain of
 CC HIV-1, HIV-2, HTLV-I or HTLV-II. (Updated on 20-MAR-2003 to correct PR
 CC field.) (Updated on 20-MAR-2003 to correct PA field.)
 XX
 XX Sequence 21 AA;
 SQ

Query Match 100.0%; Score 39; DB 2; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.19;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTTICK 8
 |||||
 DB 14 RAFTTICK 21

RESULT 108
 ID AAB15012 standard; peptide; 21 AA.
 AC AAB15012;
 DT 07-DEC-2000 (first entry)
 DE Peptide p18 derived from V3 loop of HIV IIB group 120 protein.
 XX
 XX HIV; immune; diphosphonate.

```

XX OS Human immunodeficiency virus.
XX XX WO200044758-A1.
XX PN 03-AUG-2000.
XX PD 01-FEB-2000; 2000MO-US002755.
XX PF 01-FEB-1999; 99US-0118131P.
XX PR (EISA ) EISAI CO LTD.
XX PA Hawkins LD, Ishizaka ST, Lewis M, McGuinness P, Nault A, Rose J;
XX PI Rossignol DP;
XX DR WPI; 2000-514809/46.
XX PT New diphosphonate compounds, useful as immunological adjuvants for
XX PT stimulating an immune response to an antigen.
XX PS Example 8; Page 86; 130pp; English.
XX CC The present invention relates to diphosphonate compounds useful as
XX CC immunological adjuvants. The compounds can be used for stimulating an
XX CC immune response to an antigen. The present sequence is an immunogenic
XX CC peptide used to test the ability of the compounds to cause an increase in
XX CC the immune response. The peptide consists of an amino terminal cysteine
XX CC residue, a glycine/alanine/glycine spacer and amino acids 308-322 of the
XX CC V3 loop of HIV IIIB gp120 protein
XX SQ Sequence 21 AA;

Query Match          100.0%; Score 39; DB 3; Length 21;
Best Local Similarity 100.0%; Pred. NO. 0.19;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RAFVTTGK 8
Db      13 RAFVTTGK 20

RESULT 109
AAU08699
ID AAU08699 standard; peptide; 21 AA.
XX AC AAU08699;
XX DT 18-DEC-2001 (first entry)
XX DE Retrovirus-like particle C17B73 containing a V3 (HX82) antigenic marker.
XX XX Human immunodeficiency virus; HIV; retroviral antigen; gag; pol; env;
XX KM immune response; antigenic marker; antigenic epitope; retrovirus.
XX OS Human immunodeficiency virus.
XX OS Synthetic.
XX PN US6291157-B1.
XX PD 18-SEP-2001.
XX PF 23-FEB-1998; 98US-00027955.
XX PR 23-FEB-1998; 98US-00027955.
XX PA (CONN-) CONNAUGHT LAB LTD.
XX PI Rovinski B, Cao S, Yao F, Persson R, Klein ME;
XX DR WPI; 2001-595518/67.
XX PT Differentiating between infection by human immunodeficiency virus (HIV)

```

```

PT and antisera generated by immunization against HIV, comprises use of non
PT -infectious, non-replicating HIV-like particle with heterologous,
PT antigenic anchor sequence.
XX PS Disclosure; Col 17; 28pp; English.
XX CC The invention relates to a method for determining the presence of
XX CC antibodies specifically reactive with HIV retroviral antigens in a
XX CC sample. This involves contacting a sample suspected of containing HIV-
XX CC specific antibodies with a non-infectious, non-replicating, immunogenic
XX CC HIV-like particle as an antigen. The antigen comprises an assembly of a
XX CC gag gene product, a pol gene product and a modified env gene product
XX CC containing a non-retroviral heterologous, antigenic, anchor sequence that
XX CC replaces the endogenous anchoring functions of the env gene product. The
XX CC method detects immune complex formation between HIV-specific antibodies
XX CC and the antigens. The method is also useful for identifying antisera
XX CC generated by immunisation with an immunogenic composition capable of
XX CC eliciting HIV-specific immune response. The antigenic marker may comprise
XX CC at least one antigenic epitope from another virus. This sequence
XX CC represents a retrovirus-like particle containing an antigenic marker
XX SQ Sequence 21 AA;

Query Match          100.0%; Score 39; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. NO. 0.19;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RAFVTTGK 8
Db      14 RAFVTTGK 21

RESULT 110
AAR42153
ID AAR42153 standard; peptide; 22 AA.
XX AC AAR42153;
XX DT 24-OCT-2003 (revised)
XX DT 25-MAR-2003 (revised)
XX DT 27-APR-1994 (first entry)
XX DE gp120 V3 loop sequence of HIV-1 IIIB isolate.
XX XX Human immunodeficiency virus; antigen; EISA; recombinant antibody;
XX KM HIV-neutralising monoclonal antibody; immunoglobulin; AIDS;
XX KM acquired immune deficiency syndrome; chimeric antibody;
XX KM surface glycoprotein gp120; V3 loop; epitope mapping.
XX OS Human immunodeficiency virus 1; (IIIB isolate).
XX PN WO9319785-A1.
XX PD 14-OCT-1993.
XX PF 23-MAR-1993; 93WO-US002629.
XX PR 01-APR-1992; 92US-00861701.
XX PA (MERT ) MERCK & CO INC.
XX PI Emml EA, Conley AJ, Mark GE, Johnson LS, Pfarr DS;
XX DR WPI; 1993-336600/42.
XX PT New recombinant human antibody - with HIV neutralising activity against
XX PT at least two isolates, useful for preventing or treating infection in
XX PT diagnosis, etc.
XX PS Example 16; Page 100; 154pp; English.
XX CC Antibodies able to neutralise more than one HIV-1 isolate are claimed.
XX CC The gp120 V3 loop sequences from different isolates comprising the

```

CC Principal Neutralising Determinant motif GPCR are given in AAR42153-
 CC R42151. (Updated on 25-MAR-2003 to correct PN field.) (Updated on 24-OCT-
 CC 2003 to standardise OS field)

XX
 SQ Sequence 22 AA;

Query Match 100.0%; Score 39; DB 2; Length 22;
 Best Local Similarity 100.0%; Pred. No. 0.2;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTYICK 8
 |||||
 DB 13 RAFTYICK 20

RESULT 111
 AAR57470
 ID AAR57470 standard; protein; 22 AA.
 XX
 AC AAR57470;
 XX
 DT 25-MAR-2003 (revised).
 DT 21-MAR-1995 (first entry)
 XX
 DE HIV BRU V3 loop peptide.
 XX
 KM Immunisation; vaccine; therapy; prophylaxis; defective gene;
 KM non-functional gene; template; antisense; ribozyme; bupivacaine;
 KM human immunodeficiency virus; acquired immune deficiency syndrome; HIV;
 KM AIDS; ss.
 XX
 OS Synthetic.
 XX
 PN WO9416737-A1.
 PD 04-AUG-1994.
 XX
 PF 26-JAN-1994; 94WO-US000899.
 XX
 PR 26-JAN-1993; 93US-00008342.
 PR 11-MAR-1993; 93US-00029336.
 PR 15-JUL-1993; 93US-00093235.
 PR 21-SEP-1993; 93US-00124962.
 PR 21-SEP-1993; 93US-00125012.
 XX
 PA (WEIN/) WEINER D B.
 PA (WILL/) WILLIAMS W V.
 PA (WANG/) WANG B.
 PA (CONEX/) CONEX L R.
 PA (MERV/) MERVA M J.
 PA (ZURA/) ZURAWSKI V R.
 XX
 PI Weiner DB, Williams WV, Wang B, Coney LR, Merva MJ, Zurawski VR;
 DR WPI; 1994-263787/32.
 XX
 PT Method for introducing genetic material into cells - utilizes
 PT polynucleotide function enhancer and nucleic acid free of retroviral
 PT particles, e.g. HIV immunisation.
 XX
 PS Example 3; Page 44; 136pp; English.
 XX
 CC A genetic vaccine against HIV contains a DNA construct which comprises
 CC the sequence encoding gp160. The genetic material was then introduced
 CC into the cells of an individual by (a) contacting the individual's cells
 CC with a polynucleotide function enhancer (bupivacaine) and (b)
 CC administering to the cells the nucleic acid molecule free of retroviral
 CC particles. Nucleic acid molecules which are delivered to cells may serve
 CC as genetic templates for proteins that function as prophylactic and/or
 CC therapeutic immunising agents; replacement copies of defective, missing
 CC or non-functional genes; genetic templates for therapeutic proteins;
 CC genetic templates for antisense molecules or as genetic templates for
 CC ribozymes. This peptide was derived from the V3 loop of an HIV strain (an

CC epitope targeted by HIV neutralising antibodies) and was used to
 CC determine whether the anti-gp160 antibodies elicited in mice immunised
 CC with the genetic vaccine were reactive with this region. (Updated on 25-
 CC MAR-2003 to correct PN field.)

XX
 SQ Sequence 22 AA;

Query Match 100.0%; Score 39; DB 2; Length 22;
 Best Local Similarity 100.0%; Pred. No. 0.2;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTYICK 8
 |||||
 DB 15 RAFTYICK 22

RESULT 112
 AAM07392
 ID AAM07392 standard; peptide; 22 AA.
 XX
 AC AAM07392;
 XX
 DT 16-OCT-2003 (revised)
 DT 24-FEB-1997 (first entry)
 XX
 DE HIV-1 strain IIB gp120 V3 loop sequence.
 XX
 KM HIV-1; gp120; V3 loop; common consensus PND domain; envelop; CD4;
 KM binding site; stem-loop; lysine branched peptide; AIDS.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN JP08231423-A.
 PD 10-SEP-1996.
 XX
 PF 27-FEB-1995; 95JP-00038835.
 XX
 PR 27-FEB-1995; 95JP-00038835.
 XX
 PA (TERU/) TERUMO CORP.
 PA (OKUDA/) OKUDA K.
 XX
 DR WPI; 1996-461278/46.
 XX
 PT Novel AIDS vaccine - comprises branched lysine peptide fragments derived
 PT from HIV env protein.
 XX
 PS Example 2; Page 5-6; 8pp; Japanese.
 XX
 CC This is the sequence of the V3 loop of the gp120 envelop protein from HIV
 CC -1 strain IIB. The sequence was used with a construct comprising part of
 CC the HIV-1 gp120 V3 loop common consensus PND sequence (AAM07391) fused to
 CC part of the HIV-1 CD4 binding site (AAM07391) and with the V3 loop
 CC sequences from HIV-1 strains Thai B (AAM07393) or HGP-30 (AAM07394) to
 CC generate a lysine branched peptide which is useful for the prevention and
 CC treatment of AIDS. (Updated on 16-OCT-2003 to standardise OS field)

XX
 SQ Sequence 22 AA;

Query Match 100.0%; Score 39; DB 2; Length 22;
 Best Local Similarity 100.0%; Pred. No. 0.2;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTYICK 8
 |||||
 DB 14 RAFTYICK 21

RESULT 113
 AAY07488
 ID AAY07488 standard; peptide; 22 AA.
 XX

```

AC  AAY07488;
XX
XX  17-OCT-2003 (revised)
DT  17-AUG-1999 (first entry)
XX
XX  HIV-1 strain IIB gp120 V3 loop sequence.
DE
XX  Light chain; variable region; human; HIV-1; gp120; monoclonal antibody;
KW  epitope; V3 loop; heterohybridoma; human immunodeficiency virus-1;
KM  peripheral blood lymphocyte; Epstein-Barr virus; EBV; AIDS.
XX
XX  Human immunodeficiency virus 1.
OS  US5914109-A.
XX
XX  22-JUN-1999.
PD
XX
XX  21-NOV-1994; 94US-00345321.
PF
XX  15-JUN-1990; 90US-00538451.
PR  12-APR-1991; 91US-00684090.
PR  23-APR-1992; 92US-00872675.
XX
XX  (UTNY ) UNIV NEW YORK STATE.
PA
XX  Gorny MK, Zolla-Pazner S;
PI  WPI; 1999-370481/31.
XX
XX  Heterohybridoma producing human monoclonal antibodies to human
PT  immunodeficiency virus-1.
XX
XX  Example 5; Col 24; 42pp; English.
PS
XX
CC  This sequence represents the V3 loop from the gp120 protein of the human
CC  immunodeficiency virus-1 (HIV-1) strain IIB. The invention relates to
CC  the generation of heterohybridomas producing human monoclonal antibodies
CC  (see AAX79204-X79207) to a neutralising epitope of HIV-1 prepared by
CC  transforming peripheral blood lymphocytes with Epstein-Barr virus. The
CC  antibodies can be used to treat someone infected with HIV-1 or suffering
CC  from AIDS. (Updated on 17-OCT-2003 to standardise OS field)
XX
XX  Sequence 22 AA;
SQ
XX
Query Match          100.0%; Score 39; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 0.2;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY  1 RAFTYICK 8
    |||||
    |||||
DB  13 RAFTYICK 20
XX
RESULT 114
AAY5137
ID  AAY5137 standard; protein; 22 AA.
XX
XX  AAY5137;
AC
XX
XX  12-SEP-2003 (revised)
DT  20-JUN-2000 (first entry)
XX
XX  HIV-1 IIB V3 loop peptide sequence.
DE
XX  Human immunodeficiency virus type 1; HIV-1; infection; prevent; detect;
KM  glycoprotein 140; gp140; neutralising antibody; conformational epitope;
KW  V3 loop.
XX
XX  Human immunodeficiency virus 1.
OS  US6039957-A.
XX
XX  21-MAR-2000.
PD

```

```

XX
XX  03-MAR-1997; 97US-00805889.
PF
XX  10-DEC-1993; 93US-00165314.
PR
XX  (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
XX  Doms RW, Moss B, Earl PL, Broder CC;
PI  WPI; 2000-270121/23.
XX
XX  Producing neutralizing antibodies useful for preventing, treating and
PT  diagnosing an HIV infection in a mammal comprises administering
PT  recombinant uncleaved gp140 proteins to a human.
XX
XX  Example 10; Col 12; 15pp; English.
PS
XX
CC  This sequence represents a human immunodeficiency virus type-1 IIB V3-
CC  loop peptide sequence. The peptide sequence is used to test the
CC  reactivity of the antibodies of the invention. The invention relates to a
CC  method for the production of neutralising antibodies against
CC  conformational epitopes of HIV-1 envelope proteins in humans. The method
CC  comprises administering to a human, a recombinant uncleaved gp140 protein
CC  retaining its oligomeric structure. The human produces neutralising
CC  antibodies against conformational epitopes of the HIV-1 gp140 protein
CC  found on the oligomeric structure of the gp140. The anti-HIV-1 gp140
CC  antibodies of the invention can be used for preventing and diagnosing an
CC  HIV infection in a mammal. Gp140 antibodies are useful for treating an
CC  HIV infection. A diagnostic method using the antibodies involves
CC  isolating a body fluid, preferably blood, and contacting it with a
CC  labelled monoclonal antibody for gp140, and detecting any bound antibody.
CC  (Updated on 12-SEP-2003 to standardise OS field)
XX
XX  Sequence 22 AA;
SQ
XX
Query Match          100.0%; Score 39; DB 3; Length 22;
Best Local Similarity 100.0%; Pred. No. 0.2;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY  1 RAFTYICK 8
    |||||
    |||||
DB  15 RAFTYICK 22
XX
RESULT 115
ABU07537
ID  ABU07537 standard; peptide; 22 AA.
XX
XX  ABU07537;
AC
XX
XX  23-OCT-2003 (revised)
DT  13-MAR-2003 (first entry)
XX
XX  Human N-acetylglucosaminyl transferase T4, GalNAc T4, substrate #9.
DE
XX  GalNAc T4; N-acetylglucosaminyl transferase T4; acceptor substrate;
KM  glycosylation; mucin 1; MUC1; vaccine; antiinflammatory; GalNAc-T1;
KW  GalNAc-T2; GalNAc-T3; HIV.
XX
XX  Human immunodeficiency virus 1.
OS
XX
XX  Key
FH  Modified-site 1 Location/Qualifiers
FT  /label= OTHER
FT  /note="Gln is acetylated"
XX
XX  US6465220-B1.
PN
XX  15-OCT-2002.
PD
XX
XX  21-DEC-1998; 98US-00217306.
PF
XX  21-DEC-1998; 98US-00217306.
PR

```

```

XX PA (GLYC-) GLYCOSYM APS.
XX PI Hassan FH, Clausen H, Bennett EP, Eisenkraetzer D, Gaetgens J;
XX DR WPI; 2003-147066/14.
XX PS
XX PT Glycosylating MUC1 acceptor substrate, by glycosylating substrate with N-
XX PT acetylglucosaminyltransferase T1, GalNAc-T2 or GalNAc-T3, then with
XX PT human GalNAc-T4 to glycosylate specific Ser, Thr residues in substrate.
XX PS
XX PS Example 6; Col 9; 10pp; English.
XX CC The invention relates to glycosylating a MUC1 (mucin 1) acceptor
XX CC substrate, comprising glycosylating the substrate with enzymatically
XX CC active N-acetylglucosaminyltransferase (GalNAc)-T1, GalNAc-T2 or GalNAc
XX CC -T3, or with GalNAc capable of glycosylating MUC1 glycosylation sites
XX CC that can be glycosylated by GalNAc-T1, GalNAc-T2 or GalNAc-T3, and
XX CC glycosylating the substrate with enzymatically active human GalNAc-T4 to
XX CC glycosylate specific Ser, Thr positions in the MUC1 substrate. The method
XX CC is used for glycosylating an MUC1 acceptor substrate. The glycosylated
XX CC substrates are useful in preparation of vaccines and antiinflammatory
XX CC agents. GalNAc-T4 exhibits a different substrate specificity than
XX CC previously characterized GalNAc transferases. The activity of GalNAc-T4
XX CC is unique and specific to glycosylate specific serine and threonine
XX CC residues in MUC1 tandem repeat. The present sequence is an acceptor
XX CC substrate peptide used to test the substrate specificity the human GalNAc
XX CC T4 protein, HIVHbpl20. (Updated on 23-Oct-2003 to standardise OS field)
XX SQ
XX SQ Sequence 22 AA;
XX
XX Query Match 100.0%; Score 39; DB 6; Length 22;
XX Best Local Similarity 100.0%; Pred. NO. 0.2; Mismatches 0; Gaps 0;
XX Matches 8; Conservative 0; Indels 0;
XX
XX Qy 1 RAFTTICK 8
XX Db 10 RAFTTICK 17
XX
XX RESULT 116
XX AAR04502
XX ID AAR04502 standard; protein; 23 AA.
XX AC AAR04502;
XX XX
XX DT 09-SEP-2004 (revised)
XX DT 25-MAR-2003 (revised)
XX DT 20-SEP-1990 (first entry)
XX XX
XX DE Cpd. eliciting, binding with neutralising antibodies to HIV variants.
XX XX
XX XX HIV; therapy; AIDS; principal neutralising domain; antibodies; diagnosis;
XX KM prophylaxis.
XX OS Synthetic.
XX XX
XX PN WO9003984-A.
XX PD 19-APR-1990.
XX PF 03-OCT-1988; 88US-00252949.
XX PR 03-OCT-1988; 88US-00252949.
XX PR 01-JUN-1989; 89US-00359543.
XX PR 19-SEP-1989; 89US-00407663.
XX PS
XX PA (REPK ) REPLIGEN CORP.
XX XX
XX PI Rusche JR, Putney SD, Javaherian K, Farley J, Grimalta R;
XX PI Lynn DU, Petrobre J;
XX DR WPI; 1990-147824/19.

```

```

XX XX
XX PT Principal neutralising domain of HIV variants - used for producing
XX PT peptide(s) and antibodies for diagnosis, prophylaxis and/or therapy
XX PT therapy therapy of HIV infection.
XX XX
XX PS Claim 27 (d); Page 84; 108pp; English.
XX XX
XX CC Either the N-terminal (a) or C-terminal (b), but not both, may be omitted
XX CC ; either (a) or (b) may comprise any of the following: cysteine, a
XX CC protein or other moiety capable of enhancing immunogenicity, a peptide
XX CC from an HIV principal neutralising domain, peptide capable of stimulating
XX CC T-cells, or general immune stimulant. See also AAR04427-R04506 and
XX CC AA004273-Q04279. (Updated on 25-MAR-2003 to correct PR field.) (Updated
XX CC on 25-MAR-2003 to correct PA field.) (Updated on 25-MAR-2003 to correct
XX CC PI field.)
XX CC
XX CC Revised record issued on 09-SEP-2004 : Correction to Feature Table Key
XX XX
XX SQ Sequence 23 AA;
XX
XX Query Match 100.0%; Score 39; DB 2; Length 23;
XX Best Local Similarity 100.0%; Pred. NO. 0.21; Mismatches 0; Gaps 0;
XX Matches 8; Conservative 0; Indels 0;
XX
XX Qy 1 RAFTTICK 8
XX Db 14 RAFTTICK 21
XX
XX RESULT 117
XX AAR04476
XX ID AAR04476 standard; protein; 23 AA.
XX AC AAR04476;
XX XX
XX DT 09-SEP-2004 (revised)
XX DT 25-MAR-2003 (revised)
XX DT 20-SEP-1990 (first entry)
XX XX
XX DE Human immunodeficiency virus hybrid peptide RP140.
XX XX
XX XX HIV isolates HIV-IIIB and HIV-RF; hybrid peptide RP140; therapy; AIDS;
XX KM principal neutralising domain; antibodies; diagnosis; prophylaxis.
XX XX
XX OS Synthetic.
XX XX
XX PN WO9003984-A.
XX PD 19-APR-1990.
XX PF 03-OCT-1988; 88US-00252949.
XX PR 03-OCT-1988; 88US-00252949.
XX PR 01-JUN-1989; 89US-00359543.
XX PR 19-SEP-1989; 89US-00407663.
XX PS
XX PA (REPK ) REPLIGEN CORP.
XX XX
XX PI Rusche JR, Putney SD, Javaherian K, Farley J, Grimalta R;
XX PI Lynn DU, Petrobre J;
XX DR WPI; 1990-147824/19.
XX XX
XX PT Principal neutralising domain of HIV variants - used for producing
XX PT peptide(s) and antibodies for diagnosis, prophylaxis and/or therapy
XX PT therapy therapy of HIV infection.
XX XX
XX PS Claim 8 (59); Page 76; 108pp; English.
XX XX
XX CC Peptide RP140 comprises segments of the Principal Neutralising Domain
XX CC (envelope protein) from isolates HIV-RF and HIV-IIIB. The last Cys
XX CC residue is added for the purpose of crosslinking to carrier proteins.
XX CC Cysteine residues may be added, so that the residues at or near both ends

```

Query Match	Best Local Similarity	100.0%	Score 39;	DB 2;	Length 23;
Matches	8;	Conservative	0;	Mismatches	0;
				Indels	0;
				Gaps	0;
QY	1 RAFTVIGK 8				
DB	13 RAFTVIGK 20				
RESULT 118					
AAAB6704	AAAB6704 standard; peptide; 23 AA.				
XX	AAAB6704;				
XX	11-SEP-2003 (revised)				
DT	09-APR-2001 (first entry)				
DE	HIV-1 IIIB V3-loop peptide.				
XX	HIV, Human immunodeficiency virus; immune; ss.				
OS	Human immunodeficiency virus 1.				
XX	US6171596-B1.				
PD	09-JAN-2001.				
PF	30-APR-1998; 98US-00070291.				
PR	10-DEC-1993; 93US-00165314.				
XX	03-MAR-1997; 97US-00805889.				
XX	(USSH) US DEPT HEALTH & HUMAN SERVICES.				
PI	Earl PL, Broder CC, Doms RW, Moss B;				
DR	WPI; 2001-167730/17.				
PT	Immunogenic composition for stimulating mammalian immune response,				
PT	comprises recombinant uncleaved gp140 protein retaining its oligomeric				
PT	structure such that antibodies against HIV envelope proteins are				
XX	produced.				
PS	Example 10; Col 13; 24pp; English.				
XX	The present invention relates to an immunogenic composition comprising a				
CC	recombinant uncleaved gp140 protein which is a C-terminally truncated				
CC	form of HIV-1 gp160 protein, missing the gp41 transmembrane domain, and				
CC	retaining its oligomeric structure, such that neutralizing antibodies				
CC	against conformational epitopes of HIV-1 envelope proteins found on the				
CC	oligomeric structure of are produced in an immunized human. The invention				
CC	is useful for stimulating an anti-HIV-1 env immune response in a mammal,				
CC	by stimulating the formation of neutralizing antibodies against				
CC	conformational epitopes of HIV-1 env protein in a mammal. gp140 is also				
CC	useful for preventing HIV infection in a mammal. (Updated on 11-SEP-2003				
XX	to standardise OS field)				
XX	Sequence 23 AA;				

```

Query Match# 100.0%; Score 39; DB 4; Length 23;
Best Local Similarity 100.0%; Pred. No. 0.21;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0

OY      1 RAFTTIGK 8
        |||||
Db       16 RAFTTIGK 23

RESULT 119
AAR06211
ID AAR06211 standard; peptide; 24 AA.
XX
AC AAR06211;
XX
DT 10-DEC-1990 (first entry)
XX
DE Immunosuppressant protease inhibitor.
XX
KW Organ transplant; autoimmune disease; allergy; aplastic anaemia;
   systemic erythaematodes.
XX
OS Synthetic.
XX
PN JP02157229-A.
XX
PD 18-JUN-1990.
XX
PF 07-DEC-1988; 8BJP-00310635.
XX
PR 07-DEC-1988; 8BJP-00310635.
XX
PA (NITL ) NITTO DENKO CORP.
XX
DR WPI; 1990-233739/31.
XX
PT Protease inhibiting peptide immuno-suppressant - used to suppress
PT rejection reaction in organs transplantation.
XX
PS Claim 1; Page 181; 6pp; Japanese.
XX
CC CC Protease inhibitor may be use to suppress organ transplant rejection
CC without serious side effects. It may also be used in prevention and
CC therapy of allergy, aplastic anaemia and systemic erythaematodes. See
CC also AAR06212
XX
SQ Sequence 24 AA;

Query Match# 100.0%; Score 39; DB 2; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.21;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      1 RAFTTIGK 8
        |||||
Db       15 RAFTTIGK 22

RESULT 120
AAR07018
ID AAR07018 standard; peptide; 24 AA.
XX
AC AAR07018;
XX
DT 24-OCT-2003 (revised)
DT 18-JAN-1991 (first entry)
XX
DE Residues 301-324 of HIV gp 120 protein used in isolation of sulphated
DE polysaccharide by affinity chromatography.
XX
KW HIV; AIDS; ARC; gp120; RP135.
XX
SS Human immunodeficiency virus 1.
```

XX CA2007258-A.
 PN 11-JUL-1990.
 XX 05-JAN-1990; 90CA-02007258.
 PF 11-JAN-1989; 89US-00295856.
 PR 05-JUL-1989; 89US-00375795.
 XX (RICH) MERRELL DOW PHARM INC.
 PA Cardin AD, Jackson RL;
 PI WPI; 1990-290631/39.
 DR
 XX
 XX Prepn. of anti-HIV sulphated polysaccharide - by affinity chromatography
 PT using a resin-bound peptide corresp. to a HIV gp. 120 fragment.
 XX
 PS Disclosure; Page 7; 34pp; English.
 XX
 CC Anti-HIV sulphated polysaccharide (SPS) can prevent syncytium formation
 CC in HIV infected C4 cells. SPS may be isolated by affinity chromatography
 CC with the given resin bound peptide fragment RPI35. (Updated on 24-OCT-
 CC 2003 to standardise OS field)
 XX
 SQ Sequence 24 AA;
 Query Match 100.0%; Score 39; DB 2; Length 24;
 Best Local Similarity 100.0%; Pred. No. 0.21;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RAFTTICK 8
 Db 15 RAFTTICK 22
 RESULT 121
 AAR26565 standard; peptide; 24 AA.
 XX
 AC AAR26565;
 XX
 XX 24-OCT-2003 (revised)
 DT 25-MAR-2003 (revised)
 DT 28-JAN-1993 (first entry)
 XX
 DE Sequence of peptide DB1 determined from the V3 principal neutralising
 DE domain (PND) region of HIV-1 strain HTLV-III B.
 XX
 KW Diagnostic; assay; detection; AIDS; human immunodeficiency virus.
 XX
 OS Human immunodeficiency virus 1; strain HTLV-III B.
 XX
 PN W09213682-A1.
 XX
 XX 20-AUG-1992.
 XX
 PF 29-JAN-1992; 92WO-EP000187.
 XX
 PR 30-JAN-1991; 91IT-MI000220.
 XX
 PA (SUPE-) INST SUPERIORE DI SANITA'.
 PA (CNDR) CONSIGLIO NAZ DELLE RICERCHE.
 XX
 PI De Rossi A, Pauci M, Mammano F, Panozzo M, Dettin M, Di Bello C;
 PI Chieco-Bianchi L;
 DR WPI; 1992-299983/36.
 XX
 XX Synthetic peptide(s) which enhance infectivity of HIV-1 in cellular
 PT cultures - are used for determining HIV-1 virus in blood and other
 PT biological materials.

XX Claim 1; Page 17; 31pp; English.
 PS
 XX The principal neutralizing domain (PND) of HIV-1 corresp. to a 24- amino
 CC acid sequence arranged in a loop determined by a disulfide bridge in the
 CC third hypervariable region, V3, of the protein gp 120. The central
 CC portion of the V3-PND contains a sequence which is highly conserved in
 CC different HIV-1 isolated strains, whereas the amino acids flanking this
 CC sequence are variable. The antigenic properties of V3 region are known to
 CC be virus-specific; antibodies elicited by MN-derived peptide do not
 CC neutralize HTLV-III B virus and vice-versa. (Updated on 25-MAR-2003 to
 CC correct PN field.) (Updated on 25-MAR-2003 to correct PR field.) (Updated
 CC on 25-MAR-2003 to correct PA field.) (Updated on 24-OCT-2003 to
 CC standardise OS field)
 XX
 SQ Sequence 24 AA;
 Query Match 100.0%; Score 39; DB 2; Length 24;
 Best Local Similarity 100.0%; Pred. No. 0.21;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RAFTTICK 8
 Db 15 RAFTTICK 22
 RESULT 122
 AAR29233 standard; peptide; 24 AA.
 XX
 AC AAR29233;
 XX
 XX 25-MAR-2003 (revised)
 DT 14-APR-1993 (first entry)
 XX
 DE Heteroconjugate antibody immunogen RPI35 (IIIB).
 XX
 KW V3 loop; gp41; envelope protein; MN; prototype; virus; variant; HIV;
 KW homology; heteroconjugate; enzyme; epitope mapping; replication;
 KW conjugate; immunogenic carrier; Keyhole limpet hemocyanin; KLH;
 KW ovalbumin; succinyl maleimideethyl cyclohexanylethylcarboxylate; SWCC.
 XX
 OS Synthetic.
 XX
 XX Key Location/Qualifiers
 FH Key
 FT Misc-difference 24 /note= "Not in the natural sequence of this isolate"
 FT
 PN W09220373-A1.
 XX
 XX 26-NOV-1992.
 PD
 XX 29-APR-1992; 92WO-US003616.
 PF
 XX 14-MAY-1991; 91US-00699773.
 PR
 XX (REPK) REPLIGEN CORP.
 XX
 PA Higgins PJ, Potts BJ;
 PI WPI; 1992-415475/50.
 DR
 XX Hetero-conjugate antibodies for treating HIV infections - comprise an
 FT antibody specific for an effector cell surface antigen and an antibody to
 FT a V3 loop of GP-120 envelope protein of HIV.
 XX
 PS Disclosure; Page 19; 69pp; English.
 XX
 CC The sequences given in AAR29226-35 represent peptides which were used as
 CC immunogens for the production of antibodies against HIV. These peptides
 CC may be either unconjugated or conjugated to an immunogenic carrier, eg. a
 CC keyhole limpet hemocyanin (KLH) or ovalbumin, using succinyl
 CC maleimideethyl cyclohexanylethylcarboxylate (SWCC) as a conjugating agent.

CC Viruses containing these or similar sequences may be recognised by the
 CC heteroconjugate enzymes of the invention. The antibodies raised against
 CC these sequences may be identified by standard epitope mapping techniques.
 CC These antibodies are capable, even at low concentrations, of nearly
 CC eliminating viral replication of different strains of HIV. (Updated on 25
 CC -MAR-2003 to correct PN field.)

XX Sequence 24 AA;

Query Match 100.0%; Score 39; DB 2; Length 24;
 Best Local Similarity 100.0%; Pred. No. 0.21;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFTVIGK 8
 |||||
 Db 15 RAFTVIGK 22

RESULT 123

AA32406
 ID AAR26870 standard; peptide; 24 AA.

XX AAR26870;

XX 25-MAR-2003 (revised)

DT 20-MAY-1998 (first entry)

XX HIV gp120 V3 region binding assay peptide IIIB.

XX Human immunodeficiency virus; AIDS; anti-gp120 antibodies.

XX Synthetic.

XX EP503916-A1.

XX 16-SEP-1992.

XX 11-MAR-1992; 92EP-00302064.

XX 11-MAR-1991; 91US-00668266.

PR 06-MAR-1992; 92US-00894766.

XX (IDEC-) IDEC PHARM CORP.

XX Chang-Yu1 K;

XX WPI; 1992-309986/38.

PT Anti-idiotype antibodies and methods for their selection - useful as
 PT vaccines for the prevention and treatment of HIV infection.

XX Example; Page 9; 30pp; Japanese.

XX The sequence is that of peptide IIIB, derived from the V3 region of HIV
 CC gp120, it was used in binding assays for anti-gp120 antibodies. The anti-
 CC gp120 antibodies are useful in vaccine formulations for the treatment or
 CC prevention of HIV infection. See also AAR26867-R26873. (Updated on 25-MAR
 CC -2003 to correct PN field.) (Updated on 25-MAR-2003 to correct PR field.)

XX Sequence 24 AA;

Query Match 100.0%; Score 39; DB 2; Length 24;
 Best Local Similarity 100.0%; Pred. No. 0.21;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFTVIGK 8
 |||||
 Db 15 RAFTVIGK 22

RESULT 124

AA32406
 ID AAR32406 standard; peptide; 24 AA.

XX AAR32406;

XX 25-MAR-2003 (revised)

DT 04-JUL-1993 (first entry)

XX Sequence of peptide B1 which comprises AAs 308-331 from the V3 region of
 DE HIV-1 isolate IIIB.

XX HIV-1; vaccine; dendritic core; ss.

XX Synthetic.

XX W09303766-A1.

XX 04-MAR-1993.

XX 11-AUG-1992; 92MO-US006688.

XX 13-AUG-1991; 91US-00744281.

XX (REPK) REPLIGEN CORP.

XX (VYRQ) UNIV ROCKEFELLER.

XX Tam UP, Profy AT;

XX WPI; 1993-093730/11.

PT New multiple antigen peptide(s) as HIV vaccines - include a dendritic
 PT core covalently bonded to peptide including the sequence IGPGR.

XX Example; Fig 1; 35pp; English.

XX Nine peptides from the V3 regions of HIV-1 isolates IIIB, RF and MN were
 CC incorporated into tetravalent multiple antigen peptide systems (MAPs)
 CC (see AAR32406-14). Parallel groups of three peptides with chain lengths
 CC spanning from 11-24 residues were synthesised in MAPS format for each
 CC isolate. ELIS assays demonstrated that antisera titers in mice were
 CC closely related to the length of the IIIB peptide used for the
 CC immunisation - the longer the stronger the response. There was no
 CC substantial antibody prodn. in mice against the other two series of
 CC peptides, RF (B4-B6), and MN (B7-B9), except for a low reactivity in the
 CC SP. Immunised with B8 (MN isolate). Specificity tests of the B cell
 CC response demonstrated that the T cell epitope (AAR32415) also serves as a
 CC B cell epitope. (Updated on 25-MAR-2003 to correct PN field.)

XX Sequence 24 AA;

Query Match 100.0%; Score 39; DB 2; Length 24;
 Best Local Similarity 100.0%; Pred. No. 0.21;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFTVIGK 8
 |||||
 Db 15 RAFTVIGK 22

RESULT 125

AA33190
 ID AAR33190 standard; peptide; 24 AA.

XX AAR33190;

XX 25-MAR-2003 (revised)

DT 11-JUL-1993 (first entry)

XX Sequence of HIV-1 derived V3 loop peptide.

XX AIDS; HIV; therapy; autoimmune disease; gp120; ss.

XX Synthetic.

XX W09303762-A1.


```

XX PD 04-MAR-1993.
XX PF 10-AUG-1992; 92WO-AU000423.
XX PR 13-AUG-1991; 91AU-00007725.
XX PA (BIOT-) BIOTECH AUSTRALIA PTY LTD.
XX (SVIN-) ST VINCENT'S HOSPITAL SYDNEY LTD.
XX PI Geczy AF, Russell-Jones GJ, Bell SJD, Cooper DA;
XX WPI; 1993-093727/11.
XX PT Compans. contg. E.coli outer membrane proteins Trat, OmpA or OmpF -
XX PT Increase immune response and are used for treating auto-immune diseases,
XX PT AIDS, cancer etc.
XX PS Example; Page 13; 36pp; English.
XX CC Two peptides, gp41[8] and V3 loop derived from the gp120 region of HIV-1
XX CC were synthesised and purified. To improve the solubility of the gp41[8]
XX CC peptide the sequence R5S was added to the amino terminal to produce
XX CC peptide R-S-Sgp41[8]. The immunodominant HIV-derived peptides were used to
XX CC ascertain whether E.coli outer membrane protein Trat augments the in
XX CC vitro T-cell proliferative responses. (Updated on 25-MAR-2003 to correct
XX CC PN field.)
XX SQ Sequence 24 AA;

Query Match 100.0%; Score 39; DB 2; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.21; Mismatches 0; Gaps 0;
Matches 8; Conservative 0; Indels 0;

Qy 1 RAFTYICK 8
Db 14 RAFTYICK 21

RESULT 126
AAR38165
ID AAR38165 standard; peptide; 24 AA.
XX AAR38165;
XX AC
XX DT 27-AUG-2003 (revised)
XX DT 25-MAR-2003 (revised)
XX DT 12-OCT-1993 (first entry)
XX DE V3 loop peptide N24G.
XX KW gp120; HIV-1; cytotoxic T-lymphocyte; CTL; T-helper; AIDS; infection.
XX OS Human immunodeficiency virus 1.
XX PN WO9310816-A1.
XX PD 10-JUN-1993.
XX PF 02-DEC-1992; 92WO-US010378.
XX PR 02-DEC-1991; 91US-00800932.
XX PR 16-SEP-1992; 92US-00945865.
XX PA (TEXA) UNIV TEXAS SYSTEM.
XX PI Sestry JK, Arlinghaus RB, Plateaucas CD, Nehere PV;
XX WPI; 1993-196739/24.
XX PT Peptide composition for treating and preventing viral infections -
XX PT comprise CTL-inducing epitope and HIV infection-inhibiting sequence or T
XX PT helper cell-inducing sequence.

```

```

XX PS Claim 19; Page 95; 130pp; English.
XX CC HIV gp120 V3 loop-derived peptides (AAR38170-87) are successful in
XX CC generating CTL responses, esp. peptide RISK (AAR38187); the T-helper cell
XX CC -inducing peptide includes the sequence C19A (AAR38164); HIV infection-
XX CC inhibiting peptides are given in AAR38188-206, and are esp. peptides
XX CC R15K, N24G, E13V, R8K, T13Q and H13N (AAR38165-69). The peptides may also
XX CC be derived from an influenza virus protein or a sendai virus protein
XX CC (AAR41014-15). It was observed that peptide N24G (amino acids 308-311),
XX CC with sequences derived from the V3 loop of HIV-1 IIIB, inhibits HIV-1
XX CC infection of primary human T cells by 92% at 1 microg/ml (ca. 0.4-0.6
XX CC microm). (Updated on 25-MAR-2003 to correct PN field.) (Updated on 27-AUG
XX CC -2003 to correct OS field.)
XX SQ Sequence 24 AA;

Query Match 100.0%; Score 39; DB 2; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.21; Mismatches 0; Gaps 0;
Matches 8; Conservative 0; Indels 0;

Qy 1 RAFTYICK 8
Db 15 RAFTYICK 22

RESULT 127
AAR44191
ID AAR44191 standard; peptide; 24 AA.
XX AAR44191;
XX AC
XX DT 25-MAR-2003 (revised)
XX DT 20-MAY-1994 (first entry)
XX DE gp120 V3 loop antigen B2 and lipophilic membrane anchoring group.
XX KW Antigen; B2; third variable domain; V3 loop; gp120; HIV-1; Vaccine;
XX KW strain IIIB; multiple antigenic peptide system; dendritic core;
XX KW lipophilic membrane anchoring group; mammal; humoral; immunisation;
XX KW cytotoxic T cell; CT; immune response; infection; Freund's adjuvant;
XX KW pathogen; HIV; influenza; malaria.
XX OS Human immunodeficiency virus 1.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Peptide 1..18
XX FT /label= B2 antigenic peptide
XX FT Peptide 19..24
XX FT /note= "lipophilic membrane anchoring group"
XX PN WO9322343-A1.
XX PD 11-NOV-1993.
XX PF 03-MAY-1993; 93WO-US004179.
XX PR 01-MAY-1992; 92US-00877613.
XX PA (VYRO) UNIV ROCKEFELLER.
XX PI Tam JP;
XX WPI; 1993-368723/46.
XX DR
XX PT New multiple antigen system esp. for use in HIV vaccines - contains
XX PT lipophilic membrane anchor imparting adjuvant activity, and peptide
XX PT antigens coupled to dendritic core.
XX PS Disclosure; Fig 8; 55pp; English.
XX CC The sequence given in AAR44190 is a peptide antigen, B2, which represents

```

CC residues 312-329 of the third variable domain (V3 loop) of gp120 of HIV-1 strain IIB. This sequence was attached to an amino acid linker (see also AAR44191) in the production of a multiple antigenic peptide system. This system comprises a dendritic core to which are covalently attached at least one peptide, eg. an antigenic peptide, and a lipophilic membrane anchoring group. This system may be injected into a mammal and elicits both humoral and cytotoxic T cell (CTL) immune responses. This system may be used to immunise against HIV infection. The lipophilic membrane anchoring group provides efficient adjuvant activity without the toxicity problems of Freund's adjuvant, while the dendritic structure allows multiple antigens to be attached. Optionally the antigens may be derived from different pathogens, providing vaccines which protect against more than one disease, eg. HIV, influenza and malaria. (Updated on 25-MAR-2003 to correct PN field.)

CC Sequence 24 AA;

Query Match 100.0%; Score 39; DB 2; Length 24;

Best Local Similarity 100.0%; Pred. No. 0.21; Mismatches 0; Indels 0; Gaps 0;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 RAFVITIGK 8
11 RAFVITIGK 18

RESULT 128

AAR63821 ID AAR63821 standard; peptide; 24 AA.

AC AAR63821;

DT 16-OCT-2003 (revised)

DT 25-MAR-2003 (revised)

DT 29-JUN-1995 (first entry)

DE HIV-1 gp120-24 epitope amino acids 307-330.

KW Human immunodeficiency virus type 1; HIV-1; gp120 epitopes; vaccines;

OS HIV neutralising antibodies.

OS Human immunodeficiency virus 1.

PN WO9423746-A1.

PD 27-OCT-1994.

PF 15-APR-1994; 94WO-SB000340.

PR 16-APR-1993; 93US-00048976.

PA (SYNT-) SYNTELLO VACCINE DEV AB.

PI Vahline A, Svennerholm B, Rymo L, Jeansson S, Horal P;

DR WPI; 1994-341488/42.

XX New peptide(s) comprising HIV gp120 epitope(s) - for prodn. of vaccines

PT against HIV infections.

PS Claim 1; Page 18; 77pp; English.

CC AAR63809-R63849 are epitopes from the human immunodeficiency virus type 1

CC (HIV-1) gp120, by binding one or more of these epitopes to a carrier a

CC HIV vaccine is produced. These vaccines can elicit the production of HIV-

CC neutralising antibodies in monkeys, and therefore may be used to prevent

CC HIV infections, and to heighten the immune response in HIV infected

CC humans. (Updated on 25-MAR-2003 to correct PN field.) (Updated on 16-OCT-

CC 2003 to standardise OS field)

XX Sequence 24 AA;

Query Match 100.0%; Score 39; DB 2; Length 24;

Best Local Similarity 100.0%; Pred. No. 0.21; Mismatches 0; Indels 0; Gaps 0;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 RAFVITIGK 8
9 RAFVITIGK 16

RESULT 129

AAR74608 ID AAR74608 standard; peptide; 24 AA.

AC AAR74608;

DT 16-OCT-2003 (revised)

DT 04-JAN-1996 (first entry)

DE HIV-1 gp120 peptide #5.

KW HIV-1, HIV, AIDS; gp120; mucosal cell; epithelium; vagina; rectum;

OS antibody; mucosal administration; vaccine; infection.

OS Human immunodeficiency virus 1.

PN WO9511701-A1.

PD 04-MAY-1995.

PF 25-OCT-1994; 94WO-US012152.

PR 26-OCT-1993; 93US-00143577.

PA (SYNT-) SYNTELLO INC.

PI Czerkinsky C, Holmgren J, Horal P, Svennerholm B, Vahline A;

DR WPI; 1995-178653/23.

XX HIV-1 gp120 peptide to inhibit mucosal epithelium cell infection - useful

PT in peptide vaccine to inhibit HIV-1 infection of vaginal or rectal

PT mucosa.

PS Claim 2; Page 23; 34pp; English.

CC The peptide represented in this sequence, and those represented by

CC sequences AAR74604-7 are epitopes of HIV-1 gp120 that are effective to

CC generate antibodies that inhibit infection of mucosal cells by HIV-1.

CC These peptides are administered to the epithelium in a vaccine, or are

CC used to generate mucosal antibodies and thereby inhibit infection by HIV-

CC 1. These peptides are used for inhibiting the entry of HIV into vaginal

CC and rectal mucosal epithelium. The antibodies that can be generated from

CC them are able to block subsequent infection by HIV. (Updated on 16-OCT-

CC 2003 to standardise OS field)

XX Sequence 24 AA;

Query Match 100.0%; Score 39; DB 2; Length 24;

Best Local Similarity 100.0%; Pred. No. 0.21; Mismatches 0; Indels 0; Gaps 0;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 RAFVITIGK 8
9 RAFVITIGK 16

RESULT 130

AAM67414 ID AAM67414 standard; peptide; 24 AA.

AC AAM67414;

DT 25-JAN-1999 (first entry)

DE HIV-1 peptide epitope BRU.
 XX
 XX Immunogen; vaccine; HIV-1; T-cell; B-cell; epitope; core protein; gp120;
 KW V3 loop.
 XX
 XX Synthetic.
 OS Human immunodeficiency virus 1.
 XX
 PN US5817754-A.
 XX
 PD 06-OCT-1998.
 XX
 PF 05-JUN-1995; 95US-00464329.
 XX
 PR 09-JUN-1993; 93US-00073378.
 XX
 PR 09-JUN-1994; 94US-00257528.
 XX
 PA (CONN-) CONNAUGHT LAB LTD.
 PI Chong P, Klein MH, Sia CDY;
 XX
 DR WPI; 1998-556461/47.
 XX
 PT Synthetic human immunodeficiency virus-1 peptide(s) - containing T-cell
 PT epitope and B-cell epitope(s) are candidate vaccines against HIV-1.
 XX
 PS Disclosure; Fig 3; 40pp; English.
 XX
 CC The invention relates to a novel immunogenic composition for use in
 CC vaccines for the treatment of HIV-1 comprising an HIV-1-derived T-cell
 CC epitope linked to an HIV-1-derived B-cell epitope. The T-cell epitopes
 CC are generally designed based on the p24 core protein and the B-cell
 CC epitopes from the V3 loop of the gp120 protein from various HIV-1
 CC strains. This sequence corresponds to an HIV-1 B-cell peptide epitope
 CC used to immunise a guinea pig
 XX
 SQ Sequence 24 AA;
 XX
 Query Match 100.0%; Score 39; DB 2; Length 24;
 Best Local Similarity 100.0%; Pred. No. 0.21;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RAFTTICK 8
 DB 14 RAFTTICK 21
 XX
 RESULT 131
 ID AAW98904 standard; peptide; 24 AA.
 XX
 AC AAW98904;
 XX
 DT 05-MAY-1999 (first entry)
 XX
 DE HIV-1 vaccine synthetic peptide SEQ ID NO:99.
 XX
 KM HIV-1; human immunodeficiency virus; vaccine; T-cell epitope;
 KM gag protein; B-cell epitope; gp41 protein; chimeric; infection.
 XX
 OS Synthetic.
 OS Human immunodeficiency virus 1.
 XX
 PN US5876731-A.
 XX
 PD 02-MAR-1999.
 XX
 PF 05-JUN-1995; 95US-00462507.
 XX
 PR 09-JUN-1993; 93US-00073378.
 XX
 PR 09-JUN-1994; 94US-00257528.
 XX
 PA (CONN-) CONNAUGHT LAB LTD.

XX Chong P, Klein MH, Sia CDY;
 PI WPI; 1999-189590/16.
 XX
 DR Synthetic chimeric HIV polypeptides - comprising gag protein T-cell
 PT epitope linked to gp41 B-cell epitope.
 XX
 PS Example 1; Col 71-72; 41pp; English.
 XX
 CC The present invention describes a synthetic peptide comprising an amino
 CC acid sequence containing a T-cell epitope of an HIV gag protein linked at
 CC its C terminus to an amino acid sequence containing a B-cell epitope of
 CC an HIV gp41 protein and containing the amino acid sequence: X1KDMX2;
 CC where X1 = E, A, G or Q, and X2 = A or T, or an amino acid sequence
 CC capable of eliciting an HIV-specific antiserum and recognizing the
 CC sequence X1KDMX2. The synthetic peptide is useful in vaccines against
 CC HIV infection and in diagnostic applications. AAW98892 to AAW98906, and
 CC AAW98999 to AAW99889 represent synthetic peptides from the present
 CC invention
 XX
 SQ Sequence 24 AA;
 XX
 Query Match 100.0%; Score 39; DB 2; Length 24;
 Best Local Similarity 100.0%; Pred. No. 0.21;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RAFTTICK 8
 DB 14 RAFTTICK 21
 XX
 RESULT 132
 ID AAY22581 standard; peptide; 24 AA.
 XX
 AC AAY22581;
 XX
 DT 17-OCT-2003 (revised)
 DT 19-OCT-1999 (first entry)
 XX
 DE HIV LDL binding peptide, sequence A.
 XX
 KM HIV; LDL; low density lipoprotein; human; immune response; infection;
 KM immunodeficiency; neoplastic tissue; myalgic encephalomyelitis; ME;
 KM viral infection fatigue syndrome; tuberculosis; hepatitis; AIDS; ARC;
 KM acquired immunodeficiency syndrome; AIDS related complex;
 KM HIV-infected CD4 cell; immunosuppressive peptide.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN WO9938524-A2.
 XX
 PD 05-AUG-1999.
 XX
 PF 28-JAN-1999; 99MO-IB000149.
 XX
 PR 29-JAN-1998; 98US-0072980P.
 XX
 PA (PREN/) PRENDERGAST P T.
 XX
 PI Prendergast PT;
 XX
 DR WPI; 1999-494040/41.
 XX
 PT Enhancing the immune response using a recombinant human low-density
 PT lipoprotein receptor, useful for treating viral infections, especially
 PT human immunodeficiency virus (HIV) infection.
 XX
 PS Claim 7; Page 19; 24pp; English.
 XX
 CC This sequence represents a HIV sequence that binds human low density
 CC lipoprotein (LDL), and is designated sequence "A". The invention relates

to a method for enhancing the immune response in a patient with a condition, selected from immunodeficiency (due to a viral, bacterial, mycoplasmic, fungal or parasitic infection, or from the growth of neoplastic tissue), myalgic encephalomyelitis (ME), post inoculation or viral infection fatigue syndrome, tuberculosis, or hepatitis. The method comprises using a pharmaceutical composition, comprising a recombinant human LDL receptor or a mimic molecule to the cysteine rich domain of LDL receptor. The human recombinant LDL receptor forms pharmaceutical compositions for: the treatment of acquired immunodeficiency syndrome (AIDS) or ARC (AIDS related complex); reducing syncytium formation in HIV-infected CD4 cells; treating blood or body fluid or organs to neutralise/remove immunosuppressive peptides and/or viruses; or treating hepatitis A, B or C. The pharmaceutical compositions also treat a viral infection in a human or animal host. The human recombinant LDL receptor is also useful for manufacturing medicaments for treating all the conditions given above. The human recombinant LDL receptor is a highly specific inhibitor of HIV-1 replication in vitro. (Updated on 17-OCT-2003 to standardise OS field)

Sequence 24 AA;

Query Match 100.0%; Score 39; DB 2; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.21;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFVTTGK 8
| | | | |
DB 15 RAFVTTGK 22

RESULT 133

AAV22583
ID AAY22583 standard; peptide; 24 AA.

AC AAY22583;

DT 17-OCT-2003 (revised)
DT 19-OCT-1999 (first entry)

DE HIV LDL binding peptide, sequence "A" variant.

XX HIV; LDL; low density lipoprotein; human; immune response; infection;
KW immunodeficiency; neoplastic tissue; myalgic encephalomyelitis; ME;
KW viral infection fatigue syndrome; tuberculosis; hepatitis; AIDS; ARC;
KW acquired immunodeficiency syndrome; AIDS related complex;
KW HIV-infected CD4 cell; immunosuppressive peptide.

XX Human immunodeficiency virus 1.

OS W09398524-A2.

XX 05-AUG-1999.

XX 28-JAN-1999; 99WO-IB000149.

XX 29-JAN-1998; 98US-0072980P.

XX (PREN/) PRENDERGAST P T.

XX Prendergast PT;

XX WPI; 1999-494040/41.

XX Enhancing the immune response using a recombinant human low-density
PT lipoprotein receptor, useful for treating viral infections, especially
PT human immunodeficiency virus (HIV) infection.

PS Disclosure; Page 12; 24pp; English.

XX This sequence represents a variant of the HIV sequence that binds human
CC low density lipoprotein (LDL), and is designated sequence "A" (see
CC AAY22581). The sequence "A" peptide is isolated from HIV isolate
CC IIB(BH10), and this sequence was isolated from HIV isolate IIB(BH8).

The invention relates to a method for enhancing the immune response in a patient with a condition, selected from immunodeficiency (due to a viral, bacterial, mycoplasmic, fungal or parasitic infection, or from the growth of neoplastic tissue), myalgic encephalomyelitis (ME), post inoculation or viral infection fatigue syndrome, tuberculosis, or hepatitis. The method comprises using a pharmaceutical composition, comprising a recombinant human LDL receptor or a mimic molecule to the cysteine rich domain of LDL receptor. The human recombinant LDL receptor forms pharmaceutical compositions for: the treatment of acquired immunodeficiency syndrome (AIDS) or ARC (AIDS related complex); reducing syncytium formation in HIV-infected CD4 cells; treating blood or body fluid or organs to neutralise/remove immunosuppressive peptides and/or viruses; or treating hepatitis A, B or C. The pharmaceutical compositions also treat a viral infection in a human or animal host. The human recombinant LDL receptor is also useful for manufacturing medicaments for treating all the conditions given above. The human recombinant LDL receptor is a highly specific inhibitor of HIV-1 replication in vitro. (Updated on 17-OCT-2003 to standardise OS field)

Sequence 24 AA;

Query Match 100.0%; Score 39; DB 2; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.21;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFVTTGK 8
| | | | |
DB 15 RAFVTTGK 22

RESULT 134

AAV39769
ID AAV39769 standard; peptide; 24 AA.

AC AAV39769;

DT 17-OCT-2003 (revised)
DT 26-NOV-1999 (first entry)

DE HIV1 chimeric peptide.

XX HIV; vaccine; immunogenic composition; T cell epitope; B cell epitope;
KW infection; antibody; antiviral.

XX Human immunodeficiency virus 1.

OS US5951986-A.

XX 14-SEP-1999.

XX 06-JUN-1995; 95US-00467881.

XX 09-JUN-1993; 93US-00073378.

XX 09-JUN-1994; 94US-00257528.

XX (CONN-) CONNAUGHT LAB LTD.

XX Klein WH, Chong P, Sia CDY;

XX WPI; 1999-550482/46.

XX Immunogenic composition containing synthetic fusion polypeptides
PT containing both the T and B cell epitopes of the human immunodeficiency
PT virus, useful antigens in producing vaccines.

PS Disclosure; Col 73-74; 43pp; English.

XX This sequence represents a fragment of a HIV1 protein, and can be used in
CC the immunogenic composition of the invention. The composition comprises a
CC synthetic fusion polypeptide which includes a sequence encoding 1 or more
CC T cell epitopes and a sequence encoding 1 or more B cell epitopes and a
CC carrier. Both the T cell and B cell epitopes are derived from HIV
CC proteins. The compositions are useful as vaccines against HIV infection.

CC The composition induces HIV-1-specific polyclonal antibodies that are
 CC opsonising and antiviral. The peptide components may be selected to
 CC induce a response against different viral isolates and in subjects who
 CC recognise different T cell epitopes. (Updated on 17-OCT-2003 to
 CC standardise OS field)
 CC
 CC
 SQ Sequence 24 AA;

Query Match 100.0%; Score 39; DB 2; Length 24;
 Best Local Similarity 100.0%; Pred. No. 0.21;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFTTICK 8
 Db 14 RAFTTICK 21

RESULT 135
 AAB15873
 ID AAB15873 standard; peptide: 24 AA.

AC AAB15873;

DT 17-JAN-2001 (first entry)

DE Human chemokine derived peptide #25.

XX Macrophage recruitment; chemokine derivative; MCP-1; osteoporosis;
 KM monocyte chemoattractant protein-1; inflammation; atherosclerosis; HIV;
 KM AIDS; stroke; psoriasis; autoimmune disease; hypertension; endotoxaemia;
 KM basophil-mediated disease; myocardial infarction; acute ischaemia;
 KM rheumatoid arthritis; contraception.

XX Synthetic.

OS WO200042071-A2.

PN 20-JUL-2000.

PD 12-JAN-2000; 2000MO-US000821.

XX 12-JAN-1999; 99US-00229071.

PR 17-MAR-1999; 99US-00271192.

PR 01-DEC-1999; 99US-00452406.

XX (NEOR-) NEORX CORP.

PI Grainger DJ, Tatalick LM;

XX WPI; 2000-499101/44.

PT New peptide 3, amide and heterocyclic compounds and saccharide conjugates
 PT used for inhibiting chemokine induced activity and for treating e.g.
 PT stroke, vascular diseases, autoimmune diseases and tumor growth.

XX Disclosure; Fig 18; 387pp; English.

XX The present invention concerns the identification of a number of
 CC chemokines which can be used to produce derivatives, agonists and
 CC antagonists which are then useful in disease treatment. The chemokines
 CC include sequences AAB15785-B15794, AAB15803-B15813 and AAB15831-B15848.
 CC These chemokine derivatives can be used to treat diseases such as
 CC autoimmune diseases, atherosclerosis, osteoporosis, HIV infection and
 CC AIDS, psoriasis, inflammatory diseases, hypertension, basophil-mediated
 CC diseases, endotoxaemia, myocardial infarction, acute ischaemia and
 CC rheumatoid arthritis, and can be used to prevent strokes and as
 CC contraceptives. The coding sequences for the chemokines can be used in
 CC gene therapy for the same diseases, as well as in the production of
 CC animal models

XX Sequence 24 AA;

Query Match 100.0%; Score 39; DB 3; Length 24;

Best Local Similarity 100.0%; Pred. No. 0.21;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFTTICK 8
 Db 15 RAFTTICK 22

RESULT 136
 AAB68602
 ID AAB68602 standard; peptide: 24 AA.

AC AAB68602;

DT 11-SEP-2003 (revised)

DT 25-APR-2001 (first entry)

DE HIV gp120 V3 loop peptide #2.

XX HIV gp120 V3 loop; liposome composition; HIV infection.

OS Human immunodeficiency virus 1.

PN US6180134-B1.

PD 30-JAN-2001.

PF 07-JUN-1995; 95US-00480332.

XX 23-MAR-1993; 93US-00035443.

PR 29-SEP-1994; 94US-00316436.

XX (SEQ-) SEQUS PHARM INC.

PI Zalpeky S, Woodle MC, Martin FJ, Barenholz Y;

XX WPI; 2001-201897/20.

PT Liposome composition for use in treating septic shock comprises liposomes
 PT having an outer surface layer of polyethylene glycol chains, and a
 PT polypeptide or polysaccharide effector molecule.

XX Disclosure; Fig 13; 32pp; English.

XX The present invention relates to a liposome composition comprising
 CC liposomes having an outer surface layer of polyethylene glycol chains,
 CC each having a free distal end. A polypeptide or polysaccharide effector
 CC molecule is covalently attached to a portion of the distal ends. The
 CC effector interferes with specific binding of pathogen or cell in a
 CC bloodstream to a target cell or cell matrix, and is rapidly removed by
 CC renal clearance from the bloodstream when administered in free form. The
 CC liposome composition may be used in treating a condition mediated by
 CC binding a pathogen or cell in the bloodstream, to a target cell or cell
 CC matrix. It can be used in treating septic shock, toxic shock, colonic
 CC inflammation, leukemic cell proliferation, or HIV infection. The present
 CC sequence is a peptide of the V3 loop of HIV envelope protein gp120. This
 CC peptide may be used in the composition of the present invention. gp120
 CC binds to the CD4 receptor during HIV infection of lymphocytes. By
 CC introducing the present peptide, the CD4 receptors are blocked, thereby
 CC inhibiting HIV infection. (Updated on 11-SEP-2003 to standardise OS
 CC field)

XX Sequence 24 AA;

Query Match 100.0%; Score 39; DB 4; Length 24;
 Best Local Similarity 100.0%; Pred. No. 0.21;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFTTICK 8
 Db 15 RAFTTICK 22

```

RESULT 137
AAP82464
ID AAP82464 standard; protein; 25 AA.
XX
AC AAP82464;
XX
DT 25-MAR-2003 (revised)
DT 12-NOV-1990 (first entry)
DE Peptide component of AIDS vaccine.
XX
KM AIDS vaccine; T-cells.
XX
OS Synthetic.
XX
PN EP273716-A.
XX
PD 06-JUL-1988.
XX
PF 23-DEC-1987; 87EP-00311391.
XX
PR 30-DEC-1986; 86US-00947935.
PR 12-FEB-1987; 87US-00014430.
XX
PA (USDC ) US SEC OF COMMERCE.
PA (USSH ) US DEPT HEALTH & HUMAN SERVICE.
XX
PI Delisl C, Margalit H, Cornette JL, Ouyang CS;
XX
DR WPI, 1988-184640/27.
XX
PT Synthetic peptide(s) as vaccines for AIDS - selected from peptide regions
PT which can fold as a maximally amphipathic helix recognised by T cells.
XX
PS Claim 9; Page 10; 16pp; English.
XX
CC This peptide is a component of an AIDS vaccine. It can fold as a
CC maximally amphipathic helix and is recognised by T-cells immune to the
CC AIDS virus envelope protein. See also AAP82462-63 and AAP82465-79.
CC (Updated on 25-MAR-2003 to correct PA field.)
XX
SQ Sequence 25 AA;

Query Match      100.0%; Score 39; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.22;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RAFTYICK 8
DB      9 RAFTYICK 16

RESULT 138
AAP90281
ID AAP90281 standard; protein; 25 AA.
XX
AC AAP90281;
XX
DT 09-SEP-2004 (revised)
DT 24-OCT-2003 (revised)
DT 25-MAR-2003 (revised)
DT 22-JUN-1990 (first entry)
DE Peptide 135 of HIV env gene.
XX
KM HIV; AIDS; env gene; HIV vaccine; ds.
XX
OS Simian-Human immunodeficiency virus.
OS Unidentified.
XX
PN EP306219-A.
XX
PD 08-MAR-1989.

```

```

XX
PF 25-AUG-1988; 88EP-00307889.
XX
PR 27-AUG-1987; 87US-00090080.
XX
PA (REPK ) REPLIGEN CORP.
XX
PI Rucche JR, Putney SD, Jayaherian K, Farley J, Grimalia R, Lynn D;
PI Petro U, Okeefe T;
XX
DR WPI; 1989-070387/10.
XX
PT New HIV proteins and peptide(s) - used in diagnosis, prophylaxis or
PT therapy of AIDS, esp. for prepn. of vaccines against HIV infection.
XX
PS Claim 1; Page 27; 29pp; English.
XX
CC Protein derivative stimulates a lymphocyte proliferative response in HIV-
CC infected humans, providing a means of diagnosis, protection and
CC therapeutic value. (Updated on 25-MAR-2003 to correct PR field.) (Updated
CC on 25-MAR-2003 to correct PA field.) (Updated on 24-OCT-2003 to
CC standardise OS field)
CC
CC Revised record issued on 09-SEP-2004 : Correction to location
XX
SQ Sequence 25 AA;

Query Match      100.0%; Score 39; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.22;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RAFTYICK 8
DB      15 RAFTYICK 22

RESULT 139
AAR04475
ID AAR04475 standard; protein; 25 AA.
XX
AC AAR04475;
XX
DT 09-SEP-2004 (revised)
DT 25-MAR-2003 (revised)
DT 20-SEP-1990 (first entry)
DE Human immunodeficiency virus hybrid peptide RP137.
XX
KM HIV isolates HIV-IIIB and HIV-RF; hybrid peptide RP137; therapy; AIDS;
KM principal neutralising domain; antibodies; diagnosis; prophylaxis.
XX
OS Synthetic.
XX
PN WO9003984-A.
XX
PD 19-APR-1990.
XX
PF 03-OCT-1988; 88US-00252949.
XX
PR 03-OCT-1988; 88US-00252949.
PR 01-JUN-1989; 89US-00359543.
PR 19-SEP-1989; 89US-00407663.
XX
PA (REPK ) REPLIGEN CORP.
XX
PI Rucche JR, Putney SD, Jayaherian K, Farley J, Grimalia R;
PI Lynn DU, Petrobre U;
XX
DR WPI; 1990-147824/19.
XX
PT Principal neutralising domain of HIV variants - used for producing
PT peptide(s) and antibodies for diagnosis, prophylaxis and/or therapy
PT therapy therapy of HIV infection.

```

XX PS Claim 8 (58); Page 76; 108pp; English.

CC CC Peptide RPI37 comprises segments of the Principal Neutralising Domain
 CC (envelope protein) from isolates HIV-RF and HIV-IIIB. The last Cys
 CC residue is added for the purpose of crosslinking to carrier proteins.
 CC Cysteine residues may be added, so that the residues at or near both ends
 CC form a disulfide bond, giving peptide a loop-like configuration, which
 CC can be utilised to enhance immunogenic properties of the peptides.
 CC Protein is capable of eliciting, and/or binding with, neutralising
 CC antibodies. The neutralising domain is bounded by cysteine residues which
 CC occur at positions 296 and 311. The peptides can be used as immunogens
 CC or screening reagents to generate or identify poly- or monoclonal
 CC antibodies. See also AAR04427-R04506 and AAQ04273-Q04279. (Updated on 25-
 CC MAR-2003 to correct PR field.) (Updated on 25-MAR-2003 to correct PA
 CC field.) (Updated on 25-MAR-2003 to correct PI field.)

CC CC Revised record issued on 09-SEP-2004 : Correction to Feature Table Key

CC CC Sequence 25 AA;

XX SO

QY Query Match 100.0%; Score 39; DB 2; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.22;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 1 RAFVTIGK 8
 15 RAFVTIGK 22

RESULT 140

AA08276
 ID. AAR08276 standard; protein; 25 AA.

XX AC AAR08276;

XX DT 07-MAR-1991 (first entry)

XX DE HIV peptide fragment (IIIB isolate).

XX KM AIDS; ARC; conjugate immunogen; Neisseria outer membrane protein;
 KM HIV major neutralisation determinant.

XX OS Human immunodeficiency virus.

XX PN EP402088-A.

XX PD 12-DEC-1990.

XX PS 05-JUN-1990; 90EP-00306082.

XX PR 06-JUN-1989; 89US-00362176.
 PR 06-JUN-1989; 89US-00362177.
 PR 06-JUN-1989; 89US-00362178.
 PR 06-JUN-1989; 89US-00362179.

XX PA (MERI) MERCK & CO INC.

XX PI Emint EA, Marburg S, Scolnick EM, Larson VM;

XX DR WPI; 1990-370100/50.

XX PT Conjugate immunogen for AIDS and ARC treatment - composed of neutralising
 PT determinant of HIV and Neisseria outer membrane.

XX PS Claim 2; Page 22; 24pp; English.

XX CC This peptide is derived from the HIV IIIB isolate and is cross-reactive
 CC with the HIV major neutralisation determinant (MNCD). This MNCD is used
 CC in a conjugate, covalently linked to the outer membrane protein (Omp)
 CC from Neisseria, as an immunogen for vaccination against AIDS. A cocktail
 CC of different MNCD poly-peptides can be used. See also AAR08274-75 and
 CC AAR08277

XX SO Sequence 25 AA;

QY Query Match 100.0%; Score 39; DB 2; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.22;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 1 RAFVTIGK 8
 15 RAFVTIGK 22

RESULT 141

AA08276
 ID. AAR13120 standard; peptide; 25 AA.

XX AC AAR13120;

XX DT 24-OCT-2003 (revised)

XX DT 01-OCT-1991 (first entry)

XX DE Binding site of BAT123 and BAT267 HIV antibodies.

XX KM Anti-idiotypic; antibody; gp120; HIV; human immunodeficiency virus;
 KM paratope; complementarity determining region; CDR; immunisation; vaccine;
 KM immunotoxin; T-cell; AIDS; ARC.

XX OS Simian-Human immunodeficiency virus.

XX PN WO9109625-A.

XX PD 11-JUL-1991.

XX PR 21-DEC-1989; 89US-00454161.
 PR 21-DEC-1989; 89US-00454161.
 PR 12-JUN-1990; 90US-00531789.

XX PA (TANOC) TANOX BIOSYSTEMS IN.

XX PI Chang TW, Fung MSC, Sun CRY, Sun BNC, Chang NT;

XX DR WPI; 1991-222664/30.

XX PT Monoclonal antibodies specific to the gp120 HIV envelope protein - for
 PT immunisation against HIV in treatment of AIDS or ARC.

XX PS Claim 5; Page 97; 124pp; English.

XX CC The peptide corresponds to residues 294-318 of the gp120 envelope protein
 CC of HIV-1 which is a principal neutralising determinant (PND). Abs
 CC recognise residues 294-308 (Mab BAT267) or 304-318 (Mab 123). These Mab
 CC are used to raise anti-idiotypic Abs (AAbs). The AAbs are useful for
 CC passive immunisation and as components for immunotoxins which destroy T-
 CC cells infected with HIV. They inhibit T-cell infection and syncytium
 CC formation, are group specific and neutralise specific strains of HIV-1.
 CC They can be used to treat AIDS or ARC. The AAbs can be used for active
 CC immunisation or can be admin with another vaccine to increase
 CC antigenicity. See also AAR13121. (Updated on 24-OCT-2003 to standardise
 CC OS field)

XX SO Sequence 25 AA;

QY Query Match 100.0%; Score 39; DB 2; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.22;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 1 RAFVTIGK 8
 18 RAFVTIGK 25

RESULT 142

AA15058
ID AAR15058 standard; protein; 25 AA.
XX
XX
AC AAR15058;
XX
XX
DT 03-JAN-1992 (first entry)
XX
XX
DE HIV-1 amplifier peptide #21.
XX
XX
KW human immunodeficiency virus; vaccine; human retrovirus; AIDS;
KW acquired immunodeficiency syndrome; envelope glycoprotein.
XX
OS Synthetic.
XX
XX MO9114449-A.
XX
XX 03-OCT-1991.
XX
XX 19-MAR-1990; 90US-00494749.
XX
XX 19-MAR-1990; 90US-00494749.
XX
XX (INSP) INST PASTEUR.
XX
XX Girard M;
XX
XX WPI; 1991-310366/42.
XX
XX Enhancing immunogenicity of envelope glycoprotein - for use as vaccine
XX or immunotherapeutic drug especially against HIV, HTLV-I and HTLV-II.
XX
XX Claim 13; Page 50; 71pp; English.
XX
XX This peptide is one example of an HIV-1 amplifier peptide for use in a
XX composition for enhancing the immunogenicity of an envelope glycoprotein
XX of a virus. The sequence corresponds to the major neutralisation epitope
XX (loop V3) of HIV-1 Bruhl isolate and enhances the induction of
XX persistent neutralising antibodies in the host. The amplifier peptide is
XX used in addition to an envelope glycoprotein for priming the induction of
XX neutralising antibodies. The compositions are particularly useful for
XX vaccinating against HIV, SIV, HTLV-I and HTLV-II
XX
SQ Sequence 25 AA;
Query Match 100.0%; Score 39; DB 2; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.22;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RAFTVIGK 8
Db 15 RAFTVIGK 22
RESULT 143
AAR31276
ID AAR31276 standard; peptide; 25 AA.
XX
XX AAR31276;
XX
XX 12-FEB-1993 (first entry)
XX
XX HIV principal determinant peptide.
XX
XX AIDS; ARC; human immunodeficiency virus; vaccine; Neisseria;
KW meningitidis b; outer membrane protein complex; OMPC; PND135.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX Modified-site 1 /note="bonds to the OMPC of the conjugate via this site"
XX
XX EP467700-A.
XX
XX

XX
XX 22-JAN-1992.
XX
XX 19-JUL-1991; 91EP-00306598.
XX
XX 19-JUL-1990; 90US-00555339.
XX
XX 19-JUL-1990; 90US-00555366.
XX
XX 19-JUN-1991; 91US-00715276.
XX
XX 19-JUN-1991; 91US-00715278.
XX
XX (MERI) MERCK & CO INC.
XX
XX Leanza WJ, Marburg S, Tolman RL, Emimi EA;
XX WPI; 1992-026505/04.
XX
XX Conjugate proteins comprising HIV peptide components - useful for
XX preparing vaccines for e.g. AIDS or for treating infections.
XX
XX Claim 12; Page 56; 63pp; English.
XX
XX The invention relates to a co-conjugate comprising an immunogenic protein
XX or protein complex having a first set of covalent linkages to low
XX molecular weight moieties which have an anionic or polyanionic character
XX at physiological pH, and a second set of covalent linkages to peptides
XX comprising HIV principal neutralizing determinants (PND's) or
XX immunologically equivalent peptides. Preferably at least one set of the
XX covalent linkages is comprised of maleimide derivatives; the
XX (poly)anionic moiety is composed of one to five residues of the anionic
XX form of a carboxylic, sulphonic or phosphonic acid; the immunogenic
XX protein is the outer membrane protein complex (OMPC) of Neisseria
XX meningitidis b; and the PND peptide has a linear structure, a disulphide-
XX bonded cyclic structure, an amide-bonded cyclic structure or a thioether-
XX bonded cyclic structure. The present sequence (PND135) is an example of a
XX PND peptide component used in the co-conjugate. The co-conjugate is
XX useful for inducing anti-peptide immune response in mammals, for inducing
XX HIV-neutralizing antibodies in mammals, for formulating vaccines to
XX prevent HIV infection or disease, including AIDS, or for treating humans
XX afflicted with HIV infection or disease
XX
SQ Sequence 25 AA;
Query Match 100.0%; Score 39; DB 2; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.22;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RAFTVIGK 8
Db 15 RAFTVIGK 22
RESULT 144
AAR30031
ID AAR30031 standard; peptide; 25 AA.
XX
XX AAR30031;
XX
XX 25-MAR-2003 (revised)
XX
XX 28-APR-1993 (first entry)
XX
XX HIV principle neutralising determinant 135.
XX
XX Human immunodeficiency virus; AIDS; PND; MTEP; conjugate;
KW major immune enhancing protein; vaccine; anti-HIV antibodies; immunogen;
KW passive immunisation.
XX
XX Human immunodeficiency virus.
XX
XX EP519554-A1.
XX
XX 23-DEC-1992.
XX
XX 11-JUN-1992; 92EP-00201693.
XX
XX

XX 19-JUN-1991; 91US-00715273.
XX (MERI) MERCK & CO INC.
XX Emini A, Liu MA, Marburg S, Tolman RL;
XX WPI, 1992-425771/52.
XX Conjugates of HIV-1 PND peptide(s) with the M1EP of Neisseria
PT meningitidis - useful as a vaccine for treating and preventing HIV-1
PT infection, e.g. AIDS in humans.
XX
PS Claim 9; Page 59; 66pp; English.
XX The peptide is HIV principle neutralising determinant (PND) 135 and is
CC used as part of a conjugate comprising the major immune enhancing protein
CC (M1EP) of Neisseria meningitidis covalently linked to the HIV PND. The
CC conjugate may be used to prepare vaccines against HIV infections, e.g.
CC AIDS, as research tools for studying PND structure- function
CC relationships, or as immunogens for use in the passive immunisation of
CC humans. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 25 AA;
QY Query Match 100.0%; Score 39; DB 2; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.22; Mismatches 0; Gaps 0;
Matches 8; Conservative 0; Indels 0; Gaps 0;
DB 1 RAFVTTGK 8
15 RAFVTTGK 22
RESULT 145
ID AAR26712 standard; peptide; 25 AA.
AC AAR26712;
DT 09-FEB-1993 (first entry)
DE HIV-PND-polysaccharide-protein conjugate vaccine.
XX
KW Human immunodeficiency virus; principal neutralizing determinant;
XX outer membrane protein complex; OMP; Neisseria; AIDS; PND135.
OS Synthetic.
FH Key Location/Qualifiers
FT Modified-site 1..1
FT /note= "Joins onto polysaccharide-protein complex via
this site"
PN EP468714-A.
XX
PD 29-JAN-1992.
XX
PF 19-JUL-1990; 90US-00555558.
XX
PR 19-JUL-1990; 90US-00555558.
PR 19-JUN-1990; 90US-00555974.
PR 19-JUN-1991; 91US-00715275.
XX 19-JUN-1991; 91US-00715277.
PA (MERI) MERCK & CO INC.
XX
PI Marburg S, Tolman RL, Emini EA;
XX
DR WPI, 1992-034437/05.
XX
PT HIV peptide-polysaccharide-protein conjugates - used in vaccines or to
produce antibodies to prevent or treat HIV infection.

XX Claim 9; Page 57; 63pp; English.
PS
XX The invention relates to a conjugate of an HIV principal neutralizing
CC determinant (PND), or an immunologically equivalent peptide (PEP),
CC covalently coupled to an immunogenic protein or protein complex through
CC an anionic polysaccharide linker. Pref. the immunogenic protein is the
CC outer membrane protein complex (OMP) of Neisseria meningitidis b and the
CC PND peptide has a linear structure, a disulphide-bonded cyclic structure,
CC an amide-bonded cyclic structure or a thioether-bonded cyclic structure.
CC The present sequence (PND135) is an example of a PND peptide component.
CC The conjugates are used for inducing HIV-neutralising antibodies or for
CC making vaccines to prevent contraction of HIV infection or disease. The
CC antibodies can be used for passively protecting against infection by HIV,
CC or for protecting against proliferation of HIV post-infection, or for
CC treating AIDS, or in diagnostic assays
XX
SQ Sequence 25 AA;
QY Query Match 100.0%; Score 39; DB 2; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.22; Mismatches 0; Gaps 0;
Matches 8; Conservative 0; Indels 0; Gaps 0;
DB 1 RAFVTTGK 8
15 RAFVTTGK 22
RESULT 146
ID AAR33222 standard; peptide; 25 AA.
AC AAR33222;
DT 25-MAR-2003 (revised)
DT 13-JUL-1993 (first entry)
XX
DE HIV gp120 V3 loop immunogenic peptide RP135 (IIIB).
XX
KW HIV-1; human immunodeficiency virus; antibody generation; AIDS;
XX infection; CD4 binding site; soluble CD4.
OS Synthetic.
FH Key Location/Qualifiers
FT Region 25
FT /note= "not in natural sequence of isolate"
PN WO9304693-A1.
XX
PD 18-MAR-1993.
XX
PF 02-SEP-1992; 92WO-US007511.
XX
PR 09-SEP-1991; 91US-00756677.
PR 20-JUL-1992; 92US-00916542.
PA (REPK) REPLIGEN CORP.
XX
PI Potts BJ, Whiteschaf ME, Field KG, Herlihy WC;
XX
DR WPI, 1993-100653/12.
XX
PT Synergistic compsn. for treating HIV-1 infection - comprises antibody to
PT V3 loop of gp120 and antibody to CD4 binding site of gp120 or soluble CD4
PT polypeptide.
XX
PS Example; Page 12; 56pp; English.
XX
CC The sequence is that of peptide RP135 (IIIB) used as an immunogen for the
CC generation of antibodies directed against the V3 loop of HIV gp120. These
CC antibodies can be used as part of a compsn. with antibodies directed
CC against the CD4 binding site of gp120. The antibodies act synergistically

CC to neutralise HIV-1 in the treatment of HIV infection caused by different
 CC strains. (Updated on 25-MAR-2003 to correct PN field.) (Updated on 25-MAR-
 CC -2003 to correct PI field.)
 XX

SQ Sequence 25 AA;

Query Match 100.0%; Score 39; DB 2; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.22;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
 |||||
 DB 15 RAFTVIGK 22

RESULT 147

AA41336
 ID AAR41336 standard; peptide; 25 AA.

AA41336;

DT 24-OCT-2003 (revised)
 DT 25-MAR-2003 (revised)
 DT 22-APR-1994 (first entry)

DE HIV gp120 V3 region peptide HIV-III B.

KW V3 region; HIV; envelope gp120; vaccine; human; humoral response;
 KW cellular immunity; carrier protein; human serum albumin; HSA;
 KW keyhole limpet haemocyanin; KHL; multiple antigen peptide.

OS Human immunodeficiency virus 1.

XX WO9318791-A1.

XX 30-SEP-1993.

PF 19-MAR-1993; 93WO-JP000327.

PR 26-MAR-1992; 92JP-00098602.

PR 14-AUG-1992; 92JP-00237648.

PR 15-MAR-1993; 93JP-00054239.

PA (TSDT-) TSD KK.

PI Okuda K;

DR WPI; 1993-320455/40.

PT Virus for prevention of HIV infected diseases - comprising several
 PT peptide(s) consisting of V3 region peptide of envelope Gr., 120, etc. and
 PT complex including carrier protein.
 XX
 PS Disclosure; Page 3; 35pp; Japanese.

CC The sequences given in AAR41336-39 and AAR42664 represent peptides
 CC derived from the V3 region of HIV envelope gp120. These peptides may be
 CC used in a vaccine which is effective in humans and animals and activates
 CC humoral and cellular immunity. The vaccine also contains a carrier
 CC protein containing a cysteine group, eg. human serum albumin (HSA),
 CC keyhole limpet haemocyanin (KHL) or multiple antigen peptide. (Updated on
 CC 25-MAR-2003 to correct PN field.) (Updated on 24-OCT-2003 to standardise
 CC OS field)

SQ Sequence 25 AA;

Query Match 100.0%; Score 39; DB 2; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.22;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
 |||||
 DB 15 RAFTVIGK 22

RESULT 148

AA41330
 ID AAR41330 standard; peptide; 25 AA.

AA41330;

DT 25-MAR-2003 (revised)
 DT 21-APR-1994 (first entry)

DE HIV gp120 epitope.

KW HIV; haemagglutinin; reactants; catalysts; cofactors; repressors;
 KW enhancers; hormones; binders; human immunodeficiency virus.

OS Human immunodeficiency virus.

PN WO9319170-A1.

PN 30-SEP-1993.

PF 09-MAR-1993; 93WO-US002349.

PR 16-MAR-1992; 92US-00852412.

PA (WOHL/) WOHLSTADTER J N.

PI Wohlstadter JN;

DR WPI; 1993-320737/40.

PT Obtaining a novel mol. - capable of a desired interaction with a
 PT substrate of interest and a selection molecule expressed by the host.
 XX
 PS Claim 15; Page 147; 165pp; English.

CC The HIV gp120 epitope is used to isolate, create or evolve novel mois.
 CC including (in)organic and biomolecules such as proteins, peptides,
 CC nucleic acids, oligonucleotides, lipids, and polysaccharides for use as
 CC reactants, catalysts, enzymatic cofactors, repressors, enhancers,
 CC hormones and binders for a wide variety of substrates in industrial and
 CC therapeutic products. This epitope was isolated from variable region 3 of
 CC HIV gp120 (amino acids 271-295). (Updated on 25-MAR-2003 to correct PN
 CC field.)

SQ Sequence 25 AA;

Query Match 100.0%; Score 39; DB 2; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.22;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
 |||||
 DB 15 RAFTVIGK 22

RESULT 149

AA36587
 ID AAR36587 standard; peptide; 25 AA.

AA36587;

DT 25-MAR-2003 (revised)
 DT 06-SEP-1993 (first entry)

DE Virus neutralising epitope of envelope glycoprotein of HIV.

KW Human immunodeficiency virus; gp120; gp160; EGR; VNE; immunity.

OS Synthetic.

PN WO9308836-A1.

```

XX PD 13-MAY-1993.
XX PF 28-OCT-1992; 92WO-EP002459.
XX PR 28-OCT-1991; 91US-00782154.
XX PR 28-OCT-1991; 91US-00782241.
XX PR 28-OCT-1991; 91US-00782252.
XX PA (INSP ) INST PASTEUR.
XX PI Girard M;
XX DR WPI; 1993-167398/20.
XX PT Enhancing immunogenicity of viral envelope glycoprotein - by co-
XX PT administration of viral envelope glycoprotein itself, and an oligopeptide
XX PT derivative.
XX PS Disclosure; Page 82; 107pp; English.
XX CC A novel method of enhancing the immunogenicity of an envelope
XX CC glycoprotein (EGP) of a virus (esp. HIV gp120 or gp160) in a host
XX CC comprises admin. to the host at least one EGP of the virus in an amt.
XX CC sufficient for priming vaccination and at least one peptide derived from
XX CC an amino acid sequence of the EGP (e.g. the sequence shown), where the
XX CC peptide comprises at least one virus-neutralisation epitope (VNE). The
XX CC complex is able to enhance the induction of neutralising antibodies to
XX CC the virus and to confer long lasting immunity, longer than 6 months. See
XX CC also AAR36567-86. (Updated on 25-MAR-2003 to correct PN field.)
XX SQ Sequence 25 AA;
XX
XX Query Match 100.0%; Score 39; DB 2; Length 25;
XX Best Local Similarity 100.0%; Pred. No. 0.22;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RAFTYTGK 8
DB 15 RAFTYTGK 22

```

RESULT 150
AAW72819
ID AAW72819 standard; peptide; 25 AA.
XX
AC AAW72819;
XX
DT 17-OCT-2003 (revised)
DT 13-JAN-1999 (first entry)
XX
DE HIV-1 gp120 epitope 294 to 318.
XX
KM HIV-1; gp120; epitope; monoclonal antibody; envelope; neutralise;
KM inhibits; infection; T-cell; inhibit syncytium formation; AIDS.
XX
OS Human immunodeficiency virus 1.
XX
FH Key Location/Qualifiers
FT Peptide 1..15
FT /label= peptide_a
FT 11..25
FT Peptide /label= peptide_b
XX
XX US5834599-A.
XX PN 10-NOV-1998.
XX
XX 04-MAR-1993; 93US-00026276.
XX PF
XX 29-MAY-1987; 87US-00057445.
XX PR 24-DEC-1987; 87US-00137861.
XX PR 25-APR-1989; 89US-00343540.

```

PR 05-JUN-1992; 92US-00895197.
XX  
XX (TANX-) TANOX BIOSYSTEMS INC.  
XX PA  
XX PI Sun BN, Fung SC, Kim YW, Sun CR, Chang NT, Chang T;  
XX DR WPI; 1999-008810/01.  
XX  
XX PT Antibody conjugate comprising monoclonal antibody - which binds to  
XX PT epitope within amino acid residue of gp120 which neutralises HIV-1  
XX PT conjugated with, e.g. cytotoxic agent.  
XX  
XX PS Disclosure; Col 8; 22pp; English.  
XX  
XX CC The present invention describes an antibody conjugate comprising an  
XX CC antibody (Ab) which binds to an epitope within amino acid residue 308-322  
XX CC of gp120 and neutralises HIV-1, conjugated with a cytotoxic agent, an  
XX CC anti-viral agent or an agent which facilitates passage through the blood  
XX CC brain barrier. Also described is an antibody conjugate as above but where  
XX CC the Ab binds to an epitope within amino acid residue 298-312 of gp120  
XX CC which neutralises HIV-1. The present sequence represents an HIV-1 gp120  
XX CC epitope corresponding to positions 294 to 318. The Ab are monoclonal Ab  
XX CC which bind to the gp120 protein on the envelope of HIV-1. They inhibit  
XX CC the infection of T-cells and also inhibit syncytium formation. The  
XX CC antibodies are group specific and neutralise different strains and  
XX CC isolates of HIV-1. The antibodies have a variety of uses, including the  
XX CC treatment and prevention of AIDS and AIDS related complex. They are  
XX CC especially used to kill infected T-cells. (Updated on 17-OCT-2003 to  
XX CC standardise OS field)  
XX SQ Sequence 25 AA;
XX
XX Query Match 100.0%; Score 39; DB 2; Length 25;
XX Best Local Similarity 100.0%; Pred. No. 0.22;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RAFTYTGK 8
DB 18 RAFTYTGK 25

```

RESULT 151
AAW87618
ID AAW87618 standard; peptide; 25 AA.
XX
AC AAW87618;
XX
DT 17-OCT-2003 (revised)
DT 20-MAR-2003 (revised)
DT 03-MAR-1999 (first entry)
XX
DE Epitope of HIV-1 gp120 protein.
XX
KM Epitope; gp120 protein; monoclonal antibody; HIV-1; antibody BAT123;
KM antibody BAT267; antibody BAT085; T cell infection inhibition;
KM syncytia formation; acquired immune deficiency syndrome; AIDS;
KM AIDS-related complex; passive immunisation; antiviral; cytotoxic;
KM viral load measurement; vaccine.
XX
XX Human immunodeficiency virus 1.
XX OS
XX PN US5854400-A.
XX PD 29-DEC-1998.
XX
XX 22-SEP-1992; 92US-00950571.
XX PF
XX 29-MAY-1987; 87US-00057445.
XX PR 24-DEC-1987; 87US-00137861.
XX PR 26-SEP-1991; 91US-00767533.
XX
XX (TANX-) TANOX INC.

PI Fung MSC, Sun BNC, Sun CRV, Chang NT, Chang TW;
 XX WPI: 1999-095002/08.
 XX
 PT Monoclonal antibodies directed against regions of gp120 of human immune
 PT deficiency virus-1 - are neutralising and able to inhibit infection of T
 PT cells and formation of syncytia, used for treatment, prevention or
 PT diagnosis of acquired immune deficiency syndrome.
 XX
 PS Claim 2; Col 8; 16pp; English.
 XX
 CC The present sequence represents an epitope of the gp120 protein of human
 CC immune deficiency virus (HIV)-1. The sequence comprises amino acids 298
 CC to 322 of gp120. The specification describes monoclonal antibodies which
 CC bind to sequences derived from the present epitope. Specifically, these
 CC antibodies are designated BMT23, 267 and 085. Monoclonal antibodies
 CC neutralise HIV-1, inhibiting both infection of T cells and formation of
 CC syncytia, so are used to treat acquired immune deficiency syndrome (AIDS)
 CC and AIDS-related complex, by passive immunisation, as carriers of
 CC cytotoxic or antiviral agents, and in extracorporeal systems. They can
 CC also be used as immunoassay reagents (for diagnosis or measurement of
 CC viral load) and to screen for neutralising epitopes, potentially useful
 CC in vaccine development. (Updated on 20-MAR-2003 to correct PR field.)
 CC (Updated on 17-OCT-2003 to standardise OS field)
 CC
 SQ Sequence 25 AA;
 QY
 Db 1 RAFVTICK 8
 18 RAFVTICK 25
 Query Match 100.0%; Score 39; DB 2; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.22;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 RESULT 152
 AAE09522
 ID AAE09522 standard; peptide; 25 AA.
 AC
 AC AAE09522;
 XX
 DT 19-NOV-2001 (first entry)
 XX
 DE Human immunodeficiency virus Dd haplotype peptide.
 XX
 KM Mucin; cytostatic; immunostimulant; cell mediated immune response;
 KM carcinoma; adenocarcinoma; breast cancer; dendritic cell; vaccine;
 KM gene therapy; CTL; cytotoxic T-lymphocyte.
 XX
 OS Human immunodeficiency virus.
 XX
 PN WO200157068-A1.
 XX
 PD 09-AUG-2001.
 XX
 PE 01-FEB-2001; 2001WO-AU000090.
 XX
 PR 01-FEB-2000; 2000AU-00005369.
 PR 14-JUN-2000; 2000US-00593870.
 XX
 PA (AUST-) AUSTIN RES INST.
 PA
 PI McKenzie IFC, Pieterse GA, Apostolopoulos V;
 XX
 DR WPI: 2001-541537/60.
 XX
 PT Immunostimulant peptide, used as an anti-carcinoma vaccine, comprises a
 PT an epitope of the non-VNTR, non-leader region of a mucin.
 XX
 PS Disclosure; Page 19; 84pp; English.
 XX
 CC The patent discloses peptide or polypeptides capable of eliciting an

CC immune response, comprising an amino acid sequence corresponding to an
 CC epitope of the non-central portion of varying numbers of an amino acid
 CC motif (VNTR), non-leader region of a mucin. The peptides of the
 CC invention, fusion proteins comprising the peptide and conjugate compounds
 CC with carbohydrate polymers are used to induce a cell mediated immune
 CC response against mucin in the prevention or treatment of carcinoma,
 CC preferably adenocarcinoma, most preferably breast cancer. They are also
 CC used to pulse dendritic cell for in vivo transfer and use as a vaccine.
 CC They are also used in gene therapy. The present sequence is a human
 CC immunodeficiency virus (HIV) haplotype kd peptide used as a negative
 CC control for the prediction of CTL (cytotoxic T- lymphocyte) epitopes
 CC
 SQ Sequence 25 AA;
 QY
 Db 1 RAFVTICK 8
 12 RAFVTICK 19
 Query Match 100.0%; Score 39; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.22;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 RESULT 153
 ADQ10566
 ID ADQ10566 standard; peptide; 9 AA.
 AC
 AC ADQ10566;
 XX
 DT 23-SEP-2004 (first entry)
 XX
 DE Human immunodeficiency virus T-cell epitope seqid 131.
 XX
 KM immunostimulant; cytostatic; vaccine; tumour-associated antigen SSX-2;
 KM SSX-2 antigen; epitope cluster; MHC receptor peptide binding cleft;
 KM immunogenic composition; immune response; cancer; vaccine vector;
 KM epitope liberation; human leukocyte antigen; HLA A2-specific CTL;
 KM cytotoxic T lymphocyte; T-cell epitope.
 XX
 OS Human immunodeficiency virus.
 XX
 PN US2004132088-A1.
 XX
 PD 08-JUL-2004.
 XX
 PE 10-FEB-2004; 2004US-00777053.
 XX
 PR 07-NOV-2001; 2001US-0336968P.
 PR 07-NOV-2002; 2002US-00292413.
 XX
 PA (SIMA/) SIMARD J J L.
 PA (DIAM/) DIAMOND D C.
 PA (QIUZ/) QIU Z.
 PA (LEIX/) LEI X.
 XX
 PI Simard JTL, Diamond DC, Qiu Z, Lei X;
 XX
 DR WPI: 2004-517003/49.
 XX
 PT Novel nucleic acid encoding tumor-associated antigen SSX-2, useful in
 PT inducing an immune response and in treating cancer.
 XX
 PS Disclosure; SEQ ID NO 131; 260pp; English.
 XX
 CC The invention describes an isolated nucleic acid (I) comprising a reading
 CC frame comprising a first sequence, where the first sequence encodes one
 CC or more segments of tumour-associated antigen SSX-2, which comprises a
 CC sequence of 188 amino acids (SEQ ID NO: 40), where the first sequence
 CC does not encode the complete SSX-2 antigen, and where each segment
 CC comprises an epitope cluster, the cluster comprising or encoding at least
 CC two amino acid sequences having a known or predicted affinity for a same
 CC MHC receptor binding cleft. Also described are: an isolated
 CC polypeptide comprising the amino acid sequence encoded in the reading

CC frame; and an immunogenic composition comprising (I) or the polypeptide
 CC of (1). (I) is a nucleic acid encoding a tumour-associated antigen SSX-2
 CC comprising a fully defined sequence of 188 amino acids (SEQ ID NO: 40).
 CC The nucleic acid, the encoded antigen, and composition are useful in
 CC inducing an immune response and in treating cancer. Expression cassettes
 CC are used in vaccine vectors. This is the amino acid sequence of a T-cell
 CC epitope MHC ligand associated with methods, therapies and compositions
 CC described in the invention.

XX Sequence 9 AA:

Query Match 94.9%; Score 37; DB 8; Length 9;
 Best Local Similarity 87.5%; Pred. No. 1.8e+06;
 Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTTICK 8
 |||||:
 Db 2 RAFTTICK 9

RESULT 154
 AAR04427

ID AAR04427 standard; peptide; 25 AA.

XX AAR04427;

XX 09-SEP-2004 (revised)
 DT 25-MAR-2003 (revised)
 DT 20-SEP-1990 (first entry)

XX Human immunodeficiency virus peptide 135.

XX HIV-IIIB; peptide 135; principal neutralising domain; antibodies;
 KM diagnosis; prophylaxis; therapy; AIDS.

XX Synthetic.

XX WO9003984-A.

XX 19-APR-1990.

XX 03-OCT-1988; 88US-00252949.

XX 03-OCT-1988; 88US-00252949.

XX 01-JUN-1989; 89US-00359543.

XX 19-SEP-1989; 89US-00407663.

XX (REPK) REPLIGEN CORP.

XX Rusche JR, Putney SD, Javaherian K, Farley J, Grimalia R;
 PI Lynn DU, Petrobre J;

XX WPI; 1990-147824/19.

XX Principal neutralising domain of HIV variants - used for producing
 PT peptide(s) and antibodies for diagnosis, prophylaxis and/or therapy
 PT therapy of HIV infection.

XX Claim 8 (30); Page 75; 108pp; English.

XX Peptide 135 comprises segments of the Principal Neutralising Domain
 CC (envelope protein) from isolate HIV-IIIB. The last Cys residue is added
 CC for the purpose of crosslinking to carrier proteins. Cysteine residues
 CC can be added so that that residues at or near both ends form a disulfide
 CC bond, thus giving the peptide a loop-like configuration, which is
 CC utilised to enhance the immunogenic properties of the peptide. The
 CC peptide is capable of eliciting, and/or binding with, neutralising
 CC antibodies. The neutralising domain is bounded by cysteine residues which
 CC occur at positions 296 and 331. Peptides can be used as immunogens or
 CC AAR04427-R04506 and AAR044273-004279. (Updated on 25-MAR-2003 to correct
 CC PR field.) (Updated on 25-MAR-2003 to correct PA field.) (Updated on 25-
 CC MAR-2003 to correct PI field.)

CC Revised record issued on 09-SEP-2004 : Correction to Feature Table Key
 CC XX Sequence 25 AA:

QY 1 RAFTTICK 8
 |||||:
 Db 15 RAFTTICK 22

RESULT 155
 AAR66430

ID AAR66430 standard; peptide; 15 AA.
 XX AAR66430;

XX 25-MAR-2003 (revised)

DT 03-AUG-1995 (first entry)

XX HIV-1 IIIB peptide 18-15.

XX T cell helper site; cytotoxic T cell response; neutralising antibody;
 KM human immunodeficiency virus type 1; envelope glycoprotein gp120;
 KM cluster peptide; principal neutralising determinant.

XX Synthetic.

XX WO9426785-A1.

XX 24-NOV-1994.

XX 13-MAY-1994; 94WO-US005142.

XX 14-MAY-1993; 93US-00060988.

XX (USSS) US SEC DEPT HEALTH.

XX Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shlirai M;

XX WPI; 1995-006707/01.

XX Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
 PT responses - to target antigen in hosts of different MHC haplotypes, esp.
 PT for therapeutic or prophylactic vaccines against HIV.

XX Example 1; Page 33; 120pp; English.

XX Single residues from the HIV-1 RP sequence (AAR66415) replaced residues
 CC in the HIV-1 IIIB sequence (AAR66414) to test the effect of each residue
 CC on the binding of neutralising and non-neutralising sera from animals
 CC immunised with the cluster peptides PCUS 3-18 and PCUS 6-18 (see
 CC AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
 CC R66430) showed that binding was enhanced over peptide 18 control when a
 CC tyrosine was substid. for a Val at position 11 and substitu. at positions
 CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
 CC sera was reduced when substitu. were made in the principal neutralising
 CC determinant sequence (PGRAF). In peptide 18-15, the Lys residue at
 CC position 15 in peptide 18 has been replaced by a Gln residue. (Updated on
 CC 25-MAR-2003 to correct PN field.)

XX Sequence 15 AA:

Query Match 89.7%; Score 35; DB 2; Length 15;
 Best Local Similarity 87.5%; Pred. No. 1;
 Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTTICK 8
 |||||:
 Db 8 RAFTTICK 15

```

RESULT 156
AAR66424 ID AAR66424 standard; peptide; 15 AA.
XX
AC AAR66424;
XX
DT 25-MAR-2003 (revised)
DT 03-AUG-1995 (first entry)
XX
DE HIV-1 IIB peptide 18-9.
XX
KW T cell helper site; cytotoxic T cell response; neutralising antibody;
KW human immunodeficiency virus type 1; envelope glycoprotein gp120;
KW cluster peptide; principal neutralising determinant.
XX
OS Synthetic.
XX
PN WO9426785-A1.
XX
PD 24-NOV-1994.
XX
PF 13-MAY-1994; 94WO-US005142.
XX
PR 14-MAY-1993; 93US-00060988.
XX
PA (USSH ) US SEC DEPT HEALTH.
XX
PI Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
XX
DR WPI; 1995-006707/01.
XX
PT Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
PT responses - to target antigen in hosts of different MHC haplotypes, esp.
XX
PT for therapeutic or prophylactic vaccines against HIV.
XX
PS Example 1; Page 33; 120pp; English.
XX
CC Single residues from the HIV-1 RF sequence (AAR66415) replaced residues
CC in the HIV-1 IIB sequence (AAR66414) to test the effect of each residue
CC on the binding of neutralising and non-neutralising sera from animals
CC immunised with the cluster peptides PCTUS 3-18 and PCTUS 6-18 (see
CC AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
CC R66430) showed that binding was enhanced over peptide 18 control when a
CC tyrosine was substid. for a Val at position 11 and substns. at positions
CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
CC sera was reduced when substns. were made in the principal neutralising
CC determinant sequence (PGRAP). In peptide 18-9, the Ala residue at
CC position 9 in peptide 18 has been replaced by a Val residue. (Updated on
CC 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 15 AA;
XX
Query Match 89.7%; Score 35; DB 2; Length 15;
Best Local Similarity 87.5%; Pred. No. 1;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 RAFTVIGK 8
Db 8 RVTFTIGK 15
XX
RESULT 157
AAW2329 ID AAW2329 standard; peptide; 19 AA.
XX
AC AAW2329;
XX
DT 17-OCT-2003 (revised)
DT 18-SEP-1997 (first entry)
XX
DE HIV-1 clinical strain 9622 gp120 V3 loop peptide.
XX

```

```

XX
KW Epitope; human immunodeficiency virus type 1; HIV-1; gp120; gp160;
KW monoclonal antibody; V3 loop; immunisation; mouse; splenocyte; hybridoma;
KW membrane fraction; passive immunisation; human.
XX
OS Human immunodeficiency virus 1.
XX
PN US5618922-A.
XX
PD 08-APR-1997.
XX
PF 25-JUL-1994; 94US-00279906.
XX
PR 25-JUL-1994; 94US-00279906.
XX
PA (NISP ) NISSIN SHOKUHIN KAISHA LTD.
XX
PI Yoneda Y, Ohno T, Terada M;
XX
DR WPI; 1997-225475/20.
XX
PT Monoclonal antibody specific for human immunodeficiency virus type 1 MN
PT strain - for passive immunisation against infection.
XX
PS Example 3; Col 10; 14pp; English.
XX
CC The invention relates to a novel monoclonal antibody (Mab) NM03 which
CC binds to epitopes from the human immunodeficiency virus type 1 (HIV-1).
CC The antibody was raised conventionally by immunising Balb/c mice with
CC purified live HIV-1 MN, then isolating splenocytes and fusing them to P3-
CC X63-Ag8-UI cells. Hybridomas were then screened with membrane fractions
CC from infected and non-infected H9 cells. The Mab was observed to bind to
CC a protein band of 120 kD on a Western blot of separated, denatured HIV-1
CC proteins. This binding was shown to be between residues 320-327 by
CC epitope mapping by ELISA and competitive binding. The ability of the Mab
CC to inhibit infection of cells by HIV-1 shown by infecting H9 cells with
CC live strains of HIV-1 and testing infection by a p24 assay. This peptide
CC sequence represents the V3 loop region from HIV-1 clinical strain 9622,
CC where the Mab NM03 binds. The Mab can be used for the passive
CC immunisation of humans susceptible to, or infected with HIV-1. (Updated
CC on 17-OCT-2003 to standardise OS field)
XX
SQ Sequence 19 AA;
XX
Query Match 89.7%; Score 35; DB 2; Length 19;
Best Local Similarity 87.5%; Pred. No. 1.3;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 RAFTVIGK 8
Db 6 RVTFTIGK 13
XX
RESULT 158
AAW62892 ID AAW62892 standard; peptide; 19 AA.
XX
AC AAW62892;
XX
DT 30-SEP-1998 (first entry)
XX
DE Peptide sequence of the specification.
XX
KW Monoclonal antibody; HIV-1gp120; gp160; infection; H9 cell;
KW HIV strain MN; treatment; human HIV infection.
XX
OS Synthetic.
XX
PN JP10182489-A.
XX
PD 07-JUL-1998.
XX
PF 25-DEC-1996; 96JP-00344904.
XX

```

XX 25-DEC-1996; 96JP-0034904.
 XX (NISP) NISSIN SHOKUHIN KAISHA LTD.
 XX WPI; 1998-433774/37.
 XX Monoclonal antibody which binds to HIV-1gp120 or gp160 - used to prevent
 PT and treat human HIV infection.
 XX Example 3; Page 8; 12pp; Japanese.
 XX AAW62889-900 represent peptides used to identify a peptide sequence
 CC (AAW62874) present in HIV-1gp120 or gp160 which is bound by the
 CC monoclonal antibody of the invention. The antibody neutralises in vitro
 CC the infection of H9 cell by an active HIV strain MN according to the p24
 CC analytical method. The antibody is used for treatment of human HIV
 CC infection
 XX Sequence 19 AA;
 SQ
 Query Match 89.7%; Score 35; DB 2; Length 19;
 Best Local Similarity 87.5%; Pred. No. 1.3;
 Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 RAFTYICK 8
 Db 6 RTFTYICK 13
 RESULT 159
 ABB05775
 ID ABB05775 standard; peptide; 20 AA.
 AC ABB05775;
 XX 29-AUG-2003 (revised)
 DT 07-MAY-2002 (first entry)
 XX HIV gp120 related peptide SEQ ID NO:1.
 DE Polyfunctional base sequence; microgene; industrial; cell culture;
 XX artificial matrix protein; transgenic animal; HIV.
 KM Human immunodeficiency virus 1.
 OS WO200196558-A1.
 PN 20-DEC-2001.
 PD 15-JUN-2001; 2001WO-JP005116.
 PF 16-JUN-2000; 2000JP-00180997.
 XX (NISC-) JAPAN SCI & TECHNOLOGY CORP.
 PA Shiba K;
 XX WPI; 2002-098069/13.
 DR Polyfunctional base sequence having two or more functions in different
 XX reading frames, useful for producing artificial matrix proteins for cell
 PT culture.
 PT Example 1; Page 46; 61pp; Japanese.
 XX The present invention describes a polyfunctional base sequence (NI)
 CC having two or more functions in different reading frames. Also described
 CC are: (1) a method for producing NI and artificial gene expression vectors
 CC comprising NI; (2) transgenic non-human animals comprising NI; and (3)
 CC treatments and diagnostic reagents containing an artificial protein,
 CC artificial tissues or high molecular weight artificial proteins. NI is
 CC useful for creating industrially useful artificial matrix proteins for

CC cell culture. The present sequence represents a peptide which is used in
 CC an example from the present invention. (Updated on 29-AUG-2003 to
 CC standardise OS field)
 XX Sequence 20 AA;
 SQ
 Query Match 89.7%; Score 35; DB 5; Length 20;
 Best Local Similarity 87.5%; Pred. No. 1.4;
 Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 RAFTYICK 8
 Db 12 RTFTYICK 19
 RESULT 160
 AAO15657
 ID AAO15657 standard; peptide; 20 AA.
 AC AAO15657;
 XX 08-NOV-2002 (first entry)
 DT Strong immune response induction-related peptide 1.
 XX Strong immune response induction-related peptide 1.
 DE Strong immune response induction, high-order protein structure formation;
 XX antigen presentation; HIV.
 KM Undifferentiated.
 XX WO200233074-A1.
 PN 25-APR-2002.
 PD 10-OCT-2001; 2001WO-JP008893.
 PF 13-OCT-2000; 2000JP-00314288.
 XX (NISC-) JAPAN SCI & TECHNOLOGY CORP.
 PA Shiba K, Ohno T;
 XX WPI; 2002-519151/55.
 DR Artificial protein capable of inducing a strong immune response to a
 PT peptide group for assisting antibody production in vivo to viruses and
 PT other antigens.
 XX Claim 6; Page 5; 77pp; Japanese.
 PS The invention comprises an artificial protein which induces a strong
 CC immune response to a peptide group (the protein contains all or part of
 CC the peptide group). The artificial protein assists the formation of high-
 CC order protein structure and/or assists the antigen presentation of
 CC immunocompetent cells. The artificial protein of the invention is useful
 CC for inducing a strong immune response and the preparation of effective
 CC antibodies to specific antigens, especially HIV. The present amino acid
 CC sequence represents a peptide that was used in the invention
 XX Sequence 20 AA;
 SQ
 Query Match 89.7%; Score 35; DB 5; Length 20;
 Best Local Similarity 87.5%; Pred. No. 1.4;
 Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 RAFTYICK 8
 Db 12 RTFTYICK 19
 RESULT 161
 AAR62151
 ID AAR62151 standard; peptide; 8 AA.

```

XX AC AAR62151;
XX XX
DT 27-AUG-2003 (revised)
DT 25-MAR-2003 (revised)
DT 02-MAY-1995 (first entry)
XX XX
DE HIV-1 gp120/41 protein motif similar to UI snRNP 70K protein.
XX XX
KW Small ribonucleoprotein complex; UI snRNP; 70K protein; epitope;
KW autoantibody; immunoinfective cluster virus; nuclear protein antigen;
KW systemic rheumatic disorder; human immunodeficiency virus; HIV-1;
KW systemic lupus erythematosus; mixed connective tissue disease;
KW scleroderma; glycoprotein 120; glycoprotein 41.
XX XX
OS Human immunodeficiency virus 1.
XX XX
PN WO9420141-A1.
XX XX
PD 15-SEP-1994.
XX XX
PF 10-MAR-1994; 94WO-US002631.
XX XX
PR 11-MAR-1993; 93US-00029850.
XX XX
PA (UYSC-) UNIV SOUTHERN CALIFORNIA.
XX XX
PI Douvas A, Takehana Y, Ehresmann G;
XX XX
DR WPI; 1994-302689/37.
XX XX
PT Methods for treating immunoinfective cluster virus infections - utilise
PT antibodies or fragments characteristic of auto antibodies produced by
PT patients with rheumatic disorders.
XX XX
PS Disclosure; Page 56; 106pp; English.
XX XX
CC The UI snRNP is the target of high-titre, high avidity autoantibodies
CC occurring in the systemic rheumatoid disorders of mixed connective tissue
CC disease, scleroderma and systemic lupus erythematosus. It has been found
CC that some sites in the UI snRNP 70K protein (see AAR62120-R62135) are
CC homologous to sites in HIV-1 gp120/41 (AAR62136-R62152) and that anti-RNP
CC autoantibodies can be used to neutralise HIV-1. (Updated on 25-MAR-2003
CC to correct PN field.) (Updated on 27-AUG-2003 to correct OS field.)
XX XX
SQ Sequence 8 AA;

Query Match      87.2%; Score 34; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFTTIG 7
   |||||
Db 2 RAFTTIG 8

RESULT 162
AAR62138
ID AAR62138 standard; peptide; 9 AA.
XX
AC AAR62138;
XX
DT 27-AUG-2003 (revised)
DT 25-MAR-2003 (revised)
DT 02-MAY-1995 (first entry)
XX
DE HIV-1 gp120/41 protein motif similar to UI snRNP 70K protein.
XX
KW Small ribonucleoprotein complex; UI snRNP; 70K protein; epitope;
KW autoantibody; immunoinfective cluster virus; nuclear protein antigen;
KW systemic rheumatic disorder; human immunodeficiency virus; HIV-1;
KW systemic lupus erythematosus; mixed connective tissue disease;
KW scleroderma; glycoprotein 120; glycoprotein 41.

```

```

XX OS Human immunodeficiency virus 1.
XX XX
XX PN WO9420141-A1.
XX XX
XX PD 15-SEP-1994.
XX XX
XX PF 10-MAR-1994; 94WO-US002631.
XX XX
XX PR 11-MAR-1993; 93US-00029850.
XX XX
XX PA (UYSC-) UNIV SOUTHERN CALIFORNIA.
XX XX
XX PI Douvas A, Takehana Y, Ehresmann G;
XX XX
XX DR WPI; 1994-302689/37.
XX XX
XX PT Methods for treating immunoinfective cluster virus infections - utilise
XX PT antibodies or fragments characteristic of auto antibodies produced by
XX PT patients with rheumatic disorders.
XX XX
XX PS Disclosure; Page 52; 106pp; English.
XX XX
CC The UI snRNP is the target of high-titre, high avidity autoantibodies
CC occurring in the systemic rheumatoid disorders of mixed connective tissue
CC disease, scleroderma and systemic lupus erythematosus. It has been found
CC that some sites in the UI snRNP 70K protein (see AAR62120-R62135) are
CC homologous to sites in HIV-1 gp120/41 (AAR62136-R62152) and that anti-RNP
CC autoantibodies can be used to neutralise HIV-1. (Updated on 25-MAR-2003
CC to correct PN field.) (Updated on 27-AUG-2003 to correct OS field.)
XX XX
SQ Sequence 9 AA;

Query Match      87.2%; Score 34; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFTTIG 7
   |||||
Db 3 RAFTTIG 9

RESULT 163
ADK68768
ID ADK68768 standard; peptide; 9 AA.
XX
AC ADK68768;
XX
DT 06-MAY-2004 (first entry)
XX
DE Epitope liberation-related peptide SeqID131.
XX
KW epitope liberation; substrate; proteasome; cytostatic; antibacterial;
KW protozoicide; fungicide; T-cell activator; vaccine; housekeeping epitope;
KW cytotoxic T lymphocyte; CTL; adoptive immunotherapy; neoplastic cell;
KW virus; bacterium; protozoan; fungus; housekeeping proteasome system.
XX
OS Human immunodeficiency virus.
XX
XX PN US2003228634-A1.
XX
XX PD 11-DEC-2003.
XX
XX PF 07-NOV-2002; 2002US-00292413.
XX
XX PR 07-NOV-2001; 2001US-0336968P.
XX
XX PA (SIMA/) STWARD J J L.
XX PA (DIAM/) DIAMOND D C.
XX PA (QIUZ/) QIU Z.
XX PA (LEIX/) LEI X.
XX
PI Simard JJJ, Diamond DC, Qiu Z, Lei X;

```


XX WPI; 2004-167209/16.
 DR Identifying polypeptide suitable for epitope e.g., housekeeping epitope,
 XX liberation by contacting substrate polypeptide comprising epitope of
 PT interest, with proteasome, and assaying for liberation of epitope.
 XX
 PS Disclosure; SEQ ID NO 131; 67pp; English.
 XX
 XX This invention relates to a novel method of identifying a polypeptide
 CC suitable for epitope liberation, including the steps of identifying an
 CC epitope of interest; providing substrate polypeptide sequence including
 CC the epitope, wherein the substrate permits processing by a proteasome;
 CC contacting the substrate with a composition including the proteasome,
 CC under conditions that support processing of the substrate by proteasome;
 CC and assaying for liberation of epitope. The invention may be useful for
 CC the development of compounds with a cytostatic, antibacterial,
 CC proto-oncologic or fungicidal activity acting as T-cell activators. In
 CC addition, the invention may allow development of a vaccine. The invention
 CC is useful for identifying a polypeptide suitable for epitope liberation,
 CC where the epitope is a housekeeping epitope. The compositions comprising
 CC the identified housekeeping epitopes are useful in vitro in vaccine
 CC development or in the generation or expansion of cytotoxic T lymphocyte
 CC (CTL) to be used in adoptive immunotherapy. The invention is also useful
 CC for activating T-cells against neoplastic cells, and cells infected with
 CC virus, bacterium, protozoan or fungus. CTL epitopes are identified based
 CC on the knowledge that such epitopes are, in fact, produced by the
 CC housekeeping proteasome system. Once identified, these epitopes, embodied
 CC as peptides, can be used to successfully immunise or induce therapeutic
 CC CTL responses against housekeeping proteasome expressing target cells in
 CC the host. The present sequence is that of a peptide which is related to
 CC the method of the invention.
 XX
 SQ Sequence 9 AA;

Query Match 87.2%; Score 34; DB 8; Length 9;
 Best Local Similarity 87.5%; Pred. No. 1.8e+06;
 Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RAFTYTGK 8
 |||||
 Db 2 RAFTYTGK 9

RESULT 164
 AAR62165 standard; peptide; 10 AA.

AC AAR62165;
 XX
 DT 27-AUG-2003 (revised)
 DT 25-MAR-2003 (revised)
 DT 03-MAY-1995 (first entry)

DE HIV-1 gp120 V3 loop neutralising domain.

XX epitope; autoantibody; immunoinfective cluster virus;
 KW nuclear protein antigen; systemic rheumatic disorder;
 KW human immunodeficiency virus; HIV-1; systemic lupus erythematosus;
 KW mixed connective tissue disease; scleroderma; glycoprotein 120.

OS Human immunodeficiency virus 1.

PN WO9420141-A1.

PD 15-SEP-1994.

PF 10-MAR-1994; 94WO-US002631.

XX 11-MAR-1993; 93US-00029850.

PA (UYSC-) UNIV SOUTHERN CALIFORNIA.

XX

PI Douvas A, Takehana Y, Ehremsmann G;

XX WPI; 1994-302689/37.

DR Methods for treating immunoinfective cluster virus infections - utilise
 XX antibodies or fragments characteristic of auto antibodies produced by
 PT patients with rheumatic disorders.
 XX

PS Disclosure; Page 62; 106pp; English.

XX Previous immunological analyses of the V3 loop of HIV-1 (AAR62159) have
 CC localised the main neutralising domains. The target of more than 80% of
 CC neutralising antibodies in HIV-1 infected sera from AIDS patients has now
 CC been found to overly the consensus binding sequence and domain A epitopes
 CC of the V3 gp120 protein. In AIDS, antibody titres are too low to
 CC arrest the disease; however, the homologous sequences in 70K are
 CC immunodominant targets of autoantibodies in the systemic rheumatoid
 CC disorder of mixed connective tissue disease. The titres of such
 CC autoantibodies exceed 10 power 7. The anti-gp120 autoantibodies will
 CC cross-react with HIV-1 epitopes and are useful for treating HIV
 CC infection. (Updated on 25-MAR-2003 to correct PN field.) (Updated on 27-
 CC AUG-2003 to correct OS field.)

SQ Sequence 10 AA;

Query Match 87.2%; Score 34; DB 2; Length 10;
 Best Local Similarity 100.0%; Pred. No. 1.1;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTYTG 7
 |||||
 Db 4 RAFTYTG 10

RESULT 165
 AAM54661

ID AAM54661 standard; peptide; 10 AA.

AC AAM54661;

DT 25-SEP-1998 (first entry)

DE Peptide from HIV-1 gp120 314-322.

XX Mannose; antigen; antigen-presenting cell; mannoseylated peptide; T cell;
 KW vaccine; treatment.

XX Synthetic.

PN WO9813378-A1.

PD 02-APR-1998.

PF 25-SEP-1997; 97WO-NL000536.

PR 26-SEP-1996; 96EP-00202701.

PA (UYLE-) RIJKSUNIV LEIDEN.

PI Koning F, Drijfhout JW;

DR WPI; 1998-230631/20.

XX Increasing uptake and presentation of antigen(s) - by adding mannose
 PT residue(s) to antigen for increasing T cell response, useful in, e.g.
 PT vaccines against viral infection(s).
 XX

PS Disclosure; Page 29; 47pp; English.

XX The peptides AAM5459-W54809 are examples of peptides to which at least 1
 CC (preferably 2) mannose can be attached to increase their uptake as
 CC antigens by antigen-presenting cells. Uptake of agonist mannoseylated
 CC peptides will increase the T cell response, whereas uptake of antagonist

CC peptides blocks the T cell response. Blocking binding of immunogenic
CC autoantigens can be used in treatment of type I diabetes, rheumatoid
CC arthritis, graft rejection etc., also to induce T-cell non-
CC responsiveness. Vaccines containing mannosylated antigen are used to
CC prevent or treat infections by, e.g. bacteria, viruses, fungi, helminths
CC and parasites
XX
SQ Sequence 10 AA;

Query Match 87.2%; Score 34; DB 2; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.1;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFTTIG 7
|||
Db 2 RAFTTIG 8

RESULT 166

AA62167
ID AA62167 standard; peptide; 11 AA.

AC AA62167;

DT 27-AUG-2003 (revised)

DT 25-MAR-2003 (revised)

DT 03-MAY-1995 (first entry)

DE HIV-1 gp120 V3 loop domain containing U1 snRNP 70K consensus epitope.

KW epitope; autoantibody; immunoinfective cluster virus;
KW nuclear protein antigen; systemic rheumatic disorder;
KW human immunodeficiency virus; HIV-1; systemic lupus erythematosus;
KW mixed connective tissue disease; scleroderma; glycoprotein 120;
KW U1 snRNP 70K protein.

XX Human immunodeficiency virus 1.

OS MO9420141-A1.

PN 15-SEP-1994.

PD 10-MAR-1994; 94WO-US002631.

PR 11-MAR-1993; 93US-00029850.

XX (VUSC-) UNIV SOUTHERN CALIFORNIA.

PI Douvas A, Takehana Y, Ehresmann G;

DR WPI; 1994-302689/37.

PT Methods for treating immunoinfective cluster virus infections - utilise
PT antibodies or fragments characteristic of auto antibodies produced by
PT patients with rheumatic disorders.

XX Disclosure; Page 62; 106pp; English.

CC Previous immunological analyses of the V3 loop of HIV-1 (AA62159) have
CC localised the main neutralising domain. The target of more than 80% of
CC neutralising antibodies in HIV-1 infected sera from AIDS patients has now
CC been found to overlap the consensus binding sequence and domain A epitopes
CC of the U1 snRNP 70K protein. In AIDS, antibody titres are too low to
CC arrest the disease; however, the homologous sequences in 70K are
CC immunodominant targets of autoantibodies in the systemic rheumatoid
CC disorder of mixed connective tissue disease. The titres of such
CC autoantibodies exceed 10 power 7. The anti-snRNP autoantibodies will
CC cross-react with HIV-1 epitopes and are useful for treating HIV
CC infection. (Updated on 25-MAR-2003 to correct PN field.) (Updated on 27-
CC AUG-2003 to correct OS field.)

XX Sequence 11 AA;

Query Match 87.2%; Score 34; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.3;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 167

AAW76852
ID AAW76852 standard; peptide; 11 AA.

AC AAW76852;

DT 25-JAN-1999 (first entry)

DE Fusion immunoglobulin heavy chain HIV gp120 B cell epitope #22.

KW B cell; T cell; epitope; immunoglobulin; heavy chain; gp120; IgH;
KW human immune deficiency virus; HIV; tolerance; treatment; therapy;
KW prophylaxis; vaccine; chemotherapy; immune response; modifier; tumour;
KW microbial infection; autoimmune disease; antibody; apoptosis;
KW antiviral T cell immunity.

XX Mus SP.

OS Homo Sapiens.

PN WO9836087-A1.

PD 20-AUG-1998.

PR 13-FEB-1998; 98WO-US002766.

PR 13-FEB-1997; 97US-0040581P.

XX (AMNA-) AMERICAN NAT RED CROSS.

PI Scott D, Zambidis E;

DR WPI; 1998-506315/43.

PT New fusion immunoglobulin heavy chain including gp120 epitopes and
PT related complete antibodies - DNA, vectors and transformed cells, used to
PT induce tolerance to the epitopes for treatment of human immune deficiency
PT virus infection.

PS Claim 10; Page 119; 154pp; English.

CC This sequence is an epitope used in the construction of a novel fusion
CC immunoglobulin heavy chain (IGH) protein with a mammalian, especially
CC human, IGH chain fused in frame at its N-terminus to one or more human
CC immune deficiency virus (HIV) gp120 epitopes. Fusion Ig proteins and/or
CC transfected cells are used to tolerate subjects to gp120 epitopes and to
CC maintain this tolerance, particularly for treatment of HIV infection,
CC optionally together with other therapeutic/prophylactic agents such as
CC vaccines, chemotherapeutic agents and immune response modifiers. Such
CC proteins can be used against other diseases where an immune response is
CC deleterious, e.g. microbial infection, tumours or autoimmune disease.
CC Induction of tolerance suppresses production of antibodies against gp120,
CC so prevents or inhibits 'bystander' apoptosis of uninfected T cells that
CC are bound to gp120 protein, maximising induction of protective antiviral
CC T cell immunity

XX Sequence 11 AA;

Query Match 87.2%; Score 34; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.3;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFTTIG 7
|||
Db 5 RAFTTIG 11

RESULT 168
 AAM99432
 ID AAM99432 standard; peptide; 12 AA.
 XX
 AC AAM99432;
 XX
 DT 07-DEC-2001 (first entry)
 XX
 DE Vaccine related MHC ligand peptide SEQ ID NO:535.
 XX
 KM Glutamic acid; glutamine; vaccine; major histocompatibility complex; MHC;
 KM immunomodulator; antiallergic; endocrine; neuroprotectant; virucidal;
 KM bactericidal; antiparasitic; fungicidal; cytostatic; medicine;
 KM pharmaceutical; immune disorder; immune deficiency; autoimmune;
 KM hypersensitivity; allergy; graft rejection; infection; hormonal disorder;
 KM central nervous system disease; cancer; melanoma; anti-melanoma vaccine;
 KM human immunodeficiency virus.
 XX
 OS Homo sapiens.
 XX
 PN WO200170772-A2.
 XX
 PD 27-SEP-2001.
 XX
 PF 22-MAR-2001; 2001WO-FR000872.
 XX
 PR 23-MAR-2000; 2000FR-00003711.
 XX
 PA (FABR) FABRE MEDICAMENT SA PIERRE.
 XX
 PI Klingner-Hamou C, Corvaia N, Beck A, Goetsch L,
 XX
 DR WPI; 2001-611470/70.
 XX
 PT Stabilized pharmaceutical containing N-terminal glutamic acid or
 PT glutamine, useful e.g. in anti-melanoma vaccines, is an addition salt
 PT with strong acid.
 XX
 PS Claim 9; Page 122; 149pp; French.
 XX
 CC The present invention describes a pharmaceutical compound (I) that
 CC contains an N-terminal glutamic acid (Glu) or glutamine (Gln) residue in
 CC the form of an addition salt with a strong, physiologically acceptable
 CC acid (II). Also described are: (a) a pharmaceutical composition
 CC containing at least one (I); (b) a vaccine containing at least one (I)
 CC where this is a major histocompatibility complex (MHC) ligand (Ia); (c) a
 CC method for in vitro diagnosis of diseases associated with the presence of
 CC (Ia); (d) a kit for method (c) that includes a (Ia); and (e) a process
 CC for preparing (I). (I) has immunomodulator, endocrine, antiallergic,
 CC neuroprotectant, virucidal, bactericidal, antiparasitic, fungicidal and
 CC cytostatic activities. (II) are useful, in human or veterinary medicine,
 CC in pharmaceutical compositions (for treating immune disorders, e.g.
 CC immune deficiency, autoimmune states, hypersensitivity, allergy, graft
 CC rejection, infection, hormonal disorders and central nervous system
 CC diseases), also, where (I) is a MHC ligand (Ia), in vaccines for
 CC treatment or prevention of: (1) viral, bacterial, parasitic or fungal
 CC infections; or (11) of cancers. A particular application is in anti-
 CC melanoma vaccines. (I) are also useful for in vitro diagnosis of diseases
 CC associated with interactions between MHC and (I), e.g. melanoma and human
 CC immunodeficiency virus infection. AAM98898 to AAM95952 represent peptides
 CC which can be used in pharmaceutical compounds from the present invention
 XX
 SQ Sequence 12 AA;
 XX
 Query Match 87.2%; Score 34; DB 4; Length 12;
 Best Local Similarity 100.0%; Pred. No. 1.4;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RAFTTIG 7
 |||||
 DB 6 RAFTTIG 12

RESULT 169
 AAP95357
 ID AAP95357 standard; peptide; 15 AA.
 XX
 AC AAP95357;
 XX
 DT 27-AUG-2003 (revised)
 DT 30-MAR-1992 (first entry)
 XX
 DE Variable region V3, found in the envelope protein gp120 of an AIDS or ARC
 XX causing or related virus.
 XX
 KM Vaccine; AIDS; ARC; HIV; diagnosis.
 XX
 OS HTLV-IIIB.
 XX
 FH Key Location/Qualifiers
 FT Misc-difference 3..15
 FT /note= "an example of a peptide of the invention"
 FT Misc-difference 3..13
 FT /note= "see above"
 FT Misc-difference 3..12
 FT /note= "see above"
 XX
 EN EP11219-A.
 XX
 PD 12-APR-1989.
 XX
 PF 07-OCT-1988; 88EP-00202248.
 XX
 PR 09-OCT-1987; 87NL-00002403.
 XX
 PA (DIER-) STICHTING CENT DIER.
 PA (UNAM) UNIV VAN AMSTERDAM.
 PA (UYAM-) UNIV AMSTERDAM ZIEKENHUI.
 XX
 PI Goudsmit J, Mejoen RH;
 XX
 DR WPI; 1989-108193/15.
 XX
 PT Oligopeptide(s) corresp. to beta-turn variable region of gp.120 - used
 PT for diagnosis of and prodn of vaccines against AIDS and ARC.
 XX
 PS Disclosure; Page 3; 7pp; English.
 XX
 CC The peptides of the invention comprise the beta-turn AA SQ GPG or GPGR at
 CC positions 312-314 or 312-315 in the AA numbering of HTLV-IIIB (BH10) and
 CC flanking AA SQs having a length equal to or greater than 1 and pref.
 CC equal to or greater than 2 AAs; variants in which the GPG or GPGR SQ has
 CC been replaced by a different beta-turn SQ; and variants in which the free
 CC NH2-terminal gp AA and/or the free carboxyl terminal gp. AA has been
 CC blocked or modified otherwise. (Updated on 27-AUG-2003 to correct OS
 CC field.)
 XX
 SQ Sequence 15 AA;
 XX
 Query Match 87.2%; Score 34; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.7;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RAFTTIG 7
 |||||
 DB 9 RAFTTIG 15
 XX
 RESULT 170
 AAR33460
 ID AAR33460 standard; peptide; 15 AA.
 XX
 AC AAR33460;
 XX

DT 27-AUG-2003 (revised)
 DT 25-MAR-2003 (revised)
 DT 17-DEC-2001 (revised)
 DT 03-JUL-1993 (first entry)
 XX
 DE Sequence of synthetic peptide which represents residues 315-329 of the
 DE pg160 envelope protein of HIV-1 isolate IIRB.
 XX
 KM Cytotoxic T lymphocyte; immunogenic peptide; V3 loop; treatment;
 KM glycoprotein 160.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN USN7847311-N.
 XX
 PD 01-JAN-1993.
 XX
 PF 06-MAR-1992; 92US-00847311.
 XX
 PR 26-JAN-1988; 88US-00148692.
 PR 18-SEP-1991; 91US-00760530.
 XX
 PA (USSH) US DEPT HEALTH & HUMAN SERVICE.
 PI Berzofsky JA, Takeshita T, Shirai M, Pendleton CD, Kozlowski S;
 XX
 DR WPI; 1993-093577/11.
 XX
 PT Peptide(s) for stimulation of cytotoxic T cells specific for HIV-1 -
 PT which correspond to residues 318-327 of HIV-1 gp 160 envelope
 PT glycoprotein.
 XX
 PS Disclosure; Page 9; 61pp; English.
 XX
 CC The peptide corresp. to residues 319-329 of HIV-1 strain IIRB gp. 160
 CC envelope glycoprotein. It is activated by cleavage with a protease to
 CC produce a peptide which is more active in eliciting a cytotoxic T
 CC lymphocyte (CTL) response. It can be used for the treatment and/or
 CC prophylaxis of HIV infection. (Note: Revised entry submitted to correct
 CC the patent number format of US Government-owned NTIS applications to
 CC information please visit the Derwent web site at
 CC www.derwent.com/dwpi/updates/ntis us.html.) (Updated on 25-MAR-2003 to
 CC correct PF field.) (Updated on 27-AUG-2003 to correct OS field.)
 CC
 XX
 SQ Sequence 15 AA;
 XX
 QY Query Match 87.2%; Score 34; DB 2; Length 15;
 DB Best Local Similarity 87.5%; Pred. No. 1.7;
 Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 RAFTTIG 8
 DB 8 RAFTTIG 15
 XX
 RESULT 171
 AAR62166 standard; peptide; 15 AA.
 ID AAR62166 standard; peptide; 15 AA.
 AC AAR62166;
 XX
 XX 27-AUG-2003 (revised)
 DT 25-MAR-2003 (revised)
 DT 03-MAY-1995 (first entry)
 XX
 DE HIV-1 gp120 V3 loop dominant neutralising domain in chimpanzees.
 XX
 KM epitope; autoantibody; immunoinfective cluster virus;
 KM nuclear protein antigen; systemic rheumatic disorder;
 KM human immunodeficiency virus; HIV-1; systemic lupus erythematosus;
 KM mixed connective tissue disease; scleroderma; glycoprotein 120.
 XX

OS Human immunodeficiency virus 1.
 XX
 PN W09420141-A1.
 XX
 PD 15-SEP-1994.
 XX
 PF 10-MAR-1994; 94WO-US002631.
 XX
 PR 11-MAR-1993; 93US-00029850.
 XX
 PA (UYSC-) UNIV SOUTHERN CALIFORNIA.
 PI Douvas A, Takehana Y, Ehresmann G;
 XX
 DR WPI; 1994-302689/37.
 XX
 PT Methods for treating immunoinfective cluster virus infections - utilise
 PT antibodies or fragments characteristic of auto antibodies produced by
 PT patients with rheumatic disorders.
 XX
 PS Disclosure; Page 62; 106pp; English.
 XX
 CC Previous immunological analyses of the V3 loop of HIV-1 (AAR62159) have
 CC localised the main neutralising domains. The target of more than 80% of
 CC neutralising antibodies in HIV-1 infected sera from AIDS patients has now
 CC been found to overlap the consensus binding sequence and domain A epitopes
 CC of the U1 snRNP 70K protein. In AIDS, antibody titres are too low to
 CC arrest the disease; however, the homologous sequences in 70K are
 CC immunodominant targets of autoantibodies in the systemic rheumatoid
 CC disorder of mixed connective tissue disease. The titers of such
 CC autoantibodies exceed 10 power 7. The anti-snRNP autoantibodies will
 CC cross-react with HIV-1 epitopes and are useful for treating HIV
 CC infection. (Updated on 25-MAR-2003 to correct PN field.) (Updated on 27-
 CC AUG-2003 to correct OS field.)
 CC
 XX
 SQ Sequence 15 AA;
 XX
 QY Query Match 87.2%; Score 34; DB 2; Length 15;
 DB Best Local Similarity 100.0%; Pred. No. 1.7;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RAFTTIG 7
 DB 9 RAFTTIG 15
 XX
 RESULT 172
 AAR66427 standard; peptide; 15 AA.
 ID AAR66427 standard; peptide; 15 AA.
 AC AAR66427;
 XX
 XX 25-MAR-2003 (revised)
 DT 03-AUG-1995 (first entry)
 XX
 DE HIV-1 IIRB peptide 18-12.
 XX
 KM T cell helper site; cytotoxic T cell response; neutralising antibody;
 KM human immunodeficiency virus type 1; envelope glycoprotein gp120;
 KM cluster peptide; principal neutralising determinant.
 XX
 OS Synthetic.
 XX
 PN W09426785-A1.
 XX
 PD 24-NOV-1994.
 XX
 PF 13-MAY-1994; 94WO-US005142.
 XX
 PR 14-MAY-1993; 93US-00060988.
 XX
 PA (USSH) US SEC DEPT HEALTH.
 XX

PI Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
 XX WPI; 1995-006707/01.
 XX
 PT Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
 PT responses - to target antigen in hosts of different MHC haplotypes, esp.
 PT for therapeutic or prophylactic vaccines against HIV.
 XX
 PS Example 1; Page 33; 120pp; English.
 XX
 CC Single residues from the HIV-1 RF sequence (AAR66415) replaced residues
 CC in the HIV-1 IIB sequence (AAR66414) to test the effect of each residue
 CC on the binding of neutralising and non-neutralising sera from animals
 CC immunised with the cluster peptides PCUS 3-18 and PCUS 6-18 (see
 CC AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
 CC R66430) showed that binding was enhanced over peptide 18 control when a
 CC tyrosine was substid. for a Val at position 11 and substns. at positions
 CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
 CC sera was reduced when substns. were made in the principal neutralising
 CC determinant sequence (PGRAF). In peptide 18-12, the Thr residue at
 CC position 12 in peptide 18 has been replaced by an Ala residue. (Updated
 CC on 25-MAR-2003 to correct PN field.)
 CC
 XX
 SQ Sequence 15 AA;
 XX
 Query Match 87.2%; Score 34; DB 2; Length 15;
 Best Local Similarity 87.5%; Pred. No. 1.7;
 Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 1 RAFTYICK 8
 |||||
 Db 8 RAFTYICK 15
 XX
 RESULT 173
 AAR66428
 ID AAR66428 standard; peptide: 15 AA.
 XX
 AC AAR66428;
 XX
 DT 25-MAR-2003 (revised)
 DT 03-AUG-1995 (first entry)
 XX
 DE HIV-1 IIB peptide 18-13.
 XX
 KM T cell helper site; cytotoxic T cell response; neutralising antibody;
 KM human immunodeficiency virus type 1; envelope glycoprotein gp120;
 KM cluster peptide; principal neutralising determinant.
 XX
 OS Synthetic.
 XX
 PN WO9426785-A1.
 XX
 PD 24-NOV-1994.
 XX
 PF 13-MAY-1994; 94WO-US005142.
 XX
 PR 14-MAY-1993; 93US-00060988.
 XX
 XX (USSH) US SEC DEPT HEALTH.
 PA
 PI Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
 XX
 DR WPI; 1995-006707/01.
 XX
 PT Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
 PT responses - to target antigen in hosts of different MHC haplotypes, esp.
 PT for therapeutic or prophylactic vaccines against HIV.
 XX
 PS Example 1; Page 33; 120pp; English.
 XX
 CC Single residues from the HIV-1 RF sequence (AAR66415) replaced residues
 CC in the HIV-1 IIB sequence (AAR66414) to test the effect of each residue

CC on the binding of neutralising and non-neutralising sera from animals
 CC immunised with the cluster peptides PCUS 3-18 and PCUS 6-18 (see
 CC AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
 CC R66430) showed that binding was enhanced over peptide 18 control when a
 CC tyrosine was substid. for a Val at position 11 and substns. at positions
 CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
 CC sera was reduced when substns. were made in the principal neutralising
 CC determinant sequence (PGRAF). In peptide 18-13, the Ile residue at
 CC position 13 in peptide 18 has been replaced by a Thr residue. (Updated on
 CC 25-MAR-2003 to correct PN field.)
 CC
 XX
 SQ Sequence 15 AA;
 XX
 Query Match 87.2%; Score 34; DB 2; Length 15;
 Best Local Similarity 87.5%; Pred. No. 1.7;
 Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 1 RAFTYICK 8
 |||||
 Db 8 RAFTYICK 15
 XX
 RESULT 174
 AAR66423
 ID AAR66423 standard; peptide: 15 AA.
 XX
 AC AAR66423;
 XX
 DT 25-MAR-2003 (revised)
 DT 03-AUG-1995 (first entry)
 XX
 DE HIV-1 IIB peptide 18-8.
 XX
 KM T cell helper site; cytotoxic T cell response; neutralising antibody;
 KM human immunodeficiency virus type 1; envelope glycoprotein gp120;
 KM cluster peptide; principal neutralising determinant.
 XX
 OS Synthetic.
 XX
 PN WO9426785-A1.
 XX
 PD 24-NOV-1994.
 XX
 PF 13-MAY-1994; 94WO-US005142.
 XX
 PR 14-MAY-1993; 93US-00060988.
 XX
 PA (USSH) US SEC DEPT HEALTH.
 PI Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
 XX
 DR WPI; 1995-006707/01.
 XX
 PT Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
 PT responses - to target antigen in hosts of different MHC haplotypes, esp.
 PT for therapeutic or prophylactic vaccines against HIV.
 XX
 PS Example 1; Page 33; 120pp; English.
 XX
 CC Single residues from the HIV-1 RF sequence (AAR66415) replaced residues
 CC in the HIV-1 IIB sequence (AAR66414) to test the effect of each residue
 CC on the binding of neutralising and non-neutralising sera from animals
 CC immunised with the cluster peptides PCUS 3-18 and PCUS 6-18 (see
 CC AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
 CC R66430) showed that binding was enhanced over peptide 18 control when a
 CC tyrosine was substid. for a Val at position 11 and substns. at positions
 CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
 CC sera was reduced when substns. were made in the principal neutralising
 CC determinant sequence (PGRAF). In peptide 18-8, the Arg residue at
 CC position 8 in peptide 18 has been replaced by an Ala residue. (Updated on
 CC 25-MAR-2003 to correct PN field.)
 CC
 XX
 SQ Sequence 15 AA;

Query Match 87.2%; Score 34; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.7;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 AFTVIGK 8
 |||||
 Db 9 AFTVIGK 15

RESULT 175

AA66426
 ID AAR66426 standard; peptide; 15 AA.

XX AAR66426;

XX AC 25-MAR-2003 (revised)
 DT 03-AUG-1995 (first entry)

XX DE HIV-1 IIIB peptide 18-11.

XX KW T cell helper site; cytotoxic T cell response; neutralising antibody;
 KW human immunodeficiency virus type 1; envelope glycoprotein gp120;
 KW cluster peptide; principal neutralising determinant.

XX OS Synthetic.

XX PN MO9426785-A1.

XX PD 24-NOV-1994.

XX PF 13-MAY-1994; 94WO-US005142.

XX PR 14-MAY-1993; 93US-00060988.

XX PA (USSH) US SEC DEPT HEALTH.

XX PI Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;

XX DR WPI; 1995-006707/01.

XX PT Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
 PT responses - to target antigen in hosts of different MHC haplotypes, esp.
 PT for therapeutic or prophylactic vaccines against HIV.

XX PS Example 1; Page 33; 120pp; English.

XX CC Single residues from the HIV-1 RF sequence (AAR66415) replaced residues
 CC in the HIV-1 IIIB sequence (AAR66414) to test the effect of each residue
 CC on the binding of neutralising and non-neutralising sera from animals
 CC immunised with the cluster peptides PCLUS 3-18 and PCLUS 6-18 (see
 CC AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
 CC R66430) showed that binding was enhanced over peptide 18 control when a
 CC tyrosine was substid. for a Val at position 11 and substns. at positions
 CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
 CC sera was reduced when substns. were made in the principal neutralising
 CC determinant sequence (PGRAF). In peptide 18-11, the Val residue at
 CC position 11 in peptide 18 has been replaced by a Tyr residue. (Updated on
 CC 25-MAR-2003 to correct PN field.)

XX SQ Sequence 15 AA;

Query Match 87.2%; Score 34; DB 2; Length 15;
 Best Local Similarity 87.5%; Pred. No. 1.7;
 Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RAFVIGK 8
 |||||
 Db 8 RAFVIGK 15

RESULT 176
 AAR33236

ID AAR33236 standard; peptide; 16 AA.

XX AC AAR33236;

XX DT 25-MAR-2003 (revised)

XX DT 13-JUL-1993 (first entry)

XX DE HIV-IIIB gp120 V3 loop epitope peptide RP135.

XX KW HIV-1; human immunodeficiency virus; competition assay; AIDS; infection;
 KW CD4 binding site; soluble CD4.

XX OS Synthetic.

XX PN MO9304693-A1.

XX PD 18-MAR-1993.

XX PF 02-SEP-1992; 92WO-US007511.

XX PR 09-SEP-1991; 91US-00756677.

XX ER 20-JUL-1992; 92US-00916542.

XX PA (REPK) REPLIGEN CORP.

XX PI Potts BJ, Whiteschaf ME, Field KG, Herlincy WC;

XX DR WPI; 1993-100653/12.

XX PT Synergistic compsn. for treating HIV-1 infection - comprises antibody to
 PT V3 loop of gp120 and antibody to CD4 binding site of gp120 or soluble CD4
 PT polypeptide.

XX PS Example; Page 20; 56pp; English.

XX CC The sequence is that of the HIV-IIIB V3 loop epitope peptide RP135 which
 CC was used in a competition assay to determine whether a given anti-V3 loop
 CC antibody will have strong neutralisation activity by itself, and if it
 CC has potential to act synergistically with a second agent. The assay can
 CC be used to test for potential neutralisation activity of any anti-V3 loop
 CC antibody towards any isolate by using a peptide derived from the V3 loop
 CC from the HIV isolate of interest as the competitor (Updated on 25-MAR-
 CC 2003 to correct PN field.) (Updated on 25-MAR-2003 to correct PI field.)

XX SQ Sequence 16 AA;

Query Match 87.2%; Score 34; DB 2; Length 16;
 Best Local Similarity 100.0%; Pred. No. 1.9;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVIGK 7
 |||||
 Db 10 RAFVIGK 16

RESULT 177

AA695348
 ID AAP95348 standard; peptide; 17 AA.

XX AC AAP95348;

XX DT 27-AUG-2003 (revised)

XX DT 30-MAR-1992 (first entry)

XX DE Variable region V3 sequence found in the envelope protein gp120 of an
 DE AIDS or ARC causing or related virus.

XX KW Vaccine; AIDS; ARC; HIV; diagnosis.

XX OS HTLV-IIIB.

XX PN EP311219-A.

```

PD 12-APR-1989.
XX
XX 07-OCT-1988; 88EP-00202248.
XX
XX 09-OCT-1987; 87NL-00002403.
XX
XX (DIER-) STICHTING CENT DIER.
XX (UNAM) UNIV VAN AMSTERDAM.
XX (UYAM-) UNIV AMSTERDAM ZIEKENHUI.
XX
XX Goudemits J, Mejoen RH;
XX
XX WPI; 1989-108193/15.
XX
XX Oligopeptide(s) corresp. to beta-turn variable region of gp.120 - used
XX for diagnosis of and prodn of vaccines against AIDS and ARC.
XX
XX Disclosure; Page 3; 7pp; English.
XX
XX The peptides of the invention comprise the beta-turn AA SQ GPG or GPGR at
XX positions 312-314 or 312-315 in the AA numbering of HTLV-IIIB (BH10) and
XX flanking AA SQs having a length equal to or greater than 1 and pref.
XX equal to or greater than 2 AAs; variants in which the GPG or GPGR SQ has
XX been replaced by a different beta-turn SQ; and variants in which the free
XX NH2-terminal gp AA and/or the free carboxyl terminal gp. AA has been
XX blocked or modified otherwise. (Updated on 27-AUG-2003 to correct OS
XX field.)
XX
XX Sequence 17 AA;
XX
XX Query Match 87.2%; Score 34; DB 1; Length 17;
XX Best Local Similarity 100.0%; Pred. No. 2;
XX Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 RAFVTIG 7
XX |||||
XX 11 RAFVTIG 17
XX
XX RESULT 178
XX AAP95349
XX ID AAP95349 standard; peptide; 17 AA.
XX
XX AAP95349;
XX
XX 27-AUG-2003 (revised)
XX 30-MAR-1992 (first entry)
XX
XX Variable region V3 found in the envelope protein gp120 of an AIDS or ARC
XX causing or related virus.
XX
XX Vaccine; AIDS; ARC; HIV; diagnosis.
XX
XX HTLV-IIIB.
XX
XX EP311219-A.
XX
XX 12-APR-1989.
XX
XX 07-OCT-1988; 88EP-00202248.
XX
XX 09-OCT-1987; 87NL-00002403.
XX
XX (DIER-) STICHTING CENT DIER.
XX (UNAM) UNIV VAN AMSTERDAM.
XX (UYAM-) UNIV AMSTERDAM ZIEKENHUI.
XX
XX Goudemits J, Mejoen RH;
XX
XX WPI; 1989-108193/15.
XX
XX Oligopeptide(s) corresp. to beta-turn variable region of gp.120 - used
XX for diagnosis of and prodn of vaccines against AIDS and ARC.
XX

```

```

XX
XX Disclosure; Page 3; 7pp; English.
XX
XX The peptides of the invention comprise the beta-turn AA SQ GPG or GPGR at
XX positions 312-314 or 312-315 in the AA numbering of HTLV-IIIB (BH10) and
XX flanking AA SQs having a length equal to or greater than 1 and pref.
XX equal to or greater than 2 AAs; variants in which the GPG or GPGR SQ has
XX been replaced by a different beta-turn SQ; and variants in which the free
XX NH2-terminal gp AA and/or the free carboxyl terminal gp. AA has been
XX blocked or modified otherwise. (Updated on 27-AUG-2003 to correct OS
XX field.)
XX
XX Sequence 17 AA;
XX
XX Query Match 87.2%; Score 34; DB 1; Length 17;
XX Best Local Similarity 100.0%; Pred. No. 2;
XX Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 RAFVTIG 7
XX |||||
XX 11 RAFVTIG 17
XX
XX RESULT 179
XX AAP95356
XX ID AAP95356 standard; peptide; 17 AA.
XX
XX AAP95356;
XX
XX 27-AUG-2003 (revised)
XX 30-MAR-1992 (first entry)
XX
XX Variable region V3, found in the envelope protein gp120 of an AIDS or ARC
XX causing or related virus.
XX
XX Vaccine; AIDS; ARC; HIV; diagnosis.
XX
XX HTLV-IIIB.
XX
XX EP311219-A.
XX
XX 12-APR-1989.
XX
XX 07-OCT-1988; 88EP-00202248.
XX
XX 09-OCT-1987; 87NL-00002403.
XX
XX (DIER-) STICHTING CENT DIER.
XX (UNAM) UNIV VAN AMSTERDAM.
XX (UYAM-) UNIV AMSTERDAM ZIEKENHUI.
XX
XX Goudemits J, Mejoen RH;
XX
XX WPI; 1989-108193/15.
XX
XX Oligopeptide(s) corresp. to beta-turn variable region of gp.120 - used
XX for diagnosis of and prodn of vaccines against AIDS and ARC.
XX
XX Disclosure; Page 3; 7pp; English.
XX
XX The peptides of the invention comprise the beta-turn AA SQ GPG or GPGR at
XX positions 312-314 or 312-315 in the AA numbering of HTLV-IIIB (BH10) and
XX flanking AA SQs having a length equal to or greater than 1 and pref.
XX equal to or greater than 2 AAs; variants in which the GPG or GPGR SQ has
XX been replaced by a different beta-turn SQ; and variants in which the free
XX NH2-terminal gp AA and/or the free carboxyl terminal gp. AA has been
XX blocked or modified otherwise. (Updated on 27-AUG-2003 to correct OS
XX field.)
XX
XX Sequence 17 AA;
XX
XX Query Match 87.2%; Score 34; DB 1; Length 17;
XX Best Local Similarity 100.0%; Pred. No. 2;

```


XX	09-JUN-1993;	93US-00073378.	
PR	(CONN-)	CONNAUGHT LAB LTD.	
XX	Sia CDY, Chong P, Klein MH;		
PI	WPI; 1995-036400/05.		
XX			
DR			
PT	Novel tandem synthetic HIV-1 peptide(s) - comprising T-cell epitope of		
PT	gag protein linked to B-cell epitope of V3 loop protein of an HIV-1		
PT	isolate.		
XX			
PS	Disclosure; Page 39; 69pp; English.		
XX			
CC	This sequence represents a T-cell epitope derived from the V3 sequence of		
CC	the HIV-1 isolate LAI, which may be linked to a B-cell epitope from the		
CC	V3 (MN) loop from HIV-1. These chimeric peptides may then be used in the		
CC	production of HIV-1 vaccines. These peptide sequences may also be used in		
CC	the production of multimeric peptides in which the peptides are C-		
CC	terminally modified by the addition of a Lys residue which is modified on		
CC	its epsilon amino acid to carry an additional copy of the peptide		
CC	molecule. The linear and multimeric peptides may be used for the		
CC	treatment of AIDS by acting to displace the binding of HIV virus to human		
CC	or animal cells or by disturbing the 3D organisation of the virus.		
CC	(Updated on 25-MAR-2003 to correct PN field.) (Updated on 16-OCT-2003 to		
CC	standardise OS field)		
XX			
SQ	Sequence 17 AA;		
Query Match	87.2%;	Score 34;	DB 2; Length 17;
Best Local Similarity	100.0%;	Pred. No. 2;	
Matches	7;	Conservative	0; Mismatches 0; Indels 0; Gaps 0
OY	1 RAFTVIG 7		
Db	11 RAFTVIG 17		
RESULT 183			
AAW25834			
ID	AAW25834 standard; peptide; 17 AA.		
AC	AAW25834;		
XX			
DT	25-MAR-2003 (revised)		
DT	20-OCT-1997 (first entry)		
XX			
DE	HIV B-cell strain LAI env protein V3 loop peptide.		
XX			
KW	HIV; human immunodeficiency virus; gag; T-cell; B-cell; epitope; env;		
KW	V3 loop; vaccine; determinant; chimaeric.		
XX			
OS	Synthetic.		
XX			
PN	US5639854-A.		
XX			
PD	17-JUN-1997.		
XX			
PF	09-JUN-1994; 94US-00257528.		
XX			
PR	09-JUN-1993; 93US-00073378.		
XX			
PA	(CONN-) CONNAUGHT LAB LTD.		
XX			
PI	Klein MH, Sia CDY, Chong P;		
XX			
DR	WPI; 1997-332082/30.		
XX			
PT	Tandem synthetic HIV peptide(s) useful as immunogens - comprising gag		
PT	protein T-cell epitope linked to env protein B-cell epitope.		
XX			
PS	Disclosure; Col 21; 41pp; English		

XX	The invention relates to new synthetic peptides comprising at least one
CC	amino acid sequence comprising an HIV gag protein T-cell epitope linked
CC	at its C- or N-terminus to an amino acid sequence comprising a B-cell
CC	epitope of the V3 loop of an HIV env protein, which can be used to
CC	generate vaccines against HIV-1. The T-cell epitope sequence is pref.
CC	selected from the T-helper determinant core peptides P24E, P24N, P24L,
CC	P24M and P24H while the B-cell epitopes are derived from HIV strains
CC	including CTLB-56, V3MN, CTLB-29, CTLB-55, SF2, LAI, IIB, RP, Z6, 2054,
CC	1714 and BK08. The peptides are chimeric and can be linked to a branched
CC	Lys backbone. This sequence represents the B-cell env protein V3 loop
CC	peptide from HIV-1 strain LAI. (Updated on 25-MAR-2003 to correct PF
CC	field.)
CC	
SQ	Sequence 17 AA;
Query Match	87.2%; Score 34; DB 2; Length 17;
Best Local Similarity	100.0%; Pred. No. 2;
Matches 7; Conservative	0; Mismatches 0; Indels 0; Gaps 0
QY	1 RAFTVIG 7
Dd	11 RAFVTYG 17
RESULT 184	
AAW76848	AAW76848 standard; peptide; 17 AA.
ID	
XX	
AC	AAW76848;
XX	
DT	25-JAN-1999 (first entry)
DE	
XX	Fusion immunoglobulin heavy chain HIV gp120 B cell epitope #18.
KW	B cell; T cell; epitope; immunoglobulin; heavy chain; gp120; IGH;
KW	human immune deficiency virus; HIV; tolerance; treatment; therapy;
KW	prophylaxis; vaccine; chemotherapy; immune response; modifier; tumour;
KW	microbial infection; autoimmune disease; antibody; apoptosis;
KW	antiviral T cell immunity.
XX	
OS	Mus sp.
OS	Homo sapiens.
PN	WO9836087-A1.
PD	20-AUG-1998.
PF	13-FEB-1998; 98MO-US002766.
PR	13-FEB-1997; 97US-0040581P.
PA	(AMNA-) AMERICAN NAT RED CROSS.
PI	Scott D, Zambidis E;
DR	WPI; 1998-506315/43.
PT	New fusion immunoglobulin heavy chain including gp120 epitopes and
PT	related complete antibodies - DNA, vectors and transformed cells, used to
PT	induce tolerance to the epitopes for treatment of human immune deficiency
PT	virus infection.
PS	
PS	Claim 10; Page 119; 154pp; English.
XX	This sequence is an epitope used in the construction of a novel fusion
CC	immunoglobulin heavy chain (IGH) protein with a mammalian, especially
CC	human, IGH chain fused in frame at its N-terminus to one or more human
CC	immune deficiency virus (HIV) gp120 epitopes. Fusion Ig proteins and/or
CC	transfected cells are used to tolerate subjects to gp120 epitopes and to
CC	maintain this tolerance, particularly for treatment of HIV infection,
CC	optionally together with other therapeutic/prophylactic agents such as
CC	vaccines, chemotherapeutic agents and immune response modifiers. Such

CC proteins can be used against other diseases where an immune response is
 CC deleterious, e.g. microbial infection, tumours or autoimmune disease.
 CC Induction of tolerance suppresses production of antibodies against gp120,
 CC so prevents or inhibits 'bystander' apoptosis of uninfected T cells that
 CC are bound to gp120 protein, maximizing induction of protective antiviral
 CC T cell immunity

XX
 SQ Sequence 17 AA;

Query Match 87.2%; Score 34; DB 2; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 RAFTVIG 7
 |||||
 Db 11 RAFTVIG 17

RESULT 185

AAW67350
 ID AAW67350 standard; peptide; 17 AA.

AC AAW67350;

DT 17-OCT-2003 (revised)

DT 25-JAN-1999 (first entry)

DE HIV-1 strain LAI gp120 V3 loop epitope peptide.

KM Immunogen; vaccine; HIV-1; T-cell; B-cell; epitope; core protein; gp120;
 V3 loop.

OS Human immunodeficiency virus 1.

PN US5817754-A.

PD 06-OCT-1998.

PF 05-JUN-1995; 95US-00464329.

PR 09-JUN-1993; 93US-00073378.

PR 09-JUN-1994; 94US-00257528.

PA (CONN-) CONNAUGHT LAB LTD.

PI Chong P, Klein MH, Sia CDY;

PI; 1998-556461/47.

PT Synthetic human immunodeficiency virus-1 peptide(s) - containing T-cell
 epitope and B-cell epitope(s) are candidate vaccines against HIV-1.

PS Disclosure; Col 21; 40pp; English.

CC The invention relates to a novel immunogenic composition for use in
 CC vaccines for the treatment of HIV-1 comprising an HIV-1-derived T-cell
 CC epitope linked to an HIV-1-derived B-cell epitope. The T-cell epitopes
 CC are generally designed based on the p24 core protein and the B-cell
 CC epitopes from the V3 loop of the gp120 protein from various HIV-1
 CC strains. This peptide represents the V3 loop epitope from the HIV-1
 CC strain LAI. (Updated on 17-OCT-2003 to standardise OS field)

XX
 SQ Sequence 17 AA;

Query Match 87.2%; Score 34; DB 2; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 RAFTVIG 7
 |||||
 Db 11 RAFTVIG 17

RESULT 186

AAW99958
 ID AAW99958 standard; peptide; 17 AA.

AC AAW99958;

DT 05-MAY-1999 (first entry)

DE HIV-1 vaccine synthetic peptide SEQ ID NO:35.

KM HIV-1; human immunodeficiency virus; vaccine; T-cell epitope;
 gag protein; B-cell epitope; gp120 protein; chimeric; infection.

OS Synthetic.

PN US5876731-A.

PD 02-MAR-1999.

PF 05-JUN-1995; 95US-00462507.

PR 09-JUN-1993; 93US-00073378.

PR 09-JUN-1994; 94US-00257528.

PA (CONN-) CONNAUGHT LAB LTD.

PI Chong P, Klein MH, Sia CDY;

PI; 1999-189590/16.

PT Synthetic chimeric HIV polypeptides - comprising gag protein T-cell
 epitope linked to gp120 B-cell epitope.

PS Example 1; Col 41-42; 41pp; English.

CC The present invention describes a synthetic peptide comprising an amino
 CC acid sequence containing a T-cell epitope of an HIV gag protein linked at
 CC its C terminus to an amino acid sequence containing a B-cell epitope of
 CC an HIV gp120 protein and containing the amino acid sequence: X1XDX2;
 CC where X1 = E, A, G or Q, and X2 = A or T, or an amino acid sequence
 CC capable of eliciting an HIV-specific antiserum and recognizing the
 CC sequence X1XDX2. The synthetic peptide is useful in vaccines against
 CC HIV infection and in diagnostic applications. AAW9892 to AAW98906, and
 CC AAW9899 to AAW99989 represent synthetic peptides from the present
 CC invention

XX
 SQ Sequence 17 AA;

Query Match 87.2%; Score 34; DB 2; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 RAFTVIG 7
 |||||
 Db 11 RAFTVIG 17

RESULT 187

AAW99756
 ID AAW99756 standard; peptide; 17 AA.

AC AAW99756;

DT 17-OCT-2003 (revised)

DT 26-NOV-1999 (first entry)

DE HIV1 chimeric peptide V3-LAI.

KM HIV; vaccine; immunogenic composition; T cell epitope; B cell epitope;
 infection; antibody; antiviral.

OS Human immunodeficiency virus 1.

```

XX  US95951986-A.
XX  14-SEP-1999.
XX  06-JUN-1995; 95US-00467881.
XX  09-JUN-1993; 93US-00073378.
XX  09-JUN-1994; 94US-00257528.
XX  (CONN-) CONNAUGHT LAB LTD.
XX  Klein MH, Chong P, Sia CDY;
XX  WPI; 1999-550482/46.
XX  Immunogenic composition containing synthetic fusion polypeptides
XX  containing both the T and B cell epitopes of the human immunodeficiency
XX  virus, useful antigens in producing vaccines.
XX  Example 1; Col 22; 43pp; English.
XX  This sequence represents a fragment of a HIV1 protein, and can be used in
XX  the immunogenic composition of the invention. The composition comprises a
XX  synthetic fusion polypeptide which includes a sequence encoding 1 or more
XX  T cell epitopes and a sequence encoding 1 or more B cell epitopes and a
XX  carrier. Both the T cell and B cell epitopes are derived from HIV
XX  proteins. The compositions are useful as vaccines against HIV infection.
XX  The composition induces HIV-1-specific polyclonal antibodies that are
XX  opsonising and antiviral. The peptide components may be selected to
XX  induce a response against different viral isolates and in subjects who
XX  recognise different T cell epitopes. (updated on 17-OCT-2003 to
XX  standardise OS field)
XX  SQ Sequence 17 AA;
XX  Query Match 87.2%; Score 34; DB 2; Length 17;
XX  Best Local Similarity 100.0%; Pred. No. 2;
XX  Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RAFTTIG 7
DB 11 RAFTTIG 17

```

```

PA (UUNY ) UNIV NEW YORK STATE.
PA (YEDA ) YEDA RES & DEV CO LTD.
XX Anglister J, Sharon M, Schapira M, Zolla-Pazner S, Rosen O;
XX WPI; 2004-625447/60.
XX Composition for inhibiting HIV-1 infection, comprises isolated peptide
XX molecule that mimics atomic structural conformation of V3 loop peptide of
XX HIV-1 envelope glycoprotein that is bound to, and constrained by human
XX monoclonal antibody.
XX Claim 8; SEQ ID NO 28; 127pp; English.
XX The present invention describes a composition (C1) which comprises an
XX isolated peptide molecule or isostere that mimics the three-dimensional
XX (3D) atomic structural conformation of the V3 loop peptide of the HIV-1
XX envelope glycoprotein gp120 that is bound to, and constrained by, human
XX monoclonal antibody (MAb) 447-52D, murine MAb 0.5 beta or an antigen
XX binding fragment of the MAb, where the constrained V3 loop peptide
XX differs in conformation from the same V3 loop peptide when it is in free
XX form. Also described: (1) identifying (M1) from several existing
XX compounds a molecule that is useful as an HIV-1 V3 loop immunogen or as
XX an inhibitor of binding of HIV-1 to a chemokine receptor/HIV-1 co-
XX receptor on the surface of a receptor-bearing target cell; (2) designing
XX a molecule that is useful as an HIV-1 V3 loop immunogen or as an
XX inhibitor of binding of HIV-1 to a chemokine receptor/HIV-1 co-receptor
XX on the surface of a receptor-bearing target cell; (3) a composition (C2)
XX that is useful as an HIV-1 V3 loop immunogen or as an inhibitor of
XX binding of HIV-1 to a chemokine receptor/HIV-1 co-receptor on the surface
XX of a receptor-bearing target cell; (4) an immunogenic composition (C3)
XX for induction of an anti-HIV-1 antibody response specific for a V3 loop
XX epitope, comprising (C1) and an excipient; (5) a pharmaceutical
XX composition (C4) useful for blocking the interaction of HIV-1 with an R5
XX or X4 co-receptor and thereby inhibiting HIV-1 infectivity, comprising
XX (C1) and a carrier or excipient; (6) a computing platform for generating
XX a 3D model of a constrained HIV V3 view peptide; (7) a computer generated
XX model representing the conformationally constrained structure of a V3
XX loop peptide that is bound to 447-52D or 0.5beta MAb or its antigen
XX binding fragments, comprising a 3D atomic structure defined by NC+ and
XX (8) a computer readable medium (CM) comprising, in a retrievable format,
XX data that includes a set of structure coordinates defining a 3D structure
XX of a V3 loop peptide that is conformationally constrained by being bound
XX to 447-52D or 0.5beta MAb or its antigen binding fragment. (C1) has anti-
XX HIV activities, and can be used in vaccines, and as an inhibitor of
XX binding of HIV-1 to chemokine receptor/HIV-1 co-receptor. (C1) is useful
XX for in vivo inhibition of HIV-1 infection. (C1) or (C2) is useful for
XX producing a medicament utilised for treating or preventing HIV-1
XX infection. (C3) or (C4) is useful for inducing in a subject an anti-HIV-1
XX neutralising antibody response specific for a V3 loop epitope. (C4) is
XX useful for preventing an HIV-1 infection in an uninfected subject at risk
XX for such infection or for inhibiting viral spread and disease progression
XX in an infected subject. The present sequence represents a peptide used in
XX the exemplification of the present invention.
SQ Sequence 17 AA;
QY 1 RAFTTIG 7
DB 11 RAFTTIG 17

```


XX Human immunodeficiency virus 1.
 OS Synthetic.
 PN MO2004069863-A2.
 PD 19-AUG-2004.
 PF 04-FEB-2004; 2004MO-US003304.
 PR 04-FEB-2003; 2003US-0444682P.
 PA (UNYNY) UNIV NEW YORK STATE.
 PA (YEDA) YEDA RES & DEV CO LTD.
 PI Anglistar J, Sharon M, Schapira M, Zolla-Pazner S, Rosen O;
 DR WPI; 2004-625447/60.
 XX
 PT Composition for inhibiting HIV-1 infection, comprises isolated peptide
 PT molecule that mimics atomic structural conformation of V3 loop peptide of
 PT HIV-1 envelope glycoprotein that is bound to, and constrained by human
 PT monoclonal antibody.
 PS Disclosure; SEQ ID NO 4; 127pp; English.
 XX
 CC The present invention describes a composition (C1) which comprises an
 CC isolated peptide molecule or isostere that mimics the three-dimensional
 CC (3D) atomic structural conformation of the V3 loop peptide of the HIV-1
 CC envelope glycoprotein gp120 that is bound to, and constrained by, human
 CC monoclonal antibody (Mab) 447-52D, murine Mab 0.5 beta or an antigen
 CC binding fragment of the Mab, where the constrained V3 loop peptide
 CC differs in conformation from the same V3 loop peptide when it is in free
 CC form. Also described: (1) identifying (M1) from several existing
 CC compounds a molecule that is useful as an HIV-1 V3 loop immunogen or as
 CC an inhibitor of binding of HIV-1 to a chemokine receptor/HIV-1 co-
 CC receptor on the surface of a receptor-bearing target cell; (2) designing
 CC a molecule that is useful as an HIV-1 V3 loop immunogen or as an
 CC inhibitor of binding of HIV-1 to a chemokine receptor/HIV-1 co-receptor
 CC on the surface of a receptor-bearing target cell; (3) a composition (C2)
 CC that is useful as an HIV-1 V3 loop immunogen or as an inhibitor of
 CC binding of HIV-1 to a chemokine receptor/HIV-1 co-receptor on the surface
 CC of a receptor-bearing target cell; (4) an immunogenic composition (C3)
 CC for induction of an anti-HIV-1 antibody response specific for a V3 loop
 CC epitope, comprising (C1) and an excipient; (5) a pharmaceutical
 CC composition (C4) useful for blocking the interaction of HIV-1 with an R5
 CC or X4 co-receptor and thereby inhibiting HIV-1 infectivity, comprising
 CC (C1) and a carrier or excipient; (6) a computing platform for generating
 CC a 3D model of a constrained HIV V3 view peptide; (7) a computer generated
 CC model representing the conformationally constrained structure of a V3
 CC loop peptide that is bound to 447-52D or 0.5beta Mab or its antigen
 CC binding fragments, comprising a 3D atomic structure defined by NC; and
 CC (8) a computer readable medium (CM) comprising, in a retrievable format,
 CC data that includes a set of structure coordinates defining a 3D structure
 CC of a V3 loop peptide that is conformationally constrained by being bound
 CC to 447-52D or 0.5beta Mab or its antigen binding fragment. (C1) has anti-
 CC HIV activities, and can be used in vaccines, and as an inhibitor of
 CC binding of HIV-1 to chemokine receptor/HIV-1 co-receptor. (C1) is useful
 CC for in vivo inhibition of HIV-1 infection. (C1) or (C2) is useful for
 CC producing a medicament utilised for treating or preventing HIV-1
 CC infection. (C3) or (C4) is useful for inducing in a subject an anti-HIV-1
 CC neutralising antibody response specific for a V3 loop epitope. (C4) is
 CC useful for preventing an HIV-1 infection in an uninfected subject at risk
 CC for such infection or for inhibiting viral spread and disease progression
 CC in an infected subject. The present sequence represents a peptide used in
 CC the exemplification of the present invention.
 XX
 SQ Sequence 18 AA;
 Query Match 87.2%; Score 34; DB 8; Length 18;
 Best Local Similarity 100.0%; Pred. No. 2.1;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFTTIG 7
 Db 12 RAFTTIG 18
 RESULT 192
 AAP90279
 ID AAP90279 standard; protein; 20 AA.
 XX
 AC AAP90279;
 XX
 DT 09-SEP-2004 (revised)
 DT 24-OCT-2003 (revised)
 DT 25-MAR-2003 (revised)
 DT 22-JUN-1990 (first entry)
 XX
 DE Peptide 132 of HIV env gene.
 XX
 KM HIV; AIDS; env gene; HIV vaccine; de.
 XX
 OS Simian-human immunodeficiency virus.
 OS Unidentified.
 XX
 PN EP306219-A.
 PD 08-MAR-1989.
 XX
 PF 25-AUG-1988; 88EP-00307889.
 PR 27-AUG-1987; 87US-00090080.
 XX
 PA (REPK) REPLIGEN CORP.
 XX
 PI Rusche JR, Putney SD, Jayaherian K, Farley J, Grimalta R, Lynn D;
 PI Petro J, Okeffe T;
 DR WPI; 1989-070387/10.
 XX
 PT New HIV proteins and peptide(s) - used in diagnosis, prophylaxis or
 PT therapy of AIDS, esp. for prepn. of vaccines against HIV infection.
 XX
 PS Claim 1; Page 27; 29pp; English.
 CC
 CC Protein derivative stimulates a lymphocyte proliferative response in HIV-
 CC infected humans, providing a means of diagnosis, protection and
 CC therapeutic value. (Updated on 25-MAR-2003 to correct PR field.) (Updated
 CC on 25-MAR-2003 to correct PA field.) (Updated on 24-OCT-2003 to
 CC standardise OS field)
 CC
 CC Revised record issued on 09-SEP-2004 : Correction to location
 XX
 SQ Sequence 20 AA;
 Query Match 87.2%; Score 34; DB 1; Length 20;
 Best Local Similarity 87.5%; Pred. No. 2.3;
 Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 1 RAFTTIG 8
 Db 3 RAFTTIG 10
 RESULT 193
 AAR25471
 ID AAR25471 standard; protein; 20 AA.
 XX
 AC AAR25471;
 XX
 DT 25-MAR-2003 (revised)
 DT 15-JAN-1993 (first entry)
 XX
 DE V3 loop structure.

KM Hepatitis B; surface antigen; AIDS; cytotoxic lymphocytes;
 KM disulphide loop; variable region.
 XX
 OS Synthetic.
 XX
 PN W09211291-A1.
 XX
 PD 09-JUL-1992.
 XX
 PF 16-DEC-1991; 91WO-EP002422.
 XX
 PR 20-DEC-1990; 90GB-00027623.
 PR 21-MAR-1991; 91GB-00005993.
 XX
 PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
 XX
 PI Van Wijnenale F, Baijot M, Prieels J;
 XX
 DR WPI; 1992-250032/30.
 XX
 PT New immunogenic hybrid polypeptide(s) for vaccine formulations - comprise
 PT S antigen of hepatitis B linked via spacer to heterologous antigen, e.g.
 PT gp from HSV or gp120 form HIV.
 XX
 PS Disclosure; Page 28; 38pp; English.
 XX
 CC The peptide sequence given represents the sequence from amino acid 310-
 CC 328 of the external protein gp120 from HIV. This comprises a disulphide
 CC loop in the third variable region. It was used in an example of the
 CC invention and was incorporated into hepatitis B surface antigen (HBsAg)
 CC particles. The hybrid formed in this reaction is useful as a vaccine for
 CC the prophylactic treatment of various infectious diseases eg. AIDS.
 CC Conjugation of this peptide with the HBsAg particle allows its processing
 CC to be directed via a non-endosomal route. In this way the gp120 fragment
 CC can be recognized by cytotoxic lymphocytes. (Updated on 25-MAR-2003 to
 CC correct FN field.)
 XX
 SQ Sequence 20 AA;
 QY
 Db 1 RAFTTIG 7
 14 RAFTTIG 20
 Query Match 87.2%; Score 34; DB 2; Length 20;
 Best Local Similarity 100.0%; Pred. No. 2.3;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 RESULT 194
 AAW76842
 ID AAW76842 standard; peptide; 20 AA.
 XX
 AC AAW76842;
 XX
 DT 25-JAN-1999 (first entry)
 XX
 DE Fusion immunoglobulin heavy chain HIV gp120 B cell epitope #12.
 XX
 KM B cell; T cell; epitope; immunoglobulin; heavy chain; gp120; IGH;
 KM human immune deficiency virus; HIV; tolerance; treatment; therapy;
 KM prophylaxis; vaccine; chemotherapy; immune response; modifier; tumour;
 KM microbial infection; autoimmune disease; antibody; apoptosis;
 KM antiviral T cell immunity.
 XX
 OS Mus sp.
 OS Homo sapiens.
 XX
 PN W09836087-A1.
 XX
 PD 20-AUG-1998.
 XX
 PF 13-FEB-1998; 98WO-US002766.
 XX

PR 13-FEB-1997; 97US-0040581P.
 XX
 PA (AMNA-) AMERICAN NAT RED CROSS.
 XX
 PI Scott D, Zambidis E;
 XX
 DR WPI; 1998-506315/43.
 XX
 PT New fusion immunoglobulin heavy chain including gp120 epitopes and
 PT related complete antibodies - DNA, vectors and transformed cells, used to
 PT induce tolerance to the epitopes for treatment of human immune deficiency
 PT virus infection.
 XX
 PS Claim 10; Page 119; 154pp; English.
 XX
 CC This sequence is an epitope used in the construction of a novel fusion
 CC immunoglobulin heavy chain (IGH) protein with a mammalian, especially
 CC human, IGH chain fused in frame at its N-terminus to one or more human
 CC immune deficiency virus (HIV) gp120 epitopes. Fusion Ig proteins and/or
 CC transfected cells are used to tolerate subjects to gp120 epitopes and to
 CC maintain this tolerance, particularly for treatment of HIV infection.
 CC optionally together with other therapeutic/prophylactic agents such as
 CC vaccines, chemotherapeutic agents and immune response modifiers. Such
 CC proteins can be used against other diseases where an immune response is
 CC deleterious, e.g. microbial infection, tumours or autoimmune disease.
 CC Induction of tolerance suppresses production of antibodies against gp120,
 CC so prevents or inhibits 'bystander' apoptosis of uninfected T cells that
 CC are bound to gp120 protein, maximising induction of protective antiviral
 CC T cell immunity
 XX
 SQ Sequence 20 AA;
 QY
 Db 1 RAFTTIG 7
 14 RAFTTIG 20
 Query Match 87.2%; Score 34; DB 2; Length 20;
 Best Local Similarity 100.0%; Pred. No. 2.3;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 RESULT 195
 ABP57070
 ID ABP57070 standard; peptide; 20 AA.
 XX
 AC ABP57070;
 XX
 DT 23-OCT-2003 (revised)
 DT 14-APR-2003 (first entry)
 XX
 DE HIV gp120 V3 loop derived peptide ARP740/28.
 XX
 KM Anti-human leukocyte antigen antibody; anti-HLA antibody; anti-HIV;
 KM proliferative immune response; anti-inflammatory; neuroprotective;
 KM cytoskeletal; gene therapy; vaccine; inflammatory disease; nerve damage;
 KM autoimmune disease; axonal damage; cancer; inflammatory; HIV.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN W0200304049-A2.
 XX
 PD 16-JAN-2003.
 XX
 PF 02-JUL-2002; 2002WO-GB003037.
 XX
 PR 02-JUL-2001; 2001GB-00016151.
 PR 23-NOV-2001; 2001GB-00028638.
 PR 28-JAN-2002; 2002GB-00001896.
 PR 28-MAR-2002; 2002GB-00007509.
 XX
 PA (ICEB-) ICE BIOLOGICS LTD.
 XX
 PI Dalglish AG, Cadogan M, Heeney J, White SDT;
 XX

XX WPI; 2003-210314/20.
 DR
 XX
 PT Use of anti-HLA antibody for the preparation of a medicament for treating
 PT a disease involving a proliferative immune response e.g. HIV,
 PT inflammatory diseases, autoimmune diseases, axonal/nerve damage or
 PT related impairment, cancers.
 XX
 PS Example; Page 41; 69pp; English.
 XX
 CC The present invention describes an anti-human leukocyte antigen (HLA)
 CC antibody (I) useful for the preparation of a medicament for treating a
 CC disease involving a proliferative immune response. (I) has anti-HIV,
 CC anti-inflammatory, neuroprotective and cytostatic activities, and can be
 CC used in vaccines and in gene therapy. The antibody (I) is useful for the
 CC preparation of a medicament for treating diseases involving a
 CC proliferative immune response, e.g. HIV, inflammatory diseases,
 CC autoimmune diseases, axonal or nerve damage or related impairment or
 CC cancers, and other diseases or conditions with an inflammatory component.
 CC The present sequence represents an HIV gp120 V3 loop derived peptide,
 CC which is used in the exemplification of the present invention. (Updated
 CC on 23-Oct-2003 to standardise OS field)
 CC
 SQ Sequence 20 AA;
 Query Match 87.2%; Score 34; DB 6; Length 20;
 Best Local Similarity 100.0%; Pred. No. 2.3;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RAFTTIG 7
 |||||
 Db 14 RAFTTIG 20
 RESULT 196
 AAR66425
 ID AAR66425 standard; peptide; 15 AA.
 AC AAR66425;
 DT 25-MAR-2003 (revised)
 DT 03-AUG-1995 (first entry)
 XX
 DE HIV-1 IIB peptide 18-10.
 XX
 KW T cell helper site; cytotoxic T cell response; neutralising antibody;
 KW human immunodeficiency virus type 1; envelope glycoprotein gp120;
 KW cluster peptide; principal neutralising determinant.
 XX
 OS Synthetic.
 XX
 PN WO9426785-A1.
 XX
 PD 24-NOV-1994.
 XX
 PF 13-MAY-1994; 94MO-US005142.
 XX
 PR 14-MAY-1993; 93US-00060988.
 XX
 PA (USSH) US SEC DEPT HEALTH.
 PI Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
 DR WPI; 1995-006707/01.
 XX
 PT Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
 PT responses - to target antigen in hosts of different MHC haplotypes, esp.
 PT for therapeutic or prophylactic vaccines against HIV.
 XX
 PS Example 1; Page 33; 120pp; English.
 CC Single residues from the HIV-1 RF sequence (AAR66415) replaced residues
 CC in the HIV-1 IIB sequence (AAR66414) to test the effect of each residue

CC on the binding of neutralising and non-neutralising sera from animals
 CC immunised with the cluster peptides PCUS 3-18 and PCUS 6-18 (see
 CC AAR66409 and AAR66411). Analysis of the substituted peptides (AAR66416-
 CC R66430) showed that binding was enhanced over peptide 18 control when a
 CC tyrosine was subst. for a Val at position 11 and substns. at positions
 CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
 CC sera was reduced when substns. were made in the principal neutralising
 CC determinant sequence (PGRAF). In peptide 18-10, the Phe residue at
 CC position 10 in peptide 18 has been replaced by a Ile residue. (Updated on
 CC 25-MAR-2003 to correct PN field.)
 CC
 SQ Sequence 15 AA;
 Query Match 84.6%; Score 33; DB 2; Length 15;
 Best Local Similarity 87.5%; Pred. No. 2.9;
 Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 RAFTTIG 8
 |||||
 Db 8 RAFTTIG 15
 RESULT 197
 AAR66429
 ID AAR66429 standard; peptide; 15 AA.
 AC AAR66429;
 DT 25-MAR-2003 (revised)
 DT 03-AUG-1995 (first entry)
 XX
 DE HIV-1 IIB peptide 18-14.
 XX
 KW T cell helper site; cytotoxic T cell response; neutralising antibody;
 KW human immunodeficiency virus type 1; envelope glycoprotein gp120;
 KW cluster peptide; principal neutralising determinant.
 XX
 OS Synthetic.
 XX
 PN WO9426785-A1.
 XX
 PD 24-NOV-1994.
 XX
 PF 13-MAY-1994; 94MO-US005142.
 XX
 PR 14-MAY-1993; 93US-00060988.
 XX
 PA (USSH) US SEC DEPT HEALTH.
 PI Berzofsky JA, Ahlers JD, Pendleton CD, Nara P, Shirai M;
 DR WPI; 1995-006707/01.
 XX
 PT Polypeptide inducing helper T cell, cytotoxic T cell and antibodies
 PT responses - to target antigen in hosts of different MHC haplotypes, esp.
 PT for therapeutic or prophylactic vaccines against HIV.
 XX
 PS Example 1; Page 33; 120pp; English.
 CC Single residues from the HIV-1 RF sequence (AAR66415) replaced residues
 CC in the HIV-1 IIB sequence (AAR66414) to test the effect of each residue
 CC on the binding of neutralising and non-neutralising sera from animals
 CC immunised with the cluster peptides PCUS 3-18 and PCUS 6-18 (see AAR66416-
 CC R66430) showed that binding was enhanced over peptide 18 control when a
 CC tyrosine was subst. for a Val at position 11 and substns. at positions
 CC 12,13,14 and 15 revealed a similar enhancement. Binding of both groups of
 CC sera was reduced when substns. were made in the principal neutralising
 CC determinant sequence (PGRAF). In peptide 18-14, the Gly residue at
 CC position 14 in peptide 18 has been replaced by an Ala residue. (Updated
 CC on 25-MAR-2003 to correct PN field.)
 CC
 SQ Sequence 15 AA;

Query Match 84.6%; Score 33; DB 2; Length 15;
 Best Local Similarity 87.5%; Pred. No. 2.9;
 Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 RAFVTIGK 8
 |||||
 8 RAFVTIAK 15

Db

RESULT 198
 ABB05778
 ID ABB05778 standard; peptide; 7 AA.
 XX
 AC ABB05778;
 XX
 DT 29-AUG-2003 (revised)
 DT 07-MAY-2002 (first entry)
 XX
 DE HIV gp120 related peptide SEQ ID NO:4.
 XX
 KW Polyfunctional base sequence; microgene; industrial; cell culture;
 KW artificial matrix protein; transgenic animal; HIV.
 XX
 OS Human immunodeficiency virus 1.
 OS WO200196558-A1.
 PN
 XX
 PD 20-DEC-2001.
 XX
 PF 15-JUN-2001; 2001WO-JP005116.
 XX
 PR 16-JUN-2000; 2000JP-00180997.
 XX
 PA (NISC-) JAPAN SCI & TECHNOLOGY CORP.
 XX
 PI Shiba K;
 XX
 DR WPI; 2002-098069/13.
 XX
 PT Polyfunctional base sequence having two or more functions in different
 PT reading frames, useful for producing artificial matrix proteins for cell
 PT culture.
 XX
 PS Example 1; Page 47; 61pp; Japanese.
 XX
 CC The present invention describes a polyfunctional base sequence (N1)
 CC having two or more functions in different reading frames. Also described
 CC are: (1) a method for producing N1 and artificial gene expression vectors
 CC comprising N1; (2) transgenic non-human animals comprising N1; and (3)
 CC treatments and diagnostic reagents containing an artificial protein,
 CC artificial tissues or high molecular weight artificial proteins. N1 is
 CC useful for creating industrially useful artificial matrix proteins for
 CC cell culture. The present sequence represents a peptide which is used in
 CC an example from the present invention. (Updated on 29-AUG-2003 to
 CC standardise OS field)
 CC
 SQ Sequence 7 AA;

Query Match 76.9%; Score 30; DB 5; Length 7;
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 3 FVTIGK 8
 |||||
 1 FVTIGK 6

Db

RESULT 199
 AAO15660
 ID AAO15660 standard; peptide; 7 AA.
 XX
 AC AAO15660;

XX 08-NOV-2002 (first entry)
 DT
 XX
 DE Strong immune response induction-related peptide 4.
 DE
 XX Strong immune response induction; high-order protein structure formation;
 KW antigen presentation; HIV.
 KW
 XX Unidentified.
 OS
 PN WO200233074-A1.
 XX
 PD 25-APR-2002.
 XX
 PF 10-OCT-2001; 2001WO-JP008893.
 XX
 PR 13-OCT-2000; 2000JP-00314288.
 XX
 PA (NISC-) JAPAN SCI & TECHNOLOGY CORP.
 XX
 PI Shiba K, Ohno T;
 XX
 DR WPI; 2002-519151/55.
 XX
 PT Artificial protein capable of inducing a strong immune response to a
 PT peptide group for assisting antibody production in vivo to viruses and
 PT other antigens.
 XX
 PS Example 1; Page 46; 77pp; Japanese.
 XX
 CC The invention comprises an artificial protein which induces a strong
 CC immune response to a peptide group (the protein contains all or part of
 CC the peptide group). The artificial protein assists the formation of high-
 CC order protein structure and/or assists the antigen presentation of
 CC immunocompetent cells. The artificial protein of the invention is useful
 CC for inducing a strong immune response and the preparation of effective
 CC antibodies to specific antigens, especially HIV. The present amino acid
 CC sequence represents a peptide that was used in the invention
 CC
 SQ Sequence 7 AA;

Query Match 76.9%; Score 30; DB 5; Length 7;
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 3 FVTIGK 8
 |||||
 1 FVTIGK 6

Db

RESULT 200
 AAM38251
 ID AAM38251 standard; peptide; 15 AA.
 XX
 AC AAM38251;
 XX
 DT 19-MAR-1998 (first entry)
 DT
 XX Carboxy-terminal of GPGR crest.
 DE
 XX Multivalent chimeric peptide; tandem repeat unit; human; mucin 1; MUC1;
 KW Omega loop sequence; prophylaxis; therapy; GPGR crest;
 KW pathogenic virus neutralisation; human immunodeficiency virus; HIV.
 XX
 OS Homo sapiens.
 OS
 PN WO9728187-A2.
 XX
 PD 07-AUG-1997.
 XX
 PF 29-JAN-1997; 97WO-US001726.
 XX
 PR 31-JAN-1996; 96US-00594403.


```

PR 15-OCT-1996; 96US-00730244.
XX (POPU-) POPULATION COUNCIL INC.
XX
XX Fontenot JD, Phillips DM;
XX
XX WPI; 1997-402551/37.
XX
XX New multivalent chimeric peptide(s) for neutralising pathogenic microbes
XX - comprising a loop structure of human mucin 1 and an omega loop of an
XX immunoglobulin superfamily protein.
XX
XX Example 2; Page 39; 63pp; English.
XX
XX The present sequence was used in the development of a novel multivalent
XX chimeric peptide, comprising at least 2 tandemly repeated units, where
XX the 1st portion of the repeated unit comprises a human mucin 1 (MUC1)
XX sequence which forms an extended connector and a base of a loop structure
XX of human MUC1, and a 2nd portion comprising an immunoglobulin super
XX family protein Omega loop sequence. In the peptide, the natural structure
XX of MUC1 tandem repeats can be used to present an Omega loop sequence in a
XX functional conformation that is both multivalent and biologically active.
XX It can provide prophylactic and therapeutic agents which have the binding
XX specificity of an immunoglobulin super family member protein but do not
XX have the entire protein's backbone. It can be used to neutralise
XX pathogenic viruses, e.g. human immunodeficiency virus (HIV)
XX
XX Sequence 15 AA;
XX
XX Query Match 76.9%; Score 30; DB 2; Length 15;
XX Best Local Similarity 100.0%; Pred. No. 14;
XX Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 3 FVTIGK 8
XX |||||
XX 1 FVTIGK 6
XX
XX Db
XX
XX RESULT 201
XX AAW76971
XX ID AAW76971 standard; peptide; 15 AA.
XX
XX AAW76971;
XX
XX 25-JAN-1999 (first entry)
XX
XX Fusion immunoglobulin heavy chain HIV gp120 T cell epitope #40.
XX
XX B cell; T cell; epitope; immunoglobulin; heavy chain; gp120; IGH;
XX human immune deficiency virus; HIV; tolerance; treatment; therapy;
XX prophylaxis; vaccine; chemotherapy; immune response; modifier; tumour;
XX microbial infection; autoimmune disease; antibody; apoptosis;
XX antiviral T cell immunity.
XX
XX Mus sp.
XX OS Homo sapiens.
XX
XX WO9836087-A1.
XX
XX 20-AUG-1998.
XX
XX 13-FEB-1998; 98WO-US002766.
XX
XX 13-FEB-1997; 97US-0040581P.
XX
XX (AMNA-) AMERICAN NAT RED CROSS.
XX
XX Scott D, Zambidis E;
XX
XX WPI; 1998-506315/43.
XX
XX New fusion immunoglobulin heavy chain including gp120 epitopes and
XX related complete antibodies - DNA, vectors and transformed cells, used to

```

```

PT induce tolerance to the epitopes for treatment of human immune deficiency
PT virus infection.
XX
XX Disclosure; Page 41; 154pp; English.
XX
XX This sequence is an epitope used in the construction of a novel fusion
XX immunoglobulin heavy chain (IGH) protein with a mammalian, especially
XX human, IGH chain fused in frame at its N-terminus to one or more human
XX immune deficiency virus (HIV) gp120 epitopes. Fusion Ig proteins and/or
XX transfectant cells are used to tolerate subjects to gp120 epitopes and to
XX maintain this tolerance, particularly for treatment of HIV infection,
XX optionally together with other therapeutic/prophylactic agents such as
XX vaccines, chemotherapeutic agents and immune response modifiers. Such
XX proteins can be used against other diseases where an immune response is
XX deleterious, e.g. microbial infection, tumours or autoimmune disease.
XX Induction of tolerance suppresses production of antibodies against gp120,
XX so prevents or inhibits 'bystander' apoptosis of uninfected T cells that
XX are bound to gp120 protein, maximising induction of protective antiviral
XX T cell immunity
XX
XX Sequence 15 AA;
XX
XX Query Match 76.9%; Score 30; DB 2; Length 15;
XX Best Local Similarity 100.0%; Pred. No. 14;
XX Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 3 FVTIGK 8
XX |||||
XX 1 FVTIGK 6
XX
XX Db
XX
XX RESULT 202
XX AAR90229
XX ID AAR90229 standard; peptide; 15 AA.
XX
XX AAR90229;
XX
XX 06-APR-1996 (first entry)
XX
XX Cyclic HIV PND peptide attached to annular antigen scaffold.
XX
XX annular antigen scaffold core; AASC; HIV V3 loop; lysine;
XX principal neutralising determinant; PND; cyclic; vaccine.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX Modified-site 1
XX /note= "This residue is bonded to the thiol sulphur of
XX Cys(13) via a -CO-CH2- linkage, formed by introducing a
XX bromoacetyl group onto the N-terminal and allowing the Br
XX to condense with the Cys side chain"
XX Modified-site 13
XX /note= "see above"
XX Modified-site 15
XX /note= "this is an epsilon-lys residue, the alpha-amino
XX and carboxy terminals of which are incorporated into an
XX annular antigen scaffold core of formula KKKCK as
XX described in AAR90224"
XX
XX GB2282813-A.
XX
XX 19-APR-1995.
XX
XX 07-OCT-1994; 94GB-00020263.
XX
XX 15-OCT-1993; 93US-00138514.
XX
XX (MERI ) MERCK & CO INC.
XX
XX Cunningham B, Hannah J, Tolman RL;
XX
XX WPI; 1995-141219/19.
XX
XX DR

```

XX New poly:lysine annular core for carrying epitope(s) - esp HIV V3 loop
 PT peptide, gonadotropin releasing hormone, malarial or bacterial peptide,
 PT useful in vaccines.
 XX
 PS Claim 5, Page 49; 52pp; English.
 CC
 CC New annular antigen scaffold cores are provided for antigens or epitopes
 CC such as HIV V3 loop peptides (e.g. the present sequence; but see also
 CC GB2282815; AAR90219 - AAR90223), GnRH peptides, malaria antigenic
 CC peptides or bacterial capsular polysaccharides. The scaffolds comprise a
 CC ring of 3-10 lys residues cyclised via a thioether linkage. The epitopes
 CC or antigens are bonded to each of the lys side-chain amino groups. The C-
 CC terminus of the scaffold may be linked to a moiety such as beta-alanine
 CC or a peptide providing a T cell epitope, a lipopeptide which may provide
 CC an adjuvant effect, or another moiety providing a carrier function. The
 CC scaffolds constitute effective synthetic vaccines. The present sequence
 CC represents one of four identical thioether-cyclised HIV V3 loop peptides
 CC which are attached to each of the four lys residues in the the annular
 CC scaffold core described in AAR90224
 CC
 XX Sequence 15 AA;
 SQ
 Query Match 74.4%; Score 29; DB 2; Length 15;
 Best Local Similarity 75.0%; Pred. No. 23;
 Matches 6; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1 RAFTTICK 8
 DB 8 RAFTTICK 15
 RESULT 203
 AAM32887
 ID AAM32887 standard; peptide; 15 AA.
 XX
 AC AAM32887;
 XX
 DT 16-JAN-1998 (first entry)
 XX
 DE HIV envelope glycoprotein 120 T cell epitope P10.
 XX
 KM Hydrophilic; antigenic determinant; HIV; envelope; glycoprotein; env; gp;
 KM recognition; B lymphocyte; type specific; antibody; vaccine; protection;
 KM immune response; infection; neutralisation; epitope.
 XX
 OS Human immunodeficiency virus.
 XX
 PN WO9714436-A1.
 XX
 PD 24-APR-1997.
 XX
 PF 18-OCT-1996; 96WO-US016911.
 XX
 PR 20-OCT-1995; 95US-00546515.
 PR 09-FEB-1996; 96US-00599266.
 XX
 PA (UYDU-) UNIV DUKE.
 XX
 PI Haynes BF, Palker TJ;
 XX
 DR WPI; 1997-244862/22.
 XX
 PT Synthetic human immunodeficiency virus vaccine - comprising hydrophilic
 PT peptide corresponding to at least 1 antigenic determinant of envelope
 PT glyco:protein recognised by B lymphocytes.
 XX
 PS Disclosure; Page 27; 104pp; English.
 XX
 CC An essentially pure hydrophilic peptide, comprising at least 1 antigenic
 CC determinant of human immunodeficiency virus (HIV) envelope (env)
 CC glycoprotein (gp) recognised by B lymphocytes, when covalently linked to
 CC a carrier molecule, i.e. the present sequence, induces the production of

CC high titres of protective, type specific anti-HIV antibodies (Ab) in a
 CC mammal. The peptide can be used in vaccines for producing a protective
 CC immune response to HIV infection, while a HIV neutralising Ab can be
 CC induced in a primate by administering a composition comprising HIV env
 CC peptides that disrupt gp120/gp41 interactions
 CC
 XX Sequence 15 AA;
 SQ
 Query Match 74.4%; Score 29; DB 2; Length 15;
 Best Local Similarity 87.5%; Pred. No. 23;
 Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 RAFTTICK 8
 DB 8 RAFTTICK 15
 RESULT 204
 AAM55971
 ID AAM55971 standard; peptide; 15 AA.
 XX
 AC AAM55971;
 XX
 DT 29-SEP-1998 (first entry)
 XX
 DE Map kinase kinase 3 (MKK3) N-terminal peptide.
 XX
 KM Stress-activated protein kinase 4; SAPK4; pituitary gland; asthma;
 KM stress activated kinase kinase 3; SKK3; rheumatoid arthritis; porphyria;
 KM inflammatory disease; immunoprecipitation; MKK3; map kinase kinase 3.
 XX
 OS Synthetic.
 OS Unidentified.
 XX
 PN WO9815618-A1.
 XX
 PD 16-APR-1998.
 XX
 PF 09-OCT-1997; 97WO-GB002779.
 XX
 PR 09-OCT-1996; 96GB-00021096.
 PR 15-MAY-1997; 97GB-00009781.
 XX
 PA (MED1-) MEDICAL RES COUNCIL.
 XX
 PI Cohen P, Goedert M;
 XX
 DR WPI; 1998-240806/21.
 XX
 PT New stress-activated protein kinase 4 - useful in drug screening, for,
 PT e.g. anti-inflammatory, anti-cancer and immuno-suppressing agents.
 XX
 PS Example 4; Page 63; 119pp; English.
 XX
 CC The map kinase kinase 3 (MKK3) N-terminal peptide was used to raise
 CC polyclonal anti-MKK3 antibodies. These antibodies were used in the
 CC immunoprecipitation of stress-activated protein kinases (SAPK). The
 CC invention claims for the human SAPK4 cDNA (AAV6081) isolated from a
 CC human pituitary gland cDNA library. The invention also claims that SAPK4
 CC protein (AAM55967) can be useful in a screening assay for identifying
 CC agents that inhibit its activity and/or agents that block its activation
 CC through stress activated kinase kinase 3 (SKK3). Therefore, the agents
 CC identified in the assays may be potentially useful for treating
 CC inflammatory diseases, e.g. rheumatoid arthritis, asthma and psoriasis
 CC
 XX Sequence 15 AA;
 SQ
 Query Match 74.4%; Score 29; DB 2; Length 15;
 Best Local Similarity 71.4%; Pred. No. 23;
 Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 1 RAFTTICK 7
 DB 1 RAFTTICK 7

Db 6 RTFRTIG 12

RESULT 205

AAW5898
ID AAW5898 standard; peptide; 20 AA.

XX AAW5898;

XX 16-OCT-2003 (revised)

XX 25-MAR-2003 (revised)

XX 07-SEP-1995 (first entry)

XX B cell epitope, LAI.

XX T-cell; epitope; HIV-1, core protein; p24E; B-cell; antigen; gp160; gag;

XX pol; vaccine; multimeric peptide; AIDS; 3D organisation.

XX Human immunodeficiency virus 1.

XX WO9428339-A1.

XX 22-DEC-1994.

XX 08-JUN-1994; 94WO-CA000317.

XX 09-JUN-1993; 93US-00073378.

XX (CONN-) CONNUGHT LAB LTD.

XX Sia CDY, Chong P, Klein MH;

XX WPI; 1995-036400/05.

XX Novel tandem synthetic HIV-1 peptide(s) - comprising T-cell epitope of

XX gag protein linked to B-cell epitope of V3 loop protein of an HIV-1

XX isolate.

XX Disclosure; Page 16; 63pp; English.

XX This sequence represents a B-cell epitope sequence derived from the V3

XX loop of the HIV-1 isolate, LAI. This B-cell epitope may be linked to a T-

XX cell epitope also derived from HIV-1. These chimeric peptides may then be

XX used in the production of HIV-1 vaccines. These peptide sequences may

XX also be used in the production of multimeric peptides in which the

XX peptides are C-terminally modified by the addition of a lys residue which

XX is modified on its epsilon amino acid to carry an additional copy of the

XX peptide molecule. The linear and multimeric peptides may be used for the

XX treatment of AIDS by acting to displace the binding of HIV virus to human

XX or animal cells or by disturbing the 3D organisation of the virus.

XX (Updated on 25-MAR-2003 to correct FN field.) (Updated on 16-OCT-2003 to

XX standardise OS field)

XX Sequence 20 AA;

XX

XX

XX

XX

DE HIV-1 strain IIB env protein V3 loop B-cell epitope.

XX HIV; human immunodeficiency virus; gag; T-cell; B-cell; epitope; env;

XX V3 loop; vaccine; determinant; chimeric.

XX Synthetic.

XX US639854-A.

XX 17-JUN-1997.

XX 09-JUN-1994; 94US-00257528.

XX 09-JUN-1993; 93US-00073378.

XX (CONN-) CONNUGHT LAB LTD.

XX Klein MH, Sia CDY, Chong P;

XX WPI; 1997-332082/30.

XX Tandem synthetic HIV peptide(s) useful as immunogens - comprising gag

XX protein T-cell epitope linked to env protein B-cell epitope.

XX Claim 8; Col 74; 41pp; English.

XX The invention relates to new synthetic peptides comprising at least one

XX amino acid sequence comprising an HIV gag protein T-cell epitope linked

XX at its C- or N-terminus to an amino acid sequence comprising a B-cell

XX epitope of the V3 loop of an HIV env protein, which can be used to

XX generate vaccines against HIV-1. The T-cell epitope sequence is pref.

XX selected from the T-helper determinant core peptides P24E, P24N, P24L,

XX P24M and P24H while the B-cell epitopes are derived from HIV strains

XX including CTB-56, V3MN, CTB-29, CTB-55, SF2, LAI, IIB, RF, Z6, 2054,

XX 1714 and BX08. The peptides are chimeric and can be linked to a branched

XX lys backbone. This sequence represents the HIV-1 strain IIB env protein

XX V3 loop B-cell epitope. (Updated on 25-MAR-2003 to correct PF field.)

XX Sequence 20 AA;

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

RESULT 207

AAW5850
ID AAW5850 standard; peptide; 20 AA.

XX AAW5850;

XX 25-MAR-2003 (revised)

XX 20-OCT-1997 (first entry)

XX HIV-1 strain LAI env protein V3 loop B-cell epitope.

XX HIV; human immunodeficiency virus; gag; T-cell; B-cell; epitope; env;

XX V3 loop; vaccine; determinant; chimeric.

XX Synthetic.

XX US639854-A.

XX 17-JUN-1997.

XX 09-JUN-1994; 94US-00257528.

XX 09-JUN-1993; 93US-00073378.

XX

XX

PA (CONN-) CONNAUGHT LAB LTD.
 XX Klein MH, Sia CDY, Chong P;
 XX WPI; 1997-332082/30.
 XX
 PT Tandem synthetic HIV peptide(s) useful as immunogens - comprising gag
 XX protein T-cell epitope linked to env protein B-cell epitope.
 XX
 PS Claim 8; Col 74; 41pp; English.
 XX
 CC The invention relates to new synthetic peptides comprising at least one
 CC amino acid sequence comprising an HIV gag protein T-cell epitope linked
 CC at its C- or N-terminus to an amino acid sequence comprising a B-cell
 CC epitope of the V3 loop of an HIV env protein, which can be used to
 CC generate vaccines against HIV-1. The T-cell epitope sequence is pref.
 CC selected from the T-helper determinant core peptides P24E, P24N, P24L,
 CC P24W and P24H while the B-cell epitopes are derived from HIV strains
 CC including CTB-56, V3MN, CTLB-29, CTLB-55, SF2, LAI, IIB, RF, Z6, 2054,
 CC 1714 and BX08. The peptides are chimeric and can be linked to a branched
 CC lys backbone. This sequence represents the HIV-1 strain LAI env protein
 CC V3 loop B-cell epitope. (Updated on 25-MAR-2003 to correct PF field.)
 XX
 SQ Sequence 20 AA;
 Query Match 74.4%; Score 29; DB 2; Length 20;
 Best Local Similarity 85.7%; Pred. No. 31;
 Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 1 RAFYITG 7
 ||| |||
 Db 14 RAFYITG 20
 RESULT 208
 AAW67366
 ID AAW67366 standard; peptide; 20 AA.
 XX
 AC AAW67366;
 XX
 DT 17-OCT-2003 (revised)
 DT 25-JAN-1999 (first entry)
 XX
 DE HIV-1 strain LAI V3 loop peptide epitope.
 XX
 XX Immunogen; vaccine; HIV-1; T-cell; B-cell; epitope; core protein; gp120;
 KM V3 loop.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN US5817754-A.
 XX
 PD 06-OCT-1998.
 XX
 PF 05-JUN-1995; 95US-00464329.
 XX
 PR 09-JUN-1993; 93US-00073378.
 PR 09-JUN-1994; 94US-00257528.
 XX
 PA (CONN-) CONNAUGHT LAB LTD.
 XX
 XX Chong P, Klein MH, Sia CDY;
 PT WPI; 1998-556461/47.
 DR
 XX
 PT Synthetic human immunodeficiency virus-1 peptide(s) - containing T-cell
 PT epitope and B-cell epitope(s) are candidate vaccines against HIV-1.
 XX
 PS Disclosure; Col 9; 40pp; English.
 XX
 CC The invention relates to a novel immunogenic composition for use in
 CC vaccines for the treatment of HIV-1 comprising an HIV-1-derived T-cell
 CC epitope linked to an HIV-1-derived B-cell epitope. The T-cell epitopes

CC are generally designed based on the p24 core protein and the B-cell
 CC epitopes from the V3 loop of the gp120 protein from various HIV-1
 CC strains. This peptide corresponds to the V3 loop peptide epitope from the
 CC HIV-1 strain LAI. The peptide is used to generate a hybrid T- and B-cell
 CC epitope (AAW67353). (Updated on 17-OCT-2003 to standardise OS field)
 XX
 SQ Sequence 20 AA;
 Query Match 74.4%; Score 29; DB 2; Length 20;
 Best Local Similarity 85.7%; Pred. No. 31;
 Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 1 RAFYITG 7
 ||| |||
 Db 14 RAFYITG 20
 RESULT 209
 AAW99974
 ID AAW99974 standard; peptide; 20 AA.
 XX
 AC AAW99974;
 XX
 DT 05-MAY-1999 (first entry)
 XX
 DE HIV-1 vaccine synthetic peptide SEQ ID NO:51.
 XX
 KM HIV-1; human immunodeficiency virus; vaccine; T-cell epitope;
 KM gag protein; B-cell epitope; gp120 protein; chimeric; infection.
 XX
 OS Synthetic.
 OS Human immunodeficiency virus 1.
 XX
 PN US5876731-A.
 XX
 PD 02-MAR-1999.
 XX
 PF 05-JUN-1995; 95US-00462507.
 XX
 PR 09-JUN-1993; 93US-00073378.
 PR 09-JUN-1994; 94US-00257528.
 XX
 PA (CONN-) CONNAUGHT LAB LTD.
 XX
 XX Chong P, Klein MH, Sia CDY;
 PT WPI; 1999-189590/16.
 DR
 XX
 PT Synthetic chimeric HIV polypeptides - comprising gag protein T-cell
 PT epitope linked to gp120 B-cell epitope.
 XX
 PS Example 1; Col 49-50; 41pp; English.
 XX
 CC The present invention describes a synthetic peptide comprising an amino
 CC acid sequence containing a T-cell epitope of an HIV gag protein linked at
 CC its C terminus to an amino acid sequence containing a B-cell epitope of
 CC an HIV gp120 protein and containing the amino acid sequence: X1KDMX2;
 CC where X1 = E, A, G or Q, and X2 = A or T, or an amino acid sequence
 CC capable of eliciting an HIV-specific antiserum and recognizing the
 CC sequence X1KDMX2. The synthetic peptide is useful in vaccines against
 CC HIV infection and in diagnostic applications. AAW98892 to AAW98906, and
 CC AAW98899 to AAW98989 represent synthetic peptides from the present
 CC invention
 XX
 SQ Sequence 20 AA;
 Query Match 74.4%; Score 29; DB 2; Length 20;
 Best Local Similarity 85.7%; Pred. No. 31;
 Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 1 RAFYITG 7
 ||| |||
 Db 14 RAFYITG 20

RESULT 210

AAV39699

ID AAY39699 standard; peptide; 20 AA.

XX AAY39699;

XX

DT 17-OCT-2003 (revised)

DT 26-NOV-1999 (first entry)

XX

DE HIV1 chimeric peptide IAI.

XX

KM HIV, vaccine; immunogenic composition; T cell epitope; B cell epitope;

KM infection; antibody; antiviral.

XX

OS Human immunodeficiency virus 1.

XX

PN US951986-A.

XX

PD 14-SEP-1999.

XX

PF 06-JUN-1995; 95US-00467881.

XX

PR 09-JUN-1993; 93US-00073378.

XX

PR 09-JUN-1994; 94US-00257528.

XX

PA (CONN-) CONNAUGHT LAB LTD.

XX

PI Klein MH, Chong P, Sia CDY;

XX

DR WPI, 1999-550482/46.

XX

PT Immunogenic composition containing synthetic fusion polypeptides

XX

PS Disclosure; Col 9; 43pp; English.

XX

CC This sequence represents a fragment of a HIV1 protein, and can be used in

XX

CC the immunogenic composition of the invention. The composition comprises a

XX

CC synthetic fusion polypeptide which includes a sequence encoding 1 or more

XX

CC T cell epitopes and a sequence encoding 1 or more B cell epitopes and a

XX

CC carrier. Both the T cell and B cell epitopes are derived from HIV

XX

CC proteins. The compositions are useful as vaccines against HIV infection.

XX

CC The composition induces HIV-1-specific polyclonal antibodies that are

XX

CC opsonising and antiviral. The peptide components may be selected to

XX

CC induce a response against different viral isolates and in subjects who

XX

CC recognise different T cell epitopes. (Updated on 17-OCT-2003 to

XX

CC standardise OS field)

XX

SQ Sequence 20 AA;

XX

Query Match 74.4%; Score 29; DB 2; Length 20;

XX

Best Local Similarity 85.7%; Pred. No. 31;

XX

Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

XX

OY 1 RAVFTIG 7

XX

XX

XX

XX

XX

RESULT 211

AAE88800

ID AAE88800 standard; peptide; 9 AA.

XX

AC AAE88800;

XX

DT 25-MAR-2003 (revised)

DT 23-AUG-1995 (first entry)

XX

DE Cytotoxic T lymphocyte epitope 57 derived from env gp120 protein.

XX

KM cytotoxic T lymphocyte; epitope; antigen; pathogenic; nef; gag; pol; env;

KM gp120; gp41; HIV; cell-mediated immunity; human immunodeficiency virus;

KM class II restricted.

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

RESULT 212

AAV10165

ID AAV10165 standard; peptide; 9 AA.

XX

AC AAV10165;

XX

DT 12-MAY-1999 (first entry)

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

Query Match 71.8%; Score 28; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

PR 10-JUL-1997; 97CA-02209815.
 PR 10-DEC-1997; 97US-00988320.
 XX (CTL1-) CTL IMMUNOTHERAPIES CORP.
 PA Kuendig TM, Simard JTL;
 PI WPI; 1999-120514/10.
 DR
 XX
 XX Inducing a cytotoxic T lymphocyte response - by maintaining a level of
 PT antigen in the lymphatic system of a mammal so as to provide a sustained
 PT CTL response, used to treat, e.g. AIDS.
 XX
 PS Disclosure; Page 27; 199pp; English.
 XX
 XX The present invention describes a method of inducing and/or sustaining an
 CC immunological cytotoxic T lymphocyte (CTL) response in a mammal. The
 CC method comprises: (a) delivering an antigen to the mammal at a level to
 CC induce an immunological CTL response in the mammal; and (b) maintaining
 CC the level of the antigen in the mammal's lymphatic system to maintain the
 CC immunologic CTL response. The method can be used for the delivery of e.g.
 CC a differentiation antigen, a tumour-specific multilinage antigen, an
 CC embryonic antigen, an oncogene antigen, a mutated tumour-suppressor gene
 CC antigen, or a viral antigen. They can be used for the treatment of
 CC disease such as cancer, e.g. malignant melanoma or infectious disease.
 CC e.g. Viral disease such as hepatitis or AIDS. Sustained antigen delivery
 CC to the lymphatic system provides for potent CTL stimulation that takes
 CC place in the milieu of the lymphoid organ, and it sustains stimulation
 CC that is necessary to keep CTL active, cytotoxic and recirculating through
 CC the body. AA10071 to AA10639 represent examples of peptide antigens
 CC given in the present invention
 CC
 SQ Sequence 9 AA;

Query Match 71.8%; Score 28; DB 2; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFTI 6
 |||||
 DB 4 RAFTI 9

RESULT 213
 ABG79847
 ID ABG79847 standard; peptide; 9 AA.
 XX
 AC ABG79847;
 XX
 DT 15-NOV-2002 (first entry)
 XX
 DE MHC class I molecule, viral epitope #95.
 XX
 XX Major histocompatibility complex; MHC; MHC class I molecule; virus;
 KM epitope; cytotoxic T lymphocyte response; CTL response; lymphatic system;
 KM antigen; immunogenic; malignant tumour; carcinoma; melanoma; leukaemia;
 KM lymphoma; infectious disease; hepatitis; malaria; measles; tuberculosis;
 KM acquired immune deficiency syndrome; AIDS.
 XX
 XX Human immunodeficiency virus.
 OS
 PN WO200262368-A2.
 XX
 PD 15-AUG-2002.
 XX
 PF 22-JAN-2002; 2002WO-US002033.
 XX
 PR 02-FEB-2001; 2001US-00776232.
 XX
 PA (CTL1-) CTL IMMUNOTHERAPIES CORP.
 XX
 XX Kuendig TM, Simard JTL;
 PI
 XX

DR WPI; 2002-657506/70.

XX
 XX Inducing or sustaining immunological cytotoxic T lymphocyte response in a
 PT mammal, useful for treating a mammal with malignant tumor or infectious
 PT disease, by directly administering an antigen to the lymphatic system of
 PT the mammal.
 XX
 PS Disclosure; Page 20; 73pp; English.

XX
 XX The invention relates to a method of inducing and/or sustaining an
 CC immunological cytotoxic T lymphocyte (CTL) response in a mammal
 CC comprising administering directly to the lymphatic system of the mammal:
 CC (a) an antigen in the form of a polypeptide; (b) a vector comprising a
 CC nucleic acid encoding the antigen; or (c) a non-peptide antigen. The
 CC method is useful for inducing and/or sustaining CTL response in a mammal.
 CC This is particularly useful for treating a mammal having a malignant
 CC tumour (e.g. carcinoma, melanoma, leukaemia or lymphoma) or infectious
 CC disease (e.g. hepatitis, acquired immune deficiency syndrome (AIDS),
 CC malaria, measles or tuberculosis), or in an animal having a
 CC predisposition to these diseases. The mammal may be dogs, cats, mice,
 CC cattle, sheep, pigs, goats, rabbits, or preferably humans. ABG79753-
 CC ABG80319 represent viral epitopes on major histocompatibility complex
 CC (MHC) class I molecules, used in the method of the invention
 CC
 SQ Sequence 9 AA;

Query Match 71.8%; Score 28; DB 5; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFTI 6
 |||||
 DB 4 RAFTI 9

RESULT 214
 ABR55441
 ID ABR55441 standard; peptide; 9 AA.
 XX
 AC ABR55441;
 XX
 DT 29-JUL-2003 (first entry)
 XX
 DE Peptide derived from HIV gp120 V3 loop.
 XX
 KM Antigen; Bob; gp120; lymphocyte; HIV enteropathy; HIV nephropathy;
 KM HIV-related hyperlipidemia; HIV-related infertility.
 XX
 OS Human immunodeficiency virus.
 PN WO2003037251-A2.
 XX
 PD 08-MAY-2003.
 XX
 PF 25-OCT-2002; 2002WO-US034336.
 XX
 PR 29-OCT-2001; 2001US-0341045P.
 XX
 PA (UTAH) UNIV UTAH RES FOUND.
 XX
 XX Clayton F, Fantini J;
 PI
 XX
 DR WPI; 2003-430463/40.
 XX
 XX Novel composition for reducing interactions between Bob and gp120 and for
 PT reducing symptoms of HIV enteropathy, HIV nephropathy or HIV-related
 PT infertility, comprises a Bob inhibitor that binds a region of Bob.
 XX
 PS Claim 69; Page 136; 159pp; English.
 XX
 XX The specification describes a composition for reducing an interaction
 CC between Bob and gp120. The composition comprises a Bob inhibitor that
 CC binds a region of Bob, or a substance that interacts with N-terminal

CC sequence of the first loop or the first extracellular loop domains of Bob
CC (the substance binds Bob preferentially over galactosyl ceramide). The
CC composition is useful for reducing an interaction between Bob and gp120,
CC reducing activation of lymphocytes by gp120, reducing the symptoms of HIV
CC enteropathy, HIV nephropathy, HIV-related hyperlipidemia, or HIV-related
CC infertility. The present sequence is derived from a gp120 protein V3 loop
XX
SQ Sequence 9 AA:

Query Match 71.8%; Score 28; DB 6; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFTI 6
Db 4 RAFTI 9

RESULT 215

ADK68776
ID ADK68776 standard; peptide: 9 AA.

AC ADK68776;

DT 06-MAY-2004 (first entry)

DE Epitope liberation-related peptide SeqID139.

XX epitope liberation; substrate; proteasome; cytostatic; antibacterial;
KM protozoacide; fungicide; T-cell activator; vaccine; housekeeping epitope;
KM cytotoxic T lymphocyte; CTL; adoptive immunotherapy; neoplastic cell;
KM virus; bacterium; protozoan; fungus; housekeeping proteasome system.

XX Human immunodeficiency virus.

PN US2003228634-A1.

XX 11-DEC-2003.

XX 07-NOV-2002; 2002US-00292413.

XX 07-NOV-2001; 2001US-0336968P.

PA (SIMA/) SIMARD J J L.

PA (DIAM/) DIAMOND D C.

PA (QIUZ/) QIU Z.

PA (LEIX/) LEI X.

PI Simard JTL, Diamond DC, Qiu Z, Lei X;

XX WPI; 2004-167209/16.

PT Identifying polypeptide suitable for epitope e.g., housekeeping epitope,
PT liberation by contacting substrate polypeptide comprising epitope of
PT interest, with proteasome, and assaying for liberation of epitope.

XX Disclosure; SEQ ID NO 139; 67bp; English.

CC This invention relates to a novel method of identifying a polypeptide
CC suitable for epitope liberation, including the steps of identifying an
CC epitope of interest; providing substrate polypeptide sequence including
CC the epitope, wherein the substrate permits processing by a proteasome;
CC contacting the substrate with a composition including the proteasome,
CC under conditions that support processing of the substrate by proteasome;
CC and assaying for liberation of epitope. The invention may be useful for
CC the development of compounds with a cytostatic, antibacterial,
CC protozoacide or fungicide activity acting as T-cell activators. In
CC addition, the invention may allow development of a vaccine. The invention
CC is useful for identifying a polypeptide suitable for epitope liberation,
CC where the epitope is a housekeeping epitope. The compositions comprising
CC the identified housekeeping epitopes are useful in vitro in vaccine
CC development or in the generation or expansion of cytotoxic T lymphocyte
CC (CTL) to be used in adoptive immunotherapy. The invention is also useful

CC for activating T-cells against neoplastic cells, and cells infected with
CC virus, bacterium, protozoan or fungus. CTL epitopes are identified based
CC on the knowledge that such epitopes are, in fact, produced by the
CC housekeeping proteasome system. Once identified, these epitopes, embodied
CC as peptides, can be used to successfully immunise or induce therapeutic
CC CTL responses against housekeeping proteasome expressing target cells in
CC the host. The present sequence is that of a peptide which is related to
CC the method of the invention.

XX
SQ Sequence 9 AA:

Query Match 71.8%; Score 28; DB 8; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFTI 6
Db 4 RAFTI 9

RESULT 216

ADQ10574
ID ADQ10574 standard; peptide: 9 AA.

AC ADQ10574;

DT 23-SEP-2004 (first entry)

DE Human immunodeficiency virus T-cell epitope seqid 139.

XX immunostimulant; cytostatic; vaccine; tumour-associated antigen Ssx-2;

XX Ssx-2 antigen; epitope cluster; MHC receptor peptide binding cleft;

XX immunogenic composition; immune response; cancer vaccine vector;

XX epitope liberation; human leukocyte antigen; HLA A2-specific CTL;

XX cytotoxic T lymphocyte; T-cell epitope.

XX Human immunodeficiency virus.

PN US2004132088-A1.

XX 08-JUL-2004.

XX 10-FEB-2004; 2004US-00777053.

XX 07-NOV-2001; 2001US-0336968P.

XX 07-NOV-2002; 2002US-00292413.

PA (SIMA/) SIMARD J J L.

PA (DIAM/) DIAMOND D C.

PA (QIUZ/) QIU Z.

PA (LEIX/) LEI X.

PI Simard JTL, Diamond DC, Qiu Z, Lei X;

XX WPI; 2004-517003/49.

PT Novel nucleic acid encoding tumor-associated antigen Ssx-2, useful in
PT inducing an immune response and in treating cancer.

XX Disclosure; SEQ ID NO 139; 260bp; English.

CC The invention describes an isolated nucleic acid (I) comprising a reading
CC frame comprising a first sequence, where the first sequence encodes one
CC or more segments of tumour-associated antigen Ssx-2, which comprises a
CC sequence of 188 amino acids (SEQ ID NO: 40), where the first sequence
CC does not encode the complete Ssx-2 antigen, and where each segment
CC comprises an epitope cluster, the cluster comprising or encoding at least
CC two amino acid sequences having a known or predicted affinity for a same
CC MHC receptor peptide binding cleft. Also described are: an isolated
CC polypeptide comprising the amino acid sequence encoded in the reading
CC frame; and an immunogenic composition comprising (I) or the polypeptide
CC of (I). (I) is a nucleic acid encoding a tumour-associated antigen Ssx-2
CC comprising a fully defined sequence of 188 amino acids (SEQ ID NO: 40).

CC The nucleic acid, the encoded antigen, and composition are useful in
 CC inducing an immune response and in treating cancer. Expression cassettes
 CC are used in vaccine vectors. This is the amino acid sequence of a T-cell
 CC epitope MHC ligand associated with methods, therapies and compositions
 CC described in the invention.

XX Sequence 9 AA;

Query Match 71.8%; Score 28; DB 8; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.8e+06;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFTI 6
 |||||
 Db 4 RAFTI 9

RESULT 217
 AAR3452
 ID AAR3452 standard; peptide; 10 AA.

XX AAR3452;
 AC
 DT 27-AUG-2003 (revised)
 DT 25-MAR-2003 (revised)
 DT 17-DEC-2001 (revised)
 DT 03-JUL-1993 (first entry)

DE Sequence of synthetic peptide which represents immunogenic region of the
 DE V loop of HIV isolate IIb.

XX Cytotoxic T lymphocyte; immunogenic peptide; V3 loop; treatment;
 XX glycoprotein 160.

XX Human immunodeficiency virus 1.

XX USN7847311-N.

XX 01-JAN-1993.

XX 06-MAR-1992; 92US-00847311.

XX 26-JAN-1988; 88US-00148692.

XX 18-SEP-1991; 91US-00760530.

XX (USSH) US DEPT HEALTH & HUMAN SERVICE.

XX Berzofsky JA, Taskashita T, Shitai M, Pendleton CD, Kozlowski S;

XX WPI; 1993-093577/11.

XX Peptide(s) for stimulation of cytotoxic T cells specific for HIV-1 -

XX PT which correspond to residues 318-327 of HIV-1 gp 160 envelope

XX glycoprotein.

XX Disclosure; Page 8; 61pp; English.

XX The peptide elicits cytotoxic T lymphocyte (CTL) response at concs. of

XX 10(-12) to 10(-6) M. It corresp. to residues 318-327 of HIV-1 strain IIb

XX GP. 160 envelope glycoprotein. It can be used for the treatment and/or

XX prophylaxis of HIV infection. (Note: Revised entry submitted to correct

XX the patent number format of US Government-owned NTIS applications to

XX prevent clashes with ongoing US granted patent numbers. For further

XX information please visit the Derwent web site at

XX www.derwent.com/dwpi/updates/ntis-us.html.) (updated on 25-MAR-2003 to

XX correct FF field.) (Updated on 27-AUG-2003 to correct OS field.)

Qy 1 RAFTI 6
 |||||
 Db 5 RAFTI 10

RESULT 218
 AAY10172
 ID AAY10172 standard; peptide; 10 AA.

XX AAY10172;

XX 12-MAY-1999 (first entry)

XX T cell epitope/MHC ligand SEQ ID NO:102.

XX Cytotoxic T-lymphocyte response; CTL; antigen; lymphatic system;

XX immunisation; tumour; infectious disease; immunotherapy; cancer;

XX malignant melanoma; viral disease; hepatitis; AIDS.

XX Synthetic.

XX Human immunodeficiency virus 1.

XX WO9902183-A2.

XX 21-JAN-1999.

XX 10-JUL-1998; 98WO-US014289.

XX 10-JUL-1997; 97CA-02209815.

XX 10-DEC-1997; 97US-00988320.

XX (CTL1-) CTL IMMUNOTHERAPIES CORP.

XX Kuendig TM, Simard JLL;

XX WPI; 1999-120514/10.

XX Inducing a cytotoxic T lymphocyte response - by maintaining a level of

XX antigen in the lymphatic system of a mammal so as to provide a sustained

XX CTL response, used to treat, e.g. AIDS.

XX Disclosure; Page 27; 19pp; English.

XX The present invention describes a method of inducing and/or sustaining an

XX immunological cytotoxic T lymphocyte (CTL) response in a mammal. The

XX method comprises: (a) delivering an antigen to the mammal at a level to

XX induce an immunological CTL response in the mammal; and (b) maintaining

XX the level of the antigen in the mammal's lymphatic system to maintain the

XX immunologic CTL response. The method can be used for the delivery of e.g.

XX a different antigen, a tumour-specific multineage antigen, an

XX embryonic antigen, an oncogene antigen, a mutated tumour-suppressor gene

XX antigen, or a viral antigen. They can be used for the treatment of

XX disease such as cancer, e.g. malignant melanoma or infectious disease,

XX e.g. viral disease such as hepatitis or AIDS. Sustained antigen delivery

XX to the lymphatic system provides for potent CTL stimulation that takes

XX place in the milieu of the lymphoid organ, and it sustains stimulation

XX that is necessary to keep CTL active, cytotoxic and reticulating through

XX the body. AAY10071 to AAY10639 represent examples of peptide antigens

XX given in the present invention

XX Sequence 10 AA;

Query Match 71.8%; Score 28; DB 2; Length 10;
 Best Local Similarity 100.0%; Pred. No. 25;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFTI 6
 |||||
 Db 5 RAFTI 10

RESULT 219
 AAY10547


```

ID  AAY10547 standard; peptide; 10 AA.
XX
XX  AAY10547;
AC
XX  12-MAY-1999 (first entry)
DT
XX
XX  HLA Class I motif peptide SEQ ID NO:477.
DE
XX  Cytotoxic T-lymphocyte response; CTL; antigen; lymphatic system;
KW  immunisation; tumour; infectious disease; immunotherapy; cancer;
KW  malignant melanoma; viral disease; hepatitis; AIDS.
XX
XX  Synthetic.
OS  Human immunodeficiency virus 1.
PN  WO9902183-A2.
XX
XX  21-JAN-1999.
PD
XX
XX  10-JUL-1998; 98WO-US014289.
PF
XX  10-JUL-1997; 97CA-02209815.
PR  10-DEC-1997; 97US-00988320.
XX
XX  (CTL-) CTL IMMUNOTHERAPIES CORP.
PA
XX  Kuendig TM, Simard JUL;
PI
XX  WPI; 1999-120514/10.
DR
XX  Inducing a cytotoxic T lymphocyte response - by maintaining a level of
PT  antigen in the lymphatic system of a mammal so as to provide a sustained
PT  CTL response, used to treat, e.g. AIDS.
XX
XX  Disclosure; Page 46; 1999p; English.
PS
XX  The present invention describes a method of inducing and/or sustaining an
CC  immunological cytotoxic T lymphocyte (CTL) response in a mammal. The
CC  method comprises: (a) delivering an antigen to the mammal at a level to
CC  induce an immunological CTL response in the mammal; and (b) maintaining
CC  the level of the antigen in the mammal's lymphatic system to maintain the
CC  immunologic CTL response. The method can be used for the delivery of e.g.
CC  a differentiation antigen, a tumour-specific multilineage antigen, an
CC  embryonic antigen, an oncogene antigen, a mutated tumour-suppressor gene
CC  antigen, or a viral antigen. They can be used for the treatment of
CC  disease such as cancer, e.g. malignant melanoma or infectious disease.
CC  e.g. viral disease such as hepatitis or AIDS. Sustained antigen delivery
CC  to the lymphatic system provides for potent CTL stimulation that takes
CC  place in the milieu of the lymphoid organ, and it sustains stimulation
CC  that is necessary to keep CTL active, cytotoxic and recirculating through
CC  the body. AAY10071 to AAY10639 represent examples of peptide antigens
CC  given in the present invention
XX
XX  Sequence 10 AA:
SQ
XX
XX  Query Match 71.8%; Score 28; DB 2; Length 10;
XX  Best Local Similarity 100.0%; Pred. No. 25;
XX  Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY  1 RAFVTI 6
DB  5 RAFVTI 10

```

```

XX
XX  Cytotoxic T-lymphocyte response; CTL; antigen; lymphatic system;
KW  immunisation; tumour; infectious disease; immunotherapy; cancer;
KW  malignant melanoma; viral disease; hepatitis; AIDS.
XX
XX  Synthetic.
OS  Human immunodeficiency virus 1.
PN  WO9902183-A2.
XX
XX  21-JAN-1999.
PD
XX
XX  10-JUL-1998; 98WO-US014289.
PF
XX  10-JUL-1997; 97CA-02209815.
PR  10-DEC-1997; 97US-00988320.
XX
XX  (CTL-) CTL IMMUNOTHERAPIES CORP.
PA
XX  Kuendig TM, Simard JUL;
PI
XX  WPI; 1999-120514/10.
DR
XX  Inducing a cytotoxic T lymphocyte response - by maintaining a level of
PT  antigen in the lymphatic system of a mammal so as to provide a sustained
PT  CTL response, used to treat, e.g. AIDS.
XX
XX  Disclosure; Page 26; 1999p; English.
PS
XX  The present invention describes a method of inducing and/or sustaining an
CC  immunological cytotoxic T lymphocyte (CTL) response in a mammal. The
CC  method comprises: (a) delivering an antigen to the mammal at a level to
CC  induce an immunological CTL response in the mammal; and (b) maintaining
CC  the level of the antigen in the mammal's lymphatic system to maintain the
CC  immunologic CTL response. The method can be used for the delivery of e.g.
CC  a differentiation antigen, a tumour-specific multilineage antigen, an
CC  embryonic antigen, an oncogene antigen, a mutated tumour-suppressor gene
CC  antigen, or a viral antigen. They can be used for the treatment of
CC  disease such as cancer, e.g. malignant melanoma or infectious disease.
CC  e.g. viral disease such as hepatitis or AIDS. Sustained antigen delivery
CC  to the lymphatic system provides for potent CTL stimulation that takes
CC  place in the milieu of the lymphoid organ, and it sustains stimulation
CC  that is necessary to keep CTL active, cytotoxic and recirculating through
CC  the body. AAY10071 to AAY10639 represent examples of peptide antigens
CC  given in the present invention
XX
XX  Sequence 10 AA:
SQ
XX
XX  Query Match 71.8%; Score 28; DB 2; Length 10;
XX  Best Local Similarity 100.0%; Pred. No. 25;
XX  Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY  1 RAFVTI 6
DB  5 RAFVTI 10

```

```

RESULT 220
AAY10164
ID  AAY10164 standard; peptide; 10 AA.
XX
XX  AAY10164;
AC
XX  12-MAY-1999 (first entry)
DT
XX
XX  T cell epitope/MHC ligand SEQ ID NO:94.
DE

```

```

RESULT 221
AAY03691
ID  AAY03691 standard; peptide; 10 AA.
XX
XX  AAY03691;
AC
XX  17-OCT-2003 (revised)
DT  07-JUN-1999 (first entry)
DT
XX
XX  Amino acid fragment of CTL epitope of HIV/SIV (H) string.
DE
XX  CD8+ T-cell; immune response; antigen; priming composition; CTL; epitope;
KW  cytotoxic T lymphocyte; boosting; poxvirus vector; FVV; pathogen; tumour;
KW  malaria; parasite; P. falciparum; viral; bacterial; parasitic; cancer;
KW  melanoma; HIV; breast; colon; vaccination.
XX

```

```

OS Human immunodeficiency virus 1.
XX
XX WO9856919-A2.
XX
XX 17-DEC-1998.
XX
XX
XX 09-JUN-1998; 98WO-GB001681.
XX
XX 09-JUN-1997; 97GB-00011957.
XX
XX (ISIS-) ISIS INNOVATION LTD.
XX
XX McMichael AJ, Hill AVS, Gilbert SC, Schneider J, Plebanski M,
XX Hanke T, Smith GL, Blanchard T;
XX WPI: 1999-070325/06.
XX
XX
XX Generating CD8-positive T cell response to target antigen using
XX recombinant poxvirus - for treating or preventing malaria and HIV
XX infection, also epitope strings from Plasmodium and HIV.
XX
XX
XX Claim 43; Page 20; 85pp; English.
XX
XX The invention relates to methods and reagents for generating a protective
XX CD8+ T-cell immune response against at least one target antigen. The kits
XX of the invention comprises (i) as priming composition, a source of one or
XX more CD8+ T-cell [cytotoxic T lymphocytes-(CTL)] epitopes of the target
XX antigen, plus a carrier and (ii) as boosting composition a source of CTL
XX epitopes, with at least one CTL epitope the same as used in (i), with
XX this source being a non-replicating or replication-impaired recombinant
XX poxvirus vector (PVV) plus a carrier. If the source of CTL epitopes in
XX (i) is a viral vector, then the vector in (ii) is from a different virus.
XX The kits are used to generate an immune response (prophylactic or
XX therapeutic) against pathogens or tumours, specifically against malaria
XX parasites such as P. falciparum, or HIV, and also many other bacterial,
XX viral or parasitic pathogens. The kits are also used for protective
XX response against melanoma and cancer of breast or colon, and generally
XX wherever a strong CD8+ response is protective. The boosting composition
XX may be used alone to boost a naturally primed response against malaria.
XX The specified PVV provide an excellent booster effect, better than that
XX from wild-type poxvirus, resulting in complete rather than partial
XX protection against sporozoite challenge. Also PVV are safer to use than
XX wild-type virus. Sequences AAY03651-704 represent CTL peptide epitopes of
XX the HIV/SIV (H) epitope string. (Updated on 17-Oct-2003 to standardise OS
XX field)
XX
XX
XX Sequence 10 AA;
SQ
XX
XX Query Match 71.8%; Score 28; DB 2; Length 10;
XX Best Local Similarity 100.0%; Pred. No. 25;
XX Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RAFVTI 6
XX |||||
XX 5 RAFVTI 10
Db
XX
XX RESULT 222
XX AAY03655
XX ID AAY03655 standard; peptide; 10 AA.
XX
XX
XX AAY03655;
XX
XX 07-JUN-1999 (first entry)
XX
XX HIV gag CTL peptide epitope.
XX
XX CD8+ T-cell; immune response; antigen; priming composition; CTL; epitope;
XX cytotoxic T lymphocyte; boosting; poxvirus vector; PVV; pathogen; tumour;
XX malaria; parasite; P. falciparum; viral; bacterial; parasitic; cancer;
XX melanoma; HIV; breast; colon; vaccination; PLA tumour antigen.
XX
XX Synthetic.
OS

```

```

OS Human immunodeficiency virus 1.
XX
XX WO9856919-A2.
XX
XX 17-DEC-1998.
XX
XX
XX 09-JUN-1998; 98WO-GB001681.
XX
XX 09-JUN-1997; 97GB-00011957.
XX
XX (ISIS-) ISIS INNOVATION LTD.
XX
XX McMichael AJ, Hill AVS, Gilbert SC, Schneider J, Plebanski M,
XX Hanke T, Smith GL, Blanchard T;
XX WPI: 1999-070325/06.
XX
XX
XX Generating CD8-positive T cell response to target antigen using
XX recombinant poxvirus - for treating or preventing malaria and HIV
XX infection, also epitope strings from Plasmodium and HIV.
XX
XX
XX Example 1; Page 22; 85pp; English.
XX
XX The invention relates to methods and reagents for generating a protective
XX CD8+ T-cell immune response against at least one target antigen. The kits
XX of the invention comprises (i) as priming composition, a source of one or
XX more CD8+ T-cell [cytotoxic T lymphocytes-(CTL)] epitopes of the target
XX antigen, plus a carrier and (ii) as boosting composition a source of CTL
XX epitopes, with at least one CTL epitope the same as used in (i), with
XX this source being a non-replicating or replication-impaired recombinant
XX poxvirus vector (PVV) plus a carrier. If the source of CTL epitopes in
XX (i) is a viral vector, then the vector in (ii) is from a different virus.
XX The kits are used to generate an immune response (prophylactic or
XX therapeutic) against pathogens or tumours, specifically against malaria
XX parasites such as P. falciparum, or HIV, and also many other bacterial,
XX viral or parasitic pathogens. The kits are also used for protective
XX response against melanoma and cancer of breast or colon, and generally
XX wherever a strong CD8+ response is protective. The boosting composition
XX may be used alone to boost a naturally primed response against malaria.
XX The specified PVV provide an excellent booster effect, better than that
XX from wild-type poxvirus, resulting in complete rather than partial
XX protection against sporozoite challenge. Also PVV are safer to use than
XX wild-type virus. Sequences AAY03653-60 represent CTL peptide epitopes
XX used during the course of the invention
XX
XX
XX Sequence 10 AA;
SQ
XX
XX Query Match 71.8%; Score 28; DB 2; Length 10;
XX Best Local Similarity 100.0%; Pred. No. 25;
XX Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RAFVTI 6
XX |||||
XX 5 RAFVTI 10
Db
XX
XX RESULT 223
XX AAY0357
XX ID AAY0357 standard; peptide; 10 AA.
XX
XX
XX AAY0357;
XX
XX 17-OCT-2003 (revised)
XX
XX 29-JUN-1999 (first entry)
XX
XX HIV-1 CLUAC peptide, SEQ ID NO. 16.
XX
XX HIV-1; CLUAC; cluster peptide vaccine construct; cytotoxic T lymphocyte;
XX protective mucosal CTL response; hepatitis A virus; papilloma virus;
XX feline immunodeficiency virus; feline leukaemia virus; M. tuberculosis;
XX listeria monocytogenes; M. leprae; Giardia lamblia;
XX immune response induction.
XX
XX

```

OS Human immunodeficiency virus 1.
 XX W09912563-A2.
 XX 18-MAR-1999.
 XX
 PF 11-SEP-1998; 98WO-US019028.
 XX
 PR 11-SEP-1997; 97US-0058523P.
 PR 17-FEB-1998; 98US-0074894P.
 XX
 PA (USSH) US DEPT HEALTH & HUMAN SERVICE.
 XX
 PI Berzofsky JA, Belyakov IM, Derby MA, Kelsall BL, Strober W;
 XX WPI; 1999-243663/20.
 DR
 PT Method for inducing a protective mucosal cytotoxic T lymphocyte immune
 PT response.
 PS Example 3; Page 85; 86pp; English.
 XX
 CC This sequence represents a HIV-1 cluster peptide vaccine conjugate
 CC (CIUVAC) sequence. The invention relates to a method for inducing a
 CC protective mucosal cytotoxic T lymphocyte (CTL) response in a mammalian
 CC subject, which comprises contacting a mucosal tissue of the subject with
 CC a composition comprising a purified soluble antigen. The method can be
 CC used for protection against e.g. hepatitis A virus, papilloma virus,
 CC feline immunodeficiency virus, feline leukaemia virus, listeria
 CC monocyctogenes, M. tuberculosis, M. leprae, or Giardia lamblia. The method
 CC induces long-lasting protective mucosal immune responses. (Updated on 17-
 CC OCT-2003 to standardise OS field)
 CC
 SQ Sequence 10 AA;
 Query Match 71.8%; Score 28; DB 2; Length 10;
 Best Local Similarity 100.0%; Pred. No. 25;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RAFVTI 6
 |||||
 Db 5 RAFVTI 10
 |||||
 RESULT 224
 AAY59593
 ID AAY59593 standard; peptide; 10 AA.
 XX
 AC AAY59593;
 XX
 DT 12-SEP-2003 (revised)
 DT 05-APR-2000 (first entry)
 XX
 DE HIV-1 env peptide I-10.
 XX
 KW HIV-1; env gene; cellular immunity; virus; therapy;
 KW envelope glycoprotein; infection; immunisation; immune response.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN EP972523-A2.
 XX
 PD 19-JAN-2000.
 XX
 PF 27-MAY-1999; 99EP-00401265.
 XX
 PR 29-MAY-1998; 98US-00087513.
 XX
 PA (NIH-) JAPAN HEALTH SCI FOUND.
 PA (AJIN) AJINOMOTO CO INC.
 PA (UYJE-) UNIV JEFFERSON THOMAS.
 XX

PI Kaneko Y, Kozbor D;
 XX WPI; 2000-099746/09.
 DR
 PT New composition for inducing viral immunity, useful for production of HIV
 PT vaccines.
 PS Example 3; Page 11; 28pp; English.
 XX
 CC This sequence represents a fragment of the HIV-1 env protein. The
 CC invention relates to a therapeutic composition for inducing cellular
 CC immunity against a virus, which comprises a nucleic acid encoding an
 CC envelope glycoprotein of the virus which: (a) contains a modified
 CC immunodominant epitope; and (b) induces cellular immunity to a conserved
 CC epitope of the envelope glycoprotein. The nucleic acid may be introduced
 CC into a vector DNA or a liposome and mixed with an adjuvant to prepare a
 CC vaccine effective against and induce cellular immunity against the HIV
 CC virus. The therapeutic composition can be used to prevent or treat
 CC infection. Prior art methods of immunising patients against viruses which
 CC frequently mutate have resulted in chronic immune activation and high T
 CC cell turnover because of secondary responses induced by the V3 loop
 CC mutated epitopes. The full length envelope glycoprotein expressed on the
 CC cell surface or released from HIV infected cells can also trigger
 CC detrimental effects which are essential in AIDS pathogenesis. The
 CC composition provides antigen presenting cells (APCs) which contain the
 CC modified envelope glycoprotein and are resistant to antibody-dependent
 CC cell mediated cytotoxicity (ADCC), do not form syncytia, do not undergo
 CC apoptosis and induce cellular immunity to the virus without inducing
 CC apoptosis of CD4+ T cells. The composition therefore redirects immune
 CC responses towards the conserved epitope of the envelope glycoprotein,
 CC inducing cellular immunity to multiple strains of the virus. (Updated on
 CC 12-SEP-2003 to standardise OS field)
 CC
 SQ Sequence 10 AA;
 Query Match 71.8%; Score 28; DB 3; Length 10;
 Best Local Similarity 100.0%; Pred. No. 25;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RAFVTI 6
 |||||
 Db 5 RAFVTI 10
 |||||
 RESULT 225
 AAY67361
 ID AAY67361 standard; peptide; 10 AA.
 XX
 AC AAY67361;
 XX
 DT 25-APR-2000 (first entry)
 XX
 DE Human immunodeficiency virus-10 (HIV-10) peptide.
 XX
 KW Therapeutic antigen; cytotoxic T lymphocyte; CTL; CTL immune response;
 KW cellular immune response induction method; vaccine; human; tumour;
 KW melanoma glycoprotein 75.
 XX
 OS Human immunodeficiency virus.
 XX
 PN W09963945-A2.
 XX
 PD 16-DEC-1999.
 XX
 PF 11-JUN-1999; 99WO-US013146.
 XX
 PR 12-JUN-1998; 98US-0089055P.
 PR 30-OCT-1998; 98US-0106339P.
 XX
 PA (SLOK) SLOAN KETTERING INST CANCER RES.
 PA Nikolai-Zugic J, Dyall R, Houghton AN;
 PI

DR WPI; 2000-126432/11.

XX Induction of a cellular immune response to a weakly immunogenic protein,
 XX used to target and kill tumor cells.
 PT
 XX
 XX Example 2; Page 15; 44pp; English.

CC This sequence represents a human immunodeficiency virus (HIV-10) peptide
 CC used in the method of the invention. The invention relates to a method
 CC for inducing a cytotoxic T lymphocyte (CTL) immune response to non/weakly
 CC immunogenic proteins which are expressed on tumour cells. The method for
 CC inducing a cellular immune response to a non-immunogenic or weakly
 CC immunogenic target peptide expressed on tumour cells of a mammalian
 CC subject comprises administering antigen to induce a cellular immune
 CC response to the target peptide. The antigen comprises an immunogenic
 CC portion having a major histocompatibility complex (MHC) binding domain
 CC which binds to the MHC and an immune recognition domain which is
 CC recognized by T-cells. The antigen is derived from the target peptide
 CC such that the target peptide without material alteration of the immune
 CC recognition portion. The methods are used for inducing a cellular immune
 CC response to a non-immunogenic or weakly immunogenic target peptide
 CC expressed on tumour cells of a mammalian subject. The antigens and
 CC immunogens of the invention, as well as polynucleotides encoding them,
 CC are used in vaccine compositions against tumour cells.

SQ Sequence 10 AA;

Query Match 71.8%; Score 28; DB 3; Length 10;
 Best Local Similarity 100.0%; Pred. No. 25;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVI 6
 |||||
 DB 5 RAFTVI 10

RESULT 226
 AAY94398
 ID AAY94398 standard; peptide; 10 AA.
 XX
 XX AAY94398;
 AC
 XX
 XX 21-SEP-2000 (first entry)
 DT
 XX
 XX HIV peptide used to generate a mouse hybridoma.
 DE
 XX
 XX Human; phage display; anti-inflammatory; antibody therapy;
 KW inflammatory bowel disease; rheumatoid arthritis; septic shock;
 KW multiple sclerosis; chronic inflammation; allograft rejection; panning;
 KW tumour necrosis factor alpha; TNF; CDR3;
 KW complementarity determining region; hybridoma.
 KM
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO200029004-A1.
 PN
 XX
 XX 25-MAY-2000.
 PD
 XX
 XX 02-NOV-1999; 99WO-IL000581.
 PF
 XX
 XX 18-NOV-1998; 98IL-00127127.
 PR
 XX
 XX (PEPT-) PEPTOR LTD.
 PA
 XX
 XX Plakasin D;
 PI
 XX
 XX WPI; 2000-387610/33.
 DR
 XX
 XX Small functional units of antibody heavy chain variable regions useful
 PT for diagnosis and treatment of disease.
 PS Example 1; Page 18; 48pp; English.

XX The present sequence is an HIV peptide. A gene encoding a single-domain
 CC VH protein belonging to mouse VH group I(A) was cloned from a mouse
 CC hybridoma generated against the present sequence in complex with H-2nd.
 CC The gene was amplified by PCR. The 3' primer contained a sequence which
 CC randomised 9 amino acids in the third hypervariable loop (CDR3) of the VH
 CC and therefore generated the single-domain VH library repertoire. CDR3
 CC typically makes most antigen contacts in antibody combining sites. The
 CC PCR product was reamplified to avoid non-symmetric pairing of strands due
 CC to primer exhaustion. The final product was ligated into the phagemid
 CC vector pCANTAB 5 R and electroporated into E. coli strain TGI. Phage
 CC clones capable of binding a specific antigen, e.g. Tumour necrosis factor
 CC alpha (TNFalpha), can be selected by library panning. Single-domain VH
 CC proteins can be used to treat or diagnose associated disorders. For
 CC example, disorders in which TNF plays a role include inflammatory bowel
 CC disease, rheumatoid arthritis, septic shock, multiple sclerosis, chronic
 CC inflammation and allograft rejection

SQ Sequence 10 AA;

Query Match 71.8%; Score 28; DB 3; Length 10;
 Best Local Similarity 100.0%; Pred. No. 25;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVI 6
 |||||
 DB 5 RAFTVI 10

RESULT 227
 AAY94588
 ID AAY94588 standard; peptide; 10 AA.
 XX
 XX AAY94588;
 AC
 XX
 XX 12-SEP-2003 (revised)
 DT
 XX
 XX 10-JAN-2001 (first entry)
 DT
 XX
 XX Mouse H2-d-class I restricted minimal cytolytic T lymphocyte epitope.
 DE
 XX
 XX Hepatitis B virus nucleocapsid antigen; HBcAg; T cell epitope;
 KW cytolytic T lymphocyte; immunogenic; ICE; CTL; HIV;
 KW immunodominant core epitope; immunisation; mouse.
 KM
 XX
 XX Human immunodeficiency virus 1.
 OS
 XX
 XX WO200026385-A1.
 PN
 XX
 XX 11-MAY-2000.
 PD
 XX
 XX 05-NOV-1999; 99WO-US026291.
 PF
 XX
 XX 05-NOV-1998; 98US-0107169P.
 PR
 XX
 XX (POMD-) POWDERJECT VACCINES INC.
 PA
 XX
 XX Fuller DL, Fuller JT;
 PI
 XX
 XX WPI; 2000-451623/39.
 DR
 XX
 XX Use of expression vector for nucleic acid immunization that comprises
 PT promoter and recombinant nucleic acid sequences encoding Hepatitis B core
 PT antigen and T cell epitope from antigen.
 PS Example 7; Page 41; 55pp; English.

CC The present invention relates to an immunogenic recombinant nucleic acid
 CC molecule. The molecule consists of a modified hepatitis B virus
 CC nucleocapsid antigen (HBcAg) with a T cell epitope sequence inserted
 CC within the HBcAg. The creation of a unique restriction site in HBcAg
 CC facilitated the insertion of the T cell epitope into the DNA encoding the
 CC immunodominant core epitope of the HBcAg. An example of a suitable
 CC insertion epitope is the present sequence, the mouse H2-d-restricted

CC minimal cytolytic T lymphocyte epitope of HIV IAI gp 120. Alternatively
 CC other T cell epitopes may be inserted (AA94583, AA94584, AA94585,
 CC AA94586, AA94587). The recombinant nucleic acid molecule may then be
 CC used as a reagent in various nucleic acid immunisation strategies. The
 CC advantage of this method of immunisation is that the nucleic acid
 CC reagents that encode hybrid HBcAg generate an extremely high frequency
 CC cellular immune response against the CTL epitope. (Updated on 12-SEP-2003
 CC to standardise OS field)

XX Sequence 10 AA;

Query Match 71.8%; Score 28; DB 3; Length 10;
 Best Local Similarity 100.0%; Pred. No. 25;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTI 6
 |||||
 DB 5 RAFTI 10

RESULT 228

AA15874
 ID AAB15874 standard; peptide; 10 AA.

AC AAB15874;

DT 17-JAN-2001 (first entry)

DE Human chemokine derived peptide #26.

XX Macrophage recruitment; chemokine derivative; MCP-1; osteoporosis;
 KW monocyte chemoattractant protein-1; inflammation; atherosclerosis; HIV;
 KW AIDS; stroke; psoriasis; autoimmune disease; hypertension; endotoxaemia;
 KW basophil-mediated disease; myocardial infarction; acute ischaemia;
 KW rheumatoid arthritis; contraception.

XX Synthetic.

OS W0200042071-A2.

PN 20-JUL-2000.

PD 12-JAN-2000; 2000WO-US000821.

PR 12-JAN-1999; 99US-00229071.

PR 17-MAR-1999; 99US-00271192.

PR 01-DEC-1999; 99US-00452406.

XX (NBOR-) NEORX CORP.

PI Grainger DJ, Tatalick LM;

DR WPI; 2000-499101/44.

PT New peptide 3, amide and heterocyclic compounds and saccharide conjugates
 PT used for inhibiting chemokine induced activity and for treating e.g.
 PT stroke, vascular diseases, autoimmune diseases and tumor growth.

PS Disclosure; Fig 18; 387pp; English.

XX The present invention concerns the identification of a number of
 CC chemokines which can be used to produce derivatives, agonists and
 CC antagonists which are then useful in disease treatment. The chemokines
 CC include sequences AAB15785-B15794, AAB15803-B15813 and AAB15831-B15848.
 CC These chemokine derivatives can be used to treat diseases such as
 CC autoimmune diseases, atherosclerosis, osteoporosis, HIV infection and
 CC AIDS, psoriasis, inflammatory diseases, hypertension, basophil-mediated
 CC diseases, endotoxaemia, myocardial infarction, acute ischaemia and
 CC rheumatoid arthritis, and can be used to prevent strokes and as
 CC contraceptives. The coding sequences for the chemokines can be used in
 CC gene therapy for the same diseases, as well as in the production of
 CC animal models

SO Sequence 10 AA;

Query Match 71.8%; Score 28; DB 3; Length 10;
 Best Local Similarity 100.0%; Pred. No. 25;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTI 6
 |||||
 DB 5 RAFTI 10

RESULT 229

AAB92350
 ID AAB92350 standard; peptide; 10 AA.

AC AAB92350;

DT 22-JUN-2001 (first entry)

DE Virus related peptide SEQ ID NO:1526.

XX Protection; endogenous therapeutic peptide; peptidase; conjugation;
 KW blood component; modification; succinimide; maleimide group; amino;
 KW hydroxyl; thiol; hormone; growth factor; neurotransmitter.

OS Homo sapiens.

OS Synthetic.

PN W0200069900-A2.

PD 23-NOV-2000.

PR 17-MAY-2000; 2000WO-US013576.

PR 17-MAY-1999; 99US-0134406P.

PR 10-SEP-1999; 99US-0153406P.

PR 15-OCT-1999; 99US-0159783P.

XX (CONJ-) CONJUCHEM INC.

PI Bridon DP, Ezrin AM, Milner PG, Holmes DL, Thibaudau K;

DR WPI; 2001-112059/12.

PS Disclosure; Page 704; 733pp; English.

XX The present invention describes a modified therapeutic peptide (I)
 CC comprising a therapeutically active amino acid region (III) and a
 CC reactive group (II) (e.g. succinimide and maleimide groups) attached to
 CC a less therapeutically active amino acid region (IV), which covalently
 CC bonds with amino/hydroxyl/thiol groups on blood components to form a
 CC peptidase stabilised therapeutic peptide composed of 3-50 amino acids.
 CC (I) are useful for modifying therapeutic peptides e.g. hormones, growth
 CC factors and neurotransmitters, to protect them from peptidase activity in
 CC vivo for the treatment of various disorders. Endogenous therapeutic
 CC peptides are not suitable as drug candidates as they require frequent
 CC administration due to rapid degradation by peptidases in the body.
 CC Modifying and attaching therapeutic peptides to albumin prevents or
 CC reduces the action of peptidases to increase length of activity (half
 CC life) and specificity as bonding to large molecules decreases
 CC intracellular uptake and interference with physiological processes.
 CC AAB90829 to AAB92441 represent peptides which can be used in the
 CC exemplification of the present invention

XX Sequence 10 AA;

Query Match 71.8%; Score 28; DB 4; Length 10;
 Best Local Similarity 100.0%; Pred. No. 25;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFVTI 6
 |||||
 Db 5 RAFVTI 10

RESULT 230

AAB49397

ID AAB49397 standard; peptide; 10 AA.

XX AAB49397;

XX 06-MAR-2001 (first entry)

XX HIV peptide SEQ ID NO: 12.

XX HIV; immunogenic peptide; immune response; monophosphoryl lipid A;
 XX antigen; infection; cancer; amyloid deposition.

XX Human immunodeficiency virus.

XX WO20069456-A2.

XX 23-NOV-2000.

XX 12-MAY-2000; 2000WO-US013156.

XX 13-MAY-1999; 99US-0133963P.

XX (AMCY) AMERICAN CYANAMID CO.

XX Hagen M;

XX WPI; 2001-024946/03.

XX Antigenic composition having an antigen (e.g. viral protein) and an
 XX adjuvant, useful for enhancing humoral and cellular immune response in a
 XX host or as a prophylaxis against virus, bacterium, parasite, cancer cell
 XX or allergen.

XX Example 1; Page 41; 129pp; English.

XX The present invention provides an antigenic composition comprising an
 XX antigen with a 3'-O-deacetylated monophosphoryl lipid A or monophosphoryl
 XX lipid A adjuvant. The presence of the adjuvant causes an increased immune
 XX response. The antigen may be from a pathogenic bacterium, fungus, virus
 XX or parasite, a cancer cell, an allergen or from amyloid peptide protein.
 XX The composition can be used in the prevention and treatment of infection,
 XX cancer and diseases caused by amyloid deposition. It is particularly
 XX useful against HIV, Neisseria gonorrhoeae and respiratory syncytial virus

XX Sequence 10 AA;

Query Match 71.8%; Score 28; DB 4; Length 10;
 Best Local Similarity 100.0%; Pred. No. 25;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFVTI 6
 |||||
 Db 5 RAFVTI 10

RESULT 231

AAE04801

ID AAE04801 standard; peptide; 10 AA.

XX AAE04801;

XX 10-SEP-2001 (first entry)

XX Human immunodeficiency virus env protein derived restricted CTL epitope.
 XX Human immunodeficiency virus; HIV; immunogen; anti-HIV; vaccine;

XX gene therapy; fusion protein; modified vaccinia virus Ankara vector; MVA;
 XX

KM cytotoxic T-lymphocyte; CTL; epitope.
 XX
 XX Human immunodeficiency virus.
 OS

XX WO200147955-A2.

XX 05-JUL-2001.

XX 22-DEC-2000; 2000WO-GH004984.

XX 23-DEC-1999; 99GB-00030294.

XX 14-OCT-2000; 2000GB-00025234.

XX (MEDI-) MEDICAL RES COUNCIL.
 XX (ITAI-) INT AIDS VACCINE INITIATIVE.
 XX (UINA-) UNIV NAIROBI.

XX Hanke T, Memichael AJ;
 XX

XX WPI; 2001-418221/44.

XX Novel immunogen for stimulating anti-HIV immune response, has a portion
 XX of gag protein of HIV from HIV clade, parts of p17, p24 and synthetic
 XX polypeptide comprising human cytotoxic T-lymphocyte epitopes of HIV
 XX protein.

XX Example 1; Page 8; 65pp; English.

XX The invention relates to human immunodeficiency virus immunogens and
 XX their corresponding DNA molecules. An immunogen comprises a portion of
 XX gag protein of HIV from an HIV clade, parts of p17 and p24, modified to
 XX prevent N-terminal myristoylation; and a synthetic polypeptide comprising
 XX human cytotoxic T-lymphocyte (CTL) epitopes of HIV protein. This
 XX immunogen is designed to elicit an HIV-specific immune response in
 XX humans. The immunogen is useful in the preparation of a medicament such
 XX as vaccine to prevent or treat HIV infection in a human subject. The
 XX invention also relates to method of stimulating anti-HIV immune response
 XX in a human subject which comprises administering one or more times an
 XX amount of nucleic acid molecule sufficient to prime an immune response to
 XX the immunogen, or else may be packaged within a delivery means, such as a
 XX modified vaccinia virus Ankara (MVA) to boost the immune response to
 XX common portion of the immunogens. The present sequence is human
 XX immunodeficiency virus env protein derived restricted CTL epitope related
 XX to the invention. This restricted CTL epitope is presented by a murine
 XX MHC class I used for the mouse potency assay

XX Sequence 10 AA;

Query Match 71.8%; Score 28; DB 4; Length 10;
 Best Local Similarity 100.0%; Pred. No. 25;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFVTI 6
 |||||
 Db 5 RAFVTI 10

RESULT 232

ABP25102

ID ABP25102 standard; peptide; 10 AA.

XX ABP25102;

XX 15-JUL-2002 (first entry)

XX Human MHC peptide binding assay peptide #29.
 XX HIV; HIV-1; human immunodeficiency virus; env; pol; gag; nef; vpr; vpu;

XX vif; tat; cytotoxic T lymphocyte; CTL; immune response; epitope; antigen;
 XX vaccine; HIV infection; immunisation; virucide.
 OS Homo sapiens.
 XX

PN WO200124810-A1.
XX
PD 12-APR-2001.
XX
PF 05-OCT-2000; 2000WO-US027766.
XX
PR 05-OCT-1999; 99US-00412863.
XX
PA (EPIM-) EPIMMUNE INC.
PI Sette A, Sidney J, Southwood S, Livingston BD, Chesnut R;
PI Baker DM, Cells E, Kubo RT, Grey HM;
XX
DR WPI; 2001-354887/37.
XX
PT Vaccine compositions comprising human immunodeficiency virus-1 (HIV-1)
PT peptide groups, useful for vaccinating against HIV-1.
XX
PS Example 1; Page 416; 448pp; English.
XX
CC The present invention describes a composition (I) comprising a prepared
CC human immunodeficiency virus-1 (HIV-1) group comprising an amino acid
CC sequence selected from 51 defined amino acid sequences (AB25347 to
CC ABP25397). (I) has virucide activity and can be used in vaccines. (I) may
CC be used for immunizing subjects against HIV-1 infections. The use of
CC group-based vaccines has several advantages over traditional vaccines,
CC particularly when compared to the use of whole antigens in vaccine
CC compositions. There is evidence that the immune response to whole
CC antigens is directed largely toward variable regions of the antigen,
CC allowing for immune escape due to mutations. The groups for inclusion in
CC an group-based vaccine may be selected from conserved regions of viral or
CC tumour-associated antigens, which therefore reduces the likelihood of
CC escape mutants. Furthermore, immunosuppressive groups that may be present
CC in whole antigens can be avoided with the use of group-based vaccines. An
CC additional advantage of an group-based vaccine approach is the ability to
CC combine selected groups (CTL and HTL), and further, to modify the
CC composition of the groups, achieving, for example, enhanced
CC immunogenicity. Accordingly, the immune response can be modulated, as
CC appropriate, for the target disease. Similar engineering of the response
CC is not possible with traditional approaches. ABP11501 to ABP25412
CC represent peptide sequences used in the exemplification of the present
CC invention
XX
SQ Sequence 10 AA:
XX
Query Match 71.8%; Score 28; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 RAFVTI 6
DB 5 RAFVTI 10
XX
RESULT 233
AAJ03832
ID AAJ03832 standard; peptide; 10 AA.
XX
AC AAJ03832;
XX
DT 02-JUL-2001 (first entry)
XX
DE Hepatitis C virus epitope #3823.
XX
KM Hepatitis C virus; HCV; epitope; vaccine; immunogen; HLA-binding motif;
KM antiviral.
XX
OS Hepatitis C virus.
XX
PN WO200121189-A1.
XX
PD 29-MAR-2001.
XX

PF 19-JUL-2000; 2000WO-US019774.
XX
PR 19-JUL-1999; 99US-00357737.
XX
PA (EPIM-) EPIMMUNE INC.
XX
PI Sette A, Sidney J, Southwood S, Livingston BD, Chesnut R;
PI Baker DM, Cells E, Kubo RT, Grey HM;
XX
DR WPI; 2001-308046/32.
XX
PT A new composition useful as a vaccines against hepatitis C virus.
XX
PS Disclosure; Page 188; 214pp; English.
XX
CC The present invention describes a composition comprising a prepared
CC hepatitis C virus (HCV) epitope such as those given in AAJ00010-AAJ04121.
CC These are derived from HCV HLA-binding motifs. They are useful in
CC vaccines for the prevention and treatment of HCV infection in humans. The
CC present sequence is an epitope used in the disclosure of the invention
XX
SQ Sequence 10 AA:
XX
Query Match 71.8%; Score 28; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 RAFVTI 6
DB 5 RAFVTI 10
XX
RESULT 234
AAE20153
ID AAE20153 standard; peptide; 10 AA.
XX
AC AAE20153;
XX
DT 29-AUG-2003 (revised)
DT 18-JUN-2002 (first entry)
XX
DE Human immunodeficiency virus type 1 (HIV-1) R101 peptide.
XX
KM Human immunodeficiency virus type 1; HIV-1; adjuvant; immunomodulator;
KM alpha-2-macroglobulin; 3-O-deacylated monophosphoryl lipid; MPL; GM-CSF;
KM granulocyte macrophage colony stimulating factor; immune response;
XX
OS Human immunodeficiency virus 1.
XX
PN WO200215930-A1.
XX
PD 28-FEB-2002.
XX
PF 27-AUG-2001; 2001WO-US026589.
XX
PR 25-AUG-2000; 2000US-0227624P.
XX
PA (UYDU-) UNIV DUKE.
XX
PI Haynes BF, Liao H, Patel DD;
XX
DR WPI; 2002-269315/31.
XX
XX
XX Use of 2-macroglobulin (Masterisk), 3-O-deacylated monophosphoryl lipid
XX A (MPL) and granulocyte macrophage colony stimulating factor (GM-CSF) for
XX eliciting an immune response.
XX
PS Example 2; Page 21; 53pp; English.
XX
CC The invention relates to a composition comprising activated alpha-2-
CC macroglobulin (alpha 2M asterisk), 3-O-deacylated monophosphoryl lipid A
CC (MPL) and granulocyte macrophage colony stimulating factor (GM-CSF). The

invention also relates to an adjuvant suitable for use in multivalent HIV immunogenic compositions. The compositions is useful for eliciting an immune response. The present sequence is human immunodeficiency virus type 1 (HIV-1) R01 peptide used in the exemplification of the invention. (Updated on 29-AUG-2003 to standardise OS field)

Sequence 10 AA;

Query Match 71.8%; Score 28; DB 5; Length 10;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTI 6
| | | | |
Db 5 RAFTI 10

RESULT 235
ABG1255
ID ABG1255 standard; peptide; 10 AA.

XX AC ABG1255;
XX DT 29-AUG-2003 (revised)
XX DT 21-OCT-2002 (first entry)

DE GP120 classI restricted peptide.

XX HSV; herpes; anti-HIV; cytostatic; immunomodulator; antibacterial;
XX anticiparastilic; cancer; lymphocytic leukaemia; lymphoma; glioblastoma;
XX lung cancer; infectious disease; HIV; human immunodeficiency virus;
XX human papilloma; influenza; bacteria; parasite; vaccine; tumour cells;
XX gp120.

OS Human immunodeficiency virus 1.

XX WO200256828-A2.

XX 25-JUL-2002.

XX 29-NOV-2001; 2001WO-US047808.

XX 29-NOV-2000; 2000US-0253858P.
XX 30-NOV-2000; 2000US-0250079P.

PA (UYRP) UNIV ROCHESTER.

XX Federoff HJ, Bowers WJ, Frelinger JG, Willis RA, Evans TG;
PI Dewhurst S, Hocknell PK;

XX WPI; 2002-590693/63.

XX Generating a herpesvirus amplicon particle for treating patients with
PT cancer or infectious disease, comprises transfecting a cell with an
PT amplicon vector, amplicon plasmid or nucleic acid sequence encoding an
PT accessory protein.

XX Example 8; Page 21; 68pp; English.

XX This invention relates to a method for generating a herpesvirus amplicon
XX particle comprising transfecting a cell with a Herpes simplex virus (HSV)
XX amplicon vector, an amplicon plasmid or a nucleic acid sequence that
XX encodes an accessory protein. The method of the invention may have anti-
XX HIV; cytostatic; immunomodulator; antibacterial; and antiparasitic
XX activity. The method of the invention is useful in generating herpesvirus
XX amplicon particles for treating patients with cancer (e.g. chronic
XX lymphocytic leukaemia, lymphoma, glioblastoma or lung cancer) or an
XX infectious disease such as HIV or those caused by human papilloma virus,
XX influenza virus, bacteria or parasite. The HSV amplicon particles or the
XX vectors can also be useful as vaccines. Gene therapy vectors based on the
XX herpes simplex virus exhibit a broad cellular tropism, they have the
XX capacity to package large amounts of genetic material, which makes them
XX useful in expressing multiple genes or gene sequences, they have a high

transduction efficiency, and they are maintained episomally, which makes
CC them less prone to insertional mutagenesis. In addition to infecting many
CC different types of cells, HSV vectors can also transduce non-replicating
CC or slowly-replicating cells. The method can also be carried out fairly
CC quickly. As a result, cells (such as tumour cells) can be removed from a
CC patient, treated, and readministered to the patient in the course of a
CC single operative procedure. The present sequence represents a herpes
CC simplex virus (HSV) gp120 peptide used to induce an immune response in
CC the method of the invention. (Updated on 29-AUG-2003 to standardise OS
CC field)

Sequence 10 AA;

Query Match 71.8%; Score 28; DB 5; Length 10;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTI 6
| | | | |
Db 5 RAFTI 10

RESULT 236
AAU96032
ID AAU96032 standard; protein; 10 AA.

XX AC AAU96032;
XX DT 29-AUG-2003 (revised)
XX DT 02-JUL-2002 (first entry)

DE HIV epitope, HIV-1 gp120 A2, H-2Dd, peptide sequence.

XX Vaccine; non-replicating; viral tubule; immunogen; antibody, BTV;
XX Bluetongue virus; foot and mouth disease virus; FMDV; influenza virus;
XX human immunodeficiency virus; HIV; protective immunity; epitope; TUB;
XX virus-derived tubule; anti-HIV; virucide.

OS Human immunodeficiency virus 1.

XX WO200226254-A2.

XX 04-APR-2002.

XX 27-SEP-2001; 2001WO-US030464.

XX 27-SEP-2000; 2000US-0235614P.

PA (UABR-) UAB RES FOUND.

XX Roy P;

XX WPI; 2002-339987/37.

XX A vaccine, for inducing an antiviral immune response, comprises a non-
PT replicating vaccine delivery vehicle (which comprises a non-infectious
PT recombinant viral tubule) carrying one or more immunogens.

XX Claim 8; Page 39; 65pp; English.

XX The present invention relates to a new vaccine comprising a non-
XX replicating vaccine delivery vehicle (which comprises a non-infectious
XX recombinant viral tubule) carrying one or more immunogens. The invention
XX is useful for inducing an immune response, preferably anti-viral, in a
XX subject. The administration of the vaccine is preferably followed by
XX administering one or more virus like particles carrying an immunogen. It
XX is also useful for administering to a patient for generating antibodies
XX specific for one or more immunogens, such as bluetongue virus (BTV), foot
XX and mouth disease virus (FMDV), influenza virus and human
XX immunodeficiency virus (HIV). The invention provides an effective means
XX of delivering multiple peptide components representing viral/tumour
XX antigenic groups to elicit protective immunity, which has not previously
XX been possible. The present amino acid sequence represents one of a

CC collection (AAU96022-AAU96045) of HIV epitopes that were used in the
 CC methods of the invention as immunogens. These epitopes were used to
 CC construct chimeric NS1-TUBS (virus-derived tubules) which show
 CC immunogenicity. (Updated on 29-AUG-2003 to standardise OS field)
 XX
 SQ Sequence 10 AA;

Query Match 71.8%; Score 28; DB 5; Length 10;
 Best Local Similarity 100.0%; Pred. No. 25;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVI 6
 |||||
 DB 5 RAFTVI 10

RESULT 237

ABU09700
 ID ABU09700 standard; peptide; 10 AA.

XX ABU09700;

XX 14-NOV-2002 (first entry)

XX Hepatitis B virus epitope #3652.

XX Hepatitis B virus; HBV; epitope; vaccine; HBV infection; hepatitis;

XX virucide; hepatocytic; antiinflammatory.

XX Hepatitis B virus.

XX WO200219986-A1.

XX 14-MAR-2002.

XX 08-SEP-2000; 2000WO-US024802.

XX 08-SEP-2000; 2000WO-US024802.

XX (EPIM-) EPIMUNE INC.

XX (SETT/) SETT A.

PI Sette A, Sidney J, Southwood S, Vitello MA, Livingston BD;
 PI Celis E, Kubo RT, Grey HM, Chesnut RM;

DR WPI; 2002-643192/69.

XX Vaccine composition for treating or preventing hepatitis B virus (HBV)
 PT infection, and/or for stimulating an immune response to HBV, comprises a
 PT HBV peptide epitope.

XX Disclosure; Page 196; 228pp; English.

XX The present invention relates to a composition comprising at least one
 CC hepatitis B virus epitope. This can be used in the production of a
 CC vaccine for use in preventing or treating hepatitis B virus infection.

CC The present sequence is a peptide described in the exemplification of the
 CC invention

XX Sequence 10 AA;

Query Match 71.8%; Score 28; DB 5; Length 10;
 Best Local Similarity 100.0%; Pred. No. 25;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVI 6
 |||||
 DB 5 RAFTVI 10

DB 5 RAFTVI 10

RESULT 238

ABU57440
 ID ABU57440 standard; peptide; 10 AA.

XX ABU57440;

XX 08-APR-2003 (first entry)

XX HIV cytotoxic lymphocyte epitope #4.

XX MHC; major histocompatibility complex; human; cytotoxic; anti-HIV;
 KW antiinflammatory; dermatological; antiaesthetic; antidiabetic; virucide;
 KW antiproliferative; antitumor; antineoplastic; antitubercular; AIDS;
 KW antiproliferative; immunosuppressive; inflammatory bowel disease; measles;
 KW Crohn's disease; ulcerative colitis; scleroderma; type I diabetes; pox;
 KW rheumatoid arthritis; psoriasis; atopic dermatitis; asthma; chicken pox;
 KW malignant melanoma; carcinoma; cancer; leukaemia; lymphoma; hepatitis;
 KW rubella; herpes; human immunodeficiency virus.

XX Human immunodeficiency virus.

XX WO200272631-A2.

XX 19-SEP-2002.

XX 13-MAR-2002; 2002WO-DK000169.

XX 14-MAR-2001; 2001DK-00000435.

XX 14-MAR-2001; 2001DK-00000436.

XX 14-MAR-2001; 2001DK-00000441.

XX 14-MAR-2001; 2001US-0275447P.

XX 14-MAR-2001; 2001US-0275448P.

XX (DAKO-) DAKOCYTOMATION DENMARK AS.

XX (DYNA-) DYNAL BIOTECH ASA.

XX Winther L, Petersen LO, Buus S, Schoeller J, Ruub E, Aamleim O;

XX WPI; 2002-759837/82.

XX New Major Histocompatibility Complex (MHC) molecule construct, useful for
 PT treating, preventing, stabilizing or alleviating a disease involving MHC
 PT recognizing cells e.g., cancer.

XX Disclosure; Fig 37; 304pp; English.

XX This invention relates to a new Major Histocompatibility Complex (MHC)
 CC molecule construct comprising a carrier molecule to which one or more MHC
 CC molecules are attached either directly or via one or more entities. The
 CC construct of the invention may have cytostatic, antiinflammatory,
 CC dermatological, antiaesthetic, antidiabetic, anti-HIV, virucide,
 CC antiproliferative, antitumor, antineoplastic, antitubercular, antiproliferative,
 CC antiproliferative and immunosuppressive activities and may be used in gene
 CC therapy. The MHC molecule construct is useful as a therapeutic
 CC composition in vivo or ex vivo therapy, for treating, preventing,
 CC stabilizing or alleviating a disease involving MHC recognizing cells, for
 CC monitoring MHC recognizing cells or establishing a prognosis of a disease
 CC or diagnosing a disease, or determining the status of a disease or the
 CC effectiveness of a medicament against a disease, involving MHC
 CC recognizing cells, e.g., chronic inflammatory bowel disease such as
 CC Crohn's disease or ulcerative colitis, scleroderma, type I diabetes,
 CC rheumatoid arthritis, psoriasis, atopic dermatitis, asthma, malignant
 CC melanoma, renal carcinoma, breast cancer, lung cancer, cancer of the
 CC uterus, cervical cancer, prostate cancer, brain cancer, head and neck
 CC cancer, leukaemia, cutaneous lymphoma, hepatic carcinoma, colorectal
 CC cancer, bladder cancer, rejection-related disease, Graft-versus-host
 CC related disease, or a viral disease associated with hepatitis, Acquired
 CC immunodeficiency Syndrome (AIDS), measles, pox, chicken pox, rubella or
 CC herpes. The MHC molecule construct is also useful for flow cytometry,
 CC histology or cytology. The present sequence represents a peptide used to
 CC create the MHC molecule construct of the invention

XX Sequence 10 AA;

Query Match 71.8%; Score 28; DB 5; Length 10;

QY 1 RAFTVI 6
 |||||
 DB 5 RAFTVI 10

DB 5 RAFTVI 10

Best Local Similarity 100.0%; Pred. No. 25;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFVTI 6
| | | | |
5 RAFVTI 10

RESULT 239

AAE26082
ID AAE26082 standard; peptide; 10 AA.

AC AAE26082;

DT 29-AUG-2003 (revised)

DE 14-NOV-2002 (first entry)

Human immunodeficiency virus type 1 (HIV-1) peptide, IIB.
Antigenic composition; cancer; aminoalkyl glucosamine phosphate compound;
AMP; immune response; cytotoxic T lymphocyte; allergic response; tumour;
amyloid deposition; vaccine; antifungal; antibacterial; antiparasitic;
cytostatic; immunostimulant; virucide; HIV-1 peptide.

OS Human immunodeficiency virus 1.

PN W0200238177-A2.

PD 16-MAY-2002.

PF 08-NOV-2001; 2001WO-US046943.

PR 10-NOV-2000; 2000US-0247100P.

PR 18-OCT-2001; 2001US-030345P.

PA (AMCY) AMERICAN CYANAMID CO.

PI Hagen M;

DR WPI; 2002-636409/68.

Antigenic composition for use in enhancing immune response of antigen,
has selected antigen, and combination of adjuvant comprising an
aminoalkyl glucosamine phosphate compound, and cytokine or lymphokine.

Example 1; Page 28; 94pp; English.

The invention relates to an antigenic composition comprising a selected
antigen from a pathogenic virus, bacterium, fungus or parasite, or from a
cancer or tumour cell, or from an allergen, or from a self molecule; and
an combination of adjuvant comprising an aminoalkyl glucosamine phosphate
compound (AGP), or its derivative or analogue, and a cytokine or
lymphokine, or an agonist to it. The invention is useful for increasing
the ability of an antigenic composition (enhancing immune response)
containing a selected antigen from a pathogenic virus, bacterium, fungus
or parasite to elicit an immune response especially cytotoxic T
lymphocytes; a selected antigen a cancer or tumour cell to elicit
therapeutic or prophylactic anti-cancer effect; a selected allergen to
moderate an allergic response; or a selected antigen from a molecule or
its portion representing those produced by a host in an undesired manner,
CC amount or location so as to reduce an undesired effect, in a vertebrate
host. The invention is useful for increasing the ability of an antigenic
composition to prevent or treat disease characterised by amyloid
deposition in a vertebrate host. The invention is useful as a vaccine.
CC The present sequence is HIV-1 peptide, IIB. This peptide corresponds to
CC the CTL epitope within the V3 loop of HIV-1-IIB. (Updated on 29-AUG-2003
CC to standardise OS field)

SQ Sequence 10 AA;

Query Match 71.8%; Score 28; DB 5; Length 10;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFVTI 6
| | | | |
5 RAFVTI 10

RESULT 240

AAE13217
ID AAE13217 standard; peptide; 10 AA.

AC AAE13217;

DT 29-AUG-2003 (revised)

DT 12-FEB-2002 (first entry)

DE HIV-1 class I-restricted gp120 peptide.

Cytotoxic T lymphocyte; CTL; T cell; tumour load; cancer radiotherapy;
immunostimulatory sequence oligonucleotide; ISS-ODN; chemotherapy;
immunosuppression; transplantation; autoimmune disease; infection;
acquired immune deficiency syndrome; AIDS; intracellular pathogen;
cytomegalovirus; mycobacterial infection; Epstein-Barr virus;
varicella zoster virus; human immunodeficiency virus; HIV.

OS Human immunodeficiency virus 1.

PN W0200172123-A1.

PD 04-OCT-2001.

PF 28-MAR-2001; 2001WO-US010118.

PR 28-MAR-2000; 2000US-0192537P.

PR 11-MAY-2000; 2000US-0203567P.

PR 05-JUL-2000; 2000US-0215895P.

PA (REGC) UNIV CALIFORNIA.

PA (VETE-) DEPT VETERANS AFFAIRS.

PI Raz E, Cho HJ, Richman DD, Horner AA;

DR WPI; 2002-010699/01.

Increasing antigen-specific cytotoxic T lymphocyte activity in a CD4+ T
cell deficient individual, useful to treat immunodeficiency and block HIV
infection, comprises administering immunostimulatory nucleic acid.

Example 8; Page 57; 91pp; English.

The present invention relates to a method for increasing antigen-specific
cytotoxic T lymphocyte (CTL) activity in a CD4+ T cell-deficient
individual, comprising administering an immunostimulatory sequence
oligonucleotide (ISS-ODN). The immunostimulatory nucleic acids of the
invention are used in CD4+ T cell-deficient individuals to decrease
tumour load, to treat a primary or acquired immunodeficiency,
CC particularly where the acquired immunodeficiency is temporary and due to
CC cancer radiotherapy or chemotherapy or immunosuppression following bone
CC marrow or organ transplantation, or autoimmune disease treatment, or is
CC acquired immunodeficiency syndrome (AIDS). The nucleic acids may be used
CC to treat a person at risk of becoming CD4+ T cell-deficient, particularly
CC where someone at risk of cancer recurrence. They are also used to treat
CC infection, particularly by an intracellular pathogen, especially one
CC caused by cytomegalovirus, Mycobacterium tuberculosis, M. avium, Epstein-
CC Barr virus, a fungus yeast, varicella zoster virus or human
CC immunodeficiency virus (HIV). The present sequence is a HIV-1 class I-
CC restricted gp120 peptide, used in the exemplification of the invention.
CC (Updated on 29-AUG-2003 to standardise OS field)

SQ Sequence 10 AA;

Query Match 71.8%; Score 28; DB 5; Length 10;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTI 6
 DB 5 RAFVTI 10

RESULT 241

ABG68655
 ID ABG68655 standard; peptide; 10 AA.

AC ABG68655;

DT 29-AUG-2003 (revised)

DT 07-OCT-2002 (first entry)

DE HIV-1 P18 V3 loop peptide antigen #1.

XX Eliciting an immune response; peptide antigen; T-cell epitope;

KW tumour antigen; viral antigen; non-viral vector; HIV-1;

KW T-cell co-stimulatory molecule; human immunodeficiency virus;

KW immunostimulant.

OS Human immunodeficiency virus 1; (IIB isolate).

XX US2002044948-A1.

XX 18-APR-2002.

XX 14-MAR-2001; 2001US-00810310.

XX 15-MAR-2000; 2000US-0189396P.

XX (KHE/) KHEIF S.

XX (BERZ/) BERZOFISKY J.

XX Kheif S, Berzofsky J;

XX WPI; 2002-507231/54.

XX Administering a non-viral vector encoding a co-stimulatory molecule

PT alongside a peptide or protein T cell epitope, elicits increased response

PT to the antigen and is useful to enhance peptide and protein based

PT vaccines and treatments.

XX Disclosure; Page 7; 39pp; English.

XX The present invention relates to a method for eliciting an immune

CC response in a subject. The method comprises administering a peptide or

CC protein antigen comprising T-cell epitope(s) (e.g. tumour antigen, viral

CC or non-viral antigen) coordinately with a non-viral vector comprising a

CC polynucleotide encoding a T-cell co-stimulatory molecule. Viral peptide

CC antigens may include human immunodeficiency virus (HIV) antigen,

CC hepatitis B virus (HBV), herpes simplex virus (HSV) or human papilloma

CC virus (HPV). The method is useful to elicit an immune response in a

CC subject, and to supplement and enhance peptide and protein based vaccines

CC and treatment methods. ABG68640-ABG68700 represent HIV-1 peptide antigens

CC useful in the method of the present invention. (Updated on 29-AUG-2003 to

CC standardise OS field)

XX Sequence 10 AA;

QY Query Match 71.8%; Score 28; DB 5; Length 10;

DB Best Local Similarity 100.0%; Pred. No. 25;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTI 6

DB 5 RAFVTI 10

RESULT 242

ABG80230

ID ABG80230 standard; peptide; 10 AA.

XX ABG80230;

AC 29-AUG-2003 (revised)

DT 15-NOV-2002 (first entry)

DE MHC class I molecule, viral epitope #478.

XX Major histocompatibility complex; MHC; MHC class I molecule; virus;

KW epitope; cytotoxic T lymphocyte response; CTL response; lymphatic system;

KW antigen; immunogenic; malignant tumour; carcinoma; melanoma; leukaemia;

KW lymphoma; infectious disease; hepatitis; malaria; measles; tuberculosis;

KW acquired immune deficiency syndrome; AIDS.

XX Viruses.

XX WO200262368-A2.

XX 15-AUG-2002.

XX 22-JAN-2002; 2002WO-US002033.

XX 02-FEB-2001; 2001US-0076232.

XX (CTL-) CTL IMMUNOTHERAPIES CORP.

XX Kundig TM, Simard JL;

XX WPI; 2002-657506/70.

XX Inducing or sustaining immunological cytotoxic T lymphocyte response in a

PT mammal, useful for treating a mammal with malignant tumor or infectious

PT disease, by directly administering an antigen to the lymphatic system of

PT the mammal.

XX Disclosure; Page 39; 73pp; English.

XX The invention relates to a method of inducing and/or sustaining an

CC immunological cytotoxic T lymphocyte (CTL) response in a mammal

CC comprising administering directly to the lymphatic system of the mammal:

CC (a) an antigen in the form of a polypeptide; (b) a vector comprising a

CC nucleic acid encoding the antigen; or (c) a non-peptide antigen. The

CC method is useful for inducing and/or sustaining CTL response in a mammal.

CC This is particularly useful for treating a mammal having a malignant

CC tumour (e.g. carcinoma, melanoma, leukaemia or lymphoma) or infectious

CC disease (e.g. hepatitis, acquired immune deficiency syndrome (AIDS),

CC malaria, measles or tuberculosis), or in an animal having a

CC predisposition to these diseases. The mammal may be dogs, cats, mice,

CC cattle, sheep, pigs, goats, rabbits, or preferably humans. ABG79753-

CC ABG80319 represent viral epitopes on major histocompatibility complex

CC (MHC) class I molecules, used in the method of the invention. (Updated on

CC 29-AUG-2003 to standardise OS field)

XX Sequence 10 AA;

QY Query Match 71.8%; Score 28; DB 5; Length 10;

DB Best Local Similarity 100.0%; Pred. No. 25;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTI 6

DB 5 RAFVTI 10

RESULT 243

ABG79846

ID ABG79846 standard; peptide; 10 AA.

AC ABG79846;

DT 15-NOV-2002 (first entry)

DE MHC class I molecule, viral epitope #94.

```

XX Major histocompatibility complex; MHC; class I molecule; virus;
KM epitope; cytotoxic T lymphocyte response; CTL response; lymphatic system;
KM antigen; immunogenic; malignant tumour; carcinoma; melanoma; leukaemia;
KM lymphoma; infectious disease; hepatitis; malaria; measles; tuberculosis;
KM acquired immune deficiency syndrome; AIDS.
XX
OS Human immunodeficiency virus.
PN WO200262368-A2.
XX
PD 15-AUG-2002.
XX
PF 22-JAN-2002; 2002WO-US002033.
XX
PR 02-FEB-2001; 2001US-00776232.
XX
PA (CTL1-) CTL IMMUNOTHERAPIES CORP.
XX
PI Kundig TM, Simard JUL;
XX
DR WPI; 2002-657506/70.
XX
PT Inducing or sustaining immunological cytotoxic T lymphocyte response in a
PT mammal, useful for treating a mammal with malignant tumor or infectious
PT disease, by directly administering an antigen to the lymphatic system of
PT the mammal.
XX
PS Disclosure; Page 20; 73pp; English.
XX
CC The invention relates to a method of inducing and/or sustaining an
CC immunological cytotoxic T lymphocyte (CTL) response in a mammal
CC comprising administering directly to the lymphatic system of the mammal:
CC (a) an antigen in the form of a polypeptide; (b) a vector comprising a
CC nucleic acid encoding the antigen; or (c) a non-peptide antigen. The
CC method is useful for inducing and/or sustaining CTL response in a mammal.
CC This is particularly useful for treating a mammal having a malignant
CC tumour (e.g. carcinoma, melanoma, leukaemia or lymphoma) or infectious
CC disease (e.g. hepatitis, acquired immune deficiency syndrome (AIDS),
CC malaria, measles or tuberculosis), or in an animal having a
CC predisposition to these diseases. The mammal may be dogs, cats, mice,
CC cattle, sheep, pigs, goats, rabbits, or preferably humans. ABG79753-
CC ABG80319 represent viral epitopes on major histocompatibility complex
CC (MHC) class I molecules, used in the method of the invention
XX
SQ Sequence 10 AA;
XX
Query Match 71.8%; Score 28; DB 5; Length 10;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 RAFVTI 6
Db |||||
5 RAFVTI 10
XX
RESULT 244
AAE35167
ID AAE35167 standard; peptide; 10 AA.
XX
AC AAE35167;
XX
XX
DT 28-MAY-2003 (first entry)
XX
DE HIV CTL epitope #12.
XX
KM Cytolytic T lymphocyte; epitope; vaccine; prophylaxis; HIV infection;
KM human immunodeficiency virus; acquired immune deficiency syndrome; CTL;
KM gene therapy; AIDS.
XX
OS Human immunodeficiency virus.
XX
PN WO200294313-A2.

```

```

XX
PD 28-NOV-2002.
XX
PF 20-MAY-2002; 2002WO-GB002336.
XX
PR 18-MAY-2001; 2001US-0291654P.
XX
PR 18-MAY-2001; 2001US-0291655P.
XX
PA (POWD-) POWDERJECT VACCINES INC.
PA (POWD-) POWDERJECT RES LTD.
XX
PI Fuller D, Fuller J, Haynes J, Shipley T;
XX
DR WPI; 2003-148439/14.
XX
PT Recombinant nucleic acid for the treatment and prophylaxis of acquired
PT immunodeficiency syndrome, comprises a nucleic acid sequence encoding an
PT antigen containing two or more cytolytic T lymphocyte (CTL) epitopes or
PT its analogs.
XX
PS Example 1; Col 79; 42pp; English.
XX
CC The invention relates to a recombinant nucleic acid comprising a nucleic
CC acid sequence encoding an antigen containing two or more cytolytic T
CC lymphocyte (CTL) epitopes or its analogues. Sequences of the invention
CC are used in vaccines and are useful for the treatment and prophylaxis of
CC human immunodeficiency virus (HIV) infection, particularly acquired
CC immune deficiency syndrome (AIDS). The invention is also useful in gene
CC therapy. The present sequence is HIV CTL epitope. This sequence is used
CC in the exemplification of the invention
XX
SQ Sequence 10 AA;
XX
Query Match 71.8%; Score 28; DB 6; Length 10;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 RAFVTI 6
Db |||||
5 RAFVTI 10
XX
RESULT 245
ABP60029
ID ABP60029 standard; peptide; 10 AA.
XX
AC ABP60029;
XX
DT 07-MAR-2003 (first entry)
XX
DE HIV antigenic peptide.
XX
KM TOP; thimet oligopeptidase; EC3.4.25.15; cytostatic; tumour;
KM immunostimulant; major histocompatibility complex class I; MHC;
KM T-cell immunity.
XX
OS Human immunodeficiency virus.
XX
PN WO200279388-A2.
XX
PD 10-OCT-2002.
XX
PF 01-APR-2002; 2002WO-US010385.
XX
PR 30-MAR-2001; 2001US-0280669P.
XX
PA (UYMA-) UNIV MASSACHUSETTS.
XX
PI Rock KL, Goldberg AL;
XX
DR WPI; 2003-103265/09.
XX
PT New recombinant cell comprising an exogenously derived nucleic acid

```

PT coding for a thimet oligopeptidase polypeptide, useful for modulating an
 PT antigenic response in a mammal for treating e.g., tumor.

XX Example 1; Page 50; 73pp; English.

XX The invention relates to a new recombinant cell comprising an exogenously
 CC derived nucleic acid that codes for a thimet oligopeptidase (TOP)
 CC polypeptide. The TOP polypeptide is overexpressed in the cell compared to
 CC a wild-type cell from which the recombinant cell is derived. The activity
 CC of TOP may be described as cytostatic and immunostimulatory. Thimet
 CC oligopeptidase (TOP, EC3.4.25.15) plays a key role in modulating levels
 CC of major histocompatibility complex (MHC) class I-presented peptides. The
 CC recombinant host cell of the invention is useful for modulating an
 CC antigenic response in a mammal. Methods of the invention are useful for
 CC screening a test compound for its ability to serve as an immunomodulatory
 CC agent and identifying an antigen resistant to thimet oligopeptidase
 CC degradation. A method of the invention is useful for increasing CD8 T-
 CC cell immunity, which uses vaccination with a TOP inhibitor for decreasing
 CC TOP expression or activity. The vaccination method uses treated tumour
 CC cells, antigen bearing/pulsed dendritic cells or injection of a viral
 CC vector. The recombinant host cell is useful for treating tumours. The
 CC current sequence represents an HIV (human immunodeficiency virus) gp160
 CC antigenic peptide used in an example from the invention

XX Sequence 10 AA;

Query Match 71.8%; Score 28; DB 6; Length 10;
 Best Local Similarity 100.0%; Pred. No. 25;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTYI 6
 |||||
 Db 5 RAFTYI 10

RESULT 246

ABR39122 standard; peptide; 10 AA.

XX ABR39122;

DT 23-OCT-2003 (revised)

DT 10-MAY-2003 (first entry)

XX HIV-1 gp120 CTL epitope peptide SEQ ID NO 22.

XX ADP-ribosylating exotoxin; immune response; immunisation; vaccine;
 KM adjuvant; HIV; gp120; CTL epitope.

XX Human immunodeficiency virus 1.

OS WO2003004055-A2.

PN 16-JAN-2003.

PD 26-NOV-2001; 2001WO-US043151.

XX 27-NOV-2000; 2000US-00724315.

XX (POWD-) POWDERJECT VACCINES INC.

PA Haynes JR, Arrington JE;

PI WPI; 2003-221541/21.

XX New compositions comprising nucleic acid adjuvants, useful in
 PT immunization techniques, particularly for eliciting or enhancing an
 PT immune response against an antigen in a human.

XX Example 5; Page 71; 143pp; English.

XX The invention relates to a composition comprising: (a) a first nucleic
 CC acid sequence that is a truncated A subunit coding region obtained or

CC derived from a bacterial ADP-ribosylating exotoxin; and (b) a second
 CC nucleic acid sequence that is a truncated B subunit coding region
 CC obtained or derived from a bacterial ADP-ribosylating exotoxin. Each of
 CC the truncated subunit coding regions has a 5' deletion and encodes a
 CC subunit peptide not having an amino terminal bacterial signal peptide.
 CC The composition is useful for eliciting an immune response against an
 CC antigen or for manufacturing a medicament for enhancing an immune
 CC response in a vertebrate subject (specifically a human) against an
 CC antigen. The composition is particularly useful as nucleic acid adjuvants
 CC for use in immunisation techniques. The present sequence is that of a HIV
 CC gp120 CTL epitope peptide, used in examples of the invention to test for
 CC the adjuvant effects of plasmids pPV2002 and pPV2003 in enhancing the
 CC humoral and cellular immune responses to HIV-1 gp120. (Updated on 23-OCT-
 CC 2003 to standardise OS field)

XX Sequence 10 AA;

Query Match 71.8%; Score 28; DB 6; Length 10;
 Best Local Similarity 100.0%; Pred. No. 25;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTYI 6
 |||||
 Db 5 RAFTYI 10

RESULT 247

ABP72314 standard; peptide; 10 AA.

XX ABP72314;

DT 23-OCT-2003 (revised)

DT 08-MAY-2003 (first entry)

XX HIV-1 p18 protein CD8+ T cell epitope.

XX HIV-1; antigen; epitope; infection; vaccine; glycosylceramide; adjuvant;
 KM virucide; anti-HIV.

XX Human immunodeficiency virus 1.

OS WO2003009812-A2.

PN 06-FEB-2003.

PD 24-JUL-2002; 2002WO-US023673.

XX 25-JUL-2001; 2001US-0308056P.

XX (UTNY) UNIV NEW YORK STATE.

PA Teuji M, Gonzalez-Aseguinolaza G, Nussenzweig RS, Kozuka Y;

PI WPI; 2003-266011/26.

XX Augmenting the immunogenicity of an antigen in a mammal, useful for
 PT treating cancer; viral infection and malaria, comprises immunizing the
 PT mammal with the antigen conjointly with adjuvant comprising a
 PT glycosylceramide.

XX Claim 55; Page 75; 97pp; English.

XX The present sequence is that of an HIV-specific antigen comprising the
 CC CD8+ T cell epitope of HIV-1 p18 protein. A claimed method for enhancing
 CC a T cell response to HIV antigen in a susceptible mammalian (human) host
 CC comprising co-administering an HIV-specific antigen such as the present
 CC antigen and alpha-galactosylceramide as adjuvant. The HIV-specific
 CC antigen may be presented by a recombinant virus such as a recombinant
 CC adenovirus, pox virus or Sindbis virus. This is an example of the method
 CC of the invention for augmenting the immunogenicity of an antigen in a
 CC mammal by immunising the mammal with the antigen and with a
 CC glycosylceramide adjuvant. This adjuvant enhances and/or prolongs antigen

-specific Th1-type responses, particularly CD8+ T cell responses. In an example from the invention, co-administration of alpha-galactosylceramide to mice immunised with the present T cell epitope enhanced almost 3 times the level of HIV-specific CD8+ T cell response compared to that induced in mice immunised without alpha-galactosylceramide treatment. (Updated on 23-OCT-2003 to standardise OS field)

XX Sequence 10 AA;

Query Match 71.8%; Score 28; DB 6; Length 10;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTI 6
| | | | |
Db 5 RAFVTI 10

RESULT 248

ADA50228
ID ADA50228 standard; peptide; 10 AA.

AC ADA50228;
DT 20-NOV-2003 (first entry)

XX Human immunodeficiency virus gp120 peptide.

DE
XX
XX DNA expression vector; immune response; immunopotentiating chemokine;
KM immunogenic polypeptide; infectious agent; cancerous cell;
KM immunostimulant; immunosuppressant; cytostatic; gene therapy; cancer;
KM tumour; metastatic cancer; infectious disease; autoimmune disease;
KM stimulating T cell activity; suppressing T cell activity;
KM macrophage inflammatory protein; HIV; gp120.

XX Human immunodeficiency virus.

XX US6562800-B1.

XX 13-MAY-2003.

XX 29-OCT-1999; 99US-00430470.

XX 30-OCT-1998; 98US-0106506P.

XX (UYSC-) UNIV SOUTHERN CALIFORNIA.

XX McMillan M;

XX WPI; 2003-584408/55.

PT New DNA expression vectors comprising a DNA encoding an
PT immunopotentiating chemokine and a DNA encoding a heterologous
PT immunogenic polypeptide, useful for inducing an immune response, and for
PT treating cancers.

XX Example; Col 20; 40pp; English.

PS This invention relates to a novel DNA expression vector for inducing an
XX immune response. The DNA expression vector of the invention encodes both
CC an immunopotentiating chemokine sequence as well as an immunogenic
CC polypeptide sequence which is derived from an infectious agent or
CC cancerous cell. The chemokines are preferably selected from the animal to
CC be treated. The vaccine of the invention may have immunostimulant,
CC immunosuppressant and cytostatic activities and used for a form of gene
CC therapy. The expression vector and compositions comprising the vector of
CC the invention may therefore be useful for inducing an immune response in
CC a mammal, and for treating cancers (tumours and metastatic form of
CC cancer), infectious diseases, autoimmune diseases and other diseases that
CC can be alleviated by either stimulating or suppressing T cell activity.
CC The present sequence is the amino acid sequence of the human
CC immunodeficiency virus gp120 peptide which was used during the
CC exemplification of the invention.

XX Sequence 10 AA;

Query Match 71.8%; Score 28; DB 6; Length 10;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTI 6
| | | | |
Db 5 RAFVTI 10

RESULT 249

ADE79992
ID ADE79992 standard; peptide; 10 AA.

AC ADE79992;
DT 29-JAN-2004 (first entry)

DE HIV1 carrier peptide to augment anti-malaria CD8+ T-cell immune response.

XX antimalarial; cytostatic; vaccine; immune response;
KM non-hepadnaviral antigen; hepatitis B core particle; CD8+ T-cell;
KM epitope; poxvirus vector; cancer; malaria; epitope.

XX Human immunodeficiency virus 1.

XX WO2003066833-A2.

XX 14-AUG-2003.

XX 07-FEB-2003; 2003WO-US003897.

XX 08-FEB-2002; 2002US-0354963P.

XX (UYNY-) UNIV NEW YORK MEDICAL CENT.

XX Zavala F, Birkett AJ;

XX WPI; 2003-748124/70.

PT Generating an immune response against a non-hepadnaviral antigen in a
PT mammal, useful for treating or preventing cancer or malaria, by
PT administering a priming component comprising a recombinant hepatitis B
PT core particle.

XX Disclosure; SEQ ID NO 48; 85pp; English.

PS The invention relates to a method of generating an immune response
XX against a non-hepadnaviral antigen in a mammal by administering (to the
CC mammal) at least 1 dose of a priming component comprising a recombinant
CC hepatitis B core particle (rHBP) (which is a carrier for 1 or more non-
CC hepadnaviral CD8+ T-cell epitopes of the antigen). The method may be
CC supplemented by the use of a boosting stage comprising a non-replicating
CC or replication-impaired recombinant poxvirus vector. The method is useful
CC for generating an immune response against a non-hepadnaviral antigen in a
CC mammal for treating or preventing cancer or malaria. This sequence
CC represents a peptide from human immunodeficiency virus type 1 (HIV-1)
CC used as a carrier peptide to augment the immune response against a
CC plasmidum peptide.

XX Sequence 10 AA;

Query Match 71.8%; Score 28; DB 7; Length 10;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVTI 6
| | | | |
Db 5 RAFVTI 10

RESULT 250

AD879994
ID ADE79994 standard; peptide: 10 AA.

AC ADE79994;

DT 29-JAN-2004 (first entry)

DE HIV1 carrier peptide to augment anti-malaria CD8+ T-cell immune response.

KW antimalarial; cytostatic; vaccine; immune response;

KW non-hepadnaviral antigen; hepatitis B core particle; CD8+ T-cell;

OS Human immunodeficiency virus 1.

PN WO2003066833-A2.

PD 14-AUG-2003.

PF 07-FEB-2003; 2003WO-US003897.

PR 08-FEB-2002; 2002US-0354963P.

PA (UNYNY-) UNIV NEW YORK MEDICAL CENT.

PI Zavala F, Birkett AJ;

DR WPI; 2003-748124/70.

PT Generating an immune response against a non-hepadnaviral antigen in a

PT mammal, useful for treating or preventing cancer or malaria, by

PT administering a priming component comprising a recombinant hepatitis B

PT core particle.

PS Disclosure; SEQ ID NO 50; 85bp; English.

CC The invention relates to a method of generating an immune response
CC against a non-hepadnaviral antigen in a mammal by administering (to the
CC mammal) at least 1 dose of a priming component comprising a recombinant
CC hepatitis B core particle (rHBP) (which is a carrier for 1 or more non-
CC hepadnaviral CD8+ T-cell epitopes of the antigen). The method may be
CC supplemented by the use of a boosting stage comprising a non-replicating
CC or replication-impaired recombinant poxvirus vector. The method is useful
CC for generating an immune response against a non-hepadnaviral antigen in a
CC mammal for treating or preventing cancer or malaria. This sequence
CC represents a peptide from human immunodeficiency virus type 1 (HIV-1)
CC used as a carrier peptide to augment the immune response against a
CC plasmidum peptide.

SQ Sequence 10 AA;

Query Match 71.8%; Score 28; DB 7; Length 10;

Best Local Similarity 100.0%; Pred.No. 25;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFTYI 6
|||
5 RAFTYI 10

Search completed: May 16, 2005, 10:02:57
Job time : 72 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 16, 2005, 09:45:52 ; Search time 40 Seconds
(without alignments)
14.930 Million cell updates/sec

Title: SEQ1
Perfect score: 39
Sequence: 1 refvixgk 8

Scoring table: BIOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 218077

Minimum DB seq length: 0
Maximum DB seq length: 25

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 250 summaries

Database :

Issued Patents AA:*
1: /cgn2_6/ptodata/1/1aa/5A_COMB.pep:*
2: /cgn2_6/ptodata/1/1aa/5B_COMB.pep:*
3: /cgn2_6/ptodata/1/1aa/6A_COMB.pep:*
4: /cgn2_6/ptodata/1/1aa/6B_COMB.pep:*
5: /cgn2_6/ptodata/1/1aa/PCTUS_COMB.pep:*
6: /cgn2_6/ptodata/1/1aa/backfile1.pep:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	39	100.0	8	1	US-08-260-086-6
2	39	100.0	8	3	US-08-480-332-3
3	39	100.0	8	5	PCT-US92-10378-5
4	39	100.0	9	1	US-08-704-170-44
5	39	100.0	9	4	US-09-454-204A-52
6	39	100.0	9	5	PCT-US94-02631-44
7	39	100.0	11	2	US-08-648-298-4
8	39	100.0	12	1	US-08-704-170-52
9	39	100.0	12	1	US-08-488-252-30
10	39	100.0	12	5	PCT-US94-02631-52
11	39	100.0	12	5	PCT-US95-03236-43
12	39	100.0	13	1	US-08-090-148-5
13	39	100.0	13	1	US-08-279-906A-17
14	39	100.0	14	1	US-08-111-080-6
15	39	100.0	14	1	US-08-211-980-6
16	39	100.0	14	2	US-08-455-625-9
17	39	100.0	14	2	US-08-455-625-10
18	39	100.0	14	3	US-08-455-685-9
19	39	100.0	14	3	US-08-455-685-10
20	39	100.0	14	3	US-08-060-988A-9
21	39	100.0	14	5	PCT-US92-07111-6
22	39	100.0	14	5	PCT-US94-05142-10
23	39	100.0	14	5	PCT-US94-05142-9
24	39	100.0	14	5	PCT-US94-05142-10
25	39	100.0	15	1	US-08-336-087-2
26	39	100.0	15	1	US-08-218-025A-17
27	39	100.0	15	1	US-08-218-025A-17

28	39	100.0	15	1	US-08-709-047-7	Sequence 7, Appl
29	39	100.0	15	1	US-08-479-400-2	Sequence 2, Appl
30	39	100.0	15	1	US-08-410-360-7	Sequence 7, Appl
31	39	100.0	15	1	US-08-095-332-1	Sequence 1, Appl
32	39	100.0	15	1	US-08-707-801A-7	Sequence 7, Appl
33	39	100.0	15	1	US-08-709-006-7	Sequence 7, Appl
34	39	100.0	15	1	US-08-711-175-7	Sequence 27, Appl
35	39	100.0	15	1	US-08-488-252-27	Sequence 2, Appl
36	39	100.0	15	2	US-08-021-879-2	Sequence 1, Appl
37	39	100.0	15	2	US-07-760-530-1	Sequence 3, Appl
38	39	100.0	15	2	US-07-950-571A-3	Sequence 6, Appl
39	39	100.0	15	2	US-08-975-699-6	Sequence 6, Appl
40	39	100.0	15	2	US-08-972-089-6	Sequence 11, Appl
41	39	100.0	15	2	US-08-455-625-7	Sequence 12, Appl
42	39	100.0	15	2	US-08-455-625-11	Sequence 13, Appl
43	39	100.0	15	2	US-08-455-625-12	Sequence 14, Appl
44	39	100.0	15	2	US-08-455-625-13	Sequence 15, Appl
45	39	100.0	15	2	US-08-455-625-14	Sequence 1, Appl
46	39	100.0	15	2	US-08-455-625-15	Sequence 1, Appl
47	39	100.0	15	2	US-08-395-204-2	Sequence 1, Appl
48	39	100.0	15	2	US-08-628-687-1	Sequence 1, Appl
49	39	100.0	15	2	US-07-847-311A-1	Sequence 1, Appl
50	39	100.0	15	2	US-08-986-334-13	Sequence 13, Appl
51	39	100.0	15	2	US-08-986-334-28	Sequence 28, Appl
52	39	100.0	15	3	US-08-492-076-22	Sequence 25, Appl
53	39	100.0	15	3	US-08-493-071-25	Sequence 1, Appl
54	39	100.0	15	3	US-08-480-332-1	Sequence 7, Appl
55	39	100.0	15	3	US-08-455-685-7	Sequence 11, Appl
56	39	100.0	15	3	US-08-455-685-11	Sequence 12, Appl
57	39	100.0	15	3	US-08-455-685-12	Sequence 13, Appl
58	39	100.0	15	3	US-08-455-685-13	Sequence 14, Appl
59	39	100.0	15	3	US-08-455-685-14	Sequence 15, Appl
60	39	100.0	15	3	US-08-455-685-15	Sequence 7, Appl
61	39	100.0	15	3	US-08-060-988A-7	Sequence 11, Appl
62	39	100.0	15	3	US-08-060-988A-11	Sequence 12, Appl
63	39	100.0	15	3	US-08-060-988A-12	Sequence 13, Appl
64	39	100.0	15	3	US-08-060-988A-13	Sequence 14, Appl
65	39	100.0	15	3	US-08-060-988A-14	Sequence 15, Appl
66	39	100.0	15	3	US-08-060-988A-15	Sequence 8, Appl
67	39	100.0	15	3	US-09-051-006-8	Sequence 1, Appl
68	39	100.0	15	4	US-09-389-390-1	Sequence 15, Appl
69	39	100.0	15	4	US-09-508-552-15	Sequence 9, Appl
70	39	100.0	15	4	US-09-827-688-9	Sequence 1, Appl
71	39	100.0	15	5	PCT-US92-10378-1	Sequence 7, Appl
72	39	100.0	15	5	PCT-US94-05142-7	Sequence 11, Appl
73	39	100.0	15	5	PCT-US94-05142-11	Sequence 12, Appl
74	39	100.0	15	5	PCT-US94-05142-12	Sequence 13, Appl
75	39	100.0	15	5	PCT-US94-05142-13	Sequence 14, Appl
76	39	100.0	15	5	PCT-US94-05142-14	Sequence 15, Appl
77	39	100.0	15	5	PCT-US94-05142-15	Sequence 2, Appl
78	39	100.0	16	2	US-08-657-392-28	Sequence 2, Appl
79	39	100.0	16	2	US-08-251-472-2	Sequence 35, Appl
80	39	100.0	16	2	US-08-481-905-35	Sequence 3, Appl
81	39	100.0	16	3	US-08-481-985B-35	Sequence 28, Appl
82	39	100.0	16	3	US-09-248-086-2	Sequence 2, Appl
83	39	100.0	16	3	US-08-370-476-35	Sequence 15, Appl
84	39	100.0	16	5	PCT-US94-02533-28	Sequence 28, Appl
85	39	100.0	16	5	PCT-US94-02533-28	Sequence 4, Appl
86	39	100.0	18	1	US-08-015-770B-4	Sequence 25, Appl
87	39	100.0	20	1	US-08-121-054C-3	Sequence 28, Appl
88	39	100.0	20	1	US-08-488-252-28	Sequence 3, Appl
89	39	100.0	20	3	US-08-539-436-3	Sequence 3, Appl
90	39	100.0	20	4	US-09-813-659-3	Sequence 3, Appl
91	39	100.0	20	4	US-09-549-067A-3	Sequence 4, Appl
92	39	100.0	21	2	US-08-452-503A-4	Sequence 25, Appl
93	39	100.0	21	2	US-08-453-745A-4	Sequence 18, Appl
94	39	100.0	21	2	US-08-470-419-25	Sequence 25, Appl
95	39	100.0	21	2	US-08-648-298-18	Sequence 25, Appl
96	39	100.0	21	2	US-08-761-828-25	Sequence 4, Appl
97	39	100.0	21	2	US-08-452-520B-4	Sequence 25, Appl
98	39	100.0	21	2	US-08-290-105-25	Sequence 25, Appl
99	39	100.0	21	3	US-08-776-949-25	Sequence 25, Appl
100	39	100.0	21	3	US-08-482-810-25	Sequence 25, Appl

101	39	100.0	21	3	US-09-027-955-25	Sequence 25, Appl	174	34	87.2	15	2	US-08-455-625-21	Sequence 21, Appl
102	39	100.0	21	3	US-09-636-805-25	Sequence 25, Appl	175	34	87.2	15	3	US-08-455-685-16	Sequence 16, Appl
103	39	100.0	21	4	US-09-258-128-25	Sequence 25, Appl	176	34	87.2	15	3	US-08-455-685-19	Sequence 19, Appl
104	39	100.0	21	4	US-09-635-754-25	Sequence 25, Appl	177	34	87.2	15	3	US-08-455-685-20	Sequence 20, Appl
105	39	100.0	21	4	US-08-680-525-25	Sequence 25, Appl	178	34	87.2	15	3	US-08-455-685-21	Sequence 21, Appl
106	39	100.0	22	1	US-08-636-223-25	Sequence 25, Appl	179	34	87.2	15	3	US-08-060-988A-16	Sequence 16, Appl
107	39	100.0	22	1	US-08-125-012-13	Sequence 13, Appl	180	34	87.2	15	3	US-08-060-988A-19	Sequence 19, Appl
108	39	100.0	22	2	US-08-783-818-13	Sequence 13, Appl	181	34	87.2	15	3	US-08-060-988A-20	Sequence 20, Appl
109	39	100.0	22	2	US-08-453-349-13	Sequence 13, Appl	182	34	87.2	15	3	US-08-060-988A-21	Sequence 21, Appl
110	39	100.0	22	2	US-08-345-321-2	Sequence 2, Appl	183	34	87.2	15	5	PCT-US94-02631-72	Sequence 72, Appl
111	39	100.0	22	2	US-08-979-385B-11	Sequence 11, Appl	184	34	87.2	15	5	PCT-US94-05142-16	Sequence 16, Appl
112	39	100.0	22	3	US-08-537-245-1	Sequence 5, Appl	185	34	87.2	15	5	PCT-US94-05142-19	Sequence 19, Appl
113	39	100.0	22	3	US-08-805-889-5	Sequence 5, Appl	186	34	87.2	15	5	PCT-US94-05142-20	Sequence 20, Appl
114	39	100.0	22	4	US-09-070-291-5	Sequence 5, Appl	187	34	87.2	15	5	PCT-US94-05142-21	Sequence 21, Appl
115	39	100.0	22	4	US-09-217-306B-22	Sequence 22, Appl	188	34	87.2	17	1	US-08-257-528B-35	Sequence 35, Appl
116	39	100.0	22	4	US-08-880-576-13	Sequence 13, Appl	189	34	87.2	17	1	US-08-257-528B-35	Sequence 35, Appl
117	39	100.0	24	1	US-08-097-751-1	Sequence 1, Appl	190	34	87.2	17	1	US-08-460-602A-35	Sequence 35, Appl
118	39	100.0	24	1	US-08-090-148-6	Sequence 6, Appl	191	34	87.2	17	1	US-08-463-966A-35	Sequence 35, Appl
119	39	100.0	24	1	US-08-257-528B-99	Sequence 99, Appl	192	34	87.2	17	2	US-08-463-966A-35	Sequence 35, Appl
120	39	100.0	24	1	US-08-460-602A-99	Sequence 99, Appl	193	34	87.2	17	2	US-08-463-966A-35	Sequence 35, Appl
121	39	100.0	24	1	US-08-463-966A-99	Sequence 99, Appl	194	34	87.2	17	2	US-08-463-966A-35	Sequence 35, Appl
122	39	100.0	24	1	US-08-463-966A-99	Sequence 99, Appl	195	34	87.2	17	2	US-08-463-966A-35	Sequence 35, Appl
123	39	100.0	24	2	US-08-463-966A-99	Sequence 99, Appl	196	34	87.2	17	2	US-08-463-966A-35	Sequence 35, Appl
124	39	100.0	24	2	US-08-463-966A-99	Sequence 99, Appl	197	34	87.2	17	2	US-08-463-966A-35	Sequence 35, Appl
125	39	100.0	24	2	US-08-463-966A-99	Sequence 99, Appl	198	34	87.2	17	2	US-08-463-966A-35	Sequence 35, Appl
126	39	100.0	24	2	US-08-463-966A-99	Sequence 99, Appl	199	34	87.2	17	2	US-08-463-966A-35	Sequence 35, Appl
127	39	100.0	24	2	US-08-463-966A-99	Sequence 99, Appl	200	34	87.2	17	2	US-08-463-966A-35	Sequence 35, Appl
128	39	100.0	24	3	US-08-723-425A-160	Sequence 160, App	201	34	87.2	17	3	US-08-455-685-22	Sequence 22, Appl
129	39	100.0	24	3	US-08-480-332-2	Sequence 2, Appl	202	34	87.2	17	3	US-08-060-988A-18	Sequence 18, Appl
130	39	100.0	24	3	US-09-112-206-160	Sequence 160, App	203	34	87.2	17	3	US-08-060-988A-22	Sequence 22, Appl
131	39	100.0	24	4	US-09-790-497A-14	Sequence 14, Appl	204	34	87.2	17	5	PCT-US94-05142-22	Sequence 22, Appl
132	39	100.0	24	4	US-09-790-497A-160	Sequence 160, App	205	34	87.2	20	1	US-08-257-528B-51	Sequence 51, Appl
133	39	100.0	24	4	US-09-576-824A-160	Sequence 160, App	206	34	87.2	20	1	US-08-463-966A-51	Sequence 51, Appl
134	39	100.0	24	4	US-09-680-497-160	Sequence 160, App	207	34	87.2	20	1	US-08-463-966A-51	Sequence 51, Appl
135	39	100.0	24	5	PCT-US92-06588-12	Sequence 12, Appl	208	34	87.2	20	2	US-08-463-966A-51	Sequence 51, Appl
136	39	100.0	24	5	PCT-US92-10778-3	Sequence 3, Appl	209	34	87.2	20	2	US-08-463-966A-51	Sequence 51, Appl
137	39	100.0	25	2	US-07-950-571A-1	Sequence 1, Appl	210	34	87.2	20	2	US-08-463-966A-51	Sequence 51, Appl
138	39	100.0	25	2	US-08-266-448-1	Sequence 1, Appl	211	34	87.2	20	2	US-08-463-966A-51	Sequence 51, Appl
139	39	100.0	25	3	US-08-485-324-13	Sequence 13, Appl	212	34	87.2	20	2	US-08-463-966A-51	Sequence 51, Appl
140	39	100.0	25	3	US-08-485-324-13	Sequence 13, Appl	213	34	87.2	20	2	US-08-463-966A-51	Sequence 51, Appl
141	39	100.0	25	3	US-08-447-506-13	Sequence 13, Appl	214	34	87.2	20	4	US-08-930-470-24	Sequence 24, Appl
142	39	100.0	25	3	US-08-447-506-31	Sequence 31, Appl	215	34	87.2	10	4	US-08-937-276A-5	Sequence 5, Appl
143	39	100.0	25	3	US-08-235-437-13	Sequence 13, Appl	216	34	87.2	10	4	US-09-454-204A-51	Sequence 51, Appl
144	39	100.0	25	3	US-08-235-437-13	Sequence 13, Appl	217	34	87.2	10	4	US-09-508-552-16	Sequence 16, Appl
145	39	100.0	25	3	US-08-447-515-13	Sequence 13, Appl	218	34	87.2	13	2	US-07-847-311A-20	Sequence 20, Appl
146	39	100.0	25	3	US-08-447-515-13	Sequence 13, Appl	219	34	87.2	15	3	US-08-930-917A-14	Sequence 14, Appl
147	39	100.0	25	4	US-09-593-870A-31	Sequence 31, Appl	220	34	87.2	25	2	US-08-493-235-23	Sequence 23, Appl
148	39	100.0	25	4	US-08-455-625-17	Sequence 17, Appl	221	34	87.2	20	1	US-08-279-906A-26	Sequence 26, Appl
149	39	100.0	25	2	US-08-455-625-23	Sequence 23, Appl	222	34	87.2	23	4	US-09-902-540-11814	Sequence 11814, A
150	39	100.0	25	3	US-08-455-685-17	Sequence 17, Appl	223	34	87.2	15	2	US-08-986-234-17	Sequence 17, Appl
151	39	100.0	25	3	US-08-455-685-23	Sequence 23, Appl	224	34	87.2	17	1	US-08-333-565-16	Sequence 16, Appl
152	39	100.0	25	3	US-08-060-988A-17	Sequence 17, Appl	225	34	87.2	17	2	US-08-661-479-16	Sequence 16, Appl
153	39	100.0	25	3	US-08-060-988A-23	Sequence 23, Appl	226	34	87.2	18	1	US-08-661-479-16	Sequence 16, Appl
154	39	100.0	25	5	PCT-US94-05142-17	Sequence 17, Appl	227	34	87.2	19	1	US-08-323-129D-51	Sequence 51, Appl
155	39	100.0	25	5	PCT-US94-05142-17	Sequence 17, Appl	228	34	87.2	19	2	US-08-975-693-15	Sequence 15, Appl
156	39	100.0	25	5	PCT-US94-05142-17	Sequence 17, Appl	229	34	87.2	19	2	US-08-975-693-15	Sequence 15, Appl
157	39	100.0	25	8	US-08-704-170-51	Sequence 51, Appl	230	34	87.2	19	3	US-08-972-089-15	Sequence 15, Appl
158	39	100.0	25	8	US-08-704-170-51	Sequence 51, Appl	231	34	87.2	19	3	US-08-972-089-15	Sequence 15, Appl
159	39	100.0	25	8	US-08-704-170-51	Sequence 51, Appl	232	34	87.2	19	3	US-08-972-089-15	Sequence 15, Appl
160	39	100.0	25	9	US-08-704-170-38	Sequence 38, Appl	233	34	87.2	19	5	PCT-US96-08995-1	Sequence 1, Appl
161	39	100.0	25	9	US-08-704-170-38	Sequence 38, Appl	234	34	87.2	19	5	PCT-US96-08995-1	Sequence 1, Appl
162	39	100.0	25	10	US-08-704-170-71	Sequence 71, Appl	235	34	87.2	20	1	US-08-825-852-63	Sequence 63, Appl
163	39	100.0	25	10	US-08-704-170-71	Sequence 71, Appl	236	34	87.2	20	3	US-08-825-852-63	Sequence 63, Appl
164	39	100.0	25	11	US-08-704-170-73	Sequence 73, Appl	237	34	87.2	20	3	US-08-825-852-63	Sequence 63, Appl
165	39	100.0	25	11	US-08-704-170-73	Sequence 73, Appl	238	34	87.2	20	3	US-08-825-852-63	Sequence 63, Appl
166	39	100.0	25	11	US-08-704-170-73	Sequence 73, Appl	239	34	87.2	20	3	US-08-825-852-63	Sequence 63, Appl
167	39	100.0	25	11	US-08-704-170-73	Sequence 73, Appl	240	34	87.2	20	4	US-09-723-890-64	Sequence 64, Appl
168	39	100.0	25	14	PCT-US95-03236-29	Sequence 29, Appl	241	34	87.2	20	4	US-09-723-890-64	Sequence 64, Appl
169	39	100.0	25	14	PCT-US95-03236-29	Sequence 29, Appl	242	34	87.2	20	4	US-09-723-890-64	Sequence 64, Appl
170	39	100.0	25	15	US-08-704-170-72	Sequence 72, Appl	243	34	87.2	20	4	US-09-723-890-64	Sequence 64, Appl
171	39	100.0	25	15	US-08-455-625-16	Sequence 16, Appl	244	34	87.2	20	4	US-09-723-890-64	Sequence 64, Appl
172	39	100.0	25	2	US-08-455-625-19	Sequence 19, Appl	245	34	87.2	20	4	US-09-723-890-64	Sequence 64, Appl
173	39	100.0	25	2	US-08-455-625-20	Sequence 20, Appl	246	34	87.2	20	4	US-09-723-890-64	Sequence 64, Appl

247	25	64.1	20	4	US-09-723-911-64	Sequence 64, Appl
248	25	64.1	20	4	US-09-723-911-65	Sequence 65, Appl
249	25	64.1	20	4	US-09-723-873-64	Sequence 64, Appl
250	25	64.1	20	4	US-09-723-873-65	Sequence 65, Appl

ALIGNMENTS

RESULT 1
US-08-260-086-6
Sequence 6, Application US/08260086
Patent No. 5622933
GENERAL INFORMATION:
APPLICANT: SABATIER, JEAN M
APPLICANT: BENOUD, ABDELRAZIZ
APPLICANT: YAH, NOUARA
APPLICANT: FENCUILLET, EMMANUEL
APPLICANT: MABROUK, KAMEL
APPLICANT: GLUCKMAN, JEAN-CLAUDE
APPLICANT: VAN RIETSCOTEN, JURPHAS
APPLICANT: ROCHAT, HERVE
TITLE OF INVENTION: MULTIPLE BRANCH PEPTIDE CONSTRUCTIONS
TITLE OF INVENTION: FOR USE AGAINST HIV
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:
ADDRESSEE: WEIL, GOTSCHAL & MANGES
STREET: 2882 SAND HILL ROAD
CITY: MENLO PARK
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 94025
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/260,086
FILING DATE: 15-JUN-1994
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9318901.7
FILING DATE: 13-SEP-1993
ATTORNEY/AGENT INFORMATION:
NAME: RAE-VENTER, BARBARA
REGISTRATION NUMBER: 32,750
REFERENCE/DOCKET NUMBER: 37965.0007
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 926-6200
TELEFAX: (415) 854-3713
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 8 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-260-086-6

Query Match 100.0%; Score 39; DB 1; Length 8;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTYICK 8
Db 1 RAFTYICK 8

RESULT 2
US-08-480-332-3
Sequence 3, Application US/08480332
Patent No. 6180134
GENERAL INFORMATION:

APPLICANT: Zalipsky, Samuel; Woodde, Martin; Martin, Francis;
APPLICANT: Barenholz, Yecheskel
TITLE OF INVENTION: Enhanced Circulation Effector Composition and
TITLE OF INVENTION: Method
NUMBER OF SEQUENCES: 10
CORRESPONDENCE ADDRESS:
ADDRESSEE: Delinger & Associates
STREET: 350 Cambridge Avenue, Suite 250
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94306
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/480,332
FILING DATE: 7-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/316,436
FILING DATE: 29-SEP-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/035,443
FILING DATE: 23-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Mohr, Judy M.
REGISTRATION NUMBER: 38,563
REFERENCE/DOCKET NUMBER: 5325-0115.31
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 324-0880
TELEFAX: (415) 324-0960
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 8 amino acids
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: peptide
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: Peptide 3, Fig. 13
FEATURE:
NAME/KEY: CDS
LOCATION: 1..15
US-08-480-332-3

Query Match 100.0%; Score 39; DB 3; Length 8;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTYICK 8
Db 1 RAFTYICK 8

RESULT 3
PCT-US92-10378-5
Sequence 5, Application PC/TUS9210378
GENERAL INFORMATION:
APPLICANT: BOARD OF REGENTS, THE UNIVERSITY OF
APPLICANT: TEXAS SYSTEM
APPLICANT: SASTRY, Jagannatha K.
APPLICANT: ARLINGHAUS, Ralph B.
APPLICANT: PLATSOUAS, Chris D.
APPLICANT: NEHETE, Pramod N.
TITLE OF INVENTION: METHODS AND COMPOSITIONS
TITLE OF INVENTION: FOR ELICITING IMMUNE OR ANTI-INFECTION RESPONSES
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:

ADDRESSEE: Arnold, White & Durkee
STREET: P.O. Box 4433
CITY: Houston
STATE: Texas
COUNTRY: US
ZIP: 77210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/10378
FILING DATE: 19921202
CLASSIFICATION:
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: 07/800,932
FILING DATE: December 2, 1991
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: 07/945865
FILING DATE: September 16, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Parker, David L.
REGISTRATION NUMBER: 32,165
REFERENCE/DOCKET NUMBER: UTFC305PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 512-320-7200
TELEFAX: 512-474-7577
TELEX: Not Applicable
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 8 amino acids
TYPE: AMINO ACID
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
PCT-US92-10378-5

Query Match 100.0%; Score 39; DB 5; Length 8;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVITIG 8
Db 1 RAFVITIG 8

RESULT 4
US-08-704-170-44
Sequence 44, Application US/08704170
Patent No. 5707626
GENERAL INFORMATION:
APPLICANT: Douvas, Angelina
APPLICANT: Takehana, Yoshi
APPLICANT: Ehresmann, Glenn
TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR
TITLE OF INVENTION: IMMUNOINJECTIVE CLUSTER VIRUS INFECTIONS
NUMBER OF SEQUENCES: 121
CORRESPONDENCE ADDRESS:
ADDRESSEE: Robbins, Berliner & Carson
STREET: 201 No. 5707626th Figueroa Street, Suite 500
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90012
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/704,170
FILING DATE:

CLASSIFICATION: 424
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US 08/029,850
FILING DATE: 11-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Spitals, John P.
REGISTRATION NUMBER: 29,215
REFERENCE/DOCKET NUMBER: 1920-331
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 977-1001
TELEFAX: (213) 977-1003
INFORMATION FOR SEQ ID NO: 44:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-704-170-44

Query Match 100.0%; Score 39; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVITIG 8
Db 2 RAFVITIG 9

RESULT 5
US-09-454-204A-52
Sequence 52, Application US/09454204A
Patent No. 6663871
GENERAL INFORMATION:
APPLICANT: McMichael, Andrew
APPLICANT: Hill, Adrian V.S.
APPLICANT: Gilbert, Sarah C.
APPLICANT: Schneider, Jorg
APPLICANT: Plebanski, Magdalena
APPLICANT: Hanke, Tomas
APPLICANT: Smith, Geoffrey L.
APPLICANT: Blanchard, Tom
TITLE OF INVENTION: Methods and Reagents for Vaccination
TITLE OF INVENTION: Which Generate A CD8 T Cell Immune Response
FILE REFERENCE: 2907.1000-000
CURRENT APPLICATION NUMBER: US/09/454,204A
PRIORITY APPLICATION NUMBER: PCT/GB98/01681
PRIORITY FILING DATE: 1998-06-09
PRIORITY APPLICATION NUMBER: GB 97 11957.2
PRIORITY FILING DATE: 1997-06-09
NUMBER OF SEQ ID NOS: 78
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 52
LENGTH: 9
TYPE: PRT
ORGANISM: Unknown
FEATURE:
OTHER INFORMATION: CTL Epitope of HIV-1 gp120
US-09-454-204A-52

Query Match 100.0%; Score 39; DB 4; Length 9;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVITIG 8
Db 2 RAFVITIG 9

RESULT 6
PCT-US94-02631-44
Sequence 44, Application PC/TUS9402631
GENERAL INFORMATION:

APPLICANT: Douvas, Angelina
ATTORNEY/AGENT INFORMATION:
NAME: Takehana, Yoshi
REGISTRATION NUMBER: 38,475
REFERENCE/DOCKET NUMBER: 4035/08865
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212527700
TELEFAX: 2127536237
TELEX: 236687
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 amino acids
TYPE: peptide
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
IMMEDIATE SOURCE:
CLONE: HIV gp120
US-08-648-298-4
CLASSIFICATION:
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US 08/029,850
FILING DATE: 11-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Spitalis, John P.
REGISTRATION NUMBER: 29,215
REFERENCE/DOCKET NUMBER: 1920-331
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 977-1001
TELEFAX: (213) 977-1003
INFORMATION FOR SEQ ID NO: 44:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
PCT-US94-02631-44
Query Match 100.0%; Score 39; DB 5; Length 9;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 RAFTTIG 8
DB 2 RAFTTIG 9
RESULT 7
US-08-648-298-4
Sequence 4, Application US/08648298
Patent No. 5871990
GENERAL INFORMATION:
APPLICANT: Henrik Paul Bennett
TITLE OF INVENTION: UDP-N-acetyl-alpha-D-galactosamine polypeptide
TITLE OF INVENTION: N-acetylgalactosaminyltransferase GalNAc-T3
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
ADDRESSEE: Darby & Darby PC
STREET: 805 Third Avenue
CITY: New York
STATE: NY
ZIP: 10022
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM PC compatible
OPERATING SYSTEM: DOS
SOFTWARE: Patentin Release #1.0, Version #1.30 (ERO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/648,298
FILING DATE: 15-JUN-1996

CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Green, Reza
REGISTRATION NUMBER: 38,475
REFERENCE/DOCKET NUMBER: 4035/08865
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212527700
TELEFAX: 2127536237
TELEX: 236687
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 amino acids
TYPE: peptide
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
IMMEDIATE SOURCE:
CLONE: HIV gp120
US-08-648-298-4
CLASSIFICATION:
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US 08/029,850
FILING DATE: 11-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Spitalis, John P.
REGISTRATION NUMBER: 29,215
REFERENCE/DOCKET NUMBER: 1920-331
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 977-1001
TELEFAX: (213) 977-1003
INFORMATION FOR SEQ ID NO: 52:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 amino acids
TYPE: amino acid
TOPOLOGY: linear
US-08-704-170-52
Sequence 52, Application US/08704170
Patent No. 5707626
GENERAL INFORMATION:
APPLICANT: Douvas, Angelina
TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR
TITLE OF INVENTION: IMMUNOINFECTION CLUSTER VIRUS INFECTIONS
NUMBER OF SEQUENCES: 121
CORRESPONDENCE ADDRESS:
ADDRESSEE: Robbins, Berliner & Carson
STREET: 201 No. 5707626th Figueroa Street, Suite 500
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90012
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/704,170
FILING DATE:
CLASSIFICATION: 424
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US 08/029,850
FILING DATE: 11-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Spitalis, John P.
REGISTRATION NUMBER: 29,215
REFERENCE/DOCKET NUMBER: 1920-331
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 977-1001
TELEFAX: (213) 977-1003
INFORMATION FOR SEQ ID NO: 52:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 amino acids
TYPE: amino acid
TOPOLOGY: linear

MOLECULE TYPE: peptide
US-08-704-170-52

Query Match 100.0%; Score 39; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 0.058;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
DB 5 RAFVTIGK 12

RESULT 9
US-08-488-252-30
Sequence 30, Application US/08488252
Patent No. 5763160

GENERAL INFORMATION:
APPLICANT: Chang Yi Wang
TITLE OF INVENTION: SYNTHETIC PEPTIDES AND PROCESS
TITLE OF INVENTION: OF USING SAME FOR THE DETECTION OF ANTIBODIES TO
TITLE OF INVENTION: HUMAN IMMUNODEFICIENCY VIRUS (HIV) GP120 ENVELOPE
TITLE OF INVENTION: PROTEIN, DIAGNOSIS OF AIDS AND PRE-AIDS CONDITIONS
NUMBER OF SEQUENCES: 38
CORRESPONDENCE ADDRESS:
ADDRESSEE: MORGAN & FINNEGAN
STREET: 345 PARK AVE.
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10154

COMPUTER READABLE FORM:
MEDIUM TYPE: FLOPPY DISK
COMPUTER: IBM PC COMPATIBLE
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WORDPERFECT 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,252
FILING DATE:

CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/326,676
FILING DATE: 07-Jun-1995
APPLICATION NUMBER: 07/726,605
FILING DATE: 09-Jul-1991
APPLICATION NUMBER: 07/663,262
FILING DATE: 01-Mar-1991
APPLICATION NUMBER: 07/155,321
FILING DATE: 12-Feb-1988
ATTORNEY/AGENT INFORMATION:
NAME: Maria C. H. Lin
REGISTRATION NUMBER: 29,323
REFERENCE/DOCKET NUMBER: 1151-4004 USA
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-758-4800
TELEFAX: (212) 751-6849
TELEX: 421792

INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 amino acids
TYPE: Amino acids
STRANDEDNESS:
TOPOLOGY: Unknown
US-08-488-252-30

Query Match 100.0%; Score 39; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 0.058;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
DB 5 RAFVTIGK 12

RESULT 10
PCT-US94-02631-52
Sequence 52, Application PC/TUS9402631
GENERAL INFORMATION:

APPLICANT: Douvas, Angelina
APPLICANT: Takenawa, Yoshi
APPLICANT: Ehresmann, Glenn
TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR
TITLE OF INVENTION: IMMUNOINFECTION CLUSTER VIRUS INFECTIONS
NUMBER OF SEQUENCES: 121
CORRESPONDENCE ADDRESS:
ADDRESSEE: Robbins, Berliner & Carson
STREET: 201 North Figueroa Street, Suite 500
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90012

COMPUTER READABLE FORM:
MEDIUM TYPE: FLOPPY disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/02631
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/029,850
FILING DATE: 11-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Spitalis, John P.
REGISTRATION NUMBER: 29,215
REFERENCE/DOCKET NUMBER: 1920-331
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 977-1003
TELEFAX: (213) 977-1001

INFORMATION FOR SEQ ID NO: 52:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 amino acids
TYPE: amino acid
TOPOLOGY: linear

MOLECULE TYPE: peptide
PCT-US94-02631-52

Query Match 100.0%; Score 39; DB 5; Length 12;
Best Local Similarity 100.0%; Pred. No. 0.058;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
DB 5 RAFVTIGK 12

RESULT 11
PCT-US95-03236-43
Sequence 43, Application PC/TUS9503236
GENERAL INFORMATION:

APPLICANT: University of Southern California
TITLE OF INVENTION: Methods to Diagnose and Treat HIV-1
TITLE OF INVENTION: Infection
NUMBER OF SEQUENCES: 66
CORRESPONDENCE ADDRESS:
ADDRESSEE: Campbell and Flores
STREET: 4370 La Jolla Village Drive, Suite 700
CITY: San Diego
STATE: California
COUNTRY: USA
ZIP: 92122

COMPUTER READABLE FORM:
MEDIUM TYPE: FLOPPY disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/03236
FILING DATE: 13-MAR-1995
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Imbira, Richard J.
REGISTRATION NUMBER: 37,643
REFERENCE/DOCKET NUMBER: PP-SI 1394
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 535-9001
TELEFAX: (619) 535-8949
INFORMATION FOR SEQ ID NO: 43:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
PCT-US95-03236-43

Query Match 100.0%; Score 39; DB 5; Length 12;
Best Local Similarity 100.0%; Pred. No. 0.058;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
DB 5 RAFVTIGK 12

RESULT 12
US-08-090-148-5
Sequence 5, Application US/08090148
Patent No. 5534257
GENERAL INFORMATION:
APPLICANT: Maestico, Robert Allan
APPLICANT: Stockley, Peter George
APPLICANT: Talbot, Simon John
TITLE OF INVENTION: Antigen-Presenting Capsid with
TITLE OF INVENTION: Fusion MS2-Coat Protein
NUMBER OF SEQUENCES: 6
CORRESPONDENCE ADDRESS:
ADDRESSEE: Rosenman & Colin
STREET: 575 Madison Avenue
CITY: New York
STATE: NY
COUNTRY: U.S.A.
ZIP: 10022-2585
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5", 1.44MB
COMPUTER: IBM PS2-486
OPERATING SYSTEM: MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/090,148
FILING DATE: 08/11/93
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9101550.3
FILING DATE: 01/24/91
APPLICATION NUMBER: PCT/GB92/00124
FILING DATE: 01/22/92
ATTORNEY/AGENT INFORMATION:
NAME: Nissenbaum, Israel
REGISTRATION NUMBER: 27,582
REFERENCE/DOCKET NUMBER:
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 940-6404
TELEFAX: (212) 940-6404
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 AMINO ACIDS
TYPE: AMINO ACID
TOPOLOGY: NOT RELEVANT

MOLECULE TYPE: PEPTIDE
US-08-090-148-5

Query Match 100.0%; Score 39; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.063;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
DB 4 RAFVTIGK 11

RESULT 13
US-08-279-906A-17
Sequence 17, Application US/08279906A
Patent No. 5618922
GENERAL INFORMATION:
APPLICANT: Ohno, Tsuneya
APPLICANT: Terada, Masaki
APPLICANT: Yoneda, Yukio
TITLE OF INVENTION: NM03 Antibody Materials and Methods
NUMBER OF SEQUENCES: 27
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
ADDRESSEE: Borum
STREET: 6300 Sears Tower, 233 S. Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/279,906A
FILING DATE:
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: No. 5618922and, Grete E.
REGISTRATION NUMBER: 35,302
REFERENCE/DOCKET NUMBER: 32028
TELECOMMUNICATION INFORMATION:
TELEPHONE: (312) 474-6300
TELEFAX: (312) 474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-279-906A-17

Query Match 100.0%; Score 39; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.063;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
DB 6 RAFVTIGK 13

RESULT 14
US-08-111-080-6
Sequence 6, Application 08/111080
Patent No. 555865
GENERAL INFORMATION:
APPLICANT: Ohno, Tsuneya
TITLE OF INVENTION: HIV Immunotherapeutics
NUMBER OF SEQUENCES: 38
CORRESPONDENCE ADDRESS:

ADDRESSER: Marshall, O'Toole, Gerstein, Murray &
ADDRESSEE: Borun
STREET: 6300 Sears Tower, 233 S. Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: 08/111,080
FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/748,562
FILING DATE: 22-AUG-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/07111
FILING DATE: 24-AUG-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/039,457
FILING DATE: 22-APR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Borun, Michael F.
REGISTRATION NUMBER: 25,447
REFERENCE/DOCKET NUMBER: 31629
TELECOMMUNICATION INFORMATION:
TELEPHONE: (312) 474-6300
TELEFAX: (312) 474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-111-080-6

Query Match 100.0%; Score 39; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. NO. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
Db 7 RAFVTIGK 14

RESULT 15
US-08-211-980-6
Sequence 6, Application US/08211980
Patent No. 5665569
GENERAL INFORMATION:
APPLICANT: Ohno, Tsuneya
TITLE OF INVENTION: HIV Immunotherapeutics
NUMBER OF SEQUENCES: 38
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
STREET: 6300 Sears Tower, 233 S. Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/211,980

FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/07111
FILING DATE: 24-AUG-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/039,457
FILING DATE: 22-APR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Borun, Michael F.
REGISTRATION NUMBER: 25,447
REFERENCE/DOCKET NUMBER: 31629
TELECOMMUNICATION INFORMATION:
TELEPHONE: (312) 474-6300
TELEFAX: (312) 474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-211-980-6

Query Match 100.0%; Score 39; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. NO. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
Db 7 RAFVTIGK 14

RESULT 16
US-08-455-625-9
Sequence 9, Application US/08455625
Patent No. 5932218
GENERAL INFORMATION:
APPLICANT: Betzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. D.
APPLICANT: Nara, Peter
TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,625
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050

INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..14
OTHER INFORMATION: /label= peptide
OTHER INFORMATION: /note= "p18-1, see Table V"
US-08-455-625-9

Query Match 100.0%; Score 39; DB 2; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTYICK 8
Db 7 RAFTYICK 14

RESULT 17
US-08-455-625-10
Sequence 10, Application US/08455625
Patent No. 5932218
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. D.
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455.625
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..14

OTHER INFORMATION: /label= peptide
OTHER INFORMATION: /note= "p18-2, see Table V"
US-08-455-625-10

Query Match 100.0%; Score 39; DB 2; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTYICK 8
Db 7 RAFTYICK 14

RESULT 18
US-08-455-685-9
Sequence 9, Application US/08455685
Patent No. 6214347
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 40
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455.685
FILING DATE: 31-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/060,988
FILING DATE: 14-MAY-1993
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022003
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-455-685-9

Query Match 100.0%; Score 39; DB 3; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTYICK 8
Db 7 RAFTYICK 14

Db 7 RAFVITIGK 14

RESULT 19

US-08-455-685-10

Sequence 10, Application US/08455685

Patent No. 6214347

GENERAL INFORMATION:

APPLICANT: Berzofsky, Jay A.

APPLICANT: Ahlers, Jeffrey D.

APPLICANT: Pendleton, C. David

APPLICANT: Nara, Peter

APPLICANT: Shirai, Mutsunori

TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT

TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND

TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1

NUMBER OF SEQUENCES: 40

CORRESPONDENCE ADDRESS:

ADDRESSEE: Fish & Richardson P.C.

STREET: 225 Franklin Street

CITY: Boston

STATE: MA

COUNTRY: US

ZIP: 02110-2804

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: Windows95

SOFTWARE: FASTSEQ for Windows Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/455.685

FILING DATE: 31-MAY-1995

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/060.988

FILING DATE: 14-MAY-1993

APPLICATION NUMBER: 07/847.311

FILING DATE: 06-MAR-1992

APPLICATION NUMBER: 07/751.998

FILING DATE: 29-AUG-1991

APPLICATION NUMBER: 07/148.692

FILING DATE: 26-JAN-1988

ATTORNEY/AGENT INFORMATION:

NAME: Beattie, Ingrid A.

REGISTRATION NUMBER: P-42.306

REFERENCE/DOCKET NUMBER: 08830/022003

TELECOMMUNICATION INFORMATION:

TELEPHONE: 617/542-5070

TELEFAX: 617/542-8906

TELEX: 200154

INFORMATION FOR SEQ ID NO: 10:

SEQUENCE CHARACTERISTICS:

LENGTH: 14 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: peptide

US-08-455-685-10

Query Match 100.0%; Score 39; DB 3; Length 14;

Best Local Similarity 100.0%; Pred. No. 0.068;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVITIGK 8

Db 7 RAFVITIGK 14

RESULT 20

US-08-060-988A-9

Sequence 9, Application US/08060988A

Patent No. 6294322

GENERAL INFORMATION:

APPLICANT: Berzofsky, Jay A.

APPLICANT: Ahlers, Jeffrey D.

APPLICANT: Pendleton, C. David

APPLICANT: Nara, Peter

APPLICANT: Shirai, Mutsunori

TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES

TITLE OF INVENTION: THAT ELICIT

TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND

TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1

NUMBER OF SEQUENCES: 48

CORRESPONDENCE ADDRESS:

ADDRESSEE: Fish & Richardson P.C.

STREET: 225 Franklin Street

CITY: Boston

STATE: MA

COUNTRY: US

ZIP: 02110-2804

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: Windows95

SOFTWARE: FASTSEQ for Windows Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/060.988A

FILING DATE: 14-MAY-1993

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 07/847.311

FILING DATE: 06-MAR-1992

APPLICATION NUMBER: 07/751.998

FILING DATE: 29-AUG-1991

APPLICATION NUMBER: 07/148.692

FILING DATE: 26-JAN-1988

ATTORNEY/AGENT INFORMATION:

NAME: Beattie, Ingrid A.

REGISTRATION NUMBER: P-42.306

REFERENCE/DOCKET NUMBER: 08830/022001

TELECOMMUNICATION INFORMATION:

TELEPHONE: 617/542-5070

TELEFAX: 617/542-8906

TELEX: 200154

INFORMATION FOR SEQ ID NO: 9:

SEQUENCE CHARACTERISTICS:

LENGTH: 14 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: peptide

US-08-060-988A-9

Query Match 100.0%; Score 39; DB 3; Length 14;

Best Local Similarity 100.0%; Pred. No. 0.068;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVITIGK 8

Db 7 RAFVITIGK 14

RESULT 21

US-08-060-988A-10

Sequence 10, Application US/08060988A

Patent No. 6294322

GENERAL INFORMATION:

APPLICANT: Berzofsky, Jay A.

APPLICANT: Ahlers, Jeffrey D.

APPLICANT: Pendleton, C. David

APPLICANT: Nara, Peter

APPLICANT: Shirai, Mutsunori

TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES

TITLE OF INVENTION: THAT ELICIT

TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND

TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1

NUMBER OF SEQUENCES: 48

CORRESPONDENCE ADDRESS:

ADDRESSEE: Fish & Richardson P.C.

STREET: 225 Franklin Street

CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: Fastseq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/060,988A
FILING DATE: 14-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022001
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-060-988A-10

Query Match 100.0%; Score 39; DB 3; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
Db 7 RAFVTIGK 14

RESULT 22
PCT-US92-07111-6
Sequence 6, Application PC/TUS9207111
GENERAL INFORMATION:
APPLICANT: Ohno, Tsuneya
TITLE OF INVENTION: HIV Immunotherapeutics
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
ADDRESSEE: Bicknell
STREET: Two First National Plaza, 20 South Clark
STREET: Street
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60603
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/07111
FILING DATE: 19920824
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/748,562
FILING DATE: 22-AUG-1991
ATTORNEY/AGENT INFORMATION:

NAME: Noland, Greta B.
REGISTRATION NUMBER: 35,302
REFERENCE/DOCKET NUMBER: 31016
TELECOMMUNICATION INFORMATION:
TELEPHONE: (312) 346-5750
TELEFAX: (312) 984-9740
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 amino acids
TYPE: AMINO ACID
TOPOLOGY: linear
MOLECULE TYPE: peptide
PCT-US92-07111-6

Query Match 100.0%; Score 39; DB 5; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
Db 7 RAFVTIGK 14

RESULT 23
PCT-US93-07967-6
Sequence 6, Application PC/TUS9307967
GENERAL INFORMATION:
APPLICANT: Ohno, Tsuneya
TITLE OF INVENTION: HIV Immunotherapeutics
NUMBER OF SEQUENCES: 38
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
ADDRESSEE: Borun
STREET: 6300 Sears Tower, 233 S. Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/07967
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/07111
FILING DATE: 24-AUG-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/039,457
FILING DATE: 22-APR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Borun, Michael F.
REGISTRATION NUMBER: 25,447
REFERENCE/DOCKET NUMBER: 31629
TELECOMMUNICATION INFORMATION:
TELEPHONE: (312) 474-6300
TELEFAX: (312) 474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
PCT-US93-07967-6

Query Match 100.0%; Score 39; DB 5; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFTTIGK 8
Db 7 RAFTTIGK 14

RESULT 24
PCT-US94-05142-9
Sequence 9, Application PC/TUS9405142
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/05142
FILING DATE: 13-MAY-1994
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..14
OTHER INFORMATION: /label=peptide
OTHER INFORMATION: /note="p18-1, see Table V"

PCT-US94-05142-9

Query Match 100.0%; Score 39; DB 5; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFTTIGK 8
Db 7 RAFTTIGK 14

RESULT 25
PCT-US94-05142-10
Sequence 10, Application PC/TUS9405142
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
NUMBER OF SEQUENCES: 36

CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/05142
FILING DATE: 13-MAY-1994
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..14
OTHER INFORMATION: /label=peptide
OTHER INFORMATION: /note="p18-2, see Table V"

PCT-US94-05142-10

Query Match 100.0%; Score 39; DB 5; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFTTIGK 8
Db 7 RAFTTIGK 14

RESULT 26
US-08-336-087-2
Sequence 2, Application US/08336087
Patent No. 5503829
GENERAL INFORMATION:
APPLICANT: Ladant, Daniel
APPLICANT: Leclerc, Claude
APPLICANT: Sebo, Peter
APPLICANT: Ullmann, Agnes
TITLE OF INVENTION: Recombinant Mutants for Inducing
TITLE OF INVENTION: Specific Immune Responses
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:
ADDRESSEE: Finnegan, Henderson, Faradow, Garrett &
ADDRESSEE: Dunner
STREET: 1300 I Street, N.W.
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20005-3315
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/336,087
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/011,644
FILING DATE: 29-JAN-1993
ATTORNEY/AGENT INFORMATION:
NAME: Meyers, Kenneth J.
REGISTRATION NUMBER: 25,146
REFERENCE/DOCKET NUMBER: 03495-0109-01000
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-408-4400
TELEFAX: 202-408-4400
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-336-087-2

Query Match 100.0%; Score 39; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTTGK 8
DB 8 RAFVTTGK 15

RESULT 27
US-08-218-025A-17
Sequence 17, Application US/08218025A
Patent No. 5556744
GENERAL INFORMATION:
APPLICANT: Weiner, David B.
APPLICANT: Ugen, Kenneth E.
APPLICANT: Williams, William V.
TITLE OF INVENTION: Methods and Compositions for Diagnosing
TITLE OF INVENTION: and Treating Certain HIV Infected Patients
NUMBER OF SEQUENCES: 197
CORRESPONDENCE ADDRESS:
ADDRESSEE: Howson and Howson
STREET: P.O. Box 457, 321 No. 5556744riscow Road
CITY: Spring House
STATE: Pennsylvania
COUNTRY: U.S.A.
ZIP: 19477
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/218,025A
FILING DATE: 24-MAR-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/891,451
FILING DATE: 29-MAY-1992
ATTORNEY/AGENT INFORMATION:
NAME: Bak, Mary E.
REGISTRATION NUMBER: 31,215
REFERENCE/DOCKET NUMBER: WST33A
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 540-9206
TELEFAX: (215) 540-5818
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid

TOPOLOGY: unknown
MOLECULE TYPE: peptide
US-08-218-025A-17

Query Match 100.0%; Score 39; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTTGK 8
DB 8 RAFVTTGK 15

RESULT 28
US-08-709-047-7
Sequence 7, Application US/08709047
Patent No. 5652333
GENERAL INFORMATION:
APPLICANT: Fung, Michael S.C., Sun, Bill N.C, Sun, Cecily R.Y., Kim, Young W., Yu,
APPLICANT: Liming
TITLE OF INVENTION: THE GcIg RECEPTOR, HIV-1 gp120 REGION BINDING THERETO,
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: Tanox Biosystems, Inc.
STREET: 10301 Stella Link Rd.
CITY: Houston
STATE: Texas
COUNTRY: USA
ZIP: 77025
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 inch
COMPUTER: IBM PS/2
OPERATING SYSTEM: DOS 3.30
SOFTWARE: Wordperfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/709,047
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/410,360
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Mirabel, Eric P.
REGISTRATION NUMBER: 31,211
REFERENCE/DOCKET NUMBER: TNX95-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (713) 664-2288
TELEFAX: (713) 664-8914
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
US-08-709-047-7

Query Match 100.0%; Score 39; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTTGK 8
DB 8 RAFVTTGK 15

RESULT 29
US-08-479-400-2
Sequence 2, Application US/08479400
Patent No. 5679784
GENERAL INFORMATION:
APPLICANT: Ladant, Daniel
APPLICANT: Leclerc, Claude
APPLICANT: Sebdo, Peter

APPLICANT: Ullmann, Agnes
TITLE OF INVENTION: Recombinant Mutants for Inducing
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:
ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
STREET: 1300 I Street, N.W.
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20005-3315
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/479,400
FILING DATE: 07-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/011,644
FILING DATE: 29-JAN-1993
ATTORNEY/AGENT INFORMATION:
NAME: Meyers, Kenneth J.
REGISTRATION NUMBER: 25, 146
REFERENCE/DOCKET NUMBER: 03495-0109-01000
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-408-4000
TELEFAX: 202-408-4400
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-479-400-2

Query Match 100.0%; Score 39; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVITIG 8
Db 8 RAFVITIG 15

RESULT 30
US-08-410-360-7
Sequence 7, Application US/08410360
Patent No. 5691447
GENERAL INFORMATION:
APPLICANT: Fung, Michael S.C., Sun, Bill N.C., Sun, Cecily R.Y., Kim, Young W., Yu,
APPLICANT: Liming
TITLE OF INVENTION: THE SCID RECEPTOR, HIV-1 gp120 REGION BINDING THERETO,
TITLE OF INVENTION: AND RELATED PEPTIDES AND TANGERING ANTIBODIES
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: Tanox Bioystems, Inc.
STREET: 10301 Stella Link Rd.
CITY: Houston
STATE: Texas
COUNTRY: USA
ZIP: 77025
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 inch
COMPUTER: IBM PS/2
OPERATING SYSTEM: DOS 3.30
SOFTWARE: Wordperfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/410,360
FILING DATE:

CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Mirabel, Eric P.
REGISTRATION NUMBER: 31,211
REFERENCE/DOCKET NUMBER: TNX95-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (713) 664-2288
TELEFAX: (713) 664-8914
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
US-08-410-360-7

Query Match 100.0%; Score 39; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVITIG 8
Db 8 RAFVITIG 15

RESULT 31
US-08-095-332-1
Sequence 1, Application US/08095332
Patent No. 5711947
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Takahashi, Hideaki
TITLE OF INVENTION: METHOD TO INDUCE CYTOTOXIC T LYMPHOCYTES
TITLE OF INVENTION: SPECIFIC FOR A BROAD ARRAY OF HIV-1 ISOLATES USING HYBRID
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolash & Birch
STREET: 301 N. Washington
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22046-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/095,332
FILING DATE: 23-JUL-1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/760,530
FILING DATE: 18-SEP-1991
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30,330
REFERENCE/DOCKET NUMBER: 1173-354P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-241-1300
TELEFAX: 703-241-2848
TELEX: 248345
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal

ORIGINAL SOURCE:
ORGANISM: HIV-1
INDIVIDUAL ISOLATE: I11B
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..15
OTHER INFORMATION: /label= peptide
OTHER INFORMATION: /note= "synthetic peptide, sequence = residues 315
OTHER INFORMATION: to 329 of HIV-1, isolate I11B, gp160 envelope
OTHER INFORMATION: glycoprotein."
US-08-095-332-1

Query Match 100.0%; Score 39; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFTTICK 8
DB 8 RAFTTICK 15

RESULT 32
US-08-707-801A-7
Sequence 7, Application US/08707801A
Patent No. 5728814
GENERAL INFORMATION:
APPLICANT: Fung, Michael S.C., Sun, Bill N.C, Sun, Cecily R.Y., Kim, Young W., Yu,
APPLICANT: Liming
TITLE OF INVENTION: THE GCLG RECEPTOR, HIV-1 GP120 REGION BINDING THERETO,
AND RELATED PEPTIDES AND TARGETING ANTIBODIES
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: Tanox Biosystems, Inc.
STREET: 10301 Stella Link Rd.
CITY: Houston
STATE: Texas
COUNTRY: USA
ZIP: 77025
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 inch
COMPUTER: IBM PS/2
OPERATING SYSTEM: DOS 3.30
SOFTWARE: Wordperfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/707,801A
FILING DATE: 09/04/1996
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/410,360
FILING DATE: 03/24/1995
ATTORNEY/AGENT INFORMATION:
NAME: Mirabel, Eric P.
REGISTRATION NUMBER: 31,211
REFERENCE/DOCKET NUMBER: TX95-1AA
TELECOMMUNICATION INFORMATION:
TELEPHONE: (713) 664-2288
TELEFAX: (713) 664-8914
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
US-08-707-801A-7

Query Match 100.0%; Score 39; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFTTICK 8
DB 8 RAFTTICK 15

RESULT 33
US-08-709-006-7
Sequence 7, Application US/08709006
Patent No. 5731428
GENERAL INFORMATION:
APPLICANT: Fung, Michael S.C., Sun, Bill N.C, Sun, Cecily R.Y.,
APPLICANT: Kim, Young W., Yu, Liming
TITLE OF INVENTION: THE GCLG RECEPTOR, HIV-1 GP120 REGION BINDING
THERETO AND RELATED PEPTIDES AND TARGETING
TITLE OF INVENTION: ANTIBODIES
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: Tanox Biosystems, Inc.
STREET: 10301 Stella Link Rd.
CITY: Houston
STATE: Texas
COUNTRY: USA
ZIP: 77025
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 inch
COMPUTER: IBM PS/2
OPERATING SYSTEM: DOS 3.30
SOFTWARE: Wordperfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/709,006
FILING DATE: 09-SEP-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/410,360
FILING DATE: 24-MAR-1995
ATTORNEY/AGENT INFORMATION:
NAME: Mirabel, Eric P.
REGISTRATION NUMBER: 31,211
REFERENCE/DOCKET NUMBER: TX95-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (713) 664-2288
TELEFAX: (713) 664-8914
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
US-08-709-006-7

Query Match 100.0%; Score 39; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFTTICK 8
DB 8 RAFTTICK 15

RESULT 34
US-08-711-175-7
Sequence 7, Application US/08711175
Patent No. 5739306
GENERAL INFORMATION:
APPLICANT: Fung, Michael S.C., Sun, Bill N.C, Sun, Cecily R.Y.,
APPLICANT: Kim, Young W., Yu, Liming
TITLE OF INVENTION: THE GCLG RECEPTOR, HIV-1 GP120 REGION BINDING
THERETO AND RELATED PEPTIDES AND TARGETING
TITLE OF INVENTION: ANTIBODIES
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: Tanox Biosystems, Inc.
STREET: 10301 Stella Link Rd.
CITY: Houston
STATE: Texas
COUNTRY: USA
ZIP: 77025
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 inch

Query Match 100.0%; Score 39; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFTTICK 8
DB 8 RAFTTICK 15

COMPUTER: IBM PS/2
OPERATING SYSTEM: DOS 3.30
SOFTWARE: wordperfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/711,175
FILING DATE: 09-SEP-1996
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/410,360
FILING DATE: 24-MAR-1995
ATTORNEY/AGENT INFORMATION:
NAME: Mirabel, Eric P.
REGISTRATION NUMBER: 31,211
REFERENCE/DOCKET NUMBER: TNX95-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (713) 664-2288
TELEFAX: (713) 664-8914
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
US-08-711-175-7

Query Match 100.0%; Score 39; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
DB 8 RAFTVIGK 15

RESULT 35
US-08-488-252-27
Sequence 27, Application US/08488252
Patent No. 5763160
GENERAL INFORMATION:
APPLICANT: Chang Y1 Wang
TITLE OF INVENTION: SYNTHETIC PEPTIDES AND PROCESS
TITLE OF INVENTION: OF USING SAME FOR THE DETECTION OF ANTIBODIES TO
TITLE OF INVENTION: HUMAN IMMUNODEFICIENCY VIRUS (HIV) GP120 ENVELOPE
TITLE OF INVENTION: PROTEIN, DIAGNOSIS OF AIDS AND PRE-AIDS CONDITIONS
TITLE OF INVENTION: AND AS VACCINES
NUMBER OF SEQUENCES: 38
CORRESPONDENCE ADDRESS:
ADDRESSEE: MORGAN & FINNEGAN
STREET: 345 PARK AVE.
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10154
COMPUTER READABLE FORM:
MEDIUM TYPE: FLOPPY DISK
COMPUTER: IBM PC COMPATIBLE
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WORDPERFECT 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,252
FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/326,676
FILING DATE: 07-Jun-1995
APPLICATION NUMBER: 07/726,605
FILING DATE: 09-July-1991
APPLICATION NUMBER: 07/663,262
FILING DATE: 01-Mar-1991
APPLICATION NUMBER: 07/155,321
FILING DATE: 12-Feb-1988
ATTORNEY/AGENT INFORMATION:
NAME: Maria C. H. Lin
REGISTRATION NUMBER: 29,323

REFERENCE/DOCKET NUMBER: 1151-4004 USA
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-758-4800
TELEFAX: (212) 751-6849
TELEX: 421792
INFORMATION FOR SEQ ID NO: 27:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: Amino acids
STRANDEDNESS:
TOPOLOGY: Unknown
US-08-488-252-27

Query Match 100.0%; Score 39; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
DB 8 RAFTVIGK 15

RESULT 36
US-08-021-879-2
Sequence 2, Application US/08021879
Patent No. 581767
GENERAL INFORMATION:
APPLICANT: Graham P. Allaway
TITLE OF INVENTION: Paul J. Maddon
TITLE OF INVENTION: SYNERGISTIC COMPOSITION OF CPD-BASED
TITLE OF INVENTION: PROTEIN AND ANTI-HIV-1 ANTIBODY, AND
TITLE OF INVENTION: METHODS OF USING SAME
NUMBER OF SEQUENCES: 2
CORRESPONDENCE ADDRESS:
ADDRESSEE: Cooper & Dunham
STREET: 30 Rockefeller Plaza
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10112
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/021,879
FILING DATE: 24-FEB-1993
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 41189/JPW/AJM
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 977-9550
TELEFAX: (212) 664-0525
TELEX: 422523 COOPUI
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-021-879-2

Query Match 100.0%; Score 39; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
DB 8 RAFTVIGK 15


```
RESULT 37
US-07-760-530-1
; Sequence 1, Application US/07760530
; Patent No. 5820865
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Takahashi, Hidemi
; APPLICANT: Gekman, Ronald N.
; TITLE OF INVENTION: METHOD TO INDUCE CYTOTOXIC T LYMPHOCYTES
; SPECIFIC FOR A BROAD ARRAY OF HIV-1 ISOLATES USING HYBRID
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolaiah & Birch
; STREET: 301 N. Washington
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22046-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/760,530
; FILING DATE: 19910918
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Svendsen, Leonard R.
; REGISTRATION NUMBER: 30,330
; REFERENCE/DOCKET NUMBER: 1173-354p
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-241-1300
; TELEFAX: 703-241-2848
; TELEX: 248345
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: AMINO ACID
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: HIV-1
; INDIVIDUAL ISOLATE: IIBB
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..15
; OTHER INFORMATION: /label= peptide
; OTHER INFORMATION: /note= "synthetic peptide, sequence = residues 315
; OTHER INFORMATION: to 329 of HIV-1, isolate IIBB, gp160 envelope
; OTHER INFORMATION: glycoprotein."
US-07-760-530-1

Query Match      100.0%; Score 39; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RAFTVIGK 8
DB      8 RAFTVIGK 15

RESULT 38
US-07-950-571A-3
; Sequence 3, Application US/07950571A
; Patent No. 5854400
; GENERAL INFORMATION:
; APPLICANT: Chang, Tse Wen, Fung, Michael S.C., Sun, Bill N.C., Sun, Cecily R.Y.
; APPLICANT: Chang, Nancy T.
; TITLE OF INVENTION: Monoclonal Antibodies which Neutralize HIV-1 Infection
```

```
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSEE: Tanox Biosystems, Inc.
STREET: 10301 Stelia Link Rd.
CITY: Houston
STATE: Texas
COUNTRY: USA
ZIP: 77025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Hi Density Diskette
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: DOS, Version 3.30
; SOFTWARE: Wordperfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/950,571A
; FILING DATE: 19920922
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: No. 5854400 07/767,533
; FILING DATE: 09/26/1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Mirabel, Eric P.
; REGISTRATION NUMBER: 31,211
; REFERENCE/DOCKET NUMBER: TNX87-11BBC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713-664-2288
; TELEFAX: 713-664-8914
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: AMINO ACID
; TOPOLOGY: linear
US-07-950-571A-3

Query Match      100.0%; Score 39; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RAFTVIGK 8
DB      8 RAFTVIGK 15

RESULT 39
US-08-975-699-6
; Sequence 6, Application US/08975699
; Patent No. 5858369
; GENERAL INFORMATION:
; APPLICANT: MATSUO, KAZUHIRO
; APPLICANT: CHUJO, YOSHIOMO
; APPLICANT: YAMAZAKI, AKIHIRO
; APPLICANT: HONDA, MITSUO
; APPLICANT: YAMAKAZI, SHODO
; APPLICANT: TASAKA, HIROMICHI
; TITLE OF INVENTION: ANTI-AIDS SECRETORY RECOMBINANT BCG
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
; ADDRESSER: P.C.
; STREET: 1755 S. JEFFERSON DAVIS HIGHWAY, SUITE 400
; CITY: ARLINGTON
; STATE: VA
; COUNTRY: USA
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/975,699
; FILING DATE:
```

```
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/619,512
FILING DATE: 29-MAR-1996
APPLICATION NUMBER: PCT/JP95/01515
FILING DATE: 31-JUL-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 178462/1994
FILING DATE: 29-JUL-1994
ATTORNEY/AGENT INFORMATION:
NAME: OBLON, NORMAN F.
REGISTRATION NUMBER: 24,618
REFERENCE/DOCKET NUMBER: 10-795-0X PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-413-3000
TELEFAX: 703-413-2220
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
ORIGINAL SOURCE:
ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
STRAIN: HIV-1 (JAPAN)
US-08-972-089-6

Query Match
Best Local Similarity 100.0%; Score 39; DB 2; Length 15;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTTGK 8
DB 8 RAFVTTGK 15

RESULT 40
US-08-972-089-6
Sequence 6, Application US/08972089
Patent No. 5885580
GENERAL INFORMATION:
APPLICANT: MATSUO, KAZUHIRO
APPLICANT: CHUDO, YOSHITOMO
APPLICANT: YAMAZAKI, AKIHIRO
APPLICANT: HONDA, MITSUO
APPLICANT: YAMAKAZI, SHUDO
APPLICANT: TASAKI, HIROMICHI
TITLE OF INVENTION: ANTI-AIDS SECRETORY RECOMBINANT BCG
TITLE OF INVENTION: VACCINE
NUMBER OF SEQUENCES: 27
CORRESPONDENCE ADDRESS:
ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
ADDRESS: P.C.
STREET: 1755 S. JEFFERSON DAVIS HIGHWAY, SUITE 400
CITY: ARLINGTON
STATE: VA
COUNTRY: USA
ZIP: 22202
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/972,089
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/975,699
FILING DATE:
APPLICATION NUMBER: PCT/JP95/01515
FILING DATE: 31-JUL-1995
```

```
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 178462/1994
FILING DATE: 29-JUL-1994
ATTORNEY/AGENT INFORMATION:
NAME: OBLON, NORMAN F.
REGISTRATION NUMBER: 24,618
REFERENCE/DOCKET NUMBER: 10-795-0X PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-413-3000
TELEFAX: 703-413-2220
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
ORIGINAL SOURCE:
ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
STRAIN: HIV-1 (JAPAN)
US-08-972-089-6

Query Match
Best Local Similarity 100.0%; Score 39; DB 2; Length 15;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTTGK 8
DB 8 RAFVTTGK 15

RESULT 41
US-08-455-625-7
Sequence 7, Application US/08455625
Patent No. 5932218
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. D.
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsumori
TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,625
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
```

LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..15
OTHER INFORMATION: /label= peptide
US-08-455-625-7
/note= "p1811B peptide, see Table V"

Query Match 100.0%; Score 39; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTTGK 8
DB 8 RAFVTTGK 15

RESULT 42
US-08-455-625-11
Sequence 11, Application US/08455625
Patent No. 5932218
GENERAL INFORMATION:
APPLICANT: Bezrofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. D.
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,625
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8050
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..15
OTHER INFORMATION: /label= peptide
OTHER INFORMATION: /note= "p18-3, see Table V"

US-08-455-625-11
Query Match 100.0%; Score 39; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTTGK 8
DB 8 RAFVTTGK 15

RESULT 43
US-08-455-625-12
Sequence 12, Application US/08455625
Patent No. 5932218
GENERAL INFORMATION:
APPLICANT: Bezrofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. D.
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,625
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8050
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..15
OTHER INFORMATION: /label= peptide
OTHER INFORMATION: /note= "p18-4, see Table V"

US-08-455-625-12
Query Match 100.0%; Score 39; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTTGK 8
DB 8 RAFVTTGK 15

```
RESULT 44
US-08-455-625-13
; Sequence 13, Application US/08455625
; Patent No. 5932218
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. D.
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
; TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/455,625
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/060,988
; FILING DATE: 14-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Svensson, Leonard R.
; REGISTRATION NUMBER: 30330
; REFERENCE/DOCKET NUMBER: 1173-434P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-205-8000
; TELEFAX: 703-205-8050
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..15
; OTHER INFORMATION:
; OTHER INFORMATION: /note="p18-5, see Table v"
US-08-455-625-13

Query Match 100.0%; Score 39; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTTIGK 8
DB 8 RAFTTIGK 15

RESULT 45
US-08-455-625-14
; Sequence 14, Application US/08455625
; Patent No. 5932218
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. D.
; APPLICANT: Nara, Peter
```

```
APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
; TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
; TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/455,625
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/060,988
; FILING DATE: 14-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Svensson, Leonard R.
; REGISTRATION NUMBER: 30330
; REFERENCE/DOCKET NUMBER: 1173-434P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-205-8000
; TELEFAX: 703-205-8050
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..15
; OTHER INFORMATION:
; OTHER INFORMATION: /note="p18-6, see Table v"
US-08-455-625-14

Query Match 100.0%; Score 39; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTTIGK 8
DB 8 RAFTTIGK 15

RESULT 46
US-08-455-625-15
; Sequence 15, Application US/08455625
; Patent No. 5932218
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. D.
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
; TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
; TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
```

COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,625
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000.
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..15
OTHER INFORMATION: /label=peptide
OTHER INFORMATION: /note="p18-7, see Table V"
US-08-455-625-15

Query Match 100.0%; Score 39; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTYICK 8
DB 8 RAFTYICK 15

RESULT 47
US-08-395-204-2
Sequence 2, Application US/08395204
Patent No. 5935580
GENERAL INFORMATION:
APPLICANT: Ladant, Daniel
APPLICANT: Leclerc, Claude
APPLICANT: Sebo, Peter
APPLICANT: Ullmann, Agnes
TITLE OF INVENTION: Recombinant Mutants for Inducing
TITLE OF INVENTION: Specific Immune Responses
NUMBER OF SEQUENCES: 5
CORRESPONDENCE ADDRESS:
ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
STREET: 1300 I Street, N.W.
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20005-3315
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/395,204
FILING DATE:
CLASSIFICATION: 435

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/871,795
FILING DATE: 21-APR-1992
ATTORNEY/AGENT INFORMATION:
NAME: Meyers, Kenneth J.
REGISTRATION NUMBER: 25,146
REFERENCE/DOCKET NUMBER: 03495-0109-00000
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-408-4000
TELEFAX: 202-408-4400
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-395-204-2

Query Match 100.0%; Score 39; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTYICK 8
DB 8 RAFTYICK 15

RESULT 48
US-08-628-687-1
Sequence 1, Application US/08628687
Patent No. 5939277
GENERAL INFORMATION:
APPLICANT: Rakowicz-Szulczynska, Eva M.
TITLE OF INVENTION: DETECTION AND TREATMENT OF BREAST AND
TITLE OF INVENTION: GYNECOLOGICAL CANCER
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: FISH & NEAVE
STREET: 1251 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10020
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/628,687
FILING DATE: 14-JUN-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/138,141
FILING DATE: 15-OCT-1993
ATTORNEY/AGENT INFORMATION:
NAME: Haley Jr., James F.
REGISTRATION NUMBER: 27,794
REFERENCE/DOCKET NUMBER: APOLLO/1CIP1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-596-9000
TELEFAX: 212-596-9090
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
STRANDEDNESS:
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHEICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE: internal
US-08-628-687-1

US-08-986-234-28

Query Match 100.0%; Score 39; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
DB 8 RAFTVIGK 15

RESULT 52

US-08-492-076-22
Sequence 22, Application US/08492076A
Patent No. 6060064
GENERAL INFORMATION:
APPLICANT: Adams, Sally E.
APPLICANT: Burns, Nigel R.
APPLICANT: Richardson, Simon M.
TITLE OF INVENTION: No. 6060064el Proteinaceous Particles
FILE REFERENCE: 10180.60968
CURRENT APPLICATION NUMBER: US/08/492.076A
CURRENT FILING DATE: 1995-06-28
EARLIER APPLICATION NUMBER: PCT/G893/02656
EARLIER FILING DATE: 1993-12-24
NUMBER OF SEQ ID NOS: 23
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 22
LENGTH: 15
TYPE: PRT
ORGANISM: Human immunodeficiency virus type 1
US-08-492-076-22

Query Match 100.0%; Score 39; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
DB 8 RAFTVIGK 15

RESULT 53

US-08-493-071-25
Sequence 25, Application US/08493071
Patent No. 6127149
GENERAL INFORMATION:
APPLICANT: Hirai, Yonei
APPLICANT: Koshida, Shogo
APPLICANT: Oka, Yumiko
TITLE OF INVENTION: MODIFIED EPI MORPHIN
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: LOWE, PRICE, LEBLANC & BECKER
STREET: 99 CANAL CENTER PLAZA, SUITE 300
CITY: ALEXANDRIA
STATE: VA
COUNTRY: USA
ZIP: 22314
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/493.071
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Price, Robert L.
REGISTRATION NUMBER: 22,685
REFERENCE/DOCKET NUMBER: 715-107
TELECOMMUNICATION INFORMATION:

TELEPHONE: 703-684-1111

TELEFAX: 703-684-1124

INFORMATION FOR SEQ ID NO: 25:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: peptide

US-08-493-071-25

Query Match 100.0%; Score 39; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
DB 8 RAFTVIGK 15

RESULT 54

US-08-480-332-1
Sequence 1, Application US/08480332
Patent No. 6180134
GENERAL INFORMATION:
APPLICANT: Zalipsky, Samuel; Woodle, Martin; Martin, Francis;
TITLE OF INVENTION: Enhanced Circulation Effector Composition and
NUMBER OF SEQUENCES: 10
TITLE OF INVENTION: Method
CORRESPONDENCE ADDRESS:
ADDRESSEE: Dehlinger & Associates
STREET: 350 Cambridge Avenue, Suite 250
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94306
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/480.332
FILING DATE: 7-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/316,436
FILING DATE: 29-SEP-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/035,443
FILING DATE: 23-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Mohr, Judy M.
REGISTRATION NUMBER: 38,563
REFERENCE/DOCKET NUMBER: 5325-0115.31
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 324-0880
TELEFAX: (415) 324-0960
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: peptide
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: Peptide 1, Fig. 13
FEATURE:
NAME/KEY: CDS
LOCATION: 1..15

US-08-480-332-1

Query Match 100.0%; Score 39; DB 3; Length 15;

Best Local Similarity 100.0%; Pred. No. 0.072;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
Db 8 RAFTVIGK 15

RESULT 55

US-08-455-685-7

Sequence 7, Application US/08455685

Patent No. 6214347

GENERAL INFORMATION:

APPLICANT: Berzofsky, Jay A.

APPLICANT: Ahlers, Jeffrey D.

APPLICANT: Pendleton, C. David

APPLICANT: Nara, Peter

APPLICANT: Shirai, Mutsunori

TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT

TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND

NUMBER OF SEQUENCES: 40

CORRESPONDENCE ADDRESSES: 40

ADDRESSEE: Fish & Richardson P.C.

STREET: 225 Franklin Street

CITY: Boston

STATE: MA

COUNTRY: US

ZIP: 02110-2804

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: Windows95

SOFTWARE: FASTSEQ for Windows Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/455,685

FILING DATE: 31-MAY-1995

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/060,988

FILING DATE: 14-MAY-1993

APPLICATION NUMBER: 07/847,311

FILING DATE: 06-MAR-1992

APPLICATION NUMBER: 07/751,998

FILING DATE: 29-AUG-1991

APPLICATION NUMBER: 07/148,692

FILING DATE: 26-JAN-1988

ATTORNEY/AGENT INFORMATION:

NAME: Beattie, Ingrid A.

REGISTRATION NUMBER: P-42,306

REFERENCE/DOCKET NUMBER: 08830/022003

TELECOMMUNICATION INFORMATION:

TELEPHONE: 617/542-5070

TELEFAX: 617/542-8906

TELEX: 200154

INFORMATION FOR SEQ ID NO: 7:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: peptide

US-08-455-685-7

Query Match 100.0%; Score 39; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;QY 1 RAFTVIGK 8
Db 8 RAFTVIGK 15RESULT 56
US-08-455-685-11

Sequence 11, Application US/08455685

Patent No. 6214347

GENERAL INFORMATION:

APPLICANT: Berzofsky, Jay A.

APPLICANT: Ahlers, Jeffrey D.

APPLICANT: Pendleton, C. David

APPLICANT: Nara, Peter

APPLICANT: Shirai, Mutsunori

TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT

TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND

NUMBER OF SEQUENCES: 40

CORRESPONDENCE ADDRESSES: 40

ADDRESSEE: Fish & Richardson P.C.

STREET: 225 Franklin Street

CITY: Boston

STATE: MA

COUNTRY: US

ZIP: 02110-2804

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: Windows95

SOFTWARE: FASTSEQ for Windows Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/455,685

FILING DATE: 31-MAY-1995

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/060,988

FILING DATE: 14-MAY-1993

APPLICATION NUMBER: 07/847,311

FILING DATE: 06-MAR-1992

APPLICATION NUMBER: 07/751,998

FILING DATE: 29-AUG-1991

APPLICATION NUMBER: 07/148,692

FILING DATE: 26-JAN-1988

ATTORNEY/AGENT INFORMATION:

NAME: Beattie, Ingrid A.

REGISTRATION NUMBER: P-42,306

REFERENCE/DOCKET NUMBER: 08830/022003

TELECOMMUNICATION INFORMATION:

TELEPHONE: 617/542-5070

TELEFAX: 617/542-8906

TELEX: 200154

INFORMATION FOR SEQ ID NO: 11:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: peptide

US-08-455-685-11

Query Match 100.0%; Score 39; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;QY 1 RAFTVIGK 8
Db 8 RAFTVIGK 15

RESULT 57

US-08-455-685-12

Sequence 12, Application US/08455685

Patent No. 6214347

GENERAL INFORMATION:

APPLICANT: Berzofsky, Jay A.

APPLICANT: Ahlers, Jeffrey D.

APPLICANT: Pendleton, C. David

APPLICANT: Nara, Peter


```
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 40
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,685
FILING DATE: 31-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/060,988
FILING DATE: 14-MAY-1993
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022003
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-455-685-12

Query Match 100.0%; Score 39; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTYTGK 8
DB 8 RAFTYTGK 15

RESULT 58
US-08-455-685-13
; Sequence 13, Application US/08455685
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. David
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
; TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
; TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
```

```
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,685
FILING DATE: 31-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/060,988
FILING DATE: 14-MAY-1993
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022003
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-455-685-13

Query Match 100.0%; Score 39; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTYTGK 8
DB 8 RAFTYTGK 15

RESULT 59
US-08-455-685-14
; Sequence 14, Application US/08455685
; Patent No. 6214347
; GENERAL INFORMATION:
; APPLICANT: Berzofsky, Jay A.
; APPLICANT: Ahlers, Jeffrey D.
; APPLICANT: Pendleton, C. David
; APPLICANT: Nara, Peter
; APPLICANT: Shirai, Mutsunori
; TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
; TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
; TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/455,685
; FILING DATE: 31-MAY-1995
```

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/060,988
FILING DATE: 14-MAY-1993
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022003
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-455-685-14

Query Match 100.0%; Score 39; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
DB 8 RAFTVIGK 15

RESULT 60
US-08-455-685-15
Sequence 15, Application US/08455685
Patent No. 6214347
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 40
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,685
FILING DATE: 31-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/060,988
FILING DATE: 14-MAY-1993
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:

NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022003
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-455-685-15

Query Match 100.0%; Score 39; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
DB 8 RAFTVIGK 15

RESULT 61
US-08-060-988A-7
Sequence 7, Application US/08060988A
Patent No. 6294322
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
TITLE OF INVENTION: THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/060,988A
FILING DATE: 14-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022001
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid

TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-060-988A-7

Query Match 100.0%; Score 39; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTTICK 8
DB 8 RAFVTTICK 15

RESULT 62
US-08-060-988A-11
Sequence 11, Application US/08060988A
Patent No. 6294322
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shiral, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
TITLE OF INVENTION: THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE AND
TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FASTSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/060,988A
FILING DATE: 14-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022001
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-060-988A-11

Query Match 100.0%; Score 39; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTTICK 8
DB 8 RAFVTTICK 15

RESULT 63
US-08-060-988A-12
Sequence 12, Application US/08060988A
Patent No. 6294322
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shiral, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
TITLE OF INVENTION: THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE AND
TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FASTSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/060,988A
FILING DATE: 14-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022001
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-060-988A-12

Query Match 100.0%; Score 39; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTTICK 8
DB 8 RAFVTTICK 15

RESULT 64
US-08-060-988A-13
Sequence 13, Application US/08060988A
Patent No. 6294322
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter

APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
TITLE OF INVENTION: THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESSES:
ADDRESSER: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FASTSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/060,988A
FILING DATE: 14-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022001
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-060-988A-13

Query Match 100.0%; Score 39; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
DB 8 RAFTVIGK 15

RESULT 65
US-08-060-988A-14
Sequence 14, Application US/08060988A
Patent No. 6294322
GENERAL INFORMATION:
APPLICANT: Bezotsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
TITLE OF INVENTION: THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESSES:
ADDRESSER: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA

COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FASTSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/060,988A
FILING DATE: 14-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022001
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-060-988A-14

Query Match 100.0%; Score 39; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
DB 8 RAFTVIGK 15

RESULT 66
US-08-060-988A-15
Sequence 15, Application US/08060988A
Patent No. 6294322
GENERAL INFORMATION:
APPLICANT: Bezotsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
TITLE OF INVENTION: THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESSES:
ADDRESSER: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FASTSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/060,988A
FILING DATE: 14-MAY-1993
PRIOR APPLICATION DATA:

APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022001
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-060-988A-15

Query Match 100.0%; Score 39; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTTGK 8
DB 8 RAFVTTGK 15

RESULT 67
US-09-051-006-8
Sequence 8, Application US/09051006
GENERAL INFORMATION:
APPLICANT: Mogam Biotechnology Research Institute
APPLICANT: Kim, Tae-Young
APPLICANT: Lee, Ki-Young
APPLICANT: Chang, Jin-Seo
APPLICANT: Hwang, Yu-Kyeong
APPLICANT: Choi, Myeong
APPLICANT: Cheong, Hong-Seok
TITLE OF INVENTION: Liposomes Comprising Peptide Antigens
TITLE OF INVENTION: Derived from X Protein of Hepatitis B virus
FILE REFERENCE: 0136/0E154
CURRENT APPLICATION NUMBER: US/09/051,006
CURRENT FILING DATE: 1998-03-30
NUMBER OF SEQ ID NOS: 10
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 8
LENGTH: 15
TYPE: PRT
ORGANISM: HIV
US-09-051-006-8

Query Match 100.0%; Score 39; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTTGK 8
DB 8 RAFVTTGK 15

RESULT 68
US-09-389-390-1
Sequence 1, Application US/09389390
GENERAL INFORMATION:
PATENT NO. 6558961
APPLICANT: SARPHIE
TITLE OF INVENTION: IMMUNODIAGNOSTICS USING PARTICLE DELIVERY METHODS

FILE REFERENCE: 0PF1620
CURRENT APPLICATION NUMBER: US/09/389,390
CURRENT FILING DATE: 1999-09-03
PRIOR APPLICATION NUMBER: 60/099,261
PRIOR FILING DATE: 1998-09-04
PRIOR APPLICATION NUMBER: 60/139,045
PRIOR FILING DATE: 1999-06-10
NUMBER OF SEQ ID NOS: 10
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 1
LENGTH: 15
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: synthetic
OTHER INFORMATION: construct
US-09-389-390-1

Query Match 100.0%; Score 39; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTTGK 8
DB 8 RAFVTTGK 15

RESULT 69
US-09-508-552-15
Sequence 15, Application US/09508552
Patent No. 6749856
GENERAL INFORMATION:
APPLICANT: Bertozsky, Jay A.
APPLICANT: Belyakov, Igor M.
APPLICANT: Derby, Michael A.
APPLICANT: Kelsall, Brian L.
APPLICANT: Strober, Warren
TITLE OF INVENTION: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as
FILE REFERENCE: 368200PCSE0
CURRENT APPLICATION NUMBER: US/09/508,552
CURRENT FILING DATE: 2000-06-12
PRIOR APPLICATION NUMBER: 60/058,523
PRIOR FILING DATE: 1997-09-11
PRIOR APPLICATION NUMBER: 60/074,894
PRIOR FILING DATE: 1998-02-17
NUMBER OF SEQ ID NOS: 20
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 15
LENGTH: 15
TYPE: PRT
ORGANISM: Human immunodeficiency virus type 1
US-09-508-552-15

Query Match 100.0%; Score 39; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTTGK 8
DB 8 RAFVTTGK 15

RESULT 70
US-09-827-688-9
Sequence 9, Application US/09827688
GENERAL INFORMATION:
PATENT NO. 6821955
APPLICANT: ORSON FRANK
APPLICANT: KINSEY, BERMA
APPLICANT: BHOGAL, BALDIR
TITLE OF INVENTION: MACROAGGREGATED PROTEIN CONJUGATES AS ORAL GENETIC IMMUNIZATION DI

FILE REFERENCE: P01949US1/10004014
 CURRENT APPLICATION NUMBER: US/09/827,688
 PRIOR FILING DATE: 2001-04-06
 PRIOR APPLICATION NUMBER: 60/195,680
 NUMBER OF SEQ ID NOS: 13
 SOFTWARE: PatentIn version 3.0
 SEQ ID NO 9
 LENGTH: 15
 TYPE: PRT
 ORGANISM: HIV p18
 US-09-827-688-9

Query Match 100.0%; Score 39; DB 4; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
 |||||
 DB 8 RAFTVIGK 15

RESULT 71

PCT-US92-10378-1
 Sequence 1, Application PC/TUS9210378
 GENERAL INFORMATION:
 APPLICANT: BOARD OF REGENTS, THE UNIVERSITY OF
 APPLICANT: TEXAS SYSTEM
 APPLICANT: SASTRY, Jagannadha K.
 APPLICANT: ARLINGHAUS, Ralph B.
 APPLICANT: PLATSOUOS, Chris D.
 APPLICANT: NEHETE, Pyramod N.
 TITLE OF INVENTION: METHODS AND COMPOSITIONS
 TITLE OF INVENTION: FOR ELICITING IMMUNE OR ANTI-INFECTION RESPONSES
 NUMBER OF SEQUENCES: 7
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Arnold, White & Durkee
 STREET: P.O. Box 4433
 CITY: Houston
 STATE: Texas
 COUNTRY: US
 ZIP: 77210
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: WordPerfect 5.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: PCT/US92/10378
 FILING DATE: 19921202
 CLASSIFICATION:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 07/800,932
 FILING DATE: December 2, 1991
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 07/945865
 FILING DATE: September 16, 1992
 ATTORNEY/AGENT INFORMATION:
 NAME: Parker, David L.
 REGISTRATION NUMBER: 32,165
 REFERENCE/DOCKET NUMBER: UFG305PCT
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 512-320-7200
 TELEFAX: 512-474-7577
 TELEX: Not Applicable
 INFORMATION FOR SEQ ID NO: 1:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 15 amino acids
 TYPE: AMINO ACID
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 PCT-US92-10378-1

Query Match 100.0%; Score 39; DB 5; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
 |||||
 DB 8 RAFTVIGK 15

RESULT 72

PCT-US94-05142-7
 Sequence 7, Application PC/TUS9405142
 GENERAL INFORMATION:
 APPLICANT:
 TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
 TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
 NUMBER OF SEQUENCES: 36
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Birch, Stewart, Kolaesch & Birch
 STREET: P.O. Box 747
 CITY: Falls Church
 STATE: Virginia
 COUNTRY: USA
 ZIP: 22040-0747
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 OPERATING SYSTEM: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: PCT/US94/05142
 FILING DATE: 13-MAY-1994
 CLASSIFICATION:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/060,988
 FILING DATE: 14-MAY-1993
 ATTORNEY/AGENT INFORMATION:
 NAME: Svensson, Leonard R.
 REGISTRATION/DOCKET NUMBER: 30330
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 703-205-8000
 TELEFAX: 703-205-8050
 INFORMATION FOR SEQ ID NO: 7:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 15 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 FRAGMENT TYPE: internal
 FEATURE:
 NAME/KEY: Peptide
 LOCATION: 1..15
 OTHER INFORMATION: /label= peptide
 OTHER INFORMATION: /note="p18111B peptide, see Table v"
 PCT-US94-05142-7

Query Match 100.0%; Score 39; DB 5; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
 |||||
 DB 8 RAFTVIGK 15

RESULT 73

PCT-US94-05142-11
 Sequence 11, Application PC/TUS9405142
 GENERAL INFORMATION:
 APPLICANT:

TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Birch, Stewart, Kolaesch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: IBM PC compatible
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/05142
FILING DATE: 13-MAY-1994
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..15
OTHER INFORMATION: /label= peptide
OTHER INFORMATION: /note= "p18-3, see Table V"
PCT-US94-05142-11
Query Match 100.0%; Score 39; DB 5; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 RAFTYICK 8
DB 8 RAFTYICK 15
RESULT 74
PCT-US94-05142-12
Sequence 12, Application PC/TUS9405142
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Birch, Stewart, Kolaesch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: IBM PC compatible
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/05142
FILING DATE: 13-MAY-1994
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050

SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/05142
FILING DATE: 13-MAY-1994
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..15
OTHER INFORMATION: /label= peptide
OTHER INFORMATION: /note= "p18-4, see Table V"
PCT-US94-05142-12
Query Match 100.0%; Score 39; DB 5; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 RAFTYICK 8
DB 8 RAFTYICK 15
RESULT 75
PCT-US94-05142-13
Sequence 13, Application PC/TUS9405142
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Birch, Stewart, Kolaesch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: IBM PC compatible
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/05142
FILING DATE: 13-MAY-1994
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050

; INFORMATION FOR SEQ ID NO: 13:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 15 amino acids
 ; TYPE: amino acid
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: peptide
 ; FRAGMENT TYPE: internal
 ; FEATURE:
 ; NAME/KEY: Peptide
 ; LOCATION: 1..15
 ; OTHER INFORMATION: /label= peptide
 ; OTHER INFORMATION: /note= "p18-5, see Table V"
 PCT-US94-05142-13

Query Match 100.0%; Score 39; DB 5; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
 DB 8 RAFTVIGK 15

RESULT 76
 PCT-US94-05142-14
 ; Sequence 14, Application PC/TUS9405142
 ; GENERAL INFORMATION:
 ; APPLICANT:
 ; TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
 ; TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
 ; TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
 ; NUMBER OF SEQUENCES: 36
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Birch, Stewart, Kolasch & Birch
 ; STREET: P.O. Box 747
 ; CITY: Falls Church
 ; STATE: Virginia
 ; COUNTRY: USA
 ; ZIP: 22040-0747
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: floppy disk
 ; OPERATING SYSTEM: IBM PC compatible
 ; SOFTWARE: Patent in Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: PCT/US94/05142
 ; FILING DATE: 13-MAY-1994
 ; CLASSIFICATION:
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US 08/060,988
 ; FILING DATE: 14-MAY-1993
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Svensson, Leonard R.
 ; REGISTRATION NUMBER: 30330
 ; REFERENCE/DOCKET NUMBER: 1173-434P
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 703-205-8000
 ; TELEFAX: 703-205-8050
 ; INFORMATION FOR SEQ ID NO: 14:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 15 amino acids
 ; TYPE: amino acid
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: peptide
 ; FRAGMENT TYPE: internal
 ; FEATURE:
 ; NAME/KEY: Peptide
 ; LOCATION: 1..15
 ; OTHER INFORMATION: /label= peptide
 ; OTHER INFORMATION: /note= "p18-6, see Table V"
 PCT-US94-05142-14

Query Match 100.0%; Score 39; DB 5; Length 15;

Best Local Similarity 100.0%; Pred. No. 0.072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
 DB 8 RAFTVIGK 15

RESULT 77
 PCT-US94-05142-15
 ; Sequence 15, Application PC/TUS9405142
 ; GENERAL INFORMATION:
 ; APPLICANT:
 ; TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
 ; TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
 ; TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
 ; NUMBER OF SEQUENCES: 36
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Birch, Stewart, Kolasch & Birch
 ; STREET: P.O. Box 747
 ; CITY: Falls Church
 ; STATE: Virginia
 ; COUNTRY: USA
 ; ZIP: 22040-0747
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: floppy disk
 ; OPERATING SYSTEM: IBM PC compatible
 ; SOFTWARE: Patent in Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: PCT/US94/05142
 ; FILING DATE: 13-MAY-1994
 ; CLASSIFICATION:
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US 08/060,988
 ; FILING DATE: 14-MAY-1993
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Svensson, Leonard R.
 ; REGISTRATION NUMBER: 30330
 ; REFERENCE/DOCKET NUMBER: 1173-434P
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 703-205-8000
 ; TELEFAX: 703-205-8050
 ; INFORMATION FOR SEQ ID NO: 15:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 15 amino acids
 ; TYPE: amino acid
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: peptide
 ; FRAGMENT TYPE: internal
 ; FEATURE:
 ; NAME/KEY: Peptide
 ; LOCATION: 1..15
 ; OTHER INFORMATION: /label= peptide
 ; OTHER INFORMATION: /note= "p18-7, see Table V"
 PCT-US94-05142-15

Query Match 100.0%; Score 39; DB 5; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
 DB 8 RAFTVIGK 15

RESULT 78
 US-08-657-392-28
 ; Sequence 28, Application US/08657392
 ; Patent No. 5843634
 ; GENERAL INFORMATION:
 ; APPLICANT: Brate, E.M.
 ; APPLICANT: Brennan, C.A.

APPLICANT: Bridon, D.P.
APPLICANT: Jaffe, K.D.
APPLICANT: Kraft, G.A.
APPLICANT: Mandelki, W.
APPLICANT: March, S.C.
APPLICANT: Russell, J.R.
APPLICANT: Yue, V.T.
TITLE OF INVENTION: Genetically Engineered Enzymes And Their
TITLE OF INVENTION: Conjugates For Diagnostic Assays
NUMBER OF SEQUENCES: 34
CORRESPONDENCE ADDRESS:
ADDRESSEE: ABBOTT LABORATORIES
STREET: One Abbott Park Road
CITY: Abbott Park
STATE: Illinois
COUNTRY: USA
ZIP: 60064-3500
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: SotPC
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/657,392
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/100,708
FILING DATE: July 29, 1993
ATTORNEY/AGENT INFORMATION:
NAME: Mong, Mean Kling
REGISTRATION NUMBER: 33,561
REFERENCE/DOCKET NUMBER: 5324.US.P1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (708) 938-3517
TELEFAX: (708) 938-2623
TELEX:
INFORMATION FOR SEQ ID NO: 28:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 amino acid residues
TYPE: amino acid
STRANDEDNESS:
MOLECULE TYPE: unknown
TOPOLOGY: unknown
ORIGINAL SOURCE: peptide
ORGANISM:
US-08-657-392-28

Query Match 100.0%; Score 39; DB 2; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.077;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTTICK 8
Db 9 RAFTTICK 16

RESULT 79
US-08-251-472-2
Sequence 2, Application US/08251472
Patent No. 5871746
GENERAL INFORMATION:
APPLICANT: BOUTILLON, CHRISTOPHE, MARTINON,
APPLICANT: FREDERIC, GRAS-MASSIE, HELENE,
APPLICANT: GOMARD, ELISABETH, SERGHERART,
APPLICANT: CHRISTIAN, MAGNE, REMY, TARTAR,
APPLICANT: ANDRE, LEVY, JEAN-PAUL,
TITLE OF INVENTION: CYTOTOXIC T LYMPHOCYTE
TITLE OF INVENTION: -INDUCING LIPOPEPTIDES AND USE AS VACCINES
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSEE: BIERMAN & MUSERLIAN
STREET: 600 THIRD AVENUE

CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10016
COMPUTER READABLE FORM:
MEDIUM TYPE: FLOPPY DISK
COMPUTER: IBM PC COMPATIBLE
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: ASCII
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/251,472
FILING DATE: 31-MAY-1994
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: MUSERLIAN, CHARLES A
REGISTRATION NUMBER: 19,683
REFERENCE/DOCKET NUMBER: 102.1511
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 661-8000
TELEFAX: (212) 661-8002
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 16
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: HIV-1
FEATURE:
LOCATION: ENV 312-327
US-08-251-472-2

Query Match 100.0%; Score 39; DB 2; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.077;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTTICK 8
Db 9 RAFTTICK 16

RESULT 80
US-08-484-905-35
Sequence 35, Application US/08484905
Patent No. 5976551
GENERAL INFORMATION:
APPLICANT: Mottez, Estelle
APPLICANT: Kourilsky, Philippe
TITLE OF INVENTION: An Altered Major Histocompatibility
TITLE OF INVENTION: Complex (MHC) Determinant and Methods for Using the
NUMBER OF SEQUENCES: 127
CORRESPONDENCE ADDRESS:
ADDRESSEE: Finnegan, Henderson, Farbow, Garrett &
ADDRESSEE: Dunner
STREET: 1300 I Street, N.W., Suite 700
CITY: Washington
STATE: D.C.
ZIP: 20005-3315
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy Disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/484,905
FILING DATE: 07-JUNE-1995
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/801,818

FILING DATE: 05-DEC-1991
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/792,473
FILING DATE: 15-NOV-1991
CLASSIFICATION: 530
ATTORNEY/AGENT INFORMATION:
NAME: Potter, Jane E. R.
REGISTRATION NUMBER: 33,332
REFERENCE/DOCKET NUMBER: 03495.0106-03000
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-408-4000
TELEFAX: 202-408-4400
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-484-905-35

Query Match 100.0%; Score 39; DB 2; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.077;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFTTIGK 8
Db 9 RAFTTIGK 16

RESULT 81
US-08-481-985B-35
Sequence 35, Application US/08481985B
Patent No. 6011146
GENERAL INFORMATION:
APPLICANT: Motiez, Estelle
APPLICANT: Abastredo, Jean-Pierre
APPLICANT: Kourilsky, Philippe
TITLE OF INVENTION: Altered Major Histocompatibility Complex
NUMBER OF SEQUENCES: 148
CORRESPONDENCE ADDRESS:
ADDRESSEE: Finnegan, Henderson, Farbow, Garrett &
STREET: 1300 I Street, N.W., Suite 700
CITY: Washington
STATE: D.C.
ZIP: 20005-3315
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/481,985B
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/801,818
FILING DATE: 05-DEC-1991
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/792,473
FILING DATE: 15-NOV-1991
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Meyers, Kenneth J.
REGISTRATION NUMBER: 25,146
REFERENCE/DOCKET NUMBER: 03495.0106-04000
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-408-4000
TELEFAX: 202-408-4400
INFORMATION FOR SEQ ID NO: 35:

SEQUENCE CHARACTERISTICS:
LENGTH: 16 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-481-985B-35

Query Match 100.0%; Score 39; DB 3; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.077;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFTTIGK 8
Db 9 RAFTTIGK 16

RESULT 82
US-09-248-082-2
Sequence 2, Application US/09248082
Patent No. 6015564
GENERAL INFORMATION:
APPLICANT: BOUTILLON, CHRISTOPHE; MARTINON,
APPLICANT: FREDERIC; GRAS-MASSE, HELENE;
APPLICANT: GOMARD, ELISABETH; SERGHERAERT,
APPLICANT: CHRISTIAN; MAGNE, REMY; TARTAR,
APPLICANT: ANDRE; LEVY, JEAN-PAUL
TITLE OF INVENTION: CYTOTOXIC T LYMPHOCYTE
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSEE: BIERMAN & MUSERLIAN
STREET: 600 THIRD AVENUE
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10016
COMPUTER READABLE FORM:
MEDIUM TYPE: FLOPPY DISK
COMPUTER: IBM PC COMPATIBLE
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: ASCII
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/248,082
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/251,472
FILING DATE: 31-MAY-1994
ATTORNEY/AGENT INFORMATION:
NAME: MUSERLIAN, CHARLES A
REGISTRATION NUMBER: 19,683
REFERENCE/DOCKET NUMBER: 102.1511
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 661-8000
TELEFAX: (212) 661-8002
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 16
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: HIV-1
FEATURE:
LOCATION: ENV 312-327
US-09-248-082-2

Query Match 100.0%; Score 39; DB 3; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.077;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFTTICK 8
| | | | |
DB 9 RAFTTICK 16

RESULT 83

US-08-370-476-35
Sequence 35, Application US/08370476
Patent No. 6153408
GENERAL INFORMATION:
APPLICANT: Mottez, Estelle
APPLICANT: Abastado, Jean-Pierre
APPLICANT: Kourilsky, Philippe
APPLICANT: Lome, Yu-Chun
APPLICANT: Ojcius, David
APPLICANT: Castrouge, Armenda
TITLE OF INVENTION: Altered Major Histocompatibility Complex
TITLE OF INVENTION:
NUMBER OF SEQUENCES: 127
CORRESPONDENCE ADDRESS:
ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
ADDRESSEE: Dunner
STREET: 1300 I Street, N.W., Suite 700
City: Washington
STATE: D.C.
ZIP: 20005-3315
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/370,476
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/117,575
FILING DATE: 07-SEP-1993
APPLICATION NUMBER: US 08/072,787
FILING DATE: 06-JUN-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/801,818
FILING DATE: 05-DEC-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/792,473
FILING DATE: 15-NOV-1991
ATTORNEY/AGENT INFORMATION:
NAME: Meyers, Kenneth J.
REGISTRATION NUMBER: 25,146
REFERENCE/DOCKET NUMBER: 05243.0001-01000
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-408-4000
TELEFAX: 202-408-4400
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-370-476-35

Query Match 100.0%; Score 39; DB 3; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.077;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFTTICK 8
| | | | |
DB 9 RAFTTICK 16

RESULT 84
US-08-992-877-15
Sequence 15, Application US/08992877

Patent No. 6340461
GENERAL INFORMATION:
APPLICANT: Terman, David S
TITLE OF INVENTION: SUPERANTIGEN BASED METHODS AND COMPOSITIONS FOR
TREATMENT OF INFECTIOUS DISEASE
FILE REFERENCE: superantigen
CURRENT APPLICATION NUMBER: US/08/992,877
CURRENT FILING DATE: 1997-12-17
PRIOR APPLICATION NUMBER: 60/044,074
PRIOR FILING DATE: 1997-04-17
NUMBER OF SEQ ID NOS: 78
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 15
LENGTH: 16
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: antigen
US-08-992-877-15

Query Match 100.0%; Score 39; DB 3; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.077;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFTTICK 8
| | | | |
DB 9 RAFTTICK 16

RESULT 85

PCT-US94-02539-28
Sequence 28, Application PC/TUS9402539

GENERAL INFORMATION:
APPLICANT: Brate, E.M.
APPLICANT: Brennan, C.A.
APPLICANT: Bridon, D.P.
APPLICANT: Jaffe, K.D.
APPLICANT: Krafft, G.A.
APPLICANT: Mandelki, W.
APPLICANT: March, S.C.
APPLICANT: Russell, J.R.
APPLICANT: Yue, V.T.
TITLE OF INVENTION: Genetically Engineered Enzymes
TITLE OF INVENTION: And Their
TITLE OF INVENTION: Conjugates For Diagnostic Assays
NUMBER OF SEQUENCES: 34
CORRESPONDENCE ADDRESS:
ADDRESSEE: ABBOTT LABORATORIES
STREET: One Abbott Park Road
CITY: Abbott Park
STATE: Illinois
COUNTRY: USA
ZIP: 60064-3500
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: SoftPC
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/02539
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Wong, Wean King
REGISTRATION NUMBER: 33,561
REFERENCE/DOCKET NUMBER: 5324.PC.01
TELECOMMUNICATION INFORMATION:
TELEPHONE: (708) 938-3517
TELEFAX: (708) 938-2623
TELEX:
INFORMATION FOR SEQ ID NO: 28:
SEQUENCE CHARACTERISTICS:

```

; LENGTH: 16 amino acid residues
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
; ORIGINAL SOURCE:
; ORGANISM:
PCT-US94-02539-28

Query Match
Best Local Similarity 100.0%; Score 39; DB 5; Length 16;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
DB 9 RAFTVIGK 16

RESULT 86
US-08-015-770B-4
; Sequence 4, Application US/08015770B
; Patent No. 5683695
; GENERAL INFORMATION:
; APPLICANT: Shen, De Fen
; APPLICANT: Wang, Chang Yi
; TITLE OF INVENTION: Production of recombinant proteins
; TITLE OF INVENTION: containing multiple antigenic determinants linked by
; TITLE OF INVENTION: flexible domains
; NUMBER OF SEQUENCES: 73
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: United Biomedical, Inc.
; STREET: 25 Davids Drive
; CITY: Hauppauge
; STATE: NY
; COUNTRY: USA
; ZIP: 11788
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/015,770B
; FILING DATE: 10-FEB-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Wilson, M. Lisa
; REGISTRATION NUMBER: 34,045
; REFERENCE/DOCKET NUMBER: 2002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516)273-2828
; TELEFAX: (516)273-1717
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-015-770B-4

Query Match
Best Local Similarity 100.0%; Score 39; DB 1; Length 18;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
DB 11 RAFTVIGK 18

RESULT 87
US-08-121-054C-3
; Sequence 3, Application US/08121054C
; Patent No. 5637481
```

```

; GENERAL INFORMATION:
; APPLICANT: Ledbetter, Jeffrey A.
; APPLICANT: Gilliland, Lisa K.
; APPLICANT: Hayden, Martha S.
; APPLICANT: Linsley, Peter S.
; APPLICANT: Bajorath, Jürgen
; APPLICANT: Fell, Perry
; TITLE OF INVENTION: Expression Vectors Encoding Bispecific
; TITLE OF INVENTION: Fusion Proteins and Methods of Producing Biologically
; TITLE OF INVENTION: Active Bispecific Fusion Proteins in a Mammalian Cell
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merchant & Gould
; STREET: 1150 Santa Monica Blvd., Suite 400
; CITY: Los Angeles
; STATE: CA
; COUNTRY: USA
; ZIP: 90025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/121,054C
; FILING DATE: 13-SEP-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 06/013,420
; FILING DATE: 01-FEB-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Adriano, Sarah B.
; REGISTRATION NUMBER: 34,470
; REFERENCE/DOCKET NUMBER: 30436.18US01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 310-445-1140
; TELEFAX: 310-445-9031
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-121-054C-3

Query Match
Best Local Similarity 100.0%; Score 39; DB 1; Length 20;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
DB 12 RAFTVIGK 19

RESULT 88
US-08-488-252-28
; Sequence 28, Application US/08488252
; Patent No. 5763160
; GENERAL INFORMATION:
; APPLICANT: Chang Yi Wang
; TITLE OF INVENTION: SYNTHETIC PEPTIDES AND PROCESS
; TITLE OF INVENTION: OF USING SAME FOR THE DETECTION OF ANTIBODIES TO
; TITLE OF INVENTION: HUMAN IMMUNODEFICIENCY VIRUS (HIV) GP120 ENVELOPE
; TITLE OF INVENTION: PROTEIN, DIAGNOSIS OF AIDS AND PRE-AIDS CONDITIONS
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORGAN & FINNEGAN
; STREET: 345 PARK AVE.
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
```

ZIP: 10154
COMPUTER READABLE FORM:
MEDIUM TYPE: FLOPPY DISK
COMPUTER: IBM PC COMPATIBLE
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WORDPERFECT 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,252
FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/326,676
FILING DATE: 07-Jun-1995
APPLICATION NUMBER: 07/726,605
FILING DATE: 09-July-1991
APPLICATION NUMBER: 07/663,262
FILING DATE: 01-Mar-1991
APPLICATION NUMBER: 07/155,321
FILING DATE: 12-Feb-1988
ATTORNEY/AGENT INFORMATION:
NAME: Maria C. H. Lin
REGISTRATION NUMBER: 29,323
REFERENCE/DOCKET NUMBER: 1151-4004 USA
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-758-4800
TELEFAX: (212) 751-6849
TELEX: 421792
INFORMATION FOR SEQ ID NO: 28:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 amino acids
TYPE: Amino acids
STRANDEDNESS:
TOPOLOGY: Unknown
US-08-488-252-28

Query Match 100.0%; Score 39; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.096;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTYTK 8
DB 13 RAFTYTK 20

RESULT 89
US-08-539-436-3
Sequence 3, Application US/08539436
Patent No. 613292
GENERAL INFORMATION:
APPLICANT: Ledbetter, Jeffrey A.
APPLICANT: Gilliland, Lisa K.
APPLICANT: Hayden, Martha S.
APPLICANT: Linsley, Peter S.
APPLICANT: Bajorath, Jurgen
APPLICANT: Fell, Perry
TITLE OF INVENTION: Expression Vectors Encoding Bispecific
TITLE OF INVENTION: Fusion Proteins and Methods of Producing Biologically
TITLE OF INVENTION: Active Bispecific Fusion Proteins in a Mammalian Cell
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Merchant & Gould
STREET: 1150 Santa Monica Blvd., Suite 400
CITY: Los Angeles
STATE: CA
COUNTRY: USA
ZIP: 90025
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/539,436

FILING DATE: 05-OCT-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/121,054
FILING DATE: 13-SEP-1993
APPLICATION NUMBER: US 08/013,420
FILING DATE: 01-FEB-1993
ATTORNEY/AGENT INFORMATION:
NAME: Adriano, Sarah B.
REGISTRATION NUMBER: 34,470
REFERENCE/DOCKET NUMBER: 30436.18US01
TELECOMMUNICATION INFORMATION:
TELEPHONE: 310-445-1140
TELEFAX: 310-445-9031
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 amino acids
TYPE: amino acid
STRANDEDNESS:
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-539-436-3

Query Match 100.0%; Score 39; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.096;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTYTK 8
DB 12 RAFTYTK 19

RESULT 90
US-09-813-659-3
Sequence 3, Application US/09813659
Patent No. 6482919
GENERAL INFORMATION:
APPLICANT: Ledbetter, Jeffrey A.
APPLICANT: Hayden, Martha S.
APPLICANT: Linsley, Peter S.
APPLICANT: Bajorath, Jurgen
APPLICANT: Fell, H. Perry
APPLICANT: Gilliland, Lisa K.
TITLE OF INVENTION: EXPRESSION VECTORS-ENCODING BISPECIFIC FUSION PROTEINS
TITLE OF INVENTION: AND METHODS OF PRODUCING BIOLOGICALLY ACTIVE BISPECIFIC
TITLE OF INVENTION: FUSION PROTEINS IN A MAMMALIAN CELL
FILE REFERENCE: 30436.18USD2
CURRENT APPLICATION NUMBER: US/09/813,659
CURRENT FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 09/549,067
PRIOR FILING DATE: 2000-04-13
PRIOR APPLICATION NUMBER: 08/539,436
PRIOR FILING DATE: 1995-10-05
PRIOR APPLICATION NUMBER: 08/121,054
PRIOR FILING DATE: 1993-09-13
PRIOR APPLICATION NUMBER: 08/013,420
PRIOR FILING DATE: 1993-02-01
NUMBER OF SEQ ID NOS: 32
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 3
LENGTH: 20
TYPE: PRT
ORGANISM: Homo sapiens
US-09-813-659-3

Query Match 100.0%; Score 39; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.096;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTYTK 8
DB 12 RAFTYTK 19

```
RESULT 91
US-09-549-067A-3
; Sequence 3, Application US/09549067A
; Patent No. 6623940
; GENERAL INFORMATION:
; APPLICANT: Ledbetter, Jeffrey A.
; APPLICANT: Hayden, Martha S.
; APPLICANT: Linsley, Peter S.
; APPLICANT: Bajorath, Jürgen
; APPLICANT: Fell, H. Perry
; APPLICANT: Gilliland, Lisa K.
; TITLE OF INVENTION: EXPRESSION VECTORS ENCODING BISPECIFIC FUSION PROTEINS
; TITLE OF INVENTION: AND METHODS OF PRODUCING BIOLOGICALLY ACTIVE BISPECIFIC
; FILE REFERENCE: 30436.18USC1
; CURRENT APPLICATION NUMBER: US/09/549,067A
; PRIOR FILING DATE: 2000-04-13
; PRIOR APPLICATION NUMBER: 08/539,436
; PRIOR FILING DATE: 1995-10-05
; PRIOR APPLICATION NUMBER: 08/121,054
; PRIOR FILING DATE: 1993-09-13
; PRIOR APPLICATION NUMBER: 08/013,420
; PRIOR FILING DATE: 1993-02-01
; PRIOR APPLICATION NUMBER: 08/228,208
; PRIOR FILING DATE: 1994-04-15
; PRIOR APPLICATION NUMBER: 08/008,898
; PRIOR FILING DATE: 1993-01-22
; PRIOR APPLICATION NUMBER: 07/723,617
; PRIOR FILING DATE: 1991-06-27
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-549-067A-3

Query Match      100.0%; Score 39; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.096;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy      1 RAFTTIGK 8
      |||||
Db      12 RAFTTIGK 19

RESULT 92
US-08-452-503A-4
; Sequence 4, Application US/08452503A
; Patent No. 5849475
; GENERAL INFORMATION:
; APPLICANT: Rovinski, Benjamin
; APPLICANT: Haynes, Joel
; APPLICANT: Cao, Shi Xian
; APPLICANT: Klein, Michel H
; TITLE OF INVENTION: Retrovirus-like Particles Containing
; TITLE OF INVENTION: Modified Envelope Glycoproteins
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: 330 University Avenue, 6th Floor
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/452,503A
```

```

; FILING DATE: 30-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/073,526
; FILING DATE: 09-JAN-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Stewart, Michael I
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-447 MIS:as
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-452-503A-4

Query Match      100.0%; Score 39; DB 2; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy      1 RAFTTIGK 8
      |||||
Db      14 RAFTTIGK 21

RESULT 93
US-08-453-745A-4
; Sequence 4, Application US/08453745A
; Patent No. 5866137
; GENERAL INFORMATION:
; APPLICANT: Rovinski, Benjamin
; APPLICANT: Haynes, Joel
; APPLICANT: Cao, Shi Xian
; APPLICANT: Klein, Michel H
; TITLE OF INVENTION: Retrovirus-like Particles Containing
; TITLE OF INVENTION: Modified Envelope Glycoproteins
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: 330 University Avenue, 6th Floor
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/453,745A
; FILING DATE: 30-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/073,526
; FILING DATE: 09-JAN-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Stewart, Michael I
; REGISTRATION NUMBER: 24,73
; REFERENCE/DOCKET NUMBER: 1038-445 MIS:as
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 amino acids
; TYPE: amino acid
```

```
STRANDEDNESS: single
;
; TOPOLOGY: linear
;
US-08-453-745A-4
;
Query Match      100.0%; Score 39; DB 2; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RAFVTTIG 8
      |||||
      14 RAFVTTIG 21

Db

RESULT 94
US-08-470-419-25
; Sequence 25; Application US/08470419
; Patent No. 5866320
; GENERAL INFORMATION:
; APPLICANT: ROVINSKI, Benjamin
; APPLICANT: CAO, Shi-Xian
; APPLICANT: YAO, Fei-Long
; APPLICANT: PERSSON, Roy
; APPLICANT: KLEIN, Michel H
; TITLE OF INVENTION: ANTIGENICALLY-MARKED NON-INFECTIONOUS
; TITLE OF INVENTION: RETROVIRUS-LIKE PARTICLES
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/470,419
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/290,105
; FILING DATE: August 15, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, Michael I
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-385 MTS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-470-419-25
;
Query Match      100.0%; Score 39; DB 2; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RAFVTTIG 8
      |||||
      14 RAFVTTIG 21

Db

RESULT 95
US-08-648-298-18
; Sequence 18; Application US/08648298
; Patent No. 5871990
; GENERAL INFORMATION:
; APPLICANT: Henrik Paul Clausen
; APPLICANT: Eric Paul Bennett
; TITLE OF INVENTION: UDP-N-acetyl-alpha-D-galactosamine:polypeptide
; TITLE OF INVENTION: N-acetyl-galactosaminyltransferase GalNAc-T3
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Darby & Darby PC
; STREET: 805 Third Avenue
; CITY: New York
; STATE: NY
; ZIP: 10022
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30 (BPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/648,298
; FILING DATE: 15-JUN-1996
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Green, Reza
; REGISTRATION NUMBER: 38,475
; REFERENCE/DOCKET NUMBER: 4035/08865
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212527700
; TELEFAX: 2127536237
; TELEX: 236687
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 amino acids
; TYPE: peptide
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; IMMEDIATE SOURCE:
; CLONE: HIV-V3 acceptor peptide
;
US-08-648-298-18
;
Query Match      100.0%; Score 39; DB 2; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RAFVTTIG 8
      |||||
      10 RAFVTTIG 17

Db

RESULT 96
US-08-761-828-25
; Sequence 25; Application US/08761828
; Patent No. 5879925
; GENERAL INFORMATION:
; APPLICANT: ROVINSKI, Benjamin
; APPLICANT: CAO, Shi-Xian
; APPLICANT: YAO, Fei-Long
; APPLICANT: PERSSON, Roy
; APPLICANT: KLEIN, Michel H
; TITLE OF INVENTION: ANTIGENICALLY-MARKED NON-INFECTIONOUS RETROVIRUS-LIKE PARTICLES
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Sim & McBurney
; STREET: 6TH Floor, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
```

```

; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/761,828
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/290,105
; FILING DATE: 15-AUG-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, Michael I
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-655 MIS:jb
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-761-828-25

```

```

Query Match      100.0%; Score 39; DB 2; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1 RAFTTIGK 8
Db      14 RAFTTIGK 21

```

```

RESULT 97
US-08-452-5208-4
; Sequence 4, Application US/084525208
; Patent No. 5912338 5840872
; GENERAL INFORMATION:
; APPLICANT: Rovinski, Benjamin
; APPLICANT: Haynes, Joel
; APPLICANT: Cao, Shi Xian
; APPLICANT: Klein, Michel H
; TITLE OF INVENTION: Retrovirus-Like Particles Containing
; TITLE OF INVENTION: Modified Envelope Glycoproteins
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: 330 University Avenue, 6th Floor
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: PC-DOS/MS-DOS
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/452,5208
; FILING DATE: 30-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/073,526
; FILING DATE: 09-JAN-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Stewart, Michael I
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-446 MIS:as
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163

```

```

; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-452-5208-4

```

```

Query Match      100.0%; Score 39; DB 2; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1 RAFTTIGK 8
Db      14 RAFTTIGK 21

```

```

RESULT 98
US-08-290-105-25
; Sequence 25, Application US/08290105
; Patent No. 5955342
; GENERAL INFORMATION:
; APPLICANT: ROVINSKI, Benjamin
; APPLICANT: CAO, Shi-Xian
; APPLICANT: YAO, Pei-long
; APPLICANT: PERSSON, Roy
; APPLICANT: KLEIN, Michel H
; TITLE OF INVENTION: ANTIGENICALLY-MARKED NON-INFECTIOUS
; TITLE OF INVENTION: RETROVIRUS-LIKE PARTICLES
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/290,105
; FILING DATE: August 15, 1994
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, Michael I
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-385 MIS:jb
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-290-105-25

```

```

Query Match      100.0%; Score 39; DB 2; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1 RAFTTIGK 8
Db      14 RAFTTIGK 21

```

```

RESULT 99
US-08-776-949-25
; Sequence 25, Application US/08776949

```



```
Patent No. 6025125
GENERAL INFORMATION:
APPLICANT: Rovinski, Benjamin
APPLICANT: Cao, Shi-Xian
APPLICANT: Yao, Fei-Long
APPLICANT: Persson, Roy
APPLICANT: Klein, Michel H
TITLE OF INVENTION: ANTIGENICALLY-MARKED NON-INFECTIONOUS
TITLE OF INVENTION: RETROVIRUS-LIKE PARTICLES
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: 6th Floor, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/776,949
FILING DATE: 02-JUN-1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Stewart, Michael I
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-673 MTS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-776-949-25

Query Match      100.0%; Score 39; DB 3; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RAYFTICK 8
      |||||
Db      14 RAYFTICK 21

RESULT 100
US-08-482-810-25
Sequence 25, Application US/08482810
Patent No. 6080408
GENERAL INFORMATION:
APPLICANT: ROVINSKI, Benjamin
APPLICANT: CAO, Shi-Xian
APPLICANT: YAO, Fei-Long
APPLICANT: PERSSON, Roy
APPLICANT: KLEIN, Michel H.
TITLE OF INVENTION: RETROVIRUS-LIKE PARTICLES MADE NON-
TITLE OF INVENTION: INFECTIONOUS BY A PLURALITY OF MUTATIONS
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
```

```
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/482,810
FILING DATE: 07-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/292,967
FILING DATE: 22-AUG-1994
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, Michael I
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-490 MTS:vg
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-482-810-25

Query Match      100.0%; Score 39; DB 3; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RAYFTICK 8
      |||||
Db      14 RAYFTICK 21

RESULT 101
US-09-027-955-25
Sequence 25, Application US/09027955
Patent No. 6291157
GENERAL INFORMATION:
APPLICANT: ROVINSKI, Benjamin
APPLICANT: CAO, Shi-Xian
APPLICANT: YAO, Fei-Long
APPLICANT: PERSSON, Roy
APPLICANT: KLEIN, Michel H
TITLE OF INVENTION: ANTIGENICALLY-MARKED NON-INFECTIONOUS
TITLE OF INVENTION: RETROVIRUS-LIKE PARTICLES
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: 6th Floor, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/027,955
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/290,105
FILING DATE: 15-AUG-1994
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, Michael I
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-798 MTS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
```

INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-027-955-25

Query Match 100.0%; Score 39; DB 3; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
DB 14 RAFTVIGK 21

RESULT 102
US-09-636-805-25

Sequence 25, Application US/09636805
Patent No. 6342228
GENERAL INFORMATION:

APPLICANT: ROVINSKI, Benjamin

CAO, Shi-Xian

YAO, Fei-Long

PERSSON, Roy

KLEIN, Michael H

TITLE OF INVENTION: ANTIGENICALLY-MARKED NON-INFECTIOUS
RETROVIRUS-LIKE PARTICLES

NUMBER OF SEQUENCES: 26

CORRESPONDENCE ADDRESSES:

ADDRESSEE: Sim & McBurney

STREET: 6th Floor, 330 University Avenue

CITY: Toronto

STATE: Ontario

COUNTRY: Canada

ZIP: M5G 1R7

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/636,805

FILING DATE: 10-Aug-2000

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 09/027,955

FILING DATE: 23-FEB-1998

ATTORNEY/AGENT INFORMATION:

NAME: STEWART, Michael I

REGISTRATION NUMBER: 24,973

REFERENCE/DOCKET NUMBER: 1038-1068 MIS:jb

TELECOMMUNICATION INFORMATION:

TELEPHONE: (416) 595-1155

TELEFAX: (416) 595-1163

INFORMATION FOR SEQ ID NO: 25:

SEQUENCE CHARACTERISTICS:

LENGTH: 21 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 25:

Query Match 100.0%; Score 39; DB 3; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
DB 14 RAFTVIGK 21

RESULT 103
US-09-258-128-25

Sequence 25, Application US/09258128

Patent No. 6451322

GENERAL INFORMATION:

APPLICANT: ROVINSKI, Benjamin

CAO, Shi-Xian

YAO, Fei-Long

PERSSON, Roy

KLEIN, Michael H

TITLE OF INVENTION: RETROVIRUS-LIKE PARTICLES MADE NON-
INFECTIOUS BY A PLURALITY OF MUTATIONS

NUMBER OF SEQUENCES: 26

CORRESPONDENCE ADDRESSES:

ADDRESSEE: Sim & McBurney

STREET: 6th Floor, 330 University Avenue

CITY: Toronto

STATE: Ontario

COUNTRY: Canada

ZIP: M5G 1R7

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/258,128

FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/292,967

FILING DATE: 22-AUG-1994

ATTORNEY/AGENT INFORMATION:

NAME: STEWART, Michael I

REGISTRATION NUMBER: 24,973

REFERENCE/DOCKET NUMBER: 1038-924 MIS:jb

TELECOMMUNICATION INFORMATION:

TELEPHONE: (416) 595-1155

TELEFAX: (416) 595-1163

INFORMATION FOR SEQ ID NO: 25:

SEQUENCE CHARACTERISTICS:

LENGTH: 21 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

US-09-258-128-25

Query Match 100.0%; Score 39; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.1;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
DB 14 RAFTVIGK 21

RESULT 104
US-09-635-754-25

Sequence 25, Application US/09635754

Patent No. 6518030

GENERAL INFORMATION:

APPLICANT: ROVINSKI, Benjamin

CAO, Shi-Xian

YAO, Fei-Long

PERSSON, Roy

KLEIN, Michael H

TITLE OF INVENTION: ANTIGENICALLY-MARKED NON-INFECTIOUS
RETROVIRUS-LIKE PARTICLES

NUMBER OF SEQUENCES: 26

CORRESPONDENCE ADDRESSES:

ADDRESSEE: Sim & McBurney

STREET: 6th Floor, 330 University Avenue

CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/635,754
FILING DATE: 10-Aug-2000
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 09/027,955
FILING DATE: 23-FEB-1998
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, Michael I
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-1065 MIS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1153
TELEFAX: (416) 595-1153
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 25:
US-09-635-754-25

Query Match 100.0%; Score 39; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTTICK 8
DB 14 RAFTTICK 21

RESULT 105
US-08-680-525-25
Sequence 25: Application US/08680525
Patent No. 6544327
GENERAL INFORMATION:
APPLICANT: ROVINSKI, Benjamin
APPLICANT: CAO, Shi-Xian
APPLICANT: YAO, Fei-Long
APPLICANT: PERSSON, Roy
APPLICANT: KLEIN, Michel H
TITLE OF INVENTION: RETROVIRUS-LIKE PARTICLES MADE NON-
INFECTIOUS BY A PLURALITY OF MUTATIONS
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/680,525
FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/292,967
FILING DATE: 22-AUG-1994

ATTORNEY/AGENT INFORMATION:
NAME: STEWART, Michael I
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-617 MIS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1153
TELEFAX: (416) 595-1153
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-680-525-25

Query Match 100.0%; Score 39; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTTICK 8
DB 14 RAFTTICK 21

RESULT 106
US-09-636-223-25
Sequence 25: Application US/09636223
Patent No. 6544752
GENERAL INFORMATION:
APPLICANT: ROVINSKI, Benjamin
APPLICANT: CAO, Shi-Xian
APPLICANT: YAO, Fei-Long
APPLICANT: PERSSON, Roy
APPLICANT: KLEIN, Michel H
TITLE OF INVENTION: ANTIGENICALLY-MARKED NON-INFECTIOUS
RETROVIRUS-LIKE PARTICLES
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: 6th Floor, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/636,223
FILING DATE: 29-Dec-2000
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 09/027,955
FILING DATE: 23-FEB-1998
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, Michael I
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-1064 MIS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1153
TELEFAX: (416) 595-1153
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-636-223-25

Query Match 100.0%; Score 39; DB 4; Length 21;

Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVITIG 8
Db 14 RAFVITIG 21

RESULT 107

US-08-125-012-13
; Sequence 13, Application US/08125012
; Patent No. 5593972
; GENERAL INFORMATION:
; APPLICANT: Weiner, David B.
; APPLICANT: Williams, William V.
; APPLICANT: Wang, Bin
; APPLICANT: Coney, Leslie R.
; TITLE OF INVENTION: Genetic Immunization
; NUMBER OF SEQUENCES: 34
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5593972rls
; STREET: One Liberty Place 46th Floor
; CITY: Philadelphia
; STATE: Pennsylvania
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25 mb-MD/JAF
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/125,012
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/029,336
; FILING DATE: 11-MAR-1993
; NAME: Deluca, Mark
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/008,342
; FILING DATE: 26-JAN-1993
; NAME:
; ATTORNEY/AGENT INFORMATION:
; NAME: Deluca, Mark
; REGISTRATION NUMBER: 33,229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3429
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-125-012-13

Qy 1 RAFVITIG 8
Db 15 RAFVITIG 22

Query Match 100.0%; Score 39; DB 1; Length 22;

Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 108
US-08-783-818-13

; Sequence 13, Application US/08783818
; Patent No. 5817637
; GENERAL INFORMATION:
; APPLICANT: Weiner, David B.

APPLICANT: Williams, William V.
APPLICANT: Wang, Bin

APPLICANT: Coney, Leslie R.
TITLE OF INVENTION: Genetic Immunization

NUMBER OF SEQUENCES: 34
CORRESPONDENCE ADDRESS:

ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5817637rls
STREET: One Liberty Place 46th Floor

CITY: Philadelphia
STATE: Pennsylvania

COUNTRY: USA
ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25 mb-MD/JAF

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/783,818

FILING DATE: 13-JAN-1997
CLASSIFICATION: 514

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/125,012

FILING DATE: 21-SEP-1993
APPLICATION NUMBER: 08/029,336

FILING DATE: 11-MAR-1993
CLASSIFICATION: 514

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/008,342

FILING DATE: 26-JAN-1993
CLASSIFICATION: 514

ATTORNEY/AGENT INFORMATION:
NAME: Deluca, Mark

REGISTRATION NUMBER: 33,229
REFERENCE/DOCKET NUMBER: APOL-0013

TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100

TELEFAX: 215-568-3429
INFORMATION FOR SEQ ID NO: 13:

SEQUENCE CHARACTERISTICS:
LENGTH: 22 amino acids

TYPE: amino acid
TOPOLOGY: linear

MOLECULE TYPE: peptide
US-08-783-818-13

Query Match 100.0%; Score 39; DB 2; Length 22;

Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFVITIG 8
Db 15 RAFVITIG 22

RESULT 109

US-08-453-349-13
; Sequence 13, Application US/08453349
; Patent No. 5830876
; GENERAL INFORMATION:
; APPLICANT: Weiner, David B.
; APPLICANT: Williams, William V.
; APPLICANT: Wang, Bin
; TITLE OF INVENTION: Genetic Immunization
; NUMBER OF SEQUENCES: 34
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5830876rls
; STREET: One Liberty Place 46th Floor
; CITY: Philadelphia
; STATE: Pennsylvania
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25 mb-MD/JAF
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/453,349
FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/029,336
FILING DATE: March 11, 1993
APPLICATION NUMBER: 08/008,342
FILING DATE: January 26, 1993
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Deluca, Mark
REGISTRATION NUMBER: 33,229
REFERENCE/DOCKET NUMBER: APOL-0013
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3429
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 22 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-453-349-13

Query Match 100.0%; Score 39; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFYTIK 8
Db 15 RAFYTIK 22

RESULT 110
US-08-345-321-2
Sequence 2, Application US/08345321
Patent No. 5914109
GENERAL INFORMATION:
APPLICANT: ZOLLA-PAZNER, Susan
APPLICANT: GORNY, Miroslav K.
TITLE OF INVENTION: HETEROHYBRIDOMAS PRODUCING HUMAN
TITLE OF INVENTION: MONOCLONAL ANTIBODIES TO HIV-1
NUMBER OF SEQUENCES: 22
CORRESPONDENCE ADDRESS:
ADDRESSEE: Browdy and Nelmark
STREET: 419 Seventh Street, N.W., Suite 300
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/345,321
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/07/872,675
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Browdy, Roger L.
REGISTRATION NUMBER: 25,618
REFERENCE/DOCKET NUMBER: ZOLLA-PAZNER1B
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-628-5197

TELEFAX: 202-737-3528
TELEX: 248633
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 22 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
INDIVIDUAL ISOLATE: I11B
FEATURE:
NAME/KEY: Peptide
LOCATION: 1-22
OTHER INFORMATION: /note= "This sequence corresponds
OTHER INFORMATION: to 303 to 324 of gp120 from the I11B isolate."
US-08-345-321-2

Query Match 100.0%; Score 39; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFYTIK 8
Db 13 RAFYTIK 20

RESULT 111
US-08-979-385B-11
Sequence 11, Application US/08979385B
Patent No. 5981505
GENERAL INFORMATION:
APPLICANT: Weiner, David B.
APPLICANT: Williams, William V.
APPLICANT: Wang, Bin
TITLE OF INVENTION: Compositions and Methods for Delivery of
NUMBER OF SEQUENCES: 52
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5981505r18
STREET: One Liberty Place 46th Floor
CITY: Philadelphia
STATE: Pennsylvania
COUNTRY: USA
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25 mb-MD/JAF
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/979,385B
FILING DATE: 26-NOV-1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/495,684
FILING DATE: 28-SEP-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/00899
FILING DATE: 26-JAN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/125,012
FILING DATE: 21-SEP-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/124,962
FILING DATE: 21-SEP-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/093,235
FILING DATE: 15-JUL-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/029,336
FILING DATE: 11-MAR-1993
PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/008,342
FILING DATE: 26-JAN-1993
ATTORNEY/AGENT INFORMATION:
NAME: Deluca, Mark
REGISTRATION NUMBER: 33,229
REFERENCE/DOCKET NUMBER: UPAP-0253
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3429
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 22 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-979-385B-11

Query Match 100.0%; Score 39; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
DB 15 RAFVTIGK 22

RESULT 112
US-08-537-245-1
Sequence 1, Application US/08537245
Patent No. 5985275
GENERAL INFORMATION:
APPLICANT: Neurath, A. Robert, Debnath, Asim K.,
TITLE OF INVENTION: Proteins and Peptides Modified By
NUMBER OF SEQUENCES: 1
CORRESPONDENCE ADDRESS:
ADDRESSEE: Frischauf, Holtz, Goodman & Woodward
STREET: 600 Third Avenue
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10016
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3+ inch, 0.72 mb storage
COMPUTER: IBM PC
OPERATING SYSTEM: MS DOS
SOFTWARE: ASCII
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/537,245
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/420,573
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Barth, Richard
REGISTRATION NUMBER: 28,180
REFERENCE/DOCKET NUMBER: 950157/RSB
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 972-1400
TELEFAX: (212) 370-1622
TELEX: 236268
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 22 amino acids
TYPE: amino acid
STRANDEDNESS: single stranded
TOPOLOGY: linear
MOLECULE TYPE: cDNA to genomic RNA
US-08-537-245-1

Query Match 100.0%; Score 39; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 0.11;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RAFVTIGK 8
DB 15 RAFVTIGK 22

RESULT 113
US-08-805-889-5
Sequence 5, Application US/08805889
Patent No. 6039957
GENERAL INFORMATION:
APPLICANT: Earl, Patricia L.
APPLICANT: Broder, Christopher C.
TITLE OF INVENTION: Oligomeric HIV-1 Envelope Glycoproteins
NUMBER OF SEQUENCES: 6
CORRESPONDENCE ADDRESS:
ADDRESSEE: Knobbe, Martens, Olson and Bear
STREET: 620 Newport Center Drive 16th Floor
CITY: Newport Beach
STATE: CA
ZIP: 92660
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/805,889
FILING DATE: 03-MAR-1997
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/165,314
FILING DATE: 10-DEC-1993
ATTORNEY/AGENT INFORMATION:
NAME: Fuller, Michael L.
REGISTRATION NUMBER: 36,516
REFERENCE/DOCKET NUMBER: NIH079.001A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-235-8550
TELEFAX: 619-235-0176
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 22 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE: Internal
US-08-805-889-5

Query Match 100.0%; Score 39; DB 3; Length 22;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
DB 15 RAFVTIGK 22

RESULT 114
US-09-070-291-5
Sequence 5, Application US/09070291
Patent No. 6171596
GENERAL INFORMATION:
APPLICANT: Earl, Patricia L.
APPLICANT: Broder, Christopher C.
APPLICANT: Doms, Robert W.
APPLICANT: Moss, Bernard
TITLE OF INVENTION: Oligomeric HIV-1 Envelope Glycoproteins

NUMBER OF SEQUENCES: 10
CORRESPONDENCE ADDRESS:
ADDRESSEE: Knobbe, Martens, Olson and Bear
STREET: 620 Newport Center Drive 16th Floor
CITY: Newport Beach
STATE: CA
ZIP: 92660
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/070,291
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Vensko, Nancy Wags
REGISTRATION NUMBER: 36,298
REFERENCE/DOCKET NUMBER: NIH079.1DVCPI
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-235-8550
TELEFAX: 619-235-0176
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 22 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE: internal
US-09-070-291-5

Query Match 100.0%; Score 39; DB 3; Length 22;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVITIG 8
DB 15 RAFVITIG 22

RESULT 115
US-09-217-306B-22
Sequence 22, Application US/09217306B
Patent No. 6465220
GENERAL INFORMATION:
APPLICANT: Hasean, Helie
APPLICANT: Clausen, Henrik
APPLICANT: Bennett, Eric P.
TITLE OF INVENTION: Glycosylation Using GalNac-T4 Transferase
FILE REFERENCE: 8850*1
CURRENT APPLICATION NUMBER: US/09/217,306B
CURRENT FILING DATE: 1998-12-21
NUMBER OF SEQ ID NOS: 25
SOFTWARE: PatentIn version 3.1
SEQ ID NO 22
LENGTH: 22
TYPE: PRT
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: MISC_FEATURE
OTHER INFORMATION: HIVIIB gp120
US-09-217-306B-22

Query Match 100.0%; Score 39; DB 4; Length 22;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVITIG 8
DB 15 RAFVITIG 22

Db 10 RAFVITIG 17

RESULT 116
US-08-880-576-13
Sequence 13, Application US/08880576
Patent No. 6468982
GENERAL INFORMATION:
APPLICANT: Weiner, David B.
APPLICANT: Williams, William V.
APPLICANT: Wang, Bin
APPLICANT: Coney, Leslie R.
TITLE OF INVENTION: Genetic Immunization
NUMBER OF SEQUENCES: 34
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 6468982-13
STREET: One Liberty Place 46th Floor
CITY: Philadelphia
STATE: Pennsylvania
COUNTRY: USA
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25 mb-MD/JAF
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/880,576
FILING DATE: 23-JUN-1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/125,012
FILING DATE: 21-SEP-1993
APPLICATION NUMBER: 08/029,336
FILING DATE: 11-MAR-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/008,342
FILING DATE: 26-JAN-1993
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: DeLuca, Mark
REGISTRATION NUMBER: 33,229
REFERENCE/DOCKET NUMBER: APOL-0013
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3429
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 22 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-880-576-13

Query Match 100.0%; Score 39; DB 4; Length 22;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVITIG 8
DB 15 RAFVITIG 22

RESULT 117
US-08-097-751-1
Sequence 1, Application US/08097751
Patent No. 5527666
GENERAL INFORMATION:
APPLICANT: DeRosi, Anita
APPLICANT: Pauci, Marcelia
APPLICANT: Mammano, Fabrizio
APPLICANT: Panozzo, Marina
APPLICANT: Dettin, Monica

```

; APPLICANT: Dibello, Carlo
; APPLICANT: Chieco-Bianchi, Luigi
; TITLE OF INVENTION: METHOD FOR THE DIAGNOSIS IN VITRO OF
; TITLE OF INVENTION: HIV-1 VIRUS INFECTIONS
; NUMBER OF SEQUENCES: 2
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hedman, Gibson, Costigan & Hoare
; STREET: 1185 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: DOS
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/097,751
; FILING DATE: 19930723
; CLASSIFICATION: 530
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Costigan, James V.
; REGISTRATION NUMBER: 25, 669
; REFERENCE/DOCKET NUMBER: 515-4026
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 302-8989
; TELEFAX: (212) 302-8998
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 amino acids
; TYPE: amino acid
; TOPOLOGY: circular
; US-08-097-751-1

Query Match      100.0%; Score 39; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy 1 RAFVTTGK 8
Db 15 RAFVTTGK 22

RESULT 118
US-08-090-148-6
; Sequence 6, Application US/08090148
; Patent No. 5534257
; GENERAL INFORMATION:
; APPLICANT: Mastico, Robert Allan
; APPLICANT: Stockley, Peter George
; APPLICANT: Talbot, Simon John
; TITLE OF INVENTION: Antigen-Presenting Capsid with
; TITLE OF INVENTION: Fusion MS2-Coat Protein
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Rosenman & Colin
; STREET: 575 Madison Avenue
; CITY: New York
; STATE: NY
; COUNTRY: U.S.A.
; ZIP: 10022-2585
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5", 1.44Mb
; COMPUTER: IBM PS2-486
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/090,148
; FILING DATE: 08/11/93
```

```

; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9101550.3
; FILING DATE: 01/24/91
; APPLICATION NUMBER: PCT/GB92/00124
; FILING DATE: 01/22/92
; ATTORNEY/AGENT INFORMATION:
; NAME: Nissenbaum, Israel
; REGISTRATION NUMBER: 27,582
; REFERENCE/DOCKET NUMBER:
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 940-6636
; TELEFAX: (212) 940-6404
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 AMINO ACIDS
; TYPE: AMINO ACID
; TOPOLOGY: NOT RELEVANT
; MOLECULE TYPE: PEPTIDE
; US-08-090-148-6

Query Match      100.0%; Score 39; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy 1 RAFVTTGK 8
Db 15 RAFVTTGK 22

RESULT 119
US-08-257-5288-99
; Sequence 99, Application US/082575288
; Patent No. 5638654
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/257,5288
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-336 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 99:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-257-5288-99

Query Match      100.0%; Score 39; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.11;
```


Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTTICK 8
DB 14 RAFTTICK 21

RESULT 120
US-08-460-602A-99
; Sequence 99, Application US/08460602A
; Patent No. 5759769
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: MSG 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/460,602A
; FILING DATE: 02-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/257,528
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/073,378
; FILING DATE: 09-JUN-1993
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 99:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-460-602A-99

Query Match 100.0%; Score 39; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTTICK 8
DB 14 RAFTTICK 21

RESULT 121
US-08-463-966A-99
; Sequence 99, Application US/08463966A
; Patent No. 5795955
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.

TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: MSG 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/463,966A
FILING DATE: 05-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/257,528
FILING DATE: 09-JUN-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/073,378
FILING DATE: 09-JUN-1993
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, MICHAEL I.
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-487 MIS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 99:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-463-966A-99

Query Match 100.0%; Score 39; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTTICK 8
DB 14 RAFTTICK 21

RESULT 122
US-08-465-217A-99
; Sequence 99, Application US/08465217A
; Patent No. 5800822
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: MSG 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/465,217A
FILING DATE: 05-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/257,528
FILING DATE: 09-JUN-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/073,378
FILING DATE: 09-JUN-1993
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, MICHAEL I.
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-486 MIS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 99:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-465-217A-99

Query Match 100.0%; Score 39; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFTYICK 8
Db 14 RAFTYICK 21

RESULT 123
US-08-464-329A-99
Sequence 99, Application US/08464329A
Patent No. 5817754
GENERAL INFORMATION:
APPLICANT: SIA, Charles D.Y.
APPLICANT: CHONG, Pele
APPLICANT: KLEIN, Michel H.
TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/464,329A
FILING DATE: 05-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/257,528
FILING DATE: 09-JUN-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/073,378
FILING DATE: 09-JUN-1993
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, MICHAEL I.
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-449 MIS:jb

TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 99:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-464-329A-99

Query Match 100.0%; Score 39; DB 2; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFTYICK 8
Db 14 RAFTYICK 21

RESULT 124
US-08-493-235-24
Sequence 24, Application US/08493235
Patent No. 5840313
GENERAL INFORMATION:
APPLICANT: Vahine, Anders
APPLICANT: Svennerholm, Bo
APPLICANT: Rymo, Lars
APPLICANT: Jeansson, Stig
APPLICANT: Horal, Peter
TITLE OF INVENTION: PEPTIDES FOR USE IN VACCINATION AND
INDUCTION OF NEUTRALIZING ANTIBODIES AGAINST HUMAN
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: KNOBE, MARTENS, OLSON AND BEAR
STREET: 620 NEWPORT CENTER DRIVE 16TH FLOOR
CITY: NEWPORT BEACH
STATE: CA
COUNTRY: USA
ZIP: 92660
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/493,235
FILING DATE: 20(June)1995
CLASSIFICATION: 530
ATTORNEY/AGENT INFORMATION:
NAME: Kaiser, Annemarie
REGISTRATION NUMBER: 37,649
REFERENCE/DOCKET NUMBER: METRICS.12CPC1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-235-8550
TELEFAX: 619-235-0176
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE: internal
US-08-493-235-24

Query Match 100.0%; Score 39; DB 2; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
OY      1 RAFTYICK 8
      |||||
Db      9 RAFTYICK 16

RESULT 125
US-08-462-507A-99
; Sequence 99, Application US/08462507A
; Patent No. 5876731
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/462,507A
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/257,528
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/073,378
; FILING DATE: 09-JUN-1993
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-451 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1153
; INFORMATION FOR SEQ ID NO: 99:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-462-507A-99

Query Match      100.0%; Score 39; DB 2; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      1 RAFTYICK 8
      |||||
Db      14 RAFTYICK 21

RESULT 126
US-08-146-028-160
; Sequence 160, Application US/08146028
; Patent No. 5891640
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: PROCESS FOR THE DETERMINATION OF PEPTIDES
; CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND THEIR
; TITLE OF INVENTION: IN A PROCESS FOR DETERMINATION OF ANTIBODIES OR BIOTINYLATED
; TITLE OF INVENTION: PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT EPITOPES,
```

```
      TITLE OF INVENTION: PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM
      NUMBER OF SEQUENCES: 453
      COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)
      CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/146,028
      INFORMATION FOR SEQ ID NO: 160:
      SEQUENCE CHARACTERISTICS:
      LENGTH: 24 amino acids
      TYPE: amino acid
      STRANDEDNESS: single
      TOPOLOGY: linear
      MOLECULE TYPE: peptide
US-08-146-028-160

Query Match      100.0%; Score 39; DB 2; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      1 RAFTYICK 8
      |||||
Db      15 RAFTYICK 22

RESULT 127
US-08-467-881A-99
; Sequence 99, Application US/08467881A
; Patent No. 5951986
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/467,881A
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/257,528
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/073,378
; FILING DATE: 09-JUN-1993
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-488 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1153
; INFORMATION FOR SEQ ID NO: 99:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
```

```

; TOPOLOGY: linear
; US-08-467-881A-99
Query Match
Best Local Similarity 100.0%; Score 39; DB 2; Length 24;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVITIGK 8
Db 15 RAFVITIGK 21

RESULT 128
US-08-723-425A-160
; Sequence 160, Application US/08723425A
; Patent No. 6165730
; GENERAL INFORMATION:
; APPLICANT: DELETIS, ROBERT
; TITLE OF INVENTION: PROCESS FOR THE DETERMINATION OF
; TITLE OF INVENTION: PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT
; TITLE OF INVENTION: EPITOPES AND THEIR USE IN A PROCESS FOR DETERMINATION OF
; TITLE OF INVENTION: ANTIBODIES OR BIOTINYLATED PEPTIDES CORRESPONDING ...
; NUMBER OF SEQUENCES: 453
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHAYE, P.C.
; STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
; CITY: Arlington
; STATE: VA
; COUNTRY: USA
; ZIP: 22201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/723,425A
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: SADOFF, B.J.
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 1487-13
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-816-4100
; INFORMATION FOR SEQ ID NO: 160:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-723-425A-160

Query Match
Best Local Similarity 100.0%; Score 39; DB 3; Length 24;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVITIGK 8
Db 15 RAFVITIGK 22

RESULT 129
US-08-480-332-2
; Sequence 2, Application US/08480332
; Patent No. 6180134
; GENERAL INFORMATION:
; APPLICANT: Zalipsky, Samuel, Woodie, Martin, Martin, Francis;
; APPLICANT: Barenholz, Yecheskel
; TITLE OF INVENTION: Enhanced Circulation Effector Composition and
; TITLE OF INVENTION: Method
```

```

; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dehlinger & Associates
; STREET: 350 Cambridge Avenue, Suite 250
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94306
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/480,332
; FILING DATE: 7-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/316,436
; FILING DATE: 29-SEP-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/035,443
; FILING DATE: 23-MAR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Mohr, Judy M.
; REGISTRATION NUMBER: 38,563
; REFERENCE/DOCKET NUMBER: 5325-0115.31
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 324-0880
; TELEFAX: (415) 324-0960
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 amino acids
; TYPE: amino acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
; HYPOTHEICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; INDIVIDUAL ISOLATE: Peptide 2, Fig. 13
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..15
; US-08-480-332-2

Query Match
Best Local Similarity 100.0%; Score 39; DB 3; Length 24;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVITIGK 8
Db 15 RAFVITIGK 22

RESULT 130
US-09-112-206-160
; Sequence 160, Application US/09112206
; Patent No. 6210903
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: PROCESS FOR THE DETERMINATION OF PEPTIDES
; TITLE OF INVENTION: CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND THEIR
; TITLE OF INVENTION: IN A PROCESS FOR DETERMINATION OF ANTIBODIES OR BIOTINYLATED
; TITLE OF INVENTION: PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT EPITOPES,
; TITLE OF INVENTION: PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM
; NUMBER OF SEQUENCES: 453
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
```

APPLICATION NUMBER: US/09/112,206
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/146,028
FILING DATE:
INFORMATION FOR SEQ ID NO: 160:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-09-112-206-160

Query Match 100.0%; Score 39; DB 3; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFTYICK 8
Db 15 RAFTYICK 22

RESULT 131

US-09-790-497A-14
Sequence 14, Application US/09790497A
Patent No. 6649735
GENERAL INFORMATION:
APPLICANT: De Leys, Robert
TITLE OF INVENTION: PROCESS FOR THE DETERMINATION OF PEPTIDES CORRESPONDING
TITLE OF INVENTION: TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND THEIR USE IN
TITLE OF INVENTION: A PROCESS FOR DETERMINATION OF ANTIBODIES OF
TITLE OF INVENTION: BIOTINYLATED PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT
TITLE OF INVENTION: EPITOPES, A PROCESS FOR PREPARING THEM AND COMPOSITIONS
FILE REFERENCE: 2752-16
CURRENT APPLICATION NUMBER: US/09/790,497A
CURRENT FILING DATE: 2001-02-23
PRIOR APPLICATION NUMBER: 09/576,824
PRIOR FILING DATE: 2000-05-23
PRIOR APPLICATION NUMBER: 08/723,425
PRIOR FILING DATE: 1996-09-30
PRIOR APPLICATION NUMBER: 09/146,028
PRIOR FILING DATE: 1993-11-22
PRIOR APPLICATION NUMBER: PCT/EP93/00517
PRIOR FILING DATE: 1993-03-08
PRIOR APPLICATION NUMBER: EP 92400598.6
PRIOR FILING DATE: 1992-03-06
NUMBER OF SEQ ID NOS: 600
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 14
LENGTH: 24
TYPE: PRT
ORGANISM: Human immunodeficiency virus
US-09-790-497A-14

Query Match 100.0%; Score 39; DB 4; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFTYICK 8
Db 15 RAFTYICK 22

RESULT 132

US-09-790-497A-160
Sequence 160, Application US/09790497A
Patent No. 6649735
GENERAL INFORMATION:
APPLICANT: De Leys, Robert
TITLE OF INVENTION: PROCESS FOR THE DETERMINATION OF PEPTIDES CORRESPONDING
TITLE OF INVENTION: TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND THEIR USE IN

TITLE OF INVENTION: A PROCESS FOR DETERMINATION OF ANTIBODIES OF
TITLE OF INVENTION: BIOTINYLATED PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT
TITLE OF INVENTION: EPITOPES, A PROCESS FOR PREPARING THEM AND COMPOSITIONS
TITLE OF INVENTION: CONTAINING THEM
FILE REFERENCE: 2752-16
CURRENT APPLICATION NUMBER: US/09/790,497A
CURRENT FILING DATE: 2001-02-23
PRIOR APPLICATION NUMBER: 09/576,824
PRIOR FILING DATE: 2000-05-23
PRIOR APPLICATION NUMBER: 08/723,425
PRIOR FILING DATE: 1996-09-30
PRIOR APPLICATION NUMBER: 09/146,028
PRIOR FILING DATE: 1993-11-22
PRIOR APPLICATION NUMBER: PCT/EP93/00517
PRIOR FILING DATE: 1993-03-08
PRIOR APPLICATION NUMBER: EP 92400598.6
PRIOR FILING DATE: 1992-03-06
NUMBER OF SEQ ID NOS: 600
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 160
LENGTH: 24
TYPE: PRT
ORGANISM: Human immunodeficiency virus
US-09-790-497A-160

Query Match 100.0%; Score 39; DB 4; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFTYICK 8
Db 15 RAFTYICK 22

RESULT 133

US-09-576-824A-160
Sequence 160, Application US/09576824A
Patent No. 6667387
GENERAL INFORMATION:
APPLICANT: De Leys, Robert
TITLE OF INVENTION: PROCESS FOR THE DETERMINATION OF PEPTIDES CORRESPONDING
TITLE OF INVENTION: TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND THEIR USE IN
TITLE OF INVENTION: A PROCESS FOR DETERMINATION OF ANTIBODIES OF
TITLE OF INVENTION: BIOTINYLATED PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT
TITLE OF INVENTION: EPITOPES, A PROCESS FOR PREPARING THEM AND COMPOSITIONS
FILE REFERENCE: 2752-11
CURRENT APPLICATION NUMBER: US/09/576,824A
CURRENT FILING DATE: 2000-05-23
PRIOR APPLICATION NUMBER: 08/723,425
PRIOR FILING DATE: 1996-09-30
PRIOR APPLICATION NUMBER: 09/146,028
PRIOR FILING DATE: 1993-11-22
PRIOR APPLICATION NUMBER: PCT/EP93/00517
PRIOR FILING DATE: 1993-03-08
PRIOR APPLICATION NUMBER: EP 92400598.6
PRIOR FILING DATE: 1992-03-06
NUMBER OF SEQ ID NOS: 600
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 160
LENGTH: 24
TYPE: PRT
ORGANISM: Human immunodeficiency virus
US-09-576-824A-160

Query Match 100.0%; Score 39; DB 4; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFTYICK 8
Db 15 RAFTYICK 22

RESULT 134
US-09-680-497-160
Sequence 160, Application US/09680497
Patent No. 6709828
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: PROCESS FOR THE DETERMINATION OF PEPTIDES
TITLE OF INVENTION: CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND THEIR
TITLE OF INVENTION: IN A PROCESS FOR DETERMINATION OF ANTIBODIES OR BIOTINYLATED
TITLE OF INVENTION: PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT EPITOPES,
NUMBER OF SEQUENCES: 453
PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/680,497
FILING DATE: 06-OCT-2000
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/146,028
FILING DATE: 22-NOV-1993
INFORMATION FOR SEQ ID NO: 160:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-09-680-497-160

Query Match 100.0%; Score 39; DB 4; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTTIGK 8
DB 15 RAFTTIGK 22

RESULT 135
PCT-US92-06688-12
Sequence 12, Application PC/TUS9206688
GENERAL INFORMATION:
APPLICANT: REPLIGEN CORPORATION
APPLICANT: THE ROCKEFELLER UNIVERSITY
TITLE OF INVENTION: MULTIPLE ANTIGEN PEPTIDES FOR USE AS HIV
TITLE OF INVENTION: VACCINES
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESSES:
ADDRESSER: Fish & Richardson
STREET: 225 Franklin Street
CITY: Boston
STATE: Massachusetts
COUNTRY: U.S.A.
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM PS/2 Model 502 or 55SX
OPERATING SYSTEM: IBM P.C. DOS (Version 3.30)
SOFTWARE: WordPerfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/06688
FILING DATE: 19920811
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 744,281
FILING DATE: 13 August 1992
ATTORNEY/AGENT INFORMATION:
NAME: Paul T. Clark
REGISTRATION NUMBER: 30,162

REFERENCE/DOCKET NUMBER: 00231/052W01
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 542-5070
TELEFAX: (617) 542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 24
TYPE: AMINO ACID
TOPOLOGY: linear
PCT-US92-06688-12

Query Match 100.0%; Score 39; DB 5; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTTIGK 8
DB 15 RAFTTIGK 22

RESULT 136
PCT-US92-10378-3
Sequence 3, Application PC/TUS9210378
GENERAL INFORMATION:
APPLICANT: BOARD OF REGENTS, THE UNIVERSITY OF
APPLICANT: TEXAS SYSTEM
APPLICANT: SASTRY, Jagannadha K.
APPLICANT: ARLINGHAUS, Ralph B.
APPLICANT: PLATSOUCAS, Chris D.
APPLICANT: NEHESTE, Pramod N.
TITLE OF INVENTION: METHODS AND COMPOSITIONS
TITLE OF INVENTION: FOR ELICITING IMMUNE OR ANTI-INFECTION RESPONSES
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESSES:
ADDRESSER: Arnold, White & Durkee
STREET: P.O. Box 4433
CITY: Houston
STATE: Texas
COUNTRY: US
ZIP: 77210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/10378
FILING DATE: 19921202
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/800,932
FILING DATE: December 2, 1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/945865
FILING DATE: September 16, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Parker, David L.
REGISTRATION NUMBER: 32,165
REFERENCE/DOCKET NUMBER: UFP0305PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 512-320-7200
TELEFAX: 512-474-7577
TELEX: Not Applicable
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 amino acids
TYPE: AMINO ACID
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
PCT-US92-10378-3

Query Match 100.0%; Score 39; DB 5; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.11;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTYICK 8
15 RAFTYICK 22

RESULT 137

US-07-950-571A-1
; Sequence 1, Application US/07950571A
; Patent No. 5854400
; GENERAL INFORMATION:
; APPLICANT: Chang, Tse Wen, Fung, Michael S.C., Sun, Bill N.C., Sun, Cecily R.Y.
; TITLE OF INVENTION: Monoclonal Antibodies which Neutralize HIV-1 Infection
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Tanox Biotechnology, Inc.
; STREET: 10301 Stella Link Rd.
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" 5 1/4 Density Diskette
; OPERATING SYSTEM: DOS, Version 3.30
; SOFTWARE: Wordperfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/950,571A
; FILING DATE: 19920922
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: No. 5854400 07/767,533
; FILING DATE: 09/26/1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Mirabel, Eric P.
; REGISTRATION NUMBER: 31,211
; REFERENCE/DOCKET NUMBER: TXN87-11BBC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713-664-2288
; TELEFAX: 713-664-8914
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 amino acids
; TYPE: AMINO ACID
; TOPOLOGY: Linear
; US-07-950-571A-1

Query Match 100.0%; Score 39; DB 2; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTYICK 8
18 RAFTYICK 25

RESULT 138

US-08-266-448-1
; Sequence 1, Application US/08266448
; Patent No. 5876724
; GENERAL INFORMATION:
; APPLICANT: GIRARD, Marc
; TITLE OF INVENTION: INDUCTION OF PROTECTION AGAINST VIRAL
; TITLE OF INVENTION: INFECTION BY SYNERGY BETWEEN VIRUS ENVELOPE GLYCOPROTEIN
; AND PEPTIDES CORRESPONDING TO NEUTRALIZATION EPITOPES OF
; THE GLYCOPROTEIN
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FINNEGAN, HENDERSON, FARABOW, GARRETT &

ADDRESSEE: DUNNER, L.L.P.
STREET: 1300 I Street, N.W.
CITY: Washington
STATE: D.C.

COUNTRY: U.S.A.

ZIP: 20005

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/266,448

FILING DATE: 28-JUN-1994

CLASSIFICATION: 424

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/145,664

FILING DATE: 04-NOV-1993

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/782,241

FILING DATE: 28-OCT-1991

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/672,647

FILING DATE: 18-MAR-1991

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/494,749

FILING DATE: 19-MAR-1990

ATTORNEY/AGENT INFORMATION:

NAME: Meyers, Kenneth J.

REGISTRATION NUMBER: 25,146

REFERENCE/DOCKET NUMBER: 03495.0088-13

TELECOMMUNICATION INFORMATION:

TELEPHONE: (202) 408-4132

TELEFAX: (202) 408-4400

INFORMATION FOR SEQ ID NO: 1:

SEQUENCE CHARACTERISTICS:

LENGTH: 25 amino acids

TYPE: amino acid

STRANDEDNESS:

TOPOLOGY: not relevant

MOLECULE TYPE: peptide

US-08-266-448-1

Query Match 100.0%; Score 39; DB 2; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTYICK 8
15 RAFTYICK 22

RESULT 139

US-08-485-324-13
; Sequence 13, Application US/08485324
; Patent No. 6043093
; GENERAL INFORMATION:
; APPLICANT: Mohlstadter, Jacob
; TITLE OF INVENTION: SELECTION METHODS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris, & Safford
; STREET: c/o Barry Evans
; STREET: 530 Fifth Avenue
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25

```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/485,324
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/235,437
; FILING DATE: 29-APR-1994
; APPLICATION NUMBER: US 07/852,412
; FILING DATE: 16-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Evans, Barry
; REGISTRATION NUMBER: 22,802
; REFERENCE/DOCKET NUMBER: 370132-2000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-485-324-13

```

```

Query Match      100.0%; Score 39; DB 3; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1 RAFTTIGK 8
        |||||
        15 RAFTTIGK 22

```

```

RESULT 140
US-08-485-324-31
; Sequence 31, Application US/08485324
; Patent No. 6043093
;
GENERAL INFORMATION:
; APPLICANT: Mohlstadter, Jacob
; TITLE OF INVENTION: SELECTION METHODS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris, & Safford
; ADDRESSER: c/o Barry Evans
; STREET: 530 Fifth Avenue
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
;
COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
;
CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/485,324
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/235,437
; FILING DATE: 29-APR-1994
; APPLICATION NUMBER: US 07/852,412
; FILING DATE: 16-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Evans, Barry
; REGISTRATION NUMBER: 22,802
; REFERENCE/DOCKET NUMBER: 370132-2000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 amino acids

```

```

; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-485-324-31

```

```

Query Match      100.0%; Score 39; DB 3; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1 RAFTTIGK 8
        |||||
        15 RAFTTIGK 22

```

```

RESULT 141
US-08-447-506-13
; Sequence 13, Application US/08447506
; Patent No. 6066499
;
GENERAL INFORMATION:
; APPLICANT: Mohlstadter, Jacob
; TITLE OF INVENTION: SELECTION METHODS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris, & Safford
; ADDRESSER: c/o Barry Evans
; STREET: 530 Fifth Avenue
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
;
COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
;
CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/447,506
; FILING DATE: 23-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/235,437
; FILING DATE: 29-APR-1994
; APPLICATION NUMBER: US 07/852,412
; FILING DATE: 16-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Evans, Barry
; REGISTRATION NUMBER: 22,802
; REFERENCE/DOCKET NUMBER: 370132-2000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-447-506-13

```

```

Query Match      100.0%; Score 39; DB 3; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1 RAFTTIGK 8
        |||||
        15 RAFTTIGK 22

```

```

RESULT 142
US-08-447-506-31
; Sequence 31, Application US/08447506
; Patent No. 6066499
;
GENERAL INFORMATION:

```



```

: APPLICANT: Mohlstadter, Jacob
: TITLE OF INVENTION: SELECTION METHODS
: NUMBER OF SEQUENCES: 31
: CORRESPONDENCE ADDRESSES:
: ADDRESSSEE: Curtis, Morris, & Safford
: ADDRESSSEE: C/O Barry Evans
: STREET: 530 Fifth Avenue
: CITY: New York
: STATE: New York
: COUNTRY: USA
: ZIP: 10036
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: Patentin Release #1.0, Version #1.25
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/447,506
: FILING DATE: 23-MAY-1995
: CLASSIFICATION: 435
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: US 08/235,437
: FILING DATE: 29-APR-1994
: APPLICATION NUMBER: US 07/852,412
: FILING DATE: 16-MAR-1992
: ATTORNEY/AGENT INFORMATION:
: NAME: Evans, Barry
: REGISTRATION NUMBER: 22,802
: REFERENCE/DOCKET NUMBER: 370132-2000
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (212) 840-3333
: TELEFAX: (212) 840-0712
: INFORMATION FOR SEQ ID NO: 31:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 25 amino acids
: TYPE: amino acid
: STRANDEDNESS: single
: TOPOLOGY: linear
:
: US-08-447-506-31
:
Query Match      100.0%; Score 39; DB 3; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RAFTICK 8
Db      15 RAFTICK 22

RESULT 143
: US-08-235-437-13
: Sequence 13, Application US/08235437
: Patent No. 6087177
: GENERAL INFORMATION:
: APPLICANT: Mohlstadter, Jacob
: TITLE OF INVENTION: SELECTION METHODS
: NUMBER OF SEQUENCES: 31
: CORRESPONDENCE ADDRESSES:
: ADDRESSSEE: Curtis, Morris, & Safford
: ADDRESSSEE: C/O Barry Evans
: STREET: 530 Fifth Avenue
: CITY: New York
: STATE: New York
: COUNTRY: USA
: ZIP: 10036
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: Patentin Release #1.0, Version #1.25
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/235,437
: FILING DATE: 29-APR-1994
```

```

: CLASSIFICATION: 435
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: US 07/852,412
: FILING DATE: 16-MAR-1992
: ATTORNEY/AGENT INFORMATION:
: NAME: Evans, Barry
: REGISTRATION NUMBER: 22,802
: REFERENCE/DOCKET NUMBER: 370132-2000
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (212) 840-3333
: TELEFAX: (212) 840-0712
: INFORMATION FOR SEQ ID NO: 13:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 25 amino acids
: TYPE: amino acid
: STRANDEDNESS: single
: TOPOLOGY: linear
:
: US-08-235-437-13
:
Query Match      100.0%; Score 39; DB 3; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RAFTICK 8
Db      15 RAFTICK 22

RESULT 144
: US-08-235-437-31
: Sequence 31, Application US/08235437
: Patent No. 6087177
: GENERAL INFORMATION:
: APPLICANT: Mohlstadter, Jacob
: TITLE OF INVENTION: SELECTION METHODS
: NUMBER OF SEQUENCES: 31
: CORRESPONDENCE ADDRESSES:
: ADDRESSSEE: Curtis, Morris, & Safford
: ADDRESSSEE: C/O Barry Evans
: STREET: 530 Fifth Avenue
: CITY: New York
: STATE: New York
: COUNTRY: USA
: ZIP: 10036
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: Patentin Release #1.0, Version #1.25
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/235,437
: FILING DATE: 29-APR-1994
: CLASSIFICATION: 435
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: US 07/852,412
: FILING DATE: 16-MAR-1992
: ATTORNEY/AGENT INFORMATION:
: NAME: Evans, Barry
: REGISTRATION NUMBER: 22,802
: REFERENCE/DOCKET NUMBER: 370132-2000
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (212) 840-3333
: TELEFAX: (212) 840-0712
: INFORMATION FOR SEQ ID NO: 31:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 25 amino acids
: TYPE: amino acid
: STRANDEDNESS: single
: TOPOLOGY: linear
:
: US-08-235-437-31
:
Query Match      100.0%; Score 39; DB 3; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.12;
```

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RAFVTTICK 8
DB 15 RAFVTTICK 22

RESULT 145

US-08-447-515-13
; Sequence 13, Application US/08447515
; Patent No. 6162640
; GENERAL INFORMATION:
; APPLICANT: Mohlstadter, Jacob
; TITLE OF INVENTION: SELECTION METHODS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris, & Safford
; ADDRESSEE: c/o Barry Evans
; STREET: 530 Fifth Avenue
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/447,515
; FILING DATE: 23-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/235,437
; FILING DATE: 29-APR-1994
; APPLICATION NUMBER: US 07/852,412
; FILING DATE: 16-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Evans, Barry
; REGISTRATION NUMBER: 22,802
; REFERENCE/DOCKET NUMBER: 370132-2000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-447-515-13

Query Match 100.0%; Score 39; DB 3; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTTICK 8
DB 15 RAFVTTICK 22

RESULT 146
US-08-447-515-31
; Sequence 31, Application US/08447515
; Patent No. 6162640

; GENERAL INFORMATION:
; APPLICANT: Mohlstadter, Jacob
; TITLE OF INVENTION: SELECTION METHODS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris, & Safford
; ADDRESSEE: c/o Barry Evans
; STREET: 530 Fifth Avenue

CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10036

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/447,515
; FILING DATE: 23-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/235,437
; FILING DATE: 29-APR-1994
; APPLICATION NUMBER: US 07/852,412
; FILING DATE: 16-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Evans, Barry
; REGISTRATION NUMBER: 22,802
; REFERENCE/DOCKET NUMBER: 370132-2000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-447-515-31

Query Match 100.0%; Score 39; DB 3; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTTICK 8
DB 15 RAFVTTICK 22

RESULT 147
US-09-593-870A-31
; Sequence 31, Application US/09593870A
; Patent No. 6548643

; GENERAL INFORMATION:
; APPLICANT: McKenzie, Ian F. C.
; APPLICANT: Apostolopoulos, Vassio
; APPLICANT: Pietersz, Geoff Allan
; TITLE OF INVENTION: Antigen Carbohydrate Compounds and Their
; FILE REFERENCE: 2368-McKenzie
; CURRENT APPLICATION NUMBER: US/09/593,870A
; CURRENT FILING DATE: 2000-06-14
; PRIOR APPLICATION NUMBER: 09/223,043
; PRIOR FILING DATE: 1998-12-30
; NUMBER OF SEQ ID NOS: 69
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 31
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-593-870A-31

Query Match 100.0%; Score 39; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTTICK 8
DB 12 RAFVTTICK 19

RESULT 148
US-08-455-625-17
Sequence 17, Application US/08455625
Patent No. 5932218
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. D.
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolaasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,625
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..15
OTHER INFORMATION: /label= peptide
OTHER INFORMATION: /note= "p18-9, see Table V"
US-08-455-625-17
Query Match 89.7%; Score 35; DB 2; Length 15;
Best Local Similarity 87.5%; Pred. No. 0.51;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolaasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,625
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..15
OTHER INFORMATION: /label= peptide
OTHER INFORMATION: /note= "p18-15, see Table V"
US-08-455-625-23
Query Match 89.7%; Score 35; DB 2; Length 15;
Best Local Similarity 87.5%; Pred. No. 0.51;
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

RESULT 150
US-08-455-685-17
Sequence 17, Application US/08455685
Patent No. 6214347
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 40
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA

COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,685
FILING DATE: 31-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/060,988
FILING DATE: 14-MAY-1993
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022003
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-455-685-17

Query Match 89.7%; Score 35; DB 3; Length 15;
Best Local Similarity 87.5%; Pred. No. 0.51;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RAFTTICK 8
Db 8 RAVFTICK 15

RESULT 151
US-08-455-685-23
Sequence 23, Application US/08455685
Patent No. 6214347
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
NUMBER OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 40
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,685
FILING DATE: 31-MAY-1995

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/060,988
FILING DATE: 14-MAY-1993
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022003
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-455-685-23

Query Match 89.7%; Score 35; DB 3; Length 15;
Best Local Similarity 87.5%; Pred. No. 0.51;
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFTTICK 8
Db 8 RAVFTICK 15

RESULT 152
US-08-060-988A-17
Sequence 17, Application US/08060988A
Patent No. 6294322
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
TITLE OF INVENTION: THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
NUMBER OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/060,988A
FILING DATE: 14-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.

REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022001
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-060-988A-17

Query Match 89.7%; Score 35; DB 3; Length 15;
Best Local Similarity 87.5%; Pred. No. 0.51;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 RAFVTTICK 8
| | | | |
| | | | |
Db 8 RVFVTTICK 15

RESULT 153
US-08-060-988A-23
Sequence 23, Application US/08060988A
Patent No. 6294322
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
TITLE OF INVENTION: THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE
TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: Fastseq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/060,988A
FILING DATE: 14-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022001
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear

MOLECULE TYPE: peptide
US-08-060-988A-23

Query Match 89.7%; Score 35; DB 3; Length 15;
Best Local Similarity 87.5%; Pred. No. 0.51;
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFVTTICK 8
| | | | |
| | | | |
Db 8 RVFVTTICK 15

RESULT 154
PCT-US94-05142-17
Sequence 17, Application PC/TUS9405142
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/05142
CLASSIFICATION:
FILING DATE: 13-MAY-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..15
OTHER INFORMATION: /label=peptide
OTHER INFORMATION: /note="p18-9, see Table v"
PCT-US94-05142-17

Query Match 89.7%; Score 35; DB 5; Length 15;
Best Local Similarity 87.5%; Pred. No. 0.51;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 RAFVTTICK 8
| | | | |
| | | | |
Db 8 RVFVTTICK 15

RESULT 155
PCT-US94-05142-23
Sequence 23, Application PC/TUS9405142

GENERAL INFORMATION:
APPLICANT: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
TITLE OF INVENTION: LIMPHOCYTES AGAINST HIV
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/05142
FILING DATE: 13-MAY-1994
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..15
OTHER INFORMATION: /label= peptide
PCT-US94-05142-23

Query Match 89.7%; Score 35; DB 5; Length 15;
Best Local Similarity 87.5%; Pred. No. 0.51;
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTTIGK 8
DB 8 RAFTTIGQ 15

RESULT 156
US-08-279-906A-19
Sequence 19, Application US/08279906A
Patent No. 5618922
GENERAL INFORMATION:
APPLICANT: Ohno, Tsuneya
APPLICANT: Terada, Masaki
APPLICANT: Yoneda, Yukio
TITLE OF INVENTION: NM03 Antibody Materials and Methods
NUMBER OF SEQUENCES: 27
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
STREET: Borun
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/279,906A
FILING DATE:
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: No. 5618922and, Greta E.
REGISTRATION NUMBER: 35,302
REFERENCE/DOCKET NUMBER: 32028
TELECOMMUNICATION INFORMATION:
TELEPHONE: (312) 474-6300
TELEFAX: (312) 474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-279-906A-19

Query Match 89.7%; Score 35; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 0.65;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RAFTTIGK 8
DB 6 RFTVITIGK 13

RESULT 157
US-08-704-170-51
Sequence 51, Application US/08704170
Patent No. 5707626
GENERAL INFORMATION:
APPLICANT: Douvas, Angelina
APPLICANT: Entesman, Glenn
APPLICANT: Takehana, Yoshi
TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR
TITLE OF INVENTION: IMMUNOINFECTION CLUSTER VIRUS INFECTIONS
NUMBER OF SEQUENCES: 121
CORRESPONDENCE ADDRESS:
ADDRESSEE: Robbins, Berliner & Carson
STREET: 201 No. 5707626th Figueroa Street, Suite 500
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90012
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/704,170
FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/029,850
FILING DATE: 11-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Spittals, John P.
REGISTRATION NUMBER: 29,215
REFERENCE/DOCKET NUMBER: 1920-331
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 977-1001
TELEFAX: (213) 977-1003
INFORMATION FOR SEQ ID NO: 51:
SEQUENCE CHARACTERISTICS:

LENGTH: 8 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-704-170-51

Query Match 87.2%; Score 34; DB 1; Length 8;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTTIG 7
Db 2 RAFTTIG 8

RESULT 158
PCT-US94-02631-51
Sequence 51, Application PC/TUS9402631
GENERAL INFORMATION:
APPLICANT: Douvas, Angelina
APPLICANT: Takehana, Yoshi
APPLICANT: Ehresmann, Glenn
TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR
NUMBER OF SEQUENCES: 121
CORRESPONDENCE ADDRESS:
ADDRESSEE: Robbins, Berliner & Carson
STREET: 201 North Figueroa Street, Suite 500
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90012
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/02631
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/029,850
FILING DATE: 11-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Spitals, John P.
REGISTRATION NUMBER: 29,215
REFERENCE/DOCKET NUMBER: 1920-331
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 977-1001
TELEFAX: (213) 977-1003
INFORMATION FOR SEQ ID NO: 51:
SEQUENCE CHARACTERISTICS:
LENGTH: 8 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
PCT-US94-02631-51

Query Match 87.2%; Score 34; DB 5; Length 8;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTTIG 7
Db 2 RAFTTIG 8

RESULT 159
PCT-US95-03236-25
Sequence 25, Application PC/TUS9503236
GENERAL INFORMATION:
APPLICANT: University of Southern California

TITLE OF INVENTION: Methods to Diagnose and Treat HIV-1
TITLE OF INVENTION: Infection
NUMBER OF SEQUENCES: 66
CORRESPONDENCE ADDRESS:
ADDRESSEE: Campbell and Flores
STREET: 4370 La Jolla Village Drive, Suite 700
CITY: San Diego
STATE: California
COUNTRY: USA
ZIP: 92122
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/03236
FILING DATE: 13-MAR-1995
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Imbra, Richard J.
REGISTRATION NUMBER: 37,643
REFERENCE/DOCKET NUMBER: FP-SI 1394
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 535-9001
TELEFAX: (619) 535-8949
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 8 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
PCT-US95-03236-25

Query Match 87.2%; Score 34; DB 5; Length 8;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTTIG 7
Db 2 RAFTTIG 8

RESULT 160
US-08-704-170-38
Sequence 38, Application US/08704170
Patent No. 5707626
GENERAL INFORMATION:
APPLICANT: Douvas, Angelina
APPLICANT: Takehana, Yoshi
APPLICANT: Ehresmann, Glenn
TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR
NUMBER OF SEQUENCES: 121
CORRESPONDENCE ADDRESS:
ADDRESSEE: Robbins, Berliner & Carson
STREET: 201 No. 5707626th Figueroa Street, Suite 500
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90012
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/704,170
FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/029,850
FILING DATE: 11-MAR-1993

ATTORNEY/AGENT INFORMATION:
NAME: Spitals, John P.
REGISTRATION NUMBER: 29,215
REFERENCE/DOCKET NUMBER: 1920-331.
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 977-1001
TELEFAX: (213) 977-1003
INFORMATION FOR SEQ ID NO: 38:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-704-170-38

Query Match 87.2%; Score 34; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFVITIG 7
|||
Db 3 RAFVITIG 9

RESULT 161
PCT-US94-02631-38
Sequence 38, Application PC/TUS9402631
GENERAL INFORMATION:
APPLICANT: Douvas, Angelina
APPLICANT: Takehana, Yoshi
APPLICANT: Ehresmann, Glenn
TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR
TITLE OF INVENTION: IMMUNOINFECTIVE CLUSTER VIRUS INFECTIONS
NUMBER OF SEQUENCES: 121
CORRESPONDENCE ADDRESS:
ADDRESSEE: Robbins, Berliner & Carson
STREET: 201 North Figueroa Street, Suite 500
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90012
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/02631
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US-08/029,850
FILING DATE: 11-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Spitals, John P.
REGISTRATION NUMBER: 29,215
REFERENCE/DOCKET NUMBER: 1920-331
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 977-1001
TELEFAX: (213) 977-1003
INFORMATION FOR SEQ ID NO: 38:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
PCT-US94-02631-38

Query Match 87.2%; Score 34; DB 5; Length 9;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFVITIG 7

Db 3 RAFVITIG 9
|||
|||

RESULT 162
US-08-704-170-71
Sequence 71, Application US/08704170
Patent No. 5707626
GENERAL INFORMATION:
APPLICANT: Douvas, Angelina
APPLICANT: Takehana, Yoshi
APPLICANT: Ehresmann, Glenn
TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR
TITLE OF INVENTION: IMMUNOINFECTIVE CLUSTER VIRUS INFECTIONS
NUMBER OF SEQUENCES: 121
CORRESPONDENCE ADDRESS:
ADDRESSEE: Robbins, Berliner & Carson
STREET: 201 No. 5707626th Figueroa Street, Suite 500
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90012
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/704,170
FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/029,850
FILING DATE: 11-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Spitals, John P.
REGISTRATION NUMBER: 29,215
REFERENCE/DOCKET NUMBER: 1920-331
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 977-1001
TELEFAX: (213) 977-1003
INFORMATION FOR SEQ ID NO: 71:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-704-170-71

Query Match 87.2%; Score 34; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.56;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RAFVITIG 7
|||
Db 4 RAFVITIG 10

RESULT 163
PCT-US94-02631-71
Sequence 71, Application PC/TUS9402631
GENERAL INFORMATION:
APPLICANT: Douvas, Angelina
APPLICANT: Takehana, Yoshi
APPLICANT: Ehresmann, Glenn
TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR
TITLE OF INVENTION: IMMUNOINFECTIVE CLUSTER VIRUS INFECTIONS
NUMBER OF SEQUENCES: 121
CORRESPONDENCE ADDRESS:
ADDRESSEE: Robbins, Berliner & Carson
STREET: 201 North Figueroa Street, Suite 500
CITY: Los Angeles
STATE: California

COUNTRY: U.S.A.
ZIP: 90012
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/02631
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/029,850
FILING DATE: 11-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Spitalis, John P.
REGISTRATION NUMBER: 29,215
REFERENCE/DOCKET NUMBER: 1920-331
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 977-1001
TELEFAX: (213) 977-1003
INFORMATION FOR SEQ ID NO: 71:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
PCT-US94-02631-71

Query Match 87.2%; Score 34; DB 5; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.56;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RAVFTIG 7
DB 4 RAVFTIG 10

RESULT 164
US-08-704-170-73
Sequence 73, Application US/08704170
Patent No. 5707626
GENERAL INFORMATION:
APPLICANT: Douvas, Angelina
APPLICANT: Takehana, Yoshi
APPLICANT: Ehresmann, Glenn
TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR
NUMBER OF SEQUENCES: 121
CORRESPONDENCE ADDRESS:
ADDRESSEE: Robbins, Berliner & Carson
STREET: 201 No. 5707626th Figueroa Street, Suite 500
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90012
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/704,170
FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/029,850
FILING DATE: 11-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Spitalis, John P.
REGISTRATION NUMBER: 29,215
REFERENCE/DOCKET NUMBER: 1920-331
TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 977-1001
TELEFAX: (213) 977-1003
INFORMATION FOR SEQ ID NO: 73:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-704-170-74

Query Match 87.2%; Score 34; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.62;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RAVFTIG 7
DB 5 RAVFTIG 11

RESULT 165
US-08-704-170-74
Sequence 74, Application US/08704170
Patent No. 5707626
GENERAL INFORMATION:
APPLICANT: Douvas, Angelina
APPLICANT: Takehana, Yoshi
APPLICANT: Ehresmann, Glenn
TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR
NUMBER OF SEQUENCES: 121
CORRESPONDENCE ADDRESS:
ADDRESSEE: Robbins, Berliner & Carson
STREET: 201 No. 5707626th Figueroa Street, Suite 500
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90012
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/704,170
FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/029,850
FILING DATE: 11-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Spitalis, John P.
REGISTRATION NUMBER: 29,215
REFERENCE/DOCKET NUMBER: 1920-331
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 977-1001
TELEFAX: (213) 977-1003
INFORMATION FOR SEQ ID NO: 74:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-704-170-74

Query Match 87.2%; Score 34; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.62;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RAVFTIG 7
DB 5 RAVFTIG 11

RESULT 166
PCT-US94-02631-73
Sequence 73, Application PC/TUS9402631
GENERAL INFORMATION:
APPLICANT: Douvas, Angelina
APPLICANT: Takehana, Yoshi
APPLICANT: Ehresmann, Glenn
TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR
TITLE OF INVENTION: IMMUNOINFECTION CLUSTER VIRUS INFECTIONS
NUMBER OF SEQUENCES: 121
CORRESPONDENCE ADDRESS:
ADDRESSEE: Robbins, Berliner & Carson
STREET: 201 North Figueroa Street, Suite 500
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90012
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/02631
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/029,850
FILING DATE: 11-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Spitals, John P.
REGISTRATION NUMBER: 29,215
REFERENCE/DOCKET NUMBER: 1920-331
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 977-1001
TELEFAX: (213) 977-1003
INFORMATION FOR SEQ ID NO: 73:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
PCT-US94-02631-73
Query Match 87.2%; Score 34; DB 5; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.62;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RAFTYIG 7
Db 5 RAFTYIG 11
RESULT 167
PCT-US94-02631-74
Sequence 74, Application PC/TUS9402631
GENERAL INFORMATION:
APPLICANT: Douvas, Angelina
APPLICANT: Takehana, Yoshi
APPLICANT: Ehresmann, Glenn
TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR
TITLE OF INVENTION: IMMUNOINFECTION CLUSTER VIRUS INFECTIONS
NUMBER OF SEQUENCES: 121
CORRESPONDENCE ADDRESS:
ADDRESSEE: Robbins, Berliner & Carson
STREET: 201 North Figueroa Street, Suite 500
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90012
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/02631
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/029,850
FILING DATE: 11-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Spitals, John P.
REGISTRATION NUMBER: 29,215
REFERENCE/DOCKET NUMBER: 1920-331
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 977-1001
TELEFAX: (213) 977-1003
INFORMATION FOR SEQ ID NO: 74:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
PCT-US94-02631-74
Query Match 87.2%; Score 34; DB 5; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.62;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RAFTYIG 7
Db 5 RAFTYIG 11
RESULT 168
PCT-US95-03236-29
Sequence 29, Application PC/TUS9503236
GENERAL INFORMATION:
APPLICANT: University of Southern California
TITLE OF INVENTION: Methods to Diagnose and Treat HIV-1
TITLE OF INVENTION: Infection
NUMBER OF SEQUENCES: 66
CORRESPONDENCE ADDRESS:
ADDRESSEE: Campbell and Flores
STREET: 4370 La Jolla Village Drive, Suite 700
CITY: San Diego
STATE: California
COUNTRY: USA
ZIP: 92122
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/03236
FILING DATE: 13-MAR-1995
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Imbra, Richard J.
REGISTRATION NUMBER: 37,643
REFERENCE/DOCKET NUMBER: FP-SI 1394
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 535-9001
TELEFAX: (619) 535-8949
INFORMATION FOR SEQ ID NO: 29:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
PCT-US95-03236-29
Query Match 87.2%; Score 34; DB 5; Length 14;

Best Local Similarity 100.0%; Pred. No. 0.78;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTTIG 7
Db 8 RAFTTIG 14

RESULT 169

PCT-US95-03236-52
Sequence 52, Application PC/TUS9503236
GENERAL INFORMATION:
APPLICANT: University of Southern California
TITLE OF INVENTION: Methods to Diagnose and Treat HIV-1
TITLE OF INVENTION: Infection
NUMBER OF SEQUENCES: 66
CORRESPONDENCE ADDRESS:
ADDRESSEE: Campbell and Flores
STREET: 4370 La Jolla Village Drive, Suite 700
CITY: San Diego
STATE: California
COUNTRY: USA
ZIP: 92122
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/03236
FILING DATE: 13-MAR-1995
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Imbra, Richard J.
REGISTRATION NUMBER: 37,643
REFERENCE/DOCKET NUMBER: FP-SI 1394
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 535-8949
INFORMATION FOR SEQ ID NO: 52:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
PCT-US95-03236-52

Query Match 87.2%; Score 34; DB 5; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.78;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTTIG 7
Db 8 RAFTTIG 14

RESULT 170

US-08-704-170-72
Sequence 72, Application US/08704170
Patent No. 5707626
GENERAL INFORMATION:
APPLICANT: Douvas, Angelina
APPLICANT: Takehana, Yoshi
APPLICANT: Ehresmann, Glenn
TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR
TITLE OF INVENTION: IMMUNOINJECTIVE CLUSTER VIRUS INFECTIONS
NUMBER OF SEQUENCES: 121
CORRESPONDENCE ADDRESS:
ADDRESSEE: Robbins, Berline & Carson
STREET: 201 No. 5707626th Figueroa Street, Suite 500
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.

ZIP: 90012
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/704,170
FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/029,850
FILING DATE: 11-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Spitalis, John P.
REGISTRATION NUMBER: 29,215
REFERENCE/DOCKET NUMBER: 1920-331
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 977-1001
TELEFAX: (213) 977-1003
INFORMATION FOR SEQ ID NO: 72:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-704-170-72

Query Match 87.2%; Score 34; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.84;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTTIG 7
Db 9 RAFTTIG 15

RESULT 171

US-08-455-625-16
Sequence 16, Application US/08455625
Patent No. 5932218
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. D.
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsumori
TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,625
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330

REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..15
OTHER INFORMATION: /label= peptide
OTHER INFORMATION: /note= "p18-8, see Table V"
US-08-455-625-16

Query Match 87.2%; Score 34; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.84;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy 2 AFTVIGK 8
|||
9 AFTVIGK 15

Db

RESULT 172
US-08-455-625-19
Sequence 19, Application US/08455625
Patent No. 5932218
GENERAL INFORMATION:
APPLICANT: Beizofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. D.
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsumori
TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolasch & Birch
STREET: P. O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,625
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide

FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..15
OTHER INFORMATION: /label= peptide
OTHER INFORMATION: /note= "p18-11, see Table V"
US-08-455-625-19

Query Match 87.2%; Score 34; DB 2; Length 15;
Best Local Similarity 87.5%; Pred. No. 0.84;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Cy 1 RAFTVIGK 8
|||
8 RAFTVIGK 15

Db

RESULT 173
US-08-455-625-20
Sequence 20, Application US/08455625
Patent No. 5932218
GENERAL INFORMATION:
APPLICANT: Beizofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. D.
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsumori
TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolasch & Birch
STREET: P. O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,625
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 20:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..15
OTHER INFORMATION: /label= peptide
OTHER INFORMATION: /note= "p18-12, see Table V"
US-08-455-625-20

Query Match 87.2%; Score 34; DB 2; Length 15;
Best Local Similarity 87.5%; Pred. No. 0.84;

Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RAFTTIGK 8
db 8 RAFTTIGK 15

RESULT 174
US-08-455-625-21
Sequence 21, Application US/08455625
Patent No. 5932218
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. D.
APPLICANT: Nara, Peter
TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,625
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION/DOCKET NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..15
OTHER INFORMATION: /label=peptide
OTHER INFORMATION: /note="p18-13, see Table V"
US-08-455-625-21

Query Match 87.2%; Score 34; DB 2; Length 15;
Best Local Similarity 87.5%; Pred. No. 0.84;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RAFTTIGK 8
db 8 RAFTTIGK 15

RESULT 175
US-08-455-685-16
Sequence 16, Application US/08455685

Patent No. 6214347
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 40
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,685
FILING DATE: 31-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/060,988
FILING DATE: 14-MAY-1993
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION/DOCKET NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022003
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-455-685-16

Query Match 87.2%; Score 34; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.84;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 AFTTIGK 8
db 9 AFTTIGK 15

RESULT 176
US-08-455-685-19
Sequence 19, Application US/08455685
Patent No. 6214347
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1

NUMBER OF SEQUENCES: 40
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,685
FILING DATE: 31-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/060,988
FILING DATE: 14-MAY-1993
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022003
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-455-685-19

Query Match 87.2%; Score 34; DB 3; Length 15;
Best Local Similarity 87.5%; Pred. No. 0.84;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RAFTYICK 8
| | | | |
DB 8 RAFTYICK 15

RESULT 177
US-08-455-685-20
Sequence 20, Application US/08455685
Patent No. 6214347
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 40
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,685
FILING DATE: 31-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/060,988
FILING DATE: 14-MAY-1993
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022003
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 20:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-455-685-20

Query Match 87.2%; Score 34; DB 3; Length 15;
Best Local Similarity 87.5%; Pred. No. 0.84;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RAFTYICK 8
| | | | |
DB 8 RAFTYICK 15

RESULT 178
US-08-455-685-21
Sequence 21, Application US/08455685
Patent No. 6214347
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 40
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,685
FILING DATE: 31-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/060,988
FILING DATE: 14-MAY-1993
APPLICATION NUMBER: 07/847,311

FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022003
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-455-685-21

Query Match 87.2%; Score 34; DB 3; Length 15;
Best Local Similarity 87.5%; Pred. No. 0.84;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 APTTICK 8
DB 8 APTTICK 15

RESULT 179
US-08-060-988A-16
Sequence 16, Application US/08060988A
Patent No. 6294322
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
TITLE OF INVENTION: THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE
TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
FILING DATE: 14-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022001
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070

TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-060-988A-16

Query Match 87.2%; Score 34; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.84;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 APTTICK 8
DB 9 APTTICK 15

RESULT 180
US-08-060-988A-19
Sequence 19, Application US/08060988A
Patent No. 6294322
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
TITLE OF INVENTION: THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE
TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
FILING DATE: 14-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022001
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-060-988A-19

Query Match 87.2%; Score 34; DB 3; Length 15;

Best Local Similarity 87.5%; Pred. No. 0.84;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RAFTYTGK 8
|||
Db 8 RAFTYTGK 15

RESULT 181

US-08-060-988A-20

Sequence 20, Application US/08060988A

Patent No. 6294322

GENERAL INFORMATION:

APPLICANT: Berzofsky, Jay A.

APPLICANT: Ahlers, Jeffrey D.

APPLICANT: Pendleton, C. David

APPLICANT: Nara, Peter

APPLICANT: Shirai, Mutsunori

TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES

TITLE OF INVENTION: THAT ELICIT

TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND

TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1

NUMBER OF SEQUENCES: 48

CORRESPONDENCE ADDRESS:

ADDRESSEE: Fish & Richardson P.C.

STREET: 225 Franklin Street

CITY: Boston

STATE: MA

COUNTRY: US

ZIP: 02110-2804

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: Windows95

SOFTWARE: FASTSEQ for Windows Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/060,988A

FILING DATE: 14-MAY-1993

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 07/847,311

FILING DATE: 06-MAR-1992

APPLICATION NUMBER: 07/751,998

FILING DATE: 29-AUG-1991

APPLICATION NUMBER: 07/148,692

FILING DATE: 26-JAN-1988

ATTORNEY/AGENT INFORMATION:

NAME: Beattie, Ingrid A.

REGISTRATION NUMBER: P-42,306

REFERENCE/DOCKET NUMBER: 08830/022001

TELECOMMUNICATION INFORMATION:

TELEPHONE: 617/542-5070

TELEFAX: 617/542-8906

TELEX: 200154

INFORMATION FOR SEQ ID NO: 20:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: peptide

US-08-060-988A-20

Query Match 87.2%; Score 34; DB 3; Length 15;

Best Local Similarity 87.5%; Pred. No. 0.84;

Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RAFTYTGK 8
|||
Db 8 RAFTYTGK 15

RESULT 182

US-08-060-988A-21

Sequence 21, Application US/08060988A

Patent No. 6294322

GENERAL INFORMATION:

APPLICANT: Berzofsky, Jay A.

APPLICANT: Ahlers, Jeffrey D.

APPLICANT: Pendleton, C. David

APPLICANT: Nara, Peter

APPLICANT: Shirai, Mutsunori

TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES

TITLE OF INVENTION: THAT ELICIT

TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND

TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1

NUMBER OF SEQUENCES: 48

CORRESPONDENCE ADDRESS:

ADDRESSEE: Fish & Richardson P.C.

STREET: 225 Franklin Street

CITY: Boston

STATE: MA

COUNTRY: US

ZIP: 02110-2804

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: Windows95

SOFTWARE: FASTSEQ for Windows Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/060,988A

FILING DATE: 14-MAY-1993

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 07/847,311

FILING DATE: 06-MAR-1992

APPLICATION NUMBER: 07/751,998

FILING DATE: 29-AUG-1991

APPLICATION NUMBER: 07/148,692

FILING DATE: 26-JAN-1988

ATTORNEY/AGENT INFORMATION:

NAME: Beattie, Ingrid A.

REGISTRATION NUMBER: P-42,306

REFERENCE/DOCKET NUMBER: 08830/022001

TELECOMMUNICATION INFORMATION:

TELEPHONE: 617/542-5070

TELEFAX: 617/542-8906

TELEX: 200154

INFORMATION FOR SEQ ID NO: 21:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: peptide

US-08-060-988A-21

Query Match 87.2%; Score 34; DB 3; Length 15;

Best Local Similarity 87.5%; Pred. No. 0.84;

Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RAFTYTGK 8
|||
Db 8 RAFTYTGK 15

RESULT 183

PCT-US94-02631-72

Sequence 72, Application PC/TUS9402631

GENERAL INFORMATION:

APPLICANT: Douvas, Angelina

APPLICANT: Takehana, Yoichi

APPLICANT: Ehresmann, Glenn

TITLE OF INVENTION: THERAPEUTIC STRATEGIES FOR

TITLE OF INVENTION: IMMUNOINFECTION CLUSTER VIRUS INFECTIONS

NUMBER OF SEQUENCES: 121

CORRESPONDENCE ADDRESS:

ADDRESSEE: Robbins, Berliner & Carson

STREET: 201 North Figueroa Street, Suite 500

CITY: Los Angeles

STATE: California
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 16
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..15
OTHER INFORMATION: /label=peptide
PCT-US94-05142-16 /note="p18-8, see Table V"

Query Match 87.2%; Score 34; DB 5; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.84;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFWTTIG 7
Db 9 AFWTTIG 15

RESULT 184
PCT-US94-05142-16
Sequence 16, Application PC/TUS9405142
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESSES:
ADDRESSER: Birch, Stewart, Kolaasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/05142
FILING DATE: 13-MAY-1994
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000

STATE: California
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 16
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..15
OTHER INFORMATION: /label=peptide
PCT-US94-05142-16 /note="p18-8, see Table V"

Query Match 87.2%; Score 34; DB 5; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.84;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 AFWTTIG 8
Db 9 AFWTTIG 15

RESULT 185
PCT-US94-05142-16
Sequence 19, Application PC/TUS9405142
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESSES:
ADDRESSER: Birch, Stewart, Kolaasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/05142
FILING DATE: 13-MAY-1994
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
FILING DATE: 13-MAY-1994
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000

Query Match 87.2%; Score 34; DB 5; Length 15;
Best Local Similarity 87.5%; Pred. No. 0.84;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RAFVTTGK 8
|||
Db 8 RAFVTTGK 15

RESULT 186

PCT-US94-05142-20

Sequence 20, Application PC/TUS9405142

GENERAL INFORMATION:

APPLICANT:

TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT

TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T

NUMBER OF SEQUENCES: 36

CORRESPONDENCE ADDRESSES:

ADDRESS: Birch, Stewart, Kolaesch & Birch

STREET: P.O. Box 747

CITY: Falls Church

STATE: Virginia

COUNTRY: USA

ZIP: 22040-0747

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent in Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: PCT/US94/05142

FILING DATE: 13-MAY-1994

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/060,988

FILING DATE: 14-MAY-1993

ATTORNEY/AGENT INFORMATION:

NAME: Svensson, Leonard R.

REGISTRATION NUMBER: 30330

REFERENCE/DOCKET NUMBER: 1173-434P

TELEPHONE: 703-205-8050

TELEFAX: 703-205-8000

INFORMATION FOR SEQ ID NO: 20:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: peptide

FRAGMENT TYPE: internal

FEATURE:

NAME/KEY: Peptide

LOCATION: 1..15

OTHER INFORMATION: /label= peptide

OTHER INFORMATION: /note= "p18-12, see Table V"

PCT-US94-05142-20

Query Match 87.2%; Score 34; DB 5; Length 15;
Best Local Similarity 87.5%; Pred. No. 0.84;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RAFVTTGK 8
|||
Db 8 RAFVTTGK 15

RESULT 187

PCT-US94-05142-21

Sequence 21, Application PC/TUS9405142

GENERAL INFORMATION:

APPLICANT:

TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT

TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T

TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV

NUMBER OF SEQUENCES: 36

CORRESPONDENCE ADDRESSES:

ADDRESS: Birch, Stewart, Kolaesch & Birch

STREET: P.O. Box 747

CITY: Falls Church

STATE: Virginia

COUNTRY: USA

ZIP: 22040-0747

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent in Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: PCT/US94/05142

FILING DATE: 13-MAY-1994

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/060,988

FILING DATE: 14-MAY-1993

ATTORNEY/AGENT INFORMATION:

NAME: Svensson, Leonard R.

REGISTRATION NUMBER: 30330

REFERENCE/DOCKET NUMBER: 1173-434P

TELEPHONE: 703-205-8050

TELEFAX: 703-205-8000

INFORMATION FOR SEQ ID NO: 21:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: peptide

FRAGMENT TYPE: internal

FEATURE:

NAME/KEY: Peptide

LOCATION: 1..15

OTHER INFORMATION: /label= peptide

OTHER INFORMATION: /note= "p18-13, see Table V"

PCT-US94-05142-21

Query Match 87.2%; Score 34; DB 5; Length 15;
Best Local Similarity 87.5%; Pred. No. 0.84;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RAFVTTGK 8
|||
Db 8 RAFVTTGK 15

RESULT 188

US-08-257-528B-35

Sequence 35, Application US/08257528B

Patent No. 5639854

GENERAL INFORMATION:

APPLICANT: Sia, Charles D.Y.

APPLICANT: CHONG, Pele

APPLICANT: KLEIN, Michel H.

TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides

NUMBER OF SEQUENCES: 101

CORRESPONDENCE ADDRESSES:

ADDRESS: Sim & McBurney

STREET: Suite 701, 330 University Avenue

CITY: Toronto

STATE: Ontario

COUNTRY: Canada

ZIP: M5G 1R7

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/257,528B
FILING DATE: 09-JUN-1994
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, MICHAEL I.
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-336 MIS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-257-528B-35

Query Match 87.2%; Score 34; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.95;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTTIG 7
Db 11 RAFTTIG 17

RESULT 189
US-08-460-602A-35
Sequence 35, Application US/08460602A
Patent No. 5759769
GENERAL INFORMATION:
APPLICANT: SIA, Charles D.Y.
APPLICANT: CHONG, Pele
APPLICANT: KLEIN, Michel H.
TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & Mcburney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/460,602A
FILING DATE: 02-JUN-1995
CLASSIFICATION: 424
REFERENCE/DOCKET NUMBER: 1038-450 MIS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 amino acids

TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-460-602A-35

Query Match 87.2%; Score 34; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.95;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTTIG 7
Db 11 RAFTTIG 17

RESULT 190
US-08-463-966A-35
Sequence 35, Application US/08463966A
Patent No. 5795955
GENERAL INFORMATION:
APPLICANT: SIA, Charles D.Y.
APPLICANT: CHONG, Pele
APPLICANT: KLEIN, Michel H.
TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & Mcburney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/463,966A
FILING DATE: 05-JUN-1995
CLASSIFICATION: 424
REFERENCE/DOCKET NUMBER: 1038-487 MIS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-463-966A-35

Query Match 87.2%; Score 34; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.95;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTTIG 7
Db 11 RAFTTIG 17

RESULT 191

```
US-08-465-217A-35
; Sequence 35, Application US/08465217A
; Patent No. 5800822
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/465,217A
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/257,528
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/073,378
; FILING DATE: 09-JUN-1993
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-486 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-465-217A-35
Query Match      87.2%; Score 34; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.95;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy      1 RAFVTIG 7
      |||||
Db      11 RAFVTIG 17

RESULT 192
US-08-464-329A-35
; Sequence 35, Application US/08464329A
; Patent No. 5817754
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
```

```
ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/464,329A
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/257,528
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/073,378
; FILING DATE: 09-JUN-1993
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-449 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-464-329A-35
Query Match      87.2%; Score 34; DB 2; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.95;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy      1 RAFVTIG 7
      |||||
Db      11 RAFVTIG 17

RESULT 193
US-08-462-507A-35
; Sequence 35, Application US/08462507A
; Patent No. 5876731
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/462,507A
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/257,528
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
```

APPLICATION NUMBER: 08/073,378
FILING DATE: 09-JUN-1993
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, MICHAEL I.
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-451 MIS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-462-507A-35

Query Match 87.2%; Score 34; DB 2; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.95;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIG 7
|||||
DB 11 RAFVTIG 17

RESULT 194
US-08-467-881A-35
Sequence 35, Application US/08467881A
Patent No. 5951986
GENERAL INFORMATION:
APPLICANT: SIA, Charles D.Y.
APPLICANT: CHONG, Pele
APPLICANT: KLEIN, Michael H.
TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/467,881A
FILING DATE: 06-JUN-1995
CLASSIFICATION: 424
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: 08/257,528
FILING DATE: 09-JUN-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/073,378
FILING DATE: 09-JUN-1993
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, MICHAEL I.
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-488 MIS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 amino acids
TYPE: amino acid
STRANDEDNESS: single

TOPOLOGY: linear
US-08-467-881A-35

Query Match 87.2%; Score 34; DB 2; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.95;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIG 7
|||||
DB 11 RAFVTIG 17

RESULT 195
PCT-US92-06688-13
Sequence 13, Application PC/TUS9206688
GENERAL INFORMATION:
APPLICANT: REPLIGEN CORPORATION
APPLICANT: THE ROCKEFELLER UNIVERSITY
TITLE OF INVENTION: MULTIPLE ANTIGEN PEPTIDES FOR USE AS HIV
TITLE OF INVENTION: VACCINES
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson
STREET: 225 Franklin Street
CITY: Boston
STATE: Massachusetts
COUNTRY: U.S.A.
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM PS/2 Model 50Z or 558X
OPERATING SYSTEM: IBM P.C. DOS (Version 3.30)
SOFTWARE: WordPerfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/06688
FILING DATE: 19920811
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 744,281
FILING DATE: 13 August 1992
ATTORNEY/AGENT INFORMATION:
NAME: Paul T. Clark
REGISTRATION NUMBER: 30,162
REFERENCE/DOCKET NUMBER: 00231/052MO1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 542-5070
TELEFAX: (617) 542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 17
TYPE: AMINO ACID
TOPOLOGY: linear
PCT-US92-06688-13

Query Match 87.2%; Score 34; DB 5; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.95;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFVTIG 7
|||||
DB 11 RAFVTIG 17

RESULT 196
US-08-455-625-18
Sequence 18, Application US/08455625
Patent No. 5932218
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. D.
APPLICANT: Nara, Peter

```
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESSES:
ADDRESS: Birch, Stewart, Kolasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,625
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..15
OTHER INFORMATION: /label=peptide
OTHER INFORMATION: /note="p18-10, see Table V"
US-08-455-625-18

Query Match 84.6%; Score 33; DB 2; Length 15;
Best Local Similarity 87.5%; Pred. No. 1.4;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
DB 8 RAFTVIGK 15

RESULT 197
US-08-455-625-22
Sequence 22, Application US/08455625
Patent No. 5932218
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. D.
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT
TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T
TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESSES:
ADDRESS: Birch, Stewart, Kolasch & Birch
STREET: P.O. Box 747
CITY: Falls Church
STATE: Virginia
```

```
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,625
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..15
OTHER INFORMATION: /label=peptide
OTHER INFORMATION: /note="p18-14, see Table V"
US-08-455-625-22

Query Match 84.6%; Score 33; DB 2; Length 15;
Best Local Similarity 87.5%; Pred. No. 1.4;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RAFTVIGK 8
DB 8 RAFTVIGK 15

RESULT 198
US-08-455-685-18
Sequence 18, Application US/08455685
Patent No. 6214347
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 40
CORRESPONDENCE ADDRESSES:
ADDRESS: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,685
FILING DATE: 31-MAY-1995
```

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/060,988
FILING DATE: 14-MAY-1993
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022003
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-455-685-18

Query Match 84.6%; Score 33; DB 3; Length 15;
Best Local Similarity 87.5%; Pred. No. 1.4;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RAFTYICK 8
Db 8 RAFTYICK 15

RESULT 199
US-08-455-685-22
Sequence 22, Application US/08455685
Patent No. 6214347
GENERAL INFORMATION:
APPLICANT: Bezofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 40
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,685
FILING DATE: 31-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/060,988
FILING DATE: 14-MAY-1993
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:

NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022003
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-455-685-22

Query Match 84.6%; Score 33; DB 3; Length 15;
Best Local Similarity 87.5%; Pred. No. 1.4;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RAFTYICK 8
Db 8 RAFTYICK 15

RESULT 200
US-08-060-988A-18
Sequence 18, Application US/08060988A
Patent No. 6294322
GENERAL INFORMATION:
APPLICANT: Bezofsky, Jay A.
APPLICANT: Ahlers, Jeffrey D.
APPLICANT: Pendleton, C. David
APPLICANT: Nara, Peter
APPLICANT: Shirai, Mutsunori
TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES
TITLE OF INVENTION: THAT ELICIT
TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND
TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/060,988A
FILING DATE: 14-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/847,311
FILING DATE: 06-MAR-1992
APPLICATION NUMBER: 07/751,998
FILING DATE: 29-AUG-1991
APPLICATION NUMBER: 07/148,692
FILING DATE: 26-JAN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Beattie, Ingrid A.
REGISTRATION NUMBER: P-42,306
REFERENCE/DOCKET NUMBER: 08830/022001
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid

TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-060-988A-18

Query Match 84.6%; Score 33; DB 3; Length 15;
Best Local Similarity 87.5%; Pred. No. 1.4;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
|||
Db 8 RAFVTIGK 15

RESULT 201

US-08-060-988A-22
Sequence 22, Application US/08060988A
Patent No. 629432

GENERAL INFORMATION:

APPLICANT: Berzofsky, Jay A.

APPLICANT: Ahlers, Jeffrey D.

APPLICANT: Pendleton, C. David

APPLICANT: Nara, Peter

APPLICANT: Shirai, Mutsunori

TITLE OF INVENTION: MULTIDETERMINANT PEPTIDES

TITLE OF INVENTION: THAT ELICIT

TITLE OF INVENTION: HELPER T-LYMPHOCYTE, CYTOTOXIC T LYMPHOCYTE AND

TITLE OF INVENTION: NEUTRALIZING ANTIBODY RESPONSES AGAINST HIV-1

NUMBER OF SEQUENCES: 48

CORRESPONDENCE ADDRESS:

ADDRESS: Fish & Richardson P.C.

STREET: 225 Franklin Street

CITY: Boston

STATE: MA

COUNTRY: US

ZIP: 02110-2804

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: Windows95

SOFTWARE: FastSeq for Windows Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/060,988A

FILING DATE: 14-MAY-1993

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 07/847,311

FILING DATE: 06-MAR-1992

APPLICATION NUMBER: 07/751,998

FILING DATE: 29-AUG-1991

APPLICATION NUMBER: 07/148,692

FILING DATE: 26-JAN-1988

ATTORNEY/AGENT INFORMATION:

NAME: Beattie, Ingrid A.

REGISTRATION NUMBER: P-42,306

REFERENCE/DOCKET NUMBER: 08830/022001

TELECOMMUNICATION INFORMATION:

TELEPHONE: 617/542-5070

TELEFAX: 617/542-8906

TELEX: 200154

INFORMATION FOR SEQ ID NO: 22:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: peptide

US-08-060-988A-22

Query Match 84.6%; Score 33; DB 3; Length 15;
Best Local Similarity 87.5%; Pred. No. 1.4;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
|||
Db 8 RAFVTIGK 15

RESULT 202

PCT-US94-05142-18
Sequence 18, Application PC/TUS9405142

GENERAL INFORMATION:

APPLICANT:

TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT

TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T

TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV

NUMBER OF SEQUENCES: 36

CORRESPONDENCE ADDRESS:

ADDRESSEE: Birch, Stewart, Kolasch & Birch

STREET: P.O. Box 747

CITY: Falls Church

STATE: Virginia

COUNTRY: USA

ZIP: 22040-0747

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent In Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: PCT/US94/05142

FILING DATE: 13-MAY-1994

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/060,988

FILING DATE: 14-MAY-1993

ATTORNEY/AGENT INFORMATION:

NAME: Svensson, Leonard R.

REGISTRATION NUMBER: 30330

REFERENCE/DOCKET NUMBER: 1173-434P

TELECOMMUNICATION INFORMATION:

TELEPHONE: 703-205-8000

TELEFAX: 703-205-8050

INFORMATION FOR SEQ ID NO: 18:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: peptide

FRAGMENT TYPE: internal

FEATURE:

NAME/KEY: Peptide

LOCATION: 1..15

OTHER INFORMATION: /label= peptide

PCT-US94-05142-18

Query Match 84.6%; Score 33; DB 5; Length 15;
Best Local Similarity 87.5%; Pred. No. 1.4;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RAFVTIGK 8
|||
Db 8 RAFVTIGK 15

RESULT 203

PCT-US94-05142-22
Sequence 22, Application PC/TUS9405142

GENERAL INFORMATION:

APPLICANT:

TITLE OF INVENTION: COMPOSITE SYNTHETIC PEPTIDE CONSTRUCT

TITLE OF INVENTION: ELICITING NEUTRALIZING ANTIBODIES AND CYTOTOXIC T

TITLE OF INVENTION: LYMPHOCYTES AGAINST HIV

NUMBER OF SEQUENCES: 36

CORRESPONDENCE ADDRESS:

ADDRESSEE: Birch, Stewart, Kolasch & Birch

STREET: P.O. Box 747

CITY: Falls Church

STATE: Virginia
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/05142
FILING DATE: 13-MAY-1994
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/060,988
FILING DATE: 14-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30330
REFERENCE/DOCKET NUMBER: 1173-434P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..15
OTHER INFORMATION: /label= peptide
OTHER INFORMATION: /note= "p18-14, see Table V"
PCT-US94-05142-22

Query Match 84.6%; Score 33; DB 5; Length 15;
Best Local Similarity 87.5%; Pred. No. 1.4;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RAFTYIG 8
|||
Db 8 RAFTYIAK 15

RESULT 204
US-08-257-528B-51
Sequence 51, Application US/08257528B
Patent No. 5639854
GENERAL INFORMATION:
APPLICANT: SIA, Charles D. Y.
APPLICANT: CHONG, Pele
APPLICANT: KLEIN, Michel H.
TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/257,528B
FILING DATE: 09-JUN-1994
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, MICHAEL I.

REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-336 MIS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 51:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-257-528B-51

Query Match 74.4%; Score 29; DB 1; Length 20;
Best Local Similarity 85.7%; Pred. No. 1.3;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RAFTYIG 7
|||
Db 14 RAFTYIG 20

RESULT 205
US-08-460-602A-51
Sequence 51, Application US/08460602A
Patent No. 5759769
GENERAL INFORMATION:
APPLICANT: SIA, Charles D. Y.
APPLICANT: CHONG, Pele
APPLICANT: KLEIN, Michel H.
TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sim & McBurney
STREET: Suite 701, 330 University Avenue
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5G 1R7
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/460,602A
FILING DATE: 02-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/257,528
FILING DATE: 09-JUN-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/073,378
FILING DATE: 09-JUN-1993
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: STEWART, MICHAEL I.
REGISTRATION NUMBER: 24,973
REFERENCE/DOCKET NUMBER: 1038-450 MIS:jb
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 595-1155
TELEFAX: (416) 595-1163
INFORMATION FOR SEQ ID NO: 51:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-460-602A-51

Query Match 74.4%; Score 29; DB 1; Length 20;
Best Local Similarity 85.7%; Pred. No. 1.3;

Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RAFYTG 7
|||
Db 14 RAFYTG 20

RESULT 206
US-08-463-966A-51

; Sequence 51, Application US/08463966A

; Patent No. 5795955

; GENERAL INFORMATION:

; APPLICANT: SIA, Charles D.Y.

; APPLICANT: CHONG, Pele

; APPLICANT: KLEIN, Michel H.

; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides

; NUMBER OF SEQUENCES: 101

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Sim & McBurney

; STREET: Suite 701, 330 University Avenue

; CITY: Toronto

; STATE: Ontario

; COUNTRY: Canada

; ZIP: M5G 1R7

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patentin Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/463,966A

; FILING DATE: 05-JUN-1995

; CLASSIFICATION: 424

; PRIORITY APPLICATION DATA:

; APPLICATION NUMBER: 08/257,528

; FILING DATE: 09-JUN-1994

; CLASSIFICATION: 424

; PRIORITY APPLICATION DATA:

; APPLICATION NUMBER: 08/073,378

; FILING DATE: 09-JUN-1993

; CLASSIFICATION: 424

; ATTORNEY/AGENT INFORMATION:

; NAME: STEWART, MICHAEL I.

; REGISTRATION NUMBER: 24,973

; REFERENCE/DOCKET NUMBER: 1038-487 MIS:jb

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (416) 595-1155

; TELEFAX: (416) 595-1163

; INFORMATION FOR SEQ ID NO: 51:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 20 amino acids

; TYPE: amino acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; US-08-463-966A-51

Query Match 74.4%; Score 29; DB 1; Length 20;

Best Local Similarity 85.7%; Pred. No. 13;

Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RAFYTG 7
|||
Db 14 RAFYTG 20

RESULT 207
US-08-465-217A-51

; Sequence 51, Application US/08465217A

; Patent No. 5800822

; GENERAL INFORMATION:

; APPLICANT: SIA, Charles D.Y.

; APPLICANT: CHONG, Pele

; APPLICANT: KLEIN, Michel H.

; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides

; NUMBER OF SEQUENCES: 101

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Sim & McBurney

; STREET: Suite 701, 330 University Avenue

; CITY: Toronto

; STATE: Ontario

; COUNTRY: Canada

; ZIP: M5G 1R7

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patentin Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/465,217A

; FILING DATE: 05-JUN-1995

; CLASSIFICATION: 424

; PRIORITY APPLICATION DATA:

; APPLICATION NUMBER: 08/257,528

; FILING DATE: 09-JUN-1994

; CLASSIFICATION: 424

; PRIORITY APPLICATION DATA:

; APPLICATION NUMBER: 08/073,378

; FILING DATE: 09-JUN-1993

; CLASSIFICATION: 424

; ATTORNEY/AGENT INFORMATION:

; NAME: STEWART, MICHAEL I.

; REGISTRATION NUMBER: 24,973

; REFERENCE/DOCKET NUMBER: 1038-486 MIS:jb

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (416) 595-1155

; TELEFAX: (416) 595-1163

; INFORMATION FOR SEQ ID NO: 51:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 20 amino acids

; TYPE: amino acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; US-08-465-217A-51

Query Match 74.4%; Score 29; DB 1; Length 20;

Best Local Similarity 85.7%; Pred. No. 13;

Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 RAFYTG 7
|||
Db 14 RAFYTG 20

RESULT 208
US-08-464-329A-51

; Sequence 51, Application US/08464329A

; Patent No. 5817754

; GENERAL INFORMATION:

; APPLICANT: SIA, Charles D.Y.

; APPLICANT: CHONG, Pele

; APPLICANT: KLEIN, Michel H.

; TITLE OF INVENTION: Tandem Synthetic HIV-1 Peptides

; NUMBER OF SEQUENCES: 101

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Sim & McBurney

; STREET: Suite 701, 330 University Avenue

; CITY: Toronto

; STATE: Ontario

; COUNTRY: Canada

; ZIP: M5G 1R7

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patentin Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

```

; APPLICATION NUMBER: US/08/464,329A
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/257,528
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/073,378
; FILING DATE: 09-JUN-1993
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; TELECOMMUNICATION INFORMATION:
; REFERENCE/DOCKET NUMBER: 1038-449 MIS:jb
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 51:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-464-329A-51

Query Match      74.4%; Score 29; DB 2; Length 20;
Best Local Similarity 85.7%; Pred. No. 13;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1 RAFTTIG 7
Db      14 RAFTTIG 20

RESULT 209
US-08-462-507A-51
; Sequence 51, Application US/08462507A
; Patent No. 5876731
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/462,507A
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/257,528
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/073,378
; FILING DATE: 09-JUN-1993
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-451 MIS:jb
```

```

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 51:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-462-507A-51

Query Match      74.4%; Score 29; DB 2; Length 20;
Best Local Similarity 85.7%; Pred. No. 13;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1 RAFTTIG 7
Db      14 RAFTTIG 20

RESULT 210
US-08-467-881A-51
; Sequence 51, Application US/08467881A
; Patent No. 5951986
; GENERAL INFORMATION:
; APPLICANT: SIA, Charles D.Y.
; APPLICANT: CHONG, Pele
; APPLICANT: KLEIN, Michel H.
; TITLE OF INVENTION: Tandem Synthetic HIV-1 peptides
; NUMBER OF SEQUENCES: 101
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sim & McBurney
; STREET: Suite 701, 330 University Avenue
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5G 1R7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/467,881A
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/257,528
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/073,378
; FILING DATE: 09-JUN-1993
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: STEWART, MICHAEL I.
; REGISTRATION NUMBER: 24,973
; REFERENCE/DOCKET NUMBER: 1038-488 MIS:jb
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 595-1155
; TELEFAX: (416) 595-1163
; INFORMATION FOR SEQ ID NO: 51:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-467-881A-51

Query Match      74.4%; Score 29; DB 2; Length 20;
Best Local Similarity 85.7%; Pred. No. 13;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

QY 1 RAFTIG 7
|||
Db 14 RAFTIG 20

RESULT 211
US-09-820-484-8
; Sequence 8, Application US/09820484
; Patent No. 6534062
; GENERAL INFORMATION:
; APPLICANT: Raz, Eyal
; APPLICANT: Cho, Hearn Jay
; APPLICANT: Richman, Douglas
; APPLICANT: Horner, Anthony A.
; TITLE OF INVENTION: Method for increasing a cytotoxic T
; TITLE OF INVENTION: lymphocyte response in vivo.
; FILE REFERENCE: 06510-188051
; CURRENT APPLICATION NUMBER: US/09/820,484
; PRIOR FILING DATE: 2001-03-28
; PRIOR APPLICATION NUMBER: US 60/192,537
; PRIOR FILING DATE: 2000-03-28
; PRIOR APPLICATION NUMBER: US 60/203,567
; PRIOR FILING DATE: 2000-05-11
; PRIOR APPLICATION NUMBER: US 60/215,895
; PRIOR FILING DATE: 2000-07-05
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: HIV-1 class I-restricted gp120 peptide
US-09-820-484-8

Query Match 71.8%; Score 28; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTI 6
|||
Db 5 RAFTI 10

RESULT 212
US-09-430-470-24
; Sequence 24, Application US/09430470
; Patent No. 6562800
; GENERAL INFORMATION:
; APPLICANT: McMillan, Minnie
; TITLE OF INVENTION: THE USE OF IMMUNOPOTENTIATING SEQUENCES
; TITLE OF INVENTION: FOR INDUCING IMMUNE RESPONSE
; FILE REFERENCE: 13761-725
; CURRENT APPLICATION NUMBER: US/09/430,470
; PRIOR FILING DATE: 1998-10-29
; EARLIER APPLICATION NUMBER: US 60/106,506
; EARLIER FILING DATE: 1998-10-30
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 24
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Human immunodeficiency virus (HIV)
; FEATURE:
; OTHER INFORMATION: Residues 318-327 of gp120 (Genbank accession
; OTHER INFORMATION: number g1224364)
US-09-430-470-24

Query Match 71.8%; Score 28; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTI 6

Db 5 RAFTI 10

RESULT 213
US-08-937-276A-5
; Sequence 5, Application US/08937276A
; Patent No. 6592872
; GENERAL INFORMATION:
; APPLICANT: Kimpel, Kurt
; APPLICANT: Goletz, Theresa J.
; APPLICANT: Arora, Naveen
; APPLICANT: Leppla, Stephen H.
; APPLICANT: Berzofsky, Jay A.
; TITLE OF INVENTION: Targeting Antigens to the MHC Class I
; TITLE OF INVENTION: Processing Pathway With an Anthrax Toxin Fusion Protein
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/937,276A
; FILING DATE: 15-Sep-1997
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/025,270
; FILING DATE: 17-Sep-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Weber, Kenneth A.
; REGISTRATION NUMBER: 31,677
; REFERENCE/DOCKET NUMBER: 015280-290100US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-08-937-276A-5

Query Match 71.8%; Score 28; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFTI 6
|||
Db 5 RAFTI 10

RESULT 214
US-09-454-204A-51
; Sequence 51, Application US/09454204A
; Patent No. 6663871
; GENERAL INFORMATION:
; APPLICANT: McMichael, Andrew
; APPLICANT: Hill, Adrian V.S.
; APPLICANT: Gilbert, Sarah C.
; APPLICANT: Schneider, Jorg
; APPLICANT: Plebanski, Magdalena
; APPLICANT: Hanke, Tomas

APPLICANT: Smith, Geoffrey L.
TITLE OF INVENTION: Blanchard, Tom
TITLE OF INVENTION: Methods and Reagents for Vaccination
FILE REFERENCE: 2907.1000-000
CURRENT APPLICATION NUMBER: US/09/454, 204A
CURRENT FILING DATE: 1999-12-09
PRIOR APPLICATION NUMBER: PCT/GB98/01681
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: GB 97 11957.2
PRIOR FILING DATE: 1997-06-09
NUMBER OF SEQ ID NOS: 78
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 51
LENGTH: 10
TYPE: PRT
ORGANISM: Unknown
FEATURE:
OTHER INFORMATION: CTL Epitope of HIV-1 gp120
US-09-454-204A-51

Query Match 71.8%; Score 28; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFTYI 6
Db 5 RAFTYI 10

RESULT 215
US-09-454-204A-68

Sequence 68; Application US/09454204A
Patent No. 6663871
GENERAL INFORMATION:
APPLICANT: McMichael, Andrew
APPLICANT: Hill, Adrian V.S.
APPLICANT: Gilbert, Sarah C.
APPLICANT: Schneider, Jorg
APPLICANT: Plebanski, Magdalena
APPLICANT: Hanke, Tomas
APPLICANT: Smith, Geoffrey L.
APPLICANT: Blanchard, Tom
TITLE OF INVENTION: Methods and Reagents for Vaccination
TITLE OF INVENTION: Which Generate A CD8 T Cell Immune Response
FILE REFERENCE: 2907.1000-000
CURRENT APPLICATION NUMBER: US/09/454, 204A
CURRENT FILING DATE: 1999-12-09
PRIOR APPLICATION NUMBER: PCT/GB98/01681
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: GB 97 11957.2
PRIOR FILING DATE: 1997-06-09
NUMBER OF SEQ ID NOS: 78
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 68
LENGTH: 10
TYPE: PRT
ORGANISM: Unknown
FEATURE:
OTHER INFORMATION: CTL Peptide Epitope of HIV gag
US-09-454-204A-68

Query Match 71.8%; Score 28; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFTYI 6
Db 5 RAFTYI 10

RESULT 216
US-09-508-552-16

Sequence 16; Application US/09508552
Patent No. 6743856
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Belyakov, Igor M.
APPLICANT: Derby, Michael A.
APPLICANT: Keisall, Brian L.
APPLICANT: Strober, Warren
TITLE OF INVENTION: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as
TITLE OF INVENTION: MUCOSAL CYTOTOXIC T LYMPHOCYTE RESPONSES
FILE REFERENCE: 368200PCE50
CURRENT APPLICATION NUMBER: US/09/508, 552
CURRENT FILING DATE: 2000-06-12
PRIOR APPLICATION NUMBER: 60/058, 523
PRIOR FILING DATE: 1997-09-11
PRIOR APPLICATION NUMBER: 60/074, 894
PRIOR FILING DATE: 1998-02-17
NUMBER OF SEQ ID NOS: 20
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 16
LENGTH: 10
TYPE: PRT
ORGANISM: Human immunodeficiency virus type 1
US-09-508-552-16

Query Match 71.8%; Score 28; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RAFTYI 6
Db 5 RAFTYI 10

RESULT 217
US-07-847-311A-20

Sequence 20; Application US/07847311A
Patent No. 5976541
GENERAL INFORMATION:
APPLICANT: Berzofsky, Jay A.
APPLICANT: Takeshita, Toshiyuki
APPLICANT: Shirai, Mutsunori
APPLICANT: Pendleton, C.D.
APPLICANT: Koslowaki, Steven
APPLICANT: Margulies, David H.
TITLE OF INVENTION: Potent Peptide for Stimulation of
TITLE OF INVENTION: Cytotoxic T Lymphocytes Specific for the HIV-1 Envelope
NUMBER OF SEQUENCES: 20
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolash & Birch
STREET: 301 N. Washington
CITY: Falls Church
STATE: Virginia
COUNTRY: USA
ZIP: 22046-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/847,311A
FILING DATE: 06-MAR-1992
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30,330
REFERENCE/DOCKET NUMBER: 1173-392P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-241-1300
TELEFAX: 703-241-2848
INFORMATION FOR SEQ ID NO: 20:
SEQUENCE CHARACTERISTICS:

LENGTH: 13 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: NO
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: Human Immunodeficiency Virus Type I
STRAIN: IIB
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..13
OTHER INFORMATION: /label= peptide
OTHER INFORMATION: /note= "Active peptide of HIV-1 envelope
OTHER INFORMATION: from strain IIB"
US-07-847-311A-20
Glycoprotein

Query Match 71.8%; Score 28; DB 2; Length 13;
Best Local Similarity 100.0%; Pred. No. 14;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFYTI 6
|||
Db 8 RAFYTI 13

RESULT 218
US-08-930-917A-14
Sequence 14, Application US/08930917A
Patent No. 6146635
GENERAL INFORMATION:
APPLICANT: DUARTE CANO, C. A.
APPLICANT: GUILI, N. NIETO, G. E.
APPLICANT: MART N DUNN, A. M.
APPLICANT: ALVAREZ ACOSTA, A.
APPLICANT: CARPIO MUÑOZ, E. L.
APPLICANT: QUINTANA V. D.
APPLICANT: G MEZ RODR GUEZ, C. E.
APPLICANT: SILVA RODR GUEZ, R. C.
APPLICANT: NAZ BAL G LVEZ, C.
APPLICANT: LEAL ANGULO, M. J.
TITLE OF INVENTION: System for the expression of heterologous
TITLE OF INVENTION: antigens as fusion proteins
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lackenbach Siegel Marzullo Aronson & Greenspan
STREET: One Chase Road
CITY: Scarsdale
STATE: New York
COUNTRY: U.S.
ZIP: 10583
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk 3.5" (1.4 MB).
COMPUTER: Compatible PC IBM (80486, 8 M Ram).
OPERATING SYSTEM: Windows 95.
SOFTWARE: Word Perfect 5.0 for Windows 95.
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/930,917A
FILING DATE: 16-Sep-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US97/00001
FILING DATE: 17-Jan-1997
ATTORNEY/AGENT INFORMATION:
NAME: HENRY A. MARZULLO, JR.
REGISTRATION NUMBER: 20,910
REFERENCE/DOCKET NUMBER: P-13
TELECOMMUNICATION INFORMATION:
TELEPHONE: (914) 723-4300
TELEFAX: (914) 723-4301
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 Amino acid residues

TYPE: Amino acid
STRANDEDNESS: Unknown
TOPOLOGY: Unknown
MOLECULE TYPE: Peptide
HYPOTHETICAL: No
ANTI-SENSE: No
FRAGMENT TYPE: Internal fragment
ORIGINAL SOURCE:
ORGANISM: VIH-1
INDIVIDUAL ISOLATE: IIB
FEATURE:
OTHER INFORMATION: Central region of the loop V3 belonging to the
OTHER INFORMATION: protein gp120 from the VIH-1, isolation IIB.
US-08-930-917A-14

Query Match 71.8%; Score 28; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFYTI 6
|||
Db 10 RAFYTI 15

RESULT 219
US-08-493-235-23
Sequence 23, Application US/08493235
Patent No. 5840313
GENERAL INFORMATION:
APPLICANT: Valhne, Anders
APPLICANT: Svennerholm, Bo
APPLICANT: Rymo, Lars
APPLICANT: Jeansson, Stig
APPLICANT: Horal, Peter
TITLE OF INVENTION: PEPTIDES FOR USE IN VACCINATION AND
TITLE OF INVENTION: INDUCTION OF NEUTRALIZING ANTIBODIES AGAINST HUMAN
TITLE OF INVENTION: IMMUNODEFICIENCY VIRUS
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: KNOBE, MARTENS, OLSON AND BEAR
STREET: 620 NEWPORT CENTER DRIVE 16TH FLOOR
CITY: NEWPORT BEACH
STATE: CA
COUNTRY: USA
ZIP: 92660
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/493,235
FILING DATE: 20(June)1995
CLASSIFICATION: 530
ATTORNEY/AGENT INFORMATION:
NAME: Kalsier, Annemarie
REGISTRATION NUMBER: 37,649
REFERENCE/DOCKET NUMBER: METRICS 12CPCL
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-235-8550
TELEFAX: 619-235-0176
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 25 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE: internal
US-08-493-235-23

Query Match 71.8%; Score 28; DB 2; Length 25;
Best Local Similarity 100.0%; Pred. No. 26;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RAFYTI 6
|||
Db 20 RAFYTI 25

RESULT 220

US-08-279-906A-26
Sequence 26, Application US/08279906A
Patent No. 5618922
GENERAL INFORMATION:
APPLICANT: Ohno, Tsuneya
APPLICANT: Terada, Masaki
APPLICANT: Yoneda, Yukio
TITLE OF INVENTION: NM03 Antibody Materials and Methods
NUMBER OF SEQUENCES: 27
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
ADDRESSEE: Borun
STREET: 6300 Sears Tower, 233 S. Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/279,906A
FILING DATE:
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: No. 5618922and, Greta E.
REGISTRATION NUMBER: 35,302
REFERENCE/DOCKET NUMBER: 32028
TELECOMMUNICATION INFORMATION:
TELEPHONE: (312) 474-6300
TELEFAX: (312) 474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 26:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-279-906A-26

Query Match 66.7%; Score 26; DB 1; Length 20;
Best Local Similarity 62.5%; Pred. No. 56;
Matches 5; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1 RAFYTIK 8
|||
Db 6 RAFYTIK 13

RESULT 221

US-09-902-540-11814
Sequence 11814, Application US/09902540
Patent No. 6833447
GENERAL INFORMATION:
APPLICANT: Goldman, Barry S.
APPLICANT: Hinkle, Gregory J.
APPLICANT: Slater, Steven C.
APPLICANT: Wiegand, Roger C.
TITLE OF INVENTION: Myxococcus xanthus Genome Sequences and Uses Thereof
FILE REFERENCE: 38-10(115849)B
CURRENT APPLICATION NUMBER: US/09/902,540

CURRENT FILING DATE: 2001-07-10
PRIOR APPLICATION NUMBER: 60/217,883
PRIOR FILING DATE: 2000-07-10
NUMBER OF SEQ ID NOS: 16825
SEQ ID NO 11814
LENGTH: 23
TYPE: PRT
ORGANISM: Myxococcus xanthus
US-09-902-540-11814

Query Match 66.7%; Score 26; DB 4; Length 23;
Best Local Similarity 71.4%; Pred. No. 64;
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2 AFYTIK 8
|||
Db 6 AFYTIK 12

RESULT 222

US-08-986-234-17
Sequence 17, Application US/08986234
Patent No. 5981706
GENERAL INFORMATION:
APPLICANT: Wallen, et al.
TITLE OF INVENTION: Methods for Synthesizing Heat Shock Protein Complexes
FILE REFERENCE: UMME-0008-1
CURRENT APPLICATION NUMBER: US/08/986,234
CURRENT FILING DATE: 1997-12-05
NUMBER OF SEQ ID NOS: 114
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 17
LENGTH: 15
TYPE: PRT
ORGANISM: Human immunodeficiency virus
US-08-986-234-17

Query Match 64.1%; Score 25; DB 2; Length 15;
Best Local Similarity 62.5%; Pred. No. 69;
Matches 5; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1 RAFYTIK 8
|||
Db 8 RAFYTIK 15

RESULT 223

US-08-333-565-16
Sequence 16, Application US/08333565
Patent No. 5622852
GENERAL INFORMATION:
APPLICANT: KORSMEYER, Stanley J.
TITLE OF INVENTION: Bcl-x/Bcl-2 ASSOCIATED CELL DEATH
REGULATOR
NUMBER OF SEQUENCES: 59
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Townsend and Townsend Khourie and Crew
STREET: 379 Lytton Avenue
CITY: Palo Alto
STATE: California
COUNTRY: US
ZIP: 94301
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/333,565
FILING DATE: 31-OCT-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M

REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 15726A-000700
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 326-2400
TELEFAX: (415) 326-2422
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-333-565-16

Query Match 64.1%; Score 25; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 78;
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 3 FVITIGK 8
|:|:|
Db 12 FVITIGK 17

RESULT 224
US-08-661-479-16
Sequence 16, Application US/08661479
Patent No. 5834209
GENERAL INFORMATION:
APPLICANT: KORSMEYER, Stanley J.
TITLE OF INVENTION: Bcl-X/Bcl-2 ASSOCIATED CELL DEATH
NUMBER OF SEQUENCES: 59
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend Kourie and Crew
STREET: 379 Lytton Avenue
CITY: Palo Alto
STATE: California
COUNTRY: US
ZIP: 94301
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/661,479
FILING DATE: 11-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/333,565
FILING DATE: 31-OCT-1994
ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M.
REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 15726A-000700
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 326-2400
TELEFAX: (415) 326-2422
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-661-479-16

Query Match 64.1%; Score 25; DB 2; Length 17;
Best Local Similarity 66.7%; Pred. No. 78;
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 3 FVITIGK 8
|:|:|

Db 12 FVITIGK 17

RESULT 225
US-08-100-118-6
Sequence 6, Application US/08100118
Patent No. 5580773
GENERAL INFORMATION:
APPLICANT: Kang, Chul-Yong
TITLE OF INVENTION: Design, Construction and Expression
TITLE OF INVENTION: of Chimeric Proteins for Development of AIDS
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
ADDRESSEE: Merchant & Gould
STREET: 3100 No. 5580773west Center
CITY: Minneapolis
STATE: MN
COUNTRY: USA
ZIP: 55402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/100,118
FILING DATE: 19930730
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Strodtloff, Kristine M.
REGISTRATION NUMBER: 34,259
REFERENCE/DOCKET NUMBER: 8682.6-US-01
TELECOMMUNICATION INFORMATION:
TELEPHONE: 612-332-5300
TELEFAX: 612-332-9081
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
IMMEDIATE SOURCE:
CLONE: Consensus Sequence (CS) of HIV-1 V3 loop
US-08-100-118-6

Query Match 64.1%; Score 25; DB 1; Length 18;
Best Local Similarity 62.5%; Pred. No. 82;
Matches 5; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1 RAVYITGE 8
|:|:|
Db 11 RAVYITGE 18

RESULT 226
US-08-323-192D-51
Sequence 51, Application US/08323192D
Patent No. 5786199
GENERAL INFORMATION:
APPLICANT: Palese, Peter
TITLE OF INVENTION: RECOMBINANT NEGATIVE STRAND RNA VIRUS
NUMBER OF SEQUENCES: 70
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pennie & Edmonds
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10036-2711

COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/323,192D
FILING DATE: 14-OCT-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Coruzzi, Laura A.
REGISTRATION NUMBER: 30,742
REFERENCE/DOCKET NUMBER: 7682-035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 790-9090
TELEFAX: (212) 869-9741/8864
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 51:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 amino acids
TYPE: amino acid
STRANDEDNESS:
TOPOLOGY: unknown
MOLECULE TYPE: peptide
US-08-323-192D-51

Query Match 64.1%; Score 25; DB 1; Length 19;
Best Local Similarity 62.5%; Pred. No. 87;
Matches 5; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1 RAFTYICK 8
Db 10 RAFTYICK 17

RESULT 227
US-08-975-699-15
Sequence 15, Application US/08975699
Patent No. 5858369
GENERAL INFORMATION:
APPLICANT: MATSUO, KAZUHIRO
APPLICANT: CHUJO, YOSHITOMO
APPLICANT: YAMAZAKI, AKIHIRO
APPLICANT: HONDA, MITSUO
APPLICANT: YAMAKAZI, SHUDO
APPLICANT: TASAKA, HIROMICHI
TITLE OF INVENTION: ANTI-AIDS SECRETORY RECOMBINANT BCG
TITLE OF INVENTION: VACCINE
NUMBER OF SEQUENCES: 27
CORRESPONDENCE ADDRESSES:
ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
ADDRESS: P.C.
STREET: 1755 S. JEFFERSON DAVIS HIGHWAY, SUITE 400
CITY: ARLINGTON
STATE: VA
COUNTRY: USA
ZIP: 22202
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/975,699
FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/619,512
FILING DATE: 29-MAR-1996
APPLICATION NUMBER: PCT/JP95/01515
FILING DATE: 31-JUL-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 178462/1994

FILING DATE: 29-JUL-1994
ATTORNEY/AGENT INFORMATION:
NAME: OBLON, NORMAN F.
REGISTRATION NUMBER: 24,618
REFERENCE/DOCKET NUMBER: 10-795-0X PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-413-3000
TELEFAX: 703-413-2220
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
ORIGINAL SOURCE:
ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
STRAIN: HIV-1
US-08-975-699-15

Query Match 64.1%; Score 25; DB 2; Length 19;
Best Local Similarity 62.5%; Pred. No. 87;
Matches 5; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1 RAFTYICK 8
Db 12 RAFTYICK 19

RESULT 228
US-08-972-089-15
Sequence 15, Application US/08972089
Patent No. 5855580
GENERAL INFORMATION:
APPLICANT: MATSUO, KAZUHIRO
APPLICANT: CHUJO, YOSHITOMO
APPLICANT: YAMAZAKI, AKIHIRO
APPLICANT: HONDA, MITSUO
APPLICANT: YAMAKAZI, SHUDO
APPLICANT: TASAKA, HIROMICHI
TITLE OF INVENTION: ANTI-AIDS SECRETORY RECOMBINANT BCG
TITLE OF INVENTION: VACCINE
NUMBER OF SEQUENCES: 27
CORRESPONDENCE ADDRESSES:
ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
ADDRESS: P.C.
STREET: 1755 S. JEFFERSON DAVIS HIGHWAY, SUITE 400
CITY: ARLINGTON
STATE: VA
COUNTRY: USA
ZIP: 22202
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/972,089
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/975,699
FILING DATE:
APPLICATION NUMBER: PCT/JP95/01515
FILING DATE: 31-JUL-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 178462/1994
FILING DATE: 29-JUL-1994
ATTORNEY/AGENT INFORMATION:
NAME: OBLON, NORMAN F.
REGISTRATION NUMBER: 24,618
REFERENCE/DOCKET NUMBER: 10-795-0X PCT
TELECOMMUNICATION INFORMATION:

TELEPHONE: 703-413-3000
TELEFAX: 703-413-2220
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
ORIGINAL SOURCE:
ORGANISM: HUMAN IMMUNODEFICIENT VIRUS
STRAIN: HIV-1
US-08-972-089-15

Query Match 64.1%; Score 25; DB 2; Length 19;
Best Local Similarity 62.5%; Pred. No. 87;
Matches 5; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1 RAFVITGK 8
Db 12 RAFYTTGE 19

RESULT 229
US-08-363-276B-1
Sequence 1, Application US/08363276B
Patent No. 5969109
GENERAL INFORMATION:
APPLICANT: BONA ET AL.
TITLE OF INVENTION: CHIMERIC ANTIBODIES
NUMBER OF SEQUENCES: 27
CORRESPONDENCE ADDRESS:
ADDRESSEE: Brumbaugh, Graves, Donohue &
STREET: 30 Rockefeller Plaza
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10112-0228
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/363.276B
FILING DATE: 22-DECEMBER-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: USSN 07/486,546
FILING DATE: 28-FEBRUARY-1990 (ABANDONED)
APPLICATION NUMBER: USSN 07/687,376
FILING DATE: 18-APRIL-1991 (ABANDONED)
APPLICATION NUMBER: USSN 08/327,636
FILING DATE: 24-OCTOBER-1994 (ABANDONED)
ATTORNEY/AGENT INFORMATION:
NAME: Clark, Richard S
REGISTRATION NUMBER: 26,154
REFERENCE/DOCKET NUMBER: 29889-165/29528
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-408-2558
TELEFAX: 212-765-2519
TELEX:
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
ORIGINAL SOURCE:
ORGANISM: Human Immunodeficiency Virus Type 1

FEATURE:
NAME/KEY:
LOCATION: 301...319
OTHER INFORMATION: Envelope Protein gp120
US-08-363-276B-1

Query Match 64.1%; Score 25; DB 2; Length 19;
Best Local Similarity 62.5%; Pred. No. 87;
Matches 5; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1 RAFVITGK 8
Db 10 RAFYTTGE 17

RESULT 230
US-08-755-034-1
Sequence 1, Application US/08755034
Patent No. 6204250
GENERAL INFORMATION:
APPLICANT: BOT and BONA
TITLE OF INVENTION: IMMUNIZATION OF INFANTS
NUMBER OF SEQUENCES: 20
CORRESPONDENCE ADDRESS:
ADDRESSEE: Brumbaugh, Graves, Donohue &
STREET: 30 Rockefeller Plaza
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10112-0228
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/755.034
FILING DATE: 22-NOVEMBER-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Clark, Richard S
REGISTRATION NUMBER: 26,154
REFERENCE/DOCKET NUMBER: 29889-165/29528
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-408-2558
TELEFAX: 212-765-2519
TELEX:
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
ORIGINAL SOURCE:
ORGANISM: Human Immunodeficiency Virus Type 1
FEATURE:
NAME/KEY:
LOCATION: 301...319
OTHER INFORMATION: Envelope Protein gp120
US-08-755-034-1

Query Match 64.1%; Score 25; DB 3; Length 19;
Best Local Similarity 62.5%; Pred. No. 87;
Matches 5; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1 RAFVITGK 8
Db 10 RAFYTTGE 17

```
RESULT 231
US-10-125-594-6
; Sequence 6, Application US/10125594
; Patent No. 6740747
; GENERAL INFORMATION:
; APPLICANT: Kaushik, Azad
; APPLICANT: Saini, Surinder Singh
; TITLE OF INVENTION: No. 6740747a1 Bovine VDJ Cassette, BPH1, Suitable for Antigeniza
; FILE REFERENCE: 12837-4
; CURRENT APPLICATION NUMBER: US/10/125,594
; CURRENT FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: US 60/284,899
; PRIOR FILING DATE: 2001-04-20
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE INFORMATION: Human HIV-1
US-10-125-594-6

Query Match          64.1%; Score 25; DB 4; Length 19;
Best Local Similarity 62.5%; Pred. No. 87;
Matches 5; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY      1 RAFTYTGK 8
      ||| ||| :
      10 RAFTYTGK 17

RESULT 232
PCT-US95-16718-1
; Sequence 1, Application PC/TUS9516718
; GENERAL INFORMATION:
; APPLICANT: MOUNT SINAI SCHOOL OF MEDICINE OF THE
; APPLICANT: CITY UNIVERSITY OF NEW YORK
; TITLE OF INVENTION: CHIMERIC ANTIBODIES
; TITLE OF INVENTION: COMPRISING ANTIGEN BINDING SITES AND B AND T CELL EPITOPES
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Brumbaugh, Graves, Donohue &
; ADDRESSEE: Raymond
; STREET: 30 Rockefeller Plaza
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10112-0228
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/16718
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Richard S
; REGISTRATION NUMBER: 26,154
; REFERENCE/DOCKET NUMBER: 29889-165/29528
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-408-2558
; TELEFAX: 212-765-2519
; TELEX:
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
```

```
LENGTH: 19 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
ORIGINAL SOURCE:
ORGANISM: Human Immunodeficiency Virus Type 1
FEATURE:
NAME/KEY:
LOCATION: 301...319
OTHER INFORMATION: Envelope Protein gp120
PCT-US95-16718-1

Query Match          64.1%; Score 25; DB 5; Length 19;
Best Local Similarity 62.5%; Pred. No. 87;
Matches 5; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY      1 RAFTYTGK 8
      ||| ||| :
      10 RAFTYTGK 17

RESULT 233
PCT-US96-08995-1
; Sequence 1, Application PC/TUS9608995
; GENERAL INFORMATION:
; APPLICANT: MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY
; APPLICANT: UNIVERSITY OF NEW YORK
; TITLE OF INVENTION: PEPTIDATED MODIFIED PROTEINS
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Brumbaugh, Graves, Donohue & Raymond
; STREET: 30 Rockefeller Plaza
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10112-0228
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/08995
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/477,421
; FILING DATE: 7-JUNE-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Richard S
; REGISTRATION NUMBER: 26,154
; REFERENCE/DOCKET NUMBER: 29889-165/29528
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-408-2558
; TELEFAX: 212-765-2519
; TELEX:
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; ORIGINAL SOURCE:
; ORGANISM: Human Immunodeficiency Virus Type 1
; FEATURE:
; NAME/KEY:
; LOCATION: 301...319
; OTHER INFORMATION: Envelope Protein gp120
PCT-US96-08995-1

Query Match          64.1%; Score 25; DB 5; Length 19;
```

Best Local Similarity 62.5%; Pred. No. 87;
Matches 5; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1 RAFYTGK 8
Db 10 RAFYTTGE 17

RESULT 234

US-08-279-906A-27

Sequence 27, Application US/08279906A

Patent No. 5618922

GENERAL INFORMATION:

APPLICANT: Ohno, Teuneya

APPLICANT: Terada, Masaki

APPLICANT: Yoneda, Yukio

TITLE OF INVENTION: NM03 Antibody Materials and Methods

NUMBER OF SEQUENCES: 27

CORRESPONDENCE ADDRESS:

ADDRESS: Marshall, O'Toole, Gerstein, Murray &

ADDRESS: Borun

STREET: 6100 Sears Tower, 233 S. Wacker Drive

CITY: Chicago

STATE: Illinois

COUNTRY: USA

ZIP: 60606

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/279,906A

FILING DATE:

CLASSIFICATION: 424

ATTORNEY/AGENT INFORMATION:

NAME: No. 5618922and, Greta E.

REGISTRATION NUMBER: 35,302

REFERENCE/DOCKET NUMBER: 3028

TELECOMMUNICATION INFORMATION:

TELEPHONE: (312) 474-6300

TELEFAX: (312) 474-0448

TELEX: 25-3856

INFORMATION FOR SEQ ID NO: 27:

SEQUENCE CHARACTERISTICS:

LENGTH: 20 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: peptide

US-08-279-906A-27

Query Match 64.1%; Score 25; DB 1; Length 20;
Best Local Similarity 62.5%; Pred. No. 91;
Matches 5; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1 RAFYTGK 8
Db 6 RAFYTTGE 13

RESULT 235

US-08-825-852-63

Sequence 63, Application US/08825852

Patent No. 6121416

GENERAL INFORMATION:

APPLICANT: Clark, Ross G1

APPLICANT: Lowman, Henry B.

APPLICANT: Robinson, Iain C.A.F.

TITLE OF INVENTION: Insulin-like Growth Factor Agonist Molecules

NUMBER OF SEQUENCES: 79

CORRESPONDENCE ADDRESS:

ADDRESS: Genentech, Inc.

STREET: 1 DNA Way

CITY: South San Francisco
STATE: California
COUNTRY: USA

ZIP: 94080

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: WinPatIn (Genentech)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/825,852

FILING DATE: 04-Apr-1997

CLASSIFICATION: 514

ATTORNEY/AGENT INFORMATION:

NAME: Haasek, Janet E.

REGISTRATION NUMBER: 28,616

REFERENCE/DOCKET NUMBER: P1071

TELECOMMUNICATION INFORMATION:

TELEPHONE: 650/225-1896

TELEFAX: 650/952-9881

INFORMATION FOR SEQ ID NO: 63:

SEQUENCE CHARACTERISTICS:

LENGTH: 20 amino acids

TYPE: Amino Acid

TOPOLOGY: linear

US-08-825-852-63
Query Match 64.1%; Score 25; DB 3; Length 20;
Best Local Similarity 57.1%; Pred. No. 91;
Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 2 AFYTGK 8
Db 14 AFMAVGK 20

RESULT 236

US-08-825-852-64

Sequence 64, Application US/08825852

Patent No. 6121416

GENERAL INFORMATION:

APPLICANT: Clark, Ross G1

APPLICANT: Lowman, Henry B.

APPLICANT: Robinson, Iain C.A.F.

TITLE OF INVENTION: Insulin-like Growth Factor Agonist Molecules

NUMBER OF SEQUENCES: 79

CORRESPONDENCE ADDRESS:

ADDRESS: Genentech, Inc.

STREET: 1 DNA Way

CITY: South San Francisco

STATE: California

COUNTRY: USA

ZIP: 94080

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: WinPatIn (Genentech)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/825,852

FILING DATE: 04-Apr-1997

CLASSIFICATION: 514

ATTORNEY/AGENT INFORMATION:

NAME: Haasek, Janet E.

REGISTRATION NUMBER: 28,616

REFERENCE/DOCKET NUMBER: P1071

TELECOMMUNICATION INFORMATION:

TELEPHONE: 650/225-1896

TELEFAX: 650/952-9881

INFORMATION FOR SEQ ID NO: 64:

SEQUENCE CHARACTERISTICS:

LENGTH: 20 amino acids

TYPE: Amino Acid

TOPOLOGY: Linear
US-08-825-852-64

Query Match 64.1%; Score 25; DB 3; Length 20;
Best Local Similarity 57.1%; Pred. No. 91;
Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2 AFVTIGK 8
||: |||
Db 14 AFMAVGK 20

RESULT 237

US-09-052-888-64
Sequence 64, Application US/09052888
Patent No. 6251865

GENERAL INFORMATION:
APPLICANT: Clark, Rose G1
APPLICANT: Lowman, Henry B.
APPLICANT: Robinson, Iain C.A.F.
TITLE OF INVENTION: Insulin-like Growth Factor Agonist Molecules
NUMBER OF SEQUENCES: 109
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Winpatin (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/052,888
FILING DATE: 31-Mar-1998
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Hasak, Janet E.
REGISTRATION NUMBER: 28,616
REFERENCE/DOCKET NUMBER: P1071P1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-1896
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 64:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear
US-09-052-888-64

Query Match 64.1%; Score 25; DB 3; Length 20;
Best Local Similarity 57.1%; Pred. No. 91;
Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2 AFVTIGK 8
||: |||
Db 14 AFMAVGK 20

RESULT 238
US-09-052-888-65
Sequence 65, Application US/09052888
Patent No. 6251865
GENERAL INFORMATION:
APPLICANT: Clark, Rose G1
APPLICANT: Lowman, Henry B.
APPLICANT: Robinson, Iain C.A.F.
TITLE OF INVENTION: Insulin-like Growth Factor Agonist Molecules
NUMBER OF SEQUENCES: 109
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Winpatin (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/052,888
FILING DATE: 31-Mar-1998
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Hasak, Janet E.
REGISTRATION NUMBER: 28,616
REFERENCE/DOCKET NUMBER: P1071P1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-1896
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 65:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear
US-09-052-888-65

Query Match 64.1%; Score 25; DB 3; Length 20;
Best Local Similarity 57.1%; Pred. No. 91;
Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2 AFVTIGK 8
||: |||
Db 14 AFMAVGK 20

RESULT 239
US-09-052-888-66
Sequence 66, Application US/09052888
Patent No. 6251865
GENERAL INFORMATION:
APPLICANT: Clark, Rose G1
APPLICANT: Lowman, Henry B.
APPLICANT: Robinson, Iain C.A.F.
TITLE OF INVENTION: Insulin-like Growth Factor Agonist Molecules
NUMBER OF SEQUENCES: 109
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080

STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Winpatin (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/052,888
FILING DATE: 31-Mar-1998
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Hasak, Janet E.
REGISTRATION NUMBER: 28,616
REFERENCE/DOCKET NUMBER: P1071P1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-1896
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 65:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear
US-09-052-888-65

Query Match 64.1%; Score 25; DB 3; Length 20;
Best Local Similarity 57.1%; Pred. No. 91;
Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2 AFVTIGK 8
||: |||
Db 14 AFMAVGK 20

RESULT 239

US-09-0723-890-64
Sequence 64, Application US/09723890
Patent No. 6608031

GENERAL INFORMATION:
APPLICANT: Clark, Rose G1
APPLICANT: Lowman, Henry B.
APPLICANT: Robinson, Iain C.A.F.
TITLE OF INVENTION: Insulin-like Growth Factor Agonist Molecules
NUMBER OF SEQUENCES: 109
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Winpatin (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/723,890
FILING DATE: 28-Mar-2000
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/052,888
FILING DATE: 31-Mar-1998
ATTORNEY/AGENT INFORMATION:
NAME: Hasak, Janet E.
REGISTRATION NUMBER: 28,616
REFERENCE/DOCKET NUMBER: P1071P1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-1896
TELEFAX: 650/952-9881

Query Match 64.1%; Score 25; DB 3; Length 20;
Best Local Similarity 57.1%; Pred. No. 91;
Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

```

; INFORMATION FOR SEQ ID NO: 64:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 20 amino acids
;   TYPE: Amino Acid
;   TOPOLOGY: Linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 64:
US-09-723-890-64

Query Match      64.1%; Score 25; DB 4; Length 20;
Best Local Similarity 57.1%; Pred. No. 91;
Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      2 AFTVIGK 8
      ||: ||
Db      14 AFMAVGR 20

RESULT 240
US-09-723-890-65
; Sequence 65, Application US/09723890
; Patent No. 6608031
; GENERAL INFORMATION:
;   APPLICANT: Clark, Ross G1
;   Lowman, Henry B.
;   TITLE OF INVENTION: Insulin-like Growth Factor Agonist Molecules
;   NUMBER OF SEQUENCES: 109
;   CORRESPONDENCE ADDRESS:
;   ADDRESSEE: Genentech, Inc.
;   STREET: 1 DNA Way
;   CITY: South San Francisco
;   STATE: California
;   COUNTRY: USA
;   ZIP: 94080
; COMPUTER READABLE FORM:
;   MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
;   COMPUTER: IBM PC compatible
;   OPERATING SYSTEM: PC-DOS/MS-DOS
;   SOFTWARE: Winpatin (Genentech)
;   CURRENT APPLICATION DATA:
;   APPLICATION NUMBER: US/09/723,890
;   FILING DATE: 28-Mar-1998
;   CLASSIFICATION: 514
;   PRIOR APPLICATION DATA:
;   APPLICATION NUMBER: US/09/052,888
;   FILING DATE: 31-Mar-1998
;   ATTORNEY/AGENT INFORMATION:
;   NAME: Hasak, Janet E.
;   REGISTRATION NUMBER: 28,616
;   REFERENCE/DOCKET NUMBER: P1071P1
;   TELECOMMUNICATION INFORMATION:
;   TELEPHONE: 650/225-1896
;   TELEFAX: 650/952-9881
;   INFORMATION FOR SEQ ID NO: 65:
;   SEQUENCE CHARACTERISTICS:
;   LENGTH: 20 amino acids
;   TYPE: Amino Acid
;   TOPOLOGY: Linear
;   SEQUENCE DESCRIPTION: SEQ ID NO: 65:
US-09-723-890-65

Query Match      64.1%; Score 25; DB 4; Length 20;
Best Local Similarity 57.1%; Pred. No. 91;
Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      2 AFTVIGK 8
      ||: ||
Db      14 AFMAVGR 20

RESULT 241
US-09-723-901-64
; Sequence 64, Application US/09723901
```

```

; Patent No. 6620789
; GENERAL INFORMATION:
;   APPLICANT: Clark, Ross G1
;   Lowman, Henry B.
;   TITLE OF INVENTION: Insulin-like Growth Factor Agonist Molecules
;   NUMBER OF SEQUENCES: 109
;   CORRESPONDENCE ADDRESS:
;   ADDRESSEE: Genentech, Inc.
;   STREET: 1 DNA Way
;   CITY: South San Francisco
;   STATE: California
;   COUNTRY: USA
;   ZIP: 94080
; COMPUTER READABLE FORM:
;   MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
;   COMPUTER: IBM PC compatible
;   OPERATING SYSTEM: PC-DOS/MS-DOS
;   SOFTWARE: Winpatin (Genentech)
;   CURRENT APPLICATION DATA:
;   APPLICATION NUMBER: US/09/723,901
;   FILING DATE: 28-Mar-1998
;   CLASSIFICATION: <Unknown>
;   PRIOR APPLICATION DATA:
;   APPLICATION NUMBER: 09/052,888
;   FILING DATE: 31-Mar-1998
;   ATTORNEY/AGENT INFORMATION:
;   NAME: Hasak, Janet E.
;   REGISTRATION NUMBER: 28,616
;   REFERENCE/DOCKET NUMBER: P1071P1
;   TELECOMMUNICATION INFORMATION:
;   TELEPHONE: 650/225-1896
;   TELEFAX: 650/952-9881
;   INFORMATION FOR SEQ ID NO: 64:
;   SEQUENCE CHARACTERISTICS:
;   LENGTH: 20 amino acids
;   TYPE: Amino Acid
;   TOPOLOGY: Linear
;   SEQUENCE DESCRIPTION: SEQ ID NO: 64:
US-09-723-901-64

Query Match      64.1%; Score 25; DB 4; Length 20;
Best Local Similarity 57.1%; Pred. No. 91;
Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      2 AFTVIGK 8
      ||: ||
Db      14 AFMAVGR 20

RESULT 242
US-09-723-901-65
; Sequence 65, Application US/09723901
; Patent No. 6620789
; GENERAL INFORMATION:
;   APPLICANT: Clark, Ross G1
;   Lowman, Henry B.
;   TITLE OF INVENTION: Insulin-like Growth Factor Agonist Molecules
;   NUMBER OF SEQUENCES: 109
;   CORRESPONDENCE ADDRESS:
;   ADDRESSEE: Genentech, Inc.
;   STREET: 1 DNA Way
;   CITY: South San Francisco
;   STATE: California
;   COUNTRY: USA
;   ZIP: 94080
; COMPUTER READABLE FORM:
;   MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
;   COMPUTER: IBM PC compatible
;   OPERATING SYSTEM: PC-DOS/MS-DOS
;   SOFTWARE: Winpatin (Genentech)
;   CURRENT APPLICATION DATA:
```

APPLICATION NUMBER: US/09/723,901
FILING DATE: 28-Mar-2000
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/052,888
FILING DATE: 31-Mar-1998
ATTORNEY/AGENT INFORMATION:
NAME: Hasak, Janet E.
REGISTRATION NUMBER: 28,616
REFERENCE/DOCKET NUMBER: P1071P1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-1896
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 65:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear
SEQUENCE DESCRIPTION: SEQ ID NO: 65:
US-09-723-901-65

Query Match 64.1%; Score 25; DB 4; Length 20;
Best Local Similarity 57.1%; Pred. No. 91;
Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY 2 AFTTIGK 8
||: ||
Db 14 AFMAVGK 20

RESULT 243
US-09-723-547-64
Sequence 64, Application US/09723547
Patent No. 6632794
GENERAL INFORMATION:
APPLICANT: Clark, Ross G1
Lowman, Henry B.
Robinson, Iain C.A.F.
TITLE OF INVENTION: Insulin-like Growth Factor Agonist Molecules
NUMBER OF SEQUENCES: 109
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WinPatIn (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/723,547
FILING DATE: 28-Mar-2000
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/052,888
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Hasak, Janet E.
REGISTRATION NUMBER: 28,616
REFERENCE/DOCKET NUMBER: P1071P1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-1896
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 64:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear
SEQUENCE DESCRIPTION: SEQ ID NO: 64:
US-09-723-547-64

Query Match 64.1%; Score 25; DB 4; Length 20;
Best Local Similarity 57.1%; Pred. No. 91;
Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY 2 AFTTIGK 8
||: ||
Db 14 AFMAVGK 20

RESULT 244
US-09-723-547-65
Sequence 65, Application US/09723547
Patent No. 6632794
GENERAL INFORMATION:
APPLICANT: Clark, Ross G1
Lowman, Henry B.
Robinson, Iain C.A.F.
TITLE OF INVENTION: Insulin-like Growth Factor Agonist Molecules
NUMBER OF SEQUENCES: 109
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WinPatIn (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/723,547
FILING DATE: 28-Mar-2000
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/052,888
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Hasak, Janet E.
REGISTRATION NUMBER: 28,616
REFERENCE/DOCKET NUMBER: P1071P1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-1896
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 65:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear
SEQUENCE DESCRIPTION: SEQ ID NO: 65:
US-09-723-547-65

Query Match 64.1%; Score 25; DB 4; Length 20;
Best Local Similarity 57.1%; Pred. No. 91;
Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY 2 AFTTIGK 8
||: ||
Db 14 AFMAVGK 20

RESULT 245
US-09-724-127-64
Sequence 64, Application US/09724127
Patent No. 6635619
GENERAL INFORMATION:
APPLICANT: Clark, Ross G1
Lowman, Henry B.
Robinson, Iain C.A.F.
TITLE OF INVENTION: Insulin-like Growth Factor Agonist Molecules
NUMBER OF SEQUENCES: 109

```

CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WinPatIn (Genentech)

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/724,127
FILING DATE: 28-No. 6635619-2000
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/052,888
FILING DATE: 31-Mar-1998

ATTORNEY/AGENT INFORMATION:
NAME: Hasak, Janet E.
REGISTRATION NUMBER: 28,616
REFERENCE/DOCKET NUMBER: P1071P1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-1896
TELEFAX: 650/952-9881

SEQUENCE CHARACTERISTICS:
LENGTH: 20 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear

SEQUENCE DESCRIPTION: SEQ ID NO: 64:
US-09-724-127-64

Query Match      64.1%  Score 25;  DB 4;  Length 20;
Best Local Similarity 57.1%  Pred. No. 91;
Matches 4;  Conservative 2;  Mismatches 1;  Indels 0;  Gaps 0.

OY      2  APTVITGK 8
      ||: ||
Db      14  AFMAVGR 20

RESULT 246
US-09-724-127-65
; Sequence 65, Application US/09724127
; Patent No. 6635619
; GENERAL INFORMATION:
; APPLICANT: Clark, Ross G1
;              Lowman, Henry B.
;              Robinson, Iain C.A.F.
; TITLE OF INVENTION: Insulin-like Growth Factor Agonist Molecules
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WinPatIn (Genentech)

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/724,127
FILING DATE: 28-No. 6635619-2000
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/052,888
FILING DATE: 31-Mar-1998
ATTORNEY/AGENT INFORMATION:

```

```

NAME: Hasak, Janet E.
REGISTRATION NUMBER: 28,616
REFERENCE/DOCKET NUMBER: P1071P1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-1896
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 65:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear
SEQUENCE DESCRIPTION: SEQ ID NO: 65:
US-09-724-127-65

Query Match      64.1% Score 25; DB 4; Length 20;
Best Local Similarity 57.1% Pred. No. 91;
Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0

QY      2 AFVTIGK 8
      ||: ||
Db      14 AFMAVGK 20

RESULT 247
US-09-723-931-64
Sequence 64, Application US/09723931
Patent No. 6645775
GENERAL INFORMATION:
APPLICANT: Clark, Rose G1
Lowman, Henry B.
Robinson, Iain C.A.F.
TITLE OF INVENTION: Insulin-like Growth Factor Agonist Molecules
NUMBER OF SEQUENCES: 109
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WinPatIn (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/723,931
FILING DATE: 28-No. 6645775-2000
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/052,888
FILING DATE: 31-Mar-1998
ATTORNEY/AGENT INFORMATION:
NAME: Hasak, Janet E.
REGISTRATION NUMBER: 28,616
REFERENCE/DOCKET NUMBER: P1071P1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-1896
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 64:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear
SEQUENCE DESCRIPTION: SEQ ID NO: 64:
US-09-723-931-64

Query Match      64.1% Score 25; DB 4; Length 20;
Best Local Similarity 57.1% Pred. No. 91;
Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

```


Db 14 AFMAVGK 20

RESULT 248
US-09-723-931-65
Sequence 65, Application US/09723931
Patent No. 6645775
GENERAL INFORMATION:
APPLICANT: Clark, Ross G1
Lowman, Henry B.
Robinson, Iain C.A.F.
TITLE OF INVENTION: Insulin-like Growth Factor Agonist Molecules
NUMBER OF SEQUENCES: 109
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Winpatin (Genentech)

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/723,931
FILING DATE: 28-Mar-1998
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/052,888
FILING DATE: 31-Mar-1998
ATTORNEY/AGENT INFORMATION:
NAME: Hasak, Janet E.
REGISTRATION NUMBER: 28,616
REFERENCE/DOCKET NUMBER: P1071P1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-1896
TELEFAX: 650/952-9881

INFORMATION FOR SEQ ID NO: 65:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear

SEQUENCE DESCRIPTION: SEQ ID NO: 65:
US-09-723-931-65

Query Match 64.1%; Score 25; DB 4; Length 20;
Best Local Similarity 57.1%; Pred. No. 91;
Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2 AFTVIGK 8
||: ||
Db 14 AFMAVGK 20

RESULT 249
US-09-723-873-64
Sequence 64, Application US/09723873
Patent No. 667305
GENERAL INFORMATION:
APPLICANT: Clark, Ross G1
Lowman, Henry B.
Robinson, Iain C.A.F.
TITLE OF INVENTION: Insulin-like Growth Factor Agonist Molecules
NUMBER OF SEQUENCES: 109
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Winpatin (Genentech)

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/723,873
FILING DATE: 28-Mar-1998
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/052,888
FILING DATE: 31-Mar-1998
ATTORNEY/AGENT INFORMATION:
NAME: Hasak, Janet E.
REGISTRATION NUMBER: 28,616
REFERENCE/DOCKET NUMBER: P1071P1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-1896
TELEFAX: 650/952-9881

INFORMATION FOR SEQ ID NO: 64:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear

SEQUENCE DESCRIPTION: SEQ ID NO: 64:
US-09-723-873-64

Query Match 64.1%; Score 25; DB 4; Length 20;
Best Local Similarity 57.1%; Pred. No. 91;
Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2 AFTVIGK 8
||: ||
Db 14 AFMAVGK 20

RESULT 250
US-09-723-873-65
Sequence 65, Application US/09723873
Patent No. 667305
GENERAL INFORMATION:
APPLICANT: Clark, Ross G1
Lowman, Henry B.
Robinson, Iain C.A.F.
TITLE OF INVENTION: Insulin-like Growth Factor Agonist Molecules
NUMBER OF SEQUENCES: 109
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Winpatin (Genentech)

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/723,873
FILING DATE: 28-Mar-1998
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/052,888
FILING DATE: 31-Mar-1998
ATTORNEY/AGENT INFORMATION:
NAME: Hasak, Janet E.
REGISTRATION NUMBER: 28,616
REFERENCE/DOCKET NUMBER: P1071P1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-1896
TELEFAX: 650/952-9881

INFORMATION FOR SEQ ID NO: 65:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 amino acids

TYPE: Amino Acid
 TOPOLOGY: Linear
 SEQUENCE DESCRIPTION: SEQ ID NO: 65:
 US-09-723-873-65

Query Match 64.1%; Score 25; DB 4; Length 20;
 Best Local Similarity 57.1%; Pred. No. 91;
 Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 QY 2 AFTVIGK 8
 |||: ||
 Db 14 AFMAVGK 20

Search completed: May 16, 2005, 10:03:40
 Job time : 42 secs